<DOC>
<DOCNO>WT03-B24-1</DOCNO>
<DOCOLDNO>IA053-000892-B032-103</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/Adjuncts.html 129.174.40.15 19970123185933 text/html 1569
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:58:23 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:23:23 GMT
Content-type: text/html
Content-length: 1386
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>ISSE Adjunct Faculty</TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Adjunct Faculty </CENTER>
</H2>
<HR><B>Armour, Frank</B>, Ph.D., George Mason University, 1992; American
Management Systems <BR>
<BR>
<B>Cecil, Carl P</B>., M.S., Naval Postgraduate School, 1991; U.S. Army
<BR>
<BR>
<B>Davis, Carolyn</B>, Ph.D., Texas A&amp;M University, 1988; MITRE <BR>
<BR>
<B>Dinh, Anhtuan</B>, Ph.D., George Mason University, 1995; Stanford Telecom
<BR>
<BR>
<B>Hanratty, J. M.</B>, Ph.D., Georgia Institute of Technology, 1989, US
Army <BR>
<BR>
<B>McDermott, John</B>, Ph.D.,George Mason University, 1993; Naval Research
Lab <BR>
<BR>
<B>Napoliello, Michael F.</B>, Ph.D., Virginia Tech, 1987; US Army <BR>
<BR>
<B>Nguyen, Tan N.</B>, Ph.D., George Mason University, 1992; Infodata Systems,
Inc. <BR>
<BR>
<B>Nidiffer, Kenneth</B>, D. Sc., George Washington University, 1988; Northrup-Grumman
Corporation <BR>
<BR>
<B>Rao, Jarugula S.</B>, Ph.D., Nebraska State University, 1971; Office
of Secretary of Army <BR>
<BR>
<B>Scime, Anthony</B>, M.S., Boston University, 1983; CACI <BR>
<BR>
<B>Seligman, Leonard</B>, Ph.D., George Mason University, 1995; MITRE <BR>
<BR>
<B>Smith, Kenneth</B>, Ph.D., University of Illinois, 1994; MITRE<BR>
<BR>
<I><A HREF="issue111095.html">Return to table of contents.</A></I> 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-2</DOCNO>
<DOCOLDNO>IA053-000892-B032-122</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/journal-papers.html 129.174.40.15 19970123185941 text/html 2210
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:58:32 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:23:20 GMT
Content-type: text/html
Content-length: 2027
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Journal Papers </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Journal Papers</CENTER>
</H2>
<HR><B>Vijaylakshmi Atluri, Elisa Bertino, and Sushil Jajodia</B>, &quot;Achieving
stricter correctness requirements in multilevel secure databases.&quot;
<I>Journal of Computer Security</I>, Vol. 2, No. 4, pp. 311-351. <BR>
<BR>
<B>Hassan Gomaa</B>, &quot;Reusable Software Requirements and Architectures
for Families of Systems.&quot; <I>Journal of Systems and Software</I>, April
1995. <BR>
<BR>
<B>Sushil Jajodia, Ravi Mukkamala, and K.V.S. Ramarao</B>, &quot;A view-based
dynamic replication control algorithm.&quot; <I>Nordic Journal of Computing</I>,
Vol. 1, No. 2, 1994, pp. 214-230. <BR>
<BR>
<B>Amihai Motro</B>, &quot;Intensional Answers to Database Queries.&quot;
<I>IEEE Transactions on Knowledge and Data Engineering</I>, Vol. 6, No.
3, June 1994, pp. 444-454. <BR>
<BR>
<B>Jeff Offutt and Mike Craft</B>, &quot;Using compiler optimization techniques
to detect equivalent mutants.&quot; <I>The Journal of Software Testing,
Verification, and Reliability</I>, Vol. 4, No. 3, September 1994, pp. 131-154.
<BR>
<BR>
<B>Bo Sanden</B>, &quot;Designing control systems with entity-life modeling.&quot;
<I>Journal of Systems and Software</I> 28:225-237 (April 1995). <BR>
<BR>
<B>Ravi Sandhu and Pierangela Samarati</B>, &quot;Access Control: Principles
and Practice.&quot; <I>IEEE Communications</I>, Vol. 32, No. 9, September
1994, pp. 40-48. <BR>
<BR>
<B>X. Sean Wang, Sushil Jajodia, and V. S. Subrahmanian</B>, &quot;Temporal
modules: An approach toward federated temporal databases.&quot; <I>Information
Sciences</I>, Vol. 82, 1995, pp. 103-128. <BR>
<BR>
<B>Ouri Wolfson and Sushil Jajodia</B>, &quot;An algorithm for dynamic data
allocation in distributed systems.&quot; <I>Information Processing Letters</I>,
Vol. 53, No. 2, 1995, pp. 113-119. <BR>
<BR>
<I><A HREF="issue111095.html#anchor1245648">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-3</DOCNO>
<DOCOLDNO>IA053-000892-B032-147</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/books.html 129.174.40.15 19970123190004 text/html 830
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:58:46 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:23:17 GMT
Content-type: text/html
Content-length: 648
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Books </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Books</CENTER>
</H2>
<HR><B>Sushil Jajodia</B> is co-editor of the book <I><STRONG>Information
Security: An Integrated Collection of Essays</STRONG></I>, IEEE Computer
Society Press (1995). The book is a collection of 27 essays, primarily written
by original researchers in their fields. It provides a comprehensive summary
of recent research results and development and application experience in
information security. <BR>
<BR>
<I><A HREF="issue111095.html#anchor1245648">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-4</DOCNO>
<DOCOLDNO>IA053-000892-B032-177</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/papers-in-collections.html 129.174.40.15 19970123190037 text/html 4633
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:59:09 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:23:14 GMT
Content-type: text/html
Content-length: 4450
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Papers in Collections </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Papers in Collections</CENTER>
</H2>
<HR><B>Chris Bosch, Hassan Gomaa and Larry Kerschberg</B>, &quot;Design
and Construction of a Software Engineering Environment: Experiences with
Eiffel.&quot; In <I>Readings in Object-Oriented Systems and Applications</I>,
(Rine, D. editor), IEEE Computer Society Press, 1995. <BR>
<BR>
<B>Sushil Jajodia, Boris Kogan and Ravi Sandhu</B>, &quot;A Multilevel-Secure
Object-Oriented Data Model.&quot; In <I>Readings in Object-Oriented Systems
and Applications</I>, (Rine, D. editor), IEEE Computer Society Press, 1995,
pp. 206-215. <BR>
<BR>
<B>Sushil Jajodia and Cathy Meadows</B>, &quot;Inference Problems in Multilevel
Secure Database Management Systems.&quot; In <I>Information Security: An
Integrated Collection of Essays</I>, M. Abrams et al., eds., IEEE Computer
Society Press (1995), pp. 570-584. <BR>
<BR>
<B>Sushil Jajodia, Sushil Gadia, and Gautam Bhargava</B>, &quot;Logical
Design of Audit Information in Relational Databases.&quot; In <I>Information
Security: An Integrated Collection of Essays</I>, M. Abrams et al., eds.,
IEEE Computer Society Press (1995), pp. 585-595. <BR>
<BR>
<B>Sushil Jajodia and Ravi Sandhu</B>, &quot;Toward A Multilevel Secure
Relational Data Model.&quot; In <I>Information Security: An Integrated Collection
of Essays</I>, Volume 1, (Abrams, M.A., Podell, H.J. and Sushil Jajodia,
editors), IEEE Computer Society Press, 1994, pp. 460-492. <BR>
<BR>
<B>Sushil Jajodia, Ravi Sandhu and Barbara T. Blaustein</B>, &quot;Solutions
to the Polyinstantiation Problem.&quot; In <I>Information Security: An Integrated
Collection of Essays</I>, Volume 1, (Abrams, M.A., Podell, H.J. and Sushil
Jajodia, editors), IEEE Computer Society Press, 1994, pp. 493-529. <BR>
<BR>
<B>Sushil Jajodia, Kogan, B. and Ravi Sandhu</B>, &quot;A Multilevel-Secure
Object-Oriented Data Model.&quot; In <I>Information Security: An Integrated
Collection of Essays</I>, Volume 1, (Abrams, M.A., Podell, H.J. and Sushil
Jajodia, editors), IEEE Computer Society Press, 1994, pp. 596-616. <BR>
<BR>
<B>Cathy Meadows and Sushil Jajodia</B>, &quot;Integrity in Multilevel Secure
Database Management Systems.&quot; In <I>Information Security: An Integrated
Collection of Essays</I>, M. Abrams et al., eds., IEEE Computer Society
Press (1995), pp. 530-541. <BR>
<BR>
<B>Ami Motro</B>, &quot;Responding with Knowledge.&quot; In <I>Advances
in Databases and Artificial Intelligence</I>, Vol. 1, Intelligent Database
Technology: Approaches and Applications (L. Delcambre and F. Petry, Editors),
JAI Press, 1995, pp. 1-21. <BR>
<BR>
<B>Ami Motro</B>, &quot;Management of Uncertainty in Database Systems.&quot;
In <I>Modern Database Systems: the Object Model, Interoperability and Beyond</I>
(W. Kim, Editor), Addison-Wesley/ACM Press, 1994, pp. 457-476. <BR>
<BR>
<B>Ravi Sandhu</B>, &quot;Relational Database Access Controls Using SQL.&quot;
In <I>Handbook of Information Security Management</I> (1994-95 Yearbook),
(Ruthberg, Z.A. and Tipton, H.F., editors), Auerbach Publishers, 1994, pp.
145-160. <BR>
<BR>
<B>Ravi Sandhu</B>, &quot;On Five Definitions of Data Integrity.&quot; In
<I>Database Security VII: Status and Prospects</I>, (Keefe, T. and Landwehr,
C.E., editors), North-Holland 1994, pp. 257-267. <BR>
<BR>
<B>Ravi Sandhu and Sushil Jajodia</B>, &quot;Integrity Mechanisms in Database
Management Systems.&quot; In <I>Information Security: An Integrated Collection
of Essays</I>, Volume 1, (Abrams, M.A., Podell, H.J. and Sushil Jajodia,
editors), IEEE Computer Society Press, 1994, pp. 617-634. <BR>
<BR>
<B>Len Seligman and Larry Kerschberg</B>, &quot;Federated Knowledge and
Database Systems: A New Architecture for Integrating of AI and Database
Systems.&quot; In <I>Advances in Databases and Artificial Intelligence</I>,
Vol. 1: The Landscape of Intelligence in Database and Information Systems
(L. Delcambre and F. Petry, editors). JAI Press (1995). <BR>
<BR>
<B>Roshan Thomas and Ravi Sandhu</B>, &quot;Towards a Unified Framework
and Theory for Reasoning about Security and Correctness of Multilevel Transactions.&quot;
In <I>Database Security VII: Status and Prospects</I>, (Keefe, T. and Landwehr,
C.E., editors), North-Holland 1994, pp. 309-328. <BR>
<BR>
<I><A HREF="issue111095.html#anchor1245648">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-5</DOCNO>
<DOCOLDNO>IA053-000892-B032-211</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/conference-papers.html 129.174.40.15 19970123190106 text/html 8159
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:59:50 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:23:09 GMT
Content-type: text/html
Content-length: 7976
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Conference Papers </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Conference Papers</CENTER>
</H2>
<HR><B>Paul Ammann</B>, &quot;A Safety Kernel for Traffic Light Control.&quot;
Proceedings of the <I>Tenth Annual Conference On Computer Assurance</I>
(COMPASS), Gaithersburg, MD, June 1995. <BR>
<BR>
<B>Paul Ammann and Sushil Jajodia</B>, &quot;An Efficient Multiversion Algorithm
for Secure Servicing of Transaction Reads.&quot; <I>Proc. 2nd ACM Conf.
on Computer and Communications Security</I>, Fairfax, VA, November 1994,
pages 118-125. <BR>
<BR>
<B>Paul Ammann, Sushil Jajodia, and Indrakshi Ray</B>, &quot;Using Formal
Methods to Reason about semantics-based decompositions of transactions.&quot;
<I>Proc. 21st Int'l. Conf. on Very Large Data Bases</I>, Zurich, Switzerland,
1995. <BR>
<BR>
<B>Vijayalakshmi Atluri, Elisa Bertino, and Sushil Jajodia</B>, &quot;Degrees
of isolation, concurrency control protocols, and commit protocols.&quot;
In <I>Database Security VIII: Status and Prospects</I>, (J. Biskup et al.,
eds.), North-Holland, 1994, pages 259-274. <BR>
<BR>
<B>Elisa Bertino, Sushil Jajodia, and Pierangela Samarati</B>, &quot;Enforcing
mandatory access control in object bases.&quot; In <I>Security for Object-Oriented
Systems</I>, (B. Thuraisingham, R. Sandhu, and T. C. Ting, eds.), Springer-Verlag
Workshops in Computing Series, 1994, pages 96-116. <BR>
<BR>
<B>Elisa Bertino, Luigi V. Mancini, and Sushil Jajodia</B>, &quot;Collecting
garbage in multilevel secure object stores.&quot; <I>Proc. IEEE Symp. on
Research in Security and Privacy</I>, Oakland, Calif., May 1994, pages 106-120.
<BR>
<BR>
<B>Claudio Bettini, X. Sean Wang, Elisa Bertino, and Sushil Jajodia</B>,
&quot;Semantic assumptions and query evaluation in temporal databases.&quot;
<I>Proc. of ACM SIGMOD International Conference on Management of Data</I>,
San Jose, CA, 1995. <BR>
<BR>
<B>Alex Brodsky and Y. Kornatzky</B>, &quot;The Lyric Language: Querying
Constraint Objects.&quot; <I>Proc. of ACM SIGMOD International Conference
on Management of Data</I>, San Jose, CA, 1995. <BR>
<BR>
<B>Alex Brodsky, C. Lassez, J.-L. Lassez, M.J. Maher</B>, &quot;Separability
of Polyhedra for Optimal Filtering of Spatial and Constraint Data.&quot;
<I>Proc.14th ACM SIGACT-SIGMOD-SIGART Symp. on Principles of Database Systems</I>,
San Jose, CA, 1995. <BR>
<BR>
<B>Fang Chen and Ravi Sandhu</B>, &quot;The Semantics and Expressive Power
of the MLR Data Model.&quot; <I>Proc. IEEE Symposium on Research in Security
and Privacy</I>, Oakland, California, May 8-10, 1995, pages 128-142. <BR>
<BR>
<B>Vinti M. Doshi, William R. Herndon, Sushil Jajodia, and Catherine D.
McCollum</B>, &quot;Benchmarking multilevel secure database systems using
the MITRE Benchmark.&quot; <I>Proc. 10th Annual Computer Security Applications
Conf.</I>, Orlando, FL, December 1994, pages 86-95. <BR>
<BR>
<B>Chris Dede, B. Loftin, M. Salzman, C. Calhoun, J. Hoblit, and W. Regian</B>,
&quot;The Design of Artificial Realities to Improve Learning Newtonian Mechanics.&quot;
In P. Brusilovsky, Ed., <I>Proceedings of the East-West International Conference
on Multimedia, Hypermedia, and Virtual Reality</I>, pp. 34-41, Moscow, Russia:
International Center for Scientific and Technical Information. <BR>
<BR>
<B>Elizabeth O'Hara-Schettino and Hassan Gomaa</B>, &quot;Dynamic Navigation
of Specifications and Designs: A Computer-Human Interaction Perspective.&quot;
<I>Proc. Workshop on Software Engineering and Human-Computer Interaction</I>,
International Conference on Software Engineering, Sorrento, Italy, May 1994.
<BR>
<BR>
<B>Hassan Gomaa</B>, &quot;Object-Oriented Methods for Concurrent and Real-Time
Systems.&quot; <I>Proc. CASE Japan 94 Conference</I>, Tokyo, Japan, July
1994. <BR>
<BR>
<B>Hassan Gomaa, Larry Kerschberg, Vijay Sugumaran, Chris Bosch, Iraj Tavakoli</B>,
&quot;A Prototype Domain Modeling Environment for Reusable Software Architectures.&quot;
<I>IEEE International Conference on Software Reuse</I>, Rio de Janeiro,
Brazil, November 1994. <BR>
<BR>
<B>Hassan Gomaa</B>, &quot;Domain Modeling Methods and Environments.&quot;
<I>Proc. ACM SIGSOFT Symposium on Software Reusability</I>, Seattle, April
1995. <BR>
<BR>
<B>Hassan Gomaa</B>, &quot;Design Methods for Domain Specific Software Architectures.&quot;
<I>Proc. Workshop on Software Architectures</I>, International Conference
on Software Engineering, Seattle, April 1995. <BR>
<BR>
<B>Hassan Gomaa and Larry Kerschberg</B>, &quot;Domain Modeling for Software
Reuse and Evolution.&quot; <I>Proc. Computer Assisted Software Engineering
Workshop</I> (CASE 95), Toronto, July 1995. <BR>
<BR>
<B>Ami Motro</B>, &quot;Cooperative Database Systems.&quot; <I>Proceedings
of the Workshop on Flexible Query Answering Systems</I>, Roskilde, Denmark,
November 1994, pp. 1-16. <BR>
<BR>
<B>Ami Motro, Don Marks, and Sushil Jajodia</B>, &quot;Aggregation in relational
databases: Controlled disclosure of sensitive information.&quot; <I>Proc.
European Symposium on Research in Computer Security</I>, Springer-Verlag
Lecture Notes in Computer Science, Vol. 875, 1994, pages 431-445. <BR>
<BR>
<B>Jeff Offutt</B>, &quot;Practical Mutation Testing.&quot; <I>Twelfth International
Conference on Testing Computer Software</I>, Washington, D.C., June 1995.
<BR>
<BR>
<B>Jeff Offutt, Jie Pan, and Jeffrey M. Voas</B>, &quot;Procedures for Reducing
the Size of Coverage-based Test Sets.&quot; <I>Twelfth International Conference
on Testing Computer Software</I>, Washington, D.C., June 1995. <BR>
<BR>
<B>Jeff Offutt and Zhenyi Jin</B>, &quot;Integration Testing Based on Software
Couplings.&quot; <I>Tenth Annual Conference on Computer Assurance</I> (COMPASS
95), Gaithersburg, Maryland, June 1995. <BR>
<BR>
<B>Jeff Offutt</B>, &quot;A Practical System for Mutation Testing: Help
for the Common Programmer.&quot; <I>25th Annual International Test Conference</I>
(ITC 94), Washington, D.C., October 1994. <BR>
<BR>
<B>Pierangela Samarati, Paul Ammann, and Sushil Jajodia</B>, &quot;Propagation
of Authorizations in Distributed Database Systems.&quot; <I>Proc. 2nd ACM
Conf. on Computer and Communications Security</I>, Fairfax, VA, November
1994, pages 136-147. <BR>
<BR>
<B>Bo Sanden</B>, &quot;A Restrictive Definition of Concurrency for Discrete-event
Modeling.&quot; <I>Dagstuhl Semina</I>r, Germany, February 1995. <BR>
<BR>
<B>Bo Sanden</B>, &quot;Design of concurrent software.&quot; <I>Software
Technology Conference</I>, Salt Lake City, UT, April 1995. <BR>
<BR>
<B>Bo Sanden</B>, &quot;Entity-life modeling.&quot; <I>Workshop on parallel
and distributed real-time systems</I>, Santa Barbara, CA, April 1995. <BR>
<BR>
<B>Ravi Sandhu, E.J. Coyne, H.L. Feinstein, and C.E. Youman</B>, &quot;Role-Based
Access Control: A Multi-Dimensional View.&quot; <I>Proc. Tenth Annual Computer
Security Applications Conference</I>, Orlando, Florida, December 5-9, 1994,
pages 54-62. <BR>
<BR>
<B>Ravi Sandhu and Hal Feinstein</B>, &quot;A Three Tier Architecture for
Role-Based Access Control.&quot; <I>Proc. 17th NIST-NCSC National Computer
Security Conference</I>, Baltimore, MD, October 11-14, 1994, pages 34-46.
<BR>
<BR>
<B>Ravi Sandhu and Srinivas Ganta,</B> &quot;On the Expressive Power of
the Unary Transformation Model.&quot; <I>Proc. Third European Symposium
on Research in Computer Security</I>, Brighton, UK, November 7-9, 1994,
pages 301-318. Published as Lecture Notes in Computer Science, Vol 875,
Springer-Verlag. <BR>
<BR>
<B>Roshan Thomas and Ravi Sandhu</B>, &quot;Supporting Object-based High-assurance
Write-up in Multilevel Databases for the Replicated Architecture.&quot;
<I>Proc. Third European Symposium on Research in Computer Security</I>,
Brighton, UK, November 7-9, 1994, pages 403-428. Published as Lecture Notes
in Computer Science, Vol 875, Springer-Verlag. <BR>
<BR>
<I><A HREF="issue111095.html#anchor1245648">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-6</DOCNO>
<DOCOLDNO>IA053-000892-B032-231</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/journal-editorships.html 129.174.40.15 19970123190128 text/html 2120
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:00:19 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:23:03 GMT
Content-type: text/html
Content-length: 1937
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Journal Editorships </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Journal Editorships</CENTER>
</H2>
<HR><B>Chris Dede</B> is contributing editor of <I>Journal of Artificial
Intelligence in Education, Educational Technology</I>, and <I>Futures Research
Quarterly</I>. <BR>
<BR>
<B>Amihai Motro</B> is a Member of the Editorial Board of the <I>International
Journal of Intelligent Information Systems</I>. <BR>
<BR>
<B>Sushil Jajodia</B> is founding co-editor in chief of the <I>Journal of
Computer Security</I>, IOS Press, Amsterdam. <BR>
<BR>
He also serves as an Associate Editor, <I>International Journal of Intelligent
and Cooperative Information Systems</I>, World Scientific Publishing Co.,
Singapore, January, 1991 - present. <BR>
<BR>
Additionally, Dr. Jajodia is <I>Contributing Editor, Computer &amp; Communications
Security Reviews</I>, Northgate Consultants Ltd., UK, June 1994 - present.
<BR>
<BR>
<B>Larry Kerschberg</B> is Editor-in-Chief of the <A HREF="http://www.isse.gmu.edu/JIIS/">Journal
of Intelligent Information Systems</A>, which is dedicated to concepts,
tools and techniques to integrate Artificial Intelligence and Database Systems.
The journal is published by Kluwer Academic Publishers. Please visit the
JIIS Home Page at the URL:http://www.isse.gmu.edu/JIIS/ <BR>
<BR>
<B>Ravi Sandhu</B> is a Member of the Editorial Board of the Journal of
Computer Security, IOS Press, Amsterdam, January, 1991 - present. <BR>
<BR>
Along with Dr. Ravi Ganesan of Bell Atlantic, Dr. Sandhu was Guest co-editor
for a special issue of Communications of the ACM on Computer and Communications
Security, November 1994. <BR>
<BR>
Dr. Sandhu is also a member of the International Review Board for the <I>Internet
Security Monthly</I>, 1994 - present. <BR>
<BR>
<I><A HREF="issue111095.html#anchor1245648">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-7</DOCNO>
<DOCOLDNO>IA053-000892-B032-244</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/tutorials-and-short-cour.html 129.174.40.15 19970123190137 text/html 2304
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:00:28 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:23:00 GMT
Content-type: text/html
Content-length: 2121
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Tutorials and Short Courses </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Tutorials and Short Courses</CENTER>
</H2>
<HR><B>Hassan Gomaa </B>taught a several tutorials: <BR>
<BR>
&quot;Software Design Methods for Reusable Concurrent and Real-Time Systems,&quot;
at International Conference on Software Reuse, Rio de Janeiro, Brazil, November
1994. <BR>
<BR>
&quot;A Software Design Method for Ada-based Concurrent, Real-Time and Distributed
Applications&quot;, Presented at ACM TRI-Ada 94 Conference, Baltimore, MD,
November 1994. <BR>
<BR>
&quot;A Software Design Method for Concurrent and Real-Time Systems&quot;,
at the MITRE Corp (October 1994), LCC (January 1995), ACM Professional Development
seminar, College Park, MD (April 1995), and at International Conference
on Software Engineering, Seattle (April 1995). <BR>
<BR>
<B>Sushil Jajodia and Ravi Sandhu </B><BR>
<BR>
One day tutorial on &quot;Database Security,&quot; at the 10th Annual Computer
Security Applications Conference, Orlando, Florida, December 5-9, 1994.
<BR>
<BR>
Taught parts of several intensive week long courses through GMU's Center
for Professional Development's Information Security Institute. The courses
are titled: <BR>
<BR>
Information Security Principles and Practice,&#183; Recent Developments
in Information Security,&#183; Practical Security in a Networked Environment,
and&#183; Unix Security <BR>
<BR>
<B>Bo Sanden </B><BR>
<BR>
One-day tutorial on &quot;Design of Concurrent Software&quot; at ACM TRI-Ada
94 Conference, Baltimore, MD, November 1994. <BR>
<BR>
Short course on &quot;Object-oriented analysis and design&quot; at General
Research Corporation, January 1995. <BR>
<BR>
Tutorial on &quot;Design of concurrent software in Ada&quot; at WAdaS, McLean,
Virginia, June 1995. <BR>
<BR>
<B>Ravi Sandhu </B>taught a two-day seminar on &quot;Information and System
Security,&quot; in Canberra, Sydney, Singapore and Kuala Lumpur, during
May-June 1995. <BR>
<BR>
<I><A HREF="issue111095.html#anchor1245648">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-8</DOCNO>
<DOCOLDNO>IA053-000892-B032-262</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/conference-committees.html 129.174.40.15 19970123190146 text/html 4278
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:00:37 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:22:56 GMT
Content-type: text/html
Content-length: 4095
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Conference Committees </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Conference Committees</CENTER>
</H2>
<HR><B>Alex Brodsky </B>served on the Program Committee of Next Generation
Information Technologies and Systems, 1995, Israel. He also served on an
NSF panel, and as a referee for the SIGMOD, VLDB, and PPCP (Principles and
Practice of Constraint programming) conferences. <BR>
<BR>
<B>Chris Dede</B> was Local Chair of 7th International Conference on Artificial
Intelligence and Education (Washington, DC: August 15-19, 1995) hosted by
GMU. <BR>
<BR>
<B>Hassan Gomaa</B> served on the Program Committees for:&#183; IEEE International
Conference on Software Reuse, Rio de Janeiro, Brazil, November 1994.&#183;
ACM SIGSOFT Symposium on Software Reusability, Seattle, April 1995.&#183;
ACM Tri-Ada 95 Conference, Anaheim, November 1995. <BR>
<BR>
<B>Sushil Jajodia</B> is serving on the Program Committees of several conferences:
<BLOCKQUOTE>Third ACM Conference on Computer and Communications Security,
New Delhi, India, March 1996.<BR>
<BR>
Sixth International Conference on Information Systems and Management of
Data, Bombay, India, November 15-17, 1995.<BR>
<BR>
IEEE Symposium on Research in Security and Privacy, Oakland, CA, May, 1995.<BR>
<BR>
Twelvth IFIP Int'l. Information Security Conf., Samos, Greece, May 21-24,
1996.<BR>
<BR>
ACM SIGMOD Int'l. Conf. on Management of Data, San Jose, CA, May 1995.<BR>
<BR>
Fourth ACM Conf. on Information and Knowledge Management, Baltimore, MD,
November 8-11, 1995.<BR>
<BR>
Second Int'l. Conf. on Applications of Databases, Santa Clara, California,
December 13-15, 1995. </BLOCKQUOTE>
<BR>
<B>Larry Kerschberg</B> served on the Program Committees for: 
<BLOCKQUOTE>First International Conference on Knowledge Discovery and Data
Mining (KDD95), Montreal, Canada, August 20-21, 1995. <BR>
IFIP WG2.6 Working Conference on Database Semantics (DS-6), Atlanta, Georgia,
June 1995. </BLOCKQUOTE>
<BR>
<B>Ami Motro</B> was Program Committee Co-Chair for NGITS 95, Second Int'l.
Workshop on Next Generation Information Technologies and Systems, Naharia,
Israel, June 1995. <BR>
<BR>
<B>Ami Motro</B> was a Program Committee Member for VLDB 94, The 20th International
Conference on Very Large Data Bases, Santiago, Chile, September 1994. <BR>
<BR>
<B>Ami Motro </B>was a Panel Discussant, &quot;Query Answering Systems in
the Information Society - Challenges for Research and Industry,&quot; Workshop
on Flexible Query Answering Systems, Roskilde University, Denmark, November
1994. <BR>
<BR>
<B>Dr. Motro</B> served as an ACM Lecturer during 1994-1995. <BR>
<BR>
<B>Jeff Offutt </B>served on the program committee for the 1996 IEEE International
Symposium on Software Testing and Analysis. <BR>
<BR>
<B>Bo Sanden</B> served on the Program Committee of International Symposium
on Applied Corporate Computing, Monterrey, Mexico 1994 and 1995. He was
also an invited member of the Academic Panel, Ada Dual-Use Workshop, February
1995. <BR>
<BR>
<B>Ravi Sandhu</B> is General co-chairman for ACM Conference on Computer
and Communications Security, New Delhi, India (1996). <BR>
<BR>
<B>Ravi Sandhu </B>is Program Co-Chair of IFIP WG 11.3 Working Conference
on Database Security, Como, Italy, with Pierangela Samarati of the University
of Milan. <BR>
<BR>
<B>Ravi Sandhu </B>was program co-chair for: 
<BLOCKQUOTE>ACM Conference on Computer and Communications Security, Fairfax,
Virginia, 1994, with Ravi Ganesan of Bell Atlantic. <BR>
OOPSLA-94 Conference Workshop on Security for Object-Oriented Systems (1994),
program co-chair with William Herndon of MITRE, and Steve Demurjian of University
of Connecticut. </BLOCKQUOTE>
<BR>
<B>Ravi Sandhu</B> is Student Awards Chair for the Annual Computer Security
Applications Conference, Scholarship Chair for the New Security Paradigms
Workshop, and Steering Committee Member for the IEEE Computer Security Foundations
Workshop. <BR>
<BR>
<BR>
<I><A HREF="issue111095.html#anchor1245648">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-9</DOCNO>
<DOCOLDNO>IA053-000892-B032-281</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/invited-lectures.html 129.174.40.15 19970123190153 text/html 3207
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:00:45 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:22:52 GMT
Content-type: text/html
Content-length: 3024
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Invited Lectures </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Invited Lectures</CENTER>
</H2>
<HR><B>Hassan Gomaa</B> was the invited speaker at the CASE Japan 94 Conference
on &quot;Object-Oriented Methods for Concurrent and Real-Time Systems,&quot;
in Tokyo, Japan in July 1994. At ASTEM/Kyoto University in Kyoto, he gave
a lecture on &quot;Domain Modeling for Software Reuse.&quot; <BR>
<BR>
In May 1995, he gave a talk entitled &quot;Software Architectures for Factory
Automation Systems&quot; at Siemens Corporate Research in Princeton, New
Jersey. <BR>
<BR>
Continuing with his travels in June, Dr. Gomaa was invited to speak at Bell-Northern
Research in Ottawa, Canada. &quot;A Software Design Method for Concurrent
and Real-Time Systems,&quot; was the subject of his talk. <BR>
<B><BR>
Sushil Jajodia</B> gave a Colloquium talk entitled &quot;Transaction Processing
in Multilevel Secure Databases,&quot; at Pennsylvania State University on
April 13, 1995. <BR>
<BR>
<B>Larry Kerschberg</B> visited the Center for Data-Intensive Systems at
the Oregon Graduate Institute of Science and Technology in Beaverton, to
deliver a talk on &quot;The Engineering of Large-Scale Data-Intensive Information
Systems,&quot; as part of the Center's Distinguished Speaker Series, on
March 10, 1995. Earlier that same day, at the Sequent Computer Corporation,
he presented a talk on the ARPA Program on the Intelligent Integration of
Information (I3), the ARPA I3 Reference Architecture, and the GMU I3 research
activities. <BR>
<BR>
On April 21, 1995, Dr. Kerschberg gave a lecture at the National Institute
of Standards and Technology (NIST), on the topic &quot;The Engineering of
Large-Scale Data-Intensive Information Systems,&quot; as part of the Center
for Applied Information Technology Lecture Series. <BR>
<BR>
Larry Kerschberg participated in a panel discussion on &quot;Inference Problems
in Secure Databases,&quot; at the 17th National Computer Security Conference,
October 11-14, 1994 at Baltimore, MD. <BR>
<BR>
In November, 1994, <B>Ami Motro</B> served as the keynote lecturer at the
Workshop on Flexible Query Answering Systems held at Roskilde University
in Denmark. &quot;Cooperative User Interfaces to Databases&quot; was the
title of his lecture. <BR>
<BR>
In April 1995, Dr. Motro gave a talk entitled &quot;Integrating Autonomous,
Heterogeneous and Inconsistent Databases.&quot; at the Department of Computer
and Information Science, at Temple University in Philadelphia, Pennsylvania.
<BR>
<BR>
<B>Ravi Sandhu</B> gave talks at the: 
<UL>
  <LI>Information Systems Audit and Control Association, National Capital
Area Chapter Monthly Meeting held in Washington, DC in April 1995. 
  <LI>Department of Computer Science Seminar Series at Old Dominion University
in Norfolk, Virginia, and 
  <LI>ACM Washington D.C. Chapter, March 1995. 
</UL>
<A HREF="issue111095.html#anchor1245648"><I>Return to table of contents.</I></A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-10</DOCNO>
<DOCOLDNO>IA053-000892-B032-302</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/research-grants.html 129.174.40.15 19970123190205 text/html 3830
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:00:57 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:22:48 GMT
Content-type: text/html
Content-length: 3647
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Research Grants </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Research Grants</CENTER>
</H2>
<HR><B>Paul Ammann</B> and <B>Ravi Sandhu </B>are joint Principal Investigators
on a NSF grant for research on &quot;Derivation, Modeling, and Analysis
of Access Control Systems,&quot; 1992-95. <BR>
<BR>
<B>Alex Brodsky</B> is co-PI on a grant from the Office of Naval Research
on &quot;Linear Constraint Programming,&quot; with Paris Kanellakis of Brown
University as PI, and Pascal Van-Hentenryck (Brown U.) and Jean-Louis Lassez
(IBM T.J. Watson) as co-PIs. <BR>
<BR>
<B>Chris Dede</B> is co-PI on a grant from the Bell Atlantic Foundation
to create a Distance Education Training Network, with Lynn Fontana as PI
and additional co, John O'Connor and Randy Gabel. <BR>
<BR>
<B>Dr. Dede</B> is also co-PI on two NSF grants for research: one on &quot;Educating
Engineers to Design Complex Systems&quot; with Peter Denning (GMU) and several
other co-PIs; the second with B. Loftin (University of Houston) on &quot;Assessing
the Potential of Virtual Realities in Science Education.&quot; <BR>
<BR>
<B>Hassan Gomaa</B> is Principal Investigator on a Siemens Corporate Research
grant for research on &quot;Scenario-based Analysis and Design&quot; 1994-95.
<BR>
<BR>
<B>Sushil Jajodia </B>is Principal Investigator on an NSF grant for research
on &quot;Mandatory and Discretionary Access Controls in Object-Oriented
Database Management Systems,&quot; 1993-96. He also serves as the Principal
Investigator on a NSA grant for research on &quot;Flexible Access Controls
in Database Management Systems,&quot; 1994-96. <BR>
<BR>
<B>Larry Kerschberg</B> is PI, with Co-PI's <B>Hassan Gomaa</B>, <B>Sushil
Jajodia</B> and <B>Amihai Motro</B>, on a ARPA sponsored grant for research
on &quot;Information Integration and Interchange: A Federated Systems Approach,&quot;
1992-95. <BR>
<BR>
<B>Larry Kerschberg</B> and <B>Hassan Gomaa</B> are PI and Co-PI on a grant
from the Software Productivity Consortium, the Virginia Center of Excellence
for Software Reuse and Technology Transfer (VCOE) and the Virginia Center
for Innovative Technology (CIT) to research and develop configurable and
reusable process models for software development, 1994-1995. <BR>
<BR>
<B>Jeff Offutt</B> is Principal Investigator on a grant from NSF for research
on &quot;A Comparative Evaluation of Data Flow and Mutation Testing,&quot;
1993-96. <BR>
<BR>
<B>Ravi Sandhu</B> is Principal Investigator on an NSF funded grant for
research on &quot;Role-Based Access Control: Models, Mechanisms and Tools,&quot;
1995-98. <BR>
<BR>
<B>Dr. Sandhu</B> is also the Principal Investigator on four NSA funded
grants for research: &quot;A Pragmatic Approach to the Design and Analysis
of Composite Secure Systems,&quot; 1994-96, &quot;Design of Multilevel Secure
Relational Databases,&quot; 1994-96, &quot;Architectures for Type-Based
Distributed Access Control,&quot; 1993-96 and on an NSA funded grant for
support towards the New Security Paradigms Workshop IV, 1993-96. <BR>
<BR>
<B>X. Sean Wang</B> is Principal Investigator on an NSF funded grant for
research on &quot;Towards Expressive and Efficient Queries on Sequenced
Data,&quot; 1994-97. Additionally Dr. Wang is Principal Investigator on
an NSF funded grant for research on &quot;Structural Queries on Nucleic
Acid Databases,&quot; 1994-96, with co-PIs Seymour Ginsburg of University
of Southern California and Michael Gribskov of San Diego Supercomputer Center.
<BR>
<BR>
<I><A HREF="issue111095.html#anchor1245648">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-11</DOCNO>
<DOCOLDNO>IA053-000892-B032-314</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/faculty-and-alumni-news.html 129.174.40.15 19970123190212 text/html 1588
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:01:03 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:22:44 GMT
Content-type: text/html
Content-length: 1405
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Faculty and Alumni News </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Faculty and Alumni News</CENTER>
</H2>
<HR><B>Dr. Paul Ammann</B> has been promoted to Associate Professor and
was awarded tenure. <BR>
<BR>
<B>Dr. Ravi Sandhu</B> has been promoted to Full Professor. <BR>
<BR>
We congratulate our colleagues on their well-deserved promotions! <BR>
<BR>
<B>Roshan Thomas</B>, who completed his Ph.D. under the direction of Prof.
Ravi Sandhu in Summer 1994, is with Odyssey Research Associates in Ithaca,
NY. Roshan was recently awarded a grant from ARPA for research on &quot;Task-Based
Authorizations: A New Paradigm for Access Control.&quot; Congratulations
to Roshan on winning this prestigious award. Roshan was recently married,
so he is making good progress on all aspects! <BR>
<BR>
<B>Jong Pil Yoon</B>, who worked with Dr. Kerschberg on his doctoral studies,
has recently joined the Sookmyung Woman's University in Seoul, South Korea
as an Assistant Professor; he has just received a grant for research on
&quot;Data Transmission Reduction in Multimedia Client/Server Environments,&quot;
from the Korean Department of Information and Communications. Our congratulation
to Jong Pil as he begins his research program. <BR>
<BR>
<I><A HREF="issue111095.html#anchor1245648">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-12</DOCNO>
<DOCOLDNO>IA053-000892-B032-338</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/new-courses-for-1994-199.html 129.174.40.15 19970123190222 text/html 1849
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:01:11 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:22:41 GMT
Content-type: text/html
Content-length: 1666
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>New Courses for 1994-1995 </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>New Courses for 1994-1995</CENTER>
</H2>
<HR>INFS 760, &quot;Advanced Database Management&quot; was offered by <B>Dr.
Amihai Motro</B> for the first time in Spring 1995. This course is open
to students who have taken an introductory database management course (e.g.,
INFS614). <BR>
<BR>
INFT 823, &quot;Software For Critical Systems,&quot; was offered by <B>Dr.
Paul Ammann</B> for the first time in Spring 1995. <BR>
<BR>
INFT 865, &quot;Network and Distributed Systems Security,&quot; was offered
by <B>Dr. Ravi Sandhu</B> for the first time in Fall 1994. 
<H2><CENTER>New Courses in 1995-96 </CENTER>
</H2>
<HR>SWSE 720, &quot;Advanced Software Requirements,&quot; is offered by
<B>Dr. Bo Sanden</B> in Fall 1995. This course provides a comparative study
of object-oriented analysis methods. <BR>
<BR>
INFS 770, &quot;<A HREF="../../INFS770_WWW_folder/Index770.html">Methods
for Information Systems Engineering</A>,&quot; will be offered by <B>Dr.
Larry Kerschberg</B> in Spring 1996. This course is part of the MSIS program
and is also open to doctoral students. <BR>
<BR>
INFT 821, &quot;Analysis of Software for Testing,&quot; is offered by <B>Dr.
Jeff Offut</B>t in Fall 1995. This course is part of the Special Topics
in Software Engineering Series. <BR>
<BR>
INFT 803, &quot;Multidatabase Systems,&quot; is offered by <B>Dr. Ami Motro</B>
in Spring 1996. This course is part of the Doctoral Tutorial Series. <BR>
<BR>
<I><A HREF="issue111095.html#anchor1245648">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-13</DOCNO>
<DOCOLDNO>IA053-000892-B032-360</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/the-italian-connection-a.html 129.174.40.15 19970123190247 text/html 4546
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:01:34 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:22:37 GMT
Content-type: text/html
Content-length: 4363
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>The Italian Connection at GMU </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>The Italian Connection at GMU</CENTER>
</H2>
<HR>The Italian Connection at GMU started in the summer of 1991, with the
arrival of the two explorers, <B>Elisa Bertino</B> and <B>Pierangela Samarati</B>,
to GMU on a very special mission - that of establishing a strong connection
between Italy and the USA! Their mission was so successful that they made
it a point to be present during the subsequent summers, and in 1994 they
brought along with them the rest of the army - <B>Claudio Bettini</B> and
<B>Luigi Mancini</B>. <BR>
<BR>
During this period, the Italian team has been involved mostly with <B>Professor
Jajodia</B> and other affiliates of the Center for Secure Information Systems.
The research work has focused on several topics related to database security,
including transaction management in multilevel systems, extended authorization
models, and to temporal databases. Their stay has been very productive with
the publication of a number of papers in various conferences as well as
journals. <BR>
<BR>
In order to cement this relationship, Professor Jajodia spent a <B><I>glorious</I></B>
(his words!) month this May at the University of Milan. He also had an opportunity
to visit the University of Genova. Brief biosketches of the visitors are
given below. <BR>
<BR>
<HR><I><STRONG>Elisa Bertino</STRONG></I> is professor of computer science
in the Dipartimento di Scienze dell'Informazione of the University of Milan
where she heads the Database Systems Group. <BR>
<BR>
She has also been a professor in the Dipartimento di Informatica e Scienze
dell'Informazione of the University of Genoa, Italy. Until 1990, she was
a researcher for the Italian National Research Council in Pisa, Italy, where
she headed the Object-Oriented Systems Group. She has been a visiting researcher
at the IBM Almaden Research Laboratory in San Jose, and at the MCC in Austin,
Texas. Her main research interests include database security, object-oriented
databases, distributed databases, deductive databases, multimedia databases,
interoperability of heterogeneous systems. She is a co-author of the book
<I>Object-Oriented Database Systems - Concepts and Architectures</I> , (Addison-Wesley,
1993). She is on the editorial board of the: <I>IEEE Transactions on Knowledge
and Data Engineerin</I>g, <I>International Journal of Theory and Practice
of Object Systems</I>, <I>Journal of Computer Security</I>, <I>Data and
Knowledge Engineering Journal</I>, and <I>Journal of Parallel and Distributed
Databases</I>. <BR>
<BR>
<HR><B><I>Claudio Bettini</I></B> received the Laurea degree in Computer
Sciences in 1987 and a PhD in Computer Science in 1993 from the University
of Milano. He has been an Assistant Professor at Dipartimento di Scienze
dell'Informazione, University of Milan, since 1993. His main research interest
is temporal reasoning in knowledge and data bases. <BR>
<BR>
<HR><B><I>Luigi Mancini </I></B>received the Laurea degree in Computer Science
from the University of Pisa, Italy, in 1983, and the Ph.D. degree in Computer
Science from the University of Newcastle upon Tyne, Great Britain, in 1989.
From 1989 to 1992, he was an Assistant Professor at the Dipartimento di
Informatica of the University of Pisa. Since 1992 he has been an Associate
Professor of the Dipartimento di Informatica Scienze dell'Informazione of
the University of Genoa. His research interests include database and operating
system architecture. <BR>
<BR>
<HR><B><I>Pierangela Samarati</I></B> received the Laurea degree in Computer
Science from University of Milan in 1988. Since 1990, she has been an assistant
professor at the Dipartimento di Scienze dell'Informazione, University of
Milan. Her main research interests are information systems security, database
security, authorization models, and databases. She has been a visiting researcher
at Stanford University, and at George Mason University. She is currently
serving as the Italian representative in the IFIP Technical Committee 11
on Security and Protection in Information Processing Systems. She has co-authored
the book Database Security (Addison-Wesley, 1994). <BR>
<BR>
<I><A HREF="issue111095.html#anchor1245648">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-14</DOCNO>
<DOCOLDNO>IA053-000892-B033-22</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/isse-visitors.html 129.174.40.15 19970123190312 text/html 1240
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:01:57 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:22:32 GMT
Content-type: text/html
Content-length: 1057
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>ISSE Visitors </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>ISSE Visitors</CENTER>
</H2>
<HR>ISSE has had a number of visiting scholars during the past year. We
want to acknowledge their contributions to the intellectual and research
environment of our department. Below we present their names and affiliations.
Please click here <A HREF="the-italian-connection-a.html">Italian Connection</A>
for more information.<BR>
<BR>
During the Summer of 1994 Professor <B>Alessandro D'Atri</B>, Dipartimento
di Ingegneria Elletrica, Universita dell'Aquila, Italy, visited Dr. Motro.
<BR>
<BR>
Visitors to the <B><I>Center for Secure Information Systems</I></B>: 
<BLOCKQUOTE>Professor Elisa Bertino, Dr. Pierangela Samarati, Dr. Claudio
Bettini, all of University of Milan. <BR>
Professor Luigi Mancini, University of Genova. <BR>
Professor V. S. Subrahmanian, University of Maryland. </BLOCKQUOTE>
<A HREF="issue111095.html#anchor1245648"><I>Return to table of contents.</I></A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-15</DOCNO>
<DOCOLDNO>IA053-000892-B033-44</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/other-news.html 129.174.40.15 19970123190350 text/html 1025
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:02:25 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:22:29 GMT
Content-type: text/html
Content-length: 843
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Other News </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Other News</CENTER>
</H2>
<HR><B>Chris Dede</B> completed a commissioned policy paper on &quot;Implications
for Distance Education of the National Information Infrastructure&quot;
for the U.S. Department of Education. Dr. Dede also serves on the staff
of the U.S. Advisory Council on the National Information Infrastructure,
helping with education policy. <BR>
<BR>
Since January 1995, <B>Sushil Jajodia</B> is a member of IEEE Computer Society
Awards Committee. <BR>
<B>Jeff Offutt</B> was awarded a SITE Graduate Research Assistantship for
research on &quot;Software Testing Based on Module Coupling.&quot; <BR>
<BR>
<I><A HREF="issue111095.html#anchor1245648">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-16</DOCNO>
<DOCOLDNO>IA053-000892-B033-69</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/Faculty-Photo.html 129.174.40.15 19970123190400 text/html 1709
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:02:51 GMT
Server: NCSA/1.5.2
Last-modified: Fri, 23 Feb 1996 00:39:07 GMT
Content-type: text/html
Content-length: 1526
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Faculty and Staff Photo</TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H1><CENTER>The ISSE Faculty and Staff Photo<HR><IMG SRC="../images_folder/funpict.jpg"
WIDTH="451" HEIGHT="363" NATURALSIZEFLAG="0" ALIGN="BOTTOM"><HR></CENTER>
</H1>
<P><CENTER><B>First Row:</B> <A HREF="mailto:rgossner@isse.gmu.edu">Ms.
Robbie Gossner</A> (Research Administrator), and <A HREF="mailto:smayo@isse.gmu.edu">Ms.
Sandy Mayo</A> (Deprtmental Secretary)<BR>
<B>Second Row: </B><A HREF="http://www.isse.gmu.edu/faculty/ofut/">Dr. Jeff
Offutt</A>, <A HREF="http://www.isse.gmu.edu/~csis/faculty/jajodia.html">Dr.
Sushil Jojodia</A>, Dr. Hassan Gomaa, <A HREF="http://www.isse.gmu.edu/~brodsky/brodskya.html">Dr.
Alex Brodsky</A>, <BR>
<A HREF="http://www.isse.gmu.edu/faculty/xywang/">Dr. X. &quot;Sean&quot;
Wang</A>, <A HREF="http://www.isse.gmu.edu/faculty/pammann/">Dr. Paul Ammann</A>,
and Dr. Richard Baum<BR>
<B>Third Row: </B><A HREF="http://www.isse.gmu.edu/faculty/kersch/">Dr.
Larry Kerschberg</A>, <A HREF="http://www.isse.gmu.edu/faculty/sandhu/index.html">Dr.
Ravi Sandhu</A>, <A HREF="http://www.isse.gmu.edu/~ami/">Dr. Ami Motro</A>,
and <A HREF="http://www.isse.gmu.edu:80/faculty/bsanden/">Dr. Bo Sanden</A></CENTER>
<P>The backdrop is the University Learning Center building which was under
construction at the time this photo was taken. It has now opened.<BR>
<BR>
<I><A HREF="issue111095.html#anchor1245648">Return to table of contents.</A></I>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-17</DOCNO>
<DOCOLDNO>IA053-000892-B033-86</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/doctoral-dissertations.html 129.174.40.15 19970123190408 text/html 1880
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:02:59 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:22:25 GMT
Content-type: text/html
Content-length: 1697
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Doctoral Dissertations and Masters Theses</TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Doctoral Dissertations</CENTER>
</H2>
<H2><HR><I>Dr. Sushil Jajodia</I>, Director </H2>
<B>Mohammad Abusalim</B>, &quot;A Policy for Secure Information Systems
as Applied to Saudi Arabia.&quot; Summer 1994, Currently with Saudi Government.
<BR>
<BR>
<B>Vijayalakshmi Atluri</B>, &quot;Concurrency Control in Multilevel Secure
Databases, Summer 1994, Presently Assistant Professor, Department of MS/CIS,
Rutgers University, Newark. <BR>
<BR>
<B>Michael Martin</B>, &quot;Improving Security in Multilevel Database Management
and Systems Through the Use of Query Modification.&quot; Fall 1994, Currently
with Defense Information Systems Agency. 
<H2><HR><I>Dr. Larry Kerschberg</I>, Director </H2>
<B>Len Seligman</B>, &quot;A Mediated Approach to Consistency Management
Among Distributed, Heterogeneous Information Systems,&quot; Fall 1994, presently
with the MITRE Corporation, McLean, Virginia. 
<H2><HR><I>Dr. Bo Sanden</I>, Director </H2>
<B>Anhtuan Q. Dinh</B>, &quot;A Development Method for Real-time Software
in a Parallel Environment.&quot; Fall 1994, Currently with Stanford Telecommunications
Inc., Reston. 
<H2><CENTER>Master's Theses </CENTER>
</H2>
<H2><HR><I>Dr. Jeff Offutt</I>, Director </H2>
<BR>
<B>Alisa Irvine</B>, &quot;The Effectiveness of Category-Partition Testing
of Object-Oriented Programs.&quot; Fall 1994. <BR>
<BR>
<B>Jie Pan</B>, &quot;Using Constraints to Detect Equivalent Mutants.&quot;
Summer 1994. <BR>
<BR>
<I><A HREF="issue111095.html#anchor1283805">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-18</DOCNO>
<DOCOLDNO>IA053-000892-B033-111</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/student-news.html 129.174.40.15 19970123190422 text/html 1405
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:03:11 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:45:46 GMT
Content-type: text/html
Content-length: 1222
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Student News </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Student News</CENTER>
</H2>
<HR><B>Jack Foster and Hai Le</B> passed their doctoral comprehensive examinations.
<BR>
<BR>
<B>Zhenyi Jin</B>, PhD student and Graduate Research Assistant for Dr. Jeff
Offutt, received an Outstanding Graduate Academic Award in 1994 for her
MS in Computer Science. <BR>
<BR>
<B><I>Honor Students </I></B><BR>
<BR>
The department was pleased to award twelve students with an &quot;Outstanding
Achievement Award&quot; in May. These students maintained a grade point
average of 4.0 throughout their academic curriculum and are to be congratulated
for their efforts: <BR>
<BR>
<B>M.S. in Information Systems</B>: 
<UL>
  <LI>Celeste Fort 
  <LI>Kim E. Foss 
  <LI>Penny C. Heatherington 
  <LI>Elizabeth H. Little 
  <LI>Ann M. Vari 
  <LI>Edward A. Vetock 
  <LI>Steven T. Wolter 
</UL>
<BR>
<B>M.S. in Software Systems Engineering</B>: 
<UL>
  <LI>Mohammad Al-Kahtani 
  <LI>Brenda Jacobs 
  <LI>Julia Rios-Geng 
  <LI>Edward H. Preston 
  <LI>Angela Smith 
</UL>
<BR>
<I><A HREF="issue111095.html#anchor1283805">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-19</DOCNO>
<DOCOLDNO>IA053-000892-B033-129</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/isse-seminars.html 129.174.40.15 19970123190437 text/html 1595
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:03:25 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:45:41 GMT
Content-type: text/html
Content-length: 1412
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>ISSE Seminars </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>ISSE Seminars</CENTER>
</H2>
<BR>
<HR>The department sponsors a seminar series where faculty, visitors, and
students present their research. To be placed on our electronic mailing
list for future seminars, please send e-mail to Dr. Wang at <A HREF="mailto:xywang@gmu.edu">xywang@gmu.edu</A>.
<BR>
<BR>
Dr. Yoram Kornatzky, Computer Systems Research Institute, University of
Toronto, &quot;A Probabilistic Object-Oriented Data Model.&quot; August
25, 1994. <BR>
<BR>
Mr. Yair Amir, The Transis project, Institute of Computer Science, The Hebrew
University of Jerusalem, &quot;Robust and Efficient Replication using Group
Communication.&quot; September 14, 1994. <BR>
<BR>
Professor Avigdor Gal, Technion - Israel Institute of Technology, &quot;A
Temporal Active Database.&quot; September 28, 1994. <BR>
<BR>
Prof. Manny Lehman, Department of Computing, Imperial College of Science,
Technology and Medicine, London, England, &quot;Feedback, Evolution And
Software Technology.&quot; October 4, 1994. <BR>
<BR>
Dr. Alon Levy, AI Principles Research Department, AT&amp;T Bell Laboratories,
&quot;Global Information Systems: Data Models and Query Evaluation.&quot;
April 25, 1995. <BR>
<BR>
<I><A HREF="issue111095.html#anchor1293401">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-20</DOCNO>
<DOCOLDNO>IA053-000892-B033-152</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/isse-technical-reports.html 129.174.40.15 19970123190445 text/html 4474
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:03:37 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:22:22 GMT
Content-type: text/html
Content-length: 4291
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>ISSE Technical Reports </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>ISSE Technical Reports</CENTER>
</H2>
<BR>
<HR>Listed below are Technical Reports which may be ordered from the Department
of Information and Software Systems Engineering. To obtain a copy, please
contact Sandy Mayo at (703) 993-1640 or by e-mail at <A HREF="mailto:smayo@isse.gmu.edu">smayo@isse.gmu.edu</A>.
<BR>
<BR>
Many reports are also available via anonymous ftp on the ISSE server with
the URL:<A HREF="ftp://isse.gmu.edu//pub/techrep/">ftp://isse.gmu.edu//pub/techrep/<BR>
<BR>
</A>The appropriate compressed Postscript files should be transferred as
&quot;binary&quot; files. <BR>
<BR>
&quot;Experiments with Data Flow and Mutation Testing,&quot; Jeff Offutt,
Jie Pan, Kanupriya Tewary, and Tong Zhang, June 1994, <A HREF="ftp://isse.gmu.edu//pub/techrep/94_105_offutt.ps.gz">ISSE-TR-94-105</A>.
<BR>
<BR>
&quot;A Safety Kernel for Traffic Light Control,&quot; Paul Ammann, July
1994, <A HREF="ftp://isse.gmu.edu//pub/techrep/94_106_ammann.hc">ISSE-TR-94-106</A>.
<BR>
<BR>
&quot;Algebraic Query Languages on Temporal Databases with Multiple Time
Granularities,&quot; X. Sean Wang, July 1994, <A HREF="ftp://isse.gmu.edu//pub/techrep/94_107_wang.ps.gz">ISSE-TR-94-107</A>.
Revised April 1995. <BR>
<BR>
&quot;An Application of Entity Life Modeling to Incremental Re-engineering
of Fortran Reactive Program Components,&quot; F. G. Patterson Jr. and Jean-Jacques
Moortgat, August 1994, <A HREF="ftp://isse.gmu.edu//pub/techrep/94_108_patterson.ps.gz">ISSE-TR-94-108</A>.
<BR>
<BR>
&quot;Using Constraints to Detect Equivalent Mutants,&quot; Jeff Offutt
and Jie Pan, August 1994, <A HREF="ftp://isse.gmu.edu//pub/techrep/94_109_offutt.ps.gz">ISSE-TR-94-109</A>.
<BR>
<BR>
&quot;The Dynamic-domain Reduction Approach to Test Data Generation: Design
and Algorithms,&quot; Jeff Offutt, Zhenyi Jin, and Jie Pan, September 1994,
<A HREF="ftp://isse.gmu.edu//pub/techrep/94_110_offutt.ps.gz">ISSE-TR-94-110</A>.
<BR>
<BR>
&quot;Logic Design for Temporal Database with Multiple Temporal Types,&quot;
X. Sean Wang, Claudio Bettini, Alexander Brodsky, and Sushil Jajodia, September
1994, <A HREF="ftp://isse.gmu.edu//pub/techrep/94_111_wang.ps.gz">ISSE-TR-94-111</A>.
<BR>
<BR>
&quot;The LyriC Language: Querying Constraint Objects,&quot; Alexander Brodsky
and Yoram Kornatzky, October 1994, <A HREF="ftp://isse.gmu.edu//pub/techrep/94_112_brodsky.ps.gz">ISSE-TR-94-112</A>.
<BR>
<BR>
&quot;Semantic Update Optimization in Active Databases,&quot; Jong Pil Yoon
and Larry Kerschberg, October 1994, <A HREF="ftp://isse.gmu.edu//pub/techrep/94_113_yoon.ps.gz">ISSE-TR-94-113</A>.
<BR>
<BR>
&quot;A Restrictive Definition of Concurrency for Discrete-event Modeling,&quot;
Bo Sanden, November 1994, <A HREF="ftp://isse.gmu.edu//pub/techrep/94_113_sanden.ps.gz">ISSE-TR-94-114</A>.
<BR>
<BR>
&quot;Integration Testing Based on Software Couplings,&quot; Zhenyi Jin
and Jeff Offutt, January 1995, <A HREF="ftp://isse.gmu.edu//pub/techrep/95_100_offutt.ps.gz">ISSE-TR-95-100</A>.
<BR>
<BR>
&quot;Multilevel Relational (MLR) Data Model,&quot; Fang Chen and Ravi S.
Sandhu, February 1995, <A HREF="ftp://isse.gmu.edu//pub/techrep/95_101_sandhu.ps.gz">ISSE-TR-95-101</A>.
<BR>
<BR>
&quot;The Effectiveness of Category-Partition Testing of Object-Oriented
Software,&quot; Alisa Irvine and Jeff Offutt, March 1995, <A HREF="ftp://isse.gmu.edu//pub/techrep/95_102_offutt.ps.gz">ISSE-TR-95-102</A>.
<BR>
<BR>
&quot;Multiplex: A Formal Model for Multidatabases and Its Implementation,&quot;
Amihai Motro, March 1995, <A HREF="ftp://isse.gmu.edu//pub/techrep/95_103_motro.ps.gz">ISSE-TR-95-103</A>.
<BR>
<BR>
&quot;The Problem of Optimal Approximations of Queries Using Views and Its
Applications,&quot; Alexander Brodsky and Amihai Motro, May 1995, <A HREF="ftp://isse.gmu.edu//pub/techrep/95_104_motro.ps.gz">ISSE-TR-95-104</A>.
<BR>
<BR>
&quot;Temporal Semantic Assumptions and Their Use in Database Query Evaluation,&quot;
Claudio Bettini, Sean Wang and Sushil Jajodia, June 1995, <A HREF="ftp://isse.gmu.edu//pub/techrep/95_105_wang.ps.gz">ISSE-TR-95-105</A>.
<BR>
<BR>
<I><A HREF="issue111095.html#anchor1293401">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-21</DOCNO>
<DOCOLDNO>IA053-000892-B033-169</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/cisie.html 129.174.40.15 19970123190457 text/html 2320
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:03:48 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 14:06:44 GMT
Content-type: text/html
Content-length: 2137
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Center for Information Systems Integration and Evolution</TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Center for Information Systems <BR>
Integration and Evolution</CENTER>
</H2>
<BR>
<HR>CISIE is pleased to announce its first two Industrial Partners, the
Northrop-Grumman Corporation and Interactive Development Environments. <BR>
<BR>
On February 22, 1995, Dr. Ken Nidiffer of Northrop-Grumman, presented a
$25,000 check to Dr. Andrew P. Sage, Dean of the School of Information Technology
and Engineering. Northrop-Grumman Corporation became the first CISIE Industrial
Partner, sponsoring research in the general areas of domain engineering,
software process models, and software design methods.<BR>
<P><CENTER><IMG SRC="../images_folder/Image2.GIF" WIDTH="320" HEIGHT="240"
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><BR>
<B><I><KBD>Dr. Ken Nidiffer presents Dean Andrew P. Sage with a $25,000
check <BR>
as Northrop-Grumman becomes a CISIE Industrial Partner<BR>
</KBD></I></B><IMG SRC="../images_folder/Image4.GIF" WIDTH="320" HEIGHT=
"240" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><BR>
<B><I><KBD>Provost Rossini, Dr. Nidiffer, Dean Sage, Dr. Kerschberg, CISIE
Director and Dr. Gomaa, Associate Director, on the occasion of Northrop-Grumman
Corporation becoming a CISIE Industrial Partner.</KBD></I></B></CENTER>
<P>We would also like to welcome <B><I>Interactive Development Environments</I></B>
as an Industrial Partner. <BR>
<B><I>Dr. Tony Wasserman</I></B>, CEO of IDE, donated the most recent version
of the Software through Pictures CASE tool to CISIE. <BR>
<BR>
We are using it in the development of the Knowledge-based Software Engineering
Environment (KBSEE) and our object-oriented domain modeling work.<BR>
<BR>
To Download the <B><I>CISIE Prospectus</I></B> click for <A HREF="ftp://isse.gmu.edu//pub/incoming/CISIE_folder/CISIE.pdf">Portable
Document Format(PDF)</A> or <A HREF="ftp://isse.gmu.edu//pub/incoming/CISIE_folder/CISIE.ps">Postscript</A>.<BR>
<BR>
<I><A HREF="issue111095.html#anchor1298130">Return to table of contents.</A></I>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-22</DOCNO>
<DOCOLDNO>IA053-000892-B033-196</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/kersch/newsletter95/Newsletter.html_folder/laboratory-for-informati.html 129.174.40.15 19970123190510 text/html 2393
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:03:58 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Feb 1996 13:22:14 GMT
Content-type: text/html
Content-length: 2210
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Laboratory for Information Security Technology </TITLE>
</HEAD>
<BODY BACKGROUND="../images_folder/soft-periwinkle_copy.jpg">
<H2><CENTER>Laboratory for Information Security Technology</CENTER>
</H2>
<BR>
<HR><B>Dr. Ravi Sandhu</B> has established a new <B><I>Laboratory for Information
Security Technology</I></B> (LIST), and serves as its Director. Mr. Soonam
Kahng is currently the laboratory administrator. <BR>
<BR>
LIST's mission is to provide dedicated computing and networking facilities
for experimental research in information security (INFOSEC). Experimental
INFOSEC research requires modification and enhancement of low-level system
software including the operating system kernel, operating system services
and network protocols at all layers. Such experimentation is not conducive
to simultaneous &quot;production&quot; use of the same facilities. Hence,
the importance of providing dedicated equipment for this purpose. <BR>
<BR>
LIST is a corporate internetwork in the miniature. Currently the LIST subnet
consists of SUN workstations and NCD X-terminals. Plans to incorporate Windows
NT, Novell, Windows 95 and Macintosh computers are in progress. <BR>
<BR>
LIST facilities are available to SITE Graduate Students for experimental
INFOSEC research. Students interested in using LIST equipment should contact
Dr. Sandhu (<A HREF="mailto:sandhu@isse.gmu.edu">sandhu@isse.gmu.edu</A>)
or Soonam Kahng (<A HREF="mailto:soonam@isse.gmu.edu">soonam@isse.gmu.edu</A>)
to discuss possible projects. <BR>
<BR>
LIST facilities are also available for joint projects with industrial partners.
<H2>Breaking News </H2>
<BR>
Professor Sandhu has been elected Chairman of ACM's Special Interest Group
on Security, Audit and Control (SIGSAC). SIGSAC recently (1993) launched
the highly successful <EM>ACM Conference on Computer and Communications
Security</EM>, giving itself a much needed annual flagship conference. Ravi
is looking for volunteers and suggestions on additional SIGSAC activities
(send him email at <A HREF="mailto:sandhu@isse.gmu.edu">sandhu@isse.gmu.edu</A>
).<BR>
<BR>
<I><A HREF="issue111095.html#anchor1298130">Return to table of contents.</A></I>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-23</DOCNO>
<DOCOLDNO>IA053-000892-B033-262</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/JIIS/Mission.Scope.html 129.174.40.15 19970123190611 text/html 4664
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:05:03 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 11 Mar 1996 01:49:43 GMT
Content-type: text/html
Content-length: 4481
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>JIIS Aims and Scope</TITLE>
</HEAD>
<BODY BGCOLOR="#e3c094" TEXT="#09336f" LINK="#0000ff" VLINK="#9c1894" ALINK=
"#00ff00">
<H1><CENTER>JOURNAL OF INTELLIGENT INFORMATION SYSTEMS:</CENTER>
</H1>
<H3><CENTER>Integrating Artificial Intelligence and Database Technologies</CENTER>
</H3>
<HR>
<H3>Editors-in-Chief</H3>
<STRONG>Larry Kerschberg</STRONG>, <EM>George Mason University</EM> <BR>
<BR>
<STRONG>Zbigniew Ras</STRONG>, <EM>University of North Carolina/ Charlotte<BR>
<BR>
</EM><STRONG>Maria Zemankova</STRONG>, <EM>Arlington, Virginia </EM><BR>
<HR>
<H2>MISSION of JIIS</H2>
The mission of the <EM>Journal of Intelligent Information Systems</EM> (JIIS)
is to foster and present research and development results focused on the
integration of artificial intelligence and database technologies to create
next generation information systems -- Intelligent Information Systems.
<BR>
<BR>
These new information systems embody knowledge that allows them to exhibit
intelligent behavior, cooperate with users and other systems in problem
solving, discovery, access, retrieval and manipulation of a wide variety
of multimedia data and knowledge, and reason under uncertainty. Increasingly,
knowledge-directed inference processes are being used to: 
<UL>
  <LI>discover knowledge from large data collections, 
  <LI>provide cooperative support to users in complex query formulation
and refinement,
  <LI>access, retrieve, store and manage large collections of multimedia
data and knowledge, 
  <LI>integrate information from multiple heterogeneous data and knowledge
sources, and
  <LI>reason about information under uncertain conditions. 
</UL>
Multimedia and hypermedia information systems now operate on a global scale
over the Internet, and new tools and techniques are needed to manage these
dynamic and evolving information spaces.<BR>
<BR>
JIIS provides a forum wherein academics, researchers and practitioners may
publish high-quality, original and state-of-the-art papers describing theoretical
aspects, systems architectures, analysis and design tools and techniques,
and implementation experiences in Intelligent Information Systems. The categories
of papers published by JIIS include: research papers, invited papers, meeting
, workshop and conference announcements and reports, survey and tutorial
articles, and book reviews. Short articles describing open problems or their
solutions are also welcome. <BR>
<HR>
<H2>Scope of JIIS</H2>
Topics of interest to JIIS include, but are not limited to the following:
<UL>
  <LI>Foundations and principles of data, information, and knowledge models,
  <LI>Methodologies for IIS analysis, design, implementation, validation,
maintenance and evolution, 
  <LI>User Models, intelligent and cooperative query languages and interfaces,
  <LI>Knowledge representation, integration, fusion, interchange and evolution,
  <LI>Intelligent databases, object-oriented, extended-relational, logic-based,
active databases, and constraint management, 
  <LI>Intelligent information retrieval, digital libraries, and networked
information retrieval, 
  <LI>Distributed multimedia and hypermedia information space design, implementation
and navigation, 
  <LI>Visual interfaces, visual query languages, and visual expressiveness
of IIS, 
  <LI>Machine Learning, knowledge discovery, and data mining, 
  <LI>Uncertainty Management and reasoning under uncertainty, 
  <LI>Applications and Case Studies in novel applications, e.g., global
change, scientific databases, human genome project, Earth Observing System,
manufacturing, telemedicine, education, etc.) 
</UL>
We seek papers that improve on the best academic research or the best industrial
practice. Submitted papers should be motivated by the problems they address
with compelling examples from real or potential applications. Systems papers
must contain interpreted experimentation results either on real systems
or simulations based on representative traces from real systems. Papers
from industrial organizations that discuss implementation of systems and
their use in practice are welcome. Proposals for special issues, especially
on emerging topics, are welcome. <BR>
<HR>
<H3>Paper Submissions</H3>
Please contact: Judy Kemp<BR>
Journals Editorial Office <BR>
Kluwer Academic Publishers <BR>
101 Philip Drive<BR>
Norwell, MA 02061 <BR>
Phone: 617-871-6300 <BR>
Fax: 617-871-6528 <BR>
E-Mail: <A HREF="mailto:jkemp@wkap.com">jkemp@wkap.com</A> 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-24</DOCNO>
<DOCOLDNO>IA053-000892-B033-279</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/JIIS/EditorialBoard.html 129.174.40.15 19970123190619 text/html 3493
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:05:10 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 11 Mar 1996 01:47:29 GMT
Content-type: text/html
Content-length: 3310
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>JIIS Editorial Board</TITLE>
</HEAD>
<BODY BGCOLOR="#e3c094" TEXT="#09336f" LINK="#0000ff" VLINK="#9c1894" ALINK=
"#00ff00">
<H1>JIIS Editorial Board</H1>
<HR>
<H2>Editors-in-Chief</H2>
<STRONG>Larry Kerschberg</STRONG>, <EM>George Mason University</EM> <BR>
E-mail: <A HREF="mailto:kersch@gmu.edu">kersch@gmu.edu</A><BR>
<BR>
<STRONG>Zbigniew Ras</STRONG>, <EM>University of North Carolina/ Charlotte<BR>
</EM>E-Mail: <A HREF="mailto:ras@uncc.edu">ras@uncc.edu</A><BR>
<BR>
<STRONG>Maria Zemankova</STRONG>, <EM>Arlington, Virginia </EM><BR>
E-Mail: <A HREF="mailto:mzemanko@nsf.gov">mzemanko@nsf.gov</A> <HR>
<H2>Associate Editors </H2>
<UL>
<LI><B>Alex Borgida</B>, <EM>Rutgers University</EM> 
<LI><B>Ron Brachman</B>, <EM>ATT Bell Laboratorie</EM>s 
<LI><B>Stefano Ceri</B>, <EM>Politecnico de Milano, Italy
<LI></EM><B>Misbah Deen</B>, <EM>Keele University, England</EM> 
<LI><B>Brian Gaines</B>, <EM>University of Calgary, Canada
<LI></EM><B>Jiawei Han</B>, <EM>Simon Fraser University, Canada
<LI></EM><B>Yannis Ioannidis</B>, <EM>University of Wisconsin
<LI></EM><B>Matthias Jarke</B>, <EM>RWTH Aachen, Germany</EM> 
<LI><B>Michael Kifer</B>, <EM>State University of New York/Stony Brook
<LI></EM><B>Roger King</B>, <EM>University of Colorado</EM> 
<LI><B>Catherine Lassez</B>, <EM>IBM T.J. Watson Research Center
<LI></EM><B>Richard Marcus</B>, <EM>Massachusetts Institute of Technology
<LI></EM><B>David McKeown</B>, <EM>Carnegie-Mellon</EM> 
<LI><B>Robert Meersman</B>, <EM>Free University of Brussels, Belgium
<LI></EM><B>Ryszard Michalski</B>, <EM>George Mason University</EM> 
<LI><B>Jack Minker</B>, <EM>University of Maryland</EM> 
<LI><B>Matthew Morgenstern</B>, <EM>Xerox Adv. Information Tech.</EM> 
<LI><B>Ami Motro</B>, <EM>George Mason University</EM> 
<LI><B>Setuo Ohsuga</B>, <EM>University of Tokyo</EM> 
<LI><B>Zdzislaw Pawlak</B>, <EM>Warsaw University of Technology</EM> 
<LI><B>Henri Prade</B>, <EM>University Paul Sabatier</EM> 
<LI><B>Gregory Piatetsky-Shapiro</B>, <EM>GTE Laboratories</EM> 
<LI><B>Raghu Ramakrishnan</B>, <EM>University of Wisconsin</EM> 
<LI><B>Colette Rolland</B>, <EM>University of Paris, France</EM> 
<LI><B>Doron Rotem</B>, <EM>Lawrence Berkeley Laboratory</EM> 
<LI><B>Erik Sandewall</B>,<EM> Linkoping University, Sweden</EM> 
<LI><B>Timos Sellis</B>, <EM>National Technical University of Athens</EM>
<LI><B>Salvatore Stolfo, </B><I>Columbia University</I><B>
<LI>Michael Stonebraker</B>, <EM>University of California/Berkeley</EM>
<LI><B>Rodney Topor</B>,<EM> Griffith University, Australia 
<LI></EM><B>Marianne Winslett</B>, <EM>University of Illinois/Urbana
<LI></EM><B>Carlo Zaniolo</B>, <EM>University of California/Los Angeles</EM>
<LI><B>Stan Zdonik</B>,<EM> Brown University</EM> 
</UL>
<HR>
<H2>Kluwer Representatives</H2>
<B>Publisher</B><BR>
<BR>
Mr. Alex Greene <BR>
Kluwer Academic Publishers <BR>
101 Philip Drive <BR>
Norwell, MA 02061 <BR>
E-mail: <A HREF="mailto:agreene@mail.wkap.com">agreene@mail.wkap.com</A><BR>
<BR>
<B>Editorial Supervisor </B><BR>
<BR>
Ms. Judy Kemp <BR>
Journals Editorial Office <BR>
Kluwer Academic Publishers <BR>
101 Philip Drive <BR>
Norwell, MA 02061 <BR>
Phone: 617-871-6300 <BR>
Fax: 617-871-6528 <BR>
E-Mail: <A HREF="mailto:jkemp@wkap.com">jkemp@wkap.com</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-25</DOCNO>
<DOCOLDNO>IA053-000892-B033-309</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/JIIS/X0009.html 129.174.40.15 19970123190627 text/html 1447
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:05:18 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 11 Mar 1996 02:04:05 GMT
Content-type: text/html
Content-length: 1264
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Kluwer Academic Publishers Style Documents</TITLE>
</HEAD>
<BODY BGCOLOR="#e3c094" TEXT="#09336f" LINK="#0000ff" VLINK="#9c1894" ALINK=
"#00ff00">
<H1><CENTER>Guidelines for Authors and JIIS Styles</CENTER>
</H1>
<BR>
A number of documents are available here for prospective authors or for
ftp: 
<UL>
  <LI><A HREF="Guidelines.html">Author Guidelines</A> for JIIS special issue
submissions. 
  <LI><A HREF="smjrnl.sty">Main style file: smjrnl.sty</A> for LaTeX (47K
bytes). 
  <LI><A HREF="smjfonts.sty">Optional postscript font file smjfonts.sty</A>
(19K). If you use this file, please change the names of the .tfm fonts files
at the beginning of the file to match those on your system. The default
fonts are computer modern. 
  <LI><A HREF="smjrnl.doc">Documentation: smjrnl.doc</A> (82K). 
  <LI><A HREF="smjsamp.tex">Sample file: smjsamp.tex</A> (16K), complements
the documentation. 
  <LI><A HREF="smjtmpl.tex">Template file: smjtmpl.tex</A> makes it easier
to enter the correct commands in the correct order (5K). 
  <LI><A HREF="ftp://www.isse.gmu.edu//pub/incoming/JIIS/Kluwer.tar.gz">Kluwer.tar.gz</A>:
all the above and other journal instructions as a binary compressed tar
file, available via FTP (43K). 
</UL>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-26</DOCNO>
<DOCOLDNO>IA053-000892-B033-333</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/JIIS/DataMining.html 129.174.40.15 19970123190639 text/html 4846
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:05:29 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 28 Oct 1996 14:49:22 GMT
Content-type: text/html
Content-length: 4663
</DOCHDR>
<HTML>
<!--This file created 7/15/96 18:38 by Claris Home Page version 1.0b1-->
<HEAD>
    <TITLE>JIIS - Call for Papers </TITLE>
</HEAD>
<BODY>
<X-SAS-WINDOW TOP=66 BOTTOM=624 LEFT=8 RIGHT=538> </HEAD><BODY BGCOLOR="#EEBF94">
<H2><CENTER>Call For Papers</CENTER>
</H2>
<H1><CENTER>Journal of Intelligent Information Systems (JIIS)<BR>
<BR>
<I>Special Issue on Data Mining<BR>
<BR>
Deadline Extended</I></CENTER>
</H1>
Due to the extension of the deadline of the SIGMOD/PODS conference, we have
received quite a few requests for extension of the deadline of JIIS special
issue on Data Mining.<BR>
<BR>
Here we announce that there is one week extension of the deadline of this
special issue. That is, the submission must be postmarked by Nov. 7, 1996.
But you must send an on-line abstract by Nov. 1 to <A HREF="mailto:han@cs.sfu.ca">han@cs.sfu.ca</A>
to facilitate timely review.<BR>
<BR>
Thanks for your interest.<BR>
<BR>
- Speical Issue Guest Co-editors: J. Han, R. Ng and L.V.S. Lakshmanan<BR>
<BR>
<HR>As a young, promising research area with broad applications, data mining
and knowledge discovery in databases has attracted great interest in the
research communities of database systems, machine learning, statistics,
high performance computing, information retrieval, data visualization, and
many others. As an example, ACM-SIGMOD'96 Workshop on Research Issues on
Data Mining and Knowledge Discovery (DMKD'96) held in Montreal, Canada (June
2, 1996) attracted over 100 attendees. Also, KDD'96 conference, to be held
in Portland, Oregon, August 2-4, 1996, received over 200 submissions.<BR>
<BR>
With such overwhelming interest in this area, the Journal of Intelligent
Information Systems (JIIS) is organizing a special issue on Data Mining.
The information on JIIS and instructions to authors are available at:<BR>
<P><CENTER><A HREF="http://www.isse.gmu.edu/JIIS/">http://www.isse.gmu.edu/JIIS/</A>
</CENTER>
<P><HR>The journal published a Special Issue on Knowledge Discovery in Databases
in Volume 4, Number 1, January 1995. We welcome research and applications
papers addressing the following issues to be submitted to this special issue.
<UL>
  <LI>Foundations, principles and methodologies of data mining, including
  <UL>
    <LI>Data mining methods and techniques 
    <LI>Efficiency and scalability of KDD algorithms 
    <LI>Mining different kinds of knowledge from data 
    <LI>Integration of deductive and inductive techniques 
    <LI>Statistics, probability and uncertainty in data mining 
    <LI>Maintenance of mined knowledge and knowledge-base construction 
    <LI>Knowledge evolution through learning 
    <LI>Methods for knowledge discovery in advanced database systems (including
object-oriented, deductive, spatial, temporal, textual, multimedia, heterogeneous,
transaction, and active databases, and global information systems) 
  </UL>
  <LI>Systems and implementations for data mining, including 
  <UL>
    <LI>Knowledge discovery systems, implementations, and performance 
    <LI>Languages and interfaces for knowledge discovery in databases 
    <LI>Interactive data mining and knowledge visualization 
    <LI>Integrated discovery systems 
    <LI>Systems, implementations, and performance for knowledge discovery
in advanced database systems 
  </UL>
  <LI>Knowledge discovery applications, including 
  <UL>
    <LI>Successful knowledge discovery application examples in industry,
administration, business, and science or engineering 
    <LI>New application challenges and requirements for data mining (e.g.,
science, engineering, education) 
    <LI>The inadequacy of current knowledge discovery mechanisms 
    <LI>Influence of data mining to the advances of database systems 
    <LI>Security and social impact of data mining 
  </UL>
</UL>
<HR>
<H4>IMPORTANT DATES</H4>
<DL>
  <DD>Submissions Due: November 1, 1996<BR>
Review Notice: January 31, 1997<BR>
Final Version due: March 15, 1997 
</DL>
Five hard copies of the paper, with the length limited to 20 pages, should
be submitted by November 1, 1996 to
<DL>
  <DD>Dr. <A HREF="http://fas.sfu.ca/cs/people/Faculty/Han">Jiawei Han</A><BR>
School of Computing Science<BR>
Simon Fraser University<BR>
Burnaby, B.C.<BR>
Canada, V5A 1S6<BR>
han@cs.sfu.ca 
</DL>
<HR>
<ADDRESS>JIIS Special Issue Guest Co-Editors <BR>
Jiawei Han, Simon Fraser University, Canada (<A HREF="mailto:han@cs.sfu.ca">han@cs.sfu.ca</A>).<BR>
Laks V.S. Lakshmanan, Concordia University, Canada (<A HREF="mailto:laks@cs.concordia.ca">laks@cs.concordia.ca</A>).<BR>
Raymond Ng, University of British Columbia, Canada (<A HREF="mailto:rng@cs.ubc.ca">rng@cs.ubc.ca</A>).</ADDRESS>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-27</DOCNO>
<DOCOLDNO>IA053-000892-B033-351</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/JIIS/I3TOC.html 129.174.40.15 19970123190647 text/html 1513
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:05:38 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 15 Jul 1996 13:44:04 GMT
Content-type: text/html
Content-length: 1330
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Special Issue TOC - Intelligent Integration of Information</TITLE>
</HEAD>
<BODY BGCOLOR="#e3c294">
<H1>Special Issue on the <BR>
Intelligent Integration of Information</H1>
<H2>Journal of Intelligent Information Systems, <BR>
Volume 6, Numbers 2-3</H2>
<BR>
This special issue provides an overview of several projects that try to
add value to traditional database and web access. It contains the following
papers :
<OL>
  <LI>Editor's Foreword; G. Wiederhold.
  <LI>Query Reformulation for Dynamic Information Integration; <I>Y. Arens.</I>
  <LI>Information Mediation in Cyberspace: Scalable Methods for Declarative
Information Networks; <I>S. Dao, B. Perry.</I> 
  <LI>An Approach to Information Mediation in the Industrial Domain; <I>A.
Goldschmidt</I>. 
  <LI>NCL: A Common Language for Achieving Rule-Based Interoperability Among
Heterogeneous Systems; <I>S.W. Su, et al. </I>
  <LI>Generating Data Integration Mediators that Use Materialization; <I>G.
Zhou, et al.</I> 
  <LI>CoBase: A Scalable and Extensible Cooperative Information System;
<I>W.W. Chu, et al.</I> 
  <LI>Integrating Information via Matchmaking; <I>D. Kuokka, L. Harada.
</I>
  <LI>Glossary; G. Wiederhold. * * available at: <A HREF="http://www-db.stanford.edu/pub/gio">http://www-db.stanford.edu/pub/gio</A>
</OL>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-28</DOCNO>
<DOCOLDNO>IA053-000892-B034-19</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/JIIS/ActiveDBCFP.html 129.174.40.15 19970123190658 text/html 4099
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:05:50 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 11 Mar 1996 01:47:21 GMT
Content-type: text/html
Content-length: 3916
</DOCHDR>
<TITLE>JIIS Special Issue on Active Database Systems</TITLE>
<BODY BGCOLOR="#E3C094" TEXT="#09336f" LINK="#0000FF" VLINK="#9C1894" ALINK="#00FF00">     
<H1 align=center><B>JOURNAL OF INTELLIGENT INFORMATION SYSTEMS:</B></H1>
<H3 align=center>Integrating Artificial Intelligence and Database Technologies</H3>  </B>                         
<HR><H3>
Special Issue on
<I> Active Database Systems
</I></H3>

Active database systems integrate event-based rule processing with 
traditional database functionality.  Combining databases with active 
rules yields flexible and powerful systems that can exhibit a wide 
range of reactive behavior and that can perform inferencing over 
massive data. Over the past several years there has been a great surge 
of interest in active database systems, with numerous useful research 
results, prototypes, and commercial products.  In view of the rapidly 
growing importance of active database systems, a special issue of the 
Journal of Intelligent Information Systems, planned for fall 1996, 
will be devoted to topics in this area.  Papers are solicited in, but 
not limited to, the following topics:

 <UL>
<LI> 	Active database event and rule languages and processing,
<LI>		Active database system architecture and implementation issues,
<LI>		Performance evaluation of active database systems,
<LI>		Temporal and real-time aspects of active database systems,
<LI>		Theoretical foundations of active database systems,
<LI>		Active database design issues and application development,
<LI>		Deployment of active database technology on real applications, and
<LI>		Relationship between expert systems, knowledge-base systems,
    and active database systems

</UL> <HR>                      
<H3>The Journal
</H3>
The mission of the <EM>JOURNAL OF INTELLIGENT INFORMATION SYSTEMS: 
Integrating Artificial Intelligence and Database Technologies</EM>  is to present research and development focused on the integration of 
Artificial Intelligence and Database Management technologies to 
provide models, architectures, tools, and techniques for the next 
generation of systems -- Intelligent Information Systems.  The journal 
focuses on the creation of information systems that exhibit 
intelligent behavior and embody intelligence in their reasoning and 
management processes.  The journal is an archival, peer-reviewed, 
technical journal publishing high-quality, state-of-the-art papers.
<P>

<HR>
<H3>Instructions for Submitting Papers</H3>
Manuscripts are strictly limited to 25 printed pages with a 12-point 
font and 18-point spacing (approximately 12,000 words), including all 
figures and references.  Papers must not have appeared in, nor be 
under consideration by, other journals.  Include a separate page 
specifying the title and giving the preferred address of the contact 
author for correspondence (including postal address, telephone number, 
fax number, and e-mail address).  Send four (4) copies of each 
submission to one of the two guest editors listed below.  For 
additional information, please contact one of the guest editors.
<P>
<HR><H3>Important Dates</H3>
<pre>
	<TT>Manuscripts due:		Monday, October 16, 1995
	Acceptance notification:	Monday, January 29, 1996
	Final manuscript due:		Monday, April 1, 1996
	Publication date of issue:	August/September 1996</TT>
</pre>                       
<HR><H3>																																										Guest Editors
</H3>
	
<pre>
	Sharma Chakravarthy               Jennifer Widom
	Database Systems R&D Center       Department of Computer Science
	E470 CSE Building                 Stanford University
	PO Box 116125                     Stanford, CA  94305-2140
	University of Florida             
	Gainesville, FL  32611-6125       
	sharma@cis.ufl.edu                widom@cs.stanford.edu
	(904) 392-2697 (voice)            (415) 723-7690 (voice)
	(904) 392-1220 (fax)              (415) 725-2588 (fax)
</pre>
</DOC>
<DOC>
<DOCNO>WT03-B24-29</DOCNO>
<DOCOLDNO>IA053-000892-B034-40</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/JIIS/X0007.html 129.174.40.15 19970123190707 text/html 1608
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:05:58 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 11 Mar 1996 01:51:19 GMT
Content-type: text/html
Content-length: 1425
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>JIIS Tables of Contents</TITLE>
</HEAD>
<BODY>
<H1></H1>
<H1><CENTER>Tables of Contents of <BR>
Recent Issues &amp; General Information</CENTER>
</H1>
<IMG SRC="BULLET.GIF" WIDTH="23" HEIGHT="18" ALIGN=middle NATURALSIZEFLAG=
"3"><A HREF="gopher://Gopher.wkap.nl:70/00gopher_root1%3A%5Bjournal.jiis%5Djiis.toc">Table
of Contents at Kluwer Academic Publishers.<BR>
<BR>
</A><IMG SRC="BULLET.GIF" WIDTH="23" HEIGHT="18" ALIGN=middle NATURALSIZEFLAG=
"3"><A HREF="http://www.informatik.uni-trier.de/~ley/db/journals/jiis/index.html">Table
of Contents on Dr. Michael Ley's Bibliography of Database and Logic Programming
Literature.</A><BR>
<BR>
<IMG SRC="BULLET.GIF" WIDTH="23" HEIGHT="18" ALIGN=middle NATURALSIZEFLAG=
"3"><A HREF="gopher://Gopher.wkap.nl:70/11gopher_root%3A%5B_journal._jrnl.jiis%5D">General
information about JIIS.</A><BR>
<BR>
<IMG SRC="BULLET.GIF" WIDTH="23" HEIGHT="18" ALIGN=middle NATURALSIZEFLAG=
"3"><A HREF="gopher://Gopher.wkap.nl:70/11gopher_root%3A%5B_submit._jrnl.jiis%5D">Instructions
for prospective JIIS authors.</A><BR>
<BR>
<IMG SRC="BULLET.GIF" WIDTH="23" HEIGHT="18" ALIGN=middle NATURALSIZEFLAG=
"3"><A HREF="gopher://Gopher.wkap.nl/">Kluwer Gopher site in the Netherlands.</A><BR>
<BR>
<IMG SRC="topindex.jpg" ALIGN=top ALT="[Back to top index]" WIDTH="25" 
HEIGHT="15" NATURALSIZEFLAG="3"><A HREF="index.html">Back to document index</A><BR>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-30</DOCNO>
<DOCOLDNO>IA053-000892-B034-53</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/JIIS/X0006.html 129.174.40.15 19970123190714 text/html 651
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:06:06 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 11 Mar 1996 01:51:16 GMT
Content-type: text/html
Content-length: 469
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>JIIS Subscription Information</TITLE>
</HEAD>
<BODY>
<H1>JIIS Subscription Information</H1>
<IMG SRC="BULLET.GIF" WIDTH="23" HEIGHT="18" ALIGN=middle NATURALSIZEFLAG=
"3"><A HREF="Subscriptions.html">Subscription Information</A><BR>
<BR>
Under construction.<BR>
<BR>
<IMG SRC="topindex.jpg" ALIGN=top ALT="[Back to top index]" WIDTH="25" 
HEIGHT="15" NATURALSIZEFLAG="3"><A HREF="index.html">Back to document index</A><BR>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-31</DOCNO>
<DOCOLDNO>IA053-000892-B034-156</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/~csis/jcs.html 129.174.40.15 19970123190817 text/html 578
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:07:09 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 03 Dec 1996 21:30:06 GMT
Content-type: text/html
Content-length: 396
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Journal of Computer Security</TITLE>
</HEAD>
<BODY BGCOLOR="#EBC79E" TEXT="#0000FF"
      LINK="#000000" VLINK="#FF0000" ALINK="#00FFFF">
<CENTER>
<IMG SRC="jcstitle.gif">
</CENTER>
<p>
<p>
<font size=4>
The Journal of Computer Security home page has moved. Please adjust your
links to refer to the <A HREF="http://www.jcompsec.mews.org">new page</A>
</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT03-B24-32</DOCNO>
<DOCOLDNO>IA053-000891-B004-54</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/JIIS/Guidelines.html 129.174.40.15 19970123190947 text/html 9198
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:08:36 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 11 Mar 1996 01:47:34 GMT
Content-type: text/html
Content-length: 9015
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>JIIS Guidelines</TITLE>
</HEAD>
<BODY BGCOLOR="#e3c094" TEXT="#09336f" LINK="#0000ff" VLINK="#9c1894" ALINK=
"#00ff00">
<H1><CENTER>JIIS Instructions to Authors</CENTER>
</H1>
(edited for WWW by Gio Wiederhold, Feb.1995) 
<H2>(Kluwer Publications)</H2>
Guidelines for Authors in Special Issues <BR>
<BR>
These are the Instructions for Authors for selected papers. This information
may also be useful to prospective authors <HR>
<H1><CENTER>JOURNAL OF INTELLIGENT INFORMATION SYSTEMS:</CENTER>
</H1>
<H3><CENTER>Integrating Artificial Intelligence and Database Technologies</CENTER>
</H3>
<H2>Instructions for Authors </H2>
Authors are encouraged to submit high quality, original work that has neither
appeared in, nor is under consideration by, other journals. The mission
of the JOURNAL OF INTELLIGENT INFORMATION SYSTEMS: Integrating Artificial
Intelligence and Database Technologies is to present research and development
focused on the integration of Artificial Intelligence and Database Management
technologies to provide models, architectures, tools and techniques for
the next generation of systems -- Intelligent Information Systems. The journal
focuses on the creation of information systems that exhibit intelligent
behavior and embody intelligence in their reasoning and management processes.
The journals is an archival, peer-reviewed, technical journal publishing
high-quality, state-of-the- art papers (*research papers *invited papers
*workshop and conference reports *survey and tutorial articles *book reviews)
<H3>PROCESS FOR SUBMISSION OF A SPECIAL ISSUE MANUSCRIPT</H3>
<UL>
  <LI>Authors should submit 4 hard copies of their complete manuscript to
the Special Issue Editor.
  <LI>Enclose a separate page specifying the title and giving the preferred
address of the contact author for correspondence. 
  <LI>Please include a telephone number, fax number, and e-mail address.
</UL>
<H3>PROCESS FOR SUBMISSION OF FINAL MANUSCRIPTS</H3>
After notification by the Special Issue Editor, authors should submit ONE
hard copy of their complete manuscript to:<BR>
<UL>Ms. Judy Kemp <BR>
JIIS - Editorial Office<BR>
Kluwer Academic Publishers <BR>
101 Philip Drive<BR>
Norwell, MA 02061<BR>
Tel: 617 871-6300 / FAX: 617 871-6528 <BR>
E-mail:jkkluwer@world.std.com
</UL>
For prompt attention, all correspondence should be directed to this address.
<UL>
  <LI>Enclose a separate page specifying the title and giving the preferred
address of the contact author for correspondence and return of proofs. Please
include a telephone number, fax number, and e-mail address. 
  <LI>Enclose a brief biographical sketch for each author. 
  <LI>Authors should try to keep the length of the paper (including figures)
about 30 double-spaced pages (about 15,000 words). 
  <LI>All papers should be written in English. 
</UL>
<H3>STYLE FOR MANUSCRIPTS</H3>
<NL> <LI>Typeset (10pt font), double or 1 1/2 space; use one side of sheet
only (laser printed, typewritten and good quality duplication acceptable).
<LI>Use an informative title for the paper. <LI>List all authors, in the
form first name, middle initial, last name, followed by mailing address(es)
and email address(es). <LI>Include an abstract of 100 to 250 words at the
head of the manuscript. The abstract should be a carefully worded description
of the problem addressed, the key ideas introduced, and the results. <LI>List
from three to five keywords. Some typical keyword examples are: deductive
database, machine learning, user interface, adaptive systems, distributed
systems, and Petri nets. <LI>Provide a separate double-spaced sheet listing
all numbered foot-notes in order. Acknowledgement of financial support may
be given if appropriate. <LI>References should be complete and appear in
a separate bibliography at the end of the paper. They should be listed in
alphabetical order by authors names, with the year (possibly with a/b/...)
in parentheses following the author(s) names(s). They should be referred
to in the text by [Author, year1(a/b/...); citation2Author, year2;...] </NL>
<PP   STYLE FOR ARTICLES: Author(s) last name followed by initials, for each
    author, year (possibly with a/b/c for multiple publications in one
     year, paper title, publication name, volume,  inclusive page numbers,
     month and year.

<P> STYLE FOR BOOKS: Author(s) last name followed by initials, for each
author, year (possibly with a/b/c for multiple publications in one year,
title, publisher, year of publication. <BR>
<BR>
EXAMPLES AS FOLLOWS: (sections within {} should be italicized - and the
brackets {} not included) 
<H3>REFERENCES</H3>
(Journal Paper) 
<UL>Aha, D.W., Kibler, D., and Albert, M.K. (1991). &quot;Instance-Based
Learning Algorithms&quot;, {Machine Learning} Vol. 6-1, pp. 37-66.
</UL>
(Book)
<UL>Lee, S., and Shin, Y.G. (1991). Assembly Coplanner: Cooperative Assembly
Planner Based on Subassembly Extraction. In Homem de Mello, L.S., and Lee,
Sukhan (Eds.), {Computer-Aided Mechanical Assembly Planning}. Kluwer Academic
Publishers, Boston, MA.<BR>
<BR>
<BR>
Salzberg, S. (1990). {Learning With Nested Generalized Exemplars}, Kluwer
Academic Publishers, Boston, MA.
</UL>
(Conference Proceedings)
<UL>Witkin, A. (1983) &quot;Scales space filtering,&quot; in {Proc. Int.
Joint Conf. Artif. Intell.}, Karlsruhe, West Germany, pp. 1019-1021.
</UL>
Use in text:
<UL>
  <LI>... assembler (Aha, et al. 1991).
  <LI>... in (Lee & Shin,1991; Witkin, 1983), it is shown ... 
  <LI>... as Salzberg (1990) argues.... 
  <LI>Type or mark mathematical expressions exactly as they should appear
in print. In word-processor manuscripts, use appropriate typefaces. Otherwise,
journal style and the corresponding indication for equations is as follows:
variables, italic type (indicated by underline); constants, Roman font type,
matrices and vectors, boldface type (indicated by wavy underline). It will
be assumed that letters in equations are to be set in italic type unless
you mark them otherwise. All letter symbols in text discussion must be marked
if they should be italic or boldface. 
</UL>
<H3>STYLE FOR ILLUSTRATIONS</H3>
<DIR>
  <LI>Originals for illustrations should be sharp, noise-free, and of good
contrast. We regret that we cannot provide drafting or art service. 
  <LI>Line drawings should be in laser printer output or in India ink on
paped. Use 8 1/2 X 11 inch size sheets if possible, to simplify handling
of the manuscript. 
  <LI>Each figure should be mentioned in the text, and numbered consecutively
using Arabic Numerals. Specify the desired location of each figure in the
text, but place the figure itself on a separate page following the text.
  <LI>Number each table consecutively using Arabic Numerals. Please label
any material that can be typeset as a table, reserving the term &quot;figure&quot;
for material that has been drawn. Specify the desired location of each table
in the text, but place the table itself on a separate page following the
text. Type a brief title below each table. 
  <LI>Provide a separate sheet listing all figure captions, in proper style
for the typesetter, e.g., &quot;Fig. 3. Examples of the fault coverage of
random vectors in (a) combinational and (b) sequential circuits.&quot; 
  <LI>All lettering should be large enough to permit legible reduction (at
least 10pt.). 
  <LI>Photographs should be glossy prints, of good contrast and gradation,
and any reasonable size. We will publish full color photographs, but only
with the authors understanding and acceptance that they will be expected
to finance the extra cost of the color reproduction. 
  <LI>Number each original lightly, in pencil, on the back so that they
may be matched up correctly with the Table and Figure locations in the text.
</DIR>
<BR>
NOTE: JIIS final manuscripts should be preferably prepared using LaTeX macros
and submitted electronically. LaTeX macros can be accessed as follows: <BR>
<BR>
From Internet: <BR>
<UL><KBD>ftp world.std.com <BR>
login: anonymous <BR>
Name: <I>your e-mail address</I><BR>
cd Kluwer/styles/journals <BR>
get README</KBD><BR>
and then <BR>
<KBD>mget smj*<BR>
bye</KBD>
</UL>
JIIS is a small journal as compared to a two-column large journal. So you
should &quot;mget smj*&quot; 
<H3>PROOFING</H3>
Page proofs for articles to be included in a journal issue will be sent
to the contact author for proofing, unless otherwise informed. The proofread
copy should be received back by the Publisher within 72 hours. 
<H3>COPYRIGHT</H3>
It is the policy of Kluwer Academic Publishers to own the copyright of all
contributions it publishes. To comply with the U.S. Copyright Law, authors
are required to sign a copyright transfer form before publication. This
form returns to authors and their employers full rights to reuse their material
for their own purposes. Authors must submit a signed copy of this form with
their manuscript. 
<H3>REPRINTS</H3>
First-named authors will be entitled to 25 free reprints of their paper.
<H3>End. </H3>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-33</DOCNO>
<DOCOLDNO>IA053-000891-B004-211</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/JIIS/Subscriptions.html 129.174.40.15 19970123191149 text/html 3058
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:10:41 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 11 Mar 1996 01:51:02 GMT
Content-type: text/html
Content-length: 2875
</DOCHDR>
<TITLE>JIIS Subscription Order Form</TITLE>
<BODY BGCOLOR="#E3C094" TEXT="#09336f" LINK="#0000FF" VLINK="#9C1894" ALINK="#00FF00">                    

<CENTER><H1>JIIS Subscription Order Form</H1></CENTER>
                        <P>    
   
<PRE>
Journal Title: Journal of Intelligent Information Systems 
1995, Volume 4-5 (6 issues) 
ISSN: 0925-9902  Institutional Rate: NLG:  634.00 USD:  363.00  
  
  
Ref: KAPIS
   
( ) Payment enclosed to the amount of ___________________________
( ) Please send invoice
( ) Please charge my credit card account:
   
    Card no.: |_|_|_|_|_|_|_|_|_|_|_|_|_|_|_|_|  Expiry date: ______________
   
    () Access       () American Express     () Mastercard
    () Diners Club  () Eurocard             () Visa
   
    Name of Card holder: ___________________________________________________
   
Delivery address:
   
Title       : ___________________________ Initials: _______________M/F______
   
First name  : ______________________ Surname: ______________________________
   
Organization: ______________________________________________________________
   
Department  : ______________________________________________________________
   
Address     : ______________________________________________________________
   
Postal Code : ___________________ City: ____________________________________
   
Country     : _____________________________Telephone: ______________________
   
Email       : ______________________________________________________________
   
Date        : _____________________ Signature: _____________________________
   
Our European VAT registration number is: |_|_|_|_|_|_|_|_|_|_|_|_|_|_|
   
To be sent to:
For customers in Mexico, USA and Canada:    Rest of the world:
   
Kluwer Academic Publishers                  Kluwer Academic Publishers Group
Order Department                            Journals Department
P.O. Box 358                                P.O. Box 322
Accord Station                              3300 AH Dordrecht
Hingham, MA 02018-0358                      The Netherlands
U.S.A.
   
Tel    : 617 871 6600                       Tel   : +31 78 524400
Fax    : 617 871 6528                       Fax   : +31 78 524474
Email  : kluwer@world.std.com               Email : services@wkap.nl
   
Payment will be accepted in any convertible currency. Please check the rate
of exchange with your bank. Prices are subject to change without notice. All 
prices are exclusive of Value Added Tax (VAT). Customers in the Netherlands 
please add 6% VAT. Customers from other countries in the European Community:
* please fill in the VAT number of your institute/company in the appropriate 
  space on the orderform: or
* please add 6% VAT to the total order amount (customers from the U.K. are
  not charged VAT).
 
=============================================================================
</PRE>
</DOC>
<DOC>
<DOCNO>WT03-B24-34</DOCNO>
<DOCOLDNO>IA053-000892-B030-61</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/ 129.174.40.15 19970123184629 text/html 6231
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:45:20 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 23 Jan 1997 16:03:01 GMT
Content-type: text/html
Content-length: 6048
</DOCHDR>
<HTML>
<HEAD>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
  <TITLE>ISSE Home Page (George Mason University) </TITLE>
</HEAD>
<!-- Only the first one counts.
     I prefer yellow myself, but maybe most would prefer white.
-->
<BODY BGCOLOR="#eeffff">

<P><!-- white --><BODY BGCOLOR="#ffff00"><!-- yellow --><BODY BGCOLOR="#ff0000"><!-- red --><BODY BGCOLOR="#00ff00"><!-- green --><BODY BGCOLOR="#0000ff"><!-- blue --><BODY BGCOLOR="#99cad9"><!-- teal --></P>

<P ALIGN=CENTER><IMG SRC="logo/gmulogo.gif" ALIGN="BOTTOM"> <IMG SRC="logo/graymarble_gmulogo.gif"
ALIGN="BOTTOM"></P>

<P><HR ALIGN=LEFT></P>

<H1 ALIGN=CENTER><EM>Department of Information and Software Systems Engineering</EM></H1>

<H3><A HREF="http://www.site.gmu.edu/">School of Information Technology
and Engineering</A>, <A HREF="http://www.gmu.edu/">George Mason University</A>,
<A HREF="http://www.eda.co.fairfax.va.us/fceda">Fairfax</A>, <A HREF="http://dit1.state.va.us/">Virginia</A>.</H3>

<P>&nbsp;</P>

<H1 ALIGN=CENTER><IMG SRC="image/new.gif" ALT="" ALIGN="BOTTOM"> <A HREF=
"http://www.site.gmu.edu/Dean.html">SITE needs a new Dean!</A> <IMG SRC=
"image/new.gif" ALT="" ALIGN="BOTTOM"></H1>

<P ALIGN=CENTER><HR></P>

<P ALIGN=CENTER><TABLE BORDER="10" CELLSPACING="10" CELLPADDING="0">
<TR>
<TD><A HREF="#ACAD">Academic Information</A></TD>
<TD><A HREF="#DEPT">General Departmental Information</A></TD>
<TD><A HREF="#RSRCH">Research Activities</A></TD>
<TD><A HREF="#JOURN">Scholarly Journals</A></TD>
<TD><A HREF="#LINKS">Local Links</A></TD>
<TD><A HREF="#FRIENDS">Some of Our Friends in Industry</A></TD></TR>
</TABLE>
</P>

<P><HR ALIGN=LEFT></P>

<H1 ALIGN=CENTER>Departmental Information</H1>

<P><HR ALIGN=LEFT><A NAME="ACAD"></A></P>

<H2><IMG SRC="image/small-green-box.gif" ALT="" ALIGN="BOTTOM"> Academic
Information</H2>

<UL>
  <LI><A HREF="key-contacts.html">Key Contacts</A>
  <LI><A HREF="StudentAdvisor.html">Student Advisor</A>
  <LI><A HREF="faculty/">Faculty List</A>
  <LI><A HREF="ms-infs/ms-intro.html">Master of Science in Information Systems</A>
  <LI><A HREF="swse-ms/swse-ms.html">Master of Science in Software Systems
  Engineering</A>
  <LI><A HREF="swse-ms/swse-cert.html">Certificate in Software Systems Engineering</A>
  <LI><A HREF="syllabi">Course Syllabi</A>
</UL>
          
          <P><A NAME="DEPT"></A></P>
          
          <H2>
           <IMG SRC="image/small-green-box.gif" ALT="" ALIGN="BOTTOM">General
  Departmental Information </H2></I>
  <UL>
    <LI><A HREF="/faculty/kersch/newsletter95/Newsletter.html_folder/chair-s-message.html"><I>Message
    From the Chairman</I></A>
    <LI><A HREF="/faculty/kersch/newsletter95/Newsletter.html_folder/issue111095.html"><I>ISSE
    Newsletter, Fall 1995</I></A>
  </UL>
  <P><A NAME="RSRCH"></A>
  <P><I><H2><IMG SRC="image/small-green-box.gif" ALT="" ALIGN="BOTTOM"> Research
  Activities</H2></I>
  <UL>
    <LI><A HREF="research/index.html"><I>Research Activities</I></A>
    <LI><A HREF="http://www.isse.gmu.edu/~csis"><I>GMU's Center for Secure
    Information Systems</I></A>
    <LI><A HREF="http://www.isse.gmu.edu/faculty/kersch/CISIE_folder/CISIEProspectus.html"><I>GMU's
    Center for Information Systems Integration and Evolution</I></A>
    <LI><A HREF="http://www.list.gmu.edu/"><I>GMU's Laboratory for Information
    Security Technology (LIST)</I></A>
    <LI><A HREF="students/index.html"><I>ISSE Graduate Students</I></A>
    <LI><I>Technical Reports <EM>(Coming soon ...)</EM></I>
    <LI><I>Publications <EM>(Coming soon ...)</EM></I>
  </UL>
  <P><A NAME="JOURN"></A>
  <P><I><H2><IMG SRC="image/small-green-box.gif" ALT="" ALIGN="BOTTOM"> Scholarly
  Journals</H2></I>
  <UL>
    <LI><A HREF="JIIS/index.html"><I>Journal of Intelligent Information Systems</I></A>
  </UL>
  <P><A NAME="LINKS"></A>
  <P><I><H2><IMG SRC="image/small-green-box.gif" ALT="" ALIGN="BOTTOM"> Local
  Links</H2></I>
  <UL>
    <LI><A HREF="image/gmu-campus.gif"><I>Map of GMU Campus</I></A>
    <LI><A HREF="http://www.site.gmu.edu/"><I>GMU's SITE department homepage</I></A>
    <LI><A HREF="http://www.cs.gmu.edu/"><I>GMU's CS department homepage</I></A>
    <LI><A HREF="http://cne.gmu.edu/"><I>GMU's Center for the New Engineer</I></A>
    <LI><A HREF="http://web.gmu.edu/departments/ucis"><I>GMU's UCIS homepage</I></A>
    <LI><A HREF="http://gopher.gmu.edu/"><I>Mason Link</I></A>
  </UL>
  <P><A NAME="FRIENDS"></A>
  <P><I><H2><IMG SRC="image/small-green-box.gif" ALT="" ALIGN="BOTTOM"> Some
  of Our Friends in Industry</H2></I>
  <UL>
    <LI><A HREF="http://www.amsinc.com/"><I>American Management Systems (AMS)</I></A>
    <LI><A HREF="http://www.aspex.com/"><I>Aspex, Inc.</I></A>
    <LI><A HREF="http://www.prc.com/"><I>PRC</I></A>
    <LI><A HREF="http://www.bbn.com/"><I>BBN Corporation</I></A>
    <LI><A HREF="http://www.bdm.com/"><I>BDM</I></A>
    <LI><A HREF="http://www.oracle.com/"><I>Oracle Corporation</I></A>
    <LI><A HREF="http://govt.us.oracle.com/"><I>Oracle Government</I></A>
    <LI><A HREF="http://www.saic.com/"><I>Science Applications International
    Corporation (SAIC)</I></A>
    <LI><A HREF="http://www.sed.stel.com/"><I>Stanford Telecom</I></A>
    <LI><A HREF="http://www.rstcorp.com/"><I>Reliable Software Technologies
    Corporation (RST)</I></A>
  </UL>
  <P><I><HR ALIGN=LEFT></I>
  <P ALIGN=CENTER><TABLE BORDER="10" CELLSPACING="10" CELLPADDING="0">
<TR>
<TD>  <A HREF="index.html">Top</A></TD></TR>
</TABLE>
  <P><I><HR ALIGN=LEFT></I>
  <P ALIGN=CENTER><I><FONT SIZE=+1>Number of accesses to this page since
  November 13 is: </FONT><IMG SRC="http://www.isse.gmu.edu/cgi-bin/Count.cgi?ft=0|frgb=69;139;50|tr=0|trgb=0;0;0|wxh=15;20|md=6|dd=C|st=5|sh=1|df=count2.dat"
  ALIGN="BOTTOM"></I>
  <P><I><EM>For corrections, additions or suggestions please send email to:</EM></I>
  <P ALIGN=CENTER><A HREF="mailto:webmaster@isse.gmu.edu"><I><IMG SRC="logo/mailbox.gif"
  ALIGN="MIDDLE"> webmaster@isse.gmu.edu </I></A>
  <P><I><EM>Last edited by L. Kerschberg, January 17, 1997.</EM></I>
</UL>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-35</DOCNO>
<DOCOLDNO>IA053-000892-B031-280</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/ms-infs/f-aid.html 129.174.40.15 19970123185621 text/html 945
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:55:12 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 27 Aug 1995 17:16:46 GMT
Content-type: text/html
Content-length: 763
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Financial Aid</TITLE>
</HEAD> 
<BODY>                  
<H1>Financial Aid</H1>
<P>
<HR>
Assistantship application forms are normally sent as part of the graduate
application packet or may be requested from either the Office of the Dean, School
of Information Technology and Engineering, or the department offices.  Other
support in the form of scholarships, loans, work-study or cooperative work-study
are available.  Inquiries should be made at the Office of Student <EM>Financial
Planning and Resources located in Student Union I, Room 354; telephone (703) 993-4350.</EM>
<HR>
<P>
<A HREF = "ms-intro.html">Return to Master of Science in Information Systems.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-36</DOCNO>
<DOCOLDNO>IA053-000892-B033-242</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/index.html 129.174.40.15 19970123190604 text/html 1917
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:04:55 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 17 Nov 1996 14:46:33 GMT
Content-type: text/html
Content-length: 1734
</DOCHDR>
<HTML>
<head>
<title>Welcome to Pat Farrell's homepage</title>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<body BGCOLOR="#FFFFFF" TEXT="#000000" LINK="#00008F" VLINK="#8F0000">

<strong>Pat (Patrick D.) Farrell</strong><br>
<strong>Grad Student</strong><br>
<strong>E-mail:    pfarrell@isse.gmu.edu</strong><br>
<strong>Voicemail:     703 715-7834</strong><br>

<IMG alt="_____" SRC="./color_line.gif">
<ul>
<li>My <a href="./biopage.html">Biographic page, PhD status, 
resume, commitee, etc.</a>
<li>My <a href="./hotlist.html">Hotlist.
This is a list of cool places on the Web and sources 
for more information on my interests in security, 
politics, etc. </a> I update it occasionally.

</ul>
<IMG alt="_____" SRC="./color_line.gif">
<H2>Research Interests </H2>
<UL>
<LI> Software Quality
<LI> Coupling and Cohesion for OO development
<LI><a href="./metrics.html">Metrics</a>
<LI> Digital Cash
<LI> Network Security 
</UL>
<IMG alt="_____" SRC="./color_line.gif">
<p>
Quote: "When you can measure what you are speaking about, and 
express it in numbers, you know something about it; but 
when you cannot express it in numbers, your knowledge is of 
a meager and unsatisfactory kind. It may be the beginning of 
knowledge, but you have scarcely, in your thoughts, advanced 
to the stage of science."
<p>
<I>Popular Lectures and Addresses</I>, Lord (William Thompson) Kelvin.
<p>
<IMG alt="_____" SRC="./color_line.gif"><br>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
November 16 1996  Backto <a href="./hotlist.html">Pat's hotlist</a> 
Backto <a href="./index.html">Pat's homepage</a><br>
<A HREF="http://www.isse.gmu.edu/">Back to the ISSE Homepage</A>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-37</DOCNO>
<DOCOLDNO>IA053-000892-B031-263</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/ms-infs/emp-op.html 129.174.40.15 19970123185556 text/html 1691
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:54:45 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 27 Aug 1995 17:16:42 GMT
Content-type: text/html
Content-length: 1508
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Employment Opportunities</TITLE>
</HEAD> 
<BODY>                  
<H1>Employment Opportunities</H1>
<P>
<HR>
<P>
Both industry and government offer a wide variety of positions in
information systems practice.  Traditionally, many information
systems roles in organizations have been carried out by experienced
engineers and other technically trained personnel, though often only after
lengthy apprenticeship in detailed design or analysis work.  As the complexity
of modern computer-based systems has increased, there is growing demand for
information systems skills. 
<P>
In employment, the capable information systems specialist may be given
responsibility for development of systems architecture, system standards,
database design and implementation, network design, the overall system
development plan, integration, integrated testing, or operational management of
information systems.  The responsibilities often involve managerial duties,
development of proposals, financial planning, and interaction with the client,
with correspondingly greater financial rewards than are available in less
critical aspects of the work.  Breadth of knowledge and ability to communicate
well are both especially important, as the information systems professional must
deal with specialists as well as non-technical individuals.
<P>
<HR>
<A HREF = "ms-intro.html">Return to Master of Science in Information Systems.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-38</DOCNO>
<DOCOLDNO>IA053-000892-B031-4</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/faculty/fastaff.html 129.174.40.15 19970123185224 text/html 587
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:51:13 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 21 Sep 1995 12:50:00 GMT
Content-type: text/html
Content-length: 405
</DOCHDR>
<HTML>
<HEAD><TITLE>ISSE FACULTY AND STAFF PICTURE</TITLE></HEAD>
<BODY>

<H1><B>ISSE FACULTY AND STAFF</B></H1>


<!-- JO: This doesn't work ... too bad
   <H3>Click on the faces on this picture for more information about the 
   individuals.</H3>
 <A HREF="../cgi-bin/imagemap/stuff">
-->

<HR>
<IMG SRC=funpict.gif ismap></A>

<P>
<A HREF="../index.html">Back to ISSE's home page.</A>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-39</DOCNO>
<DOCOLDNO>IA053-000892-B034-71</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/cgi-bin/imagemap/stuff 129.174.40.15 19970123190724 text/html 271
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:06:14 GMT
Server: NCSA/1.5.2
Content-type: text/html
</DOCHDR>
<title>Mapping Server Error</title><h1>Mapping Server Error</h1>This server encountered an error:<p>Wrong number of arguments, client may not support ISMAP.
</DOC>
<DOC>
<DOCNO>WT03-B24-40</DOCNO>
<DOCOLDNO>IA053-000892-B031-214</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/ms-infs/deg-req.html 129.174.40.15 19970123185510 text/html 1578
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:54:01 GMT
Server: NCSA/1.5.2
Last-modified: Fri, 08 Sep 1995 19:56:26 GMT
Content-type: text/html
Content-length: 1395
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Degree Requirements</TITLE>
</HEAD> 
<BODY>                  
<H1>Degree Requirements</H1>
<P>
<HR>
<P>
Completion of the MSIS program requires a minimum of 30 approved graduate
semester hours (10 courses).  This requirement is satisfied by the following:
<P>
<H3>Required Courses</H3>
<P>
To provide a common background in the fundamentals of information systems, the
following five courses are required of all students:
<P>
<DL>
<DD><A HREF="infs-cou.html#infs540">OR 540</A> Management Science
<DD><A HREF="infs-cou.html#infs601">INFS 601</A> Operating Systems Theory and Practice
<DD><A HREF="infs-cou.html#infs612">INFS 612</A> Data Communications and Distributed Processing
<DD><A HREF="infs-cou.html#infs614">INFS 614</A>  Database Management Systems
<DD><A HREF="infs-cou.html#infs622">INFS 622</A> Information Systems Analysis and Design
</DL>
<P>
<H3>Students must also take one of the following two courses:</H3>
<P>
<DL>
<DD>INFS 790  Information Systems Policy and Administration or
<DD>INFS 798  Research Project
</DL>
<P>
The research project is intended for research-oriented students who have
discussed a project with a graduate faculty member who has agreed to supervise
the project.
<P>
<HR>
<P>
<A HREF = "ms-intro.html">Return to Master of Science in Information Systems.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-41</DOCNO>
<DOCOLDNO>IA053-000892-B031-222</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/ms-infs/infs-cou.html 129.174.40.15 19970123185520 text/html 9647
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:54:11 GMT
Server: NCSA/1.5.2
Last-modified: Fri, 08 Sep 1995 19:53:45 GMT
Content-type: text/html
Content-length: 9464
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Information Systems Courses (INFS)</TITLE>
</HEAD> 
<BODY>                  
<H1>Information Systems Courses (INFS)</H1>
<P>
<HR>

<P>
<A NAME="infs310"><B>INFS 310 Program Structure and Design Using COBOL (3:3:0).</B>  Programming using the
COBOL language to focus on fundamental concepts of software design and software
development methodologies for database management.  INFS 310 may be used to satisfy
the prerequisite for INFS 590.

<P>
<A NAME="infs510">
<B>INFS 501 Discrete and Logical Structures for Information Systems (3:3:0).</B> 
Prerequisites: 6 credits of undergraduate mathematics.  Study of discrete and logical
structures for information systems analysis and design including basic set theory
and proof techniques, propositional and predicate logic, Boolean algebras and
lattices, trees and graphs, finite state machines, formal languages and their
relation to automata, computability and computational complexity, formal
semantics-operational, axiomatic and denotational approaches.  INFS 501 is a
foundation class and carries no credit toward the MSIS.

<P>
<A NAME="infs513">
<B>INFS 513  Introduction to Telecommunication Systems (3:3:0).</B>  Prerequisites:  Admission
to MA in Telecommunications Program, or permission of instructor.  Study of essential
technologies underlying modern telecommunications systems, and their integration
into information systems.  Transmission and transmission media, communication
techniques, wide-area networks, local area networks, integrated services digital
networks, personal communication systems.  Open-systems interconnection, and
distributed systems.  Network management and security.  Credit is not applicable
towards any MS degree in SITE.

<P>
<A NAME="infs515">
<B>INFS 515 Computer Organization (3:3:0).</B>  Prerequisites:  Undergraduate courses or
equivalent knowledge in structured programming in a high-level language.  Computer
hardware organization:  arithmetic and logical operations; combinational and
sequential logic; machine representation of numbers, characters, and
instructions; addressing techniques; microprogramming; reduced instruction set
computers.  Symbolic assembly language.  Interrupts and input/output
organization.  INFS 515 is a foundation class and carries no credit toward the MSIS.

<P>
<A NAME="infs590">
<B>INFS 590 Program Design and Data Structures (3:3:0).</B>  Prerequisite: Course work in a high
level language.  Study of the fundamentals of data structures and algorithms
applied in programming solutions to application problems.  Stresses structured
programming in a modern high-level language. Laboratory required.  INFS 590 is
a foundation class and carries no credit toward the MSIS.

<P>
<A NAME="infs540">
<B>OR 540 Management Science (3:3:0).</B>  Prerequisite:  MATH 108 and STAT 250 or DESC
200, or equivalent.  Operations research techniques and their application to
managerial decision making.  Mathematical programming, Markov processes, queuing
theory, inventory models, PERT and CPM, and simulation.  Use of contemporary
computer software for problem solving.  Note that this course is offered by the
Department of Operations Research.

<P>
<A NAME="infs601">
<B>INFS 601 Operating Systems Theory and Practice (3:3:0).</B>  Prerequisites:  INFS 501, 515
and 590; or equivalent.  Fundamental concepts including:  process
synchronization and scheduling, interprocess communication, memory
management, virtual memory, deadlocks, security and access-control, file and disk
management, performance analysis, and distributed systems.  Impact of computer
architecture on operating systems.  Case studies and comparative analysis of
operating systems.

<P>
<A NAME="infs612">
<B>INFS 612 Data Communications and Distributed Processing (3:3:0).</B> Prerequisite: INFS 501,
515 and 590; or equivalent.  Concepts and applications of telecommunications
technologies, networks and distributed information systems. Includes regulatory
issues, network pricing and management. Case studies.

<P>
<A NAME="infs614">
<B>INFS 614 Database Management (3:3:0).</B> Prerequisite: INFS 501, 515 and 590; or equivalent.
Generalized database management systems: their internal and external structure,
development, implementation, management and  use. Covers logical and physical
database design and access methods. Several commercial systems are examined.
Computing lab.

<P>
<A NAME="infs622">
<B>INFS 622 Information Systems Analysis and Design (3:3:0).</B> Prerequisite: INFS 501, 515
and 590; or equivalent. Integration of computing technologies, systems analysis,
system design practices and management criteria in the design of large scale
information management and decision support systems. Cases and computing lab.

<P>
<A NAME="infs623">
<B>INFS 623 Information Retrieval (3:3:0). Prerequisite: INFS 614.</B> This course examines
models and theories used for the design of information systems for textual and
less well structured data bases; covering hardware, software and the design,
implementation and evaluation of such systems. Laboratory (computer programming).

<P>
<A NAME="infs650">
<B>INFS 650 Object Oriented Applications for Information Systems (3:3:0).</B> Prerequisites:
INFS 501, 515 and 590; or equivalent.  Principles and applications of object-oriented methods in information systems.  The study of a variety of languages and
design methods used for class construction.  Consideration of higher-level tools
for system construction. Investigation of applications through program
construction and case studies in varied settings, such as database systems,
graphical user interfaces, knowledge-based systems, simulations, and prototyping. 
Programming projects.

<P>
<A NAME="infs680">
<B>INFS 680 Technical and Administrative Issues in Office Automation (3:3:0).</B> Prerequisite: INFS 590 (may be taken concurrently). Examines office automation as an issue
in applying the concepts of MIS in an organization. Focuses on technical issues
of hardware and software selection as well as administrative problems associated
with successful integration of the appropriate technologies. Lecture and major
class project.

<P>
<A NAME="infs696">
<B>INFS 696 Directed Readings (3:3:0).</B> Prerequisite: Graduate degree students in information
systems with at least 12 prior credit hours in MSIS program.  Research and
analysis of a contemporary problem in information system development. Prior
approval required by a faculty sponsor who supervises
the student's work. Written report or thesis proposal to be prepared.  Maximum
of 6 hours may be earned.

<P>
<A NAME="infs699">
<B>INFS 699 Advanced Topics in Information Systems (3:3:0).</B> Prerequisite: Permission of
instructor. Special topics not occurring in the regular INFS sequence will be
presented.  May be repeated for credit where distinct offerings of the course
differ in subject.  

<P>
<A NAME="infs760">
<B>INFS 760 Advanced Database Management (3:3:0).</B>  Prerequisites: INFS 614.  Study of
advanced database models and languages, database design theory, transaction
processing, recovery, concurrency, distributed database, security and integrity. 
Discussion of recent developments and research directions. 

<P>
<A NAME="infs662">
<B>INFS 762 Information Systems Security (3:3:0).</B>  Prerequisites: INFS 601, 612 and 614; or
equivalent.  Study of security policies, models and mechanisms for secrecy,
integrity and availability.  Operating system models and mechanisms for mandatory
and discretionary controls.  Data models, concepts and mechanisms for database
security.  Basic cryptography and its applications.  Security in computer
networks and distributed systems.  Control and prevention of viruses and other
rogue programs.

<P>
<A NAME="infs770">
<B>INFS 770 Methods for Information Systems Engineering (3:3:0).</B>  Prerequisite: INFS 622. 
Study of the Information Systems Engineering lifecycle.  Methodologies and
methods for data, knowledge and information engineering.  Information systems
planning including strategic information, critical success factors, and
enterprise models.  Object modeling including data semantics, entity/relationship
models, and knowledge acquisition.  Process modeling including hierarchical
function and process decomposition.  Case studies and semester group project.

<P>
<A NAME="infs790">
<B>INFS 790 Information Systems Policy and Administration (3:3:0).</B> Prerequisite: Completion
of all core courses for the M.S. in Information Systems; preferably taken in final semester
prior to graduation. Capstone course, integrates the technical and executive policy
issues of information systems. Critical executive issues are examined through
case studies and comprehensive individual project. 

<P>
<A NAME="infs798">
<B>INFS 798 Research Project (3:3:0).</B> Prerequisite: 18 hours of credit applicable towards M.S.
in Information Systems.  Research project is chosen under the guidance of a full-time graduate faculty member, resulting in a written technical report.  Prior
approval required by a faculty sponsor who supervises the student's work.

<P>
<A NAME="infs799">
<B>INFS 799 Thesis (1-6:0:0).</B> Prerequisite: 18 hours of credit applicable toward MSIS degree. 
Original or compilary work evaluated by a committee of three faculty members.


<P>
<HR>
<A HREF = "ms-intro.html">Return to Master of Science in Information Systems.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-42</DOCNO>
<DOCOLDNO>IA053-000892-B034-223</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/swse-ms/c-l-swse.html 129.174.40.15 19970123190852 text/html 5967
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:07:43 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 29 Aug 1996 16:27:14 GMT
Content-type: text/html
Content-length: 5784
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Software Systems Engineering Courses (SWSE).</TITLE>
</HEAD> 
<BODY> 
<H1>Software Systems Engineering Courses (SWSE).</H1>
<P>
<HR>
<P>
<A NAME="swse619">619 Software Construction (3:3:0).</A> Prerequisites: SWSE foundation courses or
equivalent.  In-depth study of software construction using a modern language.
Concepts such as information hiding, data abstraction, concurrency, and 
object-oriented software construction are discussed.
<P>
<A NAME="swse620">620 Software Requirements and Prototyping (3:3:0).</A> Prerequisites: SWSE foundation
courses or equivalent.  In-depth study of methods, tools, notations, and validation
techniques for the analysis and specification of software requirements. Students
participate in a group project on software requirements.
<P>
<A NAME="swse621">621 Software Design (3:3:0).</A> Prerequisites: SWSE 619 or permission of instructor. 
Concepts and methods for the architectural design of large-scale software
systems. Fundamental design concepts and design notations are introduced. Several
design methods are presented and compared, with examples of their use. Students
participate in a group software design project.
<P>
<A NAME="swse623">623 Formal Methods and Models in Software Engineering (3:3:0).</A>
Prerequisites: SWSE foundation courses or equivalent.  Formal mechanisms for specifying, 
validating, and verifying software systems.  Program verification through Hoare's method 
and Dijkstra's weakest preconditions.  Formal specification via algebraic
specifications and abstract model specifications, including initial specification
and refinement towards implementation.  Integration of formal methods with
existing programming languages, and the application of formal methods to
requirements analysis, testing, safety analysis, and object-oriented approaches.
<P>
<A NAME="swse625">625 Software Project Management (3:3:0).</A>  Prerequisites:
 SWSE foundation courses or equivalent.  Lifecycle and process models; process 
metrics; planning for a software project; mechanisms for monitoring and controlling 
schedule, budget, quality, and productivity; and leadership, motivation, and team building.
<P>
<A NAME="swse626">626 Software Project Laboratory (3:3:6).</A>  Prerequisites: 
SWSE 619, 620, 621 and 625, or permission of instructor.  Students are involved 
in  analysis, design, implementation, and management of a software system project. 
Students work in teams to develop or modify a software product, applying sound principles 
of software systems engineering. Both industrial and academic standards are used to
assess the quality of the work products.
<P>
630 Software Engineering Economics (3:3:0). Prerequisite: SWSE  625. Covers
quantitative models of the software lifecycle; cost-effectiveness analysis in
software engineering; multiple-goal decision analysis; uncertainty and risk
analysis; software cost estimation; software engineering metrics; and
quantitative lifecycle management techniques.
<P>
631 Object-Oriented Software Development (3:3:0). Prerequisite:  SWSE 619. 
Principles of object-oriented design, development, and programming.  Includes
relationships between object-oriented design concepts and software engineering
principles, techniques of object-oriented design and programming, and applying
object-oriented techniques.
<P>
632 User Interface Design and Development (3:3:0).  Prerequisite: SWSE 619 or
permission of instructor. Principles of user interface design, development, and
programming. Includes user psychology and cognitive science, adaptive user
interfaces, icon and window design, command language design, user guidance
systems, and collaborative working.
<P>
635 Software Testing and Quality Assurance (3:3:0). Prerequisite: SWSE 619, or
permission of instructor.  Concepts and techniques for testing software and assuring
its quality.  Software testing at the unit, module, subsystem, and system levels. 
Automatic and manual techniques for generating and validating test data.  The
testing process, static vs. dynamic analysis, functional testing, inspections,
and reliability assessment.  
<P>
699 Special Topics in Software Systems Engineering (3:3:0). Prerequisite:
Permission of instructor. Special topics not occurring in the regular SWSE sequence.
May be repeated for credit when semester topic is different.
<P>
720 Advanced Software Requirements (3:3:0). Prerequisites: SWSE 620 and SWSE
621. State-of-the-art and state-of-the-practice in software requirements
engineering.  In-depth coverage of selected methods, tools, notations or
validation techniques for the analysis and specification of software
requirements.  The course work includes a project investigating or applying
approaches to requirements engineering.
<P>
721 Advanced Software Design Methods (3:3:0). Prerequisites: SWSE 620  and 621.
Study of advanced design methods for large-scale software systems, including
concurrent, real-time and distributed systems.  The course work includes a
project investigating or applying software design methods.
<P>
796 Directed Readings in Software Systems Engineering (3:3:0). Prerequisite:
Permission of instructor. Analysis and investigation of a contemporary problem in
software engineering. Prior approval by a faculty member who supervises the
student's work is required. Written report.
<P>
799 Thesis (6:0:0). Prerequisite: Permission of adviser.  A research project completed
under the supervision of a faculty member, which results in a technical report
accepted by a three-member faculty committee. The report must be defended in an
oral presentation.

<P>
<HR>
<A HREF = "ms-swse.html">Return to Master of Science in Software Systems Engineering.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML> 
</DOC>
<DOC>
<DOCNO>WT03-B24-43</DOCNO>
<DOCOLDNO>IA053-000892-B034-174</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/ms-infs/elec-all.html 129.174.40.15 19970123190825 text/html 4873
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:07:16 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 27 Aug 1995 17:16:06 GMT
Content-type: text/html
Content-length: 4690
</DOCHDR>
<HTML>

<TITLE> Approved Electives for the MSIS Program</TITLE>
<H1> Approved Electives for the MSIS Program</H1>
<P>            
<HR>
<P>
MSIS students may enroll in the following approved electives so long as 
the course pre-requisites have been met.  Note that elective courses not
on this list may be taken with the prior consent of the student's faculty
advisor.
<P>

<H2>Information Systems (INFS)</H2>
<P>
<DL>
<DD><B>500</B> Quantitative Foundations (INFT)
<DD><B>623</B> Information Retrieval
<DD><B>650</B> Object Oriented Applications
<DD><B>680</B> Tech & Adminis Issues in Ofc Auto
<DD><B>696</B> Directed Readings
<DD><B>699</B> Advanced Topics
<DD><B>760</B> Advanced Database Management
<DD><B>762</B> Information Systems Security
<DD><B>770</B> Methods for Info Systems Engr
</DL>
<P>
<HR>
<H2>Software Systems Engineering (SWSE)</H2>
<P>
<DL>
<DD><B>619</B>  Software Construction
<DD><B>620</B>  Software Requirements and Prototyping*
<DD><B>621</B>  Software Design
<DD><B>623</B>  Formal Methods and Models
<DD><B>625</B>  Software Project Management
<DD><B>630</B>  Software Engineering Economics
<DD><B>631</B>  Object-Oriented Software Develop
<DD><B>632</B>  User Interface Design
<DD><B>635</B>  Software Test & Quality Assurance
<DD><B>720</B>  Advanced Software Requirements
<DD><B>721</B>  Advanced Software Design Methods
</DL>
<P>
<STRONG>* Should not be taken unless student is replacing INFS 622 as a part 
of the SWSE Certificate.  Credit will not be given for both INFS 622 and 
SWSE 620.</STRONG>
<P>
<HR>
<P>
<DL>
<H2>Computer Science (CS)</H2>
<P>
<DL>
<DD><B>531</B>  Theory of Computation
<DD><B>540</B>  Language Processors
<DD><B>580</B>  Artificial Intelligence
<DD><B>583</B>  Analysis of Algorithms
<DD><B>635</B>  Parallel Computation
<DD><B>640</B>  Advanced Program Development
<DD><B>652</B>  Computer Graphics
<DD><B>655</B>  Performance Analysis/Networks
<DD><B>672</B>  Computer Systems Perf. Evaluation
<DD><B>680</B>  Natural Language
<DD><B>681</B>  Expert Systems
<DD><B>682</B>  Computer Vision
<DD><B>683</B>  Algorithms
<DD><B>685</B>  Intelligent Systems for Robotics
<DD><B>686</B>  Image Processing
<DD><B>688</B>  Neural Networks
<DD><B>735</B>  Concurrency
<DD><B>752</B>  Interactive Graphics Software
<DD><B>782</B>  Machine Learning
<DD><B>785</B>  Knowledge Acquisition/Prob Solving
</DL>
<P>
<HR>
<P>
<H2>Psychology (PSYC)</H2>
<P>
<DL>
<DD><B>734</B>  Human Factors Engineering Seminar
<DD><B>737</B>  Psych. of Human/Technology Interface
</DL>
<P>
<HR>
<P>
<H2>Systems Engineering (SYST)</H2>
<P>
<DL>
<DD><B>612</B>  Sys Design and Integration
<DD><B>613</B>  Sys Mgmt and Evaluation
<DD><B>671</B>  Judgment/Decision Making Urban Systems Engineering (USE)
<DD><B>601</B>  Modeling and Problem Solving Elect. and Computer Eng'ing (ECE)
<DD><B>500</B>  Signals and Systems
<DD><B>511</B>  Microprocessors
<DD><B>512</B>  Real-Time Microprocessor Sys
<DD><B>516</B>  Applied Microprocessors
<DD><B>521</B>  Modern Systems Theory
<DD><B>546</B>  Parallel Computer Architecture
<DD><B>549</B>  Thry/Applic of Artificial Neural Netwks
<DD><B>624</B>  Computer Control Systems
<DD><B>639</B>  Satellite Communications
<DD><B>640</B>  Massively Parallel Systems
<DD><B>641</B>  Architecture
<DD><B>642</B>  Communication Networks
<DD><B>643</B>  Telecommunicatoin Switching Sys
<DD><B>644</B>  Image Processing
<DD><B>650</B>  Robotics I
<DD><B>744</B>  Computer Vision & Expert Systems
<DD><B>749</B>  Neural Networks for Control
</DL>
<P>
<HR>
<P>                              
<H2>Operations Research (OR)</H2>
<P>
<DL>
<DD><B>541</B>  Deterministic Models
<DD><B>542</B>  Stochastic Models
<DD><B>635</B>  Discrete System Simulation
<DD><B>643</B>  Network Modeling
<DD><B>681</B>  Contem. Issues in Decision Analysis
</DL>
<P>
<HR>
<P>                          
<H2>Statistics (STAT)</H2>
<P>
<DL>                              
<DD><B>644</B>  Applied Probability
<DD><B>654</B>  Applied Statistics
<DD><B>662</B>  Multivariate Statistical Methods
<DD><B>663</B>  Exploratory Data Analysis
<DD><B>670</B>  Survey Sampling
</DL>
<P>
<HR>
<P>                              
<H2>Management Information System (MIS)</H2>
<P>
<DL>                             
<DD><B>730</B>  Decision Support Systems
<DD><B>760</B>  Human Engineering Issues
<DD><B>780</B>  Knowledge-Based Systems
<DD><B>795</B>  Business Expert Systems
</DL>
<P>
<HR>
<A HREF = "elective.html">Return to Elective Courses.</A> <br>
<A HREF = "ms-intro.html">Return to Master of Science in Information Systems.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</HTML>                                                                           
</DOC>
<DOC>
<DOCNO>WT03-B24-44</DOCNO>
<DOCOLDNO>IA053-000892-B031-110</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/ms-infs/frequire.html 129.174.40.15 19970123185323 text/html 3237
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:52:13 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 27 Aug 1995 17:16:53 GMT
Content-type: text/html
Content-length: 3054
</DOCHDR>
<HTML>
<TITLE>Foundation Requirements</TITLE>

<H1>Foundation Requirements</H1>
<P>
<HR>
<P>
The MSIS program prepares students for research and practice in 
Information Systems. The program emphasizes a balance of technical 
and management skills. In order to ensure that students have an 
adequate background in mathematical methods, computer technology, 
and business knowledge, the program requires three foundation courses.
<P>
<EM>These foundation courses are the following three
George Mason University courses, or equivalent:</EM>
<P>
<DL>
<DD> <B>INFS 501</B> Discrete and Logical Structures for Information Systems
<DD> <B>INFS 515</B> Computer Organization
<DD> <B>INFS 590</B> Program Design and Data Structures
</DL>
<P>  
and, one of the three courses listed below
<P>
<DL>
<DD> <B>ACCT 600</B> Accounting and Reporting
<DD> <B>MGMT 600</B> Organizational Behavior and Development
<DD> <B>MKTG 650</B> Marketing Management
</DL>
<P>
<H3>The catalog descriptions of each class is as follows:</H3>
<P>
<B>ACCT 600</B>  Financial Accounting.  All aspects of accounting from the basic
concept of a transaction through financial statements and their interpretation.
<P>
<B>MGMT 600</B>  Organizational Behavior and Development.  Development, theories, and
practice of management within organizations.  Particular emphasis will be given
to human behavior and how it influences organizational effectiveness and
efficiency.  Student skills will be improved through case studies, readings,
exercises, and class discussion.
<P>
<B>MKTG 650</B>  Marketing Management.  This course develops abilities to make
marketing decisions through application of qualitative and quantitative concepts,
with emphasis on marketing research, strategic planning, consumer behavior, and
market determination.  Case studies, readings, and projects.
<P>
<HR>
<P>
When a prospective student applies to the MSIS program, he or she 
is asked to fill out a departmental self-evaluation form, indicating
whether previously taken courses may satisfy these foundation requirements. 
Upon acceptance, the student is advised of the necessary foundation courses 
to be satisfactorily completed, as articulated courses, to meet this 
requirement. Foundation courses do not earn credit toward the MSIS degree ;
however, a grade of B or better must be obtained in a foundation course. 

<P>
Students may take courses through the Cooperative Graduate Engineering 
Program in affiliation with the University of Virginia and Virginia Tech.
Appropriate courses may be transferred, with adviser approval, into this 
GMU degree program. Refer to the section on <I>Prograrns and Additional
Graduate Courses in the graduate catalog.</I>
<P>
Newly admitted students can obtain a catalog at the Admissions desk in Finley.
Others may purchase one from the Bookstore in Student Union II or by calling 
<STRONG>(703)993-2665.</STRONG> 
<P>
<HR>
<A HREF = "ms-intro.html">Return to Master of Science in Information Systems.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-45</DOCNO>
<DOCOLDNO>IA053-000892-B031-245</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/ms-infs/comp-res.html 129.174.40.15 19970123185543 text/html 2036
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:54:30 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 27 Aug 1995 17:14:33 GMT
Content-type: text/html
Content-length: 1853
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Computing Resources</TITLE>
</HEAD> 
<BODY>                  
<H1>Computing Resources</H1>
<P>
<HR>
<P>
Students in the program have access to a variety of computing systems on
campus.
<P>
<H3>The University Computing and Information Systems provides access to: </H3>
<P>
<UL>
<LI>1) Digital Equipment Corporation (DEC) VAX 8820 running VAX VMS, and 
<LI>2) a DEC VAX 8530 running Ultrix.  
</UL>
<P>
The two computers support a variety of languages including
<B>Pascal, COBOL, PL/I, SNOBOL, FORTRAN, GPSS and Simscript.</B>  Other facilities
include several microcomputer laboratories supporting C and Ada as well as a
variety of database systems, and a Graphics Laboratory.  All machines are
available through 1200/2400/4800/9600 Baud dialup.  In addition, there are a
number of IBM-PC (or equivalent) microcomputers, several SITE labs with Advanced
Workstations such as SUNs and Hewlett Packard, available for student use on
campus, as well as a Computer Graphics Laboratory which contains a variety of
workstation and mainframe-oriented graphics systems.
<P>
The Department of Information and Software Systems Engineering maintains
a heterogeneous network, shared by the Center for Secure Information Systems, the
Evolutionary Software Systems Engineering lab, and the Center for Software
Systems Engineering, for both teaching and research purposes.  It consists of a
central Sun Sparc serve supporting NeXT, Macintosh, HP9000, PC, AT&T, X-terminal,
and hand-held/portable systems with a full suite of aplications including
database, software engineering and development, office productivity, Internet
connectivity, multimedia, and multilingual capabilities.
<P>
<HR>
<A HREF = "ms-intro.html">Return to Master of Science in Information Systems.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-46</DOCNO>
<DOCOLDNO>IA053-000892-B031-134</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/ms-infs/arequire.html 129.174.40.15 19970123185356 text/html 1549
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:52:27 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 27 Aug 1995 17:14:27 GMT
Content-type: text/html
Content-length: 1366
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Admission Requirements</TITLE>
</HEAD>
<P>
<H1>Admission Requirements </H1>
<P>
<HR>
<P>
<H3>Applicants should meet the following minimum entrance requirements:</H3>
<P>
<OL>
<LI> Hold a baccalaureate degree from an accredited institution.
<LI> Have earned a grade-point average of <B> 3.0 </B> or better in the last <B> 60 </B> hours.
<LI> Show proof of a satisfactory score on the Graduate Management Admission
     Test <B> (GMAT) </B> or the Graduate Record Exam <B> (GRE).</B> The applicable test should
     have been taken <I>within five years of applying for admission</I>. The GRE/GMAT
     requirement is waived if the applicant already has a master's degree in a
     related field.
<LI> Submit the appropriate application form with three <I>letters of
     recommendation </I> from persons directly knowledgeable of the applicant's
     professional and academic competence, a one-page goals statement and work
     resume.
<LI> Submit a completed MSIS self-evaluation form which is essential to
     evaluation of foundation requirements by the department faculty.  This
     form may be obtained from the department office.
</OL>
<P>
<HR>
<A HREF = "ms-intro.html">Return to Master of Science in Information Systems.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML>                                 
</DOC>
<DOC>
<DOCNO>WT03-B24-47</DOCNO>
<DOCOLDNO>IA053-000892-B031-305</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/ms-infs/elective.html 129.174.40.15 19970123185720 text/html 1475
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:56:05 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 27 Aug 1995 17:16:36 GMT
Content-type: text/html
Content-length: 1292
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Electives</TITLE>
</HEAD> 
<BODY>   
<H1>Elective Courses.</H1>
<P>
<HR>
<P>
In order for students to pursue their individual interests, they may elect four
courses.  Guidelines for selecting elective courses are available from the
department office or <A HREF = "elec-all.html"> click here for a list of approved electives </A>. A thesis option is available; students may elect to complete
a thesis for up to 6 hours of elective credit.
<P>
<STRONG>Students may earn a Certificate in Software Systems Engineering by replacing the
INFS 622 core course with SWSE 620, and by taking the following SWSE courses as
electives:</STRONG>
<UL>
<LI>SWSE 619  Software Construction
<LI>SWSE 621  Software Design
<LI>SWSE 623  Formal Methods and Models in Software Engineering
<LI>SWSE 625  Software Project Management
</UL>
<P>
<STRONG>NOTE</STRONG> that <B>SWSE 620</B> should not be taken as an elective unless the student is
replacing INFS 622 as a part of the Software Systems Certificate program.  Credit
will not be given for taking both INFS 622 and SWSE 620; only three hours of
credit will be awarded.

<P>
<HR>
<A HREF = "ms-intro.html">Return to Master of Science in Information Systems.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-48</DOCNO>
<DOCOLDNO>IA053-000892-B031-362</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/swse-ms/swse-adv.html 129.174.40.15 19970123185747 text/html 1286
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:56:37 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 30 May 1996 13:26:42 GMT
Content-type: text/html
Content-length: 1103
</DOCHDR>
<HTML>
<HEAD><TITLE>ADVISING</TITLE></HEAD> 
<BODY>
<P>
<H1>ADVISING.</H1>
<P>
<HR>
<P>
Before the beginning of each semester, the ISSE department holds an orientation
meeting to advise incoming and continuing students.  Members of the faculty are
present to answer questions and to offer advice concerning programs of study. 
Course registration forms are signed at this time; however, a student may enroll
ahead of the orientation meeting with Departmental approval and signature.
<P>
The department also provides an advising function to students, as outlined in the
Student Advising Form available from the department.  Each student is assigned
a faculty advisor with whom the student may confer regarding queries of a
technical nature.  A Plan of Study form for the MS-SWSE degree should be
completed and submitted by the student soon after admission to the program.  
The plan serves as a planning guide for the student.

<HR>
<P>
<A HREF = "ms-swse.html">Return to Master of Science in Software Systems Engineering.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-49</DOCNO>
<DOCOLDNO>IA053-000892-B034-187</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/swse-ms/foundreq.html 129.174.40.15 19970123190832 text/html 1826
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:07:23 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 27 Aug 1995 17:35:18 GMT
Content-type: text/html
Content-length: 1643
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Listing of Foundation Classes.</TITLE>
</HEAD> 
<BODY> 
<H1>Listing of Foundation Classes.</H1>
<P>
<HR>
<P>
<B>501 Discrete and Logical Structures for Information Systems (3:3:0).</B> 
Prerequisites: 6 credits of undergraduate mathematics.  Study of discrete and logical
structures for information systems analysis and design including basic set theory
and proof techniques, propositional and predicate logic, Boolean algebras and
lattices, trees and graphs, finite state machines, formal languages and their
relation to automata, computability and computational complexity, formal
semantics-operational, axiomatic and denotational approaches.
<P>
<B>515 Computer Organization (3:3:0).</B>  Prerequisites:  Undergraduate courses or
equivalent knowledge in structured programming in a high-level language.  Computer
hardware organization:  arithmetic and logical operations; combinational and
sequential logic; machine representation of numbers, characters, and
instructions; addressing techniques; microprogramming; reduced instruction set
computers.  Symbolic assembly language.  Interrupts and input/output
organization.  
<P>
<B>590 Program Design and Data Structures (3:3:0).</B>  Prerequisite: Course work in a high
level language.  Study of the fundamentals of data structures and algorithms
applied in programming solutions to application problems.  Stresses structured
programming in a modern high-level language. Laboratory required. 

<P>
<HR>
<A HREF = "ms-swse.html">Return to Master of Science in Software Systems Engineering.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-50</DOCNO>
<DOCOLDNO>IA053-000892-B031-197</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/ms-infs/advising.html 129.174.40.15 19970123185500 text/html 1277
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:53:52 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 27 Aug 1995 17:14:20 GMT
Content-type: text/html
Content-length: 1094
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Advising</TITLE>
</HEAD> 
<BODY>                  
<H1>Advising</H1>
<P>
<HR>
<P>
Before the beginning of each semester, the ISSE department holds an orientation
meeting to advise newly admitted and continuing students.  <EM>Incoming students are
required to attend the orientation meeting.</EM>  Registration forms are signed at
this time; however, students may register ahead of the orientation meeting by
coming to the department for prior approval of classes.
<P>
The department also provides an advising function to students, as outlined in the
Student Advising Form available from the department.  Each student is assigned
a faculty adviser with whom the student may confer on matters related to degree
requirements.  A Plan of Study form for the MSIS degree should be completed and
submitted by the student soon after admission to the program.  The plan serves
as a planning guide for the student.
<P>
<HR>
<A HREF = "ms-intro.html">Return to Master of Science in Information Systems.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-51</DOCNO>
<DOCOLDNO>IA053-000895-B042-386</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/dccp/index.html 129.174.40.15 19970123194528 text/html 5149
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:44:17 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 20 Jan 1997 16:47:18 GMT
Content-type: text/html
Content-length: 4966
</DOCHDR>
<HTML>
<head>
<TITLE>The unofficial greater DC area Cypherpunks Page </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<body BGCOLOR="#FFFFFF" TEXT="#000000" LINK="#00008F" VLINK="#8F0000">


<center>
<A HREF="http://march.tico.com">
<IMG
SRC="../efm-logo.jpg"
ALT="Electronic Freedom March on Washington"></A>
</CENTER>

<H1>DCCP, Cypherpunks in the Washington DC and surrounding areas</H1>
<p>
<a href="http://www.privacy.org/ipc">
<img src="../gk7.gif" allign=right alt="Golden Key"></a><br>

Welcome to the <a href="./official.html">unofficial</a> 
DC area CypherPunks home page
<ul>
<li><a href=#NextMeeting>Next Scheduled Meeting</a>
<li><a href=#Agenda>Tentative Agenda</a>
<li><a href=#DirectionsToMeeting>Directions to the Meeting</a>
<li><a href="#WhoIsDccp>Who/What is DCCP?</a>
<li><a href="#HowToJoin">How to join DCCP</a>
</ul>
<hr>
<a name="NextMeeting">
<h2>When is the next meeting?</h2>

The Next meeting date is 
unknown, probably in late Februaru or early March.


<hr>
<a name="Agenda">
<h3>Agenda next meeting</h3>
*** The Agenda is <i>always</i> Under construction***
<br>
Potential topics of interest include:
<ul>
</ul>
<p>
There is no standardized time frame for meetings, but most meetings
run from 3 to about 5:30, and we usually then find a resturant for
food, drinks, and further discussion. Some of the resturant conversations
have been wonderful and lasted for hours.


<h3>Don't forget</h3>
<ul>
<li><a href="../nist/kmi.html">Clipper III, the GAK continues</a>
<li>Next Spring's 
 'net march on Washington
<A HREF="http://march.tico.com">
 'net march on Washington</a>
<li><a href="http://www.privacy.org">Privacy.org </a>
 
<li>We are going to try to get a couple of speakers to talk 
for about 30 minutes each. This will give the meeting a focus.
And perhaps it will attract new people. Volunteer topics/presentors
needed.
</ul>

<hr>
<a name="DirectionsToMeeting">
<h3>Directions to the next meeting</h3>
<hr>
<a name="Archives">
<h2>DCCP archives</h2>
<ul>
<li>Pat Farrell's Powerpoint presentation on <a href="./dccpsetcrypto.ppt">
Crypto protocols in SET</a>  (~202KB)
</ul>
<p>
<hr>
<a name="WhoIsDccp">
<h2>Who is on dccp?</h2>
DCCP is  
<a href="mailto:dccp@eff.org">dccp@eff.org</a>, a
mailing list for DC-area cypherpunks and 
others with interestes in privacy, cryptography, security, and networking. Since
the "networking" interests are in both the technical, electronic meaning
of the word, and the social and interpersonal meaning of the word, we
occasionally meet physically. The 
<A HREF="http://www.eff.org"> Electronic Frontier Foundation </A> 
has been kind enough to set up a mailing list on their node, eff.org.
<P>
The term "dccp" is a mixed choice. It is the obvious contraction
of DC CypherPunks. Lots of the members are in the
greater Washington DC area. The locals in this area use the term "DC"
when they mean the city, Washington, DC, that is the capitol of
the US. The term is used mostly because it is short, and partly
to differentiate it from Washington State, or towns like
Washington, Virginia.
<p>
Dccp is actually larger than its name. Many of the folks on the list are
from farther away. We regularly see folks from Baltimore, and people
have traveled from as far away as New York, NY. to attend our meetings.
<h2>Who is in charge?</h2>
In short, no one. There is no list of members, no officers, no voting rules,
etc. Folks who are interested in organizing a meeting, do so, and announce it.
The founders of the main cypherpunks list are crypto-anarchists, many
on the dccp are too, although no single label does justice to such a 
diverse goup.
<hr>
<a name="HowToJoin">
<h2>How do I join?</h2>
You join dccp by sending email to 
<a href="mailto:listserv@eff.org">the EFF listserver</a>
in the body of the message, put the line
<br>
<pre>
    add dccp
</pre>
<br>
For additional information and help, you can send mail to
<a href="mailto:listserv@eff.org">the EFF listserver</a>
with just the word "help" in the body. Or you can send mail
<a href="mailto:dccp-request@eff.org">dccp-request@eff.org</a> 
I read this address, and will try to help you out.
<h2> How do I use the list?</h2>
Just send email to 
<a href="mailto:dccp@eff.org">dccp@eff.org</a>.
<hr>
<h2>Related pointers</h2>
<ul>
<li>The <a href="ftp://ftp.csua.berkeley.edu/pub/cypherpunks/Home.html">
Berkeley cypherpunks homepage</a>
<li>A Boston Globe article featuring quotes by 
<a href="http://nytsyn.com/live/Features1/284_101195_072917_2683.html">
members of the DC Cypherpunks</a>
<li>Sending mail to <a href="mailto:cypherpunks@toad.com">the cypherpunks</a>
list.
<li>My <a href="http://www.isse.gmu.edu/~pfarrell/crypto.html">crypto
and related topics</a> page.
</ul>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 

January 20, 1997  Backto <a href="../hotlist.html">Pat's hotlist</a> Backto <a href="../index.html">Pat's homepage</a>
</body>
</HTML>



</DOC>
<DOC>
<DOCNO>WT03-B24-52</DOCNO>
<DOCOLDNO>IA053-000895-B044-124</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/kmi.html 129.174.40.15 19970123195054 text/html 50115
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:49:39 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 28 May 1996 17:03:27 GMT
Content-type: text/html
Content-length: 49931
</DOCHDR>
<HTML>
<head>
<title>
Draft Paper, "Enabling Privacy, Commerce, Security
 and Public Safety in the Global Information
  Infrastructure"
 </title>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
This document is presented as a public service. It is presented
unmodified, as distributed by NIS&T. Its availability on Pat Farrell's 
set of pages does not imply that
Pat Farrell supports this proposal.
<p>
This logo brought to you by Pat Farrell<br>
 <A HREF="http://www.privacy.org/ipc/">
 <IMG BORDER=0 SRC="../gk7.gif"
 ALT="Golden Key"><BR>
 </A>
<hr>
<center>
             Executive Office of the President<br>
               Office of Management and Budget<br>
                   Washington, D.C. 20503<br>
<p>

                        May 20, 1996
</center>
<p>

<b>MEMORANDUM FOR INTERESTED PARTIES</b>
<p>
SUBJECT:  Draft Paper, "Enabling Privacy, Commerce, Security
          and Public Safety in the Global Information
          Infrastructure"
<p><table>
<tr><td>FROM:     </td><td>Bruce W. McConnell [Initials]</td></tr>
<tr><td></td><td>          Edward J. Appel [Initials]</td></tr>
<tr><td></td><td>          Co-Chairs, Interagency Working Group on
          Cryptography Policy</td></tr>
</table>

<p>
     Attached for your review and comment is a draft paper
entitled "Enabling Privacy, Commerce, Security and Public
Safety in the Global Information Infrastructure." It presents
a vision and course of action for developing a cryptographic
infrastructure that will protect valuable information on
national and international networks.
<p>
     The draft paper is the result of the many discussions we
have had with interested parties concerning the use of
encryption. While those discussions have explored the use of
both key recoverable encryption and non-recoverable
encryption, the draft paper addresses an infrastructure which
uses key recoverable encryption. We believe such a key
management infrastructure, voluntary and supported by *private
sector* key management organizations, is the prospect of the
near future. It would permit users and manufacturers free
choice of encryption algorithm, facilitate international
interoperability, preserve law enforcement access, and, most
importantly, provide strong system security and integrity.
<p>
     Recognizing that a robust infrastructure is not yet a
reality, we are also considering measures to liberalize export
policy for some non-escrowed products. Appendix II of the
draft paper begins to summarize current policy, and we intend
to expand and improve that section.
<p>
     We believe that clearly articulating such a vision will
accelerate the ability of the United States to realize the
full advantages of the global network for commerce, security
and public safety. However, such a vision cannot become a
reality unless it is widely shared. Therefore, rather than
being a finished product, the attached paper is a draft which
we ask you to help us improve. We hope it will contribute to
constructive discussion and promote a clearer understanding of
each others' needs and concerns regarding the use of
encryption.
<p>
     We welcome your comments and look forward to further
discussion. Written comments may be sent to our attention,
Room 10236, NEOB, Washington, D.C. 20503.
<p>
[End cover letter]
<hr>
<p>
[Note:    All 25 pages of the typeset report have the word 
  "Draft" printed in large letters across the text.]
<p>
<hr>
[Head note of report] Last Modified: May 17, 1996

<p>
<h1>Enabling Privacy, Commerce, Security and Public Safety in the
Global Information Infrastructure</h1>
<p>
<h3>Statement of the Issue</h3>

     This paper outlines a course of action for developing an
infrastructure that will protect valuable national information
resources on national and international networks. Government
and industry must work together to create a security
management infrastructure and attendant products that
incorporate robust cryptography without undermining national
security and public safety. A policy for escrow of
cryptographic keys which provides a basis for bilateral and
multilateral government agreements must be determined so that
industry can produce products for worldwide interoperability.
Industry will participate in defining algorithms and protocol
standards, and will develop key escrow encryption products
suitable for the protection of both government and private
sector information and which will assure timely, lawful,
government decryption access. Government will help set
standards for the Key Management Infrastructure (KMI) and
deliver a market for robust security products. A KMI
infrastructure and attendant key escrow products will provide
many benefits, both domestic and internationally, as the US
begins to realize the advantages of the global network for
improve commerce, security and public safety.

<hr>

<h1>I.  Introduction</h1>
<p>
     Government can no longer monopolize state of the art
cryptography. It is no longer acceptable to argue that the
only information of a compelling national security interest is
government information. It is unrealistic to believe that
government can produce solutions which keep ahead of today's
rapdily changing information technology. Increasingly, all
institutions, military, civil, or corporate, will communicate
across common links. The nation's commerce is moving to
networking. With these enormous changes, means must be found
to responsibly raise the quality of cryptographic services
without jeopardizing effective law enforcement, imperiling
public safety.
<p>
     Industry and government must partner in the development
of a public key-based key management infrastructure and
attendant products that will assure participants can transmit
and receive information electronically with confidence in the
information's integrity, authenticity, and origin and which
will assure timely lawful government access. When we conduct
transactions, we rely on face-to-face interactions, or
obtaining a signature on a paper, to have confidence that
commitments will be fulfilled. Policies and infrastructure are
needed to assure we can have at least the same degree of
confidence when we interact electronically. Government bears
a significant responsibility to ensure the information
infrastructure has the features that are essential to such
confidence.
<p>
     There is a more compelling rationale for the government
to be a partner in the development of the KMI. Not only has
the Information Age sparked fundamental changes in the way we
interact, but reliance on information systems makes our
institutions vulnerable to an unprecedented degree. Almost all
institutions upon which public safety and national security
depend, ranging from the power grid to military command and
control, are at severe risk because of their presence in and
dependence upon a global information infrastructure.
<p>
     But the proliferation of quality cryptographic services
is not without risk. Keys can be lost, stolen, or forgotten --
rendering encrypted data useless. Additionally, the widespread
use of encryption without safety features such as key recovery
can pose serious risks to society. It will put at risk
important law enforcement and national security investigations
where electronic surveillance and search and seizure are
essential in preserving and prosecuting crimes, and more
importantly, in saving human life.
<p>
     Public key cryptography allows for secure authenticated
transactions with any party, known or unknown, with assurance
of data integrity and non-repudiation of the transaction.
These features, together with increased network reliability,
are needed to support electronic commerce, public services,
redefined business processes and national security.  But to
achieve its promise, public key cryptography must be based on
a key management infrastructure and attendant products that
tie individual and coprorate identities to their public key
through a series of Certificate Authorities (CA). The key
management infrastructure to do this on a global scale will be
very large and complex, but it is an essential foundation.
Without a KMI of trusted certificate authorities, users cannot
know with whom they are dealing on the network, or sending
money to, or who signed a document, or if the document was
intercepted and changed by a third part. Therefore, users will
demand a strong key management infrastructure, which may, in
turn, be based on a voluntary system of commercial certificate
authorities (CAs) operating within prescribed policy and
performance guidelines. To achieve the environment for such an
approach, a number of principles need to be accepted by
government, industry, and other users:
<p>
<ul>
<li>
    Participation in the KMI will be voluntary. Key escrow in
     the KMI will occur naturally through mutually trusted
     authorities.
<li>
    There will be a transition period during which legacy
     equipments which do not support key recovery can be used
     to communicate with users in emerging full featured KMIs.
     Government, industry, and users will need to address the
     legitimate needs of those currently using non-key
     recovery products to communicate with users of the full-
     featured KMI in a manner that protects legitimate
     government and public safety concerns. This will provide
     a stable transition path.
<li>
    Products that operate with an escrowed KMI need to be
     developed with industry taking the lead.
<li>
    Industry can continue to lead in establishing standards
     for public key certificates, encryption algorithms,
     protocols, data recovery, and security servcies.
<li>
    Certificate authorities will operate within performance
     standards set by law.
<li>
Agreements between governments will serve as the basis
for international cross certification.
<li>
    Self-escrow will be permitted under specific
     circumstances.(1)
<li>
    Export controls on Key Escrow products will be relaxed
     progressively as the infrastructure matures.
<p>
</ul>
--------<br>
(1)  The escrow agency must meet performance requirements for
     law enforcement access.
<hr>
<h1>II.  Key Management Infrastructure</h1>
<p>
     In a key management infrastructure (KMI) based on public
key cryptography, each user has one or more pairs of public
and private keys. The public and private keys differ in a such
a way that it is computationally infeasible to determine the
private key from the public key. This allows the public key to
be revealed without endangering the security of the private
key. Users can communicate securely without having to share a
"secret"; they only need to know each other's public key and
that each public key is certified by a trusted authority.
Without assurance on the "binding" of a user to a specific
public key, these keys have little or no value.
<p>
     Public key cryptography supports security services such
as authentication, confidentiality, data integrity and
nonrepudiation. Access to a user's encrypted data for which
the key is lost is a security related service referred to as
data recovery. Providing a secure and trusted means of storing
private keys within the Key Management Infrastructure is one
means of providing data recovery. This capability naturally
supports law enforcement access, under legal warrants. Thus,
the user desire for data recovery and law enforcement's
potential need for access can be accommodated in a single
locale, so long as the user trusts the key storage and law
enforcement has confidentiality of access.(2)
<p>
----------<br>
(2)  For a survey of escrow mechanisms see Dorothy Denning's
     article in the March 1996 Journal of Communications of
     the ACM. More in depth articles on solutions to escrow
     can be found in 
<a href="http://www.seas.gwu.edu/seas/ictsp/Activities/Videos_books_papers/Books/">
<i>Building in Big Brother</i> </a> a collection of
     papers edited by Professor Lance Hoffman that contains
     both technical and political responses to
     Clipper/Capstone.
<p>
<hr>
<pre>
[Diagram]
<p>
               Escrow
          -->  Authority  (private key database)
          |         |
          |         |
          |         | public keys
          |         |                        Escrow and
private   |         |                        Certificate
key       |    Certificate                   Authorities
(either   |    Authority                     can be combined
way)      |         |                        into one entity
          |         |
          |         | public key certificate
          |         | (binds IDs and keys)
          |         |
          |         |
          -->  User A (private keys and certificates)
</pre>
<hr>
<p>
     The simplest model for a KMI meets government access
requirements by relying on the certificate authorities (CAs).
However, the hierarchy could be structured to include a
separate Escrow Authority (EA) to provide law enforcement
access. Provision for split keys to enhance personal privacy
and security can be incorporated into the KMI. Either of these
mechanisms lessens the burden of key escrow on users and on
the producers of security products.
<p>
     To participate in the network a user needs a public key
certificate signed by a CA which "binds" the user's identity
to their public key. One condition of obtaining a certificate
is that sufficient information (e.g., private keys or other
information as appropriate) has been escrowed with a certified
escrow authority to allow access to a user's data or
communications.(3) (As noted before, this might be the CA or
an independent escrow authority). The certificate creation
process is pictured above.
<p>
     For users to have confidence in the KMI, CAs must meet
minimum standards for security, performance, and liability. A
Policy Approving Authority (PAA) certifies CAs for operation.
The PAA sets rules and responsibilities for ensuring the
integrity of the CAs. The PAA is also responsible for setting
CA performance criteria to meet law enforcement needs.
<p>
     If law enforcement has obtained legal authority to access
a user's encrypted data or communications, it would certify
that authorization to the escrow authority. The escrow
authority will then relinquish information sufficient to
access the user's communication.
<p>
----------<br>
(3)  This applies only to keys used for confidentiality
     purposes and not keys used for signing purposes.
<p>
<hr>
<p>
<p>
<h1>III. Some Issues</h1>
<p>
     Difficult issues include i) how to refine the application
of export controls, ii) whether and to what extent to permit
self-escrow, iii) whether legislation is required and, if so,
what it should accomplish, and iv) the certainty and extent
that government-to-government agreements can be established to
ensure timely law enforcement access to keys/information held
by a foreign country. This section of the White paper briefly
explores each.
<p>
<p>
Export Controls
<p>
     The most contentious issue surrounding encryption is
export control policy. Encryption exports are controlled to
all destinations in the interest of U.S. national security/
foreign policy under the Arms Export Control Act. These export
controls are often criticized as an impediment to the fielding
of interoperable security across the GII and the
competitiveness of U.S. industry. The government is mindful of
these criticisms and has initiated a number of reforms to ease
the impact export controls have on manufacturers and users of
encryption. The task, then, is to find a method of applying
export controls that meets the interest of national security,
public safety, privacy, and competitiveness.
<p>
     Freedom to choose any mutually trusted certificate
authority may accommodate the above interests.(4) In addition,
allowing ready export of products of any bit length to markets
where the key management infrastructure, which complies with
statuatory constraints, is in place to permit government
access to keys, would provide both a level market for U.S.
manufacturers and higher quality security products for users.
Products that meet defined performance requirements and which
will not operate until the key is escrowed with an appropriate
certificate authority will address commercial, public safety
and national security needs. Some law enforcement and national
security concerns would be protected since government agencies
would be able to obtain escrowed keys pursuant to government-
to-government agreements.
<p>
----------<br>
(4)  A mutually trusted authority is an escrow agent trusted
     by users to store keys and trusted by law enforcement to
     provide access upon certification of lawful authority.
<hr>
<p>
Transition
<p>
     We are working toward a policy that permits licensing of
key recovery encryption systems regardless of algorithm, bit
length, or whether implemented in hardware or software, once
needed infrastructure and government-to-government agreements
are in place. In the interim we recognize that the policy must
make it worthwhile for manufacturers and users to invest in
escrowed KMI. With these objectives in mind, and consistent
with applicable statutes, the interim policy will consider:
<p>
Prior to formal government-to-government agreements:
<ul><li>
    Permitting export of products that use an escrowed KMI to
     approved markets, e.g., Europe or Australia, consistent
     with the policies of the destination country.
</ul>

<p>
Prior to multi-national Public Key Infrastructure with Key
Recovery:
<ul><li>
    Reviewing, on a case-by-case basis, proposals to export
     products which require the use of an escrowed KMI to any
     destination with which the U.S. has a government-to-
     government key escrow agreement.
<li>
    Continuing and expanding the administration's previously
     announced key escrow initiative by permitting the export
     of 64 bit S/W or 80 bit H/W key escrow products that meet
     defined performance requirements, after one-time review,
     to any destination if keys will be escrowed in the U.S.,
     or in foreign countries with which the U.S. has a
     government-to-government key escrow agreement.
</ul><p>
In any condition:
<ul><li>
    Permitting the export of other products on a case-by-case
     determination that such exports are consistent with US
     interests.
</ul>
<p>
     The proposals for an interim export control policy are
founded on the assumption that the products will require the
use of an escrowed KMI in a country with which the U.S. has a
government-to-government agreement. Note that the contemplated
exports are to civil end-users; exports to military end-users
will require more extensive product review. The existing
policies applicable to unescrowed products provide substantial
flexibility and will continue as currently defined throughout
the transition period (see Appendix II). Additional requests
for near-term relief will be considered on a case-by-case
basis consistent with existing practice.
<p>
     The interim policy also reflects a judgment that overseas
escrow of key will generally be permissible with suitable
government-to-government arrangements. There is a concern that
U.S. products with keys escrowed in the U.S. will not be
salable overseas. Hence, it may be possible to permit
overseas escrow in Europe, even before government-to-
government arraignments are completed. This exception is
possible since the European countries are already moving to
implement key escrow systems and we can reasonably expect to
enter into law enforcement agreements in the near term. The
OECD's goal of negotiating multilateral cryptography
guidelines by 31 December 1996 is further evidence of European
intent and momentum in infrastructure development.
<p>
     The interim policy reflects a differentiation between
hardware and software products, i.e., hardware products with
greater bit lengths are treated more favorably under this
policy. Hardware implementations of products permit more
confident binding between encryption and the key management,
limiting the risk that the encryption can be easily stripped
from the key management and used independently of key
recovery. Software does not provide similar protection. This
said, the interim policy to permit export of 64 bit software
key recovery products would reflect a significant increase
over the bit length restrictions applicable to non-key
recovery products.
<p>
<p>
Self-Escrow
<p>
     Self-escrow will be a principal concern of many large
corporations that want to provide corporate data recovery,
protect against loss of proprietary data from use of an
outside escrow agent, and simply for reasons of efficiency and
cost. Hence, self-escrow must be considered as an acceptable
option.
<p>
     Escrow requires less architecture if the CA can be the
escrow authority. However, in those cases in which an
individual or corporation serves as its own certificate
authority, government organizations could be compelled to
request escrowed key from the subject of an investigation. The
investigation could be compromised under such circumstances.
While this risk could be avoided by adding independent escrow
authorities as another layer in the PKI, such a solution would
be costly and inefficient.
<p>
     A solution is a national policy which allows CAs for an
organization to serve as escrow authorities if they can meet
necessary performance requirements. These requirements should
be determined by government in consultation with industry and
should address timeliness, security, confidentiality of
requests for, or release of, keys, and independence of the
escrow authority from the rest of the organization. To this
end, the government should seek legislation that would shield
organization certificate authorities from internal pressures
in the course of law enforcement investigations.
<p>
<p>
Legislation
<p>
     There is some consensus that the ultimate legislative
package should include provisions to criminalize the
unauthorized disclosure/use of escrowed key, provisions to
authorize civil actions by victims against those responsible
for the unauthorized disclosure/use of escrowed key,
provisions specifying the circumstances in which escrowed key
may be requested and released (e.g., death of a family member
or employee), and establishing liability protection for
certificate authorities who exercises due prudence in the
fulfillment of their performance obligations.
<p>
     Those who endorse a larger government role would seek
legislation that would, for example, establish the government
as a major participant in the PAA, which would be responsible
to establish policies and guidelines governing certificate
issuance. In this case, the government would be authorized to
assure establishment of standards for the PKI that adequately
provide for systems security and law enforcement access.
Inasmuch as the integrity and reliability of the whole range
of network centered activities, including electronic commerce,
will depend on the integrity and reliability of the key
management certificate process, there is good reason for
government to play a substantial role.
<p>
     The enabling legislation envisioned here should reflect
the stated needs of industry and users. To that end,
government must work closely with industry and other affected
parties to develop such legislation.
<p>
<p>
Government to Government Agreements
<p>
     There is an expressed need by all governments to have
access to information affecting their own security or public
safety. Inevitably there will be situations in which the U.S.
will want access to keys in a foreign country that concern
criminal activities in violation of U.S. laws and vice versa.
The security and other technical protocols that will serve as
the framework of the GII should ensure key recovery is
possible in either circumstance. The U.S. government should
seek to frame and execute law enforcement agreements that:
<ul><li>
    will allow for timely access when authorized
<li>
    minimally impact security products
<li>
    operate within guidelines established for key recovery
     methods including trusted third parties and self-escrow
     standards used in the U.S.
</ul><p>
     It would be recognized that no agreement can guarantee
access to keys/information held in a foreign country, but
established agreements might serve as a framework to request
lawful access to keys/information. Such arrangements will be
based on the philosophy that authorized government access must
be preserved consistent with the legally recognized privacy
interests of the citizens of each country.
<p>
<hr>
<p>
<p>
<h1>IV.  Actions</h1>
<p>
     Several issues discussed in this paper raise substantial
policy questions that will not be easily resolved. The
government, however, has an interest in seeing good security
products populate the NII and GII as soon as possible.
<p>
     To demonstrate resolve and good faith, the United States
Government should immediately:
<p>
     1.   Collaborate with industry and existing standards
          groups, to develop Key Management Infrastructure
          and attendant products performance requirements
          (with a working draft completed within 6 months);
<p>
     2.   Collaborate with industry on a Federal Information
          Processing Standard (FIPS) within government that
          specifies a suite of algorithms and protocols for
          encryption, key exchange, and digital signature
          functions sufficient to protect government
          information. The resulting FIPS should provide for
          key recovery operations and should be mandatory for
          government use.
<p>
     3.   Establish a security management infrastructure for
          government use which complies with the standards
          developed jointly by industry and government. This
          is the first step in providing a market for
          industry products which support the new FIPS.
<p>
     4.   Determine an appropriate government agency to work
          with industry in specifying security requirements
          for products used in network security applications
          for protecting highly sensitive information.
<p>
     5.   Collaborate with industry to formulate legislation
          to establish viable key management infrastructure.
          Such legislation would, inter alia, set policies
          for assuring the integrity of escrowed key,
          establish an appropriate government role in this
          PAA, and address civil liability issues.
<p>
     6.   Negotiate with other governments arrangements for
          access to escrowed keys consistent with national
          sovereignty, national security, and public safety.
<p>
<p>
     As trusted partners, industry and government can share
expertise and tackle intractable problems such as the insecure
operating system. In times past, the cryptographic algorithm
was the core of the solution: now it is the easy part. The
debate over algorithms and bit lengths should end: it is time
for industry and governments to work together to secure the
GII in such a way that does not put the world at risk.
<p>
<hr>
<p>
<h1>Appendix I:  One View of a KMI</h1>
<p>
     The discussion given here is intended to provide a
description of how a KMI might be designed and operated
consistent with the tenets of the White Paper. This
description is not intended to preclude consideration of
other, equally suitable, implementations.
<p>
<p>
Introduction to KMI Based Escrow
<p>
     In a KMI based on public key cryptography, each user has
one or more pairs of public and private keys. The public and
private keys differ in such a way that it is computationally
infeasible to determine the private key from the public key.
This allows the public key to be revealed without endangering
the security of the private key. Users can communicate
securely without having to share a "secret", they only need to
know each other's public key. In practice, users may have
multiple public/private key pairs.
<p>
     The key pairs may be used in applications such as key
exchanges and digital signatures. To make use of such
applications, a user's public keys must be available to
intended recipients in a manner that the recipient can
confidently associate the user with his/her public key.
Without assurances on the "binding" of user identities to a
specific public key, these keys have little or no value.
<p>
     Thus, in the context of public key cryptography, the
strength of cryptographic mechanisms relates to protecting the
confidentiality of the private keys and the integrity of the
public keys. Ultimately, the viability of public key
cryptographic applications is dependent on the evolution of a
key management infrastructure.
<p>
<p>
KMI and Certificates
<p>
     The KMI supports the integrity of public keys through the
generation and distribution of public key certificates. The
role of a certificate is to cryptographically bind a specific
user identity with a public key and other security related
information. A trusted system entity, generally called a
Certificate Authority (CA), obtains information from an
individual sufficient to verify the individual is who he says
he is. The CA then generates and digitally signs a certificate
specific to that individual using the CA's private signature
key. Any system user can then validate the contents of that
certificate by verifying the CA's digital signature (via the
CA's public signature key).
<p>
     Certificate contents must be bound together by a
mechanism which can be authenticated. The certificate format
commonly used is based on the structure defined by the CCITT
X.509 Recommendation. This has worldwide support in industry
and governments.
<p>
     The concept of a CA can be easily extended to apply to a
large system of users where a single CA is not feasible.
Providing interoperability within a system containing multiple
CAs leads to a hierarchical structure. At the very top of the
hierarchy is a Root entity which is often referred to as a
Policy Approving Authority (PAA). The PAA represents the
single node in the hierarchy that all system users trust. The
PAA creates the overall guidelines and policies for the
operation of the KMI. The PAA exists to ensure the security
and integrity of each and every entity within the hierarchy.
Security and integrity are enforced by PAA certifying the
public keys of subordinate CAs. Each of these subordinate CAs
may also certify the public keys of other CAs or users. A
sample hierarchy is pictured below. The PAA public signature
key is possessed by all those in the hierarchy.
<p>
<hr>
<pre>
[Hierarchical Diagram]
<p>
                          PAA
                           |
                  CA1     CA2    CA3
                   |       |      |
               CA4    CA5     CA6     CA7
                |      |       |       |
     (------------------ Users ----------------)
<p>
</pre><hr>

<p>
     Any two users within a defined hierarchy can validate
each other's public key certificates through a common
certification path. A certification path is an ordered
sequence of certificates between the entity to be validated
and the trusted point in the hierarchy, i.e., PAA. This
defines a path of trust. Validation of any system certificate
requires that each certificate in the certification path be
checked by verifying the digital signature over each
certificate.
<p>
     To maintain trust in the path, the entities making up
certificate authorities must follow prescribed rules for
identifying users, issuing certificates, and protecting keys.
Adherence to these regulations can be enforced by a PAA or as
a condition of cross certification between two Certificate
Authorities.
<p>
     After a CA generates a certificate, it is transferred to
the user along with the certificates in the user's
certification path. Distribution of certificates among system
entities can be accomplished by sending them via e-mail
(quickly becomes unwieldy) or through the use of a Directory
System. Other users can then request and retrieve certificates
directly from a Directory Server.
<p>
     The hierarchical structure is designed to support
multiple communities of users who may need to communicate with
each other. It is also possible that some communities of users
in the system could remain autnomous and yet still be able to
communicate with users outside their immediate community of
interest. The PAA provides the means for such inter-community
communication by functioning as the single mutually trusted
authority for the entire hierarchy.
<p>
<p>
Cross Certification
<p>
     There could exist one or more PAAs within the U.S. and
non-U.S. KMIs. To permit communication between users of
different PAA domains, a common certification path must exist.
Cross certification will be based on the existence of accepted
policies and standard certification criteria. PAAs from each
KMI could then cross certify each other. This is accomplished
by each PAA countersigning the registered public key
certificates of the other. This cross certifying of
certificates provides a valid certification path for all users
in the respective KMIs.
<p>
<hr><pre>
[Diagram]
                              CC
              U.S. PAA<-------------->Non-U.S. PAA
          |    |   |   \                 |     |
         CA1   |   |     \     CC        |     |
               |   |       \----------->CAa   CAb
              CA2  |
                   |
                  CA3
<p></pre>
<center>      Cross Certification Options Between Distinct KMIs</center>

<p>
     This scenario permits specific entities under one PAA to
have a verifiable certification path for communications with
entities serviced by another PAA. It is important to note,
however, that the integrity of this cross certification system
is only assured by limiting cross certification to bilateral
nad direct connection between the two PAAs involved. One PAA
should not rely on the representation of another that a third
PAA has been authenticated.
<p>
<p>
Key Recovery Performance Criteria
<p>
     Key recovery provides for backup storage of a user's
private keys. This backup capability helps ensure the
availability of a user's data even after it has been
encrypted. It also provides for an effective means for law
enforcement access. Key recovery requirements would be viewed
from the perspective of the individual, the corporation, or
governments that require access. Most of the criteria to be
discussed have a dimension for key recovery on an individual
basis as well as from a corporate or government perspective.
The criteria can be grouped into three categories.
<p>
<p>
1.   Key Integrity:
<ul><li>
    Confidentiality - Key recovery storage and release
     mechanisms must preclude simple exploitation.
<li>
    Availability - Key recovery data must be available when
     subject to authorized release.
</ul>
<p>
2.   Key Accessibility:
<ul><li>
    Responsiveness - Timely access to key recovery
     information requires 24 hour responsiveness and real time
     accessibility requires a two hour response window to
     authorized requests.
<li>
    Confidentiality - Confidentiality must be maintained on
     all requests for release of key recovery information.
<li>
    Proof of Approval - Trustworthy on-line or off-line
     mechanisms must exist to support identification and
     authorized release of key recovery information.
</ul>
<p>
3.   Key Recovery Use:
<ul><li>
    Subject Message Recovery - All information related to the
     subject of the recovery request must be accessible
     through the release of key recovery information
     pertaining only to that subject.
<li>
    Release Window - The start and end dates of authorized
     key recovery periods must be enforced.
</ul>
<hr>
<pre>
Key Recovery Using KMI

[Diagram]
<p>
               Escrow
          -->  Authority  (private key database)
          |         |
          |         |
          |         | public keys
          |         |                        Escrow and
private   |         |                        Certificate
key       |    Certificate                   Authorities
(either   |    Authority                     can be combined
way)      |         |                        into one entity
          |         |
          |         | public key certificate
          |         | (binds IDs and keys)
          |         |
          |         |
          -->  User A (private keys and certificates)

</pre>
<p>
     Key recovery fits well within a public key KMI.
Interleaving key recovery within the KMI provides for a
concentration of trust that stands to benefit the individuals
from a confidentiality of private key aspect and facilitates
government access by limiting the number of access points. The
most simple model is to rely on the existing CAs within the
KMI to meet government access requirements. If necessary,
however, the hierarchy can be structured to include an Escrow
Authority (EA) as a separate trusted entity.
<p>
     EA hierarchy is intrinsically shallow when compared with
the depth of the CA hierarchy. The structure is more likened
to a peer group of EAs that all fall under the jurisdiction of
the KMIs PAA which creates guidelines and policies for EA
operation. To become a system endorsed EA entity, an EA must
be certified by the PAA. Certification encompasses
satisfactory implementation of the standards and policies put
forth by the PAA. The PAA provides the standardization for the
escrow functions to occur across multiple EA entities with an
equivalent degree of trust. It is important to stress that
some or all of the elements of the escrow infrastructure may
be the same as those in the certificate infrastructure. The
KMI supports both.
<p>
     As with the certification of subordinate CAs, the
recognition of a certified status for a particular EA is
embodied by the PAAs digital signature on the public key
certificate of the EA (thus attesting to the validity of the
service they provide). This allows a particular EA to have a
system-wide recognized signature, one that is traceable back
to a common trusted entity, the PAA.
<p>
     Two examples follow that show how the EA and CA entities
work in tandem to provide both a certificate and data recovery
service for users and law enforcement:
<p>
<p>
1.   Certificate and Recovery Registration.
<ul><li>
    In this example we have a single Escrow Authority
     distinct from the Certificate Authority. In reality, the
     EA may be the same entity as the CA or the EA may be one
     of a set of users certified by the government as an EA.
     The simple protocol described below follows closely the
     key escrow proposal made in 1993 by Silvio Micali of MIT.
<li>
    User A wishes to register, in the form of a public key
     certificate, a public key exchange key with his local
     certified KMI entity. User A does the following:
<ul>
  <li>    Identifies himself and securely distributes the
          public and private components of the key pair he
          wishes to have registered to a certified Escrow
          Authority (EA). This may be done electronically.
          Alternately, the EA could generate these keys for
          User A.
<li>
       Uniquely identifies himself to the CA. This must be
          done physically unless User A already possesses a
          valid signature key.
<li>
         Distributes the public component of the key pair he
          wishes to have certified to the CA.
</ul>
<li>
    The EA does the following:
<ul><li>
         Protectively stores the private component.
<li>
         Notifies the CA that a valid key pair has been
          "escrowed" for user A. (This notification can take
          the form of a signed message from the EA that
          contains the public key of User A.)
</ul>
<li>
    The CA does the following:
<ul><li>
         Verifies the identity of User A.
<li>
         Verifies the signature on the message received from
          the EA. This ensures that only properly escrowed
          keys are entered into the system.
<li>
         Generates a public key certificate that contains
          (at least) the public key exchange key acknowledged
          by the EA, an identifier representing User A, an
          identifier for EA, and validity period for
          certificate management.
<li>
         Digitally signs the certificate using the CA
          private signature key.
<li>
         Distributes the certificate to User A (and
          potentially to a Directory Service). User A then
          verifies the CA signature on the received
          certificate as well as the information it contains.
</ul>
<p>
     To more fully reflect the Key Integrity Criteria, the EA
entity could in fact be a set of EAs that work in conjunction
with a particular CA. Providing multiple EAs allows for
increased flexibility with respect to the generation, storage,
and recovery of key information. Not only would users have
increased flexibility of choice in selecting a certified EA,
but they essentially have a voice in who is entrusted with
protecting their keys. Specifically, the EA entity could be a
set of EAs, each of which only possesses a portion (key split)
for User A's private key component. This provides a recovery
mechanism for User A that more directly protects his private
key component since recovery of the key by other than
authorized requests would require collusion on the part of all
EAs, compromise of all EA storage mechanisms, or compromise of
all of the distribution paths used during recovery from each
EA to User A)
</ul>
<p></ul>
2.   User Key Recovery: An Archiving Example
<ul><li>
    In this example User A stores (archives) his data in
     encrypted form using a locally generated key. He must
     have alternate access to that encrypted data. Consider
     the following:
<ul><li>
         User A generates a private key (session, archive,
          message, etc.)
<li>
User A encrypts his information with this archive
key.
<li>
User A encrypts the archive key with his public key
exchange key (of which the private component is
escrowed).
<li>
The result of this encryption is stored, along with
          public escrow key, in the header portion of the
encrypted file.
<li>
Upon loss of his key exchange key, decryption of
the information is accomplished by requesting
release of the private key exchange key from the
EA.
<li>
User A identifies himself to the EA(s) holding his
private key and requests its release.
</ul>
<li>
The EA(s) does the following:
<ul><li>
Positively identifies the requestor.
<li>
Locates and securely transmits the private key
component to User A.
</ul></ul>
3.   Law Enforcement Key Recovery: An e-mail Example
<ul><li>
In this example the sender of a message, generates a
session key, encrypts the message with the session key
and encrypts the session key he uses to protect his
communications with the recipient's public key exchange
key. This encrypted session key is stored in the header
information of the encrypted message for recipient and
government recovery purposes. The key recovery process
proceeds in the following manner:
<ul><li>
Escrowed data to or from the subject of a lawful
investigation is intercepted.
<li>
The subject's public key certificate is obtained
from the data or a Directory Service.
<li>
The Escrow Authority ID is extracted from the
certificate. This allows law enforcement to locate
the private key components.
<li>
Legal authorization is obtained to receive the
appropriate escrowed private key(s) components.
<li>
Legal authorization is presented to appropriate
EA(s). This may involve working through foreign
governments.
<li>
EA(s) verifies authenticity of request.
<li>
EA(s) securely transmits the private key
component(s) to law enforcement (this could be
accomplished physically or electronically.)
<li>
  Law enforcement forms the private key from its
private key component(s) and decrypts to recover
the session key and the message.
</ul></ul>
<p>
     Law enforcement will destroy keys at the end of the
authorized period of use. Access can be also be time bounded
directly by users by repeating the registration process.
<p>
<hr>
<h1>Appendix II: Current Encryption Export Policies</h1>
     This appendix has been prepared to state clearly the
existing encryption export control policies and procedures.
<p>
     While the government recognizes that further progress is
needed in license processing, changes instituted to date have
resulted in a reduction of average license turnaround time of
39 days in 1993 to an average of 13 days in 1995. Further,
over 99% of export licenses for proposed cryptographic
products are approved each year.
<p>

Authorities
<p>
     The export of cryptographic products is regulated by the
Department of State pursuant to the Arms Export Control Act
(AECA) and its implementing International Traffic In Arms
Regulations (ITAR), and by the Department of Commerce pursuant
to the Export Administration Act (EAA) and its implementing
Export Administration Regulations (EAR).
<p>
     No license is required for the import of cryptographic
hardware or software. There are no federal laws regulating the
use of cryptographic products within the United States. A
license is required for the export of cryptographic products
to all destinations except Canada. Applications are reviewed
by the Department of Defense (NSA) for national security
implications and by State for foreign policy concerns. The
export licensing policy is consistent with U.S. national
security and foreign policy.
<p>
     The Department of Commerce controls the export of
rudimentary cryptographic products containing cryptographic
functions generally limited to purposes such as data
authentication, password protection, and access control.
Products which are determined to be covered by the Commerce
Control List (CCL), with certain foreign policy exceptions,
may be exported under a General License.
<p>
<p>
Procedures
<ul><li>
Autolist - For products reviewed and approved by NSA for
export to approved classes of end users and end uses.
Permits Department of State to process license
applications for such products without further review by
NSA.
<li>
Distribution Arrangements - Single license vehicle for
export of approved products to classes of end users in
countries or regions. Avoids need for licenses on an
export-by-export basis.
<li>
Distribution Agreements - Permits single license for
export of approved products to identified distributors.
Again, avoids export-by-export licensing.
<li>
Personal Use Exemption - Products exported for the
personal use of the exporter are excepted from pre-export
license requirements.
</ul>
<p>
Policies
<ul><li>
Products designed to use cryptography for access
control/authentication purposes are export controlled as
dual use commodities pursuant to the Export
Administration Act.
<li>
Product manufacturers determine if their products are
access control/authentication devices.
<li>
Generally, access control/authentication products are
exportable under general license procedures.
<li>
Mass-market software products verified as implementing
RC2/RC4 encryption algorithms, with 40-bit key space
limitations, are designated dual use items, to be
controlled under the Export Administration Act, after a
one-time review completed within 7 working days of
submission.
<li>
Mass-market software implementing other encryption
algorithms and key space lengths for confidentiality are
reviewed on a case-by-case basis for designation as dual
use items and control under the Export Administration
Act. By regulation, reviews must be completed within 15
days of submission.
<li>
Generally, licenses are approved for export of products
to be used in protecting U.S. proprietary information
(i.e., intellectual property).
<li>
U.S. companies and their subsidiaries are allowed to
export products with strong encryption for their internal
use.
<li>
Confidentiality encryption products that incorporate the
Data Encryption Standard (DES) are routinely approved for
export to:
<ul><li>
Financial institutions and financial applications
</ul>
<li>
Protecting financial information in Electronic
commerce applications
</ul>
<li>    Confidentiality encryption products that incorporate the
Data Encryption Standard (DES) are favorably considered
for export to:
<ul><li>
Applications involving protection of personal
medical data
<li>
Parking and toll systems; Debit applications; Other
transaction-based systems in which encryption is
configured to perform identified specific
transactions.
</ul>
<br><table></table>  <p>
</ul>
<hr>
<p>
[End]
<p>
<p>
<hr>
<h2>Credits</h2>
Thanks to Elaine Frye of NIS&T for alerting us about the availability of this 
document.
<p>
Thanks to Mr. Ed Roback, CSL/Computer Security Division,
NIS&T, for promptly faxing this document to John Young on May
21, 1996. 
<p>
Thanks to John Young (<a href="mailto:jya@pipeline.com">jya@pipeline.com</a>)
for transcribing this from a fax sent by Mr Roback.
Transcribed by JY and DN. I'd give proper credit to DN, but I don't know
who DN is...
<hr>

This logo brought to you by Pat Farrell<br>
 <A HREF="http://www.privacy.org/ipc/">
 <IMG BORDER=0 SRC="../gk7.gif"
 ALT="Golden Key"><BR>
 </A>
<hr>

Back to <a href="./nist951205.html">Pat's page on the December 5 NIST Clipper 2 </a>
meeting. 
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
May 28, 1996
Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">
Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-53</DOCNO>
<DOCOLDNO>IA053-000891-B004-3</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/hotlist.html 129.174.40.15 19970123190919 text/html 12678
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:08:05 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 08 Dec 1996 23:26:26 GMT
Content-type: text/html
Content-length: 12494
</DOCHDR>
<HTML>
<head>
<TITLE>Pat Farrell's Hotlist </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<body BACKGROUND="./ihn_back.gif">


<A HREF="http://march.tico.com">
<IMG
SRC="./efm-logo.jpg"
ALT="Electronic Freedom March on Washington" align=left border=3
></A>

<a href="http://www.eff.org/BlueRibbon/sites.html">
<img border=0 align=right src="./blueribn.gif" alt="EFF Anti-Censorship campaign"></a>
<H1>Pat's Hotlist</H1>
<P>
It reflects my current interests
in politics, technology and  and other fun ways to waste time.
Of course, hotlists, which were really hot six months ago, are
Obsolete.
DEC's <a href="#Altavista">Altavista search engine</a>
can find anything you want, instantly. There is no need for me
to maintain a list of my favorite security sources, you can
simply ask Altavista.
<h2>Index to Pat's hotlist</h2>
<CENTER>
 <TABLE border=10 cellspacing=8>  <!-- a table of buttons -->
  <TR>
   <TD> <A HREF="#ReturnOfClipper">Return of Clipper</A>                 </TD>
   <TD> <A HREF="#LocalLinks">Local Links and GMU info</A> </TD>
   <TD> <A HREF="./objects.html">OO Information</A>     </TD>
   <TD> <A HREF="./crypto.html"> Cryptography & Security</a>  </td>
   <TD> <A HREF="./netbiz.html">Electronic Commerce</A>   </TD>
   <TD> <A HREF="#NetworkingInfo">Networking</A>   </TD> </tr>
<tr>
   <TD> <A HREF="./ntinfo.html">WindowsNT</A>   </TD>
   <td> <a href="#Fun">Fun</a> </td>
    <td> <a href="#Sex">Sex</a> </td>
   <td> <a href="#WebInfo">Making WebPages</a> </td>
   <td> <a href="#TechInfo">Tech. Info.</a> </td>
   <td> <a href="#Friends">Friends' pages</a> </td>
  </TR>
 </TABLE>
</CENTER>
<hr>
<a name="ReturnOfClipper">

<h2>The Return of Clipper</h2>
The Clinton Administration is revising parts of the ill fated Clipper 
initiative, <a href="./nist/clipper2.html">aka Clipper II</a> . 
This new version is equally ill advised. It is a threat to both
the competitiveness of the US software industry, and to civil liberties.
<a href="./nist/clipper2.html">Follow this link for 
a recap of the September meeting, presentations, press coverage,
and information on the next steps</a>

<a name="GMUInformation">
<H2>Here are a few local links: </H2>
<dl>
<li>The GMU <a href="http://apollo.gmu.edu/">Registrar's office</a>
<li><A HREF="http://www.isse.gmu.edu/faculty/ofut/ofut.html"> My PhD advisor's homepage</A>
<li><A HREF="http://www.isse.gmu.edu/index.html"> GMU's ISSE department homepage</A>
<li>Local <a href="http://www.intellicast.com/weather/dca/">DC-Metro area 
weather</a> and Bob Ryan's <a href="http://wxnet4.nbc4.com/">Channel 4
weather</a>
<li><A HREF="http://www.cs.gmu.edu"> GMU's CS department homepage</A>
<li><A HREF="http://cne.gmu.edu/"> GMU's Center for the New Engineer</A>
<li><A HREF="http://www.site.gmu.edu"> GMU's SITE department homepage</A>
<li><A HREF="http://bigdipper.umd.edu:8080/gmu-public/gmu-map.html"> GMU 
campus map</A>
<li>My own <a href="./metrics.html">Software Metrics page </a> (after all,
that is my dissertation topic :-)
</dl>
<P>
<IMG alt="_____" SRC="./color_line.gif">
<P>
<H2>Good sources of information:</H2>
<dl>
<li><A HREF="http://ricis.cl.uh.edu/virt-lib/se_programs.html">
Software Engineering Programs </A>
<li><a href="http://www-soe.stanford.edu/soe/ieee/eesites.html">
Stanford's list of EE/CS sites</a>
<li><A HREF="http://www.ncsa.uiuc.edu:80/General/Internet/WWW/">
Index of /General/Internet/WWW/</A>
<li><A HREF="http://www.w3.org/hypertext/DataSources/bySubject/Overview.html"> The World-Wide Web Virtual Library: Subject Catalogue</A>
<li><A HREF="http://www.ora.com/cgi-bin/ora/currency"> Currency Conversions</A>
<li><a href="./research.html">Pointers to research sites</a>
<li>CMU's online dictionary, <a href="http://c.gp.cs.cmu.edu:5103/prog/webster">
Webster</a>
<li>The Census Bureau has interesting <a href="http://tiger.sensus.gov">
Mapping software</a>
</dl>

<P>
<IMG alt="_____" SRC="./color_line.gif">
<P>
<a name="CryptoSecurity">
<H2>Cryptographic and Security links</h2>
<a href="./crypto.html">
Cryptographic sources, PGP keys, assorted cryptoanarchy pointers</a>
<p>
The <a href="./dccp/index.html">unofficial DC-area Cypherpunks (dccp)</a>
home page.
<P>
<h2><a href="./security.html">Security sources</a></h2>
<br>
<P>
<hr>
<a name="NetworkingInfo">
<H2>General Networking pointers</H2>
<P>
<ul>
<li>A search form for 
<a href="http://web.nexor.co.uk/rfc-index/rfc-index-search-form.html">
How to find RFC documents</a>
<li><a href="http://www.winternet.com/~khayes/tcpipfaq.html">TCP/IP FAQ</A>
<li>John Marulowich's list of 
<a href="http://www.cais.com/makulow/iaptable.html"> 
Local DC/Balt area ISP/IAP</a>
<li>Ray Daly's <a href="http://www.cris.com/~raydaly/plexacce.html">
NetPlex Internet Access Providers List</a>
<li><a href="./isp.html">ISPs run/owned/employing friends of mine</a>
<li><A HREF="./legal.html">Sources for Legal information</A>
<li><A HREF="./politics.html">Sources for Political information</A>
<li><A HREF="ftp://rs.internic.net/templates/domain-template.txt"> 
How to get your own domain registered</A>
<li><A HREF="ftp://rs.internic.net/templates/internet-number-template.txt">
How to get your own IP addresses from Internic</A>
<li><A HREF="ftp://rs.internic.net/policy/rfc950.txt">
How to subnet your network (RFC950)</A>
<li><A HREF="ftp://rs.internic.net/policy/rfc1466.txt">
Guidelines for management of an IP Address Space (RFC1466)</A>
<li><a href="./censorusenet.html">Information to circumvent
censorship of UseNet groups</a> 
<li><a href="http://www.cref.net/dank/isdn/">ISDN pointers</a>
</ul>
<P>
<IMG alt="_____" SRC="./color_line.gif">
<P>
<H2>Follow this link for <a href="./news.html">online News</a></h2>
<P>

You have to wonder how long non-online news will be interesting.
<P>
<IMG alt="_____" SRC="./color_line.gif">
<P>
<H2>Government WEB pages:</H2>
Since I've lived most of my life "inside the Beltway" I think that
the Government deserves its own set of pointers. Follow this
link to <a href="./government/usgov.html">Pointers to the US Government</a>
<p>
Yohoo has<a href="http://www.yahoo.com/Government">
Lots of US Government</a> pages.
<P>
<IMG alt="_____" SRC="./color_line.gif">
<a name="Fun">
<H2>Fun places to go:</H2>
<ul>
<li>Dec's
<a href="http://www.altavista.digital.com">Altavista search engine</a>
is awesome. It is more complete and much faster than 
<A HREF="http://www.yahoo.com">Yahoo!</A> Search engine or 
<a href="http://www.lycos.com/">Lycos search engine</a>

<li> A direct link, taken from 
<a name="Altavista">
Altavista's tip page
<FORM method=GET action="http://altavista.digital.com/cgi-bin/query">
<INPUT TYPE=hidden NAME=pg VALUE=q>
<B>Search <SELECT NAME=what>
<OPTION VALUE=web SELECTED>the Web
<OPTION VALUE=news>Usenet
</SELECT>
and Display the Results <SELECT NAME=fmt>
<OPTION VALUE="" SELECTED>in Standard Form
<OPTION VALUE=c>in Compact Form
<OPTION VALUE=d>in Detailed Form
</SELECT></B><BR>
<INPUT NAME=q size=55 maxlength=200 VALUE="">
<INPUT TYPE=submit VALUE=Submit>
</FORM>

 
<li><A HREF = "http://www.infi.net/cool.html">The Cool Site of the Day</A>
<li>A cool site for <a href="http://clunix.cl.msu.edu/weather/">weather</a>
<li>An updated North American 
<a href="http://clunix.cl.msu.edu/weather/Lsa.gif">weather map</a>
<li><A HREF="http://bigdipper.umd.edu"> Black Hole,  </A>
An interesting, anti-establishment Web connection. 
<li><A HREF="http://www.unitedmedia.com/comics/dilbert/">
Today's Dilbert</A>
<li>The <a href="http://web.cnam.fr/Jargon/">online Jargon dictionary</a>
<li><A HREF="http://www.itis.com/deckmaster/magic">Magic: the Gathering</A> warning, this is Crack for Gamers
<li><A HREF="http://www.galcit.caltech.edu/~ta/barney/barney.html"> The Barney Page</A>
<li><A HREF="http://web.syr.edu/~rsholmes/dead.html"> The Dead People Server</A>
<li><A HREF="http://shuttle.nasa.gov">NASA Shuttle shots</A>
<li>Taking a hint from Dave Barry, this clown uses 
<a href="http:/http://ghg.ecn.purdue.edu/">LOX (liquid Oxygen) to light his charcoal.</a>
</ul>

<a name="WebInfo">
<H1> WWW Information </H1>
<A HREF="./webinfo.html">Making a homepage</A>
<P>
<IMG alt="_____" SRC="./color_line.gif">
<a name="Sex">
<H1>SEX on the Internet</H1>
<P>
As Senator Exon knows, Sex is the most popular thing on the Internet.
So here are some pointers to `hot' sites, snicker....
<ul>
<li><a href="http://www.playboy.com">Playboy</a> is still open, but much less
hot than before the CDA.
<li><a href="http://www.penthousemag.com/home.html">Penthouse</a> has
gone commercial and restricted.
<li>Yahoo censored most of its
Sex information as soon as the CDA was signed, Still available is the
 <a href="http://www.yahoo.com/Entertainment/Magazines/Sex/">
Directory of Sexy magazines </a>
</ul>
I can't believe those clueless politicians think their law (CDA) will have
any effect, other than clogging the courts with unenforcable 
cases and constitutional appeals. Sigh.
<p>
GMU Professor Brad Cox has a 
<a href="http://www.virtualschool.edu/mon/CyberPorn.html">
great collection of articles </a>on
<a href="http://www.cmu.edu">CMU</a> student 
Martin Rimm's
idiotic Cyberporn "study" and the Time cover story that was "based" on it.
<p>
<h3><a href="./censorusenet.html">
Instructions on getting arround UseNet "censorship" attempts</a></h3>
<IMG alt="_____" SRC="./color_line.gif">
<H1> End the monopoly</H1>
<P>
If you live in Fairfax County, you probably hate Media General Cable as 
I do. Here is a group that is trying to end the monopoly,
<a href="http://www.his.com/~tle/FCCFCChm.html">FCCFCC</a>
<p>
Or, you can look into getting a DBS (Direct Brodcast Satellite) dish. They are
only 18" in size, so you might be able to install one
in your subdivision. Here is a URL to a vendor: 
<a href=http://www.dbs.digifix.com/DBS/">Digital Broadcast OnLine</a>
<IMG alt="_____" SRC="./color_line.gif">
<a name="TechInfo">
<H1> Technical Information </H1>
<P>
<ul>
<li>Slirp is a free package that lets you talk TCI/IP over
a dumb serial line. Here is 
<a href="http://www.ece.gatech.edu/users/flur/slirp/slirp.html">
the Slirp Manual</a>
<li>One of the hotest topics in software engineering today
<a href="./objects.html">Object Oriented Everything</a>
<li>A list of more <A HREF="./misctech.html">Technical Information</A>
<li>My favorite machines were DEC's 
<a href="http://www.inwap.com/pdp10">PDP-10</a> 
and DECsystem-20.
<li>I like Windows NT and have collected some
<a href="./ntinfo.html">Assorted software and technical info on NT</a>
</ul>
<P>
<a name="Friends">
<H2>Other Home pages</H2>
<ul>
<li>My <a href="http://www.geocities.com/hollywood/7718">wiz-kid child's page</a>
</ul>
<ul>
<h3>Friends</h3>
<li>Former co-worker and now Metrics guru
<a href="http://www.pitt.edu/~business/faculty/kemerer.html">Chris Kemerer</a>
<li><A HREF="http://www.clark.net/pub/cme/home.html"> Carl Ellison's page</A>
<li><A HREF="http://www.eskimo.com/~weidai"> Wei Dai</A> Author of the C++ Crypto library
<li> Long-time ago co-worker at First Data, where we worked
on DECSYSTEM-10 timesharing machines, 
<a href="   http://www.wwa.com/~jeverett">John Everett</a>
<h3>The AMS Intranet</h3>
I worked at AMS for 18+ years. I know lots and lots of good people
there. Here are some web pages are run by technically oriented folks at AMS
as part of the AMS-Intranet.
<p>
Note: the amsinc.com domain pages are not visible outside the amsinc.com
domain.
<h4>friends</h4>
<li><a href="http://osf1.gmu.edu/~jnylund">Joel Nylund</a> who worked with me
at AMS and also is  a GMU student.
<li><A HREF="http://goldings.amsinc.com"> Chris Tatem's Linux server</A>
<li><a href="http://stout.amsinc.com">AJ's vax</a>
<li><A HREF="http://fmsaix.amsinc.com"> The FMS project's page</A>
<h4>AMSers with non-AMS pages</h4>
<li><a href="http://gwis2.circ.gwu.edu/~bmk/bk.html">Bryan Kearney</a>,
<H3>Other people you may find interesting</H3>
<li><A HREF="http://osf1.gmu.edu/~bnicks">Brian Nicks @ OSF11</a> 
<li><A href="http://web.gmu.edu/bcox">Brad Cox</a> of GMU's PSOL
<li>a guy who really doesn't like GMU is <a href="http://www.mal.com/~rob/">
Robert Shvern (aka RobLINK)</a>
<li><A href="http://www.cosc.georgetown.edu/~denning/">Dorothy Denning</a>
<li><A href="http://www.cs.gmu.edu/faculty/denning.html">Peter Denning</a>
</ul>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a>
December 8, 1996.  
Backto <a href="./hotlist.html">Pat's hotlist</a> Backto <a href="./index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-54</DOCNO>
<DOCOLDNO>IA053-000895-B046-378</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/ 129.174.40.15 19970123200129 text/html 5766
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:00:11 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 09 Jul 1996 01:00:09 GMT
Content-type: text/html
Content-length: 5583
</DOCHDR>
<HTML>
<head>
<title>NIS&T Meetings on Key Escrow </title>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>

<body>

 <A HREF="http://www.privacy.org/ipc/">
 <IMG BORDER=0 SRC="../gk7.gif"
 ALT="Golden Key"><BR>
 Protect Privacy Online: Join the Golden Key Campaign!</A>
<h1>NIS&T Meetings on Key Escrow</h1>
This page contains information relevant to the two
NIS&T Encryption Key Escrow meetings. It also has pointers to 
more recent information.

<p>


<h3>This just in</h3>
Nis&t announces the <strong>
Federal Key Management Infrastructure</strong>
Technical Advisory Commitee
<p>
For more information, see
<a href="http://www.isse.gmu.edu/~pfarrell/nist/fipstac.html">
http://www.isse.gmu.edu/~pfarrell/nist/fipstac.html</a>
<h3>Last month's news</h3>
<h4><a href="./kmi.html">May 96 Draft on Key Escrow</a></h4>
<p>
The National Research Council has released its long-awaited report on
encryption policy.  The NRC issued the following press release concerning
the report.  A summary of the report will soon be available at:
 
<a href="http://www2.nas.edu/new/index.html"> http://www2.nas.edu/new/index.html
</a>

<p>
Presentations, comments, notes, opinion, etc.
<ul>

<li><a href="./bsa.html"> Robert W. Holleyman, President, Business Software Alliance
 </a>
<li><a href="./cdt_nist.html">Center for Democracy and Technology</a>
<li><a href="./cdt_policy.html">Center for Democracy and Technology Policy</a>
<li><a href="./clipper2.html">My cover on Clipper2</a>
<li><a href="./cp1.html">PDF's cypherpunk-1 posting on Sept meeting  </a>
<li><a href="./cp2.html"> PDF's cypherpunk-1 posting on Sept meeting </a>
<li><a href="./crit56.html">Criteria 5 & 6, Sept meeting</a>
<li><a href="./david.html">David Lesher's observations</a>
<li><a href="./dec5sum.html">Martin Matietta's  Dec 5 Summary</a>
<li><a href="./denning.html">Dorothy Denning's Sept presentation</a>
<li><a href="./dpt.html">Save us from Drug dealers, pedophiles, and terrorists...</a>
<li><a href="./epic.commerce.crypto.html">EPIC document on impact for commerce
of current export rules.</a>
<li><a href="./escagent.html">Escrow Agent Criteria from December meeting</a>
<li><a href="./hoffman.html">Prof. Hoffman's September presentation</a>
<li><a href="./kam.html">TIS' Ken Mendelsen's presentation</a>
<li><a href="./kammer.html">Raymond Kammer's September presentation</a>
<li><a href="./kmi.html">May 96 Draft on Key Escrow</a>
<li><a href="./lotus.gak.announce.html">Lotus gak announce</a>
<li><a href="./national.html">National semiconductor's presentation</a>
<li><a href="./nist950906.html">PDF's September meeting writeup</a>
<li><a href="./nist951205.html">PDF's consolidated December meeting writeup</a>
<li><a href="./nsa.html">Senate Subcommittee on Technology and the Law Hearing on the 
Administration's Key Escrow Encryption Standard
Written Questions for Vice Admiral McConnell, NSA
</a>
<li>New York Times article, <a href="./nyt.html">On The Net. Privacy for computers? Clinton sets the stage
   for a debate on data encryption</a>
<li>New York Times article, <a href="./nyt951108.html">Industry Group Rebuffs U.S. on Encryption 
</a>
<li>New York Times article, <a href="./nyt960325.html">
The key issue for the Net is not smut, it is the use of encryption. 
Growing fears that Big Brother might decide to read you E-mail</a>
<li>Now obsolete, initial <a href="./old.sept.html"> writeup of Sept meeting</a>
<li><a href="./part1.html">PDF writeup, part 1 of 2, December meeting</a>
<li><a href="./pdf.nist2.html">PDF writeup, part 1 of 2, December meeting</a>
<li><a href="./pdf.nist2.short.html">Initial, short summary of Dec meeting</a>
<li><a href="./pdf.usatoday.html">PDF Letter to the Editor, USA Today</a>
<li><a href="./pdfopinion.html">PDF short summary Sept meeting </a>
<li><a href="./plesser.html">Ron Plesser letter to CIX</a>
<li>Washington Post article, <a href="./post.bu951108.html">Encryption Control Plan Sparks Industry Protest
High-Tech Groups Say Proposals Unworkable</a>
<li>Washington Post article, <a href="./post.bu960117.html">Study: Encryption Rules Hurt Exporters</a>
<li>Washington Post editorial, <a href="./post.ed951108.html">  Return of the Cyber-Censors</a>
<li>Washington Post article, <a href="./post.html">Feuding again Erupts over encryption Exports

</a>
<li><a href="./sample_solutions.html">Sept Meeting, "Sample Solutions"</a>
<li><a href="./techcrit.html">PDF notes, Technical Criteria breakout session</a>
<li><a href="./tecsec.html">TECSEC, Incorporate Sept presentation</a>
<li><a href="./tge.html">DC area cypherpunk Thomas Edward's writeup of Sept
FIPS meeting.</a>
<li><a href="./tis.html">TIS handout, Sept meeting</a>
<li>NIS&T handout, Sept meeting, <a href="./topic1.html">Topic1</a>
<li>NIS&T handout, Sept meeting, <a href="./topic2.html">Topic2:   Desirable Characteristics for Key Escrow Agent</a>
<li>NIS&T handout, Sept meeting, <a href="./topic3.html">Topic3.  64-bit Software Key
Escrow Encryption</a>
<li><a href="./vtw.html">Sept comments from Voters Telecommunication Watch</a>
<li><a href="./vtwover.html"> VTW overview</a>

</ul> 
<hr>
Back to <a href="./nist951205.html">Pat's page on the December 5 NIST Clipper 2 </a>
meeting. 
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
May 31, 1996  
Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">
Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-55</DOCNO>
<DOCOLDNO>IA053-000892-B031-412</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/swse-ms/swse-elect.html 129.174.40.15 19970123185841 text/html 4627
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:57:31 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 20 Aug 1996 12:46:23 GMT
Content-type: text/html
Content-length: 4444
</DOCHDR>
<HTML>
<HEAD><TITLE>List of pre-approved qualified electives.</TITLE></HEAD> 
<BODY>
<P>
<H1>Pre-approved MS-SWSE Electives</H1>
<P>
<HR>
<P>
Electives provide students the opportunity to gain in-depth knowledge in a
selected area, to gain breadth of knowledge, or, by careful selection, to
complete some of the core course requirements for the Ph.D. program.
A hard copy of the following listing of pre-approved qualified electives
is available from the department office. 
Students may choose other electives from offerings within the School of
Information Technology and Engineering with the consent of the faculty adviser.

<HR>
<P>
<H2>Computer Science (CS)</H2>
<P>
<DL>
<DD>531  Theory of Computation
<DD>540  Language Processors
<DD>555  Computer Communications and Networks
<DD>571  Operating Systems
<DD>580  Artificial Intelligence
<DD>583  Analysis of Algorithms
<DD>635  Parallel Computation
<DD>640  Advanced Program Development
<DD>652  Computer Graphics
<DD>655  Performance Analysis/Networks
<DD>668  Archit. and Microprogramming
<DD>671  Computer System Theory
<DD>672  Computer System Perf Eval
<DD>680  Natural Language
<DD>681  Expert Systems
<DD>682  Computer Vision
<DD>683  Parallel Algorithms
<DD>684  Graph Algorithms
<DD>686  Image Processing
<DD>688  Neural Networks
<DD>706  Concurrent Software Systems
<DD>735  Concurrency
<DD>752  Interactive Graphics Software
<DD>773  Real-Time Sys Design & Develop
<DD>782  Machine Learning
<DD>785  Knowledge Acquisition/Prob Solv
</DL>
<P>
<HR>
<H2>Electrical and Computer Engineering (ECE)</H2>
<P>
<DL>
<DD>500  Signals and Systems
<DD>511  Microprocessors
<DD>512  Real-Time Microprocessor Sys
<DD>516  Advanced Microprocessors
<DD>521  Modern Systems Theory
<DD>528  Random Processes
<DD>542  Network Archit. & Protocols
<DD>546  Parallel Computer Architectures
<DD>548  Sequential Machine Theory
<DD>549  Thry/Applic of Artif Neural Ntwks
<DD>620  Control Theory
<DD>621  Control Systems
<DD>630  Statistical Communication Theory
<DD>631  Digital Communication Theory
<DD>632  Information Theory
<DD>633  Coding Theory
<DD>634  Detection/Estimation Theory
<DD>635  Speech Processing
<DD>636  Secure Telecomm. Systems
<DD>639  Satellite Communications
<DD>640  Massively Parallel Systems
<DD>641  Architecture
<DD>642  Communication Networks
<DD>643  Telecommunication Switching Sys
<DD>644  Image Processing
<DD>650  Robotics I
<DD>651  Robotics II
<DD>744  Computer Vision & Expert Sys
<DD>749  Neural Networks for Control
</DL>
<P>
<HR>
<P>
<H2>Information Systems (INFS)</H2>
<P>
<DL>
<DD>601  Operating Sys Theory & Prac(not w/CS571)
<DD>611  Comparative Programming Languages
<DD>612  DataComm & Distr. Comp (not w/ECE  542)
<DD>614  Database Management
<DD>623  Information Retrieval
<DD>650  Object Oriented Applications
 </DL> 
<P>
<HR>
<P>
<H2>Operations Research (OR)</H2>
<P>
<DL>
<DD>541  Deterministic Models
<DD>542  Stochastic Models
<DD>635  Discrete System Simulation
<DD>641  Linear Programming
<DD>643  Network Modeling
<DD>645  Statistical Models in Ops. Research
<DD>647  Queueing Theory
<DD>681  Contemporary Issues in Decision Analysis
</DL>
<P>
<HR>
<P>
<H2>Psychology (PSYC)</H2>
<P>
<DL>
<DD>734  Human Factors Engineering Seminar
<DD>737  Psych. of Human/Tech Interface
</DL>
<P>
<HR>
<P>
<H2>Software Systems Engineering (SWSE)</H2>
<P>
<DL>
<DD>630  Software Engineering Economics
<DD>631  Object-Oriented Software Develop
<DD>632  User Interface Design
<DD>635  Software Testing and QA
<DD>699  Special Topics
<DD>720  Advanced Software Requirements
<DD>721  Advanced Software Design Methods
<DD>796  Directed Readings
</DL><P>
<HR>
<P>
<H2>Statistics (STAT)</H2>
<P>
<DL>
<DD>644  Applied Probability
<DD>652  Statistical Inference
<DD>654  Applied Statistics
<DD>655  Analysis of Variance
<DD>656  Regression Analysis
<DD>662  Multivariate Statistical Methods
<DD>663  Exploratory Data Analysis
<DD>664  Bayesian Analysis & Decision Theory
<DD>670  Survey Sampling
<DD>677  Quality Assurance
</DL>
<P>
<HR>
<P>
<H2>Systems Engineering (SYST)</H2>
<P>
<DL>
<DD>612  Sys Design and Integration
<DD>613  Sys Mgmt and Evaluation 
<DD>671  Judgment/Decision Making
<DD>760  C3I Engineering
</DL>

<HR>
<P>
<B>Note:  Maximum of two 500-level electives permitted.</B>

<HR>
<P>
<A HREF = "ms-swse.html">Return to Master of Science in Software Systems Engineering.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-56</DOCNO>
<DOCOLDNO>IA053-000894-B005-359</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/index.html 129.174.40.15 19970123202032 text/html 5766
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:19:22 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 09 Jul 1996 01:00:09 GMT
Content-type: text/html
Content-length: 5583
</DOCHDR>
<HTML>
<head>
<title>NIS&T Meetings on Key Escrow </title>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>

<body>

 <A HREF="http://www.privacy.org/ipc/">
 <IMG BORDER=0 SRC="../gk7.gif"
 ALT="Golden Key"><BR>
 Protect Privacy Online: Join the Golden Key Campaign!</A>
<h1>NIS&T Meetings on Key Escrow</h1>
This page contains information relevant to the two
NIS&T Encryption Key Escrow meetings. It also has pointers to 
more recent information.

<p>


<h3>This just in</h3>
Nis&t announces the <strong>
Federal Key Management Infrastructure</strong>
Technical Advisory Commitee
<p>
For more information, see
<a href="http://www.isse.gmu.edu/~pfarrell/nist/fipstac.html">
http://www.isse.gmu.edu/~pfarrell/nist/fipstac.html</a>
<h3>Last month's news</h3>
<h4><a href="./kmi.html">May 96 Draft on Key Escrow</a></h4>
<p>
The National Research Council has released its long-awaited report on
encryption policy.  The NRC issued the following press release concerning
the report.  A summary of the report will soon be available at:
 
<a href="http://www2.nas.edu/new/index.html"> http://www2.nas.edu/new/index.html
</a>

<p>
Presentations, comments, notes, opinion, etc.
<ul>

<li><a href="./bsa.html"> Robert W. Holleyman, President, Business Software Alliance
 </a>
<li><a href="./cdt_nist.html">Center for Democracy and Technology</a>
<li><a href="./cdt_policy.html">Center for Democracy and Technology Policy</a>
<li><a href="./clipper2.html">My cover on Clipper2</a>
<li><a href="./cp1.html">PDF's cypherpunk-1 posting on Sept meeting  </a>
<li><a href="./cp2.html"> PDF's cypherpunk-1 posting on Sept meeting </a>
<li><a href="./crit56.html">Criteria 5 & 6, Sept meeting</a>
<li><a href="./david.html">David Lesher's observations</a>
<li><a href="./dec5sum.html">Martin Matietta's  Dec 5 Summary</a>
<li><a href="./denning.html">Dorothy Denning's Sept presentation</a>
<li><a href="./dpt.html">Save us from Drug dealers, pedophiles, and terrorists...</a>
<li><a href="./epic.commerce.crypto.html">EPIC document on impact for commerce
of current export rules.</a>
<li><a href="./escagent.html">Escrow Agent Criteria from December meeting</a>
<li><a href="./hoffman.html">Prof. Hoffman's September presentation</a>
<li><a href="./kam.html">TIS' Ken Mendelsen's presentation</a>
<li><a href="./kammer.html">Raymond Kammer's September presentation</a>
<li><a href="./kmi.html">May 96 Draft on Key Escrow</a>
<li><a href="./lotus.gak.announce.html">Lotus gak announce</a>
<li><a href="./national.html">National semiconductor's presentation</a>
<li><a href="./nist950906.html">PDF's September meeting writeup</a>
<li><a href="./nist951205.html">PDF's consolidated December meeting writeup</a>
<li><a href="./nsa.html">Senate Subcommittee on Technology and the Law Hearing on the 
Administration's Key Escrow Encryption Standard
Written Questions for Vice Admiral McConnell, NSA
</a>
<li>New York Times article, <a href="./nyt.html">On The Net. Privacy for computers? Clinton sets the stage
   for a debate on data encryption</a>
<li>New York Times article, <a href="./nyt951108.html">Industry Group Rebuffs U.S. on Encryption 
</a>
<li>New York Times article, <a href="./nyt960325.html">
The key issue for the Net is not smut, it is the use of encryption. 
Growing fears that Big Brother might decide to read you E-mail</a>
<li>Now obsolete, initial <a href="./old.sept.html"> writeup of Sept meeting</a>
<li><a href="./part1.html">PDF writeup, part 1 of 2, December meeting</a>
<li><a href="./pdf.nist2.html">PDF writeup, part 1 of 2, December meeting</a>
<li><a href="./pdf.nist2.short.html">Initial, short summary of Dec meeting</a>
<li><a href="./pdf.usatoday.html">PDF Letter to the Editor, USA Today</a>
<li><a href="./pdfopinion.html">PDF short summary Sept meeting </a>
<li><a href="./plesser.html">Ron Plesser letter to CIX</a>
<li>Washington Post article, <a href="./post.bu951108.html">Encryption Control Plan Sparks Industry Protest
High-Tech Groups Say Proposals Unworkable</a>
<li>Washington Post article, <a href="./post.bu960117.html">Study: Encryption Rules Hurt Exporters</a>
<li>Washington Post editorial, <a href="./post.ed951108.html">  Return of the Cyber-Censors</a>
<li>Washington Post article, <a href="./post.html">Feuding again Erupts over encryption Exports

</a>
<li><a href="./sample_solutions.html">Sept Meeting, "Sample Solutions"</a>
<li><a href="./techcrit.html">PDF notes, Technical Criteria breakout session</a>
<li><a href="./tecsec.html">TECSEC, Incorporate Sept presentation</a>
<li><a href="./tge.html">DC area cypherpunk Thomas Edward's writeup of Sept
FIPS meeting.</a>
<li><a href="./tis.html">TIS handout, Sept meeting</a>
<li>NIS&T handout, Sept meeting, <a href="./topic1.html">Topic1</a>
<li>NIS&T handout, Sept meeting, <a href="./topic2.html">Topic2:   Desirable Characteristics for Key Escrow Agent</a>
<li>NIS&T handout, Sept meeting, <a href="./topic3.html">Topic3.  64-bit Software Key
Escrow Encryption</a>
<li><a href="./vtw.html">Sept comments from Voters Telecommunication Watch</a>
<li><a href="./vtwover.html"> VTW overview</a>

</ul> 
<hr>
Back to <a href="./nist951205.html">Pat's page on the December 5 NIST Clipper 2 </a>
meeting. 
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
May 31, 1996  
Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">
Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-57</DOCNO>
<DOCOLDNO>IA053-000892-B031-341</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/swse-ms/swse-admit.html 129.174.40.15 19970123185736 text/html 2075
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:56:27 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 30 May 1996 13:26:22 GMT
Content-type: text/html
Content-length: 1892
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Admission Requirements</TITLE>
</HEAD>
<P>
<H1>Admission Requirements </H1>
<P>
<HR>
<P>
<H3>In addition to the general admission requirements of the university, applicants
to the MS-SWSE program must meet the following minimum entrance requirements:
</H3>
<P>
<OL>
<LI>Hold a baccalaureate degree in an appropriate discipline from an
    accredited institution;
<LI>Have earned a grade point average of 3.0 or better in  the last 60 hours
    of undergraduate study.
<LI>Provide a brief (one- to two-page) statement of educational and work
    experience in the computing field that includes a statement of career
    goals in software systems engineering.
<LI>Submit a departmental self-assessment form, which can be obtained from the
    department.  This form provides summary information concerning background
    and preparation for the program;
<LI>Show proof of a satisfactory score on the Graduate Record Exam (GRE). The
    applicable test should have been taken within five years of applying for
    admission. The GRE requirement is waived if the applicant already has a
    master's degree in a related field; and
<LI>Submit the appropriate application form with three letters of
    recommendation from persons directly knowledgeable of the applicant's
    professional and academic competence.
</OL>
<P>
<HR>
<P>
Acceptance into the MS-SWSE program is based on overall assessment of the
applicant's potential ability to complete the program of study in a satisfactory
manner. Well-qualified students with minor deficiencies may be admitted to the
program in provisional status, with specified course work to be completed within
a specified time. 
<P>
<HR>
<A HREF = "ms-swse.html">Return to Master of Science in Software Systems Engineering.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML>                                 
</DOC>
<DOC>
<DOCNO>WT03-B24-58</DOCNO>
<DOCOLDNO>IA053-000892-B031-324</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/swse-ms/swse-found.html 129.174.40.15 19970123185728 text/html 1596
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:56:19 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 30 May 1996 13:25:13 GMT
Content-type: text/html
Content-length: 1413
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Foundation Requirements</TITLE>
</HEAD> 
<BODY> 
<H1>Foundation Requirements</H1>
<P>
<HR>
<P>
Students entering the MS-SWSE program must have course work or equivalent
knowledge in the following areas: a modern, block-  structured programming
language such as Ada, C, or Pascal; data structures and algorithms; machine
organization, e.g., as given in computer system architecture or assembly language
courses; and topics in discrete mathematics including sets, relations, functions,
trees, graphs, and inductive proofs.  The level of knowledge required in these
areas is equivalent to that taught in undergraduate courses in the indicated
topics, and may also be achieved by taking the following George Mason University
courses, which are referred to as the SWSE foundation courses:  
<P>
<DL>
<DD> <A HREF = "foundreq.html">INFS 501</A> Discrete and Logical Structures for Information Systems
<DD> <A HREF = "foundreq.html">INFS 515</A> Computer Organization
<DD> <A HREF = "foundreq.html">INFS 590</A> Program Design and Data Structures
</DL>
<P>  
In addition, it is desirable, though not required, that entering students have
at least one year of work experience in building and/or modifying software
systems.

<P>
<HR>
<A HREF = "ms-swse.html">Return to Master of Science in Software Systems Engineering.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-59</DOCNO>
<DOCOLDNO>IA053-000892-B031-383</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/swse-ms/swse-degree.html 129.174.40.15 19970123185813 text/html 1484
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:56:49 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 30 May 1996 13:27:17 GMT
Content-type: text/html
Content-length: 1301
</DOCHDR>
<HTML>
<HEAD><TITLE>Degree Requirements.</TITLE></HEAD> 
<BODY>
<P>
<H1>Degree Requirements.</H1>
<P>
<HR>
<P>
The Master of Science in Software Systems Engineering requires a minimum of 30
semester hours of graduate-level courses. The following six core courses (18
semester hours) are required:
<P>
<UL>
<DT><A HREF = "c-l-swse.html#swse619">SWSE 619</A> Software Construction
<DT><A HREF = "c-l-swse.html#swse620">SWSE 620</A> Software Requirements and Prototyping
<DT><A HREF = "c-l-swse.html#swse621">SWSE 621</A> Software Design
<DT><A HREF = "c-l-swse.html#swse623">SWSE 623</A> Formal Methods and Models
<DT><A HREF = "c-l-swse.html#swse625">SWSE 625</A> Software Project Management
<DT><A HREF = "c-l-swse.html#swse626">SWSE 626</A> Software Project Lab
</UL>
<P>
and either the professional track, consisting of four electives, for students
pursuing a terminal master's degree in software systems engineering, or the
research track, consisting of two  electives and a 6-semester-hour thesis, which
is primarily intended for students planning to pursue a Ph.D. degree with
emphasis on software systems engineering.

<HR>
<P>
<A HREF = "ms-swse.html">Return to Master of Science in Software Systems Engineering.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-60</DOCNO>
<DOCOLDNO>IA053-000895-B043-29</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/isp.html 129.174.40.15 19970123194543 text/html 897
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:44:33 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 11 Sep 1995 21:46:17 GMT
Content-type: text/html
Content-length: 715
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's friends who are Internet Service Providers</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>DC area ISPs run/owned by friends and acquaintances</H1>
<p>
Seems like everyone I know is getting into the Internet
as an ISP or Web providor. Don't know how any of them are
making money.
<ul>
<li><A HREF="http://www.digex.net">Doug Humphrey's DIGEX</a>
<li><A HREF="http://www.us.net">Dave Stoddards's US.Net</a>
<li><A HREF="http://www.dgs.com">Curtis Frye's DGS</a>
<li><A href="http://www.elpress.com">Rob Main's Electric Press</a>
</UL>
<P>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
July 6, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-61</DOCNO>
<DOCOLDNO>IA053-000895-B043-126</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/news.html 129.174.40.15 19970123194634 text/html 4088
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:45:21 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 26 Mar 1996 14:26:18 GMT
Content-type: text/html
Content-length: 3905
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Pointer to New sources information </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>News sources on the 'net</H1>
<p>
This page contains information to sources of what used to be called "News"
<H2>Online news sources (traditional "news" media):</H2>
<dl>
<strong>PC Trade press</strong><p>
<dd><a href="http://www.infoworld.com/">InfoWorld</a>
<dd><a href="http://www.zdnet.com/~pcweek/">PC Week</a>
<dd><a href="http://www.byte.com">Byte Magazine</a>
<dd><a href="http://www.pcmag.com">PC Magazine</a>
<dd>
Brock Meek's <a href="http://cyberwerks.com:70/1/cyberwire/">Cyberwire Dispatch</a>
<p>
<strong>Political "news"</strong><p>
<dd><a href="http://allpolitics.com">CNN and Tim's political web page</a>
<dd><A HREF="http://www.enews.com/magazines/tnr"> The New Republic </A>
(my favorite political book, even if it is too liberal)
<dd> My <A HREF="./salmon.html"> favorite paragraph</A> from TNR, all of it is in the next item.
<dd> My favorite, politically incorrect 
<A HREF="gopher://www.enews.com/00/magazines/alphabetic/mr/tnr/Archive/1994/03/032894.3"> 
TNR article.</A>
<dd>A great mag, <a href="http://www.economist.com">The Economist.</a> It is 
British, you know.
<hr>
<strong>Other "news"</strong><p>
<dd><a href="http://www.nbc4dc.com"> the local DC area NBC station</a>
<dd>Bob Ryan's <a href="http://wxnet4.nbc4.com/">DC Weather</a>
<dd><a href="http://www.nbc4dc.com/closings.html">School 
closings caused by weather</a>
<dd><A HREF="http://www.cbs.com"> CBS network </A>
<dd><A HREF="http://www.nbc.com"> NBC network </A>
<dd><a href="http://www.fox.com"> FOX? network</a>
<dd><A HREF="http://cei.net/kark/kark.html"> KARK</A>,
 NBC affiliate in Little Rock AR 
<dd><A HREF="http://timeinc.com"> Time Warner publications </A>
<dd>another site with the full text of 
<a href="http://www.pathfinder.com">Time Warner publications</a> such as Time.
<dd>See what's going on in the 
<A HREF = "http://espnet.sportszone.com/">ESPNet SportsZone</A> !
<dd>Today's top stories, courtesy of 
<A HREF = "http://www.pathfinder.com/@@v@4cWQBFsAEAQOPZ/time/daily/time/1995/latest.html">
Time Daily</A>
<dd><a href="http://www.educom.edu/web/edupage.html">Edupage</a> 
a three times a week source of computer industry news.
<dd>An eight page summary of 
<a href="http://nytimesfax.com/">the New York Times</a>
<dd>The <a href="http://www.boston.com/globe">Boston Globe online</a>
<dd><A HREF="http:/www.igc.org/fair"> Fairness and Accuracy in Reporting </A>
Although whose definition  of "fair" they use is open for debate.
<dd><A HREF="http://www.mojones.com"> Mother Jones magz </A>
<dd><A HREF="http://www.msn.fullfeed.com:80/slack"> Slack Magz </A>
<dd><A HREF="gopher://gopher.voa.gov"> Voice of America </A>
<dd><A HREF="http://www.enews.com/magazines"> List of more magazines </A>
<dd>Daily <a href="http://nytsyn.com/cgi-bin/times/lead/go">Computer news</a> from New York Times syndicate.
<dd>News of the Balmer <a href="http://www.htssports.com/orioles">Orioles</a>
</dl>
<H2>Online unnews sources</h2>
(this is too old and widespread to be considered "news")
<ul>
<li>Bruce Sterling's <a href="http://pgp.ai.mit.edu/~bal/sterling/contents.html"> 
Hacker Crackdown</a>
<li>In the December 95 issue of Scientific American, there is an interesting
article <a href="http://www.ndu.edu/ndu/inss/macnair/mcnair28/m028cont.html">
"The Mesh and the Net: Speculations on Armed Conflict in a                      
Time of Free Silicon," by Martin C. Libicki, March, 1994</a>
<li>For a while, there was a brokow.com with a transcript of 
<!a href="http://www.brokow.com" Tom Brokow's<!/a> interview
with Bill Gates.
</ul>
<P>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
March 26, 1996  Backto <a href="./hotlist.html">Pat's hotlist</a> 
Backto <a href="./index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-62</DOCNO>
<DOCOLDNO>IA053-000895-B046-115</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/ppro.html 129.174.40.15 19970123195907 text/html 1079
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:57:57 GMT
Server: NCSA/1.5.2
Last-modified: Fri, 31 May 1996 13:40:48 GMT
Content-type: text/html
Content-length: 897
</DOCHDR>
<HTML>
<head>
<TITLE>Miscellaneous Vendor Sites and sources.</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<p>
<H2>Vendor sites</H2>
<ul>
<li><a href="http://www.micron.com">Micron's homepage</a> they primarily make
memory. But they have interesting side businesses, including 
<!a href="http://www.micronics.com">Micronics motherboards</a> and
<a href="http://www.mei.micron.com">Micron and Zeos computers</a>
Opps, I guess Zeos is dead. Oh well, they still sell Micron
computers.
<li><a href="http://www.creaf.com/">Creative Labs</a>
<li><a href="http://www.buslogic.com">Buslogic SCSI controllers</a>
<li><a href="http://www.diamondmm.com">Diamond Multimeadia</a>
<li><a href="http://www.seagate.com">Seagate and Conner peripherals</a>

</ul>
<P>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
May 31 1996
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-63</DOCNO>
<DOCOLDNO>IA053-000892-B032-12</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/swse-ms/swse-computers.html 129.174.40.15 19970123185850 text/html 1396
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 18:57:41 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 30 May 1996 13:28:24 GMT
Content-type: text/html
Content-length: 1213
</DOCHDR>
<HTML>
<HEAD><TITLE>COMPUTING RESOURCES.</TITLE></HEAD> 
<BODY>
<P>
<H1>COMPUTING RESOURCES.</H1>
<P>
<HR>
<P>
Students in the program have access to a variety of computing systems on
campus.  The University Computing and Information Systems provides access to:
<OL>
<P> 
<LI>Digital Equipment Corporation (DEC) VAX 8820 running VAX VMS,  
<LI>DEC VAX 8530 running Ultrix.  
</OL>
<P>
The two computers support a variety of languages including
Pascal, COBOL, PL/I, SNOBOL, FORTRAN, GPSS and Simscript.  Other facilities
include several microcomputer laboratories supporting C and Ada as well as a
variety of database systems, and a Graphics Laboratory.  All machines are
available through 1200/2400/4800/9600 Baud dialup.  In addition, there are a
number of IBM-PC (or equivalent) microcomputers, several SITE labs with Advanced
Workstations such as SUNs and Hewlett Packard, available for student use on
campus, as well as a Computer Graphics Laboratory which contains a variety of
workstation and mainframe-oriented graphics systems.

<HR>
<P>
<A HREF = "ms-swse.html">Return to Master of Science in Software Systems Engineering.</A> <br>
<A HREF = "../index.html">Return to ISSE home page.</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-64</DOCNO>
<DOCOLDNO>IA053-000895-B043-50</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/legal.html 129.174.40.15 19970123194552 text/html 2136
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:44:41 GMT
Server: NCSA/1.5.2
Last-modified: Sat, 02 Dec 1995 19:42:11 GMT
Content-type: text/html
Content-length: 1953
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Pointer to WWW information </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>Legal Resources on the 'net</H1>
<p>
This page contains information to sources of legal and 
political information.
<ul>
<li>A good site for links concerning <a href="http://www.patents.com">
Patents and related legal  issues</a>
<li> <a href="http://www.law.miami.edu/~froomkin">A. Michael Froomkin's
homepage</a> 
<li> A. Michael Froomkin's excellent 
<A HREF="http://acr.law.miami.edu/c6.html"> 
Legal Overview of cryptographic issues.</A>
<li>Froomkin's paper on 
<a href="http://www.law.cornell.edu/jol/froomkin.htm">A. Michael     
Froomkin, Anonymity and Its Enmities, 1995 J. ONLINE L. art. 4.</a>
<li><A HREF="http://epic.org"> Electronic Privacy Information Council</a>
 (Rottenberg, Sobel, Banisar, and friends) 
You can get <a href=mailto:info@epic.org">info via mail</A>
<li><A HREF="http://www.eff.org"> Electronic Frontier Foundation </A> is keeping
a much lower profile after last year's DT sellout.
<li><A HREF="http://www.cdt.org"> Center for Democracy and Technology </A>
A spinoff from EFF run by Jerry Berman, Dan Weitzner, and company, created
after the 1994 Digital Telophony debacle.
<li><A HREF="http://w3.ag.uiuc.edu/liberty/libweb.html"> Libertarian Web </A>
<li>The <A HREF="http://www.cato.org/main/home.html">Cato Institute </A>
<li>These guys did pro-bono work on 
<a href="http://www.qualcomm.com/people/pkarn/">
Phil Karn's</a>
 export work/fight over Bruce Schneier's <i>Applied Cryptography</i> 
case, so if you need to pay a lawyer, think of 
<a href="http://venable.com/resumes/kcbsum.htm">Ken Bass</a> 
and <a href="http://venable.com/resumes/tcooper.htm">Tom Cooper
<li><a href="http://www.netresponse.com/zldf"> Phil Zimmermann's Legal Defense
Fund </A>
</UL>
<P>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 2, 1995
</body>
</DOC>
<DOC>
<DOCNO>WT03-B24-65</DOCNO>
<DOCOLDNO>IA053-000892-B034-114</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/~csis/faculty/biography.html 129.174.40.15 19970123190747 text/html 2920
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:06:39 GMT
Server: NCSA/1.5.2
Last-modified: Sat, 18 Jan 1997 21:50:15 GMT
Content-type: text/html
Content-length: 2737
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Biography of Sushil Jajodia</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#5C3317"
      LINK="#9F5F9F" VLINK="#22AA22" ALINK="#0077FF">
<h2>Biography: </h2>
<p>
<font size=4>
Sushil Jajodia is Professor of Information and Software Systems 
Engineering and Director of Center for Secure Information Systems at 
the George Mason University, Fairfax, Virginia.  He joined GMU after
serving as the director of the Database and Expert Systems Program 
within the Division of Information, Robotics, and Intelligent Systems 
at the National Science Foundation.  Before that he was the head the 
Database and Distributed Systems Section in the Computer Science and
Systems Branch at the Naval Research Laboratory, Washington and 
Associate Professor of Computer Science and Director of Graduate 
Studies at the University of Missouri, Columbia. He has also been a
visiting professor at the University of Milan, Italy and at the Isaac
Newton Institute for Mathematical Sciences, Cambridge University,
England.
<p> 
Dr. Jajodia received his Ph.D. from the University of Oregon, Eugene.
His research interests include information security, temporal
databases, and replicated databases.  He has published more than 150
technical papers in the refereed journals and conference proceedings
and has edited or coedited ten books, including Advanced Transaction
Models and Architectures, Kluwer (1997), Multimedia Database Systems:
Issues and Research Directions, Springer-Verlag Artificial
Intelligence Series (1996), Information Security: An Integrated
Collection of Essays, IEEE Computer Society Press (1995), and Temporal
Databases: Theory, Design, and Implementation, Benjamin/Cummings
(1993).  He received the 1996 Kristian Beckman award from IFIP TC 11
for his contributions to the discipline of Information Security.
<p>   
Dr. Jajodia has served in different capacities for various journals
and conferences.  He is the founding co-editor-in-chief of the Journal
of Computer Security.  He is on the editorial boards of IEEE
Concurrency and International Journal of Cooperative Information
Systems and a contributing editor of the Computer & Communication
Security Reviews. He serves on numerous conference program committees
including 1997 IEEE Symposium on Security and Privacy, 1997 Computer
Security Foundations Workshop, and 1997 Very Large Data Base
Conference.  He has been named a Golden Core member for his service to
the IEEE Computer Society.  He is a past chairman of the IEEE Computer
Society Technical Committee on Data Engineering and the Magazine
Advisory Committee.  He is a senior member of the IEEE and a member of
IEEE Computer Society and Association for Computing Machinery.
<p>
</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT03-B24-66</DOCNO>
<DOCOLDNO>IA053-000895-B046-159</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/G.html 129.174.40.15 19970123195927 text/html 730
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:58:14 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 06 Jul 1995 18:23:04 GMT
Content-type: text/html
Content-length: 548
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's 'G' (Magic: the Gathering) geek code</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
<a href="http://www.itis.com/deckmaster/magic">Magic</a>
 is most likely really Crack for Gamers, it is expensive 
and addictive. And they will probably let you 
have the first few times for free.
<p>
I'm really only G+(++) but I'm within $20 or so of being a real
G++ rated player.
<p>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
July 5, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-67</DOCNO>
<DOCOLDNO>IA053-000895-B043-300</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/w.html 129.174.40.15 19970123194822 text/html 535
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:47:11 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 03 Jul 1995 18:07:16 GMT
Content-type: text/html
Content-length: 353
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's 'W' (MS-Windows) geek code</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
I started writing professional Windows code for Windows 2.11. So you think
Win3.11 is a bug farm?
<p>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
July 3, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-68</DOCNO>
<DOCOLDNO>IA053-000895-B042-286</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/netbiz.html 129.174.40.15 19970123194406 text/html 5649
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:42:53 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 08 Oct 1996 22:14:01 GMT
Content-type: text/html
Content-length: 5466
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's list of Net business sites </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<body BACKGROUND="./ihn_back.gif">
<H1>Pat's Collection of folks doing business on the 'net.</H1>
<P>
The entries here are updated periodically as I feel like it. 
<P>
<IMG alt="_____" SRC="./color_line.gif">
<P>
<H2>Electronic commerce, Network payment systems and Digital Cash: </H2>
<P>
<ul>
<li><A HREF="http://www.ecrc.gmu.edu/index.html"> GMU's 
Electronic Commerce Resource Center</A>
<li><A HREF="http://ganges.cs.tcd.ie/mepeirce/project.html"> 
Mike Peirce's reference project. </A>
<li><A HREF="http://www.digicash.com"> Digicash </A> David Chaum's company
<li>Digicash's <a href="http://www.digicash.com/ecash/protpublish.html">
protocol used for their ecash.</a>
<li><A HREF="http://www.cybercash.com"> CyberCash</A> where I now work!
<li>CMU's <a href="http://www.ini.cmu.edu/netbill">NetBill system</a>
<li><A HREF="http://www.netmarket.com/netmarket/bin/press"> NetMarket's PR</A>
<li><A HREF="http://www.visa.com/visa/visa_pr_2_14_95.html">Visa's PR </A>
<li>A press release about 
<a href="http://www.prnewswire.com/cnoc/story/569463/18018">
Microsoft and Visa's joint security spec</a>
<li><a href="http://www.visa.com/visa-stt">Visa side of the STT spec</a>
<li>This page was supposed to have
 <a href="http://www.windows.microsoft.com/windows/pr/spt2795v.html">
Microsoft's side of their STT Visa spec</a> but I can't make it work. 
An alternate location is on the W3 pages,
 <a href="http://www.w3.org/hypertext/WWW/Payments/STT.html"> 
STT specification</a>
<li><A HREF="http://www.mondex.com">Mondex's Digital Cash System</A>
<li><A HREF="http://www.bbcnc.org.uk/bbctv/the_net/thisweek/em.html"> 
BBC transcript on electronic money </A>
<li><A HREF="http://www.u-net.com/gmlets"> LetSystems </A>
<li>a <a href="./crypto.html#cypherpunks">cypherpunk</a>'s 
<a href="http://www.cs.monash.edu.au/~jirib/ecash-cc.html">quick comparison of digital cash</a>
<li>A relatively new payment system is 
<a href="http://www.portsoft.com">Portland Software</a>
<li>For gambling on the net 'see 
<A HREF="http://www.casino.org"> the first offshore-'net casino</a> 
I'm found and 
<a href="http://www.casino.org/pre-req.html"> prerequsite information </A>
<li><a href="http://www.olworld.com/olworld/mall/mall_us/c_servic/m_electr/index.html"> hmmmm</a>
<li>A non-crypto based <a href="http://www.fv.com/">First Virtual's homepage</a>
and a <a href="http://www.fv.com/infohaus/merchants.html">
list of merchants using FV's approach</a>. 
<h3>Papers</h3>
<li>A paper on 
<a href="ftp://ftp.fv.com/pub/nsb/fv-austin.txt">
Lessons Learned by FV (ascii version)</a> 
and the same thing in <a href="ftp://ftp.fv.com/pub/nsb/fv-austin.ps">postscript</a>                             
<li>
<a href="http://www.commerce.net/information/position/position.062695.html">
Towards Enabling Secure Electronic Commerce.</a>
<li>Ron Rivest's <a href="http://theory.lcs.mit.edu/~rivest/">
Paper on Micropayment</a>
<li>A paper on <a href="http://www.eit.com/~ali">Certified Electronic Mail</a>
<li> Take a look at the article 
<a href="http://www.upside.com/resource/print/9601/ecash.html">
Showdown over e-cash</a>
It's a provocative and rather breathless account of the forthcoming demise
of banks as we know them, brought on by electronic transactions.
</a>
</ul>
<P>
<IMG alt="_____" SRC="./color_line.gif">
<P>
<H2>Real commerce on the net, check out</H2>
<ul>
<li><A HREF="http://marketplace.com"> Marketplace, home of TIA </a>
<li><A HREF="http://www.dc.enews.com/magazines/edmunds/">
Car Pricing guides </A>
<li>another car pricing service, 
<a href="http://www.webcom.com/carscost/">Cars @ Cost</a>
<li><A HREF="http://www.SpecialCar.com">Classified ads for interesting cars.</A>
<li><A HREF="http://www.clari.net">ClariNet</A>
<li><A HREF="http://www.mecklerweb.com"> MecklerWeb </A> 
has been trying to sell content for a while, with no more than mixed success.
<li><A HREF="http://www.pathfinder.com">Pathfinder/OpenMarket </A>
<li>Online books at <a href="http://clbooks.com/">Computer Literacy
bookshops</a>
<li>More online books are at <a href="http://www.amazon.com">Amazon Books</a>
<h3>The end of the 6% solution</h3>
These folks are just starting, so the end probably isn't soon.
<li><a href="http://www.realtor.com">National Association of Realtors</a> so far, has zero content.
<li><a href="http://realdirect.com">Real Direct</a> is only in the mid-West, so far.
<li>By far, the best of these three is
 <a href="http://www.us-digital.com/homeweb">HomeWeb</a> a 
division of U.S. Digital Corp.
</ul>
<hr>
<P>
<H2>General Networking pointers</H2>
<P>
<ul>
<li>John Marulowich's list of 
<a href="http://www.cais.com/makulow/iaptable.html"> 
Local DC/Balt area ISP/IAP</a>
<li>Ray Daly's <a href="http://www.cris.com/~raydaly/plexacce.html">
NetPlex Internet Access Providers List</a>
<li><a href="./isp.html">ISPs run/owned/employing friends of mine</a>
<li><A HREF="./legal.html">Sources for Legal information</A>
<li><A HREF="./politics.html">Sources for Political information</A>
</ul>
<P>
<IMG alt="_____" SRC="./color_line.gif">
<P>
<H2>Follow this link for <a href="./news.html">online News</a></h2>
<P>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a>
October 8, 1996.  Backto <a href="./hotlist.html">Pat's hotlist</a> Backto <a href="./index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-69</DOCNO>
<DOCOLDNO>IA053-000895-B045-371</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/salmon.html 129.174.40.15 19970123195751 text/html 1643
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:56:39 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 30 May 1995 23:51:12 GMT
Content-type: text/html
Content-length: 1460
</DOCHDR>
<HTML>
<TITLE>Salmon eaters, by Gregg EasterBrook</TITLE>
Magazine: The New Republic<br>
Issue: March 28, 1994<br>
Title: THE BIRDS<br>
Author: Gregg Easterbrook<br>
<hr>
    Environmentalists hold that even if many spotted owl thrive in
California, logging bans must continue in Washington and Oregon because owl
populations there are locally distinct; the birds roost in cool climates
feeding on arboreal squirrels, a "distinct" Northwest delicacy. This is
probably an accurate reading of the Endangered Species Act as written, but it
points to a deep logical fault in environmental orthodoxy. If local variations
in climate and diet convert creatures to different species, a black man who
lives in Seattle, gets rained on and eats salmon would be a different species
from a white man who lives in stifling humidity in Louisiana and dines on
gumbo. By this theory the human race contains hundreds of species. The sort of
people likely to be environmentalists maintain that when it comes to genus
homo, all individuals of all origins are exactly the same in genetic heritage.
Yet when it comes to animals, the tiniest distinction renders apparently
identical living things irrevocably separate species. The typical northern and
California spotted owls look and act more alike than the typical black
American and white African. But according to politically correct dogma,
different people are identical while similar birds are drastically different.

</html>

</DOC>
<DOC>
<DOCNO>WT03-B24-70</DOCNO>
<DOCOLDNO>IA053-000895-B044-83</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/e.html 129.174.40.15 19970123195039 text/html 567
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:49:22 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 27 Jul 1995 04:27:09 GMT
Content-type: text/html
Content-length: 385
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's 'e' geek code</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
This is obvious, my homepage says I'm working on my PhD, and at GMU, 
they essentially make you get a MS before you get into the PhD program.
<p>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
July 27, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-71</DOCNO>
<DOCOLDNO>IA053-000895-B043-341</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/V.html 129.174.40.15 19970123194841 text/html 721
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:47:30 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 20 Jul 1995 16:38:50 GMT
Content-type: text/html
Content-length: 539
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's 'V' (VMS) geek code</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
VMS is a loser, always was, always will be. DEC's only decent operating systems
were <a href="ftp://tats.wizvax.net/pub/pdp10/info/">TOPS-10</a>
 and <a href="ftp://tats.wizvax.net/pub/pdp10/info/paper.t20">TOPS-20.</a>
 And they bought Tops-20 from 
<a href="http://www.bbn.com/">BB&N.</a>
<p>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
July 3, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-72</DOCNO>
<DOCOLDNO>IA053-000895-B043-358</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/Y.html 129.174.40.15 19970123194903 text/html 708
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:47:38 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 13 Sep 1995 15:02:46 GMT
Content-type: text/html
Content-length: 526
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's 'Y' geek code</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
I actually am not <a href="mailto:tcmay@got.net">T.C.May,</a>
 but I knew him on the 'net before there
was a cypherpunks list. My <a href="/students/pfarrell/pgpkey.txt">PGP key</a> 
was created in October 1992.
<p>
Obviously, check out my <a href="../crypto.html">crypto links</a>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
September 13, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-73</DOCNO>
<DOCOLDNO>IA053-000895-B042-271</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/crypto.html 129.174.40.15 19970123194352 text/html 18435
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:42:39 GMT
Server: NCSA/1.5.2
Last-modified: Sat, 23 Nov 1996 19:01:42 GMT
Content-type: text/html
Content-length: 18251
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Crypto Sources Hotlist </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<body BGCOLOR="#FFFFFF" TEXT="#000000" LINK="#00008F" VLINK="#8F0000">


<H1>Crypto Sources, etc.</H1>
<a href="http://www.privacy.org/ipc"><img align=center src="./gk7.gif" alt=Golden Key></a><p>

This file contains cryptographic information and pointers. For specific 
information about the US Government's encryption policy, see
<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
my pages on the NIST GAK meetings</a>
<P>
<ul>
<li><a href="./nist/kmi.html">The latest from NIS&T on key escrow</a>
<li>The National Research Council has released its long-awaited report on
encryption policy.  The 
<a href="http://pwp.usa.pipeline.com/~jya/nrcindex.htm">ASCII version
of the NRC report</a>

<li>Pat's <A HREF="http://www.isse.gmu.edu/~pfarrell/pgpkey.txt"> PGP key, </A>
it is also on the usual key servers.
A good one to use is MIT's
 <a href="http://pgp.ai.mit.edu/~bal/pks-commands.html"> PGP Keyserver</a>
<li>MIT now has a <a href="http://web.mit.edu/network/pgp.html">
PGP homepage</a>
<li>Eric Bach, et al's 
<A HREF="ftp://rtfm.mit.edu/pub/usenet/news.answers/cryptography-faq">
Cryptography FAQ</A>
<li><A HREF="ftp://ftp.csn.net/mpj/getpgp.asc"> the PGP "where to get" FAQ</A>
<li>If your browser has forms capability, you can automate the process of
<a href="http://vinca.cnidr.org/software/pgp/pgp.html"> GETing PGP </a>
<li>Warlord's <a href="http://www.mit.edu:8001/people/warlord/pgp-faq.html">
PGP FAQ, Buglist, Fixes, and Improvements Page</a> 
                                                            
<li><a href="http://www.viacrypt.com">ViaCrypt's 
commercial PGP</a>
<li><A HREF="http://www.rsa.com"> RSA Data Security</A> aka PKP a 
shell company that owns critical patents. 
<li>A paper on which countries atempt to controll domestic crypto
is available from 
<a href="http://cwis.kub.nl/~frw/CRI/projects/bjk/lawsurvy.html"> 
Bert-Jaap Koops</a>
<li>A consortium of 20+ European companies are behind
<a href="http://semper.darmstadt.gmd.de/~semper">SEMPER</a>
Additional information is available <a href="<http://www.zurich.ibm.com/Technology/Security/extern/semper/">HERE</a>
<li>a paper on <a href="http://www.w3.org/hypertext/WWW/Protocols/HTTP1.0/draft-ietf-http-spec.html#AA">
How netscape authenticates passwords</a>
<li>Bert-Japp Koops's 
<a href="http://cwis.kub.nl/~frw/CRI/projects/bjk/lawsurvy.htm">
Survey of allowable Crypto</a>
<li>The German <a href="http://www.informatik.uni-hildesheim.de/~sirene">
SIRENE Crypto Research Center</a> has lots of neat papers. 
It is a professional research organization. The papers are avilable in both English and German.
<li>SIRENE's 
<a href="http://www.informatik.uni-hildesheim.de/~sirene/lit/abstr94.html">
1994 literature catalog</a>
<li>A simple, but clear <a href="./crypto/enigma.txt">description of how Enigma</a> machines work
<li>Information on the (unsuccessful, original) cypherpunk 
<a href="http://dcs.ex.ac.uk/~aba/brute-rc4.html">RC4-40 brute force attack</a>
<li>Since the first brute-force effort is over,  information on 
<a href="http://www.brute.cl.cam.ac.uk/brute/">Second generation brute
force attack</a> which was <B> successful!!!</b>
<li>a nice mathematical treatment of 
<a href="http://gatekeeper.dec.com/pub/DEC/SRC/research-reports/abstracts/src-rr-083.html">
trust</a>
<li>A paper on <a href="ftp://toxicwaste.mit.edu/pub/pgpsign/scaleweb.txt">
scaling the web of trust</a> by Derek Atkins and Jeff Schiller.
<li>Lots of information on <a href="ftp://toxicwaste.mit.edu/pub/rsa129">
MIT's break RSA-129</a> project.
<li>Some history of <a href="http://www.fas.org/pub/gen/fas/irp/nsa/">NSA written
by the Federation of American Scientists</a>
<li>John Pike's 
<a href="http://www.fas.org/pub/gen/iswg/cyberstr.html">CyberStrategies</a>
<li>Bruce Scheier's 
<a href="http://www.openmarket.com/info/cryptography/applied_cryptography.html">
 Applied Cryptography</a>
<li>Want to talk long distance for free, with security? See 
<a href="http://rpcp.mit.edu/~asears/speakfree">Speek Freely for Windows</a>
<li> Mark Manasse's paper on Millicent is                                    
    <a href="http://www.w3.org/pub/Conferences/WWW4/Papers/246/">The Millicent  
        Protocol for Inexpensive Electronic Commerce</a>                        
Of all the various payment protocols I've seen, this was one of the few         
that studied the available protocol bandwidth before designing a protocol.      
Folks with an engineering slant should appreciate the work here.    
<li>The Center For Democracy and Technology's (CDT) <a href =
"http://www.cdt.org/crypto.html">Crypto Issues Page</a>. Contains position
papers, relevant documents, and other material on US Cryptography policy.
<a href="http://www.cdt.org/">CDT</a> 
is a non-profit public interest organization based in Washington DC.
<li>The presentation I made at the November 16, 1996 
<a href="./dccp/index.html">DCCP</a> meeting on 
<a href="./dccp/dccpsetcrypto.ppt">Crypto protocols in SET</a> (~202KB)
<h3>Crypto source code</h3>
<li><a href="http://www.eskimo.com/~weidai/">Wei Dai</a> author of the C++
CryptoLib
<li>A JAVA implementation of several standard encryption algorithms,
including <a href="http://www.cs.utexas.edu/users/achou/JCrypt/packages.html">
DES, RC4, RSA, and Diffie-Hellman key exchange</a>
<h3>
Essays.</h3>

<li>Dr. Dorothy Denning's essay on crypto and the 
<a href="http://guru.cosc.georgetown.edu/~denning/crypto/Future.html">
Future</a>

<li>Hal Finney's essay on 
<a href="http://www.portal.com/~hfinney/web_of_trust.html">
Why the Web of Trust doesn't work
<li>Doug Barnes' paper on 
<a href="http://www.communities.com/paper/agnostic.html">
Chaum's blinding patent</a>
<h3>Politics</h3>
<li>I've pulled in a 
<a href="./crypto/CP-FAQ">local copy of the cypherpunks FAQ</a>
also known as Tim May's 
<A HREF="ftp://ftp.netcom.com/pub/tc/tcmay/CP-FAQ"> Cyphernomicon</A> 
 from Netcom, as it is too hard to get netcom's anon FTP server to answer.
This version is unchanged from Tim's last update.
<a href="http://www.oberlin.edu/~brchkind/cyphernomicon/">Another copy</a>
<li>Tim May's 
<a href="./crypto.manifesto.html"> Crypto-Anarchist Manifesto</a>
<li>MIT's <A HREF="http://bs.mit.edu:8001/pgp-form.html">PGP Access Form</A>
<h3>Government Policy</h3>
<li>Clipper II, it's back. Read about it on
<a href="./nistmeeting.html">NIS&T Key Escrow/export/crypto meeting page</a>
<li>The International Chamber of Commerce's 
<a href="http://www.isse.gmu.edu/~pfarrell/crypto/crypto_policy_report_12.95">
 Report of the Business-Government Forum on Global Cryptogoraphy Policy </a>
Note: the attendee list contains many names that are familiar, including
government and commercial folks.
<li><A HREF="http://www.bsa.org/bsa"> US Commerce Deptartment survey of crypto policy </A>
<li><A HREF="ftp://miyako.dorm.duke.edu"> Tom Bryce's archive </A>
<li><A HREF="http://www.ens.fr/equipes_dmi/grecc/loi.html"> Info on French crypto</A>
<li><A HREF="http://www.cnam.fr/Network/Crypto/survey.html"> 
Info on European crypto</A>
<h2>IETF documents relating to cryptography and security</h2>
<LI>IETF documents that may be interesting from a crypto viewpoint include:

Internet-Drafts are available by anonymous FTP to ds.internic.net in the
directory internet-drafts.  Other places, too -- don't ask me, tho; for
questions, please mail to Internet-Drafts@cnri.reston.va.us.
<p>
The first two seem interesting even if SKIP has no future in IPng.
The last is useful because people keep pushing GSSAPI as a standard crypto
API. :)
<pre>
       Title     : Encoding of an Unsigned Diffie-Hellman Public Value     
       Author(s) : A. Aziz, T. Markson, H. Prafullchandra
       Filename  : <a href="ftp://ds.internic.net/internet-drafts/draft-ietf-ipsec-skip-udh-00.txt"> draft-ietf-ipsec-skip-udh-00.txt</a>
       Pages     : 6
       Date      : 12/22/1995
</pre>
It is useful to be able to communicate public keys in the absence of a 
certificate hierarchy and a signature infrastructure.  This document 
describes a method by which certificates which communicate Diffie-Hellman 
public values and parameters may be encoded and securely named.            
<p>
<pre>                                                        
       Title     : Certificate Discovery Protocol                          
       Author(s) : A. Aziz, T. Markson, H. Prafullchandra
       Filename  : <a href="ftp://ds.internic.net/internet-drafts/draft-ietf-ipsec-skip-udh-00.txt"> draft-ietf-ipsec-cdp-00.txt</a>
       Pages     : 13
       Date      : 12/22/1995
</pre>
Use of Public key cryptography is becoming widespread on the Internet in 
such applications as electronic mail and IP Security (IPSEC).  Currently, 
however, a common public key certificate infrastructure does not exist 
which is interoperable with other systems and ubiquitous.  In light of 
this, we describe a protocol which may be used to exchange or retrieve 
certificates (essentially signed public keys) with or from another entity. 
The protocol may be used to request certificates from a directory/name 
server or from the entity who owns the certificate.                        
<p>
<pre>
       Title     : The Simple Public-Key GSS-API Mechanism (SPKM)          
       Author(s) : C. Adams
       Filename  : <a href="ftp://ds.internic.net/internet-drafts/draft-ietf-cat-spkmgss-05.txt"> draft-ietf-cat-spkmgss-05.txt</a>
       Pages     : 42
       Date      : 12/22/1995
</pre>
This specification defines protocols, procedures, and conventions to be 
employed by peers implementing the Generic Security Service Application 
Program Interface (as specified in RFCs 1508 and 1509) when using the 
Simple Public-Key Mechanism.
<h2>Other miscellaneous information</h2>
<li><a href="http://obscura.com/~loki/Welcome.html"> Mixmaster remailer</a> 
information
<li><a href="http://www.netresponse.com/zldf"> Phil Zimmermann's Legal Defense
Fund </A>
<li><a href="http://www.hks.net/~cactus/cactus.html">Cactus's homepage</a>
Home of Todd Masco's <a href="http://www.hks.net/~cactus/Crypto.html">
Crypto and Privacy Page</a> and the 
<a href="http://www.hks.net/cpunks/index.html">cypherpunks archives.</a>
<li><a href="ftp://ftp.psy.uq.oz.au/pub/Crypto/SSL/">
A sample SSL implementation</a> is in progress (this is in Austrailia, so 
expect the link to be slow. And ask a laywer about inporting crypto
software to the US.)
<li>Other  URLs from Eric Young's austrailian effort include 
<a href="http://www.psy.uq.oz.au/~ftp/Crypto/">general info</a>, 
<a href="ftp://ftp.psy.uq.oz.au/pub/Crypto/SSL ">his SSL implemantation</a>,
 and <a href="ftp://ftp.psy.uq.oz.au/pub/Crypto/SSLapps">apps that use SSL</a>
<li> U.S. Army Special Operations Center
<a href="http://otserver.soc.mil/docs/security/cryptography.html"> Cryptography policy </a>
<li>Visit <a href="http://www.nsa.gov:8080/museum">National Cryptographic
Museum</a>
<li><a href="http://www.quadralay.com/www/Crypt/Crypt.html">Quadralay Cpropration's crypto page</a>
<li><a href="http://www.kub.nl:2080/FRW/CRI/projects/bjk/lawsurvy.htm">
A crypto legal centre</a>
<li>Phil Karn's latest arguments with our enlightened government
over the export of 
<a href="http://www.qualcomm.com/people/pkarn/export/index.html">
software published in Bruce S' Applied Cryptography</a>


<li>From: Michael Paul Johnson <mpj@netcom.com> 
Weak keys in Diamond Encryption Algorithm fixed.
<p>
There is a class of weak keys in the Diamond Encryption Algorithm.  These are
the ones that result in all of the individual substitution arrays being the
same.  This has a probability of about 2^-40 of happening, and is not the
basis of a practical attack, but it is interesting, anyway.  Thanks to
Colin Plumb for pointing this out. 
<p>
This weakness has been eliminated in the Diamond2 Encryption Algorithm.
See ftp://ftp.csn.net/mpj/public/diamond2.ps.gz for details.  If you are in
the USA or Canada, there is a reference implementation (as well as the above
document) in
ftp://ftp.csn.net/mpj/I_will_not_export/crypto_???????/file/diamond2.zip,
where the ??????? is revealed in ftp://ftp.csn.net/mpj/README along with
an export warning.
<p>
MPJ has also put an updated description of another algorithm, the Sapphire II
Stream Cipher, in ftp://ftp.csn.net/mpj/public/sapphire.ps.gz and a reference
implementation in
ftp://ftp.csn.net/mpj/I_will_not_export/crypto_???????/file/sapphire.zip
<h2>MOSS</h2>
MIME Object Security Services. Supporters say it's a 
technically superior alternative          
to PGP, but one with an uncertain future. It's not being actively
developed by anyone other than TIS, and their TISMOSS prototype
implementation is far from being generally usable.
For more <a href="http://ds.internic.net/rfc/rfc1848.txt">
information on the standard, see RFC 1848:</a>
For more <a href="http://www.tis.com/docs/Research/moss.html">
information on the TIS effort</a>
<h2>Reputations, economics, etc.</h2>
<li> <a href="http://www.webcom.com/agorics/dsr.html"
>network routing system based on microcurrency and positive reputations  </a>
<h2>Foriegn sources for crypto information</h2>
<li><a href="ftp://ftp.dsi.unimi.it/pub/security/crypt/">
University of Milan, Italy, this site has lots of cool stuff, 
MD5 sources, etc.</a>
<li><a href="ftp://ftp.ox.ac.uk/pub/crypto/">UK</a>
<li><a href="http://pgp.rasip.fer.hr/">Croatia</a>
<li><a href="ftp://ftp.darmstadt.gmd.de/pub/crypto/">Germany</a>
<li>Another <a href="http://iaks=www.ira.uka.de/subjects/crypto.html">
German site with links</a>
<li><a href="http://psych.psy.uq.oz.au/~ftp/Crypto/">Australia</a>
<li><a href="http://www.cs.hut.fi/ssh/crypto/">Finland</a>
<H2>Crypto related Hacks:</H2>
<li>Send <a href="http://www.c2.org/remail/by-www.html">Anonymous Mail</a> 
without needing to know anything.
<li>Adam Back's <A href="http://dcs.ex.ac.uk/~aba/rsa/"> RSA in perl</a> and shirt ordering info
<P>
<h3>Crypto from NSA and related sources </h3>
<li>NSA's set of <a href="http://www.omg.org/public-doclist.html">
Cryptographic APIs</a>
<h3>Home pages of serious crypto researchers and professionals</h3>
<li><a href="http://www.clark.net/pub/cme/home.html">
Carl Ellison</a> of  Cybercash
<li> <a href="http://www.crypto.com">Matt Blaze </a> at Bell Labs.
He also has useful stuff at <a href="ftp://research.att.com/dist/mab">
ftp://research.att.com/dist/mab</a>
<li><a href="http://www-swiss.ai.mit.edu/~bal/bal-home.html">
Brian LaMaccia</a> at MIT
<li>Bob Stratton
<li>Doug <a href="http://www.digex.net">"Digex"</a> Humphery
<li><A href="http://www.qualcomm.com/people/pkarn">Phil Karn</a>
<li>MIT's <a href="http://theory.lcs.mit.edu/~rivest/">Ron Rivest</a>
<li><A href="http://www.counterpane.com">Bruce Schneier</a> author of
<i>APPLIED CRYPTOGRAPHY</i> and chief guru of 
Counterpane Systems 

<h3>Serious amateur crypto folks</h3>
<li>My former co-worker Tony Patti is publisher of the
<a href="http://www.neumann.edu/tpatti"> <i>Cryptosystems Journal</i></a>

<h3>Timestamp and timeservers</h3>
<li><a href="http://www.surety.com">Surity digital timestamp</a> service
<li><a href="http://www.bellcore.com">Bellcore may have a timestamp</a>service
<h3>Legal/Crypto pointers</h3>
Any serious discussion of cryptography quickly gets into areas
where you need legal advice. Here are <a href="./legal.html">some legal
pointers</a>
</ul>
<hr>
<a name="cypherpunks">
<h2>Cypherpunks</h2>
Of course serious crypto discussions occur (too rarely) on the 
sci.crypt newsgroup, and on the <a href="ftp://ftp.csua.berkeley.edu/pub/cypherpunks/Home.html">cypherpunks</a> mailing list. 
<P>
Send email to <a href="mailto:majordomo@toad.com">majordomo@toad.com</a>
 with the body saying 
"subscribe cypherpunks" to become a cypherpunk.
Be forewarned: the the list is very active, be prepared for 100+ email
messages a day. And sadly, the signal to noise ratio on c'punks is pretty
poor. Still, a critical resource.
<p>
There are a couple of lower volume alternatives.
<ul>
<li>Eric Blossom has a commercial 
<a href="mailto:eb@comsec.com">Cypherpunks Lite</a>
He redistributes the best 10% or so of cyppherpunks. He also charges
a modest fee, something like $20 a year. For a sample, look
at his <a href="ftp://ftp.crl.com/users/co/comsec/cp-lite">
Cypherpunk-lite archive</a>
<li>
"Cpunks Frog Forwards". 
is a similar service, with the following provisos:
<ul>
<li>There's no fee (unless you want to donate ecash)
<li>No digest format available
<li>Approximately the same statistics as Cpunks Lite (5-10% of
   all incoming messages, depending on content)
<li>No archives of previous mailings available for public review
   to aid in consumer choice
</ul>
To be added or removed, send
a polite request to the 
<a href="mailto:frogfarm@yakko.cs.wmich.edu">
human behind this address.</a>
<li>
Ray Arachelian <sunder@dorsai.dorsai.org>
runs a free filtering service of the same sort... basically stick to news and 
technical stuff, as well as other miscalenous interesting stuff, but don't 
forward whole threads, or flames, etc...
<p>
If you want in, 
<a href="mailto:sunder@dorsai.dorsai.org">
let Ray know in email and he'll add you to the list.</a>
<li>Alan Clegg also has an unmoderated digest of the cypherpunks
list. This simply reduces the volume of separate messages. 
Subscribe by sending email to <a href="mailto:majordomo@gateway.com">
majordomo@gateway.com</a> (This is a standard majordomo list, send
"help" in the body for information.)
</ul>

<p>
There is an informal Mid-Atlantic area Cypherpunks group that 
has been holding monthly meetings for a couple of months.
The group calls itself 
<a href="./dccp/index.html">dccp (DC-area CypherPunks)</a>
<hr>
<h3>Press on Cypherpunks</h3>
<ul>
<li><a href="http://www.nando.net/newsroom/ntn/info//101095/info446_33.html">  
 Cypherpunks article in The Nando Times</a>
<li>A Boston Globe article quoting some 
<a href="http://nytsyn.com/live/Features1/284_101195_072917_2683.html">
DC-area cypherpunks</a>
</ul>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
November 9,  1996  Backto <a href="./hotlist.html">Pat's hotlist</a> 
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-74</DOCNO>
<DOCOLDNO>IA053-000895-B043-322</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/O.html 129.174.40.15 19970123194831 text/html 704
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:47:20 GMT
Server: NCSA/1.5.2
Last-modified: Sat, 15 Jul 1995 14:44:42 GMT
Content-type: text/html
Content-length: 522
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's 'O' (OS/2) geek code</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
I have to use OS/2 professionally too. Yuck!
<p>
It is clear that other real users helped Robert with this code.
It took me three weeks to install the lame OS, and I never got the
much ballyhoo'd "better Windows than Windows" capability to work at
all. Give me NT anyday.
<p>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
July 15, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-75</DOCNO>
<DOCOLDNO>IA053-000895-B044-15</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/R.html 129.174.40.15 19970123195007 text/html 571
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:48:51 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 05 Jul 1995 19:54:15 GMT
Content-type: text/html
Content-length: 389
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's 'R' geek code</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
If they had had geek codes 18 or so years ago, I'd be R+++. I had an awesome 
dwarf fighter with magic armor, weapons, rings of regeneration, etc.
<p>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
July 5, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-76</DOCNO>
<DOCOLDNO>IA053-000895-B043-255</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/a.html 129.174.40.15 19970123194802 text/html 488
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:46:51 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 03 Jul 1995 14:40:27 GMT
Content-type: text/html
Content-length: 306
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's 'a' geek code</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
But you can come close looking at my undergraduate degree date.
<p>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
July 3, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-77</DOCNO>
<DOCOLDNO>IA053-000895-B042-319</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/ntinfo.html 129.174.40.15 19970123194440 text/html 2158
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:43:20 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 15 Jan 1997 20:06:07 GMT
Content-type: text/html
Content-length: 1975
</DOCHDR>
<HTML>
<head>
<TITLE>Windows NT General Information</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<body BACKGROUND="./ihn_back.gif">


<a href="http://www.eff.org/BlueRibbon/sites.html">
<img border=0 align=right src="./blueribn.gif" alt=""></a>
<h1>Windows NT</h1>
<H2>WindowsNT software sites</H2>
I have to admit that I really like WindowsNT. I'm biased, but it does
what I expect an operating system to do: it runs the software that
I care about, it has all the services you'd expect and it doesn't crash.
My professional life would be much easier if people stopped expecting to 
do real work on Dos/Windows/Win95.
<p>
So, to help folks use NT, here are some good sites.

<UL>
<LI><A HREF="http://www.microsoft.com"> Microsoft itself</A>
<li><a href="http://www.somar.com/security.htm">NT security background</a>
<LI><A HREF = "http://www.cs.umd.edu/~rgc/nt.html">Essential NT Software</A>
@ UMd
<LI>The <A HREF = "http://audrey.fagg.uni-lj.si/SHASE/">SHASE Virtual Software Library</A>
(Singapore?)
<LI>Beverly Hills Software's 
<A HREF = "http://www.bhs.com/application.center/">
Windows NT Application Center</A>
<li><a href="http://www.mcs.net/~sculptor/NTFAX-FAQ.HTML">
NT Fax software FAQ</a>
<li>DEC's 
<a href="http://www.windowsnt.digital.com/clusters/clhome.htm">Clusters for
Windows NT</a>
<li>Current versions of 
<a href="http://www.cygnus.com/gnu-win32">GNU utilities from Cygnus</a>
<li>The 
University of Texas has good NT stuff, including an old version of the 
<A HREF="ftp://microlib.cc.utexas.edu/microlib/nt/gnu/"> GNU utilities</a>
<h3>NT and the Internet</h3>

<li>I've collected a number of articles and pointers on
<a href="./ntnetworking.html">winNT, Internet networking, Web pages, etc.</a>
</UL>

<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a>
March 23, 1996.  
Backto <a href="./hotlist.html">Pat's hotlist</a> Backto <a href="./index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-78</DOCNO>
<DOCOLDNO>IA053-000895-B044-66</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/b.html 129.174.40.15 19970123195024 text/html 2420
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:49:13 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 23 Jun 1996 21:49:24 GMT
Content-type: text/html
Content-length: 2237
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's 'b' geek code</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
Recently read books include:
<ul>
<li>Primary Colors, Anonymous. recommended.
<li>Beach Music, Pat Conroy. recommended.
<li>Magic Kingdom for sale/sold. Terry Brooks. not great.
<li>The Black Unicorn. Terry Brooks. Skip it.
<li>The Calvin and Hobbes Tenth Anniversary Book, Watterson. This is much more
than a simple collection of great comic strips, even though any collection
of Calvin and Hobbes' strips is wonderful. This book contains wonderful
introductory material from Watterson, including why there are no
stuffed "hobbes" tigers at Toys-r-us. Probably the neatest part is the
running commentary, where Watterson gives us a peek into his thinking
while he worked on particular strips. Highly recommended. Too bad there 
won't be an eleventh anniversary edition.
<li>All the Troubles in the World, PJ O'Rourke. (Not nearly his best work.)
<li>Learning Perl and Programming Perl. These hardly count as books that
are read.
<li>I Sing the Body Electronic, Fred Moody. An interesting book about
how Microsoft writes software. If this is accurate, why are they rich?
<li>Software Metrics, A rigorous approach, Norman Fenton
<li>Rivethead, Ben Hamper
<li>Showstopper. On how Windows NT came to be. Same comment as for "I sing..."
above.
<li>The  Mythical Man-month, Fredrick Brooks. (I read it 20 years ago,
and just found a fresh copy. It is still an interesting book. A special
20th anniversary edition is now available. Strongly recommended.)
<li>Microserfs, Douglas Copland
<li>The Proud Tower, Barbara Tuchman. The description of anarchists
and crypto-anarchists is interesting in contrast to today's cypherpunks.
As TCMay says, today's cryptoanarchists are "not your grandfathers's 
anarchists."
<li>Contact, Carl Sagan
<li>Night Over Water, Ken Follett
<li>Apocalypse Watch, Robert Ludlum
<li>Pronto, Elmore Leonard
</ul>
<h2>Online bookstores</h2>
<ul>
<li><a href="http://www.clbooks.com/">Computer Literacy Bookshops</a>
<li><a href="http://www.amazon.com/">Amazon Books</a>
</ul>
<p>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
June 22, 1996
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-79</DOCNO>
<DOCOLDNO>IA053-000895-B042-149</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/quotes.html 129.174.40.15 19970123194222 text/html 4394
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:41:11 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 11 Apr 1996 00:09:14 GMT
Content-type: text/html
Content-length: 4211
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's List of Quotes </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>Pat's Favorite Quotes </H1>

<P>
<dl>
<dt>on scheduling
<dd>"But false scheduling to match the patron's desired date is much more 
common in our discipline than elsewhere in engineering. It is very 
difficult to make a vigorous, plausible, and job-risking 
defense of an estimate that is derived by no quantitative method, 
supported by little data, and certified chiefly
by the hunches of managers."
<p>
<i>Regenerative Schedule Disaster</i> The Mythical Man-month, 
Frederick Brooks, 1975, Addison Wesley, page 21
<p>
<dt>on metrics
<dd>
"When you can measure what you are speaking about, and 
express it in numbers, you know something about it; but 
when you cannot express it in numbers, your knowledge is of 
a meager and unsatisfactory kind. It may be the beginning of 
knowledge, but you have scarcely, in your thoughts, advanced 
to the stage of science."
<p>
<I>Popular Lectures and Addresses</I>, Lord (William Thompson) Kelvin.
<p>
<dt>on prototypes
<dd>"The management question, therefore, is not <i>whether</i> 
to build a pilot system and throw it away. You <i>will</i>
do that. The only question is whether to plan in advance 
to build a throwaway, or to promise to deliver the 
throwaway to customers. Seen this way,
the answer is much clearer. Delivering that throwaway 
to customers buys time, but it does so only at the 
cost of agony for the user, distracton for
the builders while they do the redesign,
and a bad reputation for the product that the best redesign will
find hard to live down.
<p>
Hence <i>plan to throw one away; you will, anyhow.</i>"
<p>
<i>Plan to Throw One Away</i> The Mythical Man-month, 
Frederick Brooks, 1975, Addison Wesley, page 116
<p>
<dt>on employement
<dd>"That is a terible thing to do on your last day at work".
<p>
AMS Vice President Douglas Ingling, to an employee who just
deleted a customer's entire database.
<p>
<dt>on whether software engineering is an oxymoron
<dd>"If that is what you call software engineering, 
it is a libelous insult to all
professional engineers."
<p>
Richard J. Farrell, Professional Engineer, after attending a
class in Software Engineering at GMU.
<p>
<dt>on organizations
<dd>"We trained hard - but it seemed that every time 
we were beginning to form up 
into teams we were reorganized.  I was to learn later in life that we tend to 
meet any new situation by reorganizing, and what a wonderful method it can be 
for creating the illusion of progress while actually producing confusion, 
inefficiency, and demoralization." 
<p> 
Petronius Arbiter 210 B.C. (as reported on rec.humor.funny)
<p>
<dt>on trusting your government
<dd>
J. Robert Oppenheimer, "Atomic Weapons and American Policy," Foreign
Affairs, Vol. 31, No. 4, July 1953, p. 525.
<p>
 "[We must have] candor on the part of the officials of the United States
Government to the officials, the representatives, the people of their
country.  We do not operate well when the important facts, the essential
conditions, which limit and determine our choices are unknown.  We do not
operate well when they are known, in secrecy and in fear, only to a few men.
<P>
        The political vitality of our country largely derives form two
sources.  One is the interplay, the conflict of opinion and debate, in may
diverse and complex agencies, legislative and executive, which contribute to
the making of policy.  The other is a public opinion which is based on
confidence that it knows the truth.
<p>
        Today public opinion cannot exist in this field.  No responsible
person will hazard and opinion in a field where he believes that there is
[rest of quote obliterated]
<dt>
Aristotle,
<dd>
      It is the mark of an instructed mind to rest satisfied with the
      degree of precision which the nature of the subject admits and
      not to seek exactness when only an approximation of the truth is
      possible.
</dl>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
April 10, 1996.  Backto <a href="./hotlist.html">Pat's hotlist</a> Backto <a href="./index.html">Pat's homepage</a>
</body>
</HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-80</DOCNO>
<DOCOLDNO>IA053-000895-B043-274</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/P.html 129.174.40.15 19970123194810 text/html 655
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:46:59 GMT
Server: NCSA/1.5.2
Last-modified: Fri, 08 Dec 1995 21:24:06 GMT
Content-type: text/html
Content-length: 473
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's 'P' (Perl) geek code</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
I'm just learning Perl. It looks interesting. Of course, it is interpreted,
and I don't like interpreted languages (I'm a 
compiler guy).
<p>
I just got Perl5 for NT, and I can't figure out how to make it _do_ anything.
<p>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 8, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-81</DOCNO>
<DOCOLDNO>IA053-000891-B004-32</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/metrics.html 129.174.40.15 19970123190936 text/html 1747
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:08:23 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 29 Jan 1996 14:48:13 GMT
Content-type: text/html
Content-length: 1564
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Pointer to Metrics</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>Metrics, resources and pointers</h1>
<p>
This page contains information to sources on Metrics
and OO-metrics 
<ul>
<li>A great reference is "Software Metrics: A Rigorous Approach" by 
Norman Fenton, London, Chapman and Hall, 1991.
<li>For OO-related metrics, references which you can surf to via 
<a href="http://www.cs.city.ac.uk/homes/akmal/bookmarks.html">
Akmal Chaudhri's web page</a>
<li><a href="http://www.tek.com/Network_Displays/App_Notes/met.html">OOPSLA 
workshop on OO metrics</a>
<li><a href="http://www.sbu.ac.uk/~csse/publications/OOMetrics.html">South Bank University's Center for Systems and Software Engineering list</a>
<li><a href="http://www.qucis.queensu.ca/Software-Engineering/Cmetrics.html">
a site for C-specific metrics</a>
<li> P. Haynes, T. Menzies, G. Phipps 
<i>Using The Size of Classes and Methods as       
the Basis for Early Effort Prediction; Empirical Observations, Initial
Application;</i> A Practitioners Experience Report OOPSLA '95 workshop on OO
Process and Metrics for Effort Estimation
Available from:
<a href="http://www.sd.monash.edu.au/~timm/pub/docs/papersonly.html">
http://www.sd.monash.edu.au/~timm/pub/docs/papersonly.html</a>
                                                              
<li><a href="http://www.spc.ca/spc/">Software Productivity Centre</a>
</UL>
<P>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
January 18, 1996
</body>
</DOC>
<DOC>
<DOCNO>WT03-B24-82</DOCNO>
<DOCOLDNO>IA053-000895-B046-140</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/au.html 129.174.40.15 19970123195915 text/html 473
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:58:05 GMT
Server: NCSA/1.5.2
Last-modified: Fri, 16 Jun 1995 20:29:32 GMT
Content-type: text/html
Content-length: 291
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's 'au' geek code</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
How does a red Mustang 5.0 GT convertible sound?<P>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
June 6, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-83</DOCNO>
<DOCOLDNO>IA053-000895-B043-167</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/webinfo.html 129.174.40.15 19970123194650 text/html 2891
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:45:39 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 19 May 1996 03:26:37 GMT
Content-type: text/html
Content-length: 2708
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Pointer to WWW information </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<h1>Before you start...</h1>
Check out <a href="http://www.boutell.com/faq/">the WWW FAQ</a>
<H1>A Guide to making well-designed Home pages</H1>
<p>
This contains information on making Homepages, and some 
companies that have well designed homepages that can
be used as examples.
<p>
This list is based upon a list from 
Paul Merenbloom (plmeren@2mcimail.com) that was published 
in the April 24 1995 issue of Infoworld.
<hr>
The entries here are updated periodically as I feel like it. 
<P>

<H2>Places to check out: </H2>
<dl>
<dd>A great 
<a href="http://epsilon.cs.unc.edu/~jbs/resources/topic_perlcgi.html">
tutorial on CGI using perl </a> from Professor John B Smith of UNC. 
<dd><A HREF="http://www.w3.org"> Start at the home of the Web </A> 
(Its in Switzerland, so don't expect it to be quick)
<dd><A HREF="http://www.ncsa.uiuc.edu/General/Internet/WWW/HTMLPrimer.html">
A Primer to HTML from the original Mosaic folks </A>
<dd><A HREF="http://www.ic.gov"> Our Langley VA spooks </A>
<dd><A HREF="http://www.compaq.com"> Compaq Computer Corp </A>
<dd><A HREF="http://www.elpress.com"> Electric Press </A> 
providing commercial homepages
<dd><A HREF="http://naic.nasa.gov/fbi "> FBI</A> the downtown LEA
<dd><A HREF="http://gnn.com"> Global Network Navigator </A>
<dd><A HREF="http://ds.internic.net"> InterNIC directory</A>
<dd><A HREF="http://lcweb.loc.gov/homepage/lchp.html"> Library of Congress</A>
<dd><A HREF="http://lycos.cs.cmu.edu"> Lycos search engine </A> from CMU
<dd><A HREF="http://www.microsoft.com"> Microsoft </A> Providing the last propriatary Operating Systems accepted by industry.
<dd><A HREF="http://www.ncsa.uiuc.edu/General/NCSAHome.html"> NCSA </A> the origincal Mosaic folks
<dd><A HREF="http://www.netscape.com"> Netscape's homepage </A> 
Authors of the hot Netscape browser.
<dd><A HREF="http://www.novel.com"> Novell </A> 
(How long will they stay viable?)
<dd><A HREF="http://www.quote.com"> Quotes and Stocks </A>
<dd><A HREF="http://www.sgi.com"> Silicon Graphics </A>
<dd><A HREF="http://www.w3.org/hypertext/WWW/News/9305.html"> Web News </A>
<dd><A HREF="http://www.w3.org/hypertext/DataSources/WWW/Servers.html"> Web Servers Directory</A>
<dd><A HREF="http://sunsite.unc.edu/boutell/faq/www_faq.html"> WWW FAQ </A> (frequently asked questions
<dd><A HREF="http://www.w3.org/hypertext/DataSources/bySubject/Overview.html">
WWW Virtual Library</A>
<dd><A HREF="http:// "> </A>
<dd><A HREF="http:// "> </A>
</dl>

<P>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
May 17 1996
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-84</DOCNO>
<DOCOLDNO>IA053-000895-B044-49</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/tv.html 129.174.40.15 19970123195016 text/html 621
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:49:05 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 27 Jul 1995 04:31:34 GMT
Content-type: text/html
Content-length: 439
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's 'tv' geek code</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
I watch every 
<a href="http://espnet.sportszone.com/premium/mlb/clubhouses/bal.html">
Orioles</a> game, and Brinkley every Sunday. 
Cokie is great, I could live without George, Sam is an idiot.
<p>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
July 27, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-85</DOCNO>
<DOCOLDNO>IA053-000895-B042-245</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/objects.html 129.174.40.15 19970123194342 text/html 2028
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:42:31 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 01 Apr 1996 18:44:48 GMT
Content-type: text/html
Content-length: 1845
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Pointer to Object Oriented Everything</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<H1>My Cat is Object Oriented</h1>
Object Oriented Programming (OOP) is (with the exception of Java)
one of the, if not THE, hottest
buzzwords in programming. It is also mostly hot air. See 
<i>No Silver Bullets</i> by Frederick Brooks, IEEE 1978[?].
OO is simply a fashionable way to implement the data abstraction 
and information hiding ideas of C.A. Hoare, Dijkstra, 
and others recommended twenty years ago.
<p>
Here are some pointers to useful OO stuff.
<ul>
<li>The <a href="http://st-www.cs.uiuc.edu/users/patterns/patterns.html">Patterns homepage</a>
<li>Coplien and Schmidt's 
<a href="http://st-www.cs.uiuc.edu/users/patterns/Books.html#Coplien">
Pattern Languages and Program Design</a>
<li>Doug <a href="http://www.cs.wustl.edu/~schmidt/">Schmidt's</a> 
wonderful and Free <a href="http://www.cs.wustl.edu/~schmidt/ACE.FAQ.html">
ACE wrappers </a>(C++ classes for communications)
<li>htmlized <a href="http://www.cs.wustl.edu/~schmidt/acewindex.html">
Documentation for ACE</a>
<li>James Grimm's 
<a href="http://www.mit.edu:8001/people/grimm/Int/Int.home.html">
Big Integer classes for C++</a>
<li><A HREF="http://www.ezl.com/~mpotter/ntclass.html">NTClass
ver 1.3</a>If you are a Visual C++
programmer using MFC to tame Windows NT, you should treat yourself to a growing
set of classes that will make your life easier. This includes set of
classes for 64-bit integer aritmetic.
<li>a new OO magazine: 
<a href="http://www.sigs.com/objectcurrents/">Object Currents</a>
</ul>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
April  1, 1996  Backto <a href="./hotlist.html">Pat's hotlist</a> Backto <a href="./index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-86</DOCNO>
<DOCOLDNO>IA053-000892-B034-258</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/biopage.html 129.174.40.15 19970123190906 text/html 3219
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:07:58 GMT
Server: NCSA/1.5.2
Last-modified: Fri, 08 Dec 1995 20:48:42 GMT
Content-type: text/html
Content-length: 3036
</DOCHDR>
<HTML>
<head>
<title> Pat Farrell Biographic Information</title>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<H2>Research Interests </H2>
<UL>
<LI> Software Quality
<LI> Coupling and Cohesion for OO development
<LI><a href="./metrics.html>Metrics</a>
<LI> Digital Cash
<LI> Network Security 
</UL>
<IMG alt="_____" SRC="./color_line.gif">
<p>
Quote: "When you can measure what you are speaking about, and 
express it in numbers, you know something about it; but 
when you cannot express it in numbers, your knowledge is of 
a meager and unsatisfactory kind. It may be the beginning of 
knowledge, but you have scarcely, in your thoughts, advanced 
to the stage of science."
<p>
<I>Popular Lectures and Addresses</I>, Lord (William Thompson) Kelvin.
<p>
Follow this link for more <a href="./quotes.html">software engineering
related quotes</a>

<IMG alt="_____" SRC="./color_line.gif">
<H2>PhD Status Report </H2>
<UL>
<LI>Completed all coursework
<LI>Completed Comprehensive Exam and Oral Defense
<li>Current: developing Thesis Proposal
</UL>
<p>

<H2>PhD Commitee </H2>
<UL>
<LI> Advisor: <A HREF="http://www.isse.gmu.edu/faculty/ofut/ofut.html"> Dr. A. Jeff Offutt</A>
<LI> <a href="http://www.cs.gmu.edu/faculty/frieder.html">Dr. Ophir Frieder</a>
<LI> <a href="http://www.ecrc.gmu.edu/staff/ed.html">Dr. Edgar Sibley</a> 
<LI> <a href="http://www.cs.gmu.edu/faculty/sood.html">Dr. Arun Sood </a>
</UL>
<p>
<IMG alt="_____" SRC="./color_line.gif">
<h2>Biosketch</h2>
<p>
Pat Farrell is a graduate student at GMU. He is also 
a part-time employee
of American Management Systems in Fairfax, VA.
<A HREF="http://www.amsinc.com"> AMS' home page </A> (mostly corporate PR).
Other AMS homepages are listed on my <a href="./hotlist.html">hotlist.</a>
<p>
Pat received a BS degree with in mathematics from Virginia Tech, 
Blacksburg, VA, in 1974, a MS degree in computer science from GMU
in 1993.
<p>
Pat's <A HREF="./vita.ps">curriculum vita</A> is available
(in postscript), but it is pretty small, his academic career is just starting.
His <A HREF="./resume.ps">professional resume</A> is reasonably current,
but it is very long. He has been a consultant too long. Pat's 
<a href="./geek/geek.html">geek code</a> 
is available, but it only approximates part of his technical flavor.
<p>
<IMG alt="_____" SRC="./color_line.gif">
<H2>My <a href="./hotlist.html">Hotlist</a></H2>
This is a list of cool places on the Web and sources 
for more information on my interests in security, 
politics, etc. I update it occasionally.
<A HREF="./hotlist.html">Hotlist and cool stuff</A>
<p>
<A HREF="http://www.isse.gmu.edu/faculty/ofut/hotlist.html">
<IMG alt="***" SRC="http://www.isse.gmu.edu/symbol/pinkball.gif"> my PhD advisor's hotlist</A>
<p>
<A HREF="http://www.isse.gmu.edu/">Back to the ISSE Homepage</A>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 8, 1995  Backto <a href="./hotlist.html">Pat's hotlist</a> Backto <a href="./index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-87</DOCNO>
<DOCOLDNO>IA053-000894-B003-292</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/nsa.html 129.174.40.15 19970123201201 text/html 17032
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:10:45 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:11:23 GMT
Content-type: text/html
Content-length: 16848
</DOCHDR>
<html>
<head>
<Title>NSA Testimony to Congress</title>
</head>
<body>
The opening comments here by Admiral McConnell of the NSA 
appear to parallel the comments of Mr. Michael Nelson at the September 6 
NIST Key Escrow meeting on the use of encryption by "spies, 
terrorists, and criminals."

This text is also available directly from the government at
<a href=" URL: http://csrc.ncsl.nist.gov/secnews/ees_q-a.txt">
URL: http://csrc.ncsl.nist.gov/secnews/ees_q-a.txt</a>

<hr>

Note:  The following answers were provided by NSA to the Senate
Subcommittee on Technology and the Law in response to their 
follow-
up questions to the May 3, 1994 hearings.

<hr>

     <h1>     Senate Subcommittee on Technology and the Law
 Hearing on the Administration's Key Escrow Encryption Standard</h1>

<h2>Written Questions for Vice Admiral McConnell, NSA</h2>

*Questions for Senator Pressler:
<p>
Q:   Admiral, as you are aware, critics of the Administration's
proposal argue that as a practical matter, no criminal, foreign
spy, or terrorist of any sophisticated would be foolish enough 
to
use an encryption device designed by the NSA and approved by 
the
FBI.

<p>
How do you respond? Why do[n't you] think the people whose
telecommunications the NSA and the FBI want most to decode will 
be
the very people most unlikely to use this technology?

<p>
Answer:   From what we know today, the overriding requirement 
that spies, terrorist, and criminals have is for readily available 
and easy to use equipment that interoperates.  Key escrow 
encryption is
not meant to be a tool to catch criminals.  It will make 
excellent
encryption available to legitimate businesses and private 
citizens
without allowing criminals to use the telecommunications system 
to plan and commit crimes with impunity.  We believe it would be
irresponsible for government to make excellent encryption 
broadly available knowing that its use by criminals would make it
impossible for law enforcement agencies to conduct lawful 
wiretaps against them.
<p>
The Department of Justice credits information gleaned through
wiretaps as leading to more than 20,000 felony convictions 
since
the early 1980s.  This would not have been possible if the
criminals had been using encryption systems the FBI could not
break.

<p>
Without government action, however, this fortunate situation
will change.  At present most people, and most criminals, don't 
use
encryption.  However, there is an increasing public awareness 
of
the value of encryption for protecting private personal and
business communications.  Increasing demand for encryption by 
the
public will likely lead to the widespread use of some form of
standardized encryption on the public telecommunications 
network.

<p>
This development would have great benefits for the country.
Legitimate businesses an private individuals could use the
telecommunications system secure in the knowledge that their
private information such as business records and credit card
numbers could not be intercepted by third parties.

<p>
But there is a down side.  Criminals, terrorists, and others
could also use the system to plan crimes, launder money, and 
the
like, completely secure in the knowledge that law enforcement
agencies could not listen to those communications.  Just as
legitimate businesses operate much more efficiently and 
effectively
using the telecommunications system than they could without it, 
so
will criminal enterprises be able to operate more efficiently 
and
effectively if they no longer have to avoid using the
telecommunications system.

<p>
The United States is faced with a choice.  We can sit back and
watch as the emerging national information infrastructure 
becomes
a valuable tool for criminals and terrorists to use to plan and
carry out their activities with complete security, or we can 
take
steps to maintain the current ability of government to conduct
lawful wiretaps so that prudent criminals will have to find 
other
less efficient ways to operate and foolish ones may be caught.  
Key
escrow encryption is the later option.

<p>
Q:   Would widespread use of the Skipjack algorithm harm U.S.
exports?  Do you think it is unlikely foreign businesses will
purchase American encryption technology if the U.S. Government
holds a set of the decoding keys?

<p>
     Answer:  I do not believe that widespread use of key escrow
encryption in the United States will harm U.S. exports.  If it 
has any effect at all, it could increase exports somewhat.  Key 
escrow encryption products provide another option for foreign 
purchasers that they have not had in the past; to the extent that 
foreigners doe purchase key escrow encryption products, it will mean an
increase in exports.  Meanwhile, U.S. exporters are free to
continue to sell the products they currently sell in foreign
markets and to seek license approvals for new products.
<p>
     It is difficult to predict the foreign market for U.S. key
escrow encryption technology.  Businesses that fear U.S. 
Government
interception of their communications presumably would avoid
products for which the U.S. Government hold keys.  However, 
there
are a number of reasons why foreign businesses might purchase 
them.
One major reason would be to communicate securely with U.S.
businesses that use them.  In addition, the superior level of
security provided by key escrow products (against all but 
lawful
U.S. Government access) may make them attractive to foreign
business that do not view U.S Government access as a major 
concern.
While some prospective users abroad may steer clear of key 
escrow
products because the United States will retain access, there 
may be
many who believe they are unlikely to be targeted by U.S.
intelligence in any case or for whom the superior security 
offered
by key escrow encryption products against threats of greater
concern may make key escrow products an attractive option.  For
example, a distributor of pay-TV programming may depend on
encryption to ensure that only those viewers who pay for the
service can decrypt the TV signal.  Such a distributor probably
would not be concerned about the threat of access by the United
States Government, and might favor suitable key escrow 
encryption
products over competing products that use weaker encryption
algorithms.

<p>
Q:   You were present when the previous panelist, Stephen 
Walker,
described how present U.S. laws prohibit his company from 
exporting
encryption products.  As I understand it, Senator Murray's bill
S.1846, attempts to relax these export controls somewhat.

<p>
Please give us your views on this legislation.

<p>
     Answer:  I support the Administration's position, as 
announced
by the White House on February 4, that current export controls 
must
remain in place and that regulatory changes should be 
implemented
to speed exports and reduce the licensing burden on exporters.  
The
bill you reference appears to be inconsistent with the
Administration position.  I would be happy to provide you 
further
information on the Administration's reasons for maintaining the
current export controls in an appropriate setting.

<p>
*Questions from Senator Murray:
<p>

Q:    In my office in the Hart building this February, I 
downloaded
from the Internet an Austrian program that uses DES encryption.
This was on a laptop computer, using a modem over a phone line.
The Software Publishers' Association says there are at least 
120
DES or comparable programs world wide.  However, U.S. export
control laws prohibit American exporters from selling 
comparable
DES programs abroad.

<p>
With at least 20 million people hooked up to the
Internet, how do U.S. export controls actually prevent 
criminals,
terrorists, or whoever from obtaining DES encryption software?

<p>
     Answer:  Serious users of encryption do not entrust their
security to software distributed via networks or bulletin 
boards.
There is simply too much risk that viruses, Trojan Horses,
programming errors, and other security flaws may exist in such
software which could not be detected by the user.  Serious 
users of
encryption, those who depend on encryption to protect valuable 
data
and cannot afford to take such chances, instead turn to other
sources in which they can have greater confidence.  Such 
serious
users include not only entitles which may threaten U.S. 
national
security interests, but also businesses and other major 
consumers
of encryption products.  Encryption software distribution via
Internet, bulletin board, or modem does not undermine the
effectiveness of encryption export controls.   
<p>
[Primary written questions for Admiral McConnell]

<p>
1.   The Defense Authorization Bill for Fiscal Year 1994 has
authorized $800,000 to be spent by the National Research 
Council of
the National Academy of Sciences to conduct a study of federal
encryption policy.  Can we wait to implement the key escrow
encryption program until we have the benefit of the NRC's 
study?
Do you think this study is necessary?  Should this study be
expedited?

<p>
     Answer:  We do not believe that we can wait until after 
the
NRC study is completed in 1996 to begin implementation of the 
key
escrow initiative.  The information technology industry is 
dynamic
and fast-moving, and to wait another two years or more would, 
we
believe, jeopardize the success of the initiative.  Industry 
demand
for encryption products is growing, and the technology is 
available
now to meet that demand with encryption products that provide 
an
outstanding level of security to the user conduct lawful 
wiretaps.
To wait for the completion of the NRC study to other encryption
products which would defeat lawful wiretaps.  We believe that 
such
a delay would not be in the best interest of the American 
people.

<p>
Neither do we believe that the study should be expedited.  For
our part, we will carefully consider the conclusions of the NRC
study.  We expect that it will give very careful consideration 
to
the issues, and we would not want the pressure of an 
unnecessarily
short deadline to limit the study group's ability to produce 
the
best report possible.

<p>
2.   The Administration has said that it is continuing to 
restrict
export of the most sophisticated encryption devices, in part,
"because of the concerns of our allies who fear that strong
encryption technology would inhibit their law enforcement
capabilities."  Do we really need to help our allies by 
prohibiting
the export of strong American encryption products, since those 
same
countries can simply control the encryption bought within their
borders?

<p>
     Answer:  Exports of encryption products are subject to 
review
primarily to protect U.S. national interests, including 
national
security, law enforcement, foreign policy, and other important
interests.  The law enforcement concerns of our allies are a
consideration, especially as the ability of our allies to 
combat
terrorism, drug trafficking, and other international law
enforcement problems can have direct benefits to the United 
States.
However, foreign law enforcement concerns do not drive our 
export
control policy.  We would continue to review encryption exports 
to
protect U.S. national interests even if foreign law enforcement
concerns disappeared.

<p>
3.   Do you know whether foreign governments would be 
interested in
importing key escrow encryption products to which they hold the
decoding keys?

<p>
     Answer:  Several foreign governments have expressed 
interest
in key escrow encryption technology due to their own law
enforcement concerns.  There have been some preliminary
discussions, but issues such as who would hold the escrowed 
keys
and the circumstances of government access to escrowed keys 
must be
fully vetted.

<p>
4.   The Government wants the key escrow encryption standard to
become the de facto industry standard in the United States.  
Would
the Government abandon the Clipper Chip program if it is shown 
to
be unsuccessful beyond government use?

<p>
     Answer:  We do not expect the program to be unsuccessful
beyond government.  We have developed a sound security product 
that we expect will find many uses in government information systems 
and further believe that government use will bring with it a 
commercial market, particularly in the defense sector.  We have developed 
a sound security product that we expect will find many uses in
government information systems regardless of its success in
commercial markets.

<p>
5.   Openly available devices, such as Intel-compatible
microprocessors, have seen dramatic gains, but only because
everyone was free to try to build a better version.  Given the
restrictions on who can build devices with the classified 
skipjack
algorithm, how will key escrow chips keep up with advances in
semiconductor speed, power, capacity and integration?

<p>
     Answer:  Despite the requirements that a firm must meet to
produce key escrow encryption chips, we expect that there will 
be
a number of manufacturers competing against each other to 
produce
the best product, and that such competition will drive them to 
keep
up with the latest technological advances.  It is worth noting 
that
only a few companies can produce the sophisticated 
microprocessors
you reference, yet the competition in that market has driven 
them
to achieve remarkable advances in that technology.  NSA's 
STU-III
secure telephone program provides an example of a cryptographic
product line that keeps pace with technology.

<p>
The presence of a classified algorithm does not preclude
keeping pace with technology.  Through NSA's use of a 
competitive,
multi-vendor approach, STU-III secure telephone products have
continued to evolve in response to user requirements and
technological advances despite their use of a classified 
encryption
algorithm and the consequent need for security restrictions on 
the
manufacturers.

<p>
6.   How well does the Skipjack algorithm work on
telecommunications operating at very high speeds.  Is NSA 
working
on another algorithm, called BATON, that could be used in high
speeds with a key escrow system?  Will Capstone be compatible 
with
BATON?

<p>
     Answer:  Using currently available microelectronics 
technology
the SKIPJACK algorithm could not be used for encryption at very
high speeds.  BATON is the name of an algorithm developed by 
NSA
that could be used at higher rates of speed.  We have no plans 
to
develop key escrow encryption devices using BATON, however.
Instead, we are considering another algorithm for use at high
speeds with a key escrow system.
<p>

A high-speed key escrow device based on an algorithm other
than SKIPJACK would not be "compatible with Capstone" in the 
sense
that traffic encrypted by such a device could not be decrypted 
by
Capstone, and vice versa.  However, since such a device would 
be
used for much higher-speed applications than those for which
Capstone was designed, there would be no need for it to be
compatible with Capstone in that sense.

<p>
7.   Can Capstone be used to encrypt video programming?  If so,
have cable companies been approached by any government agency 
to
use Capstone to scramble or encrypt cable program?

<p>
     Answer:  Capstone could be used to encrypt any digital 
signal,
including video programming, operating at up to about 10 
million
bits per second.  It could be used for encrypting individual 
video
channels but not for bulk encryption of many channels 
multiplexed
together in a single link.  NSA is not aware of any government
agency approaching cable companies to urge the use of Capstone.
Two manufacturers have asked us about the suitability of key 
escrow
devices for this purpose, however.

<p>
8.   Encryption software is available that can be used with 
Clipper
to encypt a message before after it has been encrypted with
Clipper.  This "double encrypting" risks bypassing the key 
escrow
feature.  If a sender first encrypts the message with software
using DES, and then transmits the message "double encrypted" 
with
Clipper, can tell you from looking at the cipher, or encrypted
text, that the underlying message was encrypted?

<p>
     Answer:  The only way to tell that a message has been 
"double
encrypted" in this way would be to decrypt the "outer layer" of
encryption, i.e. that done with Clipper.  Only then would one 
be
able to tell that the message had first been encrypted with
something else.
 
<p>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 14, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-88</DOCNO>
<DOCOLDNO>IA053-000895-B042-361</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/research.html 129.174.40.15 19970123194520 text/html 734
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:44:09 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 11 Jul 1995 16:38:05 GMT
Content-type: text/html
Content-length: 552
</DOCHDR>
<HTML>
<head>
<TITLE>Miscellaneous Research Sites and sources.</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<p>
<H2>Sources for research information: </H2>
<dl>
<dd><A HREF="http://liinwww.ira.uka.de/bibliography/index.html">
Computer Science Bibliography</a> in Germany
<dd>A US based <a href="http://glimpse.cs.arizona.edu:1994/bib/">
mirror of the CS Bib</a>
<dd><A HREF="http:// "> </A>
</dl>

<P>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
July 11, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-89</DOCNO>
<DOCOLDNO>IA053-000895-B043-74</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/politics.html 129.174.40.15 19970123194609 text/html 2543
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:44:57 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 16 Oct 1995 17:57:23 GMT
Content-type: text/html
Content-length: 2360
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Pointer to Political information </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>Political Resources on the 'net</H1>
<p>
This page contains information to sources of 
political information.
<ul>
<li>Newt's <a href="http://www.pff.org/">Progress & Freedom Foundation</a>
<li>The University of Iowa's Business School
<a href="http://www.biz.uiowa.edu/iem/index.html">real money futures market</a>
<li>A good site for links concerning <a href="http://www.patents.com">
Patents and related legal  issues</a>
<li> A. Michael Froomkin's excellent 
<A HREF="http://acr.law.miami.edu/c6.html"> 
Legal Overview of cryptographic issues.</A>
<li><A HREF="http://www.epic.org"> Electronic Privacy Information Council</a>
 (Rottenberg, Sobel, Banisar, and friends) 
You can also get <a href=mailto:info@epic.org">info via mail</A>
<li><A HREF="http://www.eff.org"> Electronic Frontier Foundation </A> 
Has left DC for the left coast.
<li><A HREF="http://www.cdt.org"> Center for Democracy and Technology </A>
A spinoff from EFF run by Jerry Berman, Dan Weitzner, and company.
<li><a href="http://www.vtw.org">Voters Telecommunications Watch</a>
<li><A HREF="http://w3.ag.uiuc.edu/liberty/libweb.html"> Libertarian Web </A>
<li><A href="http://www.lp.org/lp">Libertarian Party's homepage</a>
<li>The <a href="http://www.rahul.net/browne"> 
Libertarian's Presidential Candidate</a>
<li>The <A HREF="http://www.cato.org/main/home.html">Cato Institute </A>
<li>These guys did pro-bono work on 
<a href="http://www.qualcomm.com/people/pkarn/">
Phil Karn's</a>
 export work/fight over Bruce Schneier's <i>Applied Cryptography</i> 
case, so if you need to pay a lawyer, think of 
<a href="http://venable.com/resumes/kcbsum.htm">Ken Bass</a> 
and <a href="http://venable.com/resumes/tcooper.htm">Tom Cooper
<li><a href="http://www.netresponse.com/zldf"> Phil Zimmermann's Legal Defense
Fund </A>
<li>Tired of Fairfax county's inept, monopolistic Media General Calble?
Check out <a href="http://www.his.com/~tle/FCCFCChm.html">Fairfax
County Citizens For Cable Competition</a>
<li>a website dedicated to 
< a href="http://www.geopages.com/CapitolHill/1783">
Jeffersonian Conservatism </a> 
</UL>
<P>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
September 16, 1995
Octoberbody>
</DOC>
<DOC>
<DOCNO>WT03-B24-90</DOCNO>
<DOCOLDNO>IA053-000894-B003-129</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/cp2.html 129.174.40.15 19970123200941 text/html 7462
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:08:29 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:18:43 GMT
Content-type: text/html
Content-length: 7279
</DOCHDR>
<html>
<body>

<h1>Thursday's NIS&T Key Escrowed Encryption Export Meeting</h1>

Thursday's GAK Export meeting started with reports from the prior
afternoon's breakout meetings. I reported on the session I was in,
saying what I posted to the list yesterday (about National Semi's product,
etc.) The other breakout groups reported their problems with the
criteria, again asking that #9 be dropped, longer, keys, etc.
The presentation for Group "A" was different. 
<a href="./vtwover.html#breakspeach">It was a speach.</a>
It asked that the process be stopped to let industry develop
market-driven solutions. It was greeted by applause from the
vendors and privacy advocates, with no reaction from the
government representatives.
<p>
Randy Williams of Commerce, and Dan Cook of State, described the
current export approval process. Lots of talk of jurisdictions
and types of liscenses. I quickly got lost in the jargon.
The moderator wisecracked that the official language of the session
was English. You couldn't tell from some of the exchanges.

<p>
They were questioned on import restrictions. Both Williams and Cook
said that there are no import restrictions into the US. They also
pointed out that Treasury, not State or Commerce, has jurisdiction over
imports.

<p>
An engineer from Compaq asked a question: He said that his company
buys liscenses to software, and bundles it as "value added" to
their systems. They are interested in bundling in security features.
He asked if his computers would then be subject to export restrictions.
The answer was yes. He asked if he could purchase security software
overseas and import it. The answer was again yes. He asked if
he could install that software on his computers, again yes. And
export the computers, NO. They didn't even seem to think that this
was illogical.

<p>
So Commerce, State, and the rest of the government are activly
encouraging the development of competing software industries in
Israel, Germany and other counrties. I hate to think what they'd
do if they tried to hurt US industry.

<p>
And interesting tidbit came up after the session. In an offline
conversation, the topic of "personal use export" came up. A
reliable source said that revised regulations are being developed,
and will, be available soon. I explicitly asked if this meant
"PGP on a notebook computer" and was told, Yes, that will be allowed;
with the usual rules that it can't be for export, you can't be attempting
to sell it, etc. Personal use, carry out and carry back. The "source" was
asked if they had read Matt Blaze's personal use disaster story.
The name didn't ring a bell, but the story was well known and considered
a nightmare.

<p>
Penny Brummitt of NSA was to talk about Clipper's key escrow agents,
but called in sick.  So Jan Manning gave the presentation. (He is NSA's person
designing the Law Enforcement decrypt box for Clipper.)
He talked about Clipper's process, not as an example of what will
be required for GAK agents, but as an "existance proof" that some
agents can be found.  The essence was that Clipper escrow facilities are
strong, and staffed with people cleared to the "Secret" level. They also
tosed out the phrase "US Person" in regard to the corporate entity that is
responsible for the contract.

<p>
Geoff Greiveldinger, of the US Department of Justice, gave a frequently
inaudible recounting of the evils of strong encryption in the war
on <a href="./dpt.html">D, P, & T</a>, 
and also corrupt mayors. He was very personable. He also
sounded like a fascist. Throughout the meeting, all sides tried to
have a civil discussion, even though we disagreed. It was
impossible to stay civil through his drivel. Ruby Ridge and Furman
had been unmentionable up until his speach.

<p>
Mr. Greiveldinger said that acceptable escrow agents will be in the US.
This caused considerable concern among vendors trying to sell
in the International market.

<p>
Dan Weitzner of <a href="//www.cdt.org/">CDT</a> 
(the Center for Democracy and Technology) gave 
<a href="./cdt_nist.html">a short, rousing speach.</a> It
was a call to arms. He said that since NIS&T was ignoring the
consistant input from industry to stop this silly and stupid GAK, that
we need to immediately contact our congresscritters.

<p>
<a href="mailto:kam@tis.com">Ken Mendelson</a> 
of <a href="http://www.tis.com">TIS </a>
gave a great speach. He suggested that
the critera for escrow agents be the same as the form to export tanks
and other munitions. Then he showed the one page form used by State.
He argued that legislative solutions to the escrow agent approval process
will take too long and kill the effort.
Follow this link for a copy of the text of 
<a href="./kam.html">Ken's presentation</a>
<p>
F.W. Gerbracht, Jr a VP Merril Lynch, represented the Securities Industry
Association. He said that they are willing to work with the government,
but they need long keys, strong ciphers, and international escrow agents.
He used the phrase "unlimited algorithms and keyspace" as a requirement.
They also need buy in from their regulators, and presented a long list
of SEC, CFT, NYSE, NASDealers, and 50 state regulators, all who have
to sign off.

<p>
Nanette DiTosto of Bankers Trust gave a short, to the point presentation.
She said that BT has a commercial key escrow service, but that was not
what she wanted to get accross. She said that multinational banks demand
strong encryption and non-US escrow agents. And that they would
settle for nothing less.

<p>
Shabbir J. Safdar from <a href="http://www.vtw.org">VTW</a> gave a nice 
<a href="./vtw.html">presentation.</a> VTW is 
Voters Telecommunications Watch. They have a mailing list, at
listproc@vtw.org. He said that escrow was doomed to failure. That there
is no middle ground. 

<p>
Jack Wack of TECSEC gave a pitch for his shrinkwrapped product. He
said it is exportable now, they've jumped through all the hoops.
He also gave a great crack from his son. It went roughly like:
"Dad, if you own the data before you encrypt it, how come the
government says you don't own it after you encrypt it?"
It brought down the house. (if someone has a more accurate quote, please
let me have a copy).

<p>
Professor Hoffman of George Washington gave a great speach. He listed
the Al Gore to Maria Cantwell letter's criteria, as a matrix. He then
filled in the matrix with the Export GAK's criteria. It was painfully
obvious that the NIST/NSA propsal didn't come close. He recommended
that they focus closly on the Gore criteria, and come up with an
approach that meets all the the criteria.

<p>
While I planned on staying for the remainder of the meeting, a crisis
came up at my day job. I can't say I was looking forward to more,
a day and a half was enough for me, and I wasn't the only person leaving
early. Attendance was down visibly Thursday relative to the first day

<p>
Pat

<p>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/nist950906.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 7, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-91</DOCNO>
<DOCOLDNO>IA053-000896-B001-203</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/kam.html 129.174.40.15 19970123200838 text/html 5100
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:07:27 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:02:10 GMT
Content-type: text/html
Content-length: 4917
</DOCHDR>
<html>
<head>
<title>TIS Thoughts on Third Party Agent Criteria</title>
</head>
<body>


<h2>TRUSTED INFORMATION SYSTEMS, INC.</h2>
<h1>THOUGHTS ON THIRD PARTY AGENT CRITERIA</h1>

Delivered at the National Institute For Standard & Technology, Gaithersburg, 
Maryland
September 7, 1995

<p>
by Ken Mendelsen of <a href="http://www.tis.com">TIS</a>
<p>
<i>[Note from PFarell: this is the text from Ken's presentation.) 
</i>
<p>
        In order to being our discussion of the 10th criteria, that is, the 
notion of exportability being granted only to those products whose keys are 
escrowed with a government "approved" escrow agent, we must first make an 
exhaustive review of the current requirements for domestic or international 
key escrow agent operation:
 <p>
<i>Ken showed a blank slide and paused.
</i>
<p>
Now that we've done that, let's move on.  

<p>
        It is against this backdrop of good, solid regulatory precedent that 
we must decide what the government's third party agent regulations should be 
-- or whether there should be any at all...

<p>
        As we discuss the desirable characteristics of potential third party 
agents, it is essential that we remember that we are discussing the 
relationship between Domestic Third Party Agent regulations and the 
exportability of encryption products.  While nobody is suggesting that 
strictly domestic activities be regulated, there is one overriding 
consideration for industry....

<p>
        Public confidence in any key escrow system is ESSENTIAL for its 
success.  It is not in anyone's best interest - not even industry's - for 
known criminals to be third party agents, or for law enforcement to be unable 
to do its job....

<p>
        In the absence of government imposed regulations, industry has every 
incentive create its own rules to maintain the society's confidence in the 
integrity of the system....

<p>
        We are entering uncharted territory here.  Whenever new, dynamic and 
useful industries are created, people think of new and ever more creative ways 
to sue one another.  With all of the potential liability lurking about out 
there, companies that provide third party agent technology are going to make 
every reasonable effort to ensure those entities that choose to act as third 
party agents are not going to expose them to unreasonable liability.  These 
providers are going to find it necessary to compile certain basic information 
about the potential third party agents.  --both to show they have acted 
reasonably, and to maintain system integrity.--    However, this need must be 
balanced with the commercial reality that asking too much of potential key 
escrow agents is commercially undesirable.....

<p>
        TIS thought it might be nice to require the same information from 
potential third party agents that the State Department requires from those who 
register to export Firearms, Tanks and Military Vehicles.  Accordingly, we 
offer a possible solution....

<p>
<i>
Ken shows a one page form used by the State Department to control
exports of munitions.
</i>
<p>
        This slide is a sample Department of State application for 
registration to be a munitions exporter.  It is not terribly onerous to 
complete.  We believe it is not unreasonable for providers of third party 
agent technology to require this information from their prospective licensees 
in the ordinary course of business, and perhaps even some additional 
information regarding an
individual who can be contacted in the event of an emergency.   Good business 
practice might also require a favorable credit rating and a certificate of 
good standing from the state of incorporation.  These are things industry can 
do on its own -- without having to wait for a lengthy, and unreliable, 
legislative outcome.

<p>
        From our perspective, we would have no problem telling prospective 
third party agents that we are collecting this information for our own 
purposes, but that we would make it available to law enforcement upon request. 
 If they refuse to provide the information, we would refuse to sell them the 
technology.....

<p>
        If we require industry to wait for legislation to have "approved" 
escrow agents, the people in charge of granting export approval for encryption 
products will make Maytag repairmen look like party animals.  Industry can, 
and will, compile the information necessary to protect itself, and assist law 
enforcement when it is appropriate to do so.  

<p>
Thank you.
<p>

Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 14, 1995  Backto <a href="http//www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-92</DOCNO>
<DOCOLDNO>IA053-000894-B003-173</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/nyt.html 129.174.40.15 19970123201047 text/html 7646
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:09:32 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:15:10 GMT
Content-type: text/html
Content-length: 7463
</DOCHDR>
<html>
<head>
<title>New York Times article on NIST GAK meeting</title>
</head>
<body>
<pre>

   The New York Times, September 11, 1995, p. D7.

   Technology / Peter H. Lewis

   On The Net. Privacy for computers? Clinton sets the stage
   for a debate on data encryption.


   In terms of its ability to raise the nation's blood
   pressure, the debate over data encryption has not yet
   reached the same levels as gun control.

   But last week the Clinton Administration appeared to set
   the stage for an equally divisive debate over the degree to
   which businesses and individuals have the right to keep
   secrets when using telephones, computers and other forms of
   electronic communications.

   In two days of public hearings last week in Gaithersburg,
   Md., home of the National Institute of Standards and
   Technology, the Administration introduced its long-awaited
   proposals to relax restrictions on the export of
   cryptographic software.

   The Administration drew a line in the virtual sands of
   cyberspace, signaling that it is willing to permit
   Americans to put stronger cryptographic locks on their
   electronic data only if a spare key to those locks is made
   available on demand to law-enforcement agencies.

   There looms the conflict. Although the debate is about
   export controls the "export" issue is irrelevant in today's
   era of global electronic networks. Placing a common privacy
   program on an Internet computer in Austin, Tex., is
   effectively no different from sending a shrink-wrapped copy
   of the program to Moscow.

   The real issue is how much privacy the Government is
   willing to allow its own citizens, and the latest word from
   the Clinton Administration is that the right to electronic
   privacy, like the right to bear arms, is not absolute.

   Cryptography is the science of secret writing. In this
   digital era, it applies not just to notes, but also to
   telephone calls, money transfers, bank and credit card
   records, electronic mail, faxes and other computer files.

   The Clinton Administration's goal is to allow Americans to
   use the strongest possible cryptographic technology, while
   at the same time preserving the ability of law-enforcement
   agencies to perform court-authorized wiretaps as part of
   the effort to catch drug dealers, terrorists, child
   pornographers and other miscreants.
             
   In other words, it favors strong cryptography, but not too
   strong.

   The strength of cryptographic software is measured by the
   length of the software key necessary to encode and decode
   a message. The longer the key, the harder it is for an
   unauthorized user to decipher the message.

   In recent years, the Government has generally permitted
   Americans to export cryptographic software with key lengths
   up to 40 bits. Experts say that 40-bit keys are secure from
   casual snooping, but will fall quickly to a determined
   codebreaker.

   Last week, after more than a year of intense analysis, the
   Government introduced what it said was the best possible
   compromise.

   Under the new policy, companies can export encryption
   algorithms using 64-bit keys, which are much more secure,
   but only if spare keys are given to "escrow agents" who
   would make them available to lawenforcement agents under
   standard legal procedures, similar to legal wiretaps
   authorized by a judge. Otherwise, the 40-bit limit
   continues to apply.

   Such a "key escrow" scheme is anathema to many privacy
   advocates who fear Government abuses. The Government first
   proposed a key escrow system with its so-called Clipper
   Chip, a technology that failed to win acceptance even as a
   voluntary standard.

   The new scheme is somewhat more palatable than Clipper. Key
   escrow is still unpopular with American computer and
   software companies, which say it prevents them from
   competing against foreign companies that have no similar
   constraints, and with many multinational corporations,
   which say it prevents them from working with foreign
   companies that do not especially care for the idea of Uncle
   Sam holding the keys to their data banks.

   "If this was intended to be any sort of compromise, I don't
   think it achieved its end," said Whitfield Diffie, a Sun
   Microsystems engineer who attended the meetings. "I didn't
   see anybody who was enthusiastic."

   Raymond G. Kammer, deputy director of N.l.S.T., suggested
   that the hearings last week were intended to elicit public
   comment, and that the Administration's final position on
   cryptographic policy were still under analysis.

   But the emergence of key escrow issues at the N.l.S.T.
   proceedings suggests that key escrow is emerging as a
   nonnegotiable demand by some factions of the Clinton
   Administration, especially the Justice Department and the
   Federal Bureau of Investigation, led by Louis Freeh.

   "If this fails," said a figure familiar with the
   Administration's thinking on the proposed change in
   cryptographic policy, "it's going to lead to a very
   divisive debate. And the irony, for libertarians who oppose
   key escrow, is that if it fails, I am convinced that Louis
   Freeh cannot be true to his job without proposing domestic
   controls on data encryption."

   "He's not going to give up without a fight, and neither is
   the Justice Department," said the figure, who spoke on the
   condition he not be identified.

   Others say they do not think the Clinton Administration has
   yet arrived at a concrete position, even after more than a
   year of study and debate. "I don't think it's a final
   offer," said John Gilmore, an engineer at Cygnus Support,
   a computer company in Mountain View, Calif. "It looks to me
   like a weak strawman, a first offer, a proposal to dance."

   The question is whether American citizens and businesses
   have the patience to wait for the music to start. And the
   issue may be moot, anyway because the Internet is no more
   controlled by the United States than is the United Nations.

   "The Internet Architecture Board has specifically decided
   to ignore export controls in designing the security
   infrastructure for the next generation of Internet
   protocols," Mr. Gilmore said. "The Internet of 1998 will
   provide automatic, secure, and fully private communication,
   without key escrow, internationally."

   In other words, the Internet community is already planning
   to jump over the new line in the sand drawn last week by
   the Administration. Cryptogrophy that is stronger than the
   Government's proposed system will be built into the
   Internet by a dozen countries, and American companies and
   individuals would be foolish not to use it.

   At that point, millions of Americans will come into direct
   conflict with Government policy, and the popular
   gun-control bumper sticker may be replaced by one that says
   "If cryptography is outlawed, only outlaws will have
   cryptography."

   [End]

</pre>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 11, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-93</DOCNO>
<DOCOLDNO>IA053-000895-B047-332</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/bsa.html 129.174.40.15 19970123200530 text/html 20779
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:04:15 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 02 Jan 1996 16:16:11 GMT
Content-type: text/html
Content-length: 20595
</DOCHDR>
<html>
<title>Business Software Alliance Comments</title>
<body>
<pre>
   [Handout at Key Escrow Issues Meeting, at NIST,
   Gaithersburg, Maryland, September 6, 1995.]


   Testimony of
   Robert W. Holleyman, President, Business Software Alliance

   On The Export of Software with Encryption Capabilities

   September 6, 1995

   National Insitute of Standards and Technology
   Gaithersburg, MD


   Introduction and Summary

   My name is Robert Holleyman and I am President of the
   Business Software Alliance ("BSA"). BSA promotes the
   interests of the American software industry through its
   programs in the United States and more than 60 countries
   worldwide. Our members produce what is commonly referred to
   as "mass market" or pre-packaged software and include such
   leading companies as: Autodesk Inc., Bentley Systems, Inc.,
   Intergraph Corp., Lotus Development Corp., Microsoft Corp.,
   Novell, Inc., The Santa Cruz Operation, and Sybase, Inc.

   These companies are among America's most internationally
   competitive firms. Export sales for most of them account
   for more than one-half of revenues. Overall, the American
   software industry has a 75% worldwide market share for
   pre-packaged software. Software has been one of the fastest
   growing industries in the United States during the last 15
   years and today is larger than all but five manufacturing
   industries. Moreover, the industry has highly skilled,
   highly paid jobs.

   Unfortunately, the continued success and growth of our
   industry is directly threatened by the United States
   Government's continuing refusal to adopt realistic export
   control policies. America's software companies still are
   unable to sell worldwide software programs with encryption
   features that will provide the strong information security
   demanded by their customers.

   *Specifically, the Administration's announcement last month
   failed to provide immediate relief to software companies
   because it did nothing to liberalize export controls on
   generally available software employing non-key escrow
   encryption. Moreover, the Administration's announcement and
   the preliminary criteria set forth by NIST regarding key
   escrow encryption continue to reflect a misunderstanding of
   the market place and, if implemented in anything like their
   current form, will prevent key escrow encryption from ever
   being commercially adopted.*

   The government has come forth with government designed
   criteria focused entirely on fulfilling the government's
   desire to be able to access encrypted information. But what
   the government fails to recognize is that key escrow
   encryption approaches must be commercially desirable and
   voluntarily adopted. Computer users must want to buy
   programs with such features. America's software companies
   can't sell what users won t buy -- they have not become as
   successful as they are by trying to force their customers
   to purchase products with unwanted features. Therefore,
   unless there is market demand for key escrow encryption,
   software companies are not likely to produce programs with
   such features.

   Perhaps government officials believe that they know more
   than American industry about what computer users worldwide
   are demanding by way of information security. If that is
   so, then we must strongly disagree. We also wonder about
   the Administration's apparent decision to try and rely on
   a few companies offering specialty hardware-based key
   escrow encryption systems to "demonstrate" that they work
   and that there is a market for such systems (even if a
   limited one). Is the Administration really going to pick
   winners and losers in the computing industries when it
   comes to providing information security?

   An even more ominous interpretation of the Administration's
   recent announcements also suggests itself -- the government
   is pursing a "Son of Clipper" strategy that could lead to
   the *mandatory* use of key escrow encryption. How so?
   Clearly the government is trying to force America's
   software companies to include government sought key escrow
   features in its software as the "price" for export
   approval. Because of the companies' strong desire to
   develop and sell a single version of their programs
   worldwide, the government thus hopes to be able to have
   users abroad and in the United States use software with
   such key escrow encryption features. Even if, initially,
   the domestic use of such government approved key escrow
   encryption is only an option, it is easy to see how the
   government could then pursue legislation making its use
   mandatory and criminalizing the use of any other
   encryption. After all, at that point the government could
   argue that it was simply asking for Americans to use a
   feature in their software they already have. Yet I can
   assure you that the American software industry is not
   interested in making the installed U.S. software base
   "Clipper ready." (We also note that the government has said
   it will propose revisions to the Escrow Encryption Standard
   in line with the suggested criteria that will then cover
   electronic computer communications, not just voice
   communications!)

   In short, the Administration's "new" encryption policy
   appears to be little more than the old policy in new
   clothing. It still does not enable American software
   companies to export programs sought by their customers
   worldwide.

   Accordingly, we strongly urge the Administration to:

   +  Immediately permit the export of generally available
      software programs with non-key escrow encryption
      capabilities employing the DES algorithm or other
      algorithms at comparable strengths (56-bit key lengths)
      to maintain the American software industry's
      international competitiveness; and

   +  Permit the export of software programs employing data
      encryption and commercial key recovery systems: (1) with
      algorithms using at least 64-bit key lengths; (2) in
      which users in the U.S. or abroad are able to specify a
      key holder: (3) the key recovery system will be bound to
      the encryption function pursuant to good commercial
      practices such that the time and effort involved in
      by-passing the key recovery component or "spoofing" will
      be greater than that necessary to simply employ very
      strong (e.g. triple DES) non-key escrow encryption; (4)
      the programs themselves will not provide for multiple
      encryption; and (5) the system will identify the key
      holder without notification to the party encrypting the
      information.


   Background

   It has been three years since the U.S. Government permitted
   the export of mass market software programs with moderate
   encryption (i.e. with 40-bit keys). At that time, the
   Government committed to permit stronger encryption over
   time (i.e. to increase the key lengths) to provide adequate
   information security against commercial attacks (given
   advances in computing power) and maintain American
   companies' international competitiveness (given the
   proliferation of foreign manufactured programs with strong
   encryption). But no further export control liberalization
   occurred.

   More than a year ago, Vice President Gore agreed to study
   anew the short-run impact of existing export controls on
   the American software industry's international
   competitiveness and to reassess those controls based on the
   studies. He also called for the government to work the
   industry on exportable "key escrow encryption" systems that
   would "provide strong encryption, acceptable through users
   world wide. and address the national security needs as
   well. Key escrow encryption system can permit the use of
   very strong encryption (e.g. 128 bit keys) because the
   government will be able to obtain the keys from third party
   escrow agents in appropriate circumstances and thus be able
   to decrypt information.

   Unfortunately, during the last year American companies were
   not permitted to increase the strength of the encryption in
   their exportable programs and there was only minimal
   consultation with the software industry with regards to
   making commercial key escrow encryption systems a reality.

   On August 1 7, 1994 the Administration announced a renewed
   dialogue with industry to discuss key escrow encryption
   issues, including proposed liberalization of export
   controls for such software programs.


   The Administration's Announcement Ignores The Immediate
   Need To Liberalize Export Controls on Non-Key Escrow
   Encryption Software Programs

   The Administration's policy is silent with respect to
   permitting the use of stronger encryption in exportable
   generally available software programs. This means that
   American software companies must continue to limit the
   strength of their encryption to the 40-bit key length
   levels first proposed in 1991 and adopted in 1992.

   The failure to increase the key lengths reneges on the
   commitment made by the government at that time to regularly
   review and revise the strength of the encryption. The
   insistence on the 40-bit key length also fails to
   acknowledge that longer key lengths are the worldwide
   standard. The refusal to change this standard denies the
   existence of hundreds of foreign programs on the market
   employing DES (with 56-bits keys) and other strong
   encryption. Finally, it means that information encrypted at
   the moderate level is subject to successful attack by those
   employing commercially available resources (e.g. office
   work stations at night). Further proof was widely reported
   in the press just the other week: a French student at the
   Ecole Polytechnique "cracked" the 40-bit RSA "export
   version" security scheme used by Netscape Communications
   Corp., a company which is working hard to make the GII a
   commercial reality.

   We understand that the Department of Commerce has recently
   completed its latest study assessing the marketplace and
   the availability of foreign programs and products. We are
   confident that study confirms what our member companies'
   marketing forces have reported for some time -- growing
   availability of foreign programs and products offering
   strong security features which stand to supplant U.S.
   products if left unchecked. The White House has the study.
   The time has come to recognize reality and rectify the
   competitive disadvantage imposed on American industry.



   The Administration's Proposed Criteria Will Prevent Key
   Escrow Encryption From Ever Being Commercially Adopted

   1. The Administration Fundamentally Misunderstands the
      Marketplace.

   The Administration's "new" policy as set forth in the
   proposed criteria relies upon a government-designed
   solution intended to satisfy the government's desire to be
   able to access information. But it fails to understand the
   two reasons why computer users in the office or at home may
   want to use (and thus would be willing to buy) a commercial
   key recovery encryption system.

   First, users themselves may wish to be able to recover
   their keys easily and conveniently from someone they trust.
   A simple example will illustrate the point. When one of the
   secretaries at our counsel's law firm was let go, in a fit
   of pique she deleted six months worth of an attorney's
   files. Fortunately, the law firm was able to recover these
   files from its backup drives. But what if she had encrypted
   those files and no one else had the key? Thus, corporations
   have begun to express interest in the idea of an
   arrangement whereby the information systems manager or
   someone else in the company would hold the key. Similarly,
   among individual users, the ability to recover a key in the
   event it is lost or forgotten, coupled with possible ties
   to authentication or directory services or improved ease of
   use, could attract a number of users to a commercial key
   recovery encryption approach.

   It is important to understand, however, that users are
   really only interested in the ability to recover the keys
   to encrypted stored data -- files and such. None of our
   customers has expressed any interest in a key recovery
   system for communications. That's just not important to
   them because the key is only useful for the duration of the
   communication. Moreover, given the tremendous number of
   communications the administrative burden could be
   overwhelming.

   The second reason why users might be willing to use a key
   recovery system is the possibility of using much stronger
   encryption in programs used worldwide. Because the
   government ultimately would have access to encrypted
   information if a key recovery system was employed there
   really is no need to restrict the choice of algorithm or
   limit the key lengths. Yet the Administration's new policy
   would limit the strength of encryption keys to 64-bits when
   used with a key recovery encryption svstem..

   The greater the number of individuals at home and in
   business who employ a key recovery encryption system, the
   greater will be the government's ultimate access to
   encrypted information. But a voluntary commercial key
   recovery encryption system will be widely accepted only if
   it is a market-driven process in which people want to have
   others hold their keys. Yet the Administration's proposed
   criteria outlines a system designed for the convenience of
   the government -- not the user.

   The government contemplates "certifying" a limited number
   of key escrow encryption agents. It appears to envision
   stringent qualifications and requirements. It seems
   directed towards communications -- even though there is no
   commercial demand for key recovery systems in this area. It
   arbitrarily limits the key length size as well.
   Importantly, it fails to address the key issue of the
   ability of foreign parties to hold the keys for foreign
   users.

   Instead, it appears that the government has in mind
   imposing a telephone-based model of surveillance on all
   electronic information communications worldwide. We have
   noted that the NIST statement did say that revisions were
   being contemplated to the Escrow Encryption Standard to
   cover electronic data transmitted over computer networks
   (not just telephone networks).

   2. Criteria For A Workable Commercial Key Recovery
   Encryption System

   Let's be clear from the start -- key escrow encryption or
   key recovery encryption is not some "Holy Grail." Much as
   there is not one religion for everyone, and within any one
   religion there will always be skeptics, there are likely to
   be some computer users worldwide who will not be interested
   in letting anyone else "hold" their encryption keys. But at
   the same time, as explained above, there are several market
   driven reasons why many computer users might be interested
   in such systems. And to the extent that such systems are
   voluntarily employed within the United States and worldwide
   then we believe the U.S. Government's interests would be
   served because such systems ensure ultimate access to
   encrypted information.

   We believe commercial key recovery encryption systems that
   users would want or accept, and thus could be sold, would
   feature:

   +  A variety of encryption algorithms using at least 64-bit
      keys (and more likely much longer keys).

   +  User specification of a key holder. While users must
      have the choice of whom to give their keys, we believe
      many if not most will gravitate towards significant
      business entities as trusted third parties. Moreover, we
      believe the Administration should take steps to
      encourage -- but not require -- the formation of such
      key holders. It also is essential that foreign parties
      or entities be able to hold keys for foreign users. Yet
      the Administration' s guidelines are very vague on this
      point and seem to suggest that before this could occur
      new bilateral agreements would have to be negotiated.
      But unless and until American software companies know
      that this is possible -- and thus there is a reasonable
      prospect that foreign users will buy their programs --
      they have no incentive or reason to proceed!

   +  Binding the key recovery system to the encryption
      function pursuant to good commercial practices such that
      by-passing the key recovery component or "spoofing" the
      system will require more time and effort than would be
      involved in simply using very strong non-key escrow
      encryption (e.g. triple DES; RC2 with 128 bit key) in
      the first place.

   +  The program will not itself provide for multiple
      encryption. Thuss the system would not be designed so
      that information could be encrypted by the program
      itself more than once. Of course, no one can protect
      against the problem of "super encryption" -- the problem
      of someone encrypting information with a different non-
      key recovery system program (e.g. DES) and then using
      the program with the key recovery component.

   +  Identify the key holder without notification to the
      party encrypting the information. This could be done
      through "headers" or other technological means.

   It also should be remembered, however, that it is likely to
   take two years or so --a product cycle -- to develop and
   produce programs with commercial key recovery systems once
   the decision is made to do so. So we are really talking
   about a longer term approach -- which emphasizes yet again
   the need for immediate export control liberalization for
   non-key escrow encryption programs!


   Conclusion

   The continued delay in providing immediate relief to
   American software companies by liberalizing export controls
   on generally available software with non-key escrow
   encryption capabilities is harming the software industry.
   The Administration's inability to shake off the Clipper
   mind set is effectively precluding the adoption of
   realistic criteria for commercial key recovery encryption
   systems. Perhaps most importantly, the future of the Global
   Information Infrastructure and electronic commerce are
   being jeopardized. Instead of paving the roads, the
   Administration has left in place roadblocks on the
   Information Highway.

   The time for study is over. The time for action is now. The
   American software industry deserves the right to be able to
   compete in the world marketplace.

   Let me be clear: we are entering a new wave of computing.
   One in which consumers are demanding -- because they will
   need -- security features to be able to access and exchange
   data on a global basis. American software companies are
   presently. and arbitrarily, forced to stand on the
   sidelines as we enter this new era of computing, all
   because of outmoded restrictions which limit the ability of
   U.S. companies to sell programs abroad with greater than
   40-bit key length encryption. Nothing in the
   Administration's proposal will change this imbalance
   because the proposal does not adequately recognize that a
   key recovery system must be market driven, not government
   imposed, for it to gain popular acceptance and widespread
   utilization. By setting the bar too high, the
   Administration risks failure in satisfying its security
   objectives and, in doing so, takes the heretofore
   competitive American software industry out of its most
   important emerging market.

   It need not be this way. We urge the Administration to
   re-think its current proposal and work with the software
   industry to devise truly workable, market driven, criteria
   for exportable software programs with information security
   features.

   Thank you.

   [End]

</pre>

BBack to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 8, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-94</DOCNO>
<DOCOLDNO>IA053-000895-B043-10</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/security.html 129.174.40.15 19970123194535 text/html 2942
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:44:25 GMT
Server: NCSA/1.5.2
Last-modified: Sat, 02 Dec 1995 20:37:13 GMT
Content-type: text/html
Content-length: 2759
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Security Hotlist </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>Pat's Security Hotlist</H1>

<P>
<H2>Network security sources:</H2>
<ul>
<li><A HREF="http://www.commerce.net/information/services/security.html"> Internet Security FAQ</A>
<li><A HREF="http://ganges.cs.tcd.ie/mepeirce/Project/tools.html"> List of Internet security schemes </A>
<li><A HREF="http://www.commerce.net/software/Shttpd/Docs/Shttpd/home/html">Secure NCSA HTTP </A>
<li><A HREF="http://home.netscape.com/newsref/std/SSL.html"> Netscape's SSL protocol </A>
<li><A HREF="http://www.tis.com/Home/NetworkSecurity/WWW.html"> Trusted Information Systems </A>
<li><A HREF="http://info.internet.isi.edu/R80828-83564-1m/in-drafts/id-abstracts.html"> Secure TCP/IP IETF drafts </A>
<li><A HREF="http:// "> </A>
<li> U.S. Army Special Operations Center
<a href="http://otserver.soc.mil/docs/security/"> Security</a> information.
<li><a href="http://www-swiss.ai.mit.edu/~bal/bal-home.html">
Brian LaMaccia's homepage</a>
<li>the Information Infrastructure Task Force (IITF)
 <a href="http://ntiaunix1.ntia.doc.gov:70/0/iitf/security/fedrole.txt">
National Infrastructure Security Issues</a> forumn draft report.
<li>a nice mathematical treatment of trust is in 
<a href="http://gatekeeper.dec.com/pub/DEC/SRC/research-reports/abstracts/src-rr-083.html">
Authentication in Distributed Systems: Theory and Practice</a>
<li>Fred Cohen's <a href="http://all.net">Info Security Heaven</a>
<h2>Articles</h2>
<li> <http://www.cs.purdue.edu/coast/coast.html>   
The AI and author-ID security programs covered in the Nov 17, 1995
 Science article </a>
<li> Ross Anderson's <a href="ftp://ftp.cl.cam.ac.uk/users/rja14/robustness.ps.Z">'Robustness Principles' paper? (Crypto '95 proceedings)</a>
<h3>Not so hot security stories</h3>
<li>Financial Times on <a href="./crypto/citicorp">Citicorp Russian fraud</a>
<li>Financial Times on <a href="./crypto/netscapeRNG">Netscape's random number
generator flaw</a>
</ul>
No reasonable research into network security would be complete without
looking at what are called "firewalls." While I don't like the term,
firewalls are essential for corporate use of the Internet. The best
source that I've found on them is Brent Chapman's firewalls mailing list.
To subscribe send email to majordomo@GreateCircle.com with the message body of:
<br>
    	subscribe firewalls <yourname.host>
<hr>
And no modern discussion of security is possible without <a href="./crypto.html">cryptography.</a>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 2, 1995  Backto <a href="./hotlist.html">Pat's hotlist</a> Backto <a href="./index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-95</DOCNO>
<DOCOLDNO>IA053-000896-B001-29</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/tis.html 129.174.40.15 19970123200711 text/html 29957
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:05:58 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 02 Jan 1996 16:22:22 GMT
Content-type: text/html
Content-length: 29773
</DOCHDR>
<html><title>TIS presentation, NIST September meeting</title>
<body>
<pre>
   [Handout at Key Escrow Issues Meeting, at NIST,
   Gaithersburg, Maryland, September 6, 1995.]


   Thoughts on the NIST Key Escrow Issues Meeting Discussion
   Papers

   Trusted Information Systems

   September 1, 1995


   1    Introduction

   Trusted Information Systems(TIS) is pleased to have the
   opportunity to present a set of thoughts on Discussion
   Papers 1 and 2 prepared by NIST for the September 6-7,
   1995, Key Escrow Issues Meeting. It is exciting to see
   progress made on the export of better cryptography. The
   goal of the government to accept products into the new
   program by the end of this year is an impressive one.

   Towards that goal, TIS offers the following comments on the
   NIST discussion papers.


   2    Criteria for Criteria

   It is very important that the final criteria are, as stated
   in the NIST discussion paper, *the objectives, but not the
   exact technical method(s), by which those objectives are
   satisfied*. The criteria must also be

   +    Relevant -- the criteria must focus on meeting the
        government's goals.

   +    Objective -- the criteria cannot be subject to
        interpretation. Vendors cannot use criteria that
        change with each review of a product or each new
        product.

   +    Achievable -- the criteria must be implementable by
        vendors. This will meet the goal of both government
        and industry to export better cryptography.

   +    Acceptable -- the criteria must be accepted by, and
        result in systems that are accepted by:

        - the U.S. government with respect to export policy,

        - industry with respect to the vendors implementing
          compliant systems,

        - users who will buy the products, and

        - the international community that will 
          import compliant products.

   One must be careful not to start down the *How to* path for
   each of the issues presented. That is the job of each
   solution provider. Even though the issues begin with *how
   to*, attention must instead be focused on the particular
   government interest at issue, and each solution provider
   must be allowed to determine how to address that interest.

   The following include a few other traps that the criteria
   process must avoid.


   2.1  Don't Specify Commercial Criteria

   The criteria process must focus on the criteria that the
   government will use for determining compliance for export.
   There are plenty of additional relevant criteria for
   creating a good escrow encryption system. The job is not to
   specify the best, or even a good, system. Rather, it is to
   make sure that applicable government requirements are
   specified, and no more.

   2.2  Don't Exceed the Minimum

   The criteria process must focus on the minimum requirements
   necessary to achieve compliance for export. The
   Clipper/Capstone LEAF represents a starting point for the
   functionality of escrowed communication. The criteria must
   not exceed that functionality.

   2.3  Don't Allow Criteria Creep

   Criteria Creep must be avoided. Once criteria for export
   are established, they should remain static. Each vendor
   should be evaluated against the same criteria.

   2.4  Don't Solve the Dual Rogue Problem

   The criteria process should not attempt to solve the dual
   rogue (two cooperating entities bypassing key escrow)
   problem. Clipper does not solve it. Mike Nelson at the
   August 17 announcement clearly stated that compliant
   solutions are not expected to solve it. The criteria
   process must not attempt to write criteria that try to
   solve it.

   2.5  Don't Over Protect

   Any criteria process dealing with protection of key escrow
   mechanisms should evaluate whether it is easier or cheaper
   to write or procure compatible non-escrowed encryption than
   to disable the escrow mechanism of a compliant product.
   Remember that the use of key escrow-based encryption is not
   required for anyone, domestically or internationally. There
   will always be other choices available. The criteria should
   be that defeating the exportable key escrow mechanisms
   cannot be accomplished at a cost lower than using an
   alternative. This is clearly a balancing act of risk
   management; there are no absolute answers.


   3    Nomenclature

   The software key escrow community must use a generic
   nomenclature that does not suggest any particular
   implementation or solution. Unfortunately, the NIST issues
   are written using terms that in many cases specifically
   describe the Clipper implementation. For example, the
   criteria should be written to refer to *third party agents*
   instead of key escrow agents. Not all third party agents
   are key escrow agents. The criteria should deal with
   *decrypting information* instead of keys. The exact
   placement of the keys may differ with each solution. In
   general, the terms used in the criteria should not suggest
   an implementation or make any assumptions about an
   implementation.


   4    Issues for Escrowed Encryption Products

   The following sections address each of the issues raised in
   the NIST Discussion Paper #1. Each section begins with the
   *issue as stated by NIST*.

   4.1  Avoiding Multiple Encryption

        *How can the product be designed so as to prevent
        doubling (or tripling, etc.) the key space of the
        algorithm?*

   Ensuring that the product itself does not provide a feature
   of doubling or tripling the key space of encryption is a
   relevant and reasonable requirement. It is in the
   government's interest to mitigate the risk of a breakdown
   of the key escrow mechanism by limiting the key space
   allowed by compliant products. It is also necessary to
   ensure that the product cannot be modified to allow
   doubling or tripling from within a compliant product. This
   requires the same protections, and the same level of
   assurance, as the later issue of protecting the product
   from being modified to disable the escrow mechanism.

   However, ensuring that the product cannot be used multiple
   times to double or triple encryption constitutes trying to
   solve the dual rogue problem. Any use of a product outside
   of its features requires the cooperation of both the
   encrypting and decrypting party. Even though this is the
   dual rogue problem, because it is of special interest to
   the government, it should be explored in more detail.

   First, if a compliant product is used multiple times, then
   each key will be escrowed. Second, if a product is to
   prevent itself from being used multiple times, then it must
   maintain state about how it was used. A rogue application
   can always be written that will require 1 more bit of state
   than the product maintains, thus defeating any mechanism
   attempting to prevent multiple passes over the same data.

   4.2  Disabling Key Escrow Mechanism

        *How can products be made resistant to alteration that
        would disable or circumvent the key escrow mechanism?
        How can the "static patch" problem be avoided? How can
        this be tested?*

   Resisting the disabling or circumvention of the key escrow
   mechanism is a relevant and reasonable export requirement.
   This requirement appears in several forms in the issue
   list. It should probably be stated in the positive, that
   escrowed encryption products must always use the escrow
   feature when encrypting. This criterion must apply

   +    during product distribution and initialization,

   +    in spite of attempts to disable the escrow mechanism
        by altering the software, and

   +    in spite of postprocessing the output from a compliant
        product.

   Each of these issues needs to be looked at separately.

   The first issue is that the escrow feature is always used
   for a successful encryption, even if encryption is
   attempted during product distribution and initialization.
   This prevents a user from subverting the system by failing
   to perform some initialization step. There are several
   methods for vendors to meet this criteria.

   Protecting the integrity of the software presents
   interesting problems but gives rise to creative solutions
   as well. The ability to meet any criteria relies on the
   integrity of the software. It is also very important for
   vendors to identify the integrity boundary of their
   products. There will be a subset of the product that is
   integrity protected. Alteration of the portion of the
   product that is not integrity protected should not affect
   the compliance of the product with any of the agreed-upon
   criteria.

   Postprocessing the cyphertext to remove the escrow
   information presents certain difficult issues and needs to
   be addressed separately from the integrity of the software.
   Since postprocessing can be done outside of the escrowed
   encryption product, the only way to prevent it is to make
   it detectable or harder to accomplish than using a
   different encryption method. Remember, too, that the
   purpose of having private escrow systems is to provide
   users with functionality as well. Postprocessing the
   cyphertext removes the user's ability to use the features
   of the escrow system as well.

   4.3  Access To Escrow Information

        *What mechanisms must be designed into encryption
        products to allow authorized access to escrowed keys?
        This likely includes the identity of the key escrow
        agent(s) and a serial number for the key escrow agent
        to use to identify the key(s)/component(s) necessary
        to decrypt the message. What other information will be
        necessary to be provided to the escrw agent to
        identify the necessary key(s)/components(s)? Are there
        other comparable viable approaches?*

   This issue should to be restated to focus on the objective,
   rather than on the mechanisms. Both the government's and
   the commercial user's objective is that each encrypted
   object identifies the information necessary for the
   decryption of the object. This identity information must be
   available to law enforcement (and the user, for that
   matter) without any cryptographic processing.

   4.4  Non-escrowed Use

        *How can products be made so that they do not function
        with non-escrowed products (or tampered escrowed
        products)? How can this be tested?*

   There are two separate reasons for this issue. This issue
   addresses both the prevention of postprocessing of messages
   and the promotion of the use of escrow-enabled products.

   The first issue in nonescrowed use is the prevention of
   postprocessing of messages to remove the escrow
   information. If prevention of this attack is the goal, then
   we need to focus on this as a threat and decide on possible
   countermeasures. Outlawing interoperability is only one
   possible countermeasure.

   The second issue is the promotion of the proliferation of
   escrow-enabled products. The promotion of the use of the
   products is not a relevant requirement for the export of
   the product. Whether a product, or technology, succeeds or
   fails in the marketplace is not a relevant criteria for
   export. Furthermore, requiring compliant products to refuse
   interaction with noncompliant products may, in fact, have
   the opposite effect. The following scenarios will
   illustrate the point.

   +    *Compliant xmtr and compliant rcvr*. There is no issue
        here.

   +    *Compliant xmtr and noncompliant rcvr*. There should
        be no issue here. Since the xmtr is compliant, the
        information necessary for law enforcement access will
        be transmitted, and law enforcement needs are met.

   +    *Noncompliant xmtr and compliant rcvr*. Here is the
        alleged problem. The xmtr does not transmit the
        information necessary for law enforcement. However, in
        the world of commercial business, the receiver cannot
        dictate how people send information, so in order to be
        compatible with the noncompliant xmtr the receiver
        moves to a noncompliant product. This hinders the use
        of escrow enabled technology. Rather than having at
        least one side of the conversation using this
        technology, forcing the issue will result in no side
        using it.

   +    *Noncompliant xmtr and noncompliant rcvr*. There is no
        issue here. Neither of the products falls under these
        criteria.

   Do not underestimate the need for interoperability for
   product vendors. This issue can take many forms. There are
   already interoperability standards for encrypted electronic
   mail, such as the MIME Object Security Standard (MOSS). If
   new products cannot interoperate with the existing
   products, then the early adopters will have no one to
   communicate with and will not promote the product.

   A different form of the interoperability problem is within
   a product family. If a company makes an investment in one
   of the third party DES encryption products available today
   and later purchases compliant exportable products for use
   overseas, this would set up the compliant/noncompliant
   problem. It is unlikely that a company will also upgrade
   all of its domestic products. It is more likely that they
   will find an interoperable product overseas.

   Even if product vendors do not achieve full
   interoperability between compliant and noncompliant
   products due to technical issue and design decisions, a
   government mandate against interoperability is not an
   answer. Allowing the marketplace to control
   interoperability lets it decide how important it is in
   order to sell a product. Vendors will provide what is
   necessary in order to sell their products. The government
   criteria should not be used as a reason for products to
   fail. That is a lose-lose proposition.

   4.5  Limiting Surveillance

        *How can products be designed so that information both
        sent and received by the user can be decrypted without
        release of keys of other users?*

   This issue must be looked at with an understanding of the
   nature of the communication method. Electronic mail is a
   store-and-forward, one-way communication. The information
   is protected by the sender until the receiver receives the
   message and completes its half of the key exchange and
   decryption. It is not realistic to expect to be able to
   read a subject's incoming mail without the release of some
   information from the escrow system of the transmitter. A
   Capstone LEAF in a mail message does not do this. A new
   system should not have to, either.

   Access to both directions of communication with the release
   of information from the third party for only one of the
   users is reasonable for two-way communication.



   4.6  Practical Key Access

        *How can mechanisms be designed so that repeated
        involvement of escrow agents is not required for
        decryption for multiple files/messages during the
        specified access period?*

   Here is an example of the wording implying a specific
   solution. Not all systems have escrow agents. The true
   issue for the government is that there is some range of
   acceptable interaction with the escrow system (a collection
   of elements) for repeated decryptions under the same
   authorization. Every system proposed will be involved in
   every decryption. The issue is the form of that
   interaction. The eventual criteria must specify what is
   expected both in the form of human interaction and in the
   form of automated interaction.

   4.7  Assurance That Keys Are Escrowed

        *How can it be assured that key escrow products are
        indeed satisfactorily escrowed? For example, products
        could be required to be escrowed at time of
        manufacture or be made inoperable until properly
        escrowed.*

   This is a subset of Disabling Key Escrow. Phrased
   differently, can one circumvent key escrow specifically by
   not initializing the system properly? This should be
   discussed with the other attacks to disable or circumvent
   key escrow.

   4.8  Ability to Re-Escrow Keys

        *How can products be designed so that new keys can be
        escrowed at the user's discretion with a U.S.
        Government approved escrow agent?*

   It is not clear what this issue means. It suggests two
   different criteria. First, it suggests that if the
   underlying cryptographic system allows, or even expects,
   users to periodically change the keys that they use, then
   the escrow system must also allow users to do this. It is
   not relevant to the government's interests to require a
   system to change keys. It is good practice to change keys,
   but the government criteria must be limited to those issues
   relevant to meeting the government interests.

   Second, this issue suggests that there are multiple third
   party agents to choose from. It is vital to the commercial
   acceptance of escrowed encryption that the criteria allow
   for a choice of third party agent.

   4.9  Certified Escrow Agents

        *Can products be designed so that only escrow agents
        certified by the U.S. Government (domestic, or under
        suitable arrangements, foreign) are utilized? What
        should be the criteria for an acceptable U.S. escrow
        agent?*

   It is relevant that escrow systems make sure that they are
   dealing with valid agents for the proper operation of the
   system. However, whether the government is in a position to
   certify agents is another question.

   The entire issue of government certification of escrow
   agents and the criteria used should be separated from the
   discussion of the product criteria. This issue should be
   removed from the product list and discussed with the escrow
   agent issues list.

   5    Criteria for Key Escrow Agents

   The following sections address each of the issues raised in
   the NIST Discussion Paper #2. Each section begins with the
   issue as stated by NIST. The section titles are the
   editor's.

   Before examining this set of issues, it is necessary to
   examine the basis for establishing any criteria for third
   party agents. There is no basis for the certification of
   escrow agents for use within the United States. There is no
   legal authority or budget appropriation for a certification
   activity. The only basis would be for escrow agents in the
   United States used in conjunction with exported escrowed
   products. Remember, these criteria are only for the purpose
   of determining exportability.

   However, most importing nations of escrowed encryption will
   require the entire system to be subject to their laws. They
   will not import the encryption products without the
   software or hardware used by the third party agents. The
   real issue is the criteria for allowing export of the
   software and systems used by the third party agents, not
   the criteria for approving the organizations within the US.
   For purely domestic use, there is no basis for approving
   the agents. Authorizing legislation would be required to
   form a basis for any criteria. Futhermore, it is not
   entirely clear that government specified criteria
   regulating a domestic activity for the purpose of achieving
   exportability would be considered to have a rational basis
   by a court. Were such legislation to pass muster, however,
   it would have to fundamentally accept that the use of
   escrowed encryption domestically is a voluntary action that
   a user might take in order to gain the benefits of
   emergency recovery or other authorized third party access.
   Appropriation legislation would also be required to allow
   any licensing authority to exist and function. Given the
   pace of legislation, and the current reluctance to expand
   government operations, it is imperative that the deployment
   of these systems not rely on the passage of legislation.

   5.1  Exclusion of Organizations

        *What kinds of organizations should be excluded from
        consideration as approved key escrow agents?*

   Criteria must be positive and objective. Even discussing
   the concept of exclusion sets the stage for charges of
   restraint of trade and discrimination. There can be no
   preconceived notion about who might be able to meet a set
   of criteria.

   5.2  Legal Agreements

        *What sort of legal agreement between the government
        and the key escrow agent is necessary to stipulate the
        responsibilities of the agent? Should this include the
        terms and conditions under which release of a key is
        required?*

   This is not a criteria for third party agents. Any third
   party agent is subject to the laws of its local
   jurisdiction. If located in the United States, a third
   party agent is subject to Federal, State, and local laws.
   If current law does not address key escrow with enough
   specificity, perhaps legislation would be in order.
   Complying with any new legislation would not require the
   certification of third party agents; it would just mean
   they could comply more uniformly with the laws of their
   respective jurisdictions.

   5.3  Liability

        *How will liability for unauthorized release of key be
        handled?*

   This is not a relevant concern of the government. Civil
   liability is entirely a business concern of the third party
   agent, not a criteria of the government. Third party agents
   will be set up to be in business and to stay in business.
   State statutory law, common law, as well as business
   considerations will dictate how liability is managed.

   5.4  Criminalization

        *Should, for example, intentionally misreleasing or
        destroying a key be criminalized? Should this include
        other actions?*

   Destroying the ability to perform recovery (note the more
   generic wording) is a relevant concern of both the
   government and the business users of an escrow service.
   Misreleasing a key may not hamper the government's ability
   to meet its needs, but it certainly would cause the users
   to lose faith in the escrow system, which could then hamper
   the government's ability to meet its interests. If a third
   party destroys its ability to perform recovery, it has put
   itself out of business, preventing its clients and the
   government from accessing the information of its clients.
   Even so, this is a subject for legislation, not
   certification. Amendments to existing laws may be
   sufficient to provide the requisite deterrent and
   punishment.

   5.5  Investigation Confidentiality

        *How can the government's needs for confidentiality of
        key release be handled?*

   The third party agents are subject to the laws of their
   local jurisdictions. If the authorization presented to the
   third party agent requires confidentiality, and many, if
   not all, do, the government's needs are met. If it does
   not, then the government needs to change the wording of its
   authorizations or create legislation that specifically sets
   forth appropriate confidentiality requirements.

   5.6  Public Key Infrastructure

        *Should approval of key escrow mechanisms be tied to
        a public key infrastructure (for digital signatures
        and other purposes)?*

   It would be beneficial for key escrow mechanisms to use a
   public key infrastructure, but the development and
   deployment of key escrow technology cannot and should not
   be tied to the development and deployment of a public key
   infrastructure.

   5.7  Storage and Safeguarding of Keys

        *What procedures need to be developed for the storage
        and safeguarding of keys?*

   First, the issue really is, what steps has the third party
   taken to make sure that it can perform recovery? The
   government's needs and the needs of the commercial
   marketplace coincide here. The better the security, the
   more trust a customer will have in the third party agent.
   What steps will a third party agent take to make sure that
   it can stay in business? Standard commercial practices will
   naturally increase the level of security.

   5.8  Performance Criteria

        *What are the acceptable performance criteria (e.g.,
        around-the-clock availability, accessibility,
        reliability, etc.) for approved key escrow agents?*

   This is the only relevant criteria where the government's
   needs may exceed those of the commercial marketplace.
   However, unless the government is willing to pay for the
   cost of service above and beyond what is provided to the
   marketplace, one must look at reasonable compromises that
   third party agents can take to meet government needs
   without putting themselves out of business. For example,
   staffing a third party agency 7 days for 24 hours may be
   prohibitive. But making sure that there is always a point
   of contact with a beeper who can respond within a
   reasonable amount of time (measured in hours, not minutes)
   is reasonable.

   5.9  Export of Third Party Components

        *Under what circumstances will key escrow agents in
        foreign countries be approved?*

   This is really the key question. From the U.S. government
   point of view, there must be appropriate bilateral
   agreements with the importing country to allow the
   importing country to retrieve the recovery information and
   share it with the United States in a timely fashion, and
   vice versa. This is not a relevant criteria that a product
   vendor can influence. The government must take the lead in
   auditing and augmenting its international police agreements
   to allow its new policy to work.

   5.10 Approval Process

        *What process will be used to approve escrow agents?
        Costs/who pays?*

   After reviewing the issues, there does not appear to be a
   legal basis and or legitimate need for a government
   approval process. The issues are handled by following the
   laws of the jurisdiction of the third party agent and by
   following good commercial practice. If the government
   determines that new legislation would clarify the
   application of existing laws for the escrowed encryption
   scenario, TIS would welcome discussions on the content of
   such new legislation.


   6    An Alternative to Government Certified Third Party
        Agents

   Commercial vendors are also very concerned about third
   party agents. The failure of any third party agents casts
   a shadow on the entire escrow system. The vendors of key
   escrow systems will do everything that is commercially
   reasonable to ensure the proper and successful operation of
   the third party agents.

   It is expected that vendors will apply commercial criteria
   to "who can license" their systems. Commercial criteria
   could include requiring a corporate certificate of good
   standing, credit reports, and perhaps insurance or bonding
   requirements. Rather than sell escrow components outright,
   vendors may license components to operators with licensing
   terms that specify performance criteria.

   Compare this to government certification. The government
   would still have to operate with objective,
   nondiscriminatory criteria that would include certificates
   of good standing, credit reports, etc. The only additional
   criteria that the government has at its disposal is the
   ability to perform background checks on the principals of
   a third party agent. However, this may not be acceptable to
   commercial business interested in running a third party
   agency domestically. Furthermore, anyone can be a third
   party agent for domestic use today with no restriction
   whatsoever. In order for the government to apply any
   criteria, legislation would have to be passed. This will
   take time. Industry can, and will for its own purposes,
   start applying commercial criteria immediately.

   The marketplace is very incented to ensure the successful
   operation of third party agents. The government interest is
   limited to ensuring that the laws for searches and wiretaps
   can be executed appropriately. Let industry lead in this
   area, and both the government interests and industry
   interests will be met.


   7    Conclusion

   There are several relevant, objective, achievable, and
   acceptable criteria for the export of escrowed encryption
   products that are necessary to meet the interests of the
   government. They must be stated in a clear, generic form
   that captures the true, concise objective to be met and not
   the mechanism to use.

   There are not, however, relevant, objective, achievable,
   and acceptable criteria for the certification of third
   party agents. The government must understand the
   applicability of the existing laws that govern evidence
   gathering and work with the vendors of third party products
   to allow the marketplace to set the standards for third
   party agents.

   [End]






</pre>

Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 14, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-96</DOCNO>
<DOCOLDNO>IA053-000894-B003-318</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/dpt.html 129.174.40.15 19970123201220 text/html 919
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:11:05 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 13 Sep 1995 14:10:32 GMT
Content-type: text/html
Content-length: 737
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Comments on DPT</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>DPT, Oh My!</H1>
<p>
Every supporter of the administrations continued policies prohibiting
strong encryption technology and supporting GAK says that
without these controls, we will be at the mercy of Drug dealers,
pedaphiles, and terrorists.
<p>
This is a completely goundless statement, yet it has been repeated
in many forums. 
<p>
If the government really wanted to stop drug dealers who harm
American society, when are they going to take on RJ Reynolds, Phillip Morris,
and Anheusier Busch?
<P>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
September 8, 1995
</body>
</DOC>
<DOC>
<DOCNO>WT03-B24-97</DOCNO>
<DOCOLDNO>IA053-000895-B043-388</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/PGP.html 129.174.40.15 19970123194925 text/html 593
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:48:07 GMT
Server: NCSA/1.5.2
Last-modified: Fri, 08 Dec 1995 21:22:04 GMT
Content-type: text/html
Content-length: 411
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's 'PGP' (PGP) geek code</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
My PGP keys are on the usual keyservers, and are also on my <a href="../crypto.html">Crypto page</a>. The oldest key was created and signed in October 1992.
<p>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 8, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-98</DOCNO>
<DOCOLDNO>IA053-000892-B034-133</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/~csis/faculty/publications.html 129.174.40.15 19970123190807 text/html 13848
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:06:57 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 22 Jan 1997 21:42:45 GMT
Content-type: text/html
Content-length: 13664
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Selected Publications</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#5C3317"
      LINK="#9F5F9F" VLINK="#22AA22" ALINK="#0077FF">
<p>
<center>
<h1>Selected Publications:</h1></center>
<font size=4>
<ul>
<li> <A HREF="#books">Books and Edited Volumes</A>
<li> <A HREF="#temporal">Temporal Databases</A>
<li> <A HREF="#semantics">Formal Methods and Semantics-based Concurrency Control</A>
<li> <A HREF="#replicated">Replicated Databases</A>
<li> <A HREF="#general">Databases - General</A>
<li> <A HREF="#security">Information Systems Security</A> 
</ul>
</font>
<center><img src="color_line.gif"></center><p><p>

<A NAME="books"><h3>Books and Edited Volumes:</h3></A><p>
<font size=4>
<ul> 
<li> S. Jajodia and L. Kerschberg, eds.,
 Advanced Transaction Models and Architectures, Kluwer, 1997, In preparation.

<li> V. S. Subrahmanian and S. Jajodia, eds., 
 ``Multimedia Database Systems: Issues and Research Directions,'' 
 Springer-Verlag Artificial Intelligence Series, 1996.

<li> M. Abrams, S. Jajodia, H. Podell, eds.  
 ``Information Security: An Integrated Collection of Essays,'' 
 IEEE Computer Soceity Press, 1995.  

<li> A. U. Tansel, J. Clifford, S. Gadia, S. Jajodia,
 A. Segev, and  R. Snodgrass, eds.
 ``Temporal Databases: Theory, Design, and Implementation,''
 Benjamin/Cummings (1993).

</ul> 
</font>
<p>
<center><img src="color_line.gif"></center><p>
<p>

<A NAME="temporal"><h2>Temporal Databases:</h2></A><p>
<font size=4>
<ul> 
<li> X. S. Wang, C. Bettini, A. Brodsky, and S. Jajodia,
 ``Logical design for temporal databases with multiple
 temporal types,''
 ACM Trans. on Database Systems, To appear.
  
<li> C. Bettini, X. S. Wang, and S. Jajodia,
 ``Temporal semantic assumptions and their use in 
 database query evaluation,''
 IEEE Trans. on Knowledge and Data Engineering, To appear.

<li> C. Bettini, X. S. Wang,  and S. Jajodia,
 ``Testing complex temporal relationships involving 
 multiple granularities  and its application to data mining,''
 Proc. 15th ACM PODS Symp., Montreal, Canada, June 1996,
 pages 68-78. <A HREF="../publications/pods-96.ps">PS file</A>

<li> C. Bettini, X. S. Wang,  and S. Jajodia,
 ``A general framework and reasoning models for time granularity,''
 Proc. 3rd Int'l. Workshop on Temporal Representation and Reasoning,
 Key West, FL, May 1996. <A HREF="../publications/time96.ps">PS file</A>

<li> X. S. Wang, S. Jajodia, V. S. Subrahmanian, 
 ``Temporal Modules: An Approach Toward Federated Temporal Databases,'' 
 Information Sciences, Vol. 82, 1995, pages 103--128.   

<li> G. Wiederhold, S. Jajodia, and W. Litwin, ``Integrating temporal
data in a heterogeneous environment,'' in Temporal Databases,
A. Tansel et al., eds., Benjamin/Cummings (1993), pages 563--579.

</ul> 
</font>
<p>
<center><img src="color_line.gif"></center><p>
<p>

<A NAME="semantics"><h2>Formal Methods and Semantics-based Concurrency Control:</h2></A><p>
<font size=4>
<ul> 
<li> P. Ammann, S. Jajodia, and I. Ray,
 ``Applying formal methods to semantic-based decomposition
 of transactions,''
 ACM Trans. on Database Systems, To appear.
 <A HREF="../publications/tods96.ps">PS file</A>

<li> P. Ammann, S. Jajodia,  I. Ray, 
 ``Using formal methods to reason about semantics-based 
 decompositions of transactions,'' Proc. VLDB Conf.,
 Zurich, Switzerland, September 1995, pages 218--227.
 <A HREF="../publications/vldb95.ps">PS file</A>

</ul> 
</font>
<p>
<center><img src="color_line.gif"></center><p>
<p>

<A NAME="replicated"><h2>Replicated Databases:</h2></A><p>
<font size=4>
<ul> 

<li> O. Wolfson, S. Jajodia, and Y. Huang,
 ``An adaptive data replication algorithm,''
 ACM Trans. on Database Systems, To appear.
 <A HREF="http://www.eecs.uic.edu/~wolfson/mobile_ps/rev10.ps">PS file</A>

<li> O. Wolfson, S. Jajodia,   
 ``An algorithm for dynamic data allocation in distributed systems,''  
 Information Processing Letters, Vol. 53, No. 2, 1995, pages 113--119. 
                          
<li> S. Jajodia and D. Mutchler, 
 ``Dynamic voting algorithms for maintaining the consistency of a replicated database,''
 ACM Trans. on Database Systems, Vol. 15, No. 2, June 1990, pages 230-280.


</ul> 
</font>
<p>
<center><img src="color_line.gif"></center><p>
<p>

<A NAME="general"><h2>Databases - General:</h2></A><p>
<font size=4>
<ul> 

<li> P. Ammann, S. Jajodia, and P. Frankl,
 ``Globally consistent event ordering in one-directional 
 distributed environments,''
 IEEE Trans. on Parallel and Distributed Systems, 
 Vol. 7, No. 6, June 1996, pages 665-670.

<li> P. Ammann, S. Jajodia, and P. Mavuluri, 
 ``On-the-fly reading of entire databases,'' 
 IEEE Trans. on Knowledge and Data Engineering, 
 Vol. 7, No. 5, 1995, pages 834--838. 
  
<li> P. Ammann, V. Atluri,  and S. Jajodia, 
 ``The partitioned synchronization rule for planer partial orders,'' 
 IEEE Trans. on Knowledge and Data Engineering, 
 Vol. 7, No. 5, 1995, pages 797--809.  
 
<li> P. Ammann, S. Jajodia, 
 ``Distributed timestamp generation in planar lattice networks,'' 
 ACM Trans. on Computer Systems, Vol. 11, No. 3, August 1993, pages 205--225. 
                          
<li> S. Jajodia, R. Mukkamala, ``Reduction in transaction conflicts
using semantics-based concurrency control,'' in  Performance of
Concurrency Control Mechanisms in Centralized Database Systems,
V. Kumar, ed., Prentice-Hall (1995), pages 387--405.


</ul> 
</font>
<p>
<center><img src="color_line.gif"></center><p>
<p>

<A NAME="security"><h2>Information Systems Security:</h2></A><p>
<font size=4>
<ul> 

<li> E. Bertino, P. Samarati, and S. Jajodia, 
 ``An Extended Authorization Model for Relational Databases'',
 IEEE Transactions on Knowledge and Data Engineering, Vol. 9(1), 
 January 1997 
 <A HREF="../publications/ieee-97.ps">PS file </A>

<li>  E. Bertino, S. Jajodia, L. Mancini, and I. Ray,
 ``Advanced transaction processing in multilevel 
 secure file stores,''
 IEEE Trans. on Knowledge and Data Engineering, To appear.
 <A HREF="../publications/tkde96.ps">PS file</A>

<li> P. Samarati, E. Bertino, A. Ciampichetti, and S. Jajodia,
 ``Information flow control in object-oriented systems,''
 IEEE Trans. on Knowledge and Data Engineering, To appear.

<li> S. Jajodia, P. Samarati, V. S. Subrahmanian, and E. Bertino,
 ``A Unified Framework for Enforcing Multiple Access Control Policies,''
 Proc. ACM SIGMOD Int'l. Conf.
 on Management of Data, May 1997, To appear.

<li>Vijay Atluri, Sushil Jajodia, Tom Keefe, Cathy McCollum and Ravi
Mukkamala, "Multilevel Secure Transaction Processing: Status and
Prospects", Database Security X: Status and Prospects, P. Samarati and
R. Sandhu eds. Chapman and Hall, London 1997. <A
HREF="../publications/mlstp-survey.ps">PS file</A>

<li> V. Atluri, S. Jajodia and E. Bertino, 
 ``Alternative correctness criteria for concurrent
 execution of transactions in multilevel secure databases,''
 IEEE Trans. on Knowledge and Data Engineering, 
 Vol. 8, No. 5, October 1996, pages 839-854.

<li> P. Samarati, E. Bertino, and S. Jajodia,
 ``An authorization model for a distributed hypertext system,''
 IEEE Trans. on Knowledge and Data Engineering, August 1996,
 Vol. 8, No. 4, August 1996, pages 555--562.

<li> P. Samarati, P. Ammann, and S. Jajodia,
 ``Maintaining replicated authorizations in distributed 
 database systems,''
 Data & Knowledge Engineering, Vol. 18, No. 1, February 1996, pages
 55--84.

<li> K. P. Smith, B. T. Blaustein, S. Jajodia, and L. Notargiacomo,
``Correctness criteria for multilevel transactions,''
 IEEE Trans. on Knowledge and Data Engineering, 
 Vol. 8, No. 1, February 1996, pages 32--45.

<li> P. Ammann, S. Jajodia, and I. Ray,
 ``Ensuring atomicity of multilevel transactions,''
 Proc. IEEE Symp. on Research in Security and Privacy,
 Oakland, Calif., May 1996, pages 74-84. <A
HREF="../publications/oklnd96-indrksi.ps">PS File</A>

<li> E. Bertino, S. Jajodia, and P. Samarati,
 ``Supporting multiple access control policies in database systems,''
 Proc. IEEE Symp. on Research in Security and Privacy,
 Oakland, Calif., May 1996, pages 94-107.<A
HREF = "../publications/oklnd96-samarati.ps">PS File</A>

<li> I. Ray, E. Bertino, S. Jajodia, and L. Mancini,  
 ``An advanced commit protocol for MLS distributed database systems,'' 
  Proc. 3rd ACM Conf. on Computer and Communications Security 
  New Delhi, India, March 1996, pages 119--128. <A
HREF="../publications/acm-india.ps">PS file</A>
  
<li>  E. Bertino, S. Jajodia, and P. Samarati,
  ``A non-timestamped authorization model for relational databases,''
  Proc. 3rd ACM Conf. on Computer and Communications Security 
  New Delhi, India, March 1996, pages 169-178.
  
<li>  K. S. Candan, Sushil Jajodia and V.S. Subrahmanian,
  ``Secure mediated databases,''
   Proc. 12th Int'l. Conf. on Data Engineering, 1996, pages 28--37 . 
  <A HREF="../publications/de95.ps">PS file</A>

<li> D. G. Marks, A. Motro, S. Jajodia, 
 ``Enhancing the controlled disclosure of sensitive information,'' 
 Proc. European Symp. on Research in Computer Security,
 Rome, Italy, September, 1996.

<li> E. Bertino, S. Jajodia, and P. Samarati,
 ``Database security: Research and practice,''
 Information Systems, Vol. 20, No. 7, 1995, pages 537--556.                
                          
<li> P. Ammann, F. Jaeckle, and S. Jajodia,
 ``Concurrency control in a secure multi-level database via 
 a two-snapshot algorithm,''
 Jour. of Computer Security, Vol. 3, No. 2,3, 1994/1995, pages pages 87--113.

<li> P. Ammann, S. Jajodia, 
 ``Distributed timestamp generation in planar lattice networks,'' 
 ACM Trans. on Computer Systems, Vol. 11, No. 3, August 1993, pages 205--225. 
                          
<li> V. Atluri, E. Bertino, S. Jajodia, 
 ``Degrees of isolation, concurrency control protocols, and commit
 protocols,''
 Database Security VIII: Status and Prospects, (J. Biskup et al., eds.), 
 North-Holland, 1994, pages 259--274.
                           
<li> P. Ammann,  S. Jajodia, 
 ``An efficient multiversion algorithm for secure servicing of transaction reads,'' 
 Proc. 2nd ACM Conf. on Computer & Communications Security, 
 November 1994, pages 118--125.
                           
<li> P. Samarati, P. Ammann, S. Jajodia, 
 ``Propagation of authorizations in distributed database  systems,'' 
 Proc. 2nd ACM Conf. on Computer & Communications Security, 
 November 1994, pages 136--147.
                           
<li> A. Motro, D. Marks, S. Jajodia, 
 ``Aggregation in Relational Databases: 
 Controlled Disclosure of Sensitive Information,'' 
 Springer-Verlag LNCS, Vol. 875, 1994, pages 431--445.
                           
<li> E. Bertino, L. V. Mancini, S. Jajodia, 
 ``Collecting garbage in multilevel secure object stores,'' 
 Proc. IEEE Symp. on Research in Security and Privacy, 
 May 1994, pages 106--120. 
 
<li> P. Ammann,  S. Jajodia, 
 ``Planer lattice security structures for multilevel replicated databases,'' 
 Database Security VII: Status and Prospects, 
 (T. F. Keefe and C. E. Landwehr, eds.), 
 North-Holland, 1994, pages 125--134.
 
<li> V. Atluri, E. Bertino,  S. Jajodia, 
 ``Achieving stricter correctness requirements in multilevel secure
 databases,''
 Jour. of Computer Security, Vol. 2, No. 4, 1993, pages 311--351.


<li> S. Jajodia, B. Kogan, and R. Sandhu, ``A multilevel-secure
object-oriented data model,'' in  Readings in Object-Oriented
Systems and Applications, D. Rine, ed., IEEE Computer Society Press
(1995), pages 206--215.

<li> S. Jajodia and R. Sandhu, ``Toward a multilevel secure relational
data model,'' in Information Security: An Integrated Collection of
Essays, M. Abrams et al., eds., IEEE Computer Society Press (1995),
pages 460--492.

<li> S. Jajodia, R. Sandhu, and B. T. Blaustein, ``Solutions to the
polyinstantiation problem,'' in Information Security: An Integrated
Collection of Essays, M. Abrams et al., eds., IEEE Computer Society
Press (1995), pages 493--529.

<li> C. Meadows and S. Jajodia, ``Integrity in multilevel secure
database management systems,'' in Information Security: An Integrated
Collection of Essays, M. Abrams et al., eds., IEEE Computer Society
Press (1995), pages 530--541.

<li> S. Jajodia and C. Meadows, ``Inference problems in multilevel
secure database management systems,'' in Information Security: An
Integrated Collection of Essays, M. Abrams et al., eds., IEEE Computer
Society Press (1995), pages 570--584.

<li> S. Jajodia, S. Gadia, and G. Bhargava, ``Logical design of audit
information in relational databases,'' in Information Security: An
Integrated Collection of Essays, M. Abrams et al., eds., IEEE Computer
Society Press (1995), pages 585--595.

<li> S. Jajodia, B. Kogan, and R. Sandhu, ``A multilevel-secure
object-oriented data model,'' in Information Security: An Integrated
Collection of Essays, M. Abrams et al., eds., IEEE Computer Society
Press (1995), pages 596--616.

<li> R. Sandhu and S. Jajodia, ``Integrity mechanisms in database
management systems,'' in in Information Security: An Integrated
Collection of Essays, M. Abrams et al., eds., IEEE Computer Society
Press (1995), pages 617--634.

<li> E. Bertino, S. Jajodia, and P. Samarati, ``Access Controls in
Object-Oriented Database Systems -- Some Approaches and Issues,'' in
Advanced Database Systems, N. R. Adam and B. Bhargava, eds.,
Springer-Verlag Lecture Notes in Computer Science, Vol. 759 (1993),
pages 17--44.

<li> R. S. Sandhu and S. Jajodia, ``Data base security controls.''  in
Handbook of Information Security Management, H. F. Tipton, and Z. A.
Ruthberg, eds., Auerbach Publishers (1993), pages 481--499.
<p>
</font>
<center><img src="color_line.gif"></center><p>
</ul>
</font>
</body>
</html>
 
</DOC>
<DOC>
<DOCNO>WT03-B24-99</DOCNO>
<DOCOLDNO>IA053-000894-B003-86</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/cp1.html 129.174.40.15 19970123200917 text/html 12560
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:08:01 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:18:09 GMT
Content-type: text/html
Content-length: 12376
</DOCHDR>
<html>
<head>
<title>Pat Farrell's Cypherpunk summary of NIST meeting</title>
</head>
<body>
<p>
Here are my noted and remembered impressions from Wedensday's 
<a href="http://www.nist.gov">NIS&T </a>
conference on key escrow (aka GAK) export. Please note that there is 
a separate conference next week on creating a FIPS PUB standard for 
key escrow. That standard will be promulgated, just as GOSIP, POSIX 
and Clipper/Skipjack were promulgated. This export conference was 
separate from that FIPS standardization process.
<p>
I got stuck in a construction traffic jam, and missed the introductory
speaches. Perhaps one of the other c'punks can fill us all in on what I
missed.

<p>

The first item is that the export criteria will be changed. A small number
of bits will be added to unescrowed crypto, and 64-bit escrow'd (GAK'd)
systems will be allowed. They don't care which algorithm is used, DES, RC4,
blowfish, etc. They care about key length. If it is short enough, it is
exportable.

<p>
The conference seemed to be an attempt to co-opt industry into agreeing
that 64-bit GAK is much better than the current situation. After all,
it would be too strong for a "hacker in France" to break it.

<p>
When they opened the floor, there were a few comments/questions
that indicated that not everyone was convinced that this was a good thing.
I pointed out some graduate students don't consider "hacker" a compliment,
and that I thought Damian did a great job breaking RC4-40. I also pointed
out that it was broken again in 31 hours with a "bunch of commercial
systems, Sun and Pentiums" with no need for supercomputers. 

<p>
I then asked if the criteria were fixed, as setting criteria controls the
result. The NIS&T approved board said that changes to the criteria was 
part of why the conference was being held.

<p>
The next hour and a half was presentation from "industry." Essentially
comments on the proposal. Nearly all of the spokesmen said that the criteria
were flawed. Some said that they already had commercial products
that met most of the real needs of the industry (key recovery) but they
didn't meet the NIS&T/NSA "criteria." Probably the strongest was the
condamnation by Robert Holleyman of the Business Software Alliance.

<p>
Hollyman said that BSA represents firms such as Microsoft, Novell, Lotus,
Sybase, SCO, Autodesk, and Intergraph. He said that current policy "directly
threatens" the industry because of "The US Government's continuing refusal
to adopt realistic export control policies." He went on and on.
It was clear that his position is that the proposed policy is a mistake.
Follow this link for a 
<a href="./nist/bsa.html">copy of the BSA presentation.</a>

<p>
After the presentations, there were more questions. I proposed one
additional criteria (based on email that I received from the c'punks):
How do we expire court approved access to encrypted data, so that once the
court orders are over, the LEAs no longer have the ability to decrypt.
The answer was that with clipper, special hardware is needed, and it goes
away when the court order does. I asked how that model worked in a software
only world. There were mumbled statements about adding it as a criteria.

<p>
The conference then broke for lunch and breakout groups. The one I was in
discussed criterias 5 and 6 of Topic 3, published in my URL
<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
http://www.isse.gmu.edu/~pfarrell/nistmeeting.html</a>
They are short enought to reproduce here.

<p><i>
5.    The product shall be resistant to any alteration that would
      disable or circumvent the key escrow mechanism, to include
      being designed so that the key escrow mechanism cannot be
      disabled by a static patch, (i.e., the replacement of a
      block of code by a modified block).

<p>
6.    The product shall not decrypt messages or files encrypted
      by non-escrowed products, including products whose key
      escrow mechanisms have been altered or disabled.
</i>
<p>
After I commented that the person writing the notes has the ability to
detirmine what was said, the folks from NSA and NIS&T asked me to take 
the notes. I love it; but I did try to be objective.

<p>
In the middle of this discussion, a government-generated, but anonymnous
paper was distributed. It had 
"<a href="./nist/sample_solutions.html">Example Suggested Solutions.</a>"
 It suggested
that source code not be available for products suitable for export. It also
suggested other ideas, such as storing a checksum/hash and having the
system "check the cryptographic code several times during its use." There 
was a strong reaction against these suggestions, not because they were
bad ideas, but because the paper was delivered with no prior publication.
This precluded any planned response to its ideas.

<p>
We reworded #5 to say "want to Trust the Product." This means that it 
is untampered, works as expected, etc. We then hashed out ways to 
know this. The list ended up looking like:
<ul>
<li> is available only as object code
<li> contains some "hash" function to check for modifications
<li> contains some unique hash, with uniqueness based upon something 
        like "site," "per copy" or "per release" 
<li> Contains policies against modification, such as liscense language        
        against decompilation.
<li> OS-related security, such as runs "protected mode" instead of as a 
        wild DOS program.
</ul>
<p>
Of course, the software vendors went wild against "per copy" identifiers,
saying it would add two orders of magnitude worth of problems to 
manufacturing.

<p>
The items on the list were not "must have all of these" rather it was
a pick-and-chose menu. We also required that the standard allow
for technical innovation to keep up with the evolving state of the art.

<p>
The discussion of #6 was more lively. We took a long time figuring out what
it said. For instance, could ViaCrypt sell a product that was compatible
with PGP 2.6.2 (non-escrowed) that also worked with the new escrowed
ciphers? It seems to me, and a lot of other folks there, that such a product
would be non-exportable. We simplified the criteria to:
  "right products won't talk to wrong products."
with "right products" meaning those that are exportable, and wrong products
being those that aren't, or are hacked, or ...

<p>
We then developed "goals" including:<br>
1. One version for sale worldwide<br>
2. Allow development in the US<br>
3. Domestic Law Enforcement Agencies want Escrowed (I almost wrote GAK :-)<br>
4. Must interoperate with everything<br>
5. Receiver can only decrypt if escrow agencies can decrypt.<br>

<p>
This leads to a bunch of issues and observations, including:
a. Can goals 1, 2, and 4 be met simultaneously?

<p>
There was a suggestion of a "friendly man-in-the-middle" who would
receive a GAK'd conversation, and strip off the GAK parts, and reencrypt
it, and retransmit it to a non-GAK user. Which leads to:
b. Can we prohibit a friendly MITM?

<p>
The big issue was:
c. Startup compatibility. No one will buy products unless they have
sales attractiveness. This means compatibility with existing systems.
Yet the criteria #6 seems to say that approved products must refuse
backwards compatibility.

<p>
This was labeled a "non starter" by the group.

<p>
The consensus was that companies can develop a substantial competitive
advantage by developing off-shore and offering both escrowed encryption
and compatibility with existing systems.

There was a discussion of grandfathering in some technologies.
This was to help interoperability. The conversation became fuzzy,
Grandfather technologies included DES, 3-DES, IDEA, and long key RC4.

One key idea was that it may make sense to allow software that encrypts with
escrowed keys, but can also decrypt with any algorithm. This allows the LEA's
to access outgoing messages, while allowing interoperability.
<p>
The discussions frequently wandered to discuss the language of the criteria.
The wording was considered simultaneously too subjective  and impractical.
For example, we considered the phrase "tamper resistant" to be preferable 
to the original "prevent tampering," because it is impossible to absolutly
prevent modification to software.
<p>
The issue of interoperability was raised repeatedly. 
It is critical that exportable products interoperate with other,
existing export products. 

<p>
The last issue in the session was that the length of the key, 64-bits,
was defined in criteria #1. There was no discussion at the conference on
this criteria. It seems that the NIS&T and NSA folks believe that
this is a closed topic. The folks in the session did not agree. They
felt that 64-bits was not enough.

<p>
Once the breakout session was over, the entire conference met together, 
and the "reporter" from each session reported their comments and findings.

<p>
All breakout sessions had suggested changes. The group that discussed
criteria #9 recommended removing it. The group that discussed criteria #2 
(no multiple encryption) reported that industry was working on a general 
solution to the problem of key recovery, and that their solution would 
probably appear as quickly without the government's "help." 

<p>
Several groups identified that there are at least two separate 
problem domains: communications and data storage. Communications 
typically is short term, and has unique keys for each session. 
Data storage has far fewer keys that are used
for long periods. Several speakers suggested that while communications
keys were not suited to be escrowed, there was a large need for
key recovery for data storage. There was no response from the government
representatives to any of these points. One government speaker
did say that there would be a Federal key escrow standard, period.

<p>
After the combined session, there were more break-out sessions. In the one
that I attended, the folks from National Semiconductor described their
<a href="./national.html">CAKE system.</a>
 This is a smartcard/PCMCIA device that uses 2000+ bit 
public/private key encryption and signatures. They are hoping for export
approval; it is necessary for the project to be viable.  The system looks
pretty interesting, but it too complicated to describe here. In short, 
random session keys are generated and signed with a Data Recovery Center's
public key. The LEAs could then send encrypted session keys to the DRC, 
which would decrypt them, and return the unencrypted session keys which
the LEA could then used to decrypt the messages.

<p>
While this is a hardware system, its concepts could be transfered to 
a software implementation.

<p>
One obvious problem is that NS' system doesn't meet criteria #8 (retuiring
repeated involvement of the escrow agent), since it may require
hundreds or thousands of session key decipherments. It also has
a number of attractive features, such as never sending the private
key anywhere, only the session key is escrowed.

<p>
The general discussion showed concerns that in the international
community, requiring government escrow may cause loss of valuable data,
as some foriegn governments are not as trustworthy as the US. It was
the consensus that requiring users to have 50 or more escrow centers was
unworkable. Yet this could be required for large multinational companies
working in 50 or more countries, if each required a local key escrow service.

<p>
The NS model would allow both date stamping of session keys, and periodic
rekeying. Either would satisfy my "unaccepted" Citeria #11, technical
limits to the time that a court ordered decryption could be executed.

<p>
There was a discussion of changing the criteria so that only the transmission
of data was concerned with escrow. This would simplify the issue of
multinational escrow. We did not resolve whether this would be sufficient
or acceptable.

<p>
Thursday, we will talk about 
<a href="./techcrit.html">suitable escrow agencies.</a>
<p>
Pat


<hr>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/nist950906.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 7, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-100</DOCNO>
<DOCOLDNO>IA053-000896-B001-155</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/vtw.html 129.174.40.15 19970123200809 text/html 9952
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:06:56 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 22:49:26 GMT
Content-type: text/html
Content-length: 9769
</DOCHDR>
<html>
<head>
<title>VTW Comments to NIS&T on Clipper II</title>
<!author=Sender: shabbir@panix.com>
</head>
<body>
<hr>
<h1>COMMENTS SUBMITTED FOR NIST KEY ESCROW WORKSHOP REPORT</h1>


<h2>INTRODUCTION</h2>
Thank you for the opportunity to speak here today.  I am Shabbir J.
Safdar from the VTW (Voters Telecommunications Watch).  VTW is a public
advocacy organization based in New York City.  We monitor civil
liberties issues in telecommunications for the public and when civil
liberties coincides with good business practices, small business
interests.
<p>

There are a number of problems with the key escrow proposals (both
Clipper and Commercial Key Escrow) that have been put before us.  Today I
will be addressing some of the problems with the current proposal and
exploring some myths surrounding the debate.

<p><pre>
For further information, you can reach VTW at:
	Listserver:	listproc@vtw.org
	Email:	vtw@vtw.org
	WWW:	http://www.vtw.org
	Gopher:	gopher -p1/vtw gopher.panix.com

</pre>
<p>
TRUE OR FALSE?

<p>
True or False: Industry is clamoring for key escrow

<p>
True.  Industry is not, however, clamoring to put their keys in the hands of
disinterested third parties.

<p>
True or False: Export controls are preventing foreign adversaries from
obtaining commercial cryptographic technology

<p>
This is true if we're speaking of US commercial cryptographic technology,
but false if were speaking about the hundreds of products available
overseas.  As recently as this year Colombia declared a state of
emergency and used that opportunity to conduct a number of raids on
suspected Cali Cartel offices.  They found that Cartel members were using
encryption to hide stored data files containing counter-intelligence
information, encryption devices to hide their real time communications,
and were also conducting their own surveillance program on the Colombian
law enforcements communications.
<p>

Presumably, they did not have a warrant.

<p>
(References for this incident can be found in the May 26th 1995 Wall
Street Journal cover story and the July 3, 1995 Baltimore Sun.)

<p>

True or False: Export controls are preventing foreign adversaries from
obtaining public domain cryptographic technology

<p>
False.  The availability of public domain PGP overseas is currently a
somewhat tired but true joke within forums such as this one.  In addition,
the newest product in the PGP family, PGPFone, was released for download
on the Internet for US and Canadian sites only.  With explicit warnings and
annoying measures in place, it clearly informed the user (who could not
download it without being on a site within the US or Canada) that export
of PGPFone outside the US violated ITAR.
<p>

PGPFone was available on a European server three days and four hours
later.
<p>


Issues raised by the use of key escrow agents

<p>
OVERSIGHT
<p>
Because the event of releasing a key is in and of itself secret, it is very
difficult for an insider within the escrow structure to report wrongdoing
without compromising their knowledge of an investigation.

<p>
As we know from experience, oversight of a secret government process
does not work adequately to engender public trust.

<p>
NO EVIDENCE OF A MARKET ABROAD FOR ESCROWED PRODUCTS
<p>
There is no evidence that suggests that there is a market abroad for
commercial key escrow products.  Contrary to the statements and
optimism of the fine gentleman from the White House, it is unlikely that
China will allow its citizenry to use communications products it cannot
wiretap.
<p>

Considering that these people have first-hand experience with a tyrannical
regime and it potential for damage, it is unlikely that Chinese dissidents
will use key escrowed devices knowing that they can be accessed by the
government.
<p>

DAMAGE STEMMING FROM A WRONGFUL DISCLOSURE IS TOO HIGH
<p>
The damages an escrow agent might be responsible for in the case of a
wrongful key release is going to be greater than anyone can afford. 
Imagine the amount of money that is involved in a campaign, a new patent,
a new pharmaceutical drug, or a financial acquisition.  Who can afford to
be liable for such damages?
<p>

DOCUMENTS LIVE FOREVER UNDER KEY ESCROW
<p>
The escrow agents can never be allowed to destroy a key, because you can
never prove that you have stopped using a key.  This means that if your
traditional records management system involves destroying an encrypted
document and its decryption keys after seven years.

<p>
Under commercial key escrow you will now have to worry about the
existence of any document or communication forever because there will
always be a decryption key available.  In addition, because people tend to
be less careful with transmission and storage of encrypted documents
(because, after all they're encrypted) the likelihood of someone having
made a rogue copy is more likely than under a non-key escrowed
encryption system where you would have used a Brinks-mailed floppy disk
instead of an open-line transfer.
<p>

ESCROW AGENTS CANNOT ENFORCE CONSTRAINTS OF THE WARRANT
<p>
Because law enforcement agents are not involved in the collection of the
seized material, they cannot verify that when they are presented with a
warrant, that the officers in question acted in a manner appropriate to the
judge's orders.  Escrow agents are then reduced to nothing more than
safety deposit box services.  Although this might meet the needs of law
enforcement, this does not support the requirement of trust between the
public and the escrow agent.
<p>

VOLUNTARY KEY ESCROW IS NOT CREDIBLE
<p>
Although the word voluntary has been bandied about publicly throughout
the Administration's key escrow debacle, the FBI, the NSA, and the
Department of Justice have all stated in documents obtained through the
Freedom of Information Act that for key escrow to work, other forms of
non-escrowed cryptography must be criminalized.  Although this is no
surprise to anyone who has thought about the problem, this casts doubt on
the Administrations commitment to the continued availability of other
forms of cryptography.  These documents can be found on the Electronic
Privacy Information Center World Wide Web site at URL:http://www.epic.org.

<p>
In addition, the very fact that escrowed products are going to enjoy
preferential export treatment (64 bits versus 40 bits), indicates that a
choice between escrowed and non-escrowed products is not a voluntary
choice, but one weighted with inappropriate incentives.
<p>

WIRETAP ABUSES DO OCCUR
<p>
Although it gives us no joy to point it out, throughout recent history there
have been cases of abuses of surveillance authority.  It makes no sense to
empower an already human-fallible system with additional powers such
that the magnitude and damage of the human errors is increased.

<p>
EXECUTIVE BRANCH IS AN INAPPROPRIATE LOCATION FOR BOTH ESCROW
AGENTS AND ESCROW AGENTS' REGULATORY AGENCIES
<p>
The regulatory structure that has been discussed so far involves the
regulation of escrow agents solely by the Executive Branch.  Thus far no
one has suggested that legislation is necessary, though many have
suggested that it might be an alternative.
<p>

Should final regulatory authority rest entirely within the Executive
Branch, escrow agents would be subject to the political whims of
whatever the current administration felt was appropriate.   A process that
does not have an appeals escape clause (one that allows you to predict the
number of appeals you will have to file and when you will be appealing to
a judicial body) can arbitrarily control the actions of escrow agents.

<p>
Without a judicial appeals process that goes outside the executive
branch, a key escrow agent or a key escrow customer will end up appealing
to the very same agency that is a party to any dispute.


<p>
CONCLUSION
<p>
It is an interesting game that we play here today with extremely high
stakes.  We continually fight over what some call the "grey area" of access
to data and communications.  Public advocates assert that law
enforcement enjoys significant access to data already, but that a
guarantee of access to data is not acceptable.

<p>
Law enforcement insists that the public has significant ability to keep
data confidential, but that a guarantee of confidentiality is not
acceptable.

<p>
It is not clear if there is a middle ground where both these parties can
find solace, but key escrow (either commercial key escrow or through
government held keys) is not that middle ground.

<p>
<hr>
<pre>
SUBSCRIPTION AND REPRODUCTION INFORMATION

      *** Know of someone ANYWHERE with a fax machine but without net ***
      *** access that's interested in VTW's issues?  Tell them to     ***
      *** call and get on our weekly fax distribution list at         ***
      *** (718) 596-2851 (or email us their fax number.		      ***

         To get on the distribution list for BillWatch, send mail to
      listproc@vtw.org with "subscribe vtw-announce Firstname Lastname"
			     in the subject line.

	To unsubscribe from BillWatch (and all other VTW publications)
	send mail to listproc@vtw.org with "unsubscribe vtw-announce"
			     in the subject line.

         Email vtw@vtw.org with "send billwatch" in the SUBJECT LINE
		  to receive the latest version of BillWatch

	For permission to reproduce VTW alerts contact vtw@vtw.org

</pre>
<hr>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 11, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell//hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-101</DOCNO>
<DOCOLDNO>IA053-000895-B043-195</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/misctech.html 129.174.40.15 19970123194717 text/html 2619
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:46:03 GMT
Server: NCSA/1.5.2
Last-modified: Fri, 13 Sep 1996 12:06:43 GMT
Content-type: text/html
Content-length: 2436
</DOCHDR>
<HTML>
<head>
<TITLE>Miscellaneous Technical Sites and sources.</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<p>
<H2>Sites for the geek: </H2>
<dl>
<dd>Perl FAQs in 
<http://www.khoros.unm.edu/staff/neilb/perl/metaFAQ/metaFAQ.html">html, </a>
<a href="ftp://ftp.khoros.unm.edu/pub/perl/metaFAQ.ps">Postscript, and 
<a href="ftp://ftp.khoros.unm.edu/pub/perl/metaFAQ.txt">Ascii.
<dd> <a href="http://w4.lns.cornell.edu/~pvhp/ptk/ptkFAQ.html">Perl/Tk faq</a>
<dd><A HREF="http://www.intel.com/procs/p6/"> Intel PR on the P6 </A>
(Sextium?) 
<dd><A HREF="http://asustek.asus.com.tw"> ASUS </A> Taiwan PC Motherboards, 
also try <a href="http://www.magi.com/~gebara"> an US mirror for ASUS</a>, which
should be faster than the link to taiwan.
<dd><A HREF="http://www.infinet.com/~venkat"> A vendor's page, with some
low-tech info on CPU sockets, EDO, etc. </A>
<dd><a href="http://www.ecs.com.tw/gemini.html">Gemini motherboards</a>
<dd><A HREF="http://www.LCS.com">An ASUS reseller </A>
<dd><a href="http://www.ba.com/nr/95/may/smds.html">Bell Atlantic ISDN/SMDS</a>
<dd>
<a href="http://fohnix.metronet.com/~rcollins/undoc/UndocumentedIntel.html">
Undocumented tech info on Intel chips</a>
<dd>Assorted information on Windows 95 is on 
<a href="http://www-dccs.stanford.edu/NetConsult/Win95Net/faq.html">
Win95netbugs list</a>
<dd><a href="http://www.micron.com">Micron's homepage</a> they primarily make
memory. But they have interesting side businesses, including 
<a href="http://www.mei.micron.com">Micron and (now defunct) Zeos computers</a>.
But, while similarly named, they are not related to 
<a href="http://www.micronics.com">Micronics motherboards</a> 
<dd>Doug <a href="http://www.cs.wustl.edu/~schmidt/">Schmidt'</a>s 
wonderful and free <a href="http://www.cs.wustl.edu/~schmidt/ACE.FAQ.html">
ACE wrapper's FAQ</a>
<dd>A position paper I wrote <a href="./tech/smallplus.html">On Language
Wars, Smalltalk versus C++</a>
<dd>A position paper I wrote <a href="./tech/performance.html">
ON Performance</a>
<dd>James Grimm's 
<a href="http://www.mit.edu:8001/people/grimm/Int/Int.home.html">
Big num class for C++</a>
<dd>My current computers is a Pentium Pro 200 workstation with 
parts from lots of vendors. <a href="./ppro.html">Driver and 
vendor contacts</a>

</dl>
<P>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
January 29, 1996
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-102</DOCNO>
<DOCOLDNO>IA053-000895-B045-103</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/tge.html 129.174.40.15 19970123195512 text/html 6022
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:54:01 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 22:55:36 GMT
Content-type: text/html
Content-length: 5839
</DOCHDR>
<HTML>
<head>
<TITLE>NIS&T FIPS PUB standard meeting for Key Escrow </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1> Tom Edwards report on the FIPS PUB meeting on Key Escrow</H1>
This report was prepared by 
<a href="mailto:tedwards@Glue.umd.edu"> 
 Thomas Grant Edwards <tedwards@Glue.umd.edu> </a>
<p>

I went to the NIST "Developing Key Escrow Encryption Standards Workshop" 
held in Gaithersburg, MD on Sept. 15, 1995.  It turns out I know the guy
who was running the conference so I knew I couldn't miss it...and I knew I
had to wear my Cypherpunks t-shirt to show the flag (and it stood out, as
there were few without suits there). I got to meet Dorothy Denning for the
first time.  I was mentioning how government key-escrow doesn't sound too
bad to some in the libertarian/cypherpunk world, say for instance to
ensure FOIA requests are not encrypted away.  She said that would never be
a problem, just getting the government to give you FOIA documents in the
first place is the problem. 
<p>
In a nutshell, this was a conference to begin work on a FIPS for software 
key encryption escrow.  Industry people there felt that a FIPS would be a 
great way to standardize key escrow for data recovery.  However, except 
for one guy at IBM who said they tap employees phones alot, most industry 
people felt that it was not needed for tapping their real-time 
communications.  There was a lot of talk from government people about the 
need for Law Enforcement to get access to encrypted real-time 
communication between government employees.  This, to say the least, 
squicked many attendees, and there seemed to be much tension between the 
sides on that issue.
<p>
I asked a couple of industry people and privacy advocates the question "Am
I just paranoid, or is this FIPS a trial balloon for mandated civillian
key escrow?"  I got many "yes" answers.  I also heard the occasional "this
sounds like son-of-clipper" comments in the breakout groups. 
<p>
One noteworthy point is that RSA sent in a position paper to try to get 
the Digital Signature Standard replaced by RSA signatures for inclusion 
in key escrow FIPS due to its "virtual non-availability in commercial 
products," and noted that the US Govt. has free use of RSA sigs.
<p>
Another noteworthy point is that NIST made clear that the key escrow FIPS 
should _not_ involve SECRET algorithms.  
<p>
The Workshop consisted of a discussion of goals and objectives by Ray
Kammer (Deputy Director, NIST) and some initial thoughts on standards
development by Miles Smid (NIST).  Here is the gist of the overhead
slides: 
<p>
The Goals of the workshop were based on the August 17 announcement by the
Administration to allow for exportability of 64-bit software key escrow
encryption, plans to allow Federal agencies to use Escrowed Encryption
Standards compliant hardware devices for data communications, and the
development of a FIPS for key escrow, implementable in software.  This
escrow FIPS would be used by Federal agencies in conjunction with
FIPS-approved encryption techniques.  This workshop was held to help 
begin the FIPS development.  The workshop goals included 
<ol>
<li> Providing 
input to the govt. on drafting a software key escrow encryption standard; 
<li> Helping govt. to identify additional policy and technical issues that 
need to be addressed and 
<li> providing the govt. with thoughts on drafting 
and follow-up
</ol>

The FIPS process involves developing the draft FIPS, a 90 day comment 
period, then addressing comments, and then it goes to the Secretary of 
Commerce for signature, and becomes effective six months after the 
signature.  
<p>
The purpose of the New Escrow FIPS is to foster a wider use of escrow 
technology...this means: no requirement for SECRET algorithms, software 
and hardware implementations, and exportability.  It also will provide a 
government validation of escrow systems meeting the 
standard...theoretically allowing for security, integrity, and availability.
<p>
Threats examined included compromise (unauthorized disclosure of keys and 
data recovery), and denial of service (modification or loss of keys, use 
of bogus recovery fields, and improper system operation).
<p>
The FIPS will provide common formats and procedures which will facilitate 
data recovery and lower cost.  Applicability of the FIPS will include the 
US Govt. and contractors.  Applications include both stored and 
transmitted data.  Encryption algorithms must be FIPS approved.  And 
finally desirable features include: auditing, configuration control, 
backup capability, and efficiency.
<p>
The questions asked to the breakout groups included:
<ol>
<li> Is a standard interface for the release of keys desirable?
<li> What documentation is required?
<li> How will operational procedures be developed?
<li> How will conformance be validated?
<li> Will security be evaluated?  If so, under what criteria and by whom?
<li> How will configuration control be maintained?
<li> Are new FIPS-approved algorithms necessary?
<li> Should escrowing be built into the Public Key Infracstructure?
<li> Is a standard escrow system identification field needed?
<li> Is split knowledge required?
<li> Do systems which permit data to be encrypted for both storage and 
transmission need to provide for both kinds of escrow?
<li> Does the government require special features (2-hour access, 
continuous real-time decryption, etc.)?
</ol>
<p>Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II </a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
Novermber 9, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-103</DOCNO>
<DOCOLDNO>IA053-000895-B042-234</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/geek.html 129.174.40.15 19970123194333 text/html 1649
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:42:22 GMT
Server: NCSA/1.5.2
Last-modified: Fri, 08 Dec 1995 21:25:46 GMT
Content-type: text/html
Content-length: 1466
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's geek code (Version 3.0)</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
I've been a geek forever, at least 35 years. I used to be an Engineer. 
Not a "software engineer" but a real Engineer, 
working at an Engineering firm with
a hundred other professional Engineers. I used to hang
a sliderule on my belt so I'd be ready as I walked across campus. What's 
<a href="./sliderule.html"> a sliderule?</a>
<p>
Consult the
<a href="http://krypton.mankato.msus.edu/~hayden/geek.html"> Master Copy</A>
directly from Robert. This has been updated to reflect version 3.0, look 
<a href="./geek.2.1.html">here for Pat's version 2.1 geek code</a> 
<p><code>
GM/CS d- s++:+++ <a href="./a.html>!a</a> C+++$ U--- 
<a href="./P.html">P+</a> L-- E- W++ 
N++ K- <a href="./w.html">w++++$ </a><a href="./O.html">O--</a> 
M- <a href="./V.html">V</a> PS+++ PE++ 
<a href="./Y.html">Y+++ </a> <a href="./PGP.html">PGP++</a> 
t-- !5 X <a href="./R.html">R </a>
<a href="./tv.html">tv+ </a><a href="./b.html">b++</a> DI+++ D--- G+ 
<a href="./e.html">e+++>++++</a> h(----)++ r+++ y++++ 
</code>
<P>
I've seen version 3.0 codes fit on one line, mine takes two. Guess there
are too many entries with too many +++'s.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 8, 1995  Backto <a href="../hotlist.html">Pat's hotlist</a> Backto <a href="../index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-104</DOCNO>
<DOCOLDNO>IA053-000894-B003-200</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/post.html 129.174.40.15 19970123201104 text/html 4437
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:09:46 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 22:59:43 GMT
Content-type: text/html
Content-length: 4254
</DOCHDR>
<html>
<head>

<title>Feuding again Erupts over encryption Exports</title>
</head>

<h1>Feuding again Erupts over encryption Exports</h1>
<center>
Elizabeth Corcoran<br>
Washington Post Staff Writer<br>
<br>
Copyright (c) Washington Post, All rights reserved.<br>
<br>
Business Section, Page C2, September 16, 1995<br>
</center>

<p>
After a brief August honeymoon, feuding has broken out again among the
U.S.  government, industry and civil liberty advocates trying to devise
rules that would permit high-technology companies to more easily export
sophisticated technologies that scramble information.
<p>
Yesterday, the various parties sat down in a day-long meeting to discuss the
technology, which keeps information safe from eavesdroppers, but found
little common ground. Government officials tried to put a positive light on
the process, but several private sector people who attended said they felt
"confused," and "burned" by the discussions.
<p>
"This whole thinkg is like trying to find a way through a maze that none of
us have found a way through before," said Steve Walker, president of Trusted
Information Systems, an information security company in Brentwood, Maryland.
"Everybody would like everything, and we're all going to have to give up
something."
<p>
Both industry and government thought they saw possible grounds for
compromise in August, when Clinton administration officials said they were
willing to let companies export sohpisticated encryption technologies that
provided some private organizations would hold onto a spare key for
unlocking scrambled information. That way if law enforcement officials had
the proper court authorization, they could get a peek at otherwise locked
information.
<p>
But sparkls began to fly a few weeks later when the administration met with
industry and others to explore precisely how such a policy would work. For
example, although the new policies would let companies export more complex
encryption technology than current law permits, businesses began worrying
that the most sophisticated techniques would still be out of bounds.
<p>
Others worried about who would hold the spare keys. Since U.S. law
enforcement agencies want to be able to reach the keys, some felt thgey
should in most cases be held in the United States unless the federal
government had struck a deal with its foreign counterparts that would
enable, say, the FBI to obtain spare keys stored elsewhere on short notice.
<p>
"There is not going to be an export market fo products" that require that
the spare key be left in the United States," said David Sobel of the
Electronic Privacy Information Center, an electronic privacy advocacy group.
As long as foreign companies can sell products unencumbered by the spare-key
requirement, "ours won't be competitive," he asserted.
<p>
Clint Brooks, advisor to the director of the National Security Agency,
countered that there were few "facts" that demonstrated that U.S. companies
woule lose sales if they could export the kind of encryption technology that
the government was proposing to permit. "We just need to find out," he said,
in a telephone interview.
<p>
Others attending yesterday's meeting felt that there were too many groups
trying to tug the emerging policy from very different concerns. "There's the
government wanting to have seccure messages ... domestic security issues and
espionage issues...[as well as]...industry coming in with its agenda of
selling products overseas. Oh, its going to be hard," said Jeff Rulifson a
technology director for Sun Microsystems, Inc. Mountain View, Calif.
<p>
Government officials say they hope to draft a new set of proposals during
the next few weeks and circulate them for another round olf comments. In the
meantime, at least two industry groups are scrambling to draft their own
versions of an encryption policy.

<hr>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 16, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-105</DOCNO>
<DOCOLDNO>IA053-000895-B046-432</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/part1.html 129.174.40.15 19970123200154 text/html 9727
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:00:43 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 10 Dec 1995 19:45:18 GMT
Content-type: text/html
Content-length: 9544
</DOCHDR>
<HTML>
<head>
<TITLE> NIST Escrow Export Meeting, December 5, 1995</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1> 
NIST Key Export meeting, December 5, 1995 Long version, Part 1 of N</h1>

This covers the product criteria, except interoperability.
<p>

This really needs a hypertext media. I'll build one for html page. Please
bear with me on this, pure ASCII mail version.
This is a write-up of stuff I left out of the summary.
I'll merge them together on my nistpage, probably Friday.
You've already seen the short write up.
<p>
There is a fair amount of information on the NIST web server. Use url:
<a href="http://csrc.ncsl.nist.gov/keyescrow/">
  http://csrc.ncsl.nist.gov/keyescrow/ </a>
<p>
As David Lesher noted, one of the most significant things was obvious in
the parking lot.  Unlike September's meeting, this time it was empty.
Inside the hall, it was obvious that no one came. It was packed in
September, and now, entire rows were empty. I'm bad at guessing numbers,
but its easy  to guess that only 1/3 as many people showed. Maybe less.
<p>
>The meeting was hosted by Ed Roback of NIST,

<p>
The meeting was in general a repeat of September's meeting, and similar
meetings that have been going on for years. Both sides talk past each
other. I think this has degenerated into a parallel with the abortion
debate. There is no common ground.

<p>

>He said that they have studied the encryption that is supposed to be widely available on the Internet.
>He said that viewed by crypto experts, not much is very good. He mentioned "two incidents" where
>Netscape had weak implementations. He feels that companies will not trust software over the 'net. that
>they "want the US Government to say that 'this is good enough'."

<p>
I assume that the "two incidents" don't count breaking RC4-40.  I can't
remember two Netscape security incidents, unless he means to count RJC's
buffer overflow, all I can remember is Ian's key generation problem.

<p>
>Clint Brooks, of NSA, then went over the revised criteria. He claimed that they
>were surprised at the industry concern over "one product" for worldwide markets.

<p>
He stated that they were addressing "not domestic policy, per se, but we
keep wrapping around" because of the 'one product' issue.

<p>
The criteria are on the NIST page,
<a href="http://csrc.ncsl.nist.gov/keyescrow/criteria.txt">
url: http://csrc.ncsl.nist.gov/keyescrow/criteria.txt</a>

<p>
They handed out a guide to the changes in the criteria between September
and now. This is available from NIST as url:
<a href="http://csrc.ncsl.nist.gov/keyescrow/bground.html">
http://csrc.ncsl.nist.gov/keyescrow/bground.html</a>

<p>
Here is a portion of it:
<ul>
<li> Old Criterion 1.     Moved to #7;
<li>Old Criterion 2.     Moved to #8;
<li>Old Criterion 3.     Split into #1 and #2
<li>Old Criterion 5.     Moved to #10
<li>Old Criterion 6.     Moved to #9;
<li>Old Criterion 7.     Moved to #5;
<li>Old Criterion 8.     Moved to #6;
<li>Old Criterion 9.     Deleted.
<li>Old Criterion 10.    Moved to #3;
</ul>
<p>
Only in Washington. Oh yeah, they also clarified a lot of the wording.
<p>

<h3>Ideas that I thought important enough to make notes of concerning the
criteria:</h3>

<p>
These criteria do not address either hardware nor non-escrow encryption.
Export controls of these are not changed, they can be exported with the
current procedures.

<p>
Brooks said that these rules are not applicable to the protection of
internal data for US corporations, even for overseas locations of US firms.
He said that getting permission to export for _internal corporate use_ is
easy, if it is to protect corporate secrets and for internal communication.
I took this to mean that a multi-national, US-based corporatgon can get a
permit for ViaCrypt and export it for their own use. [later in the day,
some people mentioned that this isn't nearly as easy as Brooks claimed.]

<p>
He said that the intent in the new wording is flexibility. They don't want
to prescribe implementation details, he wants industry to invent what
sells. He specifically stated that the meetings were not about setting
standards. This caused at least a fair amount of confusion, probably due to
the fact that NIST used to be called National Bureau of Standards, and NBS
set standards all the time. For example, a couple of folks were interested
in interoperability, say between a Netscape encryption system and one made
by, say, Microsoft. This meeting did not address this level of
interoperability.

<p>
about #2, "The product's key escrow cryptographic functions shall be
inoperable until the key(s) is escrowed in accordance with #3." Brooks said
that the intent was to allow vendors to make a single product that doesn't
activate the key-escrow function if not needed. The idea was that when the
keys are escrowed, the encryption engine would be activated. He also said
that "manufacturers may not want to be in the key escrow business" and
would therefore want to ship products that could be activated by a third
party escrow agent.

<p>
While talking about #3, "3. The product's key escrow cryptographic functions' key(s)
     shall be escrowed with escrow agent(s) certified by the U.S.
     Government, or certified by foreign governments with which
     the U.S. Government has formal agreements consistent with
     U.S. law enforcement and national security requirements."

<p>
He stated that this does not preclude the use of "other agents." This
became a major issue throughout the day. Ken Mendelson, staff attorney at
TIS, asked (roughly) "Under what authority does the US Government grant
certification to agents?" The response was a run around. Another hot issue
was whether you can "hold your own keys" rather than using a third party.
Seems that the corporate users are arguing that they want to hold their own
keys, and the government reacted to that favorably (not unfavorably?).
[Later in the day, Geoff Greiveldinger was asked if US citizens have the
right to hold their own keys. Geoff was forced to admit that, "yes, you can
hold your own keys"]

<p>
#5, "5.    The product's key escrow feature shall allow access to the
      key(s) needed to decrypt the product's ciphertext regardless
      of whether the product generated or received the ciphertext."

<p>
Contains a significant change that was not discussed in September. It means
that having the key for either end is sufficient. Brooks conceded that this
was a big change, but claimed it was needed. The claim that one-ended
surveillance is easier is most likely true.  It clearly is easier if one
end is US based and using GAK and the other is foreign where there is
respect for civil liberties.

<p>
He even claimed that it made the system less intrusive: His argument was
roughly:

<p>
Lets say they are snooping on me.  With one-ended, they can read all of my
messages, to and from, without needing the keys of my correspondents. (lets
pick Geoff G. as an arbitrary correspondent) With two ended, they'd have to
get both my key and Geoff's, and then they could read all of the messages
Geoff gets or sends.

<p>
I said it was _their_ argument. Seems to me to be groundless, unless they
got the keys of everyone in the chain, all of the folks that I talk to, all
of the folks that everyone I talk to, etc.

<p>
on "7.    The product's key escrow cryptographic functions shall use
      an unclassified encryption algorithm with a key length not
      to exceed sixty-four (64) bits."

<p>
This is really aimed at session keys, or at least non-RSA keys. I suggested
that they really needed some wording that make it clear.

<p>
>He said that the 64-bit key limit is not meant to restrict RSA keys to
>64-bits, but rather to restrict the session keys that are encrypted using
>RSA. Unspoken was the assumption that the 2000 bit RSA secret key would have to be escrowed.

<p>
on "8.    The product's key escrow cryptographic functions shall not
      provide the feature of multiple encryption (e.g., triple-
      DES)."

<p>
He pointed out that the wording used to say "prevent" and now just says
"not provide".  He acknowledged that "prevent" was impossible.

<p>
on "9.    The product's key escrow cryptographic functions shall
      interoperate only with key escrow cryptographic functions in
      products that meet these criteria, and shall not
      interoperate with the cryptographic functions of a product
      whose key escrow encryption function has been altered,
      bypassed, disabled, or otherwise rendered inoperative."

<p>
Brooks said that this was intended to allow multiple modes, such as
compatibility with other encryption schemes. Of course, he said, the other
modes are subject to export restrictions.

<p>
Somewhere in the discussion, Ed Appel took over for Brooks. Appel is
"Director of Counter Intelligence Programs, National Security Council, The
White House" He was introduced as FBI.

<p>
>There were some interesting (and bad IMHO) implications of interoperability.
I'll cover them more in the next section

<hr>
Back to <a href="./nist951205.html">Pat's page on the December 5 NIST Clipper 2 </a>
meeting. 
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 7, 1995  
Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">
Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-106</DOCNO>
<DOCOLDNO>IA053-000894-B003-244</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/david.html 129.174.40.15 19970123201137 text/html 3945
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:10:26 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:06:21 GMT
Content-type: text/html
Content-length: 3762
</DOCHDR>
<html
<head>
<link rev="made" href="mailto: wb8foz@netcom4.netcom.com">
<Title>David Lesher's Comments on the Meeting </title>
</head>
<body>


I (<a href="mailto:wb8foz@nrk.com">David Lesher</a>) attended the NIST Key Escrow conference this week. Here are my
impressions.
<p>
In theory, NSA/NIST scheduled it to seek consensus from industry on
how to set up a Gov't Access to Keys (hereafter GAK) program they'd
be happy with. The bait was, NSA would allow export of same.

<p>
The rub was, NSA attempted to set all the ground rules before
starting. They had ten conditions any proposal had to meet.
(http://www.eskimo.com/~joelm/criteria.txt) With the rules 
<a href="../crypto/topic3.html">available on-line,</a> 
I'll not duplicate them all. But #1 is roughly:

<p>
	unclassified algorithm NTE 64 bits.

<p>
and #10:

<p>
	Only key agents sanctioned by USG. Sanctioning
	by formal agreements "consistent with US law enforcement
	and National Security requirements."

<p>
The conference was attended by I'd guess 150 Industry Bigwigs.  LOTS
of expensive suits ;-}. There were also more declared NSA types than
I'd ever seen before anywhere outside the Fort. Specific names I saw:
(and no, I can't spell...)

<p><pre>
	Win Diffe of Sun
	D. Denning
	Stuart Baker, late of NSA
	Lance Hoffman of GWU
	Carl Ellison of TIS
	Edward Scheidt of TECSEC
</pre>
<p>
It opened with speeches by Ed Roback & Ray Kammer of NIST.  The meat
started with Michael Nelson of the White House. He attempted to
justify the GAK policies but did not appear to make any converts.  He
made (IMHO) denigrating remarks about trusting ~"code from the 'Net'
with your secrets" but evaded questions about why anyone would trust
keys given to other governments...

<p>
(Prevailing throughout the conference was a dichotomy.  The official
justification for the conference was "export use" but when questions
arose the specter of the 4 Horsemen of the Net-Apocalypse came up
again and again.)

<p>
Then the meeting broke up into working groups.  Each group discussed
some subset of the 10 rules then reported back to the whole. We
actually did this three times.  Intermixed with this were various
presentations. (See the www site.)

<p>
At best, the working groups came back with no suggestions; at
worst they returned in open revolt.

<p>
The end result was a parsec wide gap between industry & NSA.
Seemingly EVERY speaker the second day prefaced his/her remarks with
some form of "Do not assume our presence here is an endorsement,
because it is NOT.." The Merrill-Lynch VP representing the
securities industry association saw nothing to take back to his
members.

<p>
But it was Robert Holleyman, President of the Business Software
Alliance who drew the biggest standing ovation. (<a href="./bsa.html">
Read his paper on the WWW site.</a>)
 His closing sentence seemed to say it all:
<p>
<i>	Instead of paving the roads, the Administration has left
in place roadblocks on the Information Highway.
</i>
<p>
Everyone who mentioned it felt the FIPS meeting planned for the
15th was premature at best.

<p><pre>
-- 
A host is a host from coast to coast.................wb8foz@nrk.com
& no one will talk to a host that's close...........(v)301 56 LINUX
Unless the host (that isn't close).........................pob 1433
is busy, hung or dead........vr vr vr vr.................20915-1433
</pre>


Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 8, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-107</DOCNO>
<DOCOLDNO>IA053-000895-B045-67</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nistmeeting.html 129.174.40.15 19970123195430 text/html 1195
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:53:20 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 22 May 1996 01:37:40 GMT
Content-type: text/html
Content-length: 1012
</DOCHDR>
<HTML>
<head>
<TITLE>Information on the NIS&T Key Escrow Export meetings</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>NIS&T Key Escrow Export Meeting Information</H1>
<h2>The NIS&T meeting on key escrow export</h2>
The Clinton Administration is revising parts of the 
ill fated Clipper initiative. There have been two public meetings.
The first was held September 6 and 7, 1995.  The second was held
December 5, 1995. 
<p>
<a href="./nist/kmi.html">The latest on key escrow from NIS&T</a>
<p>
<a href="./nist/nist950906.html">September meeting</a>
<p>
<a href="./nist/nist951205.html">December meeting</a>
<p>
May 1996, Draft paper 
<a href="./nist/kmi.html"> "Enabling Privacy, Commerce, Security and Public Safety in the Global 
Information Infrastructure"</a>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
May 21 1995.  Backto <a href="./hotlist.html">Pat's hotlist</a> Backto <a href="./index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-108</DOCNO>
<DOCOLDNO>IA053-000895-B048-24</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/tecsec.html 129.174.40.15 19970123200656 text/html 14254
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:05:38 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 02 Jan 1996 16:17:46 GMT
Content-type: text/html
Content-length: 14070
</DOCHDR>
<html><title>TECSEC remarks, NIST Sept Meeting</title>
<body>
<pre>
   [Handout at Key Escrow Issues Meeting, at NIST,
   Gaithersburg, Maryland, September 6, 1995.]


   Private Escrow Key Management: A Method and Its Issues

   Remarks by
   Edward M. Scheidt, CEO & 
   Dr. Jon L. Roberts, President
   TECSEC, Incorporated

   [No date]


   Introduction

   During the past few years a debate has been raging around
   the conflict between the rights of an individual to privacy
   in information to foster its competitiveness and the
   Government's need to access information for national
   security and law enforcement purposes. At the heart of the
   debate is the difficulty in arriving at a position whereby
   a robust implementation of an encryption process can be
   accomplished that protects sensitive private or industrial
   data yet insures that the government can have access to
   information if that information is part of a criminal
   conspiracy or enterprise, or other action hostile to the
   United States.

   The U. S. Government initially tendered a cryptographic
   scheme known as the Clipper Escrow Key management plan.
   Using communication encryption technology, the government
   wanted to mandate an encryption process for which it
   maintained the key used for the decrypting of information
   transiting any communications path. This key would be split
   and distributed to escrow agents. The split key would have
   to be combined if the government were to use the key to
   decrypt and monitor criminal or other such activities. That
   methodology met with howls of protest from much of U.S.
   society (industry and private) due to a certain mistrust of
   the government and its handling of private information (for
   example, various IRS scandals). The debate has shifted from
   the technical solution provided by the Clipper initiative
   to alternate methods that define key escrow in terms of a
   commercial or private entity.

   A NIST-sponsored key escrow meeting was held on August 17,
   1995 to listen to the government's proposal to work towards
   a solution which industry and the international community
   would accept and which would provide needed security to
   private information. The meeting was a positive step
   towards resolving the conflicting issues surrounding
   cryptography. The government's proposal to extend the key
   length of any cryptographic algorithm used to 64 bits to
   enable export of cryptographic products more readily is a
   small step towards industry's desire for "good"
   cryptography. As a result, the government has set the stage
   to extend cryptography into the broader international field
   of electronic commerce. Privacy is still an issue and must
   be included in the resultant key escrow solution.

   Since the very onset ofthe debate TECSEC has espoused
   private key escrow as the only method that individuals,
   industry and the international community would accept for
   cryptography. A split key method has been developed that
   could satisfy many of the issues. The technology is called
   Constructive Key Management ("CKM"), the resultant product
   using CKM is called VEIL. VEIL is a software key management
   design that utilizes multiple key splits with labels as
   cryptographic triggers. It offers complete administrative
   control of the key, and it includes an inherent method to
   construct the key used for encrypting a file or database
   that results in a fixed header and audit information. By
   defining the roles of the escrow agent as a mix between
   government and private as necessarv VEIL can be applied to
   solve the private key escrow question


   The Internet: A Paradox for Information Flow and
   Information Control

   At the heart of the escrow debate lies the philosophical
   goal of competition. Economic competition on an
   international electronic information highway such as the
   Internet can only be fostered with a judicious balance
   among the free flow of information, the respect for the
   privacy of selected information, and the legitimate
   requirements of law enforcement and national security
   concerns.

   The information highway of the Internet is already handling
   large amounts of critical data where privacy is becoming a
   more visible issue. Access to presidents, universities,
   electronic commerce, government databases -- all of these
   activities are available on today's Internet. While
   government, industry and individuals want equal access to
   the Intemet, they do not necessarily want equal access to
   all the data that is flowing over the Internet ...
   especially if it is their own!

   Industry has always had a concern for keeping valuable
   information of all types (corporate, healthcare, personnel)
   safe from increasingly sophisticated curious hackers and
   those with more malevolent objectives. Data security and
   privacy are big businesses for both U. S. industries and
   our foreign competitors. The U. S. security industry, like
   industry in general, must have an environment where it can
   compete overseas. Some foreign obstacles to this
   competition are bad enough, but must we have additional
   obstacles in the name of restrictive key escrow policies?
   The compromise lies in defining a privately managed key
   escrow scheme in which the governrnent can participate and
   share in its administration and control, but only when
   absolutely necessary.

   Key escrow and encryption offer a methodology to achieving
   privacy on the Internet by capitalizing on trends in
   information processing and protection. Traditionally,
   communications security technology has been concerned with
   the protection of the mechanics of information processing
   and not with protecting the information itself. Thus the
   emphasis has been concerned with protecting the channels of
   communications. If the security paradigm is moved to file
   management and protection, a new methodology to protect
   information emerges that can shift the protection of
   information to the user of that information and away from
   the manager of the means of communicating that information.
   Since the nature of file management and the encryption
   process necessitates the retention of keys to recover prior
   encrypted files, the user of the information would be
   responsible for protecting that information: hence, private
   escrow key management.


   The Private Key Escrow Process

   There are different approaches to private key escrow that
   need to be addressed. Of importance is that the individual
   or the company must have confidence that they are in
   control of the release of their information. Proprietary
   data can determine a company' s competitiveness. It should
   not simply be available to third parties. Key escrow agent
   responsibility may be administered through the company or
   through a third party. Liability issues and confidence will
   dictate the extent to which third party agents are used.

   One method to private key escrow is where the company
   maintains the keys in a split form and the government has
   access through the judicial process. The key escrow agent
   is the company. (In some current banking implementations
   the keys are split between two senior bank officials to
   ensure that no one person has total access. The keys are
   reassembled when needed.) The government's access to the
   keys and the protected information is through regulation
   and legislation that are enforced through the judicial
   process. No one would need to turn over their keys to
   encrypted files without a showing of probable cause as is
   now done to obtain subpoenas. Failure to comply with a
   subpoena could result in fines or other penalties. How long
   key splits are maintained may be limited to a period of how
   long the file is retained. It should be pointed out that
   this form of key escrow does not offer the government any
   technical means to access encrypted information without the
   company's participation.

   A second method of private key escrow could include an
   additional key split for the government's use. The scenario
   becomes key splits for the company and a key split for the
   government. To reconstruct the key used for encrypting the
   information mathematically could remain rigorous but now
   the government would retain one of the splits. The
   government key split could be fixed, whereas, the company's
   key splits could be dynamic. Of course other variations are
   possible on the mix of key splits. An additional key split
   could be reserved for a foreign government's use and only
   known to them. In the latter scenario key splits would be
   administered by the U. S. government, a local government
   authority, and the company. Administering the process can
   be streamlined though a hierarchical key management scheme.
   The government would still have to exercise its authority
   through the judicial process.

   The costs of key escrow could be assumed by the company if
   the company is responsible for the key splits. The more the
   government wants to administer the key escrow process, the
   more the company would want to shift the costs of the
   process to the government


   What if the Private Key Escrow Process Is Not Used?

   If the governrnent elects to accept another method to key
   escrow other than a private form, there will be no domestic
   U.S. solution to cryptography. The individual or industry
   must believe they have control over their information and
   have trust in the encryption process. If that trust does
   not exist, industry will be reluctant to get involved.

   A consequence of such policy will be that the import of
   cryptographic products will increase for non-escrow
   techniques since the government currently does not regulate
   imports. It might be possible for the government to
   administer import control under the current Department of
   State regulations for cryptography.

   Other actions that could happen include:

   --   Jobs in the cryptographic field are lost to off shore
        industries.

   --   U.S. Ieadership in cryptography will be lost.

   --   U.S. industries would be vulnerable to outside
        intelligence activities through foreign product trap
        doors.

   --   U.S. international businesses will be forced to use
        non-U. S. technology.


   Private Escrow Key Management: A Method

   Constructive Key Management (CKM) offers a technology that
   capitalizes on combining key splits, a label process based
   on cryptographic triggers which associates the key splits
   to the inforrnation processes, and a three step process for
   creating and distributing the key splits. A Label Maker
   begins the process for creating the labels and their
   respective key splits, a Key Disk Maker identifies the
   labels, key splits, access authority to the individual
   including read/write authority and stores that resultant
   data on a token (a floppy disk), and a Workstation Setup is
   offered that can limit what algorithms are present at a
   workstation (algorithrns and labels can be used to separate
   data within a three dimensional organizational array). In
   the case of VEIL, the user is given a floppy disk to
   encrypt and decrypt files that an administrator authorizes
   based on organizational structure and procedures. The key
   management process can be viewed as a house key management
   process -- the physical key is made with notches that only
   work with your home's lock, can be keyed to open only one
   lock or many, shared with only those who you would want
   access to your home, and can be readily replaced at the
   locksmith. This variation on the older technology of crypto
   ignition key management where key splits were the
   predominant feature, facilitates the key handling process
   and makes the user part of that process. VEIL is an
   implementation of the CKM technology that includes
   application program interface capabilities, multiple
   algorithm management, and token management. Version 2.0
   uses a floppy disk for a token. The algorithm(s) are bound
   to the key escrow prograrn. An export version with single
   DES (Data Encryption Standard) has been approved for
   Canada, England, and Australia (governments).


   Private Escrow Key Management: Conclusion

   Constructive Key Management is one encryption methodology
   of probably several that can meet the intent of key escrow.
   Defining the role of specific key splits can expand or
   minimize government's involvement. The technology is
   flexible. A demonstrable product, VEIL, is available.

   With the advent of increased usage on the Internet with
   cryptographic products, the government will need to wrestle
   with the more difficult situation of controlling free
   access to encryption products. In short, how does the
   government extend its current munitions control over
   encryption products to the Internet? Already, encryption
   products well beyond those currently sanctioned through
   export regulation are available, from the U.S., over the
   Internet. The desired balance is the realization of
   encryption as a possible weapon and encryption as a vehicle
   for fostering economic competitiveness

   The debate concludes with the question, Who is going to
   decide how the privacy of information is protected? The
   resultant answer has far reaching impact on the economic
   competitiveness of U.S. commerce.

   [End]






</pre>

BBack to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 8, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-109</DOCNO>
<DOCOLDNO>IA053-000895-B047-277</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/topic2.html 129.174.40.15 19970123200501 text/html 3194
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:03:50 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 02 Jan 1996 16:18:28 GMT
Content-type: text/html
Content-length: 3011
</DOCHDR>
                  <html>
<title>NIST Desirable Characteristics for Key Escrow Agents</title>
<body>
<pre>
-----------------------------
Key Escrow Issues Meeting, September 6-7, 1995
Discussion Paper #2


                      Discussion Issues:  
         Desirable Characteristics for Key Escrow Agents


In the government's recent announcement of its intent to allow
the export of 64-bit software key escrow encryption products, one
stipulation was that the keys would be escrowed with an approved
key escrow agent.(*1)  Exactly what qualifications/considerations
are appropriate for approval as a key escrow agent have not been
defined.  Some of the issues which need to be discussed and
resolved include the following:

*    What kinds of organizations should be excluded from
     consideration as approved key escrow agents? 

*    What sort of legal agreement between the government and the
     key escrow agent is necessary to stipulate the
     responsibilities of the agent?  Should this include the
     terms and conditions under which release of a key is
     required?  

*    How will liability for unauthorized release of key be
     handled?

*    Should, for example, intentionally misreleasing or
     destroying a key be criminalized?  Should this include other
     actions?                           

*    How can the government's needs for confidentiality of key
     release be handled?

*    Should approval of key escrow agents be tied to a public key
     infrastructure (for digital signatures and other purposes)? 

*    What procedures need to be developed for the storage and
     safeguarding of keys?

*    What are the acceptable performance criteria (e.g., around-
     the-clock availability, accessibility, reliability, etc.)
     for approved key escrow agents?

*    Under what circumstances will key escrow agents in foreign
     countries be approved?

*    What process will be used to approve escrow agents? 
     Costs/who pays?
---------
(*1)  "Approved," for the purposes of this discussion, means that
the government (or its agent) has formally granted permission for
an organization to hold keys for exportable encryption products.


Note:  These issues will be discussed at the Key Escrow Issues
Meeting to be held September 6-7,
1995 (9:00 a.m. - 5:00 p.m.) at the National Institute of
Standards and Technology (Gaithersburg,
Maryland).  The meeting will be open to the public, although
seating is limited.  Advance registration
is requested, please contact Arlene Carlton on 301/975-3240, fax:
301/948-1784 or e-mail:
carlton@micf.nist.gov.

8/25/95


</pre>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 8, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrel/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-110</DOCNO>
<DOCOLDNO>IA053-000895-B047-305</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/topic3.html 129.174.40.15 19970123200516 text/html 5815
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:04:04 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 02 Jan 1996 16:17:15 GMT
Content-type: text/html
Content-length: 5632
</DOCHDR>
<html><title>Topic Paper 3, Export Criteria, NIST September Meeting</title>
<body>
<pre>
Key Escrow Issues Meeting, September 6-7, 1995


Discussion Paper #3


Export Criteria Discussion Draft -- 64-bit Software Key
Escrow Encryption


As discussed at the SPA/AEA meeting on August 17, 1995,
the Administration is willing to allow the export of
software encryption provided that the products use
algorithms with key space that does not exceed 64 bits
and the key(s) required to decrypt messages/files are
escrowed with approved escrow agents. On the same date,
the September 6-7 key escrow issues meeting at NIST was
also announced.  The two principal topics at the meeting
will be:  discussion of issues of exportability of 64-bit
software key escrow encryption and 2) desirable
characteristics for key escrow agents.


In order to help make most productive use of the limited
time available at the upcoming meeting and to better
focus deliberation, the following criteria are being
distributed for discussion purposes.  Since it is
important that final criteria be clear, straightforward,
consistent, and implementable, please review these draft
criteria and be prepared to discuss how they may be
refined and made more specific.


Draft Export Criteria for Software Key Escrow Encryption


Software key escrow encryption products meeting the
following criteria will be granted special export
licensing treatment similar to that afforded other
mass-market software products with encryption.


1.   The product will use an unclassified encryption
     algorithm (e.g., DES, RC4) with a key length not to
     exceed 64 bits.


2.   The product shall be designed to prevent multiple 
     encryption (e.g., triple-DES).


3.   The key required to decrypt each message or file
     shall be accessible through a key escrow mechanism
     in the product, and such keys will be escrowed
     during manufacture in accordance with #10.  If such
     keys are not escrowed during manufacture, the
     product shall be inoperable until the key is
     escrowed in accordance with #10.


4.   The key escrow mechanism shall be designed to
     include with each encrypted message or file, in a
     format accessible by authorized entities, the
     identity of the key escrow agent(s), and
     information sufficient for the escrow agent(s) to
     identify the key or key components required to
     decrypt that message.


5.   The product shall be resistant to any alteration
     that would disable or circumvent the key escrow
     mechanism, to include being designed so that the
     key escrow mechanism cannot be disabled by a static
     patch, (i.e., the replacement of a block of code by
     a modified block).


6.   The product shall not decrypt messages or files
     encrypted by non-escrowed products, including
     products whose key escrow mechanisms have been
     altered or disabled.


7.   The key escrow mechanism allows access to a user's
     encrypted information regardless of whether that
     user is the sender or the intended recipient of the
     encrypted information.


8.   The key escrow mechanism shall not require repeated
     involvement by the escrow agents for the recovery
     of multiple decryption keys during the period of
     authorized access.


9.   In the event any such product is or may be
     available in the United States, each production
     copy of the software shall either have a unique key
     required for decrypting messages or files that is
     escrowed in accordance with #10, or have the
     capability for its escrow mechanism to be rekeyed
     and any new key to be escrowed in accordance with
     #10.


10.  The product shall accept escrow of its key(s) only
     with escrow agents certified by the U.S. Government
     or by foreign governments with which the U.S.
     Government has formal agreements consistent with
     U.S. law enforcement and national security
     requirements.


Note: Software products incorporating additional
encryption methods other than key escrow encryption
methods will be evaluated for export on the basis of each
encryption method included, as is already the case with
existing products. Accordingly, these criteria apply only
to the key escrow encryption method incorporated by a
software product, and not to other non-escrowed
encryption methods it may incorporate.  For instance,
non-escrowed encryption using a key length of 40 bits
or less will continue to be exportable under existing
export regulations.

- - -

Please also review discussion paper #1 (distributed
earlier), which raises a number of issues involving
exportability criteria and how exportable products could
be designed.  Discussion paper #2 (also previously
distributed) presents questions involving key escrow
agents.


Note:  These issues will be discussed at the Key Escrow
Issues Meeting to be held September 6-7, 1995 (9:00 a.m.
- 5:00 p.m.) at the National Institute of Standards and
Technology (Gaithersburg, Maryland).  The meeting will be
open to the public, although seating is limited.  Advance
registration is requested, please contact Arlene Carlton
on 301/975-3240, fax: 301/948-1784 or e-mail:
carlton@micf.nist.gov.

9/1/95

</pre>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 8, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-111</DOCNO>
<DOCOLDNO>IA053-000895-B047-255</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/topic1.html 129.174.40.15 19970123200448 text/html 4817
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:03:34 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 02 Jan 1996 16:19:16 GMT
Content-type: text/html
Content-length: 4634
</DOCHDR>
<html><title>Nist Sept Meeting, Overview</title>
<body>
<pre>

Key Escrow Issues Meeting, September 6-7, 1995
Discussion Paper #1


                      Issues -- Export of 
                 Software Key Escrowed Encryption


On August 17, 1995, the Administration announced its proposal to
permit the ready export of software encryption provided that the
products use algorithms with key space that does not exceed 64
bits and the key(s) required to decrypt messages/files are
escrowed with approved escrow agents.  Under the proposal,
products will be reviewed to verify that they satisfy the
criteria and, if so, they will be transferred to the Commodity
Control List administered by the Department of Commerce where the
products can be exported under a general license (in much the
same way that 40-bit RC2/RC4 encryption is licensed today).  

We are working toward creating broadly stated criteria that are
in the nature of performance specifications.  To meet these
criteria, encryption products will need to implement key escrow
mechanisms that cannot be readily altered or bypassed so as to
defeat the purposes of key escrowing.  

The criteria, when finalized and published, will state the
objectives, but not the exact technical method(s), by which those
objectives are satisfied.  This is to provide software publishers
the flexibility to design methods for meeting our stated
objectives in a manner that is compatible with the design of
their products.  There are, therefore, a number of questions we
must work together to answer in order to draft effective
criteria.  These questions are:  

*    Avoiding multiple encryption -- How can the product be
     designed so as to prevent doubling (or tripling, etc.) the
     key space of the algorithm? 

*    Disabling the key escrow mechanism -- How can products be
     made resistant to alteration that would disable or
     circumvent the key escrow mechanism?  How can the "static
     patch" problem be avoided?  How can this be tested?

*    Access to escrow information -- What mechanisms must be
     designed into encryption products to allow authorized access
     to escrowed keys?  This likely includes the identity of the
     key escrow agent(s) and a serial number for the key escrow
     agent to use to identify the key(s)/component(s) necessary
     to decrypt the message.  What other information will be
     necessary to be provided to the escrow agent to identify the
     necessary key(s)/component(s)?  Are there other comparable
     viable approaches?

*    Non-escrowed use -- How can products be made so that they do
     not function with non-escrowed products (or tampered
     escrowed products)?  How can this be tested?

*    Limiting surveillance -- How can products be designed so
     that information both sent and received by the user can be
     decrypted without release of keys of other users?

*    Practical Key Access -- How can mechanisms be designed so
     that repeated involvement of escrow agents is not required
     for decryption for multiple files/messages during the
     specified access period?

*    Assurance that keys are escrowed -- How can it be assured
     that key escrow products are indeed satisfactorily escrowed?

     For example, products could be required to be escrowed at
     time of manufacture or be made inoperable until properly
     escrowed.

*    Ability to re-escrow keys -- How can products be designed so
     that new keys can be escrowed at the user's discretion with
     a U.S. Government approved escrow agent?

*    Certified escrow agents -- Can products be designed so that
     only escrow agents certified by the U.S. government
     (domestic, or under suitable arrangements, foreign) are
     utilized?  What should be the criteria for an acceptable
     U.S. escrow agent? 

                         --------------

With your input, we are hopeful that this effort will lead to
definitive criteria, which will facilitate the development of
exportable products and help minimize the time required to obtain
export licenses.  The Administration seeks to finalize such
criteria and make formal conforming modifications to the export
regulations before the end of 1995.  
</pre>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 8, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-112</DOCNO>
<DOCOLDNO>IA053-000895-B046-226</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/crit56.html 129.174.40.15 19970123200008 text/html 16272
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:58:51 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 22:58:09 GMT
Content-type: text/html
Content-length: 16088
</DOCHDR>
<html>
<head>
<title>NIS&T Key Escrow Export Meetting, Breakout on #5 and #6</title>
</head>
<body>
<p>
<h2>Criteria #5 and #6</h2>
Recorded/reported by Pat Farrell<br>
PhD Graduate Student<br>
School of Information Technology and Engineering<br>
George Mason University<br>
Fairfax, Virginia
<h2>Breakout Groups C1 and C2</h2>
This document reports on the first breakout session for groups
C1 and C2 for the NIS&T's Encryption Key Escrow Expost meeting. The
breakout session was held at approximately 1:30 PM, on September 6, 1995.
<p>
Groups c1 and c2 were small and were combined into one. The group
discussed criterias 5 and 6 of Topic 3.
They are short enough to reproduce here.

<p>
5.    The product shall be resistant to any alteration that would
      disable or circumvent the key escrow mechanism, to include
      being designed so that the key escrow mechanism cannot be
      disabled by a static patch, (i.e., the replacement of a
      block of code by a modified block).

<p>
6.    The product shall not decrypt messages or files encrypted
      by non-escrowed products, including products whose key
      escrow mechanisms have been altered or disabled.

<p>
After I commented that the person writing the notes has the ability to
detirmine what was said, the folks from NSA and NIS&T asked me to take 
the notes. I should insert the standard disclaimer here: just because I'm
taking notes in the breakout session, don't assume that I'm endorsing
the concepts being discussed.

<p>
In the middle of this discussion, a government-generated, but anonymnous
paper was distributed. It had "Example Suggested Solutions." It suggested
that source code not be available for products suitable for export. It also
suggested other ideas, such as storing a checksum/hash and having the
system "check the cryptographic code several times during its use." There 
was a strong reaction against these suggestions, not because they were
bad ideas, but because the paper was delivered with no prior publication.
This precluded any planned response to its ideas.

<p>
There was a fair amount of discussion as to what the criteria meant.
The government's wording is bureacratic and wordy at best, and
open to too much subjective interpretation. There was a strong desire for a 
crisply worded criteria. This was to allow the goverment evaluators to
easily make decisions in the approval process without requiring subjective
evaluations. It also allows vendors to set sharp-edged criteria for
their developers and engineers to use while developing products.
<p>
The group reworded #5 to say "want to Trust the Product." This means that it 
is untampered, works as expected, etc. We then hashed out ways to 
know this. The list ended up looking like:
<ul>
<li> is available only as object code
<li> contains some "hash" function to check for modifications
<li> contains some unique hash, with uniqueness based upon something 
        like "site," "per copy" or "per release" 
<li> Contains policies against modification, such as liscense language        
        against decompilation.
<li> OS-related security, such as runs "protected mode" instead of as a 
        wild DOS program.
</ul>
<p>
Representatives of the software vendors objected strongly
 against "per copy" identifiers,
saying it would add two orders of magnitude worth of problems to 
manufacturing.

<p>
The items on the list were not "must have all of these" rather it was
a pick-and-chose menu. We expected exportable products to have some 
combination of these, not all of them. 
We also required that the standard allow flexibility
for technical innovation to keep up with the evolving state of the art.
<p>
I pointed out that some of the goals that we just listed are not
completely realistic with the current state of the art. For example, the
definition of "object code" is quite fluid with modern super-scaler
CPUs that reinterpret instructions and convert them on the
fly from one format to another. Similarly, many modern Object Oriented
languages blur the distinctions between source and executable. Still other
languages typically are shipped with source code to everything,
and don't really have a concept of "object code."
<p>
The discussion of #6 was more lively. We took a long time figuring out what
it said. For instance, could ViaCrypt sell a product that was compatible
with PGP 2.6.2 (non-escrowed) that also worked with the new escrowed
ciphers? It seems to me, and a lot of other folks there, that such a product
would be non-exportable. 
<p>
We tried to invent a rewording of Criteria #6 that said, clearly, what
we thought the Government wanted it to say. The result was:
<p><i>
	The product shall check for the presence of properly constructed
escrow field (information) prior to decryption of any message. If the
field is missing or improperly formed, the product will not decrypt the 
message. Equivalent approaches are acceptable.</i>
<p>
After a lot of discussion, we decide that our "improved" wording was not
that much better. We tried again. 
We simplified the criteria to:
  "right products won't talk to wrong products."
with "right products" meaning those that are exportable, and wrong products
being those that aren't, or are hacked, or ...
<p>
We then talked about modifying it to say:
  "right products won't talk to wrong products or anything else."
The group thought that this seemed to be closer to what 
the LEA (law enforcement agencies) community wanted. It was definitely not 
what the commercial software vendors wanted.
<p>
We then developed "goals" including:<br>
1. One version for sale worldwide<br>
2. Allow development in the US<br>
3. Domestic Law Enforcement Agencies want Escrowed (I almost wrote GAK :-)<br>
4. Must interoperate with everything<br>
5. Receiver can only decrypt if escrow agencies can decrypt.<br>

<p>
This leads to a bunch of issues and observations, including:
<p>
First Issue (A) Can goals 1, 2, and 4 be met simultaneously?
<p>
No one could argue that they could be met. Goal 4 was required to allow 
the product to have "sales attractiveness." It was the consensus that
sales attractiveness meant that it had to interoperate with existing standards.
This seemed to require that the software be developed in a country,
such as Isreal or Germany, that understands the needs of the business
community.
<p>
There was a suggestion of a "friendly man-in-the-middle" who would
receive an escrowed conversation, and strip off the escrowed encryption 
parts, and reencrypt it, and retransmit it to a non-escrowed user. 
This "friend" is only friendly to parties that want to destroy the 
effectiveness of key escrowed encryption. I guess this means that friendship is 
relative.
This concern leads to:
<p>
Second Issue (B) Can we prohibit a friendly MITM?
<p>
We could not invent a solution. It appeared to the group that any
technical solution was suseptible to this "attack." It was not
clear how important this issue is to the LEA community.
<p>
The last and biggest issue was:
<p>
Third Issue (C). Startup compatibility. No one will buy products unless 
they have
sales attractiveness. This means compatibility with existing systems.
Yet the government's criteria #6 seems to say that approved products must refuse
backwards compatibility.

<p>
This was labeled a "non starter" by the group. Interoperability was
declared a requirement.

<p>
The consensus was that companies can develop a substantial competitive
advantage by developing off-shore and offering both escrowed encryption
and compatibility with existing systems.

<p>
There was a discussion of grandfathering in some technologies.
This was to help interoperability. The conversation became fuzzy,
Grandfather technologies included DES, 3-DES, IDEA, and long key RC4.
There is a clear conflict here. DES and triple-DES are commonly used today 
in commercial (although not exportable) systems. IDEA and long key RC4 are
gaining acceptance. All four of these are clearly candidates for
interoperability.
<p>
One key idea was that it may make sense to allow software that encrypts with
escrowed keys, but can also decrypt with any algorithm. This allows the LEA's
to access outgoing messages, while allowing interoperability.
<p>
The discussions frequently wandered to discuss the language of the criteria.
The wording was considered simultaneously too subjective  and impractical.
For example, we considered the phrase "tamper resistant" to be preferable 
to the original "prevent tampering," because it is impossible to absolutly
prevent modification to software.
<p>
The issue of interoperability was raised repeatedly. 
It is critical that exportable products interoperate with other,
existing export products. 

<p>
The last issue in the session was that the length of the key, 64-bits,
was defined in criteria #1. There was no discussion at the conference on
this criteria. It seems that the NIS&T and NSA staff believe that
this is a closed topic. The people in the session did not agree. They
felt that 64-bits was not enough.

<p>
Once the breakout session was over, the entire conference met together, 
and the "reporter" from each session reported their comments and findings.

<p>
All breakout sessions had suggested changes. The group that discussed
criteria #9 recommended removing it. The group that discussed criteria #2 
(no multiple encryption) reported that industry was working on a general 
solution to the problem of key recovery, and that their solution would 
probably appear as quickly without the government's "help." 

<p>
Several groups identified that there are at least two separate 
problem domains: communications and data storage. Communications 
typically is short term, and has unique keys for each session. 
Data storage has far fewer keys that are used
for long periods. Several speakers suggested that while communications
keys were not suited to be escrowed, there was a large need for
key recovery for data storage. There was no response from the government
representatives to any of these points. One government speaker
did say that there would be a Federal key escrow standard, period.
<p>
This last statement caused me to reflect on the value of
participating in the session.
<a name="opinion">
<hr> </a>
<h2>Pat Farrell's personal opinion</h2> 
I believe that there was a lot of talking, and 
very little listening at the meeting.
<ol>
<h3>What I heard the industry say was:</h3>
<li>there are two separate classes of encrypted data, 
communications and long term storage. There is a commercial need for
key recovery (key escrow) for long term storage. There is no
commercial need for key recovery for communications.
<li>Industry has no essential problem with cooperating with
government and LEA needs for key escrow, as long as it
is acceptable to, and driven by, the market.
<li>Without interoperability with current defacto standards
(e.g. strong algorithms, long keys, triple-DES, IDEA, etc.)
the products will not succeed in the market.
<li> there is no such thing as a US Domestic market. There is one,
worldwide market.
<li>If there are no restrictions on importing software, and serious
restrictions on exporting it, industry will be driven offshore.
<h3>What I head from the privacy and civil liberty advocates:</h3>
<li>Encrypted speach is free speach, protected under the Constitution.
<li>Attempts to regulate and restrict domestic use of strong encryption will
result in a loud, messy, and very public fight.
<li>This is not a technical debate, it is a political one, and should
occur in a political forum.
<h3>Yet what I heard from the government folks was:</h3>
<li>These standards are voluntary.
<li>The LEA community wants and requires escrow of keys used for communications.
<li>The need for this was justified by a number of heart-tugging appeals to the emotions with unsubstantiated
claims of rampant crime caused by Drug Dealers, pedophiles, and terrorists
that requires key escrow.
<li>that a standard would be set essentailly as proposed, 
without regard to the comments of industry, privacy advocates, 
or civil liberty advocates.
</ol>
It is clear to me that the groups were talking past each other. I believe
that there are legitimate LEA concerns, and that industry wants
to be responsive to those concerns. 
<p>
I have not heard any
credible justification for and explanation of the LEA concerns. 
I have been following this debate since 1992, and have yet
to see a emotion-free explanation as to why the LEAs are so adamantly
against cryptography. After years of honing their arguments, I'd expect
a solid, fact-filled case from the LEAs.
The public record fails to show any significant number of
investigations that have been hindered by criminal use of cryptography.
Statements that
these standards are <i>voluntary</i> and will stay voluntary are simply
not credible when the only justifications given are domestic examples
with no more solid grounding than Time Magazine's cries that the Internet
is being overrun with pornography. The LEAs need to tone down their rhetoric
and base the discussion on facts if they want to he heard.
<p>
I have described myself as a PhD student. I have a strong interest in
security. I had a peer-reviewed paper published in the National
Computer Security Conference (1992).
To support my family while working on my PhD, I have a 
part-time job developing software.
I work at a large (5000+ staff, $400 million yearly revenue) company.
I can't speak for the company, but I can say what I see as an employee.
We used to sell mainframe finiancial applications to banks, insurance firms,
and large multinational companies. We can not longer sell mainframe software;
our customers insist on client/server solutions. I have looked hard, and found
only one solution to the security and authentication issues that 
are caused by client/server architectures. That solution is strong 
cryptography. The customers do not, yet,  have the experience to understand
that they need strong encryption, at least as strong as Kerberos. They 
don't see it now, but they will soon. We will
have to provide security and authentication for our systems.
<p>
Of concern with the topic of these export meetings, the company's
growth is in Europe. We compete today against European software firms. I have
personal interests (I like living in Virginia) in 
being able to develop and sell software that
competes with the European developed code. They will not be restricted
to 64-bit, US escrowed keys. This is the market reality that my firm sees.
<p>
The government is offering 64-bit encryption, including DES. They
are sorely behind the times. While still in use, DES is
considered too weak for serious consideration.
Today, the standards for encryption are 2000 bit public key (RSA) for
long term keys, and 128-bit (IDEA) or 168-bit (3-DES) session keys.
Industry says that session keys are not worth escrowing. Yet they are
too long to be acceptable to the government. Simply stating that only
64 bit keys are acceptable is not a realistic position for the 
LEAs to take if they want to claim that this is a credible conversation.
<p>
Standardizing on weak encryption, that meets neither the needs of business
nor the privacy needs of citizens, based upon the weak justification
presented to date by the LEAs
is not appropriate for a free democratic society. 
<p>
I have tried to accurately report the discussions, with the hope
that the two or three sides can reach a common ground. I did not see
any progress during the breakout session, or at any other time
during the two days.
<hr>
Follow this link to the writeup of <a href="./techcrit.html">
next breakout session, Technical Criteria</a>
<p>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/nist950906.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 7, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-113</DOCNO>
<DOCOLDNO>IA053-000895-B047-375</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/kammer.html 129.174.40.15 19970123200559 text/html 8964
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:04:46 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 02 Jan 1996 16:24:22 GMT
Content-type: text/html
Content-length: 8781
</DOCHDR>
<html><title>NIST Outline, September KEY Escrow Meeting</title>
<body>
<pre>

   [Outlines of talks by Raymond Kammer and Michael Nelson on
   Key Escrow Issues Meeting, at NIST, Gaithersburg, Maryland,
   September 6, 1995.]


   Goals and Objectives: 
   Software Key Escrow Issues Meeting

   Raymond G. Kammer, Deputy Director National Institute of
   Standards and Technology

   September 6-7, 1995


   Perspective

   1.   Last year, we held two workshops on key escrow issues.
        A fundamental question was raised:

          Can a software key escrow method be bound to an
          encryption algorithm in a robust manner to permit
          export of strong algorithms (e.g., DES)?

   2.   On August 17, 1995, the Administration announced that
        it would permit the export of software encryption with
        64-bit key space if the key(s) required for decryption
        were escrowed with approved escrow agents.

   3.   Given parameters in #2, draft export criteria have
        been developed. See Discussion paper #2. (Dr. Nelson
        will review in next presentation.)


   Goals and Objectives

   During the course of this meeting, we would like to:

   1)   understand industry reaction to the draft export
        criteria; For example, are they clear,
        straightforward, consistent and implementable?

   2)   begin a dialog to finalize the criteria and establish
        the procedural/regulatory changes in a timely manner;

   3)   explain how the USG envisions the export process
        working for these software products;

   4)   listen to industry's concerns on issues requiring
        attention so we can focus our activities to be as
        responsive as possible;

   5)   discuss issues involving desirable characteristics for
        key escrow agents and approaches to developing and
        implementing an approval process;
             
   6)   provide industry the opportunity to express its
        concerns on issues related to key escrow encryption

   7)   identify areas for follow-up discussion / meetings.

   Questions?

   [End Kammer]

----------

   Draft Software Key Escrow Export Criteria

   Michael Nelson
   [White House Office of Science and Technology Policy]

   presented to the:
   Software Key Escrow Issues Meeting
   National Institute of Standards and Technology

   September 6-7, 1995


   Historical Perspective

   On July 20, 1994, Vice President Gore wrote to then Rep.
   Maria Cantwell of establishing a goal:

        of trying to develop a key escrow system that will
        provide strong encryption, be acceptable to commercial
        users worldwide, and address our national security
        needs as well.

   He also stated:

        Such a key escrow system would be implementable in
        software, firmware, hardware, or any combination
        thereof, would not rely upon a classified algorithm,
        would be voluntary, and would be exportable.

   In 1994, two Key Escrow Alternatives meetings were held by
   NIST to discuss alternatives to Clipper. Five key questions
   were raised:

   1.   Has NSA determined that there is no way of binding a
        software key escrow method to an algorithm in a manner
        that will be robust enough to permit export of strong
        encryption (e.g., DES)?

   2.   If NSA believes that software can be used effectively,
        will they try to work with industry to define
        acceptability criteria based upon the strength of the
        algorithms to be used?

   3.   Does NSA anticipate foreign governments allowing use
        of U.S. controlled (read "escrowed") cryptography?
        Specifically, does the NSA envision U.S. escrow of
        keys for U.S.-originated cryptography used in other
        countries?

   4.   Can key escrow products be freely exported provided
        that no algorithms are included, with the anticipation
        that foreign users can insert their own algorithms?

   5.   Provided that software solutions are acceptable, what
        will the evaluation or approval process look like? Is
        it a one-time review?

   We believe that the draft export criteria address most, if
   not all, of these questions.


   Draft Export Criteria
   for Software Key Escrow Encryption

   Software key escrow encryption products meeting the
   following criteria will be granted special export licensing
   treatment similar to that afforded other mass-market
   software products with encryption.

   1.   The product will use an unclassified encryption
        algorithm (e.g., DES, RC4) with a key length not to
        exceed 64 bits.

   2.   The product shall be designed to prevent multiple
        encryption (e.g., triple-DES).

   3.   The key required to decrypt each message or file shall
        be accessible through a key escrow mechanism in the
        product, and such keys will be escrowed during
        manufacture in accordance with #10. If such keys are
        not escrowed during manufacture, the product shall be
        inoperable until the key is escrowed in accordance
        with #10.

   4.   The key escrow mechanism shall be designed to include
        with each encrypted message or file, in a format
        accessible by authorized entities, the identity of the
        key escrow agent(s), and information sufficient for
        the escrow agent(s) to identify the key or key
        components required to decrypt that message.

   5.   The product shall be resistant to any alteration that
        would disable or circumvent the key escrow mechanism,
        to include being designed so that the key escrow
        mechanism cannot be disabled by a static patch, (i.e.,
        the replacement of a block of code by a modified
        block).
 
   6.   The product shall not decrypt messages or files
        encrypted by non-escrowed products, including products
        whose key escrow mechanisms have been altered or
        disabled.

   7.   The key escrow mechanism allows access to a user's
        encrypted information regardless of whether that user
        is the sender or the intended recipient of the
        encrypted information.

   8.   The key escrow mechanism shall not require repeated
        involvement by the escrow agents for the recovery of
        multiple decryption keys during the period of
        authorized access.

   9.   In the event any such product is or may be available
        in the United States, each production copy of the
        software shall either have a unique key required for
        decrypting messages or files that is escrowed in
        accordance with #10, or have the capability for its
        escrow mechanism to be rekeyed and any new key to be
        escrowed in accordance with #10.

   10.  The product shall accept escrow of its key(s) only
        with escrow agents certified by the U.S. Government or
        by foreign governments with which the U.S. Government
        has formal agreements consistent with U.S. law
        enforcement and national security requirements.

   *Note: Software products incorporating additional
   encryption methods other than key escrow encryption methods
   will be evaluated for export on the basis of each
   encryption method included, as is already the case with
   existing products. Accordingly, these criteria apply only
   to the key escrow encryption method incorporated by a
   software product, and not to other non-escrowed encryption
   methods it may incorporate. For instance, non-escrowed
   encryption using a key length of 40 bits or less will
   continue to be exportable under existing export
   regulations.*


   Conclusions and Summary

   1.   We welcome the opportunity to work with you to refine,
        clarify and finalize the export criteria for 64-bit
        software key escrow encryption.

   2.   We also need your thoughts on desirable
        characteristics for key escrow agents and what sort of
        approval process should be established.

   3.   We need to understand your priorities for government
        activities to make all of this happen.

   4.   As we move forward, let us not lose sight of our
        concerns to provide strong encryption that meets users
        needs and does not harm national security and law
        enforcement

   [End Nelson]






</pre>

Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 8, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-114</DOCNO>
<DOCOLDNO>IA053-000895-B043-96</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/censorusenet.html 129.174.40.15 19970123194623 text/html 3225
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:45:13 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 17 Jan 1996 20:33:47 GMT
Content-type: text/html
Content-length: 3042
</DOCHDR>
<HTML>
<head>
<TITLE>Intsructions on avoiding censorship of UseNet</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<body BACKGROUND="./ihn_back.gif">
<H1>UseNet Censorship Workarrounds</H1>
<ul>
<li>This gopher site has a <a href="gopher://gopher.msu.edu"> 
full uncensored UseNet feed</a>
<li>Community ConneXion, founded in June of 1994, is the leading provider
of privacy on the Internet. They provide anonymous and pseudonymous
Internet access and web pages in addition to powerful web service,
virtual hosts, and web design consultation.  Information is available
from their web pages at 
<a href="http://www.c2.org/"> http://www.c2.org/. </a>
More information on the uncensored promotion is available at 
<a href="http://www.c2.org/uncensored/"> http://www.c2.org/uncensored/.</a>
<li>
Cheaper still (and more compatible with GUI newsreaders) try AltNet:
<pre>
   > telnet news.alt.net nntp
   Trying 204.137.156.2...
   Connected to tofu.alt.net.
   Escape character is '^]'.
   200 Mail <a href="mailto:info@alt.net">info@alt.net</a> for info about $5/month NNTP access (posting ok).
</pre>

If you can't afford $5/month, you can't afford Compu$erve.
<li>Duncan Frissell <frissell@panix.com>'s 
<a href="http://www.cs.umass.edu/~lmccarth/cypherpunks/banned.html">
Idiots Guide to Reading Banned Newsgroups via CompuServe</a> aka
<a href="http://www.cs.umass.edu/~lmccarth/cypherpunks/banned.html">
http://www.cs.umass.edu/~lmccarth/cypherpunks/banned.html</a>
</ul>
<h3>Instructions on getting arround UseNet "censorship" attempts</h3>

From: Duncan Frissell <frissell@panix.com> <br>
To: cypherpunks@toad.com <br>
Subject: Compuserve *hasn't* banned newsgroups<br>
<p>
So I'd heard that CompuServe had banned access to all those naughty
newsgroups including my favorite alt.binaries.erotic.senior-citizens.  Could
this be true?  I fired up my CompuServe Internet Dialer (the PPP software
packaged with WinCim and logged on to the nets.  Sure enough.  The popular
binaries groups were missing from news.compuserve.com.  But not to be
deterred...
<p>
I grabbed a copy of the Free Agent newsreader available at:
<br>
<a href="http://www2.interpath.net/forte/agent/freagent.htm">
http://www2.interpath.net/forte/agent/freagent.htm</a>
<br>
or
<br>
<a href="ftp.forteinc.com/pub/free_agent/fagent10.zip">
ftp.forteinc.com/pub/free_agent/fagent10.zip</a>
<p>
I grabbed the latest list of open NNTP Servers from:
<br>
<a href="http://dana.ucc.nau.edu/~jwa/open-sites.html">
http://dana.ucc.nau.edu/~jwa/open-sites.html</a>
<p>
I pointed my copy of Free Agent at CPCNET's open news server (198.70.185.5)
and grabbed a list of groups sure enough, there were the seasoned citizens
in all their glory.  And I was checking out those binaries via CompuServe.
<p>
Don't tell the Bavarians. 
<p>
</ul>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a>
January 15, 1996.  
Backto <a href="./hotlist.html">Pat's hotlist</a> Backto <a href="./index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-115</DOCNO>
<DOCOLDNO>IA053-000895-B045-79</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/ntnetworking.html 129.174.40.15 19970123195502 text/html 6103
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:53:28 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 15 Jan 1997 20:06:49 GMT
Content-type: text/html
Content-length: 5920
</DOCHDR>
<HTML>
<head>
<TITLE>Pat Farrell's Pointer to information about NT and the Internet</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
Microsoft's WindowsNT operating has the potential to be a great Internet host.
But Microsoft is not very facile with Internet standards, and
most Internet "experts" have a serious Unix-bias.
<p>
This is a list of helpful information for making a Windows NT computer
be a full member of the Internet community.
<ul>
<li>Read the "site description" at <a href="http://www.somar.com">Somar
software for info on how to Gateway to the Internet with NT</a>
<li><a href="http://www.somar.com/security.htm">NT security background</a>
<li>John Piraino's guide for 
<a href="http://www.execpc.com/~jpiraino/ppp.html">Connecting NT Workstations
to the 'net using PPP</a>
<li>Software.com has a lot of NT software, including a
<a href="http://www.software.com/">Free BIND (DNS daemon) for NT</a>
<li>An article about enabling NT's 
<a href="http://w3.melig.co.il/Vadim/routing.htm">RAS tcp/ip routing</a>
It tells you about regedt32 entries that you have to create.
<li>Here is some more information:
<blockquote>
After you configure your registry to enable packets from other sources 
and turn on IP routing, you must do 3 other things
<ol>
<li>  Partician your net into at least 2 subnets.  You can do this from 
the TCP/IP configuration under the networks control panel.  I'm using the 
subnet mask 255.255.255.128  Your RAS IP address must fall into a 
different subnet than your server's IP or workstations.
<p>
RAS IP         152.160.184.254 (upper subnet *.*.*.128-255)<br>
Server IP      152.160.184.100 (lower subnet *.*.*.0-127)<br>
Workstation IP 152.160.184.10  (lower subnet *.*.*.0-127)<br>
<p>
<li>  Add static routes to your routing table for each workstation.  Go to 
DOS prompt on the server and type route add (workstation IP) (server IP)
<p>
You now should be able to ping your server with RAS running, and IP 
addresses outside your net.

3.<li> Set the DNS entry on your workstations to the DNS address of your 
ISP. 
</ol>
I'm putting up a complete and detailed instructions on my Web page
<a href="http://www.owenrudy.com/"> www.owenrudy.com</a>, should be up in next couple of days.....
If you have any other questions email me at ocreger@ic.net
</blockquote>
<li>and still more:
<blockquote>
Next thing is to make sure, that the IP-Addres you use 
for RemoteAccess is always the same 
(you'll need it to specify the routings)
<p>
At last you must tell all your Clients to use the NT-Machine as deault gateway and enter 
persistent routes on your NT-Machine for each Client.
<p>
Example: let's say your RAS-IP-Address is 192.0.1.1 
and the LAN-IP-Address of your Gateway is 
192.0.2.1, your Clients have Addresses 192.0.2.2 etc.
<p>
Enter the following Line for each Client:
<p>
route -p 192.0.2.2 192.0.2.1
<br>
(don't forget the -p or you'll have to do it again after your next reboot)
<p>
</blockquote>
<li>and this...
<blockquote>
And acutally your RAS connection will deliver you TWO IP addresses,
one on the client and one on the server. My NT server has IP address
A1 on the NIC with gateway address G1. The RAS server give the clients
address C1, but it also keeps an address C2 for the RAS server. On the
client side I'm set up with Nic address A2, gateway empty (as to be
filled by the RAS connection).

I can set up a static route with the ROUTE command. I can route back
from the server by entering C1 as destination address, and C2 as the
gateway address. That way, NT routes all packets it can not address on
the local subnet mask to G1 except packets to C1. Those go via C2 to
C1. Basically you tell NT to use a different gateway address for a
certain IP. This gateway address over RAS seems to be the second RAS
ip address (the one that the RAS server keeps) and not the RAS client
address. Means it seems to use C2 rather than C1.
<p>
I'm not all the way there, but I'm pretty darn close to get RAS full
routing to work.
<p>
Hier my IP addresses:<br>
NT server 1.1.1.10
<p>
Gateway to the Internet on this LAN (ISDN via Pipeline 50) 1.1.1.1<br>
RAS IPs 1.1.1.20-1.1.1.22 (Range set in RAS setup)<br>
NT client (on a different LAN) 1.1.2.10<BR>
NT client demands 1.1.1.22 as it's RAS IP address.
<p>

<pre>
gateway--------LAN-NT Server-RAS-----------RAS-NT server-LAN<br>
1.1.1.1       1.1.1.10       1.1.1.20          1.1.1.22      1.1.2.10
</pre>
<p>


As I said, I'm almost there. If anyone has been there yet, please drop
me a note.
<p>

Frank
<p>
--
see http://www.techex.com/~frank for signature
(finger is currently disabled)
--0i<p>
</blockquote>
</UL>

<P>
<IMG alt="_____" SRC="./color_line.gif">
<P>
<li>Dec's
<a href="http://www.altavista.digital.com">Altavista search engine</a>
is awesome. It is more complete and much faster than 
<A HREF="http://www.yahoo.com">Yahoo!</A> Search engine or 
<a href="http://www.lycos.com/">Lycos search engine</a>

<li> A direct link, taken from Altavista's tip page
<FORM method=GET action="http://altavista.digital.com/cgi-bin/query">
<INPUT TYPE=hidden NAME=pg VALUE=q>
<B>Search <SELECT NAME=what>
<OPTION VALUE=web SELECTED>the Web
<OPTION VALUE=news>Usenet
</SELECT>
and Display the Results <SELECT NAME=fmt>
<OPTION VALUE="" SELECTED>in Standard Form
<OPTION VALUE=c>in Compact Form
<OPTION VALUE=d>in Detailed Form
</SELECT></B><BR>
<INPUT NAME=q size=55 maxlength=200 VALUE="">
<INPUT TYPE=submit VALUE=Submit>
</FORM>

 
<A HREF="./webinfo.html">Making a homepage</A>
<P>
<ul>
<li>Slirp is a free package that lets you talk TCI/IP over
a dumb serial line. Here is 
<a href="http://www.ece.gatech.edu/users/flur/slirp/slirp.html">
the Slirp Manual</a>
</ul>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a>
March 19, 1996.  
Backto <a href="./hotlist.html">Pat's hotlist</a> Backto <a href="./index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-116</DOCNO>
<DOCOLDNO>IA053-000895-B047-183</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/welcome.html 129.174.40.15 19970123200400 text/html 2250
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:02:50 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 22 May 1996 01:33:57 GMT
Content-type: text/html
Content-length: 2067
</DOCHDR>
<HTML>
<head>
<title> Welcome message, NIS&T Key Escrow Export Meeting, September 1995</title>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
September 1, 1995
<p>
<p>
Dear Participant:
<p>
<p>
Thank you for agreeing to participate in the two-day
meeting on software key escrow encryption.  We are
anxious to work with you and other industry
representatives to facilitate development of exportable
key escrow encryption in software products.  I look
forward to the workshop being an important step in that
process.
<p>
<p>
I have attached a draft agenda for the two days.  I
propose that we spend the majority of our time discussing
a set of export criteria.  In order to move that
discussion along, a draft set of criteria is attached. 
The criteria state, in general terms, the government's
needs with respect to exportable software, consistent
with its law enforcement and national security
requirements.  Since it is important that the final
criteria be clear, straightforward, consistent, and
implementable, Mike Nelson of the Office of Science and
Technology Policy will spend a few minutes describing
these criteria on the first morning of the meeting. 
After that, we would like to hear your perspectives on
them and work with you to refine them.  On the second
day, we plan to discuss the export licensing process for
such products, and begin exploring characteristics of
acceptable key escrow agents.
<p>
<p>
Again, thank you for your participation.  I look forward
to seeing you there.
<p>
<p>
Sincerely,
<p>
/ s /
<p>
<p>
Raymond G. Kammer
Deputy Director
<p>
<p>
<hr>
Back to <a href="./nist951205.html">Pat's page on the December 5 NIST Clipper 2 </a>
meeting. 
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
May 21 , 1996
Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">
Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-117</DOCNO>
<DOCOLDNO>IA053-000895-B047-353</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/denning.html 129.174.40.15 19970123200544 text/html 10460
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:04:32 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 02 Jan 1996 16:15:30 GMT
Content-type: text/html
Content-length: 10276
</DOCHDR>
<html>
<title>D.E.R.Denning's Comments on Draft Criterial</title>
<body>
<pre>
   [Handout at Key Escrow Issues Meeting, at NIST,
   Gaithersburg, Maryland, September 6, 1995.]


   *Comments* on Draft Criteria for Software Key Escrow
   Exportability

   Dorothy E. Denning

   Sept. 5, 1995


   1.   The product will use an unclassified encryption
        algorithm (e.g., DES, RC4) with a key length not to
        exceed 64 bits. [No comment]

   2.   The product shall be designed to prevent multiple
        encryption (e.g., triple-DES). [No comment]

   3.   The key required to decrypt each message or file shall
        be accessible through a key escrow mechanism in the
        product, and such keys will be escrowed during
        manufacture in accordance with #10. If such keys are
        not escrowed during manufacture, the product shall be
        inoperable until the key is escrowed in accordance
        with #10.

        *Comment. The requirement as written suggests a
        Clipper-like model where each product has its own
        individual escrowed key. With some key escrow systems,
        for example, TIS's CKE and Fortress's KISS, the keys
        held in escrow are master keys shared by multiple
        products/users. A product encrypts the session/file
        key (or, in the case of KISS, the user's private key)
        under this master key. The master key could be
        pre-loaded into the product (e.g, as with KISS) or it
        could be downloaded into the product during program
        initialization (e.g., TIS). Further, we do not want to
        prevent a product from operating at all prior to
        escrow. As with the TIS or Banker's Trust (BT)
        proposals, the product needs to operate in order to be
        initialized with keys! All that's needed is to prevent
        data encryption. Finally, the requirement as written
        does not make it clear that the product in question is
        the one that was used to encrypt the data (which,
        strictly speaking, may be something other than a
        message or file, e.g, an image object). The following
        is a possible rewrite:

          The key required to decrypt data that has been
          encrypted by a product shall be accessible through
          a key escrow mechanism in the product. A product
          shall not encrypt data unless the key needed for
          decryption has been escrowed in accordance with
          #10.*

   4.   The key escrow mechanism shall be designed to include
        with each encrypted message or file, in a format
        accessible by authorized entities, the identity of the
        key escrow agent(s), and information sufficient for
        the escrow agent(s) to identify the key or key
        components required to decrypt that message.

        *Comment. It is not necessary to identify the escrow
        agents as long as there is information that will
        readily lead to their identity. For example, the BT
        proposal identifies the user and the user's escrow
        center. The escrow center has a record of the escrow
        agents used by that user. As another possibility, a
        product might be designed to always use a particular
        escrow agent(s), so knowing the name of the product
        would be sufficient to identify the agents (as in the
        case of Clipper). Possible rewrite:

          The key escrow mechanism shall be designed to
          include with each encrypted message or file, in a
          format accessible by authorized entities,
          information that readily leads to the identity of
          the key escrow agent(s), and information sufficient
          for the escrow agent(s) to identify the key or key
          components required to decrypt that message.*

   5.   The product shall be resistant to any alteration that
        would disable or circumvent the key escrow mechanism,
        to include being designed so that the key escrow
        mechanism cannot be disabled by a static patch, (i.e.,
        the replacement of a block of code by a modified
        block).

        *Comment. The product should also be resistant to
        circumvention without alteration, for example, by
        passing in special parameters. Possible rewrite:

          The product shall be resistant to any use or
          alteration that would disable or circumvent the key
          escrow mechanism, to include being designed so that
          the key escrow mechanism cannot be disabled by a
          static patch (i.e., the replacement of a block of
          code by a modified block).*

   6.   The product shall not decrypt messages or files
        encrypted by non-escrowed products, including products
        whose key escrow mechanisms have been altered or
        disabled.

        *Comment. For generality, change to:

          The product shall not decrypt data encrypted by
          non-escrowed products, including products whose key
          escrow mechanisms have been altered or disabled.*

   7.   The key escrow mechanism allows access to a user's
        encrypted information regardless of whether that user
        is the sender or the intended recipient of the
        encrypted inforrnation.

        *Comment. Does it matter whose keys are used, i.e.,
        sender's or receiver's? As worded, this would allow
        for the use of either. If it can be either, then it
        may be necessary to go to many escrow agents to
        decrypt a subject's communications, for example, the
        escrow agent for each person who sends a message to
        the subject. They might be in foreign countries. If
        the intent is to restrict it to the key of the subject
        of an investigation, it might be reworded as:

          The key escrow mechanism allows access to a user's
          encrypted information using only the keys
          associated with the user regardless of whether that
          user is the sender or the intended recipient of the
          encrypted information.*

   8.   The key escrow mechanism shall not require repeated
        involvement by the escrow agents for the recovery of
        multiple decryption keys during the period of
        authorized access.

        *Comment. What is meant by involvement? Participation
        by individuals? What if the escrow agents provide an
        automated way of obtaining keys after an initial
        start-up (e.g., through a TIS data recovery center)?*

   9.   In the event any such product is or may be available
        in the United States, each production copy of the
        software shall either have a unique key required for
        decrypting messages or files that is escrowed in
        accordance with #10, or have the capability for its
        escrow mechanism to be rekeyed and any new key to be
        escrowed in accordance with #10.

        *Comment. Is the purpose of this to ensure that if a
        key is compromised, all program copies are not
        compromised with it -- thus, a single copy can be
        tossed or an entire product line can be rekeyed?*

   10.  The product shall accept escrow of its key(s) only
        with escrow agents certified by the U.S. Government or
        by foreign governments with which the U.S. Government
        has formal agreements consistent with U.S. law
        enforcement and national security requirements. [No 
comment]


   [End first section of comments]


   Comments on Issues for Key Escrow Agents

   *Comment. Where do entities such as the Bankers Trust
   escrow center (which is involved in the escrow process and
   is needed to find out what escrow agents to go to get keys)
   or the Fortress KISS archive center (which performs an
   auditing/archiving role) fit into this? They don't hold
   keys, but their performance is critical to the system. It
   would seem that any entity that is operationally involved
   in key escrow should satisfy certain properties.*

   1.   What kinds of organizations should be excluded from
        consideration as approved key escrow agents? [NC]

   2.   What sort of legal agreement between the government
        and the key escrow agent is necessary to stipulate the
        responsibilities of the agent? Should this include the
        terms and conditions under which release of a key is
        required? [NC]

   3.   How will liability for unauthorized release of key be
        handled? [NC]

   4.   Should, for example, intentionally misreleasing or
        destroying a key be criminalized? Should this include
        other actions?

        *Comment. It should be a criminal offense to:

        a)  make a key available to someone knowing that that
            person does not have lawful authority to use the
            key,

        b)  obtain or use a key without lawful authority,

        c)  obstruct, impede, or prevent the use of keys when
            there is lawful authority*

   5.   How can the government's needs for confidentiality of
        key release be handled? [NC]

   6.   Should approval of key escrow agents be tied to a
        public key infrastructure (for digital signatures and
        other purposes)?

        *Comment. Should use of the public key infrastructure
        be conditioned on using key escrow encryption?*

   7.   What procedures need to be developed for the storage
        and safeguarding of keys? [NC]

   8.   What are the acceptable performance criteria (e.g.,
        around-the-clock availability, accessibility,
        reliability, etc.) for approved key escrow agents? [NC]

   9.   Under what circumstances will key escrow agents in
        foreign countries be approved? [NC]

   10.  What process will he used to approve escrow agents?
        Costs/who pays? [NC]

   [End]






</pre>

BBack to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> 
January 2, 1996  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-118</DOCNO>
<DOCOLDNO>IA053-000894-B003-224</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/plesser.html 129.174.40.15 19970123201127 text/html 15190
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:10:13 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:04:40 GMT
Content-type: text/html
Content-length: 15006
</DOCHDR>
<html>
<head>
<title>Ron Plesser's comments on NIST GAK meetings</title>
<!a href="(John Gilmore) mailto:gnu@toad.com">
</head>
<body>

<pre>
From: John Gilmore <gnu@toad.com> 
Wed, 13 Sep 1995 19:19:15 -0700
To: cypherpunks@toad.com, gnu@toad.com
Subject: Ron Plesser's take on NIST GAK meeting

I converted a document in some proprietary Windows binary format to ASCII.
Formatting mistakes are mine.

Ron Plesser is a very experienced lobbyist.  He was involved in the
passage of the ECPA, among other things.  He's CIX's lawyer, and sent
this document to CIX (the Commercial Internet Exchange), which passed
it on to its membership.

        John Gilmore
</pre>
<hr>

PIPER & MARBURY L.L.P.  Memorandum
<p>
To:  Interested Parties<br>
From:  Ron Plesser<br>
Date:  September 11, 1995<br>
Subject:  NIST Key Escrow Encryption Meeting<BR>
<p>

The National Institute of Standards and Technology on September 6 and 7
held a meeting on issues regarding key escrow encryption, focusing on
export criteria for software and desirable characteristics for U.S. key
escrow agents.  Ten draft software key escrow export criteria were put
forth by NIST for consideration and possible revision (see below).  Key
escrow encryption is the recent Administration proposal for an
alternative to Clipper Chip, which industry opposed.  Key escrow would,
in the Administration's view, allow the export of software with strong
encryption.  In summary, the government would permit the general
licensing of 64-bit-key encryption provided that it be manufactured
with a key that would be maintained by independent escrow agents who
were certified by the U.S. government.  Foreign escrow agents could be
used where there was a bi-lateral agreement with the particular country
involved.

<p>
NIST Deputy Director Ray Kammer provided an overview of the goals of
the meeting, and said that NIST plans to issue a Federal Register
notice containing a "revised set of thoughts" in three weeks.  There
will be a 60-day comment period following publication of the revised
principles in the Federal Register.  The  NIST will then review the
comments received and determine whether there is enough consensus to
proceed.  There will be additional meetings on September 15, 1995 to
discuss the Federal government's requirements for its own information
processing standards for key escrow encryption.  This meeting will take
place at the Gaithersburg, Maryland Hilton Hotel from 9:00 a.m. to 5:00
p.m.

<p>
It was clear from the meeting, both in presentations and conversation
during breaks, that most computer systems and certainly those used by
large entities will have key escrow systems for encryption.  There was
even a person who spoke who said that they are doing this now.  Many
people at the meeting acknowledged that key escrow would be implemented
at some point for domestic as well as for exported programs.  The issue
is who would hold the key.  For example, could a company hold its own
keys or could an independent agent be used?

<p>
The people who create mass market software, however, still expressed
significant opposition to key escrow.  While the government went to
some length to express that this solution is neutral as to software or
hardware, it has to be acknowledged that hardware-based systems are
easier to control.

<p>
The subject that was not well discussed was encryption in relation to
network services and the internet.  It was discussed in relation to the
issues of interoperability and the ability to decrypt both sides of a
communication.

<p>
The assumption that I and others had at the outset was that the
Administration had made progress in the last year in raising itself
from the ashes of Clipper Chip.  By the end of the meeting that was not
altogether clear.  There will remain a great deal of controversy
surrounding this issue.  Congress is sure to get involved and it will
get messier before it gets resolved.

<p>
Administration Comments

<p>
Mike Nelson, who is special assistant for information technology to the
White House Office of Science and Technology Policy and co-chair of the
inter-agency working group on encryption, provided a historical
overview of the data encryption issue.  He said that the proposed
64-bit-key encryption is 17 million times stronger than the 40-bit-key
encryption currently allowed to be exported.  Under the proposed
policy, software with 64-bit-key encryption could be exported to
friendly countries under certain conditions, all of which require that
a key to that encryption be available in the U.S. from an independent
third-party.  Mr. Nelson stated that the new policy will open up new
market opportunities for the U.S. computer software industry, and that
key escrow has the potential to become a de facto global standard.  The
Administration policy for 40-bit-key encryption will continue as-is,
and no keys will have to be escrowed for such systems.   Mr.              
Nelson said that the government's main concern is that strong
encryption products not be available in the mass market.      


<p>
In response to questioning, Mr. Nelson stated that the 64-bit-key limit
is being imposed because the government is not certain that the key
escrow system will work.  Once the system is up and running, longer
keys may be allowable.  He said that the draft criteria are based on
national security needs, and that they were pushed as far as possible
to meet commercial needs.  Mr. Nelson added that the Administration is
discussing the possibility of federal legislation with Hill staff to
avoid varying state laws on encryption.

<p>
Industry Perspectives

<p>
General reaction was mixed to the government's proposal.  Most heavy
industrial and commercial users of encryption seemed accepting of the
Administration's position.  To them this meant greater flexibility and
would mean that most larger systems could get export licenses for
64-bit-key systems and this would expand the capacity to sell larger
systems abroad.  This position was exemplified by Trusted Information
Systems (TIS), representatives of which spoke several times.  In a
presentation, Peter Dinsmore of TIS offered restatements of the
criteria to make them more commercially viable, and a set of "criteria
for the criteria," which are as follows:  1) don't specify commercial
criteria, 2) don't exceed the minimum, 3) don't allow criteria creep,
4) don't solve the dual-rogue problem, 5) don't over protect, and 6)
use generic nomenclature.  He recommended that criteria six and nine be
removed altogether, a view that was echoed by other participants.

<p>
The mass market software industry and the public interest groups were
very opposed to the Administration proposal.  They do not believe that
64-bit key is sufficient, and they do not believe that anyone will buy
U.S.-manufactured software with a key that is to be held by a third
party under at least some control by the government.  There was a fair
amount of confusion on the issue at the meeting, but it now seems clear
that the government would permit foreign escrow where there are
bi-lateral agreements with friendly nations.  In a presentation, Bob            
Holleyman of the Business Software Alliance criticized the
Administration's failure to "liberalize export controls on generally
available software employing non-key escrow encryption."  Also, he
stated that the Administration's proposal and the draft criteria
"continue to reflect a misunderstanding of the market place and, if
implemented in anything like their current form, will prevent key
escrow encryption from ever being commercially adopted."  Mr.
Holleyman recommended a number of features for a marketable system,
including a variety of encryption algorithms using at least 64-bit
keys and user specification of a key holder. 

<p>

In addition, the representative of MCI strongly objected to the
proposal as an incursion into the private sector and as an impediment
to the development of a strong information infrastructure.  Encryption
guru Whit Diffie of Sun Micro Systems and others objected to the
proposal.
<p>
Danny Weitzner of the Center for Democracy and Technology said that CDT
was going to go to Congress and object to the implementation of this
proposal.  They thought that it was a bad deal and the government
should not be placed in the position of directing standards and
requiring back doors into encryption systems.

<p>
Discussion of Criteria Six, Seven and Eight

<p>
Following the industry presentations, participants divided into groups
to discuss various criteria.  The group that discussed criteria six,
seven and eight made the following observations and recommendations.

<p>
There seemed to be universal objection to criterion six.  This would
limit the interoperability of systems.  It effectively states that
exported 64-bit key cannot be used to decrypt messages that were
encrypted with a higher value.  This would make it very difficult for
U.S. companies to interact with foreign subsidiaries. The internet
would find great difficulty in connection with this criteria.

<p>
Regarding criterion seven, concern was raised that in the context of
e-mail, it would be onerous to do key escrow for every transmission.
Concern also was raised about maintaining the integrity of intellectual
property in instances in which the escrow agent is in a foreign
country.  In effect, when one chooses an escrow center, one also is
selecting a legal system.  A request was made for a supplemental
document explaining applicable existing laws.

<p>
Concern was raised that all of the criteria are focused on the voice
communication paradigm, rather than on the dynamic data communications
environment.  Laws also are focused on this paradigm, and law moves
slowly whereas computer technology moves rapidly.  In addition, the
criteria do not address varying international laws on issues such as
privacy.  Companies will have to comply with the laws of the strictest
countries.  Concern was raised that privacy considerations are not as
apparent in the criteria as ease of access by law enforcement
agencies.  Also, innocent parties could be de-escrowed.  In addition,
it was emphasized that encryption must not interfere with use of
existing software.  Information was requested on two encryption
schemes, Banker's Trust and Fortress.

<p>
It was recommended that the TIS restatement of criterion seven be
adopted.  This restatement is as follows:  "The key escrow mechanism
allows access to both sides of a simultaneous (i.e., two-way)
communication with only access to the decrypting information from one
of the users."  It also was recommended that for bi-directional
communications, both parties negotiate a common key and escrow it, and
that for one way communications, the sender select the escrow key.

<p>
Regarding criterion eight, it was agreed that the technology issues,
international issues, and privacy issues are the same as those for
criterion seven.  It was noted that certain implementations would
require escrowing of the session key, which is unrealistic.  It was
agreed that with one court order, law enforcement agencies should have
the ability to decrypt a stream of messages.  However, there must be a
time limit on decryption.  It was agreed that agents should be able to
implement an automated system.

<p>
General Review/Comments on All Criteria

<p>
Industry and government representatives met less formally with the
objective of reviewing each of the criteria and attempting to reconcile
differences.  However, this did not occur; instead, broader issues were
discussed.  There was a certain amount of tension during this session,
as each side complained that the other did not understand its needs.
Industry members said that it seemed that implementation of the draft
criteria, or a version thereof, is a foregone conclusion on the part of
government, without industry input concerning the entire concept.
Specifically, industry members challenged the 64-bit maximum as being
arbitrary and unnecessary.  They said that although 56-bit encryption
was discussed with government last year, technology moves rapidly, and
now 64 bits are not enough.  A NIST representative countered that the
National Security Agency is "putting a big card on the table" with 64
bits.

<p>
Industry members also protested that the criteria do not meet the needs
of the global marketplace.  Consumers will not buy products designed to
meet these criteria because they already have access to 64-bit
encryption with no keys either free or at a low cost.  They argued that
the scope of the criteria (e.g., criterion nine) is broader than the
stated objective of exportability, and requested more information as to
why each criterion is being proposed.  Concern also was raised that
foreign countries with bi-lateral agreements with the U.S. will act
against U.S. key escrow agents.  Also, industry will not know the terms
of these agreements.

<p>
Export Procedures
<p>

Officials of Department of State and the Department of Commerce
explained in general terms how this program would work.  Each
application would go first to the State Department for a jurisdictional
certification on technical aspects.  If State were satisfied that the
criteria had been met, then it would certify the application over to
the Commerce Department for general licensing procedures.  There would
also be an escrow package, that would have to be certified.  It was not
clear who would control the certification of escrow agents.

<p>
Escrow Agents

<p>
The issue of who could be an escrow agent and how they would be
controlled was discussed, but not resolved.  The issues of liability
for wrongful release, the conditions of release, and related questions
were not resolved.  It seemed clear to me that escrow agents would have
to be independent of the user entity.  If this law firm were to use an
encryption package in its London office, the key would have to be
placed with a third party.

<p>
Conclusion

<p>
While no issues were resolved at the meeting, it provided a valauble
forum for the exchange of ideas between government and industry.  Focus
now turns to Congress, and to the crafting of a constructive response
to the upcoming Federal Register notice.  The Administration seems open
to changes.  The mass market software industry and the public interest
community seem negative.  We will continue to keep you informed.


<p>
<i>Mr Plesser then included a list of the 10 criteria. Rather than
repeat them here, the <a href="http://www.isse.gmu.edu/~pfarrell/crypto/topic3.html">NIST 10 criteria link</a> can be used.
</i>
<p>

Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 15, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-119</DOCNO>
<DOCOLDNO>IA053-000895-B046-312</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/dec5sum.html 129.174.40.15 19970123200048 text/html 18303
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:59:35 GMT
Server: NCSA/1.5.2
Last-modified: Sat, 23 Mar 1996 13:55:39 GMT
Content-type: text/html
Content-length: 18119
</DOCHDR>
<HTML>
<head>
<title>Third Party Summary of Dec 5 1995 NIST Encryption Escrow meeting </title>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
United State Department of Commerce<br>
National Institute of Standards and Technology<br>
Gaithersburg, Marylsnd 20899-0001<br>
<p>
March 5, 1996
<p>
The enclosed document is an unofficial summary of the
December 5, 1995 meeting held at the National Institute of
Standards and Technology to discuss the 64-bit software key
escrow encryption exportability initiative. If you would
like to be on a distribution list to receive future
information related to key escrow encryption export
criteria, please send your name, address and e-mail address
to me no later than April 1, 1996.
<p>
Elaine Frye<br>
Information Specialist<br>
Computer Security Division<br>
National Institute of Standards and Technology<br>
Building 820, Room 426<br>
Gaithersburg, MD 20899<br>
<a href="mailto:elaine.frye@nist.gov">
e-mail: elaine.frye@nist.gov</a><br>
_________________________________________________________
<p>
<center>
Summary
<p>
(This summary was prepared by an outside observer
from Martin Marietta Energy Systems, Inc.)
<p>
<p>
<p>
Proposed 64-bit Software<br>
Key Escrow Encryption Export Criteria Meeting
<p>
Place:      National Institute of Standards and Technology
(NIST)
<p>
Date:       December 5, 1995
</center>
<p>
Moderator:  Ed Roback, National Institute of Standards and
            Technology (NIST)
<p>
Panel:      Ed Appel, Michael R. Nelson, Ray Kammer, Geoff
            Greiveldinger, Clint Brooks
<p>
Industry
Presenters: Bill Sweet, Ken Mendelson, Dorothy Denning,
            Melanie Janin, Ed Scheidt, Doug Miller,
            Shabbir Safdar, Viktor Hampel
<p>
<p>
<h2>I.   Ed Roback, National Institute of Standards and
     Technology</h2>
<p>
     Welcome
<p>
     Mr. Ed Roback, serving as moderator for the meeting,
     opened the meeting with a welcome, announcements
     (including notice the meeting would be taped) and
     introductions of the panel members.
<p>
<p>
<h2>II.  Michael R. Nelson, Co-Chairman IWG/ET</h2>
<p>
     Perspectives, Objective of Criteria, and Future Plans
<p>
     Dr. Michael R. Nelson presented the Administration's
     perspectives, objectives, and future plans. He
     explained the five goals and objectives for the
     December 5 meeting. They were as follows:
<p>
     1. explain the criteria to ensure that they are
        clearly understood;
<p>
     2. discuss the Administration's proposed desirable
        characteristics for key escrow agents and approach
        to developing and implementing an approval
        process;
<p>
     3. understand reactions and desired changes to the
        draft criteria and proposed key escrow agent
        characteristics;
<p>
     4. explain the Administration's plans to revise and
        implement these criteria (with revisions, as
        appropriate);
<p>
     5. identify other areas requiring follow-up
        attention.
<p>
     Several questions from the audience included a request
     for assurance that the current issue is not
     establishing domestic regulation and why the key
     length was being limited to 64-bit keys. Dr. Nelson
     assured the group, the current discussion related to
     EXPORT criteria only. He stated that the key length
     (of the symmetric session key) is currently limited to
     64-bits to see if this concept results in products for
     which the key escrow mechanism cannot be easily
     defeated. If, as time passes, the concept proves
     viable and resistant to attack, changes may be
     appropriate.
<p>
<h2>III. Clint Brooks, National Security Agency</h2>
<p>
     Exportability Criteria Discussion
<p>
     Dr. Clint Brooks reviewed the Draft Software Key
     Escrow Encryption Export Criteria (11/95 version),
     including the six criteria associated with the key
     escrow feature, the two criteria associated with the
     key length feature, and one criterion each associated
     with the interoperability feature and design,
     implementation, and operational assurance. Criterion
     five, which requires a product's key escrow feature to
     allow access to the key(s) needed to decrypt the
     product's ciphertext regardless of whether the product
     sent or received the information, generated the most
     discussion. Dr. Brooks explained the primary need for
     the requirement was for Law Enforcement Agencies (LEA)
     to access a subject's communications when authorized.
<p>
     Criterion five generated such discussion that Mr. Ed
     Allen (FBI) supplemented Dr. Brooks presentation by
     detailing the LEA objective(s) for criterion 5. Some
     of the rationale included, LEA's gaining subject['s]
     key is consistent with the current approach of
     electronic surveillance (i.e. tapping lines) and helps
     preserve the ability to react in real time by
     obtaining *only* the subject's key. Mr. Allen
     addressed several questions regarding cooperation and
     status of agreements with other countries and he noted
     the Mutual Legal Assistance Treaty (MLANTS) would need
     to be modified.
<p>
<h2>
IV.  Geoff Greiveldinger, U.S. Depsrtment of Justice</h2>
<p>
     Draft Key Escrow Agent Characteristics
<p>
     Mr. Geoff Greiveldinger reviewed the draft Key Escrow
     Agent Characteristics consisting of twenty criteria
     addressing escrow system integrity and security and
     key aceess requirements. The group questions primarily
     centered around criterion seven which requires at
     least one person who possess[es] a SECRET clearance
     for purposes of processing classified requests and
     requirements to maintain auditable records. Several
     participants, including one from Netscape, stated they
     do not endorse the Administration's proposal and that
     they are losing sales and having products returned,
     because of their inability to export products with
     marketable key escrow features. Questions were raised
     regarding what agency would grant approval and
     maintain valid holders. Additional concerns regarding
     escrow agents who later went out of business were
     raised.
<p>
<p>
<h2>V.   Industry Perspectives</h2>
<p>
<h3>     Bill Sweet, Trusted Information Systems Inc.</h3>
<p>
     Is There a Path to Global Information Security?
<p>
     Mr. Sweet's presentation included views that customers
     do not want escrow controlled by lots of other people,
     information owners should control their assets, not
     the government -- the information is someone else's
     property, the current proposal gives control to the
     receiver not where it should be with the sender, and
     American companies do not want some foreign countries
     to have access to keys. One key question was whether
     companies can designate where keys can be escrowed,
     even if the location is not the United States. Dr.
     Nelson responded that in addition to being held with
     an agent approved by the U.S., the current proposal
     does not disallow a company from designating somewhere
     other than the U.S., for example, Holland. Answers to
     questions regarding bilateral agreements with other
     countries were answered when a clear statement was
     made that no bilateral agreement need exist if keys
     are deposited in the U.S. A bilateral agreement is
     only necessary, when keys are exclusively held by
     another country.
<p>
<h3>
     Kenneth A. Mendelson, Trusted Information Systems,
     Inc.
</h3>
     A Private Sector Proposal for Trusted Third Party
     (a.k.a. Data Recovery Center) Registration
<p>
     Mr. Mendelson described his proposal for a
     vendor-based registration framework, including a
     "Trusted Third Party Application Form". He believes
     already-established procedures can be used to collect
     the required information.
<p>
<h3>
     Dorothy E. Denning, Georgetown University
</h3>
     Criterion #5: Access Through Sender and Receiver
     Rationale, Technical Approaches, Exposure Risks, and
     Wording
<p>
     Dr. Denning reviewed different approaches to key
     escrow encyption and to satisfying criterion #5,
     showing that the criterion is met by most products and
     proposals for key escrow. She also discussed the
     privacy implications of criterion #5 vs. one that
     would require access *only* through the sender,
     concluding that criterion #5 is *not* more invasive of
     privacy. Finally, her submitted paper discusses a
     concern that the current wording does not obligate the
     sending product to ensure access through the receiving
     product and suggests a rewrite. Her paper can be
     accessed at
<p>
        http://www.cosc.georgetown.edu/~denning/crypto/
<p>
<h3>
     Melanie Janin, U. S. Council for International
     Business
</h3>
     Comments on Encryption Policy at The National
     Institute of Standards and Technology (NIST)
<p>
     Ms. Janin presented a comparison of the U.S. Council's
     "Business Requirement for Encryption," issued over one
     year ago, with the U.S. Government's proposed policy.
     She found that some of the U.S. Council's requirements
     have been satisfied, some not, and some are unclear.
     Ms. Janin emphasized the U.S. Council's desire to meet
     with the Government to clarify some of these
     unresolved issues.
<p>
<h3>
     Ed Scheidt, Tecsec
</h3>
     Mr. Scheidt believed the next steps were to get moving
     and test products and the policy because it is
     essential to provide immediate relief for escrowed
     encryption and we need to rely on the Administration
     to bring U.S. privacy products to the rest of the
     world.
<p>
<h3>
     Shaber Safdar, Voters Telecommunications Watch
</h3>
     Mr. Safdar described an Internet survey of security
     professionals the Voters Telecommunications Watch
     group is conducting. The survey was posted one week
     prior to the December 5 meeting. They have received a
     total of 26 responses. Twenty-four of the twenty-six
     respondents stated they would never purchase software
     or hardware with law enforcemcnt access. Sixteen of
     these twenty-four responded they are already using
     products without law enforcerncnt access. Respondents
     would support industry in quest of market driven
     cryptographic standards.
<p>
<h3>
     Robert W. Holleyman II, Business Software Alliance
</h3>
     Testimony of Robert W. Holleyman II, President,
     Business Software Alliance, on Encryption Export
     Policy and thc U.S. Software Industry: Chipping Away
     at America's International Competitiveness.
<p>
     Mr. Holleyman believes that despite concerns expressed
     by companies and association, and privacy advocates,
     during previous NIST meetings, little has changed in
     the Administration's proposal. He believes the
     proposal is unworkable and unacceptable. He states
     that information security is critical and 40-bit keys
     are pathetic and although the proposal of 64-bit keys
     is an improvement, it is insufficient. He proposes a
     Cost of Cracking Adjustment (COCA), in which an
     automatic increase in the permissible key length by
     two bits every three years. The base length is based
     on immediately permitting the export of generally
     available software progruns employing the Data
     Encryption Standard (DES) algonthm or other algorithms
     at comparable strengths.
<p>
<p>
     David Sobol, Electronic Privacy Information Center
<h3>
     Comments on Draft Export Criteria for Key Escrow
     Encryption
</h3>
     Mr. Sobol states that users are unlikely to adopt key
     escrow systems on a voluntary basis, and is afraid
     what is voluntary will become standard and result in
     the eventual prohibition of non-escrowed products. He
     questions the role of public comment in the process,
     because it is frequently solicited but never heeded,
     referencing the 1993 proposed Escrowed Encryption
     Standard, or Clipper. Most comments were negative, as
     NIST acknowledged in its Federal Register notice
     adopting the standard. Another major issue, is the
     Cryptographic Competitiveness Study conducted by the
     Bureau of Export Administration has not been released.
     EPIC has initiated litigation under the FOIA seeking
     the release of the study. (Note: It was released on
     1/18/96.)
<p>
<h3>
     Padgett Peterson, Lockheed Martin
</h3>
     Mr. Peterson commented that major corporations must be
     able to become licensed key agents, the issue of
     property rights is important, and policies must
     guarantee confidentiality to customers.
<p>
<h3>
     Alex McIntosh, PC Security Limited (UK)
</h3>
     Mr. McIntosh described a system his company designed
     for Shell. He believes control should be delivered to
     the desktop and states the issue of liability has been
     ignored and we must understand who will be liable.
<p>
<h3>
     Doug Miller, Software Publishers Association
</h3>
     Comments of thc Software Publishers Association on
     11/95 Draft Export Criteria for Key Escrow Encryption
<p>
     Mr. Miller states member companies are poised to meet
     the needs of a secure, private, and trusted Global
     Information Infiastructure (GII), but cannot because
     of the barriers the U.S. cryptography policy continues
     to impose. Although the 11/95 draft criteria reflect
     a few of the suggested changes, the changes made are
     minor compared with the fundamental problems of the
     proposal. Members have analyzed the global marketplace
     for encryption and concluded key escrow systems will
     simply not be marketable in a world in which non-
     escrow encryption is widely available at greater than
     40 bits. He further states that the Department of
     Commerce study will say there are not strong products
     out there but members of SPA say they are loosing
     business and bilateral agreanents will take a long
     time; U.S. companies need immediate relief.
<p>
<h3>
     Viktor E. Hampel, Hampel Consulting
</h3>
     A Consumer Protection Act for Digital Products
     (Proposal for an International Standard on the
     Labeling of Digital Products)
<p>
     Mr. Hampel reported that accountability had been
     unanimously agreed upon as the key issue for
     electronic commerce during panel discussions of the
     recent international elecro-optical engineering
     conference in Philadelphia, which included
     representation from such diverse groups as NSA and the
     electronic publishing association. To promote
     accountability in electronic transactions, Mr. Hampel
     proposed the labeling of digital products in a
     structured header to protect the intellectual property
     rights of providers -- equivalent to the visual
     copyright notices found on title pages of bound
     literary works. The descriptive digital product labels
     in the header would uniquely identify their source and
     contents and thus also help consumers decide what
     products they wish to see, hear, buy and use --
     equivalent to the *visual* food labels on containers.
     According to Mr. Hampel's proposal, the proposed
     structures of the information header could be based on
     the international CALS Standards for the enveloping of
     digital data products, and on FIPS PUB 188 for the
     labeling of data. International standard for certified
     Public-Key digital signatures would bind the header
     information to the registered digital product to
     protect its integrity and authenticity.
<p>
<h2>
VI.  Wrap-up and Adjourn
</h2>
     Questions from the audience during the wrap up session
     included:
<p>
     What is the current time line for implementing the
     policy?
<p>
     The response was today if the draft criteria is met an
     export license can be obtained. Final policy can be
     expected in a few months since the last thing the
     Administration wants are criteria which preclude
     solutions to things government or industry needs.
<p>
     If a message is sent to 187 countries, where does the
     Data Recovery Center (DRC) have to be located?
<p>
     The response was that the escrow center could be in
     the U.S. or another country with which the U.S. has
     appropriate law enforcement and national security
     arrangements. However, the agent has to be certified.
<p>
     When and how will the policy be published?
<p>
     The Administration hopes to be completed in a few
     months and since the policy is a loosening of
     restrictions it does not have to go in the Federal
     Register for comment. Final implementation is likely
     to be a notice with criteria in the Federal Register.
<p>
     Several questions centered around the requirement for
     a SECRET clearance for at least one person for each
     Certified Escrow Agent.
<p>
     Responses included information that the person with
     the clearance does not have to run the DRC but can
     hold any position and standards will have to be
     developed for the certifying process. Other issues
     revolved around multinational companies which may be
     in compliance for 25% U.S.-owned one day and the next
     day may not be within the legal limits.
<p>
<p>
     Overall, the meeting did appear to help clarify the
     draft criteria for participants. No new significant
     issues were raised.
<p>
     [End]
<p>
<p>
<hr>
Back to <a href="./nist951205.html">Pat's page on the December 5 NIST Clipper 2 </a>
meeting. 
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
March 23, 1996 
Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">
Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-120</DOCNO>
<DOCOLDNO>IA053-000896-B001-130</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/vtwover.html 129.174.40.15 19970123200758 text/html 11805
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:06:44 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 22:50:05 GMT
Content-type: text/html
Content-length: 11621
</DOCHDR>
<html>
<head>
<title>VTW BillWatch Issue 17: Overview on Clipper II</title>
<!author=Sender: shabbir@panix.com>
</head>
<body>
<hr>
<h2>ACTION ALERTS</h2>

<h3>Clipper II is here, and you should be mad.</h3>

This week <a href="http://www.vtw.org/>VTW</a> traveled to Maryland to the National Institute of
Standards and Technology (NIST) to voice our opposition to the new Son
of Clipper plan being proposed by the White House.  Lucky for us, we
were not alone.  An army of industry representatives came to nervously
show their opposition as well.  VTW was allowed 4-6 minutes to present
our problems with the key escrow program.  The full text of 
<a href="./vtw.html">our comments
is available</a>, and a copy is being included into the NIST workshop
report. 

<hr>
CHANGES IN US CRYPTOGRAPHY POLICY
<p>
In BillWatch (Issue #14) we described the background surrounding the
announcement of the government's new "Key Escrow" proposal.  In this
issue we give a report on the outcome of the NIST Key Escrow workshop
(Sep. 6th and 7th in Gaithersberg MD) where the trial lead balloon of
Clipper II was presented to industry and the public.

<p>
<h1>	Clipper II: Don't trip over the dogs and ponies</h1>

<p>
INTRODUCTION
<p>
Last year many people announced that "Clipper is dead".  Contrary to
that belief, several civil liberties organizations warned that 
although the use of the Clipper Chip is probably dead, the public had
not heard the last from the government on their war on your right to
have a private conversation.  Indeed, as predicted, the government
proposed a new program this summer called Commercial Key Escrow ("Son
of Clipper" or "Clipper II").

<p>
WHAT IS COMMERCIAL KEY ESCROW?
<p>
Remember the Clipper Chip?  It was a scheme that allowed you to have a
private conversation (encrypted) with any other person, except that the
government would have a built-in way of decoding that conversation.  Many
people found it unacceptable to have government-designed built-in back
doors to telephones and software.

<p>
Under Clipper II, the government still requires those back doors be built
into the products.  However the encryption key that scrambles your
conversation would be held by a third party, another company called a
"commercial escrow agent".  When law enforcement wanted to decrypt
your files or your communications they would go to the escrow agent and
demand the keys to decrypt your information.

<p>
This is even worse than the original Clipper for a number of reasons
outlined in the presentations given by civil liberties advocates.
Instead of the government telling you that you had to let them listen
to your conversations, under commercial key escrow they require that
both they and an "escrow company" have access to your encryption keys.

<p>
Both public advocates and industry representatives viewed this as just as
unacceptable as the original Clipper proposal.

<p>
NIST HOLDS SOMETHING AKIN TO A PUBLIC FORUM
<p>
This week (Sep 6th and 7th) NIST (National Institute of Standards and
Technology) conducted a key escrow workshop" in Gaithersburg Maryland.
Advertised as a place for industry to bring their concerns over key
escrow but "open to the public", it was heavily attended by industry
representatives.  A few advocates of the public interest crashed the
party anyway and to NIST's credit, we were not turned away and even
allowed to present our dissenting views.  Representatives from the ACLU
(American Civil Liberties Union), CDT (Center for Democracy and
Technology), EPIC (Electronic Privacy Information Center) and VTW
(Voters Telecommunications Watch) all were in attendance to critique
the proposal.  A transcript of VTWs testimony is available at the end
of this document. [actually, I split the document into smaller parts.
Follow this link for <a href="./vtw.html">VTW's comments on Escrow</a>]

<p>
Here's how the workshop worked:
First, NIST, in concert with the law enforcement and intelligence
communities, came up with a set of ten criteria for a commercial key
escrow system and for certifying escrow agents.  No public input was
solicited.

<p>
Second, while representatives of the White House uttered the mantras of
"export decontrol" and "foreign markets", industry representatives were
shown a complicated scheme whereby law enforcement would have access
to the keys, all while consumers would still be allowed to encrypt their
data.

<p>
At the workshop, industry representatives were broken up into groups and
charged with examining and improving the standards for commercial key
escrow proposed by the Administration.

<p>
As expected, this scheme backfired.  As each group reported back to the
larger audience, industry representatives fell over each other to ensure
that no one considered their attendance at this workshop an endorsement
of commercial key escrow.  Two of the groups experienced what could best
be described as revolts.  In one group several individuals, led by an
representative from the ACLU, tried to pass a resolution to remove the
restrictions on export of cryptography, something clearly unacceptable to
the government.  It was defeated on a tie vote of 7-7.

<p><a name="breakspeach">
A second industry working group made their report and published the
following statement,

<p>
<i>	[..] There is a concern that we will be viewed as endorsing the
	[government proposal].  Specifically, we are worried that a
	report from these meetings will reflect a consensus and
	endorsement of the policy proposals put forth by the government
	when this is not the case.  The process is driven too much by
	the concerns of law enforcement and national security.  It is
	not industry led and market driven.  We see little attempt to
	find the common ground that meets market export needs, law
	enforcement and national security.

<p>
	The best next step is to table the criteria and work with
	industry organizations to further define what can and cannot
	work.  Crippled cryptography will be a commercial flop for
	everybody.

<p>
	We are also concerned that FIPS will be decided on the 15th and
	the entire exercise will be slam dunk.  [..]
</i>
<p>


WHY THE RUSH?
<p>
Industry representatives, while not repeating the mantra "My attendance
should not constitute an endorsement of key escrow", were all asking "Why
are we in such a hurry?"  The answer may lie in a review of key escrow
history.

<p>
When the original Clipper plan was announced many suspected it was
because a manufacturer was about to release an encrypting telephone
device of DES (Data Encryption Standard) strength.  Dissuaded from
releasing that product, they were convinced to allow the government to
try their hand at a Clipper version of that product.

<p>
Similar rumors were thick at the workshop this week.  The rumor mill
suggested that another company is about to release a secure telephone
product domestically that does not have a built-in government back door. 

<p>
However noting the lack of marketplace enthusiasm for Clipper products,
the company is not rumored to be waiting for a key escrow proposal to be
finished.  They will simply be releasing the product for the domestic
market only.  Keep an eye out for product announcements to see if this
rumor is true.

<p>
IS CLIPPER II OR COMMERCIAL KEY ESCROW A "SLAM DUNK"?
<p>
Many have critiqued the administrations cryptography policy as being
too dominated by law enforcement and national security interests.
Indeed the original Clipper proposal proposed by NIST went through a
period of public comment.  NIST received 185 comments on the proposal,
183 of them opposing it.  Over the objections of the public and
industry and with the support of only law enforcement and the
intelligence community, NIST went ahead and made the Clipper proposal a
standard.

<p>
Even before the workshop was over, the question of whether the
commercial key escrow proposal would become a FIPS (Federal Information
Processing Standard) standard was answered.  The "shoe dropped" twice
on the first day of the workshop.  The first indication came when a
high-profile NSA representative admitted during a break that the
government was going to go forward with Clipper II as an experiment,
hoping it would be acceptable by the marketplace.

<p>
The second, more public, indication that Clipper II would become a
national standard came during a session wrapup given by NIST staffer Ed
Roback.  In talking about the possibility of Clipper II becoming a
standard, Mr. Roback confessed on the podium, "Well, it's been more or
less decided that it's going to happen."

<p>
DO PUBLIC ADVOCATES HAVE A SENSE OF HUMOR?
<p>
The futility of stopping such an unpopular proposal set a Kafka-esque
tone to the proceedings.  Attendee Carl Ellison suggested the following
alternative to the government's key escrow proposal.  The NSA and the
FBI could each generate a PGP key which he would sign.  Those public
keys would each be include in products.  When you as a user of such
products are encrypting stored data or a communication, you will have
the option of choosing whether or not to store an encryption key
available for those two agencies.
<p>

It certainly fits the model of a voluntary system.  Users who do not
wish to voluntarily use the system simply choose not to enclose a copy
of their keys for law enforcement and the intelligence community.
Somehow we expect it will not be embraced by the White House.

<p>
WHAT CAN YOU DO?
<p>
Within a few weeks NIST will issue a request for comments on making
Clipper II (Commercial Key Escrow) a FIPS standard (Federal Information
Processing Standard).  It is most important that when that happens you
submit an objection to the standard.  Having this record of public
opposition to the proposal will serve public advocates well in the debates
over such schemes in the future.  Take some time to review the testimony
below and watch for announcements about the standards process.

<p>
WHERE CAN I LEARN MORE?
<p>
You can follow this link to <a href="./vtw.html"> 
find VTW's testimony on the Clipper II proposal.</a>
Testimony from the Center for Democracy and Technology should be available soon at:

<p>
	<a href="http://www.cdt.org/"> URL:http://www.cdt.org/</a>

<p>

<hr>
<pre>
SUBSCRIPTION AND REPRODUCTION INFORMATION

      *** Know of someone ANYWHERE with a fax machine but without net ***
      *** access that's interested in VTW's issues?  Tell them to     ***
      *** call and get on our weekly fax distribution list at         ***
      *** (718) 596-2851 (or email us their fax number.		      ***

         To get on the distribution list for BillWatch, send mail to
      listproc@vtw.org with "subscribe vtw-announce Firstname Lastname"
			     in the subject line.

	To unsubscribe from BillWatch (and all other VTW publications)
	send mail to listproc@vtw.org with "unsubscribe vtw-announce"
			     in the subject line.

         Email vtw@vtw.org with "send billwatch" in the SUBJECT LINE
		  to receive the latest version of BillWatch

	For permission to reproduce VTW alerts contact vtw@vtw.org

____________________________________________________________________________
    End VTW BillWatch Issue #17, Date: Thu Sep  7 22:35:25 EDT 1995
<hr>
</pre>


Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 11, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-121</DOCNO>
<DOCOLDNO>IA053-000896-B001-175</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/hoffman.html 129.174.40.15 19970123200827 text/html 10861
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:07:13 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:02:52 GMT
Content-type: text/html
Content-length: 10677
</DOCHDR>
<html>
<head>
<Title>Professor Lance J. Hoffman's Presentation</title>
<center>
<h1><a href="http://www.seas.gwu.edu/faculty/hoffman/">
Professor Lance J. Hoffman</a></h1>
<h2><a href="http://www.seas.gmu.edu/seas/instctsp/ictsp.html">
Institute for Computer and Telecommunications Systems Policy</a></h2>
<h2>George Washington University</h2>
</center>
Presentation to NIS&T Encryption Exort Key Escrow workshop.
<p>
This presentation was given Thursday September 7, 1995.
<p>
<i>Note from pfarrell: 
The tables use <strong>
Netscape 1.1 extensions</strong>, and may not look correct with other browsers.
This presentation was submitted as WordPerfect
tables. I couldn't make them into HTML, so I reentered the data. 
Any typos are mine.</i>
<h2>Slide 1, Vice President Gore's Criteria</h2>
This slide shows the criteria contained in Vice President Gore's letter
to Rep. Maria Cantwell, 20 July 1994.
<CENTER>
<TABLE COLSPEC="C20 C20 C20 C20" BORDER=2>
<TR><TD> NIS&T Key Escrow Draft Software Criteria Number.
</TD><TD> Strong Crypto	
</TD><td> OK for Commercial
</td><td> OK for National Security</td></TR>
<TR><TD> 1</td><td> </td> <td> </td> <td> </td></tr>
<tr><td> 2</td></tr>
<tr><td> 3</td></tr>
<tr><td> 4</td></tr>
<tr><td> 5</td></tr>
<tr><td> 6</td></tr>
<tr><td> 7</td></tr>
<tr><td> 8</td></tr>
<tr><td> 9</td></tr>
<tr><td> 10</td></tr>
</TABLE>
</CENTER>
This visual is based upon Mike Nelson's 6 September 1995 slide.

<h2>Slide 2, Nothing Magic about Ten Criteria</h2>
We can add or delete criteria to Satisfy the Vice President's Requirements.
<CENTER>
<TABLE COLSPEC="C20 C20 C20 C20" BORDER=2>
<TR><TD> NIS&T Key Escrow Draft Software Criteria Number.
</TD><TD> Strong Crypto	
</TD><td> OK for Commercial
</td><td> OK for National Security</td></TR>
<TR><TD> 1</td><td> </td> <td> </td> <td> </td></tr>
<tr><td> 2</td></tr>
<tr><td> 3</td></tr>
<tr><td> 4</td></tr>
<tr><td> 5</td></tr>
<tr><td> 6</td></tr>
<tr><td> 7</td></tr>
<tr><td> 8</td></tr>
<tr><td> 9</td></tr>
<tr><td> 10</td></tr>
<tr><td> 11</td></tr>
<tr><td> 12</td></tr>
</TABLE>
</CENTER>


<h2>Slide 3, Seem to Have Got National Security Requirements Right </h2>
<CENTER>
<TABLE COLSPEC="C20 C20 C20 C20" BORDER=2>
<TR><TD> NIS&T Key Escrow Draft Software Criteria Number.
</TD><TD> Strong Crypto	
</TD><td> OK for Commercial
</td><td> OK for National Security</td></TR>
<TR><TD> 1</td><td> </td><td> </td><td> + </td></tr>
<TR><TD> 2</td><td> </td><td> </td><td> + </td></tr>
<TR><TD> 3</td><td> </td><td> </td><td> + </td></tr>
<TR><TD> 4</td><td> </td><td> </td><td> + </td></tr>
<TR><TD> 5</td><td> </td><td> </td><td> + </td></tr>
<TR><TD> 6</td><td> </td><td> </td><td> + </td></tr>
<TR><TD> 7</td><td> </td><td> </td><td> + </td></tr>
<TR><TD> 8</td><td> </td><td> </td><td> + </td></tr>
<TR><TD> 9</td><td> </td><td> </td><td> + </td></tr>
<TR><TD> 10</td><td> </td><td> </td><td> + </td></tr>
<TR><TD> 11</td><td> </td><td> </td><td>  </td></tr>
<TR><TD> 12</td><td> </td><td> </td><td>  </td></tr>
</TABLE>
</CENTER>


<h2>Slide 4, Only Criteria #1 Addresses <i>Strong</i> Crypto</h2>
<CENTER>
<TABLE COLSPEC="C20 C20 C20 C20" BORDER=2>
<TR><TD> NIS&T Key Escrow Draft Software Criteria Number.
</TD><TD> Strong Crypto	
</TD><td> OK for Commercial
</td><td> OK for National Security</td></TR>
<TR><TD> 1</td><td> </td><td> </td><td> + </td></tr>
<TR><TD> 2</td><td> -- </td><td> </td><td> + </td></tr>
<TR><TD> 3</td><td> -- </td><td>  </td><td> + </td></tr>
<TR><TD> 4</td><td> -- </td><td>  </td><td> + </td></tr>
<TR><TD> 5</td><td> -- </td><td>  </td><td> + </td></tr>
<TR><TD> 6</td><td> -- </td><td> </td><td> + </td></tr>
<TR><TD> 7</td><td> -- </td><td> </td><td> + </td></tr>
<TR><TD> 8</td><td> -- </td><td>  </td><td> + </td></tr>
<TR><TD> 9</td><td> -- </td><td> </td><td> + </td></tr>
<TR><TD> 10</td><td> -- </td><td> </td><td> + </td></tr>
<TR><TD> 11</td><td> -- </td><td> </td><td>  </td></tr>
<TR><TD> 12</td><td> -- </td><td> </td><td>  </td></tr>
</TABLE>
</CENTER>


<h2>Slide 5, Only Four of the Draft Criteria Satisfy Commercial Requirements</h2>
<CENTER>
<TABLE COLSPEC="C20 C20 C20 C20" BORDER=2>
<TR><TD> NIS&T Key Escrow Draft Software Criteria Number.
</TD><TD> Strong Crypto	
</TD><td> OK for Commercial
</td><td> OK for National Security</td></TR>
<TR><TD> 1</td><td> </td><td> </td><td> + </td></tr>
<TR><TD> 2</td><td> -- </td><td> </td><td> + </td></tr>
<TR><TD> 3</td><td> -- </td><td> + </td><td> + </td></tr>
<TR><TD> 4</td><td> -- </td><td> + </td><td> + </td></tr>
<TR><TD> 5</td><td> -- </td><td> + </td><td> + </td></tr>
<TR><TD> 6</td><td> -- </td><td> </td><td> + </td></tr>
<TR><TD> 7</td><td> -- </td><td> </td><td> + </td></tr>
<TR><TD> 8</td><td> -- </td><td> + </td><td> + </td></tr>
<TR><TD> 9</td><td> -- </td><td> </td><td> + </td></tr>
<TR><TD> 10</td><td> -- </td><td> </td><td> + </td></tr>
<TR><TD> 11</td><td> -- </td><td> </td><td>  </td></tr>
<TR><TD> 12</td><td> -- </td><td> </td><td>  </td></tr>
</TABLE>
</CENTER>


<h2>Slide 6, Four Criteria Don't Satisfy Commercial Requirements</h2>
<h3>I don't know about Two Others</h3>
<CENTER>
<TABLE COLSPEC="C20 C20 C20 C20" BORDER=2>
<TR><TD> NIS&T Key Escrow Draft Software Criteria Number.
</TD><TD> Strong Crypto	
</TD><td> OK for Commercial
</td><td> OK for National Security</td></TR>
<TR><TD> 1</td><td> not! </td><td> not! </td><td> + </td></tr>
<TR><TD> 2</td><td> -- </td><td> not! </td><td> + </td></tr>
<TR><TD> 3</td><td> -- </td><td> + </td><td> + </td></tr>
<TR><TD> 4</td><td> -- </td><td> + </td><td> + </td></tr>
<TR><TD> 5</td><td> -- </td><td> + </td><td> + </td></tr>
<TR><TD> 6</td><td> -- </td><td> not! </td><td> + </td></tr>
<TR><TD> 7</td><td> -- </td><td> ??? </td><td> + </td></tr>
<TR><TD> 8</td><td> -- </td><td> + </td><td> + </td></tr>
<TR><TD> 9</td><td> -- </td><td> ??? </td><td> + </td></tr>
<TR><TD> 10</td><td> -- </td><td> not! </td><td> + </td></tr>
<TR><TD> 11</td><td> -- </td><td> </td><td>  </td></tr>
<TR><TD> 12</td><td> -- </td><td> </td><td>  </td></tr>
</TABLE>
</CENTER>


<h2>Slide 7, Stay Focused</h2>
So up to six criteria have to be tweaked or redone to 
meet Vice President Gore's Goals.
<p>
But 23 of the 3 x 10 = 30 matrix cells are OK -- stay focused on the remaining 
seven.
<p>
<CENTER>
<TABLE COLSPEC="C20 C20 C20 C20" BORDER=2>
<TR><TD> NIS&T Key Escrow Draft Software Criteria Number.
</TD><TD> Strong Crypto	
</TD><td> OK for Commercial
</td><td> OK for National Security</td></TR>
<TR><TD> 1</td><td> Tweak/Fix </td><td> Tweak/Fix </td><td> + </td></tr>
<TR><TD> 2</td><td> -- </td><td> Tweak/Fix </td><td> + </td></tr>
<TR><TD> 3</td><td> -- </td><td> + </td><td> + </td></tr>
<TR><TD> 4</td><td> -- </td><td> + </td><td> + </td></tr>
<TR><TD> 5</td><td> -- </td><td> + </td><td> + </td></tr>
<TR><TD> 6</td><td> -- </td><td> Tweak/Fix </td><td> + </td></tr>
<TR><TD> 7</td><td> -- </td><td> Tweak/Fix </td><td> + </td></tr>
<TR><TD> 8</td><td> -- </td><td> + </td><td> + </td></tr>
<TR><TD> 9</td><td> -- </td><td> Tweak/Fix </td><td> + </td></tr>
<TR><TD> 10</td><td> -- </td><td> Tweak/Fix </td><td> + </td></tr>
</TABLE>
</CENTER>
23 out of 30 are done.  <strong>STAY FOCUSED!</strong>
<h2>Slide 8, Gore's Characteristics</h2>
Vice President Gore's Characteristics for Key Escrow Agents 
(source: letter to Rep. Maria Cantwell, 20 July 1994)
<p>
<strong>STAY FOCUSED</strong>
<p>
<CENTER>
<TABLE COLSPEC="C20 C20 C20 C20" BORDER=2>
<TR><TD>Gore Characteristics (possibilities offered at workshop (Below))
</TD><TD> No Unauthorized Surveillance
</TD><td> Key Disclosure only Under Legal Authorization 
</td><td> Audit Procedures</td>
</td><td> Liability</td>
</td><td> Private Sector</td>
</td><td> Number of Escrow Agents.</td>
</TR>
<tr><td> Excluded Organizations</td></tr>
<tr><td> Government/Agent Legal agreement</td></tr>
<tr><td> Liability</td></tr>
<tr><td> Criminalization</td></tr>
<tr><td> Govt. need for confidentialility</td></tr>
<tr><td> tie agent approval to public key infrastructure</td></tr>
<tr><td> storage/safeguard criteria</td></tr>
<tr><td> performance criteria</td></tr>
<tr><td> Foreign agents</td></tr>
<tr><td> approval process and costs</td></tr>
</TABLE>
</CENTER>
<strong><i>STAY FOCUSED!</i></strong>
<h2>Slide 9, Stay Focused on getting an OK in every cell</h2>
<CENTER>
<TABLE COLSPEC="C20 C20 C20 C20" BORDER=2>
<TR><TD> What area
</td><td> #
</TD><TD> Strong Crypto	
</TD><td> OK for Commercial
</td><td> OK for National Security
</TD><TD> No Unauthorized Surveillance
</TD><td> Key Disclosure only Under Legal Authorization 
</td><td> Audit Procedures
</td><td> Liability
</td><td> Private Sector
</td><td> Number of Escrow Agents.</td> </TR>
<tr><td>C</td><td> 1</td><td> </td><td></td><TD>OK</td></tr>
<tr><td>R</td><td> 2</td><td>OK </td><td></td><TD>OK</td></tr>
<tr><td>Y</td><td> 3</td><td>OK </td><td> OK </td><TD>OK</td></tr>
<tr><td> P</td><td> 4</td><td>OK </td><td> OK </td><TD>OK</td></tr>
<tr><td> T</td><td> 5</td><td>OK </td><td> OK </td><TD>OK</td></tr>
<tr><td> O</td><td> 6</td><td>OK </td><td> </td><TD>OK</td></tr>
<tr><td> </td><td> 7</td><td>OK </td><td> </td><TD>OK</td></tr>
<tr><td> </td><td> 8</td><td>OK </td><td> OK </td><TD>OK</td></tr>
<tr><td> </td><td> 9</td><td>OK </td><td> </td><TD>OK</td></tr>
<tr><td> </td><td> 10</td><td>OK </td><td> </td><TD>OK</td></tr>
<tr><td>A</td><td> 11</td><td> </td><td></td><TD> </td></tr>
<tr><td> G</td><td> 12</td><td> </td><td></td><TD> </td></tr>
<tr><td> E</td><td> 13</td><td> </td><td></td><TD> </td></tr>
<tr><td> N</td><td> 14</td><td> </td><td></td><TD> </td></tr>
<tr><td> T</td><td> 15</td><td> </td><td></td><TD> </td></tr>
<tr><td> S</td><td> 16</td><td> </td><td></td><TD> </td></tr>
<tr><td> </td><td> 17</td><td> </td><td></td><TD> </td></tr>
<tr><td> </td><td> 18</td><td> </td><td></td><TD> </td></tr>
<tr><td> </td><td> 19</td><td> </td><td></td><TD> </td></tr>
<tr><td> </td><td> 20</td><td> </td><td></td><TD> </td></tr>
</TABLE>
</CENTER>
<strong><large><i>STAY FOCUSED!</i></large></strong>
<p>
The presentation presented by 
<a href="http://www.seas.gwu.edu/faculty/hoffman/">
Professor Lance J. Hoffman</a><br>
<a href="http://www.seas.gwu.edu/seas/instctsp/ictsp.html">
Institute for Computer and Telecommunications Systems Policy</a><br>
George Washington University
<hr>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 14, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-122</DOCNO>
<DOCOLDNO>IA053-000894-B004-35</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/old.sept.html 129.174.40.15 19970123201304 text/html 5435
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:11:52 GMT
Server: NCSA/1.5.2
Last-modified: Sat, 16 Sep 1995 15:50:11 GMT
Content-type: text/html
Content-length: 5252
</DOCHDR>
<HTML>
<head>
<TITLE>Information on the NIS&T Key Escrow Export meeting</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>NIS&T Key Escrow Export Meeting Information</H1>
<h2>The NIS&T meeting on key escrow export</h2>
The Clinton Administration is revising parts of the 
ill fated Clipper initiative. The key action was a two day long
meeting on key escrow and export regulations that took place
September 6 and 7, 1995. 
<p>
<a href="./nist/pdfopinion.html">Pat's Overview Opinion</a>
<p>
<h2>Key information on the meeting include:</h2>
<ul>
<h3>Agenda and official information</h3>
<li><a href="./crypto/welcome">Welcome message</a>
<li>Potential <a href="./crypto/attendees">attendees</a>
<li><a href="./crypto/agenda">agenda</a>
<h3>Position papers:</h3>
<li>Topic 1 <a href="./crypto/topic1.html">General issues</a>
<li>Topic 2 <a href="./crypto/topic2.html">Escrow agent characteristics</a>
<li>Topic 3 <a href="./crypto/topic3.html">Export issues</a>
<h3>Handouts and presentations on Criteria</h3>
<li><a href="./nist/bsa.html"> Business Software Aliance</a>
<li><a href="./nist/denning.html"> Dorothy Denning's comments</a>
<li><a href="./nist/kammer.html"> Kammer and Nelson's presentation</a>
<li><a href="./nist/national.html">National Semiconductor's CAKE</a>
<li><a href="./nist/tecsec.html"> TECSEC's product</a>
<li><a href="./nist/tis.html"> TIS's comments on the criteria</a>
<li>During the first breakout session, in the technical discussion
of criteria # 5 and #6, an authorless (presumably government issued)
"Example Potential Solutions" paper was distributed. It caused a lot
of grumbling amongst the attendees, as they were supposed to discuss it,
without any prior chance to read or react to it. Here are two versions
of it, First,
<a href="./nist/sample_solutions.html"> 
Anonymous Sample Solutions (HTML by PDF)</a> 
and a simple ASCII version <a href="./nist/sample_solutions.txt">
Sample Solutions (ASCII text by John Young)</a>
<p>
I have not seen an electronic version of the paper that I received. It
contains the following paragraph:
<p>
"Example Solutions to export criteria 5 and 6 are identified below to help
give a better feel for approaches that implementors may take to satisfy the criteria. The information in
this paper is not intended to represent fail-safe, cookie cutter solutions to
the criteria, but only to 
generate more detailed discussions."
<p>
It is also interesting to note that John Young has an electronic document
with all of the sample solutions (a solution for each of the ten criteria).
I never saw a paper document with all ten solutions. The one that was 
handed to me had only two criteria, #5 and #6. I talked to attendees
of other breakouts, and they had received nothing.
<h3>Handouts and presentations on "approved" escrow agents</h3>
<li>CDT's presentation is available twice, I've made 
<a href="./nist/cdt_nist.html">a local copy </a>as CDT's web server is slow,
and here is a link to <a href="http://www.cdt.org/crypto/cdt_nist_090795.html">
CDT's own copy of their presentation </a>
<li><a href="./nist/vtwover.html"> VTW's Overview (from BillAlert)</a>
<li><a href="./nist/vtw.html"> VTW's Presentation</a> 
<li><a href="./nist/hoffman.html">Professor Hoffman of GWU </a>
<li><a href="./nist/kam.html">Ken Mendelsen's Presentation's text </a>
<h3>Notes from the breakout sessions that I recorded</h3>
<li>"official" report sent to NIST of breakout session on 
<a href="./nist/crit56.html">Session C1/C2, Criteria 5 and 6</a>
<li>"official" report sent to NIST of breakout session on 
<a href="./nist/techcrit.html">Criteria Technial discussion</a>
<li><a href="./nist/cp1.html">Cypherpunks posting, day 1 (HTML)</a> and a
PGP-signed 
<a href="./nist/cp1.asc"> (ASCII version) Cypherpunks posting, day 1</a>
<li><a href="./nist/cp2.html">Cypherpunks posting, day 2 (HTML)</a> and a
PGP-signed 
<a href="./nist/cp2.asc"> (ASCII version) Cypherpunks posting, day 2</a>
<h3>Media coverage</h3>
<li><a href="./nist/nyt.html>New York Times coverage</a>
<li><a href="./nist/post.html">Washington Post business section coverage</a>
<h3>Links to other attendee's comments and reactions</h3>
<li><a href="./nist/plesser.html">Ron Plesser's analysis</a>
<li><a href="http://www.clark.net/pub/cme/html/nist-ske.html">Carl Ellison's public comments</a>
<li>Carl Ellison's 
<a href="http://www.clark.net/pub/cme/html/nist-ske.html#geoff">Open 
letter to Geoff Greiveldinger</a> and Carl's paper proving
that <a href="http://www.clark.net/pub/cme/html/no-ke.html">the Goverment
Doesn't Want Key Escrow</a>
<li><a href="./nist/david.html">David Lesher's posting</a>
<li>CDT released policy paper on Clipper II, 
<a href="./nist/cdt_policy.html"> 
this is a local copy</a> and here is 
<a href="http://www.cdt.org/publications/pp2440911.html">
a link to CDT's own (slow) site</a>
<h3>Related public testimony</h3>
<li><a href="./nist/nsa.html">NSA Clipper testimony</a> sounds a lot
like the NIST testimony from the Government speakers.
</ul>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 16, 1995.  Backto <a href="./hotlist.html">Pat's hotlist</a> Backto <a href="./index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-123</DOCNO>
<DOCOLDNO>IA053-000896-B001-219</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/techcrit.html 129.174.40.15 19970123200856 text/html 3668
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:07:37 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 22:57:13 GMT
Content-type: text/html
Content-length: 3485
</DOCHDR>
<html>
<head>
<title>Breakout Session C1/C2, Technical Criteria</title>
</head>
<body>
<h2>Technical Criteria</h2>
Recorded/reported by Pat Farrell<br>
PhD Graduate Student<br>
School of Information Technology and Engineering<br>
George Mason University<br>
Fairfax, Virginia.
<p>
This records notes and comments from the second C1/C2 breakout session at
the NIS&T Encryption Key Escrow Export meeting. The session occured
about 4:00 PM on September 6, 1995.
<p>
The session started with the folks from National Semiconductor described their
CAKE system. This is a smartcard/PCMCIA device that uses 2000+ bit 
public/private key encryption and signatures. They are hoping for export
approval; it is necessary for the project to be viable.  The system looks
pretty interesting, but it too complicated to describe here. In short, 
random session keys are generated and signed with a Data Recovery Center's
(DRC) public key. The LEAs could then send encrypted session keys to the DRC, 
which would decrypt them, and return the unencrypted session keys which
the LEA could then used to decrypt the messages.

<p>
While this is a hardware system, its concepts could be transfered to 
a software implementation.

<p>
One obvious problem is that CAKE's system doesn't meet criteria #8 (requiring
repeated involvement of the escrow agent), since it may require
hundreds or thousands of session key decipherments. 
<p>
A second problem exists if the National Semiconductor product's 
approach is implemented in software. It is possible that the software could
modified so that a bogus DRC key is used. The rest of the protocol 
would work, but the sessions would not be recoverable. This would 
preclude any authorized government access to the sessions.
<p>
It also has a number of attractive features, such as 
never sending the private key anywhere, only the session key is escrowed.
<p>
The general discussion showed concerns that in the international
community, requiring government escrow may cause loss of valuable data,
as some foriegn governments are not as trustworthy as the US. It was
the consensus that requiring users to have 50 or more escrow centers was
unworkable. Yet this could be required for large multinational companies
working in 50 or more countries, if each required a local key escrow service.

<p>
The CAKE model would allow both date stamping of session keys, and periodic
rekeying. Either would satisfy my "unaccepted" Citeria #11, technical
limits to the time that a court ordered decryption could be executed.

<p>
There was a discussion of changing the criteria so that only the transmission
of data was concerned with escrow. This would simplify the issue of
multinational escrow. We did not resolve whether this would be sufficient
or acceptable.

<p>
I believe that most of the participants had "run out of steam" before,
or during, this session. It did not generate the lively discussions
that occured constantly during the earlier session.
<hr>
Follow this link to the <a href="./crit56.html">writeup of
the breakout session on Criterias #5 and 6.</a>
<p>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/nist950906.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 7, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-124</DOCNO>
<DOCOLDNO>IA053-000895-B046-257</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/escagent.html 129.174.40.15 19970123200028 text/html 8881
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:59:17 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:03:57 GMT
Content-type: text/html
Content-length: 8698
</DOCHDR>
<HTML>
<head>
<TITLE> NIST/NSA criteria for acceptable Escrow Agent</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
Note, this was manually typed by pfarrell, as the government 
hasn't yet posted
this to their web page.
<p>
<H1> Key Escrow Agent Criteria</h1>

<h2>Introduction</h2>

An often heard concern regarding key escrow encryption 
is that users of such encryption are vulnerable to abuse 
of the escrowed key by the escrow agents or others. Many 
have suggested that changes in the law were needed that 
specifically, criminalize any such abuses. We agree that 
such laws will be beneficial in deterring act by anyone to 
access escrowed keys without authority or to undermine 
the integrity of the escrow key system.
<p>
However, the availability of criminal prosecution is not 
alone sufficient. Key escrow agents must be selected no 
only with a view towards assuring the availability of 
escrowed keys for properly authorized government 
officials, but also to assure that the escrow agents have 
the commitment and means to protect the confidentiality 
of integrity of the keys they escrow and the escrow 
system. This will be particularly important if, as expect 
will occur, some key escrow products will be designed 
such that the escrow agent could discern the identity of 
the user from the keys and other information that is 
escrowed with them.

<p>
The following criteria were drafted with these principals 
in mind. We have not yet addresses conditions under 
which users can be the sole repository of the keys for 
their system. We recognize that some organizations or 
people do not want anybody but themselves to escrow 
their keys. However, since an important reason for 
escrowing is to preserve effective law enforcement, we 
must assure authorized officials can reliably and timely 
obtain access to escrowed keys through entities 
independent of the subject of electronic surveillance. 
Thus we welcome suggestions on how best to meet this 
range of interests.
<p>
In considering the criteria appropriate for approving 
escrow agents, we considered what the government needs 
to assure it has timely and reliable access when 
authorized and what key escrow encryption users would 
want to ensure that the escrowing of keys foes not 
undermine their security. Of course, the government is 
also a user of key escrow encryption products and shares 
with other users an interest to ensure the integrity and 
security of the escrow system. Similarly, organizations 
interested in data recovery share the governments 
interest to have a system through which access to 
escrowed key is enabled under appropriate 
circumstances. With these considerations in mind, we 
developed criteria in two categories, Escrow System 
Integrity and Security and Key Access Requirements. 
We expect that prospective escrow agents that meet 
criteria such as these would be considered approved 
escrow agents for export purposes, to hold keys for 
government systems, etc.
<p>
Note that keys and/or key components for devices that 
may process classified information shall be escrowed with 
escrow agents entities selected by the US government, 
and that those escrow agents entities may be required to 
meet more stringent requirements.
<p>
<h2>Escrow System Integrity and Security</h2>
<p>
1. Escrow agent entities shall devise and institutionalize 
policies, procedures, and mechanisms to ensure the 
confidentiality, integrity, and availability of key escrow 
related information.
<p>
a. Escrow agents entities shall be designed and operated 
so that a failure by a single person, procedure, or 
mechanism does not compromise the confidentiality, 
integrity, or availability of the key and/or key 
components (e.g. two person control of keys, split key, 
etc.)
<p>
b. Unencrypted escrow key and/or key components that 
are stored and/or transmitted electronically shall be 
protected (e.g., via encryption) using approved means.
<p>
c. Unencrypted escrowed key and/or key components 
stored and/or transferred via other media/methods shall 
be protected using approved means (e.g. safes).
<p>
2. Escrow agent entities shall ensure due form of escrow 
key access requests and authenticate the requests for 
escrowed key and/or key components.
<p>
3. Escrow agent entities shall protect against disclosure 
of information regarding the identity of the 
person/organization whose key and/or key components 
is requested, and the fact that the key and/or key 
components was requested or provided.
<p>
4. Escrow agent entities shall enter key/key components 
into the escrowed key database immediately upon receipt.
<p>
5. Escrow agent entities shall escrow at least two copies 
of any key and/or key component in independent 
locations to help ensure the availability of such key 
and/or key component due to unforeseen circumstances.
<p>
6. Escrow agent entities that are certified by the U.S. 
government shall work with developers of key escrow 
encryption products to develop and support a feature that 
allows the product to verify to one another that the 
products keys have been escrowed with a U.S.-certified 
agent.
<p>
<h2>Key Access Requirement</h2>
<p>
7. An escrow agent entity shall employ one or more 
persons who possess a SECRET clearance for purposes of 
processing classified (e.g. FISA) requests to obtain keys 
and/or key components.
<p>
8. Escrow agent entities shall protect against 
unauthorized disclosure information regarding the 
identity of the organization requesting the key and key 
components.
<p>
9. Escrow agent entities shall maintain data regarding all 
key escrow requests received, key escrow components 
released, database changes, system administration 
accesses, and dates of such events, for purpose of audit 
by appropriate government officials and others.
<p>
10. Escrow agent entities shall maintain escrowed keys 
and/or key components for as long as such keys may be 
required to decrypt information relevant to a law 
enforcement investigation.
<p>
11. Escrow agent entities shall provide key/key 
components to authenticated requests in a timely fashion 
and shall maintain a capability to respond more rapidly 
to emergency requirements for access.
<p>
12. Escrow agent entities shall posses and maintain a 
Certificate if Good Standing from the State of 
Incorporation (or similar local/national authority).
<p>
13. Escrow agent entities shall provide to the U.S. 
government a Dun & Bradstreet/TRW number or similar 
credit report pointer and authorization.
<p>
14. Escrow agent entities shall possess and maintain an 
Errors & Omissions insurance policy.
<p>
15. Escrow agent entities shall provide to the U.S. 
government a written copy of, or a certification of the 
existence of, a corporate security policy governing the key 
escrow agent entitys operation.
<p>
16. Escrow agent entities shall provide to the U.S. 
government a certification that the escrow agent entity 
will comply with all applicable federal, state, and local 
laws concerning the provisions of escrow agent entity 
services.
<p>
17. Escrow agent entities shall provide to the U.S. 
government a certification that the escrow agent entity 
will transfer to another approved escrow agent the escrow 
agent entitys equipment and data in the event of any 
dissolution or other cessation of the escrow agent entity 
operations.
<p>
18. Escrow agent entities for products sold in the U.S. 
shall not be a foreign country or entity thereof, a national 
of a foreign country, or a corporation of which an alien is 
an officer or more than one-fourth of the stock which is 
owned by aliens or which is directly or indirectly 
controlled by such a corporation. Foreign escrow agent 
entities for products exported from the U.S. will be 
approved on a case by case basis as law enforcement 
agreement and national security agreements can be 
negotiated.
<p>
19. Escrow agent entities shall provide to the U.S. 
government a certificate that the escrow agent entity will 
notify the U.S. government in writing of any changes in 
the forgoing information.
<p>
20. Fulfillment of these and the other criteria is subject to 
periodic recertification.
<p>
<hr>
Back to <a href="./nist951205.html">Pat's page on the December 5 MIST Clipper 2 </a>
meeting. 
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 7, 1995  Backto 
<a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a>
 Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-125</DOCNO>
<DOCOLDNO>IA053-000896-B001-105</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/cdt_nist.html 129.174.40.15 19970123200746 text/html 15929
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:06:31 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:16:42 GMT
Content-type: text/html
Content-length: 15745
</DOCHDR>
<html>
<head>
<title>Testimony of CDT Deputy Director Daniel Weitzner at NIST 9/7/95</title>
</head>
<body>
<p>
<p>
<p>
<h3><center>Testimony of<br>
Daniel J. Weitzner, Deputy Director<br>
<p>
on behalf of the<br>
<p>
Center for Democracy and Technology<br>
<p>
On Privacy and Security Policy Issues Raised by<br>
Commercial Key Escrow Systems
<p>
September 7, 1995<br>
National Institute of Standards and Technology
Gaithersburg, MD<br>
</h3></center>
<p>
<p>
<p>
<p>
<p>
<p>
<h3>I. Introduction</h3>
<p>
My name is Daniel Weitzner, Deputy Director of the Center for Democracy and Technology.  The Center is pleased to have opportunity to provide comments on the Administrations proposed private key escrow policies.  The Center for Democracy and Technology is an independent, non-profit public interest policy organization in Washington, DC. The Center's mission is to develop and implement public policies to protect and advance individual liberty and democratic values in new digital communications media. The Center achieves its goals through policy development, public education, and coalition building.  CDT also coordinates the Digital Privacy and Security Working Group (DPSWG), an ad hoc coalition of more than 50 computer, communications, and public interest organizations and associations working on communications privacy issues.  In the past, members of the Working Group have strongly opposed the Administration's Clipper Chip and worked on the Digital Telephony bill now passed into law. 
<p>
CDT is pleased that the Administration has made the commitment to develop a comprehensive communications security policy.  The original announcement to base such a policy on the private key escrow principles espoused in the Vice President' letter of July 1994 had great promise.  As we will illustrate below, however, the policy announced in September 1995 falls far short of the goals outlined by the Vice President and the needs of individual users and the industry.  Indeed, without substantial modification, the policy offers little to users, the market, or privacy advocates.  However, we remain committed to working with the Administration and the Congress to develop a comprehensive and balanced encryption policy that will meet user privacy needs and the legitimate interests of law enforcement agencies.  We continue to believe that the Gore letter contained the road map for such a policy and hope that the current efforts can be redirected along those lines.
<p>
<h3>II.	The Promise of the Gore Letter:  Potential for policy breakthrough to meet the needs users, industry, and law enforcement</h3>
<p>
With the explosive growth of the Internet and other interactive media, United States encryption policy has gone from a relatively unnoticed backwater of national security policy, to a highly visible and highly contentious area of technology policy of great concern to many industry groups and privacy advocates alike.  In this transition, there have been some missteps, including the Clipper Chip initiative.  After an unsuccessful effort to build support for the Clipper Chip in the market and the policy arena, the Clinton Administration announced its intention to develop a new encryption policy that would strike a more reasonable balance between the needs of users, the demands of the computer and communications marketplace, and the legitimate needs of law enforcement.  
<p>
The move away from reliance on the Clipper Chip marked an important turning point in the development of encryption policy.  First announced in a letter from Vice President Al Gore to Congresswoman Maria Cantwell on July 20, 1994, the Administration made a commitment to develop a policy framework that would promote the development of encryption systems that would meet the following criteria:
<p><ol>
<li><b>Implementation in hardware or software:</b>  After the hardware-only Clipper solution, the Administration recognized that any system must, according to the Gore letter, be "implementable in software, firmware, hardware, or any combination thereof."
<p>
<li><b>Public, unclassified algorithms:</b>  In order to assure users that their communications are truly secure, systems must employ encryption algorithms that are public, and thus subject to scrutiny by the broadest possible technical community.  Thus, the Vice President promised that the new policy "would not rely upon a classified algorithm."
<p>
<li><b>Voluntary:</b>  Although the Clipper Chip was always described as a voluntary technology, considerable fears arose that its use might one day become mandatory.  The Gore letter asserted that any new policy must be based on purely voluntary standards.
<p>
<li><b>Fourth Amendment privacy safeguards:</b>  Electronic surveillance constitutes an invasion of the most private realms of individual activity.  In order to protect individuals from unnecessary or excessive invasions by law enforcement agencies, Congress and the courts have instituted careful safeguards in the realm of traditional electronic surveillance through the telephone.  The Vice President's letter called for the extension of these protections in the form of "safeguards to provide for key disclosure only under legal authorization and should have audit procedures to ensure the integrity of the system."
<p>
<li><b>Statutory liability rules to protect users:</b>  In order to encourage users to trust private escrow systems, "escrow holders should be strictly liable for releasing keys without legal authorization," according to the Gore letter.
<p>
<li><b>Multiple escrow agents:</b>  Users must be free to chose their own escrow agents, unlike the Clipper proposal, so the Vice President declared that "a new key escrow encryption system must permit the use of private-sector key escrow agents as one option.... Having a number of escrow agents would give individuals and businesses more choices and flexibility in meeting their needs for secure communications."
</ul><p>

<h3>III.	Current Administration Proposal Fails to Meet High Standards Set out by the Vice President</h3>
<p>
The policy announced by the Administration in its September 1, 1995 paper, unfortunately fails to meet many of the criteria that the Vice President himself announced just one year ago in the above mentioned letter.  On hearing that the Administration had set out to develop a new encryption policy based on the principles outlined in the Gore letter, the Center for Democracy and Technology was guardedly optimistic that a genuine policy breakthrough was possible.  However, having had the opportunity to review the current proposal, every principle, except the first (software implementation) and second (public algorithms), thoughtfully outlined in the July 1994 letter is violated or, in one case, left in doubt, by the September 1995 policy statement.
<p>
The September 1995 policy statement diverges from the July 1994 letter in the following critical respects.  In our view, these divergences represent fundamental defects in the proposed policy and must be corrected.
<p><ul>
<li><b>Not Voluntary:</b>  The current proposal effectively compels all domestic users to use key escrow systems if they ever intend to communicate internationally.  Point 6 of the export criteria requires that an exportable system must not interoperate with any system that non-escrow systems.  Thus, in order for a user in the United States to communicate with anyone who uses a United States-made system on the Internet but outside of the United States, the American user must employ a key escrow system.  Domestic users are not legally compelled to use key escrow products, but the proposed policy forces, in practice, all but the most insular Internet user is propelled toward a key escrow system.  A policy based on such compulsion can hardly be called voluntary.
<p>
<li><b>Inadequate Security: </b> Point 1 precludes export of systems with key lengths beyond 64 bits.  Though this key size is larger than what is currently exportable, it is a level of security already judged inadequate for some applications.  Given the rate at which computing power increases, even a 64 bit key would be subject to attach before long.  
<p>
The premise of the key escrow policy is to provide law enforcement and national security agencies a "front door" to be used to decrypt messages when the agency obtains proper legal authorization.  Yet, the architects of the current policy apparently are not willing to trust that key escrow systems will meet law enforcement needs inasmuch as the key length limit suggests that the Administration is intent on maintaining an extra-legal method of decrypting communications.  The Gore letter contains no suggestion that key escrow systems would also be subject to key length limits but the Administration seems to have lost faith in its own proposal.  Such a half-hearted effort cannot be the basis of a long-lasting policy.
<p>
<li><b>No privacy protection for users of escrowed systems:</b>  The ten export principles make no mention of privacy safeguards which the Vice President previously recognized as necessary to safeguard individual privacy and Fourth Amendment principles.  Any escrow policy must contain safeguards against abuse and statutory liability provisions for the operators of private escrow systems.
<p>
<li><b>Fails to Promote International Interoperability:</b>  Points 6 and 10 of the export criteria raise grave doubts as to the likelihood that the current proposal will give rise to a secure global communications environment.  Point 10 forces users in other countries (and their governments) to accept United States-based escrow of all keys until bilateral access agreements are entered into.  Such tactics seem unlikely to produce satisfactory international agreements, and hold global communications security hostage to the completion of such agreements.
</ul><P>

<h3>IV.	Recommendations to Restore Current Process to Principles of Gore Letter</h3>
<p>
The Administration's September 1 paper leaves many privacy concerns unanswered or simply rejected, and falls far short of the goals set in the Gore letter of July 1994.  However, CDT still believes that the Administration has embarked on a serious process which, along with appropriate Congressional involvement, can lead to a long-lasting resolution to the encryption policy morass that exists today.  CDT recommends the following steps be taken immediately to supplement the September 1 policy framework.
<p><ul>
<h3>A.	Legislation to protect user privacy, address legitimate law enforcement needs, and guarantee voluntariness</h3></ul>
<p>
Encryption is now a key enabling technology in the development of the National and Global Information Infrastructure.  The growth of electronic commerce, the protection of intellectual property, and the very viability of cyberspace as an economic, social, cultural and political arena depend on the widespread availability of strong encryption.  As such, encryption policy can no longer be made in the closed halls Executive Branch national security policy.  
<p>
Like the Clipper Chip before it, the proposed key escrow policy framework places the National Security Agency in control of private sector computer security policy.  Such a role for the NSA is both detrimental to the growth of the information infrastructure and contrary to the principles of the Computer Security Act of 1987.  The Computer Security Act clearly established that neither military nor law enforcement agencies are the proper protectors of personal privacy.  When considering the law, Congress asked, "whether it is proper for a super-secret agency [the NSA] that operates without public scrutiny to involve itself in domestic activities...?"  The answer was a clear "no."
<p>
As important as the principle of civilian control was in 1987, it is even more critical today.  The more individuals around the country come to depend on secure communications to protect their privacy, the more important it is to conduct privacy and security policy dialogues in public, civilian forums.
<p>
If encryption policy is to be based on private key escrow as proposed by the Administration, legislative action is required to assure:
<p><ol>
<li><b>Complete voluntariness: </b> No government action should compel individuals or corporations to use key escrow systems;
<p>
<li><b>User choice of among multiple private escrow agents:</b>  Any entity that meets statutory criteria should be allowed to be an escrow agent.  Free market mechanisms should be allowed to meet the varying needs of users;
<p>
<li><b>User choice of encryption algorithm: </b>Different users with different applications will need varying degrees of security and should be allowed to chose the level and type of encryption appropriate to their needs.  Individual choice and market innovation, not government fiat, should guide choice of encryption algorithm;
<p>
<li><b>Statutory framework for law enforcement access and agent liability for improper disclosure:</b>  Under law, a private escrow agent could only legally disclose a users to those who are approved by the user, or to an authorized law enforcement agency, upon presentation of a 4th Amendment warrant. Private escrow agents (PEAs) would operate under a statutory framework which requires a PEA to hold private keys for users under a special standard of care and creates remedies in the event of unauthorized disclosure.  
<p>
In providing assistance to enable law enforcement to decrypt communications, the PEA may not disclose the target's private key to law enforcement.  However, as stated in the ten criteria and as much as is technically feasible, law enforcement should be assured speedy, uninterrupted access to decrypted communications once the surveillance is judicially approved.
<p>
<li><b>Audit trails for law enforcement access: </b>PEA's would be legally required to configure their systems in such a way to create a trusted and complete audit trail of all key access events.  This audit function would provide key holders with the ability to seek damages from the PEA if necessary and could act as a check on law enforcement activity. 
</ol><p>
<h3>B.	Export Control Reform</h3>
<ol><p>
<li><b>Full Export Authorization:</b>  Private key escrow systems that meet these principles should be fully exportable, under Commerce Department jurisdiction.
<p>
<li><b>End key-size limitations: </b> All properly escrowed encryption systems must be eligible for export, regardless of key size.  Since escrow systems would give law enforcement and national security agencies access to all communications, there can no longer be any justification for limiting key size.
<p></ol></ul>

<h3>V.	Conclusion</h3>
<p>
As measured by the demands of privacy and security, and by the standards set out in the 1994 Gore letter, the current key escrow policy proposals fall short of the mark.  However, CDT remains committed to working within the process set out by the Administration, and with the Congress, toward a speedy resolution of all of these critical encryption policy issues.
<p>
<p>
For more information, please contact:
<p>
Daniel Weitzner, CDT Deputy Director <a href = "mailto:djw@cdt.org">djw@cdt.org</a><br>
Jonah Seiger, CDT Policy Analyst <a href = "mailto:jseiger@cdt.org">jseiger@cdt.org.</a>
<p>
<hr size = 2>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 11, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-126</DOCNO>
<DOCOLDNO>IA053-000895-B042-349</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/clipper2.html 129.174.40.15 19970123194511 text/html 2428
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:43:55 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 22 May 1996 16:46:14 GMT
Content-type: text/html
Content-length: 2245
</DOCHDR>
<HTML>
<head>
<TITLE>Clipper II, the idiocy continues</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
 <A HREF="http://www.privacy.org/ipc/">
 <IMG BORDER=0 SRC="../gk7.gif"
 ALT="Golden Key"><BR>
 Protect Privacy Online: Join the Golden Key Campaign!</A>

<H1>Clipper II Information</H1>
or are we up to Clipper III by now, sigh.

<h2>The NIS&T meeting on key escrow export</h2>
The Clinton Administration is reviving and revising parts of the 
ill fated and ill advised Clipper initiative.
<p>
<ul>
<li>First, there was Dorothy Denning's Trial Balloon to Ban encryption
<li>In early Spetember, there was
a two day long
<a href="../nistmeeting.html">meeting on key escrow and export regulations </a>
that took place
September 6 and 7, 1995. 
<li>This was followed up by a meeting to establish a FIPS PUB standard.
Local cypherpunk Thomas Edwards produced 
<a href="./tge.html">a summary of the NIST FIPS PUB meeting</a>
<li>Next, on December 5, there was a folllowup meeting.
<a href="./nist951205.html">Follow this link for information on
this meeting</a>
<li>Recently, there is the <a href="./kmi.html">
Draft, Key Management Infrastructure</a><img src="../new.gif">
</ul>
Here are some  news articles and "letters to the editors"
covering the issues behind Clipper 2:
<ul>
<li>My USA Today letter, <a href="./pdf.usatoday.html"> in response to
USA Today's wonderful October 24 editorial.</a>
<li>A <a href="./nyt951108.html">New York Times article.</a>
<li>A <a href="./post.bu951108.html">Washington Post story from Nov 8th's
business section.</a>
<li>A Washington Post story:
 <a href="./post.bu960117.html">Export Rules Hurt Export</a>
<li>A New York Times editorial (Mar 25, 96):
<a href="./nyt960325.html">The key issue for the Net is not smut, it is the use of
encryption</a>
<li>An unrelated <a href="./post.ed951108.html">Washington Post editorial 
from Nov 8</a> against stupid governmnet regulation of the Internet.
</ul>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> 
March 25, 1996.  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-127</DOCNO>
<DOCOLDNO>IA053-000895-B043-232</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/geek.2.1.html 129.174.40.15 19970123194750 text/html 1588
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:46:39 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 27 Jul 1995 05:16:44 GMT
Content-type: text/html
Content-length: 1405
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Pat's geek code (version 2.1) </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<h2>This is an old, obsolete geek code</h2>
I've been a geek forever, at least 35 years. I used to be an Engineer. 
Not a "software engineer" but a real Engineer, 
working at an Engineering firm with
a hundred other professional Engineers. I used to hang
a sliderule on my belt so I'd be ready as I walked across campus. What's 
<a href="./sliderule.html"> a sliderule?</a>
<p>
Since this is an obsolete geek code, you need an obsolete definition, 
you can get the 
<a href="http://krypton.mankato.msus.edu/~hayden/html/codes/geek-2.1">
Geek code 2.1</a>
Or you may want to get  the currrent
<a href="http://krypton.mankato.msus.edu/~hayden/geek.html"> Master Copy</A>
directly from Robert. And you may want to check out 
<a href="./geek.html">Pat's current geek code</a>
<p><code>
GM/CS d--- H- s++:+++ g? p? <a href="./au.html">au+*</a> <a href="./a.html>!a</a> w+@ v++ C+++$ U--- P--- L-- 3-- E- 
N++ K- <a href="./w.html">W++++$</a> M- <a href="./V.html">V</a> po--- Y+++ t-- 5-- j++ <a href="./R.html">R</a> <a href="./G.html">G++</a> <a href="./tv.html">tv+</a> <a href="./b.html">b++</a> !D B-- 
e+++(++++) u+** h(----)++ f+ r+++ !n y++++ 
</code>
<P>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
July 27, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-128</DOCNO>
<DOCOLDNO>IA053-000895-B045-282</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/dccp/official.html 129.174.40.15 19970123195642 text/html 616
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:55:31 GMT
Server: NCSA/1.5.2
Last-modified: Sun, 03 Sep 1995 17:52:41 GMT
Content-type: text/html
Content-length: 434
</DOCHDR>
<HTML>
<head>
<TITLE>The official greater DC area Cypherpunks Page </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
The cypherpunks are essentially an anarchy. There is no one in charge.
How can we have an official anything?
<p>
Backto <a href="./index.html">DC area cypherpunks page</a>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
September 1, 1995
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT03-B24-129</DOCNO>
<DOCOLDNO>IA053-000895-B047-403</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/national.html 129.174.40.15 19970123200633 text/html 12900
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:05:15 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:00:19 GMT
Content-type: text/html
Content-length: 12716
</DOCHDR>
<html>
<head>
<link rev="made" href="mailto:jya@pipeline.com"> 
</head>
<body>

   <title>Commercial Cryptography Ideas
      for Success.</title>

National Semiconductor's "Commercial Cryptography Ideas
      for Success." This contains the CAKE program and a
      "Proposed NIST Escrow Certificate Heirarchy." 
<p>
   [Handout at Key Escrow Issues Meeting, at NIST,
   Gaithersburg, Maryland, September 6, 1995]


<p>
   [Page 1]

   [Header all pages] Commercial Key Escrow Issues


<p>
   Commercial Cryptography Ideas For Success

<p><pre>
   Bill Sweet
   Director of Marketing
   iPower Business Unit
   National Semiconductor
   1090 Kifer Road, M/S 16-225
   Sunnyvale CA 94086-3737
   408-721-51 93 (voice)
   408-245-7906 (fax)
</pre>
<hr>
<pre>
   New Government Software Export Criteria

   Export criteria [*and comments*] for software:

   1.   Unclassified algorithms up to 64 bits with an
        acceptable key escrow system [*DES. IDEA, CAST... ?*]

   2.   Must be designed to prevent multiple encryptions
        (triple DES) [*O.K if escrow access for each pass?*]

   3.   System must not operate until approved key escrow
        agent is selected [*factory-installed default O.K.?*]

   4.   Messages must contain easy pointers to the proper
        escrow agent and keys so access will always be
        available for authorized requests

   5.   The key escrow mechanism must be resistant to user
        modification (strong binding strength)

   6.   If the key escrow mechanism is illegally modified, the
        system should cease to work

   7.   The key escrow system must allow access at either the
        sender's or the receiver's end of the messaging
        process [*Sender picks escrow agent? -- negotiated key
        if simultaneous conversation?*]

   8.   The escrow system should not require repeated escrow
        agent involvement for multiple messages during the
        period of authorized access [*automated sequence
        through escrow agent's computer O.K.?*]

   9.   Systems sold in the US need to be escrow-enabled, or
        have the capability for escrow agents to be selectable
        (rekeyed) [*certificate upload in the factory or field
        O.K.?*]

   10.  The escrow agents must be approved by the U.S.
        Government, or a foreign government with reciprocal
        national security and law enforcement access for the
        U.S. Government [*a list of likely early candidates
        would help ...*]


   [Page 3]

   Export Requirement #11 (Industry Request)

   The stronger the escrow binding mechanism, the stronger the
   encryption allowed to be exported...

   Why is this important?

   +  Encryption strength is a moving target

   +  High end security applications need triple DES or other
      strong encryption algorithm and are willing to pay for
      it

   +  Domestic manufacturers need to compete with foreign
      unescrowed strong encryption (e.g., triple DES)

   +  Government wants stronger binding mechanisms (you get
      what you reward...)


   [Page 4]

   Commercial Automated Key Escrow (CAKE)

   Combines the TIS Commercial Key Escrow scheme with a
   powerful National PersonaCard 201 CAKE token providing
   strong encryption with a secure escrow mechanism

   +  The card will automatically create a Data Recovery Field
      (DRF) by encrypting the message key and sender ID with
      the public key of a Data Recovery Center (DRC) and
      attaching the DRC's plaintext identity

   +  This DRF is attached to the message envelope and goes
      anywhere the encrypted message goes including archival
      storage

   +  DRF discipline is enforced at both sender and receiver
      locations

   +  Users register with the DRC of their choice via
      uploading a DRC certificate

   +  Any organization in good standing should be able to
      possess its own DRC

   Unlike strong software encryption, the CAKE token:

   +  Is tamper-proof and counterfeit-proof to all users

   +  Cannot be spoofed by software-masquerading-as-a-token

   +  Can securely enforce escrowing, even with corrupt host
      software

   +  Can be export-controlled (cannot be copied & distributed
      over the Internet)


   [Page 5]

   CAKE Cryptographic Details

   1.   Sender's CAKE token creates a random block-encryption
        message key (typically DES) and encrypts a message.

   2.   Sender's token encrypts the message key with each
        receiver's public key creating N lockboxes (encrypted
        keys)

   3.   It uses the Data Recovery Center's (DRC) public key to
        encrypt the message key and the sender's identity, and
        attaches the DRC's plaintext identifier to create a
        Data Recovery Field (DRF)

   4.   Sender's token hashes the message to obtain a message
        digest

   5.   Sender's token encrypts the message digest with
        sender's private key, creating a digital signature

   6.   Sender & token transmit his certificate, the DRC
        certificate, receivers' lockboxes (encrypted keys),
        DRF, encrypted message, and signature to receiver

   7.   Receiver obtains certificates, lockboxes, DRF,
        encrypted message, and signature. Receiver's token
        verifies the two certificate issuers' signatures with
        the issuers' public keys and obtains sender's and
        DRC's authenticated public keys

   8.   Receiver's token unlocks his lockbox containing the
        message key with his private key (ignoring the other
        receivers' lockboxes)

   9.   Receiver's token calculates the anticipated DRF using
        information from the certificates and the message key

   10A. If the newly calculated DRF does not match the
        transmitted DRF, the receiver's token will not decrypt
        the message or disclose ths message key

   10B. If the DRF is correct, the receiver's token decrypts
        the message with the message key

   11.  Receiver's token hashes the message to obtain a
        message digest

   12.  Receiver's token decrypts the signature with the
        sender's public key to obtain the sender's message
        digest

   13.  Receiver's token compares its message digest with the
        sender's and determines if the signature (and message)
        are valid


   [Box]

   Data Recovery Center

      A user, corporation or government can determine the Data
      Recovery Center's ID(s) from the DRF(s) attached to
      locked (encrypted) file(s) and request that file(s) be
      unlocked. Upon proper authentication, the DRC uses its
      private key to decrypt the DRF(s) and deliver the
      decrypted message key(s) to the requesting party, who
      then decrypts the message(s)

   [Box]

   Verify-Me Challenge

      In a "who are you" challenge, the challenging party
      sends the challenged token a random number, which the
      challenged token returns encrypted with the Verify-Me
      private key and the factory certificate authenticating
      the Verify-Me public key and the device identity. If the
      random number is decrypted with the factory-certified
      public key, the challenged token proves its identity
      (and that the device is hardware, model # xxxx).


   [Page 6]

   Some Evident Truths To Ponder

   +  Public key encryption is the commercial wave of the
      future (secret key systems don't scale)

   +  Hardware and software products need a simple way of
      designating and redesignating escrow agents

   +  The simplest way to implement escrow agent designations
      is via expiration-dated certificates digitally signed by
      authorities (organizations) certified by the U.S.
      Government

   +  This means NIST should maintain the root key for escrow
      certificates

   +  In order to provide for escrow agent decertification,
      the U.S. Government needs to maintain an on-line
      Internet database of approved escrow agent certificates,
      as well as certificate revocation lists


   [Page 7]

   Proposed NIST Escrow Certificate Hierarchy

   [Chart]

   NIST Root Key (Public Key) (*Key Escrow Certification
   Authority*)

   [Lines from Root key to four columns]

   [Column 1]

   Trusted Information Systems Commercial Key Escrow System

      TIS Administrator's Certificate

         Certificate Version
         Serial Number
         Signature Algorithm
         Issuer (NIST Escrow Authority)
         Validity Dates
         Subject (owner=TIS Admin)
         TIS DRC Admin's Public Key
         Certifying Signature (NIST)

      [Line down to]

      Data Recovery Center (DRC) Certificate (*TIS
      Franchisee*)

         Certificate Version
         Serial Number
         Signature Algorithm
         Issuer (TIS Admin)
         Validity Dates
         Subject (owner=DRC Admin)
         Data Recovery Ctr Public Key
         Signature (TIS Admin)


   [Column 2]

   Independent Key Escrow Agents (e.g., Other Government
   Agencies)

      Independent Key Escrow Agent's Certificate (*NIST
      Franchisee e.g., Other Government Agencies*)

         Certificate Version
         Serial Number
         Signature Algorithm
         Issuer (NIST Escrow Authority)
         Validity Dates
         Subject (owner=Escrow Agent)
         Escrow Agent's Public Key
         Certifying Signature (NIST)


   [Column 3]

   Bankers Trust Commercial Key Escrow System

      Bankers Trust Administrator's Certificate

         Certificate Version
         Serial Number
         Signature Algorithm
         Issuer (NIST Escrow Authority)
         Validity Dates
         Subject (BT Administrator)
         IOO's Public Key
         Certifying Signature (NIST)

      [Line down to]

      Key Escrow Agent Certificate (*BT Franchisee*)

         Certificate Version
         Serial Number
         Signature Algorithm
         Issuer (BT Administrator)
         Validity Dates
         Subject (owner=Escrow Agent)
         Escrow Agent's Public Key
         Signature (BT Admin)

   [Column 4]

   Other Commercial Key Escrow System

      Other Administrator's Certificate

         Certificate Version
         Serial Number
         Signature Algorithm
         Issuer (NIST Escrow Authority)
         Validity Dates
         Subject (owner=Other Admin)
         SECURExchange's Public Key
         Certifying Signature (NIST)

      [Line down to]

      Key Escrow Agent Certificate (*Other Franchisee*)

         Certificate Version
         Serial Number
         Signature Algorithm
         Issuer (Other Admin)
         Validity Dates
         Subject (owner=Escrow Agent)
         Escrow Agent's Public Key
         Signature (Other Admin)


   [Page 8]

   Electronic Commerce Infrastructure Problems

   +  Lack of an exportable strong encryption capability to
      compete in global markets

   +  Lack of a global certificate hierarchy

   +  Lack of rational crypto standards

      +  NIST promotes Skipjack and secret KEA key exchange
         and DSS signaturing standards

      +  Industry uses RSA key exchange and signaturing, and
         prefers DES and triple DES

      +  A rational escrow standard (or two) needs defining
         *fast*.

   +  Lack of government & industry cooperation means:

      +  U.S. industry is *not* taking a leadership role in
         world electronic commerce markets in the area of
         security

      +  If U.S. industry is *not*, then the U.S. Government
         is *not*, because U.S. industry dominance is the
         government's *only* effective weapon for control of
         global crypto systems


   [Page 9]

   A Proposal: Government/Industry Cooperation

   +  NIST should recognize commercial, government & popular
      foreign crypto standards

   +  Industry should build personality-agile crypto products

      +  Choice of algorithms, key exchange systems,
         signature standards, escrow schemes and
         price/performance alternatives

   +  NIST should maintain root keys and certificate/CRL
      databases for *both* escrow and user certification
      systems

   +  U.S. Government should help establish international
      standards & systems (root keys, standards, certification
      & legal issues)

   +  Both plan on a *global* scale


   [End]
</pre>

Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 8, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-130</DOCNO>
<DOCOLDNO>IA053-000895-B046-288</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/pdf.nist2.html 129.174.40.15 19970123200037 text/html 37067
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:59:25 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 02 Jan 1996 19:19:27 GMT
Content-type: text/html
Content-length: 36883
</DOCHDR>
<HTML>
<head>
<TITLE>Report on the December 5 Clipper II meeting </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
Under construction...
<H1> Clipper II, meeting December 5 1995 </H1>
<p>
<h2>Table of contents</h2>
<ul>
<li><a href=#Summary>Summary</a>
<li>Comments on <a href=#ProductCriteria>product criteria</a>
<li>Comments on <a href=#Interoperability>interoperability concerns</a>
<li>comments on <a href=#AgentCriteria>key escrow agent entity criteria</a>
<li>Comments on <a href=#Presentations>presentations</a>
<li><a href=#Closing>Government Closing remarks and misc.  comments</a>
<li><a href=#WhoWho>Who's Who</a>
<li><a href=#MyOpinion>My Personal Opinions</a>
<li><a href=#Epilog>Copyrights and other similar stuff</a>
</ul>
<a name="Summary">
<hr>
<h2>Summary</h2>
One of the most significant things was obvious in
the parking lot.  Unlike September's meeting, this time it was empty.
Inside the hall, it was obvious that no one came. It was packed in
September, and now, entire rows were empty. I'm bad at guessing numbers,
but its easy  to guess that only 1/3 as many people showed. Maybe less.
<p>
The meeting was hosted by <a href=#Roback>Ed Roback </a>
of NIST, who quickly introduced
<a href=#Nelson>Mike Nelson</a> of the White House. 
Mike is clearly a political guy.
His handout says: "We believe that our proposal for exportable 64-bit key
escrow encryption meets these goals [the goals of VP Gore's letter to Rep
Cantwell, July 20, 1994]." He said that the criteria describe a solution,
but not the only solution.  He said it does not preclude other
implementations in the future. He anticipates that the State Department
will issue guidance based upon these criteria in "early 1996," and that
between now and then, any product that meets the criteria will be elegible
for expidited approval. Of course, the existing (slow as molasass) process
will continue.

<p>
I asked the first questions from the floor. The two questions were:
(1) Is this meeting concerned solely with export
of software, or does it deal with controling domestic use of strong
cryptography? and (2) since the 64-bit limit was severly criticized at
the Sept meeting, why is it still needed if there is also escrow?

<p>
His answer was that there is "no intention to control domestic encryption"
and on the 64-bit issue, that the government is "not certain it will
work." he says they "want to see it implemented and want to see
how it works" because 64-bit encryption is very strong. If the escrow
doesn't work, they don't want a lot of softare to be in widespread use.
<p>
He said that they have studied the encryption that is supposed to be widely
available on the Internet. He said that viewed by crypto experts, not
much is very good. He mentioned "two incidents" where Netscape had
weak implimentations. He feels that companies will not trust software
over the 'net. that they "want the US Government to say that 'this is
good enough'."
<p>
[I don't know what two incidents that he spoke of. There were four separate
noteworthy postings about Netscape, two were breaking RC4-40, Ian Goldberg
showed that the random seed was ineptly implemented, and Ray Cromwell
showed a trivial buffer overflow bug that could lead to serious 
security problems.]
<p>
Clint Brooks, of NSA, then went over the revised criteria. He claimed that
they were surprized at the industry concern over "one product" for
worldwide markets. There were lots of questions. He eventually admitted
that because of the "one product" concern, export regulations will effect
domestic products. [all the more reason for Netscape to keep building ten
or whatever it is.]
<p>
Brooks admitted that it is impossible to prevent multiple encryption.
Cypherpunks would do that by using PGP and then sending it using GAK.
He said "as a person, you can set up a secure communication method, and
nothing can be done about it." His concern is not that smart people can
have stronger crypto, but that strong crypto will be easy and widely used.
<p>
He said that the 64-bit key limit is not meant to restrict RSA keys to
64-bits, but rather to restrict the session keys that are encrypted using
RSA. Unspoken was the assumption that the 2000 bit RSA secret key would
have to be escrowed.
<p>
There were some interesting (and bad IMHO) implications of interoperability.
I'll cover them more in the long version. Basically, they admitted that
the interoperability restrictions made it stupid to have an export
version, you should have a strong domestic version, and an international
version developed offshore for sale to the rest of the world.
<p>
They admitted that there can be no controls over export of data, so once
interoperating software is available both domestically and from offshore
sources, there is no value in the export controlled, crippled version.
<p>
My favorite policeman, <a href=#GeoffG>Geoff Greiveldinger,</a> 
then described the
characteristics of an acceptable key escrow agent. There was a long list
of criteria, all unseen before the meeting. The general reaction
of the audience was that these were "yet another set of criteria that
must be met." Geoff claimed that they were simply trying to address
the questions raised at the earlier meeting about who is an
acceptable escrow agent. One point that caused a lot of concern
was that at least one employee of the escrow agent has to have a SECRET
clearence.
<p>
Industry, with a few exceptions, soundly said that this is a dumb idea,
that there is no market, that the criteria are too hard, etc. Except
Padgett Petersen, representing Lockheed-Martin. He said that LM thought
that the criteria were just peachy. The  usual civil liberties folks
also soundly trashed it.
<p>
There was a representative from Netscape. He said that they, as a company
think this is a terrible idea. They oppose it now, and will be issuing
a company policy soon. I didn't catch his name, and couldn't find him
to get the obviously carefully prepared text. 
<p>
One of what I thought were the most important admissions was made 
by Geoff G. in response to a question phrased about corporations
"holding their own keys." He was forced to admit that we
do "have a right to hold your own keys."
<a name="ProductCriteria">
<hr>
<h2>Product Criteria</h2>
This covers the product criteria, except interoperability.
<p>
There is a fair amount of information on the NIST web server. Use url:
<a href="http://csrc.ncsl.nist.gov/keyescrow/">
http://csrc.ncsl.nist.gov/keyescrow/</a>
<p>
Nelson said that they have studied the encryption that is 
supposed to be widely available on the Internet.
He said that viewed by crypto experts, not much is 
very good. He mentioned "two incidents" where
Netscape had weak implementations. He feels that companies 
will not trust software over the 'net. that
they "want the US Government to say that 'this is good enough'."
<p>
Clint Brooks, of NSA, then went over the revised criteria. He claimed that they
were surprised at the industry concern over "one product" for worldwide markets.
<p>
He stated that they were addressing "not domestic policy, per se, but we
keep wrapping around" because of the 'one product' issue.
<p>
The criteria are on the NIST page,
<a href="http://csrc.ncsl.nist.gov/keyescrow/">
url: http://csrc.ncsl.nist.gov/keyescrow/criteria.txt</a>

<p>
They handed out a guide to the changes in the criteria between September
and now. This is available from NIST as url:
<a href="http://csrc.ncsl.nist.gov/keyescrow/bground.html">
http://csrc.ncsl.nist.gov/keyescrow/bground.html</a>

<p>
Here is a portion of it:
<ul>
<li> Old Criterion 1.     Moved to #7;
<li>Old Criterion 2.     Moved to #8;
<li>Old Criterion 3.     Split into #1 and #2
<li>Old Criterion 5.     Moved to #10
<li>Old Criterion 6.     Moved to #9;
<li>Old Criterion 7.     Moved to #5;
<li>Old Criterion 8.     Moved to #6;
<li>Old Criterion 9.     Deleted.
<li>Old Criterion 10.    Moved to #3;
</ul>
<p>
Only in Washington. Oh yeah, they also clarified a lot of the wording.
<p>
<h3>Ideas that I thought important enough to make notes of concerning the
criteria:</h3>
<p>
These criteria do not address either hardware nor non-escrow encryption.
Export controls of these are not changed, they can be exported with the
current procedures.
<p>
Brooks said that these rules are not applicable to the protection of
internal data for US corporations, even for overseas locations of US firms.
He said that getting permission to export for _internal corporate use_ is
easy, if it is to protect corporate secrets and for internal communication.
I took this to mean that a multi-national, US-based corporatgon can get a
permit for ViaCrypt and export it for their own use. [later in the day,
some people mentioned that this isn't nearly as easy as Brooks claimed.]
<p>
He said that the intent in the new wording is flexibility. They don't want
to prescribe implementation details, he wants industry to invent what
sells. He specifically stated that the meetings were not about setting
standards. This caused at least a fair amount of confusion, probably due to
the fact that NIST used to be called National Bureau of Standards, and NBS
set standards all the time. For example, a couple of folks were interested
in interoperability, say between a Netscape encryption system and one made
by, say, Microsoft. This meeting did not address this level of
interoperability.
<p>
about #2, <blockquote>"The product's key escrow cryptographic functions shall be
inoperable until the key(s) is escrowed in accordance with #3."</blockquote>
Brooks said
that the intent was to allow vendors to make a single product that doesn't
activate the key-escrow function if not needed. The idea was that when the
keys are escrowed, the encryption engine would be activated. He also said
that "manufacturers may not want to be in the key escrow business" and
would therefore want to ship products that could be activated by a third
party escrow agent.

<p>
While talking about #3, 
<blockquote>3. The product's key escrow cryptographic functions' key(s)
shall be escrowed with escrow agent(s) certified by the U.S.
Government, or certified by foreign governments with which
the U.S. Government has formal agreements consistent with
U.S. law enforcement and national security requirements.
</blockquote>
<p>
He stated that this does not preclude the use of "other agents." This
became a major issue throughout the day. Ken Mendelson, staff attorney at
TIS, asked (roughly) "Under what authority does the US Government grant
certification to agents?" The response was a run around. Another hot issue
was whether you can "hold your own keys" rather than using a third party.
Seems that the corporate users are arguing that they want to hold their own
keys, and the government reacted to that favorably (not unfavorably?).
[Later in the day, Geoff Greiveldinger was asked if US citizens have the
right to hold their own keys. Geoff was forced to admit that, "yes, you can
hold your own keys"]
<p>
<blockquote> "5.    The product's key escrow feature shall allow access to the
key(s) needed to decrypt the product's ciphertext regardless
of whether the product generated or received the ciphertext."</blockquote>
<p>
Contains a significant change that was not discussed in September. It means
that having the key for either end is sufficient. Brooks conceded that this
was a big change, but claimed it was needed. The claim that one-ended
surveillance is easier is most likely true.  It clearly is easier if one
end is US based and using GAK and the other is foreign where there is
respect for civil liberties.
<p>
He even claimed that it made the system less intrusive: His argument was
roughly:
<blockquote>
Lets say they are snooping on me.  With one-ended, they can read all of my
messages, to and from, without needing the keys of my correspondents. (lets
pick Geoff G. as an arbitrary correspondent) With two ended, they'd have to
get both my key and Geoff's, and then they could read all of the messages
Geoff gets or sends.
</blockquote>
<p>
I said it was <i>their</i> argument. Seems to me to be groundless, unless they
got the keys of everyone in the chain, all of the folks that I talk to, all
of the folks that everyone I talk to, etc.
<p>
Several questioners asked if <i>any</i> will met criteria #5.
<a href=#Smid>Miles Smid</a> described a trick for meeting Criteria #5, 
if you encrypt the session key with your own public 
key, in addition to the key of your destination, and 
if you have escrowed your private key with an Escrow 
Agent, then nearly any approach meets criteria #5.
<p>
<blockquote>"7.    The product's key escrow cryptographic functions shall use
an unclassified encryption algorithm with a key length not
to exceed sixty-four (64) bits."</blockquote>
<p>
This is really aimed at session keys, or at least non-RSA keys. I suggested
that they really needed some wording that make it clear.
<p>
He said that the 64-bit key limit is not meant to restrict RSA keys to
64-bits, but rather to restrict the session keys that are encrypted using
RSA. Unspoken was the assumption that the 2000 bit RSA secret key would have to be escrowed.
<p>
<blockquote>"8.    The product's key escrow cryptographic functions shall not
provide the feature of multiple encryption (e.g., triple-
DES)."</blockquote>
<p>
He pointed out that the wording used to say "prevent" and now just says
"not provide".  He acknowledged that "prevent" was impossible.
<p>
<blockquote>"9.    The product's key escrow cryptographic functions shall
interoperate only with key escrow cryptographic functions in
products that meet these criteria, and shall not
interoperate with the cryptographic functions of a product
whose key escrow encryption function has been altered,
bypassed, disabled, or otherwise rendered inoperative."
</blockquote>
<p>
Brooks said that this was intended to allow multiple modes, such as
compatibility with other encryption schemes. Of course, he said, the other
modes are subject to export restrictions.
<p>
Somewhere in the discussion, Ed Appel took over for Brooks. Appel is
"Director of Counter Intelligence Programs, National Security Council, The
White House" He was introduced as FBI.
<p>
Ed Appel: the LEAs are very interested in Criteria #5 
(two ended decryption) as they have more than 100 
international offices.
<p>
There were some interesting (and bad IMHO) implications of interoperability.
I'll cover them more in the next section
<a name="Interoperability">
<hr>
<h2>Interoperability Issues</h2>
Part 2 of three hasn't been written, it is supposed to 
address the issues related to interoperability. I 
decided it was better to get this part out than to 
wait.

<a name="AgentCriteria">
<hr>
<h2>Key Escrow Agent Entity Criteria</h2>
<p>
Geoff G. says that the discussions on agent criteria 
are simply a follow-on to the main criteria #3.
The criteria themselves have been spam'd to the list.
They are also available at url:
<a href="http:/www.isse.gmu.edu/~pfarrell/nist/escagent.html">
http:/www.isse.gmu.edu/~pfarrell/nist/escagent.html</a>
<p>
There was a lot of reactions to the SECRET clearance
requirement, which they claimed was to handle
secure investigations (e.g. FISA). 
The logic is that since some investigations are classified,
and since you can't even see a classified document 
unless you have a proper clearance, each Key Escrow Agent Entity,
must have at least one properly cleared employee. This
was not a popular requirement.
<p>
David Lesher asked a series of questions concerning 
the requirement that the Key Escrow Entity employ a 
person with a SECRET clearance. They included: what 
agency will issue the clearance? Who will authorize 
for the BI (background investigation)? Who will pay 
for it? Who does the existing RBOC clearances? Geoff 
dodged nearly all of them. He acknowledged that "they" 
will have to pay, but made no effort to define who 
"they" are.
<p>
Geoff said that they may want legislation support for 
protecting against illegal release of keys, failure to 
release, etc.
<p>
A fair number of the agent criteria would be considered
professional business practice (no single point of
failure, dual locations, etc.) if you thought that
escrowing keys was a good thing.
<p>
<a name="Presentations>
<hr>
<h2> User/Industry presentations</h2>
<h3>Bill Sweet of TIS</h3>
Bill gave a presentation about his CKE product, and 
how hard he is working to "find a global solution."
<p>
This is actually the same product that Bill talked 
about in September when he worked for National 
Semiconductor. It was impressive then (private keys 
are NOT escrowed, only session keys, etc.) and is 
still not approved for export.
<p>
Bill talked about "information owners," they 
ultimately decide which security systems get deployed 
"in spite of various government requirements around the 
world." He said that "if rational key escrow systems 
are not offered, or do not adequately protect their 
information, owners will use unescrowed encryption 
from whatever sources available (Germany, et al)."
<p>
Bill talked about a UK University (Royal Holloway) 
study on UK/European needs for key escrow. He said 
that there was a lot of overlap with the NIST 
criteria, but that there were criteria that were 
judged as totally unacceptable. The first and loudest 
finding was:
<p>
"the use of the scheme should provide visible benefits 
to the user."
<p>
This begs the obvious question, what 
visible benefits to the user does GAK bring?
<p>
Two other interesting findings in the study were:
<ul>
<li> An entity with a warrant should not be able to 
fabricate false evidence."
<li> Abuse by either side should be detectable by the 
other.
</ul>
He suggested that these criteria be added to the NIST 
list of 10.
<p>
Bill went on to look at the NIST criteria. He said, 
concerning Criteria #3 (agents certified by US 
Government or reciprocal agreement), that "this is a 
show stopper!" because:
<ul>
<li>no reciprocal agreements exist today, anywhere.
<li>what about countries where justice systems are 
different, and what about where "these agreements are 
not desirable (e.g. Nigeria, Mexico, Saudi Arabia, 
Argentina, Poland, etc.)?
<li> even for NATO countries, agreements will be 
different (Germany has data privacy laws, in Greece), 
or we may not want to be reciprocal (in Greece, the 
government likes to bug the opposition)
</ul>
He also says that Criteria #7, 64-bit keys, is 
unacceptable. CE Infosys currently sells a PCMCIA (PC 
Card) encryptor that does triple-DES at T1 speeds. TIS 
uses it, and sells it in the US. [as an aside, I was 
told that they can import and resell them, but when 
one breaks, TIS cant ship it back to Germany for 
repairs. Sigh.]
<p>
Sweet had two recommendations:
<ul>
<li>develop a tiered crypto policy, with hardware and 
software under differing levels of rules,
<li> allow a pilot project, where TIS can sell VPN 
(virtual private networks) using strong encryption. A 
VPN is the use of the Internet as a private network 
for a corporation by adding appropriate firewalls, 
encryption, etc.
</ul>
It seems to me that while TIS' CKE doesn't meet the 
criteria, it could be made to, with a few changes.
They've have to change the design to allow GAK
for any one target. (Criteria #5) This would mean
for generating one DRF (ie., LEEF) for each recipient 
as well as for the sender (as opposed to just for 
the sender) The neat thing about CKE is that each 
LEEF holds only the session key -- so you never 
give away your private key. (I think the govenment
really expects that we'll be willing to 
escrow our private keys. Fat chance!)
<p>
But this is a bit of a catch 22, because 
to follow all the criteria, you can't stop there.
<ul>
<li>For each encryption, you generate a DRF for the 
sender and each recipient
<li>
For each DRF generated, you must have and check 
a certificate chain for the chosen DRC and 
refuse to encrypt unless all recipients and 
the sender have validly certified (ie., USGovt
approved) DRC public keys.
<li>
Each receiving application must refuse to 
decrypt unless every other recipient and 
the sender have validly certified DRC
public keys. This gets into the interoperability
issues that I need to write up...
<li>
I don't know how they can meet the revised #6. It
seems to be designed specifically to break CKE.
</ul>
To get govie approval, each DRC needs to meet all the
key escrow agent entity criteria. I'm really not at
all convinced that it is actually practical. This is
sad, because CKE is obviously designed with the spirit
of the government at heart, with just some modifications
to make it marketable. Guess TIS needs an Ireland office 
too.
<p>
<h3>Ken Mendelson of TIS</h3>
Ken gave a solid presentation describing how all of 
the Governments need for data about key escrow agents 
could be met with a commercial "vendor registration" 
approach instead of a Government mandated 
"certification" scheme. This would be in keeping with 
the current "spend less money, have less government 
bureaucratic rules" political climate. I have copies 
of his slides, Id rather not type them in. With any 
luck, hell put them up on the TIS web site url: 
http://www.tis.com
<p>
<h3>Dorothy Denning of Georgetown University</h3>
<p>
Dorothy Denning gave a presentation based upon an article that 
will be published in the March 96 Communications of 
the ACM. It analyzes currently available products (and 
vapor products) and sees how well they meet Criteria 
#5. It says that eight of the sixteen approaches that 
she surveyed currently meet Criteria #5. She lists her 
web page as http://www.cosc.georgetown.edu/~denning, 
but as of Sunday 12/10, the text is not available.
<p>
<h3>Melanie Janin, US Council for International Business</h3>
Ms. Janins speech presented the US Council for 
International Business comments on GAK. They are a NY 
based trade group, representing 300 clients. They 
dont like GAK. She called for a coherent policy on 
all encryption. Major topics in the presentation 
include:
<ul>
<li>free choice
<li>open to the public
<li>international acceptance
<li>flexibility of implementation
<li>User key management
<li>Key escrow (where they "embrace key escrow as one 
possible method of managing encryption keys.")
<li>Liability
</ul>
<h3>Ed Scheidt, Tecsec</h3>
Presented both comments on the criteria and his 
companys VEIL and Export VEIL Version 2.0 products. 
He raised a number of points, including:
<ul><li>how do we protect our commercial information unless 
we have the best cryptography?
<li>we need "constructive key management technology" to 
manage keys, key splits, and different algorithms for 
extended data separation.
<li>solution must address issues such as international 
trust in a key escrow.
</ul>
He said that his "Export VEIL 2.0" product meets "the 
intent of 11/95 export criteria today."
<p>
<h3>Daniel Weitzner of CDT</h3>
<p>
Mr. Weitzner agreed to shorten his presentation so 
that he could yield some time to VTW.
<p>
He opened by pointing out that while the schedule had 
both him and Jerry Berman were supposed to talk, Jerry 
was too busy to make the meeting. "Jerry is out 
defending pornographers, so Ill be here defending 
terrorists."
<p>
I expect that his text will be on CDTs webpage, url: 
http://www.cdt.org. Ill just enter the key points.
<p>
The first thing he said is that "this is the wrong 
forum" and that "the [NIST] process will not work." He 
proposed a open, privately sponsored forum to develop 
alternatives that will work.
<p>
"The NIST proposal will not provide adequate security, 
privacy, promote secure communications worldwide, or 
guarantee user privacy." Major issues are:
<ul>
<li>Inadequate security
<li> No viable policy framework for the long-term
<li> Hinders the deployment of globally interoperable 
secure systems
<li> not necessarily voluntary
<li> not viable in the marketplace
<li> no constitutional privacy protections
<li> will not meet the needs of law enforcement, since it 
will "not deny criminals or terrorists access to 
strong encryption, the stated objective of the 
policy."
</ul>
<h3>Shaber Safdar, Voters Telecommunication Watch</h3>
Described the results of an Internet-based, non-
scientific survey that the VTW recently made. Not 
surprisingly, those who replied were overwhelmingly 
against the NIST proposal. I dont have the slides, 
but VTW has a website with most of their information. 
The url is <a href="http://www.vtw.org">
http://www.vtw.org</a>
<p>
There were 26 respondents to the survey. 24 out of 26 
said that they would never buy products with law 
enforcement access. 16 out of 24 are already using 
security products.
<p>
He described a Technology Pledge that VTW is 
presenting to politicians (available at url: 
<a href="http://www.vtw.org/pledge/">
http://www.vtw.org/pledge/)</a> and stated that Rep. 
Ronald Wyden (D-OR) signed the pledge with pro-
freedom, pro-market answers.
<h3>David Sobol, EPIC</h3>
As expected, EPIC doesnt like much about the NIST 
proposal. Their comments are on their web page, url:
<a href="http://www.epic.org/crypto/EPIC_Statement.html">
http://www.epic.org/crypto/EPIC_Statement.html</a>
<p>
A key statement is "Given the reality that users are 
unlikely to adopt key escrow systems on a voluntary 
basis, we believe that the current policy will result 
in the eventual prohibition of non-escrowed products. 
Indeed, documents released to EPIC under the Freedom 
of Information Act (FOIA) reveal that NSA and FBI 
concluded nearly three years ago that
<blockquote>
Technological solutions such as they are, will 
only work if they are incorporated into all 
encryption products."
</blockquote>
Major points 
<ul>
<li>Public comment is frequently solicited but never 
heeded.
<li>Relevant information has not been released. 
<li>The proposal conceals the attempt to expand 
wiretapping capability 
</ul>
As a result, EPIC proposes the following Policy 
Recommendations
<ul>
<li>Relax export controls on encryption and permit the 
free flow of encryption products across national 
borders
<li>Withdraw FIPS 185 (the Clipper standard for voice, 
fax,...  and low speed data networks in the 
federal government)
<li>Remove "cryptology" from items that may be 
classified ...  under executive order
<li>Do not fund the Telephone Carrier Compliance Program         
(the "Digital Telephony" proposal)
<li>Do not permit the use of classified algorithms for         
public networks
<li>Examine the activities of the National Security 
Agency ... since passage of the Computer Security 
Act of 1987.
</ul>
NOTE: during Mr. Sobels discussion, a FBI 
representative sitting at the head table said  that 
the issues addressed by key escrow are "not just 
wiretapping, they include search and seizure of all 
stored media." I was not able to identify the person. 
He was sitting at Ed Appels seat, but did not have a 
namecard. No one sitting near me recognized him 
either.
<h3>Padgett Petersen, Lockheed Martin</h3>
Noted Internet personality, Padgett Petersen took a 
rarely held position, he spoke as a Security officer 
of Lockheed Martin, rather than speaking as a private 
net-citizen.
<p>
He said that "these criteria are acceptable and can be 
made to work." He also said that "without US 
agreements, there is no reason to be concerned with 
export." Lockheed Martin was looking forward to 
participating in using and buying the escrowed 
products that will hit the market as a result of this 
process.
<h3>Robert Hollyman, Business Software Alliance</h3>
Mr. Hollyman said that "the facts are clear, companies 
are unanimous against" the NIST proposal. His members 
agree that:
<ul>
<li> security is critical
<li> 40 bit is not viable
<li> the 1992 government review requires a change in 
policy.
<p>
He recommended:
<li> immediate approval of DES or equal strength 
alternative for export.
<li> encourage companies to build encryption software by 
submitting code to NIST (under non-disclosure) for 
review
<li> add two bits ever three years to allowable key 
lengths in recognition of Moores law. He called this 
a COCA allowance (cost of cracking algorithms).
<li> removal of restrictions on interoperability because 
they are artificial and antithetical to the Global 
Information Infrastructure.
</ul>
He stated that the current criteria are vague, and 
will take years for approval. Yet he notes that in 
industry, the average life cycle of software is 18 
months.
<h3> Alex McIntosh, PC Security</h3>
PC Security sells key management systems. Shell is a 
customer. He addresses a couple of areas that his 
commercial customers ask. 
<p>
The first question is "why encrypt?" He said that the 
answer is to protect confidential data. These data 
include email, PC files, and archival data. 
<p>
This leads to the obvious question, why use key 
management? The two separate answers are to have  
operational backup and to allow compliance with 
internal and external law enforcement.
<p>
He said that he has a surprise for the NIST folks 
concerning key escrow agents. The corporate customer 
is the key escrow agent.
<p>
Other key observations:
<ul><li> Companies, such as Shell, often do business in 
countries where they can not trust the government.
<li> Shell handles over a million email messages a day. 
This defines engineering requirements for any system 
to meet.
<li> Liability is a huge issue, and the amounts are 
huge. Geologic information, market strategies, etc. 
are worth staggering amounts of money. The "US 
Government can NOT cover Shells liabilities."
</ul>
<h3>Doug Miller, Software Publishers Association</h3>
Mr. Miller said that his members need immediate relief 
from the current encryption export policies. "our 
members are poised, but cannot leap, because of the 
barriers that U.S. cryptographic policy continues to 
impose." He wants to be able to export 56-bit DES. His 
position paper says, "we believe the discussion should 
also include assessment of the exportability of 
products employing the DES algorithm. DES-strength 
(56-bit) products can compete with 179 foreign 
products (80 of which are software products) that 
employ DES. Liberalization of the export restrictions 
of software with encryption capabilities is essential 
if U.S. companies are to compete with strong, widely 
available non-escrowed products."
<h3> Viktor Hampel, Hampel Consulting </h3>
Proposed "a Consumer Protection Act for Digital 
Products to support electronic commerce and to 
control the increasing abuse and lack of security on 
the national information highways." A copy can be 
obtained from Hampel Consulting, 1515 Jefferson Davis 
Highway, Crystal Square Suite 913, Arlington VA 22202-
3312.
<p>
In his remarks, Mr. Hampel said that trust is 
important between business. Business worries about 
issues as varied as what accountability is in the 
system and how much is the per minute interest on a 
billion dollar money transfer? These cause business to 
need solutions that NIST hasnt raised.
<p>
He recommended that a public key infrastructure be 
included into the Uniform Commercial Code.
<a name="Closing">
<hr>
<H2> Closing comments.</h2>
Mike Nelson noted that the meeting had some time for 
floor questions.
<p>
He was asked what is the timeframe for finishing the 
process. He danced, saying that promising a fixed date 
for policy decisions is bad for your career, but 
thought it would be done in a couple of months.
<p>
Someone asked about the "Personal Use" export process 
(the one that will allow you to export PGP on a laptop 
computer for personal use, and that was promised for 
"in a couple of weeks" at the September NIST meeting). 
They said that it is about to go to the Federal 
Register, and should be available within weeks.
<p>
Nelson was asked about foreign escrow agents. He said 
that "if there exists bilateral diplomatic agreements, 
then the US will allow specification of Foreign Escrow 
agents." [Of course, no such agreements exist now.]
<p>
Ed Appel of the White House said that the intent is to 
make export "as easy as 40-bit" is under the existing 
policies. The existing export policies will continue.
<p>
He also said "so far, we are only controlling export" 
and that "the government has very strong cryptography 
available to them, so they are not worried about 
export." He said they hope to control export in two 
ways, first by applying the combined purchasing power 
of the US Government to encourage the market, and by 
controlling export.
<hr>
After the meeting closed, I invited both Mike Nelson 
and Ed Appel to the next <a href="http://www.isse.gmu.edu/~pfarrell/dccp/">
DC Cypherpunks meeting. </a>
Somehow I expect it when they declined. But they
both said they were interested in future meetings.
We'll see if they were just being polite.
<p>
<a name="WhoWho">
<hr>
<h2>Who is Who amongst the Government folks</h2>
<ul>
<li><a name="Appel">Ed Appel's card says <br>
Director of CounterIntellegence Programs<br>
National Security Council<br>
The White House
<p>
He is clearly a very smart law enforcement guy.
<p>
<li><a name="GeoffG">Geoff Greiveldinger is 
listed in the agenda as being with "U.S. Department
of Justice." He is clearly very high up in the organization. All of
the examples he gives are domestic, so he is probably FBI instead of NSA.
He also constantly refered to "equipment" instead of software.<p>
<li><a name="Nelson">Mike Nelson's card says <br>
Michael R. Nelson, PhD.<br>
Special Assistant, Information Technology<br>
Executive Office of the President<br>
Office of Science and Technology Policy<br>
OEOB (Old Executive Office Building, on the White House grounds)
<p>
He is a geophysist by degree. An impressive politician.
<p>
<li><a name="Roback">Ed Roback works at NIST. He coordinated
these meetings. After the meetings, a number of us kidded him
about "comming out" and admiting that he really is
only doing this because NSA insists.<p>
<li><a name="Smid">Miles Smid works at NIST. He is rumoured to have
been the brains behind the design of the Clipper system. He knows
a lot about cryptography. Other rumours say he learned about
Cryptography while employed at NSA.
</ul>

<a name="MyOpinion">
<hr>
<h2>Pat's Opinions</h2>
The meeting was in general a repeat of September's meeting, and similar
meetings that have been going on for years. Both sides talk past each
other. I think this has degenerated into a parallel with the abortion
debate. There is no common ground.
<p>
The biggest items that I heard was the admission by Geoff G. that 
we do have "the right to hold your own keys." This admission
means that they know they have no expectation that outlawing
unescrowed encryption is constitutional. This, sadly, doesn't mean
that they won't try.
<p>
<h3>What I think it means:</h3>
<p>
I believe that the government deeply wants to restrict domestic use of
strong encryption, but they have no legal justification for doing so.
They can't expect that they will get it if they go to Congress. So they
are attempting an end-arround using the export criteria, which they
<strong>do control.</strong> 
They hope that the pain of having multiple versions will be
so high that no vendor will bother, and all we'll have is crippled
software.
<p>
The usual civil liberties lobby folks (CDT, EPIC, etc.) want to
hold their own, industry sponsored meetings to develop workable systems.
<p>
I think that the real key is for everyone, worldwide to insist on
both strong crypto and interoperability. The Germans are already
writing fine software and making fast hardware. Microsoft and Netscape
can easily afford to do some of their development offshore. If the products
sell and are deployed, it won't matter what the govies want.
<p>
<a name="Epilog">
<hr>     
<h2>Copyright, Epilog, etc.</h2>
A note on quoting within this document: I did not take a 
tape recorder to the meeting. Words in quotes were taken
from either my hardcopy of handouts, words in documents
on cited webpages, or from my notes. I tried hard to 
keep the words accurate and in context. There may be some
cases where my quotes are incorrect. If I've misquoted
anyone, it is not delibrate, and if told, I'll post
corrections.
<p>
Copyright (c) 1995, Pat Farrell.
Permission granted to electronically redistribute, provided
it is transmitted in the whole and unaltered.
<hr>
Back to <a href="./nist951205.html">Pat's page on the December 5 NIST Clipper 2 </a>
meeting. 
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 10, 1995  
Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">
Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-131</DOCNO>
<DOCOLDNO>IA053-000895-B045-227</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/nyt960325.html 129.174.40.15 19970123195619 text/html 7147
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:55:07 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 25 Mar 1996 15:38:11 GMT
Content-type: text/html
Content-length: 6964
</DOCHDR>
<HTML>
<head>
<title>
The key issue for the Net is not smut, it is the use of
encryption
 </title>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<p>
<h1>
The key issue for the Net is not smut, it is the use of
encryption</h1>
<p>
<h3>   Growing fears that Big Brother might decide to read your
   E-mail.</h3>
<p>
<i>The New York Times,</i> March 25, 1996, p. D5.<br>
By Denise Caruso
<p>
Copyright (c) 1996, New York Times, All Rights Reserved.
<p>
The current uproar over the Internet is about smut and what
can be made public on the global computer network. But the
next public-policy tangle will be about what we're allowed
to keep secret.
<p>
Earlier this month, a bipartisan group from both houses of
Congress introduced versions of legislation called the
Encrypted Communications Privacy Act of 1996. This bill,
which outlines the proper use of encryption technologies
for privacy and security, is by far the most critical piece
of Internet legislation yet introduced.
<p>
Encryption uses a mathematical key to scramble and
unscramble digital messages so they can be read only by
their intended recipients and not by human or electronic
snoopers. Legislation about this powerful technology is
especially important when viewed in light of two laws
already on the books.
<p>
One of these, the Digital Telephony Act, signed into law in
1994, allows Federal law-enforcement agencies to update the
telephone network with the most pervasive surveillance
equipment in history.
<p>
The other, the freshly signed Communications Decency Act,
bans "indecent" material from the Internet. It is a law
that many legislators seemed to feel was on shaky ground
even as Congress was passing it. A constitutional challenge
to the law is currently being heard in Federal District
Court in Philadelphia.
<p>
Though the encryption bill as written is receiving
qualified support from industry and civil libertarians,
some worry that changes made in committee could make the
bill too restrictive, completing a triumvirate of Big
Brother legislation that would give law enforcement the
ability and rationale to monitor all the electronic
messages of citizens, leaving little or no recourse for
private or secure communication.
<p>
Such restrictions threaten to suffocate the Internet. As
new users and businesses flock daily to the Internet, their
need to protect confidential business data and messages
becomes a key issue in making the Net safe enough to be
useful. Computer security experts say that many of today's
problems on the Net -- minors getting access to
pornography, security breaches of corporate data, the need
to prove one's identity -- could be solved by using
encryption.
<p>
Today, using encryption of any kind is still perfectly
legal inside the United States. Historically, it was mostly
used to protect secret military communications, so the
technology is still classified as munitions -- the same
threat to national security as a boatload of artillery
shells. Thus any products containing encryption are subject
to strict export controls.
<p>
Law-enforcement and national security officials say that
widespread use of strong encryption would enable terrorists
and organized-crime syndicates to communicate with
impunity. They say export control is the only way to keep
this genie in its bottle, at least when it comes to
foreign, not domestic crime.
<p>
In addition, security experts have persuaded the Clinton
Administration to propose an encryption method called "key
escrow" that would give the Government access to
information even after it had been encrypted. Key-escrow
systems generate a decrypting key that is held by a trusted
third party. When law-enforcement agents show up with a
court warrant, the trustee hands over the key to unlock the
message.
<p>
So far, the Clinton Administration's proposals, which
include a key-escrow system called Clipper have been
universally reviled by both civil libertarians and the
computer industry, which claims it stands to be deprived of
up to $60 billion annually by the year 2000 because of
export controls. They argue that any country today can make
and sell encryption products stronger than what can be
legally exported from the United States and that people
won't use a system like key escrow because it has a
built-in security compromise.
<p>
One defender of key-escrow policy is Dorothy Denning, a
professor of computer science at Georgetown University and
a consultant to the military industry. She argued in a
letter to Senator Patrick J. Leahy Democrat of Vermont --
one of the sponsors of the new legislation -- that such a
system was vital to public safety and security.
<p>
James Barksdale, president of the Netscape Communications
Corporation, whose popular Web-browser software has
built-in encryption capabilities, called Ms. Denning's
solution a "stopgap measure."
<p>
"Key escrow is an unworkable idea, and we do not support
it," Mr. Barksdale said. "Key escrow will be defeated just
like Prohibition was defeated by bathtub gin -- all it took
was a big bag of sugar and a long weekend."
<p>
Policy watchdogs like the 
<a href="http://www.cdt.org">
Center for Democracy and Technology </a>
and the  <a href="http://www.eff.org">
Electronic Frontier Foundation, </a>
both
outspoken advocates for privacy rights and due process,
agree that the bill is headed in the right direction. It
does not dictate the use of a key escrow system, eases
export controls for "mass market" products (like
Netscape's), prohibits any restriction on the domestic use
or sale of encryption, and provides a "personal use" policy
for American travelers who use encryption while outside the
country.
<p>
But the bill is sure to face a fight as it moves through
the House and the Senate, and the key-escrow and
export-control proponents marshal their experts.
<p>
David Farber, a professor of computer science at the
University of Pennsylvania and a board member of the
Electronic Frontier Foundation, says encryption policy
always turns into "a religious discussion" between those
who fear terrorism and those who want to live without fear
of constant surveillance.
<p>
But, he adds, if you take privacy discussions to the
people, their attitudes are pretty clear. " If you ask the
American public what they think of national I.D. cards, for
example, a huge percentage are opposed to them," he said.
"Why? They're not hiding anything. They just don't want the
Government to have that type of power."
<p>
[End]
<p>
<hr>
Back to <a href="./nist951205.html">Pat's page on the December 5 NIST Clipper 2 </a>
meeting. 
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
March 25, 1996
Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">
Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-132</DOCNO>
<DOCOLDNO>IA053-000895-B043-218</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/geek/sliderule.html 129.174.40.15 19970123194741 text/html 1277
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:46:27 GMT
Server: NCSA/1.5.2
Last-modified: Sat, 12 Oct 1996 16:30:35 GMT
Content-type: text/html
Content-length: 1094
</DOCHDR>
<HTML>
<HEAD>
<TITLE>What is a sliderule?
</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<body background="./sliderule.jpg">
<h2>The real answer is:</h2>
If you have to ask, you're too young to understand.
<h2>A more meaningful answer is:</h2>
An expensive stick used to add (or subtract) numbers. 
When you add logarithms of numbers, you multiply. Subtract to divide.
When you add logarithms of the logarithms of numbers, you can do
exponentiations.
<p>
The stick can be made of a number of materials. Cheap ones were plastic.
Better ones were bamboo, or ivory covered bamboo.
<p>
Serious <a href="./geek.html">geek</a> sliderules had twenty 
or more scales. Pat had, of course, a very serious sliderule in 1969.
<p>
Sliderules became practically obsolete by 1970, by 1974 they were used only
by old-timers. Pat still has his as a symbol of his geekdom.
<p> 
<a href="http://www.ozemail.com.au/~gamers/adavie/slide/">
Lots more on sliderules</a>
<hr>
<P>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
June 5, 1995
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-133</DOCNO>
<DOCOLDNO>IA053-000895-B045-169</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/nyt951108.html 129.174.40.15 19970123195546 text/html 3239
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:54:32 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:14:22 GMT
Content-type: text/html
Content-length: 3056
</DOCHDR>
<HTML>
<head>
<TITLE> 
Industry Group Rebuffs U.S. on Encryption
</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
<!From: John Young jya@pipeline.com >
</head>
<body>

<H1>
Subject: Industry Group Rebuffs U.S. on Encryption
 </H1>
   <h2>The New York Times, November 8, 1995. </h2>
<p>

   Industry Group Rebuffs U.S. On Encryption
<br>
   By John Markoff
<p>

   The campaign by the Clinton Administration to create a
   standard for data encryption acceptable to industry, civil
   liberties and law enforcement groups broke down yesterday
   when a group including some of the nation's most powerful
   technology companies rejected a compromise proposal.
<p>
   The aim is to set a policy that meets the needs of
   electronic commerce as well as the concerns of the National
   Security Agency and other Federal offices that are opposed
   to the proliferation of data-coding software, feeling it
   will make it impossible for them to gather intelligence
   overseas.
<p>
   The Administration offered a compromise plan and had been
   seeking comment from the public. But the industry coalition
   said yesterday that it found the Government unwilling to
   compromise. Thus, the group of 37 companies said, it would
   formulate its own policy proposal to present to the White
   House and to Congress in the next six months.
<p>
   High-technology industries want a data-coding standard
   secure enough that both businesses and overseas customers
   could use it for sensitive financial and business
   correspondence. They seek a longer and more powerful
   encryption key than the Government is willing to grant, and
   object to Government demands that law enforcement agencies
   have "back-door" access to such transmissions that would
   allow them to intercept coded messages.
<p>
   The letter is signed by several of the country's leading
   computer, software and on-line companies, among them
   America Online, Apple Computer, AT&T, Eastman Kodak
   I.B.M.'s Lotus Development division, MCI Communications,
   Microsoft, Novell, Oracle Sybase and Tandem Computers.
<p>
   On Aug. 17, the Administration proposed a liberalization of
   export-control procedures for "key escrow" software
   products, or those providing law-enforcement access.
<p>
   "The current policy directive also does not address the
   need for immediate liberalization of current export
   restrictions," the letter said "Such liberalization is
   vital to enable U.S. companies to export state-of-the-art
   software products during the potentially lengthy process of
   developing and adopting a comprehensive national
   cryptography policy."
<p>
   [End]


<p>Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
Novermber 9, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>


</DOC>
<DOC>
<DOCNO>WT03-B24-134</DOCNO>
<DOCOLDNO>IA053-000895-B046-78</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/tech/smallplus.html 129.174.40.15 19970123195853 text/html 24339
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:57:42 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 20 Dec 1995 18:38:44 GMT
Content-type: text/html
Content-length: 24155
</DOCHDR>
<HTML>      
<BODY bgcolor="FFFF80">
<head>
<title>Pat Farrell's Views on C++ versus Smalltalk</title>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
Under Construction. Feedback welcome.
<h1>Language Wars Considered Harmful</h1>
Many folks within AMS think that Smalltalk is "the AMS Standard."
This is simply not true. What is true is that the first version 
of Object Core was written in Smalltalk, and some of 
the early OO work at AMS was written in one or another flavor of
Smalltalk. However, AMS uses lots 
of tools to build systems.
<p>
Popular tools used by AMS include:
<ul>
<li>C++
<li>PowerBuilder
<li>Visual Basic
<li>plain old C
<li>Cobol
</ul>
There is currently a large effort to build C++ ObjectCore. The first 
release was shipped to internal AMS projects on September 1, 1995.
<p>
<h2>Abstract</h2>
It is counterproductive to talk about comparing the <strong>languages</strong>
C++ and Smalltalk. We do not develop in a language, we develop in
a programming environment. 
The programming environment includes obvious components such as
the language, compiler, debugger, 
editor, source code revision system.
It also includes any existing program code such as copylibs, macros or
pre-existing objects.
<p>
Mathematician and Computer Science
pioneer Alan Turing proved that all languages are effectively identical,
their results can be mapped to a Turing machine. What is important to
managers and developers is the effectiveness of the programming environment.
<p>
I believe that the decision to select a specific tool is often
flawed because the decision makers do not understand the impact of
two critical factors:
<ul>
<li>The selection of criteria and their weighting drives the selected 
solution without regard to the merit of the competing products. Once
the criteria are selected, so it the answer. And
<li>The decision can only be made according to the facts that are true
at that single point in time. The rapid advances in the computer industry
frequently result in changes that obsolete the analysis within months
of its completion.
</ul>
The global AMS community is slowly beginning to realize 
that the 1992 Smalltalk versus C++
decision was not final. Most of the folks who took part
in that decision process knew this then.
This paper is a modest attempt to bring 
that discussion into a more current realistic perspective and distribute 
it to a wider audience.
<h2>History</h2>
AMS' decision to implement early OO systems in Smalltalk was strongly 
influenced <i>Criteria for Comparing OO Languages</i>  by 
John Baker and Jim Talvitie, published internally on May 21, 1992.
This paper presents criteria for analysis in the style of Milt Hess' famous 
<i>Writing Decision Paper</i> guide.
<p>
Unfortunately, Baker and Talvitie's paper did more than just define
the criteria. It also attempted to make some judgment of the competing
products. I believe that when there are large numbers of criteria (in this
case, more than 20 pages of them), that the specification of
the criteria and the evaluation of alternatives against those criteria
should be separate activities. As they said in their paper:
<pre>
    "In many cases, these guidelines are contradictory and more
     elaborate criteria must be considered."
</pre>
<p>
With the paper, Baker and Talvitie presented the following criteria "as a
starting point."
<ol>
<li>Productivity
<li>Development Environment
<li>Simplicity
<li>Support for Distributed Processing
<li>Interoperability with other Languages
<li>Flexibility
<li>Portability
<li>Reusability of Code
<li>Performance
<li>Encapsulation
<li>Database Support
<li>Integration with GUI Tools
<li>Prepackaged Code Libraries
<li>Industry Acceptance.
</ol>
While I feel that this list has considerable duplication that results in 
<a href=#Biases>biases[1],</a> <a name="backBiases">
and that the <a href=#Ordering>ordering[2]</a>
<a name="backOrdering">implies a relative weight that is inconsistent
with AMS' real-world implementation experiences, this list can serve
as a valid <i>starting point</i>.
<p>
One critical problem is that some of these criteria are extremely time
sensitive. The developments of the past three and a half years
have not been kind to their assessments on criteria such as 
"Integration with GUI Tools,"  "Prepackaged Code Libraries," and
"Industry Acceptance." 
<p>
There is a more fundamental problem with Baker and Talvitie's criteria and 
subsequent analysis: they suggest that execution performance is not the
most vital criteria. As I pointed out at the time, AMS' experience
has shown that run-time execution speed of the application is critical.
Slow application are not accepted by users. Batch systems that take twenty
hours to do the "nightly" processing are not accepted. Performance counts.
It is not the only criteria, but it has always been vital for success,
and will remain so
for the foreseeable future. 
<h1>It is not the language, it is the development environment</h1>
Since it is impossible to evaluate languages, we have to evaluate
specific products that implement the language. I have <a href=#Experience>
professional experience[3]</a>
 with<a name="backExperience">:
<ul>
<li>Microsoft Visual C++
<li>Borland C++
<li>ParcPlace VisualWorks
</ul>
Within this document, I will differentiate between artifacts of the
specific implementation, and differences that are architectural.
Of course, as IBM's release of VisualAge (a true compiler for
their Smalltalk implementation) shows, even the architectures can change.
<h2>Performance</h2>
In their paper's section on performance, Baker and Talvitie write:
<p>
"One cannot easily compare languages on performance <i>per se,</i>
since performance depends upon how the language is used. A badly performing
system can be written in any language."
<p>
These two sentences are true. But they imply that it is acceptable
to ignore the essential performance differences between implementations.
A more reasonable evaluation can be made if you ask a question similar to:
"What are the differences between the execution performance of 
implementations that are identical except for the tools used? If we code
two solutions to the same problem, and expend a 
<a href=#SimilarEffort>similar amount[4] </a> 
<a name="backSimilarEffort">
of tuning effort, can we expect to see significant 
differences?" This is the question
that is critical when (and it is not a question of "if") the 
performance of the system becomes
an acceptance issue.
<p>
The performance characteristics of the implementations depends on a lot of
issues. I would not place nearly as much importance on "degree of support
for static binding" as did Baker and Talvitie. This discussion assumes
that the algorithms are implemented with relative 
parity (not O(n^2) for one language against O(n ln n) for the other).
<p>
For modern computer systems, I believe that the most important
criteria are:
<ul>
<li>Compatibility with the Operating Systems process/thread 
scheduling and management. 
<li>Compatibility with the Operating System's virtual memory management
(VMM) system. All AMS programs are huge. Virtual memory is effective when the 
program has good locality of reference.
<li>Compatibility with the advanced features of modern CPUs, including
parallel instruction execution, speculative execution, register
renaming, etc.
</ul>
VisualWorks has a very arrogant approach to the Operating System. It 
essentially ignores it. It has its own scheduler and process implementation.
Because of its "polling" approach to window and process scheduling,
it is effectively impossible to multi-task VisualWorks with other
applications on a single CPU, even when the operating system supports
preemptive multitasking. VisualWorks simply consumes 100% of the available
CPU. The stories of folks expecting to support many users with X-Terminals
on a Unix system and discovering the feature that a practical limit is
three or four images are legendary.
<p>
It is unclear whether any OO development tool makes any provisions to 
consider compatibility with any VMM.
<p>
All modern C++ compilers know to eliminate the considerable call/return
setup overhead for inlined functions. For small functions, the resulting
code has better locality than it would if they were executed as
traditional subroutines.
<p>
Modern CPUs can only reach their impressive speeds when the code is tuned
for the specific characteristics of the CPU. Hand coded assembler is 
no longer the way to write fast code, only an optimizing compiler can
perform the instruction scheduling, loop unrolling, and graph analysis
functions that are needed to reach peak speed.
<p>
My Smalltalk experience was with VisualWorks, an implementation of Smalltalk that
"compiles" source code into "byte-code" which is a machine independent
encoding that is more compact and faster to execute than pure source code.
This approach was called "p-code" by the UCSD Pascal system. A similar
approach is used by Sun Microsystem's <a href="./java.html">JAVA</a> language. 
Regardless
of the quality of the virtual machine, the execution time will not
approach that of native, compiled code.
There is simply no way that an interpreted language's virtual machine
can perform the required optimizations. 
The Intel Pentium Pro has a nine stage pipeline. Only when all nine stages
are consistently filled can it approach its performance potential.
With the small size of OO routines (in either language) there
will be processor stalls even if all of the functions of the routine
were converted into optimal assembly instructions. The optimization must
look at larger units of work.
Modern CPU performance requires
optimizing compilers. Note: this is an implementation issue, not a language 
issue. VisualWorks, <a href="./java.html">JAVA</a>, and UCSD Pascal are three separate languages.
Additionally, I've been told that IBM's VisualAge Smalltalk actually
produces code that is compiled into true, optimizable, machine instructions.
<p>
<h2>With the benefit of hindsight</h2>
Let's revisit the three that have not aged well. They are:
<ul>
<li>Integration with GUI Tools
<li>Prepackaged Code Libraries
<li>Industry Acceptance.
</ul>
and look at them in some detail.
In 1992, when the paper was written, C++ had some
impact into the Unix world, but the Unix world was
still populated by large, expensive multi-user systems and high-end
workstations.
In the PC world, C++ was virtually invisible,
GUI development was done in C using the Windows SDK -- hardly an OO 
environment. Today, the picture is completely changed. While the
quantitative lead in PC GUI development is held by tools such as
VisualBasic and PowerBuilder, serious work is done with C++, specifically
Microsoft's Visual C++.

<h3>Integration with GUI Tools</h3>
In 1992, C++ GUI tool integration was essentially non-existent.
Today, there are essentially no differences in the ease of design and
implementation of GUI code between the
current Visual C++ (release 4.0) and Smalltalk.
<p>
One could even argue that a complete switch has occured due to Visual C++'s
support for VBX controls. There is a rich market of third party
products that make GUI building in both Visual C++ and VisualBasic
much more productive than the language products themselves.
<h3>Prepackaged Code Libraries</h3>
Code Libraries for C++ are standardized today in a way
few could have foreseen in 1992. Then, Baker and Talvitie 
accurately characterized it as "fairly chaotic." Today, the class library
for mainstream C++ programmers is Microsoft's MFC (Microsoft Foundation 
Classes). I'm not about to try to defend MFC's many warts here, that 
would be clearly out of scope for this document.
<p>
Rather, we need to simply observe the market acceptance of MFC. It is offered
by Microsoft for Windows 3.1x, Windows NT, Windows 95, and for the Macintosh.
It is licensed by several competing compiler vendors including Watcom and
Symatec. It has been ported to the X-Windows/Unix world by 
<a href="./bristol.txt">Bristol Technologies,</a>
and is currently being ported to VMS by Digital.
<a href=" http://www.infoworld.com/pageone/testcenter/49altsol.htm">
(For a mini-review of MFC/Bristol's approach, follow this link)</a>
<p>
Additionally, it is no longer necessary to pick only one class library.
ANSI strings are now part of C++, as are the Standard Template Library
collections. These are supported by all modern C++ compilers. The issue
of code libraries has been replaced by worries about Microsoft's
dominance.
<p>
The concept of focusing on the class library may be outdated. This view that
the libraries are important is traditional for pure OO languages. 
Microsoft's OLE is designed to use a different pattern:  reuse
components that stay encapsulated in separate executables. This allows
reuse between programs written in dissimilar languages. Given the difficulty
of reaching consensus on language choise (see Baker and Talvitie or even this
document as proof), perhaps code libraries are obsolete.
<p>
I expect that until a totally new programming model, such as <a href="./java.html">JAVA</a> on
the Web, can displace Microsoft's overwhelming popularity, MFC is the answer
when the question is "what class library do I use for my C++ work?"
<h3>Industry Acceptance.</h3>
Baker and Talvitie wrote
"At the moment, it seems clear that C++ has wider acceptance, especially, but
not only, in the Unix world." I believe that in today's PC world, MS Visual 
C++ has vastly greater acceptance than all flavors of Smalltalk combined.
<p>
Baker and Talvitie's closing statement in their paper is "The Ultimate
ability of either Smalltalk or C++ to penetrate the
commercial world of AMS clients will probably be decided by factors other
than pure technical merit." I have to give them credit for accurately
forecasting the future. It is Microsoft's marketing power, together with
a couple of lucky breaks (such as adding VBX support into Visual C++)
that have changed the penetration numbers. For now, Smalltalk is
relegated to niche markets.
<h2>Additional criteria to consider</h2>
In addition to the criteria suggested by Baker and Talvitie, I suggest
that any evaluation that takes place now consider the following:
<ul>
<li>Compliance with the native Operating System look and feel. Windows 95 has
a very different look-and-feel. While acceptance has been slow, in a few
years it will be on our customer's desks. VisualWorks did not provide
an accurate Windows look and feel in the four years between Windows 3.0 
release (May 1990) and when I stopped developing using the package (December
1994). How long will our customers be willing to delay requiring Win95?
<li>Timeliness of the vendor's acceptance of new industry developments.
Microsoft's pushes into new technology for component reuse,
such as OLE, OLE automation, and
distributed OLE, will be expected by our customers.
When will the toolsuite support these developments?
<li>Cost premium afforded skilled staff with experience with the tools.
Staff experienced with OO tools are expensive. What level of premium 
are we willing to pay? How do we trade off these premiums against
vendors' claims of increased productivity?
</ul>
<h2>Dead Issues</h2>
Issues that only fan the flames rather than showing light.
<p>
Over the past few years, the C++ community has liberally copied good ideas 
that were once exclusively the property of Smalltalk. C++ has 
run-time-type-interface (RTTI) which provides the delayed binding
that Smalltalk provides. Even before it supported RTTI, Microsoft's Visual C++
provided a dynamic runtime facility.
The class browser of Microsoft's Visual C++ 4.0
is comparable to that on VisualWorks. Several companies offer products that
replace the C++ memory management system with a Smalltalk-style
garbage collection system. For example, look at
<a href="http://www.geodesic.com">Geodesic system's</a>
<p>
Similarly, the speed of the edit-compile-link-debug cycle has improved
dramatically in C++ implementations with the use of precompiled headers, 
incremental compilation and incremental linkers. Smalltalk, like other 
interpreted languages used to have a substantial advantage. I recently timed
the compile-link-debug cycle time at less than six seconds 
for a Windows program using MSVC4.0 on
my old 486/66. 
The program used all of the huge Win32 header heirarchy, which takes a very
long time to compile from scratch. Smart implementations have removed this
as an effective criteria for discrimination. 
<p>
One prime issue used to be that C++ supported multiple inheritance (MI).
This issue has considerably less interest today. MI
is at best a very dangerous tool. I've worked on two projects that
tried to use MI, both pulled it out as unworkable.

<h2>An Issue that I wish were dead: portability</h2>
Portability is a major issue. It is much more of an issue for
AMS than for most other software developers because of the nature
of our client base. A large percentage of AMS' customers are
in one of the following groups:
<ul>
<li>The US Federal Government;
<li>Telecommunications firms; and
<li>Educational Institutions.
</ul>
These three groups are about the only computer users in existance that still
think that Unix is viable on the desktop. The majority of the rest
of the industry simply puts a version of Windows on the desk and moves
on.
<p>
Portability is expensive. It is easy for the customers to specify, and
it is very hard to deliver.
<p>
Portability of the desktop application is an area that Smalltalk claimed to
own when Baker and Talvitie's paper was written.
And at a high level, VisualWorks Smalltalk delivered. It was possible
to take a Smalltalk image (program) file, move it to a new platform, and
execute it. There were very few changes needed, demonstrably better than
any C or C++ implementation that I've worked with.

<p>
This portability came at a significant price, primarily performance
and compliance with the native look-and-feel. As mentioned above, 
VisualWorks only approximated the native look and feel of the underlying
operating system. The application worked the same on all platforms. 
It never matched the
expected look and feel of other, native applications. This became a serious
acceptance criteria when FMS was delivered to Columbia University.
<p>
The current C++ Object Core development team is committed to delivering
identical functionality on three platforms, Sun Sparc with Solarias, 
HP PA with HP/UX, and Windows NT. While we don't have exact figures
on the cost of writing, porting, testing, and maintaining the codebase
on the three platforms, I estimate it as at least 30% of the total project
effort. I could believe that it has cost as much at 50% of the total
project effort. What I can't tell is whether or not this increase
in cost was worthwhile. In a year, I expect that the penetration of
Windows NT Servers will be significant. Would a decision to write only 
for Windows NT appear better then? Only time will tell.

<h2>Where are we now, using the 30 month old criteria?</h2>
In the interest of time, I haven't revisited every criteria. You can either
accept my quick assessment, or invent your own. You might even
be able to convince me to change some of these.
<p>
The fact that this document doesn't go into depth on a criteria doesn't mean
that it should be ignored. For example, I feel that the 
encapsulation that C++ compilers
require for "private" functions and variables is much more powerful
than the Smalltalk protocol of labeling a group of functions "private" and
hoping that no programmer looks behind the curtain.
<CENTER>
<TABLE COLSPEC="C20 C20 C20 C20" BORDER=2>
<TR><TD>Critieria for Comparing OO Languages.
</td><td>MSVC++</td>
<td>Visual Works</td></TR>
<TR><TD>Productivity</td><td> = </td><td> =  </td></tr>
<TR><TD>Development Environment</td><td> = </td><td> = </td></tr>
<TR><TD>Simplicity</td><td> - </td><td>  + </td></tr>
<TR><TD>Support for Distributed Processing</td><td> + </td><td> . </td></tr>
<TR><TD> Interoperability with other Languages</td><td> + </td><td>only C-style</td></tr>
<TR><TD> Flexibility</td><td> + </td><td> . </td></tr>
<TR><TD>Portability</td><td> +  </td><td> ++ </td></tr>
<TR><TD>Reusability of Code</td><td> = </td><td> = </td></tr>
<TR><TD> Performance</td><td> ++  </td><td> - </td></tr>
<TR><TD> Encapsulation</td><td> + </td><td> . </td></tr>
<TR><TD>Database Support</td><td> + </td><td> . </td></tr>
<TR><TD>Integration with GUI Tools  </td><td>= </td><td> = </td></tr>
<TR><TD>Prepackaged Code Libraries  </td><td>= </td><td> = </td></tr>
<TR><TD>Industry Acceptance. </td><td>  +++ </td><td> -  </td></tr>
</TABLE>
</CENTER>
Then adding in the additional criteria described in this paper.



<CENTER>
<TABLE COLSPEC="C20 C20 C20 C20" BORDER=2>
<TR><TD>New Critieria for Comparing OO Languages.
</td><td>MSVC++</td>
<td>Visual Works</td></TR>
<TR><TD>OS scheduling and management. </td><td> + </td><td> -  </td></tr>
<TR><TD>virtual memory management(VMM).</td><td> + </td><td> - </td></tr>
<TR><TD>Optimizing compiler</td><td> + </td><td>  - </td></tr>
<TR><TD>OS Native Look and Feel</td><td> ++ </td><td> - </td></tr>
<TR><TD>Timeliness of new developments</td><td> + </td><td> - </td></tr>
<TR><TD>Cost premium for Staff</td><td> ? </td><td> ? </td></tr>
</TABLE>
</CENTER>
<h2>Conclusion</h2>
It is counterproductive to talk about comparing the <strong>languages</strong>
C++ and Smalltalk. We do not develop in a language, we develop in
a programming environment. 
The programming environment includes obvious components such as
the language, compiler, debugger, 
editor, source code revision system.
It also includes any existing program code such as copylibs, macros or
pre-existing objects.
<p>
Given the competitive nature of the computer industry, rapid advances
are being made in the quality of development environments. We must be aware
that we are shooting at a moving target. Even this document is probably
dated as it is written. After a few months pass, any product specific
information will be outdated.
<p>
The global AMS community is slowly beginning to realize 
that the 1992 Smalltalk versus C++
decision was not final. Most of the folks who took part
in that decision process knew this then.
This paper is a modest attempt to bring 
that discussion into a more current and realistic perspective.
By using the WWW, I hope to distribute 
it to a wider audience.
<hr>
<h2>Footnotes</h2>
<a name="Biases">
[1]<br>
For example, if the weighting is uniform, then by repeating areas
such as productivity, simplicity, and Integration with GUI tools
as three separate topics, they have three times the weight as
a topic, such as performance, that is not repeated. If the weightings
are ordered more heavily towards the top of the list, since productivity is
number one, and simplicity is number three, the effect is even stronger.
<a href=#backBiases>Back to the text</a><br>
<a name="Ordering">
[2]<br>
I find the placement of Performance as 8th out of 14 as
wildly inconsistent with AMS experience. And making Industry
Acceptance dead last would imply that we prefer to build everything
ourselves -- hardly a prescription for reuse.
<a href=#backOrdering>Back to the text</a><br>
<a name="Experience">
[3]<br>
I define professional experience as AMS paying me to write programs in a specific 
language.
<a href=#backExperience>Back to the text</a><br>
<a name="SimilarEffort">
[4]<br>
Here is an example of how criteria are interdependent.
If one tool provides superior productivity, it is possible that
the development will be done much more quickly, allowing
for a greater amount of tuning effort without exceeding the
development budget. This assumes that we haven't already
spent the development savings elsewhere.
<a href=#backSimilarEffort>Back to the text</a><br>


<hr>
Copyright (c) 1995, Patrick Farrell, all rights reserved.
<hr>
<A HREF="./disclaimer.html"> PDF</a> 
December 18, 1995  
  Backto <a href="./default.htm">Pat's AMS Intranet page</a>
  Backto <a href="./hotlist.html">Pat's hotlist</a> 
  Backto <a href="./biopage.html">Pat's Biographic page </a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-135</DOCNO>
<DOCOLDNO>IA053-000895-B045-402</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/government/exec.html 129.174.40.15 19970123195807 text/html 4249
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:56:52 GMT
Server: NCSA/1.5.2
Last-modified: Sat, 09 Sep 1995 15:38:10 GMT
Content-type: text/html
Content-length: 4066
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Pointer to US Federal Executive Branch</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
I have tried to put agencies in the proper branch. For example, the Library
of Congress and the GAO are <a href="./congress.html">Legislative, </a>
not executive agencies.
<H1>Executive Branch resources and pointers</h1>
<p>
<ul>
<li>Look at Bill at the <A HREF="http://www.whitehouse.gov/">White House</A>
<h2>Cabinet level agencies</h2>
<li><a href="http://www.usda.gov"> Agriculture (USDA)</a>
<li><a href="http://www.doc.gov"> Commerce</a> Favorite DOC agencies:
<ul>
<li><a href="http://www.census.gov">Census Bureau</a>
<li><a href="http://www.noaa.gov">NOAA</a>
<li><a href="http://www.nws.noaa.gov">Weather forecasts</a>
<li><a href="http://www.nist.gov">National Institute of Standards and Technology</a> (Formerly National Bureau of Standards.)
</ul>
<li><a href="http://www.dtic.dia.mil/defenselink"> Defense</a>
 the Four Services:
<ul>
<li><a href="http://www.dtic.dia.mil/airforcelink">Air Force</a>
<li>Army
<li>Marines
<li><a href="http://www.ncts.navy.mil">Navy</a>
</ul>
<li><a href="http://www.ed.gov"> Education</a>
<li><a href="http://www.doe.gov"> Energy</a>
<li><a href="http://www.os.dhhs.gov"> Health and Human Services </a>
<li><a href="http://www.hud.gov"> Housing and Urban Development</a>
<li><a href="http://www.usgs.gov/doi"> Interior (although this is at USGS)</a>
<ul>Agencies in DOI
<li><a href="http://www.blm.gov">Bureau of Land Management (BLM)</a> aka
the Land Office.
<li>Minerals Management Service
<li>Bureau of Reclaimation
<li>Bureau of Indian Affairs
<li><a href="http://www.usgs.gov">US Geological Survey</a>
</ul>
<li><a href="http://www.usdoj.gov"> Justice</a>
<li><a href="http://lcweb.loc.gov/global/executive/labor.html"> Labor</a>
<li><a href="http://www.dosfan.lib.uic.edu/dosfan.html"> State (unofficial)</a>
<li><a href="http://www.dot.gov"> Transportation</a>
<li><a href="http://www.ustreas.gov"> Treasury</a>
<li><a href="http://www.va.gov"> Veterans Administration</a>
<h2>Other agencies and offices</h2>
<li><a href="http://www.ssa.gov">Social Security Administration</a> Will
it be broke when I retire? you bet!
<li><a href="http://www.fda.gov">Food and Drug Administration</a>
<li><a href="http://www.gsa.gov">General Services Administration</a> the procurement folks.
<li><a href="http://www.nh.gov">National Institues of Health</a>
<li><a href="http://www.usps.gov"> US Postal Service</a>
<li><A HREF="http://www.odci.gov">CIA</A> the local spooks, just down the road
<li><A HREF="http://www.fbi.gov">FBI</A> is downtown, 20 minutes away 
<li>the <a href="http://www.nsa.gov:8080/">NSA</a> International spooks,
 arround the Beltway a bit
<li>the 
<a href="http://www.nsa.gov:8080/museum">National Cryptographic Museum</a> is next door to NSA
<li><a href="http://www.si.edu/">Smithsonian Institute</a> (not Institution!)
<li><a href="http://www.yahoo.com/Government">Lots of US Government</a> pages.
<li><A HREF="http://shuttle.nasa.gov">NASA Shuttle shots</A>
<h2>Related sites of interest</h2>
<li><a href="http://www.abanet.org"> American Bar Association </a>
<li><a href="http://broadway.vera.org/pub/ocjsites.html"> Criminal Justice Sites</a>
<li><a href="http://www.embasy.org"> Embassies</a>
<li><a href="http://www.odci.gov/ic"> Intellegence community</a>
<li><a href="http://www.yahoo.com/government/judicial_branch"> Judicial 
sources list from Yahoo</a>
<li><a href="http://www.nra.org"> the National Rifle Association</a>
<li><a href="http://copnet.uwyo.edu"> Police Departments (copnet) </a>
<li><a href="http://www.cs.oberlin.edu/students/pjaques/prison/home.html"> 
Prisoners</a>
<li><a href="http://www.law.indiana.edu/law/lawindex.html"> Virtual Law Library</a>
</ul>
Back to Pat's <a href="./usgov.html">overview page</a>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 1, 1995.  Backto <a href="../hotlist.html">Pat's hotlist</a> Backto <a href="../index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-136</DOCNO>
<DOCOLDNO>IA053-000895-B045-122</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/nist951205.html 129.174.40.15 19970123195519 text/html 3409
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:54:09 GMT
Server: NCSA/1.5.2
Last-modified: Sat, 23 Mar 1996 14:04:12 GMT
Content-type: text/html
Content-length: 3226
</DOCHDR>
<HTML>
<head>
<TITLE>December 5 Clipper II meeting </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
<H1> Clipper II, meeting December 5 1995 </H1>
Dispite the complete lack of industry support for Clipper II, aka Key Escrow,
<a href="./nist950906.html">(documented on my Sept 6-7 page)</a>
the Clinton administration is pressing ahead.
<p>
An earlier version of this page said: 
<blockquote>" The complete NIST proposal is available at:

 <a href="http://csrc.ncsl.nist.gov/keyescrow/criteria.txt">
 http://csrc.ncsl.nist.gov/keyescrow/criteria.txt</a> "
</blockquote> but this is
<strong>not true.</strong> That page contains only the criteria for products
that can be approved. If  you read it, you'll see that parts are still
prety vague.
<p>
NIST held a meeting to discuss the
proposed exportability criteria for the 64-bit software key escrow
encryption on December 5. According to NIST, "this meeting continues the
industry-government dialog of an earlier NIST-sponsored meeting held in
September." I think a more accurate statement is that the government 
continued to go through the motions of pretending to listen to industry.
The <a href="./crit56.html#opinion">sad comment</a> that I 
made about the September meeting is still true.
<p>
Official NIST Information on the December 5 meeting is available at:
 <a href="http://csrc.ncsl.nist.gov/keyescrow/dec5.html">
 http://csrc.ncsl.nist.gov/keyescrow/dec5.html</a>
At the meeting, the government presented their 
<A href="./escagent.html"> criteria for "acceptable"
escrow agent entities.</a> 
This document was not made availble before the meeting.
I have manually typed in a copy from the hardcopy that was handed out.
<ul>
<li> <a href="./pdf.nist2.html">My HTMLized writeup of the meeting</a>
 It is about 37KB of text.
<li><a href="http://home.netscape.com/newsref/ref/encryption_export.html">
Netscape's public statement on GAK</a>
<li><a href="http://www.cdt.org/">CDT's statement for the record</a>
<li>a review of the proposed NIST export
written before the meeting <a href="http://www.hotwired.com/wired/3.11/departments/cyber.rights.html">Brock Meeks' column in the November 1995 issue
of Wired.</a>
<li> Martin Marietta Energy Systems' <a href="./dec5sum.html">
 summary of the December meeting.</a>
 It was prepared by someone (so far unnamed) from
Martin Marietta Energy Systems, Inc.
<p>
Ancient documents, obsoleted by the above html document
<p>
<li> My <a href="./pdf.nist2.short.html">initial summary </a>
<li>
Part one of my long posting (on criteria)
<a href="./long1.txt"> (ASCII as posted to cypherpunks) </a>
<li><a href="">Part two, on the agent criteria</a>
<li><a href="long3.txt">Part three, on the industry presentations 
(ascii, PGP signed)</a>
<li><a href="./part1.html">An HTML'd version of my long posting.</a>
</ul>
<p>
<p>Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
January 2, 1996  
Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-137</DOCNO>
<DOCOLDNO>IA053-000895-B047-159</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/pdfopinion.html 129.174.40.15 19970123200349 text/html 2764
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:02:38 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:09:16 GMT
Content-type: text/html
Content-length: 2581
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Short opinion overview</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>Short opinion of the NIST GAK meeting</H1>
The Clinton Administration is revising parts of the ill-advised and 
ill fated Clipper initiative. The key action was a two day long
meeting on key escrow and export regulations that took place
September 6 and 7, 1995. 
<p>
It is my belief that this meeting was a staged presentation. 
Nearly every industry representative said that this was a fatally flawed
idea. It was "a non-starter." The government
representatives said that they heard the comments, but insisted
on proceeding.
<p>
It is clear to me that the government intends that industry provide crippled
encryption "for export." Never stated was the expectation that since
industry has repeatedly said that they want only one version worldwide 
of products, that Domestic products will be crippled. The testimony
of  Geoff Greiveldinger (from the US Justice Department) was focused
on domestic crime -- if the meeting was about export, why the focus
on domestic areas?
<p>
It is equally clear from representatives of IBM, Compaq, DEC, Lotus, and
others that I talked to, that crypto product development will
simply move offshore. Ireland, Israel, and Germany already have
significant experience in developing commercial software.
<p> 
It is depressing to hear our Commerce department chasing technology and
jobs overseas.
<p>
I believe that strong encryption is necessary for security, privacy, and
authentication for client/server systems. It wasn't 
needed for mainframe systems.
It is critical for client/server systems. But todate, few client/server systems
are operational, and those have only modest size. As a result,
the need for security, privacy, and authentication is not
recognized by the purchasers of software systems. It will take some
public failures before the need is recognized and accepted. With the
policies that the Clinton Administration is pushing onto a very 
reluctant industry, the development of these critical tools 
will occur outside the US.

<hr>
Follow this 
<a href="./crit56.html#opinion">link to a longer comment</a>
that was submitted to NIS&T.
<p>
Back to Pat's <a href="../nistmeeting.html">NIS&T Key Escrow Export page</a>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 16, 1995.  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-138</DOCNO>
<DOCOLDNO>IA053-000894-B003-262</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/cdt_policy.html 129.174.40.15 19970123201146 text/html 15991
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:10:35 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:17:32 GMT
Content-type: text/html
Content-length: 15807
</DOCHDR>
<html>
<head>
<title>CDT Policy Post No. 24 -- Administration's New Crypto Conference 
Flops at Conference</title>
</head>
<body>
<pre>

------------------------------------------------------------------------
   ******    ********    *************
  ********   *********   *************
  **         **      **       ***               POLICY POST
  **         **      **       ***
  **         **      **       ***               September 11, 1995
  **         **      **       ***               Number 24
  ********   *********        ***
   ******    ********         ***

  CENTER FOR DEMOCRACY AND TECHNOLOGY
------------------------------------------------------------------------
  A briefing on public policy issues affecting civil liberties online
------------------------------------------------------------------------
CDT POLICY POST Number 24                       September 11, 1995

CONTENTS: (1) Administration's New Crypto Policy Flops At Conference
          (2) The Administration's Proposal
          (2) Subcribe To The CDT Policy Post Distribution List
          (3) About CDT, Contacting Us

This document may be re-distributed freely provided it remains in its
entirety.
------------------------------------------------------------------------

(1) ADMINISTRATION CRYPTO POLICY FLOPS AT CONFERENCE

On September 6 and 7, the Clinton Administration unveiled a new national 
cryptography policy at a conference sponsored by the National Institute 
of Standards and Technology (NIST). 

CDT believes that the new proposal fails to provide adequate privacy 
protection, would effectively eliminate the domestic market for non-
escrowed encryption applications, and is weighed too heavily toward the 
interests of the National Security Agency.

The administration has proposed to relax export controls on 
cryptographic applications (both software and hardware) with key lengths 
up to 64 bits provided that:

* The keys required to decrypt a message or file are escrowed with an 
  agent certified by the US government (including private entities)

* The product does not decrypt messages or files encrypted with non-
  escrowed products or products whose escrow mechanisms have been 
  altered or disabled.

* As well as eight other criteria (the proposal is attached below).

NEW PROPOSAL FAILS TO ADHERE TO CRITERIA IN GORE LETTER TO CANTWELL.

In a July 1994 letter to then Representative Maria Cantwell, Vice 
President Gore announced that the Administration intended to re-examine 
its cryptography policy. The Gore letter, which was widely viewed as an 
abandonment of the Clipper Chip Government Key Escrow scheme, pledged to 
develop a policy framework that would promote the development of 
encryption systems that would meet the following criteria:

* Implementation in hardware of Software
* Public, Unclassified Algorithms
* Voluntary
* Forth Amendment privacy Safeguards
* Statutory liability rules to protect users
* Multiple Escrow Agents

On hearing that the Administration had set out to develop a new 
encryption policy based on the principles outlined in the Gore letter, 
the Center for Democracy and Technology was guardedly optimistic that a 
genuine policy breakthrough was possible.  However, having had the 
opportunity to review the current proposal, every principle, except the 
first (software implementation) and second (public algorithms), outlined 
in the July 1994 letter is violated or, in one case, left in doubt, by 
the September 1995 policy statement.

The September 1995 policy statement diverges from the July 1994 letter 
in the following critical respects.  In our view, these divergences 
represent fundamental defects in the proposed policy.

* NOT VOLUNTARY:  The current proposal effectively compels all domestic 
  users to use key escrow systems if they ever intend to communicate 
  internationally.  Point 6 of the export criteria requires that an 
  exportable system must not interoperate with any system that non-
  escrow systems.  Thus, in order for a user in the United States to 
  communicate with anyone who uses a United States-made system on the 
  Internet but outside of the United States, the American user must 
  employ a key escrow system.  Domestic users are not legally compelled 
  to use key escrow products, but the proposed policy forces, in 
  practice, all but the most insular Internet user toward a key escrow 
  system. Moreover, this proposal further illustrates that the 
  Administration seeks to use export controls to push the domestic use 
  of escrowed cryptography. A policy based on such compulsion can hardly 
  be called voluntary. 

* INADEQUATE SECURITY:  Point 1 precludes export of systems with key 
  lengths beyond 64 bits.  Though this key size is larger than what is 
  currently exportable, it is a level of security already judged 
  inadequate for some applications.  Given the rate at which computing 
  power increases, even a 64 bit key would be subject to attach before 
  long. Ironically, even the Clipper Chip provided a stronger (80 bit) 
  key length

  The premise of the key escrow policy is to provide law enforcement 
  and national security agencies a "front door" to be used to decrypt 
  messages when the agency obtains proper legal authorization.  Yet, the 
  architects of the current policy apparently are not willing to trust 
  that key escrow systems will meet law enforcement needs inasmuch as 
  the key length limit suggests that the Administration is intent on 
  maintaining an extra-legal method of decrypting communications.  The 
  Gore letter contains no suggestion that key escrow systems would also 
  be subject to key length limits but the Administration seems to have 
  lost faith in its own proposal.  Such a half-hearted effort cannot be 
  the basis of a long-lasting policy.

* NO PRIVACY PROTECTION FOR USERS OF ESCROWED SYSTEMS:  The ten export 
  principles make no mention of privacy safeguards which the Vice 
  President previously recognized as necessary to safeguard individual 
  privacy and Fourth Amendment principles.  Any escrow policy must 
  contain safeguards against abuse and statutory liability provisions 
  for the operators of private escrow systems.

* FAILS TO PROMOTE INTERNATIONAL INTEROPERABILITY:  Points 6 and 10 of 
  the export criteria raise grave doubts as to the likelihood that the 
  current proposal will give rise to a secure global communications 
  environment.  Point 10 forces users in other countries (and their 
  governments) to accept United States-based escrow of all keys until 
  bilateral access agreements are entered into.  Such tactics seem 
  unlikely to produce satisfactory international agreements, and hold 
  global communications security hostage to the completion of such 
  agreements.

NSA/ADMINISTRATION SEEK TO RUSH IMPLEMENTATION OF NEW POLICY

The NIST Key escrow conference was billed as an opportunity to begin a 
dialogue between the administration and industry on the new cryptography 
policy. However, as the conference began it quickly became apparent that 
many of the critical policy issues, including the 64 bit key length, 
interoperability with non-escrow products, and some requirements for key 
escrow agents (including whether individuals, corporations, and foreign 
entities are eligible) have already been decided. 

The Administrations attempt to rush many of the critical policy 
decisions drew sharp reaction from virtually all of the conference 
participants, including CDT, other public interest groups, and 
representatives from several major software and hardware manufacturers. 
Although the administration and NSA officials all indicated that they 
got the message, they still intend to publish a revised policy in the 
next 30 days for comment.

INDUSTRY BALKS

Industry reaction to the new policy proposal was, with a few limited 
exceptions, decidedly negative. Both during formal presentations and in 
small group sessions, representatives from several of the largest 
hardware manufacturers and software publishers questioned whether the 
market would support products designed to adhere to the administration's 
proposal, particularly in light of the 64 bit key length limit.

CDT believes that the administration must make every effort to 
accommodate the concerns of the public, civil liberties groups, software 
publishers, hardware manufacturers, users, and other interested parties 
before adopting any new national cryptography policy. The current 
proposal fails to address many of the critical concerns of public 
interest groups and industry, and should be abandoned.

NEXT STEPS

The administration intends to published a revised policy within the next 
30 days (October 7). CDT will closely monitor this issue and will inform 
you as it develops.

PATHS TO RELEVANT DOCUMENTS:

More information, including CDT's testimony from the NIST conference,
other conference documents, etc. can be found at CDT's Crypto Issues 
Page:

URL:http://www.cdt.org/crypto.html

------------------------------------------------------------------------

(2) THE ADMINISTRATION'S NEW CRYPTOGRAPHY POLICY

9/1/95 Proposed Cryptography Policy for Software Key Escrow

Key Escrow Issues Meeting, September 6-7, 1995
Discussion Paper #3

            Export Criteria Discussion Draft --
           64-bit Software Key Escrow Encryption

As discussed at the SPA/AEA meeting on August 17, 1995, the
Administration is willing to allow the export of software
encryption provided that the products use algorithms with key
space that does not exceed 64 bits and the key(s) required to
decrypt messages/files are escrowed with approved escrow agents. 
On the same date, the September 6-7 key escrow issues meeting at
NIST was also announced.  The two principal topics at the meeting
will be:  discussion of issues of exportability of 64-bit
software key escrow encryption and 2) desirable characteristics
for key escrow agents. 

In order to help make most productive use of the limited time
available at the upcoming meeting and to better focus
deliberation, the following criteria are being distributed for
discussion purposes.  Since it is important that final criteria
be clear, straightforward, consistent, and implementable, please
review these draft criteria and be prepared to discuss 
how they may be refined and made more specific.  

                          --- Draft Export Criteria ---

for Software Key Escrow Encryption 

Software key escrow encryption products meeting the following
criteria will be granted special export licensing treatment
similar to that afforded other mass-market software products with
encryption.  

1.    The product will use an unclassified encryption algorithm
      (e.g., DES, RC4) with a key length not to exceed 64 bits.

2.    The product shall be designed to prevent multiple
      encryption (e.g., triple-DES).

3.    The key required to decrypt each message or file shall be
      accessible through a key escrow mechanism in the product,
      and such keys will be escrowed during manufacture in
      accordance with #10.  If such keys are not escrowed during
      manufacture, the product shall be inoperable until the key
      is escrowed in accordance with #10.

4.    The key escrow mechanism shall be designed to include with
      each encrypted message or file, in a format accessible by
      authorized entities, the identity of the key escrow
      agent(s), and information sufficient for the escrow
      agent(s) to identify the key or key components required to
      decrypt that message.

5.    The product shall be resistant to any alteration that would
      disable or circumvent the key escrow mechanism, to include
      being designed so that the key escrow mechanism cannot be
      disabled by a static patch, (i.e., the replacement of a
      block of code by a modified block).

6.    The product shall not decrypt messages or files encrypted
      by non-escrowed products, including products whose key
      escrow mechanisms have been altered or disabled.

7.    The key escrow mechanism allows access to a user's
      encrypted information regardless of whether that user is
      the sender or the intended recipient of the encrypted
      information.

8.    The key escrow mechanism shall not require repeated
      involvement by the escrow agents for the recovery of
      multiple decryption keys during the period of authorized
      access.

9.    In the event any such product is or may be available in the
      United States, each production copy of the software shall
      either have a unique key required for decrypting messages
      or files that is escrowed in accordance with #10, or have
      the capability for its escrow mechanism to be rekeyed and
      any new key to be escrowed in accordance with #10.

10.   The product shall accept escrow of its key(s) only with
      escrow agents certified by the U.S. Government or by
      foreign governments with which the U.S. Government has
      formal agreements consistent with U.S. law enforcement and
      national security requirements.

Note: Software products incorporating additional encryption
methods other than key escrow encryption methods will be
evaluated for export on the basis of each encryption method
included, as is already the case with existing products. 
Accordingly, these criteria apply only to the key escrow
encryption method incorporated by a software product, and not to
other non-escrowed encryption methods it may incorporate.  For
instance, non-escrowed encryption using a key length of 40 bits
or less will continue to be exportable under existing export
regulations.

------------------------------------------------------------------------

(3) HOW TO SUBSCRIBE TO THE CDT POLICY POST LIST

CDT Policy Posts, which is what you have just finished reading, are the 
regular news publication of the Center For Democracy and Technology. CDT 
Policy Posts are designed to keep you informed on developments in public 
policy issues affecting civil liberties online.

SUBSCRIPTION INFORMAITON

1. SUBSCRIBING TO THE LIST

To subscibe to the policy post distribution list, send mail to 
"Majordomo@cdt.org" with:

    subscribe policy-posts 

in the body of the message (leave the subject line blank)


2. UNSUBSCRIBING FROM THE LIST

If you ever want to remove yourself from this mailing list,
you can send mail to "Majordomo@cdt.org" with the following command
in the body of your email message:

    unsubscribe policy-posts youremail@local.host (your name)

(leave the subject line blank)

-----------------------------------------------------------------------
(4) ABOUT THE CENTER FOR DEMOCRACY AND TECHNOLOGY/CONTACTING US

The Center for Democracy and Technology is a non-profit public interest
organization. The Center's mission is to develop and advocate public
policies that advance constitutional civil liberties and democratic
values in new computer and communications technologies.

Contacting us:

General information on CDT can be obtained by sending mail to 
info@cdt.org

World-Wide-Web:

   http://www.cdt.org/

ftp:

   ftp://ftp.cdt.org/pub/cdt/

snail mail:

Center For Democracy and Technology
1001 G Street, NW Suite 700 East
Washington, DC 20001
voice: +1.202.637.9800
fax:   +1.202.637.0968
                                  ###

</pre>
<hr size = 2>


Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 11, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-139</DOCNO>
<DOCOLDNO>IA053-000895-B046-200</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/nist950906.html 129.174.40.15 19970123195950 text/html 5345
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:58:39 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 22 May 1996 01:35:11 GMT
Content-type: text/html
Content-length: 5162
</DOCHDR>
<HTML>
<head>
<TITLE>NIS&T Key Escrow Export September meeting</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>September NIS&T Key Escrow Export </H1>
<h2>The NIS&T meeting on key escrow export</h2>
The Clinton Administration is revising parts of the 
ill fated Clipper initiative. There have been two public meetings.
The first was held September 6 and 7, 1995.  The 
<a href="./nist951205.html">second was held December 5, 1995. </a>
<p>
<a href="./pdfopinion.html">Pat's Overview Opinion</a>
<p>
<h2>Key information on the meeting include:</h2>
<ul>
<h3>Agenda and official information</h3>
<li><a href="./welcome.html">Welcome message</a>
<li>Potential <a href="./attendees">attendees</a>
<li><a href="./agenda">agenda</a>
<h3>Position papers:</h3>
<li>Topic 1 <a href="./topic1.html">General issues</a>
<li>Topic 2 <a href="./topic2.html">Escrow agent characteristics</a>
<li>Topic 3 <a href="./topic3.html">Export issues</a>
<h3>Handouts and presentations on Criteria</h3>
<li><a href="./bsa.html"> Business Software Aliance</a>
<li><a href="./denning.html"> Dorothy Denning's comments</a>
<li><a href="./kammer.html"> Kammer and Nelson's presentation</a>
<li><a href="./national.html">National Semiconductor's CAKE</a>
<li><a href="./tecsec.html"> TECSEC's product</a>
<li><a href="./tis.html"> TIS's comments on the criteria</a>
<li>During the first breakout session, in the technical discussion
of criteria # 5 and #6, an authorless (presumably government issued)
"Example Potential Solutions" paper was distributed. It caused a lot
of grumbling amongst the attendees, as they were supposed to discuss it,
without any prior chance to read or react to it. Here are two versions
of it, First,
<a href="./sample_solutions.html"> 
Anonymous Sample Solutions (HTML by PDF)</a> 
and a simple ASCII version <a href="./sample_solutions.txt">
Sample Solutions (ASCII text by John Young)</a>
<p>
I have not seen an electronic version of the paper that I received. It
contains the following paragraph:
<p>
"Example Solutions to export criteria 5 and 6 are identified below to help
give a better feel for approaches that implementors may take to satisfy the criteria. The information in
this paper is not intended to represent fail-safe, cookie cutter solutions to
the criteria, but only to 
generate more detailed discussions."
<p>
It is also interesting to note that John Young has an electronic document
with all of the sample solutions (a solution for each of the ten criteria).
I never saw a paper document with all ten solutions. The one that was 
handed to me had only two criteria, #5 and #6. I talked to attendees
of other breakouts, and they had received nothing.
<h3>Handouts and presentations on "approved" escrow agents</h3>
<li>CDT's presentation is available twice, I've made 
<a href="./cdt_nist.html">a local copy </a>as CDT's web server is slow,
and here is a link to <a href="http://www.cdt.org/crypto/cdt_nist_090795.html">
CDT's own copy of their presentation </a>
<li><a href="./vtwover.html"> VTW's Overview (from BillAlert)</a>
<li><a href="./vtw.html"> VTW's Presentation</a> 
<li><a href="./hoffman.html">Professor Hoffman of GWU </a>
<li><a href="./kam.html">Ken Mendelsen's Presentation's text </a>
<h3>Notes from the breakout sessions that I recorded</h3>
<li>"official" report sent to NIST of breakout session on 
<a href="./crit56.html">Session C1/C2, Criteria 5 and 6</a>
<li>"official" report sent to NIST of breakout session on 
<a href="./techcrit.html">Criteria Technial discussion</a>
<li><a href="./cp1.html">Cypherpunks posting, day 1 (HTML)</a> and a
PGP-signed 
<a href="./cp1.asc"> (ASCII version) Cypherpunks posting, day 1</a>
<li><a href="./cp2.html">Cypherpunks posting, day 2 (HTML)</a> and a
PGP-signed 
<a href="./cp2.asc"> (ASCII version) Cypherpunks posting, day 2</a>
<h3>Media coverage</h3>
<li><a href="./nyt.html>New York Times coverage</a>
<li><a href="./post.html">Washington Post business section coverage</a>
<h3>Links to other attendee's comments and reactions</h3>
<li><a href="./plesser.html">Ron Plesser's analysis</a>
<li><a href="http://www.clark.net/pub/cme/html/nist-ske.html">Carl Ellison's public comments</a>
<li>Carl Ellison's 
<a href="http://www.clark.net/pub/cme/html/nist-ske.html#geoff">Open 
letter to Geoff Greiveldinger</a> and Carl's paper proving
that <a href="http://www.clark.net/pub/cme/html/no-ke.html">the Goverment
Doesn't Want Key Escrow</a>
<li><a href="./david.html">David Lesher's posting</a>
<li>CDT released policy paper on Clipper II, 
<a href="./cdt_policy.html"> 
this is a local copy</a> and here is 
<a href="http://www.cdt.org/publications/pp2440911.html">
a link to CDT's own (slow) site</a>
<h3>Related public testimony</h3>
<li><a href="./nsa.html">NSA Clipper testimony</a> sounds a lot
like the NIST testimony from the Government speakers.
</ul>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
December 7, 1995.  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-140</DOCNO>
<DOCOLDNO>IA053-000892-B033-221</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/research/ARPA-ONR/N00014-92-J-4038.html 129.174.40.15 19970123190553 text/html 10724
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:04:43 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 28 Jul 1994 08:10:12 GMT
Content-type: text/html
Content-length: 10540
</DOCHDR>
<HTML><HEAD><STRONG>ONR Progess Report</STRONG>
<TITLE>ONR Progress Report</TITLE>
</HEAD>
 
<BODY>
 
<H1>ProjectTitleLine:</H1>
<B>Information Integration and Interchange:  A Federated Systems Approach</B>
<TITLE>ONR Progess Report:  N00014-92-J-4038  AO8977</TITLE>
<H2>ContractPeriodOfPerformance:</H2> August 1992 - July 1995
 
<H2>ContractNumber:</H2>  N00014-92-J-4038  AO8977
 
<H2>R&T:</H2> 3331003knw03
 
<H2>InvestigatorsLine:</H2>  Larry Kerschberg, Sushil Jajodia, Hassan Gomaa, Ami
hai Motro
 
<H2>InstitutionLine:</H2>  George Mason University
 
<H2>POC:</H2> kersch@gmu.edu
 
<H2>Objective:</H2>
 
This research addresses information integration and interchange in a 
federation of heterogeneous information systems.  Individual systems 
may have distinct naming conventions, different meanings for similar 
data entities, differing time measurement schemes, and diverse 
uncertainty management schemes.  The goal is to investigate a 
federated architecture that allows individual systems to retain 
autonomy and responsibility over data and knowledge, while still 
sharing information with the other members of the federation.  
 
<H2>Approach:</H2>
 
The federation architecture consists of a <I>Federation Manager</I> to
handle the formulation, planning and processing of global queries,
and Federation Interface Managers (FIMs) to serve as agents for
local information systems, called federation constituents.  Local
users have access to their respective local information systems,
and perform the operations defined therein.  Each FIM contains an
object-oriented specification of the data and services the local
information system will provide to the federation.  FIMs may
communicate directly with each other, or may request assistance
from the Federation Manager to resolve different types of
inconsistencies, specifically terminology, time units and temporal
data model inconsistencies, and inconsistencies in answers provided
by different databases.  The Federation Manager contains several
cooperating modules that help to resolve inconsistencies:  an
active intelligent thesaurus to resolve semantic heterogeneity, a
temporal mediator to resolve temporal inconsistencies arising from
different temporal granularities in constituent databases, and a
harmony agent the integrates conflicting information from
constituent databases.
 
<H2>Hardware_Software_Prototypes_Available:</H2>
 
The Knowledge-Based Software Engineering Environment (KBSEE) has
been developed by Drs. Gomaa and Kerschberg under a NASA-sponsored
research project.  This environment is used for the domain modeling
portion of the I3 research.  The KBSEE runs on Sun Sparcstations
under Sun OS, and requires NASA's TAE user interface manager and
CLIPS expert system shell, as well as IDE's Software through
Pictures.  NASA has installed the KBSEE at Goddard Space Flight
Center in Code 520 for evaluation.  The key technologies being
exported are:  1) domain-independent tools for specifying domain
models, and 2) knowledge-based tools to generate target system
specifications from selected system features.  
 
 
<H2>Transitions:</H2>
 
<H3>Process Engineer's Expert Advisor</H3>
 
The KBSEE was used on a grant from the Virginia Center of Excellence
for Software Reuse and Technology Transfer, a Center of Excellence
funded by ARPA and located at the Software Productivity Consortium
(SPC) in Herndon, Virginia.    A domain model was specified for the
family of software process models that can be "generated" from the
Evolutionary Spiral Model (ESP) developed at SPC.  The KBSEE was
used to specify the domain model and the Knowledge-based
Requirements Elicitation Tool, KBRET, assists a Process Engineer to
select the requirements of a particular project, and then generate
the process model and the activities best suited to the project
requirements.  
 
<H3>Earth Observing System Data and Information System (EOSDIS)</H3>
 
The KBSEE is being used to create a domain model of the EOSDIS 
Core System, under a contract with Hughes Applied Information Systems.  
The goal is to characterize the major components of the EOSDIS Core 
System (ECS) and then map the domain model to a client/server model 
that can drive a performance analysis model. <p> 
Several information integration issues are also addressed; 
specifically EOSDIS must interchange data with other agengies 
such as NOAA, International Partners, and associated data centers.  
Information integration and interchange is important to the 
generation of EOS Standard Products as well as for supporting 
user-specified derived products.  EOSDIS must support the concept of 
a <EM>federation</EM> of cooperating information systems.
 
<H3>Center for Information Systems Integration and Evolution</H3>
 
The Center for Information Systems Integration and Evolution is 
a <i>new</i> center at George Mason University which will focus 
on the important research and development issues confronting the 
nation in areas such as business process re-engineering, data, 
information and knowledge interchange, information integration in 
large-scale systems, and information systems evolution.<p>
We are witnessing the <i>right-sizing</i> and <i>re-engineering </i>of 
organizations to better address customer needs and to meet business 
imperatives for inserting information technology solutions.  
New architectures are being investigated which bring the computing 
resource to customers so as to capture information at its source, 
and to share that information as a corporate resource.  <p>
Moreover, there is a need to address <i>national challenges</i> such 
as health care, advanced manufacturing technology, the national 
information infrastructure and crisis management, all of which require 
inter-disciplinary approaches to the problem, therefore bringing together 
domain experts as well as information-, computer- and software- scientists 
and engineers to create new information system paradigms.  <p>
Large-scale systems require the integration and interchange of information 
from heterogeneous autonomous data systems. Examples are: the Logistics 
Anchor Desk involving collaborative planning among distinct agencies and 
the integration of information from multiple heterogeneous databases, 
the Human Genome Project, the Earth Observing System Data Information System 
(EOSDIS), and the Defense Information Systems Agency's efforts 
to integrate and evolve existing information systems. <p>
The Center's Director is Dr. Larry Kerschberg and the 
Associate Director is Dr. Hassan Gomaa. 
Please contact Dr. Kerschberg (kersch@gmu.edu) for more information.<p>
 
<H2>LookingForTransitionOpportunities:</H2>
 
Larry Kerschberg participated in an ARPA Working Group to develop ideas for a 
new ARPA Initiative called the Logistics Anchor-Desk.  The Working Group 
meeting was held in conjunction with ARPA Planning Initiative PI Meeting 
held at Tucson, Arizona, February 23-25, 1994.
 
There has been considerable interest within the ARPA I3 community in 
our plan to provide independent agents that will interact with other systems 
to help them resolve information inconsistencies (and other possible 
services related to information uncertainty). Specifically, we 
have agreed to cooperate with the following projects:  
 
<OL>
<LI>Project SIMS at ISI (Yigal Arens)
<LI>Project CoBase at UCLA (Wesley Chu)
<LI>Project at SRI (Xiaolei Qian)
</OL>
 
<H2>HonorsReceived: </H2>
 
<H3>Journal Editorships:</H3>
 
<UL>
<LI>Larry Kerschberg, Editor-in-Chief, <I>Journal of Intelligent Information Sys
tems</I>, Kluwer Academic Publishers.
<LI>Sushil Jajodia, Editor-in-Chief, <I>Journal of Computer Security</I>, IOS Pr
ess, Amsterdam.
<LI>Sushil Jajodia, Associate Editor, <I>Journal of Intelligent and Cooperative 
Information Systems</I>.
<LI>Amihai Motro, Editorial Board Member, <I>Journal of Intelligent Information 
Systems</I>.
</UL>
<H3>Conference Committees:</H3>
<H4>Larry Kerschberg</H4>
 
<UL>
<LI><B>General Chair</B>, <I>1993 ACM-SIGMOD International Conference on Managem
ent of Data</I>, held at the Omni Shoreham Hotel, Washington, D.C., May 1993.  
</UL>
<B>Program Committee Member:</B> 
<UL>
<LI><I>Knowledge Discovery in Databases</I>, American Association for Artificial
 Intelligence (AAAI), July 1993 and July 1994.
<LI><I>IEEE Workshop on Interoperability in Multidatabase Systems</I>, April 199
3.
<LI><I>IEEE Research Issues in Data Engineering - Active Database Systems<I>, Ap
ril 1994.  
</UL>
<H4>Sushil Jajodia</H4>
 
<UL>
<LI><B>Chair of Steering Committee</B> for <I>International Conference on 
Parallel and Distributed Information Systems</I> (Issues, Architectures, 
and Algorithms). The 3rd PDIS conference will be held October 1994 in Austin, TX
.
</UL>
<B>Program Committee Member:</B> 
<UL>
<LI><I>2nd ACM Conference on Computer and Communications Security</I>, Nov. 2-4,
1994. 
<LI><I>IEEE Symposium on Research in Security and Privacy</I>, Oakland, CA, May,
 1994. 
<LI><I>20th Very Large Data Base Conference</I>, Santiago, Chile, Sept. 12-15, 1
994. 
<LI><I>3rd European Symp. on Research in Computer Security</I>, Brighton, U.K., 
Nov. 7-9,  1994. 
<LI><I>International Conference on Information Systems and Management of Data</I
>, Madras, India, Oct. 25-27, 1994. 
<LI><I>International Symp. on Object-Oriented Methodologies and Systems</I>, Pal
ermo, Italy, Sept. 21-22, 1994. 
<LI><I>IEEE International Conference on Parallel and Distributed Information Sys
tems</I>, Austin, TX, Oct. 1994. 
<LI>13th IEEE Symposium on Reliable Distributed Systems, Irvine, CA, Oct. 25-27,
 1994. 
<LI>ACM SIGMOD International Conference on Management of Data, San Jose, CA, 199
5.
</UL>
<H4>Hassan Gomaa</H4>
 
<B>Program Committee Member:</B>
<UL>
<LI><I>Second International Workshop on Configurable Distributed Systems</I>, Pi
ttsburgh, PA, March 1994.  
<LI><I>Third International Conference on Software Reuse</I>, To be held in Rio d
e Janeiro, Nov. 1994.
</UL>
<H4>Amihai Motro</H4> 
 
<UL>
<LI><B>Co-organizer:</B> NSF/ESPRIT Workshop on Uncertainty Management in Inform
ation Systems (UMIS), Avalon (Santa Catalina), CA, April 1993.
</UL>
<B>Program Committee Member:</B>  
<UL>
<LI><I>ACM-SIGMOD 93</I>, International Conference on Management of Data, Washin
gton, DC, May 1993.
<LI><I>AAAI 93 Workshop on Knowledge Discovery in Databases</I>, Washington, DC,
 July 1993.
<LI><I>20th International Conference on Very Large Data Bases</I>, Santiago, Chi
le, Sept. 1994.
</UL> 
 
</BODY>
 
<STRONG>End of ONR Progress Report</STRONG>

</DOC>
<DOC>
<DOCNO>WT03-B24-141</DOCNO>
<DOCOLDNO>IA053-000895-B046-52</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/government/spook.html 129.174.40.15 19970123195837 text/html 3453
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:57:27 GMT
Server: NCSA/1.5.2
Last-modified: Mon, 09 Oct 1995 15:38:23 GMT
Content-type: text/html
Content-length: 3270
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Pointer to spooks</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>Spooks</h1>
<h2>aka black money, and the Intellegence Community</h2>
There are lots of spook agencies arround DC. This lists the ones
I know, if you know of more, please <a href="mailto:pfarrell@isse.gmu.edu">
email me the information.</a>
<p>
Alphabetically:
<ul>
<li><a href="http://www.odci.gov/cia"> Central Intellegence Agency</a>
<li><!a href="http://www. ">Defense Intellegence Agency </a>
<li><a href="http://www.fbi.gov"> Federal Bureau of Investigation</a>
<li>National Reconnasence Office
<li><a href="http://www.nsa.gov:8080">National Security Agency </a>
<li>Not a spook agency, but still an interesting place is
 <a href="http://www.nsa.gov:8080/museum"> National Cryptographic Museum</a>
<li><!a href="http://www."> Secret Service</a>
</ul>
Locations of spook offices.
<p>
CIA
<ul>
<li>Headquarters are in Langley VA. Just off Rt 123 between McLean and
the George Washington Parkway. There is a big sign, you can't miss it. The sign was put up about 10 years ago. Before that, there was no sign, but everyone
knew where it was, and that was in the heavily guarded, unmarked compound.
<li>Offices in Roslyn VA. There are several ugly blue office 
buildings in Roslyn that are used as overflow office space. They have
been in use at least since 1969.
<li>Offices in Vienna. I know they are there, but don't know which building.
I know that folks working there hang out at the Vienna Inn, a dive bar.
If you know, please <a href="mailto:pfarrell@isse.gmu.edu">mail me </a>
<li>Offices in Reston. Ditto
<li>Offices in Lake Fairfax (outside Reston). Rumour has it that the CIA
has most of the building on Bussiness Circle that has prominent PRC signs
on it. I know that the guards are not PRC guards, and that PRC has only
a few floors.
</ul>
<p>
NSA
<ul>
<li>HQ is clearly in Fort Meade MD.
<li>other offices?
If you know, please <a href="mailto:pfarrell@isse.gmu.edu">mail me </a>
</ul>
NRO
<ul>
<li>there was a big deal made a year or so ago about the NRO's secret
headquarters that was being built as a defense contractor's office
just outside of Dulles Aiport.
<li>Other offices?
If you know, please <a href="mailto:pfarrell@isse.gmu.edu">mail me </a>
</ul>
<p>
DIA
<ul>
<li>HQ is in Arlington VA, within a few blocks of the Pentagon. I'll have
to drive arround to get the exact spot next time I go to Whitey's.
</ul>
<p>
FBI
<ul>
<li>HQ is a big, ugly building on Pennsylvania Avenue downtown.
<li>Regional offices are all over the country.
</ul>
<p>
Unknown agency, but clearly spooks
<ul>
<li>
 1517 Westbranch Drive 
<p>
Go out to Tysons Corner in Northern Virginia, take Exit 11 off I-495 [aka       
the infamous "Beltway"] and head west on Rte 123. Take the first right
onto Tysons Blvd, and then another right onto Galleria Drive, and then
yet another right onto Westbranch Drive.
</ul>                                           
<p>
Back to Pat's <a href="./usgov.html">Government overview</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 1, 1995  Backto <a href="../hotlist.html">Pat's hotlist</a> Backto <a href="../index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-142</DOCNO>
<DOCOLDNO>IA053-000895-B043-142</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/government/usgov.html 129.174.40.15 19970123194642 text/html 1353
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:45:31 GMT
Server: NCSA/1.5.2
Last-modified: Fri, 01 Sep 1995 18:11:27 GMT
Content-type: text/html
Content-length: 1170
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Pointer to US Federal Government</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
This page provides pointers to the US Federal Government resources on the WEB.
This reflects the current status, which is quite an expansion from what
the founding fathers expected. Blame all the growth on the New Deal
Democrats.
<H1>Overall Structure</h1>
As every kid learns in civics class, the US Federal government was
delibrately split into three branches.
<p>
<ol>
<li><a href="./exec.html">Executive Branch</a> from the President 
on down. Note that most of the what folks think of as "government" is here.
<li><a href="./congress.html">Legislative</a> all those congresscritters.
<li><a href="./judicial.html">Judicial</A> all those judges.
</ol>
While usualy part of the Executive branch, the spooks are interesting to
a lot of folks, so I give them a 
<a href="./spook.html">special spook section.</a>
<P>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> August 1, 1995  Backto <a href="../hotlist.html">Pat's hotlist</a> Backto <a href="../index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-143</DOCNO>
<DOCOLDNO>IA053-000895-B046-96</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/tech/performance.html 129.174.40.15 19970123195900 text/html 627
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:57:51 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 20 Dec 1995 18:38:53 GMT
Content-type: text/html
Content-length: 445
</DOCHDR>
<HTML>      
<BODY bgcolor="FFFF80">
<head>
<title>Pat Farrell's Guide to Performance</title>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>
Under construction.

<h1></h1>
<hr>
<A HREF="./disclaimer.html"> PDF</a> 
November 30, 1995
  Backto <a href="./default.htm">Pat's AMS Intranet page</a>
Backto 
<a href="./hotlist.html">Pat's hotlist</a> 
  Backto <a href="./biopage.html">Pat's Biographic page </a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-144</DOCNO>
<DOCOLDNO>IA053-000895-B045-48</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/crypto.manifesto.html 129.174.40.15 19970123195422 text/html 5108
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:53:13 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 06 Jun 1995 15:30:42 GMT
Content-type: text/html
Content-length: 4925
</DOCHDR>
From: tcmay@netcom.com (Timothy C. May)
Subject: The Crypto Anarchist Manifesto
Date: Sun, 22 Nov 92 12:11:24 PST
<p>
Cypherpunks of the World,
<P>
Several of you at the "physical Cypherpunks" gathering yesterday in
Silicon Valley requested that more of the material passed out in
meetings be available electronically to the entire readership of the
Cypherpunks list, spooks, eavesdroppers, and all. <Gulp>
<p>
Here's the "Crypto Anarchist Manifesto" I read at the September 1992
founding meeting. It dates back to mid-1988 and was distributed to
some like-minded techno-anarchists at the "Crypto '88" conference and
then again at the "Hackers Conference" that year. I later gave talks
at Hackers on this in 1989 and 1990.
<P>
There are a few things I'd change, but for historical reasons I'll
just leave it as is. Some of the terms may be unfamiliar to you...I
hope the Crypto Glossary I just distributed will help.
<P>
(This should explain all those cryptic terms in my .signature!)
<P>
--Tim May
<P>
...................................................
<P>
The Crypto Anarchist Manifesto
<P>
Timothy  C.  May
tcmay@netcom.com
<P>

A specter is haunting the modern world, the specter of crypto 
anarchy. 
<P>
Computer technology is on the verge of providing the ability for 
individuals and groups to communicate and interact with each other 
in a totally anonymous manner. Two persons may exchange 
messages, conduct business, and negotiate electronic contracts 
without ever knowing the True Name, or legal identity, of the other. 
Interactions over networks will be untraceable, via extensive re-
routing of encrypted packets and tamper-proof boxes which 
implement cryptographic protocols with nearly perfect assurance 
against any tampering. Reputations will be of central importance, far 
more important in dealings than even the credit ratings of today. 
These developments will alter completely the nature of government 
regulation, the ability to tax and control economic interactions, the 
ability to keep information secret, and will even alter the nature of 
trust and reputation.
<P>
The technology for this revolution--and it surely will be both a social 
and economic revolution--has existed in theory for the past decade. 
The methods are based upon public-key encryption, zero-knowledge 
interactive proof systems, and various software protocols for 
interaction, authentication, and verification. The focus has until now 
been on academic conferences in Europe and the U.S., conferences 
monitored closely by the National Security Agency. But only recently 
have computer networks and  personal computers attained sufficient 
speed to make the ideas practically realizable. And the next ten 
years will bring enough additional speed to make the ideas 
economically feasible and essentially unstoppable. High-speed 
networks, ISDN, tamper-proof boxes, smart cards, satellites,  Ku-band 
transmitters, multi-MIPS personal computers, and encryption chips 
now under development will be some of the enabling technologies. 
<P>
The State will of course try to slow or halt the spread of this 
technology, citing national security concerns, use of the technology 
by drug dealers and tax evaders, and fears of societal disintegration. 
Many of these concerns will be valid; crypto anarchy will allow 
national secrets to be trade freely and will allow illicit and stolen 
materials to be traded. An anonymous computerized market will 
even make possible abhorrent markets for assassinations and 
extortion. Various criminal and foreign elements will be active users 
of CryptoNet. But this will not halt the spread of crypto anarchy.
<P>
Just as the technology of printing altered and reduced the power of 
medieval guilds and the social power structure, so too will 
cryptologic methods fundamentally alter the nature of corporations 
and of government interference in economic transactions. Combined 
with emerging information markets, crypto anarchy will create a 
liquid market for any and all material which can be put into words 
and pictures. And just as a seemingly minor invention like barbed 
wire made possible the fencing-off of vast ranches and farms, thus 
altering forever the concepts of land and property rights in the 
frontier West, so too will the seemingly minor discovery out of an 
arcane branch of mathematics come to be the wire clippers which 
dismantle the barbed wire around intellectual property.
<P>
Arise, you have nothing to lose but your barbed wire fences!
<P>
<pre>
.....................................................................
Timothy C. May         | Crypto Anarchy: encryption, digital money,  
tcmay@netcom.com       | anonymous networks, digital pseudonyms, zero 
408-688-5409           | knowledge, reputations, information markets,
W.A.S.T.E.: Aptos, CA  | black markets, collapse of governments.
Higher Power: 2^756839 | PGP Public Key: by arrangement.
</pre>

</DOC>
<DOC>
<DOCNO>WT03-B24-145</DOCNO>
<DOCOLDNO>IA053-000895-B045-139</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/pdf.usatoday.html 129.174.40.15 19970123195527 text/html 2404
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:54:17 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:10:15 GMT
Content-type: text/html
Content-length: 2221
</DOCHDR>
<HTML>
<head>
<TITLE>PDF's USA Today letter to the Editor </TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>USA Today supports strong encryption </H1>
<h2>Copyright (c) 1995, Gannett, All rights reserved</h2>
In the October 24 edition of USA Today, they came out strongly against
Clipper 2. So I wrote a letter congratulating them, and added a couple
of paragraphs. This was printed in Monday, October 30 1995's
edition.
<h2>Page 12A, USA Today, October 30, 1995</h2>
It was interesting to see the placement,
right under the letter from Kammer of NIST.

<p>p.s. the editors picked the headline, not me



<h1>Cyber-sucking Sounds</h1>

All security is relative. Having a police cruiser in your driveway will
probably deter burglars. Having a squad of U.S. Marines protecting you will
deter almost anything.
<p>

Absolute statements about security on the Internet are very difficult to
make accurately. But providing very good security today is easy.
Govvernment restrictions are the primary reason it is not widely
available.
<p>

I was at the National Institute of Standards and Technology meetings in
Septamber on the export of "key escrow" cryptography software.
The commercial vendors were united that there is no commercial market for
escrowed communications. They stated there is a huge international market
looking for cryptography-based security products. If these products
cannot be developed and sold in the United States, there are able software
engineers in Israel, Ireland, India, and other countries that will be glad
to make and sell them.
<p>

Ross Perot talked about the giant sucking sound of unskilled
factory jobs. This is far more serious. It is the sound of
high pay, non-polluting jobs that are filled with our college
graduates disapearing.
<p>

Pat Farrell
<br>
Falls Church, VA

<p>Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
Novermber 9, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-146</DOCNO>
<DOCOLDNO>IA053-000895-B045-192</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/post.bu951108.html 129.174.40.15 19970123195601 text/html 4564
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:54:51 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 02 Jan 1996 16:20:17 GMT
Content-type: text/html
Content-length: 4381
</DOCHDR>

<HTML>
<head>
<TITLE> Washington Post report, Novermber 8, 1995</title>
</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
<!From: John Young jya@pipeline.com> 
</head>
<body>

   The Washington Post, November 8, 1995
<br>
Page 1, Business section


<h1>   Encryption Control Plan Sparks Industry Protest</h1>

<h2>      High-Tech Groups Say Proposals Unworkable</h2>

   By Elizabeth Corcoran
<p>

   High-technology companies and advocacy groups are writing
   to Vice President Gore and House Speaker Newt Gingrich to
   protest what they contend are unworkable federal proposals
   for controllng the export of data scrambling technology.
<p>
   The letters deepen an industry-government rift that began
   only days after federal officials unveiled an outline of
   what they hoped would be a palatable plan at an industry
   meeting in August.
<p>
   Two separate coalitions are criticizing the
   administration's draft proposal, which the government
   circulated on the Internet on Monday.
<p>
   Current export regulations prohibit companies froan sending
   overseas any encryption, or data-scrambling technology,
   that exceeds a certain degree of sophistication. The
   government argues that it needs to be able to peek at
   messages and files with proper court authorization -- to do
   its job of protecting U.S. citizens from terrorist groups
   and other malevolent organizations.
<p>
   In July, some French students demonstrated they could
   readily break the type of encryption technology that the
   U.S. government lets companies export. In August, the
   administration said it would let companies include more
   complex types of encryption, provided they pledged to
   entrust to an authorized agent a "spare key," or the means
   for unscrambling the information.
<p>
   Unlike early proposals in which the government said it
   would hold such keys, the administration is suggesting that
   companies and individuals would be able to select private
   keyholders, much the way people pick their banks.
<p>
   But after a brief honeymoon, industry and civil liberties
   groups began to find flaws with the details in the new
   proposals. This week's letters indicate that whatever
   fragile compromise the government had hoped it had found
   has grown even weaker.
<p>
   One coalition, pulled together by the Washington advocacy
   group Center for Democracy and Technology, includes about
   three dozen high-tech companies and associations. The group
   has promised to draft an alternative plan within six
   months.
<p>
   "There is a very serious message here: that national
   security can't be controlling the Internet," said Jerry
   Berman, executive director of the center. "There are other
   issues, global competitiveness and privacy, that need to be
   placed in the balance -- and the administration's policy
   doesn't do that."
<p>
   A second coalition of about 10 free-market and libertarian
   groups, led by another policy group, Americans for Tax
   Reform, plans to send their letter to Gingrich in the next
   day or two. The group contends the administration's
   encryption proposals are an encroachment on citizens' civil
   rights.
<p>
   The administration's proposals would not restrict tbe
   encryption technologies that people use within U.S.
   boundaries. But it would require that if they
   electronically send an encrypted message to parties outside
   the United States, a spare key must be stored with an
   authorized agency.
<p>
   "Even though we recognize [the administration] has worked
   hard on its proposals, it's not the right direction," said
   Rebecca Gould, director of policy at the Business Software
   Alliance, a trade association of software firms.
<p>
   "We've been in this [debate] since July 1994," she added,
   a long time for companies that churn out a new version of
   most products every 18 months. "That means lost sales for
   us and a loss of U.S. industry sales abroad."
<p>


<p>Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
Novermber 9, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-147</DOCNO>
<DOCOLDNO>IA053-000895-B045-255</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/post.ed951108.html 129.174.40.15 19970123195629 text/html 4171
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:55:17 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 22:59:05 GMT
Content-type: text/html
Content-length: 3988
</DOCHDR>
<HTML>
<head>
<TITLE> 
Return of the Cyber-Censors
</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>
Return of the Cyber-Censors
 </H1>
   <h2>The Washington Post, November 8, 1995.</h2>

   When the Senate passed its ill-advised "Exon amendment" to
   the telecommunications bill last spring, which would
   criminalize the transmission of obscene, pornographic or
   "indecent" material on the Internet, the measure got an
   overwhelming 84 votes, many of them from senators who
   didn't understand the implications of the move. Only a few
   weeks later, the House went even more overwhelmingly the
   other way, voting 420 to 4 for an amendment (co-sponsored
   by Reps. Ron Wyden and Christopher Cox) that would bar the
   Federal Communications Commission from regulating
   cyberspace and would instead make it legally easier for
   commercial Internet providers to use their own technical
   tools to regulate questionable material.
<p>
   The contrast was the result of a burst of public discussion
   in which more technologically astute members, including
   House Speaker Newt Gingrich, caught on to the disturbing
   fact that the kinds of far-reaching liability imposed by
   Sen. James Exon's formulation -- hastily adapted from an
   existing measure on telephone transmission -- would cripple
   practically any commercial Internet provider and
   effectively lame the new medium as a venue for moneymaking
   activity.
<p>
   Now these vastly different measures are in conference
   committee along with the rest of the telecommunications
   bill (in other areas of which, we remind readers once
   again, The Washington Post Co. has some interests). But the
   seeming clarity afforded by the House response to the Exon
   amendment and by Mr. Gingrich's appreciation of the need
   for untrammeled development of the new medium is nowhere to
   be seen. A letter from Christian Coalition head Ralph Reed,
   Phyllis Schlafly and other prominent spokesmen for the
   religious right is urging the conferees toward an
   Exon-style approach that's as destructive now as it ever
   was. The House bill also could end up including an
   amendment sponsored by Rep. Henry Hyde that adds some
   criminal liability to the transmission of obscene (but not
   "indecent") images via the new technologies.
<p>
   The argument against "criminalizing" the transmission of
   "indecent" images via the Internet remains stark and
   simple, and it goes not to the awfulness of child
   pornography or even to the ability of parents to control
   what their children do on the computer (a wide variety of
   off-the-shelf technological filters now exist that let
   parents do this themselves) but to the impossibility of
   regulation by the electronic middleman industries that are
   developing.
<p>
   Commercial providers such as America Online continue to
   pass along millions of messages a day, the interactive
   "newsgroups" unfold quickly and internationally, and the
   kind of central filtering envisioned by would-be regulators
   erases the very quality that makes the Internet a live and
   promising medium -- its inexpensive accessibility. If the
   Internet were like a telephone system, there would at least
   be the possibility of identifying a specific "sender" and
   "recipient." On the Internet it's "receivers" who do the
   selecting of what to look at and where. Giving those
   recipients the tools they need remains the way to go. The
   conferees should resist the urge to censor cyberspace.
<p>

<p>Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
Novermber 9, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrelhttp://www.isse.gmu.edu/~pfarrelll/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-148</DOCNO>
<DOCOLDNO>IA053-000895-B045-206</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/post.bu960117.html 129.174.40.15 19970123195610 text/html 3456
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:54:59 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 17 Jan 1996 20:41:10 GMT
Content-type: text/html
Content-length: 3273
</DOCHDR>
<body>
<title>
The Washington Post
Study: Encryption Rules Hurt Exporters</title>

The Washington Post<br>
January 17, 1996
  <p> 
Study: Encryption Rules Hurt Exporters
<p>
<p>
   By Elizabeth Corcoran
   Washington Post Staff Writer
<p>
<p>
   U.S. export restrictions on technology for encrypting information are
   slowing American companies' success in some foreign countries and
   retarding the growth of an international market for such technology,
   according to a new report released by the U.S. Commerce Department.
<p>
   The study is likely to become the latest ammunition in the struggle
   between the administration and many U.S. high-tech companies and civil
   liberties advocates over how tightly the United States should control
   the export of sophisticated data scrambling, or encryption,
   technology. Both sides are likely to try to use the report to their
   advantage.
<p>
   U.S. businesses contend that they are losing market share to foreign
   competitors because they are not allowed to include the most
   sophisticated encryption technology in their software products.
<p>
   "The day we show lost market share [in the overall market for
   software] is the day that we start losing the whole ballgame," said
   Rebecca Gould, director of policy for the Business Software Alliance.
<p>
   The report, which was commissioned in late 1994 by the national
   security adviser and carried out by the Commerce Department's Bureau
   of Export Administration and the National Security Agency, aimed to
   assess the impact of encryption export controls. It assigns no dollar
   values to any sales lost by U.S. companies, but notes that there are
   many foreign-made encryption products available overseas. On the other
   hand, some of those products do not work well, the report says.
<p>
   Still, it cites evidence that U.S firms are not making significant
   progress in the business of selling encryption technology.
<p>
   In three countries -- Switzerland, Denmark and the United Kingdom --
   market share for U.S. encryption products declined during 1994, the
   report said. Sources in 14 countries said that export controls "limit"
   U.S. market share, while those in another seven countries said such
   controls have "either no impact or no major impact."
<p>
   Although the report maintains that sources in "most" countries
   indicated that U.S. market share is "keeping pace" with overall
   demand, in many of the countries surveyed, "exportable U.S. encryption
   products are perceived to be of unsatisfactory quality."
<p>
   Today, a Washington-based policy group supported by a dozen major
   computer companies plans to release its own commentary on export
   encryptions, calling for the government to lift its export
   restrictions.

<hr>
Back to <a href="./nist951205.html">Pat's page on the December 5 NIST Clipper 2 </a>
meeting. 
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
January 17, 1996
Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">
Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-149</DOCNO>
<DOCOLDNO>IA053-000895-B046-7</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/government/congress.html 129.174.40.15 19970123195817 text/html 1844
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:57:06 GMT
Server: NCSA/1.5.2
Last-modified: Fri, 01 Sep 1995 18:20:15 GMT
Content-type: text/html
Content-length: 1661
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Pointer to US Federal Legislative Branch</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>Legislative Branch resources and pointers</h1>
<p>
It is interesting that the House, which has Newt, as fair WEB sites but
few congressmen have email. The Senate, which has no WWW site, by contrast has
email access for most of its members.
<ul>
<li>The Senate's Webpage is RSN. There is an old fashioned
<a href="gopher://gopher.senate.gov">gopher site</a>. 
<li>A fair number of senator's offices are on email either. See the
<a href="gopher://ftp.senate.gov:70/00h/member_e-mail">
Senate email directory</a>
<li>The <a href="http://www.house.gov">House of Representatives</a> is much more up to date as a WWW presence.
<li>The House also claims the Library of Congress' 
<a href="http"/thomas.loc.gov">Thomas legislative site</a>
<li>The Library of Congress has two more sites (librarians are into
information) so try  <a href="http://www.loc.gov"> the main LOC site</a>
and  their <a href="http://lcweb.loc.gov"> 'web' site</a>
<li>Information on <a href="http://ast1.spa.umn.edu/juan/congress.html">
contacting your congresscritters.</a>
<li><a href="http://www.gao.gov">General Accounting Office</a>
<li><a href="http://www.ota.gov">Office of Technology Assessment</a>
<li>Congressional Research Office.
</ul>
<P>
Back to Pat's <a href="./usgov.html">US Government overview page</a>
<P>
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 1, 1995  Backto <a href="../hotlist.html">Pat's hotlist</a> Backto <a href="../index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-150</DOCNO>
<DOCOLDNO>IA053-000895-B046-33</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/government/judicial.html 129.174.40.15 19970123195828 text/html 849
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:57:18 GMT
Server: NCSA/1.5.2
Last-modified: Fri, 01 Sep 1995 16:23:27 GMT
Content-type: text/html
Content-length: 667
</DOCHDR>
<HTML>
<head>
<TITLE>Pat's Pointer to US Federal Judicial Branch</TITLE>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<body>

<H1>Judicial Branch resources and pointers</h1>
<p>
<ul>
<li><a href="http://www.uscourts.gov">U.S. Courts</a>
<li><a href="http://www.fjc.gov">Federal Judicial Center</a>
<li>The Supreme Court Website is "barely on the horizon" according to the Post.
</ul>
Back to <a href="./usgov.html">overview page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 1, 1995.  Backto <a href="../hotlist.html">Pat's hotlist</a> Backto <a href="../index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-151</DOCNO>
<DOCOLDNO>IA053-000895-B046-336</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/pdf.nist2.short.html 129.174.40.15 19970123200101 text/html 5923
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 19:59:49 GMT
Server: NCSA/1.5.2
Last-modified: Wed, 06 Dec 1995 04:25:03 GMT
Content-type: text/html
Content-length: 5740
</DOCHDR>
<p>
I just got back from the NIST GAK export meeting. This is
a short writeup of a summary. I'll post a longer version later
this evening or early tomorrow morning.

<p>
The meeting was hosted by Ed Roback of NIST, who quickly introduced
Mike Nelson of the White House. Mike is clearly a political guy.
His handout says: "We believe that our proposal for exportable 64-bit key
escrow encryption meets these goals [the goals of VP Gore's letter to Rep
Cantwell, July 20, 1994]." He said that the criteria describe a solution,
but not the only solution.  He said it does not preclude other
implementations in the future. He anticipates that the State Department
will issue guidance based upon these criteria in "early 1996," and that
between now and then, any product that meets the criteria will be elegible
for expidited approval. Of course, the existing (slow as molasass) process
will continue.

<p>
I asked the first questions from the floor. The two questions were:
(1) Is this meeting concerned solely with export
of software, or does it deal with controling domestic use of strong
cryptography? and (2) since the 64-bit limit was severly criticized at
the Sept meeting, why is it still needed if there is also escrow?

<p>
His answer was that there is "no intention to control domestic encryption"
and on the 64-bit issue, that the government is "not certain it will
work." he says they "want to see it implemented and want to see
how it works" because 64-bit encryption is very strong. If the escrow
doesn't work, they don't want a lot of softare to be in widespread use.

<p>
He said that they have studied the encryption that is supposed to be widely
available on the Internet. He said that viewed by crypto experts, not
much is very good. He mentioned "two incidents" where Netscape had
weak implimentations. He feels that companies will not trust software
over the 'net. that they "want the US Government to say that 'this is
good enough'."

<p>
Clint Brooks, of NSA, then went over the revised criteria. He claimed that
they were surprized at the industry concern over "one product" for
worldwide markets. There were lots of questions. He eventually admitted
that because of the "one product" concern, export regulations will effect
domestic products. [all the more reason for Netscape to keep building ten
or whatever it is.]

<p>
Brooks admitted that it is impossible to prevent multiple encryption.
Cypherpunks would do that by using PGP and then sending it using GAK.
He said "as a person, you can set up a secure communication method, and
nothing can be done about it." His concern is not that smart people can
have stronger crypto, but that strong crypto will be easy and widely used.

<p>
He said that the 64-bit key limit is not meant to restrict RSA keys to
64-bits, but rather to restrict the session keys that are encrypted using
RSA. Unspoken was the assumption that the 2000 bit RSA secret key would
have to be escrowed.

<p>
There were some interesting (and bad IMHO) implications of interoperability.
I'll cover them more in the long version. Basically, they admitted that
the interoperability restrictions made it stupid to have an export
version, you should have a strong domestic version, and an international
version developed offshore for sale to the rest of the world.

<p>
They admitted that there can be no controls over export of data, so once
interoperating software is available both domestically and from offshore
sources, there is no value in the export controlled, crippled version.

<p>
My favorite policeman, Geoff Greiveldinger, then described the
characteristics of an acceptable key escrow agent. There was a long list
of criteria, all unseen before the meeting. The general reaction
of the audience was that these were "yet another set of criteria that
must be met." Geoff claimed that they were simply trying to address
the questions raised at the earlier meeting about who is an
acceptable escrow agent. One point that caused a lot of concern
was that at least one employee of the escrow agent has to have a SECRET
clearence.

<p>
Industry, with a few exceptions, soundly said that this is a dumb idea,
that there is no market, that the criteria are too hard, etc. Except
Padgett Petersen, representing Lockheed-Martin. He said that LM thought
that the criteria were just peachy. The  usual civil liberties folks
also soundly trashed it.

<p>
There was a representative from Netscape. He said that they, as a company
think this is a terrible idea. They oppose it now, and will be issuing
a company policy soon. I didn't catch his name, and couldn't find him
to get the obviously carefully prepared text. If someone from Netscape, are
you listening Jeff W? could get me the text, I'll add it to my writeup.

<p>
 ******************

<p>
What I think it means:

<p>
I believe that the government deeply wants to restrict domestic use of
strong encryption, but they have no legal justification for doing so.
They can't expect that they will get it if they go to Congress. So they
are attempting an end-arround using the export criteria, which they
_do control_. They hope that the pain of having multiple versions will be
so high that no vendor will bother, and all we'll have is crippled
software.

<p>
The usual civil liberties lobby folks (CDT, EPIC, etc.) want to
hold their own, industry sponsored meetings to develop workable systems.

<p>
I think that the real key is for everyone, worldwide to insist on
both strong crypto and interoperability. The Germans are already
writing fine software and making fast hardware. Microsoft and Netscape
can easily afford to do some of their development offshore. If the products
sell and are deployed, it won't matter what the govies want.

<p>
Pat
</DOC>
<DOC>
<DOCNO>WT03-B24-152</DOCNO>
<DOCOLDNO>IA053-000896-B001-60</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/sample_solutions.html 129.174.40.15 19970123200724 text/html 9385
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:06:12 GMT
Server: NCSA/1.5.2
Last-modified: Thu, 07 Dec 1995 23:22:04 GMT
Content-type: text/html
Content-length: 9202
</DOCHDR>
<html>
<head>
<title>
   Example Potential Solutions for the Draft Export Criteria
   for Software Key Escrow Encryption
</title>
</head>
<body>
   [Handout at Key Escrow Issues Meeting, at NIST,
   Gaithersburg, Maryland, September 6, 1995.]
<p>

<h1>   Key Escrow Issues Meeting, September 6-7, 1995
   Discussion Paper #4</h1>


<p>
<b>   Example Potential Solutions for the Draft Export Criteria
   for Software Key Escrow Encryption</b>

<p>

   Example solutions to the export criteria are identified
   below to help give a better feel for the approaches that
   implementors may take to satisfy the criteria. The
   information in this paper is not intended to represent
   fail-safe, cookie cutter solutions to the criteria, but
   only to generate more detailed discussions.

<p>
   [Note: the numbered articles are the ten key escrow
   criteria proposed by the Government in Discussion Papers 1,
   2 and 3. The *comments* are the solutions suggested by the
   Government in this Paper #4.]

<p>
   1.   The product shall use an unclassified encryption
        algorithm (e.g. DES, RC4) with a key length not to
        exceed 64 bits.

<p>
<i>        It is important to understand that key in this
        context is related to the number of bits needed to
        decrypt a message which are not available over the
        communications channel. For some encryption algorithms
        the key is defined to be a number of bits which are
        kept secret and a number of bits which are transmitted
        in the clear (message key / initialization vector /
        salt). This criterion only specifies the number of
        secret bits.</i>

<p>
   2.   The product shall be designed to prevent multiple
        encryption (e.g. triple-DES).

<p>
        <i>One way to do this would be for the encryption
        program to store the ciphertextfile name and the first
        n (e.g. 16) bytes of cipher for the last k (e.g. 8)
        encryptions. When the encryption routine is called,
        the program checks to see if the input file name is in
        the ciphertextfile list or the first n bytes of the
        file match any of the k cipher text streams stored.
        Likewise, a plaintext header could be appended to each
        ciphertextfile which says the file is encrypted. The
        encryption program would look for this header before
        encryption; if found, the program would not proceed
        with the encryption. These are just examples of what
        could be done. Each vendor's constraints will be
        different.</i>

<p>
   3.   The key required to decrypt each message or file shall
        be accessible through a key escrow mechanism in the
        product, and such keys will be escrowed during
        manufacture in accordance with #10. If such keys are
        not escrowed during manufacture, the product shall be
        inoperable until the key is escrowed in accordance
        with #10.

<p>
        <i>One way of doing this is for each user to have a
        Public and Private Escrow Key. The public escrow key
        is bound in a certificate signed by the Escrow
        Agent(s). This certificate would contain a key ID, the
        escrow agents's ID and the Public Escrow key. A header
        of the encrypted message could contain this
        certificate along with the message key, encrypted
        using the Public Escrow key. If the product is not
        escrowed during manufacture, the software will check
        to see if it has a valid escrow key prior to
        encrypting messages.</i>

<p>
   4.   The key escrow mechanism shall be designed to include
        with each encrypted message or file, in a format
        accessible by authorized entities, the identity of the
        key escrow agent(s), and information sufficient for
        the escrow agent(s) to identify the key or key
        components required to decrypt that message.

<p>
        <i>Following the example for criterion #3, the
        certificate that contained the user's escrow key would
        also contain the identity of the escrow agents holding
        the corresponding pffvate escrow key.</i>

<p>
   5.   The product shall be resistant to any alteration that
        would disable or circumvent the key escrow mechanism,
        to include being designed so that the key escrow
        mechanism cannot be disabled by a static patch (i.e.
        the replacement of a block of code by a modified
        block).

<p>
        <i>Probably the most important aspect of this criterion
        is that source code for a product should not be
        available. Also it is important that the cryptography
        be integrated into the application in some nontrivial
        way. One way of achieving this criterion is for the
        application to store a hash or checksum of the
        cryptographic code in several places and check the
        cryptographic code several times during its use. One
        can prevent a static patch by making the hash or
        checksums dependent on a program ID code or something
        else that is unique about that copy of the software.
        Perhaps one of the best ways to defeat hackers from
        "patching around" the escrow would be a commitment
        from vendors to make each new release of the software
        be immune to existing static patches and patch
        programs.</i>

<p>
   6.   The product shall not decrypt messages or files
        encrypted by non-escrowed products, including products
        whose key escrow mechanisms have been altered or
        disabled.

<p>
        <i>If one follows the steps outlined under criterion #3,
        a receiving program could verify the escrow
        certificate contained in the message header, extract
        the escrow public key, and verify that the encrypted
        message decryption key is also found in the header. If
        it is not there, decryption does not proceed.</i>

<p>
   7.   The key escrow mechanism allows access to a user's
        encrypted information regardless of whether that user
        is the sender or the intended recipient of the
        encrypted information.

<p>
        <i>The message header could contain the decryption key
        encrypted under both the sender's public escrow key
        and the recipient's public escrow key. Then access to
        either the sender's or recipient's private escrow key
        would allow access to the decryption key.</i>

<p>
   8.   The key escrow mechanism shall not require repeated
        involvement by the escrow agents for the recovery of
        multiple decryption keys during the period of
        authorized access.

<p>
        <i>If the public and private escrow keys are unique to
        users, then the escrow agents could turn over the
        private escrow keys to the authorized parties. The
        private escrow key would allow access to keys
        encrypted with the corresponding public escrow key and
        not require repeated involvement with the escrow
        agents.</i>

<p>
   9.   In the event any such product is or may be available
        in the United States, each production copy of the
        software shall either have a unique key required for
        decrypting messages or files that is escrowed in
        accordance with #10, or have the capability for its
        escrow mechanism to be re-keyed and any new key to be
        escrowed in accordance with #l0.

<p>
        <i>Following the example in criterion #3, the software
        could accept the load of a new escrow certificate. The
        software could store a "root" public key which is used
        to verify a certificate containing the escrow agent
        public key which in turn is used to sign the
        individual user's escrow certificate. Hence the header
        might contain both the escrow agent certificate signed
        by the root and the user certificate signed by the
        escrow agent(s). Once escrowed, the software could
        store the ID of the escrow agents and not accept loads
        of new escrow keys except from those agents.</i>

<p>
   10.  The product shall accept escrow of its key(s) only
        with escrow agent(s) certified by the U.S. Government
        or by foreign governments with which the U.S.
        Government has formal agreements consistent with US
        law enforcement and national security requirements.

<p>
        <i>Following the example in criterion #9, if the "root"
        authority only signed the certificates of escrow
        agents (foreign and domestic) approved by the U.S.
        Government then only keys escrowed by approved escrow
        agents will be accepted as valid by the software
        packages.</i>

<p>
   [End]

<p>
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nistmeeting.html">
NIS&T Key Escrow/Export Meeting</a> page.
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> 
PDF</a> September 10, 1995  Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-153</DOCNO>
<DOCOLDNO>IA053-000894-B004-15</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/lotus.gak.announce.html 129.174.40.15 19970123201253 text/html 4397
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:11:37 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 21 May 1996 21:29:21 GMT
Content-type: text/html
Content-length: 4214
</DOCHDR>
<HTML>
<head>
<title>Lotus-Security - Lotus Announces Compromise for Export of Strong
Encryption
 </title>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
<p>
Subject: infoMCI FLASH - Lotus-Security - Lotus Announces Compromise for Export of Strong
Encryption

<p>
[infoMCI FLASH]
                                i n f o M C I  F L A S H
<p>
infoMCI (sm)
Lotus-Security - Lotus Announces Compromise for Export of Strong
Encryption
<p>
By ELIZABETH WEISE
AP Cyberspace Writer
<p>
SAN FRANCISCO (AP) _ Lotus Development Corp. announced a
compromise with the federal government Wednesday that will allow it
to put better security features into the international version of
its Notes program.
<p>
While the arrangement assures the government it can access data
under extreme circumstances, it represents an advance in the
strength of security allowed in software exported from the United
States.
<p>
Federal law prohibits the export of certain high-level
encryption programs, which are defined as a munition under a Cold
War-era arms control act.
<p>
Encryption programs take ordinary data and put it in secret form
that cannot be accessed without the proper data ``key.'' The
government's arbitrary standard for cracking encryption programs
when needed is at a technical level described as ``40-bit.''
<p>
Some software programs sold in the United States, including
Lotus Notes, now use stronger 64-bit encryption. Lotus has been
under pressure to bring such security to Notes users overseas.
<p>
Although 40-bit encryption is quite strong, highly-sophisticated
attacks using several computers have been able to break it
recently.
<p>
``Our customers have basically lost confidence in 40-bit
cryptography,'' said Ray Ozzie, president of Iris Associates, the
unit of Lotus that developed Notes.
<p>
``That left us in a bind. We are the vendor that's supposedly
selling a secure system to them and they are saying it's no good,''
Ozzie told a standing room audience at the RSA Data Security
conference.
<p>
Changes in the general export laws seemed unlikely so Lotus
negotiated an interim solution.
<p>
The export version of Lotus Notes 4.0, which went on sale last
week, includes 64-bit encryption but the company has given the U.S.
government a special code that unlocks the final 24 bits.
<p>
For companies that use the international version of Notes, it's
as if Lotus put two strong locks on a door and gave a key for one
to the U.S. government. Thieves have to get break through two
locks, the government only one.
<p>
``This protects corporate information from malicious crackers
but permits the government to retain their current access,'' Ozzie
said. He acknowledged the solution was only a compromise and said
Lotus wants to see better data security methods developed
worldwide.
<p>
However, many participants at the conference saw the move as a
cosmetic answer to the tension between corporate desires for the
best security and government's interest to access data when
necessary.
<p>
``It's a useful stopgap measure that has no value in the long
run,'' said Donn Parker, a senior security consultant with SRI
International, a computer research company in Menlo Park, Calif.
<p>
Simson Garfinkel, author and computer security expert, said he's
not sure international buyers of Notes will like the solution.
<p>
``Foreign companies don't want the U.S. government to spy on
their data any more than the U.S. government wants foreign
companies to be able to spy on theirs,'' Garfinkel said.
<p>
International Business Machines Corp. bought Lotus in July,
citing the success of Notes, a sophisticated communications and
database program.
<p>
AP-DS-01-17-96 1619EST
<p>
  (66413)
<p>
*** End of story ***
<p>
<p>
<p>
<p>
<hr>
Back to <a href="./nist951205.html">Pat's page on the December 5 NIST Clipper 2 </a>
meeting. 
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
May 21, 1996
Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">
Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
<p>
</DOC>
<DOC>
<DOCNO>WT03-B24-154</DOCNO>
<DOCOLDNO>IA053-000894-B003-346</DOCOLDNO>
<DOCHDR>
http://isse.gmu.edu:80/students/pfarrell/nist/epic.commerce.crypto.html 129.174.40.15 19970123201237 text/html 17749
HTTP/1.0 200 Document follows
Date: Thu, 23 Jan 1997 20:11:20 GMT
Server: NCSA/1.5.2
Last-modified: Tue, 21 May 1996 21:18:42 GMT
Content-type: text/html
Content-length: 17565
</DOCHDR>
<HTML>
<head>
<title>
EPIC: Commerce Report on Crypto Availability
</title>
<link rev="made" href="mailto:pfarrell@isse.gmu.edu">
</head>
Subject: EPIC: Commerce Report on Crypto Availability
<p>
        Commerce Releases Crypto Availability Report
<p>
The US Department of Commerce today released a report on the
international market for encryption software. The report, which was
jointly produced by the Commerce Department's Bureau of Export
Administration and the National Security Agency reviews the foreign
availability of encryption products and other nations' import, export and
domestic use policies.
<p>
The report finds that there are foreign products available which "can have
an impact on US competativeness" and that US export controls "may have
discouraged US software producers from enhancing the softare features of
general purpose software to meet the anticipated growth demand by foreign
markets. It anticipated that there is a steadily increasing demand for
crypto to be included in general use software products becuase of well
publicized break-ins.
<p>
A large portion of the report has been redacted by the NSA. EPIC filed
suit under the Freedom of Information Act in December 1995 to obtain a
full copy of the report and will continue to demand its release. EPIC
believes that the US goverment should remove export controls on public
domain and commerical software that contains encryption and end the policy
of demanding that key escrow be implimented in all encryption software.
<p>
Enclosed in the Commerce Department Press Release and Executive Summary
of the report. The full report is over 100 pages. EPIC will make every
effort to make the full report available in electronic form as soon as
possible.
<p>
More information on crypto policy is available at the EPIC Web Site at
<a href="http://www.epic.org/crypto/">
http://www.epic.org/crypto/</a>

<p>
<center>
                UNITED STATES DEPARTMENT OF
                         COMMERCE <br>
                         NEWS         <br>
                    WASHINGTON DC.20230
<p>
                                               OFFICE OF THE SECRETARY
<p>
</center>
<p>
FOR IMMEDIATE RELEASE<br>
Thursday, January 11,1996<p>   
CONTACT: Carol Hamilton     <br>
(202) 482-4883
<p>
                                          Eugene Cottilli<br>
                                          (202) 482-2721
<p>
<p>
<p>
DEPARTMENT OF COMMERCE RELEASES STUDY ON THE
INTERNATIONAL MARKET FOR ENCRYPTION SOFTWARE
<p>
<p>
<p>
Washington, D.C. -- The growth of an international market for encryption
software is being slowed by strong export controls, both in the United
States and other major countries. Moreover,the quality of products offered
abroad varies greatly, with some not providing the level of protection
advertised.
<p>
The study, jointly prepared by the Commerce Department's Bureau of Export
Administration (BXA) and the National Security Agency (NSA), evaluates the
current and future market for computer software with encryption, which
allows users to protect their data using codes. The study also reviews the
availability of foreign encryption software and assesses the impact that
U. S. export controls on encryption have on the competitiveness of the
software industry.
<p>
"Our study provides a clear snapshot of the international competition in
this segment that the software industry faces," said Cornmerce Secretary
Ron Brown. "Better understanding of the products and the marketplace gives
us the tools to ensure that our export control policies are appropriate,"
he added.
<p>
The study noted encryption software presently accounts for only a small
percentage of the total computer software but should grow substantially as
the U.S. and other countries deveiop and expand public networks and
electronic commerce.
<p>
The study found that the U.S. software industry still dominates world
markets. In those markets not offering strong encryption locally, U.S.
software encryption remains the dominant choice. However, the existence of
foreign products with labels indicating DES (Data Encryption Standard) or
other strong algorithms, even if they are less secure than claimed, can
nonetheless have a negative effect on U. S competitiveness. The study also
notes that the existence of strong U.S. export controls on encryption may
have discouraged U.S software producers from enhancing the security
features of general purpose software products to meet the anticipated
growth in demand by foreign markets.
<p>
<p>
page 2
<p>
All countries that are major producers of commercial encryption products
were found to control exports of the products to some extent. A few
countries (e.g., France, Russia, and Israel) control imports and domestic
use of encryption, as well.
<p>
As part of the study, NSA evaluated twenty-eight different foreign
encryption software products, finding that some were less secure than
advertised. Because customers lack a way to determine actual encryption
strength, they sometimes choose foreign products over apparently weaker
U.S. ones, giving those foreign products a competitive advantage.
<p>
                                  -30-
<p>
<p>
<center>
                                  A STUDY OF
                            THE INTERNATIONAL MARKET
                             FOR COMPUTER SOFTWARE
                                WITH ENCRYPTION
</center>
<p>
<p>
<p>
[Note: This is a redacted copy of the ogigional secret decoment. Brackets
[] accompanied by the origional classifications have been used to indicate
location and size of excised classified text]
<p>
<p>
                                  Prepared by
                     the U.S. Department of Commerce and
                        the National Security Agency
                                   for the
                           Interagency Working Group on
                     Encryption and Telecommunications Policy
<p>
<p>
<p>
EXECUTIVE SUMMARY
<p>
<p>
BACKGROVND
<p>
In late 1994, the President's National Security Advisor directed that an
interagency report be prepared assessing the current and future
international market for software products containing encryption and the
impact of export controls on the U.S. software industry. The report was to
include an assessment ofthe impact of U.S. encryption export controls on
the international competitiveness of the U.S. computer software industry
and a review of the types, quality, and market penetration of
foreign-produced encryption software products. This paper presents the
joint efforts of the Department of Commerce/Bureau of Export
Administration and the National Security Agency to complete this tasking.
(U)
<p>
EXPORT CONTROLS
<p>
All countries that are major producers of commercial encryption products
control exports of those products to some extent. Control methodologies
and licensing practices vary, however, and a few countries, most notably
=46rance, Russia and Israel also control imports and/or domestic use of
encryption. There is a significant amount of international cooperation in
controlling encryption exports. (U)
<p>
Some European and other countries apparently treat exports to the United
States of DES- based software more liberally than the United States treats
DES exports to those countries. Some countries have stated that they
generally restrict DES exports to financial end-uses. In general, no
independent verification of these licensing practices was obtained.
However, in some cases the U.S. was able to obtain DES products from them
for non-financial end-uses. It is possible that some countries may allow
these exports based on their political/economic/military relationship with
the destination country (e.g., within the European Comrnunity, or former
COCOM), for end uses that are considered legitimate commercial
applications of the technology, or, in the case of exports to the United
States, because DES is a national standard. (U)
<p>
As the technology and the marketplace have evolved, the USG export control
authorities have relaxed licensing constraints on cryptographic products
several times over the past 10 years. These changes have usually been made
after industry pressures and internal debate to balance national security
and economic concerns. (U)
<p>
<p>
DOMESTIC AND INTERNATIONAL MARXETS
<p>
While presently encryption software accounts for only a small percentage
of the total software market (1-3%), according to numerous information
security experts contacted in the course of the study, the future growth
trend for this sector is expected to be great.
<p>
The market for encryption in distributed computation, databases, and
electronic mail is beginning to expand exponentially as the U.S. and other
countries develop and popularize electronic commerce, public networks, and
distributed processing. (U)
<p>
Encryption in these environments will often be implemented in software, as
opposed to hardware, because it is generally less expensive and simpler to
install and upgrade. Absent changes in government standards, for the next
ten years, encryption software will primarily use DES and RSA-licensed
encryption algorithms. Other non-standard and company proprietary
algorithrns will be used primarily for security-specific products for
small niche markets. (U)
<p>
Certain developments are promoting greater use by the general public of
software-based network security features, including encryption, throughout
the industrialized world. They include ever increasing use, fueled by well
publicized "break-ins," of distributed databases, popular acceptance and
usage of global networks, and the development and use of electronic
commerce. (U)
<p>
These developments are ongoing at one stage or another in practically all
of the countries surveyed for this assessment. Less technologically
advanced countries, where demand for encryption software is reportedly
negligible, will soon undergo widespread development and computerization
leading to increased demand for encryption so~ware within the next 10
years. (U)
<p>
The overwhelming majority (75%) of general-purpose software products
(e.g., word processors, spread sheet programs, and database programs)
available on foreign markets today are of U.S. origin. Cornmerce
Department analyses indicate that the U.S. has few viable foreign
competitors for such products, and of those general-purpose products with
encryption features, all were found to be of U.S. origin. (U)
<p>
In the security specific software market, however, U. S. manufacturers
face competition in several foreign markets from such encryption exporting
countries as the United Kingdom, Germany, and Israel. To a large extent,
markets for these products tend to be "national. " Not only do export
controls affect sales, but local vendors of security-specific products are
at a competitive advantage in that they are better situated to work
closely with end- users and develop encryption solutions tailored to meet
the conditions of the local environment. (U)
<p>
NSA confirmed the existence of a significant number of foreign
security-specific software products with encryption features,
predominantly from Western European suppliers. Security-specific products
are usually not available on the shelf at retail stores either in the U.S.
or abroad, but can be purchased through direct contact with the
manufacturer. (U)
<p>
<p>
                                   ES-2
<p>
BXA attempted to quantify U.S. competitiveness and market share in 31
foreign countries where encryption is thought to have significant demand.
While sources in the countries surveyed had limited access to import
statistics or market literature on encryption software and encountered
nwnerous difficulties in evaluating this complex market, definite
conclusions may be drawn from the responses. (U)
<p>
Sources in 14 countries indicated that U.S. export controls limit U.S.
market share in their countries. Sources in seven countries indicated that
export controls have either no impact or no major impact. (U)
<p>
Sources in most countries indicated that the U.S. market share is keeping
pace with overall demand despite the impact of U.S. export controls, which
may promote indigenous production or reduce U. S. market penetration. In
all known cases, the U.S. holds the majority of the general-purpose
encryption software market. (U)
<p>
Three exceptions are Switzerland (where the U.S. market share reportedly
declined in 1994, while the market shares of other European countries
rose), Denmark and the United Kingdom, which reported unspecified declines
from previous years. Sources in all three countries attribute the decline
to U.S. export controls, which they claim promote the development and sale
of indigenous encryption products. (U)
<p>
In many countries surveyed, exportable U. S. encryption products are
perceived to be of unsatisfactory quality. (U)
<p>
<p>
ANALYSIS OF FOREIGN PRODUCTS
<p>
NSA used various methods to procure encryption software products from a
variety of countries and companies, as reflected in the TIS database and
other sources. Altogether, 28 products from 22 foreign producers in 10
countries were acquired for the purposes of this study. Of these, 21
purportedly use the DES algorithm, while the remaining 7 use proprietary
algorithms. (U)
<p>
[
<p>
<p>
<p>
<p>
                                           ] (S)
<p>
<p>
<p>
<p>
<p>
                                    ES-3
<p>
ECONOMIC IMPACT
<p>
In the absence of significant foreign competition, the impact of U.S.
export controls on the international market shares of general-purpose
products is probably negligible. Customers are often unaware of the
encryption features in these products and primarily base purchases on the
features implementing the primary function of the product (e.g., word
processing or database). (U)
<p>
[
<p>
<p>
<p>
                   ] (S)
<p>
BXA attempted to quantify the economic impact of export controls on the
U.S. software industry by forwarding a detailed voluntary questionnaire to
206 software vendors and other interested parties. Thirty six encryption
software manufacturers provided completed surveys out of the 71 returned.
By and large, the companies were unable or unwilling to quantify the costs
of export controls, but did provide substantive explanations of how and
why they believe they are adversely affected. (U)
<p>
Some general-purpose software companies claim that export controls have
affected their plans to expand security features to meet anticipated
growing demand. These companies believe that they could expand their
domestic and international customer base with such features. (U)
<p>
The export licensing process itself is not a major obstacle to U. S.
competitiveness. Only seven survey respondents use the Department of State
licensing system. While they continue to have some complaints about the
administrative burdens and time delays associated with State's process,
several noted that there had been improvements in recent years. Only two
of the survey respondents had been denied licenses by the Department of
State. (U)
<p>
Numerous survey respondents indicated that they avoided applying for
export licenses from the Department of State altogether. Some larger
companies whose products tended to be general-purpose in nature either
developed two ~fersions of so~ware, or incorporated an encryption
algorithm they knew would qualify for Commerce general licenses. (U)
<p>
Many smaller, security-specific software firms, on the other hand, elected
to limit their sales to the domestic market only. These companies
indicated a high level of foreign interest in purchasing their products,
and therefore lost potential sales. While it is difficult for them to
quantify their potential market, they believe it to be sizeable. They
claim their small size limited their ability to develop two versions of
their products, and the fact that their products were for secunty purposes
<p>
<p>
                                  ES-4
<p>
specifically requires them to incorporate strong encryption. Only one
company was able to provide specific examples where a foreign competitor
o~ta ned a sale due to an export license denied by U.S. authorities. (U)
<p>
There is little evidence that U.S. export controls have had a negative
effect on the availability of products in the U.S. marketplace. A broad
range of products with secure algorithms exist in the U. S. market and
availability of products is based principally on the level of customer
demand. Export controls may have hindered incorporation of strong
encryption algorithms in some domestic mass-market, general-purpose
products, since some companies find developing and maintaining two
versions of a product infeasible. (U)
<p>
The existence of foreign products with labels indicating DES or other
strong encryption algorithms, even if they are less secure than claimed,
can nonetheless have a negative effect on U.S. competitiveness. Most
encryption users base their purchasing decisions on the advertised product
features, along with price, company reputation, etc. (U)
<p>
<hr>
Back to <a href="./nist951205.html">Pat's page on the December 5 NIST Clipper 2 </a>
meeting. 
Back to Pat's<a href="http://www.isse.gmu.edu/~pfarrell/nist/clipper2.html">
Clipper II page.</a> 
<hr>
<A HREF="http://www.isse.gmu.edu/students/pfarrell/disclaimer.html"> PDF</a> 
May 21, 1996
Backto <a href="http://www.isse.gmu.edu/~pfarrell/hotlist.html">
Pat's hotlist</a> Backto <a href="http://www.isse.gmu.edu/~pfarrell/index.html">Pat's homepage</a>
</body>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-155</DOCNO>
<DOCOLDNO>IA018-000193-B004-155</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/ 206.86.52.80 19970105110032 text/html 4533
HTTP/1.0 200 OK
Date: Sun, 05 Jan 1997 11:00:34 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4351
Last-modified: Thu, 21 Nov 1996 23:57:24 GMT
</DOCHDR>
<HTML>
<HEAD>
   
<TITLE>BioGlobe Home Page</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">
<FORM
METHOD="POST" ACTION="http://www.webtechs.com/html" ENCTYPE="x-www-form-encoded">
<INPUT NAME="recommended" VALUE="0" TYPE="hidden">
<INPUT NAME="level" VALUE="Mozilla" TYPE="hidden">
<INPUT NAME="input" VALUE="0" TYPE="hidden">
<INPUT NAME="esis" VALUE="0" TYPE="hidden">
<INPUT NAME="render" VALUE="0" TYPE="hidden">
<INPUT
NAME="URLs" VALUE="http://www.halsoft.com/html-val-svc/about.html" TYPE="hidden">
<CENTER><applet code=WebBurst19.class width=430 height=230>
<IMG BORDER=0 ALIGN=left WIDTH=430 HEIGHT=230 SRC=smwrld/A.GIF>
<param name="files" value="smwrld/">
<param name="Data" value="72,73,147,120,442,0,147,120,8,1,120,147,1">
</applet></CENTER>
<CENTER><H4> Please be patient  while the java applet loads.</H4></CENTER>
<P><BR> 
</P>
<P></P>
<CENTER><TABLE> <TR> <TD VALIGN="bottom" ALIGN="CENTER" COLSTART="1">
<IMG SRC="Graphics/english_button.gif" WIDTH="30" HEIGHT="27"></TD>
<TD VALIGN="TOP" ALIGN="top" COLSTART="2">
<A HREF="Companies/sosei.html"><IMG SRC="Graphics/sosei.gif" BORDER="0"><FONT
SIZE="5">Sosei Co., Ltd.</FONT></A>
<BR> BioGlobe Web Site
<BR> 7F, MS Bldg.,
3-4-9 Misaki-cho
<BR> Chiyoda-ku, Tokyo 101 Japan
<BR> TEL: 81-3-5210-3290<BR>
FAX: 81-3-5210-3291 
</TD> <TD VALIGN="bottom" ALIGN="CENTER" COLSTART="3">
<IMG SRC="Graphics/JAPANESE.GIF" WIDTH="32" HEIGHT="32"></TD>
</TR>  </TABLE></CENTER> 
<P><IMG SRC="Graphics/line14.gif" WIDTH="600" HEIGHT="4" ALIGN="bottom"> 
</P>
<P></P>
<CENTER>
<A HREF="about.html"><IMG
SRC="Graphics/information.gif" BORDER="0" WIDTH="125" HEIGHT="50" ALIGN="BOTTOM"></A>
<A
HREF="membership.html"><IMG
SRC="Graphics/membership.gif" BORDER="0" WIDTH="125" HEIGHT="50" ALIGN="BOTTOM"></A>

<A HREF="jpn.html"><IMG SRC="Graphics/fjap.gif" BORDER="O" WIDTH="125" HEIGHT="50" ALIGN="BOTTOM"></A><IMG SRC="Graphics/new.gif" BORDER="0" ALIGN="TOP"><BR>

<A HREF="wwwresources.html"><IMG
SRC="Graphics/resources.gif" BORDER="0" WIDTH="125" HEIGHT="50" ALIGN="BOTTOM"></A>
<A
HREF="http://www.bio.org/biocentury/index.html"><IMG
SRC="Graphics/biocentury.gif" BORDER="0" WIDTH="125" HEIGHT="50" ALIGN="BOTTOM"></A>

<A HREF="http://cos.gdb.org"><IMG SRC="Graphics/cos.gif" BORDER="0" WIDTH="125" HEIGHT="50" ALIGN="BOTTOM"></A><IMG SRC="Graphics/new.gif" BORDER="0" ALIGN="TOP"><BR>
<A
HREF="licensefund.html"><IMG
SRC="Graphics/licensef.gif" BORDER="0" WIDTH="125" HEIGHT="50" ALIGN="BOTTOM"></A>

<A HREF="pressnews.html"><IMG SRC="Graphics/pressr.gif" BORDER="0" WIDTH="125" H
EIGHT="50" ALIGN="BOTTOM"</A><BR>
<P>
</P>
<CENTER><FONT SIZE="2"><A HREF="about.html">BioGlobe Information</A><BR>
<A HREF="membership.html">BioGlobe Membership List</A><BR>
<A HREF="jpn.html">For Japanese</A><BR>
<A HREF="wwwresources.html">Biotech Resources on the Internet</A> <BR>
<A HREF="http://www.bio.org/biocentury/index.html">BioCentury</A> <BR>
<A HREF="http://cos.gdb.org">COS</A><BR>
<A HREF="licensefund.html">License Fund</A><BR>
<A HREF="pressnews.html">BioGlobe Press Releases and News Bulletins</A><BR>
</P></CENTER>
<P>If you have some interest or questions about License Fund, please contact
Sosei (Ei Yamada, <A HREF="mailto:eyamada@sosei.com">eyamada@sosei.com</A>).
</P>
<P><IMG SRC="Graphics/line14.gif" WIDTH="600" HEIGHT="4" ALIGN="bottom"></P>
<P>

<FONT SIZE="4"><A HREF="BioCentury2/kanjipg.htm"><IMG
SRC="Graphics/BC_button.gif" BORDER="0" WIDTH="48" HEIGHT="48" ALIGN="bottom">BioCentury
Now!</A> in Japanese
</FONT>
</P>
<P>
<IMG SRC="Graphics/line14.gif" WIDTH="600" HEIGHT="4" ALIGN="bottom"></P>
<P>
<!--<INPUT TYPE="submit" VALUE="Validate this URL"><IMG
SRC="Graphics/valid_html.mcom.gif" WIDTH="48" HEIGHT="32" ALIGN="bottom"><I><BR>-->
Updated November 17, 1996<BR> </P>
<TABLE> <TR><TD COLSTART="1">Copyright &#169; 1996 <BR> All rights
reserved.<P>
Write the <A HREF="mailto:ccarmack@genweb.com">WebMaster</A> </P></TD>
<TD COLSTART="2"> <A HREF="http://www.genweb.com/">GenWeb
</A></TD> <TD COLSTART="3"> <A HREF="http://www.genweb.com/"><IMG
SRC="Graphics/genweb.gif" ALIGN="bottom" WIDTH="54" HEIGHT="54"></A></TD> </TR>
</TABLE>
<P><BR>
</P>
<P></P>
<CENTER>Graphics by <BR>
<IMG SRC="Graphics/in_image.gif" WIDTH="72" HEIGHT="31" ALIGN="bottom"><BR>
<B>DESIGN</B> <BR>
<I><A HREF="mailto:inimage@netgate.net">inimage@netgate.net</A></I> </CENTER>
</FORM>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-156</DOCNO>
<DOCOLDNO>IA064-000377-B048-330</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/sosei.html 206.86.52.80 19970112094659 text/html 11768
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:47:03 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 11585
Last-modified: Sun, 12 May 1996 19:30:19 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Sosei Home Page</TITLE></HEAD>
<BODY BGCOLOR=#FFFFFF><H1><IMG  Align=top SRC="../Graphics/sosei.gif">Sosei Co., Ltd.</H1><H3>Corporate Profile</H3>
<HR>
7F, MS Bldg., 3-4-9 Misaki-cho, Chiyoda-ku<BR>
Tokyo, Japan 101<BR>
Telephone: 81-3-5210-3290<BR>
Fax: 81-3-5210-3291<P>

<B>History:</B><BR>
<TABLE BORDER=1>
<td><B>1990</B></td><td align = right><EM>June</EM></td><td><IMG SRC="../Graphics/sosei_bullet.gif">&#32;S. Tamura and T. Nakamura incorporated Sosei</td><tr>

<td><B>1991</B></td><td align = right><EM>April</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;S. Tamura became full time President and CEO</td><tr>

<td rowspan =3><B>1992</B></td><td align = right valign=top><EM>May</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Agreement with Sumitomo on HGF signed<BR>
<IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Recieved first payment</td><tr>

<td align = right><EM>September</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;S.R. One invested $875K</td><tr>

<td align = right><EM>December</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;New office opened in Tokyo</td><tr>

<td rowspan =2><B>1993</B></td><td align = right><EM>January</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;M. Kimura, Director of Planning and Marketing, hired</td><tr>

<td align = right><EM>May</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Reported first profit (fiscal year; June-May)</td><tr>

<td rowspan=3 ><B>1994</B></td><td align = right valign=top><EM>January</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Schroder Ventures, S.R. One, Oxford Bioscience and Biotechnology Investment (Rothschild Asset Management) committed to invest $4M</td><tr>

<td align = right><EM>July</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Nisshin Oil committed to fund IP3/IP4 project</td><tr>

<td align = right><EM>December</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;T. Kiley and T. Watanabe joined the Board<tr valign=middle>

<td valign=middle rowspan=4><B>1995</B><td align = right valign=top><EM>March</EM><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Sosei License Option Fund being raised ($4M committed as of April 31)<tr>

<td align = right><EM>June</EM><P></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Baruch Blumberg (Nobel Laureate, discovered of HBV) became a Board Member and Scientific Advisor</td><tr>

<td align = right><EM>July</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;E. Yamada, Senior Director of Scientific Affairs, hired</td> 
<tr>
<td align = right valign= top><EM>September</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;T. Watanabe nominated to Representative Director and Chairman of Investment Committee, License Fund.</td>
<tr>
<td><B>1996</B>
<td align=right><EM>February</EM></td><td><IMG SRC="../Graphics/sosei_bullet.gif">&#32;Joined ERATO Project (Mikoshiba Calciosigmal Net)</td>
</TABLE><P>

<B>Founders: </B>Shinichi Tamura and Tetsuo Nakamura<P>

<B>Incorporation: </B>June 22, 1990<P>

<B>Corporate Overview:</B><BR>
<BLOCKQUOTE><I>Business:</I><BR>
Seed Money Investment and License of Intellectual Property Rights. To become the most reliable "cultural interpreter" between innovative biotech firms in the U.S./Europe and conservative but reliable medical and pharmaceutical companies and research labs in Japan by:<P>
1. Accessing novel biopharmaceutical science in Japan by
expediting the licensing and commercialization of university
discovered technologies.<P>

2. Developing strategic licensing arrangements with such science both inside and outside Japan.<P>
3. Providing the most reliable platform in Japan for small biotech firms in the U.S. and Europe looking for Japanese corporate partners to establish most efficient global R&amp;D strategy.</BLOCKQUOTE><P>

<B>Track Record / May, 1995</B><BR>
<BLOCKQUOTE>Only major deals, for which Sosei played a pivotal role, with size close to or in excess of two billion yen are listed.</BLOCKQUOTE>

<TABLE border = 4>
<th>Date</th><th>Licenser</th><th>Area</th><th>Licensee</th><th>License Fee</th><tr>

<td ALIGN=CENTER VALIGN=MIDDLE>May<BR>1995</td><td ALIGN=CENTER VALIGN=MIDDLE>Geron</td><td>Anticancer</td><td>Kyowa Hakko</td><td>$30M(+royalty)<tr>

<td ALIGN=CENTER VALIGN=MIDDLE>April<BR>1994</td><td ALIGN=CENTER VALIGN=MIDDLE>Pharmacyclics</t><td>MRI contrast medium</td><td> n.a.</td><td>n.a.</td><tr>
                                       
<td ALIGN=CENTER VALIGN=MIDDLE>March<BR>1994</td><td ALIGN=CENTER VALIGN=MIDDLE>Agene</td><td>Aging Project</td>
<td> Ministry of Welfare<BR>
 Nippon Roche<BR>
 Meiji Seika<BR>
 Eisai<BR>
 Kissei Pharmaceutical<BR>
</td><td>3 billion yen (equity)</td><tr>

<td ALIGN=CENTER VALIGN=MIDDLE>June<BR>1993</td><td ALIGN=CENTER VALIGN=MIDDLE>GenPharm</td><td>Human antibody</td><td>Eisai</td><td>2.5 billion yen (+royalty)</td><tr>

<td ALIGN=CENTER VALIGN=MIDDLE>May<BR>1992</td><td ALIGN=CENTER VALIGN=MIDDLE>Sosei </td><td>HGF</td><td>Sumitomo  Pharmaceutical</td><td>n.a.</td><tr>

<td ALIGN=CENTER VALIGN=MIDDLE>1989-1990</td><td ALIGN=CENTER VALIGN=MIDDLE>IDEC</td><td>Idiotype antibody</td><td> Institute of Immunology Zenyaku</td>
 <td>2.3 billion yen (+royalty)</td></TABLE><BR>

<B>Why Sosei is Successful:</B>
<BLOCKQUOTE>1. Sosei has invented an efficient system to identify and obtain important biopharmaceutical technology arising in top-tier Japanese universities.<P>

2. Sosei has already identified and obtained key technology in a variety of medically important areas (e.g. liver disease).<P>

3. Sosei has already established a track record of strategic alliances both for itself (e.g. Sumitomo-unannounced significant deal) and for third parties (e.g. Geron - $30M)<P>

4. Sosei's management, business advisors and shareholders represent top quality  experience in global licensing and investment activities.<P>

5. Sosei has outstanding scientific advisors especially in hepatology and gerontology related research.<P>

6. Sosei's international set-up has given it unique acess to U.S.,
Europe and Japan for funding, markets, technology and patenting and
regulatory flexibility.<P>

7. Relationships are accelerating Sosei's rapid progress:<P>

<UL><LI> Sumitomo Pharmaceutical Co., Ltd. has made a serious commitment for HGF development, ensuring significant license fees and royalties paid to Sosei.
<LI> Sosei has helped Koseisho (Japanese FDA/NIH) set up consortium (Agene) providing research funds for the aging project as well as strong ties to the member companies ($30M fund).
<LI> Tokyo University and Osaka University give access to innovative technologies in Japan.
</UL>

8. Global venture capital funding already established:<P>

<UL><LI> $0.9M investment from S.R. One in Sept. '92.
<LI> $4M investment commitment from Schroder, S.R. One, Oxford Bioscience and Biotechnology Investments Limited (Advised by Rothschilds) in January, 1994.
<LI>$4M raised for the <A HREF = "../licensefund.html">License Fund</A> in mid 1995.
</UL></BLOCKQUOTE>

<B>Latest Corporate Partners (Example):</B>
<UL><LI> Sumitomo Pharmaceuticals
<LI> Snow Brand
<LI> Kissei
<LI> Takara Shuzo
<LI> Nisshin Oil
<LI> Fujirebio
<LI> Institute of Immunology
<LI> Genentech
<LI> GenPharm
<LI> Geron
<LI> ONYX
<LI> <A HREF = "http://www.generics.co.uk">Generics Group</A>
<LI> ERATO (Exploratory Research for Advanced Technology): JRDC - Ministry of Science and Technology
<LI> Tokyo University
<LI> Osaka University
<LI> Hokkaido University
<LI> Ochanomizu University
<LI> Hiroshima Universiy
<LI> Mitsubishi Chemical
</UL>

<B>Management:</B><P>
Shinichi Tamura - President and CEO, Board Director, Co-founder<BR>
<a href="mailto:stamura@sosei.com">stamura@sosei.com </a> 
<P>
Tetsuo Watanabe - Representative Director, Chairman of Investment Committee<P>

Ei Yamada - Senior Director, Scientific Affairs<BR>
<a href="mailto:eyamada@sosei.com">eyamada@sosei.com</a><P>

Masaya Kimura - Director, Planning & Marketing<BR>
<a href="mailto:maya@sosei.com">maya@sosei.com</a><P>

<B>Board of Directors:</B><P>
<a href="mailto:stamura@sosei.com">Shinichi Tamura</a><BR>
Representative Director, President and CEO<BR>
Ex-representative Director (CEO), Genentech Ltd.(Genentech, Japan)<P>

Nobuo Matsuki<BR>
Chairman<BR>
General Partner, Schroder PTV Partners K.K.<BR>
<A HREF="mailto:nmatsuki@magical.egg.or.jp">nmatsuki@magical.egg.or.jp</A><P>

James E. Foley<BR>
Vice President, SmithKline Beecham International<BR>
<A HREF="mailto:James.FOLEY@nca.sb.com">James.FOLEY@nca.sb.com</A><P>

Baruch S. Blumberg<BR>
Nobel Prize Laureate<BR>
Master of Balliol College at Oxford University<BR>
<a href="mailto:BS_Blumberg@fccc.edu">BS_Blumberg@fccc.edu</a><P>

Jeremy Curnock Cook<BR>
Director, Rothschild Asset Management Ltd., Advisors to BIL<P>

Tom Kiley<BR>
Former VP of Corporate Development and General Counsel for Genentech<BR>
<A HREF="mailto:tomkiley@aol.com">tomkiley@aol.com</A><P>

Jonathan J. MacQuitty</a><BR>
President and CEO of GenPharm International<BR>
<a href="mailto:lhunter353@aol.com">lhunter353@aol.com</A><P>

Shoko Matsui<BR>
Partner, Schroder PTV Partners K.K.<BR>
<a href="mailto:smatsui@magical.egg.or.jp">smatsui@magical.egg.or.jp</a><P>

Edmund M. Olivier<BR>
General Partner, Oxford Bioscience Partners<BR>
<a href="mailto:olivier@realm.net">olivier@realm.net</a><P>

Tetsuo Watanabe<BR>
Representative Director, Chairman of Investment Committee, License Fund<BR>
Senior Advisor of Asahi Chemical Industry Co., Ltd.<P>

<B>Business Advisors:</B><P>

Hans Vauthier<BR>
Former Director of marketing and member of the Pharma Management Committee CIBA-GEIGY AG<P>

Tetsuo Nakamura<BR>
President and CEO of Institute of Immunology<P>

Clifford Orent<BR>
Chairman, President & Chief Executive Officer of Terrapin Technologies, Inc.<BR>
<a href="mailto:orent@trpntech.com">orent@trpntech.com</a><P>

<B>Scientific Advisors:</B><P>

Baruch S. Blumberg, M.D., Ph.D.<BR>
Nobel Prize Laureate<BR>
Master of Balliol College at Oxford University<BR>
<a href="mailto:BS_Blumberg@fccc.edu">BS_Blumberg@fccc.edu</a><P>

Toshifumi Kagiya, M.D., Ph.D.<BR>
Director, Osaka Health Office of All Nippon Airways<BR>
Assistant Professor at Osaka University<BR>
Focused on Cardiovascular Research<P>

Katsuhiko Mikoshiba, M.D.<BR>
Professor at Tokyo University<BR>
Focused on Signal Transduction, Neuroscience<P>

Richard Miller, M.D.<BR>
President and CEO at Pharmacyclics<BR>
Co-founder of IDEC and CellPro<BR>
Assistant Professor at Stanford University<BR>
Focused on Oncology<BR>
<A HREF="mailto:Richard@Pclx.com">Richard@Pclx.com</A><P>

Toshikazu Nakamura, Ph.D.<BR>
Professor at Osaka University<BR>
Discoverer of HGF<BR>
Focused on Cell Biology, Hepatology<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated; February 7, 1996.
Copyright &copy; 1996 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!--  INFORMATION ABOUT THE CONTACT PERSON FILLING OUT THIS FORM
Date:April 5, 1995
Name: Shinichi Tamura
Title: President and CEO
Company Name: Sosei Co., Ltd.
Adress: 7F, MS Bldg., 3-4-9 Misaki-cho, Chiyoda-ku
City: Tokyo
State: Tokyo
Zip Code: 101
Telephone Number: 81-3-5210-3290
Fax Number: 81-3-5210-3291
e-mail: 1.tamura@sosei.com 2. mail08110@pop.net> -->

<!-- revised: Sunday, June 4, 1995; 5:00 PM >

<!-- revised: Wednesday,  July 12, 1995 -->
<!-- revised: Saturday, 09/23/95 CC -->
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-157</DOCNO>
<DOCOLDNO>IA064-000377-B048-364</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/about.html 206.86.52.80 19970112094739 text/html 9785
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:47:34 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 9603
Last-modified: Sun, 12 May 1996 19:55:00 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Info about BioGlobe</TITLE></HEAD><BODY BGCOLOR=#FFFFFF>

<H1><CENTER>Information about BioGlobe</CENTER></H1><P><HR>

<H3>Background of <I>BioGlobe</I> Web site and Mailing List:</H3><P>
<BLOCKQUOTE>Emerging and established biotechnology companies in the US and Europe have identified Japanese companies as potential commercial partners and visit Japan regularly to develop relationships that hopefully lead to technology-related partnerships, investment, and research funding. To facilitate development of these relationships, several organizations and consulting groups have organized partnering conferences to bring biotechnology closer to interested Japanese companies in the hope that discussions will lead to partnering agreement supporting research and product development by the biotech partner. US and European biotech companies are realistic in their aspirations, and see business cooperation with Japanese companies as a potential source of funding in return for technology rights for Japanese and SEA markets where their technology would otherwise go undeveloped.<P>

Japanese companies, on the other hand, are finding themselves having to respond to changes in the Japanese pharmaceutical environment caused in part by government's response to rising healthcare costs:<P>

&#42     Forced to take more risk by the changing regulatory environment- i.e., pricing guidelines that reward innovation.<BR>
&#42     Must compete among themselves and with foreign-affiliated companies for technology that allows breakthrough innovation.<BR>
&#42     Western companies are more and more proactive in obtaining Japan/SEA rights in their biotechnology deals and are willing to provide the same financial terms as Japanese companies as part of a worldwide agreement.<BR>
&#42     Foreign-affiliated companies are more willing than Japanese companies to assume high risk projects while providing for the long-term strategic interests of their biotech partner.<P>

The vast number of biotechnology companies visiting Japan to present their technology, however, has overwhelmed the capacity for most Japanese companies to understand, both scientifically and commercially, the implications of the technology presented and make informed investment decisions. The consequence many times is a polite hearing and lunch, with the biotechnology message lost or not entirely appreciated. Biotechnology companies leave feeling  good, when in reality they are the victims of Japanese politeness. This scenario can be avoided on both sides by more focused presentations to companies pre selected based on research and commercial interests, given an opportunity to review and comment informally on introductory information provided by the biotechnology company. BioGlobe provides a communication tool to allow both Japanese and emerging biotechnology companies a competitive advantage to make productive use of time and money in progressing partnering initiatives and relationship building in Japan.<P>

BioGlobe provides an interface between Western and Japanese business cultures, allowing each side to better appreciate the nuances of 'deal making' in Japan. Differences in definition of risk, an appreciation of the regulatory and commercial healthcare environment, which, for many technologies is problematical, and problems inherent in communicating in a second language for Japanese can be attenuated, allowing quality communication between both scientists and commercial people on both sides of the discussion. BioGlobe and <A HREF = "Companies/sosei.html">Sosei</A>, on behalf of subscribing companies , can facilitate opportunities, technical assessments and deal making, increasing understanding and the probability that an agreement will emerge.
<P>

<A HREF = "Companies/koseisho.html">Koseisho</A> (Ministry of Health and Welfare) understand that cutting-edge healthcare technology is required for the Japanese pharmaceutical industry to remain worldwide players and for government to reduce healthcare costs. <A HREF = "Companies/koseisho.html">Koseisho</A> is lending support to BioGlobe to encourage interaction with both themselves, providing dialogue as they consider new regulatory policies, and industry to progress government's responsibility to society in providing the best healthcare possible.<P>

<A HREF="Companies/sosei.html">Sosei</A> is both a biotechnology company with its own research programs, and an asset-development company focused on value-added bi-directional biopharmaceutical technology transfer between Japan/SEA and the West. <A HREF = "Companies/sosei.html">Sosei</A> is funded by several US and European venture capital groups, and has successfully concluded partnering relationships in Japan for both its own technologies and several US biotechnology companies.<P>

<A HREF = "Companies/krp.html">Kyoto Research Park</A> (<A HREF="Companies/krp.html">KRP</A>), 100% subsidiary of Osaka Gas company, where 80 companies and R&D institutions are located in the center city of Kyoto, operates a research park.  KRP consists of 8 buildings and has three primary objectives:<P>

<UL><LI>Promotion of technological innovation and the development of new core technologies.
<LI>To foster the development of high technology venture businesses.
<LI>To facilitate entry by foreign firms into the Japanese market.
</UL>

Among <A HREF="Companies/krp.html">KRP's</A> support services, <A HREF="Companies/krp.html">KRP</A> organizes the Life Science Technology Transfer Forum (LSTTF), which encourages information exchange between industry and academia in life science-related fields.  It also provides foreign firms with opportunities to meet the LSTTF members through presentation, exhibition and business matching meeting, etc. at the LSTT forum.<P>

<A HREF = "http://www.generics.co.uk">Generics Group</A> is a uniquely innovative global organisation combining excellence in the strategic application of technology in business. Founded in 1986 it is already Europe's leading laboratory based business and technology consulting and investment company.<A HREF = "http://www.generics.co.uk">Generics</A> is  the preferred partner of many major international corporations in the US, Japan and Europe. <A HREF = "http://www.generics.co.uk">Generics</A> also invests in its own scientific research programmes in many areas in addition to the Life Sciences, for example, in new materials, optics and magnetics. These are then commercialised through royalties or through incorporation in a new business venture. The Group has therefore extensive experience in creative technology transfer between and within corporations in most industry sectors. <A HREF = "Companies/sosei.html">Sosei</A> and <A HREF = "http://www.generics.co.uk">Generics</A> intend to collaborate further in  pursuit of their common goals to establish the most effective and efficient R&D system from a global perspective.<P>
 
<A HREF = "http://www.bio.org/biocentury/index.html">BioCentury</A> is widely known as the leading provider of analysis, interpretation and commentary relating to biotechnology industry development, corporate strategy, and shareholder value.  BioGlobe and <A HREF = "http://www.bio.org/biocentury/index.html">BioCentury</A> are mutually hyperlinked to each other's home page to facilitate collaborations.<P></BLOCKQUOTE>

<H3>Initial Subscribers:</H3>
<B>Japan:</B>
<UL><LI> Toshiaki Hirai - Director, R&D Promotions, <A HREF="Companies/koseisho.html">Koseisho</A>
<LI> <a href=mailto:stamura@sosei.com>Shinichi Tamura</a> - President & CEO, <A HREF="Companies/sosei.html">Sosei</A> (core)
<LI>  <a href=mailto:eyamada@sosei.com>Ei Yamada</a> - Senior Director, <A HREF="Companies/sosei.html">Sosei</A> (core)
<LI> Takayuki Kimura - Managing Director, <A HREF="Companies/krp.html">Kyoto Research Park</A>
<LI> <a href=mailto:james.foley@nca.sb.com>Jim Foley</a> - SmithKline Beecham, VP
<LI> Hiro Furuichi - Managing Director, <A HREF="Companies/agene.html">Agene</A> (Koseisho consortium)
<LI> Asahi Chemical
<LI> <A HREF = "Companies/kaketsuken.html">Chemo-Sero-Therapeutic</A>
<LI> Fujirebio
<LI> Hitachi Chemical
<LI> <A HREF = "Companies/iatron.html">Iatron</A>
<LI> Kissei
<LI> Kyowa Hakko
<LI> <A HREF = "Companies/meiji.html">Meiji Milk</A>	                  
<LI> <A HREF="Companies/mitsubishi.html">Mitsubishi Chemical</A>
<LI> <A HREF = "Companies/nisshinbo.html">Nisshinbo</A>
<LI> <A HREF = "Companies/nisshin.html">Nisshin Oil</A>
<LI> Ono
<LI> <A HREF = "Companies/takara.html">Takara Shuzo</A>
<LI> (+ decision makers of other pharmaceutical companies)
</UL>

<B>US:</B>
<UL><LI> <a href=mailto:ccarmack@genweb.com>Condie Carmack</a>, <A HREF = "http://www.genweb.com/">GenWeb</A> (US core, Technical Operator)
<LI> Peter Sears - President, S.R. One
<LI> Ned Olivier - General Partner, OBP
<LI> David Flores - President and Publisher, <A HREF="http://www.bio.org/biocentury/index.html">BioCentury</A>
<LI> (+ a few more VCs, law firm, accounting firm, etc.)
</UL>

<B>Europe:</B><BR>
<UL>
<LI> Gordon Edge - Chairman, <A HREF = "http://www.generics.co.uk">Generics Group</A>
<LI> Jeremy Curnock Cook - GP, Rothschild Asset Management
<LI> Astra Hassle
</UL>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated May 12, 1996.
Copyright &copy; 1996 <A HREF = "http://www.genweb.com/">GenWeb </A>.<A HREF="http://www.genweb.com/"><IMG  Align=Center SRC="Graphics/genweb.gif"></A>
All rights reserved.</FONT></ADDRESS>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-158</DOCNO>
<DOCOLDNO>IA064-000377-B049-24</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/membership.html 206.86.52.80 19970112094805 text/html 3403
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:48:04 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3221
Last-modified: Mon, 23 Sep 1996 00:42:15 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
   <TITLE>BioGlobe Membership List</TITLE>
   <META NAME="GENERATOR" CONTENT="User-Agent: Mozilla/3.0Gold (Macintosh; I; PPC)">
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<H1 ALIGN=CENTER>BioGlobe Membership List</H1>

<P>
<HR><FORM method="POST" action="http://www.sosei.com/cgi/wwwwaissosei.cgi">This
is a searchable index of information.<BR>
<B>Note:</B> <I>This service can only be/ used from a forms-capable browser.</I></P>

<P> Enter keyword(s): <INPUT type=text name="keywords" value="" size=30><INPUT type=submit value="  Search  "><INPUT type=reset value="  Reset  "></P>

<P></FORM>
<HR><B>Japan</B>:<BR>
</P>

<UL>
<LI><A HREF="http://www.sosei.com/Companies/koseisho.html">Koseisho</A>
</LI>

<LI><A HREF="http://www.sosei.com/Companies/sosei.html">Sosei</A> </LI>

<LI><A HREF="http://www.sosei.com/Companies/krp.html">Kyoto Research Park</A>
</LI>

<LI><A HREF="http://www.sosei.com/Companies/agene.html">Agene</A> </LI>

<LI><A HREF="http://www.sosei.com/Companies/takara.html">Takara Shuzo</A>
</LI>

<LI><A HREF="http://www.sosei.com/Companies/mitsubishi.html">Mitsubishi
Chemical</A> </LI>

<LI><A HREF="http://www.sosei.com/Companies/iatron.html">Iatron</A> </LI>

<LI><A HREF="http://www.sosei.com/Companies/fujisawa.html">Fujisawa</A>
</LI>

<LI>Kyowa Hakko </LI>

<LI>Fujirebio </LI>

<LI>Asahi Chemical </LI>

<LI>Kissei </LI>

<LI><A HREF="http://www.taiho.co.jp/">Taiho</A> </LI>

<LI><A HREF="http://www.sosei.com/Companies/nisshin.html">Nisshin Oil</A>
</LI>

<LI><A HREF="http://www.sosei.com/Companies/nisshinbo.html">Nisshinbo Industries,
Inc.</A> </LI>

<LI>Hitachi Chemical </LI>

<LI><A HREF="http://www.sosei.com/Companies/kaketsuken.html">Kaketsuken</A>
</LI>

<LI><A HREF="http://www.sosei.com/Companies/meiji.html">Meiji Milk</A>
</LI>
</UL>

<P><B>US:</B> </P>

<UL>
<LI><A HREF="http://www.sosei.com/Companies/genpharm.html">GenPharm International</A>
</LI>

<LI>S.R. One </LI>

<LI><A HREF="http://www.bio.org/biocentury/index.html">BioCentury</A> </LI>

<LI><A HREF="http://www.sosei.com/Companies/ipi.html">Interneuron Pharmaceuticals,
Inc.</A> </LI>

<LI><A HREF="http://www.sosei.com/Companies/onyx.html">ONYX Pharmaceuticals</A>
</LI>

<LI><A HREF="http://www.sosei.com/Companies/terrapin.html">Terrapin Technologies,
Inc.</A> </LI>

<LI><A HREF="http://www.sosei.com/Companies/geron.html">Geron</A> </LI>

<LI>SmithKline Beecham </LI>
</UL>

<P><B>Europe:</B><BR>
</P>

<UL>
<LI><A HREF="http://www.generics.co.uk">Generics Group</A> </LI>

<LI><A HREF="http://www.medisan.se/">Medisan</A> </LI>

<LI><A HREF="http://www.oxfordsp.com">Oxford Science Park</A> </LI>

<LI>Rothschild Asset Management </LI>

<LI>Astra Hassle </LI>
</UL>

<P><A HREF="http://www.sosei.com/"><IMG SRC="http://www.sosei.com/Graphics/home_button.gif" HEIGHT=53 WIDTH=59 ALIGN=CENTER></A><A HREF="http://www.sosei.com/">
Home Page</A></P>

<P> 
<HR></P>

<ADDRESS><FONT SIZE=+0>Updated May 12, 1996. Copyright &copy; 1996 <A HREF="http://www.genweb.com/">GenWeb
</A>.<A HREF="http://www.genweb.com/"><IMG SRC="http://www.sosei.com/Graphics/genweb.gif" HEIGHT=54 WIDTH=54 ALIGN=CENTER></A>
All rights reserved.</FONT></ADDRESS>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-159</DOCNO>
<DOCOLDNO>IA064-000377-B049-62</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/jpn.html 206.86.52.80 19970112094825 text/html 4529
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:48:28 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4347
Last-modified: Fri, 22 Nov 1996 04:59:21 GMT
</DOCHDR>
<HTML>
<HEAD>
<title>For Japanese</title>
</head>
<body bgcolor="#FFFFFF">

@@@@@<center><h2>{Fl</h2></center>

1. <a href="PressNews/advertisement.html">Fl</a><p>

2. <a href="http://www.bio.org/biocentury/index.html">BioCentury</a><p>

AEI@oCIAiJAPXXUNoCIoEEImBioCenturyg{yxB@EAk@AEIsjI[_[B]B@<p>

"Without a question, BioCentury is the most insightful publication on the biotech industry. More than just 'news' BioCentury brings timely analysis and thought-provoking issues to the fore, inspiring concepts that shape business strategy."<br>

-John Walker<br>
President &  CEO<br>
Arris Pharmaceutical Corp.<br>
South San Francisco, California<p>

"Karen Bernstein knows the undercurrents of the industry.  She
effectively connects the dots of what's going on in biotech and brings the
relationship of those events into focus.  I get a deeper understanding
of the news when I read BioCentury.  It provides me with the insight I need
as a CEO."<br>

-David Holveck<br>

Chief Executive Officer<br>
Centocor Inc.<br>
Malvern, Pennsylvania<p>
 
"BioCentury is essential because it keeps me abreast of the U.S. trends. 
As a senior manager of a Canadian biotech company, I have to know what's
going on in the U.S.  It's where the industry's trends are set.  It's
where we consummate deals and continue to grow in this difficult
environment."<br>

-Graham Strachan<br>
President & CEO<br>
Allelix Biopharmaceuticals Inc.<br>
Toronto, Canada<p>

"BioCentury is a tool that increases my productivity. It provides useful
information on business and financial developments and gives me an
overview of the sector every week and if there's a major event mid-week
you let us know about it with the BioCentury Extra service."<br>

-Henri Zinsli<br>
Head Corporate Business Development<br>
Ciba-Geigy Ltd.<br>
Basle, Switzerland<p>

"Karen Bernstein's foresight in identifying the need for an informative
weekly round-up of events and interpretative comment on the world's
biotech industry has been enormously vindicated by the success of
BioCentury."<br>

-Dr. Keith McCullagh<br>
Chief Executive<br>
British Biotech plc<br>
Oxford, England<p>

"As a regular reader of a number of health care publications and as head
of the biotechnology investment practice at E.M. Warburg, Pincus, I am
consistently impressed by both the depth and insight of BioCentury."<br>

-James E. Thomas<br>
Managing Director<br>
E.M. Warburg, Pincus & Co. Inc.<p>


<p>AoCIE_Laguna Niguel, 1996@Special Recognition AwardB@oBioCentury]fB@o{\mnAyx^B@oCIAeBioCenturyL_IjB</p>



3. <a href="http://cos.gdb.org">Community of Science (COS)</a><p>


<p>{NPOgB@COSJohn Hopkins wASEJi_wy@eIf[^x[XB@X@`s_`gf[^x[XB@Expert f[^x[XpgbvxBqdq[MB@MedlineA AgranteIB@SEJi_w@A[bpf[^o^B@{f[^x[XxIxICANZXxIio_vB@AIIJjpvB</p>



	<hr>

<pre>Date created: 11/16/96
Last modified: 11/16/96
Copyright &#169; 1996, Sosei
</address></pre>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT03-B24-160</DOCNO>
<DOCOLDNO>IA064-000378-B001-15</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/wwwresources.html 206.86.52.80 19970112094835 text/html 18720
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:48:41 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 18537
Last-modified: Tue, 19 Nov 1996 05:58:57 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Biotechnology Resources</TITLE></HEAD><BODY BGCOLOR=#FFFFFF>
<H1>Biotechnology Resources on the Internet</H1><HR>

<H3>Biotech Companies/Vendors on the Net</H3><BR>

Sosei Co. Ltd.,<BR>
<A HREF="http://www.sosei.com">http://www.sosei.com</A></P>

Biotech Company WWW Registry<BR>
<A HREF="http://www.data-transport.com">http://www.data-transport.com</A><P>

<!--Clinical Trials Advisor (twice-monthly advisor on the practicalities of successful clinical trials)
http://www.medville.com/cta.htmlhttp://www.medville.com/cta.html -->

BioResearch Ireland (BRI) is established to commercialise biotechnology research
in Irish universities and research institutes.<BR> 
 <A HREF="http://www.commerce.ie/cb/bioresearch">http://www.commerce.ie/cb/bioresearch</A><P>

Biotechnology Companies listed alphabetically<BR>
<A HREF="http://www.informatik.uni-rostock.de/HUM-MOLGEN/biotech/companies/">http://www.informatik.uni-rostock.de/HUM-MOLGEN/biotech/companies/</A><P>

Vendors of Scientific Supplies and Equipment<BR>
<A HREF="http://www.arabidopsis.com/!sv.html">http://www.arabidopsis.com/!sv.html</A><P>

BIO Online<BR>
<A HREF="http://www.bio.com/">http://www.bio.com</A><P>

BioSpace<BR>
<A HREF="http://www.biospace.com/">http://www.biospace.com</A><P>

BioData<BR>
<A HREF="http://www.biodata.com/">http://www.biodata.com</A><P>


MEDMarket Healthcare Manufacturing Industry Index<BR>
<A HREF="http://web.frontier.net/MEDMarket/indexes/indexmfr.html">http://web.frontier.net/MEDMarket/indexes/indexmfr.html</A>

<H3>FDA</H3><BR>
CBER FTP subdirectory<BR>
<A HREF = "ftp://cdv2.cder.fda.gov/cber">ftp://cdv2.cder.fda.gov/cber</A><P>

CDER FTP site<BR>
<A HREF = "ftp://cdv2.cder.fda.gov/">ftp://cdv2.cder.fda.gov</A><P>

CDRH Electronic Docket (via fedword)<BR>
[Go to "Health Mall"; choose gateway list}<BR>
<A HREF = "telnet://fedworld.gov/">telnet://fedworld.gov</A><P>

Center for Food Safety and Nutrition<BR>
(CFSAN Web site<BR>
<A HREF = "http://vm.cfsan.fda.gov/">http://vm.cfsan.fda.gov</A><P>

FDA BBS<BR>
<A HREF = "telnet://fdabbs.fda.gov/">telnet://fdabbs.fda.gov</A>; login:bbs<P>

FDA Web site<BR>
<A HREF = "http://www.fda.gov/fdahomepage.html">http://www.fda.gov/fdahomepage.html</A><P>

National Center for Toxicological Research (NCTR)<BR>
<A HREF = "http://www.fda.gov/nctr">http://www.fda.gov/nctr</A><P>

<H3>Other Government Resources</H3><P>

Centers for Disease Control Web server<BR>
(has MMWR and CLIA information)<BR>
<A HREF = "http://www.cdc.gov/">http://www.cdc.gov/</A><P>

Department of Health and Human Services<BR>
Web server (provides links to many HHS Web and gopher servers)<BR>
<A HREF = "http://www.os.dhhs.gov/">http://www.os.dhhs.gov/</A><P>

FedWorld by telnet - NTIS Gateway to many government BBSs<BR>
<A HREF = "telnet://fedworld.gov/">telnet://fedworld.gov</A><P>

Government Printing Office<BR>
<A HREF = "http://www.access.gpo.gov/">http://www.access.gpo.gov/</A><P>

Library of Congress gopher server (access to most government gophers)<BR>
<A HREF = "gopher://marvel.loc.gov/">gopher://marvel.loc.gov/</A><P>

Library of Congress Web server<BR>
<A HREF = "http://lcweb.loc.gov/">http://lcweb.loc.gov/</A><P>

National Technology Information Service (NTIS) Web server<BR>
<A HREF = "http://www.fedworld.gov/">http://www.fedworld.gov/</A><P>

Occupational Safety and Health Administration (OSHA) Web server<BR>
<A HREF = "http://www.osha.gov/">http://www.osha.gov/</A><P>

The Federal Web locator<BR>
<A HREF = "http://www.law.vill.edu/Fed-Agency/fedwebloc.html">http://www.law.vill.edu/Fed-Agency/fedwebloc.html</A><P>

U.S. Central Intelligence Agency (CIA) Web server (CIA World Fact Book, maps, employment)<BR>
<A HREF = "http://www.odci.gov/">http://www.odci.gov</A><P>

USDA APHIS Gopher server (ha biologics and biotechnology regulations from 9 CFR)<BR>
<A HREF = "gopher://gopher.aphis.usda.gov/">gopher://gopher.aphis.usda.gov/</A><P>

<H3>Regulatory, Patent, and Legal Resources</H3>


Newsgroup for use by those in the regulatory profession<BR>
alt.pharm.reg-affairs
(Use it as a form to seek and exchange information)<P>



RAinfo - The Regulatory Affairs Information Home Page
<A HREF="http://www.nando.net/ads/ckbus/RAinfo/reglink1.htm">http://www.nando.net/ads/ckbus/RAinfo/reglink1.htm</A><P>

The North Carolina Regulatory Affairs Forum Home Page
<A HREF="http://www.nando.net/ads/ckbus/ncraf/ncraf.htm">http://www.nando.net/ads/ckbus/ncraf/ncraf.htm</A><P>


CNIDR United States Aids Patent Database<BR>
<A HREF="http://patents.cnidr.org/">http://patents.cnidr.org/</A><P>

Cornell Law Library<BR>
<A HREF="http://fatty.law.cornell.edu/">http://fatty.law.cornell.edu/</A><P>

Federal Register (1994 to present) and U.S. Code through GPO<BR>
<A HREF="telnet://librot1.lib.unc.edu/">telnet://librot1.lib.unc.edu</A>; login: LIBRARY<P>

Federal Register (table of contents only)<BR>
<A HREF="http://gopher.nara.gov:70/1/register">http://gopher.nara.gov:70/1/register</A><P
>http://gopher.nara.gov:70/1/register


Federal Register and Code of Federal Regulations (Fee based; 30-day free trial available; more convenient, reliable, current and rapid than GPO Access server)<BR>
<A HREF="http://www.counterpoint.com/">http://www.counterpoint.com</A><P>

Federal Regulations; List by N. Lagace and J Brandt: v1.0; 11/94<BR>
<A HREF="gopher://una.hh.lib.umich.edu/11/inetdirsstacks/fedreg">gopher://una.hh.lib.umich.edu/11/inetdirsstacks/fedreg</A><P>

Intellectual Property Policies<BR>
<A HREF="http://infonet.welch.jhu.edu/policy/intellectual_prop_guide/som_intpol.html">http://infonet.welch.jhu.edu/policy/intellectual_prop_guide/som_intpol.html</A><P>

ISO 9000 Information<BR>
<A HREF="http://www.iso.ch/">http://www.iso.ch</A><P>

Listing of Japanese AIDS patents<BR>
<A HREF="http://www.netaxs.com/~aengel/JapanAIDSPatents/">http://www.netaxs.com/~aengel/JapanAIDSPatents/</A><P>

Patent and Trademark Office Web site (no patents available)<BR>
<A HREF="http://www.uspto.gov/">http://www.uspto.gov/</A><P>

Patent Guidance Information<BR>
<A HREF="http://sunsite.unc.edu/patents/intropat.html">http://sunsite.unc.edu/patents/intropat.html</A><P>

RAPS Web server (experimental)<BR>
<A HREF="http://www.halcyon.com/rapsdemo/">http://www.halcyon.com/rapsdemo/</A><P>

Seamless Web site - Law and Legal Resources<BR>
<A HREF="http://www.ingress.com/tsw">http://www.ingress.com/tsw</A><P>

US EPA Rules, Regulations and Legislation<BR>
<A HREF="http://www.epa.gov/Rules.html">http://www.epa.gov/Rules.html</A><P>

U.S. Patent Office Archives (full text retrieval, 1994 to present)<BR>
<A HREF="http://town.hall.org/cgi-bin/srch-patent">http://town.hall.org/cgi-bin/srch-patent</A><P>

<H3>Pharmaceutical Resources</H3>

Clinical Trials Agreements, research policy, and more.<BR>
<A HREF="gopher://msd.medsch.wisc.edu:70/77/">gopher://msd.medsch.wisc.edu:70/77/</A><P>

Clinical Trials Data Management mailing list<BR>
Send an email message to:<BR>
<a href=mailto:datamgt@alex.ctrg.rr.uwo.ca>datamgt@alex.ctrg.rr.uwo.ca</a> with the word JOIN on the subject line.<P>

Clinical Trials mailing list<BR>
Send an email message to:<BR>
<a href=mailto:majordomo@world.std.com>majordomo@world.std.com</a> with "subscribe clinical_trials" (no quotes) as the message.<P>

Pharmacy at the University of Oklahoma<BR>
<A HREF="http://www.cpb.uokhsc.edu/pharmacy/pharmint.html">http://www.cpb.uokhsc.edu/pharmacy/pharmint.html</A><P>

PharmInfo Net (Rx drugs, past issues of Medical Science Bulletin)<BR>
<A HREF="http://pharminfo.com/">http://pharminfo.com/</A><P>

PharmWeb<BR>
<A HREF="http://www.mcc.ac.uk/pharmweb/">http://www.mcc.ac.uk/pharmweb/</A><P>

Table of Contents for Pharmaceutical Journals<BR>
<A HREF="gopher://topgun.adis.co.nz/">gopher://topgun.adis.co.nz</A><P>

WWW Version of Physician' GenRx<BR>
(US$295/yr)<BR>
<A HREF="http://www.icsi.net/GenRx.html">http://www.icsi.net/GenRx.html</A><P>

WWW Virtual Libary - Statistics<BR>
<A HREF="http://www.stat.ufl.edu/">http://www.stat.ufl.edu</A><P>

<H3>Biotechnology Resources</H3>

HUM-MOLGEN - Communication Forum in Human Molecular Genetics<BR>
<A HREF="http://www.informatik.uni-rostock.de/HUM-MOLGEN/hum-mol.html">http://www.informatik.uni-rostock.de/HUM-MOLGEN/hum-mol.html</A><P>

Nest Group Molecular Biology WWW Resources<BR>
<A HREF="http://world.std.com/~nestgrp/molbiol.html">http://world.std.com/~nestgrp/molbiol.html</A><P>

Baylor College of Medicine Genome Center<BR>
<A HREF="http://gc.bcm.tmc.edu:8088/">http://gc.bcm.tmc.edu:8088/</A><P>

BioMolecular Engineering Research Center<BR>
<A HREF="gopher://bmerc-gopher.bu.edu:70/1">gopher://bmerc-gopher.bu.edu:70/1</A><P>

Biotech Resources on the Internet<BR>
<A HREF="http://www.biospace.com/industry/internetlinks.html">http://www.biospace.com/industry/internetlinks.html</A><P>

BIZ-BIOTECH mailing list (technical and business aspects of biotechnology)<BR>
Send an email message to:<BR>
<a href=mailto:listserv@netcom.com>listserv@netcom.com</a> with the message subscribe biz-biotech<P>

Easy access to the BIONET newsgroups<BR>
<A HREF="http://www.xensei.com/users/chi/bionews.html">http://www.xensei.com/users/chi/bionews.html</A><P>

Human Genome Resources<BR>
<A HREF="gopher://marvel.loc.gov:70/11/global/med/med/genome">gopher://marvel.loc.gov:70/11/global/med/med/genome</A><P>

Immunology Home Page<BR>
<A HREF="http://golgi.harvard.edu/biopages/immuno.html">http://golgi.harvard.edu/biopages/immuno.html</A><P>

Johns Hopkins University Bioinformatics Web Server. Access to Prot-Web (a collection of protein databases at Hopkins, and an extensive list of other biology-related WWW servers.<BR>
<A HREF="http://www.gdb.org/hopkins.html">http://www.gdb.org/hopkins.html</A><P>

"Kinetic Protein Images" and software for viewing<BR>
<A HREF="gopher://orion.oac.uci.edu:1071/11/protein/Kinemage">gopher://orion.oac.uci.edu:1071/11/protein/Kinemage</A><P>

Laboratory Medicine and Pathology<BR>
<A HREF="http://synapse.uah.ualberta.ca/synapse/000p0025.htm">http://synapse.uah.ualberta.ca/synapse/000p0025.htm</A><P>

NCBI Medline Searches of Biotechnology Subjects (free)<BR>
<A HREF="http://atlas.nlm.nih.gov:5700/Entrez/index.html">http://atlas.nlm.nih.gov:5700/Entrez/index.html</A><P>

Protein Data Bank Site (Brookhaven National Lab)<BR>
<A HREF="gopher://pdb.pdb.bnl.gov/">gopher://pdb.pdb.bnl.gov</A><P>

Protein Science Journal<BR>
<A HREF="http://www.prosci.uci.edu/">http://www.prosci.uci.edu/</A><P>

The National Center fro Biotechnology Information<BR>
has a database of all known DNA sequences and much more.<BR>
<A HREF="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</A><P>

The World Wide Web Virtual Libary: Biotechnology<BR>
<A HREF="http://www.cato.com/interweb/cato/biotech/">http://www.cato.com/interweb/cato/biotech/</A><P>

Web Resources for Protein Scientists<BR>
<A HREF="http://www.prosci.uci.edu/ProSciDocs/WWWResources.html">http://www.prosci.uci.edu/ProSciDocs/WWWResources.html</A><P>

<H3>Toxicology and Environmental Resources</H3>

Chemical Industry Institute of Toxicology<BR>
<A HREF="http://www.ciit.org/">http://www.ciit.org/</A><P>

Ennvironmental Health and Toxicology WWW server<BR>
<A HREF="http://tamas.nlm.nih.gov/">http://tamas.nlm.nih.gov/</A><P>

EPA Gopher<BR>
<A HREF="gopher://gopher.epa.gov/">gopher://gopher.epa.gov</A><P>

National Center for Toxicological Research Gopher<BR>
<A HREF="gopher://gopher.nctr.fda.gov/">gopher://gopher.nctr.fda.gov/</A><P>

National Toxicology Program<BR>
<A HREF="http://www.niehs.nih.gov/ntp/ntp.html">http://www.niehs.nih.gov/ntp/ntp.html</A><P>

Toxic Hazard Identification and Toxicity Testing in DHHS<BR>
<A HREF="http://www.os.dhhs.gov/0/os_home/toxic.html">http://www.os.dhhs.gov/0/os_home/toxic.html</A><P>

Toxicology and Environmental Health Information Program<BR>
<A HREF="gopher://gopher.nlm.nih.gov/11/">gopher://gopher.nlm.nih.gov/11/</A><P>

US EPA Public Library<BR>
<A HREF="telnet://epaibm.rtpnc.epa.gov/">telnet://epaibm.rtpnc.epa.gov</A><P>

<H3>Chemistry and Chemical Engineering Resources</H3>

American Chemical Sosiety Gopher<BR>
<A HREF="gopher://acsinfo.acs.org/">gopher://acsinfo.acs.org/</A><P>

Chemical Engineering (Manufacturing and Process)<BR>
<A HREF="http://galaxy.einet.net/galaxy/Engineering-and-Technology/Manufacturing-and-Processing/Chemical-Engineering.html">http://galaxy.einet.net/galaxy/Engineering-and-Technology/Manufacturing-and-Processing/Chemical-Engineering.html</A><P>

Chemistry Resource List<BR>
<A HREF="http://vm.cfsan.fda.gov/chemist.html">http://vm.cfsan.fda.gov/chemist.html</A><P>

Chemistry, Chemical Engineering, Materials Research<BR>
<A HREF="gopher://una.hh.lib.umich.edu/00/inetdirsstacks/acadlist.chemist">gopher://una.hh.lib.umich.edu/00/inetdirsstacks/acadlist.chemist</A><P>

Material Safety Data Sheets<BR>
<A HREF="gopher://atlas.chem.utah.edu/11/MSDS">gopher://atlas.chem.utah.edu/11/MSDS</A><P>

NetBiochem - Complete Medical Biochemistry course<BR>
<A HREF="http://ubu.hahnemann.edu/Heme-Iron/NetWelco.htm">http://ubu.hahnemann.edu/Heme-Iron/NetWelco.htm</A><P>

UCLA Chemistry WWW Server List (very comprehensive list)<BR>
<A HREF="http://www.chem.ucla.edu/chempointers.html">http://www.chem.ucla.edu/chempointers.html</A><P>

WWW Virual Library - Biochemistry<BR>
<A HREF="http://golgi.harvard.edu/biopages/biochem.html">http://golgi.harvard.edu/biopages/biochem.html</A><P>

WWW Virtual Library - Chemical Engineering<BR>
<A HREF="http://www.che.ufl.edu/WWW-CHE/outline.html">http://www.che.ufl.edu/WWW-CHE/outline.html</A><P>

<H3>Biomedical Resources</H3>

Sterling Clinical Resources<BR>
Maintains a list of clinical trials for people looking to participate in studies for new drugs or devices<BR>
<A HREF="http://www.primenet.com/~iwpp/sterling.html">http://www.primenet.com/~iwpp/sterling.html</A><P>

BIOSCI Electronic Communication Forums<BR>
<A HREF="http://www.bio.net/">http://www.bio.net</A><P>

Internet Conferences<BR>
<A HREF="http://www.fest.com/Conferences/drug-dev/"> http://www.fest.com/Conferences/drug-dev/</A><P>

APStacts (American Physiological Society)<BR>
<A HREF="gopher://oac.hsc.uth.tmc.edu:3300/11/publications/apstracts">gopher://oac.hsc.uth.tmc.edu:3300/11/publications/apstracts</A><P>

Atlas of CNS Pathology from the Brigham and Women's Hospital<BR>
<A HREF="http://count51.med.harvard.edu/AANLIB/home.html">http://count51.med.harvard.edu/AANLIB/home.html</A><P>

Biological Links<BR>
<A HREF="http://info.er.usgs.gov/network/science/biology/index.html">http://info.er.usgs.gov/network/science/biology/index.html</A><P>

More Biological Links<BR>
<A HREF="http://vm.cfsan.fda.gov/biologic.html">http://vm.cfsan.fda.gov/biologic.html</A><P>

Complete List of Biomedical WWW Sites<BR>
<A HREF="http://golgi.harvard.edu/biopages/all.html">http://golgi.harvard.edu/biopages/all.html</A><P>

Glaxo Anatomy Project - 3D Geometric Database of the Human Body<BR>
<A HREF="http://www.vis.colostate.edu/library/gva/gva.html">http://www.vis.colostate.edu/library/gva/gva.html</A><P>

Guide to Medically Related Internet<BR>
<A HREF="gopher://una.hh.lib.umich.edu/00/inetdirsstacks/medclin%3amalet">gopher://una.hh.lib.umich.edu/00/inetdirsstacks/medclin%3amalet</A><P>

Hospital Web Sites (icluding patient education materials)<BR>
<A HREF="http://indy.radiology.uiowa.edu/">http://indy.radiology.uiowa.edu</A><P>

John Hopkins Medical Institution home page<BR>
<A HREF="http://infonet.welch.jhu.edu/">http://infonet.welch.jhu.edu/</A><P>

Library of Normal and Pathological Histology Images<BR>
<A HREF="gopher://guru.med.cornell.edu/">gopher://guru.med.cornell.edu</A><P>

Links to Biomedical and Clinical Information<BR>
<A HREF="http://www.med.uiuc.edu/Medical.Indices.html">http://www.med.uiuc.edu/Medical.Indices.html</A><P>

Strategic Use of the Internet in Drug Development<BR>
<A HREF="http://www.fest.com/Conferences/drug-dev/">http://www.fest.com/Conferences/drug-dev/</A><P>

Oncolink Web Site<BR>
<A HREF="http://cancer.med.upenn.edu/">http://cancer.med.upenn.edu/</A><P>

The World Wide Web Virtual Library: Biosciences<BR>
<A HREF="http://golgi.harvard.edu/biopages.html">http://golgi.harvard.edu/biopages.html</A><P>

Urbana Atlas of Pathology<BR>
<A HREF="http://www.med.uiuc.edu/titlePage.html">http://www.med.uiuc.edu/titlePage.html</A><P>

WebPath - Patholgy from the University of Utah<BR>
<A HREF="http://www-medlib.med.utah.edu/WebPath/webpath.html">http://www-medlib.med.utah.edu/WebPath/webpath.html</A><P>

<H3>Online Documentation Concerning the World Wide Web (W3)</H3>

Entering the World-Wide Web: A Guide to Cyberspace<BR>
<A HREF="http://www.eit.com/web/www.guide">http://www.eit.com/web/www.guide</A><P>

Internet Documentation and FAQs (Frequently asked questions)<BR>
<A HREF="http://groucho.gsfc.nasa.gov/Code_520/locator/surf.html#internet-docs">http://groucho.gsfc.nasa.gov/Code_520/locator/surf.html#internet-docs</A><P>

Hitchhikers' Guide to the Internet<BR>
<A HREF="gopher://riceinfo.rice.edu/00/Computer/AroundTheNet/Networks/Hitch">gopher://riceinfo.rice.edu/00/Computer/AroundTheNet/Networks/Hitch</A><P>

World Wide Web and Mosaic: User's Guide<BR>
<A HREF="http://elib.cme.nist.gov/fasd/pubs/schlenoff94.html">http://elib.cme.nist.gov/fasd/pubs/schlenoff94.html</A><P>

Handbook on Running a World Wide Server<BR>
<A HREF="http://info.mcc.ac.uk/CGU/SIMA/handbook/handbook.html">http://info.mcc.ac.uk/CGU/SIMA/handbook/handbook.html</A><P>

Essential Mosaic and HTML<BR>
<A HREF="http://kawika.hcc.hawaii.edu/htmlstart.html">http://kawika.hcc.hawaii.edu/htmlstart.html</A><P>

Internet Information and Navigators<BR>
<A HREF="http://library.tufts.edu/www/internet.html">http://library.tufts.edu/www/internet.html</A><P>

Welcome to the Big Dummy's Guide to the Internet<BR>
<A HREF="http://cs.dal.ca/bdgtti-entry.html">http://cs.dal.ca/bdgtti-entry.html</A><P>

The use of WWW in Biological Research<BR>
<A HREF="ftp://bioftp.unibas.ch/archive_data/www94paper_explode/paper.html">ftp://bioftp.unibas.ch/archive_data/www94paper_explode/paper.html</A><P>

Biocomputing Survival Guide<BR>
<A HREF="http://www.ch.embnet.org/jam/jam.html">http://www.ch.embnet.org/jam/jam.html</A><P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated January 29, 1996.
Copyright &copy; 1996 <A HREF = "http://www.genweb.com/">GenWeb </A>.<A HREF="http://www.genweb.com/"><IMG  Align=Center SRC="Graphics/genweb.gif"></A>
All rights reserved.</FONT></ADDRESS>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-161</DOCNO>
<DOCOLDNO>IA064-000378-B001-59</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/licensefund.html 206.86.52.80 19970112094844 text/html 5528
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:48:50 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5346
Last-modified: Sun, 17 Nov 1996 21:38:41 GMT
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Sosei License Fund</TITLE>
</HEAD>
<BODY BGCOLOR=#FFFFFF>
<IMG SRC="Graphics/sosei.gif">
<FONT SIZE =5><A HREF="../Companies/sosei.html">SOSEI</A> LICENSE FUND #1</FONT><P>

Under difficult circumstances for fund raising, many biotech companies are
visiting Japan to secure corporate partners for the Asian market. This strategy
is oftentimes preferred to giving up the worldwide right to a multi-national
company, for the biotech company can keep at least the North American and
European rights intact rendering it more flexibility for future business
development. Such being the case, the biotech company needs a quick cash
injection and a reasonable R&D support from a Japanese partner to maintain
its business.<BR>
<BR>
The biotech company will first approach the top-tier full fledged companies.
It would be the ideal partner if a deal can be finalized in a reasonable
time scale, which is an exception rather than a rule. The biotech company
cannot afford such a time consuming lengthy negotiations.<BR>
<BR>
The second target is a company belonging to the medium-tier group. The biotech
companies will have a difficulty to find a right window for these relatively
unknown companies. These companies sometimes lack adequate capacity for
due diligence and sophisticated product development capabilities. Despite
a possibility of a quick deal with a company in this group, the biotech
company may have to face with claims for misrepresentation or non-performance
later on.<BR>
<BR>
The third choice is a new comer to the pharmaceutical industry. Some of
these companies have extremely flexible strategy and can move relatively
quickly. They are oftentimes cash rich and eager to license innovative technologies
to consolidate their pharmaceutical business platform. Sometimes they also
lack due diligence capabilities and are yet to establish the development
and marketing forces. Hence their strong motivation to secure their own
development or marketing partners. In many cases, these parners are the
top-tier companies in Japan.<BR>
<BR>
In consideration of the above situation, <A HREF="../Companies/sosei.html">Sosei</A> has recently launched a new fund (<A HREF="../Companies/sosei.html">Sosei</A>
License Fund #1) with some of these cash rich new comers. <A HREF="../Companies/sosei.html">Sosei</A> will help
them (the partners) with the due diligence and provide a sizable option
fee for Asian rights to a biotech company in a much shorter time scale than
it would take to negotiate with a traditional Japanese company. <A HREF="../Companies/sosei.html">Sosei</A> will
also support the research, whenever appropriate, to add value to the technology
in concern to meet with requirements from Japanese companies. The partners
have 3 months' exclusive evaluation period and <A HREF="../Companies/sosei.html">Sosei</A> is free to negotiate
with any other party when this period expires. The license fee will be eventually
paid in by the partners or third parties to be identified. The biotech company
can keep a majority portion of the license fee, depending on its relative
contribution.<BR>
<BR>
<A HREF="../Companies/sosei.html">Sosei</A> is extremely well connected to the decision makers of the Japanese
pharmaceutical companies and is updated with precise needs of most of the
companies. Therefore, <A HREF="../Companies/sosei.html">Sosei</A> can afford a needs-oriented business leading
to a very high success rate of the partnering. This is evidenced by the
<A HREF="../Companies/sosei.html">Sosei's</A> track record as an efficient deal maker.<P>
<HR><BR>
<CENTER><IMG SRC="Graphics/sosei_lic_color.gif"></CENTER><P>
<H3>TRACK RECORD (May, 1995)</H3>
Only major deals, for which <A HREF="../Companies/sosei.html">Sosei</A> played a pivotal role, with size close
to or in excess of two billion yen are listed.<P>
<TABLE border> <TH>Date</TH><TH>Licenser</TH><TH>Area</TH><TH>Licensee</TH><TH>License
Fee</TH><TR> <TD>May 1995</TD><TD>Geron</TD><TD>Anti-cancer</TD><TD>Kyowa
Hakko</TD><TD>$30M(+royalty)<TR> <TD>April 1994</TD><TD>Pharmacyclics</T><TD>MRI
contrast medium</TD><TD> n.a.</TD><TD>n.a.</TD><TR> <TD>March 1994</TD><TD>Agene</TD><TD>Aging
Project</TD> <TD> Ministry of Welfare<BR>
Nippon Roche<BR>
Meiji Seika<BR>
Eisai<BR>
Kissei Pharmaceutical<BR>
</TD><TD>3 billion yen (equity)</TD><TR> <TD>June 1993</TD><TD>GenPharm</TD><TD>Human
antibody</TD><TD>Eisai</TD><TD>2.5 billion yen (+royalty)</TD><TR> <TD>May
1992</TD><TD><A HREF="../Companies/sosei.html">Sosei</A> </TD><TD>HGF</TD><TD>Sumitomo Pharmaceutical</TD><TD>n.a.</TD><TR>
<TD>1989-1990</TD><TD>IDEC</TD><TD>Idiotype antibody</TD><TD> Institute
of Immunology Zenyaku</TD> <TD>2.3 billion yen (+royalty)</TD></TABLE><BR>
<BR>
<A HREF="restricted/licfund.html">License Fund List</A> (subscriber only area)<BR>
Examples of License Fund candidates available for Japanese Partners.<BR>
<UL>
<LI><A HREF="restricted/thenewdds.html">New DDS Technology</A>
<LI><A HREF="restricted/electrorotationass.html">Electrorotation Assay</A><P>
</UL>
<A HREF="http://www.sosei.com/"><IMG SRC="Graphics/home_button.gif" ALIGN=
middle WIDTH="59" HEIGHT="53">Home Page</A><BR>
<BR>
<HR>
<ADDRESS><FONT SIZE=3>Updated February 13, 1996. Copyright &copy; 1996 <A HREF="http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-162</DOCNO>
<DOCOLDNO>IA064-000378-B001-83</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/pressnews.html 206.86.52.80 19970112094856 text/html 2965
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:49:01 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2783
Last-modified: Sun, 17 Nov 1996 21:35:23 GMT
</DOCHDR>
<HTML><HEAD><TITLE>BioGlobe Press Releases and News Bulletins</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<H1><CENTER>BioGlobe Press Releases and News Bulletins</CENTER><HR></H1>
<UL>
<LI> <A HREF = "http://www.prnewswire.com/cgi-bin/tnproc?INDUST=HEA-MTC">Today's Pharmaceutical, Biotechnology & Healthcare News</A> from PR Newswire<P>
</UL>
<IMG SRC="../Graphic
s/sosei_bullet.gif"><A HREF="Companies/sosei.html">Sosei</A>
<UL>
<LI> <A HREF = "PressNews/advertisement.html">To Japanese Researchers</A> May 
1996
<IMG ALIGN=TOP SRC="Graphics/new.gif">
<LI> <A HREF = "PressNews/miko1.html">Transducing genes into Cerebral Neurocyte
</A> Feb 1996
<LI> <A HREF = "PressNews/miko2.html">Identifying Epilepsy-inhibiting Proteini
</A>
Feb 1996
<LI> <A HREF = "PressNews/soseipr1.html">Sosei Co., Ltd. Appoints Professor
Baruch S. Blumberg</A> June 1995
<LI> <A HREF = "licensefund.html">Sosei License Fund #1</A> June 1995


<LI><A HREF="restricted/licfund.html">Licence Fund</A> (Subscribers Only)
<UL>
<LI> <A HREF = "restricted/thenewdds.html">The New DDS
<LI> <A HREF = "restricted/electrorotationass.html">Electrorotation Assay
</UL></UL>

EY Bioscience
<UL><LI> <A HREF = "PressNews/prnb12.html">Topic on Hepatitis C Virus</A> (#12)
<LI> <A HREF = "PressNews/prnb15.html">Topic on Hepatitis B Virus</A> (#15)
</UL>

<A HREF="Companies/genpharm.html">GenPharm International</A>
<A HREF="PressNews/genpharmpr1.html"><UL><LI> GenPharm annouces high affintiy human antibodies from transgenic mice; signs a new agreement with Eisai</A> December 5, 1995
</UL>

<A HREF="Companies/terrapin.html">Terrapin Technologies, Inc.</A><BR>
<A HREF="PressNews/terrapinpr1.html"><UL><LI>Terrapin Completes $13.7 Million Mezzanine Financing</A> December 20, 1995</UL>

<A HREF="Companies/koseisho.html">Koseisho</A>
<UL><LI> <A HREF = "PressNews/prnb18.html">Autoimmune Disease Mouse Model</A> (#18)
<LI> <A HREF = "PressNews/prnb20.html">The decision of investment and financing items for fiscal 1994</A> (#20)
<LI> <A HREF = "PressNews/prnb22.html">New Establishment of Subcommittee of the Central Pharmaceutical Affairs Council etc.</A> (#22)
<LI> <A HREF="PressNews/koseishonews1.html">The Guideline for Safety and Quality Assurance of the Drugs for Gene Therapy."</A>
</UL>

<A HREF="Companies/krp.html">Kyoto Research Park</A>

<UL><LI> <A HREF="PressNews/lstt.html">LSTT Forum</A> August 1995
</UL>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated May 12, 1996.
Copyright &copy; 1996 <A HREF = "http://www.genweb.com/">GenWeb </A>.<A HREF="http://www.genweb.com/"><IMG  Align=Center SRC="Graphics/genweb.gif"></A>
All rights reserved.</FONT></ADDRESS>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-163</DOCNO>
<DOCOLDNO>IA064-000378-B001-109</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/kanjipg.htm 206.86.52.80 19970112094906 text/html 2412
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:49:12 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2230
Last-modified: Sat, 13 Apr 1996 00:16:09 GMT
</DOCHDR>
<HTML>
<HEAD> 

<BODY background = "graphics/white-mi.gif">
<TITLE> BioCentury Now!</TITLE>
</HEAD>


<BODY>

<IMG  Align=Top SRC="graphics/fish10.gif"><p>


BioCentury(TM) Now ! BioCentury(TM) Now BioCentury Publications Inc. BioGlobe C^[lbg  T[rXB BioCentury AkoCIeNmW[YBy_]L]B\[ZCA{Fl^AhB<P>

y[WABioCentury BioGlobepB<P>


<A HREF="news/thiswk.htm">

Tj[X: y[W</A>ABioGlobef[^[x[XBioCentury VLv{B<P>

BioCentury Cu[: ABioCentury ALv{BJeS[A{ANepANZXB Cu[JeS[ALB<P>

<A HREF="library/indstr/indstrk.htm">Y\</A><BR>
<A HREF="library/corstr/costrk.htm"></A><BR>
<A HREF="library/allpart/allpartk.htm">gp[gi[Vbv</A><BR>
<A HREF="library/regul/regulk.htm">K</A><BR>
<A HREF="library/tech/techk.htm">Zp</A><BR>
<A HREF="library/fi/fik.htm"></A><P>

<A HREF="about/aboutk.htm">BioCentury</A>Fy[WABioCentury TvyT[rXB<P>

<A HREF="commun/commk.htm">BioCenturyM</A>Fy[WA BioCenturyWB`B\B<P>



<H5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-164</DOCNO>
<DOCOLDNO>IA064-000378-B001-188</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/krp.html 206.86.52.80 19970112094928 text/html 7450
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:49:36 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 7268
Last-modified: Sun, 12 May 1996 20:26:23 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Kyoto Research Park Corporation</TITLE></HEAD>
<BODY BGCOLOR=#FFFFFF>
<H1>Kyoto Research Park Corporation</H1><H3>Corporate Profile</H3><HR>
17 Chudoji, Minami-machi, Shimogyo-ku<BR>
City: Kyoto, 600, Japan<BR>
Telephone: 81-75-315-8665<BR>
Fax: 81-75-322-5348<P>

<B>Capital:</B> 2000 million yen<P>

<B>Employees:</B> 80 (including the staff of KRP's subsidiary,  Science Center International Corp.)<P>

<B>Facilities:</B>
<BLOCKQUOTE>Approximately 9 hectares of total space (East and West Blocks) in central Kyoto Rental labs and offices (including wet labs); Conference facilities; Parking lots; Amenity facilities (gym, indoor swinning pool, cafeterias, bar)</BLOCKQUOTE><P>

<B>Buildings:</B><BR>
<I>East Block (total floor space: 48,000 square meters):</I><BR>
<UL><LI> Science Center Building #1 (rental labs and offices/conference facilities)
<LI> Science Center Building Annex (rental labs and offices)
<LI> Atrium (rental conference facility)
<LI> ASTEM (Advanced Software Technology and Mechatronics Research Institute)
<LI> Kyoto Municipal Industrial Center
<LI> Kyoto Comprehensive Center for Small and Medium Enterprises (Kyoto Prefecture's center) 
</UL><BR>
<I>West Block (total floor space: 50,000 square meters/150,000 square meters more under plan):</I><BR>
<UL><LI> Science Center Building #3 (rental labs especially for chemical/physical use)
<LI> Science Center Building #4 (rental labs and offices, especially for computer-related R&D,  multi media, etc./conference facilities)
<LI> KRP Gas Building (100% tenanted by Osaka Gas Kyoto Branch)
</UL>

<B>Tenant organizations:</B> Approx. 90 as of May 18, 1995<P>

<B>Corporate Overview:</B><BR>
<BLOCKQUOTE>Kyoto Research Park Corporation (KRP) was incorporated in 1987 as a 100% subsidiary of Osaka Gas Co., Ltd.(OG), as a developer and administrator of Kyoto Research Park, the very first urban research park in Japan established by private initiative.<P> 

KRP is conveniently located in central Kyoto, the city of the old and the new. Kyoto is known for an academic city with more than 40 universities and colleges,  including Kyoto University, Kyoto Prefectural University of Medicine,  just to name a few. KRP has strong networks with faculty members of those companies. Kyoto has also been home to venture businesses--there are sevaral such companies who started as venture businesses and are now big names with dominant market shares.<P>

Kyoto is also part of "Kansai" or western Japan, covering the areas of Osaka and Kobe. Most of the major pharmaceutical/biotechnology firms in Japan have their headquarters in Kansai.<P>

With the environs illustrated as above,  and with its extensive networks both in Japan and abroad,  KRP's business is not limited to offering rental facilities. KRP also puts as its important missions the items below:<P>

<OL><LI> to promote technological innovation and the development of new core technologies.
<LI> to foster the development of high technology venture businesses.
<LI> to facilitate entry by foreign firms into the Japanese market.
</OL>

Description of some of current tenant firms and services provided follow:<P>

o KRP's Tenant Companies in the Biotechnology/Pharmaceutical Fields 
(as of May, 18, 1995)<P>

(for the services/programs noted *,  please refer to the descriptions below)<P>

Cruachem K.K. (development, manufacturing, marketing and sales of reagents and instruments for use in synthesizing DNA and RNA; the first Venture Buiness Aid Program*case)<P>

KAC Co., Ltd. Kyoto Technical Center (contract business involving animal experimentation)<P>

Kansai Research Institute (KRI) (contract-based research and consultation involving new materials, electronics, biology; also wholly subsidiary of Osaka Gas)<P>

HSP Research Institute Inc. (basic research on heat shock protein)<P>

Maruho Corporation, Limited (R&D of products for hemorrhoinds, digestive disorders, asthma, skin ailments and orthopedic surgical fields)<P>

Janssen-Kyowa Corporation, Limited (insect repellent, acure rejection response treatment, digestive and antibacterial medication, etc.)<P>

DLB Systems, Inc. (R&D and marketing of computer systems for pharmaceutical companies; the Company is located in U.S.---headquartered in U.K.---and uses KRP's Direct Representative Office Services*)<P>
 
o KRP Venture Business Aid Program<P>

This is a program developed in collaboration with a U.S. venture capitalist firm S.R.One, Ltd. to enable foreign bio-venture firms to use a KRP rental lab in exchange for a portion of the firm's stock equal in value to the rent for the agreed upon period.<P> 

o Direct Representative Office (DRO) Services:<P>

DRO Services enable the companies to establish a base in Kyoto without having to rent actual office space and hire any additional staff.  Multilingual staff will work as the company's local staff and optional consultation services are also available at request.<P>  

For further information on DRO Services, please contact:<BR>
Ms. Andrea Cnobloch<BR>
ITEC Administrator<BR>
Kyoto Research Park,  SCB #4, ITEC
1, Awata-cho, Chudoji, Shimogyo-ku, Kyoto 600 Japan<BR>
Phone: +81-75-315-8681<BR>
Fax: +81-75-315-9070<BR>
E-mail: <a href=mailto:KTC00462@niftyserve.or.jp>KYC00462@niftyserve.or.jp</a><P>

o Life Science Technology Transfer Forum (LSTTF):<P>

Among KRP's support services, KRP organizes the Life Science Technology Transfer Forum (LSTTF), which encourages information exchange between industry and academia in life science-related fields.  It also provides foreign firms with opportunities to meet the LSTTF members through presentations, exhibitions and business matching meetings and so forth at the LSTT Forum.<P>

KRP will provide foreign companies with opportunities to establish relations with Japanese companies through the LSTT Forum.  KRP also plans and organizes tours to life science-related organizations and companies in Europe, U.S.A., and other regions.<P>

For further information on LSTTF, please contact:<BR>
Ms. Nobuko Yutoku<BR>
LSTTF Secretariat<BR>
SCI-Kyoto Research Park<BR>
17 Chudoji, Minami-machi, Shimogyo-ku, Kyoto 600 Japan<BR>
Phone: +81-75-315-8665<BR>
Fax: +81-75-322-5348<BR>
E-mail: <a href=mailto:office@krp.co.jp>office@krp.co.jp</a><P></BLOCKQUOTE>

<B>Current Corporate Partners:</B><BR>
<BLOCKQUOTE>o Science Center International Corp. (SCI)<BR>
Joint venture between KRP and UCSC. The Chairman of the board, Mr. Peter Sears, is the President of S.R. One, Limited, a venture capital specializing in biotechnology fields.<P>

o University City Science Center (UCSC) in Philadelphia, U.S.A.</BLOCKQUOTE><P>

<!-- INFORMATION ABOUT THE CONTACT PERSON FILLING OUT THIS FORM
Date: May 19, 1995

Name: Takayuki Kimura (Mr.)
Title: Managing Director
Address: 17 Chudoji, Minami-machi, Shimogyo-ku
City: Kyoto
State: Kyoto
Zip Code: 600
Telephone Number: 81-75-315-8665
Fax Number: 81-75-322-5348
E-mail: office@krp.co.jp >

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
</HTML>



</DOC>
<DOC>
<DOCNO>WT03-B24-165</DOCNO>
<DOCOLDNO>IA064-000378-B001-151</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/koseisho.html 206.86.52.80 19970112094920 text/html 8847
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:49:21 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 8665
Last-modified: Sun, 12 May 1996 20:33:03 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Koseisho</TITLE></HEAD>
<BODY BGCOLOR=#FFFFFF>
<H1>Koseisho</H1><H3>Corporate Profile</H3><HR>
Ministry of Health and Welfare<BR>
Pharmaceutical Affairs Bureau<BR>
Research and Development Division<BR>
Business Address: 1-2-2 Kasumigaseki Chiyoda-ku<BR>
Tokyo 100-45<BR>
Tel +81-3-3593-8915<BR>
FAX +81-3-3503-0595<P>

<B>Employees:</B> 15<P>
 
<B>History:</B><BR>
Establishment of Research and Development Division; 1st July 1994<P>

<B>Founders:</B> Government<P>

<B>Date Established:</B> 1st July 1994<P>

<B>Subsidiary of:</B> Pharmaceutical Affairs Bureau<P>

<B>Corporate Overview:</B><BR>
<BLOCKQUOTE><OL><LI>Planning, investigation and coordination on research and development of drugs.<BR>
<LI>Financial mediation and promotion on research and development of drugs.<BR>
<LI>Designation of orphan drugs and orphan medical devices.<BR>
<LI>Direction and supervision of " The Organization for Drug ADR Relief, R&D Promotion and Product Review: 1) Research promotion. 2) Development promotion on orphan drugs and orphan medical devices.<BR>
<LI>Japanese Pharmacopoeia </OL><P>

<B>Outline of systems for promotion of orphan drug development:</B><P>

<I><B>The roles of the Drug Organization;</B></I><P>

<I>Granting;</I><BR>
The Drug Organization (The organization for Drug ADR relief, R&D promotion and Product review) makes grants to be used for the R&D of the said medicines and devices to private companies that have been disignated by The Ministry of Health and Welfare (MHW) as manufacturers or importers of ORPHAN DRUGS. The R&D cost subject to the granting is the direct one for the R&D and the amounts of grants are limited to one half of the cost. At the time of application for subsidies, each private company is required to submit an outline of R&D, cost, schedules for the R&D activities and other information. The Drug Organization makes grants after surveying these data. The manufacturers or importers of ORPHAN DRUGS to whom the grants are given will pay a part of their proceeds or profits (if exceed 100 million yen) after ORPHAN DRUGS are launched into the market (the total amount of payment is limited to that of the grant).<P>

<I>Guidance and Advice;</I><BR>
In order to accelerate R&D of medicines and devices designated ORPHAN DRUGS, the Drug Organization provides guidance and advice for both of the R&D procedures of ORPHAN DRUGS and the preparation of New Drug Approval (NDA) in cooperation with the MHW.<P>

<I>Authorization for Tax Deduction;</I><BR>
Based on the Special Taxation Measures Law, the Drug Organization authorizes the development costs of ORPHAN DRUGS that will be required for the period subjected to the grant, responding to the application from each company. Once authorized, six percent of their ORPHAN DRUGS R&D costs exclusive of the amount of grants given by the Drug Organization is deducted from their tax. The tax deduction is limited to 10% of the corporation tax or the income tax for the term.<P>

<I>Additional preferential measures for orphan drugs;</I><P>

In addition to the supports for development promotion by the Drug Organization, ORPHAN DRUGS can receive following preferential measures from the MHW.<P>

1. Priority in the Examination for New Drug approvals;<BR>
ORPHAN DRUGS are given the highest priority in the examination for New Drug Approvals.<BR>
2. Extension of the Term for Re-examination;<BR>
The terms for re-examination of ORPHAN DRUGS are extended to the maximum of 10 years, compared with 6 years of ordinary new drugs.<P>  

<B>Outline of Japanese Pharmacopoeia:</B><P>

The Japanese Pharmacopoeia (JP) provides, based on Article 41 of the Pharmaceutical Affairs Law, authoritative standards, specifications and testing methods for drugs.<BR>
Since it was first published in June 1886, it has been continuously revised in accordance with progress in pharmaceutical development and advances and improvements in science and technology.<P>

The JP consists of Part I and Part II, and includes basic drugs which are important for health care with respect to necessity and frequency of use.<BR>
Part I:  widely used pharmaceutical raw materials,
            widely used basic preparations, and
            drugs which are not widely used but are essential for health care.<BR>
Part II: combination drugs,
            drugs produced from natural substances, 
            basic substances required for manufacturing formulated preparations, and
            sanitary and surgical materials, etc.<P>

The Pharmaceutical Affairs Law specifies that the JP shoul undergo general revision at least every 10 years. Since the 9th revised JP appeared in April 1976, it has been revised every 5 years. in the current 12th edition of the JP, Part I contains 750 items, and Part II, 471 items.<P>

Japanese Pharmacopoeia Drug Information (JP-DI), which was published in 1991, contains information on the clinical use of drugs listed in the JP.<P></BLOCKQUOTE>

<B>Current Corporate Partners:</B><BR>
<UL><LI>The Organization for Drug ADR Relief, R&D Promotion and Product Review<BR>
<LI>Japan Health Science Foundation<P>
</UL>

<BLOCKQUOTE><B>1. Outline of The Organization for Drug ADR Relief, R&D Promotion and Productive Review</B><P>

On the basis of the assets contributed by the government and private sectors, the organization energically supports private corporation' activities for research and development drawing on sophisticated technologies. The major objective lies in opening up new horizons for the health and medical industry through the promotion of R&D activities.<P>

Each year, the organization has become increasingly active in undertakings, which can be divided into three fields: investment, financing and the support of R&D operations.
Eleven laboratories have already been established through the investments. In addition, there are twenty-five experimental research projects which have received risk money and they are steadily showing results. Seminars on recent R&D trends have been well received.<P>

<I>Investment activities;</I><BR>
The organization invests in research and development, chiefly from the basic stages, through joint projects participated in by a number of companies.<P>

<I>Financing Operations;</I><BR>
The organization mainly finances research and development from the applied research stage, supporting technological developments which are expected to produce tangible solutions to important health and medical problems in Japan.<P>

<I>Research Support Operations;</I><BR>
In addition to investment and financing, the organization supports R&D activities for drugs, medical equipment, etc.<P>

<B>2. Outline of Japan Health Sciences Foundation:</B><P>

Japan Health Sciences Foundation was organized and was a nonprofit corporation backed by the ministry and funded by 152 (as of February, 1994) companies in such industrial sectors as pharmaceuticals, chemicals, food products, medical supplies and textile goods.<P>

The foundation has an opportunity to make a real contribution to the health and welfare of mankind by promotion both advanced and basic sciences and technology in the fields of health care, pharmaceuticals, medical and welfare equipment, and public hygiene. 
To achieve this aim, the foundation plans to assemble top researchers and specialists from industry, education and government, provided them with opportuinities to do joint reserach, and serve as a liason or catalyst for them.<P>

<I>Main activities;</I><BR>
The fields covered by the foundation include medical and pharmaceutical sciences based on advanced science and technology in molecular biology and biotechnology, medical supplies and public hygiene. Projects now under way include the Human Science Basic Research Project and the Promotion Project for the Development of Anti-AIDS Drugs, among others. In addition, six kinds of general activities, including R&D promotion and regulations & standards, are being carried out by supporting member companies to help promote the development of human sciences.<P></BLOCKQUOTE>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!-- INFORMATION ABOUT THE CONTACT PERSON FILLING OUT THIS FORM
Date: April 12, 1995
Name: Toshiki Hirai
Title: Director
Address: 1-2-2 Kasumigaseki, Chiyoda-ku
City: Tokyo 
State: Tokyo 
Zip Code: 100-45 
Telephone number: +81-3-3593-8915
Fax number: +81-3-3503-0595 
e-mail address: hirai@nihs.go.jp >
</DOC>
<DOC>
<DOCNO>WT03-B24-166</DOCNO>
<DOCOLDNO>IA064-000378-B001-209</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/agene.html 206.86.52.80 19970112094949 text/html 3656
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:49:45 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3474
Last-modified: Sun, 12 May 1996 19:30:10 GMT
</DOCHDR>
<HTML><HEAD><TITLE>AGENE</TITLE></HEAD><BODY BGCOLOR=#FFFFFF></BODY></HTML>
<H1>AGENE Research Institute Co., Ltd.</H1><H3>Corporate Profile</H3><HR>

200 Kajiwara, Kamakura-shi, Kanagawa Pref.<BR>
Kamakura Kanagawa 247<BR>
Telephone: 81-467-46-9590<BR>
Fax: 81-467-48-6595<P>

<B>Employees:</B> 19<P>

<B>Facilities:</B> Head Office and Research Institute<P>

<B>History:</B>
Founded in March, 1994.<P>
<B>Investor:</B> The Organization for Drug ADR Relief, R&D Promotion and Product Review<P>

<B>Participating companies:</B><BR>
<UL><LI> Nippon Roche K. K.
<LI> Eisai Co., Ltd.
<LI> Kissei Pharmaceutical Co. 
<LI> Meiji Seika Kaisha, Ltd.
</UL>

<B>Date Established:</B> March 17, 1994<P>

<B>Legal Form:</B> Corporation, Non-public<P>

<B>Corporate Overview:</B>
<BLOCKQUOTE>AGENE Research Institute Co., Ltd. (AGENE) is focusing on research of individual aging and cellular aging.<BR>
First we are investigating the cloning and the functions of Werner's syndrome genes and regulatory genes in cell proliferation.  Because these approaches will give the answers about the mechanism directing diseases resulting from aging. For example, aging specific diseases such as cataract, scleroderma, osteoporosis and arteriosclerosis are known to be rapidly induced in Werner's syndrome.<BR>
Second we are going to develop screening system of therapeutic drugs by some progeria animals developed by us and the assay system of aging genes expression, which will contribute the development for new therapeutics against aging associated diseases. The research period is 7 years and the research budget is 3.1 billion yen. In near future, employees will be 20.</BLOCKQUOTE><P>

<B>Research Plan:</B><BR>
<BLOCKQUOTE>1. Identification of aging genes from cells in Werner's syndrome patients. And analysis
of the genes function.<P>
2. Development of screeing system for drugs acting gene expression by aging genes derived from Werner's syndrome patients.<P>
3. Development of transgenic mice as progeria animal models induced by WS genes.<P>
4. Identification of suppressive genes in cell proliferation specifically associated aging cells in mammalian cell culture system. And analysis of the genes function. Development of screening system for drugs regulating suppressive function in such genes.</BLOCKQUOTE><P>

<B>President:</B> Hiroaki Shigeta from Nippon Roche K. K.<P>

<B>Board of Directors:</B><BR>
<UL><LI> Yasuhiro Furuichi, Ph.D.
<LI> Masaji Ohno Ph.D. from Eisai Co. Ltd.
<LI> Masanori Iwadare, Ph.D. from Kissei Pharmaceutical Co.
<LI> Suzui Watanabe, Ph.D. from Meiji Seika Kaisha, Ltd.</UL>
      
<B> Auditor:</B><BR>
<UL><LI> Takeyuki Hashimoto from Nippon Roche K. K.
<LI> Akio Inoue from Eisai Co. Ltd.
<LI> Hideo Saito from Kissei Pharmaceutical Co.
<LI> Akio Takahashi from Meiji Seika Kaisha, Ltd.
</UL>


<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated October 24, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!-- INFORMATION ABOUT THE CONTACT PERSON FILLING OUT THIS FORM
Date: June 27, 1995
Name: Yasuhiro Furuichi
Title: Director & Head of Research Institute
Address: 200 Kajiwara, Kamakura-shi, Kanagawa Pref.
City: Kamakura
State: Kanagawa
Zip Code: 247
Telephone Number: 81-467-46-9590
Fax Number: 81-467-48-6595
Revised October 24 by Ei Yamada
</DOC>
<DOC>
<DOCNO>WT03-B24-167</DOCNO>
<DOCOLDNO>IA064-000378-B002-2</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/mitsubishi.html 206.86.52.80 19970112095058 text/html 8317
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:51:04 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 8135
Last-modified: Sun, 12 May 1996 19:30:16 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Mitsubishi Chemical Corporation</TITLE></HEAD>
<BODY BGCOLOR=#FFFFFF><H1>Mitsubishi Chemical Corporation</H1>
<H3>Corporate Profile</H3>
<HR>
2-24, Higashishinagawa 2-chome, Shinagawa-ku<BR>
Tokyo, Japan 140<BR>
Telephone: 81-3-5463-0721<BR>
Fax: 81-3-5463-0703<P>

<B>Employees:</B> 14,303<P>

Facilities:<BR>
<I>6 R&amp;D Centers:</I><BR>
<UL><LI> Yokohama
<LI> Yokkaichi
<LI> Tsukuba
<LI> Mizushima
<LI> Kashima
<LI> Kurosaki
</UL>
<I>10 Plants</I><BR>
<UL><LI> Kashima
<LI> Kurosaki
<LI> Yokkaichi
<LI> Naoetsu
<LI> Mizushima
<LI> Sakaide
<LI> Chigasaki
<LI> Tsukuba
<LI> Matsuyama
<LI> Odawara
</UL>
<I>39 Overseas</I><BR>

<I>Subsidiaries in 16 countries including:</I>
<UL><LI> Mitsubishi Chemical America, Inc. (Control of investment in North America; import/export business; manufacture /sales of products)<BR>
<LI> Seradyn, Inc. (Manufacture/sales of diagnostic equipment, reagents and quality analytical instruments)<BR>
<LI> Mitsubishi Chemical Europe GmbH (Import/Export business; liaison activities)<BR>
<LI> Mitsubishi Chemical (UK) Plc. (Clinical Research of Pharmaceuticals, Financing, Sales of Products)<P>
</UL>

<B>History</B>
<BLOCKQUOTE>Founded as Nippon-Tar Industries in 1934 as a chemical business unit of the  Mitsubishi Zaibatsu. In accordance with the Enterprise Readjustment and Reorganization Plan, the company restarted as Nihon Kasei Kogyo in 1950. Life Science Institute for basic life science research and Bioscience Laboratory for applied pharmaceutical R&amp;D were established in 1971. Pharmaceutical business started by the launch of Theodur&#174 in 1984. Mitsubishi Kasei Corp. acquired pharmaceutical R&amp;D of Mitsubishi Petrochemical Co. Ltd. in 1987. Pharmaceuticals and diagnostic company now exists as a inner company of Mitsubishi Chemical Corp.</BLOCKQUOTE><P>

<B>Established:</B> June, 1950<P>

<B>Subsidiaries (Pharmaceuticals and Diagnostic Companies)</B>
<UL>
<LI>Institute of Life Science</LI>
<LI>Institute of Toxicology and Environmental Science</LI>
<LI>Tokyo Tanabe Co., Ltd.</LI>
<LI>Dia Iatron Co., Ltd.</LI>
<LI>Seradyn, Inc.</LI>
<LI>Kasei Synthelabo</LI>
<LI>Yuka Medias, Co., Ltd.</LI></UL>

<B>Legal Form:</B> Public Corporation<P>

<B>Stock/Financial History</B><UL>
<LI>Offering, February, 1990, 140,631 (ten thousand stocks)</LI>
<LI>Stock split, May, 1991, 154,839 (ten thousand stocks)</LI>
<LI>Merger with Mitsubishi Petrochemical Co., 219,055 (ten thousand
stocks)</LI>
<LI>Total assets: 1426 billion yen</LI></UL><P>

<B>Investments:</B>
<UL><LI> Nikken Chemicals Co., Ltd.<BR>
<LI> Tokyo Tanabe Corporation, Ltd.<BR>
<LI> Kasei Synthelabo<P>
</UL>

<B>Private Placement<I>In domestic market:</B></I><BR>
<UL><LI> #15 issued in 2/26/90, 2 billion Yen<BR>
<LI> #11 issued in 6/28/94, 10
<LI> billion Yen<BR>
<LI> #12 issued in 6/28/94, 10 billion Yen<P>
</UL>

<I>In Euro-market:</I><BR>
<UL><LI> issued in 6/27/91, 3 billion Yen<BR>
<LI> issued in 2/18/94, 10 billion Yen<BR>
<LI> issued in 7/29/94, 10 billion Yen<P>
</UL>

<B>Principal Investors:</B><BR>
<UL><LI> The Meiji Mutual Life Insurance Co.<BR>
<LI> Nippon LifeInsurance Co.<BR>
<LI> The Mitsubishi Bank, Ltd.<P>
</UL>

<B>Corporate Overview</B><BR>
<BLOCKQUOTE>Mitsubishi Chemical Corporation (MCC) is a Japanese diversified chemical company heads more than 350 subsidiaries and affiliates in the group, which appears worldwide. MCC consists of 9 Business Groups or Inner Companies:<BR>
<UL><LI> Basic Petrochemicals Company
<LI> Industrial Chemicals Company
<LI> Polymer Products Company
<LI> Fiber Intermediates Company
<LI> Specialty Chemicals Company
<LI> Pharmaceuticals and  Diagnostic Company
<LI> Information and Electronics Company
<LI> Carbon and Agriculture Products Company
<LI> Functional Materials Company
</UL>

Our pharmaceuticals business activity are comprised of three main areas:  pharmaceuticals, diagnostic reagents and diagnostic instruments, and bulk substances and bovine serums. (Pharmaceuticals and diagnostic company) Pharmaceutical and Diagnostic Company in MCC orients a R&amp;D based pharmaceutical business unit. Total number of research and development employees is 650 including the Institute of Life Science. In pharmaceuticals area, MCC has succeeded in developing many new chemical entities for treating disorders of the central nervous system, cardiovascular system, immune system including allergies, and now MCC is making further efforts in medicinal research into disease affecting adults and the aged, in particular. In October 1993, MCC launched its 10th pharmaceutical product, a new anti-platelet aggregation agent Anplag&#174;. Sales of this product were consigned to Tokyo Tanabe Co., Ltd., and we expectthis company's annual sales of the product to reach YEN 10 billion. MCC also launched a new type of asthma medicine, Theodur&#174; Syrup, the world's first sustained release pediatric theophyillin syrup. We are engaged in developing our international business activities in positive manner. We have entered into business tie-ups with some pharmaceuticals companies in Europe and USA to establish the firm position abroad as well as at home. Our company is moving ahead with development of new medicines and expanding our  business activities from a global point of view.</BLOCKQUOTE>

<B>Technology Overview (Pharmaceuticals and Diagnostic Company)</B>
<BLOCKQUOTE>Following Theodur&#174;, sustained-release anti-asthma drug, MCC introduced a variety of pharmaceuticals, including Romet&#174;, an anti-allergic agent, Alnert&#174;, anti-thrombotic agent, Novastan, the t-PA Grtpa&#174; and Hepatitis-B vaccine Mitsubishi&#174;. Novastan&#174; was developed using MCC's molecular design technique, making it the first anti-thrombotic agent in the world. GRTPA&#174; and Hepatitis-B vaccine Mitsubishi&#174; are new type drugs developed using gene-recombinant technology. MCC has launched its anti-platelet agent, Anplag&#174; and anti-rheumatic agent, Mover&#174;.</BLOCKQUOTE><P>

<B>Agreements (Pharmaceuticals and Diagnostic Company)</B><BR>
<I>Licensing Agreements</I><BR>
<UL><LI> Genentech
<LI> Merz
<LI> Synthelabo
<LI> Schering Plough<P>
<I>Corporation Agreement</I><BR>
<UL><LI> ASTRA
<LI> MMD
</UL>
</UL><P>

<B>Products on Market:</B>
 Theodur&#174;, Myse&#174;, Romet&#174;, Alnert&#174;, Celeport&#174;, Vasomet&#174;, Novastan&#174;, Slonnon, Grtpa&#174;, r-HB Vaccine&#174;, Kerlong&#174;, Anplag&#174;, Mover&#174;, CRH<P>

<B>Products in R&amp;D<</B>P>
15 products under clinical evaluation and 5 products in preclinical stage<P>

<B>Current Corporate Partners</B><UL>
<LI>ASTRA</LI>
<LI>MMD</LI></UL>

<B>Management:</B><BR>
Masahiko Furukawa, Chairman of the Board<BR>
President: Akira Miura<P>

<B>Managing Directors:</B><BR>
Hideo Fukutani, Yousuke Ariyoshi, Keiichi Higuchi, Takashi Saito,
Naotoki Sawada, Takeo Okunishi, Yasuo Harada, Hiroshi Imada, Kanji
Shono, Arata Makino, Takeru Onoda, Morihisa Takano, Tsuyoshi Yamamoto, Shoei Yokoyama, Hideo Watanabe, Yoshimichi Nakamura, Yoshihisa Narukawa<P>

<B>Board of Directors:</B> J.L.Stitt, Ichiro Kagawa, Muneo Suzuki,
Kohsuke Kanaya, Masatoshi Shimosaka, Takayori Tsuboi, Teruo Kobori,
Junichi Yamaguchi, Takehiko Sugasawa, Kazuhiro Matsui, Norihiko
Nishiyama, Yuichi Matsumoto, Kiyoshi Sasaki, Tetsuo Komuro, Yoshimi
Shibata, Masaaki Nishikawa, Yoshitoshi Tsunoda, Kouji Matsuda, Masanori Namikawa, Keisuke Mizukami, Toshihiko Aritake, Tadashi Ohira, Mitsuo Sagara, Koichiro Maekawa, Yoshihisa Shoda, Masamitsu Odagiri, Kizo Yamada, Kenichi Yoshimi, Eiichi Ono, Mitsuyoshi Mitsuoka<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
<!-- revised Saturday, June 3, 1995 4:55AM >

<!-- Subject Terms:
Senile dementia, Schizaphrenia, Arrhythmia, Hyperlipidemia,
Hypertension, Gastro intestinal disorders, Asthma, Rhinitis, Allergic dermatological diseases, Diabetes, Bone diseases, Imaging.<P> >
</DOC>
<DOC>
<DOCNO>WT03-B24-168</DOCNO>
<DOCOLDNO>IA064-000378-B003-8</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/PressNews/advertisement.html 206.86.52.80 19970112095416 text/html 5786
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:54:17 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5604
Last-modified: Sun, 17 Nov 1996 07:47:31 GMT
</DOCHDR>
<HTML>
<HEAD></HEAD>
<BODY BGCOLOR="#FFFFFF">
{FliwE)<BR>
To Japanese Researchers<P>

{^wIiOwEB
A{]COiBOZpCZXAIVJACOisFV{JBEsioiFdiltiazem, FK506jAB{ZpCO]ApDvVIbxAB<P>

IAZpIAlXciwNSFj{ZpigDwBA{O[BOAwZp/VZpJconwZpi(ERATO)AIJcB(Special Report on Japanese Science, Nature / Science; November, 1992Q)<P>

{A{nCXNoBcOAzA[AGprBAgKvBA{AIeAOA~BAwwCZXAmILKwsnBAB]oB<P>

LAiJAb[KvA~\KvoICtB
Sosei Co., Ltd.ADIAygxBDGZpEoB<P>

Sosei Co., Ltd.d_wA{wIvAyWVNwB\A{AEBXAWALA{lvVNw}LBiUTNwQOOONSlPUBj
Sosei Co., Ltd. AO[o_yiCZXEnoB<P>

ASosei Co., Ltd.LfAvWFNgxBvWFNgbiWBOAV_^I]AFlAB<P>

E-mail address: <A HREF=mailto:eyamada@sosei.com>eyamada@sosei.com</A><P>



1. EBqvWFNg<P>

wqAEq{lEBqHepatocyte Growth Factor(HGF)BAqtnEYAEpqAtpS[BAAtAznAV}\BAHGF induceriB{MvA{vWFNg[_[B<BR>
GenentechyZFCZX_B<P>

2. EvWFNg<P>

wqFAEECa2+A@Ca2+oAECa2+UgNEpdvBAovIP3eBEJjYAsEnE@\@\AA@\B{ejA{vWFNg[_[B
VKQB<BR>
{NxVZpcERATO PJB<P>

3. TGF-beta super family vWFNg<P>

kCwlATGF-betaTGF-beta super familyATGF-betaVOi`B}iImMBATGF-beta}gbNX~tTGF-betaVOifBJjY VOixB<BR>
_B<P>

4. TelomerasevWFNg<P>

qwqAEVvvmEVhIAeA\lyfTelomeraseJnByfLEAyf\iBAIB<BR>
BCOcollaborationB<P>


5. XN[jOvWFNg<P>

wjANnRWJBALpdBA_onAbZCnSARswBAVAbZCngVniBVjA{vWFNg[_[B<BR>
OAyx`[pIgB<P>

</BODY></HTML>


</DOC>
<DOC>
<DOCNO>WT03-B24-169</DOCNO>
<DOCOLDNO>IA064-000378-B002-180</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/genpharm.html 206.86.52.80 19970112095213 text/html 3683
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:52:10 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3501
Last-modified: Sun, 17 Nov 1996 18:21:20 GMT
</DOCHDR>
<HTML> 
<HEAD><TITLE>GenPharm International</TITLE></HEAD> 
<BODY BGCOLOR="#FFFFFF">
<IMG BORDER= 0 SRC="../Graphics/genpharm.gif">
<H2>GenPharm International, Inc.</H2>
<H3>Corporate Profile</H3>
<!--<A HREF = "ipijp.html"><IMG  Align=Middle SRC="../Graphics/japanese.gif"></A
> <A HREF = "ipijp.html">Japanese Translation</A>-->
<HR>
297 N. Bernardo Avenue<BR>
Mountain View, CA 94043<BR>
(415) 964-7024 (voice)<BR>
(415) 964-3537 (fax)<P>
<HR>
<B>Company Officers:</B><BR>
<A HREF="MAILTO:lhunter353@aol.com">Jonathan MacQuitty, CEO</A><P>
<B>Employees:</B>	13<P>
<B>Facilities:</B>	15,000 sq. ft. of laboratory office and animal facilities in the U.S.<P>

<B>Principal Investors:</B><P>


<CENTER><TABLE BORDER=5>
<TR><TD>Abingworth Management</TD><TD>Institutional Venture Partners</TD></TR>
<TR><TD>Atlas Ventures</TD><TD>Kleiner, Perkins, Caufield & Byers</TD></TR>
<TR><TD>Charterhouse Venture</TD><TD>Kokusai Finance Co., Ltd.</TD></TR>
<TR><TD>Collagen Corp.</TD><TD>Merrill, Pickard, Anderson & Eyre</TD></TR>
<TR><TD>Daiwa</TD><TD>New Enterprise Associates</TD></TR>
<TR><TD>Delphi Ventures</TD><TD>Newtek Ventures</TD></TR>
<TR><TD>Eli Lilly</TD><TD>Nichimen Corp.</TD></TR>
<TR><TD>Euroventures</TD><TD>PaineWebber Development</TD></TR>
<TR><TD>Fairfield Venture Partners</TD><TD>SED Ventures</TD></TR>
<TR><TD>Fujigin Capital Co.</TD><TD>Sequoia Capital</TD></TR>
<TR><TD>Funai Capital Corp.</TD><TD>Techno-Venture Co. Ltd.</TD></TR>
<TR><TD>Genencor International</TD><TD></TD></TR>
</TABLE></CENTER><P>

<B>Corporate Overview:</B><P>

Develop and commercialize fully human monoclonal antibodies based on transgenic animal technology.<P>

<B>Research & Development:</B><P>

HuMAb-Mouse (tm) transgenic system for the production of fully human MAbs.<P>

<B>Agreements:</B><P>


<!-- Table Tag -->
<CENTER><TABLE CELLSPACING=3 CELLPADDING=3 BORDER=3>
<TR><TH>Name</TH><TH>Products</TH><TH>Content of Agreement</TH><TH>Date</TH></TR>
<TR><TD>Baylor Univ.</TD><TD>murine embryonic stem cells</TD><TD>license to technology developed by Dr. Allan Bradley</TD><TD>1990</TD></TR>
<TR><TD>DNX</TD><TD>microinjection technology</TD><TD>cross-licensing agreement with right to sublicense transgenic animal products</TD><TD>1991</TD></TR>
<TR><TD>Eisai Co Ltd.</TD><TD>human MAbs for one unnamed antigen</TD><TD>exclusive rights for Asia or one antigen</TD><TD>1993</TD></TR>
<TR><TD>Genencor Int.</TD><TD>molecular biology and other technology for transgenic applications</TD><TD>exclusive R&D agreement</TD><TD>1988</TD></TR>
<TR><TD>Medical Research Council</TD><TD>dominant activating sequences</TD><TD>license to technology developed by Dr. Frank Grosveld</TD><TD>1991</TD></TR>
<TR><TD>Univ. of Utah</TD><TD>homologous recombination techniques for gene targeting and MAb production</TD><TD>exclusive rights to technology developed by  Dr. Mario Capecchi</TD><TD>1990</TD></TR>
</TABLE></CENTER>
<P>
<A HREF="http://www.sosei.com/"><IMG ALIGN=MIDDLE SRC="../Graphics/home_button.gif"><A HREF="http://www.sosei.com/">&nbsp;Home Page</A><P>
<HR>
</BODY>

<ADDRESS><FONT SIZE=3>Updated December 18, 1995.<BR>
Copyright &copy: 1996 <A HREF="http://www.genweb.com/">GenWeb</A>. All rights reserved.</FONT></ADDRESS>

<!-- Contact Person:
Date:		12/18/95
Name:	Leslie Flint
Title:		Director Administration
Address:	GenPharm International, Inc.
		297 N. Bernardo Avenue
City		Mountain View
State:		CA
Zip:		94043
Telephone:	(415) 964-7024
Fax:		(415) 964-3537
e-mail:	lflint@genpharm.com-->
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-170</DOCNO>
<DOCOLDNO>IA064-000378-B003-339</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/PressNews/genpharmpr1.html 206.86.52.80 19970112095625 text/html 4250
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:56:31 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4068
Last-modified: Sun, 12 May 1996 20:18:04 GMT
</DOCHDR>
<HTML><HEAD><TITLE>GenPharm announces high affinity human antibodies from transgenic mice; signs a new agreement with Eisai</TITLE></HEAD>
<BODY BGCOLOR=#FFFFFF>
<H3><B>GenPharm announces high affinity human antibodies from transgenic mice; signs a new agreement with Eisai<P></B></H3>

<B>MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Dec. 5, 1995</B>--<BR>GenPharm International Inc. announced today at the 6th International Conference on Antibody Engineering in La Jolla, Calif., the generation of high affinity human IgG antibodies suitable for therapeutic use. These antibodies were produced from GenPharm's HuMAb-Mouse(TM), a transgenic mouse line containing human antibody genes that rearrange to form high affinity human antibodies. The mice can be used to generate monoclonal human antibodies to a wide variety of antigens, including human antigens.<P>

GenPharm's initial transgenic mouse was described in the British journal `Nature` (Nature 368:856). The work presented today covers the addition of other human sequences into the mouse along with extensive characterization of fully human IgG antibodies generated by it. These monoclonal antibodies had affinity levels suitable for therapeutic use with the highest affinity at greater than 10 to the 10th.<P>

Separately, GenPharm announced today that it had signed a renewal of its R&D Collaboration Agreement with Eisai Co. Ltd., a leading Japanese human health care company headquartered in Tokyo. The original agreement with Eisai, worth up to $25 million for research and milestone payments, was established in 1993.<P>

`We are delighted with Eisai's confidence in the value of GenPharm's novel technology and look forward soon to bringing important medical products to the clinic for the benefit of human patients,` commented Jonathan MacQuitty, Ph.D., chief executive officer of GenPharm International.<P>

GenPharm International Inc. is a world leader in the development of human monoclonal antibodies from transgenic mice for therapeutic and diagnostic uses.<P>

<I>Background</I><P>

GenPharm's transgenic HuMAb-Mouse contains key sequences from unrearranged human antibody genes as well as having inactivated mouse antibody genes. The human sequences code for both the human heavy and light chain segments of human antibodies. The human gene sequences function well in the mouse undergoing rearrangement to provide a wide repertoire of human antibodies similar to that in humans. Most importantly, the human antibodies in the transgenic mice undergo class switching and somatic mutation from low affinity IgM class antibodies to high affinity human IgG class antibodies.<P>

GenPharm has now generated human IgG antibodies using its transgenic mouse system with affinities that exceed 10 to the 10th. Antibodies for therapeutic use need affinities in this range to have clinical utility. In addition, because 
these antibodies are generated from human sequences, they should avoid the rejection problems that have often affected mouse-based antibodies.<P>

Another important feature of GenPharm's HuMAb-Mouse is its ability to react against human antigens. Thus, unlike most antibodies produced in humans, GenPharm's mice can generate human antibodies with high affinity against human antigens. This allows for the possibility of using human antibodies to control a wide range of inflammatory conditions, autoimmune diseases and cancers. GenPharm has already generated human IgG antibodies to various human antigens, including IgE, CD4 and the cancer antigen CEA.<P>

Because the human sequences in the HuMAb-Mouse can generate high affinity human IgG directly in the mice, it is unnecessary to subject the human antibodies produced to any further manipulation, either to `humanize` the antibodies or to improve their affinity or specificity. Because the antibodies have been matured `in vivo,` they naturally have the specificity and affinity necessary for proper binding to the target antigen.<P>

CONTACT: GenPharm International Inc., Mountain View Jonathan MacQuitty, 415/988-2401
<BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-171</DOCNO>
<DOCOLDNO>IA064-000378-B002-295</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/terrapin.html 206.86.52.80 19970112095341 text/html 14450
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:53:42 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 14267
Last-modified: Sun, 12 May 1996 19:30:20 GMT
</DOCHDR>
<HTML><IMG WIDTH=140 HEIGHT=78  SRC="../Graphics/terrapin.gif"><HEAD><TITLE>Terrapin Technologies</TITLE></HEAD>
<BODY BGCOLOR=#FFFFF>
<H3>Corporate Profile</H3>
<!--<A HREF = "ipijp.html"><IMG  Align=Middle SRC="../Graphics/japanese.gif"></A> <A HREF = "ipijp.html">Japanese Translation</A>-->
<HR>

<P>Terrapin Technologies, Inc.<BR>
750 Gateway Blvd.<BR>
South San Francisco, CA 94080<BR>
(415) 244-9303<BR>
(415) 244-9388 (fax)</P>

<H2>Company Officers:</H2>


<P>Clifford Orent<BR>
Chairman and Chief Executive Officer</P>

<P>Reinaldo F. Gomez, Ph.D.<BR>
Vice President, Project Management</P>

<P>Lawrence J. Kauvar, Ph.D.<BR>
Vice President and Chief Scientist</P>

<P>Marvin I. Siegel, Ph.D.<BR>
Vice President, Research and Development</P>

<P>Sharon E. Tetlow<BR>
Vice President and Chief Financial Officer<BR>
<A HREF="mailto:tetlow@mx.trpntech.com">tetlow@mx.trpntech.com</A></P>

<P><B>Employees:  </B>approximately 62 (21 Ph.D.s)</P>
<P><B>Facilities:  </B>20,000 square feet</P>

<H2>Company Overview:</H2>
<P>Terrapin is a privately held pharmaceutical discovery company which has achieved considerable success in establishing:</P>
<UL>
<LI> A proprietary, enabling technology for rapidly identifying novel,
small-molecule therapeutic compounds.
</LI>
<LI> Product leads offering significant competitive advantages&#150;&#150;including TER199 and TER286 for use in the fields of oncology/hematology, and a family of small molecules for the treatment of diabetes.
</LI>
<LI> An innovative exploratory program focused on novel disease targets and novel product candidates for major T-cell-mediated immunological diseases and disorders.
</LI>
</UL>
<P>Terrapin&#146;s mission is to build a portfolio of novel pharmaceuticals that address important medical needs in sizable markets. Utilizing its patented molecular fingerprinting technology, the Company has already identified several
small-molecule product leads which have proven biological activity against key disease mechanisms. The most significant of these are TER199, which addresses the $1 billion colony stimulating factor market in oncology/hematology, and the diabetes compounds which could lead to a major advance in the $3 billion diabetes market. In addition, the Company&#146;s
exploratory program in T-cell regulation is leading to broad therapeutic opportunities in the multi-billion dollar autoimmune disease, transplantation and asthma markets.</P>
<P>To commercialize its drug discoveries, Terrapin intends to establish corporate partnerships and, where appropriate, to retain U.S. rights to molecules it wants to develop for its own portfolio. Discussions are currently in progress with major pharmaceutical and biotechnology companies, with the goal of entering into collaborative and/or licensing arrangements on initial product leads. This strategy will allow the Company to pursue a number of drug discovery projects simultaneously, maximizing the value of its technology while also
taking advantage of the clinical trial, marketing and distribution
infrastructure of its partners.</P>  
<H2>Program Overview:</H2> 
<H3> Oncology/Hematology</H3>
<P>TER199 &#150;&#150; This novel, orally active molecule has been shown in preclinical (in vivo) studies to accelerate the reappearance of circulatingneutrophils, platelets, erythrocytes and lymphocytes following their suppression by chemotherapeutic agents. TER199 thus has the potential of being used in placeof colony stimulating factors in all clinical applications&#150;&#150;such as the rescue of myelosuppression following chemotherapy, the treatment of
neutropenia, and the transplantation of bone marrow&#150;&#150;while also having the advantage of oral bioavailability. In addition, TER199 offers the opportunity to provide the potential benefits of MGDF and TPO for platelet growth and the treatment of thrombocytopenia. Terrapin expects to file its Investigational New Drug application in 1996 to initiate human clinical studies in cancer patients. </P>
<P>TER286 &#150;&#150; A tumor-activated compound, TER286 only becomes toxic when encountering elevated levels of glutathione S-transferase (GST) isozymes. GSTs have been shown to be responsible for drug resistance, and levels of certain GSTs are elevated in difficult-to-treat cancers such as lung, ovarian and breast cancer. TER286<B> </B>has exhibited excellent efficacy in animal tumor model systems and in primary human tumor cells in culture, often outperforming currently used products such as taxol, cisplatin and fluorouracil. In animals, TER286 also exhibits significantly reduced bone marrow toxicity compared to currently available therapies. To develop TER286, Terrapin intends to establish a strategic alliance with a corporate partner that can bring the product to market as part of a portfolio of cancer-fighting agents.</P> 
<H3> Diabetes</H3>
<P>Terrapin scientists have discovered a family of small molecules which directly activate the human insulin receptor. These molecules offer the potential to regulate both insulin and blood glucose levels with oral therapy. The Company&#146;s most promising diabetes lead has been shown to interact directly with the insulin receptor and to potentiate insulin&#146;s action in intact cell studies. Further validating this treatment approach, Terrapin has demonstrated a lowering of blood glucose and circulating insulin levels in preclinical (in vivo) models of type II (adult onset) diabetes. Terrapin plans to apply its medicinal chemistry expertise, alone or with a strategic partner, to identify a novel compound based on its leads for entry into human clinical studies. </P> 
<H3> Immunology</H3>
<P>The discovery and development of safe and effective agents for the treatment of chronic inflammatory, allergic and autoimmune conditions represents a broad scientific and commercial opportunity for Terrapin. Company research has led to newly discovered intracellular proteins that provide the mechanistic basis for regulating T-cell activities. These intracellular proteins offer the promise of much-needed molecular specificity for controlling inflammation &#150;&#150; without the toxicity common with other immunosuppressives. The Company&#146;s work centers on both novel molecular targets and novel product candidates, initially for the treatment of autoimmune disease, transplant rejection and asthma.</P>  
<H2>Proprietary Drug Discovery Technology</H2>  
<P>The Company&#146;s innovative molecular fingerprinting technology, known as TRAP&#153;, has been the driving force for the success of Terrapin&#146;s projects. This powerful technology is designed to accelerate drug discovery and early product development activities that currently represent major productivity bottlenecks for pharmaceutical and biotechnology companies. Moreover, it allows
the discovery of drug candidates from large chemical libraries at an
unprecedented level of efficiency.</P>
<P>TRAP classifies small molecules by distinct computer-readable patterns, or &#147;molecular fingerprints,&#148; based on specific protein-binding characteristics. By computationally screening its large database of highly diverse chemicals, Terrapin can rapidly identify compounds that are likely to interact with a given disease target. Unlike other computer screening techniques, TRAP is distinctive in being able to search among compounds with vastly different chemical
structures, based on properties directly relevant to potential pharmaceutical utility. Furthermore, TRAP can predict functional relationships without prior knowledge of the structure of either the molecule or the disease target. As a result, scientists can identify medically relevant lead compounds without depleting precious supplies of rare materials and can intelligently apply sophisticated modern chemistry, such as combinatorial chemistry and computer modeling of molecules, to develop novel product candidates. </P>
<P>Protecting its technology, Terrapin has established a strong proprietary position with patents and trade secrets. Fourteen patents have been issued or allowed, protecting the core technology, composition of matter and use. Numerous additional patent applications are pending.</P>
<H2>Investors: </H2>
<P>Since its inception, Terrapin has raised over $35 million in funding from both venture capital and private investors. Venture investors include Burr, Egan, Deleage &amp; Co.; Weiss, Peck &amp; Greer; Oxford Bioscience Partners; Advent International; Delphi Bioventures; Hambrecht &amp; Quist Capital Management; Alpha Partners; MDS Health Ventures Capital Corp., GIMV and Sofinnova. Private investors include the Swanson Family Fund Ltd. and Dr. Alejandro Zaffaroni.</P>
<P><B>Founded: </B>1986</P>
<P><B>First Round Venture Funding:</B> 1991</P>
<P><B>Business Strategy and Corporate Partnering Opportunities</B>:</P>
<P>One of the key strengths of Terrapin&#146;s technology is that it can be applied to a wide range of small-molecule drug discovery and development projects. At the same time, it has broad applicability beyond therapeutics to a variety of other commercial arenas. Terrapin has chosen to concentrate on innovative human therapeutics that address significant market needs and to recognize value in other areas, where appropriate, through out-license or spin-off.</P>
<P>In addition to building its own therapeutic portfolio, Terrapin expects to collaborate with biotechnology and pharmaceutical companies which are exploring their own disease-related targets. Terrapin believes that the ability of its technology to rapidly qualify targets of opportunity, discover therapeutic leads and optimize product candidates increases the probability of finding a compound
of significant therapeutic and commercial value. Currently, through an agreement with Japan Tobacco Inc., Terrapin is using its TRAP technology to create a fingerprint database for a highly diverse chemical library of 20,000 compounds. In addition, through agreements with a number of biotechnology companies, Terrapin is using its TRAP technology to detect compounds in its own diverse library that are active against targets of interest to its collaborators.</P>
<H2>Scientific Advisory Board:</H2>  
<P><I>Amnon Altman, Ph.D.</I><BR>
Member and Head, Division of Cell Biology La Jolla Institute for Allergy and Immunology, La Jolla, CA</P>
 
<P><I>Joseph Bertino, M.D.</I><BR>
Chairman, Molecular Pharmacology and
Therapeutics Memorial Sloan Kettering Cancer Center, New York, NY</P>
 
<P><I>J. Michael Bishop, M.D.</I><BR>
Director of the G. W. Hooper Research
Foundation University of California San Francisco, CA</P>

<P><I>Richard Borch, M.D., Ph.D.</I><BR>
Dean&#146;s Professor of Oncology and Director of the Cancer Center, University of Rochester Medical Center, Rochester, NY</P>

<P><I>Michael Buchmeier, Ph.D.</I><BR>
Associate Member of Neuropharmacology Scripps Research Institute, La Jolla, CA</P>

<P><I>Ira Goldfine, M.D.</I><BR>
Director, Division of Diabetes and Endocrine
Research University of California San Francisco, CA</P>

<P><I>Jordan Gutterman, M.D.</I><BR>
Chairman, Clinical Immunology &amp;
Biological Therapy M.D. Anderson Cancer Center, Houston, TX</P>

<P><I>Michael Julius, Ph.D.</I><BR>
Professor and Chair, Department of Immunology University of Toronto, Toronto, Ontario, Canada</P>

<P><I>Bengt Mannervik, Ph.D.</I><BR>
Professor, Karin &amp; Herbert Jacobsson Endowed Chair  in Biochemistry, Uppsala University, Uppsala, Sweden</P>

<P><I>Daria Mochly-Rosen, Ph.D.</I><BR>
Associate Professor of Molecular
Pharmacology Stanford University School of Medicine, Stanford, CA</P>
 
<P><I>Theodore Puck, Ph.D.</I><BR>
Director of the Eleanor Roosevelt Institute for Medical Research, University of Colorado, Denver, CO</P>

<P><I>David Rocke, Ph.D.</I><BR>
Professor of Statistics, Graduate School of
Management University of California, Davis, CA</P>

<P><I>Gerald Rubin, Ph.D.</I><BR>
John D. MacArthur Professor, Genetics University of California, Berkeley, CA</P>

<P><I>John Sedat, Ph.D.</I><BR>
Professor of Biochemistry University of
California, San Francisco, CA</P>

<P><I>John Tainer, Ph.D.</I><BR>
Associate Member of Molecular Biology Scripps Research Institute, La Jolla, CA</P>

<P><I>Kenneth Tew, Ph.D.</I><BR>
Chairman, Pharmacology Fox Chase Cancer
Institute, Philadelphia, PA</P>

<P><I>Harel Weinstein, D.Sc.</I><BR>
Chairman, Physiology and Biophysics Mount Sinai Medical Center, New York, NY</P>  
<H2>Board of Directors:</H2> 
<P><I>Annette Bianchi</I><BR>
General Partner of Weiss, Peck and Greer Venture Partners, L.P.</P>

<P><I>Jean Deleage  </I><BR>
Managing Partner of Burr, Egan, Deleage &amp; Co.</P>

<P><I>Jerrold L. Glick</I><BR>
General Partner of Columbia Group Limited</P>  

<P><I>Reinaldo Gomez, Ph.D </I><BR>
Vice President, Project Management, Terrapin Technologies, Inc.</P>

<P><I>James M. Gower </I><BR>
Biopharmaceutical industry consultant</P> 
 
<P><I>Charles Hsu, Ph.D.</I><BR>
General Partner of the Walden Group</P>   

<P><I>Lawrence Kauvar, Ph.D. </I><BR>
Vice President and Chief Scientist, Terrapin Technologies, Inc.</P>

<P><I>Edmund M. Olivier </I><BR>
General Partner of Oxford Bioscience Partners</P>

<P><I>Clifford Orent</I><BR>
Chairman and Chief Executive Officer, Terrapin Technologies, Inc.</P>

<P><I>Costa Sevastopoulos, Ph.D.</I><BR>
Independent Consultant and Limited Partner of Delphi Ventures I and II</P>  

<P><I>Gary T. Steele</I> <BR>
President and CEO, Landec Corporation</P>  

<P><I>Max Wilhelm, Ph.D.</I><BR>
 Recently retired as Director, R&amp;D
International and a member of the Pharmaceuticals Division Management Committee of Ciba-Geigy AG</P>  

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated April 29, 1996
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!-- Date:    March 18, 1996
Name of Company: Terrapin Technologies, Inc.
Address:   750 Gateway Blvd.
City:    South San Francisco
State:    California
Zip Code:   94080
Telephone #:  (415) 244-9303
Fax #:   (415) 244-9388
email domain name: trpntech.com--></HTML>


</DOC>
<DOC>
<DOCNO>WT03-B24-172</DOCNO>
<DOCOLDNO>IA064-000378-B003-376</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/PressNews/terrapinpr1.html 206.86.52.80 19970112095633 text/html 3534
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:56:41 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3352
Last-modified: Sun, 12 May 1996 19:33:30 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Terrapin Completes $13.7 Million Mezzanine Financing</TITLE>
</HEAD>
<BODY BGCOLOR=#FFFFFF>
(BW) (TERRAPIN-TECHNOLOGIES) Terrapin Completes $13.7 Million Mezzanine
Financing<BR>
<BR>
Business Editors and Medical Writers<BR>
<BR>
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE) --Dec. 20, 1995--Terrapin Technologies,
Inc., a privately held pharmaceutical discovery company, has received another
$2 million from both current and new investors, and completed its mezzanine
financing with a total of $13.7 million invested.<BR>
<BR>
Lead mezzanine investors are funds under management by Hambrecht &amp; Quist
Capital Management.<BR>
<BR>
&quot;We have exceeded our goal for this financing and are very encouraged
by the strong vote of confidence.&quot; said Clifford Orent, company chairman
and chief executive officer. &quot;As we forge ahead our near-term focus
is on product candidates which address major medical needs in the fields
of oncology/hematology and diabetes. We believe our novel treatment approaches
represent significant breakthroughs.&quot;<BR>
<BR>
Terrapin's lead product candidate, TER199, is a novel, orally active molecule
which addresses the $1 billion colony stimulating factor market. The company's
goal with this product is to provide a single, oral therapy that can protect
and restore bone marrow in patients undergoing chemotherapy.<BR>
<BR>
Therapeutic applications include rescuing cancer patients from myelosuppression
after chemotherapy, treating neutropenia, enhancing bone marrow transplantation,
stimulating platelet growth, and treating thrombocytopenia.<BR>
<BR>
Preclinical (in vivo) studies have shown that TER199 has the extraordinary
capability to accelerate the reappearance of circulating neutrophils, platelets,
erythrocytes and lymphocytes following their suppression by cytotoxic agents.
Terrapin's objective is to file an investigational new drug application
(IND) in 1996 to initiate human clinical studies.<BR>
<BR>
Terrapin's diabetes program is focused on a family of compounds, including
TER3938, which directly activate the human insulin receptor and could lead
to a major advance in the $3 billion diabetes market.<BR>
<BR>
The company believes that its treatment approach offers the opportunity
to more effectively regulate glucose and insulin plasma diabetes. In preclinical
(in vivo) models of type II (adult onset) diabetes, TER3938 has been shown
to lower blood glucose and circulating insulin levels.<BR>
<BR>
The company is now applying its medicinal chemistry expertise to identify
a novel compound based on TER3938 for entry into human clinical studies.<BR>
<BR>
Terrapin is building a portfolio of product candidates targeting unmet medical
needs in oncology/hematology, diabetes and immunology. Working with corporate
partners and on its own behalf, the company is utilizing its proprietary
molecular fingerprinting technology, known as TRAP (TM), to rapidly identify
small-molecule drug candidates which offer significant medical potential.<BR>
<BR>
This powerful technology allows the discovery of therapeutic leads from
large chemical libraries at an unprecedented level of efficiency.<BR>
<BR>
Terrapin is located in South San Francisco, California<BR>
<BR>
--30--<BR>
<BR>
CONTACT: Terrapin Technologies, Inc.<BR>
Clifford Orent, 415-244-9303 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-173</DOCNO>
<DOCOLDNO>IA064-000378-B004-81</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/PressNews/koseishonews1.html 206.86.52.80 19970112095730 text/html 16555
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:57:32 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 16372
Last-modified: Sun, 12 May 1996 20:27:52 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Guidelines for Safety and Quality Assurance of the Drugs for Gene Therapy</TITLE>
</HEAD>
<BODY BGCOLOR=#FFFFFF>
The following is the tentative translation of Koseisho's news.<BR>
This was notified by <A HREF="../Companies/koseisho.html">Koseisho</A> on 15th November 1995.<BR>
<HR>
<H2><CENTER>The Guideline for Safety and Quality Assurance of the Drugs
for Gene Therapy<BR>
</CENTER></H2>
<UL>
<LI><A HREF="#rules">Section 1 General Rules</A>
<LI><A HREF="#production">Section 2 Production Method of the Drugs for the Gene Therapy</A>
<LI><A HREF="#standards">Section 3 Standards, Test Methods and Formulation Designs of the Drugs for Gene Therapy</A>
<LI><A HREF="#stability">Section 4 Stability of the Drugs for GeneTherapy</A>
<LI><A HREF="#preclinical">Section 5 Preclinical Safety Test of the Drugs for Gene Therapy</A>
<LI><A HREF="#efficacy">Section 6 Efficacy Test of the Drugs for Gene Therapy</A>
<LI><A HREF="#internal">Section 7 Internal Kinetics etc. of the Drugs for Gene Therapy</A>
<LI><A HREF="#facilities">Section 8 Facilities and Equipment to produce the Drugs for Gene Therapy</A>
<LI><A HREF="#others">Section 9 The Others</A>
</UL>
<HR>
<H4><A NAME="rules">Section 1 <EM>General Rules</A>
</EM></H4>
<OL><LI>Objective<BR>
<BR>
This guideline regulates the basic items necessary for safety and quality
assurance of the drugs for gene therapy.<BR>
<LI>Definition
</B>
<OL>
<LI>&quot;Gene therapy&quot; means that the genes or the gene transduced cells are administered into humans for the disease treatment etc.  <LI>&quot;Master cell bank&quot; means that after minimum generations of growth of the stock strains for all cell seeds used for production under certain culture conditions, they are divided into the number of ampoules.
<LI>&quot;Working cell bank&quot; means the recombinant cells obtained by pooling one or more cells in the master cell bank are further cultured under the conditions confirmed to be stable, and are divided into the ampoules.
<LI>&quot;Vector&quot; means the transport vehicle used for transducing the objective genes into host cells. In the case of using recombinant viruses, those including the transduced genes are called viral vectors. When the plasmids including the objective genes are directly transduced into cells, the plasmid DNAs are called Vectors. 
<LI>&quot;Viral vector&quot; means the recombinant viruses used as vectors, in which the recombinant viral genomes transduced the objective genes instead of the wild type viral genomes are packaged. 
<LI>&quot;Non-viral vector&quot; means transport vehicles other than viral vectors.
<LI>&quot;Helper&quot; means the viruses or their genes used to complement the creation of viral vectors.
<LI>&quot;Packaging cells&quot; means the cells in which the helper sequences are integrated.
<LI>&quot;Work area&quot; means the area where recombinant objects are directly dealt with and produced.
</OL> </OL>
<HR>
<H4>Section 2 <I><A NAME ="production">Production Method of the Drugs for the Gene Therapy</A></I></H4>
<OL>
<LI><H4>Classification by gene transducing methods</H4>
Choose the appropriate gene transducing method. It is especially necessary to confirm the following items.
  <OL>
  <LI>In the case of transducing using viral vectors
    <OL>
    <LI>Clarify the particle and the gene structure of the viral vectors.
    <LI>Clarify the basis used to select the viruses and helper or packaging
cells.
    <LI>Concerning transduced genetic materials 
      <UL>
      <LI>a. Clarify the derivation, construction means, amplifying method and purifying method of the plasmids etc. used for creating viral vectors, and show they are appropriate. Clarify the derivations of all the elements. Clarify the construction means and the amplifying method etc. of the objective genes, and show they are appropriate. When the plamids used for making viral vectors, objective genes, viral vectors and the viruses etc. are produced by the cell bank system, clarify the preparation method, control method, and renewal method etc., and show they are appropriate.
      <LI>b. Clarify the base sequences, the cleavage map by the restriction enzymes, and the configurations of elements of the plasmids used to create DNA or RNA and viral vectors transduced into humans. Investigate also whether the harmful genes in the recombinant DNA used for creating the viral vectors are present or not.
      <LI>c. Examine the expression mechanism of the genes transduced into humans, when the gene expression is designed to undergo some regulatory mechanism, clarify the regulation mechanism and the experimental basis, and show they are appropriate.
      </UL>
    <LI>Show that the production and purification method of viral vectors are controlled appropriately. In the case of using the packaging cells, show that the derivation, production method, the biological features of the packging cells, the production procedures of the viral vector producing cells, the isolation/purification method, the cell bank system and the culture method etc. are controlled appropriately.
    <LI>In the case of transducing with non-viral vectors
      <OL>
      <LI>Clarify the structure and the elements of the non-viral vectors inducing the genetic materials transduced into humans.
      <LI>Clarify the characteristics of the said gene transducing methods.
      <LI>Concerning the transduced genetic materials
        <UL>
        <LI>a. Clarify the derivation, the construction means, amplifying method and purifying method of DNA or RNA transduced with non-viral vectors, and show they are appropriate. Clarify the derivations of all the elements. Clarify the construction means and amplifying method etc. of the objective genes, and show they are appropriate. When DNA or RNA and the objective genes transduced with non-viral vectors are produced by the cell bank system, clarify their preparation method, control method and renewal method etc., and show they are appropriate.
        <LI>b. Clarify the base sequences, the cleavage map by the restriction enzymes and the element's configurations of DNA or RNA transduced into humans.
        <LI>c. Examine the expression mechanism of the genes transduced into humans. When the gene expression is designed to undergo some regulatory mechanism, clarify the regulation mechanism and the experimental basis, and show they are appropriate.
        </UL>
      <LI>Show the production and purification methods of the non-viral vectors including the genetic materials transduced into humans are controlled appropriately. Concerning all the elements of the vectors (proteins, sugars, lipids etc.), clarify the derivations, production methods, purification methods and structures or the composition, properties and quality control methods etc., and show they are appropriate. In the case of using the materials derived from organisms, confirm there are no possibilities of the contamination of microorganisms.
      </OL>
    <LI>In the case of transducing DNA or RNA directly without vectors 
      <OL>
      <LI>Show the theoretical basis of the transduction method. 
      <LI>Concerning the transduced genetic materials
        <UL>
        <LI>a. Clarify the derivation, construction means, amplifying method and purifying method of the recombinant DNA, and show they are appropriate. Clarify the derivations of all the elements. Clarify the construction means and amplifying method etc. of the objective genes, and show they are appropriate. When the recombinant DNA used or the objective genes are produced by the cell bank system, clarify their preparation method, control method and renewal method etc., and show they are appropriate. 
        <LI>b. Clarify the base sequences, the cleavage map by the restrictive enzymes, the elements' configurations of DNA or RNA introduced into humans.
        <LI>c. Examine the expression mechanism of the genes transduced into humans. When the gene expression is designed to undergo some regulatory mechanism, clarify the regulation mechanism and the experimental basis, and show they are appropriate.
        </UL>
      </OL>
    </OL>
  </OL>
<H4>
<LI>Classification by treatment methods</H4> 
Explain that the treatment methods of the drugs for gene therapy are designed appropriately in view of the target cells' features. It is also necessary to explain the following items.
  <OL>
  <LI>In the case of using ex vivo method<BR>
Show that the basis for selecting the cell donors, cell culture procedures, the standards which the gene transducing procedures and the gene transducing cells should meet, and the treatment method are appropriate.
  <LI>In the case of using <I>in vivo </I>method<BR>
Show the method to administer the drugs for gene therapy. Show also whether there is the possibility that the gene will be transduced into other cells except the target cells (especially the series of reproduction cells).
  </OL>
</OL>

<H4><HR><A NAME="standards">Section 3 <I>Standards, Test Methods and Formulation Designs of the Drugs for Gene Therapy</A></I></H4>
In order to assure the qualities of the drugs for gene therapy, confirm the production process as well as the standards and the test methods of the final products and perform appropriate quality control of the materials. It is necessary to confirm sufficiently concerning the followings.
<OL><LI>Establish, if necessary, the appropriate purity test of the substances thatmay be mixed, remained or added in the production process, and decomposed substances besides the materials. The establishment basis should be examined with due regard to the results of the process validation.
<LI>Show that there is no possibility of contamination by bacteria, &nbsp; contaminated viruses, mycoplasmas and mold etc. using the appropriate tests. Perform the process validation, if necessary, concerning the possible virus mixing.
<LI>Show that there is no possibility of contamination by endotoxin using the appropriate tests. Confirm that samples does not prevent detecting endotoxin in the test methods used.
<LI>Explain logically in the case when there are special prescription for formulations as the drugs for gene therapy.
<LI>Show how to perform between-lot production control of bulk materials and formulations. Establish the appropriate standards and test methods and show the basis to choose.</OL>

<H4><HR><A NAME="stability>Section 4 <I>Stability of the Drugs for GeneTherapy</A></I></H4>
After considering the distribution period of bulk materials and formulations, perform the appropriate stability tests of then and decide the storage methods and the term of validity. Examine storage in other methods except the prescribed methods or storage over the term of validity and confirm the limits of their stability. Explain logically that the lot number used in each test is appropriate.<BR>
In performing the stability tests, you should refer to the accompanying sheet 2, &quot;Guideline how to perform the stability tests&quot; and &quot;Guideline for the stability tests&quot; (Pharmaceutical Affairs Bureau Council No. 30, Apr. 21, 1994) in &quot;Treatment of the results from stability tests which should be attached on applying the approval for producing (importing) new drugs&quot; (Pharmaceutical Affairs Bureau New Drug Council No.43, Feb. 15, 1991 and Pharmaceutical Affairs Bureau Council No.413, June 30, 1992).

<H4><HR><A NAME="preclinical">Section 5 <I>Preclinical Safety Test of the Drugs for Gene Therapy</A></I></H4>
Perform the appropriate tests using animal models and <I>in vitro </I>concerning the safety of products. The safety tests should reflect the dose routes of the products in humans. It is necessary to examine throughly and confirm the safety about the following items.
<OL>
<LI>Examine appropriately that the vegetative viruses does not appear.
Explain the examination methods are appropriate.
<LI>Confirm the possibility that the drugs will damage cells or tissues.
<LI>Investigate the stability, existing conditions and the number per
cell etc. of the transduced genes and show they does not affect human bodies.
<LI>Explain the safety range of the products expressed by the transduced
genes.
<LI>Explain the possibility of the change of proliferation potency, tumor formation and malignant alyteration of cells.
<LI>Explain the possibility that the components of products, products expressed by the transduced genes and gene transducing cells will cause undesirable immunological reactions.
<LI>When the final products are produced sufficiently, consider performing the general toxicity tests. In performing the tests, you should refer to &quot;Guideline how to perform the toxicity tests&quot; (Pharmaceutical Affairs Bureau Council 1 No.24, Sep. 11, 1989 and Pharmaceutical Affairs Bureau New Drug Council No.88, Aug. 10, 1993) appended to &quot;Guideline for the toxicity tests necessary to apply the approval for producing (importing) new drugs&quot;.
</OL>
<H4><HR>Section 6 <I><A NAME="efficancy">Efficacy Test of the Drugs for Gene Therapy</A></I></H4>
<OL>
<LI>By the tests designed appropriately using cultured cells and experimental animals, examine the efficiency of gene transduction, structures and stability of the transduced genes, expression efficiency by the transduced genes and their durability, biological activities of the products expressed by the genes, expected effects on cells, tissues and individuals etc. 
<LI>When there are appropriate animals as a disease model, examine the treatment efficacy using them.
</OL>
<H4><HR>Section 7 <I><A NAME="internal">Internal Kinetics etc. of the Drugs for Gene Therapy</A></I></H4>
<BLOCKQUOTE>By the tests of the drugs for gene therapy or the gene transducing cells concerning the internal kinetics such as absorption and distribution using the experimental animals, presume the survival period of the gene transducing cells in humans etc. and explain that the objective effects can be accomplished sufficiently.<BR>
In particular, when the drugs for gene therapy or gene transducing cells are required to reach the specific sites (for example, tissues), explain their localization sufficiently. In performing the tests, you should refer to &quot;Guide line for the tests of drug kinetics&quot; appended to &quot;Guideline for the tests of drugs kinetics necessary to apply the approval for producing (importing) new drugs etc.&quot; (Pharmaceutical Affairs Bureau New Drug Council No.6, Jan. 29, 1991).</BLOCKQUOTE>

<H4><HR>Section 8 <I><A NAME="facilities">Facilities and Equipment to produce the Drugs for Gene Therapy</A></I></H4>
<OL>
<LI>To possess the work area.
<LI>The work area must meet the following standards.
<OL>
<LI>To be separated from other area.
<LI>To possess incubation devices ready for use.
<LI>To possess the equipment to examine the physicochemical, biological and immunological properties of the recombinant objects and the drugs for gene therapy used.
<LI>To possess the following equipment.
<OL>
<LI>the equipment to store the recombinant objects
<LI>the equipment to prepare the medium
<LI>the equipment to wash and sterilize the instruments, appliances and containers etc. used for production or test
<LI>clothing-change rooms for the people engaged in production
</OL>
<LI>To possess the other necessary equipment and devices
</OL></OL>

<H4>Section 9 <I><A NAME="others">The Others</A></I></H4>
<OL>
<LI>For the safety and quality assurerance of the drugs for gene therapy, the manufacturers and importers of the drugs for gene therapy can demand the Welfare Minister to confirm that the safety and quality of the drugs concerned are suitable to this guideline.
<LI>The manufacturers and importers of the drugs for gene therapy should collect information about gene therapy, and report to the Welfare Minister immediately when they discover the findings having effects on the evaluation of the drugs for gene therapy they are dealing with.
</OL>
</BODY>
<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated January 8, 1996.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb </A>.<A HREF="http://www.genweb.com/"><IMG  Align=Center SRC="../Graphics/genweb.gif"></A>
All rights reserved.</FONT></ADDRESS>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-174</DOCNO>
<DOCOLDNO>IA064-000378-B004-115</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/PressNews/lstt.html 206.86.52.80 19970112095742 text/html 1218
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:57:48 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1036
Last-modified: Sun, 12 May 1996 19:33:24 GMT
</DOCHDR>
<HTML><HEAD><TITLE>LSTT Forum</TITLE></HEAD><BODY BGCOLOR=#FFFFFF>
LSTT Forum<BR>
medical and pharmaceutical industry in the 21st century<P>

Date: August 3, 1995<BR>
Place: Kyoto Research Park (17 Chudoji Minamimachi<BR>
Shimogyo-ku Kyoto<BR>
600 Japan)<P>

Program:
The plan for reorganizing the medical and pharmaceutical industry in Japan<P>

Mr. Shingo Kano (Nomura Research Institute)
The changes of medical and pharmaceutical administration, and the role of life science<P>

Mr. Tadashi Obara (OCA office)<P>

*Simultaneous interpretation will not be provided.<BR>
Participation fee: 10,000 yen<P>

For further information, please contact:<BR>
Nobuko Yutoku<BR>
Tel: 81-75-315-8665<BR>
Fax: 81-75-322-5348<P>


<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
</HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-175</DOCNO>
<DOCOLDNO>IA064-000378-B004-150</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/news/thiswk.htm 206.86.52.80 19970112095805 text/html 1371
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:58:03 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1189
Last-modified: Fri, 11 Oct 1996 00:14:52 GMT
</DOCHDR>

<HTML><HEAD><TITLE>New This Week</TITLE></HEAD>

<BODY background ="../graphics/white-mi.gif">

<H1><CENTER>New This Week</H1></CENTER><P>

<B><A HREF
="/BioCentury2/archive/1996/2qtr/040196a5.htm">Ngpi
Fv</A></B><br>

LANg{uvvO
-ApiFDAFXb
"B 1996NSP (1,240 )y- 1996NSW (1,800 )<p>
<!-- Make a copy of this and put in Regulatory -->

<H5><HR>
<A HREF="http://www.sosei.com/home.html"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle
Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury
Home Page</A>

<HR>

Copyright (c) 1996 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>

</BODY></HTML>






</DOC>
<DOC>
<DOCNO>WT03-B24-176</DOCNO>
<DOCOLDNO>IA064-000378-B004-193</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/indstr/indstrk.htm 206.86.52.80 19970112095816 text/html 3945
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:58:22 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3763
Last-modified: Wed, 18 Sep 1996 23:38:40 GMT
</DOCHDR>

<HTML>
<BODY background = "../../graphics/white-mi.gif">

<HEAD><TITLE> Industry Structure</TITLE></HEAD>

<H1><CENTER>Y\'</H1></CENTER><P>

LvAep'"NB<P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/031196a1.htm">
hCcoCIeNmW[</A></B><br>
LA AK QAoCIeNmW
[hCc"_B1996N311
(4,200 ).<P>

<B><A HREF ="/BioCentury2/archive/1995/4qtr/120495a1.htm"> _oCIeNmW[</A></B><BR>
LAAJ_oCIeNmW[X_AEeyt@N^[qB 1995N124 (3,150 )<P>

<B><A HREF="../../archive/1995/3qtr/0710a1.htm">Redefining the Biotech Industry ioCIebNY'`j</A></B><BR>
QXg_]AA"`Z"XJ' AIsis Pharmaceuticals Inc.'' Stanley T. CrookeoCIeNmW[l'e[}_cB^Cv{' AoCIeNmW['"I'lVi""\ 'B 7.10.95 (3780)<P>

CrookeAY"""WZp""Idv'NRiboGene Inc. Kenneth Ludlum"_`_c"WJB Ludlum_]A<A HREF="../../archive/1995/2qtr/0530a4.htm">When Infatuation Ends</A>QB30.5.95 (1580)<P>


<B><A HREF="../../archive/1995/2qtr/0501a1.htm">Reality II i  IIj</A></B><BR>
Centocor Inc. ReoPros""_]AoCIeNmW[''~"I_cBAV'W"
AJa@oc"'fe[}BoCIeNmW['`"WARXgd'AV'Ai'AA}[PeC"NBVJ"A'" B1.5.95 (1700)
<P>
_]"A<A HREF="../../archive/1995/2qtr/0424a1.htm"> I </A>QB<P>


<B><A HREF="../../archive/1995/2qtr/0424a1.htm">Reality Ii  Ij</A></B><BR>
LARXgR"g[a@UACentocor Inc.ReoProAnCXXN`pgpR"R'W""'Ae^B(2950) B"bA<A HREF="../../archive/1995/2qtr/0424a3.htm">ReoPros""vO</A>B24.4.95 (475)<P>

'""A<A HREF="../../archive/1995/2qtr/0501a1.htm"> II </A>Q<P>

<B><A HREF="../../archive/1995/1qtr/0130a5.htm">Words of Wisdomi'mbtj</A></B><BR>_]ASyntex, Alza Corp., DNAX Ltd., y Affymax N.V.'n Alejandro ZaffaronioCIeNmW[zbgAV"fBeXSZv^['`"'Au"@`Av'iJ"BRXgWvbV[w"I"y[X"FA"'v@'B30.1.95 (800)<P>

<H5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>

</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-177</DOCNO>
<DOCOLDNO>IA064-000378-B004-237</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/corstr/costrk.htm 206.86.52.80 19970112095829 text/html 3054
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:58:34 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2872
Last-modified: Fri, 11 Oct 1996 00:15:40 GMT
</DOCHDR>
<HTML>
<BODY background = "../../graphics/white-mi.gif">

<HEAD><TITLE> Corporate Strategies</TITLE></HEAD>



<H1><CENTER></H1></CENTER><P>


LvAep'"NB<P>


<B><A HREF ="/BioCentury2/archive/1996/1qtr/032596a1.htm">ReoPro
}[PeCOF No"</A></B><br>

LAp[gi[Eli LillyN'}[PeCO'"ACentocor
Inc.RR'a@B
1996NRQT  (3,400 ).<p>

<B><A HREF ="../../archive/1995/3qtr/0731a5.htm">Chugai's Worldwide Strategyi`EKCO[oj</A></B><BR>
iK}IT'`EKCO[o"B`EKCAChugai Biopharmaceuticals (CBI) y Gen-ProbeAJoCIebN"LB"{BiK}ACBIWiGen-Probef'fyipAaCoc'nB31.7.95 (870) "LA"{s"e[}Bi650)<P>

<B><A HREF="../../archive/1995/3qtr/0717a1.htm">Rebuilding Genentech iGenentechj</A></B><BR>
G. Kirk Raab'EArthur Levinson'''"'bB'A Roche Holdings Genentech'"IoCIJ""F B'"A'"Roche call option $82.50A$60B Genentech'"'Louis LavigneGNE'"IoCIp'B17.7.95 (2750)<P>

<B><A HREF="../../archive/1995/2qtr/0508b1.htm">biosys, the Consolidatoribiosys "ij</A></B><BR>
oCIE'J"""ObiosysLBbiosysCrop Genetics International"AAgriDyne Technologies Inc.b'B8.5.95 (650)<P>

<B><A HREF="../../archive/1995/1qtr/0327b1.htm">Pfizergen Network Take Shape (Pfizergenlbg[Nj</A></B><BR>
Pfizergen APfizer Central Research"\"I'glbg[NB"`qoCIeNmW[]"@Z"IBA PfizerA"I'g'A'"\'B27.3.95 (750)<P>

<H5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>

</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-178</DOCNO>
<DOCOLDNO>IA064-000378-B004-267</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/allpart/allpartk.htm 206.86.52.80 19970112095858 text/html 5309
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:58:52 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5127
Last-modified: Thu, 26 Sep 1996 23:59:23 GMT
</DOCHDR>

<HTML>
<BODY background = "../../graphics/white-mi.gif">
<HEAD><TITLE> Alliances & Partnering</TITLE></HEAD>

<H1><CENTER>'gp[gi[Vbv</H1></CENTER><P>

<B><A HREF="/BioCentury2/archive/1996/1qtr/031996ex.htm">Athena-EElan-w"</A></B><br>
LAAeiEj[TCGX-G-w"W
B1996N319(1,220 ).<P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/011596a1.htm"> Zp'g </A></B><BR>
LA'" Zp"{"--tSosei Co. Ltd.pVAv[`B1996"N115" (1,900 )B <p>

LvAep'"NB<P>
<B><A HREF ="/BioCentury2/archive/1995/4qtr/1113a1.htm">
ArrisKhepriB</A></B><BR>
vKhepri Pharmaceuticals Inc.Arris Pharmaceutical Corp. AiKoCIeNmW[ dv'fBLA-vgeCYx[XivOfZpJAB'lB 1995N1113 (3,100 )
<P>

<B><A HREF ="/BioCentury2/archive/1995/4qtr/1023a1.htm">p[gi[W</A></B><BR>
{k'BAoCIebNWp[gi[Vbv'|eVIB
LA AvironNeoprobe Corp. \zgWqBoCIebNOAsj'rWlXK''qB Oct. 23, 1995 (3250 words)

<B><A HREF ="/BioCentury2/archive/1995/3qtr/0918a1.htm">]"I'</A></B><BR>
'g"'v'vbV[AoCIeNmW[}[PbgETCY\''XBLA'p[gi[VbvEB1995"N918" (3,350 )<P>


<B><A HREF="/BioCentury2/archive/1995/2qtr/0626a1.htm">Amylin's New DealiAmylinV'gj</A></B><BR>
Amylin Pharmaceuticals Inc.pgi[LA""AaWi AC137 amylin agonist compound'"'iKi""w"Io"IXNJo[ Johnson & Johnson'gB Glaxo-WellcomeAw"IJ"AAmylin"LB26.6.95 (1870)<P>

<B><A HREF="/BioCentury2/archive/1995/2qtr/0605a1.htm">Pharma Partners for BiotechioCebNpgi[j</A></B><BR>
gbvE}l[W"goCIeNmW[pgi[LBwA'm"IL 'BWA<A HREF="../../archive/1995/2qtr/0605a4.htm>Explaining Valuations </A>Li""si'B5.6.95 (650)<P>

<B><A HREF="/BioCentury2/archive/1995/2qtr/0522b1.htm">Aviron Finds Korean PartneriAviron'pgi[j</A></B><BR>
LA Aviron n"{[EO[v"o[ Sang-A''gBv'''gAN`"pgi['T""xLB22.5.95 (750)<P>

<B>Chiron's Gene Therapy EffortsiChiron"`q"j</B><BR>
"LA Chiron"`qvO"BA Chiron<A HREF="/BioCentury2/archive/1995/2qtr/0410b1.htm">Progenitor Inc.</A>"ECXyGNXvbVI"EVXepLB10.4.95 (550)<P>

"A Chiron<A HREF="/BioCentury2/archive/1995/2qtr/0425a1.htm">Viagene Inc.</A>"_cLB25.4.95 (1250)<P>

<B><A HREF ="/BioCentury2/archive/1995/1qtr/0306a3.htm">Isis: The Power Positioning DealiIsisFp['_'gj</A></B><BR>

a"Isis Pharmaceuticals Inc.Boehringer Ingelheim International GmbhJ"vO""LBA'lZp"AAaCoc|[gtHIB 6.3.95 (1300)<P>

<B><A HREF="/BioCentury2/archive/1995/1qtr/0213a1.htm">Reasons to Take Over AmgeniAmgen"Rj</A></B><BR>

\A Amgen""""T'AEI[XL"Zl"qLB"'y Amgen"RXgbg'c_B13.2.95 (1900)<P>

<H5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>

</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-179</DOCNO>
<DOCOLDNO>IA064-000378-B004-306</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/regul/regulk.htm 206.86.52.80 19970112095909 text/html 2386
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:59:16 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2204
Last-modified: Tue, 25 Jun 1996 20:38:15 GMT
</DOCHDR>

<HTML>
<BODY background = "../../graphics/white-mi.gif">
<HEAD><TITLE>Public Policy & Regulation</TITLE></HEAD>

<H1><CENTER>K</H1></CENTER><P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/012296a1.htm">
Cephalon-''c_</A></B><br>

LACephalon-kdMyotrophin
IGF-1gpTreatment
INDFDA'B1996N122 (3,000
)<P>

<B><A HREF="../../archive/1995/3qtr/0724a1.htm">J</A></B><BR>
_]A FDAf[^'i"KpK''O"'BLA"F'OJFDA''Nqy` qB 24.7.95 (2,600)<P>

<B><A HREF="../../archive/1995/2qtr/0515a1.htm">"`q"'~@W"</A></B><BR>
WF~[EtL"oX'c'g'@"h"AlA"g"YWGjbN""`q"'~BLA'o"I"_`B (1,300) The <A HREF ="../../archive/1995/2qtr/0515a3.htm">Appeal for Petitioners </A>A""'^"w"l'B@[_['SB (1,500 ) 15.5.95<P>


<B><A HREF="../../archive/1995/2qtr/0417a1.htm">[</A></B><BR>
_]AoCIeNmW['l"_AU.S. FDA '~'l"C@"IfgpB 17. 4.95 (1,375 )<P>

<H5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>

</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-180</DOCNO>
<DOCOLDNO>IA064-000378-B005-28</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/tech/techk.htm 206.86.52.80 19970112095923 text/html 5028
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:59:24 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4846
Last-modified: Thu, 05 Sep 1996 23:08:06 GMT
</DOCHDR>

<HTML>
<BODY background = "../../graphics/white-mi.gif">
<HEAD><TITLE>Technology</TITLE></HEAD>

<H1><CENTER>Zp</H1></CENTER>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/031196b1.htm">
"-: MitoKor- </A></B><br>
LAMitoKor-JDNAN
aCA_oa'""WQ_Zp-B
1996 N311(1,210 ).<p>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/030496b1.htm">
"-: Inflammatics Inc.- </A></B><br>
LAInflammatics-E}`'u ,@
Ex[XuN`JvB
1996N34 (5,570 ).<p>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/022696b1.htm">
"-: Biotrin Holdings Ltd-</A></B><br>
LAA- mBiotrin-oCI}[J[
B 1996N226 (1,500 ).<P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/010896b1.htm"> '"-F oCIkbN- </A></B><BR>
LABioNumerik Pharmaceuticals Inc.X[p[ER"s[^qV~[V"\tgEGApViJ"vOB 1996"N18"(1,150 ).<p>

<B><A HREF ="/BioCentury2/archive/1995/4qtr/121195a4.htm"> N(NIH)'`qW</A></B><BR>
LAN(NIH)fCN^[ovA'`qA'is ]_B 1995N1211 (1000 )B SAAhXQFhttp://www.nih.gov/newsB<P>

<B><A HREF ="/BioCentury2/archive/1995/4qtr/1120a7.htm">"-F Desmos -</A></B><BR>
LAgDtKp_Desmos Inc.vOB-AgDHwAE-AiB 1995N1120 (950 )
<P>

<B><A HREF ="/BioCentury2/archive/1995/4qtr/1106c1.htm">"-F Exelixis -</A></B><BR>
LAExelixis Pharmaceuticals Inc.  QmwvO-B-AiiKiJA'`qaCAmfpB 1995N116 (1,050 ).
<P>

<B><A HREF ="/BioCentury2/archive/1995/4qtr/1023a8.htm">o- </A></B><BR>
BioCentury AVoCIeNmW[-T-nB LAApollon Inc. -"BN`'`qpDNAApollonZpB Oct. 23, 1995 (1000 words).
<P>

<B><A HREF ="/BioCentury2/archive/1995/3qtr/0925a1.htm">I[bp</A></B><BR>
B'nc_A[bpoCIeNmW[Wx`[ABT BioGlobeALWZpA'`q-uwvJiniKO--B1995N925(1,050 )<P>

<B><A HREF="/BioCentury2/archive/1995/3qtr/0731a1.htm">'</A></B><BR>
 Amgen  OB }EXLAmgen s"'}'Al'p'mB (2,480 ) "A <AHREF="../../archive/1995/3qtr/0731a3.htm">Clinical Results</A>A AMGN AbVFAbNtF['w'uwv<I>Science</I>ERLvB (2,400 ) 31.7.31 <P>


<B><A HREF="/BioCentury2/archive/1995/2qtr/0612b1.htm">TPO [X Amgen D</A></B><BR>
o[g\"AXeB[u"XEAiXg Edward Hurwitz  thrombopoietin  Amgen D B" AMGN s""' TPO s'S'B12.6.95 (790 )<P>


<B><A HREF="/BioCentury2/archive/1995/1qtr/0221a1.htm">ALS tsjS_'N</A></B><BR>
''d Syntex/Synergents"_BALS J"aC'm"@p"s''xyB 21.2.95 (1,400 )<P>

<H5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>

</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-181</DOCNO>
<DOCOLDNO>IA064-000378-B005-57</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/fi/fik.htm 206.86.52.80 19970112095940 text/html 2674
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:59:46 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2492
Last-modified: Thu, 08 Feb 1996 23:17:55 GMT
</DOCHDR>
<HTML>
<BODY background = "../../graphics/white-mi.gif">

<HEAD><TITLE>Finance & Investment</TITLE></HEAD>



<H1><CENTER></H1></CENTER>


<B><A HREF="../../archive/1995/3qtr/0807a1.htm">Biotech Bulls</A></B><BR>
AoCIeNmW[WbB {I}NoxBAVKADXpAATdIsB 7.8.95 (3000)<P>


<B><A HREF="../../archive/1995/1qtr/0227a1.htm">pZp</A></B><BR>
oCIeNmW[EZpT[rXvLBiVKJAZpAWFm~bNAwAXN[jOci]dgB 27.2.95<P>


<B><A HREF="../../archive/1995/1qtr/0109b1.htm">NCi[Ep[LY[j</A></B><BR>

x`[ELs^NCi[Ep[LYER[tBhoC[YRNUpV^Wfe[}LBOAZpVKniAoCIeNmW[EsBANCi[Ep[LYATEN`JRNUgbvE}l[Wg`[A{B\B9.1.95 (780)<P>


<B><A HREF="../../archive/1995/1qtr/0103a1.htm">{`</A></B><BR>
_]AY{Ir1994 NsA1995 NqB1993N18%AoCIZ`[100wW1994N29%BAEJiKAmB1995NA[iAILiB 3.1.95 (2,350 )<P>

<H5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-182</DOCNO>
<DOCOLDNO>IA064-000378-B005-80</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/about/aboutk.htm 206.86.52.80 19970112095953 text/html 2904
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:59:57 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2722
Last-modified: Thu, 08 Feb 1996 21:21:25 GMT
</DOCHDR>
<HTML>
<BODY background = "../graphics/white-mi.gif">



<H1><CENTER>BioCentury(TM)</H1></CENTER><P>


BioCenturyBernstein Report on BioBusinessAoCITGXYJA-]_AJLsBoCIeNmW[YAz*AxsWB<P>



TTi'jBioCentury t@bNXC[[MBocA-nA'WApgi[VbvWAAXGB}\KvABioCentury Ot@bNXC[[MB<P>

"WKaren Bernstein, Ph.D.AhoCITCGX"lB SloCIeNmW[Woc"Ay-RT^gBernsteinmAYe[_[BlfB<P>

BioCenturyIAv[`Tj[X\O|[gB|[gAgA\A'\Ase[} B<P>

y-\DG"WAhoCU[plLxB<P>

BioCentury s`AoCITCGXoEI[XBAslAc_Ay-cB<P>


AJBioCentury lkgbvE}l[Wg-AB"B{"AB<P>


<H4></H4><P>

<A HREF="../about/editk.htm">BioCentury "WAhoCU[</A>F EogAhoCU[B<P>

<A HREF="testk.htm">BioCentury"</A>F BioCenturyT[rX"B<P>

<A HREF="../sample/samplek.htm">s{</A>F BioCentury y- BioCenturyO{B<P>

<A HREF="../commun/commk.htm">BioCentury M</A>F BioCentury"W`BdB<P>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>

</BODY></HTML>




</DOC>
<DOC>
<DOCNO>WT03-B24-183</DOCNO>
<DOCOLDNO>IA064-000378-B005-124</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/commun/commk.htm 206.86.52.80 19970112100007 text/html 1278
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:00:12 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1096
Last-modified: Thu, 08 Feb 1996 21:37:46 GMT
</DOCHDR>
<HTML>
<BODY background = "../graphics/white-mi.gif">


<H1><CENTER>BioCenturyC[[M</H1></CENTER><P>

<A NAME="Communicating with BioCentury">BioCenturyC[[M</A><P>

ICMF BioCenturyWAwAWF <A HREF="mailto:schmtter@cris.com">biocenturypub@sosei.com.</A><P>

XZF<BR>
BioCentury Publications Inc.<BR>
PO Box 1246<BR>
San Carlos CA 94070-1246<BR>
USA<P>

dbF<BR>
db: 415/595-5333<BR>
t@bNX: 415/595-5589<P>


<H5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-184</DOCNO>
<DOCOLDNO>IA064-000378-B002-228</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/ipi.html 206.86.52.80 19970112095258 text/html 7679
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:52:54 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 7497
Last-modified: Tue, 01 Oct 1996 18:08:10 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Interneuron Pharmaceuticals, Inc.</TITLE></HEAD>
<BODY  BGCOLOR=#FFFFFF>
<IMG  Align=Middle SRC="../Graphics/ipi.gif"><H1>Interneuron Pharmaceuticals, Inc.</H1>
<H3>Corporate Profile</H3>
<A HREF = "ipijp.html"><IMG  Align=Middle SRC="../Graphics/japanese.gif"></A> <A HREF = "ipijp.html">Japanese Translation</A>
<HR>

99 Hayden Avenue MA 02173<BR>
Telephone +1-617-861-8444<BR>
Fax +1-617-861-3830<P><BR>

<B>Company officers / titles:</B><BR>
<UL><LI> Glenn L. Cooper, M.D., President & CEO<BR>
<LI> Mark S. Butler, EVP, Chief Administrative Officer, General Counsel<BR>
<LI> Bobby W. Sandage, Jr. Ph.D., EVP, Research & Development, Chief Science Officer<BR>
<LI> Thomas F. Farb, EVP, Finance and Chief Financial Officer<BR>
<LI> Brian R. Anderson, SVP, Marketing and Commercial Development<BR>
<LI> Takashi Kiyoizumi, M.D., Ph.D., VP, Business Development and Strategic Planing<BR>
<LI> Richard E. Gammans, Ph.D., VP, Clinical Research<BR>
<LI> William B. Boni, VP, Corporate Communications<BR>
<LI> Tessa W. Cooper, VP, Human Resources<BR>
<LI> Dale Ritter, VP and Corporate Controller<BR>
<LI> Sonja Loar, Pharm.D., VP, Regulatory & Scientific Affairs
</UL>

<B>Employees:</B> approximately 65, 6 PhDs, 1 MD, 1 MD/PhD, 1 JD<P>

<B>Facilities:</B> 20,000 sq. feet<P>

<B>Company Overview:</B><BR>
Interneuron Pharmaceuticals, Inc. is developing an extensive pipeline of pharmaceutical and biotechnology-based products. The company's programs target central nervous system disorders, including obesity, stroke, anxiety, insomnia, and Parkinson's disease.
Earlier stage core technologies with broad potential therapeutic applications are the focus of two majority-owned subsidiaries.  These include Progenitor, Inc., which is developing gene and cellular therapies based upon the potential of novel, early stem cells, and Transcell Technologies, Inc., which is developing drug transport and oligosaccharide synthesis technologies. Interneuron stock is listed in NASDAQ under IPIC.

<P>A third subsidiary, Intercardia, Inc., is developing cardiopulmonary products.  Intercardia's lead product, bucindolol, is in Phase III clinical testing for the treatment of congestive heart failure sponsored by the National Institutes of Health and Veterans Administration.  Intercardia completed its initial public offering in February, 1996 and its stock is currently traded in NASDAQ under ITRC.</P>

<P>The newest subsidiary of Interneuron is InterNutria, Inc.  InterNutria's focus is nutritional approaches to behavioral modification and the management of conditions including premenstrual syndrome (PMS), and athletic performance.
</P>

<B>Interneuron Program Overview:</B><P>
<TABLE BORDER =6>
<th>Program</th><th>	Disease Targets</th><th>Stage of Development</th><tr>
<td>Redux</td><td>Obesity</td><td>Launched</td><tr>

<td>Bucindolol</td><td>Congestive Heart Failure</td><td>Phase III</td><tr>

<td>Citicoline</td><td>Stroke</td><td>Phase III</td><tr>

<td>Pagoclone</td><td>Anxiety/panic disorders</td><td>Phase II/III to begin fall 1996</td><tr>

<td>Dihydrexidine</td><td>Parkinson's disease</td><td>Phase I</td><tr>

<td>Melatonin analog (IP 100-9) </td><td> Insomnia</td><td>Pre-IND</td><tr>

<td>Melzone</td><td>Insomnia</td><td>Pre-launch as a dietary supplement</td>
</TABLE><P><BR>

<B>Investors:</B><BR>
Interneuron was founded in 1988 by Lindsay A. Rosenwald, M.D., current Chairman of the Castle Group in New York, and Richard J. Wurtman, M.D., Professor of Neuroscience at MIT.   Interneuron went public in March 1990 and has raised approximately $196 million through public offerings, warrant exercises and private placements.<P><BR>

<B>Business Strategy and Corporate Partnering Opportunities:</B><BR>
<I>Key elements in Interneuron's business strategy include:</I><P>

<UL><LI> In-licensing clinical and late pre-clinical stage compounds with defined pathways to the clinic and to market.

<LI> Developing products and leading-edge technologies with broad applications and large, unsatisfied markets.

<LI> Establishing corporate marketing partnerships that will help ensure penetration of target markets as rapidly as possible.

<LI> Creating technological synergies among its companies.
</UL><P><BR>

<B>Scientific Advisory Board:</B><P>
Richard J. Wurtman, M.D., Chairman<BR>
Professor of Neuroscience and Director, Clinical Research Center<BR>
Massachusetts Institute of Technology<P>

Julius Axelrod, Ph.D.<BR>
Nobel Laureate<BR>
Guest Researcher, Laboratory of Cell Biology<BR>
National Institute of Mental Health<P>

Jan K. Blusztajn, Ph.D.<BR>
Assistant Professor<BR>
Boston University School of Medicine<P>

Thomas Chase, M.D.<BR>
Chief, Experimental Therapeutics Branch<BR>
National Institute of Neurological Disorders and Stroke<P>

John Growdon, M.D.<BR>
Associate Professor of Neurology<BR>
Harvard Medical School<P>

Israel Hanin, Ph.D.<BR>
Professor and Chairman<BR>
Department of Pharmacology and Experimental Therapeutics<BR>
Loyola University<P>

Bartley Hoebel, Ph.D.<BR>
Professor of Psychology<BR>
Princeton University<P>

Marvin E. Jaffe, M.D.<BR>
Former President<BR>
R.W. Johnson Pharmaceutical Research Institute<P>

Donald Jenden, M.D., Ph.D.<BR>
Professor of Pharmacology<BR>
UCLA Medical School<P>

Zaven Khachaturian, Ph.D.<BR>
Associate Director of Neuroscience and Neuropsychology<BR>
National Institute on Aging<P>

Donald F. Klein, M.D.<BR>
Professor of Psychiatry<BR>
Columbia University College of Physicians and Surgeons<P>

Steven Younkin, M.D., Ph.D.<BR>
Professor of Pathology and Pharmacology<BR>
Case Western Reserve University School of Medicine<P>

Judith J. Wurtman, Ph.D.<BR>
Research Scientist<BR>
Massachusetts Institute of Technology<P><BR>

<B>Board of Directors:</B><P>
Lindsay A. Rosenwald, M.D.<BR>
Chairman<BR>
The Castle Group Ltd.<BR>
Paramount Capital, Inc.<P>

Glenn L. Cooper, M.D.<BR>
President and Chief Executive Officer<BR>
Interneuron Pharmaceuticals, Inc.<P>

Harry J. Gray<BR>
President<BR>
Harry Gray Associates<P>

The Honorable Alexander M. Haig, Jr.<BR>
Former United States Secretary of State<BR>
Chairman<BR>
Worldwide Associates, Inc.<P>

Peter Barton Hutt<BR>
Partner, Covington and Burling<BR>
Former Chief Counsel, United States Food and Drug Association<P>

Malcolm Morville, Ph.D.<BR>
President and Chief Executive Officer<BR>
Phytera, Inc.<P>

Robert K. Mueller<BR>
Director, Arthur D. Little, Ltd.<P>

Lee J. Schroeder<BR>
President<BR>
Lee Schroeder Associates, Inc.<P>

David B. Sharrock<BR>
Former Executive Vice President and Chief Operating Officer<BR>
Marion Merrell Dow Inc.<BR>
Director, Marion Merrell Dow Inc.<P>

Richard J. Wurtman, M.D.<BR>
Professor of Neuroscience and Director, Clinical Research Center<BR>
Massachusetts Institute of Technology<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated October 1, 1996.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!-- INFORMATION ABOUT THE CONTACT PERSON FILLING OUT THIS FORM
Date: August 18, 1995

Name: Takashi Kiyoizumi, M.D., Ph.D.
Title: Vice President, Business Development & Strategic Planning
Business Address: 99 Hayden Avenue, Lexington, MA 02173
State: Massachusetts
Zip Code: 02173
Telephone Number: +1-617-861-8444
Fax Number: +1-617-861-3830
E-mail address: takak@halcyon.com -->
</HTML>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-185</DOCNO>
<DOCOLDNO>IA064-000378-B002-256</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/onyx.html 206.86.52.80 19970112095320 text/html 9681
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:53:25 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 9499
Last-modified: Sun, 12 May 1996 19:30:17 GMT
</DOCHDR>
<HTML><HEAD><TITLE>ONYX Pharmaceuticals</TITLE></HEAD><BODY BGCOLOR=#FFFFFF>
<IMG Align=Middle SRC="../Graphics/onyx.gif">
<H3>Corporate Profile</H3>
<A HREF = "onyxjp.html"><IMG  Align=Middle SRC="../Graphics/japanese.gif"></A>  <A HREF = "onyxjp.html">Japanese Translation</A>
<HR>

ONYX Pharmaceuticals<BR>
3031 Research Drive<BR>
Richmond, CA 94806<BR>
510-262-8772<BR>
510-222-9758 (fax)<P>

<B>Company Officers:</B><BR>
Hollings C. Renton<BR>
President and Chief Executive Officer<P>

Dr. Frank McCormick<BR>
Chief Scientific Officer<P>

Dr. William Gerber<BR>
Chief Operating Officer<P>

<B>Employees:</B>
85 employees, including 35 Ph.D./M.D.s<P>

<B>Facility:</B>

ONYX Pharmaceuticals is a 40,000 square foot facility located in Richmond, CA<P>

<B>Founders:</B> <BR>

ONYX was founded in 1992 as a spin-off from Chiron Corporation, based on the leading research of Frank McCormick, Ph.D. and his laboratory in the areas of Ras oncogenes, and of founding scientific advisors in tumor suppressor genes, and signal transduction.<P>

<B>Date Established:</B>
April 24, 1992<P>

<B>Investments:</B>  ($000) <P>


<CENTER>	<table border=4>
<tr><th align=center>Series A <th align=center>	Series B	<th align=center>Series C	<th align=center>Series D	<th align=center>Future Committed <tr>
<td align=center>	400	<td align=center>	5,000	<td align=center>	12,200	<td align=center>	17,100	<td align=center>	7,333
</table><P></CENTER>

<B>Principal Investors:</B><BR>
A group of leading venture capital investors including, Avalon Ventures, Institutional Venture Partners, Kleiner Perkins Caufield & Byers, Sprout Group, Sierra Ventures, Robertson, Stephens & Co., Sequoia Capital, New York Life, Mutual of New York, Alex Brown, Forward Ventures.  In addition to Chiron, Bayer, and Parke-Davis.<P>

<B>Financial History:</B><BR>
ONYX is privately held and to date has raised $42 million in equity.<P>

<B>Corporate Overview:</B><BR>
The mission of ONYX is to develop novel therapeutics to treat serious diseases.  Our central research activity is to combine the latest molecular biology techniques with the expanding knowledge of intracellular signaling pathways to develop new strategies for therapeutic discovery.  Our business model is to stay focused on research and drug discovery, while seeking corporate partners for clinical development and commercialization.<P>

<B>Agreements:</B><P>
<CENTER><TABLE BORDER =4>
<TR><TH align=center>Company	<TH align=center>		Field		<TH align=center>		Date<TR>
<TD align=center>Bayer		<TD align=center>		Ras	<TD align=center>			May 1994<TR>
<TD align=center> Parke-Davis	<TD align=center>	Cell Cycle Regulation	<TD align=center>May 1995 <TR>
<TD align=center> Eli Lilly	<TD align=center>		Breast Cancer<TD align=center>	May 1995</TABLE><P></CENTER>

<B>Technology Overview:</B><P>
ONYX has established three initial drug discovery programs with a near-term focus on molecular oncology:<P>

<EM>Ras Signaling:</EM><BR> 
ONYX's first drug discovery program, now the subject of the ONYX/Bayer collaboration, focuses on the Ras signaling pathway.  Ras is a protein which is activated by a family of growth factors and plays a key role in controlling cell growth and differentiation.

Small molecule drugs that turn off Ras activity or reduce it to normal levels may offer effective new therapies for many cancers, as well as other hyperproliferative diseases such as rheumatoid arthritis and psoriasis.<P>

<EM>Cell Cycle Regulators:</EM><BR>
ONYX research also focuses on proteins involved in regulating the cell cycle.  ONYX and its corporate partner, the Parke-Davis division of Warner-Lambert, hope to develop new therapeutics for cancer and other diseases.  Potential products may act by restoring the normal function of mutated cell cycle proteins or by otherwise restoring the normal growth/death cycle to abnormal cells.<P>

<EM>Adenovirus Therapy for p53 Mutated Tumors:</EM><BR>
A key discovery was made at ONYX that adenovirus can be modified to selectively replicate in and kill tumor cells deficient in p53, but not normal cells.  In vitro  and in vivo  experiments have validated the concept, and the product is scheduled to enter the clinic early in 1996.  This discovery is being extended to other viruses and diseases.<P>

<B>Current Corporate Partners:</B>
<UL><LI> Bayer
<LI> Parke-Davis
<LI> Eli Lilly
</UL>

<B>Corporate Partnering Opportunities:</B><BR>
ONYX will continue to apply its strategy to create corporate alliances for each of its product programs. The company expects to complete an alliance in the area of adenovirus therapy for p53-mutated tumors in 1996.  It is also seeking with Warner-Lambert a Japanese partner for the cell cycle collaboration.<P>

<B>Management:</B><BR>
Dr. Frank McCormick - <a href=mailto:frank@ONYX-pharm.com>frank@ONYX-pharm.com</a><BR>
Dr. Frank McCormick is a recognized leader in the research of ras oncogenes and GAP proteins, two major molecular targets for ONYX.  Prior to the formation of ONYX, Dr. Frank McCormick was vice president of therapeutics and biological research at Chiron Corporation.  He began his career at Cetus Corporation as a staff scientist in 1981 and was director of molecular biology prior to becoming vice president, discovery research in 1990.  Dr. McCormick completed post-doctoral research at the State University of New York at Stony Brook and the Imperial Cancer Research Fund in London.  He received his Ph.D. in biochemistry from Cambridge University in England.  He is the author of over 100 publications in leading journals.<P>

Hollings C. Renton - <a href=mailto:hollings@ONYX-pharm.com>hollings@ONYX-pharm.com</a><BR>
Prior to joining ONYX in 1993, Hollings Renton was the President and Chief Operating Officer of Chiron Corporation.  He assumed that position in 1991 on Chiron's acquisition of Cetus Corporation, where he had been President since 1990 and Chief Operating Officer since 1987.  He holds an M.B.A. from the University of Michigan.<P>

Dr. William Gerber - <a href=mailto:bgerber@ONYX-pharm.com>bgerber@ONYX-pharm.com</a><BR>
Dr. Gerber comes to ONYX from Chiron Corporation, where he has been president of the Chiron Diagnostics business unit since Chiron's merger with Cetus Corporation in December 1991. He joined Cetus in 1987 as senior director of corporate ventures and was named vice president and general manager, PCR (Polymerase Chain Reaction) division in November 1988.  He earned a bachelor of science degree and a doctor of medicine degree from the School of Medicine, University of California, San Francisco Medical Center.<P>

<B>Board of Directors:</B><BR>
Sam Colella<BR>
Institutional Venture Partners<BR>
3000 Sand Hill Rd.<BR>
Building 2, Suite 290<BR>
Menlo Park, CA 94025<P>

Brook Byers<BR>
Kleiner Perkins Caufield & Byers<BR>
2750 Sand Hill Road<BR>
Menlo Park, CA 94025<P>

Kevin Kinsella<BR>
Sequana Therapeutics, Inc.<BR>
11099 North Torrey Pines Rd.<BR>
Ste 160<BR>
LaJolla, CA 92037<P>

Walter Moos<BR>
Chemical Therapeutics<BR>
Chiron Corporation<BR>
4560 Horton Street<BR>
Emeryville, CA 94608<P>

Kathleen LaPorte<BR>
Sprout Group<BR>
3000 Sand Hill Rd., 4-270<BR>
Menlo Park, CA 94025-7114<P>

Wolfgang Hartwig, Ph.D.<BR>
Vice President Research<BR>
Bayer Corporation<BR>
400 Morgan Lane<BR>
West Haven, CT 06516-4175<P>

Frank McCormick, Ph.D.<BR>
Chief Scientific Officer<BR>
ONYX Pharmaceuticals<BR>
3031 Research Drive<BR>
Richmond, CA 94806<P>

Hollings Renton<BR>
President and CEO<BR>
ONYX Pharmaceuticals<BR>
3031 Research Drive<BR>
Richmond, CA 94806<P>

<B>Scientific Advisory Board:</B><BR>
Eric Fearon, M.D.<BR>
Division of Molecular Medicine & Genetics<BR>
4301 MSRB 3, Box 0638<BR>
University of Michigan Medical Center<BR>
1150 W. Medical Center Dr.<BR>
Ann Arbor, MI 48109-0638<P>

Henry Bourne, M.D.<BR>
UCSF Department of Pharmacology<BR>
1210 Science Building - Box 0502<BR>
San Francisco, CA 94143<P>

Edward R. Harlow, Jr., Ph.D. (Chairman)<BR>
MGH Cancer Center<BR>
Laboratory of Molecular Oncology<BR>
Building 149-13th Street<BR>
Charlestown, MA 02129<P>

Peter M. Howley, M.D.<BR>
Chairman, Dept. of Pharmacology<BR>
Harvard Medical School<BR>
200 Longwood Avenue, Bldg. D2 Room 630<BR>
Boston, MA 02115<P>


Owen N. Witte, M.D.<BR>
UCLA McDonald Research Lab<BR>
10833 Le Conte Avenue<BR>
Los Angeles, CA 90024-1662<P>

Arnold J. Levine, Ph.D.<BR>
Chairman and Professor<BR>
Department of Molecular Biology<BR>
Lewis Thomas Laboratory<BR>
Princeton University<BR>
Princeton, NJ 08544-1014<P>

Burton Christensen, Ph.D.<BR>
48 Philhower Road<BR>
Lebanon, NJ 08833<P>

Eileen White, Ph.D.<BR>
Center for Advanced Biotechnology and Medicine<BR>
679 Hoes Lane<BR>
Piscataway, NJ 08854<P>

Bruce A.J. Ponder, Ph.D.<BR>
CRC Human Cancer Genetics Group<BR>
Level 3, Laboratories Block, Box 238<BR>
Addenbrooke's Hospital<BR>
Hills Road<BR>
Cambridge, England CB2 2QQ<P>

Dr. Douglas Hanahan<BR>
Hormone Research Institute, Rm. HSW 1090<BR>
UC San Francisco<BR>
School of Medicine<BR>
San Francisco, CA 94121<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated October 10, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!-- Contact Person:
Dr. William Gerber
Chief Operating Officer
ONYX Pharmaceuticals
3031 Research Drive
Richmond, CA  94806
510-262-8772
Fax:  510-222-9758 >
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-186</DOCNO>
<DOCOLDNO>IA064-000378-B003-164</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/PressNews/miko1.html 206.86.52.80 19970112095528 text/html 3594
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:55:32 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3412
Last-modified: Fri, 24 May 1996 03:12:59 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML><HEAD><TITLE>Transducing genes into Cerebral Neurocyte</TITLE></HEAD>
<BODY BGCOLOR=#FFFFFF><IMG SRC="../Graphics/sosei.gif" ALT="Sosei logo" ALIGN="BOTTOM">
<H2><A HREF="../Companies/sosei.html">Sosei Co., Ltd.</A></H2>
<P>

<B>Transducing genes into Cerebral Neurocyte</B></P>
<BLOCKQUOTE><P>Transducing genes into Cerebral Neurocyte  Riken and Tokyo
University have developed new techniques:  The Institute of Physical and
Chemical Research (Riken) and Tokyo University, Institute of Medical Science
have developed techniques for transducing genes into cerebral neurocytes. It has
been said that genes can't be transduced into Cerebral neurocytes which unlike
common cells don't divide. This problem was cracked by changing the method of
transduction and the genes themselves. Gene therapy creates a road to the cure
of cerebral diseases such as Parkinson's Disease and Alzheimer's Disease.  Road
to the treatment of Parkinson's Disease The group which developed the new
techniques consists of Katuhiko Mikosiba, a chief researcher for Riken and Izumu
Saito, an assistant professor at Tokyo University,  Institute of Medical
Science. Adenoviruses of strong infectivity were used as the vehicles for genes
used for transducing external genes into cells (vectors). Retroviruses are
generally used as the vectors which transduce genes into cancer cells or
hemocytes. Retroviruses, however,  are not applicable for cerebral neurocytes
which terminate cell division. When adenoviruses are used, there is a
possibility of side effects as a result of transducing genes into the cells
other than the desired cerebral neurocytes. Therefore,  a special method was
devised so that the transduced genes would act only in cerebral neurocytes.  To
put it in greater detail:  before transducing therapeutic genes, the genetic
sequence called &quot;promoter&quot; which is activated only in cerebral
neurocytes is transduced. A method was devised so that the therapeutic genes do
not begin to act until the &quot;promoter&quot; sequence is activated.  The
group was successful in transducing the genes into mouse cerebral tissues the
genes which produce the substances whose pigments color the specific cerebral
neurocytes. It was concluded that these techniques can be used for the gene
therapy intended for cerebral neurocytes. As the experiments with animals were
successful, the group, together with Professor Nishino of Nagoya Municipal
University, aims to treat Parkinson's Disease using gene therapy. Parkinson's
disease is caused by a deficiency of tyrosine hydroxylase. Therefore, it is
expected that the disease can be cured by transducing the genes which produce
this enzyme. In parallel with this, they plan to tackle Huntington's Chorea by
gene therapy. They say that many patients with Alzheimer's Disease will also be
the subjects of gene therapy.  This work was supported in part by a grant from
<A HREF="../Companies/sosei.html">Sosei</A>.</P></BLOCKQUOTE>
<P>
This work was supported in part by a grant from <A HREF="../Companies/sosei.html">Sosei</A>.
</P>
<P><A HREF="http:///www.sosei.com"><IMG
SRC="../Graphics/home_button.gif" ALT="Sosei Home Page" ALIGN="BOTTOM">Home
Page</A></P>
<HR>
<P>Updated: March 4, 1996.</P>
<P>Copyright &#169; 1996 <A HREF="http://www.genweb.com">GenWeb</A> All rights
reserved.</P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-187</DOCNO>
<DOCOLDNO>IA064-000378-B003-200</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/PressNews/miko2.html 206.86.52.80 19970112095546 text/html 2009
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:55:52 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1827
Last-modified: Fri, 24 May 1996 03:15:50 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Identifying Epilepsy-inhibiting Protein</TITLE></HEAD>
<BODY BGCOLOR=#FFFFFF><IMG SRC= "../Graphics/sosei.gif" ALT="Sosei logo" ALIGN="BOTTOM">
<H2><A HREF="../Companies/sosei.html">Sosei Co., Ltd.</A></H2>
<P>

<B>Identifying Epilepsy-inhibiting Protein</B></P>
<BLOCKQUOTE><P>The University of Tokyo and the Institute of Cancer  Professor
Katsuhiko Mikosiba, The University of Tokyo Institute of Medical Science  et al.
found that a known protein which acts in cells inhibits epilepsy. The mice
lacking the genes which produce this protein developed the symptoms of epilepsy.
Thesymptoms disappeared when they received the therapeutic drugs for epilepsy.
The group considers that some cases of ill-defined epilepsy are caused by
abnormality in this protein. This protein is one of a group of receptors called
inositol-1,4,5-triphosphate receptors (IP3). It is known as the protein which
controls the storage site of calcium ions in cells. The knockout mice lacking
IP3 had difficulty in walking at nine days and developed epileptic fits at
fifteen days. In receiving s drug such as barbital their fits stopped and in
receiving the drugs which inhibit the action of the drug their fits recurred.
Finding of the relationship between epilepsy and IP3 will advance the
clarification of the epileptic mechanism. The results of this study were
published in the English science journal &quot;Nature&quot; on January 11.
</P></BLOCKQUOTE>
<P>
This work was supported in part by a grant from <A HREF="../Companies/sosei.html">Sosei</A>.
</P>
<P><A HREF="http:///www.sosei.com"><IMG
SRC= "../Graphics/home_button.gif" ALT="Sosei Home Page" ALIGN="BOTTOM">Home
Page</A></P>
<HR>
<P>Updated: March 4, 1996.</P>
<P>Copyright &#169; 1996 <A HREF="http://www.genweb.com">GenWeb</A> All rights
reserved.</P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-188</DOCNO>
<DOCOLDNO>IA064-000378-B005-163</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/ipijp.html 206.86.52.80 19970112100024 text/html 6781
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:00:22 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 6599
Last-modified: Sun, 12 May 1996 19:30:13 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Interneuron Pharmaceuticals, Inc.</TITLE></HEAD>
<BODY BGCOLOR=#FFFFFF>
<IMG  Align=Middle SRC="../Graphics/ipi.gif"><H1>C^[j[Et@[}X[`JYECN</H1>
<H3>Tv</H3>
<HR>

99 Hayden Avenue MA 02173<BR>
db: +1-617-861-8444<BR>
t@bNXF +1-617-861-3830<P><BR>

<B> / E:</B><BR>
<UL><LI> Glenn L. Cooper, M.D.,  & CEO<BR>
<LI> Mark S. Butler, , SC, <BR>
<LI> Bobby W. Sandage, Jr. Ph.D., , J, wSC<BR>
<LI> Thomas F. Farb, , ^SC<BR>
<LI> Brian R. Anderson, , }[PeCO/J<BR>
<LI> Mu M.D., Ph.D., , JEoc<BR>
C[C: <A HREF=mailto:takak@halcyon.com>takak@halcyon.com</A><BR>
<LI> Richard E. Gammans, Ph.D., , <BR>
<LI> William B. Boni, , LS<BR>
<LI> Tessa W. Cooper, , lS<P><BR>
</UL>

<B>:</B>  25A Ph.D.6l,  M.D.1l,  M.D./Ph.D.1lAJ.D.Pl<P>

<B>{:</B> 20,000tB[g<P>

<B>Tv:</B><BR>
C^[j[Et@[}X[`JYECNAioCIeNmW[WiCJB[iAAp[L\aAAAss_onWaCBqAKpL|eVjZpd_uBAVcE|eV`qEWJvWFj^[ECNAISZpJgXZEeNmW[YECNB<P>

OqAC^[J[fCAECNASxWiJB C^[J[fCAvibucindolol ASsSOisNqERlIB<P>

C^[j[VqAC^[j[gADCNAh{EH@SAv[`pAoO(PMS)AVLAds@FXaCC^[j[gA_B<P><BR>

<B>C^[j[vOTv:</B><P>
<TABLE BORDER =6>
<th>vO</th><th>aC</th><th>JiK</th><tr>
<td>Dexfenfluramine</td><td></td><td>NDAo</td><tr>

<td>Bucindolol</td><td>TS</td><td>O</td><tr>

<td>Citicoline</td><td></td><td>^O</td><tr>

<td>Pagoclone</td><td>s/|</td><td></td><tr>

<td>Dihydrexidine</td><td>p[L\a</td><td></td><tr>

<td>Low-dose melatonin</td><td>s</td><td></td><tr>

<td>Melatonin analog (IP 100-9)</td><td>s</td><td>INDO</td>
</TABLE><P><BR>

<B>:</B><BR>
C^[j[ Aj[[NLbZEO[vLindsay A. Rosenwald, M.D.}T`ZbcHw_owRichard J. Wurtman, M.D.A 1988NnB 1990N3A C^[j[AJhBB<P><BR>

<B>pgi[\:</B><BR>
<I>C^[j[ v_:</I><P>

<UL><LI>smiKOB

<LI>LKpAsio\i[ZpJB

<LI> v^[QbgsZmp[gi[gB

<LI> qZpIiB
</UL><P><BR>

<B>wS:</B><P>
Richard J. Wurtman, M.D., Chairman<BR>
Professor of Neuroscience and Director, Clinical Research Center<BR>
Massachusetts Institute of Technology<P>

Julius Axelrod, Ph.D.<BR>
Nobel Laureate<BR>
Guest Researcher, Laboratory of Cell Biology<BR>
National Institute of Mental Health<P>

Jan K. Blusztajn, Ph.D.<BR>
Assistant Professor<BR>
Boston University School of Medicine<P>

Thomas Chase, M.D.<BR>
Chief, Experimental Therapeutics Branch<BR>
National Institute of Neurological Disorders and Stroke<P>

John Growdon, M.D.<BR>
Associate Professor of Neurology<BR>
Harvard Medical School<P>

Israel Hanin, Ph.D.<BR>
Professor and Chairman<BR>
Department of Pharmacology and Experimental Therapeutics<BR>
Loyola University<P>

Bartley Hoebel, Ph.D.<BR>
Professor of Psychology<BR>
Princeton University<P>

Marvin E. Jaffe, M.D.<BR>
Former President<BR>
R.W. Johnson Pharmaceutical Research Institute<P>

Donald Jenden, M.D., Ph.D.<BR>
Professor of Pharmacology<BR>
UCLA Medical School<P>

Zaven Khachaturian, Ph.D.<BR>
Associate Director of Neuroscience and Neuropsychology<BR>
National Institute on Aging<P>

Donald F. Klein, M.D.<BR>
Professor of Psychiatry<BR>
Columbia University College of Physicians and Surgeons<P>

Steven Younkin, M.D., Ph.D.<BR>
Professor of Pathology and Pharmacology<BR>
Case Western Reserve University School of Medicine<P>

Judith J. Wurtman, Ph.D.<BR>
Research Scientist<BR>
Massachusetts Institute of Technology<P><BR>

<B>:</B><P>
Lindsay A. Rosenwald, M.D.<BR>
Chairman<BR>
The Castle Group Ltd.<BR>
Paramount Capital, Inc.<P>

Glenn L. Cooper, M.D.<BR>
President and Chief Executive Officer<BR>
Interneuron Pharmaceuticals, Inc.<P>

Harry J. Gray<BR>
President<BR>
Harry Gray Associates<P>

The Honorable Alexander M. Haig, Jr.<BR>
Former United States Secretary of State<BR>
Chairman<BR>
Worldwide Associates, Inc.<P>

Peter Barton Hutt<BR>
Partner, Covington and Burling<BR>
Former Chief Counsel, United States Food and Drug Association<P>

Malcolm Morville, Ph.D.<BR>
President and Chief Executive Officer<BR>
Phytera, Inc.<P>

Robert K. Mueller<BR>
Director, Arthur D. Little, Ltd.<P>

Lee J. Schroeder<BR>
President<BR>
Lee Schroeder Associates, Inc.<P>

David B. Sharrock<BR>
Former Executive Vice President and Chief Operating Officer<BR>
Marion Merrell Dow Inc.<BR>
Director, Marion Merrell Dow Inc.<P>

Richard J. Wurtman, M.D.<BR>
Professor of Neuroscience and Director, Clinical Research Center<BR>
Massachusetts Institute of Technology<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated October 23, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!-- y[WeAF
Date: 1995N818

O: MuAwm
E: AJEocS
Z: 99 Hayden Avenue, Lexington, MA 02173
B: Massachusetts
X: 02173
db: +1-617-861-8444
t@bNX: +1-617-861-3830
C[C: takak@halcyon.com -->
</HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-189</DOCNO>
<DOCOLDNO>IA064-000378-B002-328</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/geron.html 206.86.52.80 19970112095355 text/html 6586
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:54:00 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 6404
Last-modified: Sat, 23 Dec 1995 08:57:42 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Geron Corporation</TITLE><HEAD><BODY>
<H1><IMG  Align=Middle SRC="../Graphics/geronlo.gif"> Geron Corporation</H1><H3>Corporate Profile</H3>
<A HREF = "geronjp.html"><IMG  Align=Middle SRC="../Graphics/japanese.gif"></A> <A HREF = "geronjp.html">Japanese Translation</A>
<HR>
200 Constitution Avenue<BR>
Menlo Park, CA 94025<BR>
(415) 473-7700<BR>
fax (415) 473-7701<BR>
e-mail: <a href=mailto:info@geron.com>info@geron.com</a><P>

<B>Company Officers</B><P>
Mr. Ronald W. Eastman, President & CEO<BR>
Mr. Richard Haiduck, VP Corporate Develpment<BR>
Dr. Calvin Harley, VP, Research<BR>
Ms. Jeryl Hilleman, VP, Finance and Administration<BR>
Mr. Kevin Kaster, Chief Patent Counsel & VP, Intellectual Properties<BR>
Dr. Daniel Levitt, VP Development<BR>
Dr. Michael West, Founder and VP, New Technologies<P>

<B>Employees:</B> approximimately 70 (29 Ph.D.s; 1 M.D./Ph.D.; 1 JD)<P>

<B>Facilities:</B> 18,000 square feet<P>

<B>Company Overview</B><P>
<BLOCKQUOTE>Geron Corporation is the first biopharmaceutical company to focus exclusively on the development of therapeutic products for diseases of aging, including cancer. Geron's ability to address a diversity of age-related disease states is based on insights into the fundamental biological mechanisms of cellular aging - and conversely, into the process by which cancer cells escape "aging" by becoming "immortal".<P>
Geron believes that many diseases of aging are due primarily to genetically programmed aging, or senescence, of cells in the various bodily tissues. Geron and its collaborators have pioneered the understanding of the genetic "clock" of cellular senescence. The clocking mechanism consists of Telomeres -- repeated DNA sequences found at the ends of chromosomes. telomeres shorten each time a cell divides until they reach a critically short length which is associated with the onset of cell senescence. At the opposite extreme, the age-related disease of cancer occurs because of the failure of cells to senesce owing to mutations that confer replicative immortality.<P>

Geron's research programs seek to intervene with the fundamental mechanisms underlying age-related disease through modulation of cell senescence. Further, Geron seeks to develop therapeutics to treat cancer by inhibiting the immortalizing enzyme telomerase.<P></BLOCKQUOTE>

<B>Geron Scientific Program Overview*</B>
  <table border>
        <tr><th align=center>Program<th>Description<th>Disease Target
        <tr><td align=left>Telomerase Inhibition<td>Induce cell death by inhibiting the enzyme telomerase, restoring tumor cell's normal biological "clock"<td>Cancer therapeutics and diagnostics
          <tr><td align=left>Senescent Gene Expression<td>Identify and develop factors specific to young versus senescent cells to provide therapies to restore normal cell function selectively. Provide models to screen for and test modulators of senescent gene expression<td>Therapeutics and diagnostics for age-related disorders such as atherosclerosis, immunosenescence, BPH, neurodegenerative diseases, osteoarthritis and skin ulcers.
          <tr><td align=left>Telomer Length Modulation<td>Increase normal cell replicative life span by extending telomere repeats at the end of chromosomes<td>Therapeutics and diagnostics for age-related disorders
        <tr><th rowspan=1><th colspan=1>
     </table>
         *All programs are currently in the stage of Research<P>

<B>Investors:</B>
Geron has raised over $30 million to-date from leading private investors including Kleiner Perkins Caufield and Byers, Venrock Associates, CW Group, Oxford Venture Partners, Domain Associates, and Biotechnology Investments, Ltd.<P>

<B>Founded:</B>  1992<P>

<B>Corporate partnering opportunities:</B><BR>
Geron is currently searching for a pharmaceutical partner in the U.S. and Europe for telomerase inhibition for cancer, and worldwide, in senescent gene expression for age-related disease. Geron is also interested in developing a relationship with a diagnostics company for telomerase diagnostics in Europe and Japan.<P>

<B>Scientific Advisory Board:</B><P>

Gunter K. Blobel, M.D., Ph.D.<BR>
Lasker Award recipient, Howard Hughes Medical Institute, Rockefeller University<P>

Vincent J. Cristofalo, Ph.D.<BR>
Director of the Center for Gerontological Research and the Medical College of Pennsylvania<P>

Carol Greider, Ph.D.<BR>
Cold Spring Harbor Laboratory<P>

Douglas Hanahan, Ph.D.<BR>
University of California, San Francisco<P>

Leonard Hayflick, Ph.D.<BR>
Cellular gerontology pioneer, University of California, San Francisco<P>

Thomas Maciag, Ph.D.<BR>
American Red Cross and George Washington University<P>

Jerry Shay, Ph.D.<BR>
University of Texas Southwestern Medical Center at Dallas<P>

James D. Watson, Ph.D.<BR>
 Nobel Laureate, President of Cold Spring Harbor Laboratory<P>

Woodring Wright, M.D., Ph.D.<BR>
University of Texas Southwestern Medical School at Dallas<P>

<H3>Clinical Advisory Board:<P></H3>

Robert N. Butler, M.D.<BR>
Pulitzer Prize winner and Chairman<BR>
Department of Geriatrics and Adult Development, Mount Sinai Medical Center<P>

George Martin, M.D.<BR>
Professor of Pathology, Adjunct Professor of Genetics, Director, Alzheimer's Disease Research Center University of Washington<P>

Lewis T. Williams, M.D., Ph.D.<BR>
University of California, San Francisco<P>

<H3>Board of Directors:<P></H3>

Dr. Alexander E. Barkas<BR>
Chairman, General Parner of Kleiner Perkins Caufield & Byers<P>

Mr. Brian R. Dovey<BR>
General Partner of Domain Associates<P>

Mr. Ronald W. Eastman<BR>
President and CEO of Geron<P>

Mr. Charles M. Hartman<BR>
General Partner of CW Group<P>

Mr. Thomas D. Kiley<BR>
Former Vice President and General Counsel of Genentech, Inc.<P>

Mr. Patrick F. Latterell<BR>
General Partner of Venrock Associates<P>

Dr. Michael D. West<BR>
Founder and Vice President, New Technologies of Geron<P>

<B>Business Advisory Board</B><P>

Mr. Jack L. Bowman<BR>
Retired Company Group Chairman, Johnson & Johnson<P>

Mr. Robert A. Swanson<BR>
Chairman of the Board, Genentech<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated July 1, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-190</DOCNO>
<DOCOLDNO>IA064-000378-B001-313</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/meiji.html 206.86.52.80 19970112095046 text/html 4014
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:50:52 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3832
Last-modified: Sun, 21 Jul 1996 23:28:29 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Meiji Milk</TITLE></HEAD>
<BODY BGCOLOR=#FFFFFF>
<H1>Meiji Cell Technology Center<BR>
</H1><H3>A Division of Meiji Milk Products Co., Ltd.</H3><BR><H3>Corporate Profile</H3>
<HR>

540, Naruda<BR>
Odawara Kanagawa 250<BR>
Japan<BR>
Telephone: 81-465-37-5211<BR>
Fax: 81-465-37-0981<P>

6,053 employees<P>

<B>Facilities:</B><BR>
<I>Meiji Milk Products-Offices and Plants</I>
<UL><LI> Head Office in Tokyo
<LI> Central Research Institute in Higashimurayama
<LI> Meiji Institute of Health Science in Odawara
<LI> Meiji Cell Technology Center in Odawara
<LI> Training Center in Higashimurayama
<LI> 16 Branches and Offices
<LI> 7 Operational Divisions and Bases
<LI> 28 Plants
</UL>
<I>Overseas Office:</I>
<UL><LI> Taipei Office
<LI> Bangkok Office
<LI> Melbourne Office
<LI> Meiji Dairy Products Hong Kong Ltd
</UL>
 
<B>Date Established:</B> December 21, 1917<P>

<B>Major Affiliated Companies:</B><BR>
<table border>
<td>Production and sale of milk, dairy products and ice cream</td>
<td>Tochigi Meiji Milk Co., Ltd. etc.</td><tr>
<td>Sale of milk, dairy products, ice cream, etc.</td>
<td>Tokyo Meinyu Sales Co. Ltd. etc.</td><tr>
<td>Production and sale of other food products</td>
<td>Meiji Fat & Oil Co., Ltd. etc.</td><tr>
<td>Livestock-related operations</td>
<td>Meiji Feeds Manufacturing Co., Ltd. etc.</td><tr>
<td>Catering industry operations</td>
<td>Meiji Cheese Salon Co., Ltd. etc.</td><tr>
<td>Transportation operations</td>
<td>Tokyo Milk Transportation Inc. etc.</td><tr>
<td>Others</td>
<td>Meiji Travel Co., Ltd. etc.</td><tr>
</table><P>

<B>Legal Form: </B>Corporation Public<P>

<B>Corporate Overview:</B><BR>
<I>Major Operations;</I>
<UL><LI> Production, processing and sale of milk.
<LI> Production and sale of dairy products and infants products.
<LI> Production and sale of soft drinks and food products.
<LI> Production and sale of animal feed products.
<LI> Processing and sale of agricultural and livestock products.
<LI> Manufacturing and sale of dairy equipment and other machinery and tools.
<LI> Management of restaurants, athletic facilities, recreational facilities and parking lots.
<LI> Real estate operations.
<LI> Management of livestock operations, etc.
<LI> Manufacture and sales of ethical pharmaceutical and over-the-counter pharmaceutical products, cosmetics and medical equipment.
</UL>

<BLOCKQUOTE>The Meiji Institute of Health Science (MIH) was founded in Odawara, Kanagawa in 1984, with the main research goal of contributing to good health. At MIH, we are involved in cutting-edge R&D activities, ranging from basic research in the life science sectors to development research in fields as diverse as immunogenetics, embryology, and cellular biology, which have already brought exciting results including a new B-type vaccine.<P>

All projects underway are in areas of advanced research. Our researchers investigate subjects they themselves proposed, while carrying on exchanges with other research institutes and universities both in Japan and overseas. To commercialize pharmaceuticals, MIH is also engaged in research on mass-production technologies using cell cultures in collaboration with the adjoining Meiji Cell Technology Center.<P>
</BLOCKQUOTE>
<B>President:</B> Hisashi Nakayama<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!-- INFORMATION ABOUT THE CONTACT PERSON FILLING OUT THIS FORM
Date: May 25, 1995
Name: Sadatoshi Sakuma
Title: Director
Address: 540, Naruda
City: Odawara
State: Kanagawa
Zip Code: 250
Telephone Number: 81-465-37-5211
Fax Number: 81-465-37-0981 >
</HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-191</DOCNO>
<DOCOLDNO>IA064-000378-B002-116</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/takara.html 206.86.52.80 19970112095141 text/html 7735
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:51:46 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 7553
Last-modified: Sun, 12 May 1996 19:30:20 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Takara Shuzo</TITLE>
</HEAD>
<BODY BGCOLOR=#FFFFFF>
<H1>Takara Shuzo Co., Ltd.<BR>
Biomedical Group</H1><H3>Corporate Profile</H3><HR>
Seta 3-4-1<BR>
Otsu, Shiga 520-21<BR>
Telephone +81-(0)775-43-7235<BR>
Fax 81-(0)775-43-2312<P>

<B>Management:</B><BR>
<UL><LI> Chairman: Akira Tanabe<BR>
<LI> President: Hisashi Ohmiya<BR>
<LI> President, Biomedical Group: Ikunoshin Kato, Ph.D.<BR>
<LI> Director, Sales & Marketing Hiroshi Kihara, Ph.D.<BR>
<LI> Associate Director Business Development, Licensing:<a href=mailto:btn00000@biotechnet.com> Susumu Sano, Ph.D.</a><P>
</UL>

2096 employees (4/95)<P>

<B>Facilities:</B> Central Research Laboratories Factory in Kusu.<P>

<B>History:</B><BR>
<BLOCKQUOTE>Established in 1925, Takara Shuzo Co., Ltd. (a publicly held Japanese company having headquarters at Higashi-no-Toin, Shijo-dori, Shimogyo-ku, Kyoto, Japan) has fostered the development of the fermentation technology that is the foundation of corporative business and steadily evolved into a comprehensive fermentation enterprise and has expanded and diversified its products ranging from Sake, foods to biomedicals.<P></BLOCKQUOTE>

<B>Date Established:</B> September 6, 1925.<P>

<B>Subsidiaries / Divisions:</B><BR>
<UL><LI> Biotechnology Research Laboratories
Seta 3-4-1, Otsu, Shiga 520-21 Japan.
<LI> Alcoholic Beverage Research Laboratories
<LI> Seasoning and Foods Research Laboratories
<LI> Agri-Products Development Center
<LI> Bioproducts Operations & Manufacturing Division
<LI> Biomedical Center
<LI> Gene Analysis Center
<LI> Takara Biotechnology (DALIAN) Co., Ltd.
<LI> Takara Biomedical Europe SA.<P>
</UL>

<B>Legal Form:</B> Public listed stocks Company <P>

<B>Investments:</B><BR>
<UL><LI> Lark Sequencing Technology Inc. (1990)<BR>
<LI> Research Institute for Glycotechnology-Aomori, Japan. (1991)<BR>
<LI> BioCollege Kyoto (1992)<BR>
<LI> Cytel Corporation (1994)<P>
</UL>

<B>Corporate Overview:</B><BR>
<BLOCKQUOTE>Biomedical Group, recognized as one of the most highly ranked biotech-companies in Japan, has pursued a technology-driven business and has seized over 50% of Japanese market of regents for use in genetic engineering research: These products include restriction endonucleases and modifying enzymes which are indispensable to biotechnology research. Although R & D effort have focused mainly on research fields, several prospective seeds have been nurtured in the fields of <I>in vitro</I> diagnostics and pharmaceuticals which are this group's ultimate goal.<P>
</BLOCKQUOTE>
<B>Agreements:</B><P>
<table border>
<th>Name</th>	<th>Products</th>	<th>Contents of Agreement</th>	<th>Date</th>
<tr>
<td>Cytel Corp.</td>	<td>Theradigm <tt><FONT SIZE=2>(TM)</FONT></tt> technology nonviral infectious disease target and ex vivo cellular therapy</td>	<td>collaborative research and licensing agreement</td><td>6/94</td>
<tr>
<td>FMC Corp.</td>	<td>bioproducts	<td>distribution agreement for Japan</td>	<td>2/86</td>
<tr>
<td>Hoffmann-La Roche Inc/ Roche Molecular Systems, Inc.</td>	<td>PCR-related products <td>worldwide licensing agreement	<td>12/93</td>
<tr>
<td>Labimap SA</td>	<td>instrument for molecular biology	<td>distribution agreement for Japan and China	<td>4/94</td>
<tr>
<td>Lark Sequencing Technologies Inc.</td>	<td>contract DNA sequencing	<td>distribution agreement for Japan, South Korea, Taiwan, Oceania, and Singapore</td><td>6/90</td>
<tr>
<td>Eli Lily and Co.</td>	<td>antifungal agent	<td>licensing agreement</td>	<td>7/91</td>
<tr>
<td>Nippon Kayaku Co., Ltd.</td>	<td>antifungal agent	<td>licensing agreement</td>	<td>7/91</td>
<tr>
<td>Pan Vera Corp.</td>	<td>biomedical research reagents	<td>distribution and supply agreement	<td>7/93</td>
<tr>
<td>Perkin-Elmer Japan</td>	<td>Sciex Corp's LC / mass spectroscopy system</td>	<td>distribution agreement for Japan</td>	<td>4/90</td><tr>
<td>Tanox Biosystems, Inc.</td>	<td>Migis <tt><FONT SIZE=2>(TM)</FONT></tt> MAb products for treating IgA nephropathy	<td>Licensing and development agreement</td>	<td>10/94</td>
<tr>
</table><P>

<B>Technology Overview:</B><BR>
<BLOCKQUOTE>The Biomedical Group that is one of diversified operations of Takara Shuzo Co., Ltd. has been a leading supplier, distributer and manufacture of research products since the first product release of restriction enzyme to the market in 1979, and has kept the top share of domestic market of reagents for use in genetic engineering research. Its success in commercializaion of research use reagents for cell biology and glycobiology, immunology as well as genetic engineering and molecular biology has promoted further expansion of product lines into instrumentation, which consequently has rendered Takara as comprehensive supplier in the biotech-research supporting industry. Another field the biomedical Group has pursued is Diagnostic Reagents and Pharmaceuticals. By capitalizing on our R & D achievement in biotechnology, recent progresses have born the fruits: They are, for example, a new anti-fungal agent R106  that was licensed out to a few pharmaceutical establishments both in Japan and overseas, and an immunosoppressant Deoxyspergualin that was on market. The joint development program of IgA Nephropathy treatment and Ex vivo Cellular Therapy for cancer are in progress.<P></BLOCKQUOTE>

<B>Products on Market:</B><BR>
<UL><LI> Deoxyspergualin (immunosuppressive agent).<BR>
<LI> UFC (Urinary Free L-Fucose) test kit (tumor maker).<BR>
<LI> Reagents and instruments for genetic engineering, protein engineering, immunology, glycobiology.<BR>
<LI> Enzymes for diagnostic use.<BR>
<LI> Genetic analysis computer software.<BR>
<LI> DNA amplification system.<BR>
<LI> Multiblotter system.<BR>
<LI> Genomic DNA extractor.<BR>
<LI> LC/mass spectroscopy system.<BR>
<LI> FMBIO (Fluorescent Method Bio Image Analyzer.)<BR>
<LI> Glyco TAG, PALSTATION (carbohydrate analysis system).<BR>
<LI> Electrophoresis apparatus.<BR>
<LI> Custom service - DNA synthesis, DNA sequencing, peptide synthesis, peptide sequencing, production of antibodies, and carbohydrate analysis.<P>
</UL>

<B>Current Corporate Partners:</B><BR>
<UL><LI> Cytel Corp<BR>
<LI> FMC Corp<BR>
<LI> Hoffmann-La Roche Inc/Roche Molecular Systems, Inc.<BR>
<LI> Lark Sequencing Technologies Inc.<BR>
<LI> Pan Vera Corp<BR>
<LI> Perkin-Elmer<BR>
<LI> Tanox Biosystems, Inc.<P>
</UL>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!-- Subject Terms:
Human Diagnostics: Cancer Tests; DNA Probes; Immuociagnostics; 
Diagnostic Reagent; Genetic Screening.
Human Therapeutics: Anti-infectives; Biologicals; Wound Healing;
Immunotherapy
Industrial Biotechnology: Industrial / Laboratory Enzymes; Specially Chemicals; 
Fine Chemicals.
Biotechnology: Molecular Biology; DNA / Genetic Synthesis;
Fermentation / Microorganism Development; Peptide / Protein Synthesis;
Reagents / Research Materials; Software Programs; Separation Equipment / Technology; Instrumentation.

<!-- INFORMATION ABOUT THE CONTACT PERSON FILLING OUT THIS FORM
Date: May 15, 1995

Name: Susumu Sano, Ph.D.
Title: Associate Director
Address: Seta 3-4-1,
City: Otsu
State: Shiga, Japan
Zip Code: 520-21
Telephone Number: +81-(0)775-43-7235
Fax Number: 81-(0)775-43-2312
E-mail Address: btn00000@biotechnet.com >
</HTML>

<!-- Revised June 3, 1995 5:37PM >
</DOC>
<DOC>
<DOCNO>WT03-B24-192</DOCNO>
<DOCOLDNO>IA064-000378-B001-280</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/iatron.html 206.86.52.80 19970112095035 text/html 4385
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:50:40 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4203
Last-modified: Sun, 12 May 1996 19:30:12 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Iatron Laboratories, Inc.</TITLE></HEAD>
<BODY BGCOLOR=#FFFFFF><H1>Iatron Laboratories, Inc.</H1>
<H3>Corporate Profile</H3>
<HR>
1-1, Higashi-Kanda 2-Chrome,Chiyoda-ku<BR>
Tokyo 101<BR>
Telephone: 03-3862-1761<BR>
Fax: 03-3862-1760<P>

<B>Employees:</B>  445<P>

<B>Facilities:</B>
<UL><LI> 2 Research Laboratories (Tokyo Research Lab., Central Research Laboratory in Chiba Pref.)<BR>
<LI> 1 Plant (Chiba Pref.)<BR>
<LI> 1 Animal Farm (Chiba Pref.)<P>
</UL>

<B>History:</B><BR> 
<BLOCKQUOTE>Founded in June, 1992 as a diagnostic reagent maker. Since then the company has been expanding to a top-ranking manufactruer in the clinical diagnostics. In August, 1981 Dia-Iatron was established
to distribute Iatron's products under a joint venture agreement with
Mitsubishi Chemical Corporation.<P></BLOCKQUOTE>

<B>Date Established:</B> June 22, 1962<BR>
<BR> <B>Subsidiaries:</B><BR>
<UL><LI> Dia-Iatron Co., Ltd. (Sales of diagnostics and related instruments and devices)<BR> 
<LI> Laboratories for Biochemical Analysis (Commercial laboratories)<BR> 
<LI> Iatron Bio Supply Co., Ltd. (Laboratory reagens and instruments)<P>
</UL>
<B>Legal Form:</B> Corporation, Non-public<P>

<B>Corporate Overview:</B><BR> 
<BLOCKQUOTE>Iatron Laboratories, Inc. (Iatron) first introduced Reagent Kits in Japan for the determination of serum transaminase (GOT and GPT) has grown to a top-ranked manufacturer in the clinical diagnostics.<P>
Iatron first utilized enzymes in Japan to commercialize many lipid determinations kits. Iatron has developed, utilizing antibodies based on its own technology, clinical reagents provided with antigen-antibody reaction mechanism, and also the latex reagents jointly with Mitsubishi Chemical Corp. Iatron, through the cooperation with European based companies is marketing monoclonal antibodies.<P>
Iatron has entered into business tie-ups with many
pharmaceutical and diagnostics companies throughout the world to
establish the solid position abroad and home.<P></BLOCKQUOTE>

<B>Technology Overview:</B><BR>
<BLOCKQUOTE>Iatron with 50 capable researchers, has been energetically engaged in the research work. As a result of such research work, Iatron has succeeded in developing world famous clinicalreagents for Thrombosis such as D-Dimer and Protein C and the "Candida Check" for identification of Candida species.<P>
In the field of analytical instruments, Iatron is marketing its own patented product "Iatroscan" throughout the world and also selling world wide famous "Liquid Handling System" made by the German company Eppendorf for the Japanese market.<P></BLOCKQUOTE>

<B>Products on Market:</B><BR>
<I>Clinical reagents:</I><BR>
<UL><LI> D-Dimer<BR>
<LI> Protein C (Clinical reagents for Thrombosis)<BR>
<LI> IATRO LQ series (Lipid determination kits)<BR>
<LI> IATRO PPI Test (Latex agglutination method)<BR>
<LI> Candida Check<BR>
<LI> Crypto Check (Diagnostics for identification of candida and cryptococcus)<BR>
<LI> Monoclonal antibodies and other products totalling up to 200 products for research use.<P>
</UL><I>Instruments:</I><BR>
<UL><LI> Iatroscan (TLC/FID systems)<BR>
<LI> Centrofuges.<P>
</UL>

<B>Current Corporate Partners:</B><BR>
<UL><LI> Mitsubishi Chemical Corporation<BR>
<LI> Ryukakusan Pharmaceutical Company<BR>
<LI> Asahi Chemical Industry Co.,Ltd.<BR>
<LI> Unitika, Ltd.<BR>
<LI> Toyobo Co., Ltd.<BR>
<LI> Novocastra Laboratories Ltd., United Kingdom<BR>
<LI> Murex Diagnostics Limited, United Kingdom<BR>
<LI> Poli Industria Chimica S.P.A., Italy<BR>
<LI> E. Merck, Germany<P>
</UL>

<B>Management:</B><BR>
<UL><LI> Chief Executive Officer, President: Yasuo Fujii<BR>
<LI> Senior Executive Director, Vice President, Osamu Naito<BR>
<LI> Managing Directors: Osamu Chuma, Shigeki Nozawa, Hidenobu Nogi<BR> Board of Directors: Tsutomu Ohira, Koji Toi<P>
</UL>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!-- Revised Saturday, June 3, 1995:11:36 AM. >

</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-193</DOCNO>
<DOCOLDNO>IA064-000378-B003-266</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/PressNews/prnb12.html 206.86.52.80 19970112095604 text/html 3315
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:56:10 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3133
Last-modified: Sun, 12 May 1996 19:33:26 GMT
</DOCHDR>
<HTML><HEAD><TITLE>BioGlobe BB #12</TITLE></HEAD><BODY BGCOLOR=#FFFFFF>

<CENTER><H1>BioGlobe Bulletin Board</H1></CENTER><P>
<HR>

To: bioglobe@iijnet.or.jp<BR>
Subject: [bioglobe 12] Topic on Hepatitis C Virus <P>

<BLOCKQUOTE>I would like to introduce some topics periodically on research and development in Japanese universities and companies from my experience as a subscriber. A topic I introduce today is a matter Japanese researchers have constructed for a long time from the time of hepatitis B virus, that is a topic about hepatitis C virus. I explain the RD circumstances of hepatitis C virus in Japan. As you know, interferons are currently used for the treatment of chronic hepatitis (HCV)whose market size is more than US$1 billion in Japan. However, the efficacy is limited to a small part of the patients due to insufficient suppression of HCV replication. Therefore, another reliable anti-HCV agent is necessary to control HCV hepatitis. Recombinant DNA techniques revealed that HCV had a positive-strand RNA of approximately 9400 nt long which coded a single polyprotein about 3010 amino acids. In contrast to the cleavage of the structural proteins of the virus by the host enzyme, the non-strucural proteins are released by the action of virus-coded proteinases which are serine type proteinase and metalloproteinase. Especially, serine type proteinase is proven to be different from already known enzymes and this enzyme is expected to be an attractive target for an antiviral therapy. Japanese NIH, NCI and some companies have independently cloned original HCV proteinase genes from the HCV positive sera into a plasmid of E.coli and have checked the activity to cleavage a substrate protein. In the long run, the in vitro HCV proteinase assay system has been established. Furthermore, using this assay system, screening of inhibitors against this enzyme has started in each party. Especially, of several cleavage sites, NS5A/NS5B substrate site as the best substrate for the cleavage in trans has been expected and already some kinds of inhibitors have been detected. This type of enzyme is different from the host-derived known enzymes so that a ideal drug without a side effect may be available in very near future. Fortunately, some persons from a basic research field have entered with NMR and X-rays analysis. In Japan, the diagnostic system has been established so that I expect by some calculation after 40 years HCV will be disappeared. The problem we should solve is to cure persons of chronic hepatitis and patients of chronic hepatitis shifted to cirrhosis and hepatoma whose patients number is more than 1 million at this time in Japan. I believe firmly glad tidings will be available in very near future!<P> </BLOCKQUOTE>

Ei Yamada<BR>
EY Bioscience<BR>
ID:PXW06273@niftyserve.or.jp<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
</DOC>
<DOC>
<DOCNO>WT03-B24-194</DOCNO>
<DOCOLDNO>IA064-000378-B003-423</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/PressNews/prnb20.html 206.86.52.80 19970112095659 text/html 1662
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:57:04 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1480
Last-modified: Sun, 12 May 1996 19:35:17 GMT
</DOCHDR>
<HTML><HEAD><TITLE>BioGlobe BB #20</TITLE></HEAD><BODY BGCOLOR=#FFFFFF>

<CENTER><H1>BioGlobe Bulletin Board</H1></CENTER><P>
<HR>

To: bioglobe@iijnet.or.jp<BR>
From:Toshiki Hirai, Research and Development Division, Pharmaceutical Affairs Bereau,<BR>
the Ministry of Health and Welfare<P>

"The decision of investment and financing items for fiscal 1994"<P>

March 8, 1995<BR>
The Organization for Drug ADR Relief, R&D Promotion and Product Review (reference)<BR>
Investment and Financing Division, R&D Promotion Department Toshiaki Kondo<BR>
9F Shinkasumigaseki Bldg 3-2, 3-chome Kasumigaseki Chiyoda-ku Tokyo 100 TEL:03-3506-9541<P>

<BLOCKQUOTE>1.The Organization for Drug ADR Relief, R&D Promotion and Product Review has decided one item for investment(the amount;30 million yen) and two items for financing(the amount;45 million yen).<P>

2.These items are the results of selection from candidates applied from September 16 to 30, 1994, after careful consideration. This choice of the investment item made 12 corporations as total corporations invested by this organization which contained 11 corporations selected from fiscal 1987 to 1993<P></BLOCKQUOTE>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-195</DOCNO>
<DOCOLDNO>IA064-000378-B005-210</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/onyxjp.html 206.86.52.80 19970112100055 text/html 9094
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:00:57 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 8912
Last-modified: Sun, 12 May 1996 19:30:18 GMT
</DOCHDR>
<HTML><HEAD><TITLE>ONYX Pharmaceuticals</TITLE></HEAD><BODY BGCOLOR=#FFFFFF>
<IMG Align=Middle SRC="../Graphics/onyx.gif">
<H1>ONYX t@[}X[`JY</H1><H3>Corporate Profile</H3>
<A HREF = "onyx.html"><IMG  Align=Middle SRC="../Graphics/english_button.gif"></A> <A HREF = "onyx.html">{</A>
<HR>

ONYX Pharmaceuticals<BR>
3031 Research Drive<BR>
Richmond, CA 94806<BR>
510-262-8772<BR>
510-222-9758 (fax)<P>

<B>F</B><BR>
Hollings C. Renton<BR>
ACEO<P>

Dr. Frank McCormick<BR>
wSC<P>

Dr. William Gerber<BR>
SC<P>

<B>F</B>
35lmwmA85lB<P>

<B>{F</B>

ONYX PharmaceuticalsAJtHjABAb`hsuA
40,000tB[g{B<P>

<B>nF</B> <BR>

ONYXARasIRWFrank McCormick, Ph.D.AAA}`qMngwDGA`ER[|[VXsEItB<P>

<B>nF</B>
1992N424<P>

<B>z:</B>  ($000) <P>


<CENTER>	<table border=4>
<tr><th align=center>V[Y A <th align=center>	V[Y B	<th align=center>V[Y C	<th align=center>V[Y D	<th align=center>{ <tr>
<td align=center>	400	<td align=center>	5,000	<td align=center>	12,200	<td align=center>	17,100	<td align=center>	7,333
</table><P></CENTER>

<B>vF</B><BR>
Chiron, Bayer  Parke-DavisAAvalon Ventures, Institutional Venture Partners, Kleiner Perkins Caufield & Byers, Sprout Group, Sierra Ventures, Robertson, Stephens & Co., Sequoia Capital, New York Life, Mutual of New York, Alex Brown, Forward VenturesADx`[ELs^B<P>

<B>wiF</B><BR>
ONYX AA42Shs{BB<P>

<B>TvF</B><BR>
ONYX CAdaCVKiJBSAVK@JAVqwZpAgEMHmtBiVKJd_IpAJip[gi[_B<P>

<B>gF</B><P>
<CENTER><TABLE BORDER =4>
<TR><TH align=center>	<TH align=center>				<TH align=center>		t<TR>
<TD align=center>Bayer		<TD align=center>		Ras	<TD align=center>			1994N5<TR>
<TD align=center> Parke-Davis	<TD align=center>	ETCN <TD align=center>1994N5<TR>
<TD align=center> Eli Lilly	<TD align=center>		<TD align=center>	1994N5</TABLE><P></CENTER>

<B>ZpTF</B><P>
ONYXAZIqw_AOVKiJvOB<P>

<EM>RasMF</EM><BR> 
ONYXiVKJvOARasMHe[}AAONYX/BayerJiBRasAt@N^[N`AEBRas~AAx}qiALIV\AE}`BaB<P>

<EM>ETCNM[^[F</EM><BR>
ONYXAETCN`_BONYXp[gi[Warner-LambertParke-DavisAaCVJwBi\iARNETCN`@\AE^STCNB
<P>

<EM>p53RAfmECXF</EM><BR>
ONYXAAfmECXIIAEp53sEEdvBRZvgAii1996N\B AECXaCWJB<P>

<B>p[gi[F</B>
<UL><LI> Bayer
<LI> Parke-Davis
<LI> Eli Lilly
</UL>

<B>p[gi[W@F</B><BR>
ONYX AeivOpB p53RAfmECX1996NBA Warner-LambertETCN{p[gi[TB<P>

<B>ocF</B><BR>
Dr. Frank McCormick - <a href=mailto:frank@ONYX-pharm.com>frank@ONYX-pharm.com</a><BR>
Dr. Frank McCormick AqWONYXRas IRMGAP`mxwBONYXnOA Dr. Frank McCormick AChiron CorporationEwSBoA 1981N Cetus CorporationwX^btA1990NAVKSqwSfCN^[B  Xgj[EubNsj[[NBwhcmBpPubWwwUmBLES_fB<P>

Hollings C. Renton - <a href=mailto:hollings@ONYX-pharm.com>hollings@ONYX-pharm.com</a><BR>
1993NONYXOAHollings Renton AChiron CorporationSCB ChironCetus CorporationEABOACetus Corporation1987NSCA1990NACB~VKBwocwCmB<P>

Dr. William Gerber - <a href=mailto:bgerber@ONYX-pharm.com>bgerber@ONYX-pharm.com</a><BR>
Dr. Gerber A1991N12ACetus Corporation ChironffAAChiron Corporation ONYXB 1987NR[|[gEx`[SfCN^[CetusA1988
N11PCR (Polymerase Chain Reaction)EACBJtHjABwTtVXREfCJEZ^[AwUwmwmB<P>

<B>F</B><BR>
Sam Colella<BR>
Institutional Venture Partners<BR>
3000 Sand Hill Rd.<BR>
Building 2, Suite 290<BR>
Menlo Park, CA 94025<P>

Brook Byers<BR>
Kleiner Perkins Caufield & Byers<BR>
2750 Sand Hill Road<BR>
Menlo Park, CA 94025<P>

Kevin Kinsella<BR>
Sequana Therapeutics, Inc.<BR>
11099 North Torrey Pines Rd.<BR>
Ste 160<BR>
LaJolla, CA 92037<P>

Walter Moos<BR>
Chemical Therapeutics<BR>
Chiron Corporation<BR>
4560 Horton Street<BR>
Emeryville, CA 94608<P>

Kathleen LaPorte<BR>
Sprout Group<BR>
3000 Sand Hill Rd., 4-270<BR>
Menlo Park, CA 94025-7114<P>

Wolfgang Hartwig, Ph.D.<BR>
Vice President Research<BR>
Bayer Corporation<BR>
400 Morgan Lane<BR>
West Haven, CT 06516-4175<P>

Frank McCormick, Ph.D.<BR>
Chief Scientific Officer<BR>
ONYX Pharmaceuticals<BR>
3031 Research Drive<BR>
Richmond, CA 94806<P>

Hollings Renton<BR>
President and CEO<BR>
ONYX Pharmaceuticals<BR>
3031 Research Drive<BR>
Richmond, CA 94806<P>

<B>wF</B><BR>
Eric Fearon, M.D.<BR>
Division of Molecular Medicine & Genetics<BR>
4301 MSRB 3, Box 0638<BR>
University of Michigan Medical Center<BR>
1150 W. Medical Center Dr.<BR>
Ann Arbor, MI 48109-0638<P>

Henry Bourne, M.D.<BR>
UCSF Department of Pharmacology<BR>
1210 Science Building - Box 0502<BR>
San Francisco, CA 94143<P>

Edward R. Harlow, Jr., Ph.D. (Chairman)<BR>
MGH Cancer Center<BR>
Laboratory of Molecular Oncology<BR>
Building 149-13th Street<BR>
Charlestown, MA 02129<P>

Peter M. Howley, M.D.<BR>
Chairman, Dept. of Pharmacology<BR>
Harvard Medical School<BR>
200 Longwood Avenue, Bldg. D2 Room 630<BR>
Boston, MA 02115<P>


Owen N. Witte, M.D.<BR>
UCLA McDonald Research Lab<BR>
10833 Le Conte Avenue<BR>
Los Angeles, CA 90024-1662<P>

Arnold J. Levine, Ph.D.<BR>
Chairman and Professor<BR>
Department of Molecular Biology<BR>
Lewis Thomas Laboratory<BR>
Princeton University<BR>
Princeton, NJ 08544-1014<P>

Burton Christensen, Ph.D.<BR>
48 Philhower Road<BR>
Lebanon, NJ 08833<P>

Eileen White, Ph.D.<BR>
Center for Advanced Biotechnology and Medicine<BR>
679 Hoes Lane<BR>
Piscataway, NJ 08854<P>

Bruce A.J. Ponder, Ph.D.<BR>
CRC Human Cancer Genetics Group<BR>
Level 3, Laboratories Block, Box 238<BR>
Addenbrooke's Hospital<BR>
Hills Road<BR>
Cambridge, England CB2 2QQ<P>

Dr. Douglas Hanahan<BR>
Hormone Research Institute, Rm. HSW 1090<BR>
UC San Francisco<BR>
School of Medicine<BR>
San Francisco, CA 94121<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  z[Ey[W</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated October 10, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
<!--  

<P>ADr. William GerberB
Dr. William Gerber
Chief Operating Officer
ONYX Pharmaceuticals
3031 Research Drive
Richmond, CA  94806
510-262-8772
Fax:  510-222-9758</P>
</HTML>



  -->
</DOC>
<DOC>
<DOCNO>WT03-B24-196</DOCNO>
<DOCOLDNO>IA064-000378-B003-306</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/PressNews/prnb15.html 206.86.52.80 19970112095615 text/html 2139
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:56:21 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1957
Last-modified: Sun, 12 May 1996 19:33:27 GMT
</DOCHDR>
<HTML><HEAD><TITLE>BioGlobe BB #15</TITLE></HEAD><BODY BGCOLOR=#FFFFFF>

<CENTER><H1>BioGlobe Bulletin Board</H1></CENTER><P>
<HR>


Subject: [bioglobe 15]<BR>
Topic on Hepatitis B Virus<P>

<BLOCKQUOTE>A topic I introduce today is a new matter of Hepatitis B Virus. Professor K.Murakami of Kanazawa University, Cancer Center, in Japan, reported the relationship between X protein and some transcription factor, that was a first finding and very interesting. 
As you know, Hepatitis B Virus has gene X in its own genome and when this virus is infected to human or chimpanzee hepatocytes, protein X is usually expressed in the cells. However, the function of protein X has never been elucidated for a long time. He has challenged to produce protein X and MW800K protein derived from hepatocytes by E.coli expression system and confirmed them to be associated. Especially, protein X was found to bind specifically to RPB5 protein of some kinds of transcription factors. Furthermore, he expected this protein X and RPB5 protein complex might activate some genes related hepatocellular carcinoma. This news was derived from Nikkan Kogyo Shinbun(Jan.19,1995) and later I will confirm the content of this new result. Any way, the story of protein X and some transcription factor binding seems to be likely. If it is, we will be able to make a assay system for screening of binding inhibitors for cancer prevention. In Japan 24000 persons lost their lives due to hepatoma in 1994, and 20-30% of them was caused by Hepatitis B virus infection. Further studies have to be done.<P></BLOCKQUOTE>

Ei Yamada<BR>
EY Bioscience<BR>
PXW06273@niftyserve.or.jp<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
</DOC>
<DOC>
<DOCNO>WT03-B24-197</DOCNO>
<DOCOLDNO>IA064-000378-B003-403</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/PressNews/prnb18.html 206.86.52.80 19970112095646 text/html 1980
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:56:53 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1798
Last-modified: Sun, 12 May 1996 19:33:27 GMT
</DOCHDR>
<HTML><HEAD><TITLE>BioGlobe BB #18</TITLE></HEAD><BODY BGCOLOR=#FFFFFF>

<CENTER><H1>BioGlobe Bulletin Board</H1></CENTER><P>
<HR>


To: bioglobe@iijnet.or.jp<BR>
Subject: [bioglobe 18] Autoimmune disease mouse<P>

<BLOCKQUOTE>Ladies and Gentlemen:<BR>
A topic I introduce today is a success of some autoimmune disease mouse model. Dr.S.Sakaguchi in JRDC has established the mouse which had some kind of autoimmune disease sympton without CD4 and CD25 T cells. First, he found, in case CD4 and CD25 T cells were present on low level in mice, autoimmune disease was observed in high frequency. Second, CD4 and CD25 deficient T cells were injected into some mice without T cells, so that insulin dependent diabetes, thyroiditis, ovaritis, gastritis with pernicious anemia and arthritis were appeared, which was very similar to human autoimmune disease sympton. The other way, to this type of mice, CD4 and CD25 T cells were added, as a result, above sympton was disappeared. To make sure, he challenged to make mice without genes of CD4 and CD25. As expected, autoimmune disease was observed. The symptons of autoimmune diseases were a little different among different genetics mice. From these results, it is likely that some T cells in normal mice attack normal cells, and CD4 and CD25 T cells are usually suppressing above T cells to do it. This idea may be applied to prevention and therapy for autoimmune disease and cancer.<P>
</BLOCKQUOTE>
Ei Yamada<BR>
PXW06273@niftyserve.or.jp<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
</DOC>
<DOC>
<DOCNO>WT03-B24-198</DOCNO>
<DOCOLDNO>IA064-000378-B004-35</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/PressNews/prnb22.html 206.86.52.80 19970112095715 text/html 15136
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:57:16 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 14953
Last-modified: Sun, 12 May 1996 19:33:29 GMT
</DOCHDR>
<HTML><HEAD><TITLE>BioGlobe BB #22</TITLE></HEAD><BODY BGCOLOR=#FFFFFF>

<CENTER><H1>BioGlobe Bulletin Board</H1></CENTER><P>
<HR>

To: bioglobe@iijnet.or.jp<BR>
From: eyamada@mb.tokyo.infoweb.or.jp (Ei Yamada)<BR>
Subject: [bioglobe 22] News from Koseisho<BR>
From:Toshiki Hirai, Research and Development Division, Pharmaceutical Affairs Bureau, the Ministry of Health and Welfare<P>

"New Establishment of Subcommittee of the Central Pharmaceutical Affairs Council"<BR>
March, 9, 1995<BR>
Research and Development Division, Pharmaceutical Affairs Bureau the Ministry of Health and Welfare<P>

<BLOCKQUOTE>It is expected that research on gene therapy will progress hereafter, so that the subcommittee for confirming safety of gene therapy products has been newly organized under Biotechnology Special Session of Subcommittee of the Central Pharmaceutical Affairs Council. Furthermore, the former subcommittee for Confirmation under Guideline for Manufacturing Drugs by Application of Recombinant DNA Technology has been changed to Subcommittee. <P>

Contents are as follows.<P>

1.The name of Subcommittee<BR>
(1)Subcommittee for Gene Therapy Products (2)Subcommittee for Recombinant DNA Technology Application Drugs<P>

2.A mission of;<BR>
(1) Subcommittee<P>

It is to prepare the guideline for evaluating quality and safety of Gene Therapy Products and improving the guideline as technology advences. Furthermore, according to requests from companies to conduct therapy, it is to confirm whether the gene therapy products to be scheduled fits the guideline.<P>

(2) Subcommittee<P>

It is to confirm whether recombinant DNA technology application drugs fit Guideline for Manufacturing Drugs by Application of Recombinant DNA Technology according to requests from manufacture companies.<P>

(reference)<P>

1.Biotechnology Special Session<P>

It is provided in rules of Subcommittee of the Central Pharmaceutical Affairs Council that Biotechnology Special Session is to examine and consider appropriate use of Guideline for Manufacturing Drugs by Application of Recombinant DNA Technology and important matters on biotechnology concerned with pharmaceuticals. <P>

Above important matters are to prepare the guideline for evaluating quality and safety on gene therapy products before clinical study, and confirm whether gene therapy products to be scheduled fit the guideline according to requests from companies to conduct clinical trial.<P>

2.The relationship with Central Assessment Committee for Gene Therapy<P>

Central Assessment Committee on Gene Therapy is to evaluate comprehensively scientific appropriateness and ethics of a working plan for clinical study on gene therapy from the view point of an expert, when a head of a working institution to conduct gene therapy asks a opinion from the Minister of Welfare.<P>

Biotechnology Special Session is to confirm suitability of safety, manufacture method and quality of gene therapy products according to requests from companies to conduct gene therapy.<P>

Central Assessment Committee on Gene Therapy; Object;Clincal study on gene therapy<BR>
Applicant;Head of a working institution to conduct gene therapy Role;To evaluate comprehensively scientific appropriateness and ethics of a working plan for clinical study on gene therapy<P>

Biotechnology Special Session;<BR>
Object;Gene therapy products<BR>
Applicant;company to conduct gene therapy Role;To confirm suitability of safety, manufacture method and quality of gene therapy products.<P>

"The decision of investment and financing items for fiscal 1994"<P> 

March 8, 1995<BR>
The Organization for Drug ADR Relief, R&D Promotion and Product Review (reference)<BR>
Investment and Financing Division, R&D Promotion Department Toshiaki Kondo<BR>
9F Shinkasumigaseki Bldg 3-2, 3-chome Kasumigaseki Chiyoda-ku Tokyo 100 TEL:03-3506-9541<P>

1.The Organization for Drug ADR Relief, R&D Promotion and Product Review has decided one item for investment(the amount;30 million yen) and two items for financing(the amount;45 million yen). <P>

2.These items are the results of selection from candidates applied from September 16 to 30, 1994, after careful consideration. This choice of the investment item made 12 corporations as total corporations invested by this organization which contained 11 corporations selected from fiscal 1987 to 1993. But in the cases of 2 corporations the investment should stop in March,1995 so that 10 corporations will continue from April, 1995. The choice of two financing items made 27 corporations which contained 25 selected from fiscal 1987 to 1993.<P>

3. The outline of investment item is as follows.<P>

The theme name of research; Research on gene therapy products. The name of corporation; DNAVEC Research Inc. Participating companies; Hisamitu, kyowa, Sankyo, Shionogi, Yamanouchi, Sumitomo and Tanabe.
The outline of research theme;<BR>
Gene therapy is expected very much to apply to, cancers whose usual therapies have been ineffective, and chronic diseases or hereditary diseases whose medicinal treatment have not been satisfactory and whose treatment is necessary for all one's life.<P>

This research is focusing on establishment of gene transfer method as most suitable, and making a process practicable on gene therapy against various diseases.<P>

For above purpose, this research is to develop new vectors, control method of gene expression and vectors production technology on a large scale.<P>

4. The outline of financing two items are as follows.<P>

The theme name of research; Development of drugs for IgA nephropathy. The outline of research;<BR>
This research and development is focusing on development of monoclonal antibodies against IgA nephropathy for therapy.<P>

The theme name of research; Research on desage form and efficacy on herbal medicines. This research is focusing on analysing the relationship between preparation methods and efficacies or medicinal actions in herbal medicines. <P>

5.Contents of research on gene therapy products.<P>

1)Present state and necessity;<P>

Gene therapy has been desiged as a fundamental therapy to hereditary diseases and intractable diseases, and in 1990 a first trial in the world was applied to hereditary immunodeficiency disease(adenosine deaminase deficiency disease) as therapeutics.
As a result, a dramatic efficacy was recognized so that clinical studies has been widely applied, for example, against cancers whose mortal rate is higher. In the world, more than 90 sorts of clinical studies on gene therapy were granted permission, and more than 200 cases in fact have been in force. Furthermore, hereafter, it's number is expected to increase. On the other hand, in Japan, "An expert committee on gene therapy" was established by the Ministry of Health and Welfare in October, 1991, and " Guideline of clinical study on gene therapy" was approved in April, 1993. Furthermore, "Central Assessment Committee for Gene Therapy" was established in February,1994 and possibility on application of gene therapy has been started to examine in Japanese medical institutions. In some medical institutions, applications on clinical studies using virus vectors developed by foreign venture companies were already submitted to an ethics committee in each institution.<P>

Thus, everyone expects much from gene therapy. However, a clinical study on gene therapy in Japan is following in the footsteps of the foreign countries because of using virus vectors introduced from foreign venture companies. These existing virus vectors
are unsatisfactory from the view points of cell specificity in gene transfer, the rate of gene transfer and the gene expression rate, so that it is very difficult to conduct gene therapy with a wide use.<P> 

Therefore, this research is focusing on developing new types of vector constructions on original gene therapy and their production methods, which have high efficiency and safety in order to anchor forthcoming gene therapy in Japan with a highly wide use and
high safety.<P>

2)Technical development;<P>

This is to develop new types of vectors with higher therapeutic value than existing vectors by two types of basic approaches, "study on construction of new vectors on gene therapy" and "search on reinforcing efficacy on new gene therapy.<P>

1]Study on construction of new vectors on gene therapy; This is to develop new types of vectors with gene transfer metods with target cells specificity, high transfer rate and high physical stability.<P> 

2]Search on reinforcing efficacy on new gene therapy; This is to develop control methods of gene expression on gene therapy for high rate of gene expression, organ specificity and irritability of gene expression(region, time control). It is also to conduct applied research of new therapeutic gene to reinforce remedial value. <P>

3]Study on production of new vectors on gene therapy; This is to develop production technology for above vectors on gene therapy. It is also to establish technology for quality guaranteed on gene therapy.<P>

3.Expected effectiveness;<P>

1]It is expected to develop new vectors on gene therapy with higher efficiency than existing vectors.<BR>
2]It is expected to develop new and effective therapeutic method by new gene therapy<BR>
with high efficacy, against incurable diseases, cancer or viral diseases.<BR>
3]Above results are expected to apply widely to autoimmune diseases such as chronic articular rheumatism, chronic diseases such as hyperpiesia, incurable diseases such as Alzheimer disease and senile dementia.<P>

4.Outline of new corporation;<P>

The name of corporation;DNAVEC research Inc. Corporations investing;Hisamitsu, Kyowa, Sankyo, Shionogi, Sumitomo, Tanabe and Yamanouchi. The total amount of investment;48.2 million yen, the amount invested by this organization;30 million yen.<P>

"The Minister of Welfare's designation of orphan drugs and orphan medical instruments"<P>
March 9,1995<BR>
Reseach and Development Division, Pharmaceutical Affairs Bureau the Ministry of Health and Welfare<P>

1.Outline of orphan drugs designated;<BR>
(1)This is the third designation of orphan drugs etc(The first;15,November,1993, The second;1,July,1994).<BR>
(2)This designation contains 11 drugs(10 companies) and 2 medical instruments(2 companies) which are anti-AIDS, drugs against leukemia etc.<P>

2.Support action;<BR>
This is to promote research and development for drugs etc designated as orphan.<BR>
(1)Support of development by The Organization for Drug ADR Relief,R&D promotion and Product Review(grant, advice and direction).
(2)Favorable treatment on tax system.<BR>
(3)Priority examination.<BR>
(4)Prolongation of reexamination term.<P>

(reference)<P>

1.View of system;<BR>
This is a special support action on research and development of drugs. Because research and development of drugs and medical instruments against incurable diseases, AIDS etc has not fully advanced for small number of patients in spite of necessity from the view point of medical treatment.<P>

2.Outline of system;<BR>
The Minister of Welfare can designate drugs with passing marks as orphan drugs etc according to applications from companies. Regarding drugs designated orpah drug etc, the support action which includes grant-in-aid, tax subtraction, priority examination and prolongation of reexamination term is adopted.<P>

(1)Designation criteria;<BR>
Patients number is less than 50,000.<BR>
High necessity of medical treatment.<BR>
High probability of development.<BR>

(2)Grant-in-aid;<BR>
Grant from The Organization for Drug ADR Relief, R&D Promotion and Product Review because of reducing cost for development of orphan drugs etc(budget;4 hundred million for fiscal 1995).<P>

(3)Direction and Advice;<BR>
Direction and advice by The Organization for Drug ADR Relief, R&D Promotion and Product Review on research and development about orphan drugs etc.<P>

(4)Tax subtraction;<BR>
6% tax reduction of research and development which is less than 10% of the corporation profit tax.<P>

(5)Priority examination;
Priority examination than other drugs for the purpose of offering orphan drugs etc as soon as possible.<P>

(6)Prolongation of reexamination term;<BR>
Prolongation of reexamination term from 6 to 10 years.<P>

A list of articles planned to designate;<P>

1. Product name;<BR>
N-[(1S,2R)-3-(4-amino-N isobutylbenzensulfonamide)-1-benzyl-2-hydroxypropyl] carbamate (3S)-tetrahydro-3-furylester-mesilate Efficacy;Anti-viral drug against AIDS and synptomatic and asymptomatic HIV infected patients Company;Kissei<P>

2.Product name;Interferon beta<BR>
Efficacy;Senile disciform macular degeneration with subfoveal and/or juxtfoveal choroidal neovascularization Company;Toray<P>

3.Product name;Etidronate disodium<BR>
Efficacy;Ossification of posterior longitudinal ligament of the spine(OPLL) Company;Sumitomo<P>

4.Product name;Cladribine<BR>
Efficacy;Hairy cell leukemia Company;Yansen-Kyowa<P>

5.Product name;Anti-human CD11a mouse monoclonal antibody.<BR> Efficacy;Rejection sympton and GVHD in bone marrow transplantation of severe complex immunodeficient patients Company;Pasteur-Merieux<P>

6.Product name;
(R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-N-[(R)-2-N-(isoquinorine-5-yloxyacet yl)amino-3-methylthiopropanoyl]amino-4-phenylbutanoyl]-1,3-thiazoridine-4-ph enylbutanoyl]-1,3-thiazoridine-4-carboxyamide Efficacy;AIDS patients, symptomatic and asymptomatic HIV infected patients with less than 400 CD4 lymphocytes before treatment Company;Japan Energy<P>

7.Product name;Cyclophsphamide<BR>
Efficacy;Pretreatment of bone marrow transplantation in acute leukemia, chronic myelogenous leukemia and malignant lymphoma Company;Shionogi<P>

8.Product name;Stavudine<BR>
Efficacy;HIV infected patients Company;Bristol-Myers<P>

9.Product;Somatropin(gene recombinant product)<BR>
 Efficacy;Maintenance and increase of body weight for AIDS patients Company;Serono-Japan<P>

10.Product name;Foscarnet sodium<BR>
Efficacy;Retinitis infected with CMV for AIDS patients Company;Astra-Japan.<P>

11.Product name;Mesna<BR>
Efficacy;Urinary organs disease by administraion of Cyclophsphamide(pretreatment before bone marrow transplantation)
Company;Shionogi<P>

Medical Instrument;<P>



1.Magnetic cells separation system.<BR>
Separation and isolation of Hematopoiesis stem cells in homoplastic bone marrow transplantation, autoplastic bone marrow transplantation and autoplastic peripheral blood stem cells transplantation Company;Baxter<P>

2.Lymphocytes separation instrument.<BR>
Removal of T lymphocytes in homoplastic bone marrow transplantation Company; Asahi Medical<P></BLOCKQUOTE>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
</DOC>
<DOC>
<DOCNO>WT03-B24-199</DOCNO>
<DOCOLDNO>IA064-000378-B005-243</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/geronjp.html 206.86.52.80 19970112100115 text/html 5733
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:01:14 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5551
Last-modified: Sat, 23 Dec 1995 08:57:46 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Geron </TITLE>
<H1><IMG  Align=Middle SRC="../Graphics/geronlo.gif">Geron </H1><H3>Tv</H3></HEAD><BODY><A HREF = "geron.html"><IMG  Align=Middle SRC="../Graphics/english_ button.gif"></A> <A HREF = "geron.html">English Translation</A>
<HR>
200 Constitution Avenue<BR>Menlo Park, CA 94025<BR>
dbF(415)473-7700<BR>
t@bNXF(415) 473-7701<BR>
E-CF<a href=mailto:info@geron.com>info@geron.com</a><P>

<B></B><P>
Mr. Ronald W. Eastman A\<BR>
Mr. Richard Haiduck AAJ<BR>
Dr. Calvin Harley A A<BR>
Ms. Jeryl Hilleman AA<BR>
Mr. Kevin Kaster A@AmIL<BR>
Dr. Daniel Levitt AAJ<BR>
Dr. Michael West AnAVZp<P>

<B>]F</B>70liPh.D 29lAwm^Ph.D PlA@wmPlj<P>

<B>{F</B>18,000tB[g<P>

<B>T</B><P>
<BLOCKQUOTE>Geron AVaCJ_oCIB Geron VAalZAEV{IwJjY|tAEusvuVv@uB<P>

Geron VaCAXgDE`qvOVVNlB Geron EVA`quvvnB JjY[--F[fILV{j_ (DNA) AJsB[AEVAAEZBEZB _ANAaC XsRVENB<P>

Geron vOAEVNAaCb{IJjYB X immortaling enzyme telomerase }A@WwB <P></BLOCKQUOTE>   

<B>Geron wIvOT *</B>
  <table border>
        <tr><th align=center>vO<th>Description<th>Disease Target<tr><td align=left>Telomerase }<td>Enzyme telomerase }AEWIwuvvEUB
<td>@f@
<tr><td align=left>V`q
<td>IWE@\AVEEmvmFWB V`qffAB
<td>Ae[dAimmunosenescenceiuVjABPHAneurodegenerativei_ojaANAQfB<tr><td align=left> [<td>F[[AWIEB
<td>NAQf
<tr><th rowspan=1><th colspan=1>
     </table>vOiKB<P>  

<B> : </B>
Geron  Kleiner Perkins Caufield and ByersAVenrock AssociatesACW GroupAOxford Venture PartnersADomain Associates  Biotechnology Investments 3,000hBB<P>

<B>F</B>1992N<P>

<B>p[gi[g@F</B><BR>
Geron A telomerase }AJ[bpANAaCV`qEIAp[gi[{B 
Geron A[bp{ telomerase f diagnostics WWSB <P>   

<B>wIF</B><P>
Gunter K. Blobel, M.D., Ph.D.<BR> 
LaskerAn[hEq[YAbNtF[w<P>

Vincent J. Cristofalo, Ph.D. <BR>
VlaZ^[yVojAww<P>

Carol Greider, Ph.D.<BR>
R[hEXvOEn[o[<P>
     
Douglas Hanahan, Ph.D.<BR>
JtHjAwATtVXRZ<P>

Leonard Hayflick, Ph.D.<BR>
EVlawJAJtHjAwATtVXRZ<P>

Thomas Maciag, Ph.D.<BR>
AJ\W[WEVgw<P>

Jerry Shay, Ph.D.<BR>
_XeLTXETEXEGX^wZ^[<P>

 James D. Watson, Ph.D.<BR>
m[xAR[hEXvOEn[o[ <P>

Woodring Wright, M.D., Ph.D.<BR>
_XeLTXETEXEGX^wZ^[<P>

<H3>a@AF<P></H3>
Robert N. Butler, M.D.<BR>
s[c@[<BR> 
VlwlA}EgEViCZ^[<P>

George Martin, M.D.<BR>
awA`wAAAcnC}[Z^[AVgw<P>

Lewis T. Williams, M.D., Ph.D. <BR>
JtHjAwATtVXRZ<P>

<H3>F<P></H3>
Dr. Alexander E. Barkas<BR>
A Kleiner Perkins Caufield & Byers <P>

Mr. Brian R. Dovey<BR>
Domain Associates <P>

Mr. Ronald W. Eastman<BR>
Geron \<P>

Mr. Charles M. Hartman <BR>
CW O[v<P>

Mr. Thomas D. Kiley<BR>
Genentech Om<P>

Mr. Patrick F. Latterell<BR>
Venrock Associates <P>

Dr. Michael D. West<BR>
nAGeron VZp<P>

<B>rWlX : </B><P>

Mr. Jack L. Bowman<BR>
O Johnson & Johnson O[v<P>

Mr. Robert A. Swanson<BR>
AGenentech <P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-200</DOCNO>
<DOCOLDNO>IA064-000380-B022-175</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/homepg.htm 206.86.52.80 19970112101724 text/html 2545
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:17:30 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2363
Last-modified: Thu, 08 Feb 1996 18:15:44 GMT
</DOCHDR>
<HTML><HEAD>
<BODY background = "graphics/white-mi.gif">
<TITLE> BioCentury Now!</TITLE></HEAD>

<BODY>
<IMG  Align=Top SRC="graphics/fish10.gif"><p>

  
Welcome to BioCentury(TM) Now!, the Internet information service provided to BioGlobe by BioCentury Publications Inc. of the United States. BioCentury is widely considered to be the leading U.S. provider of analysis and commentary relating to biotechnology industry development in North America. We are honored to be invited by Sosei Co. Ltd. to share our information with the Japanese audience. <P>

This page describes the information provided by BioCentury to BioGlobe subscribers.<P>

<A HREF="news/thiswk.htm">New This Week</A>: This page contains Japanese-language abstracts of new articles from BioCentury that have added to the BioGlobe database.<P>

BioCentury Library: This area contains Japanese-language abstracts of other articles from BioCentury. The abstracts are organized into several categories. If you want to read more, each abstract is linked directly to the complete English-language article. The Library categories include:<P>

<A HREF="library/indstr/indstr.htm">Industry Structure</A><BR>
<A HREF="library/corstr/costr.htm">Corporate Strategies</A><BR>
<A HREF="library/allpart/allpart.htm">Alliances & Partnering</A><BR>
<A HREF="library/regul/regul.htm">Public Policy & Regulation</A><BR>
<A HREF="library/tech/tech.htm">Technology</A><BR>
<A HREF="library/fi/fi.htm">Finance & Investment</A><P>

<A HREF="about/about.htm">About BioCentury</A>: This page contains information about BioCentury and its services.<P>

<A HREF="commun/comm.htm">Communicating with BioCentury</A>: This page provides information that will enable you to send messages to BioCentury and its editors. <P><P>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/homepg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>


</DOC>
<DOC>
<DOCNO>WT03-B24-201</DOCNO>
<DOCOLDNO>IA064-000380-B023-83</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/indstr/indstr.htm 206.86.52.80 19970112101905 text/html 4559
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:19:09 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4377
Last-modified: Wed, 18 Sep 1996 23:39:00 GMT
</DOCHDR>

<HTML>
<BODY background = "../../graphics/white-mi.gif">
<HEAD><TITLE> Industry Structure</TITLE></HEAD>



<H1><center>Industry Structure</H1></center><P>

Each of the following abstracts is linked directly to the complete English-language article.<P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/031196a1.htm"> Biotechology in Germany</A></B><br>
This article describes the emergence of biotechnology in Germany despite cultural and financial roadblocks. March 11, 1996 (4,200 words).<P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/010296a1.htm">1995 Was Successful for U.S. Biotech </A></B><BR>
The biotechnology sector emerged from a prolonged down period in 1995, reporting strong clinical data, obtaining product approvals, creating strong corporate partnerships, and raising $3.5 billion in the equity markets. This 
article discusses the factors underlying this upswing and considers the possibilities of continued improvement into 1996. Jan. 2, 1996 (3,600 words)

<B><A HREF ="/BioCentury2/archive/1995/4qtr/120495a1.htm"> Agricultural Biotechnology's Future </A></B><BR>
This article discusses the consolidation of U.S. agricultural biotechnology companies and considers the factors influencing future development of the sector. Dec. 4, 1995 (3,150 words)<P>

<B><A HREF="../../archive/1995/3qtr/0710a1.htm">Redefining the Biotech Industry</A></B><BR>

This Guest Commentary is by Mr. Stanley T. Crooke, Chairman and CEO of antisense pioneer Isis Pharmaceuticals Inc. Mr. Crooke discusses the future of the human therapeutic sector of biotechnology. He identifies five types of companies and their fundamentals for success. He proposes that biotechnologys long-term value be defined as enabling drug discovery platforms. 7.10.95 (3780 WORDS)<P>

Mr. Crooke wrote in response to Mr. Kenneth Ludlum of RiboGene Inc., who discusses the changing importance of technology in the evolution of several industrial sectors. See <A HREF="../../archive/1995/2qtr/0530a4.htm"> When Infatuation Ends</A> for Mr. Ludlums Commentary. 30.5.95 (1580 WORDS)<P>


<B><A HREF="../../archive/1995/2qtr/0501a1.htm">Reality II</A></B><BR>

This Commentary about Centocor Inc.s ReoPro market introduction discusses the implications for biotechnology arising from economic decisions by U.S. hospitals about whether or not to add new drugs to their formularies. The challenge for biotechnology is how to create, price, and market new drugs in this frugal context, and even whether or not to begin new drug development. 1.5.95 (1700 WORDS)<P>

See <A HREF="../../archive/1995/2qtr/0424a1.htm">Reality I</A> for the first part of this Commentary.<P>

 
<B><A HREF="../../archive/1995/2qtr/0424a1.htm">Reality I</A></B><BR>

This story discusses the impact of cost control in the formulary decision at six hospitals about ReoPro, Centocor Inc.s anti-platelet antibody for use in high-risk angioplasty (2950 WORDS). An accompanying story discusses <A HREF="../../archive/1995/2qtr/0424a3.htm">ReoPros Launch Program</A>. (475 WORDS) 24.4.95 <P>

See <A HREF="../../archive/1995/2qtr/0501a1.htm">Reality II</A> for the second part of this analysis.<P>


<B><A HREF="../../archive/1995/1qtr/0130a5.htm">Words of Wisdom</A></B><BR>

In this Commentary, Alejandro Zaffaroni, founder of Syntex, Alza Corp., DNAX Ltd., and Affymax N.V., describes hot areas in biotechnology and models for drug discovery. He advocates first studying receptors and proteins of interest, then developing products through the 'virtual' company. His ideas recognize the cost pressures, rate of scientific discovery, and suggest a way to return value to investors. 30.1.95 (800 WORDS)<P>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/homepg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>




</DOC>
<DOC>
<DOCNO>WT03-B24-202</DOCNO>
<DOCOLDNO>IA064-000380-B023-126</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/corstr/costr.htm 206.86.52.80 19970112101922 text/html 3263
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:19:25 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3081
Last-modified: Fri, 11 Oct 1996 00:16:02 GMT
</DOCHDR>
<HTML>
<BODY background = "../../graphics/white-mi.gif">

<HEAD><TITLE> Corporate Strategies</TITLE></HEAD>



<H1><CENTER>Corporate Strategies</H1></CENTER><P>

Each of the following abstracts is linked directly to the complete English-language article.<P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/032596a1.htm"> ReoPro marketing -- one year later </A></B><br>
This story discusses how hospitals have responded to Centocor Inc.'s anti-platelet antibody after a year of marketing by partner Eli Lilly. March 25, 1996 (3,400 words).<p>

<B><A HREF ="../../archive/1995/3qtr/0731a5.htm">Chuga's Worldwide Strategy</A></B><BR>

President Osamu Nagayama discusses Chugais worldwide strategy. Chugai is the only Japanese company to own two U.S. biotech companies, Chugai Biopharmaceuticals (CBI) and Gen-Probe.  Nagayama explains Chugais strategy to create a disease management company using CBIs therapeutic products and Gen-Probes diagnostic and post-therapeutic monitoring products. (890 WORDS) An accompanying story describes the changing fortunes of the Japanese pharma markets (150 WORDS) 31.7.95 <P>

<B><A HREF="../../archive/1995/3qtr/0717a1.htm">Rebuilding Genentech</A></B><BR>

This story identifies two external fronts for CEO and President Arthur Levinson following the departure of G. Kirk Raab.  The first front is the perception that Roche Holdings wishes to turn GNE into an R&D affiliate from a fully integrated biopharmaceutical company. The second front is that the true cap on the common stock is $60, not the $82.50 call option held by Roche. GNE CFO Louis Lavigne is adamant that GNE will remain a fully integrated biopharmaceutical company. 17.7.95 (2750 WORDS)<P>

<B><A HREF="../../archive/1995/2qtr/0508b1.htm">biosys, the Consolidator</A></B><BR>

This story discusses efforts by biosys to consolidate biopesticide developers. BIOSs merger with AgriDyne Technologies Inc. follows its acquisition of Crop Genetics International. 8.5.95 (650 WORDS)<P>

<B><A HREF="../../archive/1995/1qtr/0327b1.htm">Pfizergen Network Takes Shape</A></B><BR>

Pfizergen is a network of strategic alliances announced by Pfizer Central Research.  Its purpose is to marry genetic research and biotechnology to traditional drug discovery methods. Pfizer currently has five strategic alliances with biotech companies and expects to announce more. 27.3.95 (750 WORDS)<P>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/homepg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-203</DOCNO>
<DOCOLDNO>IA064-000380-B023-150</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/allpart/allpart.htm 206.86.52.80 19970112101940 text/html 5244
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:19:43 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5062
Last-modified: Thu, 26 Sep 1996 23:59:17 GMT
</DOCHDR>

<HTML>
<BODY background = "../../graphics/white-mi.gif">

<HEAD><TITLE> Alliances & Partnering</TITLE></HEAD>
<P>
<B><A HREF ="/BioCentury2/archive/1996/1qtr/031996ex.htm"> Behind the Athena-Elan deal </A></B><br>
This story describes the motivations behind the merger of Athena Neurosciences and Elan Corp. plc. March 19, 1996 (1,220 words).<P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/011596a1.htm"> Trading Technology </A></B><BR>
This article describes a new approach used by Sosei Co. Ltd. to link emerging technology in the U.S. and Europe with collaborators in Japan. Jan. 15, 1996 (1,900 words).<P>

<B><A HREF ="../../archive/1995/4qtr/1113a1.htm">How Arris and Khepri reached a merger </A></B><BR>
The planned merger of Khepri Pharmaceuticals Inc. into Arris Pharmaceutical Corp. reflects the critical choices facing early- to mid-stage biotechnology companies. This article discusses the factors of technology development, financing and strategy that the companies considered in deciding to merge their protease-based drug programs. Nov. 13, 1995 (1,100 words)

<B><A HREF ="../../archive/1995/4qtr/1023a1.htm">Partnering in Korea</A></B><BR>
Looking beyond Japan, companies in North America and Europe may be finding Korea as a potential market for biotech partnering. This article reviews transactions constructed in Korea by Aviron and Neoprobe Corp. It describes how Korea offers a market with its own history and its own business customs that biotech companies will need to learn before making deals. Oct. 23, 1995 (3,250 words)
<P>
<B><A HREF ="../../archive/1995/3qtr/0918a1.htm">Wishful thinking</A></B><BR>
Conflicting pressures involving both corporate collaborations and the demands of 
investors invite biotechnology companies to make their market size projections 
as large as possible. This article analyzes the problems this presents in reaching 
partnership deals. Sept. 18, 1995 (3,350 words)


<B><A HREF="../../archive/1995/2qtr/0626a1.htm">Amylin's New Deal</A></B><BR>
This story discusses Amylin Pharmaceuticals Inc.'s change of partners, aligning with Johnson & Johnson to cover the scientific and financial risk of getting its AC137 amylin agonist compound from Phase II trials through product launch in the diabetes area. Glaxo-Wellcome is out of scientific development but maintains an equity position in Amylin. 26.6.95 (1870 WORDS)<P>

<B><A HREF="../../archive/1995/2qtr/0605a1.htm">Pharma Partners for Biotech</A></B><BR>
In this story, pharmaceutical executives describe what they want to see from biotechnology companies as potential partners. Key is science, followed by intellectual property. (2575 WORDS). A related story,<A HREF="../../archive/1995/2qtr/0605a4.htm"> Explaining Valuations</A>, explains the difference between valuations in pharma deals vs. stock market offerings. 5.6.95 (650 WORDS)<P>


<B><A HREF="../../archive/1995/2qtr/0522b1.htm">Aviron Finds Korean Partner</A></B><BR>
This story explains the significance of Aviron's collaboration with Sang-A, a Korean pharmaceutical company and member of Hanbo group. The quickly concluded deal culminated a widening of the vaccine company's search partners. 22.5.95 (750 WORDS)<P>

<B>Chiron's Gene Therapy Efforts</B><BR>
These two stories describe Chiron's program to build its gene therapy program. The first story describes Chiron's access to <A HREF="../../archive/1995/2qtr/0410b1.htm">Progenitor Inc.'s </A> nonviral delivery and expressions systems. 10.4.95(550 WORDS)<P>

The second story discussed the terms and implications of Chiron's acquisition of <A HREF="../../archive/1995/2qtr/0425a1.htm">Viagene Inc. </A>25.4.95 (1250 WORDS)<P>

<B><A HREF ="../../archive/1995/1qtr/0306a3.htm">Isis: The Power Positioning Deal</A></B><BR>
The analysis reviews plans by Isis Pharmaceuticals Inc. and Boehringer Ingelheim International Gmbh to combine their R&D programs to focus on inflammatory diseases. Key is the ability to combine broad platform technologies or build disease management portfolios. 6.3.95 (1300 WORDS)<P>

<B><A HREF="../../archive/1995/1qtr/0213a1.htm">Reasons to Take Over Amgen</A></B><BR>
This story discusses the reaction of six leading Wall Street analysts to a frenzied week of trading of Amgen stock based on takeover rumors. They argue that the costs of the deal could outweigh benefits for the buyer and AMGN's shareholders. 13.2.95 (1900 WORDS)<P>

<h5><HR>

<A HREF="http://www.sosei.com/home.html"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/homepg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-204</DOCNO>
<DOCOLDNO>IA064-000380-B023-187</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/regul/regul.htm 206.86.52.80 19970112101949 text/html 2224
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:19:54 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2042
Last-modified: Thu, 08 Feb 1996 23:23:56 GMT
</DOCHDR>

<HTML>
<BODY background = "../../graphics/white-mi.gif">
<HEAD><TITLE>PUBLIC POLICY & REGULATION</TITLE></HEAD>

<H1><CENTER>Public Policy & Regulation</H1></CENTER><P>


<B><A HREF="../../archive/1995/3qtr/0724a1.htm">What to Disclose</A></B><BR>

The Commentary asks how the public benefits from the U.S. FDA's strict interpretation of rules governing promotion of clinical trial data. The article states that the FDA should be required to show that the public's health is jeopardized by pre-approval announcements. 24.7.95 (2,600 WORDS)<P>

<B><A HREF="../../archive/1995/2qtr/0515a1.htm">Religious Move to Stop Gene Patents</A></B><BR>

A coalition of U.S. church groups is working with Jeremy Rifkin's Foundation of Economic Trends to stop patenting of human and animal genes and transgenic animals. This story describes the political campaign from both points of view. (1,300 WORDS) The <A HREF ="../../archive/1995/2qtr/0515a3.htm">Appeal for Petitioners </A>is the full text of a letter sent to religious leaders from organizers of the patent protest. (1,500 WORDS) 15.5.95<P>


<B><A HREF="../../archive/1995/2qtr/0417a1.htm">Power of Zero</A></B><BR>

This commentary discusses value creation by biotechnology companies and uses a multiplicative model to demonstrate the arbitrary power the U.S. FDA has to wipe out a project's accrued value. 17. 4.95 (1,375 WORDS)<P>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>



</DOC>
<DOC>
<DOCNO>WT03-B24-205</DOCNO>
<DOCOLDNO>IA064-000380-B023-224</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/tech/tech.htm 206.86.52.80 19970112101958 text/html 5547
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:20:03 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5365
Last-modified: Thu, 05 Sep 1996 23:07:41 GMT
</DOCHDR>

<HTML>
<BODY background = "../../graphics/white-mi.gif">
<HEAD><TITLE>TECHNOLOGY</TITLE></HEAD>



<H1><CENTER>Technology</H1></CENTER>
<p>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/031196b1.htm"> Emerging Company Profile: MitoKor </A></B><br>
This story describes technology developed by MitoKor to focus on diseases mediated by defects in mitochondrial DNA, especially in neurodegenerative and metabolic disorders. March 11, 1996 (1,210 words).<p>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/030496b1.htm"> Emerging Company Profile: Inflammatics Inc.</A></B><br>
This story describes plans by Inflammatics to develop a cell-based immunotherapeutic vaccine for rheumatoid arthritis and other autoimmune reactions. March 4, 1996 (5,570 words).<p>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/022696b1.htm"> Emerging Company Profile: Biotrin Holdings Ltd.</A></B><br>
This story describes Biotrin's biomarkers to detect demage and treatment effects in transplanted organs. Feb. 26, 1996 (1,500 words).<P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/010896b1.htm"> Emerging Company Profile: BioNumerik </A></B><BR>
This article describes BioNumerik Pharmaceuticals Inc.'s drug discovery program using supercomputers and molecular simulation software. Jan. 8, 1996 (1,150 words).<p>

<B><A HREF ="/BioCentury2/archive/1995/4qtr/121895b1.htm"> Emerging Company Profile: Jenner Technologies </A></B><BR>
This article describes Jenner Technologies Inc.'s technology for developing recombinant therapeutic vaccines for cancer. Dec. 18, 1995 (4,000 words).<p>


<B><A HREF ="/BioCentury2/archive/1995/4qtr/121195a4.htm"> U.S. NIH Report on Gene Therapy </A></B><BR>
This article summarizes a report to the Director of the National Institutes of Health. It concludes that the prospects for immediate clinical progress in gene therapy have been exaggerated. Dec. 11, 1995 (1000 words). The full report is posted on http://www.nih.gov/news<P>

<B><A HREF ="/BioCentury2/archive/1995/4qtr/1120a7.htm">Emerging Company Profile: Desmos</A></B><BR>
This article describes Desmos Inc.'s programs, which are focused on internal applications of tissue adhesion. The company is working on tissue engineering, cell therapy and organ transplantation. Nov. 20, 1995. (950 words)
<P>

<B><A HREF ="/BioCentury2/archive/1995/4qtr/1106c1.htm">Emerging Company Profile Exelixis</A></B><BR>

This article describes Exelixis Pharmaceuticals Inc.'s functional genomics program. The company uses living models to elucidate the connection between genes and disease in order to optimize drug targets. Nov. 6, 1995 (1,050 words).<p>


<B><A HREF ="../../archive/1995/4qtr/1023a8.htm">Emerging Company Profiles</A></B><BR>

BioCentury has begun a new weekly feature that profiles new biotechnology companies. This article on Apollon Inc. is one such profile. It describes Apollon's technology for facilitated DNA injections for vaccine or gene therapy. Oct. 23, 1995 (1,000 words).

<p>
<B><A HREF ="../../archive/1995/3qtr/0925a1.htm">Entrepreneural Europe</A></B><BR>

An increase in biotechnology ventures in Europe is causing discussion about 
whether entrepreneural enterprises are beginning to flower in Europe. This week 
on BioGlobe, BioCentury offers profiles of three such early stage companies, 
which are developing chimeric technology, gene therapy and "combinatorial 
biology." Sept. 25, 1995 (1,050 words)
<p>


<B><A HREF="../../archive/1995/3qtr/0731a1.htm">Sorting Out Fat From Fiction</A></B><BR>
This story addresses the publicity created by Amgen's OB mice and the dramatic increase in Amgen's market capitalization, and discusses what remains unknown about the human applications. (2,480 WORDS) In a related story, <A HREF="../../archive/1995/3qtr/0731a3.htm">Clinical Results</A>, three articles from <I>Science</I> authored by AMGN, Roche, and Rockefeller University are summarized. (2,400 WORDS) 31.7.31 <P>


<B><A HREF="../../archive/1995/2qtr/0612b1.htm">Questions About Amgen's Lead in TPO Race</A></B><BR>
In this story, Robertson, Stephens analyst Edward Hurwitz says Amgen's lead in thrombopoietin may be tenuous. He speculates that AMGN is developing a truncated version of TPO in order to be first to market. 12.6.95 (790 WORDS)<P>


<B><A HREF="../../archive/1995/1qtr/0221a1.htm">ALS Setback Raises Some Root Issues</A></B><BR>
This story discusses the implications of the demise of the Syntex/Synergen program in amyotrophic lateral sclerosis. It notes development of drugs to treat ALS has been slowed by lack of understanding of the disease and the absence of animal models. 21.2.95 (1,400 WORDS)<P>


<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>






</DOC>
<DOC>
<DOCNO>WT03-B24-206</DOCNO>
<DOCOLDNO>IA064-000380-B023-255</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/fi/fi.htm 206.86.52.80 19970112102010 text/html 2889
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:20:12 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2707
Last-modified: Thu, 08 Feb 1996 23:16:24 GMT
</DOCHDR>

<HTML>
<BODY background = "../../graphics/white-mi.gif">
<HEAD><TITLE>FINANCE & INVESTMENT</TITLE></HEAD>



<H1><CENTER>Finance & Investment</H1></CENTER>


<B><A HREF="../../archive/1995/3qtr/0807a1.htm">Biotech Bulls</A></B><BR>
This story describes the emergence of a long-awaited rally in biotechnology stocks. The rally is supported by increasing share prices based on fundamentals and macroeconomic events. But the relative absence of new investors, continued investor preference for mature companies, and sluggishness of initial public offerings indicate that the market will be selective. 7.8.95 (3000 words)<P>


<B><A HREF="../../archive/1995/1qtr/0227a1.htm">The Intersection of Art and Technology</A></B><BR>
This story discusses return on investment at it applies to technology service providers in the biotechnology sector. Interviews with executives from drug discovery and enabling technology companies provide a framework for valuation of genomics, combinatorial chemistry and drug screening companies. 27.2.95<P>


<B><A HREF="../../archive/1995/1qtr/0109b1.htm">Kleiner Perkins Breaks its Rules</A></B><BR>
This feature discusses a new business and financing model at Corixa Corp. applied by the venture capital firm Kleiner Perkins Caufield & Byers. With previous start-ups built almost solely around differentiating technology, the now uncertain financing environment for biotechnology has prompted the firm to put together a top management team and a significant financing package for Corixa, which is developing T cell vaccines. 9.1.95 (780 words)<P>


<B><A HREF="../../archive/1995/1qtr/0103a1.htm">Capitalist Road</A></B><BR>
This commentary analyzes 1994 market performance compared with industry fundamentals and looks ahead to 1995.  The BioCentury 100 Index was down 29% in 1994 on top of an 18% decline in 1993. Yet this performance may be "normal" for this stage of industry development.  Investment in 1995 will focus on companies with advanced products, cash and financial resources. 3.1.95 (2,350 words)<P>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>




</DOC>
<DOC>
<DOCNO>WT03-B24-207</DOCNO>
<DOCOLDNO>IA064-000380-B023-298</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/about/about.htm 206.86.52.80 19970112102021 text/html 3444
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:20:26 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3262
Last-modified: Thu, 08 Feb 1996 21:10:25 GMT
</DOCHDR>
<HTML>
<HEAD><BODY background = "../graphics/white-mi.gif"> </HEAD>


<H1><CENTER>About BioCentury(TM)</H1></CENTER><P>

BioCentury, the Bernstein Report on BioBusiness, is the leading U.S. publication focused on bioscience industry development, corporate performance and valuations. Its goal is to be the most thoughtful and complete U.S. publication serving the biotechnology industry today.<P>

BioCentury is delivered via facsimile or electronic mail each weekend (U.S. time). It covers current trends in management issues, company formation, clinical activities, partnering and financial strategies and public policy. When events demand more immediate coverage, BioCentury Extra editions are sent via fax or email during the week.<P>

Editor-in-Chief Karen Bernstein, Ph.D., is among the most respected and independent bioscience analysts in the U.S. Through her personal connections to hundreds of biotechnology executives, financiers, investors and consultants, Dr. Bernstein's analysis reflects the current thinking of the most influential leaders in the industry.<P>

BioCentury's analytical approach is complemented by a complete report of each week's news, organized into sections devoted to alliances and other business announcements, clinical trial reports, and stock market information.<P>

These efforts are supported by a prominent panel of Editorial Advisors, representing the corporate sector and investment community.<P>

BioCentury supplements its publishing activity by sponsoring conferences on Wall Street that have been well-attended by institutional investors and bioscience companies from North America and Europe. The conferences, like the journal, provide the industry with an independent forum for discussion, analysis and debate.<P>

A growing audience of senior company managers and institutional investors in North America, joined by increasing numbers of readers in Europe, consider BioCentury to be a most useful tool for industry surveillance in the U.S. We hope that our information proves to be as valuable to our Japanese audience.<P>

<H4>Find Out More</H4><P>

<A HREF="../edit/edit.htm">BioCentury Editorial Advisory Board</A>: A list of advisors from the corporate and financial communities.<P>

<A HREF="test.htm">Testimonials by BioCentury readers</A>: Comments from subscribers about BioCentury's information service.<P>

<A HREF="../sample/sample.htm">Sample issues</A>: See complete editions of BioCentury and BioCentury Extra<P>

<A HREF="../commun/comm.htm">Communicating with BioCentury</A>: How to send messages to BioCentury and its editors.<P><P>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/homepg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>




</DOC>
<DOC>
<DOCNO>WT03-B24-208</DOCNO>
<DOCOLDNO>IA064-000380-B024-18</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/commun/comm.htm 206.86.52.80 19970112102029 text/html 1330
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:20:34 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1148
Last-modified: Thu, 08 Feb 1996 21:34:14 GMT
</DOCHDR>
<HTML>
<BODY background = "../graphics/white-mi.gif">


<H1><CENTER>Send electronic mail to BioCentury: </H1></CENTER><P>

Online communications: BioCentury's editorial, subscription and business departments are at the same address: <A HREF="mailto:schmtter@cris.com">biocenturypub@sosei.com.</A><P>

Our postal address is:<BR>
BioCentury Publications Inc.<BR>
PO Box 1246<BR>
San Carlos CA 94070-1246<BR>
USA<P>

Our phone numbers are:<BR>
Voice: 415/595-5333<BR>
Fax: 415/595-5589<P>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/homepg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>




</DOC>
<DOC>
<DOCNO>WT03-B24-209</DOCNO>
<DOCOLDNO>IA064-000380-B026-36</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/about/test.htm 206.86.52.80 19970112102614 text/html 3244
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:26:18 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3062
Last-modified: Thu, 08 Feb 1996 21:32:08 GMT
</DOCHDR>
<HTML>
<BODY background = "../graphics/white-mi.gif">


<H1><CENTER>Testimonials by BioCentury readers</H1></CENTER><P>


<I>"Most other publishing companies in the life sciences world simply rewrite press releases.  BioCentury is different.  It helps me stay on top of the trends.  In fact, I often beg, borrow and 'steal' ideas from BioCentury.  It's the most efficient use of my time."</I><BR>
			        	       -- G. Steven Burrill, Managing Director, Burrill & Craves<P>

<I>"Karen Bernstein knows the undercurrents of the industry.  She effectively connects the dots of what's going on in biotech and brings the relationship of those events into focus.  I get a deeper understanding of the news when I read BioCentury.  It provides me with the insight I need as a CEO."</I><BR>
				         -- David Holveck, Chief Executive Officer, Centocor Inc.<P>

<I>"BioCentury is far more than a collection of the week's press releases.  It's insightful and thought-provoking.  I just wish you didn't share it with my competitors."</I><BR>
				                                        -- Skip Klein, Analyst, T. Rowe Price<P>

<I>"In addition to being very strong scientifically, Karen Bernstein ties together events and deals into themes that explain where biotech is headed. And, because of her extensive industry contacts, she knows who has influence.  She's a very strong spokesperson for the industry."</I><BR>
				                   	-- Alan C. Mendelson, Partner, Cooley Godward <P>

<I>"I rank BioCentury at the top of the pile when it comes to covering issues affecting biotechnology in Washington."</I><BR>
				                                      -- Marc Ostro, Analyst, UBS Securities<P>

<I>"BioCentury is essential because it keeps me abreast of the U.S. trends.  As a senior manager of a Canadian biotech company, I have to know what's going on in the U.S.  It's where the industry's trends are set.  It's where we consummate deals and continue to grow in this difficult environment."</I><BR>
			-- Graham Strachan, President & CEO, Allelix Biopharmaceuticals Inc.<P>

<I>"How could anyone in biotech, especially small company CEOs, not view BioCentury as required weekly reading?  It's a market research report, and strategic business consulting report, delivered to your office every Monday morning."</I><BR>
			   -- Thomas Wiggans, President & CEO, Connective Therapeutics Inc.<P><P>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>



</DOC>
<DOC>
<DOCNO>WT03-B24-210</DOCNO>
<DOCOLDNO>IA064-000380-B026-64</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/sample/sample.htm 206.86.52.80 19970112102621 text/html 2067
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:26:27 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1885
Last-modified: Thu, 08 Feb 1996 22:58:09 GMT
</DOCHDR>
<HTML>


<BODY background = "../graphics/white-mi.gif">
<H1><CENTER>Sample issues</H1></CENTER><P>

To see a complete edition of BioCentury as it is published in English, you must use Adobe's Acrobat(TM) Reader. This easy-to-use software is available without charge for Macintosh, Windows, DOS, SunOS and Solaris systems. The Acrobat technology will allow you to see the documents exactly as they were designed, as well as to search the text and to make annotations directly on the document. The Acrobat Reader, as well as instructions for downloading and installing it, are available from <A HREF="http://www.adobe.com/Software.html">Adobe.</A> <p>
<p>
<A HREF="../pdfs/1995/3qtr/0731bc.pdf">BioCentury, 31 July 1995, Part 1</A><BR>
<A HREF="../pdfs/1995/3qtr/0731bc2.pdf">BioCentury, 31 July 1995, Part 2</A><BR>
<A HREF="../pdfs/1995/3qtr/0731bc3.pdf">BioCentury, 31 July 1995, Part 3</A><BR>
<A HREF="../pdfs/1995/3qtr/0816xtra.pdf">BioCentury extra, 16 August 1995</A><P>


You also can receive current editions of BioCentury each week for a four-week trial subscription period. This trial service is free. Use <A HREF="../commun/online.htm">Online Delivery of BioCentury</A>: to arrange for this trial subscription.<P>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/homepg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>


</DOC>
<DOC>
<DOCNO>WT03-B24-211</DOCNO>
<DOCOLDNO>IA064-000380-B026-99</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/commun/online.htm 206.86.52.80 19970112102635 text/html 3660
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:26:37 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3478
Last-modified: Thu, 08 Feb 1996 21:39:23 GMT
</DOCHDR>
<!Online Delivery of BioCentury->

<HTML>

<BODY background = "../graphics/white-mi.gif">

<HEAD><TITLE>BioCentury ICzB@</TITLE></HEAD><BODY>



<H1><CENTER>BioCentury ICzB@</CENTER></H1>

<!You may have BioCentury sent to you in one of two ways.->
Q@P BioCentury B
<!You may download BioCentury from a special area on BioGlobe using a password. ->
pX[hp BioGlobe  BioCentury _E[hB
<!This password will be provided to you. ->
pX[hB
<!Alternatively, you may have BioCentury sent directly to you via electronic mail.->
ABioCentury dq[B<P>

<!You may receive this service for four weeks without charge.->
STT[rXB<P>

<!Later, as a BioGlobe subscriber, you will benefit from a lower price by using the Internet if you choose to subscribe after the trial period. ->
ABioGlobe wAwwAInternet 
piB
<!This is because BioCentury can be made available to you at the same price as is charged in the United States: US$860 (83420 as of 21 Aug. 1995 when US$1 =97). ->
 BioCentury AJiB 
US 860hi83,420~F1995NW21 US 1h97~j
<!By comparision, higher telecommunications costs require us to charge$2000 (194000) to deliver BioCentury via facsimile.->
AMot@bNX BioCentury  
US2,000hi194,000~jB<P>

<!To download BioCentury, you must use Adobe's Acrobat(TM) Reader.->
BioCentury _E[h Adobe  Acrobat(TM) Reader gB
<!This easy-to-use software is available without charge for Macintosh, Windows, DOS, SunOS and Solaris systems.->
g\tgEFA MacintoshAWindowsADOSASunOS  Solaris VXepB
<!The Acrobat technology will allow you to see BioCentury exactly as it appears in print, as well as to search the text and to make annotations directly on the document.->
Acrobat eNmW[eLXg{AlAm BioCentury 
\B 
<!The Acrobat Reader, as well as instructions for downloading and installing it, are available from Adobe.->
Acrobat Reader  _E[hCXg[gplA
<A HREF="http://www.adobe.com/Software.html">Adobe.</A> B<P>

<!To proceed, go to Ordering BioCentury.->
iA<A HREF="orderbio.htm">Ordering BioCentury iB</A>.<P>


<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of 
BioCentury Publications Inc. All other trade marks are the property of their 
respective owners. </H5><P>



</BODY></HTML>



</DOC>
<DOC>
<DOCNO>WT03-B24-212</DOCNO>
<DOCOLDNO>IA064-000380-B024-51</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/commun/orderbio.htm 206.86.52.80 19970112102041 text/html 3293
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:20:44 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3111
Last-modified: Thu, 08 Feb 1996 22:40:29 GMT
</DOCHDR>
<HEAD>
<HTML>
<BODY background = "../graphics/white-mi.gif">


<TITLE>Ordering BioCentury</TITLE></HEAD><BODY>


<CENTER><I><H1>Ordering BioCentury Online</H1></I></CENTER>

<P>
Thank you very much for your interest. Please provide the information requested below. Please use Roman characters. Please read the following before completing this order document:<P>


Upon receipt of this order, BioCentury Publications Inc. will provide you with access to BioCentury for four weeks. You will not be charged for this trial subscription period. You also have no obligation to subscribe after the trial.<P>


By sending us this order, you are acknowledging that you have read the instructions regarding the Adobe Acrobat(TM) Reader on the <A HREF="onlinek.htm">previous page</A> and understand that Acrobat is required to read the downloaded BioCentury pages.<P>

Please select one of the two choices below, which will determine how you will receive BioCentury:

<HR>

<FORM METHOD="POST" ACTION="../../cgi/bcform.cgi">
<P>

<INPUT TYPE="radio" NAME="serve" VALUE="Choice 1: Password"><FONT SIZE=5> Choice 1: </FONT> I would like to receive a free trial of BioCentury from BioGlobe using a password. I understand that I will be provided with a password, which will expire after th

e trial period unless I choose to subscribe.<P>

<INPUT TYPE="radio" NAME="serve" VALUE="Choice 2: Email"> <FONT SIZE=5>Choice 2: </FONT> I would like to receive a free trial of BioCentury using electronic mail.
I understand that some corporate electronic mail systems do not permit the downloading of files from outside the company. If this is the case, I will be provided with a password for obtaining BioCentury from BioGlobe.

<p>Finally, please provide the following in Roman characters:
<PRE>
Name:                            <INPUT TYPE="text" NAME="name" SIZE="40">
Title:                           <INPUT TYPE="text" NAME="title" SIZE="40">
Company:                         <INPUT TYPE="text" NAME="company" SIZE="40">
Address 1:                       <INPUT TYPE="text" NAME="address1" SIZE="40">
Address 2:                       <INPUT TYPE="text" NAME="address2" SIZE="40">
Telephone: (include city code):  <INPUT TYPE="text" NAME="telephone" SIZE ="20">
Facsimile: (include city code):  <INPUT TYPE="text" NAME="facsimile" SIZE="20">
Electronic mail address:         <INPUT TYPE="text" NAME="email" SIZE="40">
<HR></PRE>


<INPUT TYPE="submit" VALUE="Send in the order!">
<INPUT TYPE="reset" VALUE="Clear the order form">
<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>



</DOC>
<DOC>
<DOCNO>WT03-B24-213</DOCNO>
<DOCOLDNO>IA064-000380-B023-49</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/commun/onlinek.htm 206.86.52.80 19970112101856 text/html 2329
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:19:01 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2147
Last-modified: Thu, 08 Feb 1996 21:41:40 GMT
</DOCHDR>

<HTML>
<BODY background = "../graphics/white-mi.gif">


<HEAD><TITLE>Ordering BioCentury</TITLE></HEAD><BODY>


<H1><CENTER>BioCentury ICzB</CENTER></H1>

Q@P BioCentury B<P>

pX[hp BioGlobe XyVAEGA BioCentury _E[hBpX[hB<P>

ABioCentury C[B<P>

ST'T[rXB<P>

<ABioGlobe !w"AwwAInternet piB <P>

 BioCentury AJiB US 860hi83,420~F1995NW21 US 1h97~j<P>

AMot@bNX BioCentury  US2,000hi194,000~jB
<P>

BioCentury _E[h Adobe  Acrobat(TM) Reader gB<P>

g\tgEFA MacintoshAWindowsADOSASunOS  Solaris VXepB<P>

Acrobat eNmW[eLXg{AlAm BioCentury \B<P>

Acrobat Reader  _E[hCXg[gplAAdobe B<P>

<A HREF="http://www.adobe.com/Software.html">Adobe.</A> <P>

iAOrdering BioCentury iB<P>

<A HREF="orderbio.htm">BioCentury </A>.<P>


<H5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-214</DOCNO>
<DOCOLDNO>IA064-000378-B002-74</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/nisshin.html 206.86.52.80 19970112095119 text/html 4305
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:51:24 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4123
Last-modified: Sun, 21 Jul 1996 17:51:02 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Nisshin Oil</TITLE></HEAD>
<BODY BGCOLOR=#FFFFFF>

<H1>The Nisshin Oil Mills, Ltd.</H1><H3>Corporate Profile</H3>
<HR>
(Head Office):1-23-1, Shinkawa<BR>
Chuo-ku, Tokyo, 104 JAPAN<BR>
Telephone: +81-(0)3-3206-5122<BR>
Fax: +81-(0)3-3206-6458<P>

<B>Key Personnel in Head Office:</B>
<UL><LI> Shigeo Nonoyama, General Manager, Pharmaceutical Division
<LI> Yukio Matsumoto, Manager, Development Dept., Pharmaceutical Division
</UL>

<B>Research Laboratory:</B><BR>
3-1, Chiwaka-cho, Kanagawa-ku,<BR>
Yokohama-shi, Kanagawa, 221, JAPAN<BR>
Telephone (Research Laboratory): +81-(0)45-461-0155<BR>
Fax (Research Laboratory): +81-(0)45-461-2350<P>

<B>Key Personnel in Research Laboratory:</B><BR>
<UL><LI> Naohumi Takahashi, Scientist, Pharmaceutical Division
</UL>

<B>Employees:</B> 1,512 (89 in Pharmaceutical Division)<P>

<B>Facilities:</B><BR>
Head office and 9 branches<BR>
2 plants in Yokohama & Kobe (The area of Yokohama plant is 233,000 square meters)<BR>
Central Research Laboratory in Yokohama<P>

<B>Date Established:</B> March 7, 1907<P>

<B>Subsidiaries:</B> 24 subsidiaries, 12 affiliates including middle scale pharmaceutical company, Kobayashi Seiyaku Kogyo<P>

<B>Legal Form:</B> Stock Company

<B>Financial Information (1994):</B>
<UL><LI> Net sales <137 billions yen>
<LI> Total assets <169 billion yen>
<LI> Operating income <6.7 billions yen>
<LI> Net income <2.5 billions yen>
</UL>

<B>Corporate Overview (Business Strategy):</B>
<BLOCKQUOTE>Nisshin Oil is a top producer of cooking oils and fats in Japan.
Through its long terms of experience in the oils and fats processing area Nisshin Oil have gained various techniques concerning oils and fats chemistry as well as the applied food technologies. Nisshin Oil launched to extend its business to the pharmaceutical areas as one of the diversified managements in 1987.  Nisshin Oil is mainly engaged in synthesizing and developing several kinds of lipids such as glyco lipids with its own proprietary technology, and, furthermore, is developing novel oral preparation of vaccines through collaboration with Japanese National Institute of Health as well. Emphasis is being place on the areas such as immunostimulants, immunosuppressants, carcinostatics, cancer-diacrisis and so on. Also, Nisshin Oil is interested in cooperating with established drug companies on an individual product basis especially in drugs related to allergy, genitourinary disease, immunology, diabetes, osteoporosis, cancer, rheumatoid arthritis, intracellular Ca2+ antagonist or agonist, dermatosis and other characteristic drugs on the niche area.</BLOCKQUOTE><P>

<B>Products in Research:</B><BR>
<OL><LI>Orally-active intestinal elution formulation system for the delivery of vaccines such as influenza (Joint development with Japanese NIH)<BR>
<LI>Muramyl peptide derivatives as immunomodulators<BR>
<LI>Monoclonal antibodies as diagnostics<P>
</OL>

<B>Products on Market:</B><BR>
<OL><LI>Mexirate (mexiletine HCl) : arrhythmia
<LI>Ritodol (ritodrine HCl) : threatened premature delivery
<LI>Calfina (alfacalcidol) : osteoporosis</OL>

<B>Board of Director:</B><BR>
<UL><LI> President: Mitsuo Fukawa
<LI> Senior Managing Directors: Akashi Sera, Hiroyuki Sakaguchi, Jokei Akitani
<LI> Managing Directors: Hiyoshiro Yamada, Kohji Kawa, Hiromichi Shimizu, Kenjiro Tanaka
<LI> Directors: 11 people including Minoru Fukuta (Pharmaceutical Division)
<LI> Statutory Auditors: 3 people
</UL><P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!-- INFORMATION ABOUT THE CONTACT PERSON FILLING OUT THIS FORM

Name: Yukio Matsumoto 
Title: Manager
Address: 1-23-1, Shinkawa, Chuo-ku, Tokyo, 104 JAPAN
City: Tokyo
State: Tokyo
Zip Code: 104
Telephone Number: 81-3-3206-5122
Fax Number: 81-3-3206-6458 >

<!-- Subject Terms:
Glyco lipid, oral vaccine, Monoclonal antibody, Muramyl peptide >

</HTML>


</DOC>
<DOC>
<DOCNO>WT03-B24-215</DOCNO>
<DOCOLDNO>IA064-000378-B003-229</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/PressNews/soseipr1.html 206.86.52.80 19970112095556 text/html 2937
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:56:03 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2755
Last-modified: Fri, 24 May 1996 03:09:01 GMT
</DOCHDR>
<HTML><BODY BGCOLOR=#FFFFFF>For Immediate Release<P>

<A HREF="../Companies/sosei.html">SOSEI CO., LTD.</A> APPOINTS PROFESSOR BARUCH S. BLUMBERG,
A NOBEL PRIZE LAUREATE, TO BOARD DIRECTOR AND SCIENTIFIC ADVISOR<P>

TOKYO -- JUNE, 1995 --<A HREF="../Companies/sosei.html">Sosei Co., Ltd.</A> today announcedthe appointment of Professor Baruch S. Blumberg who discovered the Hepatitis B Virus, and with his colleague Irring Millman invented the hepatitis B Crossing, to the position of Board Director and Scientific Advisor.<P>

	Professor Blumberg spent his career in medicine and was the Master of Balliol College at Oxford University from 1989 to 1994, currently has an appointments at the Fox Chase Cancer Center in Philadelphia, Pennsylvania. Professor Blumberg has been awarded several scientific prizes including the Nobel Prize for Physiology and Medicine for 1976. Other prizes were Modern Medicine Disting. Achievement award, Internat. award Gairdner Found., Karl Landsteiner Meml. award of the Am. Assn. Blood Banks and others. He is a Fellow Nat. Acad. Scis., Royal Coll. Physicians' mem, Assn. Am. Physicians, Am. Soc. Clin. Investigation mem., Am. Soc. Human Genetics mem. etc.<P>

 	"We are pleased and extremely fortunate to have Professor Blumberg join <A HREF="../Companies/sosei.html">Sosei</A>," commented Mr. Tamura, <A HREF="../Companies/sosei.html">Sosei's</A> President and CEO. "He brings with him the operational skills and strategic talent in research and development needed to bring our company and products into the pharmaceutical market. He will advise in the biopharmaceutical field, especially our original projects in liver disease including the Hepatocyte Growth Factor, at <A HREF="../Companies/sosei.html">Sosei</A>."<P>

     	<A HREF="../Companies/sosei.html">Sosei's</A> desire is to become the most reliable "cultural interpreter" between innovative biotech firms in the U.S./Europe and medical and pharmaceutical companies and research labs in Japan by;<P>

1. Accessing novel biopharmaceutical science in Japan by expediting the licensing and commercialization of university discovered technologies.<BR>
2. Developing strategic licensing arrangements with such science both inside and outside Japan.<BR>
3. Providing the most reliable platform in Japan for small biotech firms in the U.S. and Europe looking for Japanese corporate patners to establish the most efficient global R&D strategy.<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-216</DOCNO>
<DOCOLDNO>IA064-000378-B002-151</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/fujisawa.html 206.86.52.80 19970112095154 text/html 9075
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:51:57 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 8893
Last-modified: Sun, 21 Jul 1996 23:35:25 GMT
</DOCHDR>
<HTML> 
<HEAD><TITLE>Fujisawa Pharmaceutical Co., Ltd.</TITLE></HEAD> 
<BODY BGCOLOR=#FFFFFF>

<P><H2>Fujisawa Pharmaceutical Co., Ltd.</H2>
1-6, 2-chome, Kashima, Yodogawa-ku<BR>
Osaka 532<BR>
Telephone: 81-6-390-1132<BR>
Fax: 81-6-304-5726</P><HR>

<P>Employees: 7,800</P>

<P>Fujisawa Pharmaceutical Co., Ltd., which was founded more than 100 years ago, in 1894, is a leading pharmaceutical manufacturer based in Japan. Building on its proud history, the Company is steadily expanding its operations around the globe. Fujisawa has approximately 7,800 employees working at its various facilities, including those of its subsidiaries, scattered all over the world.</P>

<P>Fujisawa's research and development expenses, equivalent to 12.8% of net sales during fiscal 1995, and the large share of its R&D staff, about 23% of all employees, clearly illustrate the Company's firm commitment to R&D. Based on its corporate philosophy, "Challenging the unknown frontier known as humans and contributing to healthier, more prosperous lives for people around the world," Fujisawa remains committed to vigorous R&D efforts in its quest for innovative pharmaceutical products with true clinical significance and to making them available in the global market.</P>

<P><B><I>Summary of Business Results</I></B><BR>
Consolidated net sales for fiscal 1995 came to Y284.0 billion(US$3,191 million), up 4.4% on the previous term. In addition to higher sales, we were able to cut production costs in Japan and overseas and to curtail various expenses through higher operational efficiency and economy. Income before taxes and net income, however, dropped to Y25.8 billion(US$290 million) and Y5.4 billion(US$60 million), respectively. These declines are attributable to the absence of such special revenue as recorded for the previous term.</P>

<P><B><I>Investment</I></B><BR>
Plant and equipment investment during the term totaled Y10.6 billion(US$120 million), which mainly went to the upgrading of synthesizing facilities at our Osaka and Takaoka Plants and to the partial reconstruction of our Exploratory Research Laboratories in Tsukuba.</P>

<P><B><I>R&D Activities</I></B><BR>
Treating research and development as a top priority, we continued with brisk investment, spending a total of Y36.5 billion(US$410 million), roughly the same amount as in the previous year and representing 12.8% of net sales.</P>

<P>Turning to Prograf, after the drug was approved in Japan for the supplemental indication of treatment of graft versus host diseases in bone marrow transplantation in July 1994, an NDA was filed for prophylaxis of rejection in kidney transplantation in September 1994.</P>

<P>In other developments on the R&D front, after obtaining approval for the human growth factor mecasermin, we launched the drug in February 1995 under the name of Somazon. In January 1995, we filed ad NDA for the injectable cephalosporin antibiotic cefoselis. Other products under NDA examination in Japan are the hypnotic agent zolpidem and the oral antipollakiuria agent vamicamide.</P>

<P><B><I>Fujisawa on the World Stage</I></B><BR>
Fujisawa's international strategy began to take shape with the licensing out to overseas companies of the parental cephalosporin antibiotic cefazolin (Cefamezin in Japan) in the early 1970s, with the licensees being such leading companies as then SmithKline & French, Eli Lilly, and then Bristol Myers. Today, although it no longer enjoys patent protection, cefazolin is still marketed in over 60 countries worldwide as a standard antibiotic for infectious diseases. Another internationally successful original Fujisawa product is the oral cephalosporin cefixime (Suprax in the US). Sold in over 50 countries, cefixime boasts substantial market shares, particularly in Europe.</P>

<P>In 1981, the Company established a joint venture company, Fujisawa SmithKline Corporation, with then SmithKline & French of the US for its parental cephalosporin antibiotic ceftizoxime(Cefizox in the US). We gained the experience of developing ceftizoxime for the US market, as well as producing and marketing it there. As a result, we decided to establish a direct presence abroad, and since then have laid the groundwork for our own development and marketing of drugs overseas.</P>

<P>Meanwhile, seeing a bright future for healthcare in the US, in 1985 we acquired a stake in Lyphomed, Inc. to have another base in the US. This was followed by a friendly takeover of Lyphomed in 1989, and Fujisawa SmithKline Corporation was renamed Fujisawa Pharmaceutical Company. Similarly, we had acquired a stake in Klinge Pharma GmbH of Germany in 1983.</P>

<P>As the latest step in our international expansion directed at our own development of compounds and marketing in the world market, in April 1990 we merged Fujisawa Pharmaceutical Company and Lyphomed into the new subsidiary Fujisawa USA, Inc., which operates, together with PMP Fermentation Products, Inc., under Fujisawa Holding Company. In November 1991 we established Fujisawa GmbH in Munich,  
Germany, with the aim of directly developing and marketing our immunosuppressant Prograf in the European market. In 1992, the Ireland Plant was completed for the formulation of Prograf for the European and US markets. Our current international strategy takes a two-pronged approach to drug development and marketing: through our own overseas subsidiaries on the one hand, and through licensing alliances with active overseas companies on the other.</P>

<P><B><I>Review of Operations</I></B><BR>
Consolidated sales in fiscal 1995 amounted to Y284.0 billion(US$3,191 million), up 4.4% on the previous term. Net income for the term, however, dropped 26.3% to Y5.4 billion(US$60 million). Looking at results by area, sales in Japan came to Y242.3 billion(US$2,723 million), in the US to Y22.6 billion(US$254 million), in Europe to Y17.0 billion(US$191 million), and in Asia to Y2.1 billion(US$23 million), accounting for 85.3%, 8.0%, 6.0% and 0.7% of total sales respectively.</P>

<P><B><I>Net Sales by Product Line(Consolidated:FY1995)</I></B><BR>
Ethical Drugs 87.2%<BR>
Consumer Products 5.2%<BR>
Medical Equipment and Supplies 1.1%<BR>
Chemicals and Animal Health Products 6.5%</P>

<P><B><I>Sales of Ethical Drugs by Therapeutic Category</I></B><BR>
Antibiotics and Biological Preparations 34.9%<BR>
Nervous System, Sensory Organs and Antiallergic Drugs 19.7%<BR>
Cardiovascular and Respiratory System Drugs 18.6%<BR>
Digestive System Drugs 16.5%<BR>
Vitamins and Metabolic Drugs 4.6%<BR>
Others 5.7%</P>

<P><H3>Board of Directors and Auditors</H3></P>

<P><B><I>Representative Directors</I></B><BR>
Tomokichiro Fujisawa, Ph.D.<BR>
Chairman of the Board</P>

<P>Akira Fujiyama<BR>
President and Chief Executive Officer</P>

<P>Michio Iida<BR>
Senior Managing Director, Chief Financial Officer</P>

<P>Hatsuo Aoki, Ph.D.<BR>
Senior Managing Director, Chairman & CEO of Fujisawa USA, Inc.</P>

<P><B>Managing Directors</B><BR>

Toshio Fujii<BR>
Managing Director</P>

<P>Yoshihiro Horiguchi<BR>
Managing Director</P>

<P>Michiaki Imazumi<BR>
Managing Director, Sales & Marketing Division, Ethical Pharmaceuticals</P>

<P>Hitoshi Oyasu<BR>
Managing Director, Research & Development Division</P>

<P>Kyoji Murayama<BR>
Managing Director, Legal Affairs</P>

<P><B>Directors</B><BR>

Yoji Yoshida<BR>
Executive Director, General Administration<P>

<P>Hiroshi Yamamoto<BR>
Executive Director, Management Information System<P>

<P>Noboru Maeda<BR>
Managing Director of<BR>
Fujisawa Europe GmbH & Fujisawa GmbH

<P>Masanobu Kohsaka, Ph.D.<BR>
Executive Director, Product Research & Development Division<P>

<P>Toshio Konomi<BR>
Executive Director, Manufacturing Division, Ethical Pharmaceuticals</P>

<P>Shuji Inoue<BR>
Associate Executive Director, Ethical Pharmaceuticals Division</P>

<P>Takao Takaya, Ph.D.<BR>
Executive Director, Drug Discovery Division</P>

<P>Koichi Sejima<BR>
Executive Director, Human Resources</P>

<P>Hideo Tanaka<BR>
Executive Director, Tokyo Business Branch</P>

<P>Takeshi Shimomura<BR>
Associate Executive Director, Sales & Marketing Division, Ethical Pharmaceuticals</P>

<P><B>Auditors</B><BR>
Taketoshi Kuwabara<BR>
Atsushi Nakao<BR>
Masahiko Kinbara<BR>
Seihei Yamawaki<BR><P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_butto
n.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 11, 1996.
Copyright &copy; 1996 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!--INFORMATION ABOUT THE CONTACT PERSON FILLING OUT THIS FORM
Date: June 11, 1996

Name: Naoki Tani
Title: Senior Manager, Licensing Department, R&D Division
Address: 1-6, 2-chome, Kashima, Yodogawa-ku
City: Osaka
State: Osaka
Zip Code: 532
Telephone Number: 81-6-390-1132
Fax Number: 81-6-304-5726-->
</BODY> 
</HTML> 
</DOC>
<DOC>
<DOCNO>WT03-B24-217</DOCNO>
<DOCOLDNO>IA064-000378-B002-38</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/nisshinbo.html 206.86.52.80 19970112095110 text/html 5935
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:51:16 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5753
Last-modified: Sun, 12 May 1996 19:30:17 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Nisshinbo Industries, Inc.</TITLE></HEAD><BODY BGCOLOR=#FFFFFF>
<H1>Nisshinbo Industries, Inc.</H1><H3>Corporate Profile</H3><HR>

1-18-1, Nishiarai Sakaecho, Adachi-ku<BR>
Tokyo 123 Japan<BR>
Telephone: 81-3-3887-7801<BR>
Fax: 81-3-3886-3199<P>

<B>Employees:</B> 6,134<P>

<B>Facilities:</B> 
<UL><LI> Head Office in Tokyo
<LI> Osaka branch
<LI> Nagoya Branch
<LI> New York Representative Office
<LI> Detroit Representative Office
<LI> Nisshinbo do Brasil Industria Textil Ltd.
<LI> Nisshinbo California Inc. 
<LI> Nisshinbo Europe B.V.
</UL>

<B>Date Established:</B> February 5, 1907<P>

<B>Legal Form:</B> Corporation Public<P>

<B>Corporate Overview:</B><BR>
<BLOCKQUOTE>Nisshinbo Industries, Inc. was founded in 1907 as a manufacturer of cotton yarns and threads, and quickly assumed a position of leadership in the industry. The Company's history has been characterized by strategic moves taken in advance of competitors and designed to raise productivity, improve quality and add value--all in response to customers' needs. Today, Nisshinbo is a total textiles manufacturer, controlling operations from spinning to finishing. This gives the Company and advantage in the development of truly distinctive products and in quality control. Through the application in other fields of technologies and expertise originally accumulated in the textiles area,  Nisshinbo has diversified its operations into the manufacture of automobile brakes, machine tools, polyurethane foams, paper products, and label printing operations. Non-textile business now accounts for almost 40% of net sales and the intension is to increase this share to 50% or more within a context of overall growth. Nisshinbo has targeted certain strategic products to form the basis of this growth: VAF (value-added finishing) products, including the best-selling <B>SUPER SOFT PEACHPHASE</B>, new-generation anti-lock braking and traction control systems, CNC machine tools, and non-fluorocarbon polyurethane foam. All are supported by the Company's advanced production technologies, feature high added-value, and have excellent prospects for growth. Nisshinbo has a sound financial structure, a highly skilled work force and a management with a proven record of success. Nisshinbo also has an unrivaled reputation for its ability to satisfy customers. That's why Nisshinbo faces the future with confidence.<P>

In June 1994, Mr. Tatsuo Tanabe became chirman of Nisshinbo. Mr. Akihiro Mochizuki was appointed president. Management takes this opportuinity to thank Mr. Tanabe for his leadership in his eight-year term as president, during which he set a strategic guideline for Nisshinbo in the direction of appropriate diversification into value-added products. This is a course that Nisshinbo will continue to follow.<P>

<I>Financial Results for Fiscal 1994;</I><BR>
In fiscal 1994 (April 1, 1993-March 31, 1994), we posted non-consolidated net sales of Y162,410 million (US$1,624 million), 9.5% down from fiscal 1993. Operation income was Y2,317 million (US$23 million), a decrease of 15.1%. Net income was Y2,934 million (US$29 million), down 57.9%. Unlike in fiscal 1993, we did not sell fixed assets to bolster net income.<P>

<I>Capital Investment;</I><BR>
Capital expenditure for fiscal 1994 totaled Y10,389 million (US$104 million), a decrease of 32.8% from fiscal 1993. This decline reflects our concentration on expanding production capacity and updating production facilities for products with good prospects. The major items of expenditure were further expansion of friction materials production capacity at the Tatebayashi Plant, the same for disc brake production capacity at the Nagoya Plant, reinforcing finishing processing for SS and SSP at the Miai Plant, and modernization of the Hamamatsu Plant and other spinning and weaving plants.<BR>
In fiscal 1995, we plan to increase investment by about 70%, again focusing on facilities for successful products.<P>

<I>International Activities;</I><BR>
Export sales amounted to Y13,268 million (US$133 million), down 23.4%. The main cause of the drop was the appreciation of the yen. The export ratio was 8.2%, a decrease of 1.5 points. Textile exports suffered badly, but sales of non-textiles were slightly up.<BR> 
We conducted two important technical tie-up agreements during fiscal 1994. Under an agreement with ITT Automotive Europe GmbH, NT20 will be marketed through ITT's international network and also by ourselves. Our agreement with Bankok Spring Industrial Co., Ltd. allows the Thai company to manufacture and assemble brake components using Nisshinbo technologies. This is the fourth and the most significant technology transfer agreement with Asian countries.</BLOCKQUOTE><P>

<B>Management:</B><BR>
<UL><LI> Chairman: Tatsuo Tanabe
<LI> President: Akihiro Mochizuki
<LI> Senior Managing Director: Keiji Okumura, Atsushi Mihara
<LI> Managing Director: Shinsuke Takahashi, Toshio Suzuki, Yukio Hosoya, Hisao Ishikawa
<LI> Director: Suguru Miyazu, Akio Fujimori, Etsuo Ishii, Tsuyoshi Sugaizumi, Osamu Kitauchi, Kazuo Tomizawa, Yoshimasa Hasegawa, Seiji Yamamoto, Yoshikazu Sashida  
</UL>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!-- INFORMATION ABOUT THE CONTACT PERSON FILLING OUT THIS FORM
Date: May 25, 1995

Name: Soichiro Takenishi
Title: Deputy General Manager
Address: 1-18-1, Nishiarai Sakaecho, Adachi-ku
City: Tokyo
State: Tokyo
Zip Code: 123
Telephone Number: 81-3-3887-7801
Fax Number: 81-3-3886-3199 >
</DOC>
<DOC>
<DOCNO>WT03-B24-218</DOCNO>
<DOCOLDNO>IA064-000378-B001-247</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/kaketsuken.html 206.86.52.80 19970112095014 text/html 9777
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:50:14 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 9595
Last-modified: Sun, 12 May 1996 19:30:13 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Kaketsuken</TITLE></HEAD><BODY BGCOLOR=#FFFFFF>
<H1>The Chemo-Sero-Therapeutic Research Institute</H1><H3>(also known as Kaketsuken, the abbreviation for its Japanese name)<P>
Corporate Profile</H3><HR>
668 Okubo Shimizu<BR>
Kumamoto 860 Japan<BR>
Telephone: 81-96-344-1211<BR>
Fax: 81-96-345-1345<P>

Kyosuke Mizuno, D.V.M., Ph.D.<BR>
General Manager<BR>
Kikuchi Research Center<BR>
Kaketsuken<BR>
Kyokushi, Kikuchi<BR>
Kumamoto 869-12<BR>
Japan<BR>
Telephone : 81-968-37-3100<BR>
Fax: 81-968-37-3616<BR>
email: <a href=mailto:LDP03333@niftyserve.or.jp>LDP03333@niftyserve.or.jp</a><P>

<B>Mission:</B><BR>
<UL><LI> To discover and develop ethical biological products
<LI> To contribute public health and natural science
</UL>

<B>Financial Information </B> (1$=Y90, 1994 Fiscal year):<BR>
Capital; 22.2 Million US$<BR>
Net Sales; 212.3 Million US$<BR>
Income before taxes; 40.1 Million US$<BR>
R&D Expenditure; 30.5 Million US$<P>

<B>Number of Products on Market:</B><BR>
<I>Human vaccines;</I><BR>
<BLOCKQUOTE>14 products (AIMMUGEN; lyophilized vaccine for hepatitis A. BIMMUGEN; recombinant vaccine for hepatitis B, Influenza HA vaccine, Japanese Encephalitis Vaccine, etc.)</BLOCKQUOTE><P>

<I>Animal Vaccines;</I><BR>
<BLOCKQUOTE>52 products (infectious Bursal Disease Vaccine,OILVAX; oil adjuvant vaccines for Newcastle disease, infectious bronchitis and infectious coryza, Rabies Vaccine etc.)</BLOCKQUOTE><P>

<I>Blood plasma products;</I><BR>
<BLOCKQUOTE>11 products (VENILON; sulfonated immunogloblin for infectious diseases, Human Serum Albumin, BOLHEAL; tissue glue for wound healing, etc.)</BLOCKQUOTE><P>

<I>Clinical diagnostic reagents;</I><BR>
<BLOCKQUOTE>81 products (NEW SEROCLIT series for HBs, anti-HBs, and anti-HTLV-I, CHEMO-SERO EIA series for HCV antibody, etc.)</BLOCKQUOTE><P>

<B>R&D programs:</B><BR>
<BLOCKQUOTE>Protein C (plasma derived and recombinant) for DIC, Antisense oligo for hepatitis C, HIV chimeric antibody, Deoxycoformycin for adult T cell leukemia. Super antigen for rhematoid arthritis. Poultry vector vaccines and more research programs for mainly biological products.</BLOCKQUOTE><P>

<B>Current Corporate Partners:<BR></B>
<BLOCKQUOTE>Teijin, Fujisawa, Merck, MRC, Upjohn, Behringwerke, ISIS, and other partners of biopharmaceutical companies.</BLOCKQUOTE><P>

<B>Corporate Partnering Opportunities:</B><BR>
<BLOCKQUOTE>Kaketsuken is interested in seeking licensing opportunities and joint research programs for pharmaceutical products and technologies as follows;
Novel anti-viral agents, Therapeutic vaccines, Recombinant plasma proteins for human use, Blood coagulation or thrombosis factors, Wound healing products and its related growth factors, Novel biological products for immunological diseases, Ultrasensitive diagnostic technology, Gene therapy products, Novel adjuvant and DDS for vaccines and anti-virals, and other novel technology for developing biological products.</BLOCKQUOTE><P>

<B>Employees:</B> 953 (April 1, 1995)<P>

<B>Facilities:</B><BR>
<I>Head Office;</I><BR>
<BLOCKQUOTE>The site covers 19 acres. Y-shaped main building has four stories including one basement. Annexes are for blood plasma products for Veternary, for the research of Avian leucosis and for management. These buildings have totally 8.4 acres. They provide the space for research production, quaility control, marketing and administration. Most of the facilities are centrally controlled having an integrated system.</BLOCKQUOTE><P>

<I>Kikuchi Research Center;</I><BR>
<BLOCKQUOTE>The site covers 34.6 acres on the foot of Mt. Aso. Research building has six stories including one basement. Annexes are for recombinant vaccine products, for pathology and for management. The Research Center is steadily becoming the center of our research and development activities and, in parallel with this, we are working to expand the range of our expertise in the field of biotechnology.</BLOCKQUOTE><P>

<I>Aso Laboratory;</I><BR>
<BLOCKQUOTE>The site covers 114,000 square meter on a slope of Mt. Aso, in Aso National Park. The laboratory keeps horses for immunization against bacterial toxins, snake venoms, etc. It also has facilities for raising SPF animals, e.g. chicken, duck and swine. These SPF animals as well as SPF eggs are provided for research and production of various vaccines.</BLOCKQUOTE>

<B>History:</B>
<BLOCKQUOTE>1945: Founded as The Chemo-Sero-Therapeutic Research Institute on the instigation of Toyoichi Ohtawara, M.D., D.M.Sc., Professor of Kumamoto Medical College, and contributed to the preventive medicine by providing biological products.<P>
1949: Opened Tokyo Office<P>
1950: Commenced the production of biologics for veterinary use<P>
1959: Dedicated College of Medical Technology<P>
1962: Opened Aso Laboratory<P>
1966: Commenced production of blood plasma products<P>
1972: Began to produce reagents for laboratory diagnosis<P>
1985: Completed the work of Kikuchi Research Center<P>
1988: Began to produce recombinant Hepatitis B vaccine</BLOCKQUOTE><P>

<B>Date Established:</B> December, 1945<P>

<B>Legal Form:</B> Japanese Research Foundation <P>

<B>Corporate Overview:</B><BR>
<BLOCKQUOTE>For achieving fulfilness of the principle of foundation, a number of reaserch developments for new biologics are conducted adapting every social demand.
Main research field is consisted of applied microbiology and immunology covering the development of immunoprophylactics, such as vaccines, toxoids and antibody preparations, diagnostic reagents, therapeutic plasma fractions and so forth for human or animal use. The reseach activity was actually originated on preventive medicine and currently its expansion has been desired according to the alteration of medical and social manifestations. The research, in consequence, is increasing its activity year and year, rapidly applying the recent progress of gene- and bio-engineering.</BLOCKQUOTE><P>

<BLOCKQUOTE>The site covers 34.6 acres. The Research Center is equipped with the most advanced technology and facilities and has become a center for research on gene recombination and cell fusion.</BLOCKQUOTE><P>

<B>Main Research Projects (Medical):</B>
<UL><LI> Studies on vaccines and toxoids for human use
<LI> Infectious viral diseases and their prevention
<LI> Infectious bacterial diseases and their prevention
<LI> Hepatitis and Hepatitis viruses
<LI> Studies on plasma protein
<LI> Properties of plasma proteins
<LI> Immunoglobulins
<LI> Blood coagulation factors
<LI> Studies on gene recombination and cell fusion
<LI> Studies on reagents for laboratory diagnosis
</UL><P>

<B>Main Research Projects (Veterinary):</B><BR>
<UL><LI> Studies on infectious diseases of animals
<LI> Infectious viral diseases and their prevention
<LI> Infectious bacterial diseases and their prevention
<LI> Protozoal diseases
<LI> Production and control of SPF animals
<LI> Pathological and microbiological diagnosis of diseases of domestic animals
<LI> Studies on fish diseases
<LI> Diagnostic methodology
<LI> Causative agents of infectious diseases and their prevention
</UL><P>

<B>Production:</B>
<BLOCKQUOTE>Improvement of manufacturing processes and introduction of new technologies are always done to wake the assurance of safety, efficacy and quality of the product.
Vaccines, antitoxins and antivenoms are produced for human and animal use. Blood plasma products, such as albumin, immunoglobulin and coagulation factors, and furthermore diagnostic reagents are also produced. An expansion of manufacturing facilities was completed in 1981, which increased the capacity of plasma fractionation.
These manufacturing facilities assure conformance to Current Good Manufacturing Practices.</BLOCKQUOTE><P>

<B>Blood Plasma Products:</B><BR>
<BLOCKQUOTE>High quality products such as Human albumin, Venilon, Confact F, Novact M, Bolheal etc. are manufactured in the well equipped and automated new plant which assure conformance to Current Good Manufacturing Practices.</BLOCKQUOTE><P>

<B>Vaccines and Antitoxins for Human Use:</B>
<BLOCKQUOTE>Vaccines and antitoxins, such as Hepatitis A vaccine, Hepatitis B vaccine, influenza vaccine, Japanese encephalitis vaccine and Habu antivenom are manufactured as the measures for preventive medicine.</BLOCKQUOTE><P>

<B>Vaccines and Diagnostic Reagents for Vaterinary Use:</B><BR>
<BLOCKQUOTE>Vaccines and diagnostic reagents for poultry, canine, swine, bovine,fish and equine use are manufactured in main laboratory. SPF eggs and animals produced at Aso laboratory are provided for quality control test and for production of various vaccines.</BLOCKQUOTE>

<B>Board of Directors:</B><BR>
<UL><LI> Director General, President: Saneo Nonaka, M.D., D.M.Sc.
<LI> Senior Exective Vice President: Mitsuo Sakoh, D.M.Sc., Ph.D.  
<LI> Executive Director: Sadao Susumi, Shinji Yamada, D.V.M., Ph.D. 
<LI> Directors: Akitsugu Kaku, Kyoji Uchino, Kennosuke Honda, Akinobu Funatsu, Shigeto Uchikura
</UL>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated September 27, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!-- INFORMATION ABOUT THE CONTACT PERSON FILLING OUT THIS FORM
Date: June 28, 1995
Name: Kyosuke Mizuno, D.V.M., Ph.D.
Title: General Manager
Address: Kyokushi 
City: Kikuchi
State: Kumamoto
Zip Code: 869-12
Telephone Number: 81-968-37-3100
Fax Number: 81-968-37-3616
e-mail: LDP03333@niftyserve.or.jp >
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-219</DOCNO>
<DOCOLDNO>IA064-000378-B007-269</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/3qtr/0918a1.htm 206.86.52.80 19970112100709 text/html 21596
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:07:07 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 21413
Last-modified: Fri, 12 Apr 1996 22:51:15 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Wishful thinking</TITLE></HEAD>


<BODY background = "../../../graphics/white-mi.gif">

<B>From BioCentury, September 18, 1995</B><P>

<H3><I><CENTER>Assessing market potential</H3></CENTER></I>



<H1><CENTER>Wishful thinking</CENTER></H1>



<center><b>By Karen Bernstein<br>



Editor-in-Chief</center></b><p>



One of the constant dilemmas for biotech companies is the multiple audiences to whom they must appeal on a regular basis. For the Wall Street audience, it is generally in a company's interest to project the largest possible market size and hence the maximum future revenue stream for its products in development -- a game that sellside analysts often play with even greater fervor (more on that at a later date). But for a second critical audience, potential pharmaceutical company partners, such projections, and the valuations they imply, can be deal breakers.<P>



Dealmakers from the pharmaceutical side provide mixed reviews about their experiences in negotiating with biotech companies. As might be expected, those whose experiences have been negative can wax long and eloquent on the problems they've run into, while those whose negotiations have run more smoothly tend to trundle along quietly on their way.<P>



Whatever the reality, biotech companies need to know how the pharmaceutical companies look at market projections, and how the senior companies look at biotech proposals. Coming in with reasonable numbers from the beginning, or a willingness to listen to the other side's numbers, can speed the process considerably, and ultimately can make the difference between walking out with a deal or walking out empty-handed.<P>





<B><CENTER>The criticisms</B></CENTER><P>



Critics of biotech proposals aren't hard to find. According to David Brush, director of licensing at Astra Merck, the majority of biotech company proposals considerably overstate the potential market size of their products compared to pharmaceutical company estimates. The differences between the two sides can be substantial. <P>



"I hate to stereotype too much, but if you say it's $100 million, they'll say it's $200-$300 million and up to $500 million, so it can be 200-300 percent off," Brush said. "For example, we're one of the few companies in the gastrointestinal area. A company will come to us and say, The inflammatory bowel disease population is X.' Our M.D.s will look at it and say, This portion of the population will be treated with steroids; this portion will be treated another way,' resulting in a lower number."<P>



That's also the opinion of Eileen Mendel and Andrew Becker of The Mendel Group, which consults to biotech companies. They can recite a list of biotech companies whose first products, often second-line therapies or products designed to replace existing treatments, they expect will be far smaller than most Wall Street analyst and company estimates.<P>



<B><CENTER>$82 million gap</B></CENTER><P>



They cited an experience with a drug for which the biotech company had estimated a $100 million potential market. The prospective partner pegged the market at $18 million. The biotech company, they said, had assumed extensive off-label use, little of which was actually likely to occur. At the same time, there was only one potential suitor for the drug.<P>



"The key is that for the majority of companies that only will have one or two suitors, the companies have to get real," Becker said. "If the biotech company had come up with reasonable numbers to begin with, the deal would have gotten done faster."<P>



The reason for the frequent disparity in numbers, said Brush, is not that biotech companies are ignorant, but that the two sides use different methodologies for building their models, and have different motivations behind the building of their projections.<P>



For the biotech companies, the obvious motivation is to build a model showing the biggest market possible in order to lure investors. "Their perception is that if they don't come in with $1 billion projections, people won't listen to them -- I don't know where they get that from," said Ronald Pepin, director of external licensing and technology at Bristol-Myers Squibb. "But you have to think that pharma companies are doing their homework. If someone came to BMS with a $200 million cancer drug we would listen."<P>



At the pharma companies, with no outside constituency to impress, the goal is to project future revenues accurately. "At Bristol-Myers Squibb, where I was previously, and here at Astra Merck, we build our market forecasts not to build the biggest market but to build a realistic market," Brush said. <P>



"They all come in with overinflated estimates of their markets and what kind of market penetration they're going to have," said Pepin. "We don't listen to their market projections -- we do our own." Still, he said, it helps biotech companies to come in with realistic estimates, because it gives the senior partner more faith that the biotech company is realistic about other things as well.<P>



One test he uses to see whether the biotech company really believes in its numbers is to offer a low royalty up to a certain amount of sales and a higher royalty thereafter. "You find out fast that they think their numbers are soft," he said.<P>





<B><CENTER>Different drivers</B></CENTER><P>



The disparity in estimates isn't simply due to different ways of calculating market size, however. Sherry Reynolds, acting president and COO of Exelixis Pharmaceuticals Inc. (Cambridge, Mass.) pointed out that some of the gap can be attributed to standard bargaining positions, as each side begins with high and low bids.<P>



 "Where biotech companies are missing the boat is they say osteoporosis' or cancer' and clearly their drug is only going to be effective in a subset of the patient population, but you only know that once you get into the clinic," said Reynolds. "I don't know that the pharmaceutical companies are any better at it than the biotech companies, but they'll narrow it down sooner as part of the bargaining process."<P>



In fact, because dealmakers like Brush have to present their proposals to committees within their companies for comment and approval, all the incentives work in the opposite direction, to underestimate rather than overestimate a product's potential. "No one on the pharma side wants to overestimate the market. We look at net present value, cash flow, add in the milestone payments," he said. "You can't go in front of your management with a negative value. They'll ask for your numbers and your assumptions. You can't go in and say you're estimating you'll get 100 percent of a market, or 50 percent of the market. You don't want to say it's a $100 million market and have it turn out to be $20 million. It's OK if you say it's $20 million and it turns out to be $50 million."<P>



Reynolds agreed. "They have to position the deal internally. Those market projections have to fit with the parameters of a deal that can be sold internally. No matter how you discount it back, you have to get to a number that can be sold internally."<P>



Another issue cited by Reynolds is the vastly greater resources of the pharma side. "One reason the biotech numbers may be off is because it's very expensive to do that kind of detailed analysis. It's time-consuming and the companies can't afford it. The pharma industry has access to better numbers through its access to the best databases."<P>



<B><CENTER>Find flex points</B></CENTER><P>



The result, Brush said, is "a more complex scenario that tries to forecast more of a real world type of situation. It just reflects the different motivations: one to raise money, and one to create a realistic scenario. But because of those different motivations, it sometimes becomes harder to close the gap."<P>



Reynolds suggested that one way to bridge that gap is for companies to focus on the later-stage numbers in a deal -- e.g., on the future royalty stream, and on how they can share in the benefits if the numbers turn out to be better than projected. For example, if the sales are over X million dollars, the royalty rate would increase.<P>



"Biotech companies should find where the flex points are internally at the pharmaceutical company and help them sell the deal internally, by being willing to put in milestones and other things that are totally dependent on success. If they believe in the product, they should be willing to do that," she said.<P>



Other licensing executives have had more positive experiences in their negotiations with biotech companies. "When you really sit down and talk to them, my experience is that the majority are very realistic," said Anders Wiklund, executive vice president at Pharmacia. "On the last couple of deals, and some I'm talking to now, they have had a pretty good understanding of the potential market for their products."<P>



That includes an understanding of the indications, competition, pricing assumptions and the timing of product approvals. Pharmacia always develops its own numbers as part of the discussions. "If they come up the same it's easy to deal with the issues. We have not had any serious discrepancies in our negotiations," he said.<P>



Juergen Schrenk, vice president of technology management at Corange Ltd., also said it's rare in his experience to see companies come in with their numbers off by an order of magnitude. But when it occurs it's quite discouraging. <P>



<B><CENTER>One wonders</B></CENTER><P>



"It makes you wonder whether they think you're stupid, or it's an outright lie or they didn't do their homework," he said. "But we also see companies come in with good numbers. You have to remember that these are often new markets and our people sometimes have a hard time making estimates. As long as the overall market size is correct, it's our job to reduce that to a more realistic approach."<P>



Schrenk also has had pleasant surprises in his negotiations with biotech companies. "We're looking at a company now that addresses a market that really doesn't exist yet -- their technology could replace an existing technology and actually expand the market quite a bit. These guys are more conservative than our market people. If anything, I'd tell them to be more bold."<P>



Having realistic numbers also increases Schrenk's confidence that the company will be down to earth in other areas, like technical issues. "I'm a big believer in honesty. I like dealing with a realistic, down to earth company."<P>



In Wiklund's view, developing a reasonable estimate of market size takes time, and is something that is teased out as discussions proceed. "It's hard to estimate the market before the scientists have come up with what they think are reasonable indications. So that comes reasonably late in my experience.<P>



"But the important thing is what do you do with these numbers," Wiklund continued. "The important area where market estimates come into play is when you deal with upfront payments and milestones. What we have done a few times is agreed on a higher royalty rate if some higher market size is achieved. And we might pay higher milestones if it's a significant indication versus a minor indication."<P>



Brush suggested that biotech companies, rather than assuming the pharma companies are trying to drive a hard bargain by low-balling their market estimates, should try to validate the numbers. In the end, he said, flexibility is important. "Nobody wants to enter into something with unrealistic expectations."<P>



Thomas Wiggans, president and CEO of Connective Therapeutics Inc. (Palo Alto) pointed out that it doesn't take too many different assumptions to create a very wide gap between projections. This is particularly true when companies are looking at new markets. And before a company has real data, there's not much that can be done beyond estimating the number of patients, the price and the market penetration. Still, he said, when both sides compare notes, it's usually impossible to be orders of magnitude apart. <P>





<B><CENTER>Finding an accommodation</B></CENTER><P>



One way to avoid such problems is to work with the potential partner to develop numbers. "In discussions with potential partners, we frequently focus on presenting the science and the product, and work with them in developing a product profile, asking them to give us their view of the market opportunity," said Laurence Korn,  chairman and CEO of Protein Design Labs Inc. (PDLI, Mountain View, Calif.). "In my experience, our numbers tend to be pretty much the same as theirs within a small percentage. We've never had a disagreement on the market potential of a compound, and that comes from working together to develop a picture of the overall market, and to develop a product profile and clinical development strategy."<P>



PDLI develops a product profile -- the half-life, safety, and other characteristics. If the product then shows efficacy, given its other properties, the company asks what kind of market share its potential partner would anticipate. "We don't come in and say we'll get 100 percent of the market. We listen to them because we want to hear their story and how they envision capturing the market." Thus allowing the pharma company to lay out its estimates can help the biotech company determine if this is a partner that sees a high potential for the product and is willing to work to capture market share.<P>



A high implies a low, too<P>



That doesn't mean that biotech companies don't need to do their homework first and have a realistic sense of the potential market and thus the worth of a compound. "We have somebody in-house who goes out and assesses markets," said Jeremy Levin, president and CEO of Cadus Pharmaceuticals Inc. (New York). "That was one of my first hires at Cadus."<P>



Cadus thus starts with primary research, including interviews with clinicians. The company then double-checks its numbers by looking at publicly available documents where similar calculations have been done, such as analyst reports, as well as through conversations with others in the field.<P>



Biotech companies also need to have a clear sense of the high and low bids that form the parameters of potential deals. "In the case of Geron, we came up with high and low possible bids, whereas a lot of people start with a high bid but don't know what their bottom is," said Becker of The Mendel Group. The company, which successfully negotiated a Japanese deal, presented a knowledgeable picture of the cancer field in Japan, and it structured a realistic deal, he said. "They really did their homework and went in and presented a good case."<P>



"Unless you've crunched all the numbers," added Mendel, "you don't know what you're able to accept on the low end."<P>



They advise their clients to find a consultant to do objective, realistic market models with several price points, so companies can discuss high and low estimates based on interviews with potential users. "The pharma company will generally use their own team to do a reality check, but if they have to do it all, it will take longer," Mendel said.<P>



"The pharma company will do a back-of-the-envelope calculation," said Becker. "If the biotech company comes in with a market estimate that's off by 400 percent, that acts as a red flag. Then the biotech company needs to be able to accept that it doesn't have a $250 million product. What's holding back partnering is people get wedded to their products and their science. These are science-based companies and they fall in love with it."<P>





<B><CENTER>The concrete mindset</B></CENTER><P>



Another problem, more common in the past than today, occurs when biotech companies begin negotiations with a set idea of the total value they expect from a deal. "In the past, companies had a dollar figure in mind and tried to get the numbers to add up to that," Brush said. "Now the majority, especially the smaller companies, are more flexible, more willing to work with you, and they are more willing to be compensated when they hit certain milestones. Some of the more established biotech companies are the ones that come in and do what you saw in 1990 and 1991 -- they come in and say, We want $50 million.' A lot of smaller companies are trying to work with you to get their first or second deal."<P>



In part, the top-down focus is a function of the ongoing problem created by the dual audience that biotech companies face: the investment community and the pharmaceutical companies. However, this is not the way to get a deal done.<P>



"My opinion is there's too much peer pressure or environmental pressure to come in with big numbers," said Wiggans. "That occurs for two reasons: because big numbers get attention, and because small biotech companies are pretty naive, and have never done market projections. The fact that there's pressure to have billion dollar markets discourages people from coming in with accurate numbers to either pharmaceutical companies or investors. It creates an unrealistic environment. As biotech companies become more sophisticated and have the experience to come in with good numbers, my guess is they get penalized for it."<P>



<B><CENTER>Impact of top-down</B></CENTER><P>



The initial presentation of deals is based on a top-down model at least 50 percent of the time, Reynolds said. "When you ask biotech CEOs who their customer is, they all recognize the pharmaceutical industry, but equally important is the investment community. So lots of times they're saying, My competition got this deal.' But just because one company got a deal of one size and this one got another, they're not necessarily comparable because they may be in different project areas. The problem is that investors focus on that number in assessing companies. It's an investor-driven problem."<P>



Trying to peg a negotiation to the last big deal doesn't help get a partnership, said Pepin. "When Max Link was at Corange, a company came to us and said, You'd better hurry, because we're talking to Max Link.' I said, You'd better get that deal, because there's no way we're going to match it.'"<P>



Mendel agreed. "Looking at comparables isn't really a negotiation on your product."<P>



The tighter budgets for biotech companies is making it easier for the pharma companies to do deals with them. "One of the helpful things is the trend of venture capitalists to put less money into these companies," Brush said. "That is having a trickle down effect: it's driving the move away from the kind of attitude that companies came with, saying we need $50 million or $100 million.' The newer companies have had less money pumped into them that they feel they have to recover, and they seem to be more flexible."<P>





<B><CENTER>The valuation trap</B></CENTER><P>



It's one thing to present unrealistic projections to the outside world. But it's another thing altogether to build a company and spend money on the basis of such projections. When that happens, companies can face reverse sticker shock when they try to realize the value of their investment through a partnership, only to find that they've already put in more money than the rest of the world thinks it's worth.<P>



"One company came in a few years ago and we said their product was worth $2 million," said Brush. "They turned white and said, But we've put $6 million into the company.' So they're saying they can't negotiate down because they've put the money in. They never did license their compound and they ended up merging into another company."<P>



In these and other situations, biotech companies can get hamstrung by a combination of their valuations and the rate at which they're spending money, putting themselves into a position where they feel compelled to turn down a deal that implies a smaller market size for a product and hence a lesser valuation for the company.<P>



"They can't do the market numbers realistically because if they do that, and it leads to a smaller market, then they won't be attractive to the venture capitalists or public investors unless the business plan -- i.e., the burn rate -- is scaled down to match the likely revenues," Becker said.<P>



There have been times, Brush said, when he lays all the numbers out on the table and shows prospective partners all the models. Even then, the smaller companies have said they can't go for the valuation. "So they end up with nothing or say they'll go talk to someone else," he said.<P>



In the instances where companies do come in with more realistic expectations or more flexibility, it's because they haven't backed themselves into a valuation corner, he said.<P>





<h5><HR>



<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0

SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>

<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0

SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>



<HR>



Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>



BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>







</BODY></HTML>





</DOC>
<DOC>
<DOCNO>WT03-B24-220</DOCNO>
<DOCOLDNO>IA064-000380-B020-328</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/3qtr/0925a1.htm 206.86.52.80 19970112101341 text/html 7809
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:13:45 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 7627
Last-modified: Thu, 23 May 1996 21:56:05 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Entrepreneurial Europe</TITLE></HEAD><P>

<BODY background = "../../../graphics/white-mi.gif"><P>

<B>From BioCentury, September 25, 1995</B><P>



<H1><CENTER>Entrepreneurial Europe</CENTER></H1><P>


<I>Among the hallway topics at last week's BioPartnering Europe conference in London, one could hear debated whether Europe was on the brink of creating a critical mass of homegrown biotechnology ventures. As is usually the case, commentary ranged from the optimistic to the skeptical. To provide a flavor of the emerging biotech enterprise in Europe, BioCentury this week offers profiles of three early-stage companies that are pursuing chimeric technology, gene therapy, and "combinatorial biology". </I><P>

<B><CENTER>XTL's chimeric technology</B></CENTER><P>

When Martin Becker joined XTL Biopharmaceuticals Ltd. as President and CEO in November 1994 from Syntex Corp., XTL had technology but no business strategy. Becker has spent the past few months focusing the company's efforts on the use of its chimeric animal technology to develop fully human monoclonal antibodies and the creation of improved animal models that can be used in-house and in conjunction with corporate partners to develop improved lead compounds.<P>

Based in Rehovot, Israel, XTL was formed to develop engraftment technology, developed by Yair Reisner at the Weizmann Institute of Science, that enables the production of chimeric rodents with functioning human immune systems and other human tissues. XTL was incorporated in 1992 by Yeda, Weizmann's licensing and business development arm.<P>

While looking for ways to eliminate graft rejection, Reisner found that by severely irradiating mice and reconstituting their hematopoietic systems by transplanting cells from SCID (severe combined immunodeficiency) mice, he could reconstitute their myeloid and erythroid lineages without producing mouse antibodies. Peripheral blood lymphocytes from human donors and/or other human tissue then can be transplanted, leading to a human/mouse chimera.<P>

<B><CENTER>Exploiting the asset</B></CENTER><P>

The question then was what to do with these mice. One possibility was to make human antibodies. The mice have a fully human lymphoid system, so when they are given an antigen, they have a human antibody response. They generate HLA-restricted cytotoxic T lymphocytes (CTLs) following immunogen administration, in contrast to hu/SCID mice, which generally display anergy and have difficulty generating CTLs, according to the company. <P>

The mice also can be produced using differing extant strains, such as BALB/c, nude and BNX, which allows XTL to choose different strains for different purposes.<P>

Becker believes that one advantage of using fully human antibodies versus humanized antibodies is that the former have higher affinity and thus may require less drug to achieve an equivalent treatment effect. The antibodies show proper maturation, with class switching from IgM to IgG, he said.<P>

It also is possible to put other human tissue into the mice, such as liver. When the company puts in liver that has been infected with hepatitis C or B virus ex vivo, nucleic acid sequences of HBV and HCV start appearing in the blood two weeks after transplant. To derive high-affinity antibodies, XTL is putting lymphoid cells in its mice from human patients who have successfully cleared the virus, and boosting their response with a vaccine.<P>

The company has isolated 10 MAbs against HBV thus far and is developing them  for passive immunotherapy of needlestick, neonates born to mothers with HBV, and liver transplant in recipients with HBV. XTL intends to have a clinical candidate within eight months.<P>

XTL has formed its first corporate partnership in its hepatitis C program, signing an option agreement with the BioChem Therapeutics Inc. subsidiary of BioChem Pharma Inc. (BCHXF), to explore use of the mice as a model to test drugs against HCV.<P>

The rodents thus can serve both as animal models of disease and as sources of human monoclonal antibodies. However, XTL doesn't intend to develop its animal model capabilities into a service business. The company will use them either to aid in the development of its own compounds or as part of a collaboration for which it would receive royalties.<P>

In the area of autoimmune disease, XTL is developing MAbs to gamma interferon, which plays an important role in biasing the immune system to a Th1 response. When that response is over-amplified, as it is in many autoimmune diseases, it can lead to the generation of auto-aggressive CTLs that cause tissue destruction. The company is targeting multiple sclerosis, rheumatoid arthritis, lupus and Type I diabetes. <P>

Gamma interferon also plays an important role in XTL's third program in organ rejection, where blocking interferon gamma may be useful in preventing allograft rejection or in transplant rescue.<P>

The company also is working to develop new animal models. One project is to develop a model of MS that is more relevant than the currently used EAE model. Another goal is to develop a good mouse model of hepatitis. The best existing model is the chimpanzee, which is expensive . The company also is developing models for immunotherapy of human tumors.<P>

Like most startups these days, XTL has no intention of becoming fully integrated, but plans to collaborate with corporate partners to conduct clinical development and marketing. XTL believes it can add value to lead compounds from its alliance partners by providing improved animal models for drug development.<P>

XTL has raised $8 million to date and is in the midst of a private placement in the U.S., Israel and the U.K. with the goal of raising at least $3.5 million. The company aims to achieve profitability in seven years, using pharmaceutical alliances to partially fund R&D. Prior to an initial public offering in about three years, XTL anticipates needing one or two small ($3.5-$6 million) private placements.<P>

While Israel is clearly off the beaten path of biotech, XTL's location confers certain advantages, Becker said. It's a good place to do clinical trials, with a base of highly educated clinicians and scientists, modern infrastructure, a less expensive work force and less government bureaucracy. <P>

In addition, because much of Europe, with the exception of the U.K., isn't well-served by venture capital, European academics have few outlets for the development of their inventions and are eager to collaborate with what biotech companies do exist -- even as far away as Israel, Becker said.<P>

Unusual among Israeli biotech companies, the core management team at XTL has previous experience at biotech and pharmaceutical companies. In addition to Becker's experience at Syntex, COO Zachi Berger has been at Pharmos Corp. and Vice President of Research Shlomo Dagan came from ImClone Systems Inc. and an Israeli biotech company, Biomakor. <P>


<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-221</DOCNO>
<DOCOLDNO>IA064-000378-B008-241</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/1qtr/0306a3.htm 206.86.52.80 19970112100914 text/html 9517
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:09:18 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 9335
Last-modified: Thu, 23 May 1996 22:59:12 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Isis: The power positioning deal</TITLE></HEAD>

<BODY background = "../../../graphics/white-mi.gif"><P>
<b> From BioCentury, March 6, 1995</b>

<h1>Isis: The power positioning deal</h1></center><p>

<center><b>By Karen Bernstein<br>
Editor-in-Chief</center></b>

The big cell adhesion deal between Isis Pharmaceuticals Inc. and Boehringer Ingelheim International GmbH is one of only a handful of transactions in which pharma and biotech companies have combined R&D programs. But more are likely to follow, as companies seek power positions in the new pharmaceutical environment by combining broad platform technologies or building disease management portfolios.<p>

The companies last week announced that they had signed a letter of intent to combine Boehringer's monoclonal antibody programs in cell adhesion with ISIP's antisense and small molecule combinatorial chemistry programs in that area. The collaboration is focused on inflammatory diseases. <p>

<center><b>Combining strengths</center></b><p>

The program therefore will combine Boehringer's strengths in MAbs, small molecules, molecular and cell biology and high throughput screens, with ISIP's antisense and combinatorial chemistry expertise. <p>

Other program combinations that come to mind are Nextran, which allies technologies from Baxter Healthcare, Cantab Pharmaceuticals plc (CNTBY), DNX Corp. (DNXX) and SangStat Medical Corp. (SANG) in the transplant field; and the retinoids deal between Allergan and Ligand Pharmaceuticals Inc. (LGND).<p>

Perhaps key to these transactions are terms that seem especially favorable to the biotech partner. In ISIP's case, the deal gives the biotech company a financial independence that will allow it to choose the timing of its next foray into the equity markets. A combination of equity investments, a large line of credit, and 50-50 profit sharing elevate ISIP's stature as a partner going forward.<p>

"The pharmaceutical companies are seeing a role for relationships with smaller companies and understanding the importance of providing a mechanism for ensuring their survival, rather than just extracting products from them," said ISIP Chairman and CEO Stanley Crooke. "This is the first step on the way to thinking what happens to you happens to us.' <p>

<center><b>Ensure survival</center></b><p>

"If the smaller companies are valuable for their ability to create technology and product opportunities, it's important to structure deals that ensure they can survive. This is a more constructive model than some past models."<p>

However, PaineWebber investment banker Stelios Papadopoulos cautions that these kinds of deals won't become common: their frequency will be limited by the number of biotech companies with deep technologies and cash resources.<p>

Nevertheless, more of these transactions will be created as the pharmaceutical companies gain a greater appreciation of what the biotech companies with good science have to offer. Papadopoulos said he's been working on an even larger deal, but with similar characteristics to the ISIP agreement. <p>

John Wilkerson, chairman of The Wilkerson Group, also is working on several major deals. But he pointed out that acceptance of the importance of the biotech industry to big pharma is still uneven. Many pharma companies are still debating the big issue of 1994  the importance of dominating market channels versus drug innovation  with most spread across the spectrum between those two extremes.<p>

George Rathmann, chairman and CEO of Icos Corp., agreed with Wilkerson's assessment. However, the fact that at least some pharma companies are more willing to look favorably on biotech companies as true partners is a big improvement over the situation 10 years ago, when Rathmann was at Amgen Inc. Back then, he said, potential partners would turn down offers of EPO for $10 million and a 10 percent royalty, and they'd  argue about whether milestones would be credited against future royalties.<p>

"So a lot has progressed since 1985 -- but the needs are greater," Rathmann said. "Companies weren't expecting to spend $1 billion to get a product to market. A lot of the pain is being caused by how much it costs to succeed."<p>

Rathmann also pointed out that, even with a changed attitude on the part of pharma companies, it's still not easy for biotech companies to get a good deal. <p>

"The leverage of the pharmaceutical companies and the needs of the biotech companies makes it hard on average to wait for the good deal. And when you're negotiating you have to use your leverage -- pharmaceutical companies have to represent the interests of their stockholders, not the interests of the world. It's not so simple to get a fair deal that brings a return commensurate with the value of what the biotech company is bringing."<p>

Two changes are making the pharmaceutical companies more interested in Isis-Boehringer type deals, according to Papadopoulos. "Pharmaceutical companies are appreciating that some of the technologies being pursued by biotech companies are meaningful," he said.<p>

<center><b>Pharma limits</center></b><p>

Pharma companies also realize they're not structured to tackle the newer technologies, due to the limits and inertia that arise from their size, as well as their preoccupation with the restructuring of pharmaceutical markets, Papadopoulos said. "So they're saying, We'll work with biotech companies.'<p>

Ten years from now, Papadopoulos said, biotech companies may play a critical role in the early-stage translation of technology into product development opportunities, a capability that hasn't existed historically in the pharmaceutical sector.<p>

The Boehringer deal is potentially worth more than $100 million to ISIP, including more than $50 million in potential milestones. Boehringer will make a $28.5 million equity investment, buying 1.9 million shares for $15 a share, giving the Ingelheim, Germany, company an 8 percent equity position. <p>

Subsequent equity investments, predicated on milestones, will be done at a "significant premium" to the market value at the time, according to Crooke. <p>

While Boehringer's ultimate stake in the Carlsbad, Calif., company depends on the stock's price when additional investments are made, Crooke said he doubted it would exceed 15 percent. Because the purchases would be at a premium to market, Boehringer's investment would represent less dilution than if ISIP sold stock in the public market. ISIP has 20 million shares outstanding prior to the deal.<p>

<center><b>Credit line choices</center></b><p>

The deal also includes a $40 million line of credit to ISIP, repayable in stock or cash, which the company would use only if the equity market remains unattractive. "The line of credit has a fairly long payback period, making it an attractive insurance policy for us," Crooke said. "The deal provides us the financing strength and flexibility to go back to the market when the opportunity is right. This changes the financial fundamentals of the company in a very real way."<p>

While ISIP doesn't have to go back to the markets in the near term, it probably will raise money once more if the price is attractive, Crooke said. ISIP had $43 million in cash at Dec. 31. The Boehringer transaction, plus the renewal of the company's agreement with Ciba-Geigy, will provide enough funding for the company to "run its business aggressively for several years," he said. The targets in the Ciba deal are undisclosed.<p>

Products in the collaboration include Boehringer's BIRR1, which is a murine anti-ICAM-1 (intracellular adhesion molecule 1) monoclonal antibody in Phase III trials for kidney transplant rejection and stroke, and in Phase II for burns. The partners' clinical stage portfolio also includes ISIP's 2302 ICAM-1 antisense drug in Phase I studies for inflammation. <p>

<center><b>Profit sharing</center></b><p>

In preclinical development are a humanized version of BIRR1; an anti-E-Selectin MAb; an anti-P-Selectin MAb; and ISIP's VCAM and E-Selectin antisense drugs, which will target a range of inflammatory conditions.<p>

The companies will share equally in funding the R&D program and will share equally in profits from any commercialized products. The exception is BIRR1, which Boehringer will continue to fund. <p>

ISIP will receive a "modest" royalty on BIRR1 sales, Crooke said. "It made more sense for BIRR1 to be outside the basics of the program because it was so far along, but we wanted to tie it in," he said. He noted that it would have been difficult for ISIP to fund half of the expenses for the trials. <p>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>





</DOC>
<DOC>
<DOCNO>WT03-B24-222</DOCNO>
<DOCOLDNO>IA064-000378-B010-23</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/4qtr/1023a8.htm 206.86.52.80 19970112101320 text/html 7298
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:13:21 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 7116
Last-modified: Thu, 23 May 1996 21:53:02 GMT
</DOCHDR>

<HTML><HEAD><TITLE>Redefining the biotech industry</TITLE></HEAD>

<BODY>
<b> From BioCentury, October 23, 1995</b>

<H1>Apollon Inc.</H1><P>

Malvern, Penn.<BR>
Technology: Facilitated DNA injection for vaccination or gene therapy<BR>
Founded: 1992 by Vincent Zurawski Jr.<BR>
University collaborators: University of Pennsylvania, Massachusetts General Hospital, and University of Zurich<BR>
Corporate partners: Centocor Inc.<BR>
Clinical status: Phase I/II study in HIV<BR>
Disease focus: Infectious diseases, cancer, and autoimmune diseases<BR>
Number of employees: 39<BR>
Funds raised: $14 million<BR>
Funding sources: Centocor Inc., DSV Partners, Chancellor Capital Management, and Technology Leaders<BR>
CEO: Vincent Zurawski Jr.<BR>
Patents: None<P>

<h5><HR>
</H5>
<center><h3><p><i>Emerging Company Profile</h3></p></i>

<h1>Apollon: Facilitated DNA vaccines</h1></CENTER>

Some people just like to be "where it's at." Vincent Zurawski Jr. was the first researcher at Massachusetts General Hospital to work on monoclonal antibodies, and he was one of the co-founders of Centocor Inc. After 15 years working with MAbs, he was ready for a new challenge.<P>

Zurawski was responsible for the development of CNTO's diagnostic products, and at the end of his tenure there was working full time on cancer. But "this was the age of DNA and molecular genetics, and I wanted to get into that," he said.<P>

In 1992, Zurawski founded Apollon Inc., which is focused on pharmaceutical and vaccine products using "facilitated" DNA injection and delivery technology. The vaccines, delivered via intramuscular injection, contain DNA that encodes antigenic proteins. <P>

Following vaccination, foreign proteins are synthesized inside cells and then presented to the immune system through the major histocompatibility system in a way that stimulates both T cell and antibody responses. <P>

<CENTER><B>Facilitation</CENTER></B><P>

One advantage of DNA-based vaccines is that DNA is very pliable, and scientists can put a lot of genes into a vaccine, thus generating an immune response against several proteins simultaneously. But a critical issue is achieving the level of gene expression required for clinical utility. <P>

Apollon is using facilitating agents to enhance DNA uptake and gene expression. Its first generation facilitator is bupivacaine, a local anesthetic that produces higher levels of expression and immune response of both cytotoxic T lymphocytes (CTLs) and antibodies. <P>

HIV and T cell lymphoma are its first targets. The company chose those indications because the seriousness of the diseases made it easy to get into the clinic quickly and probably will smooth the regulatory path. <P>

"Even if the risks in HIV are high, if you can prove it's safe, you can establish a hypothesis of safety for getting into other kinds of patients," Zurawski said. "Our next group of patients won't be HIV-positive, or have advanced cancer, but probably will have a non-life-threatening but difficult-to-treat disease."<P>

A $4.2 million NIH grant has given the company the ability to build a broader program that can evaluate different vaccine constructs and do more in-depth primate work. The company also hopes to announce shortly a major pharma company deal that will include HIV as one of the target vaccines.<P>

Another advantage of DNA vaccines, Zurawski said, is that the manufacturing technology can be used across its entire line of Genevax products. The plasmid vectors designed to carry the genes for different products are very similar, enabling generic methods of vaccine development and manufacture. <P>

<CENTER><B>Increased clinical opportunities</CENTER></B><P>

"Because it's all DNA, I don't have to redevelop the manufacturing process for every antigen I want to immunize against," said Zurawski. "That means we can get into the clinic with a number of different DNA constructs that code for different responses. That's an advantage in testing for HIV." <P>

For example, Apollon's first generation Genevax-HIV vaccine expresses a modified version of the gp160 envelope protein and an additional non-structural protein. Apollon also plans to look at a vaccine using a core protein (gag) polymerase construct.<P>

"We can mimic a live attenuated vaccine response with a generically manufactured product," Zurawski said. "We can control the pieces of the virus against which an immune response is directed. And we can already manufacture it in 30,000-dose batches."<P>

The manufacturing process uses fermentation and downstream processing including column chromatography -- both well-known processes. While the company has had to make the process reproducible and economically viable, it doesn't have the added burden of trying to develop a novel manufacturing technology.<P>

Apollon's first clinical trial, which started in June, is a dose-escalation Phase I/II study of Genevax-HIV in 15 HIV-positive patients with CD4 counts above 500. Doses will range from 30-300 g. Apollon will start a similar trial in Switzerland before year-end.<P>

<CENTER><B>Small molecules</CENTER></B><P>

The company also plans to start a T cell lymphoma trial this year using a vaccine that encodes V-beta chains, part of the T cell receptor, on tumor cells. Similar T cell receptor-directed constructs may be useful in autoimmune diseases where immunization against a specific subset of disease-causing T cells is desired.<P>

The company has signed a license agreement with CNTO to exploit the Genevax technology in certain cancers.<P>

The Malvern, Penn., company also plans to develop small molecule drugs aimed at targets discovered by its molecular and cellular biologists.<P>

Apollon's small molecule program is focused on Vpr, a protein produced by HIV that works as part of a complex with an intracellular protein, rip-1, to render cells more susceptible to viral replication (see BioCentury, April 17, 1995). Vpr also has been shown to inhibit tumor cell proliferation and to drive differentiation of cells. The company is working to identify drug candidates that mimic, inhibit or enhance Vpr's activity. (More on Vpr, see Clinicals, page B7.)<P>

Apollon has raised $14 million, and probably will do another private round before going public. The funding from the soon-to-be announced deal, together with other revenues, will enable Apollon to break even this year and in 1996 if it chooses to do so.<P>


<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-223</DOCNO>
<DOCOLDNO>IA064-000378-B007-234</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/4qtr/1023a1.htm 206.86.52.80 19970112100650 text/html 21444
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:06:51 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 21261
Last-modified: Thu, 23 May 1996 21:52:56 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Putting together partners in Korea</TITLE></HEAD>

<BODY background = "../../../graphics/white-mi.gif"><P>

<b> From BioCentury, October 23, 1995</b><P>

<CENTER><h1>Putting together partners in Korea</h1></CENTER><P>

<CENTER><B>By Karen Bernstein<BR>
Editor-in-Chief</B></center><P>

When companies think "Asian markets," they generally think "Japan." But doing so risks missing out on opportunities in other Asian countries hungry for modern therapeutics. <P>

By focusing on Japan, companies also may mistakenly assume that all Asian countries are alike, whereas in reality the cultures and business structures are as varied as in Europe. Therefore putting together Asian partnering deals requires more than a knowledge of Japanese culture and pharmaceutical companies.<P>

For example, the Korean pharmaceutical sector is going through tremendous change, both in terms of the companies involved and government policy on issues that affect foreign companies wanting to do business in Korea. As always, periods of fluidity are periods of opportunity.<P>

<CENTER><B>Size of market</CENTER></B><P>

The Korean health care industry is well-developed for a country of its size -- about 44 million people, with health care accounting for 7 percent of manufacturing GNP, according to Roberts Mitani Inc. The New York company is an investment and banking firm that locates Asian capital for promising U.S. health care technologies, usually including a corporate component. At least a dozen Korean pharma companies have annual sales of more than $100 million, and Korea is one of the largest exporters of antibiotics and vaccines to the Southeast Asian and Chinese markets.<P>

According to Laurent Ayasse, managing director of Pacific Century Pte Ltd., the Korean pharmaceutical market is the third largest in Asia after Japan and China, with $3.2 billion in sales versus $37 billion in Japan.<P>

"If you look at Asia from a U.S. biotech point of view as 'Japan' -- full stop -- this is more and more completely wrong in terms of opportunities," said Ayasse, whose company is composed of a Hong Kong-based group of pharmaceutical executives who help find Asian partners and funding for U.S. companies.<P>

<CENTER><B>Two recent deals</CENTER></B><P>

"There's a huge Asian market ex-Japan that multinationals aren't well-equipped to commercialize," said Bruce Roberts, president of Roberts Mitani.<P>

Two recent deals have highlighted the potential of the Korean market as an untapped source of corporate partnerships. In September, Neoprobe Corp. granted Damon Pharm Ltd. marketing rights in Korea and certain other Asian countries for NEOP's RIGS system for the surgical detection and treatment of cancer. In May, Aviron (Burlingame, Calif.) and Sang-A, a member of the Hanbo Group conglomerate, entered into a vaccine collaboration. <P>

Sang-A made a 10-25 percent equity investment and will participate in future financings. Damon invested $1 million in NEOP and has an option to invest up to an additional $3 million by Nov. 30.<P>

The experiences of NEOP and Aviron in putting those deals in place, and the expertise of the middlemen who helped arrange the deals -- Roberts Mitani for NEOP and Pacific Century for Aviron -- provide a roadmap for other biotech companies interested in accessing the Korean market and partners.<P>


<CENTER><B>The Korean players</CENTER></B><P>

The Korean pharmaceutical market is bifurcated between more traditional, family held pharmaceutical companies, and companies that have come out of the large publicly held industrial conglomerates, called chaebol. Both have a long history of in-licensing and distributing products from Japanese, European, and occasionally, U.S. pharmaceutical companies.<P>

The family owned companies started a period of significant growth in the 1960s, selling OTC and ethical drugs, as well as herbal medicines and health tonics, in Korea and Southeast Asia. By the late 1960s, they had become relatively large pharmaceutical companies.<P>

The OTC and tonics markets became increasingly competitive. The tonics business could be especially profitable, but required a great deal of advertising, which cut margins. One way to maintain overall profits was to license in ethical drugs at low royalty rates, according to Roberts.<P>

By the early 1980s, these companies realized they couldn't pursue that model forever, because of international competition and the decreased willingness of suppliers to license their products and technologies at low cost. "The family firms with herbal medicines don't have a choice about moving into modern technology," said Ayasse. "The makers of tonic drinks also need higher value added products as advertising cuts into their returns."<P>

As multinational drug companies have established their own relationships with Korean hospitals and pharmacies, they have become less willing to go through an intermediary. "The multinational companies wanted higher royalties or to enter the Korean market themselves," said Jeffrey Oh, senior advisor and Korean specialist to Roberts Mitani. "This is very similar to what happened in Japan."<P>

<CENTER><B>Conglomerates enter</CENTER></B><P>

As a result, Korean companies started looking for products they could in-license and then develop themselves, rather than licensing finished compounds.<P>

By this time as well, the Korean conglomerates had noted the opportunities in pharmaceuticals, and chaebol such as Samsung, which made its name in semiconductors, set up pharma divisions. Samsung's pharma division was spun off in 1994 and is now independent. <P>

According to Vera Kallmeyer, vice president of business development at Aviron, Samsung has built a state-of-the-art hospital in Seoul, with a research center next door. "They have 62 research projects ongoing that they finance. They are investing in the future -- doing basic research on their own and looking for alliances in the U.S. So there's fairly high demand for high-tech from the U.S."<P>

Other chaebol that have entered pharmaceuticals include LG, one of the largest electronics companies in Asia, which operates a pharma company through its LG Chemical subsidiary. Sunkyong and Cheil also have pharma companies.<P>

"A lot of these big conglomerates are involved in construction, steel, and have made billions of dollars," said Kallmeyer. "They realize the future is in high value-added industry, so all are trying to get into the life sciences. It's like Japan was 20 years ago. Concurrently, a lot of the small, privately held, traditional medicine companies with unproven herbal medicines are realizing they have no future."<P>

Still, despite the resources of the pharmaceutical companies, and the interest in novel technologies, R&D as a percent of sales remains low -- about 3-4 percent according to Ayasse.<P>

<CENTER><B>Identifying the players</CENTER></B><P>

Kallmeyer believes that the main opportunity for U.S. companies is to ally with the chaebol. Aviron's partner, Sang-A, was a small, privately held pharmaceutical company purchased by Hanbo three years ago. The son of the chairman was put in charge with a mission to build a health care company.<P>

NEOP's partner, Damon, is a relatively new company, founded by former executives of Boryung Pharmaceuticals. It had turnover of just under $100 million in 1994, ranking it about number 12 or 13 in the Korean market. "The executives who formed it were seeing the new technology pass them by at Boryung, and they didn't want that to happen," said David Bupp, president of NEOP (Dublin, Ohio).<P>

Thus by the end of the 1980s, the family owned companies faced competition on two fronts: Korean conglomerates and Western multinationals starting to set up their own operations in Korea. This has left them with a choice of directions for the future, Roberts said: tying up with a conglomerate, as Sang-A did, focusing on consumer products, or finding ways to source high value-added products. Companies pursuing the latter course, he noted, is the group of interest to biotech companies.<P>

<CENTER><B>The role of the government</CENTER></B><P>

The government bureaucracy in Korea is in many ways similar to its Japanese counterpart, with elite status and power. However, according to Roberts Mitani, it is increasingly divided into two groups with different historical experiences: an older generation that is quite conservative and favors protectionism, and a younger generation that favors open markets and modernization, and is willing to bring in outside capital and to invest in foreign technology. <P>

As a result, said Oh, there is conflict within the bureaucracy, and industry gets mixed signals from the government. "My own reading is the government wants to open up and modernize industry," he said.<P>

There have been clear improvements in the area of intellectual property. "In the past, there was minimal protection for use and methodology patents," Roberts said. "Some companies found that patents would be duplicated and you couldn't successfully prosecute. That's improving a great deal with international harmonization, and in 1994, Korea announced that it will provide the same extent of protection as the U.S. Patent and Trademark Office."<P>

That's also Kallmeyer's interpretation. The government is working to reset policies, particularly regarding trade barriers and intellectual property, she said. "The government is realizing that to compete, Korea needs a patent policy to Western standards, and they need state-of-the-art medicine to survive in the marketplace."<P>

The government also has adopted GMP standards for manufacturing, putting Korea in a position to be a Pacific Rim exporter for U.S. companies.<P>

The market also is becoming easier for foreign companies to enter. For a long time, Kallmeyer said, foreign companies weren't allowed to sell drugs under their own label. As a result, all the major international pharmaceutical companies have had to go through local Korean companies.<P>

That is changing, however, and the resulting competition has provided an impetus to the Korean companies to seek out stronger technologies. <P>

However, conflicting signals from the government still can cause problems at the level of the individual deal. "We have to put in a lot of time with the bureaucracy to understand how policy will be applied to a particular deal," Roberts said. "Even if the policy is clear, there are lots of exceptions in how it is interpreted. So we work closely with the Ministry of Finance and the Bank of Korea."<P>

It takes time, for instance, to get permission to export capital, though that's hardly a problem unique to Korea. "That was the reason our deal, even though it was signed at the end of August, took until late September to announce," said Bupp.<P>

One thing that may be faster than in the U.S. is the regulatory process. NEOP anticipates starting a 9-12 month clinical trial of RIGScan in early 1996. The review cycle will be three months, Bupp said, meaning the product could be on the market in mid-1997.<P>

<CENTER><B>The role of the Korean banking community</CENTER></B><P>

As elsewhere in the Korean economy, relationships are changing between Korean companies and capital.<P>

The banking industry has been tied closely only to the electronics and automotive industries. In part that has been because the financial community has been dominated by government-owned banks or big conglomerates, and the banking sector has been required by the government to make subsidized loans to industries considered strategic. That has left little capital available to smaller, innovative companies -- again a situation similar to that in Japan.<P>

Oh said the financial and pharma communities are just now recognizing the upside of working together. "I feel like a matchmaker. Right now they're dating, and hopefully they will get engaged. To some degree they needed an outside party to do that."<P>

"A common concern of family controlled businesses is that they want to invest, but they are wary of investing in substantial upfront payments," said Roberts. "So the question is how to get a check written for that upfront amount."<P>

Sunkyong Securities Ltd.'s role in providing investment banking services in the NEOP deal was novel, he said. "Before this transaction, the only help the banking community would provide would be in the form of lending money to a Korean pharmaceutical company for very high interest rates, not on the basis of the potential of the novel technology.<P>
"
Venture capital also has been oriented to industrial products and computers, Ayasse said. "I don't know if that will change."<P>

<CENTER><B>The Korean health care market</CENTER></B><P>

All Korean citizens are insured by government-backed medical insurance. According to Oh, premiums are relatively low, service is good, and most products are reimbursed. Reimbursement decisions are made by a quasi-government entity whose members include physicians, bureaucrats, university professors and pharmaceutical executives.<P>

But even when products are declared reimbursable, it takes several years until a budget is appropriated to cover the product. For example, magnetic resonance imaging was made reimbursable in 1994, but procedures won't be fully reimbursed until 1996, because the funds have just been appropriated.<P>

Another difference with the U.S. health care system is the greater role of pharmacists, who have more discretion than their U.S. counterparts. Patients who aren't seriously ill will often go to pharmacists for treatment, which then will be confirmed with their doctors. Koreans also commonly use Chinese herbal medicines.<P>

<CENTER><B>Advice to U.S. companies</CENTER></B><P>

Even more so than in Japan, where many U.S. companies have contacts, and where there are several annual meetings to introduce U.S. companies to Japanese pharmaceutical companies, the U.S. side needs a local matchmaker with long-standing relationships. <P>

"It's appropriate to be introduced by a mutual friend," said Oh. "If I introduce myself cold turkey, there's a greater than 90 percent chance I won't get anything done. It's very important to use an intermediary who knows both sides and can communicate both parties' interests. That's been the practice for several hundred years."<P>

For NEOP, the ability to enter a candidate company at a high level made a difference. "At two companies we got referred to the manager of business development," Bupp said. "Those two situations became somewhat more protracted. On the two that came into the home stretch, we came in at the presidential/CEO level."<P>

Middlemen also can negotiate even when the U.S. company is back home, Kallmeyer said. "Through Pacific Century I usually knew ahead of time what the other side's position was, and they could explain my position or tell me if something was unacceptable."<P>

As might be expected, it is critical to learn about Korean business habits.<P>

Protocol is very important, from the proper forms of address to how to sit. For example, said John Ridihalgh, chairman and CEO of NEOP, "when you shake hands, if you want to show respect you put the other hand underneath your arm. You never pour your own beer -- you let somebody else pour it for you: usually someone from the other side, though not necessarily. There's a lot of ceremony."<P>

Hospitality is equally important. Executives are expected to bring a gift -- it doesn't have to be expensive. And when Korean executives come to the U.S., they will bring a gift here. Ridihalgh came home with a year's supply of ginseng tea. <P>


Companies coming to Korea will be entertained almost constantly. Knowing how to play golf, how to sing karioke, and how to drink are imperative. "You may not spend a minute by yourself," said Kallmeyer.<P>

Trusting relationships are built in part through sharing entertainment. "Relationships are everything that count in Korea," she said. "That's where the socializing comes in -- you have to drink together and sing together -- there's a lot of bonding that goes on."<P>

Those relationships can be more important than the product itself, short of a miracle cure that cures all ailments, Oh said. And informal meetings can be more important than formal ones: the former can be where the actual contract gets written.<P>

Some of this relationship-building may be easier than in Japan, because many Korean scientists speak English. Many receive their graduate or post-doctoral training in the U.S., and virtually all return to Korea, Kallmeyer said.<P>

<CENTER><B>Be later stage</CENTER></B><P>

Roberts Mitanyi also advises executives to study Korean history, culture and the Korean pharmaceutical industry, to learn how it modernized and where it's going.<P>

Companies looking for Korean partners should have a product at least in Phase II studies, if not in Phase III, Kallmeyer said. The ideal product will be in an area attractive in the Asian marketplace, such as hepatitis, cardiovascular disease, cancer and allergy, and it will have Korean patent protection, she said. <P>

As in many negotiations, it's best not to send the CEO or chairman of the company in at the beginning. "The system is very hierarchical," Kallmeyer said. "Whatever the CEO or chairman says is written in stone. So it's better to go in with a more junior person who can come back and say, 'My boss didn't agree with this.' It's also good to make meeting summaries and agree to them on both sides."<P>

In addition, unless the first meeting is with a very senior Korean executive, sending the CEO to make the initial presentation can send the message that there's a level of desperation on the U.S. side, Roberts said.<P>

Another rule of thumb for Korea, which is applicable elsewhere, is to know what you want. Korean companies typically want manufacturing rights, and they want to control the technology, said Bupp. "We had made the decision going in that we wanted to retain manufacturing and would supply a finished product. <P>

"By stating that very clearly, we eliminated some prospects, but we had clear objectives. If you don't do that until the end, both parties can walk away with a sour taste in their mouth."<P>

It's also important to read the hidden messages between the lines. "As in Japan, Koreans never say 'no,'" Kallmeyer said. "You have to read when the momentum is lost. The signals may be as subtle as having a dinner scheduled with the chairman and instead a manager shows up, or meetings get postponed."<P>

<CENTER><B>Quicker decisions</CENTER></B><P>

Although it varies, in some cases decisions in Korea can be made very quickly -- faster than in Japan. While it can still take time to do the due diligence, once a decision is made, the deal can be completed almost overnight, Oh said. <P>

"It's not like Japan, which is a bottom-up system," said Kallmeyer. "There are more privately held companies, 20-25 year old companies which the founder is still heading. If you can convince the top guy, it's a done deal."<P>

Bupp also felt that NEOP's deal went remarkably fast. The U.S. company started the process in early April. In June the two sides executed a letter of intent and in July a memorandum of understanding laying out the business terms was written. The deal was signed in August. <P>

"One advantage of doing business in countries like Korea or Singapore -- outside Japan -- is they're very straightforward business people," Bupp said. "They're hard negotiators, but when a decision is made, it's done very quickly. It's not a protocol-driven process. Here the scientists were brought in at the back side. In Japan you need to have the thought leaders buy in first -- that's one of the reasons it takes longer."<P>

As in Japan, once the deal is done, it's important to continue to invest in the relationship. "Americans tend to consider the contract a finished document," said Roberts. "Asians think of contracts as a starting point."<P>

With that in mind, it's critical to figure out ahead of time what kinds of operational support will be required by the Korean partner. Providing the proper support can also ensure that data generated in Korea will be applicable to regulatory submissions in other countries. <P>

For example, NEOP plans to pursue a stomach cancer indication for its RIGS products in Korea and will need to make sure that the Korean and U.S. protocols are in sync.<P>

<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-224</DOCNO>
<DOCOLDNO>IA064-000378-B007-188</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/4qtr/1113a1.htm 206.86.52.80 19970112100629 text/html 20219
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:06:31 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 20036
Last-modified: Thu, 23 May 1996 21:53:26 GMT
</DOCHDR>
<HTML><HEAD><TITLE>How Arris, Khepri putt deal together</TITLE></HEAD>

<BODY background = "../../../graphics/white-mi.gif"><P>

<B>From BioCentury, November 13, 1995</B><P>

<CENTER><H1>How Arris, Khepri put deal together</CENTER></H1><P>

<b><center>By Karen Bernstein<br>
Editor-in-Chief</b></center><p>
Despite the stated desire of nearly everyone in biotech to consolidate the industry, mergers don't grow on trees. Last week's announcement of a definitive agreement under which Arris Pharmaceutical Corp. will acquire Khepri Pharmaceuticals Inc. illustrates one solution to several of the key issues facing early to mid-stage biotech companies: both companies faced the problem of building critical mass in a fragmented industry, while Khepri in particular was caught in the limbo of mezzanine venture financing.<p>
With the exception of genomics and screening companies, the financing choices for mid- to late-stage private companies are extremely constrained. For many of these companies, corporate partnering may not be an option until they have identified and begun testing lead compounds. And the fewer the options, the less leverage companies have with mezzanine funders, who have struck increasingly tough bargains as their exit vehicle -- the IPO market -- has been less and less generous.<p>
Those funding realities place strong constraints on young companies, which can find themselves with technology that they don't have enough money to develop.<p>

<CENTER><h3>What Khepri needed</CENTER></h3><P>
Both ARRS and Khepri are developing therapeutics based on proteases, catalytic proteins that alter the structure and function of other proteins and peptides by cutting the targeted molecule.<p>
With $3 million in the bank at Oct. 31, 44 employees and an annual burn rate of $7.5 million, Khepri's choices were to do another funding round or look for a merger. The company has raised $23 million in three rounds of financing since its founding in 1992. At its last round in November 1994, it raised $11 million at $1.50 a share.<p>
<b><center>Timetable slips</b></center><P>
At the same time -- and not unusually -- Khepri found that its timeline for getting its first compounds into the clinic had slipped. "There were things we'd hoped to accomplish, like IND filings and corporate partnering, that didn't happen," said Alex Barkas of Kleiner Perkins Caufield & Byers, a Khepri investor. "If we'd had partners to offset the burn, that would have reduced the need for equity financing. There are lots of reasons why that didn't happen, but at the end of the day it didn't matter why."<p>
Barkas said that companies developing compounds -- as opposed to platform technologies -- face an initial period where it can be difficult to find partners. "It's easy for products with Phase II data. But in that in-between period when you have compounds in preclinical development, or Phase I or early Phase II, people say, 'Maybe we should wait, even if we have to pay more.'"<p>
Whether Khepri decided to go with more venture funding or an acquisition, the reality of the current environment is that valuations have been pushed down for companies with compounds in preclinical development and no corporate partners. <p>
At ARRS's share price of $9.875 prior to the announcement of the deal, the transaction is worth $20 million to Khepri shareholders -- less than the $30 million post-money valuation Khepri had at its last funding round. But Khepri was unlikely to do any better by tapping the financial markets.<p>
"This is reflective of the market for relatively young, private companies," said Khepri President and CEO Ron Henriksen. "Not only have a whole number of players gone away, but those who have stayed are acting like value players. We could have anticipated a very tough next round valuation discussion and a valuation down from the previous round."<p>
Having decided that a merger was the way to move forward, Khepri looked for an older, more established, public company, and came up with four or five candidates. <p>

<CENTER><h3>What ARRS needed</CENTER></h3><P>
ARRS, meanwhile, was looking for additional capabilities and technologies. A common criticism is that most of the so-called "target" companies don't have enough technology to keep a sufficient number of collaborations going to ensure that one or two will be successful. <p>
ARRS's approach to those issues has been two-fold: to focus on targets that address very large markets, and to aim for six active research partnerships at any one time. Some of those then will graduate to clinical development so that, several years out, there will be three or four programs in the clinic with new research collaborations coming up behind them. <p>
"That's a sustainable model: the partners bring cash and reduce the burn rate," said John Walker, president and CEO. "Our Bayer and Pharmacia deals both call for double-digit royalties, while both partners pay the full costs of R&D. We think that's the kind of model you have to strive for, though you can't get double-digit royalties every time."<P>
To make that scenario fly requires a broad opportunity base, which is why ARRS set out to find a new set of targets that fit with its in-house capabilities.<P>
ARRS initiated talks with Khepri in June 1994, in a meeting between Walker, Henriksen and Barkas. "We had already planned to make a bigger drive in protease technology," Walker said. "Alex picked up the obvious synergy between the two  companies."<P>
The companies continued discussions through August 1994, meeting with various board members. But by then Khepri was distracted by a funding round. ARRS then approached Khepri again last January, after ARRS had signed a partnering deal with Bayer AG, and made an offer that wasn't accepted. ARRS then picked up the thread again in August.<P>
ARRS wanted to expand its program beyond serine into cysteine proteases, Walker said. "We had discussions with other companies and universities, and kept coming back to Khepri, given its proximity, its scientists, and the depth and breadth of its technology."<p>

<CENTER><h3>Assessing the synergy</CENTER></h3><P>
Critical to any company thinking about long-term survival is having enough internal opportunities to withstand the inevitable failures of one program or another. At the end of the day, said Barkas, there will be one or two protease companies, one or two transcription factor companies, and so on. "I think there's a first mover advantage here," he said.<p>
ARRS believes the combination will create the most extensive portfolio of new targets of any company pursuing protease drug discovery. The company has long believed that to be successful, discovery companies need prolific pipelines of future product opportunities, Walker said. <p>
There are four main classes of proteases -- serine, cysteine, metalloproteases and aspartyl -- each of which is characterized by the chemical mechanism used by the protease to cleave chemical bonds. Proteases can either activate or inactive their target proteins.<p>
ARRS has been focused on serine proteases, while Khepri has pursued cysteine proteases. But in another year, said Henriksen, they would have been two protease companies competing for corporate deals as each moved into the other's area.<p>
The companies also have different R&D strengths. Khepri has expertise in protease biology, genomics and chemistry to produce reversible and irreversible cysteine protease inhibitors, while ARRS has combinatorial chemistry, screening, rational drug design, pharmacology and its Delta technology.<p>
ARRS hasn't fully disclosed the Delta technology, but it consists of a plasma component used in the design of protease inhibitors to provide structural anchoring at the catalytic site, allowing researchers to design in specificity.<p>
One of the key drawbacks to working with proteases has been the lack of specificity of compounds. Scientists have been able to design potent compounds, but because proteases show a great deal of homology at the catalytic site, specificity has been elusive. "Building in both specificity and potency has been the holy grail of protease inhibition," said Walker.<p>
The merger will allow ARRS to pursue multiple protease targets in parallel, increasing the number of potential partnering opportunities. ARRS plans to adapt its Delta technology for serine proteases to Khepri's cysteine targets, and to expand its internal cloning and expression capabilities through expertise acquired from Khepri.<p>

<CENTER><h3>Valuing the deal</CENTER></h3><P>
One of the hardest parts of M&A discussions is agreeing on the relative valuations of the companies. By this time, Khepri had concluded that it would take a stiff haircut in its next funding, giving it an incentive to be more flexible in any merger talks.<p>
From its side, ARRS had several ways of estimating the value of Khepri. "First, we knew we needed to build what Khepri already had, so there was an opportunity cost to us," said Walker. "That accounts for the majority of the investment decision. Our first assessment was a scientific one: we did a make-vs.-buy analysis."<p>
Beyond that, Khepri brought genomics capability and cysteine protease chemistry that ARRS couldn't build in-house. <p>
On the other hand, ARRS judged that Khepri on its own would be worth less than if it were folded into another company with more resources. "In terms of building value, a broader, more prolific pipeline was worth more than Khepri's smaller pipeline," Walker said. "And the cash we have provides more certainty that Khepri will be able to bring that pipeline to fruition. <p>
"That was a very strong consideration when we were looking at the technology value early on. It's not just the technology value, but the ability of the company to do something with that technology -- and that relates to the availability of capital."<p>
ARRS therefore estimated that the combined companies would be worth more than what ARRS would pay for Khepri.<p>
To make the deal work, Khepri's shareholders had to come to the same conclusion -- that Khepri ultimately would be worth more as part of ARRS than it would be on its own. Thus for Khepri's VCs, the calculus isn't that they'd put $23 million into the company and are getting back stock worth about the same amount.<p>
"This is not a cash-out liquidation event," said Grant Heidrich of the Mayfield Fund, a Khepri investor. "The value of Arris stock is different than if someone had given me cash. I'm not looking at today's value, I'm looking at what will be there in the future."<P>
Barkas also doesn't view it as a liquidation. "Because of the synergies that became apparent here, when we compare it to the alternatives for the company, we said this looks pretty attractive. <p>
"We had a company trapped in mid-stage financing hell, because of the absence of any true mid-stage and mezzanine financing in the biotech sector. That vacuum means the alternatives are going public or refinancing at increasingly less attractive valuations with other venture capitalists who have the same goals you had when you first invested -- and they want to invest at similar valuations. Or you could bring in mezzanine investors who are typically investing in public or private stocks and tend to put onerous terms into their agreements.<p>
"When you look at that as your alternative as compared with doing this, from a valuation standpoint it's probably a wash. And the upside is better here, on a train that's already moving."<p>
In the actual discussions between ARRS and Khepri, the valuation issue was dealt with by setting aside the actual amount of money implied by the deal. That varied with the price of ARRS shares and was at a high of $28 million in early September when ARRS was trading at $13.875. Instead, the parties focused on the number of shares Khepri stockholders would receive. In that way, both sides estimated the proportion of value each company brought to the party. <p>
Under the terms of the deal, ARRS will acquire Khepri in a two-stage closing. At the first closing in December, ARRS will issue 1.5 million shares of stock, of which 1 million will not become eligible for sale until January 1997. On Dec. 30, 1996, ARRS will issue, at its discretion, either 525,000 additional shares of stock or pay the equivalent in cash.<p>
Khepri shareholders will own 16.4 percent of ARRS on a fully diluted basis. Before the deal, ARRS has 10.7 million shares outstanding fully diluted and 8.75 million non-fully diluted.<p>

<CENTER><h3>Combining the programs</CENTER></h3><P>
Khepri has two products in preclinical development, CPI-1 and rNEP, and two in R&D, cathepsin O2 (CatO2) and ICI-1. <p>
CPI-1 (cysteine protease inhibitor-1) is a small molecule inhibitor of cathepsins B,L and S, which are implicated in the tissue destruction associated with rheumatoid arthritis. Recombinant human neutral endopeptidase (rNEP) is a protease that inactivates a wide range of peptide mediators involved in the airway inflammation associated with asthma and chronic obstructive pulmonary disease (COPD).<p>
ICI-1 is a small molecule inhibitor of the interleukin-1 converting enzyme, ICE, a cysteine protease that promotes inflammation by changing inactive IL-1 to its active form. ICE is implicated in inflammatory bowel disease. <p>
CatO2 is another cysteine protease associated with the bone breakdown seen in osteoporosis.<p>
The company is in discussions with potential partners for all of these programs.
ARRS has focused on inhibition of serine proteases, with most of its research on tryptase, an enzyme with potential to treat asthma and other inflammatory diseases.<p>
The tryptase program is in development with Bayer, under a $70 million November 1994 deal to develop orally active inhibitors of tryptase and chymase, enzymes that play an important role in asthma, allergic rhinitis and allegic conjunctivitis. <p>
APC 366, ARRS's first generation tryptase inhibitor, is part of that deal. The compound is in a Phase IIa trial in asthma, with results to be announced at the end of the first quarter of 1996. A second generation oral inhibitor is in preclinical development.<p>
Work on chymase is in discovery. Chymase is implicated in respiratory ailments, as well as in cardiovascular inflammation.<p>
ARRS is addressing the role of serine proteases in the clotting cascade under a $40 million Sept. 1995 deal with Pharmacia AB to develop oral therapeutics for blood clotting disorders. The partners are developing inhibitors of three serine proteases: Thrombin, Factor Xa and Factor VIIa. The companies have lead candidates in preclinical evaluation.<p>
ARRS also has a separate, broad program in receptor-based discovery technology focused on oral cytokine and growth factor mimetics. It has early drug leads with Amgen Inc. for an oral mimetic of erythropoietin, while a collaboration with Pharmacia in human growth hormone is slightly ahead of the EPO program. ARRS is in early research on its own in G-CSF (granulocyte-colony stimulating factor) and TPO (thrombopoietin).<p>
In addition, ARRS has two other collaborations with Pharmacia: a deal covering ARRS's molecular diversity and high throughput screening technologies, and a collaboration to apply ARRS's artificial intelligence technology to Pharmacia's in-house drug development.<p>
ARRS is internally organized into three groups with different R&D responsibilities. A core discovery group will incorporate Khepri's general technology expertise, while Khepri's protease programs will be folded into the protease group. A third group has responsibility for the receptor programs.<p>
Within the protease program, decisions will be made on prioritizing the various programs. ARRS's two partnered programs will have top priority. Next, Walker said, will be Khepri's cathepsin programs in rheumatoid arthritis. "We see partnering opportunities over a reasonable period, so we want to apply the necessary science and ensure a collaboration," he said.<p>
ICE and CatO2 are earlier and will have lower priority. ARRS plans to apply its Delta technology to those molecules. <p>
Finally, ARRS will complete ongoing preclinical studies of rNEP, which falls outside its small molecule focus, and evaluate partnering opportunities based on the data.<p>
The combined company will have 152 employees, and ARRS plans a reduction of about 15 percent. ARRS's burn rate in 1995 was less than $3 million, and was projected to rise to $6 million in 1996. Combined with Khepri's projected 1996 burn of $8-$9 million, that would total $14-$15 million. <p>
The company has committed to reduce the combined burn by 25 percent going forward. In 1996, operating expenses are projected at $26 million, with a burn rate of $11-$12 million. Those figures don't account for increased revenues that might accrue from new corporate partnerships.<p>
The acquisition will be accounted for as a purchase. ARRS will take write off the bulk of the purchase price as in-process R&D this quarter. A decision hasn't been made on the fate of Khepri Canada, a 50 percent owned subsidiary.<p>

<CENTER><h3>Finding first principles</CENTER></h3><P>
Having successfully navigated an acquisition, Walker thinks the difficulties of putting together Tier II and III biotech companies are myriad. Even before the practical issues of negotiating between competing egos and notions of value, are the fundamental issues of finding companies that are truly synergistic -- beyond the trite use of that word in every merger announcement.<p>
"There needs to be complementarity of science -- not redundancy but complementarity," said Walker. "While program overlap may present an opportunity to cut the combined burn rate, that's a financial issue, not a business growth issue. Growth is best accomplished by complementarity."<p>
Also critically important is equality between the two sides coming together. "That's difficult," said Walker, "because of competition on the management teams over who's going to make decisions. With any organization, you clearly have to define who has the leadership role. Where people get into difficult straits is figuring out who will do that."<p>
In this case, Henrikson will stay on until the end of the year, while three members of Khepri's management, Dave Estell, Don Payan and Jean Warner, will stay on as ARRS vice presidents.<p>
But while the realities of management mean there can't be two chiefs, at the employee level, mergers and acquisitions can be accomplished in such a way that the members of the junior company don't feel like victims. <p>
"Even though this is billed as an acquisition, we made a very specific commitment to the Kepri and Arris people that scientifically this is a merger of equals," Walker said. "The reductions will be borne by both companies, not solely by Khepri. That's a very important message, because you need to insure there's no we/they orientation, but a unified group of scientists."<p>
Finally, true mergers are hard to pull off if the companies aren't geographically proximate, and there's no reason to expect that one company's perfect partner will be located next door, as Khepri and ARRS are in South San Francisco.<p>
Finding all of those elements in one package will be very hard for most companies, he concluded. <p>


<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-225</DOCNO>
<DOCOLDNO>IA064-000378-B009-363</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/4qtr/1120a7.htm 206.86.52.80 19970112101237 text/html 7200
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:12:36 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 7018
Last-modified: Thu, 23 May 1996 21:53:39 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Desmos: A zipper for tissue adhesion</TITLE></HEAD>

<BODY background = "../../../graphics/white-mi.gif"><P>

<b> From BioCentury, November 20, 1995</b>

<CENTER><h2><i>Emerging Company Profile</h2></i><P>

<h1>Desmos: A zipper for tissue adhesion</h1></CENTER><P>


<b>Desmos Inc.</b><BR>
San Diego, Calif.<BR>
Technology: Tissue engineering, cell therapy and organ transplantation<BR>
Founded: 1993 to commercialize discoveries of scientists Vito Quaranta and Jonathan Jones<BR>
University collaborations: Northwestern University Medical School, Scripps Research Institute<BR>
Corporate partners: None<BR>
Disease focus: Tissue and organ transplantation<BR>
Number of employees: 20<BR>
Funds raised: $1.5 million<BR>
Funding sources: Sanderling; Burr, Egan, Deleage<BR>
CEO: Fred Middleton, Sanderling<BR>
Patents: 4 issued<p>

Desmos Inc. is focusing on tissue engineering and cell therapy, concentrating on internal applications of tissue adhesion.<P>

In tissue engineering, the company is looking at the way epithelial cells are organized, attach to the skin, and differentiate. In cell therapy, Desmos is working on pancreatic islet cell transplantation and in vivo use of implanted cells. The company also is working on periodontal uses of cells.<P>

Desmos was founded to commercialize discoveries in epithelial cell growth and attachment by Vito Quaranta of the Scripps Research Institute and Jonathan Jones of the Northwestern University Medical School.<P>

Although epithelial cells account for more than 90 percent of the body's cell types, many kinds are difficult to culture and grow. Desmos' founding scientists have discovered a novel laminin, a class of proteins found in the extracellular matrix. The protein, Desmosin, plays a role in helping epithelial cells attach to the extracellular matrix, signal other cells and organize into body tissues.<P>

<CENTER><B>How it works</CENTER></B><P>

Desmosin is found in the basement membrane of epithelial tissues and, with another protein, a cell adhesion receptor called integrin alpha6-beta4, anchors the epithelial cells to the matrix. In addition, alpha6-beta4 may signal cells to stop growing, or to spread, or to refrain from migrating. <P>

This receptor and desmosin work together like two halves of a zipper to hold epithelial cells to their framework, resulting in the formation of attachment sites called hemidesmosomes. Company scientists discovered that certain epithelial cells cultured on Desmosin matrices spontaneously develop hemidesmosomes.<P>

The company is developing a Desmosin matrix, similar to that found in the body, for growing epithelial cells to be used in medical applications involving a wide variety of epithelial cells. According to Desmos, because the matrix provides an attractive environment for cells, it can be used to grow such cells in greater numbers than ever before from a small number of donor cells, and also to coat synthetic implants or prostheses for increased biocompatibility.<P>

Initially, Desmos will use Desmosin to treat periodontal disease: Desmosin will be employed to reattach gum epithelia to teeth, and to titanium dental implants. <P>

The second planned application is the treatment of Type I (insulin-dependent) diabetes by expanding healthy porcine pancreatic islet cells and subsequently implanting them into patients -- eliminating the need for insulin injections.<P>

The two initial applications were chosen because of market potential, said Charlotte Clark, vice president of business development. According to Clark, more than half of all Americans over 45 have periodontal disease, and about 500,000 receive implants each year. Of these, 5-10 percent of patients experience poor tissue attachment, and there are no known protocols for managing this problem.<P>

<CENTER><B>Insulin program</CENTER></B><P>

Clark estimated that 2.5 million Americans use insulin, including Type I and some Type II diabetics. Some 500,000 of these individuals could benefit from pancreatic islet cell transplantation, but transplant rejection and donor scarcity have limited the efficacy of such an approach.<P>

Both programs are in the research/early preclinical phase. In the periodontal program, titanium implants coated with Desmosin connected to the bone and gum after 30 minutes, said Director of Research Scott Glaser. Desmos is aiming to file its first IND, for use of Desmosin with dental implants, in late 1996 or early 1997. <P>

A second indication would be to treat gums and teeth affected by periodontal disease with Desmosin to promote reformation of the gum epithelia around the treated teeth.<P>

In its pig islet transplantation program, Desmos has succeeded in growing adult pig cells in the Desmosin medium, and is talking to potential corporate partners about delivery systems for the cells.<P>

Eventually, Desmos hopes to develop human islet cells for transplantation. On average, 500,000-800,000 islet cell clusters would be needed, with an average of 2,000 cells per cluster, Glaser said. IND timing for the diabetes program will depend on the choice of delivery system and the corporate partner.<P>

"We believe our technology is also transferable to neurons, hepatocytes, cartilage, and other cell types," Clark said. <P>

<CENTER><B>Extending the technology</CENTER></B><P>

Over the long term, Desmos will explore additional technology applications, including liver tissue engineering for transplantation, and the use of Desmosin to coat a range of implantable devices to improve biocompatibility and reduce formation of blood clots or fibrotic tissue at the implantation site. These programs will most likely be developed through corporate partnerships or licensing agreements, Clark said.<P>

Desmos plans to license its Desmosin matrix to companies and researchers for use in other applications requiring epithelial cells. It currently is supplying seven academic institutions with Desmosin for research purposes only, including the University of California at Los Angeles, the University of Helsinki, and the Fred Hutchinson Cancer Center.<P>

Desmos received seed financing of $1.5 million from Sanderling and Burr, Egan, Deleage & Co. in 1994. It is raising a second venture round from the original funders and new sources, and hopes to raise about $5 million.<P>


<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-226</DOCNO>
<DOCOLDNO>IA064-000378-B010-1</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/4qtr/1106c1.htm 206.86.52.80 19970112101304 text/html 7617
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:13:08 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 7435
Last-modified: Thu, 23 May 1996 21:53:15 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Exelixis: Tightly focused vision for genomics</TITLE></HEAD>

<BODY background = "../../../graphics/white-mi.gif"><P>
<b> From BioCentury, November 6, 1995</b><P>

<CENTER><h2><i>Emerging Company Profile</h2></i><P>

<h1>Exelixis: Tightly focused vision for genomics</h1></CENTER><P>


<b>Exelixis: Tightly focused vision for genomics</b><br>
Cambridge, Mass.<br>
Technology: Functional genomics<br>
Founded: 1995 by Spyridon Artavanis-Tsakonas, Corey Goodman, Gerald Rubin, Charles Cohen, Stelios Papadopoulos and Sherry Reynolds<br>
University collaborations: University of Edinburgh<br>
Corporate partners: None<br>
Clinical status: NA<br>
Disease focus: NA<br>
Number of employees: 15<br>
Funding: Atlas Venture, Oxford Bioscience Partners, PaineWebber, and Evolution Partners (an institutional investor that co-invests with PaineWebber)<br>
CEO: None, search ongoing<br>
Patents: None<p>

As is generally the case with new discovery platforms, genomics has sprouted a plethora of companies, each of which is tackling the problem of translating genetic information into useful drug candidates from a slightly different angle.<p>

The emphasis of these companies ranges from high throughput sequencing, to the use of large patient populations to hunt for disease markers in polygenic diseases, to the use of differential display to look at gene expression in diseased and healthy tissue.<p>

Although all the genomics companies are looking at the function of genes, Exelixis Pharmaceuticals Inc. believes the key question is what level of function researchers need to understand in order to choose optimal drug discovery targets. <p>

<center><b>Living model systems</center></b><p>

"To do that, you need to put genes in a living model system," said Sherry Reynolds, a founder and acting president and COO. "Understanding function in terms of gene expression is different than understanding how the molecule behaves in a biochemical or genetic pathway. If the end game is getting products, you want to focus your energies as soon as possible on optimal targets."<p>

The 1995 startup is focused on functional genomics, elucidating the connection between genes and disease in living model systems. The Cambridge, Mass., company uses model systems to identify critical genes in disease pathways, determine their functional relationships and select targets for therapeutic intervention.<p>

The company believes that its Drosophila and mouse model systems will provide the missing link between structural genomics -- which uses random sequencing, differential cDNA display and positional cloning to find genes -- and the discovery of optimal targets for drugs.<p>

"Just finding one mutation in one gene doesn't mean you know how to treat a clinical population," said Reynolds. "The ras (oncogene) pathway is a good example. Ras itself is not a very good therapeutic target. It's really been work in model systems, systematically mutating the genome, that has led to a better understanding of its function and how it communicates with the rest of the pathway. That will enable the choice of promising therapeutic targets."<p>

Exelixis, the Greek name for evolution, bases its approach on the premise that a thorough understanding of a disease pathway is necessary to identify critical regulatory molecules and the selection of targets for drug discovery. Because genes, gene functions and interactive genetic pathways are highly conserved across species, the company believes it will be able to use its platforms to identify targets and generate animal models of human disease.<p>

Exelixis is using the fruit fly, Drosophila melanogaster, to identify key regulatory molecules for drug discovery. The Pathfinder model is useful because of its high degree of structural and functional homology with humans, and because of its amenability to rapid large-scale mutagenesis.<p>

The company puts human genes of interest into its Pathfinder Screen to create a mutated phenotype. Researchers then mutate that strain one gene at a time to look for other genes that modify the target gene -- i.e., to find other critical elements in the target gene's biochemical pathway. <p>

<center><b>The trap</center></b><p>

The screen thus reveals the genes whose full expression is crucial for the function of the pathway and encode the key regulatory proteins. Once those have been discovered, the company sets up functional assays to screen for small molecules that turn on or off elements in the pathway of interest.<p>

Exelixis's second platform is its Excel Trap. The trap is designed to selectively trap secretory and transmembrane proteins in mice. All of the major biotechnology products commercialized to date, such as the interferons and G-CSF, are members of those classes of proteins. <p>

A vector designed to trap out those proteins is inserted into mouse embryonic stem cells, and the transformed cells then are put into mice. Because the vector also contains the beta-galactosidase reporter gene, researchers can quickly see in which tissues the genes are expressed. If a particular protein looks promising, the company then can develop a mouse line for further study.<p>

The technology is licensed from the University of Edinburgh, and Exelixis is working with William Skarnes of the Centre for Genome Research at the university to enhance the technique.<p>

The two platforms also can be used interactively: genes found using the mouse technology can be put into the Drosophila model to gain further understanding of functional pathways, while genes identified using Drosophila can be used to create knockout mice.<p>

Exelixis has identified about 10 human genes, which it is putting into its Pathfinder screen in a variety of disease areas. "These genes represent a sampling of technical issues -- they are clinically relevant and demonstrate the company's capabilities," Reynolds said.<p>

Exelixis plans to collaborate with corporate partners to assess the function of known human disease genes, and to license genes from academic institutions for de novo target discovery in conjunction with its own in-house efforts. Corporate partnering, which will be one of the cornerstones of the company's business model, is a particular area of expertise for Reynolds, who played a lead role in the Millennium Pharmaceuticals Inc.-Hoffmann LaRoche transaction.<p>

Because its focus on functional genomics doesn't require the same infrastructure that companies need for sequencing or positional cloning, Exelixis believes it will require less capital than many other genomics companies. The company raised $4 million in its first round of funding earlier this year and is planning to raise a series B round of $5-$10 million this fall.<p>


<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-227</DOCNO>
<DOCOLDNO>IA064-000378-B006-337</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1996/1qtr/032596a1.htm 206.86.52.80 19970112100436 text/html 21754
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:04:37 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 21571
Last-modified: Wed, 18 Sep 1996 23:42:01 GMT
</DOCHDR>
<HTML><HEAD><TITLE>ReoPro marketing -- on year later </TITLE></HEAD><BODY background="images/white-mi.gif">

<b>From BioCentury, March 25, 1996</b><P>
<center>
<h1>ReoPro marketing -- on year later</h1></center>

<b><center>By Karen Bernstein<br>
Editor-in-Chief</b></center><p>
When Eli Lilly launched ReoPro just over a year ago, the slow ramp up of Centocor Inc.'s anti-platelet antibody caught many on Wall Street by surprise. A number of analysts had predicted first year sales for the drug in the range of $70-$150 million. Instead, Lilly's ReoPro sales for 1995 totalled $22.8 million.<p>
The picture brightened over the year. After beginning marketing in February, sales increased every quarter, from $1 million in the first quarter, to $3 million in the second, $6.5 million in the third and $12.3 million in the fourth. By the end of 1995, ReoPro had received formulary approval at more than 70 percent of the Tier I, II and III hospitals that account for 80 percent of the angioplasties in the U.S., according to CNTO President and CEO David Holveck.<p>
Still, the drug ran into resistance on several of fronts, among them the increasing use of stents and the bleeding issues associated with use of ReoPro and heparin. In addition, the some hospitals resisted the up front-costs of ReoPro because they would be unable to capture the presumed cost savings from the drug's effect on complications from angioplasty procedures, which would come downstream <i>(see BioCentury, April 24, 1995).</i><p>
A year later, cardiologists have more experience working with the GPIIb/IIIa inhibitor, and CNTO and Lilly have more selling. Most importantly, the companies now have data from two clinical trials that were halted early because of positive outcomes -- the EPILOG all comers angioplasty trial and the CAPTURE refractory unstable angina study <i>(see BioCentury Extras, Dec. 15 and Dec. 21, 1995).</i> Those trials have added important information on how to control bleeding by administering lower doses of weight-adjusted heparin with ReoPro, which both should improve patient outcomes and shift the cost/benefit toward the drug. <p>
In addition, the CAPTURE data provide a rationale for extending use of ReoPro from the catheterization lab into community hospitals, where non-interventional cardiologists would use the drug to stabilize patients with unstable angina.<p>
<b><center>New economic model</b></center>
CNTO hasn't recalculated the economic model that came out of the original EPIC study. Based on that model, ReoPro saved $1,100-$1,200 per patient at six months, while the drug costs $1,350. By reducing the need for transfusions and extra time in the hospital to manage bleeding, the company expects that the cost advantage has been tilted in favor of ReoPro, Holveck said. The company expects to submit its economic analysis of the EPILOG data to the FDA by the end of the year, he said.<p>
The key pharmacoeconomic battle isn't over the savings at six months, but on the savings in the acute setting, he said. "So a good portion of the economic sales pitch in reality has been focused on the drug's effectiveness in getting patients in and out of the cath lab." Part of the savings comes by eliminating the need for pretreating patients with one or two days of heparin or with ticlopidine, a platelet mediator, Holveck said. ReoPro also saves time during procedures by eliminating or reducing the need to fight thrombus, which means more patients can be moved through the cath lab, he said. Finally, with fewer adverse events after procedures, patients can get out of the hospital faster.<p>
But even absent definitive pharmacoeconomic data, marketing of ReoPro will be helped by the confirmatory efficacy and safety data provided by multiple clinical studies, Holveck said. "In retrospect, while you can get approval based on one trial, the medical community likes to see another trial. We started to pick up momentum after December. Having been through the pharmacy committees prior to that allowed us to have a quicker build after the data came out."<p>
The sales pitch for ReoPro also has evolved away from a message that put the drug into competition with stents, Holveck said. "The initial launch emphasized the use of ReoPro to reduce abrupt closure, which caused competition. The message today is, 'If you're going to use any devices, it's better to have ReoPro on board.' People feel comfortable with both, especially if they're going to stent smaller vessels. That's all starting to come together."<p>
Lilly's sales reps haven't yet started targeting the non-invasive cardiologists whose practices are likely to be affected by the CAPTURE data, Holveck said. That process will start at the American College of Cardiology meeting this week in Orlando, Fla. "I think non-invasive cardiologists will be interested when a patient presents with hot unstable angina," he said. "You can cool them down with ReoPro and then transport them to cath labs."<p>
Holveck said he doesn't know if the education process will be as long for this group of cardiologists. "People have said to me that non-invasive cardiologists are more pharmacologically in tune, but I don't know. I've talked to a few and they seem to have a quicker grasp of how to manage patients with drugs."<p>
To get a sense of how the clinical community has reacted to the new data and to the past year's experience with the drug, BioCentury surveyed five hospitals about their use of ReoPro in the past year and their projections going forward.<p>

<h3>The Cleveland Clinic</h3>
The Cleveland Clinic (Cleveland, Ohio) spent about $300,000 on ReoPro in 1995 to treat about 225 patients, according to Tom Franko, quality assurance pharmacist at the clinic. He expects use to increase this year, although he's not sure by how much.<p>
Part of the increased use, Franko said, will be driven by the positive data from the CAPTURE and EPILOG trials.<p>
"Those studies showed it was unethical to continue the studies as far as the placebo group was concerned," Franko said. "We will review use based on the new studies to understand which patients will benefit -- we have to do that. Ethically, there are issues regarding quality of life, mortality and morbidity. The organization will look for opportunities of direct benefit to patients and proceed accordingly."<p>
The Cleveland Clinic hasn't quantified the cost/benefit of ReoPro, a calculation that now may be more complicated because CAPTURE and EPILOG showed a benefit on mortality. <p>
"I don't know how to quantitate the value of a life," Franko said. "The experience with alteplase (Genentech's Activase tPA) gives you an idea that these agents will be used. Alteplase is very costly, but has 70 percent of the market, and it saves 1 life per 100. I don't yet know how cardiologists will use the agent based on the new studies, but we won't wait until the studies are published to increase use."<p>
The clinic still is analyzing its 1995 costs of ReoPro, to see if the HCFA reimbursement for angioplasty covered the addition of ReoPro to the procedure. The clinic also is studying the combined use of ReoPro with stents.<p>
As of now, the clinic is still using the drug only in high-risk angioplasty patients and is making use decisions on a case-by-case basis, he said.<p>

<h3>Texas Heart Institute</h3>
Texas Heart Institute in Houston used ReoPro in about 250 angioplasty patients in 1995, and expects usage to rise this year. "We're now using it in 25-40 percent of all of our angioplasties," said Terry Ferguson, associate director of cardiology research. "It's still targeted to high-risk angioplasty, but high risk is in the eye of the beholder. I'd be surprised if usage crept above 40 percent, but with the EPILOG results, who knows?"<p>
The institute spent $800,000 to $1.2 million on the drug in 1995, with use starting in April. This year, usage may increase by about 25 percent, Ferguson said.<p>
About half of the usage is in combination with stents. Cardiologists at the institute use stents in 40-50 percent of their procedures. They do close to 2,000 angioplasties annually.<p>
Importantly, the circumstances in which ReoPro is given have shifted dramatically as physicians have become more comfortable with the drug. Initially, 75-80 percent of use was for bailout, after other interventions had failed. Prophylaxis accounted for only 15-20 percent of use, Ferguson said. That has now reversed, with 75-80 percent of use for prophylactic purposes.<p>
It's not yet clear how much impact EPILOG and CAPTURE will have, because cardiologists at the institute are already believers in the drug, Ferguson said. Nevertheless, he said EPILOG in particular may have "far-reaching implications" because it extends the benefit to low-risk patients. <p>
The results of CAPTURE, which was aimed at patients who present with symptoms at community hospitals, ultimately could extend use, he said. But as with cardiac catheterization labs, Ferguson expects that doctors at community hospitals will need to go through the same learning curve before ramping up use of ReoPro.<P>
Ferguson said that while he doesn't have hard numbers on ReoPro, "my suspicion is that it is cost effective and what we're saving in terms of downstream complications is covering the cost of ReoPro." <p>
Purchases are still affected by ongoing clinical trials of other therapies where patients receive drugs for free, but that impact may be limited by the good ReoPro data. "Since EPIC and EPILOG, you've changed the standard that people are held up to," Ferguson said. "So ethically you need to work out some sort of mechanism so you can give ReoPro." <p>
Among ongoing trials are a ReoPro/stent study, trials of GPIIb/IIIa inhibitors from Merck and Roche, and oral GPIIb/IIIa inhibitors from Roche/Genentech and Boehringer Ingelheim, he said. <p>
<h3>Herman Hospital, University of Texas </h3>
Despite its location in the same city as the Texas Heart Institute, the experience of Herman Hospital cardiologists is an object lesson in the obstacles ReoPro continues to face among cardiologists who remain focused on heparin.<p>
H. Vernon (Skip) Anderson, a cardiologist at the hospital, estimates that about two dozen patients received ReoPro in 1995, out of a total of about 650 angioplasties. The drug was given primarily to two groups of patients: patients with acute myocardial infarction who had failed thrombolytics and received angioplasty; and patients with unstable angina with a thrombus in the vessel who were to receive angioplasty, or who developed a thrombus in the vessel during intervention. He doubts the number of patients who receive the drug will increase by anything close to 25 percent this year.<p>
The primary issue among Herman Hospital cardiologists -- though not with Anderson, who participated in the EPILOG trial and is familiar with how to use ReoPro -- is bleeding. "We've had some bleeding problems -- a number of groin bleeds and internal bleeds -- and it has soured some people a little bit," he said. "The problem is heparin. I, being familiar with the data, understand the necessity of weight-adjusted heparin. But I have not been successful in educating enough of my colleagues around here. The dominant attitude is, 'If there's a thrombus in the vessel, I need more heparin, not less.' So increased usage depends on getting out that message. Right now there's a very negative impression of ReoPro: that it's a dangerous drug and you have to be careful when you give it. Getting the EPILOG results out should help."<p>
Another factor in the low ReoPro usage at Herman Hospital is stent use. "People like stents," Anderson said. "They have low restenosis rates and people say they can use a stent and give patients aspirin instead of an expensive drug. I point out that you can only use stents in 50 percent of patients."<p>
There are several ongoing trials at Herman, including a stent trial and the ReoPro/stent trial. One trial that Anderson would like to see is of ReoPro in patients who've had previous vein grafts. "We see a fair amount of people who've had grafts before. I'd like to see data on ReoPro use in patients coming in for angioplasty on eight, 10 or 12-year old vein grafts."<p>

<h3>Lennox Hill Hospital</h3>
ReoPro is being used in about 10 percent of the cardiac interventions at Lennox Hill Hospital in New York. The 1,600 interventions performed annually include angioplasty, stents and rotoblator procedures, according to Jeffrey Moses, a cardiologist at the hospital. Only about 20 percent of the hospital's procedures are pure angioplasties, he said. About 65 percent involve stents.<p>
The goal of Lennox Hill is to keep ReoPro usage at about the 10 percent level. The cath lab's complication rate is very low -- below 1 percent for infarctions and out-of-lab closures, Moses said. "With that low a baseline, how much lower can you get?"<p>
At those complication rates, he said, it would cost $300,000 to $400,000 to lower the infarct rate. "The dilemma isn't whether it's a good drug, it's an economic issue now," Moses said.<p>
Because using ReoPro on all patients would be too expensive, the hospital is setting up a formal policy and procedures for its use. Last year, clinicians reached a consensus that ReoPro was appropriate where there was thrombus, myocardial infarction, vein grafts, or vessels too small or too distal to stent, Moses said. The guidelines will be finalized this year.<p>
Lennox Hill was an early adopter of ReoPro, so the data from the EPILOG trial haven't had much of an impact on use. The hospital has had one cerebral bleed with use of the drug. Moses' solution to the potential for bleeding is to omit the use of heparin when he's giving ReoPro. "Except in unusual situations, I just don't use heparin with it. I let ReoPro carry the day."<p>
As for the impact of the CAPTURE trial, Moses has doubts as to how widely the drug will be used at community centers, except in special situations. "I don't see any role for ReoPro in community hospitals," he said. "CAPTURE was done in settings where angioplasty was scheduled for the next day, where you knew you'd be done in 24 hours. But if I'm at a community hospital, I don't know if it will be done the next day. Say I give ReoPro on Tuesday, and the angioplasty is done on Friday. You can't redose because of the potential antibody response. We don't yet know enough about how important the antibody issue is."<p>

<h3>Cedars-Sinai Medical Center</h3>
ReoPro use has gone up at Cedars-Sinai in Los Angeles over the past year from the 10 percent of the 850 annual angioplasties originally projected to about 30 percent of patients. The center initially issued guidelines that the drug not be used in stented patients -- which constitute 80 percent of its patients -- but it quickly became clear that these patients were most likely to benefit from ReoPro, because they were already the most at risk for reclosure, according to Charles Lacy, director of drug information services.<P>
Along the way, Cedars-Sinai surveyed the guidelines of 20 hospitals that perform more than 300 angioplasties annually. All had seen increased use of ReoPro over the course of 1995, from initial rates of 5-20 percent to an average use in 33 percent of angioplasty patients by year end, Lacy said. He noted that one institution was keeping use to 20 percent by acting as the purchasing agent for the cath lab and making the cath lab pay for drug. <P>
The center also did a cost analysis of its own patient population, comparing costs for stented patients with and without ReoPro, and unstented patients with and without ReoPro. "We found the cost of care was much greater in the patients who received ReoPro than in those who didn't,  for a net loss of $2,000 per patient on average," Lacy said.<p>
But the study also illustrated the pitfalls of cost/benefit analyses. "It was a flawed study because the patients who received ReoPro were sicker patients, so it wasn't ReoPro per se that was causing the increased costs," Lacy said. "But it did identify the worst case-scenario of loss for the hospital."<p>
By the fourth quarter, use was up to 30 percent of patients. "This was in part because of the successes seen in use and the small numbers of adverse effects," Lacy said. "Bleeding really only occurred in patients who shouldn't have gotten the drug, such as older or smaller individuals, or those who had already had a bleeding episode."<p>
As a result, Cedars-Sinai revamped its ReoPro guidelines. "We changed the criteria to include stent patients, and we changed the contraindication of low weight to a strong warning to always weight-adjust heparin," Lacy said. "We also changed to include patients who had recently received thrombolysis such as tPA or streptokinase. We had originally said it was contraindicated for those patients."<p>
There have been two bleeding episodes at Cedars-Sinai, one of which was an eye bleed that resulted in blindness, the other being a minor bleed from the catheter site. Both patients were poor candidates for therapy, Lacy said.<p>
Once the EPILOG data appeared, the center also decided to be proactive in adjusting its practice to fit the new information, even though the data haven't been published and subjected to full scientific scrutiny. "EPILOG has definitely increased use," he said. "Everything that was contraindicated before is at worst now a strong warning: patient weight, age, prior thrombolytic use, even prior ReoPro use." Even though the data are unpublished, "it's better to budget for it now," Lacy said.<p>
Use also has been extended to lower-risk patients with grade C lesions but not necessarily a clot. The presence of a lesion implies that these patients are at risk for negative consequences. Previously, use was restricted to patients in whom a clot could be seen.<p>
<b><center>Budgeting</b></center><p>
The center is building a formal budget for ReoPro. "We're anticipating final use in 35 percent of patients," Lacy said. The center is paying the full price of $1,350, in line with the other hospitals surveyed -- the drug doesn't appear to be widely discounted.<p>
Next to be considered will be the CAPTURE data. Even more so than the EPILOG data, the implications for CAPTURE to hospital budgets are daunting. "I don't know what we'll do if the data are of the same gravity as the EPILOG data -- and it looks like it is," Lacy said.<p>
Unlike Moses at Lennox Hill, Lacy said that Cedars-Sinai cardiologists aren't convinced that ReoPro will be restricted to one-time use. "If you believe just because it's an antibody you can't use it twice, then use in the CAPTURE setting would be restricted to patients who would be PTCA (angioplasty) candidates very shortly." he said. "However our cardiologists who've looked at this suggest that the 6-1/2 percent of patients who develop antibodies to ReoPro are just developing antibodies consistent with reactions to any large molecule. That's because the presence of antibodies hasn't translated into any kind of negative reaction like anaphylaxis."<p>
Lacy expects that cardiologists will experiment, giving ReoPro to patients who already have received it once. Likely candidates are high-risk patients who are receiving a second angioplasty, with stents. "When the patient is saved, with no bleeding, no restenosis, and no anaphylaxis, we'll see physicians starting to use it no matter what the FDA says."<p>
If that proves to be the case, and the CAPTURE data in non-interventional settings hold up, then "it could easily double, triple or infinitely increase the number of doses we need," Lacy said. <p>
"The bottom line is that our concern and expectation is that use of this drug will greatly increase," he said. "Originally, the manufacturer suggested it should be used in 30 percent of patients. We thought that was too high and expected it to be used in 10-15 percent, though we were trying to keep it at 5-10 percent. Now it's turning out the projection of the manufacturer is too low."<p>
Thus in the short term, Lacy expects that use of ReoPro will increase dramatically. However, in two to five years he anticipates that use will decline as other drugs and alternative therapies enter the market. These will range, he predicted, from other GPIIb/IIIa inhibitors, to excimer laser angioplasties, to stents impregnated with heparin. The latter, he said are showing similar mortality reductions to ReoPro in large clinical trials.<p>
Finally, Cedars-Sinai is trying to minimize wastage of the drug, which comes in 10 mg vials costing $450. Patients receive an average of 24.7 mg, wasting about 5.3 mg per patient. "The company now accepts back partial vials, and we're exploring the best mechanism for storing that and reducing our overall costs," Lacy said. "The drug should be priced at a cost per milligram."<p>

<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-228</DOCNO>
<DOCOLDNO>IA064-000378-B009-262</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1996/1qtr/022696b1.htm 206.86.52.80 19970112101150 text/html 9557
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:11:53 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 9375
Last-modified: Thu, 23 May 1996 22:03:30 GMT
</DOCHDR>

<HTML><HEAD><TITLE> Emerging Company Profile</TITLE></HEAD><p>

<BODY background = "../../../graphics/white-mi.gif"><p>
<b> From BioCentury, February 26, 1996</b><p>

<b><center> Biotrin Holdings Ltd</b> </center> <br>
Dublin, Ireland<BR>
Technology: Biomarkers to assess organ damage<BR>
Disease focus: Transplantation and virology<BR>
Founded: 1992 by Cormac Kilty<BR>
University collaborators: Trinity College, University of Washington at Seattle, University of Berne, Columbia University and the University of Leiden<BR>
Corporate partners: None<BR>
Clinical status: NA<BR>
Number of employees: 51<BR>
Funds raised: 2.2 million<BR>
Funding sources: Biotechnology Investments Ltd., ICC Venture Capital and FORBAIRT (an Irish development agency) <BR>
President: Cormac Kilty<BR>
Patents: One issued in U.S. covering liver transplant marker<P>

<h1><center> Biotrin: Zeroing in on organ damage</h1></center> <BR>

Biotrin Holdings Ltd. operated for its first year and a half without venture money, which meant it needed products in order to survive. Now with $2.5 million in sales in 1995 from the sale of test kits for the virology and transplant markets, the Dublin, Ireland, company is focused on creating a franchise in biomarkers that can rapidly and specifically detect damage and treatment effects in transplanted organs. <P>
The company was formed in 1992 through the merger of Syncor Ltd. and Biotrin International Ltd. Syncor was founded in 1991 to license technology from European academia and develop novel blood tests. Biotrin International was formed in 1991 as a diagnostics distribution company. <P>
<B><CENTER>First product</B></CENTER><P>

The merged company's first product was a test for parvovirus B19, which President Cormac Kilty said has become the leading test outside of the U.S. With its sales track record, Biotrin has been able to combine venture funds with sales revenues to fund further development. <P>

While parvovirus is Biotrin's cash cow, the main focus of the company is in transplantation. Biotrin markets test kits that assess tissue damage --not rejection per se --to provide clinicians with rapid information on the status of organs and their response to treatment. The biomarkers in Hepkit for the liver and Nephkit for the kidney are both based on the specificity in the liver and kidney of different forms of the protein glutathione-S transferase (GST). <P>

<B><CENTER>Rapid response</B></CENTER><P>

Because GST-based biomarkers appear rapidly in response to damage and decline equally quickly in response to treatment, and because they are highly cell-specific, the company believes they represent an improvement over standard markers used to monitor organ damage. <P>

Hepkit-alpha measures serum alpha-GST, a marker of hepatocyte injury that rises rapidly in acute organ rejection and declines rapidly in response to rejection treatment. <P>

Hepkit-pi measures pi-GST, which is found only in the cells that line the bile duct and is thus a specific marker for injury in that area. Hepkit was launched in Europe in late 1994. <P>

In a study of 55 liver transplant recipients presented in May 1995 at the European I.H.P.B.A. Congress in Athens, Greece, researchers noted that a significant rise in alpha-GST was seen with onset of rejection, which normalized within three days after the start of rejection therapy. In contrast, levels of the liver markers AST (aspartate aminotransferase) and ALT (alanine aminotransferase) failed to increase significantly with onset of rejection, and took one to two weeks to decline following therapy. <P>

Hepkit-alpha also may distinguish between rejection and hepatitis C reinfection in liver transplant, Kilty said. This is because HCV shows up in hepatocytes but not the bile duct during the initial infection. <P>

<B><CENTER>Urine biomarkers</B></CENTER><P>

Nephkit-alpha and -pi measures GST biomarkers in urine. The alpha form appears only in the proximal tubule of the kidney, an area that is damaged by toxic levels of immunosuppressant drugs such as cyclosporine. The pi form is found only in the distal tubule and is elevated in kidney rejection. <P>

In a study published in Nephron in 1994, acute rejection led to increased excretion of the pi-isoenzyme but not of the alpha form. Cyclosporine-induced toxicity led to increased excretion of the alpha form but not pi. The test therefore was able to distinguish between rejection and drug-induced toxicity. In contrast, the commonly used marker, serum creatinine, rises in connection with both cyclosporine-induced nephrotoxicity and rejection, and thus doesn't distinguish between the two. In addition, changes in the GST markers appear one to two days earlier than changes in the level of serum creatinine. <P>

"You have a much higher success rate when you detect damage early," said Kilty. "You can have 30-40 percent of kidney tubules not working before you start to see a rise in creatinine levels. So you can have a lot of damage before creatinine starts to rise." <P>

In addition to monitoring post-transplant organ function, the GST tests can be used to assess the quality of donated organs prior to transplantation. Biotrin plans to present data from a trial in the Netherlands showing a direct correlation between levels of GST in donor kidneys and graft outcomes. <P>

Biotrin targets its marketing to the specialized organ transplantation market. About 20 percent of European liver centers are using Hepkit, Kilty said. He estimated the U.S. and European hospital market for liver transplant at $15 million, and the market for kidney transplant at $20 million. <P>

<B><CENTER>Drug development use</B></CENTER><P>

The company also sees a great deal of potential in marketing to pharmaceutical companies, for use of the markers in R&D to detect drug-induced toxicity or other organ damage. Biotrin is working closely with a U.S. pharmaceutical company to develop the markers for use in drug development, Kilty said. <P>

"They're taking a couple of drugs they have on the market with known toxicities and running them in three systems: rat in vivo, rat liver slices and rat primary hepatocytes," Kilty said. "If it works, they'll use GST in all their trials." <P>

While the acute use market is relatively small, Biotrin sees its biggest potential opportunity in the home testing market, which Kilty estimates at up to $300 million in the U.S. and Europe. About 150,000 surviving kidney, liver and heart/lung transplant patients require regular monitoring, he said. Biotrin will find a partner to sell to the home testing market. <P>

The company also has acquired a pancreatitis marker, trypsinogen activation peptide (TAP), that it hopes will supplant amylase, the currently used marker. Any patient who presents at a hospital emergency room with acute abdominal pain is tested for acute pancreatitis, said Kilty. However, amylase misses 30 percent of acute pancreatitis cases. Amylase tests are currently a $50 million market, Kilty said. The company will seek a partner for TAP. <P>

Biotrin recently licensed a sepsis marker, an activatable form of serum amyloid A. The company is interested in working with companies developing sepsis products to aid in clinical trials. <P>

Finally, Biotrin has launched an alpha-GST-based product to monitor pig xenotransplants and is developing a pi version. Other products in development include assays for use in rats and dogs, for preclinical drug testing, as well as products geared to organ selection and immediate post-transplant use. The company also plans to develop tests for rejection of heart transplant. <P>

In Biotrin's viral diagnostics line, the bulk of test kit sales are in the general medicine market, but there is a growing market in blood screening, and Biotrin believes the largest potential market is in pregnancy testing. <P>

<B><CENTER>Parvovirus </B></CENTER><P>

Discovered in 1977, parvovirus is generally mild, causing a rash and joint pain. Half of adult women have immunity, having been exposed to the virus as children. But when pregnant women are infected during the second trimester, the virus results in a 5 percent rate of miscarriage. <P>

Biotrin is seeking a co-marketing partner for its parvovirus products in the U.S., where no product has been approved. <P>

Biotrin also is marketing diagnostics for herpes virus 6, adenovirus and respiratory viruses. In 1994, the company purchased its diagnostics distributors in France and Germany. <P>

Biotrin is in the midst of a funding round. The company is seeking to raise 3 million ($4.5 million), primarily to develop its U.S. business and to enter the home testing market. <P>


<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>


</DOC>
<DOC>
<DOCNO>WT03-B24-229</DOCNO>
<DOCOLDNO>IA064-000378-B009-301</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1996/1qtr/010896b1.htm 206.86.52.80 19970112101209 text/html 8661
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:12:10 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 8479
Last-modified: Thu, 23 May 1996 22:03:04 GMT
</DOCHDR>
<HTML><HEAD><TITLE> BioNumerik Pharmaceuticals Inc. </TITLE></HEAD><p>
<p>
<BODY background = "../../../graphics/white-mi.gif"><p>
<b> From BioCentury January 8, 1996</b><p>
<p>
<h1><center> Emerging Company Profile </h1> </center> <p>

<b>BioNumerik Pharmaceuticals Inc.</b><br>
San Antonio, Texas<br>
Technology: Drug discovery using parallel supercomputers and molecular simulation software<br>
Founded: 1992 by Frederick Hausheer<br>
University collaborators: The Johns Hopkins Oncology Center, Lawrence Livermore Labs, Roswell Park Cancer Institute, Southwest Foundation for Biomedical Research<br>
Corporate partners: Cray Research Inc.<br>
Clinical status: Phase I<br>
Disease focus: Cancer and cardiovascular disease<br>
Number of employees: 18<br>
Funds raised: $16.5 million<br>
Funding sources: Southwestern Bell Corp.; USAA Inc.; B.P. Investment Partners; Kinetic Concepts Inc.; Woodside Fund and Bioven Partners<br>
CEO: Frederick Hausheer<br>
Patents: Three issued on MDAM, two issued on camptothecin derivatives, and two allowed on the CETP peptide technology<br>
BioNumerik: Super simulations<p>

Frederick Hausheer has been thinking about how to use supercomputers to design drugs since 1986, when he first used a Cray computer while at the National Cancer Institute and Johns Hopkins, and saw the potential of computer simulation to develop drugs.<p>
He reasoned that drug development is a numbers game. In cancer, for example, Hausheer estimates that if 1 in 10,000 molecules makes it into the clinic, and 1 in 40,000 shows a 20 percent response rate, it would take a century to find the 1 in a million that constitutes a cure. <p>
<b><center>'A different approach'</b></center><p>
Most companies play that numbers game by generating large numbers of molecules via traditional or automated screening methods. The problem, Hausheer says, is the resulting drugs can have major toxicities. "Shoe polish and jet fuel will kill cells," he said. "We need to address the problems of toxicity up front, and the only way to do that is to use a different approach."<p>
While rational drug design is useful, it too isn't sufficient in his view. "Crystal structure isn't a real structure, it's an average structure," he said. "Patients are not crystalline. There's no question it's important to know how the nose cone impacts on the target, but it's no less important to know how the drug gets there in the first place."<p>
Hausheer founded BioNumerik in 1992 to focus on mechanism-based drug discovery, breaking down drug targeting, metabolism and delivery to the atomic level to characterize mechanism and optimize molecular leads. BioNumerik focuses from the start on delivery, targeting, biochemical pathways and formulation. The company begins with existing compounds to re-engineer or optimize existing drugs that have problems with toxicity, delivery or efficacy. The analysis of diseases and drugs on a molecular basis is made possible through the use of supercomputing.<p>
The supercomputing functions as a way of running "human" trials on millions of compounds before ever getting into real people. "The idea is to use computers to simulate how the drug is operating in the patient's body," Hausheer said. The company can use its Cray computers to test the behavior of up to 1030 molecules in models of the human system.<p>
This approach relies on complex computational software models running on parallel supercomputers to simulate the molecular interactions and transformations of compounds in the body.<p>
 BioNumerik has relationships with Cray Research and with Lawrence Livermore National Laboratory. Under a 1994 agreement with Cray, BioNumerik is acting as a pharmaceutical beta-test site for Cray and receives the use of supercomputer hardware and software support. A 1994 CRADA with Lawrence Livermore is developing pharmaceutical discovery software for use on massively parallel computers. The company has exclusive rights to all software developments arising from both relationships.<p>
<b><center>Analyze before committing</b></center><p>
"It's a way to get at the truth about a drug's mechanism of action faster and more reliably," said Hausheer. "This is an attempt to analyze compounds in advance of committing significant laboratory resources." The approach isn't intended to replace the work of bench scientists, but to make that work more efficient and productive.<p>
BioNumerik has 10 products in development, of which it estimates five will be in the clinic in the next 24 months. The company's first drug, MDAM, is a nonpolyglutamylatable antifolate whose parent, methotrexate, is a widely used anticancer agent. <p>
Methotrexate is toxic to healthy cells because it is polyglutamylated in the body -- successive glutamic acid groups are added to the molecule, causing methotrexate to be retained in the cell -- while MDAM is nonpolyglutamylatable. MDAM is taken up by tumor cells 3-12 times more rapidly than methotrexate, and can be given to animals in doses 4-50 times greater with the same level of toxicity. <p>
In mouse models of bowel cancer, tumor doubling time was 8.4 days with MDAM versus 4.6 days with methotrexate. There were 25 percent complete and 50 percent partial responses with MDAM versus none for methotrexate, and maximum weight loss was 8.9 percent for MDAM versus 14 percent for methotrexate.<p>
MDAM was in-licensed from Gopal Nair at the University of Alabama College of Medicine in Mobile, and BioNumerik performed the preclinical work in 18 months at a cost of $1.5 million. The compound is in Phase I trials at Johns Hopkins.<p>
The company's second compound is a novel cisplatin formulation (BNP7787) containing a protective agent designed to protect against the kidney toxicity associated with existing versions of the drug. A potential competitor to U.S. Bioscience Inc.'s Ethyol, the compound is 100 percent protective in a Fischer rat model, which is highly correlated with human toxicity. <p>
Rats treated with cisplatin alone experienced significant weight loss (10.5 percent) and reduced white blood cell counts (64,000), enlarged kidneys and other signs of acute kidney failure. Rats treated with BNP7787 gained 5.5 percent of body weight, with white blood cell counts of 105,000, and no evidence of kidney damage. The toxicity of Ethyol in rats is eight times greater than BNP7787, according to the company.<p>
Studies in tumor-bearing rats indicate that the compound retains and even increases the anti-tumor activity of cisplatin. BioNumerik plans to file an IND this quarter. The company designed and developed the compound in-house in 13 months.<p>
BioNumerik also has developed lipophilic camptothecin derivatives for cancer, with greater activity than existing water soluble camptothecins. Use of camptothecins, which are topoisomerase I inhibitors, has been limited by their high toxicity and difficulty to administer due to their poor solubility in water, as well as the high variability in effects from patient to patient. Existing compounds also are susceptible to multiple drug resistance, but Hausheer said BioNumerik's compounds are insensitive to MDR and MRP drug resistance. <p>
BioNumerik's small molecule lipophilic camptothecins potentially are orally deliverable, and would be suitable for chronic low-dose therapy. The company projects filing an IND on a lead compound in the second half of the year.<p>
A fourth program is developing small peptide inhibitors of cholesterol ester transfer protein (CETP). The compounds have shown prolonged elevation of HDL (high density lipoprotein) in baboons. BioNumerik also is developing a small molecule that has shown the ability to significantly raise HDL and lower LDL when administered orally in baboons.<p>
The company has raised $16.5 million and is spending $300,000 a month.<p>
<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-230</DOCNO>
<DOCOLDNO>IA064-000378-B006-9</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1996/1qtr/031196a1.htm 206.86.52.80 19970112100212 text/html 27251
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:02:11 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 27068
Last-modified: Thu, 05 Sep 1996 23:17:08 GMT
</DOCHDR>

<HTML><HEAD><TITLE> Biotech in Germany </TITLE></HEAD><p>

<BODY background = "../../../graphics/white-mi.gif"><p>
<b> From BioCentury, March 11, 1996</b><p>

<h1><center> Biotech in Germany Against all odds, a sector emerges</h1> </center> <p>

<B><center>By Karen Bernstein
Editor-in-Chief</B></center><br>
Five years ago -- maybe even two years ago -- most people would have declared the German biotechnology sector dead, never given a chance by the combined memories of eugenics and Green Party fears of genetic engineering. <P>
Times have changed. The growing number of successful biotech drugs has pointed up the life-saving potential of the technology, while the worst fears of genetically altered escapees into the environment have proven to be unfounded. <P>

At the same time, the structural decline of older German industry has, much as elsewhere in the industrialized world, pointed up the necessity of supporting dynamic, young economic sectors. <P>

<b><center>Economic conditions</b></center><P>

As a result, a small, but dynamic and growing biotech sector is beginning to emerge, supported by a variety of government agencies. This group of entrepreneurs, venture capitalists, academics and government supporters is well aware of the distance it must travel to catch up with its U.S. counterparts. But it has also identified the critical issues it faces and is taking steps to either remedy or work around the impediments in the German economy that have made it difficult to grow a high-risk sector. <P>

With some 1,200 biotechnology companies, Americans tend to take the sector for granted. But novel industries don't grow on trees. The German experience is a potent reminder that possessing an industrial potential is no guarantee that it can or will develop. Sophisticated science isn't enough without the right economic conditions. <P>

<b><center>The nascent German industry has two difficult hurdles to overcome. </b></center><P>

First and foremost are the regulations and structures that determine the capital and stock markets. The effect of these is to make risk capital scarce in a wealthy country. As a result, while the rest of the world views Germany as an economic powerhouse (despite increasing unemployment and problems with integrating the eastern portion of the country into the west), the Germans we talked to during a recent visit see their nation living off the proceeds from older, maturing industries. Their vision is of a country in danger of being left behind by the new technologies. <P>

Underlying the unavailability of capital is a strong cultural aversion to risk. Entrepreneurs are given few incentives to start ventures, and expect to be stigmatized for failure. Unlike the U.S., where CEOs of failed companies simply move on to the next startup, in Germany one shot is all you get. <P>

<b><center>Lack of incentives</b></center><P>

At the same time, both university scientists and pharmaceutical company middle management -- who in the U.S. would head startups -- have been inclined to stay in safe positions with stable employment rather than to head out into the entrepreneurial unknown. In part, that's because the rules on stock options make them useless as a vehicle to reward success. <P>

Thus while unemployment -- a growing problem in the scientific community -- may shift perceptions toward risk-taking, for the moment all the financial incentives favor people staying at their corporate jobs or university posts. <P>

 "For Germany, the question is how to remain competitive," said Rolf Schneider-Gunther, a general partner at Atlas Venture GmbH, one of only two German venture funds active in the sector. "I just came back from Asia and they don't even talk about Europe anymore. We're off the radar screen." <P>

He estimates that there are 72 biotech companies in Germany, of which the majority are service providers. "These are nice businesses, but not good investments," Schneider-Gunther said, noting that one investor he knows sees only three biotech companies of interest in Germany. <P>

Helmut Schuhsler of TVM Techno Venture Management, the other venture firm active in life sciences, estimates that there are 30 to 600 biotech companies in the country, depending on how the sector is defined. Many are small supply businesses with revenues. <P>

"It's hard to do therapeutics in Germany because there's no venture capital for it," Schuhsler said. "If Atlas and TVM don't like it, there's no money"<P>


<b><center>Capital</b></center></P>

The key to the German biotech dilemma lies in the country's capital structure. "Venture capital is not even a niche in Germany," said Schneider-Gunther. "The reason is you don't have a base of institutional investors providing funds to venture capitalists. Because we have a different social security system, you don't have pension funds as you do in the Anglo-Saxon world. And some types of insurance companies can't invest in venture capital -- instead they invest in large companies and real estate. So the amount of capital available for venture capital is low." <P>

The same problem shows up in the market -- or lack thereof -- for public equities. "Because there are no pension funds, you don't have huge amounts of capital searching for investments -- even if it's only 1 percent of a fund's capital going into high risk stocks," said Metin Colpan, president and CEO of Qiagen GmbH (Hilden), a nucleic acid purification company. <P>

The flip side of the coin is that there's no exit strategy for investors. There are only about 500 public companies in Germany, according to Ronald Mertz, deputy director of the Bavarian State Ministry of Economics, Transportation and Technology. The hurdles for qualifying for a listing on the German stock exchange are high, including a minimum annual turnover of DM100 million (about $70 million) and three years of profitability. <P>

Nor are there investment bankers in the U.S. sense, or sell side analysts to cover stocks. There certainly are no banking boutiques that specialize in biotech, as there are in the U.S. <P>

That puts German biotech startups in a bind. Venture investors want more than potential earnings per share or stock dividends -- they need a way of realizing some multiple on their investment in some finite period. The only way to get that is through the stock market or an acquisition strategy. Now only the U.S. and London exchanges are available for listing, while the potential for the planned EASDAQ (European Association of Securities Dealers Automated Quotation system) only can be proven once the European equivalent of NASDAQ is launched. <P>

Colpan sees the U.S. market as the most logical of the three possibilities for German companies looking to go public. NASDAQ would entail meeting legal hurdles including accounting standards and having a U.S.-based corporate entity. "I don't know how American investors would view a German company going public in the U.S. if it has all of its assets and activities in Germany," he said. <P>

Schneider-Gunther sees the London exchange as the better vehicle. While "great hopes" are riding on EASDAQ, he predicted that it will take time to establish the new exchange as the vehicle of choice for technology companies. Ultimately, he expects that the large German insurance companies -- which already invest in tech stocks -- will buy stocks quoted on EASDAQ. "They will become active players once they're confident it's a liquid market," he said. The new exchange is in the process of raising $15 million to get started. <P>

<b><center>First on EASDAQ</b></center><P>

Ironically, U.S. companies may be the first to benefit from the new exchange. Schuhsler expects that, at least initially, the investment banks and analysts for EASDAQ will be American, rather than French or German banks. And the first companies they will take public on the new exchange will be companies that have already gone public on NASDAQ. "They won't take indigenous European companies first because that will be too risky, so the first EASDAQ companies will be U.S. companies, while European companies will go public on NASDAQ first," he said. <P>


<b><center>Taxation and stock options</b></center><P>

While Germany doesn't have a capital gains tax, it remains hard to attract German managers to biotech because there's no way to reward them. In the U.S., the formula has been simple: the upside lies in the stock options. That isn't possible in Germany, where options are only attractive at the time a company is founded. Founders' stock is taxed at only half of the marginal tax rate up to a certain valuation. <P>

The situation is different for employees, and there are no special provisions for employee incentives. Schuhsler gave as an example a hypothetical startup company that has been given a speculative value of DM10 a share by the VCs. If employees then were given options at DM1, they would immediately be taxed as if they had received regular income of DM9 -- the difference between the valuation and the option price -- even though they haven't exercised the options and have received no money from them. <P>

"If I can't give people stock options, why should they join a small company with the attendant risk?" Schuhsler asked. <P>

In addition, employee options are taxed at a high marginal rate. Thus, Schneider-Gunther said, if an employee received options at DM50 and exercised them at DM100, about DM28 out of the DM50 gain would disappear in taxes. <P>

The way out of this dilemma has been to issue options at the value of the previous funding round. But that isn't as good a deal as employees usually get: most options are issued at 10-25 percent of the prior round, Schuhsler said. <P>


<b><center>Risk-averse culture</b></center><P>

Qiagen's Colpan believes that the major problem facing German companies isn't lack of capital, but the risk-averse culture. "Germans don't grow up to be entrepreneurs," he said. "They grow up to be in a secure environment, thinking about the pension they'll get at 65. So it's hard to recruit the type of management and people necessary to a company." <P>

It's still hard to pull managers out of big pharma to run biotech companies, Schuhsler said. "People in Germany don't yet see the opportunity, they see the risk. They think about their mortgage, their security." <P>

In addition, there are strong penalties for failure. "In Germany, when you start a company and fail you are stigmatized, maybe for life," said Schneider-Gunther. <P>

This is reinforced by an older generation that lost everything it had in not one, but two, world wars, said Carola Schropp of E.B.D. Group, a San Diego, Calif., firm that facilitates business between the U.S. and Europe. <P>

As a result, TVM looks to bring in 30-40 year olds who are running divisions or departments at pharma companies and don't expect to make it to the top. The firm also looks to the U.S. and U.K. for managers. <P>

The problem of identifying the over-achievers likely to be attracted to the challenge of startup companies is exacerbated by the country's egalitarian university system. <P>

"All universities are officially the same," Schropp said. "In the U.S. there's a big difference between the unknown state universities and the top tier universities which are educating 0.1 percent of American students. This is a hidden disadvantage of the German system." <P>

In addition, the very notion of starting a company with the idea of eventually exiting it is foreign to German business culture. "In Germany, if you build up a company, you don't think of selling it," said Schneider-Gunther. "You grow it and pass it on to the next generation. As a result, mid-sized companies are virtually all privately held. They're not interested in venture capital because they don't want to sell off equity. Allowing a financial institution into a company is seen as a weakness, as in, 'He can't do it any more.'"<P>

Still, it is getting easier to recruit management to German biotech, Schuhsler said. The pharmaceutical trend toward downsizing and outsourcing R&D is both making jobs inside pharma less secure and making it easier to see how smaller companies will have a role to play in the sector. <P>

In addition, he said, people are noticing what's been going on in the U.S. "They know that by running a company you can get wealthy and gain a reputation. So in the future it will be more possible to get these people once we've taken one or two companies public and they see there's money to be made." <P>


<b><center>Sources of technology</b></center><P>

In the U.S., much of the drive behind new biotech startups has come from university professors eager to see their discoveries commercialized, and university licensing offices looking to supplement university incomes. <P>

The situation in Germany is potentially more lucrative for academic researchers, because unlike their U.S. counterparts, professors at German universities own the technology they develop -- not the university. There are also fewer restrictions on their ability to start companies based on the technology they've discovered, said Mertz of the Bavarian ministry. <P>

But few took advantage of those rights in the past: it wasn't seen as acceptable to license out technology and make money on it. That attitude is reminiscent of a similar debate that raged in American academia 15 or 20 years ago over the ethics of professors becoming involved with industry. While that debate is well-settled in the U.S., attitudes have changed more slowly in Germany. <P>

Germany also remains behind the U.S. in terms of links between experimental and clinical sciences, according to Gert Riethmuller, who heads the Institute of Immunology at Munich University. Riethmuller was instrumental in the development of Centocor Inc.'s Panorex antibody for colorectal cancer, and has worked with other U.S., U.K. and Danish companies over the years. <P>

"Medical research in Germany is still backward in comparison to other countries," he said. "I couldn't stay in the clinic and do research at the same time, as one could do at Sloan Kettering, or Massachusetts General Hospital, or New York University. The integration of basic research into the clinic is one of the main problems in German medical science. You do see people testing experimental drugs in clinical trials. The problem is earlier, at the research stage." <P>

<b><center>Medical schools</b></center><P>

There is a similar lack of emphasis on research at German medical schools, which are focused on training practitioners, he said. <P>

Nevertheless, this situation also is improving, Riethmuller said, as clinical units are being started within university hospitals. <P>

He has a program in genetics and immune responses, which is running six projects on a DM3.6 million annual budget. Much of the funding is coming from U.S. companies, both biotech and pharmaceutical, for specific projects. <P>

Another critical difference between the U.S. and German systems is the extremely hierarchical nature of German universities, which affords full professors certain privileges they don't get in the U.S., according to Horst Domdey, a scientist at MediGene GmbH in Munich. For example, a full professor with a certain amount of laboratory space can keep all of that space until retirement -- even if it's unutilized. Nor does he or she have to cover the cost of the overhead. <P>

The system allows researchers to pursue long-term projects and obviates the need to write new grant proposals every year. On the other hand, it can mean that lab space is dominated by dead wood and sits idle, giving no outlet for aggressive young researchers. <P>

Parallel to, but outside of the university system, are the numerous institutes of The Max Planck Society. The institutes are mainly devoted to basic research. In particular, they focus on fields that can't be adequately pursued in universities, either because of their interdisciplinary character, or because of requirements for equipment that universities can't afford. The institutes have 11,000 employees, including 3,500 scientists, plus 3,500 fellows and guest scientists from around the world. Its budget of DM1.7 billion is mainly supplied by the federal and state governments. <P>

<b><center>Tech transfer subsidiary</b></center><P>

The institutes are set up as centers of excellence around a key researcher, who is given freedom to hand pick a team. Researchers receive 80 percent of their budget in cash, with the remainder from grants. <P>

Max Planck has set up a subsidiary, Garching Innovation GmbH, to patent and help commercialize discoveries. Unlike the universities, inventions by Max Planck researchers are owned by the institute, not the scientist. However, the institute won't force scientists to file patents. <P>

"When we're aware of something with commercial possibilities, we try to convince the scientist to file a patent," said Garching's Rainer Herbeck. "But the Max Planck Society would never force a scientist to file a patent. If the scientist wants to publish as soon as possible because of competition, he can do that. So the first priority is publication." <P>

There is also a generation gap in the willingness of scientists to file patents, with a general sentiment among the older researchers that they shouldn't earn money off of publicly funded research. "The older directors don't think about patents, or because their work is publicly funded, they don't want to file," said Garching's Jorn Erselius. "The younger directors are more aware of the commercial potential of their work." <P>

For work that is commercialized, 30 percent of the royalties go to the specific institute, 30 percent to the scientist, and the remaining 40 percent to the Society (see story, page A4). <P>

<b><center>German pharma companies</b></center><P>

German pharma companies have been slower than their counterparts elsewhere to jump on the biotech bandwagon. Until recently, they have remained more wedded to traditional medicinal chemistry, Mertz said. In addition, they generally have been interested in later stage technology. When they have considered partnering, Qiagen's Colpan noted, they have tended to look to the U.S. rather than to German companies. <P>

That has started changing, Schneider-Gunther said, as companies such as Hoechst and Bayer are increasingly active in partnering with biotech companies. To date, most deals have been with U.S. companies, and much of the future of German biotech depends on the position these larger companies take vis-a-vis the small German companies, he said. <P>

One positive sign is that German pharma interest in domestic biotech is growing. This is because the pharma side feels it's been over-hyped by some U.S. companies, Schuhsler said. "They're looking at the investments they've made and asking what they got for it. It's a general perception. They also believe there's good German science that hasn't been exploited." <P>


<b><center>Government initiatives</b></center><P>

Perhaps most indicative of the new German attitude toward biotech is a series of government initiatives, at both the federal and state levels, designed to foster a domestic industry (see story, page A5). <P>

Years of the hostile political climate for biotech resulted in moves by pharmaceutical companies such as Bayer, Hoechst and BASF to locate their biotechnology businesses out of the country. That now is changing, as evidenced by the convergence in policy of two very different German states: Bavaria, which is run by a conservative government, and North Rhine-Westphalia (NRW), which has a socialist/Green government. <P>

"The shift occurred with the first products on the market -- people can now see that genetically engineered drugs work," said Mertz. "There is also the job situation: public awareness of our fading competitiveness in many fields is growing." <P>

Schneider-Gunther added that the public's awareness of biotech and its importance has shifted dramatically in the past three or four years, as worry about the German economy has grown. "Germany overall is relying to a large extent on old, established industries, but jobs in these industries are being exported to low wage countries," he said. "The future relies on technology and 'brainware.' The U.S. has 25 percent of the world GDP, but 45 percent of the information technology GDP. The same applies to biotech." <P>

In Bavaria, the initiative to support biotech came from the top, with the prime minister issuing a declaration earlier this decade that the government would promote biotech. In NRW, the impetus was from the bottom. A local initiative in Cologne in 1991 included the chemical trade unions, the chamber of commerce, scientists from Max Planck and companies such as Bayer. The local initiative formally became a state initiative in 1994. <P>

<b><center>Crystal ball</b></center><P>

Cologne's interest in biotech was driven by a reading of the city's future economic prospects. "People feared there was a structural change occurring," said Patricia Solaro, managing director of BioGenTec NRW, the state's biotech initiative. "Steel, coal, chemistry and the car industry are all declining, and we need to find new industrial sectors. Cologne is the fifth largest chemistry location in Europe. We said we have to support biotech because it will be the next key technology for our area." <P>

The Green Party in NRW is learning to differentiate between those aspects of biotech it finds acceptable and those it is against, Solaro said. However, she noted that the situation in some other states isn't as positive. In Hessen, for example, the socialist/Green coalition remains strongly anti-biotech. <P>

Solaro estimated that DM80 million ($56 million) in venture capital was invested in German biotech in 1995, compared to DM49 million in 1994 and about DM20 million in 1993. That makes the DM40 million available from Bavaria and NRW a significant addition to the capital base for biotech. For comparison, $380 million in venture capital was invested in the U.S. last year. <P>


<b><center>Looking forward</b></center><P>

German biotech today enjoys a core of dedicated entrepreneurs, venture capitalists and government officials working hard to build a small, but sustainable sector. The amount of capital is expanding; there is a growing realization that biotech is an overall positive for the nation's economy; the domestic pharmaceutical companies are gaining interest; and there is evidence of shifts in the culture favoring more entrepreneurialism and risk-taking. <P>

Assuming that its technology base has commercial value, Germany ultimately will need to change its stock market and securities regulations to free up domestic capital -- the alternative is to import capital and/or export technology. <P>

There is also a need to change rules regarding stock option incentives in order to attract entrepreneurial talent. And whether capital is domestic or imported, there must be an exit strategy for investors. <P>

With the possible exception of the stock option rules, these changes are not simple. The lack of investment capital and of an exit vehicle for investors are deeply rooted in the entire postwar structure of the German economy, encompassing everything from the way in which society provides social security to the private saving behavior of individual citizens. The kinds of pension funds and mutual funds that fuel the U.S. stock market can't be created by fiat. <P>

These kinds of structural impediments to growth are timely reminders to the U.S. industry that for all of its complaints -- about capital gains taxes, patent issues, price controls in CRADAS, FDA foot-dragging on drug approvals -- the industry's battles occur within an economic framework whose scaffolding is fundamentally supportive of high-risk investment. <P>

In fact, given the ability of capital and technology to move internationally, any shortcomings in one country's economic or financial structure provide an opportunity for entrepreneurs from elsewhere to take advantage of the situation. As Mertz observed, one effect of the lack of opportunity in Germany is that know-how remains relatively cheap. <P>

One potential solution for German biotech is to set up U.S. subsidiaries -- or conversely, to set up American companies with German subsidiaries. <P>

One company planned from the start as a U.S. company is Sequenom Inc. Founded in 1994, the genomics company is based in Boston. "At the time, we didn't believe you could do genetic engineering in Germany," said President and CEO Nola Masterson. "The climate hadn't been supportive financially or scientifically. In addition, the company combines German technology from the University of Hamburg and U.S. technology from Johns Hopkins and Boston University." <P>

At the same time, Sequenom has been able to take advantage of government grants and loans in Germany via its Hamburg subsidiary. "German investors -- including government agencies and TVM -- have liked the fact that we're a U.S. 'Inc.', because we planned to be global from day one," said Masterson. <P>

This example points out that the German industry will need both short- and long-term strategies to survive and mature as the structural impediments are broken down. For example, exporting technology to sources of capital may be a risky but necessary avenue until a more viable German investment climate can be constructed. <P>

Under these circumstances, it is perhaps ironic that the future of the German industry in the long-term may depend less on money and more on the short-term ability of its leaders to develop the kinds of creative approaches to business that are the hallmarks of the U.S. experience. <P>

This kind of talent -- in creating and negotiating novel deals, and inventing capital structures to work around road blocks -- is based primarily on intellectual capacity and experience. The Germans have the former, and they can import the latter for a relatively low price. It is the one aspect of entrepreneurism where the barriers to entry can be reduced, and a small sector, like Germany's, can hope to create a more level playing field. <P>


<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-231</DOCNO>
<DOCOLDNO>IA064-000378-B009-182</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1996/1qtr/031196b1.htm 206.86.52.80 19970112101114 text/html 8949
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:11:17 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 8767
Last-modified: Thu, 23 May 1996 22:03:57 GMT
</DOCHDR>

<HTML><HEAD><TITLE> Emerging Company Profile </TITLE></HEAD><p>

<BODY background = "../../../graphics/white-mi.gif"><p>

<b> From BioCentury, March 11, 1996</b><p>

<B>MitoKor</B><BR>
San Diego, Calif.<BR>
Disease focus: Alzheimer's disease, Parkinson's disease, non-insulin dependent diabetes mellitus and schizophrenia<BR>
Technology: Genetic sequencing of mitochondrial DNA defects<BR>
Clinical status: Preclinical therapeutic; diagnostic in clinic<BR>
Founded: July 1992 by Dean Cuplin and W. Davis Parker <BR>
University collaborations: University of California at San Diego, University of Virginia<BR>
Corporate partners: Two undisclosed pharmaceutical companies<BR>
Number of employees: 20<BR>
Funds raised: $8 million <BR>
Investors: El Dorado Ventures, Forward Ventures, SenMed Medical Ventures, SR One, MDS Health Ventures<BR>
Acting CEO: Doug Reed<BR>
Patents: One allowed for diagnosis and treatment of Alzheimer's<P>

<h1><center> MitoKor: The mitochondrial connection </h1> </center> <p>

The diseases targeted by MitoKor --  Alzheimer's and Parkinson's, non-insulin dependent diabetes mellitus(NIDDM), and schizophrenia -- might appear to be unconnected. What they all share, however, is a defect in the mitochondrial DNA of related organs, according to Robert Davis, vice president and chief scientific officer. <P>
Mitochondria are the principal sites for the synthesis of ATP (adenosine triphosphate), which stores and supplies energy in cells. In the mid-1980s, molecular biologist Giuseppe Attardi of the California Institute of Technology reported on the significant role mitochondria play in a number of rare childhood muscle and nerve diseases. <P>

<b><center>More common than thought</b></center><P>

Since then, Attardi and others have demonstrated that mitochondrial dysfunction -- caused by defects in their DNA -- plays an important role in more common neurodegenerative, metabolic and psychiatric disorders that affect adults, such as Alzheimer's and Parkinson's diseases, NIDDM and schizophrenia. <P>

MitoKor (formerly Applied Genetics), was founded in 1992 by Dean Cuplin of GE Capital Ventures and Davis Parker, a neurologist at the University of Virginia. Parker's specialty, the biochemical effects of the electron transport chain in Parkinsons' and Alzheimer's diseases, led him to look for a mitochondrial characterization of these diseases, and to the analysis of patient tissues for evidence of mitochondrial damage. <P>

Integral to MitoKor's approach is creating cellular models of mitochondrial diseases, or cybrid cells, an expansion of Attardi's original research on cybrid cell technologies. <P>

<b><center>Cellular model</b></center><P>

Cybrid (cytoplasmic hybrid) cells use human neuroblastoma cells from which mtDNA has been removed, leaving the mitochondria themselves intact. Mutant human donor mtDNA is then fused into the energy-producing organelles, producing a cellular model of disease. <P>

The company is focusing on identifying and isolating mtDNA mutations that accumulate and thereby become problematic -- causing apoptosis in slowly dividing cells such as neurons, muscle, and pancreatic beta-cells. <P>

Normal and mutated mitochondria may co-exist in each cell in varying ratios, which allows mutated mtDNA to persist. It is only when the ratio of normal/mutated mtDNA tips toward greater mutational burden that the clinical symptoms of mitochondrial disorders appear, according to Davis. <P>

How much mutation is required for a mtDNA-based degenerative disorder to appear varies according to the individual, the organ system, and tissue affected. mtDNA is constantly exposed to free radical oxygen as a product of oxidative phosphorylation, which causes breaks in DNA chains that interfere with normal replication. Because mtDNA has no effective self-repair system, the mutations are replicated and passed down through generations of cells. <P>

<b><center>Free radicals</b></center><P>

In addition, Davis said, in some mitochondrial diseases such as Alzheimer's and Parkinson's, malfunctioning mitochondria themselves produce free radicals, which damage other cellular structures, such as neurons and muscle. <P>

According to MitoKor, 60-70 percent of Alzheimer's is associated with mtDNA defects: specific point mutations in two mitochondrial genes have been linked to a form of sporadic Alzheimer's, which accounts for about 95 percent of all cases of the disease. The other 5 percent are considered familial, which is linked to Mendelian genetic inheritance. <P>

According to the company, the two mitochondrial mutations correspond to a high density of beta amyloid plaques and neurofibrillary tangle in the brains of patients with sporadic disease, determined upon autopsy. Conversely, these mutations are not found in patients with familial disease, senile dementia, or the Lewy Body variant of Alzheimer's (evidenced by brain lesions, high beta amyloid plaques, but few neurofibrillary tangles, and no known genetic link). <P>

MitoKor has developed a method of diagnosing mitochondrial sporadic Alzheim-er's (MSAD), and is developing therapeutics based on its understanding of the role of decreased oxidative phosphorylation and energy metabolism in these patients. <P>

The company has developed a cellular model for MSAD that is adaptable to high volume, automated screening of potential therapeutics using its cybrid cells. MitoKor has identified several small molecule therapeutic candidates that have effectively reversed the Complex IV cytochrome oxidase defect found in its cybrids by preventing increases in the concentration of free radicals. Cytochrome oxidase's main function is electron transport. The compounds are in preclinical testing. <P>

<b><center>In vitro test</b></center><P>

MitoKor also has developed a blood-based in vitro test for MSAD that incorporates the specific point mutations in mtDNA that encode for cytochrome oxidase. The test is being used by two undisclosed pharmaceutical companies in Phase II and III trials to confirm diagnoses of more than 800 symptomatic sporadic Alzheimer's patients. This test will be offered as a service in the reference laboratory by the end of the year, Davis said. <P>

The company also has investigated a mitochondrial inherited factor in Parkinson's, which it believes may account for its sporadic occurrence, by creating cybrid cells with mitochondria donated by Parkinson's patients. These cells are deficient in the mitochondrial enzyme NADH:ubiquinone oxidoreductase (Complex I), also involved in electron transport, which has been shown to be deficient in the brains and blood of Parkinson's patients. The company is screening for therapeutic compounds, and searching for defects in the genes that encode for Complex I. <P>

In diabetes, MitoKor has found evidence of mtDNA dysfunction in the blood of NIDDM patients. Formation of free radicals and alkylation of DNA and proteins occur regularly in pancreatic islet beta cells, and the unprotected mitochondrial genome is open to attack from these free radicals. MitoKor is creating cybrid cell models of NIDDM that overproduce free radicals, and has begun genetic screening of NIDDM tissues to isolate the specific event that causes the disruption in mitochondrial activity. <P>

<b><center>Schizophrenia connection</b></center><P>

Finally, MitoKor believes that schizophrenia has a genetic component and that its sporadic occurrence involves a mixture of mutations of nuclear DNA and mtDNA. A study of autopsied brains of schizophrenics by researchers at the Institute of Psychiatry in London isolated five gene clones that indicate the disease is linked to mutations in mtDNA. MitoKor has begun work with cybrid cell models of the disease to search for its genetic cause. <P>

The company raised $650,000 in seed financing in 1992 from El Dorado Ventures, and raised $4 million in first round funding from El Dorado, SR One, SenMed and MDS Health Ventures. MitoKor has a $3.4 million bridge loan from the same group, and is in the midst of raising a $6-$7 million round. <P>

<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-232</DOCNO>
<DOCOLDNO>IA064-000378-B005-301</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1996/2qtr/040196a5.htm 206.86.52.80 19970112100137 text/html 20892
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:01:37 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 20709
Last-modified: Wed, 18 Sep 1996 23:45:33 GMT
</DOCHDR>

<HTML><HEAD><TITLE> Clinton's cancer drug reforms </TITLE></HEAD><p>

<BODY background = "graphics/white-mi.gif">

<b>From BioCentury, April 1, 1996</b><p>

<center><h2><i>Washington</i></h2>

<h1>Clinton's cancer drug reforms</h1> </center> <p>

<b><center>By Steve Usdin<br>
Contributing Editor</b></center><p>
WASHINGTON -- President Bill Clinton on Friday announced a series of administrative actions by the FDA to speed development and approval of cancer drugs that in some respects goes beyond steps the agency has taken to accelerate the path of AIDS drugs to market.<p>
The steps represent significant regulatory departures that may have implications beyond cancer. The FDA will take a proactive role in fostering development of drugs and ensuring that they are available to patients, including soliciting applications for U.S. approval for products approved overseas and, for the first time, taking foreign regulatory approvals into consideration.<p>
Administration officials suggested that similar steps may be undertaken to speed development and approval of therapies for all serious and life-threatening diseases. Clinton and FDA Commissioner David Kessler compared the new actions to the accelerated approval mechanisms for AIDS drugs implemented in 1992.<p>
Kessler told reporters at the White House that "we want very much to create the same kind of incentive, the same kind of stimulus, for the development of all drugs, not only for AIDS and cancer, but of all serious and life-threatening diseases."<p>
<b><center>Accepting risk</b></center><p>
Kessler also signaled a thawing of FDA's "zero risk" attitude. "We are taking some risks," he said. "One day we are going to make a mistake, but I believe that is OK, especially when we are dealing with diseases for which there are no available therapies."<p>
The cancer drug initiative consists of four elements: accelerated approval for cancer drugs; expanded access for drugs approved in other countries; increased cancer patient representation at FDA advisory committee meetings; and less red tape for additional uses of approved cancer drugs. <p>
Clinton said the changes, which went into effect immediately, "will cut development time for cancer drugs by as much as several years." He added that  "at the same time, FDA will cut its review time of these drugs from 12 months to 6 months."<p>
The reforms are part of Vice President Al Gore's National Performance Review or "reinventing government" initiative. Gore said the changes "will mean an end to all of the stories that we used to hear about interminable delays" in approving cancer therapies.<p>
Following are highlights of the changes:<p>
<h3>Accelerated approvals</h3>
Cancer drugs can receive accelerated approval based on demonstration of tumor shrinkage in patients with refractory malignant diseases or for those who have no adequate alternative.<p>
Accelerated approval usually will be contingent on the sponsor's agreement to conduct post-approval studies to "further define the utility of the new agent for the approved and/or other indications, either alone or in combination with other agents," FDA said.<p>
At the White House briefing, Kessler said "this will allow us to rely on smaller, shorter studies for the initial approval of cancer drugs." He added: "Use of similar approaches to drug evaluation and review in our experience with AIDS therapies has been a powerful stimulus to the development of new and important agents, especially for people who need them most."<p>
The agency stated that it will not require that post-approval studies be conducted in the exact population for which the approval was granted. <p>
Post-approval studies of products intended to remove treatment-associated toxicities will have to evaluate their effect on survival and/or demonstrate correlations between the surrogate measures used in the accelerated approval and clinical benefit. The agency said the new policy will encourage sponsors to submit supplemental applications for secondary indications and expedite their approval.<p>
According to an FDA document released Friday, "therapies for cancer patients have usually been approved on the basis of objective response to the agent (tumor shrinkage) together with direct evidence that the therapy produces measurable clinical benefit. Typical approval end points have included response rate together with increased patient survival, decreased recurrence rate, increased disease-free interval, and/or improved quality of life. It has been assumed that durable, complete clinical response (complete disappearance of detectable tumor) is a valid surrogate for such clinical benefit, but it is only infrequently achieved.<p>
"Much more commonly, partial tumor shrinkages are induced, and evidence has accumulated that such responses are often directly linked to longer or better patient survival. In fact, for certain new agents, FDA has already begun to rely on a reasonably high rate of verifiable objective partial response to the therapy as a basis for approval of agents to treat refractory malignancies, without requiring evidence of improved survival or quality of life."<p>
<h3>Therapies approved abroad</h3>
Kessler announced a major crack in the wall FDA has erected against the admission of regulatory decisions from foreign countries. "We will expedite the availability of promising medications that have been approved in certain other countries," he said. <p>
Kessler described a proactive approach under which FDA "will approach regulatory bodies in other countries and survey them. If there are drugs approved in those countries (for cancer) that are not approved here, we will approach the manufacturer and ask the manufacturer to give us the same information they supplied to countries abroad and see whether we can make the drug available under expanded access. Patients can have access to it at the same time that we are getting the data to determine ultimately if the drug works." <p>
Expanded access mechanisms applicable to cancer drugs include Treatment INDs, Group C drugs made available through the National Cancer Institute, and "compassionate use" (single patient) protocols.<p>
If there is no U.S. sponsor, the agency plans to encourage the foreign sponsor to file an IND and then encourage submission of an expanded access protocol.<p>
The FDA said that foreign regulatory authorities considered under this policy must "be identified as having review practices, review standards, and access to specialized expertise in the evaluation of agents for use in cancer treatment that are sufficient to allow FDA to conclude that a marketing approval action by that authority is likely to provide an adequate basis for proper consideration of an expanded access protocol for U.S. patients." Countries that use English will be contacted first, according to the agency, with initial contact planned within 30 days.<p>
<h3>Patient representation</h3>
Many FDA advisory panels, including those that consider cancer drugs, already have consumer representatives. The new policy ensures that all advisory panels dealing with cancer therapies have an ad hoc consumer representative and that he or she has "experience with the specific malignancy for which a therapeutic product is under consideration," FDA said.<p>
The agency will publish a notice in the Federal Register and conduct an outreach campaign to attract participants.<p>
<h3>Policy on INDs</h3>
"We will eliminate unnecessary paperwork that used to delay or discourage cancer research by non-commercial clinical investigators," Kessler said. <p>
The agency stated that  INDs needn't be submitted for studies of new uses of an approved drug or biological product if the agent "will be used in generally the same patient population and in generally the same manner for which the agent was approved, and the study is not intended to support approval of the new use or to support a significant change in the labeling or advertising of the product."<p>
FDA said unnecessary INDs are sometimes submitted when investigators or Institutional Review Boards incorrectly believe they are required. In other instances, manufacturers agree to provide free drugs and, incorrectly, think FDA will view the donation of product as a promotional activity if an IND is not filed.<P>
FDA stated that it will not consider supply of a marketed product for use in a study as  a promotional activity if it is being used in a physician-initiated, bona fide clinical investigation.<p>

<hr>
<b>From BioCentury, April 8, 1996</b><p>
<center><h2><i>The details matter</i></h2>
<h1>Wait-and-see on cancer drug reforms</h1></center>

<b><center>By Steve Usdin<br>
Contributing Editor</b></center><p>
WASHINGTON -- The FDA's administrative reform of its regulation of cancer therapies represents a public commitment by the agency to put into uniform practice measures that it has, for the most part, already implemented on an ad hoc basis, according to several senior managers of biotech companies with cancer therapies in the pipeline.<p>
Although they welcomed the recent proclamations by President Clinton and FDA Commissioner David Kessler that the agency would transform its best practices into standard operating procedures, the industry executives told BioCentury that the tone of the announcements may be more important than the substance, and the most important audience might be FDA staff, rather than the patients and industry officials to whom they were ostensibly addressed.<p>
<b><center>Recalibrating risk</b></center><p>
A change from the FDA's current tendency to a one size fits all, zero-risk tolerance policy to a policy that allows for higher risk quotients in the case of all life-threatening diseases, would be more important than any of the specific policy changes, they said.<p>
If the attitudes Kessler expressed permeated the agency <i>(see BioCentury, April 1), </i>sponsors would see fewer bureaucratic impediments and patients and physicians would have more options for dealing with often fatal cancers for which there are no effective therapies. On the other hand, in the absence of such a cultural change, the "new" policies might have little impact.<p>
Some executives are skeptical of Kessler's claims that FDA's decision to accept surrogate data, especially evidence of tumor shrinkage, will play a dramatic role in speeding the development of new cancer drugs. They pointed out that tumor shrinkage has been the basis of approvals for cancer therapies in the past, notably the approval of Taxotere for ovarian cancer, and the agency has accepted it as the primary end point in several ongoing Phase II and III trials for cancer therapies. <p>
<b><center>Beyond shrinkage</b></center><P>
And although there may be some diminution in the degree of linkage between tumor shrinkage and clinical effect required for approval, manufacturers still will have to demonstrate that their products provide patient benefit and have some durability in order to persuade physicians to use them and insurance companies to pay for them.<p>
Similarly, there was some skepticism and ambivalence among the executives about the increased use of accelerated approvals and expanded access protocols for cancer therapies. The benefits of these and other "reforms" to cancer patients and the manufacturers will depend in large measure on how they are implemented, they said.<p>
Accelerated approvals, for example, are contingent on post-market studies. The fruits of accelerated approval could be soured if FDA imposes onerous Phase IV trial requirements.<p>
Likewise, expanded access can get potentially effective therapies to patients rapidly and can help sponsors by educating physicians. The benefits of expanded access programs can be lost, however, if they make it more difficult to conduct well-controlled trials.<p>
Paul Abrams, president and CEO of NeoRx Corp. (NERX -- Seattle, Wash.), said that "the most important thing in my opinion is not that you now can get approval based on responses to surrogates. The most important thing, if it is carried forward, is the infusion within the agency of the concept that we are taking a very different risk profile with regard to approval of these drugs.<p>
"Before it was 'you cannot make any mistake or off with you heads.' Now they are saying that type of zero-risk profile is no longer warranted in patients with these dreadful diseases for which there is no therapy. If that is infused within the bureaucracy, it will be the most important element. Then you will be dealing with people throughout the entire drug development phase who have a different attitude about what you are doing."<p>
Abrams said the commitment to review cancer therapies in six months, half the period FDA is committed to at present, has limited importance. He noted there are numerous ways to suspend the clock, such as sending letters requesting additional information.<p>
The reduced review time "is much less important to me than if the philosophy of zero risk will be changed for products such as those we are developing for cancer and other life threatening or serious diseases for which there is no other treatment," Abrams said.<p>
"If it doesn't pervade the agency and people are looking for the same degrees of certainty as before, then all you'll get is the letter that stops the tolling of review time."<p>
<b><center>'More muscle'</b></center><p>
Regarding Kessler's announcement that FDA will start approving drugs based on tumor shrinkage, without requiring survival or other demonstration of clinical benefit, Abrams said that "they have actually been operating on the basis of approving drugs for tumor regressions as opposed to survivor indicators for quite some time.<p>
"Bristol-Myers' Taxol was approved on the basis of a 25 percent response rate in patients with ovarian cancer. It is not new that this can happen. The fact that it has become a little more public and now is stated as a policy as opposed to something happening in the ranks puts more muscle behind the policy. It makes it less likely for the agency as a whole to say 'we can't do that'."<P>
Abrams said the new policies will not change NERX's product development plans. Development plans for the company's cancer therapies already were predicated on an understanding that FDA will approve cancer therapies based on good response of surrogate markers in Phase II trials.<p>
"Our products are being designed with the hope that we can cause tumor regressions without the side effects and toxicities that have been associated with most systemic therapies for cancer. Our operating premise was, is, and will remain until there is reason for changing, that if you have a product that has a high safety profile and it can cause the same type of tumor regression that was seen before, it is a high value-added product and should be looked on favorably by the agency."<p>
Similarly, the product development strategy at Agouron Pharmaceuticals Inc. (AGPH -- La Jolla, Calif.) already had taken for granted the assumptions underlying the FDA's announcement. "We've assumed that approval was a possibility based on robust Phase II data because there was significant precedent for that in the agency already," said President and CEO Peter Johnson.<p>
Johnson withheld predictions about the impact of the policies pending explanation of how they will be implemented. "I'm concerned to know the full details. No doubt the agency's intentions are good and it wants to get drugs through the development pipeline quicker, but I will reserve judgement on the extent to which it is a major improvement until we learn more about how the agency plans to administer the approach."<p>
Johnson expressed particular concern about the implementation of accelerated approvals, which are contingent on Phase IV post-marketing trials. "The announcement emphasizes accelerated approval, which puts an emphasis on post-approval studies. To know if this is a significant step forward, we need to know what the requirements for Phase IV studies will be," he said.<p>
<b><center>New indications</b></center><p>
Johnson suggested that accelerated approval could be burdensome if FDA required inappropriately difficult, time-consuming or expensive Phase IV studies. He noted that accelerated approval is not currently required in order to obtain a product approval based on Phase II data. "Taxol got full approval from Phase II data based on a historical comparator," said Johnson.<p>
William Rastetter, president and CEO of Idec Pharmaceuticals Corp. (IDPH -- La Jolla, Calif.), is optimistic that the commitment to reduced review times will be helpful. "If the FDA lives up to a six-month review, it will change the timing of our product launch, which certainly is good news," he said. "If FDA reviews cancer applications in six months and gives them the same priority it has given to AIDS drugs, that will have a tremendously positive impact on companies developing cancer drugs."<p>
I. Craig Henderson, chairman and CEO at Sequus Pharmaceuticals Inc. (SEQU -- Menlo Park, Calif.), also emphasized the importance of the commitment to speeding approvals.<p>
"It will be a while before we see what it actually means," he said. "One of the things that will make a lot of difference is if it impacts on companies that are going back for additional indications. That is the status we are in. If FDA were to streamline that process, it would be absolutely great news and would have a profound impact."<p>
Speeding up approvals of supplemental applications would be a significant change because of the high level of off-label use in oncology, Abrams said. "The history of cancer therapy is that it is exceedingly rare that the major use for a product has been the initial indication it was approved for," he said. "Usually it is used in other doses or schedules or for other diseases. The medical community is still not very smart about knowing how to treat cancer, so it is hard to believe that any one company at any one time will find the best way to use a drug the first time they apply to put it on the market."<p>
Despite the public blessing of the tumor shrinkage surrogate end point, Rastetter predicted that companies are not likely to design trials to look at tumor remission without also considering duration of response. It will be very difficult, he said, to convince oncologists and patients to use a product if durability of response has not been demonstrated.<p>
Edward Erickson, president and CEO of DepoTech Corp. (DEPO -- San Diego, Calif.) also concluded that although the FDA's moves send positive signals, "they are not breakthroughs. They are going public with basic things that have been going on for some time." He said DEPO had negotiated with FDA "some years ago on trials with response rate as the primary end point.<p>
"It turned out that we showed survival benefit in an interim analysis of the data, so it was not relevant. But we used response rate as the primary end point in the trial. So we've really been operating under the guidelines that FDA has now gone public with."<p>
<b><center>Caution on access</b></center><p>
Ed Silverman, COO of The Liposome Co. Inc. (LIPO -- Princeton, N.J.), cautioned that FDA must be careful about implementing expanded access. "If there is pressure to make drugs available for expanded access too early, it could potentially preclude the ability to do real clinical trials. Without real clinical trials, it is difficult to persuade physicians to use drugs," he said.<p>
"Expanded access should be used when trials are well underway or have been completed, once you know you have a winner. Expanded access is a good way to pre-market the drug and it is ethically sound. But if you start expanded access too early, you can't do placebo trials and you can't prove that drugs work."<p> 
The agency has scheduled a meeting of the Oncologic Drugs Advisory Committee on April 19 to discuss implementation of the new regulations. <P>

<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-233</DOCNO>
<DOCOLDNO>IA064-000380-B025-158</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/4qtr/121895b1.htm 206.86.52.80 19970112102413 text/html 5849
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:24:16 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5667
Last-modified: Thu, 23 May 1996 21:54:10 GMT
</DOCHDR>
<HTML><HEAD><TITLE> Emerging Company Profile </TITLE></HEAD><p>
<BODY background = "../../../graphics/white-mi.gif"><P>

<b> From BioCentury December 18, 1995</b><p>
<p>
<p>
<h1><center> Jenner Technologies: Cheap cancer vaccines</center></h1><p>

<b>Jenner Technologies Inc.</b><br>
Danville, Calif.<br>
Technology: Recombinant therapeutic cancer vaccines<br>
Founded: December 1992 by Lynn Spitler<br>
Corporate partners: None<br>
University collaborations: None<br>
Clinical status: Phase I/II<br>
Disease focus: Cancer<br>
Number of employees: 3 full time, 3 part time<br>
Funds raised:  $2.3 million<br>
Funding sources: Private investors<br>
CEO: Anthony Maida III<br>
Patents: One issued patent<p>


Jenner Technologies Inc., named after small pox vaccine pioneer Edward Jenner, is trying to emulate his success in solid tumors. And the company is trying to do so without spending hundreds of millions of dollars. <p>
In its three years of existence, Jenner has spent only $1.7 million of $2.3 million raised, while reaching the clinic with two therapeutic cancer vaccines based on whole tumor antigen. Each vaccine cost about $700,000, and Jenner is spending only $100,000 a year on overhead. <p>
The first vaccine, OncoVax P for prostate cancer, began a Phase I/II trial in October, and a second, OncoVax CL for colorectal and lung (small cell and non-small cell) cancers, is expected to begin Phase I/II testing in1996. <p>
The company was founded in 1992 by Lynn Spitler, formerly with Xoma Corp., where she oversaw the development and first clinical trial of an anti-melanoma immunotoxin. Spitler believed that to be effective, therapeutic tumor vaccines, or immunotherapies, must be efficiently recognized by the immune system. In addition, such vaccines must be able to target metastatic as well as visible disease. <p>
Spitler's experience with monoclonal antibodies led her to conclude that tumor antigens, not antibodies, were the key to creating a strong immune response. Because humans have many HLA (human leukocyte antigen) types, Spitler theorized that presenting the patient's immune system with whole antigens rather than single epitopes would allow an individual's immune system to select its own proper epitope to which to respond.<p>
<b><center>Delivery vehicles</b></center><p>
As delivery vehicles, Spitler chose liposomes, which are naturally taken up by the reticuloendothelium. That system rids the body of toxins and as such is a direct channel to the immune system's key cells and sites. As it turns out, liposomal formulation of a vaccine enhances the production of antigen-specific cytotoxic T lymphocytes. <p>
Adding an adjuvant capable of inducing a CTL response should enhance efficacy as well. Ultimately, combining more than one antigen into a vaccine "cocktail" may improve its performance, said CEO Anthony Maida III.<p>
Spitler and Maida are co-holders of a patent application for Jenner's prostate cancer vaccine, based on recombinant prostate-specific antigen (PSA). PSA is found on normal and cancerous prostate tissue, but nowhere else in the body, making it an ideal target. <p>
Jenner exclusively licensed its second antigen, KSA, from Eli Lilly and Co. In addition to being present in colorectal and lung tumors, KSA is found on pancreatic and ovarian tumors, which the company may choose to target in the future.<p>
Maida and Spitler believe their targets and their technology are superior to other immunotherapies. For example, use of peptides as antigens represent only one epitope of an antigen, while the use of anti-idiotypic antibodies as antigens represents a single B cell epitope unlikely to elicit a CTL response. According to Jenner, antigens cause the body to mount a broader immune response than antibodies, including production of CTLs.<p>
<b><center>'Off the shelf'</b><center><p>
The company also believes that gene therapies probably will be expensive compared to Jenner's "off the shelf" products. <p>
Jenner has kept its burn rate low by spending money on science rather than infrastructure. In the company's virtual, or "leveraged resource management" model, as much as risk possible is contracted out. Crucial research has been done under a CRADA with Walter Reed Army Institute of Research, which formulated the PSA antigen. <p>
A second institution is responsible for cloning and expressing of antigen, while Northview Labs in Emeryville, Calif., does the toxicology, and purification is done in Rockville, Md.<p>
Maida believes that out-sourcing gives him more, rather than less, control over the execution of Jenner's science than the in-house alternative. And it saves money by taking advantage of existing facilities and personnel. "I can afford the best -- I have access to $20-$50 million of facilities with this approach," he said.<p>
Jenner has recently begun raising a planned $5 million round of financing. A first round of $1.7 million was raised through a private placement in May 1993; a $600,000 round completed last March.<p>
<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-234</DOCNO>
<DOCOLDNO>IA064-000380-B022-100</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/4qtr/110195ex.htm 206.86.52.80 19970112101706 text/html 5907
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:17:04 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5725
Last-modified: Thu, 23 May 1996 21:53:09 GMT
</DOCHDR>

<HTML><HEAD><TITLE> CEPH's ALS </TITLE></HEAD><p>

<BODY background = "../../../graphics/white-mi.gif"><P>

<b> From BioCentury, November 1, 1995</b><p>

<h1><center> CEPH's ALS data holds up </h1> </center> <p>

<B><CENTER>By Karen Bernstein<br>
Editor-in-Chief</B></CENTER><P>
Cephalon Inc. shareholders breathed a sigh of relief after the company on Tuesday announced that results of its first pivotal trial of Myotrophin in amyotrophic lateral sclerosis have been confirmed by a second pivotal trial in Europe. <P>
Based on the results of the two studies, CEPH and partner Chiron Corp. plan to submit an NDA in the first quarter of 1996. CEPH shares rose 25 cents, closing at $30. Shares of partner Chiron Corp. were up $3 to $91. <P>
<B><CENTER> Statistical significance</B></CENTER> <P>
The 183-patient European study of Myotrophin (insulin-like growth factor-1) reached statistical significance on the three end points evaluated thus far. On the primary measure of deterioration based on the Appel ALS Rating Scale (AALS) score, patients on drug showed 22 percent less deterioration than those on placebo (p<0.038). The comparable score in the North American study was 25 percent less deterioration at the same 1 mg/kg dose (see BioCentury Extras June 12 and 13 for full North American data). <P>
<A HREF ="/BioCentury2/archive/1995/2qtr/061295ex.htm"> BioCentury Extra, June 12, 1995</A><P>
<A HREF ="/BioCentury2/archive/1995/2qtr/061395ex.htm"> BioCentury Extra, June 13, 1995</A><P>
The Appel score includes assessments of swallowing, speech, respiratory function, muscle strength, and function of upper and lower extremities. <P>
Data were remarkably similar between the North American and European trials, which would characterize a well-designed and executed set of studies. <P>
On the secondary end point of disease progression (slopes), patients on placebo progressed by a mean rate of 4.6 AALS points per month versus 3.7 points for patients on drug, a difference of 0.84 (p<0.042). In the North American study, the numbers were 4.2 for patients on placebo versus 3.3 for patients on 0.1 mg of drug, a difference of 0.93. The differences in the two trials were within the same confidence intervals, making them essentially the same. <P>
<B><CENTER> Delayed morbidity</B></CENTER> <P>
On the other secondary end point analyzed thus far, the drug delayed the onset of disease-related morbidity as measured by time until a deterioration in respiratory capacity (forced vital capacity) or advanced stage of disease (Appel score (3) 115) compared to placebo (p<0.045). This outcome also was significant in the North American trial (p=0.01). <P>
According to Michael Murphy, senior vice president for worldwide clinical research, a study in the July issue of Brain showed that changes in the Appel score are closely linked with the odds of survival at any given time, lending added weight to the clinical relevance of this score. <P>
At the end of the study, the Appel score of patients on placebo was 92 versus 86 for patients on drug. In the North American trial, the scores were 95 for the placebo group and 86 for the 0.1 mg group. <P>
Baseline Appel scores were 68.59 in the European trial and 68.89 in the North American study. <P>
On average, the group receiving placebo experienced a 20-point deterioration by the sixth month of treatment, while the treated group reached that threshold at nine months. In the North American trial, the placebo group crossed the 20-point threshold at six months, while the 0.1 mg group never crossed it. <P>
Patients in the European study haven't been followed for long enough to show a mortality benefit. In the North American group, a survival benefit didn't appear until 15 months. That study to date shows a six month survival benefit at 18 months of followup. <P>
<B><CENTER>Manufacturing</B></CENTER><P>
CEPH hasn't yet looked at the sickness impact profile (SIP), the patient's subjective evaluation of condition month to month. <P>
IGF-1 is a protein found in muscle and other tissue that mediates regeneration of the peripheral nervous system. <P>
The data were presented at the International Symposium on ALS/MND in Dublin. The study was conducted at eight centers in six countries. After an evaluation period of up to three months, patients were randomized to receive either placebo (n=59) or 0.1 mg/kg/day of drug (n=124) by subcutaneous injection for up to nine months. <P>
There were no statistically significant differences between drug and placebo for adverse events. <P>
CHIR (Emeryville, Calif.) is scaling up manufacturing at its Vacaville, Calif., plant. The company has started validation runs, which it anticipates completing within 90 days. If necessary to meet demand, CHIR can also use capacity at its Puerto Rico plant to fill and finish the product. <P>
CEPH (West Chester, Penn.) is supplying drug out of its Beltsville, Md., plant on an open label basis to patients who participated in both trials. The companies are awaiting FDA clearance to make Myotrophin available under a Treatment IND. <P>

<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-235</DOCNO>
<DOCOLDNO>IA064-000378-B009-331</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/4qtr/121195a4.htm 206.86.52.80 19970112101221 text/html 7808
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:12:24 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 7626
Last-modified: Thu, 23 May 1996 21:54:00 GMT
</DOCHDR>
<HTML><HEAD><TITLE> Gene therapy wins faint praise </TITLE></HEAD><p>
<p>
<BODY>
<p>
<b> From BioCentury December 11, 1995</b><p>
<p>
<p>
<h1><center> Gene therapy wins faint praise </h1> </center> <p>

WASHINGTON -- Gene therapy has been over-hyped, false expectations of rapid progress have been raised, and NIH should shift its spending in the field to basic research, according to a report submitted to NIH Director Harold Varmus.<p>
The report by an ad hoc committee appointed by Varmus to assess the NIH investment in gene therapy was presented last week at a meeting of the Advisory Committee to the Director.<p>
Another committee presented a report assessing the activities of the NIH Recombinant DNA Advisory Committee (RAC). <p>
The report on NIH investment concluded that although somatic gene therapy "offers extraordinary potential, in the long-term, for the management and correction of human disease," there have been few if any results achieved to date. <p>
"While the expectations and the promise of gene therapy are great, clinical efficacy has not been definitively demonstrated at this time in any gene therapy protocol, despite anecdotal claims of successful therapy and the initiation of more than 100 Recombinant DNA Advisory Committee (RAC)-approved protocols," according to the report. <p>
<b><center>Science lacks maturity</b></center><p>
The lack of results largely stems from the immaturity of the basic science. "Significant problems remain in all basic aspects of gene therapy," the report said. "Major difficulties at the basic level include shortcomings in all current gene transfer vectors and an inadequate understanding of the biological interaction of these vectors with the host."<p>
In addition, the report said, "in the enthusiasm to proceed to clinical trials, basic studies of disease pathophysiology, which are likely to be critical to the eventual success of gene therapy, have not been given adequate attention.<p>
The report criticized the majority of gene protocols, saying they yield little useful data. The "very low frequency of gene transfer, reliance on qualitative rather than quantitative assessments of gene transfer and expression, lack of suitable controls, and lack of rigorously defined biochemical or disease endpoints," has limited the ability to interpret most trials, the ad hoc committee concluded. <p>
The panel members warned that the "overselling" of clinical results, by investigators and their sponsors, threatens to "undermine confidence in the integrity of the field." In their presentation to Varmus, the panel members said exaggerated media reports of impending gene therapy cures have led some people to take dangerous decisions about health care treatment and reproduction. <p>
The panel said it "recommends a concerted effort on the part of scientists, clinicians, science writers, research advocates, research institutions, industry, and the press to inform the public about not only the extraordinary promise of gene therapy, but also its current limitations."<p>
The report also suggests that NIH should not expand its recently funded three central vector production facilities. "Uncertainties regarding which vectors may be best suited for specific clinical studies argue against establishing a large national infrastructure for vector production," said the report. "Furthermore, the relative costs of vector production at the NIH supported sites should be carefully compared with those incurred in producing vectors under contracts to industry."<p>
The panel estimated that NIH spends about $200 million a year on gene therapy research, which it estimated is about equal to that of the private sector in the U.S. <p>
While the report acknowledges industry's role in developing gene therapies, it also warns of potential conflicts of interest between the private sector's pursuit of profit and NIH's mission to promote public health. <p>
"First, industry is skilled in translational research and the development of drug products. Second, it has significant experience in meeting high manufacturing and quality control standards, and maintains a professional staff dedicated to regulatory and clinical issues. Third, a high level of scientific and technical expertise characterizes modern biotechnology and pharmaceutical companies."<p>
On the other hand, the panel warned that "the field is at risk to the extent that the premature initiation of clinical studies and overzealous, uncritical reports of clinical results are used by industry to promote investment and perceived research dominance."<p>
In addition, the report said, "decisions regarding diseases to be treated need to be made by investigators on scientific rather than financial criteria."<p>
The panel also said it is important "that issues of proprietary control not limit the development of clinical protocols." It said that several scientists have complained about "logistical difficulties encountered in gaining industrial approval to perform clinical studies in which cytokines and other reagents were to be obtained from several, often competing companies."<p>
Although it is too early to assess the impact of "the licensing of a broad patent to a single company for ex vivo gene therapy," the committee expressed concern "that broad patents of this kind will ultimately retard implementation of successful gene therapy protocols once they are developed."<p>
<p>
<b><center>RAC evaluation</b></center><p>
The second ad hoc committee's report suggested that the RAC does not have sufficient expertise to pass judgement on the scientific merits of the protocols it receives and should restrict its consideration to safety issues.<p>
The panel concurred with the newly introduced policy under which RAC only reviews protocols that represent a significant departure from those that have been approved in the past. Routine protocol review will be handled by FDA. <p>
The committee's report listed several types of protocols that the RAC should continue to review, including: "the use of novel vectors, particularly in cases in which modified human pathogens (such as herpes viruses or lentiviruses) are being evaluated; gene transfer in utero, potential germ line modification, and other similar manipulations; and gene transfer in normal volunteers."<p>
<p>
<b><center>Full text available online</b></center><p>
The full text of the NIH and FDA documents reported on Pages A4 and A7 can be accessed on the Internet.<p>
The text of the NIH report on gene therapy investment is posted at<A HREF="http://www.nih.gov/news"> http://www.nih.gov/news</A><p>
The FDA's announcement on the elimination of lot release requirements, and the agency's proposed guidances on industry dissemination of reprints and reference texts can be accessed through BioCentury's homepage on BIO Online. <p>
Thehyperlink to the Gopher address is located at  <A HREF="http://synapse.bio.com/century/new.html"> http://synapse.bio.com/century/new.html </A><p>
<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-236</DOCNO>
<DOCOLDNO>IA064-000378-B006-41</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/4qtr/120495a1.htm 206.86.52.80 19970112100224 text/html 20683
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:02:26 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 20500
Last-modified: Thu, 23 May 1996 21:53:54 GMT
</DOCHDR>
<HTML><HEAD><TITLE> Contemplatingagbiotech's future</TITLE></HEAD><p>
<p>
<BODY background = "../../../graphics/white-mi.gif"><P>
<p>
<b> From BioCentury December 4, 1995</b><p>
<p>
<p>
<h1><center> Contemplating agbiotech's future </h1> <p>
<b>By Karen Bernstein<br>
Editor-in-Chief</b></center><P>
It sometimes appears as if the agricultural biotechnology companies are disappearing before our eyes. Monsanto plans to buy half of Calgene Inc., biosys has acquired AgriDyne Technologies Inc. and Crop Genetics International, and ESCAgenetics Corp. has let most of its employees go. There are hardly enough companies to call ag bio a sector, stocks of the public companies trade at an average price of $3.86, and if biotech companies on the pharmaceutical side think venture capital is scarce, they should talk to their ag bio cousins.<p>
But while a superficial look at ag bio might lead to reports of its untimely demise, a closer inspection reveals a more complex -- and interesting -- picture. <p>
As in drug development, biotechnology has been fully integrated into the tools of plant breeding and pest control. The regulatory issues surrounding transgenic crops, herbicides and pesticides have largely been resolved. With the exception of bovine somatotropin, the anti-biotech forces have been unable to mobilize consumers against transgenic foods. And most importantly, the number of marketed ag bio products is much larger than a casual observer might guess, with numerous new products coming through the pipeline.<p>
To understand why investors have abandoned the sector and, more importantly, to understand what ag bio companies must accomplish going forward, it pays to look at where companies have stumbled in the past. <p>
<b><center>Early science</b></center><p>
Ag bio started later than biopharmaceuticals, and from a lower science and funding base. Work in the early 1980s focused on the basic enabling technology to transform plants and express genes. Only in the latter half of that decade was there any true commercial development, according to Simon Best, CEO of <b><center>Zeneca Plant Science. </b></center><p>
"When we started in 1981, no one knew how to get a gene into a plant," said Russell Smestad, co-general manager of Agracetus Inc., a Middleton, Wis., subsidiary of W.R. Grace. "We invested a lot of time and energy coming up with a toolkit that was enabling. As a result the timeline seemed atrociously long. Now the development cycle is a more normal seven to 10 years."<p>
<b><center>Commercialization</b></center><p>
Beyond technology development came the commercialization issues. "Years ago, I was soundly criticized for raising money when I had no apparent need for it," said Jerry Caulder, chairman and CEO of Mycogen Corp., a San Diego crop protection company that sells both biopesticides and transformed seed. "I said if you think research is expensive, wait until you do development." <p>
In addition, he said, "you have to couple that with the non-glamorous aspects of agriculture -- we never could raise the monies health care could raise. We've actually been better managers of money than people in health care."<p>
While a few companies, such as Monsanto Co. and Pioneer Hi-Bred have put significant sums into early stage research, they are the exception, said Smestad. "The agricultural industry doesn't have 15 percent of sales to put into research -- the profit margins aren't there," Smestad said.<p>
<b><center>Production and distribution</b></center><p>
But beyond the core technology, the factor that emerges as key is the complexity of production, marketing and distribution in agriculture, which in many respects makes the manufacture and marketing of drugs look simple. <p>
In general, a single drug can be used on patients anywhere in the world, but for plants, a different hybrid needs to be developed for every geographical region. And novel value-added traits are only commercially viable so long as yields can be maintained.<p>
In fact, said Robert Serenbetz, president and CEO of DNA Plant Technology Corp. (Oakland, Calif.), it's when all four of the biggest ag bio companies -- DNAP, Calgene Inc., Ecogen Inc., and MYCO -- made the step from R&D to commercialization that they ran into problems.<p>
"The real hang-up continues to be marrying traditional plant breeding with molecular biology," said Roger Salquist, chairman and CEO of CGNE (Davis, Calif.). "You do a transformation and you still have to do several generations of traditional breeding, while new varieties are coming onto the market every year. So you're always playing catch-up. <p>
"That means you need to have a very powerful trait, because you'll be working with a variety that isn't the latest one with marginally better agronomic properties.  And you have to do it in multiple growing conditions, which means doing it in several varieties."<p>
To complicate matters, the addition of new traits to crops won't necessarily change the overall dynamics of the business. Take herbicide resistance, for example. The ag-chemical companies would like the seed companies to sell seeds with resistance to their chemicals. "If they do -- and they will -- there won't then be any differentiation in the seed industry, so they won't be able to charge more," said Smestad. "So the competitive edge will still be yield. Thus the first things coming down the pike will make the industry different, but not necessarily more attractive economically. So biotech will be successful because all crops will be transgenic, but certain traits won't change the economics of the industry."<p>
This is not simply because agricultural products are commodities -- in fact, said Serenbetz, both seeds and chemicals are often highly differentiated. Rather, he said, the problem is the industry's cost structure: farmers can't pay the same kind of money for their inputs that the health care sector has been willing to bear for drugs.<p>
<b><center>P&L obsession</b></center><p>
James Reilly, chairman, president and CEO of Ecogen, a crop protection company in Langhorne, Penn., observed that farmers and growers have been very open to looking at new products. What they're not willing to do is pay a premium. "Unlike the pharmaceutical industry, growers aren't worried about life and death," he said. "What they're worried about is their P&L."<p>
For example, economics, as well as performance, affected the introduction of biopesticides based on Bacillus thuringiensis. Bt products have slower initial kill time. But farmers, who were used to fast-acting chemicals, were being asked to pay premium prices for the new biologicals.<p>
"I'm not sure if it was the slower action or pricing that slowed down acceptance" Smestad said. "The bio companies tried to price their products the same as chemicals. But if the biological is slower, farmers are losing crop while the insects are still active. The most important factor in anybody's equation is price. Pricing lower would have helped acceptance. The rule of thumb is to capture 25-30 percent of the value created, not 100 percent."<p>
In fact, good quality Bts will cause an insect to stop eating in about two minutes, even if it doesn't die for 24 hours. But the quality of the initial manufacturing proved to be low, further eroding the economics of the biopesticides.<p>
"Most of us felt we could just toll (contract) manufacture these products, but that was wrong," said Caulder. "In the past we tried for both market share and to keep margins up, and it didn't work. <p>
"Being a slower kill would have gone away as an issue if there had been competitive pricing, but toll manufacturers don't have much incentive to reduce price. We refused to sell the low quality product (that many of them produced), so we ended up having to sewer a lot of product. We've now spent $10 million for our own dedicated fermentation tanks. Now we can get high quality and we have brought costs down."<p>
biosys ran into similar price versus results issues when it introduced its nematode products, said Edwin Quattlebaum, president and CEO of the Columbia, Md., crop protection company. "When I first came to biosys, the board was telling me to increase prices, and we were already two to three times the cost of traditional chemistry. I cut prices and tripled market share in one year. For the last three to four years, we've doubled our share each year. A 10-15 percent premium is the maximum you can get, and even that's hard. That puts phenomenal pressure on your cost of goods."<p>
<p>
<b><center>Driven by distribution </b></center><p>
For companies like EECN, said Reilly, distribution will be the key issue for the next five years. The big task is putting together the detail sales force to get products to dealers, and to educate dealers and pest control advisors (PCAs).<p>
"The grower will come into the dealer, and he will have a recommendation from a PCA licensed by the state," Reilly said. "A Zeneca or Monsanto will have 40 people on the West Coast alone who can call on the dealers. They also have to know the PCAs. So it's necessary to have a large sales force -- that becomes the partnering issue."<p>
Companies also need more than one product for the sales force to sell. The initial focus of ag bio companies on single technologies wasn't viable, said Reilly, whose company now has four technologies and product lines.<p>
BIOS agrees that companies must have multiple technologies to succeed. "Companies thought their technology would be a home run," said Quattlebaum, "but the fact is that most technologies are singles, and it takes the same infrastructure for four or five technologies as it does for one, especially if they're complementary."<p>
<b><center>Branded prices hold</b></center><p>
For the branded food crops, premium pricing has proven to be less of an issue than some observers had predicted, said Serenbetz. Both DNAP and CGNE have been able to maintain their $1.99 tomato price to consumers. <p>
But other issues have affected margins. "If you harvest a field of tomatoes, not 100 percent will be able to be sold as MacGregor or FreshWorld Farms. Then you're at the mercy of the commodity price," he said. <p>
This year, the devaluation of the Mexican peso has lowered the cost of Mexican tomato production to one-third of the U.S. cost. The result has been a 15-20 year low in the price of commodity tomatoes.<p>
Similarly, bad weather in one part of the country can ruin an entire crop, as well as sales of pesticides and herbicides. Thus EECN's third quarter product sales were hurt by bad weather in the Mississippi delta, reinforcing the company's drive to expand its distribution to minimize the impact of bad conditions in one area.<p>
In the end, the complexity of the production and distribution process has led all of the independent companies to look at a more integrated structure, including multiple alliances in production, distribution and marketing.<p>
<p>
<b><center>Luring investors back</b></center><p>
Investors won't return to the sector until they see evidence they can make a return on their money. <p>
"There's no success model to convince people to put their money in there," said CGNE's Salquist. "The perception is that it takes longer and it's lower value than pharmaceuticals, and it will stay that way until we have a blockbuster. We're the model for the industry and we've got to start showing a profit." <p>
CGNE expects to be profitable in fiscal 1997, which starts July 1, 1996. CGNE has two engineered products on the market, its Flavr Savr tomato and BXN bromoxynil-resistant cotton, and is scaling up production of laurate canola. A second oils product also may be on the market by next year.<p>
<b><center>Broadened product lines</b></center><p>
DNAP is marketing tomatoes, cherry tomatoes, mini-peppers and carrots developed through either somaclonal variation or traditional breeding. Sugar snap peas will be launched in 1996. The company's engineered tomato has been taken off the market until patent issues with Monsanto are resolved.<p>
Four Monsanto products were approved in 1995: insect-resistant potatoes and cotton containing a Bt gene, soybeans that can be sprayed with Roundup herbicide, and a delayed-ripening tomato that the company currently doesn't plan to market. A fifth product, Roundup-ready cotton, may be approved by year-end and seven other plant products are in development.<p>
MYCO sells three Bt-based biopesticides and a line of corn plants containing Bt or natural resistance to insects. In 1996, it will begin sales of genetically engineered corn. The company will be on the edge of profitability from revenues in the fiscal year ending in August 1996.<p>
EECN also isn't far from profitability, Reilly said. It has improved manufacturing efficiency, has developed the novel technologies it bought earlier in the decade, and a cash infusion of up to $25 million from Monsanto and the technology validation of that deal will enhance the company's reputation with distributors, he said <p>
EECN has three Bt products on the market and will introduce two new products in 1996, one of which will replace an existing product. Two biofungicides and five pheromone-based products are marketed, and the company is a small player in nematodes.<p>
BIOS sells nematode products and is the second or third largest Bt contract manufacturer for companies such as EECN and Ciba-Geigy. It has two virus-based pest control products on the market and a third in development through its purchase of Crop Genetics. Also on the market are neem-based botanical insecticides through its acquisition of AgriDyne. <p>
Zeneca (Wilmington, Del.) will launch its first genetically modified product, processing tomatoes for tomato paste, in Europe next spring and in the U.S. later in the year.<p>
The blockbusters that will make the industry a success are just coming on the market, said Smestad. Both Monsanto's Bt cotton and the transgenic tomato products developed by several companies will be significant products, he predicted. <p>
Although it has no products of its own on the market, Agracetus helped develop Monsanto's Roundup-ready soybeans and CGNE's BXN cotton. <p>
<b><center>Evaluating deals</b></center><p>
Smestad thinks Monsanto's planned investment in CGNE should be viewed as an indicator of success rather than of failure: it's a measure of the value Monsanto puts on CGNE's technology and it makes CGNE a more fully integrated company. <p>
Monsanto's equity investment in EECN will gain access to its Bt library for in-plant uses. Similarly, Pioneer Hi-Bred's $30 million investment in MYCO to access its Bt crop protection technology further validates the importance of these technologies, Caulder said.<p>
One factor still slowing down the potential returns on certain genetically engineered crops is the lack of international regulatory harmonization and the lagging public acceptance of biotech outside the U.S. Zeneca's Best estimates that Japan is one to two years behind the U.S. and that Europe is two to three years behind. <p>
This is a major issue for field crops such as corn and soybeans, which rely on an open market for exports. If engineered crops have to be separated from non-engineered crops, the former simply won't be developed. As a result, said Best, the industry is working very hard to promote regulatory harmonization. Only when that is accomplished will sales of these crops take off in a big way, he said.<p>
<p>
<b><center>A place for small companies? </b></center><p>
The first generation of ag bio players have mixed feelings about the prospects for new, small companies. "I used to think you needed a $100 million revenue base, but I now think it's larger than that," Salquist said. <p>
"It takes too much money to get started, and it's more complicated than developing a protein," he said. "By definition you have to be fully integrated -- you have to be either a seed company or a processor or both, and that's big business, with the exception of some niches like the cotton business." <p>
The barriers to entry have been formidable. Not only did funds dry up after progress at the first generation of companies proved to be slower than anticipated, but intellectual property barriers also turned out to be critical when there were initially few ways of transforming plants.<p>
But that's all changing, said Zeneca's Best, who even though he comes from a large company, is one of the most sanguine about the future of small ag bio companies.<p>
Best, along with Smestad, argues that new ways to transform plants are being developed, together with novel promoters and transformation markers, all of which will lower technological barriers to entry. As a result, Best expects to see the formation of new companies and university spinouts from 1997 through the end of the decade.<p>
Nevertheless, barriers on the commercialization side will remain high, and few small companies will become fully integrated. Best thus expects to see a pattern resembling the research boutique model on the pharma side: small companies that provide novel technology that is partnered with the major seed and chemical companies, but with the capability to market niche products in the fruit and vegetable arenas.<p>
Trends that work in favor of smaller companies include the branding of crops that were previously commodities, and the increasing emphasis on value-added traits. "Most large players are actively seeking to drive the market that way," said Best. "In field crops, it takes only small value changes to trigger big shifts in use, as long as yield remains high."<p>
Agracetus also has concluded that branded, value-added traits are the only way to go. The company's goal is to be a niche player focused on high value-added traits for industry and pharmaceuticals. These include specialty cotton fibers and the use of plants as bioreactors to produce pharmaceuticals and industrial enzymes.<p>
"What we're trying to do with our fiber program will be to contract production and then we will sell directly to the textile industry customer at a premium price," said Smestad. "An independent farmer couldn't produce our specialty products -- there's too much involved for him to prove the product has added value. You need an identity preservation system to track the product from the seed stage through final production. <p>
"To make it work, you have to be fully vertically integrated rather than an independent commodity producer. You don't have to own it all -- you can do it through alliances, which is more cost-effective."<p>
One model for the next generation of companies is NovaFlora Inc., a 1993 startup focused on development of value-added ornamental plants using tissue culture, somaclonal variation and genetic engineering. The Philadelphia company just began test marketing its first product, a miniature rose, and anticipates it will only take $2 million to reach profitability.<p>
Knowing that venture capital is unavailable for ag companies, NovaFlora received its startup funding from its first corporate partner, Star Rose Co., the second largest rose grower in the U.S. behind Jackson & Perkins. Having a partner from the start also avoids the commercialization problems that bedeviled the first generation of ag bio companies. "From our rose rollout, we can see the wisdom of working with a large, established partner," said President and CEO Michael Dobres. "It's very cost-effective, and through a royalty stream we have a guaranteed profit margin built in."<p>
Dobres said the flower industry, and roses in particular, is ideally suited for the value-added potential of biotech. The market is highly differentiated, the products aren't commodities, and consumers are constantly looking for innovative new plants.<p>

<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-237</DOCNO>
<DOCOLDNO>IA064-000380-B022-70</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/2qtr/061395ex.htm 206.86.52.80 19970112101649 text/html 9479
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:16:53 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 9297
Last-modified: Thu, 23 May 1996 21:55:18 GMT
</DOCHDR>

<HTML><HEAD><TITLE> Cephalon's timeline </TITLE></HEAD><p>

<BODY background = "../../../graphics/white-mi.gif"><p>

<b> From BioCentury, June 13, 1995</b><p>

<h1><center> Cephalon's timeline for NDA </h1> </center> <p>

<B><CENTER>By Steve Usdin<br>
Contributing Editor</B></CENTER><P>
NEW YORK -- Cephalon Inc. plans to file an NDA for Myotrophin (insulin-like growth factor-1) for amyotrophic lateral sclerosis (ALS) at the end of the year or in early 1996, according to President and CEO Frank Baldino Jr. <P>

The company on Monday revealed data from its pivotal Phase III trial of the drug, showing statistically significant, dose-related consistent success in slowing the progression of ALS with no related adverse safety issues <A HREF ="/BioCentury2/archive/1995/2qtr/061295ex.htm"> (see Monday's BioCentury Extra for details)</A>. <P>

CEPH shares climbed $7.875 to close at $18.375 on 6 million shares traded. <P>

On Monday, the company added details to its initial announcement of the clinical results and also released retrospective data pointing to a statistically significant higher rate of survival for patients taking the higher tested dose of 0.01 mg/kg/day of Myotrophin compared to the placebo group. <P>

<B><CENTER>'Heroic effort' </B></CENTER><P>

Baldino said the company will make a "heroic effort" to file an NDA before year-end, but it may not be able to do so until early 1996. He predicted that the FDA will take about one year to approve the drug. <P>

The agency has requested and received data disks from CEPH, in advance of its formal submission, and is working with the company to expedite the review, he said. <P>

William Rutter, chairman of partner Chiron Corp., said relatively minor changes will have to be made to CHIR's manufacturing facility in Vacaville, Calif., to permit commercial production of the drug. He predicted that it will take 18 months to adapt the plant to use a different yeast and receive FDA certification. Myotrophin is currently being manufactured at CEPH's pilot plant in Beltsville, Md. <P>

Manufacturing and marketing costs will be split evenly under the companies' agreement. CHIR will handle commercial manufacturing and CEPH will continue to provide product for trials. <P>

CHIR will receive 50 percent of the profits from U.S. sales of Myotrophin. CEPH's share will be minus an allocation of 11.5 percent of gross sales, which will go to Cephalon Clinical Partners L.P. <P>

The data presented Monday and at a scientific meeting in France on Saturday will be integrated into a formal scientific paper "within a few weeks," said Eugene Lai of the Baylor College of Medicine, a principal investigator in the trial. He told BioCentury that the paper will flesh out some of the scientific explanations for what occurred, but it will not include any data beyond what has been presented to date. <P>

The primary end point of the North American Phase III pivotal trial in 266 patients was the Appel ALS (AALS) Rating Scale, a six-point patient evaluation system designed to provide a quantitative measure of clinical status. CEPH cited medical literature indicating that a 20 point change in AALS score represents a clinically significant shift in patient well-being. <P>

<B><CENTER>Average baseline</B></CENTER><P>

The average baseline AALS score was 70. Patients with a score of 52 experience some weakness and other symptoms and frequently need minor aid such as a cane, but are independent and can live alone. At 74.5 points, patients are no longer independent and must restrict their diets to soft food; at 99 points speech is slurred and suction is required to compensate for decreased swallowing ability; at 119 points patients are homebound and wheelchair bound; and at 135 points patients have no ability to speak, are quadriplegic and require total care and tube feedings. <P>

Patients receiving the 0.1 mg dose progressed at a mean rate of 3.3 AALS points per month, while those on placebo progressed at a rate of 4.2 points (p = 0.01), said Michael Murphy, senior vice president for worldwide clinical research. The results are based on a last observation carried forward (locf) analysis, and a less rigorous analysis would produce more favorable results, he said. <P>

As a group, patients on placebo crossed through the AALS 20-point level of progression at six months, Murphy said. In contrast, patients on the high dose of Myotrophin did not cross that threshold during the nine-month trial. <P>

<B><CENTER>Secondary end point</B></CENTER><P>

The secondary end point was the sickness impact profile (SIP), an independent measure of patient perceived sickness. Telephone interviewers asked each patient 135 questions related to 12 physical and psychosocial categories assessing aspects such as sleep and rest, emotional behavior, body care and movement, home management, mobility, social interaction, ambulation, alertness behavior, communication, work, recreation, and eating. <P>

The SIP change from baseline at the end of the study was 5 for the high dose group and 9 for the placebo group (p=0.01). For the psychosocial component of SIP, patients getting the high dose registered a mean increase of 1, compared to 4 for the placebo group (p=0.03). The physical sub-component values were 8 for the drug group and 11 for the placebo group (p=0.1). <P>

CEPH hasn't conducted a detailed analysis of the AALS sub-components. <P>

Although death was not included in the protocol as an end point, a statistical analysis of survival was performed on a post hoc basis. The survival data show a statistically significant benefit from the Myotrophin high dose over the placebo arm, but several factors limit the utility of this analysis. <P>

Under the protocol, patients progressing beyond a threshold level were forced out of the trial and the nine-month duration limited the ability to study survival. There were 32 dropouts from the study. <P>

Murphy said evaluation of the protocol and the subsequent open-label study after 15 months on an intent-to-treat basis demonstrated a 16 percent trend in favor of the high dose Myotrophin arm over placebo (p =0.04). There were a total of 100 deaths during the trial. <P>

Baldino said Myotrophin has "three domains of effect -- muscle, motor neuron survival and peripheral nerve sprouting," but scientists have not determined its mechanism of action in ALS. <P>

Recently completed trials of Rhone-Poulenc Rorer's Riluzole demonstrated an impact on survival, but not on quality of life, in ALS patients. <P>

Lai said "it makes sense for the sake of the patients" to conduct combination trials with Myotrophin and Riluzol. <P>

<B><CENTER>Phase IV</B></CENTER><P>

Murphy indicated that following an FDA approval, the company will initiate Phase IV trials of Myotrophin to determine if a higher dose has greater clinical effect. He said the 0.1 mg daily dose was well tolerated with few reported adverse events, so it is likely that a higher dose could be administered. <P>

For the 10 most significant adverse events, only one, injection site pain, presented a statistical difference between the Myotrophin and placebo arms, and it was in favor of Myotrophin. The placebo arm experienced 85.6 percent injection site pain compared to 77 percent for the high dose Myotrophin group. 
The only other adverse events with a statistical difference were not clinically important, said Murphy. These included: injection site inflammation (24 percent high dose, 7 percent placebo), hair growth/texture (15 percent high dose, 3 percent placebo), sweating (23 percent high dose, 12 percent placebo), knee pain (11 percent high dose, 1 percent placebo), and facial edema (9 percent high dose, 1 percent placebo). One patient was discontinued for non-compliance. <P>

UBS Securities analyst David Crossen said Myotrophin is potentially a billion dollar product. "There are 30,000 cases in the U.S., another 60,000 worldwide, and about 10,000 new cases are reported annually," he said. "So you could get 100,000 people taking it. If you can charge $10,000 for a year's therapy, you have a billion dollar market worldwide." <P>

He said the pricing might have to "crack" if competing products come to market. He mentioned development of CNTF for ALS by CytoTherapeutics Inc. (CTII) <P>

If physicians opt for combination therapy of Myotrophin and CNTF, Riluzole, or another compound, the price also could be forced down, Crossen said. <P>

The last ALS patient in a European trial of Myotrophin was treated on June 3. Murphy said the European trial will be officially closed on July 3. <P>


<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-238</DOCNO>
<DOCOLDNO>IA064-000380-B024-98</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1996/1qtr/010296a1.htm 206.86.52.80 19970112102102 text/html 23252
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:21:01 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 23069
Last-modified: Thu, 23 May 1996 22:02:58 GMT
</DOCHDR>
<HTML><HEAD><TITLE>1995 was a very fine year</TITLE></HEAD><p>
<p>
<BODY background = "../../../graphics/white-mi.gif"><p>
<p>
<b> From BioCentury January 2, 1996</b><p>
<p>
<p>
<h1><center> 1995 was a very fine year <br>
Performance pays off </h1> </center><p>
<b><center> By Karen Bernstein<br>
Editor-in-Chief</b></center>
It was a good year. Actually, it was a great year. Biotech companies in 1995 did just about everything biotech companies are supposed to do: they reported outstanding clinical data, they got products approved and they proved increasingly attractive to pharmaceutical companies, which stepped up to the plate for both alliances and acquisitions.<p>
If 1994 seemed like the year of the failure -- although it wasn't nearly as bad as the popular perception would have it (see BioCentury Jan. 3, 1995) -- the last half of 1995 conversely may have left the impression that biotech could do no wrong. <p>
If this wasn't entirely true, Wall Street chose to ignore the fine points. Witness The BioCentury 100: It closed the year at 1298.85, up 80 percent, easily beating the S&P 500, which rose 34 percent in 1995. Of the 267 stocks tracked by BioCentury in the year, 206 gained in value. Among those priced at $2.50 or more, prices more than doubled for 86.<p>
The bottom line, as measured by The Carson Group's Life Sciences Indexes, was that the 11 large-cap biotechs gained $14.4 billion in market cap, to $33.3 billion, a 76 percent gain. The 190 smaller cap companies in the Carson index did even better, jumping 100 percent to $21.8 billion. The $10.9 billion gain more than erased the $7 billion drubbing of 1994.<p>
Two key triggers in the second half were Cephalon Inc.'s announcement in June of positive Phase III data for Myotrophin IGF-1 in ALS, and, late in the year, Centocor Inc.'s announcement that two trials of its ReoPro platelet inhibitor in angioplasty were stopped early because of positive results. The former opened up the equity market, while the latter caused a mini-explosion of stock prices at the end of the year. <p>
In addition, the market's reaction to AMGN's announcement in July of preclinical data for its leptin obesity protein -- adding $735 million to its market cap -- showed renewed willingness of investors to reward companies for the potential of biotech products.<p>
In between, the stream of positive clinical and regulatory events seemed endless. Among the most significant of these in the second half, in addition to CEPH and CNTO, were positive Phase III data for Genzyme Corp.'s Seprafilm in abdominal and gynecological surgeries; Genentech Inc.'s Phase III trial of Activase tPA in stroke; Phase III data for DepoTech Corp.'s DepoCyt in neoplastic meningitis; Phase III results for acellular pertussis vaccines from Chiron Corp., Connaught and SmithKline Beecham; Phase III results for Guilford Pharmaceuticals Inc.'s Gliadel implant for malignant glioma; Cygnus Inc.'s results for its GlucoWatch transdermal device to monitor glucose; Phase III data on Neoprobe Corp.'s RIGScan CR49 to detect colorectal cancer; and Phase III results for Vivus Inc.'s MUSE alprostadil for erectile dysfunction.<p>
<b><center>The approvals list</b></center><p>
FDA panel recommendations, agency approvals or approvable letters came for Biogen Inc.'s Avonex beta interferon for multiple sclerosis; Chiron's Vitrasert ganciclovir implant for CMV retinitis; BioChem Pharma Inc.'s 3TC for AIDS; Sequus Pharmaceuticals Inc.'s Doxil liposomal doxorubicin for Kaposi's sarcoma; The Liposome Co. Inc.'s Abelcet liposomal amphotericin B for aspergillosis infection; Interneuron Pharmaceuticals Inc.'s Redux dexfenfluramine in obesity; MedImmune Inc.'s RespiGam for respiratory syncytial virus; NeoRx Corp.'s Verluma for staging small cell lung cancer; and QLT Phototherapeutics Inc.'s Photofrin for esophageal cancer.<p>
There were only a few disappointments: Amgen Inc.'s Infergen consensus interferon in a Phase III trial in chronic hepatitis C and G-CSF in community-acquired pneumonia; a Phase II/III trial of Protein Design Labs Inc.'s Zenapax antibody to prevent graft-versus-host disease; a Phase III trial of Telor Ophthalmic Pharmaceuticals Inc.'s Xarano ethacrynate sodium in cataracts; CytRx Corp.'s RheothRx in a Phase II/III study in heart attack; a Phase III study of Immunex Corp.'s Pixykine IL-3/GM-CSF fusion protein in bone marrow transplant; and negative FDA advisory panels on Oncor Inc.'s Inform Her-2/neu breast cancer test and Immunomedics Inc.'s CEA-Scan imaging agent for colorectal cancer.<p>
M&A activity, while never as extensive as pundits predict, showed that in critical areas, such as gene therapy, acquisitions provided another avenue to get a return on investment. Notable acquisitions in the second half of the year included Sandoz's acquisition of Genetic Therapy Inc. for $295 million, Rhone-Poulenc Rorer's acquisition of the remainder of Applied Immune Sciences Inc. for $84.4 million and Schering-Plough's purchase of Canji Inc. for $54.5 million.<p>
The potential size of some corporate partnerships also signaled the pharmaceutical industry's belief in the future of the technology. Among the deals with potential of more than $50 million in the latter half of 1995 were Corange's $100 million deal with GeneMedicine Inc. to develop gene therapies for cancer; Bayer's $71 million deal with Myriad Genetics Inc. to discover genes for obesity, osteoporosis and asthma; Pasteur Merieux's $50 million deal with North American Vaccine Inc. to develop a meningitis vaccine; Hoechst Marion Roussel's $150 million deal with Cell Genesys Inc. for a gene therapy product for AIDS; Eli Lilly's $50 million deal with Millennium Inc. in atherosclerosis and the genomics company's $60 million deal with Astra to develop products for inflammatory respiratory disorders; American Home Products' $100 million deal with Apollon Inc. for DNA-based vaccines; Solvay's $50 million combinatorial chemistry deal with ArQule Inc.; and Pfizer's $60 million deal with Neurogen Corp. for obesity and eating disorders.<p>
The hard work paid off with an opening of the equity market. For the year, companies raised a total of $3.5 billion in equity, compared to $2.3 billion in 1994. The 1995 take included $1.5 billion in follow-on offerings ($1 billion over 1994), $599 million in initial public offerings, $1 billion in other financings and $377 million in venture capital (see page A15 for a list of fourth quarter funding activity).<p>
<p>
<b><center>Who's buying</b></center><p>
It's not so much that the buyers have changed, as that they're buying more stock. "It's the same old crowd of core buyers," said PaineWebber banker Stelios Papadopoulos, plus momentum and emerging growth players. These investors are buying both on offerings and in the open market.<p>
Among the handful of new players are some growth funds, plus some contrarian funds who were buying the sector in the first half of 1995 and stuck with it. "They basically got the 'bug,'" said Eric Roberts, a banker at Dillon, Read. In addition, he's seen overseas investors who have followed the lead of the European pharmaceutical companies into the biotech group. Those companies saw their chance to enter into biotech collaborations in 1994 and 1995 when there was less competition from the public equity markets, he said.<p>
Roberts believes the growth funds are leading the open market buying. "Some of those emptied biotech out of their portfolios in 1994 and kept it out until September 1995 or even later, and now feel they've missed the boat," he said.<p>
Momentum players also have played a role. They were buyers in the fall, although they dropped off in November, according to Peter Ginsberg, an analyst at Vector Securities International. Now, their interest is piqued again, he said. "They're not back in like they were in August, September and October, but their interest level is coming back because stocks have moved well recently."<p>
Market watchers are agreed that the growth fund buying is spurred by a continued rotation out of technology stocks. "Aggressive tech money has been looking for a home," said Stanley Weinstein, publisher of The Professional Tape Reader in Hollywood, Fla. "I put out a sell on that group in September, and a lot of those stocks have dropped 50 percent in the last three months."<p>
Despite all the hooplah over tech stocks such as NetScape, the biotech sector actually out-performed tech stocks in 1995, according to Hambrecht & Quist banker Dennis Purcell. According to his figures, tech was up 50 percent on the year, while biotech rose 50-60 percent. "If you ignored biotech this year, it was detrimental to your performance as a fund manager," he said.<p>
The Carson Group, which monitors buying behavior for public companies, analyzed the top 15 investors on nine follow-on offerings, and found that much of the money was put in by a group of high turnover funds that are "sector timers." For example, Janus invested $20.3 million, Strong Capital invested $10.5 million and Peregrine put in $9.7 million into the nine offerings.<p>
According to Carson Group figures, Nicholas Applegate invested a net of $49 million in the sector between the second and third quarters, with an average of $3.3 million per position. Peregrine invested a net of $39 million in the third quarter, with an average of $8.6 million per position. Janus invested a net of $35 million, with an average of $7.3 million per position. <p>
Some of these funds and other, similar funds that invested lesser amounts already have sold the shares.<p>
Carson Group analyst Wayne Rothbaum also has heard that money is coming into the U.S. from investors in Taiwan, who've got the jitters from China's saber rattling. "These people want to keep their money in an area they're familiar with, like high tech, but the tech stocks have already peaked," he said. "So the next best group in the technology sector is biotech." <p>
<p>
<b><center>How long the rally can last</b></center><p>
There's a consensus that this rally can last one or two more quarters, if not more, and that as a group the sector isn't overvalued, even if some individual companies are getting a little toppy. "The kinds of stocks that are in fashion do tend to get ahead of themselves," said Michael Dovey, a banker at Montgomery Securities. "For example, you get one protease inhibitor approved and everybody else goes up. For stocks like that, investors are seeing the glass as half full: they're looking at how big it can get rather than at the risks that are there. But the industry overall isn't overvalued."<p>
Papadopoulos also doesn't see any alarming over-valuations. "We really have not hit extraordinary price highs, and most stocks are not at ridiculous prices," he said. "Take Isis: it went public at $10 in 1991. A couple of hundred million dollars later, it's a less risky company and the stock is $13. Athena went public at $12 four years ago, and it's barely at that price today. You may say that was a really crazy time against which we're gauging these comparisons, but this isn't an all-time high."<p>
As might be expected, the successes are leading to a revamping of valuation models. Rothbaum has thrown out his old model, which put late-stage companies with Phase III data or NDAs at $180-$250 million market caps and early-stage companies at $70-$150 million. "Everything has shifted up by $50-$100 million," he said. Later-stage companies are now getting valued at $250-$400 million, or even higher, with some market caps close to $1 billion.<p>
<b><center>Convergence</b></center><p>
Several positive factors have converged to support the continued health of biotech stocks. The spate of clinical successes has restored investor faith, while the critical mass of about 150 products in late-stage development virtually insures that there will be a continued flow of news. Even more important, there's a growing list of biotech products on the market and hence the opportunity for an expanding group of companies to report positive earnings. <p>
The continued political pressure on the FDA to move drugs to market has paid off in a friendlier atmosphere at the agency. "There's been a sea change at the FDA," said Vector's Ginsberg. "The questions the FDA is posing to advisory panels are now biased toward a 'yes' answer. In the past, they were biased toward a 'no' answer or requests for more data."<p>
It's now clear, said Oppenheimer & Co. banker Peter Crowley, that the FDA is going to approve as many drugs as it can, and let the market sort out what will get sold. "They're going back to what they're supposed to do, and managed care will analyze the pharmacoeconomics," he said.<p>
But industry-specific factors alone aren't necessarily sufficient to create a rally. "I never thought that the news in itself is such a major contributor," said Papadopoulos. "In a given environment, the Centocor news could have been a blah, or $2 on the stock. It's the receptivity of the market and the alternative investment opportunities."<p>
Investors have a lot of money to play with coming into 1996, money they made in both high tech and biotech in 1995. This cash is one factor that is going to keep driving valuations upward, said Purcell. <p>
In November, $13 billion flowed into all stock funds, he said, and while very little has been explicitly earmarked for health care, many growth funds have looked to sectors other than high tech to put that money to work. <p>
<b><center>First quarter prospects</b></center><p>
All of this makes biotech stocks a good place for growth-oriented investors to park their money. According to Ginsberg, there has been a positive inflow into health care sector funds in every week since August.<p>
"This is only the tip of the iceberg," said Rothbaum. But it's here that the thin floats of many biotech companies come into play. "People are calling me trying to find shares and they can't get any," he said. "They're looking for companies with good science that haven't yet run up, but they can't find shares, and that's what's driving prices up. <p>
"The people who have held the sector for a long time aren't going to sell now. They've sat through 80 or 100 percent drops and they won't sell now with a 50 percent rise. With an average 10-15 million share float, someone who wants to buy 400,000 shares can't get them."<p>
Rothbaum sees the big explosion coming this quarter, as fair weather investors come into the sector. "It will be back to 1991," he said. "They will propel valuations. So even though I can say a $900 million market cap is ridiculous, these unsophisticated investors don't know that, they don't understand valuations, and they don't care what they pay."<p>
Once that happens, Rothbaum predicted that the seasoned investors will start to take profits. "The rally is sustainable until the smart money decides that valuations have reached the point at which they're content to sell," he said. "There has to be asset allocation at some point: investors have to take profits and move money to new companies. Then the fair weather investors will panic."<p>
But Rothbaum doesn't think that will result in the same kind of bear market the sector has been subject to in the past, because there's now a critical mass of companies with earnings and late-stage products that will provide a core of real news for the group. "That critical mass will smooth the volatility -- it will never be as bad as it was again," he said. "It's just like the big caps never truly collapsed a couple of years ago, because they have earnings and growth."<p>
Dovey also doesn't foresee another crash-and-burn scenario. "I think we're past the stage where people say the industry is a fraud. Now people are taking a more rational approach. Analysts will have to evaluate companies on revenues and earnings, and once that paradigm shifts there's no turning back."<p>
The optimism of investment bankers is echoed in technical analysis. Weinstein put a "buy" on the biotech group two months ago. "The charts look great in your sector," he said. "It will be a real hot place for the next six months."<p>
In the short-term, Weinstein thinks the sector is somewhat over-extended and is likely to correct in the coming weeks. But he is advising his clients to buy on corrections, and he expects money from the high tech sector to continue flowing into biotech. <p>
<b><center>The offerings market</b></center><p>
The big hope, of course, is that bankers eager for fees and companies desperate for money don't kill the goose by flooding the market with too much stock. Some banks have turned away banking business -- though in some cases this also had to do with the significant turnover among analysts last year, leaving several banks with periods when they lacked analysts to support offerings. <p>
The sector is as robust as it's ever been, said Papadopoulos. "It's financially in good condition, and for the first time in a very long time deals have performed well. Better than three-quarters of the deals are trading above their offer prices, and that is what sustains a deals market, not the fundamentals."<p>
Crowley estimates that follow-ons are up 22 percent from where they were priced, while IPOs are up 23 percent, a nice change from the usual scenario. Of the 37 follow-ons he's tracked, 30 are up, while 10 of 13 IPOs are up.<p>
<b><center>Who can, who can't</b></center><p>
The theory remains that banks should be selective about which companies they take to the Street. "The key word for '96 will still be 'selective,'" said Dovey. Companies that will be candidates for follow-on offerings will be similar to those that got the market going last August: those with reasonably high market caps and good news, he said. <p>
Alex. Brown banker Russell Ray seconded that sentiment. "From my perspective, the market window concept is probably passe for the time being," he said. "What you have is a willingness to invest on a selective basis, and the gold standard continues to be product-specific clinical news and sales events. Beyond that, investors will buy broad technology which has been validated by corporate partners. Away from that it becomes much, much more difficult to get anybody to pay attention."<p>
"Investors want to take implementation risk, not clinical risk," according to Dovey. "Companies in the middle of the clinical process, in Phase I/II or Phase II, who will have no data for quite awhile, still have problems. Even though the share prices of some of these companies have gone up, there's a difference between stocks rallying from $5 to $8 on volume of 10,000 shares and investors being willing to buy 2 million shares of that stock."<p>
Nearly all the companies that met the criteria -- late-stage products or limited cash requirements before profitability -- raised money from August to October, said Roberts, and bankers discouraged companies that didn't fit this profile from filing. "As a result, we didn't see the old model where the good companies financed first, and were followed by bad companies which raised money at inflated valuations and then traded down to their true valuations in the aftermarket."<p>
The same selectivity will hold for IPOs, Dovey said. As a result, he expects to see more M&A activity among private companies, as venture capitalists realize they can't take every company public. "Among the VCs I've talked to, I don't think their view of the public market is that great," he said. "So they've got to be thinking about other avenues of liquidity."<p>
A key test this quarter will be whether bankers hold the line and continue to turn away business. This could be tough. "Companies are all lining up for the first quarter," said Roberts. But as the year wears on, the overall equity market (not just biotech) will be about 15 months old, and Roberts thinks more general concerns about equities will arise. "We'll also see concern about biotech, and we may repeat the pattern of the past if we're not careful."<p>
The trick for investors, Purcell said, will be to ferret out those companies still valued at $100 million that are in late-stage clinical trials, and guess which of those will become $500 million companies in the near term.<p>
He also sees a stronger class of IPOs in 1996. Many private companies have organized themselves on the assumption that they could never go public, he said. Ironically, as a result, they have much sounder business plans than they might have otherwise.<p>
<b><center>Reality check</b></center><p>
Ultimately, all of the products now reporting positive clinical data will be tested in the marketplace. Some, like Merck's Fosamax for osteoporosis, and BioChem Pharma's 3TC for AIDS, probably will be adopted rapidly. Others, like CNTO's ReoPro for angioplasty, will ramp up more slowly.<p>
At some point -- possibly starting in late 1996, but certainly by 1997 -- there will be enough sales history on new products for investors to begin to correlate how valuations based on clinical trial results end up tracking with actual sales. If the managed care reality turns out to be a bit less rosy than the predictions of companies and Wall Street analysts, expectations will ratchet down. Noted Alex. Brown's Ray: "It seems to me one of the interesting unexplored areas is do investors today need to factor in price resistance from managed care buyers for novel therapeutics."<p>
Guessing how these new products will do on the market will be one of the key questions in 1996, said Purcell. "We haven't matured enough as an industry yet to develop a consensus on how to look at it."<p>
Whatever the reasons, negative surprises will occur, said Dovey, and it's the responsibility of companies and analysts to keep expectations within reasonable bounds. <p>
"That's where the new breed of analysts will have to be better at thinking about how drugs will be used," he said. "The responsibility of the sell side is to help set those expectations, and in general to set them lower than they've been in the past. I don't think there are that many analysts out there who are good at doing that. So when companies have great Phase III data, stocks will run ahead of themselves. <p>
"The issue of expectations and management is critical. If the industry can get that right, then we'll have a less volatile sector."<p>
<h5><HR>

<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-239</DOCNO>
<DOCOLDNO>IA064-000380-B022-32</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1995/2qtr/061295ex.htm 206.86.52.80 19970112101638 text/html 5531
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:16:43 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5349
Last-modified: Thu, 23 May 1996 21:55:04 GMT
</DOCHDR>

<HTML><HEAD><TITLE> Cephalon - ALS endpoint </TITLE></HEAD><p>

<BODY background = "../../../graphics/white-mi.gif"><p>

<b> From BioCentury, June 12, 1995</b><p>

<h1><center> Cephalon hits ALS endpoint</h1> </center> <p>

<B><CENTER>By Karen Bernstein<BR>
Editor-in-Chief </B></CENTER><P>

Cephalon Inc. this morning reported positive results on the most widely anticipated trial of 1995, its Phase II/III study of Myotrophin IGF-1 (insulin-like growth factor-1) in 266 patients with amyotrophic lateral sclerosis.<P>
Patients on the high dose of 0.1 mg/kg/day of drug experienced less disease severity, slower progression of disease and better functional ability than patients on placebo. The benefits, which were dose-related, were evident as early as the first few months of therapy, the West Chester, Penn., company said. <P>
Data were presented on Saturday at the World Federation of Neurology Committee on Motor Neuron Diseases in Talloires, France. A neurologist who attended the presentation said the physicians reacted positively to data that "looks very promising. But no neurologist will make a decision until it's peer reviewed and examined in detail." The company didn't discuss survival data at the meeting. <P>
The announcement was made prior to the open of the market. <P>
CEPH's three-arm study enrolled 266 patients with active disease (Appel ALS rating score of 40-80) in the U.S. and Canada. Patients were evaluated for three months and then treated for nine months with 0.05 or 0.1 mg/kg/day of drug or placebo. Patients then were rolled over into an open-label study. <P>
The primary end point was change on the Appel scale. The trial was powered to detect a 12-15 point difference between drug and placebo. After nine months of therapy, patients receiving the 0.1 mg dose showed 25 percent less deterioration than patients on placebo in analyses of both rate of change and functional severity of disease (p less than or equal to 0.01 on both measures). <P>
<B><CENTER>Other endpoints</B></CENTER><P>
Patients also experienced a slower decline in lifestyle, as measured by 20-point changes on the Appel scale (logrank analysis p=0.002; Wilcoxon analysis p=0.001). The slower decline in lifestyle was confirmed by another secondary end point, an independent assessment of sickness and disability (p=0.01). <P>
The 0.05 dose showed positive effects that didn't reach statistical significance on both the primary and lifestyle end points. <P>
The Appel scale includes assessment of swallowing, speech and respiratory function, as well as muscle strength of upper and lower extremities, and function of upper and lower extremities. An Appel score of 30 is normal for a healthy individual. On average, the group receiving placebo experienced a 20-point deterioration by the sixth month of treatment, while the 0.1 mg group never reached that threshold. <P>
Myotrophin was well-tolerated. Side effects included mild injection site inflammation, changes in hair growth or texture, sweating and mild knee pain. <P>
Secondary end points were clinical global impression of change, in which physicians evaluated change in patients' condition month to month; clinical global impression of therapy, in which physicians evaluated patients month to month against baseline; and sickness impact profile, the patient's subjective evaluation of condition month to month as described to independent reviewers. <P>
A European study in 183 patients will be completed in July. The two-arm study is comparing Myotrophin at 0.1 mg/kg with placebo. IGF-1 is a protein found in muscle and other tissue that mediates regeneration of the peripheral nervous system. <P>
CEPH did two Phase I trials to establish a safe dose: a 48-patient study in healthy volunteers, and a study in 17 ALS patients. <P>
"We didn't think you could do a small study of short duration and demonstrate anything meaingful," said spokesperson Jason Rubin. "So we designed a study in a large enough patient population that it might be a pivotal finding." <P>
The company is collaborating with Chiron Corp. to develop Myotrophin under a 1994 agreement to develop therapeutics for neurological diseases.</A>. <P>
The other drug for ALS, which recently reported positive data, is Rhone-Poulenc Rorer's Rilutek (riluzole). RPR announced in April that the glutamate antagonist showed a statistically significant survival benefit in a preliminary analysis of a Phase III trial in 959 patients. <P>
As presented at the American Academy of Neurology meeting in May, the drug led to a 17.4 percent increase in 12-month survival. The company's analysis so far hasn't shown a significant change in the rate of deterioration of muscle function.<P>


<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-240</DOCNO>
<DOCOLDNO>IA064-000378-B009-221</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1996/1qtr/030496b1.htm 206.86.52.80 19970112101133 text/html 6808
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:11:28 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 6626
Last-modified: Thu, 23 May 1996 22:03:38 GMT
</DOCHDR>

<HTML><HEAD><TITLE> Emerging Company Profile </TITLE></HEAD><p>

<BODY background = "../../../graphics/white-mi.gif">

<b> From BioCentury, March 4, 1996</b><p>

<b>Inflammatics Inc. </b><BR>
West Chester, Penn.<BR>
Technology: Mononuclear cell-based immunotherapy vaccines<BR>
Disease focus: Rheumatoid arthritis, multiple sclerosis, other autoimmune reactions<BR>
Founded: 1995 by B. Jackson Smith and Nigel Smart<BR>
University collaborators: Thomas Jefferson University Medical College<BR>
Corporate partners: None<BR>
Clinical status: Hospital-sponsored small Phase I; Phase I/II to begin in the spring<BR>
Number of employees: 2 plus 3 contract workers<BR>
Funds raised: $100,000 <BR>
Funding sources: Ben Franklin technology loan<BR>
CEO: Nigel Smart <BR>
Patents: One issued for determination of cartilage damage from synovial fluid<P>


<h1><center> Inflammatics: Building on serendipity</h1> </center> <p>

The idea for a cell-based immunotherapeutic vaccine treatment for rheumatoid arthritis came to J. Bruce Smith, a rheumatologist and professor of medicine at Jefferson Medical College in Philadelphia, from witnessing an improvement of symptoms in many of his RA patients during pregnancy.<P>
Smith discovered that the women who improved during pregnancy were carrying fetuses with HLA (human leukocyte antigen) types dissimilar to themselves but similar to that of the father -- which meant the fetuses could be seen as "allografts" or foreign grafts. <P>
<b><center>Protein shields</b></center><P>
He understood that a pregnant woman's immune system produces proteins that shield the developing fetus from rejection as a foreign body, and that this protective mechanism -- known as the TH2 response -- involves suppressing the inflammatory response, including the cytokines IL-10 and IL-4. <P>
Smith hypothesized that a similar response could be induced in RA patients who were not pregnant by introducing foreign white blood cells. In addition, Smith and a colleague had other experience preventing repeated spontaneous abortion in non-RA women using a similar approach -- giving white blood cells from the father to stimulate a TH2 response. <P>
<b><center>Basis for company</b></center><P>
Smith and Nigel Smart, formerly of Allelix Pharmaceuticals, also believed that a mononuclear cell-based approach could be effective in other autoimmune diseases, such as multiple sclerosis (MS). They founded Inflammatics in July 1995 as a virtual company to develop vaccines for RA and other autoimmune conditions, based on their mononuclear cell vaccine. <P>
Results of an open-label RA vaccine trial in 11 female patients immunized with allogeneic white blood cells were published recently in the Journal of Rheumatology. In that study, seven patients showed significant improvement in at least two of five measures of active RA. <A HREF ="/BioCentury2/archive/1996/1qtr/021296a1.htm">(see BioCentury, Feb. 12)</A>. Side-effects were temporary local pain and swelling at the site of subcutaneous injection. <P>
The company plans to begin a controlled, blinded, cross-over trial by mid-April in 120 men and women. Patients will receive injections every five weeks from the same donor -- either a spouse or a friend. Smith said that even if the vaccine only works with women, it still would be a substantial contribution, as 70 percent of RA patients are women. <P>
A cell-based immunotherapeutic would be significantly less expensive than the cost of traditional DMARDs (disease modifying anti-rheumatic drugs), such as methotrexate, injectable and oral gold, and anti-malarials, according to the company. Treatment of a patient with advanced RA can run $14,000-$22,000 per year with DMARDs, which includes testing for toxicity. In contrast, the cost of the cell-based therapy includes $80-$90 for a unit of blood, and less than $50 for the cost of preparing the cells (separating the white blood cells), according to Smith. <P>
<b><center>Other approaches</b></center><P>
Other DMARDs/immunological approaches on the market or in development include Sandoz's Sandimmune, SmithKline Beecham's chimeric anti-CD4 monoclonal antibody licensed from IDEC Pharmaceuticals Corp., Immunex Corp.'s interleukin-1 receptor and TNF receptor, and Immune Response Corp.'s therapeutic vaccines based on T cell receptor inhibitors, according to Smart. <P>
The company was started in December 1995 with a $100,000 loan from the Ben Franklin Foundation. The loan is renewable for three years. Inflammatics is in the process of raising $3 million in venture capital, which Smart expects will cover the first clinical trial, plus development activities for the next two years. <P>
Inflammatics plans to remain virtual for its first 18 months. Smart expects that Inflammatics will, at two years, then look to a private placement or perhaps an IPO for $12-$20 million, assuming positive results from the upcoming Phase I/II trial. <P>
The company also will seek partners for its programs. Inflammatics expects to manufacture its own vaccine, and will pay for it via equity financing or a partnership with a blood processing company. <P>
Ultimately, Inflammatics expects to develop a synthetic peptide-based pharmaceutical to treat RA and other diseases. In the medium term, it may also purify and resynthesize synthetic analogs of alloantigens to develop a second-generation, more active compound that it is now using. <P>
The company plans to focus next on MS, using the same types of cells. It also plans to target psoriatric arthritis, which accounts for about 10 percent of psoriasis patients. Other future therapeutic targets will include graft rejection and sarcoidosis. <P>
The company is in the early stage of developing a specific treatment diagnostic for RA, which will be based either on tissue typing or cytokine production, and will be used to determine who would be most likely to benefit from the immunotherapy, and which types of cells to use in the treatment. <P>

<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-241</DOCNO>
<DOCOLDNO>IA064-000378-B009-12</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1996/1qtr/012296a1.htm 206.86.52.80 19970112100951 text/html 17833
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:09:52 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 17650
Last-modified: Thu, 23 May 1996 22:03:19 GMT
</DOCHDR>
<HTML><HEAD><TITLE> Cephalon setback begs questions. </TITLE></HEAD><P>
<P>
<BODY background = "../../../graphics/white-mi.gif"><p>
<P>
<b> From BioCentury, January 22, 1996 </b><P>
<P>
<h1><center> Cephalon setback begs questions </h1> </center> <P>
<P>
<B><CENTER>By Karen Bernstein<BR>
Editor-in-Chief</B></CENTER><BR>
Investors lopped a quick $12.50 off Cephalon Inc. stock on Friday, which closed at $23.375 on 9.9 million shares traded, after the FDA waited until the last moment to inform the company that it wasn't prepared to approve a Treatment IND for Myotrophin IGF-1 to treat amyotrophic lateral sclerosis. <P>
Shares of partner Chiron Corp. were down $5.50 to $104 on 1.6 million shares traded.<P>
In a brief statement, CEPH and CHIR said the agency had concerns as to whether the data submitted from CEPH's European study support the results of the previous North American study. <P>
In June, CEPH reported that in the 266-patient Phase II/III North American trial, patients on the high dose of 0.1 mg/kg/day of insulin-like growth factor-1 experienced less disease severity, slower progression of disease and better functional ability than patients on placebo (see BioCentury Extras, June 12 and 13, 1995). <P>
<A HREF ="/BioCentury2/archive/1995/2qtr/061295ex.htm"> June 12, 1995, Extra</A><BR>
<A HREF ="/BioCentury2/archive/1995/2qtr/061395ex.htm"> June 13, 1995, Extra</A><P>
<B><CENTER>Less robust</B></CENTER><P>
The company subsequently reported positive results from its 183-patient European study <A HREF ="/BioCentury2/archive/1995/4qtr/110195ex.htm"> (see BioCentury Extra, Nov. 1, 1995)</A>. Although none of the European results were as robust as those of the first trial, the company reported that they were within the same confidence intervals. <P>
Survival was not an end point in either trial.<P>
One red flag in the European study was an excess of deaths in the treatment group, which appears to contradict the North American findings. There were five deaths among the 59 patients in the placebo group (8.5 percent) versus 18 deaths among the 124 patients on drug (14.5 percent).<P>
CEPH's post-hoc analysis of survival data in the North American study showed a mean survival difference of 164 days (5.5 months) favoring treated over untreated patients. The analysis on the 138 patients who had died by 18 months includes data on 259 of the 266 patients for whom the survival status was known. The 7 patients for whom there was no data were considered "alive" for purposes of the analysis, as that was the most conservative way of assessing them, according to company spokesperson Mary Fisher.<P>
Neither CEPH nor CHIR had spoken to the FDA as of Friday, and as a result both companies said they did not know the specific issues being raised by the agency. A meeting with FDA officials had not been scheduled as of last week.<P>
CEPH President and CEO Frank Baldino noted that the Treatment IND hasn't been rejected and that the FDA is not questioning the data from the first trial. "They agree that the North American study is impeccable," he said. "But they want some understanding of how we've reached our conclusions on the European study. Our job is to convince the FDA that the second study is supportive."<P>
<P>
<B><CENTER>Bureaucratic issues</B></CENTER><P>
Because the agency wouldn't comment on its decision, it's only possible to speculate on the FDA's rationale. The possibilities fall into two basic categories: the FDA, for political or tactical reasons, wants to tighten up the Treatment IND process, or there's something wrong with the data relating to efficacy and/or safety.<P>
Taking the bureaucratic theories first, one possibility is that the FDA has become sensitive to the potential for "misuse" of the Treatment IND, if companies come to see it as tantamount to a drug approval. An offhand comment by a Rhone-Poulenc Rorer official at the FDA advisory panel on Rilutek (riluzole) last September, which implied that the FDA had affirmed the safety and efficacy of the ALS drug by granting a Treatment IND, may have raised the agency's antennae.<P>
As in most areas, the FDA appears to have a great deal of latitude in how it interprets its rules. The regulations (21 CFR 312.34) state that "In the case of a serious disease, a drug ordinarily may be made available for treatment use under this section during Phase 3 investigations or after all clinical trials have been completed; however, in appropriate circumstances, a drug may be made available for treatment use during Phase 2."<P>
The regulations further state that drugs may be granted Treatment INDs if: "i) the drug is intended to treat a serious or immediately life-threatening disease; ii) there is no comparable or satisfactory alternative drug or other therapy available to treat that stage of the disease in the intended patient population."<P>
An interim rule effective in October 1988 further stated: "If the preliminary analysis of test results appears promising, FDA may ask the sponsor to submit a treatment protocol to be reviewed under the treatment IND regulations. Such a treatment protocol, if submitted and granted, would serve as a bridge between the completion of early stages of clinical trials and final marketing approval.<P>
"Once phase 2 testing and analysis is completed by the sponsor and a marketing application is submitted, FDA will evaluate the data utilizing a medical risk-benefit analysis. As part of this evaluation, FDA will consider whether the benefits of the drug outweigh the known and potential risks of the drug and the need to answer remaining questions about risks and benefits of the drug, taking into consideration the severity of the disease and the absence of satisfactory alternative therapy."<P>
<B><CENTER>Line in the sand</B></CENTER><P>
Given the common perception that the FDA has become less arbitrary on drug approvals in the face of political pressure to move drugs to market faster, it's also possible that the agency sees Myotrophin as a good case to make the point that it won't be pushed too far. <P>
Because RPR's Rilutek had shown a survival benefit as a primary end point, and was first to reach the market for ALS, the agency isn't under pressure to approve Myotrophin as the sole available therapy. The FDA is thus freer to focus on the possible shortcomings of the European study, particularly if there are concerns about deaths in that trial.<P>
"The FDA is not in a position where they have to approve a second agent, because there's already one out there with a survival effect," said Benjamin Brooks, professor of neurology and director of the ALS Clinical Research Center at the University of Wisconsin, Madison. "There's also an ongoing trial of BDNF, which may have a survival benefit and an effect on breathing," he said. "So the FDA may say it has time to really evaluate the safety of IGF-1."<P>
A Phase III study of brain-derived neurotrophic factor, being developed by Regeneron Pharmaceuticals Inc. (REGN, Tarrytown, N.Y.) and Amgen Inc. (AMGN, Thousand Oaks, Calif.), is fully enrolled, with results expected at the end of 1996.<P>
One investigator from the Myotrophin trial, Eugene Lai of Baylor College of Medicine in Houston, also thinks the FDA may have a point to prove. "The FDA is between a rock and a hard place," he said. "There's a demand for new drugs, but they don't want to be viewed as pushovers. The approval of Rilutek was a political decision because there was no other treatment. Now the pressure is off and they can be more careful and more scientific. So other companies and drugs will be served notice that they're not easy."<P>
Any inconsistencies between data from the first and second trials would also slow the agency down, said Brooks. "Having more data now may be confusing to the FDA. If results are similar to the old analysis, things tend to go along smoothly. But if it requires a new analysis, the clock tends to get reset."<P>
<P>
<B><CENTER>Understanding the data</B></CENTER><P>
Bureaucratic maneuvering would be irrelevant if there is something wrong with the data. Assuming the FDA would like to notch another drug approval on its belt, the fact that the agency felt compelled to delay a Treatment IND for Myotrophin would imply that the FDA sees problems that it can't ignore. <P>
"By the letter of the law, a Treatment IND is granted where there's a high probability of approval," said Merrill Lynch analyst Jeffrey Casdin. "So what they're saying right now is there's not a high probability of approval at this point in time."<P>
Casdin, who has been one of the most thoughtful critics of the data, considers the European study to be non-confirmatory. Specifically, the primary end point in the North American trial was disease progression over nine months of therapy, using a three point slope to plot progression (p=0.01). In the European trial, the corresponding p value using a three point slope was 0.06, not significant. But the European study used as its primary end point a two-point slope, which was significant (p=0.04), but less so than the first study. Other results in the European study also were not as robust.<P>
The excess deaths in the European treatment group also raise questions, Casdin said. "Clearly the FDA had to dig into mortality questions because of the imbalance." However, he noted that time has passed since those data were released, and it's possible that the imbalance has disappeared as more patients from both the treatment and control groups have died.<P>
Casdin said that if IGF-1 does cause excess mortality, one plausible explanation would be based on the fact that the growth factor stimulates muscle cell growth. Adding muscle mass can increase muscle strength, but muscle cells require nerves. As a result, he said, neurons that are already compromised by the disease would be additionally stressed, which could lead to greater degeneration.<P>
<B><CENTER>User point of view</B></CENTER><P>
If safety is an issue, it's not obvious to the clinicians using the drug, although their experience is with relatively small groups. Based on their own experiences, none of the Myotrophin investigators interviewed by BioCentury said there was any evidence that people on drug were dying earlier than those on placebo, and two thought they were seeing at least some mortality benefit.<P>
Deborah Gelinas of Forbes North MDA/ALS Center in San Francisco has six or seven patients still alive after three years out of 45 in the initial study at her center. "In this disease, there should be zero alive at this point," she said. "We're especially seeing a benefit in certain patients who have just deteriorated more slowly."<P>
"I can't think why the FDA turned it down, because it was a very good study and a very good drug," said Gelinas. "I'm totally astounded. I've been an investigator on both the Myotrophin and Rilutek trials, and the Myotrophin data are not marginal at all."<P>
Lai also said that about one-third of the 36 patients who were in the trial at his center are still alive. He's still seeing slower progression in the patients who started the trial on Myotrophin compared to those who switched over later, "although the difference is so small that all the investigators may not recognize it until you put all the data together and analyze it  it's pretty much like all drugs for progressive diseases."<P>
Another Myotrophin investigator, Ruediger Kratz of Georgetown University Hospital in Washington, is more cautious about the actual clinical benefit. Of the 23 patients at his center who were in the trial, six are alive. "That's not much different than what we'd normally expect at this time period," he said. "Does it prolong people's lives?  so far only statistically. In clinical terms, three months is not something you notice. But patients on Myotrophin are definitely not dying earlier."<P>
<B><CENTER>Internal to company</B></CENTER><P>
Other clinicians express doubts about the European data. "I don't know all the negatives the FDA saw," said Brooks, "but one thing the scientific community had as a concern was that all the analyses were internal to the company, and no one knew what was included and what wasn't included. In contrast, the riluzole study was opened finally and everyone knew what the data were."<P>
Brooks also said he had concerns based on the asymmetries with respect to deaths. "I think what we all would be concerned about is safety because of that mortality imbalance, though it might just be the way things go in a small study." He also noted that if enough studies of any drug are done, there will inevitably be a negative trial.<P>
Merit Cudkowicz, a neurologist at Massachusetts General Hospital, who wasn't a participant in the Myotrophin trials, also has interpreted the results cautiously. "The European data doesn't look as good as the North American data, and the North American data wasn't great," she said. "It's always been hard to form an opinion about IGF-1. Since no one knew what to make of the North American data, it was hard to know what to think about the European data."<P>
Gelinas is putting her newly diagnosed patients on Rilutek if they request it, although she said the benefit is too small to see on an individual basis. "The statistics showed a benefit in 1,000 patients, but it must be a very small benefit," she said. "In the trial, some of the patients who I thought were doing well turned out to be on placebo. But the side effects aren't terrible, so I have no qualms in patients going on it."<P>
Like Gelinas, Baylor's Lai is putting his newly diagnosed ALS patients on Rilutek if they want it. "It is scientifically proven, although I grit my teeth a little about the price," he said. "Like all such drugs, the dropout rate will tell: after paying that much money, patients will only stay on it if they benefit."<P>
Kratz, Brooks and other clinicians all see combination therapy as the real upside. "I want both drugs approved so I can try them together," Kratz said. "You can expect more benefit if you can work on two aspects of the disease."<P>
Kratz believes that the optimal dose for Myotrophin hasn't yet been determined. "Because the side effects are negligible, we felt we maybe didn't give enough," he said. The Georgetown clinician said he expects that Myotrophin ultimately will be approved. "I am also quite convinced that our data are not any worse than the Rilutek data, and the FDA itself has said the North American data are sound."<P>
Brooks predicted that Myotrophin will be approved, although another study may be required.<P>
On that score, CEPH's Baldino said a new trial is the worst case scenario. He pointed out that the company has an ongoing study in Japan, of the same size as the European trial, which will be fully accrued mid-year. End points are the same as for the North American trial, with the primary end point being change on the Appel functional rating scale. Secondary end points include quality of life and forced vital capacity (FVC), a measure of lung function.<P>
<P>
<B><CENTER>The communications issue</B></CENTER><P>
Wrapped up in all these questions about the data is a communications problem between the company and members of both the clinical and Wall Street communities. Although no individuals want to go on the record with their gripes, clinicians complained immediately after the European study was presented in Dublin that the company presented the data, rather than the investigators, and about the lack of time for questions.<P>
Several observers from both the clinical and analyst communities, none of whom wanted to be named, last week noted that the company has discussed multiple versions of the data, which is confusing at best, and at worst raises concerns about the actual data. One suggested that the company would be well-served by having an outside statistical group, preferably from a university, do an independent analysis.<P>
In a similar vein, there are rumblings about the delay in publishing the North American study. The skeptical view is that this implies that the data can't pass muster. However,Gelinas of Forbes North MDA/ALS Center said the problem is merely one of verbosity. <P>
"One thing that definitely has hurt us was not having a publication out," she said. "It's been delayed because of the people spearheading the publication committee. They made a tentative submission, and got comments back that they should cut it. Even I get bored reading it, so you know it's too long."<P>
There also has been confusion about whether the data analysis should have been based on a two-point slope or a three-point slope. Several Wall Street analysts have complained privately that the company has been inconsistent in answering this question. As a result, analysts have been busily constructing their own analyses, which only adds to the confusion. <P>
The end result is that only an FDA review will provide the ultimate answers.<P>
<P>
<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-242</DOCNO>
<DOCOLDNO>IA064-000380-B022-146</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1996/1qtr/021296a1.htm 206.86.52.80 19970112101717 text/html 6752
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:17:23 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 6570
Last-modified: Thu, 23 May 1996 22:03:24 GMT
</DOCHDR>

<HTML><HEAD><TITLE> BIO, FDA talk new reform agenda </TITLE></HEAD><p>

<BODY background = "../../../graphics/white-mi.gif"><p>

<b> From BioCentury, February 12, 1996</b><p>

<h1><center> BIO, FDA talk new reform agenda </h1> </center> <p>

<b><center>By Steve Usdin<BR>
Contributing Editor</b></center><P>
WASHINGTON -- Fourteen biotech CEOs met last week with FDA Commissioner David Kessler to discuss proposals for speeding early-stage drug development, providing some optimism that the door to administrative reform remains open at the agency. <P>

Meanwhile, House Commerce Committee Chairman Thomas Bliley announced dates for hearings on the agency and suggested that the House Republican leadership finally will introduce reform legislation soon. <P>

The biotech summit with Kessler focused on exploring ways FDA can speed early-stage drug development, Biotechnology Industry Organization President Carl Feldbaum said. In contrast to most of the reforms announced to date, which focus on the final stage of the approvals process and manufacturing and distribution of approved products, the changes under discussion would benefit emerging companies. <P>

<B><CENTER>Specific ideas</B></CENTER><P>

The executives came into the meeting with seven or eight specific ideas and the meeting focused on the "nuts-and-bolts" of how FDA can reduce delays at the front end of the drug development process. <P>

Feldbaum said the discussion was the third such meeting with Kessler since major administrative FDA reforms were announced last November. Several teleconferences between BIO CEOs and Kessler and his staff also have been held. <P>

Although the FDA did not put specific proposals on the table, or commit itself to a timetable for proposing or implementing solutions, Feldbaum said Kessler seemed committed to "work out the glitches" in the approvals process, especially delays in the FDA's response mechanisms. <P>

The commissioner was accompanied by Director Kathryn Zoon of the Center for Biologics Evaluation and Research (CBER), and Deputy Commissioner and policy advisor Mary Pendergast. Pendergast played a key role in negotiations between the biotech industry and FDA leading up to the last set of reform announcements. The 10-year FDA veteran is expected to be Kessler's point person in translating commitments made at the conference table into action. <P>

<B><CENTER>'Drug lag'</B></CENTER><P>

Feldbaum said "there is every indication" that there will be further meetings with Kessler, with "intense staff-to-staff interaction" in the interim. <P>

A focus on the front end of the development process would be well placed, according to "Untimely Access: An Analysis of America's 'Drug Lag'," a report by Robert Goldberg released last week by The Center On Neuroscience, Medical Progress & Society at George Washington University Medical Center in Washington. The report attacks Kessler's recent assertions that FDA has eliminated the "drug lag" and that it has speeded up drug development. <P>

Goldberg's report notes that although the time for reviewing NDAs "declined from 33 months in 1987 to 19 months in 1992," the total drug development period has increased from 8.2 years in 1962 to 15 years in 1993. The time required to discover a drug, approximately 2.6 years, has remained flat throughout that period, according to Goldberg. He attributes the increased development time in part to increases in the time required to gain FDA approval for Phase I and Phase II trials. <P>

ICOS Chairman and CEO George Rathmann, who attended the meeting with Kessler, told BioCentury that FDA has continually increased its demands for tests and paperwork in the earliest stages of clinical development over the past 20 years. Although the increased regulatory burden has increased the cost of development and prevented patients from getting effective therapies, the safety profile of approved drugs has not improved, according to Rathmann. <P>

On the legislative front, Virginia Republican Bliley announced that the Commerce Committee will hold hearings on FDA reform on Feb. 27. He said that legislation introduced by the committee members will include provisions "transferring FDA reviews to third-party organizations whenever possible." <P>

Bliley said he and Speaker Newt Gingrich hope the legislation, which has not been introduced, will be enacted this year. Bliley acknowledged, however, that presidential politics and the crowded House schedule may preclude passage in this Congress. <P>

Bliley's staff counsel, John Cohrssen, said that in addition to mandating third party reviews, the House legislation also may attempt to speed IND approvals. <P>

<B><CENTER>Lowered expectations</B></CENTER><P>

Cohrssen, however, also was not overly optimistic about the prospects for legislation this year. "FDA reform may take longer than just this Congress or a couple of Congresses," he said. <P>

On the Senate side, legislative hearings will be held Feb. 27 and 28th on the reform bill, S 1477, introduced in December by Labor and Human Resources Committee Chairman Nancy Kassebaum, R-Kan., according to Jane Williams, the key staff member responsible for the bill, which has bipartisan support. <P>

Speaking at a panel discussion sponsored by the Progress & Freedom Foundation on the prospects for FDA reform in 1996, Williams said markup is tentatively scheduled for March 15. She said enactment of the bill is a "top priority" for Kassebaum, who will not seek reelection after her term expires this year. <P>

David Nexon, a senior aide to Democratic Sen. Edward Kennedy of Massachusetts, who specializes in health care , said "Kennedy strongly supports bipartisan, responsible reform." But Nexon warned "there is no chance" that modification of the fundamental structure of food and drug regulation will be enacted. "Sweeping reforms don't have a chance, " Nexon said. <P>


<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>



</DOC>
<DOC>
<DOCNO>WT03-B24-243</DOCNO>
<DOCOLDNO>IA064-000378-B007-156</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/archive/1996/1qtr/011596a1.htm 206.86.52.80 19970112100615 text/html 12157
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:06:17 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 11974
Last-modified: Thu, 23 May 1996 22:03:11 GMT
</DOCHDR>
<HTML><HEAD><TITLE> Linking emerging companies to Japan. </TITLE></HEAD><p>

<BODY background = "../../../graphics/white-mi.gif"><p>

<b> From BioCentury January 15, 1996</b><p>

<h1><center> Trading tech </h1> </center> <p>

<b><center>By Karen Bernstein<br>
Editor-in-Chief</b></center>
Scratch below the surface of the cultural gulf between Japanese pharmaceutical companies and biotech companies in the West, and there are two practical problems lurking: biotech companies can't wait as long as it takes for Japanese companies to do a deal, and the Japanese companies are uncomfortable with early stage technology.<p>
Rather than continue to try to fit a square peg into a round hole, Shinichi Tamura of Sosei Co. Ltd. (Tokyo) has set about to recarve the terrain. Sosei, together with an undisclosed Japanese pharmaceutical company, Rothschild's Biotechnology Investments Ltd., Schroder Pacific Technology Partners and Oxford BioScience Partners, set up a $5 million feasibility fund last summer to play the role of both investor, risk-taker and matchmaker.<p>
According to Rothschild's Jeremy Curnock Cook, the original concept of Sosei was to apply in Japan, where science and technology in academic institutions languishes for lack of commercial support. The plan, he said, was to buy rights from these institutions and then sell it to pharmaceutical companies. <p>
<b><center>Going outside</b></center><p>
Sosei raised the first fund ($5 million) in 1993 from BIL, S.R. One, Schroder and Oxford.<p>
The initial plan exposed the Americans and Europeans to what was going on in Japanese academia, and to see how ideas being developed there matched up with the investors' portfolio companies. "It was a way to pull out Japanese technology," Curnock Cook said. "It was all on a very unstructured basis -- a cross-fertilization."<p>
The program was designed as an experiment, Curnock Cook said, "and it has worked because Japanese universities don't have the same industrial interfaces that universities elsewhere have. <p>
"But it also let us say to Shinichi, 'While you're talking to Mr. Sumitomo, here are some other ideas from U.S. and European companies from our portfolios that might be interesting to Japanese companies, especially ones that weren't front-line pharmaceutical companies."<p>
He added: "You wouldn't go to Chugai and say they didn't have a sensible intelligence network. But you can go to a smaller company and have a conversation about that."<p>
From there, Tamura began to think about how to make a profit from the transactions and raised the second fund last year. The only way to build buiseness on in-licensing of technology from biotech companies to Japanese pharma companies was to become a principal rather than just an agent, Curnock Cook said.<p>
<b><center>Untapped market</b></center><p>
"He feels, and we agree, that there's an untapped market of Japanese companies who don't communicate well with the outside world, and therefore need an interface with someone like Shinichi," said Curnock Cook. "It's also important to make sure the Japanese client isn't disappointed, as happened in early deals when Japanese companies took over-promotion at face value."<p>
Even beyond problems of hype, overly polished presentations can be viewed with suspicion in Japan. "Business schools in the U.S. teach presentation skills," Tamura said. "In Japan and Europe, presentations are often still clumsy. In Japan, if we see a skillful presentation by a scientist at a business meeting, we tend to believe it's wrong. We still believe he has to be clumsy to be real."<p>
Building on this insight, Tamura came up with the idea of putting together a licensing fund that would commit itself to buying the rights to technologies, which it then would resell in Japan. <p>
His goal is to solve the very different problems of the two sides.<p>
Time is one of the critical issues for the biotech side. When biotech companies had larger and longer commitments of venture capital funding, they could tolerate the year to year-and-a-half of negotiations with Japanese companies that was typically required to put a deal together, said Tamura. But with a less certain funding environment, and the decision by many venture capitalists to limit their investments in individual companies, the wait has become more difficult.<p>
On the Japanese side, mid-tier companies have become increasingly fearful, Tamura said. They know they need new technology to develop globally acceptable drugs, and they know they need to capture some of it from overseas. The question is how to gain access to it, and then how to evaluate it. <p>
<b><center>Changing the model</b></center><p>
"By the time they decide to buy the technology, it's already been acquired by somebody else," he said. "So I said, 'Let's change the roles.' We'll make the decision. Sosei will acquire the technology first on behalf of potential Japanese clients. We'll function as if we were a general partner, and the clients could invest as limited partners."<p>
The fund has been structured so that Sosei typically can pay $500,000 for a six-month option, or tie its payments to milestones. "Then we work hard to close a deal with Japanese companies, or else we lose money," Tamura said. <p>
 "We know the needs in Japan, and we ask the U.S. and European companies what they want from a deal. Sometimes we pre-negotiate a deal -- for example the biotech company may want $10 million. Sometimes we just set a split -- for example, they get 80 percent and we get 20 percent."<p>
Sosei has reviewed more than 100 technologies thus far. Many of the initial proposals came from companies in the portfolios of Rothschild, Oxford and Schroder. In addition, Tamura asked the funds to show him some of the deals they had passed on.<p>
About 65 of the initial proposals came from U.S. companies, but it's been easier to work on deals for the European companies, Tamura said. <p>
"The pricing is higher in the U.S. because they are more sophisticated," he said. "The Europeans can take a $500,000 deal to start with, partly because the technology is earlier and partly because they have less infrastructure to pay for. We're telling some start up people in the U.S. to stay virtual for as long as possible. We can incubate the technology in Japan and leave the U.S. and European rights intact."<p>
Once Sosei has optioned a technology, it will spend three or four months introducing it to the limited partners -- the Japanese companies connected to Sosei. If they don't show interest, Sosei then is free to negotiate with any Japanese company. Even if the technology is licensed outside of the inner circle, the limited partners still will receive some distribution of the proceeds.<p>
Although the role of an Asian principal can help remove the hesitation of Japanese companies to investing in early-stage biotechs, the model also increases the comfort level of European investors who don't want to duplicate the U.S. model of venture investing. "Some European companies and European venture capitalists don't think the U.S. model is the best, but they don't know what else to do," Tamura said. <p>
"In the U.S., it's easier to raise a small amount of money to polish up technology, make it more sophisticated, then raise more money," he said. "In Europe, the technology and the presentation is often not as polished, but the underlying science is good. Europe lacks money and infrastructure, and a lot of scientists still think quick money isn't something they should pursue. Our model is one possibility for Europe."<p>
<b><center>Excess capacity</b></center><p>
The model also takes advantage of the excess development capacity in Japan, Tamura said, combining it with novel technology from the West. "In Japan, facilities are abundant and people are capable of steady development. In the bubble economy companies set up lots of capacity, and because of the culture, they can't lay off people. At the same time, they need innovative ideas to serve as a platform for new business. So the idea is to bring in new technology for development in Japan."<p>
"Shinichi sees this as a $500,000-a-pop exercise," said Curnock Cook. "It gives the biotech company a way to say it's been paid for the technology, and it gives him something to trade with. In our view, there is a demand for an entity that can interface in this way between Japanese companies that recognize they're being left behind and don't know what to do about it, and biotech companies that until recently were concerned about funding and didn't know how to get beyond Tokyo airport."<p>
Sosei has closed its first deal, between The Generics Group (Cambridge, U.K.) and an undisclosed Japanese company. Sosei bought an Asian option to Generics' discovery that it can use electric fields to denature DNA, and found the Japanese partner.<p>
The technology has potential applications in any area where it's necessary to denature nucleic acids, such as DNA diagnostics, according to Denise Pollard-Knight, divisional director of life sciences at Generics. The technology is rapid, and it simplifies the automation of different types of processes, she said. <p>
Generics is looking at other ways to apply electric fields to sample preparation in areas such as diagnostics, sequencing, probes and amplification systems.<p>
The company tends to look for partners at a very early stage of development, so it needs to find companies with the imagination to see the potential in its discoveries, Pollard-Knight said. "Several years ago we looked at working with Japanese companies, but it's very difficult with early-stage technology. It's not that we don't have Japanese partners -- we do have another Japanese contract, but in that case the technology is more developed."<p>
Company Chairman Gordon Edge said Sosei acts as an intermediary at a key stage in the development process. <p>
"Japanese corporations like to look at tangible pieces of technology, not concepts, whereas in the U.S. and Europe companies start projects at the 'exploring the concept' stage," he said. "That's very difficult to do in Japan. But demanding tangible technology can mean that by the time they're interested, you've adopted a manufacturing process that's not relevant to the ultimate partner."<p>
Sosei has identified the need to manage this intermediate stage, said Edge, "where you upgrade the technology to the visibly tangible stage, but it's not yet complete."<p>
In this case, Sosei continues to fund some of the development work for the Generics project, as well as acting as an intermediary between the two parties to the deal. <p>
Sosei Senior Director Ei Yamada is still heavily involved, said Pollard-Knight. "Sometimes he will act as a translator for 'coded' messages from the Japanese partner, helping us interpret what they really want. <p>
"He also helps to discuss the direction of the program and explain any changes. The Japanese are very good at later stage development and as a result mostly think about the details, which doesn't always get the improvements that we need."<p>
Sosei is about to close a second deal for Generics, and a third deal for a German company. In addition, it is in the process of purchasing three other options, two from European companies and one from a U.S. company.<p>
<H5><HR>
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0^M
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border
 =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>
<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks
of BioCentury Publications Inc. All other trade marks are the property of
their respective owners. </H5><P>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-244</DOCNO>
<DOCOLDNO>IA027-000294-B005-211</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/pa2.html 206.119.5.80 19970120072602 text/html 33536
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:32:30 GMT
Last-modified: Friday, 29-Sep-95 03:33:39 GMT
Content-length: 33353
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  "html.dtd">
<HTML>
<HEAD>

<title>Tyner - Crisis of the two party system</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>The Crisis of the Two Party System</h1>
<h2>by Jarvis Tyner</h2>

<p><em>This article was reprinted from the <strong>August 1995</strong>   
issue of 
<strong>Political Affairs</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p>The 1996 presidential race is well on its way. It is taking 
place at a time when the danger from the right is very 
great, when tens of millions of working-class families are 
experiencing hard economic times, at a time when the rights 
and well-being of all working people, especially the 
racially oppressed, are under attack.</p>

<p>Alienation from the two dominant capitalist parties is at an 
all-time high. A majority of the 18-and-over population is 
not voting. Millions of American voters are electorally 
homeless. Over one-third are presently registered 
independent, and the idea of a third party is supported by a 
majority of the people. Among African American voters 
support for a third party is in the high 70-percent range 
and growing. In most polls well over a majority of trade 
unionists think we need a pro-working-class third party.</p>

<p>Putting aside right-wing third-party forms, there are 
presently numerous efforts by progressive forces -- 
nationally, regionally and locally -- to bring about and 
build third-party formations. Tens of thousands vote for and 
have joined various left-wing and progressive third-party 
formations. National parties like the Greens and the New 
Party are successfully fielding candidates for office. Labor 
Party Advocates (LPA) has signed up tens of thousands of 
supporters, mostly trade unionists, and are planning to hold 
a founding convention in 1996. This movement has real 
support, but is struggling with the question of whether to 
run candidates and how to build in the communities as well 
as among trade unionists. Other groups are busy organizing, 
networking and calling conferences.</p>

<p>There are also many independent forces that are active 
within the Democratic Party who want to see a third party 
come about and are ready to cooperate with such a formation. 
They have seen the way the right wing took over the 
Republican Party in state after state and gained dominance 
in Congress by working in the grassroots, outside as well as 
within the Republican Party structure. They appreciate the 
positive impact that an active, viable, labor-based, multi-
racial people's party pushing from the left would have. They 
don't quite see how to bring it about, but are ready to help 
if they can. At the same time they are concerned that this 
not take away from their efforts to defeat the ultra-right 
danger and the effort to put the best possible people into 
elected office today.</p>

<p><strong>Real vs. phony independence</strong> - Real independence means more 
than independence of the parties of big business -- it must 
include independence from the policies of big business first 
and foremost. That is why conservative forces such as those 
associated with the Patriot Party and Ross Perot -- though 
he received a lot of legitimate independent votes in 1992 -- 
do not represent real independence. Similarly with the 
prospect of a bid for the presidency by Colin Powell -- 
while he speaks of being independent he is closely tied in 
with monopoly capital, particularly the military-industrial 
complex.</p>

<p>Rather, we're talking about labor forces, elected officials 
and active voters in the African American, Mexican American 
and Puerto Rican communities. We are talking about peace, 
anti-racist, senior, women, youth and student, environmental 
activists -- these are the real independents who want an 
alternative to an electoral system dominated by the two 
parties of big business. They want a party that's on the 
side of the people, where they can elect progressives and 
fight on issues in an honest and principled way. They must 
be seen as progressive independents.</p>

<p>Communists are active in the various progressive third-party 
formations. We see the need for a broad, national, mass 
electoral party where diverse progressive trends can 
increase their strength, work together and win.</p>

<p>At the same time, such a formation does not and cannot 
replace the Communist Party. The Communist Party has a long 
and heroic history of running candidates nationally and in 
localities across the country -- and in some cases being 
elected. There is a Communist electoral constituency in 
America that can be built on and expanded. The Communist 
Party, however, has a revolutionary working-class program 
that transcends electoral struggles and deals with the need 
to change society as a whole. Its candidates not only 
present immediate solutions to today's problems but bring 
forward a Marxist-Leninist outlook and present more 
fundamental class solutions up to and including socialism.</p>

<p>We are a contributing stream in the mighty river of 
progressive politics in America today. We have good working 
relations with numerous independent grassroots political 
formations around the country who are involved in building 
independence from the ground up.</p>

<p>Communist Party Chairman Gus Hall recently pointed out, 
"Building a nationwide mass progressive peoples party is 
going to happen sooner or later."</p>

<p>The U.S. body politic is pregnant with the idea of the need 
to build a third, people's party. The deeper the crisis of 
capitalism, the fewer solutions the capitalist parties have 
and therefore the stronger the third-party trend becomes.</p>

<p>While a united third party may not be immediately 
realizable, we believe a united progressive third-party 
movement is realizable now. And it must be worked for now. 
The question is, what needs to be done in order to help 
guarantee the best preconditions so that the birth will be a 
success, and that what is born is what the people need and 
want, and not another form that is basically running 
interference for the ruling class?</p>

<p>For one thing, what is needed is greater working unity of 
the progressive independent forces. No one trend is strong 
enough or diverse enough to meet the national challenge 
alone. Finding the forms for broad working unity is key.</p>

<p>A proposal is circulating -- Presently there is a lot of 
discussion taking place on how to unite independents. There 
is a proposal for action that comes from friendly 
independent forces and that we are circulating and 
discussing. It requires the fullest input from our Party 
membership and leadership. It is an important proposal.</p>

<p>We favor it because it calls for bringing together all of 
the independents -- including those still within the 
Democratic Party -- based on issues, and to struggle 
particularly against the right-wing danger and around the 
growing economic and civil rights emergency in the country. 
We favor it because we think independents should come 
together to support progressive jobs legislation, like the 
Martinez public works jobs bill (HR 1591), and agree to run 
candidates all across the country based on a progressive 
program.</p>

<p>We think independents should end their rivalries and pledge 
to cooperate and not oppose each other. We think 
independents should agree to launch a united national effort 
to democratize the electoral system by making it easier to 
get on the ballot and by eliminating the influence of big 
corporate money through campaign finance reform -- 
conservative independents are also involved in this fight. 
We think independents should come together to agree on a 
list of ultra-right elected officials to run united 
independent candidates against (labor can play a big role in 
this regard). Independents should come together to defend 
motor voter legislation and promote more democratic methods 
of elections like proportional representation. We are for 
grassroots local, statewide and regional conferences, as 
well as a national conference called together on the basis 
of action not philosophy. All of this has to be related not 
only to the goal of a people's party but also to the need to 
defeat the ultra right in the '96 elections.</p>

<p><strong>Role of the Communists</strong> - Our party has a role to play in 
this historic process of building towards a people's party. 
In local areas we are running as Communists for public 
office. But we must not rule out a presidential ticket -- 
which I will discuss later.</p>

<p>Besides running our own candidates, we must contribute to 
advancing the broad movement for political independence 
overall. Independent forces also have a role to play in the 
immediate 1995 and '96 elections. Like a lot of other 
forces, Communists must help figure out how to move things 
forward and positively affect short-term and long-term 
developments.</p>

<p>This is a difficult challenge, especially when 14 months 
from now we face a presidential election with such a strong 
danger from the right.</p>

<p>We must enter this 1996 electoral struggle in a very active 
way. Our role is very much needed. We must help clarify the 
issues and link them to mass fightback. We must help build 
unity and increase the confidence of those involved in the 
fight. For example, the fight for the Martinez bill would 
not be complete without having candidates strongly advocate 
it.</p>

<p>We are in a very complicated situation tactically. The level 
of organization and unity of the people's independent forces 
is far behind what is needed. The sentiments among the 
working-class masses at the grassroots are beyond the 
policies of not only the Democratic and Republican parties, 
but beyond most progressive independent organizations as 
well.</p>

<p>In reading ultra-right and Republican Party material, it's 
clear that the enemy is fully aware of the potential for 
change and is out to block and misdirect real independence. 
They are well financed, well organized and in motion.</p>

<p>While different independent forces might agree on basics, 
there are real differences -- real contradictions between 
those working on various levels of the broad progressive 
movement for independence. Our role is very much needed to 
help find the ways to build unity and help move things 
forward. We must move quickly.</p>

<p>Danger from the right -- As we said, the 1996 election 
struggle is well on its way. The right-wing Republicans are 
out not only to hold their own but to win the White House 
and increase their majority position in the Congress. They 
are working for a situation where they will control the 
judicial, legislative and executive branches of government. 
Powerful forces in the ruling class want a situation where 
passage of their reactionary program is virtually 
guaranteed. That's why we must accelerate the fight to 
advance political independence.</p>

<p>Just recently William Bennett, himself a reactionary 
Republican, accused presidential candidate Pat Buchanan of 
"flirting with fascism." Buchanan is more than flirting in 
my view. We must not forget that there is a fascist element 
out there -- not just the KKK, skinheads and Nazis, but 
forces with a powerful influence in the Republican Party.</p>

<p>As it is, the right-wing measures already being proposed and 
implemented have created an economic as well as a civil 
rights emergency in the nation.</p>

<p>The recent racist Supreme Court decisions against 
affirmative action sounds the alarm. This needs to be seen in 
relation to the anti-immigrant Proposition 187, the effects 
of a long-term racist propaganda campaign against 
affirmative action as well as all entitlements, and the 
vicious attempts to eliminate welfare. These decisions 
codify the blame-the-victim big lie and open the floodgates 
-- not only for more racist attacks but attacks on labor's 
right as well. The ruling class is out to split the working 
class to make it easier to further worsen our conditions of 
life.</p>

<p>As their real program is being exposed, the right-wing 
Republicans who now dominate the Senate and House are losing 
mass support, but they remain confident they can defeat 
Clinton in '96 because they do not count on the grassroots 
of working people being mobilized and organized.</p>

<p>Clinton's tendency is to cooperate with the Contract forces. 
Efforts like his joint appearance with Gingrich in New 
Hampshire are his preferred direction. However, he can be 
moved.</p>

<p>His speech supporting affirmative action shows that despite 
his politically conservative outlook he can be forced in a 
better direction. But if he continues to push his balancing-
the-budget and other conservative programs, his chances of 
building a winning electoral coalition by November '96 are 
slim. For one thing he will build the abstention trend among 
democratic voters.</p>

<p>We want to score a major defeat of the right in '96 because 
the alternative is unacceptable. As bad as it is now, it 
could get worse. A right-wing dominance of all three 
branches of government would mean a terrible road ahead for 
the people.</p>

<p>Advocating the third-party option alone is not an adequate 
answer. We should not use efforts towards future strategic 
goals to run away from present tactical challenges. The 
economic and civil rights emergency of today has to be top 
priority in all we do.</p>

<p>Lesser Evil -- As the right gets stronger, the lesser-of-
two-evils dilemma becomes stronger too. Basically it is 
structured into all politics under capitalism. After almost 
a year of the 104th Congress, the idea of the lesser evil is 
influencing many voters today. Its impact cannot be ignored; 
it will influence the 1996 elections.</p>

<p>A lot of people are suffering and want relief. The best way 
to achieve long-term relief is to build a powerful 
independent movement and party -- yet such a party cannot be 
built devoid of struggle against the right danger. The best 
way to meet the lesser-evil problem is to establish a 
"better good" alternative. The big tactical challenge is how 
far we can go down the road to advancing the building of a 
"better good" as we meet the challenges of today.</p>

<p>Simply tailing the Democrats is not the way. The pressures 
to do that, especially in the presidential race, are very 
great because the prospects of building a viable national 
"better good" are more difficult.</p>

<p>But in local and congressional races there are signs that 
many real independent challenges can be initiated and won. 
Real victories are possible in 1996 if we understand that, 
even with the lesser-evil problem most sharply expressed on 
the level of the presidential race, it is still possible to 
pressure that election to the left, defeat many right-wing 
candidates and programs on a local, state and congressional 
levels, and that these local fights can have a positive 
impact on the whole electoral struggle. Finding tactics that 
will move the people is key.</p>

<p>New Independent Trends -- There are some new trends out 
there that show that independence is gaining strength. Along 
with the positive results experienced by those building 
third-party formations -- especially those who are building 
from the bottom up -- there are signs that political 
independence is gaining support among organized strategic 
forces. The willingness to defy the Democratic Party 
hierarchy, reject the machine and move outside the two-party 
system is gaining broader acceptance. The idea of running 
candidates as independents, including for president, is 
widely accepted now; it's not considered a "way out" thing 
to do anymore.</p>

<p>After Clinton's latest budget betrayals which undermined the 
whole fight against the Contract in Congress and 
strengthened the right, many progressive forces in the 
Democratic Party were enraged and openly talked about a 
break with Clinton.</p>

<p>The pressures for Jesse Jackson to run have gotten very 
strong. At the recent Rainbow meeting in Atlanta, the slogan 
"Run Jesse Run" reemerged. At a July '95 meeting sponsored 
by Essence magazine in New Orleans, according to the Wall 
Street Journal the African American leaders there were 
generally of the opinion that if President Clinton continues 
moving to the right with such initiatives as his balanced 
budget and affirmative action review, distancing himself 
from the leadership of minority and women's organization and 
other liberals, "Mr. Jackson will feel obligated to run. And 
if the president fights for their agenda, he won't run ..." 
The same article quoted Jackson as saying, "We will not sit 
idly by and watch the great gains of the past evaporate."</p>

<p>Jackson's aides say that they are studying their options, 
including the possibility of running as an independent in 
the general election. This idea is getting a lot of support, 
including among some Congressional Democrats. Incumbents are 
saying that among their constituents, Jackson's being at the 
top of the ticket would help them more then sharing a ticket 
with Clinton. As of this writing, Jackson has not committed 
himself. The main tactic at this point seems to be to apply 
maximum pressure from the left. That is a good tactic and is 
having an impact on Clinton.</p>

<p><strong>Labor</strong> - In the labor movement there is growing alienation 
from the Democrats. Of great importance is the fact that in 
the platform of both groups vying to replace Kirkland as 
head of the AFL-CIO, there is a totally new position 
regarding support of political independence of labor. This 
trend is all over the labor movement.</p>

<p>At the recent Coalition of Black Trade Unionists (CBTU) 
convention, First Vice President Willie Baker said that 
Black workers are no longer the "plow horse" for the 
Democratic Party. They are saying, "no more carte blanche." 
Candidates will be supported based on issues and "let the 
chips fall where they may."</p>

<p>In labor, especially in the leadership circles, there is 
strong pressure that says labor must support Clinton, 
despite the disappointments, due to the danger from the 
right. Such pressure is enormous on the level of the 
presidential race; at the same time, many more top trade 
union leaders today are ready and willing to break with the 
machine on the level of local and congressional candidates.</p>

<p>The continued anger in the ranks of labor over the 
Democrats' betrayal around NAFTA, GATT and the Worker 
Replacement Bill is creating a more favorable climate, 
especially for the Sweeney slate. The pressure for change in 
basic policy in the AFL-CIO is enormous right now. This 
could be a decisive factor in the coming elections if 
mobilized.</p>

<p>The platform of the Sweeney group calls for a "new labor 
movement" and states, "While we must reach out and embrace 
other progressive forces for change, we must above all build 
our own power by creating a strong grassroots political 
voice for working people in this country." Sweeney says that 
the labor movement needs to "exact a price" from candidates 
before endorsing them for public office. This view was 
frantically attacked by Al Shanker, showing a growing 
desperation among conservative labor leaders.</p>

<p>Speaking at the recent Jobs with Justice conference, George 
Becker, president of the United Steelworkers, called for 
shifting labor's money to elect workers to Congress. Can 
these openings be a basis for building local coalitions of 
independent forces around supporting united labor candidates 
for Congress?</p>

<p>The power that the new mergers will bring to the labor 
movement cannot be overemphasized. Greater clout in 
political action is one of the important reasons given for 
the merger of the Textile unions and the mega-merger of the 
Auto Workers, Machinists and Steelworkers. These are new 
openings for approaching labor.
</p>
<p>Another challenge is around the recent racist Supreme Court 
decisions against redistricting. Can independent forces help 
build broad-based coalitions of all the independent forces 
in response? Why not coalitions that would work to guarantee 
the re-election of Congresswomen Cynthia McKinney and Nydia 
Velazquez? This could be linked to establishing a national 
list of 20 to 30 extreme right-wing Congressmen to target 
for defeat.</p>

<p><strong>The Abstention Factor</strong> - More and more, the ruling class 
relies on the abstention of millions of working-class voters 
to guarantee the election of reactionaries. The abstention 
factor is determining the outcome of most elections today. 
As we said, tens of millions of voters do not identify with 
either the Republican or Democratic parties.</p>

<p>In the 1992 presidential election no candidate received a 
majority. Clinton received a plurality. Over 19 million 
voters -- about 19 percent -- voted for the "independent" 
candidate and billionaire businessman Ross Perot.</p>

<p>In the 1994 mid-term elections only about 38 percent of the 
electorate came out. While they won a lot of races, the 
Republicans actually won by default. The overwhelming 
majority of voters decided not to vote, leaving the field 
open for the more conservative section of the electorate, 
and those most taken in by right-wing demagogy, to determine 
the outcome. In that and other elections the right has a 
power far beyond its actual numerical strength.</p>

<p>Increasingly with the capitulations and moves to the right 
by the Democratic Party, the working-class majority of the 
electorate is opting for a "no confidence, no vote" tactic. 
The danger of this approach is that, by default, it is 
leaving the field open to domination by a minority of voters 
who are wealthy reactionaries.</p>

<p>The answer cannot be simply to work harder to get folks to 
register and vote. The abstention trend is not only a vote 
against the two dominant parties but is rooted in the 
growing lack of confidence in capitalism itself. The answer 
must include advancing the struggle for peace, jobs, justice 
and equality. It must include the struggle to promote 
people's candidates, to create a democratic progressive 
alternative to build the greater good, so that the people 
will have something to vote for. It's becoming clear that 
constant, defensive appeals to come out to vote do not hold 
a lot of sway with large numbers of voters. More is needed.</p>

<p><strong>The Class Issue Is Key</strong> - According to a recent survey 
conducted by Curtis Gans of the Committee for the Study of 
the American Electorate, 60 percent of persons with incomes 
of $50,000 or more voted in 1994, up from 59.2 percent four 
years prior. Only 19.9 percent of those with incomes under 
$5,000 came out, down from 32.2 percent. For voters making 
$5,000 to $10,000 a year, only 23.3 percent voted compared 
to 30.9 percent previously.</p>

<p>The study found that while 46.9 percent of whites said they 
voted, which was an increase from 1990, only 37 percent of 
African-Americans and 19.1 percent of those classified 
Hispanic came out. In each case that was a decrease from 
1990.</p>

<p>As our Party has said, the outcome in the '94 elections was 
not due to an ideological shift to the right by the working-
class majority, as some continue to claim, but rather 
because the active electorate in 1994 tended to be high-
income conservative voters.</p>

<p>Yet some use the same results to keep pushing the "angry 
white men" notion. This idea is pushed in order to hide the 
class issue and encourage and justify racism. The aim is to 
take the justifiable anger of white workers toward the 
system and its ruling class, and misdirect it towards non-
white workers.</p>

<p>Most opinion polls show that there has been no rightward 
shift by working people. As I said earlier, as the class 
essence of the right wing's program is more and more 
exposed, those who advocate the Contract are losing support. 
Helping to popularize a class understanding is key to unity 
in advancing political independence and in defeating the 
ultra right in the coming elections.</p>

<p>For example, while a majority supports a balanced budget and 
lower taxes, they do not support or trust the likes of Newt 
Gingrich. And when you get to the specifics of what is to be 
cut to "balance the budget," a majority do not support the 
anti-working-class, racist measures proposed by the right 
wing to achieve it. To support these measures is to support 
more massive giveaways to the rich at the expense of the 
people. There is a strong class revulsion against these 
policies.</p>

<p>Cutting the military budget, cutting "wealthfare" 
(entitlements for the rich) and taxing the rich are all 
popular, majority ideas among masses of working people.</p>

<p>Even among Republicans, those presidential candidates who 
continue to emphasize the right-wing economic proposals in 
the Contract are falling behind those who have shifted to 
so-called moral issues.</p>

<p><strong>How To Proceed</strong> - Basically what is needed is greater unity 
of the independent forces working on all levels of the 
movement for independent politics. This includes sections of 
labor, African Americans and Latinos, third-party movements, 
those working to democratize the electoral process and 
forces who are still organizationally inside the Democratic 
Party but whose politics are independent and to the left of 
the dominant forces in the party. This includes grassroots 
activists, leaders of mass organizations and elected 
officials.</p>

<p>In the proposal that our Party is in agreement with, there 
are a number of ideas to build on. For example, independents 
could come together to agree on a program to convince 
candidates to run on. One of the most exciting ideas would 
be that everyone -- no matter whether they support the 
Greens, LPA, the New Party, or if they are a reform Democrat 
or a Communist -- all agree to support the same candidates 
for public office.</p>

<p>The proposal projects holding a series of local meetings or 
conferences to help lay the basis for building for a 
national conference. The purpose of local conferences is to 
develop local action programs around the economic and civil 
rights emergency. They could be organized around targeting 
particular extreme-right candidates for defeat.</p>

<p>Take Connecticut, where there have been some excellent 
examples of successful grassroots electoral independence. It 
is a state where the economic emergency is very severe, and 
where Governor Rowland is trying to destroy welfare and 
privatization is high on his agenda. There are municipal 
elections this year and most independent forces are 
involved. In New Haven they are working to put a jobs bill 
referendum on the ballot. In other cities they are working 
on the municipal elections. They are organizing for a real 
fight this year. Can there be a coming-together of 
independent forces to organize and coordinate their efforts?</p>

<p>In New Mexico a very important national Green Party 
conference was held. Our party's presence was welcomed by 
the many independent activist who were there. Virginia 
Brodine, chair of our environmental commission, took part in 
a workshop and on a panel of third parties representing our 
party. She was very well received. We also set up a very 
successful Party literature table.</p>

<p>Our comrades who attended the Green Party conference in 
Washington D.C. last month were also warmly welcomed by its 
organizers. In general, our presence at third-party movement 
events is appreciated and often openly acknowledged. Many 
forces may not agree with us on every issue but they respect 
our contributions, our experiences and our outlook for a 
socialist future.</p>

<p>In California, defense of motor voter laws, defeating the 
affirmative action referendum and the ongoing struggle to 
overturn Proposition 187 are at the center of the electoral 
struggle. With so many third-party forces there, it would 
seem that some form of getting together around a concrete 
issue is possible.</p>

<p>In Oregon there will be a referendum on proportional 
representation on the Eugene ballot. In New York, the 
economic emergency is very severe with the presence of a 
right-wing Republican mayor in New York City and a right-
wing Republican governor in Albany -- the elections must be 
linked to the growing fightback. Certainly in Ohio -- not 
only with Rick Nagin in Cleveland but in Youngstown/ Warren 
in particular -- we ought to have a Communist candidate to 
offer all those households who received our message during 
the homecoming activities a chance to vote for the party of 
Gus Hall.</p>

<p>Thus, all around the country the question is: what can be 
initiated among various independent forces on a local level 
to use the elections to advance the fightback? What can be 
done to strengthen the fight for the Martinez bill vis-a-vis 
the coming elections? This must be a period where hundreds 
of labor, African American, Latino, youth, women and senior 
progressive independents are challenging for public office. 
The real independents must come to the fore.</p>

<p><strong>Communist Candidates</strong> - As I said, we must be prepared to 
launch Communist candidates for public office in the 1996 
elections in as many states and districts as possible. At 
this point, a goal should be for at least one candidate in 
every Party district. I think the time is ripe for running 
Young Communist League members for office as well. Youth 
candidates have a special appeal, particularly when voter 
alienation is so high.</p>

<p>We also must not rule out running for president. In fact we 
must examine all the technical requirements for running a 
presidential slate. The Jackson forces say that it is fairly 
easy in 27 states. What should we do? For one thing, we 
could at least go for a number of key states in order to 
have a voice in the very important national debate.</p>

<p>In the course of these electoral activities, the 
opportunities are very great to build our party and press, 
and broaden the Party's contact with independent forces, 
elected officials and especially rank-and-file activists. 
Electoral activities have always been an excellent way to 
build the Party. This could accelerate our mass recruitment 
in the streets.</p>

<p>The situation calls for a higher level of unity of the 
independent forces and a more coordinated relationship 
between them. With such unity it will be much more possible 
to defeat the right and build towards a mass national 
people's party. While we favor political independence all 
the way up to the presidential race, if there is not a mass 
united independent candidate for president we will still be 
building pressure from the grassroots.</p>

<p>We should keep in mind that while an independent progressive 
presidential challenge may be difficult to realize in 1996, 
by the year 2000 -- after electing a lot of independents on 
the local and Congressional levels especially -- it would be 
a natural.</p>

<p>The objective possibility is that by that time, we could be 
in a position to build a strong coalition people's party, 
greatly democratize the electoral process in America and 
launch a formidable challenge to the old parties of big 
business -- not only at the point of production, on the 
street and on campus, but at the ballot box as well. So let 
us take today's challenge very seriously, and take it to 
others, and help make the breakthroughs that are so possible 
in this period a reality.</p>

(Jarvis Tyner is a member of the National Board of the 
Communist Party USA).

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-245</DOCNO>
<DOCOLDNO>IA027-000294-B005-173</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/pa1.html 206.119.5.80 19970120072515 text/html 15689
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:31:54 GMT
Last-modified: Friday, 29-Sep-95 03:33:39 GMT
Content-length: 15506
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>PA Editorial - The Class Struggle and Labor</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>The Class Struggle and Labor</h1>
<h2>Editorial</h2>

<p><em>This article was reprinted from the <strong>August 1995</strong>   
issue of 
<strong>Political Affairs</strong>. For subscription
information  
see
below. All rights reserved - may be used with PA
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p>In June of this year, the Labor Department issued figures on 
productivity and wages that were so alarming they should 
have been featured in newspaper headlines and network TV 
newscasts across the country.</p>

<p>Robert Reich, Secretary of the Labor Department which 
chronically under stresses the true state of affairs where 
the working class is concerned, reported to the New York 
Times that there "has been a shift from earned to unearned 
income, from paychecks to dividends and capital gains." The 
Times was worried enough to devote an editorial to the 
subject in which it warned that if this trend continued, 
"the consequences could be explosive."</p>

<p>The Times went on to note that while wages fell by 2.3 
percent (and have been falling for more than two decades) 
and benefits (health, vacations, pensions, etc.) were cut by 
3 percent, "productivity -- output per hour of work -- shot 
up by 2 percent last year and by a gaudy 2.7 annual rate at 
the beginning of this year ... Profits," it continues, "are 
near record levels and stock prices have surged 15 percent 
since January."</p>

<p>A bit uneasy about the implications of its own quoted 
figures, the Times equivocates: "By some measures, these are 
beautiful times." Obviously, not the measure of working men 
and women. For workers these figures translate into less 
food on the table and a sharp decline in living standards. 
With increasing attacks on "safety net" provisions, the 
average worker today stands in the greatest peril since the 
early Depression days.</p>

<p>Practically every day now you can pick up a newspaper at 
random and read something like the following:</p>

<blockquote>The MCI Communications Corporation, while announcing a 21 
percent rise in earnings, said yesterday that it would 
restructure the company, dismissing 2,500 to 3,000 employees 
by the end of the year.... (New York Times, Aug. 3, 1995)
</blockquote>
<p>What's going on? How has it been possible for workers to get 
into a situation where the harder they work, the more they 
produce, the less they get paid? Even worse: the more they 
produce in a shorter and shorter period, the fewer of them 
are needed. And so many find themselves "downsized," 
unemployed, redundant, "too young to die, too old to work." </p>

<p>It's absolute insanity -- even from the point of view of 
corporate America which must realize this process is killing 
the goose that lays the golden egg. Or is there a delusion 
among them that they can go on forever driving workers to 
produce more and more and pay less and less?</p>

<p>Ironically enough, the historic accomplishment of the New 
Deal of over 60 years ago -- which the Republican Yahoos of 
today want to dismantle -- are precisely the cushions which 
have prevented "explosions" of the type the New York Times 
fears and the removal of which will put them back on the 
political agenda.</p>

<p>The drive to disaster seems programmed. Finance capital is 
driven to produce higher and higher profits by the very 
nature of the system, even though that is the one-way ticket 
to suicide. Maximum profits is hailed as the law of the 
land, despite the fact that the mills and factories are 
literally slaughtering workers, currently at the rate of one 
killed roughly every hour and a half. This adds up to over a 
million U.S. workers killed on the job since the 1920s. The 
words of author Edison Bowers in 1930 hold true: "The 
workshop is more dangerous than the battlefield."</p>

<p>Big business has no interest in the worker as a human being, 
but only as a source of profit. Indeed, corporate bosses 
have no interest even in the goods their factories produce -
- of which they know nothing -- only in profit. Production 
is a pretext, not an end. If producing frogs legs made a 
better profit than making steel, the steel mills would be 
close up in an instant to make room for frogs. </p>

<p>Big Banks run the economy and today are identical with the 
government, which has degenerated into nothing more than its 
obedient servant ready to gratify its every wish, including 
openly transforming the armed forces into bill collectors on 
delinquent customer-countries all over the world.</p> 

<p>Although by its nature capitalism always exerts force to 
lower wages to the level of subsistence -- its ideal is the 
worker who is paid just enough to maintain his or her 
ability to work and reproduce -- the course of labor history 
shows that workers can create a counter force even greater 
by means of militant labor action.</p> 

<p>But militant labor action is exactly what was missing from 
the top leadership of labor which presided with remarkable 
complacency over the decline of the labor movement from the 
merger of the CIO and AFL in 1955. Small wonder that only 
some 15 percent of the working class is organized into trade 
unions.</p>

<p>The leadership of the AFL-CIO under George Meany and Lane 
Kirkland was governed by the notion so loudly proclaimed by 
the late David Dubinsky, lifetime president of the 
International Ladies Garment Workers Union, that "unionism 
needs capitalism like a fish needs water."</p>

<p>As a consequence of this kind of class collaborationist 
thinking, labor almost completely forfeited the independent 
political posture of the working class. Workers have few 
voices to speak on their behalf in Congress or state 
legislatures, many of which have passed right-to-work laws 
that did serious damage to the labor movement in those 
states. Labor has no daily press, no face to show the public 
on TV. Hollywood, which has slandered workers almost since 
its birth, only now and then produces a movie that reflects 
the reality of workers' lives. </p>

<p>Labor has been hemmed in and hobbled by a series of laws, 
including Taft-Hartley, Landrum-Griffin, the reversal of the 
Norris-LaGuardia anti-injunction law -- all of it 
culminating in the "hollowing out" of the National Labor 
Relations Board so that only the face remains. </p>

<p>The right and power to call strikes has been severely 
curtailed, not only with devices like the mandatory 60-day 
"cooling off" period (as though strikes were called in the 
heat of passion rather than as the last resort), limiting 
the number of pickets a union can employ and how close they 
can come to the place being picketed, forbidding "secondary" 
picketing and boycotts, and so on. Judges can and 
increasingly do levy huge fines against unions and issue 
injunctions that effectively break strikes. </p>

<p>On occasion Congress, if "stirred up," can and has passed 
laws breaking a strike by forcing the workers to return to 
work. The president too has the power to break a strike, as 
President Reagan (a.k.a. T-10, his code number when he was 
an informer for the FBI and president of the Screen Actors 
Guild as well) proved when he broke the Air Traffic 
Controllers union in 1981.</p> 

<p>The notorious "amendment" to the bankruptcy laws -- the so-
called Chapter 11 -- makes it possible for a company 
unwilling to pay decent wages, or wanting to get out from 
under pension, health and vacation obligations, to declare 
"bankruptcy" and then legally cancel all such contracts and 
obligations, and "reorganize" itself shorn of previous 
commitments. Thousands of workers have lost wages and 
benefits by this device.</p> 

<p>When whole companies arbitrarily shut down, as did the steel 
industry in Western Pennsylvania,, Ohio and Illinois, 
workers suffered enormous losses. Almost overnight their 
homes -- into which they had invested not only their hard-
earned wages but much of their lives -- lost value; some had 
to be abandoned as the owners were forced to look for work 
elsewhere.</p>

<p>What we see in this portrait of the American working class 
is the "market economy" at its very best. Attempts to revive 
it with NAFTAs, GATTs and other opiate dreams are calculated 
to shift the cost of a mammoth redistribution of wealth in 
the world onto the backs not only of Third World workers but 
of American workers as well. They will have their short run 
of hope and illusion and ultimately collapse, leaving the 
situation even worse than when they found it.</p> 

<p>There is only one "cure" for the evils of capitalism and it 
still is socialism -- no doubt a more mature and wiser 
socialism than before, but socialism nevertheless. Life is a 
pitiless master but it rewards those who master its lessons. </p>

<p>History is not over. It has just begun. The class struggle 
has not lessened. It has intensified.</p>

<p>Meanwhile, labor is under direct attack and must defend 
itself. Part and parcel of the attack are the actions of 
Congress, the Supreme Court and the White House annulling 
and reversing certain key advances in the struggle of 
African Americans, Latinos and other minorities. These 
attacks must not be seen in isolation from the simultaneous 
attacks on the rights of labor in general.</p>

<p>Killing affirmative action, cutting projects like Head 
Start, outlawing electoral districts that allow for African 
Americans as well as Latinos to be represented in Congress 
and in state legislatures are aimed against economic 
interests as well as civil rights. Affirmative action is 
tied directly into jobs, Head Start and other projects into 
training for jobs. Political representation is an economic 
question as well. Low wages for any section of labor has the 
effect of lowering the wages of all labor.</p>

<p>Our country cannot survive half-union and half non-union. 
The old union slogan still applies -- an injury to one is an 
injury to all.</p>

<p>Serious as the situation is for the laboring masses, it is 
far from hopeless. On the contrary, the signs are 
multiplying that the long period of setbacks for the working 
class is definitely over. The brazen, arrogant assault on 
the hard-won rights of the workers that has been launched in 
Congress has been a wake-up call to all of labor and all 
progressive forces in the country, ranging from feminists to 
environmentalists, who are under attack. In fact, a natural, 
objective united front of such forces has risen and is 
taking shape. We are at the beginning of a new phase in the 
struggle of democratic America for its birthright -- for its 
native, homegrown, people's America.</p>

<p>There are many impressive straws in the winds of change. 
That Lane Kirkland had to resign while still in office is 
one of them. Before him the AFL had only three presidents in 
over 100 years. None resigned, none were defeated in 
elections, and all lived to a ripe old age. To be forced to 
resign while still in office is tantamount to a preliminary 
tremor that presages an earthquake to come.</p>

<p>Another hefty straw in the wind was the extraordinary 
reception that the AFL-CIO steelworkers local in Warren, 
Ohio extended to Gus Hall last July. Only yesterday, as time 
goes, Communists were driven out of office in the AFL-CIO 
and some locals even refused to accept them as members. To 
turn the town inside out welcoming the biggest Communist of 
them all is something nobody could have predicted only 
months ago!</p>

<p>Another positive note is the unification of three major 
unions -- the United Steelworkers, Auto Workers and the 
International Association of Machinists. In so doing, the 
labor movement takes a big step toward reversing the flaws 
and weaknesses it developed since the Cold War dismantling 
of the CIO. It will also help accelerate other mergers in 
labor -- construction, railroads and teachers come 
immediately to mind.</p>

<p>Added to that is the new, militant note sounded by John 
Sweeney, who heads the "New Voices for American Workers" 
ticket in opposition to the official slate, pledging the 
unions to "recreate a labor movement that will improve the 
lives of working people, not just protect them from current 
assaults." He promises to build "a new progressive political 
movement. We will remind CEOs and the right-wing zealots in 
public office that disrespecting working people is a one-way 
road to hell."</p>

<p>Linda Chavez-Thompson, running for AFL-CIO executive vice-
president on the New Voices ticket said during a recent 
rally in Chicago that the new labor leadership would "change 
the face of labor. It will be my face. It will be your 
face." And Richard Trumka, head of the Miners union who is 
running for secretary-treasurer, told the same rally, "We 
cannot win by running and hiding but only by standing 
together and fighting together."</p>

<p>It's an entirely new ball game. The slate is being wiped 
clean of the do-nothing, class collaborationist past. Old 
illusions, fears and false hopes are being shed. It's a new 
working class we see today -- more militant, more united, 
more class conscious, and more left in it outlook.</p> 

<p>These developments are so basic that Gus Hall recently 
pointed to the beginnings of a new period in U.S. political 
life -- an era in which the working class comes front and 
center into shaping the direction of the class struggle. All 
developments will from now on relate in one way or another 
to this new factor.</p>

<p>Already the ruling class has begun to make adjustments. 
Witness Clinton's recent speech on affirmative action in 
which he said the program has been good for the country. 
Witness his sharpened attacks on the Republican budget. 
Witness most importantly the blunting of the right-wing 
offensive. The ultra-right drive to force the Contract on 
America down the throat of the country is beginning to slow 
down and lose steam in the face of mounting resistance from 
the people.</p>

<p>Workers, Black, white and Brown are angry and are beginning 
to take action. And where the working class goes so goes the 
rest of the country. A working-class explosion is brewing 
below. It's unstoppable. It's inevitable. It will change 
America.</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-246</DOCNO>
<DOCOLDNO>IA027-000294-B005-317</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/docs/health-3.html 206.119.5.80 19970120072711 text/html 30224
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:33:44 GMT
Last-modified: Sunday, 26-May-96 17:01:02 GMT
Content-length: 30041
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD HTML//EN//2.0" "html.dtd">
<HTML><HEAD>
<title>Phil Benjamin, The National Health Care Debate of 1994</title>
<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing   http://www.hartford-hwp.com -->
</head>
<BODY><a name="top">
<h1>The National Health Care Debate of 1994</h1>
<h2>by Phil Benjamin</h2>
<p> Advocates of reforming the health care system - promised by 
President Clinton in the 1992 elections - have been 
successful in preventing the corporate health care industry 
from enacting anti-people health legislation in the 1993-94 
Congress. This must be seen as a victory, not a defeat. 
While such an assessment may seem to make a positive out of 
a negative, the facts speak for themselves. </p>

<p> Let's look at the history of this health care reform 
effort. As the old adage says, "those who fail to learn from 
history are doomed to repeat it." After extensive public 
hearings, the Clintons introduced their very "moderate" 
health bill in the fall of 1993. Progressives immediately 
saw the weaknesses in this bill, especially its pro-
insurance company bias, but publicly withheld their 
criticisms. </p>

 <p>This period of time required having a flexible approach to 
the Clinton program, even though everyone knew the 
president's legislation must be improved. While continuing 
to garner supporters for the single-payer legislation, they 
struggled to improve the Clinton bill through intensive 
lobbying and political struggle. But by early 1994 it became 
clear that the Clintons and their congressional supporters 
were hell-bent on passing any legislation, regardless of its 
content. By that time, the handwriting was on the wall.</p>

<p> That "compromise for passage" approach of the White House 
and congressional leaders sent a very clear message to the 
health care profiteers. "We won't fight you," rather, "we 
will work with you in getting a bill that you favor passed." 
In fact, the White House, along with the Senate's collection 
of George Mitchells and Pat Moynihans, would not pass any 
legislation that did not have monopoly's support. 
Significantly, the House Democrats, with the exception of 
the single-payer leaders, took a back seat during the whole 
process. Each of these House members knew they had to face 
re-election in the fall of 1994. They were caught between 
health industry campaign contributions and the desires of 
their constituents.</p>

<p> By this time, Clinton had revealed his true colors with the 
crude tactics he used to win passage of NAFTA. As the summer 
of 1994 approached, the Clinton administration's reputation 
was at an all-time low among labor and community people. </p>

 <p>From late winter through spring, the mad grab for profits 
and power became painfully clear when Met Life combined its 
health-profit business with The Travelers. Metrahealth, the 
new corporate name, anticipates a customer base of 13 
million and $17.6 billion in revenue. Two of the "Big 5" 
leaders in the insurance industry saw the future and acted 
accordingly. </p>

<p> The "smaller" insurance carriers in the Health Insurance 
Association of America, who are not among the Big Five, 
scrambled for their market share. Fearing they would be left 
out of legislation, they conducted an advertising campaign 
against the White House proposals. This campaign, which cost 
over $15 million, was credited with putting a lethal knife 
in the heart of health care reform. </p>

 <p>It is important to understand the reasons why the campaign 
succeeded. The ad campaign demagogically raised legitimate 
questions in people's minds such as how do you guarantee 
universal health care in a system run by the insurance and 
drug monopolies? The ad campaign cleverly played on this 
sentiment.</p>

<p> The campaign of the "smaller" insurance companies was 
effective with the mass media and some leading members of 
Congress. It galvanized the anti-reform forces to increase 
their activities against any government involvement. The 
"Big Five" didn't shed any tears, since they knew they were 
on the winning side in any game being proposed by the White 
House. They would garner the lion's share of the profits, 
regardless of the current legislative outcome. </p>

<p> It appeared that the Big Five would have settled for a 
Medicare-style bill that would guarantee these giant 
corporations super-profits. As third-party intermediaries, 
the insurance carriers do very well under a program modeled 
after the current Medicare program. In order to gain their 
support, the White House assured these insurance monopolies 
a level of super profits, similar to their third-party role 
in Medicare.</p>

<p> In spite of the attacks on health care reform, polls 
continued to show the people's confidence in government 
involvement in health financing and delivery. Opinion polls 
expressed satisfaction with government insurance programs 
such as Federal Social Security, Federal Social Disability 
Insurance, Medicare, Unemployment Insurance and even, to 
some extent, Workers' Compensation. Many veterans still rely 
on their federal veterans benefits, including what is left 
of the veteran hospital system. Compared to their horrid 
experience with the private insurance company system, the 
choice was obvious. The hatred of the private insurance 
carriers remains at an all-time high. These polls were 
deliberately kept out of the public eye.</p>

<p> Editorialists from the New York Times to commercial 
television continually supported the most conservative 
congressional legislation. They constantly heaped uncritical 
praise on privatization proposals. Politicians, however, 
were well aware of the public sentiment for national health 
care. While they wouldn't stand up to their friends in the 
corporate health care industry, they also feared incurring 
the wrath of the voters. This was the main reason for the 
failure of Congress to act. Even with all the power and 
wealth of the transnational health monopolies, Congress was 
forced not to pass a pro-monopoly bill.</p>

 <h4>Monopolization</h4>

<p> All during this period, major consolidation moves in the 
profit-making hospital field were taking place. Columbia 
Health Care (CHC), the country's largest profit chain, 
bought the Hospital Corporation of America (HCA) for $5.6 
billion. That chain became even bigger when the Wall Street 
Journal reported that, on October 6, Columbia/HCA bought 
Health/Trust Inc. for $3.6 billion in newly-issued stock. 
This deal, if it holds up, will increase Columbia/HCA to 311 
hospitals with 170,00 employees and an estimated $15 billion 
in annual revenue. The Wall Street Journal reported that the 
Federal Trade Commission will review the transaction, but 
there is little doubt that it will be approved. </p>

<p> A week after the Columbia/HCA transaction, National Medical 
Enterprises (NME) bought American Medical Holdings for 
almost $2 billion. This keeps NME as the second largest for-
profit hospital chain with 71 hospitals, 63,200 employees 
and revenues over $5 billion. NME recently paid a record 
$380 million to settle federal criminal charges after 
pleading guilty to six counts of paying kickbacks in the 
referral of Medicare, patients and one count of conspiracy 
to make illegal payments.</p>

<p> With these previous and current dealings, the profit-making 
hospital system is clearly yet another monopoly influence 
peddler throwing its weight around in Congress and in the 
Clinton administration.</p>

 <h4>Figures Don't Lie, Liars Figure</h4>

 <p>Another feature of the great health care reform period of 
1993-94 was the barrage of facts and figures that every side 
used to push its point. Think tanks on all sides were busy 
grinding out studies that supported their positions. 
Clearly, if the playing grounds were level and logic had its 
day, the objective situation presented by the progressive 
forces would have prevailed. The extensive public hearings 
held by Hillary Clinton's Administrative Task Force, during 
the first part of 1994, pointed the congressional debate 
toward a progressive conclusion. If there was ever any truth 
to the adage "Figures don't lie, liars figure" this was the 
year. </p>

<p> But figures were not the only weapons being misused. The 
redefinition of words took on a whole new level when every 
player in the game said that their program was "universal." 
Those assertions were not adequately challenged.</p>

<p> When it became clear that everyone in Congress was trying 
to include a benefit to senior citizens in the form of a 
Medicare prescription drug program, the transnational drug 
corporations sprang into action. Since any Medicare 
prescription drug program would be significantly determined 
by government regulation, each drug transnational vied for 
an advantage. One way to gain the most profit was by 
eliminating the competition. Thus the increasing 
monopolization of the international drug cartels had a 
profound effect on the health care debate. </p>

 <p>The drug transnationals Eli Lilly (PCS Health Systems), 
Smith Kline and Beecham (the British transnational), 
Diversified Pharmaceuticals, and Merck (Medco Containment) 
bought drug purchasing companies so that they, as 
manufacturers, could control the flow of their drugs. These 
purchasing companies were set up to arrange the purchase of 
drugs at discounted prices for employers, labor unions and 
other large consumers. Billions of dollars changed hands in 
these transactions. For example, Lilly purchased PCS for $4 
billion. This is all the more remarkable since PCS had 
profits in the low millions. This acquisition will affect 
over 51 million people or 20 percent of the U.S. population. 
Lilly's intention was quite clear.</p>

<p> Smith Kline and Beecham purchased Diversified for $2.3 
billion, and Merck paid $6.6 billion for Medco. In another 
major drug company transaction, Roche Holding bought Syntax 
for $5.3 billion. To top off this orgy of billion-dollar 
transitions, American Home Products bought American Cyanamid 
for an incredible $8.5 billion.</p>

 <p>All of these drug manufactures have honed their extensive 
kickback schemes to physicians and hospitals/health centers 
to gain an even greater competitive advantage. These 
kickbacks are the subject of Senate investigation. In the 
meantime they continue to take place and the general public, 
especially senior citizens, are being taken advantaged of. </p>

<p> The business sections of newspapers were replete with 
articles about these transactions. To boost this profit 
direction, the Wall Street Journal's (August 25, 1994) front 
page story stated, "With Congress Stalled Health Care is 
Shaped by the Private Sector." To put some brakes on this 
movement, once the barn door was closed, the Journal 
cautioned that anti-trust laws were certainly being 
violated.</p>

 <p>Therefore, while the insurance companies are often pointed 
to by some as the culprit for the high costs of health care, 
other members of the transnational health monopolies are 
also involved. That includes the drug monopolies, profit-
making hospital chains, medical equipment and supply 
companies and international financial organizations.</p>

 <h4>Self-Destructive Competition</h4>

<p> All of these outfits were united to kill any progressive 
legislation. Once they were assured that the White House was 
not advocating a progressive health bill, each corporation 
and industrial association set about gaining their own 
advantage within the context of some kind of federal health 
legislation. This competitive advantage lobbying sent 
members of Congress and their staffs into a tizzy. Hundreds 
of millions of dollars were spent in lobbying Congress. 
Millions were spent in contributions in the 1994 
congressional elections. This period of time became a 
bonanza of money for elected and aspiring politicians and 
"Beltway" consultants. </p>

<p> A September, 1994 Citizen Action report found that the 
health and insurance industry gave candidates $13.6 million 
from January through June, 1994, a 96 percent increase over 
the previous comparable period. This compares to a 10 
percent jump in non-health related industry contributions.</p>

<p> This new situation gave a conservative compromiser like 
Clinton headaches. It seemed that a new bipartisan proposal, 
engineered by combinations of monopoly capital, was coming 
down the pike every month to satisfy the profiteers. Each 
proposal pushed the health care debate further to the right 
and against the health care of everyday people. This 
bipartisan, monopoly effort contained more Democrats than 
Republicans. Who said there isn't a dimes worth of 
difference between the two parties of monopoly? </p>

<p> Republican Party policy, led by Senate leader Bob Dole, 
after initially beginning with the then- obligatory 
allegiance to "we also want health care reform," easily 
settled into their more comfortable pro-monopoly position. 
In this instance, however, the Republicans could sit back 
and watch the Democrats kill themselves. </p>

 <p>Contradictions in the drive among competing corporate 
interests in the drug, insurance, profit-making hospital 
chains, medical supply and equipment and financial 
corporations to gain advantage over each other contributed 
to their own legislative downfall.  </p>

<h4>People's Power: The Decisive Factor</h4>

<p> The main ingredient in this anti-people, profit lobbying 
mix that proved to be the decisive factor was the people 
themselves. As indicated, polls showed the overriding 
sentiment for a national (universal) system of health care. 
The single-payer movement developed to carry the fight into 
the halls of Congress. The leaders of that movement came 
from important sections of the labor movement and major 
community groups. It was and remains a broad and effective 
political movement.</p>

<p> Representative Jim McDermott of Washington State (one of 
only two physicians in Congress) in the House and Senator 
Paul Wellstone from Minnesota, gave congressional leadership 
to the movement. Labor and community leaders were relentless 
in lobbying members of Congress in their home offices or in 
Washington. Rallies were held in Washington and in every 
large town voicing the cry, "no profits in health care." The 
people's message was heard. The movement didn't get what we 
wanted, but it did stop the health care industry from 
enacting its own legislation. Given the balance of forces, 
this must be seen as a peoples' victory.</p>

 <p>From the outset, the labor movement had two general 
viewpoints. These viewpoints reflected the two political 
strains in the organized labor movement in the U.S. One 
trend generally fights for its members by struggling against 
monopoly capital, and the other collaborates with big 
business. The basic difference in the approaches is between 
class- struggle trade unionism and class collaboration. </p>

<p> The collaborationists were lead by AFL-CIO President Lane 
Kirkland. They helped organize and/or joined joint labor and 
management committees as the way to gain health care reform. 
Some of these committees even included the insurance 
companies. White House and Congressional leaders loved this 
collaboration strategy. They knew that ultimately, after 
some loud talk, these labor leaders would agree to anything 
the White House and its corporate supporters would put 
forward. </p>

<p> But progressive and left-of-center international unions did 
not agree with the Kirkland sellout and fought against it. 
Kirkland and his right-wing allies fought hard against the 
anti-profit health care group. While the single-payer 
movements strength came from the progressive unions, 
Kirkland's collaboration stopped a united front against the 
monopolies from being formed. Votes in the AFL-CIO's Health 
Committee were routinely divided down the middle, eight for 
single-payer and eight against. There are opportunities to 
win a few of the latter group away from Kirkland. </p>

<h4> Single-Payer: a Compromise Itself</h4>

<p> In his September 5, 1994 speech, McDermott called for an 
end to the congressional health reform effort since the 
debate had moved too far toward an anti-people health bill. </p>

<p> In his remarks he made an impassioned plea to his corporate 
constituency. While his stand for the single-payer 
legislation was more than admirable, he showed his 
limitations when he said that corporations had nothing to 
fear from the single-payer proposal. After all, he said, 
only the financing would be government organized. The 
delivery of health care, he assured, would remain in private 
hands. </p>

<p> McDermott as much as said that his legislation was not the 
same as socialized medicine. This is not Great Britain, he 
argued, it is just like the Canadian system. Physician fee-
for-service and private hospitals and clinics were to be 
preserved. Clearly, he is sending the wrong message - being 
unfairly critical of a superior health program in order to 
sell yours is the wrong path to go down. </p>

<p> At the turn of 1994, the single-payer movement felt that 
large corporations, such as the auto industry, would benefit 
from a single-payer-style approach. The auto manufacturers 
were looking for a way to reduce or unload their health 
benefits, averaging about $800 per car, onto the federal 
treasury. While those positions were stated behind closed 
doors, these same corporate giants never had a mass media 
campaign to win their point of view. There are probably too 
many health industry monopolists on their boards of 
directors. The argument for socializing the financing of 
health care carried some weight. And since a significant 
number of people in this country are already covered through 
a government-run financing mechanism, this would not be 
perceived as a radical solution. It all seemed to make 
sense.</p>

<p> The debates at this time were among health-care advocates 
who were part of the health-care scene for years. The 
debating lines were drawn and logic seemed to be carrying 
the day. But a new feature came through in this period when 
a group organized in 1992-93, called the "Jackson Hole 
Group," came into the fray. Named for a corporate retreat in 
Wyoming, the "Jackson Hole Group" represented the 
concentration of profit power in the health industry. While 
it seemed to have a distinct U.S. tinge, in fact, it also 
represented the combined power of transnational health 
profiteers. </p>

 <p>At first they were not taken seriously. At the time their 
crude profits-above-all-else approach seemed so obvious as 
to render them without any credibility. </p>

<p> The "Jackson Hole Group," which brought the crudest form of 
lobbying to the halls of Congress, saw all too well the 
logic and effectiveness of the single-payer compromise. 
Although they saw its value in nudging out the far more 
progressive and logical method of delivering health care, 
that is, the British National Health Service ( the financing 
and delivery system of the BNHS is in government hands, not 
insurance companies), they waged a fierce campaign to defeat 
single-payer. </p>

<p> Progressive health care advocates remember that in the 
1970s Congressman Ronald V. Dellums had proposed a national 
health service for this country. The largest health care 
organization in the world, the American Public Health 
Association, endorsed that proposal. Practitioners in the 
health care field supported this proposal because it began 
to deal with the discrimination in the delivery of health 
care which leads to wide disparity of health status. It also 
dealt with the unfair financing of health care. Prevention 
of disease is a main ingredient of a national health 
service. This legislation is still alive and well. </p>
<p>The Communist Party, USA has long endorsed and fought for a 
fully government-run and financed health care system. But, 
all of these pro-people forces coalesced behind the single-
payer movement, given the tactical and strategic position 
that it was in. The single-payer proposal was a giant step 
along the way toward the goal of national health service (at 
least for those who have that as their goal). </p>

 <p>The staying power of Congressman McDermott and the almost 
100 congressional single-payer supporters was made possible 
by labor and the grass- roots movement. There was an 
understanding of the limitations of a single-payer approach, 
but they realized its power in deflecting the organized 
profit group led by the "Jackson Hole" mob. The failure of 
that profit group to win congressional approval for its 
program is a real victory. </p>

<p> The single-payer strategy proved to be an effective one. 
But in the upcoming struggle a more advanced strategy will 
be required. Indeed, the legislative solutions have to be 
expanded to meet the health care crises that continue to 
escalate.</p>

 <h4>The CIA Factor</h4>

 <p>Another factor which also must be included in the health 
debates is the fact that the U.S. government, through its 
CIA operatives, has been successfully overturning 
governments throughout the world on the basis that 
government programs do not work. The privatization taking 
place in the former socialist countries and in Western 
Europe are cases in point. These same forces could not allow 
the U.S. to go in a direction that increases the 
government's responsibility to take care of its people. </p>

<p>Government sources say well over $100 billion would be saved 
by not having the insurance, drug, profit-making hospital 
chains, medical supply and equipment companies and finance 
capital involved. It doesn't matter how logical a 
government-run program might be, government funded people-
serving programs don't fit into the grand scheme of 
international capital. Because of the drastic results it 
brings, privatization is now being rejected here in the U.S. 
and throughout the world. </p>

<p> While privatization brings profits to corporations, it 
leaves a steady stream of death and dying in its path. This 
is not being lost on those in the line of fire.</p>

 <h4>Remember the AMA</h4>

 <p>A word must be said about the American Medical Association 
and other segments of organized medicine. Remember when they 
were the power brokers in national health policy? Now they 
are relegated to a "pawn in the game" status. When the 
health industry monopolies say its time to cry about "free 
choice of physician" and "quality of health care," they hold 
a press conference. The AMA is caught in a contradiction. 
Single-payer legislation would maintain the free choice of 
doctors like in Canada, while the Clinton and Republican 
plans would put physicians under the control of the 
insurance carriers and other profiteers. </p>

 <p>Because the Democratic Party betrayed its campaign 
promises, the November elections brought more Republicans 
into office. The Clinton administration has failed to 
deliver on any substantive campaign promise, especially to 
labor and community forces.</p>

<p> The mass media will report that this more right-of-center 
Congress will mean death to any health care reform. That 
need not be the case. On the contrary, the failure of the 
for-profit industry to win their victory in 1994 will give 
single-payer advocates energy to continue the struggle. Our 
side must increase the stakes by broadening the legislative 
health agenda. After all, the crisis in health care has 
increased, so the solutions need to be more far reaching.</p>

<p> Since immunization and other preventive programs will 
continue to be cut, infectious diseases will escalate. 
Pneumonia, measles, sexually transmitted diseases (gonorrhea 
and syphilis) and AIDs will intensify at a dramatic rate. 
This is already happening.</p>

<p> Infant mortality and longevity rates will worsen. Cancers 
that are confinable through early detection programs will 
increase. </p>

 <p>In each of these instances, the anti-working-class and 
racist edge will be more apparent than ever before, with 
racially and nationally oppressed and rural people bearing 
the brunt of the attack. The sharp distinctions in the two-
class system of health care that is growing in the U.S. will 
further widen.</p>

<p> We must get back to putting the health and welfare of 
people above profits. The popular slogan, "health care is a 
human right" will lead us in the next period. Its simple 
message will reach millions of people. That means the 
funding of public hospitals and community health centers is 
a top priority. Recruiting people-orientated physicians 
under strictly observed affirmative action guidelines, to 
work as salaried doctors to provide medical care is a 
realizable goal. Public health service physicians have done 
that in the past and they can, with proper funding, do it in 
the future. Nurses, social workers and other health care 
workers need to be recruited into health care in the same 
manner. The communities who suffer the most must be the 
venue of this recruitment drive. They are also far more 
interested in community service and not using their medical 
degrees to reach mega-buck life styles.</p>

<p> The agenda for the next phase of health reform must be 
expanded to fit the needs of the people's health, not the 
financial statements of the health monopolies. For example, 
guaranteeing full prevention services and long-term care is 
desperately needed. Also, every person in the U.S. must be 
covered, not just the 85 to 95 percent being talked about. 
In Canada, they refer to all patients being covered, not 
citizens. Given the large number of immigrants, with or 
without papers, the U.S. needs the same approach.</p>

<p>Highlighting these elements will increase the value of the 
already active seniors movement and bring millions of 
immigrants into the struggle.</p>

<p> To defeat the health monopolies will require this kind of 
mass, people's movement. The single-payer movement is an 
excellent starting point from which to build a broader 
movement. Involving organizations like Jobs With Justice is 
an example of how this movement can be broadened.</p>

 <p>It is never too late to increase our demands. At the same 
time, Congress must be pressured to hold the widest possible 
hearings into the monopolization of the health industry. 
Congressional hearings must also investigate the massive 
financial contributions monopoly gave to members of 
Congress. This legalized extortion must be revealed for its 
anti-democratic goals. This kind of congressional action can 
be part of a one-two punch strategy to knockout the 
monopolies.</p>

 <p>A big word of caution on moving toward a state-by-state 
solution. This has been seen as a fallback position by 
activists. State-plan advocates point to Canada as an 
example for the U.S. However, Canada has just 7 provinces, 
not 50 states. There are entirely different histories 
associated with these national divisions. The current 
monopolization of the industry precludes a state-based 
solution, even for tactical reasons. Once states with strong 
unions take this action, states where labor is weak would 
never see these benefits. The experience of Medicaid in 
different parts of the country is a case in point. The 
monopolies will play one state against the other, just as 
they do with labor organizing.</p>

<p> When the New York Times, on September 30th, devotes a 
front-page story to the California referendum on single-
payer - after the death of the national reform effort - it 
should give cause to worry about this direction. This does 
not, however, diminish the value of state and local 
referenda to dramatize the crisis in health care and the 
need for national reform. On the contrary, these kinds of 
local actions make perfect tactical and strategic sense.</p>

 <p>Any labor negotiator knows that you never end up with what 
you start out with and if you start out with a basic 
compromise, the final result will be less. Even if we are to 
end up with the single-payer compromise, let's increase the 
stakes now and negotiate from a higher vantage point. The 
last round showed that by starting out with the single-payer 
public/private mix, with some profit monopolies in key 
positions, we almost ended up with a total disaster. Let's 
not repeat that mistake.</p>

<p> Mass actions must be increased so that the sentiments of 
the people can be heard. Rallies in Washington D.C. and at 
home will be necessary. Direct actions at the offices of 
politicians and in the offices of corporate America must be 
increased. Referendums, petitions and similar mass actions 
need to be stepped up. The mass-struggle experiences of the 
last two years will be invaluable as we head toward the next 
period. A people's health movement, more successful than 
ever, can emerge from these struggles. </p><br>

<center><table border=2 cellpadding=6 cellseparation=2><tr>
<td><a href="health.html#toc">Table of contents</a></td>
<td><a href="../index.html">The CPUSA page</a></td>
<td><a href="health-4.html">To the next part</a></td>
</tr></table>
<img src="line-blue.gif"><br><em><font size=2><a href="mailto://brownh@hartford-hwp.com">
Hartford Web Publishing</a></font>
</em></center></body></html>
</DOC>
<DOC>
<DOCNO>WT03-B24-247</DOCNO>
<DOCOLDNO>IA027-000294-B005-352</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/docs/health-4.html 206.119.5.80 19970120072748 text/html 29846
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:34:16 GMT
Last-modified: Sunday, 26-May-96 17:01:19 GMT
Content-length: 29663
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD HTML//EN//2.0" "html.dtd">
<HTML><HEAD><title>the Health Commission, CPUSA, The Destruction of OSHA Reform</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing   http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>The Destruction of OSHA Reform</h1>
<h2>by the Health Commission, CPUSA</h2>

<p> It came as no surprise to workers and their unions that 
Republicans took over the Senate and the House of 
Representatives, and are readying themselves to retake the 
White House in 1994. Although trade unionists voted two to 
one in favor of Democratic candidates, the broken promises 
of the Clinton presidency insured that the overall voter 
turnout of working people would be low. </p>

<p> The die was cast when President Clinton, in office hardly 
more than one year, called organized labor a "bunch of 
strong-armed goons." He pulled out all stops to get the 
North American Free Trade Agreement (NAFTA) passed, and 
wasn't above slandering the labor movement to do so.</p>

<p> This is the same president who refused to lift a finger to 
get the anti-scab bill (S-55) enacted and who reneged on his 
promise of national health care. Clinton increasingly came 
to be seen as pro-monopoly and anti-labor. </p>

<p> In the background throughout these struggles was the 
workers' battle to reform the 1970 Occupational Safety and 
Health Act. The abbreviated phrase for this effort became 
"OSHA reform."</p>

<h4> Auto Workers Strike Over Speed Up</h4>

 <p>On September 13, 1994, Clinton's Labor Secretary Robert 
Reich announced the demise of the OSHA reform legislation. 
At the same time, auto workers were taking matters into 
their own hands. "The Big 3 (Ford, Chrysler and General 
Motors) can't make cars and trucks fast enough" was the New 
York Times headline. While the Ford Motor Company's sales 
rose 14.5 percent to $3.5 million, autoworkers represented 
by the United Auto Workers Union fell 10 percent, from 
106,600 to 96,000. </p>

<p> At the Livonia, Michigan GM engine plant, local union 
leaders pointed to layoffs as the reason for the increase in 
health and safety problems. GM is producing more engines 
today than in 1992, yet the workforce has been reduced from 
1,500 to 1,000 workers. After weeks of struggle and a major, 
week-long strike, GM agreed to rehire 799 workers, admitting 
that the layoffs were the culprit. The strike was a reaction 
to the super-exploitation taking place in the auto industry, 
and it caused extensive production problems for the company. </p>

 <p>It soon became a painful reality that despite this 
increasing exploitation, revision of the OSHA law, a 
supposed Clinton priority, would die a silent death. Job 
safety and health has not been a priority in either the 
Clinton or Democratic Party agendas and we will all suffer 
for it.</p>

 <h4>Reform Needed</h4>

<p> During the first 20-plus years of the federal OSHA 
legislation, President Carter's was the only Democratic 
administration. OSHA head Dr. Eula Bingham was very 
sympathetic to workers and their unions, which made her very 
unpopular with the Carter administration. Then-Secretary of 
Labor Ray Marshall often fought for a strong OSHA law. 
Marshall did a far better job representing the interests of 
working people than has Reich. Marshall's positions also 
made him very unpopular with the Carter administration and 
Democratic Party bigwigs.</p>

 <p>Promising in the 1980 election campaign to throw "OSHA into 
the ocean," the Reagan/Bush team, once elected, pulled every 
possible administrative trick to kill its effectiveness.</p>

<p> Ironically, in 1978-80, before the 12 years of Republican 
rule began, the Democrats, in 1978-80, led by Senator Edward 
Kennedy, engineered the first thrust against regulation in 
general, and OSHA in particular. The 1980 Occupational 
Safety and Health "Improvement" Act, actually authored by 
Democratic Party Congressional leaders, attempted to kill 
OSHA enforcement and other important safety and health 
rules. Only a broad-based grassroots movement stopped them.</p>

 <p>During the Reagan/Bush years, the job safety and health 
movement fought every effort to administratively kill 
enforcement. Each change was met with stiff resistance. Out 
of that fightback movement came the effort to reform the 
law. Many meetings within the labor movement and in 
coalitions among safety and health activists were held to 
develop a legislative agenda to make OSHA stronger.</p>

<p> The OSHA reform legislation was "drafted" in the period 
from the 1980s to 1992. The House Labor Committee passed the 
legislation in 1992. The final legislative proposal, while 
having many progressive aspects, could have been much 
stronger if a class struggle approach had been taken by all 
of labor. </p>

 <p>It was against this background that leaders of the safety 
and health, labor, medical/scientific and community 
movements prepared for the 1992 presidential elections. The 
Democratic Party platform and Bill Clinton's campaign 
promises contained the basis for OSHA reform that would 
significantly improve the safety and health of workers. </p>

<p> The election of Bill Clinton also brought a significant 
Democratic Party margin in both the U.S. Senate and House of 
Representatives. This increased the hope for the passage of 
reform. This was supposed to be the "no veto Congress" 
everyone fought for. </p>

<h4> Election Hopes Dimmed</h4>

 <p>From the beginning of the Clinton administration, with the 
appointment of lackluster people like Robert Reich to head 
the Department of Labor and Donna Shalala to head Health and 
Human Services (this is where the National Institute for 
Occupational Safety and Health (NIOSH) is housed), the 
worrying began. They were appointed over more qualified and 
aggressive candidates. The impact of the Democratic 
Leadership Council (DLC), the right-wing of the Democratic 
Party that controls the Party's strategies and appointments, 
and the AFL-CIO collaborationist policy began to take hold. 
When Reich, in September 1994 sent OSHA reform to the grave, 
he added insult to injury by warning that only if the bill 
gets "reworked" will it be reconsidered in 1995. In 
Washington Beltway jargon, that means, make it more 
acceptable to Big Business.</p>

<p> To head up OSHA, the White House and Reich refused highly 
qualified candidates who were proposed by organized labor. 
Joe Dear, a state of Washington official and a career 
administrator, was selected to head OSHA. A similar scenario 
took place in the appointment of the NIOSH head. Appointing 
a qualified labor union expert to head OSHA, and a labor 
recommended medical/scientist to head NIOSH, would have sent 
the right message to corporate profiteers in reverse of what 
Reagan/Bush did in 1981 by hiring incompetent corporate 
people to head the Department of Labor and OSHA.</p>

 <h4>Mass Mobilization Is Key</h4>

 <p>For almost five years the labor movement and its allies 
mobilized to pressure members of Congress to pass OSHA 
reform. Local COSH groups (committees on safety and health) 
showed remarkable effectiveness in pressuring local elected 
officials. But as the list of sponsors in the House and 
Senate grew, an eerie silence started to come from the 
newly-elected officials in the White House, Congress and the 
Department of Labor.</p>

 <p>For a number of years, "Worker Memorial Days" (April 28th 
each year), speeches and related activities were used to 
agitate for the passage of OSHA reform legislation. These 
special mobilization days, sponsored by the National AFL-CIO 
and supported by local grassroots groups, reached into every 
nook and cranny in the United States. Lobbying took place in 
Washington, D.C. and at the local offices of legislators. 
State legislatures and locally elected officials passed 
supporting resolutions.</p>

<p> During the first stages of the Clinton administration, all 
of the routine legislative activities took place. Union 
lobbyists met with administration and congressional staffs. 
Extensive labor/management meetings (in accordance with DLC 
and AFL-CIO orders) were held to attempt to work out a 
consensus on key issues. Things seemed to be generally on 
course.</p>

 <p>But other events were pointing in a different direction. 
Clinton was in full gear getting the anti-labor NAFTA bill 
passed, while the anti-scab bill was in the process of being 
killed. Health reform was on the road to ruin. Contrary to 
right-wing allegations that Clinton and congressional 
leaders were pursuing socialized medicine, they were, in 
reality, preparing health care for the insurance and drug 
industries, for-profit hospitals and banking monopolies (see 
Political Affairs, November, 1994.) The White House 
legislative agenda was appearing markedly anti-labor.</p>

 <p>While the White House and Congress were doing their dirty 
deeds, the Washington D.C. Beltway "permanent government" 
was being utilized to kill reform. Increasingly well known 
to unions is the use of Department of Labor lawyers, in its 
infamous Solicitor's Office, to pick reform legislation 
apart. Movement activists are familiar with the Office of 
Management and Budget (OMB). The OMB was used by those 
opposed to an effective OSHA to stop progressive regulatory 
activity in the 1970s and early '80s. In recent times, the 
Solicitor's Office has become the vehicle to fight against 
progressive change. It is the one-two punch of the OMB and 
the Solicitor's Office that has subverted the original 
intent of Congress.</p>

 <p>All important OSHA regulatory actions taken against 
employers must be cleared through the Solicitor's Office, 
and the first stop for the Solicitor's Office is the 
Secretary of Labor. If the Secretary of Labor were an 
independent-minded leader, someone willing to fight the 
increasingly anti-labor White House, then maybe workers 
would have gotten an even break. That was the struggle under 
the Carter administration when Marshall and Bingham often 
helped labor with its agenda.</p>

<p> That is not the case under Clinton. As months dragged on, 
it became painfully clear that Secretary Reich - who once 
said that unions should not be necessary - cared little 
about workers and their unions and a lot more about his 
career with the Clinton administration. The difference 
between the labor departments under Carter and Clinton has 
become increasingly clear, with the understanding that 
Carter was hardly the standard for a pro-worker 
administration.</p>

<p> Department of Labor lawyers were assigned to working 
committees dealing with each key aspect of the pending law. 
They brought with them the political power of the Secretary 
of Labor, the White House, leaders of the Democratic Party 
in the House and Senate and their allegiance to big 
business. The leaders of the Senate and House Committees 
were usually very supportive of a strong OSHA law, but when 
they went to their Democratic leaders the message was 
increasingly clear: tone it down or it won't see the light 
of day. Active grassroots labor lobbying kept these leaders 
honest and supportive. But above that level, the struggle 
was far less effective. The darkness fell like a lead 
balloon.</p>

<h4> Corporations Evade Law</h4>

 <p>The key elements of the OSHA reform legislation are its 
enforcement provisions. From the beginning, employers 
assigned their attorneys to determine how they could avoid 
the law or use it as a shield against legal actions by 
workers and their unions. By the end of OSHA's first 10 
years, this shield was used to conceal employers' disregard 
for safety and health laws. The legal term is pre-emption. 
The courts ruled that if there is a federal law, then if 
someone is disabled or killed the employer cannot be 
indicted by the courts. The only remedy is through 
inspections. This is similar to how employers use workers' 
compensation as a legal shield against lawsuits from workers 
who become disabled or die on the job. </p>

<p> By the early part of the 1980s, local district attorneys 
were being pressured to take worker-killing employers into 
court. In Chicago, the owners of Film Recovery Inc. were 
found guilty of killing a worker who they willfully exposed 
to cyanide. They tried to use the OSHA shield, but the local 
district attorney successfully indicted and convicted the 
employer. One company official served some jail time, but 
the owner of the company fled to Utah and was not brought 
back to serve time. This case, however, provided an 
important precedent. </p>

<p> In Brooklyn, New York, the owners of Pymm Thermometer Co. 
were brought into court for seriously endangering their 
employees. Mercury poisoning was the issue here. At first, 
the courts ruled this could not be done, since the only 
remedy was OSHA. Federal pre-emption was, again, the issue. 
That later changed and the owners of Pymm faced criminal 
penalties. </p>

<p> In Hamlet, North Carolina, at a major poultry factory fire 
disaster, 25 workers were killed due to locked exits. This 
was very similar to the New York City Triangle Shirtwaist 
fire in 1911 where over 150 women garment workers were 
killed, also due to locked exits. This disaster elevated 
corporate criminal penalties. It became a centerpiece of 
OSHA reform. The Department of Labor Solicitor's Office 
fought hard against this provision and ultimately won. </p>

 <h4>Who Will Run Workplace Committees?</h4>

<p> An outcome of OSHA legislation could have been the federal 
requirement that every plant and workplace must have a 
safety and health committee through which detection, control 
and prevention of job safety and health hazards take place. 
This kind of a system, in various forms, is very popular 
around the world and would have been popular at shops here 
at home. The former socialist countries had these 
committees. </p>

 <p>In Sweden, plant-based safety and health committees are 
established by law throughout the country. These are 
labor/management committees. But, in a very advanced form, 
these committees must be chaired by the labor union at the 
plant, and there must be at least one more union member than 
management members. The logic is that without this pro-labor 
provision, workers and their unions would not have any faith 
in these committees. </p>

<p> At the least, the demand should have been that every 
worksite have a legally recognized union committee. What was 
proposed however was a system of labor/management committees 
of equal numbers and status. Under this kind of system, 
workers and their unions would surely be at risk if they 
told the truth. Employer retaliation would be swift against 
militant representatives on these committees. Sanctions 
against employers who discriminate against workers who 
exercise their rights is almost non-existent. The union-only 
committee would have afforded workers time to conduct 
private meetings during working hours. No wonder corporate 
leaders would not like this kind of proposal. </p>

<p> This proposed labor/management committee system was 
supported by workers and their unions, because many did not 
know that a union-only system was possible. When OSHA reform 
came under attack, this provision did not ignite much 
fightback. While it's true a strong local union could win 
the right to union-run committees, this is rare. Here again, 
the class collaborationist policies of the Kirkland 
leadership pushes in the direction of a labor/management 
system. If that strategy was meant to win legislative 
support, it totally failed. But along with that failure 
comes a disarming of workers' ability to fight for a more 
militant program. </p>

<h4> One Unified, Strong Law</h4>

 <p>When OSHA was enacted, Congress refused labor's efforts to 
create one safety and health law protecting all workers. The 
goal was to correct that "compromise" and eliminate the 
legal and administrative loopholes that employers use to 
gain an advantage over workers. </p>

<p> Under OSHA reform, the following federal agency safety and 
health laws were meant to be brought together under a 
strengthened law. These areas include: Mine Safety and 
Health Administration (all underground work); Department of 
Transportation (railroad, trucking, airlines); Department of 
Energy (all atomic energy sites); Jones Act (high seas); and 
Federal Workers. The new unified law was not meant to reduce 
standards, but to use the most stringent rules from each 
area.</p>

<p> Since unions have multiple jurisdictions, a local union 
committee composed of representatives from each regulatory 
area would put the union in the driver's seat. It would have 
prevented employers from trying to hide behind regulation 
overlap gaps. This provision is especially important for 
public workers who are excluded from federal OSHA coverage. </p>

<p> When OSHA was passed one of the most backward of all 
congressional compromises was the "states rights" 
provisions. Under this provision, any state could enact its 
own OSHA law as long as its program was "as effective as" 
the federal law. Twenty-four states went this route. All the 
Southern and Southwestern states took the road of states' 
rights. Unfortunately, California, Oregon, Washington, and 
Michigan, states with relatively strong labor movements, 
also took this route. </p>

<p> OSHA had a State Plan Office which was supposed to monitor 
this program. It has been underfunded from the beginning. 
Reform did not attempt to eliminate this provision. It 
merely called for more oversight. This was clearly not 
enough. By not calling for the elimination of these state 
plans, valuable local support was lost. </p>

<p> The disaster at Hamlet highlighted the state plan debacle. 
At that non-union site, North Carolina inspectors failed to 
adequately inspect the plant. Even with this disaster, 
bringing all states under the federal law was not fully 
considered. Investigations and committees were established 
and a lot of militant words came from North Carolina and 
federal officials. But, ultimately, nothing happened. </p>

 <p>The hidden government of the U.S. Department of Labor's 
Solicitor's Office was a target. This office, as much as the 
infamous Office of Management and Budget, has been 
responsible for destroying the effectiveness of OSHA. When 
workers and their unions complain about the failure of OSHA 
to seek the strongest penalties against employers, the 
culprit is usually the Solicitor's Office. Its directives 
come from the pro-corporate offices of the White House and 
the Democratic Party's political machine. </p>

<h4> Equity With EPA</h4>

 <p>More often than not, community environmental hazards are 
created at the factory. Factory workers face occupational-
related illnesses and injuries in far stronger doses than do 
people living in the community. Yet the EPA receives funding 
well over 10 times that of OSHA. The reverse funding 
strategy should have taken place. From its inception the EPA 
was seen as the more important agency. It was given its own 
government status and is not under any other agency. The 
same was wanted for OSHA. The lower bureaucratic status 
radically reduced its funding potential.</p>

 <p>Over the years, there have been some very successful 
working relationships between pro-EPA and OSHA activists. 
Right-wing and corporate ideologues are continually trying 
to drive wedges between worker and community safety and 
health activists. But it has been more difficult to divide 
the two in recent times. For example, the Sierra Club and 
other environmental organizations gave strong support to 
anti-NAFTA activities. </p>

 <p>Combining OSHA and EPA could be a good idea, but only if 
the best of both laws was used as the common denominator. 
For example, OSHA has far stronger (at least intended) 
enforcement powers than EPA. In reality, the difference is 
probably not a lot, but stronger enforcement powers are 
needed for both laws. Unfortunately, Congress and the White 
House have chosen both low funding and weak enforcement 
powers to kill the real strength of both laws. </p>

<p> In the Eula Bingham/Ray Marshall administration, $15 
million was distributed each year for labor education and 
training programs. This program was essential to spawning a 
nationwide safety and health awareness program. By contrast, 
Reich has offered a paltry $1.5 million each year.</p>

<p> These educational programs were instrumental in bringing 
safety and health to every corner of the United States. They 
served as an incentive for the training of safety and health 
professionals into the field of health and safety. Since 
most of the funding went to labor unions, it helped unions 
establish and expand safety and health programs. No wonder 
corporate power said no to an educational program similar to 
the Marshall/Bingham period. The Clinton/Reich regime made 
no effort to increase funding of this important program.</p>

<p> An important part of the bill would have established a 
national rule of protecting workers from repetitive motion 
and lifting hazards. This field of science has become known 
as ergonomics. It is estimated that $100 billion in lost 
work time is due to such injuries. The future of a new 
standard on ergonomics, given the unwillingness of the 
Clinton administration to fight corporate lobbying efforts 
and Congressional Republicans, is rather dim. Nancy 
Kassebaum (R-Kan.), the new head of the Senate Labor 
Committee, has rejected this OSHA proposal, saying it is 
better left to state and local governments. </p>

<p> OSHA reform did not improve the federal marshal inspection 
system. When union representatives raised the issue of 
hiring more inspectors, they were told it was not possible 
because there is "too much anti-government feelings." These 
officials said that labor/management committees and the 
voluntary compliance that would come through that 
cooperation would take care of enforcement. This far-fetched 
idea was not believed.</p>

<p> Fear of inspections remains a crucial union strategy to 
force employer compliance. Therefore, the 1,500 federal 
inspectors in 26 states is totally inadequate. An even lower 
level of inspectors exists in the other 24 state plan 
inspection systems. </p>

<p> A reasonable demand would be to immediately put 10,000 
federal inspectors into the field to protect workers from 
the super-exploitation being faced by workers, and 20,000 if 
all states were covered by federal OSHA. </p>

 <h4>International Health and Safety</h4>

 <p>"One international working class, one struggle against the 
transnationals" - That is rapidly becoming the workers' 
demand from every corner of the world. In the Western 
Hemisphere, the failed struggle against NAFTA with its 
intent to lower working standards in Mexico, Canada and the 
United States was a new eye-opener. The cry of 
internationalism was heard in all three countries. GATT 
negotiations are bringing the same response - in this case 
it includes Europe (notably Scandinavia) and Asia. The 
International Monetary Fund and the World Bank, with their 
transnational corporate directors, are licking their profit-
chops at the potential of NAFTA, GATT and other trade deals. </p>

<p> The collapse of socialism in the Soviet Union and eastern 
Europe has exposed all workers to greater exploitation. The 
power, at this time, is clearly in the hands of the 
transnational corporations (TNCs). The disastrous and widely 
reported increase in child labor exploitation is but one 
example.</p>

<p> But the turnaround is coming. Health and safety activists 
have long learned that standards and enforcement in the 
United States are well below other countries. Through the 
phony cry of tearing down trade barriers, TNCs are seeking 
the lowest common denominator from all countries. This is an 
arena of struggle that must be increased. </p>

 <h4>Health Reform</h4>

 <p>That the struggle for health care reform and OSHA reform 
took place at the same time should have helped both 
struggles. But some lobbyists and strategists saw them as 
competing for Congressional action. Many health activists 
understand that real health reform should start at the 
workplace.</p>

<p> A unified health program is needed for both workers on the 
job and people living in the communities, regardless of 
where they work or live. One of the weaknesses of the great 
health care reform struggles of the 1992-94 period was the 
lack of inclusion of work-related health delivery issues. 
The work-relatedness of diseases and injury, and their 
prevention, must be addressed in the next period of health 
reform struggle. Over 100,000 workers die each year from 
work-related illnesses and injuries. Tens of thousands are 
disabled and rely on health services either through their 
workers' compensation insurance or the regular system of 
employer paid group insurance. </p>

<p> Since it is practically impossible for workers to win 
compensation claims for work-related illnesses, they must 
rely on the health system everyone else is saddled with for 
treatment of illnesses. This will bring tens of thousands of 
workers and their families into the struggle for real health 
care reform. Workers and their unions can give valuable 
examples of their experiences with workers' compensation 
carriers as an example of how all insurance carriers treat 
people. They will also be able to describe the evils of 
state plans to gain benefits since the decrepit workers' 
compensation system is entirely state-based.</p>

<p> This combined struggle would have united the health care 
and the OSHA reform struggles. The enemies of both pieces of 
legislation were certainly working together. The disastrous 
experience with OSHA state plans, workers' compensation and 
state-based Medicaid and Medicare, even in their quasi-
federal form, must be not repeated with single payer state 
plans. The Republican-controlled Congress will reject 
federal action in favor of state solutions.</p>

<p> Class collaboration in the trade union movement must be 
overcome. The road to full achievement of worker and labor 
rights does not go through the dead-end of labor/management 
cooperative schemes. Business unionism that relies on 
collaborating with employers is a McCarthyite holdover that 
has not been successful in winning any victories for workers 
or their unions. The failure of the Clinton administration 
to support any of the key labor issues in its first two 
years shows the bankruptcy of the labor/management strategy. 
Safety and health activists can help to lead workers and 
their unions out of this dead-end approach. </p>

<p> Keeping the pressure on Congress and the White House must 
continue. But that pressure must switch from top-level 
individual lobbying efforts to mass struggle tactics. The 
labor movement and its community allies can not match the 
financial contributions to politicians from the 
corporations. Corporate power and money can only be balanced 
through the mobilization of large numbers of people. The 
lobbying of politicians in state capitols and in the halls 
of Congress also means that grassroots tactics and 
strategies are needed.</p>

<p> Such grassroots struggles could include: workplace actions 
around safety and health; building local committees; forming 
and joining with broad-based coalitions for social change; 
building Worker's Memorial Day activities; public 
demonstrations at corporate offices; national demonstrations 
in Washington; joining the struggles for national health 
care with the fight for strict OSHA enforcement; and 
building national and international working-class unity that 
will put an end to the destructive policies of GATT and 
NAFTA. </p>

 <p>With the Republicans controlling the Senate and the House 
of Representatives, and with the White House moving even 
more to the right, the importance of mass action has grown. 
Political pundits predict a further demise of labor unions 
and the end of progressive positions on social and economic 
issues. But history shows that when the working class is 
mobilized its power can overcome politicians and their 
corporate backers. With the conditions of workers' safety 
and health growing worse every day, the willingness to join 
in fightback activities will increase dramatically. Now is 
the time to unleash the power of workers through independent 
political action, sparked by grassroots worksite actions on 
issues of health and safety.</p>

<center><table border=2 cellpadding=6 cellseparation=2><tr>
<td><a href="health.html#toc">Return to table of contents</a></td>
<td><a href="../index.html">Return to the CPUSA page</a></td></tr></table>
<img src="line-blue.gif"><br><em><font size=2><a href="mailto://brownh@hartford-hwp.com">
Hartford Web Publishing</a></font>
</em></center></body></html>
</DOC>
<DOC>
<DOCNO>WT03-B24-248</DOCNO>
<DOCOLDNO>IA027-000294-B005-284</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/docs/health-2.html 206.119.5.80 19970120072644 text/html 10692
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:33:24 GMT
Last-modified: Sunday, 26-May-96 17:00:41 GMT
Content-length: 10509
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD HTML//EN//2.0" "html.dtd">
<HTML><HEAD><title>Don Sloan, The Hippocratic Oath vs Profits in Health</title>
<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing   http://www.hartford-hwp.com -->
</head>
<BODY><a name="top">
<h1>The Hippocratic Oath vs Profits in Health</h1>
<h2>by Don Sloan</h2>

 <p>"There is no concrete evidence that would not allow for the 
patient to be discharged." That was the reply given recently 
by a nurse and her doctor supervisor at the other end of a 
long distance number at one of the major insurance carriers 
in the country to my request that my patient be authorized 
for a fourth post-op day in the hospital after major 
surgery. Without such a sanction, the insurance company 
would deny payment to the hospital. This so-called "carve 
out" is aptly labeled. Hospitals are quickly learning not to 
bite the hand that feeds them. Sides are being drawn - on 
one are the patient and the doctor; on the other are the 
third party carriers and their extensions, the hospitals.</p>

 <p>This scenario is becoming commonplace in the daily workings 
of America's physicians and their insurance company bosses. 
For assured payments, the physician must now request 
permission for treatment of either a medical or surgical 
nature. Indeed, any form of hospitalization short of a life-
threatening emergency must first be cleared through the 
carrier's offices.</p>

 <p>How has this come about in these past few years? The answer 
is in the euphemism for a health care program for America. 
It is called managed care or competition, as engineered by 
the Health Maintenance Organization (HMO) and/or the 
Preferred Provider Organization (PPO), two forms of groups 
of physicians and their ancillary health care 
professionals.This is all very much a part of the equation 
we are coming to know as the Contract With America.</p>

 <p>All of the nation's physicians recently received a mailing 
from the various states' departments of Social Service. This 
is the same Medicaid that took several hits along the way 
during the Reagan and Bush administrations and is now 
heading for even greater dismemberment. What is the real 
message and intent of these newly contrived programs? That 
corporate America is finding ways to outsmart and 
outmaneuver the American medical community and the American 
people in trying to convince us that something is being done 
to improve our health care delivery.</p>
<p>The U.S. remains the world's only developed country without 
a comprehensive health care package for its citizens. The 
insurance industry, the only one along with organized 
baseball that is exempt from antitrust regulations, is 
continually seeking new ways and means and tricks to keep it 
that way. Thus, managed care, with a corporate mother and a 
congressional father, is being applied in the spirit of 
privatization of Medicaid and even Medicare. Indeed, 
Medicare has gone through changes this past decade that 
allowed for third-party carriers such as Blue Cross to 
supervise and disperse funds from the Medicare pool, all, of 
course, after skimming the pot as a commission. That all of 
these systems sop up an almost one-third in administrative 
expenses as compared to, for example, the ten percent in 
Canada, is no surprise. </p>

 <p>Once the insurance cabal got its proverbial feet in the 
door, it went for the whole picture, and it now dictates the 
lengths of hospital stay, the procedures allowed, and even 
the after discharge care. The penalty for disobedience or 
even resistance is severe. Carve outs are liberally applied, 
and after the hospitals are denied their reimbursements, the 
patients are left with the burden of payment. Many have been 
pestered by collection agencies. </p>

<p> Some of these standards for lengths of stay and procedural 
codes that are used for billing purposes are based on the 
Diagnosis Related Group (DRG) formula created for Medicare 
and adopted by most if not all of the insurance providers or 
on formulas of the carrier's own making. The goal is the 
same - to reduce the number of patient-hospital days to the 
barest minimum. The status of the patient has little to do 
with it. The physicians' fees are not affected in any direct 
way; they remain the same no matter the extent of the care 
offered the patient because they are preset by the code. 
Happily, the doctor can remain altruistic with regard to 
patient care. However, there are subtle penalties meted out 
for physicians who do not keep the short stay goals of the 
carrier in mind. </p>

<p> The insurance people are in an all out competition war. 
Medical services are being peddled like just another 
commodity. CEOs and heads of operations at the nation's 
multinationals are being wined and dined as a part of the 
hard sell. U.S. Healthcare, the Blues (Blue Cross/Blue 
Shield), Aetna and the others have hired high powered 
Madison Avenue agencies to hawk their wares to both the 
corporate buyer and the media listener and consumer. Many 
are using celebrities as a part of the glitz of this ad 
campaign.</p>

<h4> Merger Craze</h4>

 <p>More, in this now hectic atmosphere that is being created 
by Wall Street's merger craze, medicine as an industry is 
not escaping the rush. Just as Chemical and Chase are 
seeking to control more of the banking business business-
driven conglomerates are reaching out with their tentacles 
that are engulfing medical PPOs and hospitals. This type of 
consolidation alone would reshape the entire health care 
picture in America, putting more and more of the emphasis on 
profit, business, and net worth. </p>

 <p>In New York State, with the nation's largest Medicaid 
enrollment, it is no wonder that newly elected governor 
George Pataki, is already busy clearing the way for Medicaid 
to come under the control of a managed care unit. This is a 
part of his often announced plans for a privatization 
blueprint in general, which includes many other public 
services.</p>

<p> That mass mailing to doctors indicated that in certain 
areas in the state, such managed care is now mandatory. It 
is anyone's guess as to how soon the whole program will 
convert to such a status.</p>

 <p>Has the buying public benefited in any way? Are the doctors 
providing better care for their patients? Are hospital 
services more sensitive to patient needs? Are there any 
rewards for the buying public in the forms of reduced 
premiums or deductibles? The answer to all four is No! The 
hospitals are under the gun, as already noted, to obey the 
rules of the DRGs, and the timed discharges and their 
rewards, in the form of no carve-outs, are given only if the 
patients are discharged as quickly as possible. This past 
month, in a move that should have been embarrassing to the 
provider insurance company, Governor Christie Whitman of New 
Jersey used an executive order to allow post-cesarean women 
to stay three days instead of two in the hospital; other 
states are taking notice.</p>

<p> Doctors are seeing more and more patients in the same time 
frames with the obvious less astute care that comes with a 
fast take. Moreover, if anything, patient insurance premiums 
have risen. The funds have simply shifted from physicians 
and hospitals and other health providers to the insurance 
company coffers.</p>

<p> Medicaid's credibility is owed to the fact that it is the 
only plan available to the poor. But that is where it stops. 
Vast improvements are needed in the forms of more funding 
and more comprehensive services for all. The solution is 
within internal improvement and not in a sellout to private 
carriers. By the same token, physician control is also 
lacking. A plan to demystify, deglorify, and 
deprofessionalize the medical community is long overdue. The 
logical overseer would be a civilian review board. </p>

<p> Apparently, more and more states are encouraging their 
Medicaid participants to enroll in their strictly-for-profit 
HMOs, and this is happening all over. Florida is the first 
state to have started such a program and they are well under 
way. There followed the expected windfall of Medicaid monies 
into the HMOs. </p>

 <p>The subterfuge used is the claim that Medicare and Medicaid 
are not being gutted but "saved." The report that Medicare 
will be "broke" by the year 2002 is a trick at its best. As 
with Social Security, monies are being siphoned off from 
Medicare by every administration in a Peter-to-pay Paul 
arrangement. Peter is the entitlements that are for the 
people; Paul becomes the military complex and the Pentagon. </p>

<p> Another euphemism for fund cutting of the Medicaid program 
is the block grant. This is the plot out of the early Reagan 
years when monies for Medicaid were allocated in a lump sum, 
always bearing the boast that it is "more than enough." When 
the earmarked reserves are met, patients are denied medical 
care, either through a raise in the eligibility criteria or 
by just closing the doors of the health station or clinic. 
It is as simple as that. And as cruel.</p>

<p> The proverbial worm seems to have turned. The American 
medical community is awakening to its role on the side of 
the patient and opposed to the insurance industry and the 
health care conglomerate. It is regrettable that physician 
organizations are not oriented toward that thinking, 
although they may be in the future. The buying public has 
long been victimized by a system that placed them second to 
profit. It should welcome the doctors as a part of that 
equation. Until America joins the ranks of the other 
industrialized nations and provides its people with their 
rights to total health care, Medicare and Medicaid will have 
to suffice. Vigilance will be needed to protect what we have 
already fought for and won. </p>

<center><table border=2 cellpadding=6 cellseparation=2><tr>
<td><a href="health.html#toc">Table of contents</a></td>
<td><a href="../index.html">The CPUSA page</a></td>
<td><a href="health-3.html">To the next part</a></td>
</tr></table>
<img src="line-blue.gif"><br><em><font size=2><a href="mailto://brownh@hartford-hwp.com">
Hartford Web Publishing</a></font>
</em></center></body></html>
</DOC>
<DOC>
<DOCNO>WT03-B24-249</DOCNO>
<DOCOLDNO>IA027-000294-B005-249</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/docs/health-1.html 206.119.5.80 19970120072630 text/html 13180
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:33:04 GMT
Last-modified: Sunday, 26-May-96 17:00:30 GMT
Content-length: 12997
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD HTML//EN//2.0" "html.dtd">
<HTML><HEAD><title>David Lawrence, Organizing Against Profit in Health Care</title>
<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing   http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Organizing Against Profit in Health Care</h1>
<h2>by  David Lawrence</h2>

<p>The principal factor destroying our health care system and 
increasingly limiting our access to it, is the drive to 
maximize profit. Moreover, it is the more destructive drive 
to maximize profit by huge multinational corporations in 
contrast to the petty capitalist entrepreneur physician of 
decades ago. Fee-for-service medicine, where the physician 
receives a fee for each medical procedure, has predominated 
in the delivery of medicine in the United States for about 
150 years. Until the 1940s, however, entrepreneurial 
"cottage craft" physicians ran a fairly low-budget business. 
As a result, the fees charged remained relatively low. </p>

<p> Spurred by technological advancements resulting from World 
War II, high-tech medicine experienced explosive growth from 
that period until the present day. As a result of this 
extraordinary change in the field of medicine, the 
techniques of medical care have been radically altered, and 
just as importantly the social organization of medicine has 
been fundamentally changed. </p>

<p> Medical specialties proliferated alongside the burgeoning 
medical technology industry. The family practice physician 
and surgeon of the last century proliferated into dozens of 
specialties. The practice of modern medicine has become 
defined by its expanding technology, and by those with the 
capital to purchase that technology and to purchase the 
services of those who can operate it. The solo fee-for-
service physician of decades ago is being forced into group 
practice in order to afford to practice, and in order to 
maximize the profits of practice. Many physicians were 
forced into mutually dependent relationships with hospitals. 
Hospitals had the capital with which to purchase the 
products of the medical technology industry, and physicians 
had the expertise to utilize the technology and the ability 
to steer patients to it.</p>

<p> From its humble condition in the last century, medicine 
suddenly became a powerful trillion-dollar engine in the 
American capitalist economy. The manufacturers of medical 
technology and pharmaceuticals became huge multinational 
corporations, cashing in on inventions and discoveries often 
supported significantly by government and paid for by tax 
dollars. These industries pushed their products, frequently 
unsafe or ineffective, into every nook and cranny of 
hospitals and clinics - creating "profit centers" where 
there had been closets, staff rooms, even vacant lots.</p>

 <p>Hospitals sprouted up across the country, propelled by an 
ever increasing proportion of for-profit, investor-owned 
enterprises. In the mad rush for the profits of corporate 
control, big regional chains of hospitals were acquired by 
huge multi-billion dollar multinational chains. Even the 
public sector was sacked as county hospitals were purchased 
by the chains or contracted out to for-profit management 
companies. Physician salaries increased as they charged more 
and more, fueled by the utter lack of accountability. 
Physicians could double and triple their income by "self 
referring," i.e., becoming investors in laboratories and 
diagnostic imaging facilities (such as x-rays and CAT scans) 
and then referring their own patients to these enterprises.</p>

<p> The health insurance industry didn't really care, since 
their profits exploded in direct relationship to the rising 
costs of health insuhttp://www.cubaweb.cu/an inconsequential presence in 1940 to a 
dominant financial industry in the United States currently 
worth hundreds of billions of dollars. </p>

 <h4>More Medicine, More profit</h4>

<p> The key mantra in this history has been "more medicine is 
more profit." Hospitals did everything they could to attract 
more physicians in order to capture their patients - every 
bed a potential profit center. Physicians over-treated 
patients for the same reason - every patient encounter added 
to the bottom line. Despite the occasional appearance of 
protest, the insurance industry had no reason to change the 
situation because they were wallowing in ever-increasing 
profits.</p>

 <p>The fact that tens of millions of Americans had been priced 
out of this medical profits machine did not matter to the 
health care industry and was not enough to change the 
system. Rather, two emerging processes have coalesced in 
recent years resulting in the managed care onslaught. First, 
the hundreds of billions of health care dollars have been 
concentrated in the hands of a few huge health insurance 
companies, a few giant hospital chains, and a few mammoth 
managed care organizations. Physicians have not competed 
well against the multinational corporations and have lost 
financial and political control to them. Secondly, the 
Fortune 500 industries have grown tired of transferring 
their potential profits to health insurers and providers. 
They want cheaper health care with more stable costs year 
after year.</p>

 <h4>Rise of Health Maintenance Organizations</h4>

 <p>The old health care industry lines blurred as the biggest 
health insurance companies went on a binge purchasing health 
maintenance organizations (HMOs), and hospital chains 
started their own. HMOs are a form of managed care where 
members pay a fixed fee to a corporation that controls which 
health care providers its members will have access to. Some 
of the earlier HMOs such as Kaiser, Health Insurance Plan of 
New York, and Group Health Cooperative of Puget Sound, were 
established as cooperatives or non-profits and focused on 
service rather than profit. However, most newer HMOs are 
investor-owned strictly for-profit enterprises. </p>

 <p>These profit-seeking HMOs gobble up the health care 
resources in a region, then offer a packaged deal to 
industry and government. This has turned on its head the old 
mantra, "more medicine is more profit." Since HMOs are paid 
a fixed sum to provide for the medical needs of a specific 
population, the new HMO industry mantra is "less medicine is 
more profit." Far from being merely a theoretical issue, 
mounting evidence indicates that the quality of health care 
is plummeting under the greedy control of for-profit HMOs. 
This is of particular concern since in 1992 about 550 HMOs 
controlled the health of over 41 million Americans, and the 
growth of HMO coverage remains explosive.</p>

 <p><a name="R1">In the early 1970s, California contracted with over 50 HMOs 
to provide care for 300,000 Medicaid enrollees. In just a 
few years the entire program was awash in a quality of care 
scandal and was abandoned. In the early and mid-1980s, 
Arizona and Ohio had similar devastating experiences. <a href="#N1">(1)</a> </p>

<p><a name="R2">During the past five years Florida has repeated the 
experiments with HMOs for over a third of a million 
residents. A major state newspaper characterized the outcome 
as "a separate and dangerously unequal care system." In 
addition, evaluators found that some HMOs spend as little as 
half their revenues for medical care, and most of the HMOs 
were given overall evaluations of "poor" or "very poor." <a href="#N2">(2)</a></p>

 <p><a name="R3">Last year the Center for the Study of Services tried to 
gather member-satisfaction ratings for 250 health plans and 
by federal employees. Sixty of the plans refused to let 
their members respond to the questionnaires. <a href="#N3">(3)</a></p>

<p><a name="R4"> In 1992 fewer than 100 HMOs covered 1.6 million people on 
Medicare. Today, 165 HMOs are responsible for the health 
care of 2.5 million Medicare recipients, and another 70 HMOs 
are waiting in the wings to make their killing in the 
marketplace. The states, eager to reduce their financial 
burden, are abandoning their Medicaid patients to for-profit 
HMOs with little or no significant evaluation. Mounting 
evidence indicates widespread fraudulent and deceptive 
marketing practices, paralleling the long history of similar 
abuses in long-term care and Medigap insurance sales to the 
elderly. <a href="#N4">(4)</a></p>

 <p><a name="R5">Recently, a few dozen corporate bigwigs, representatives of 
government and members of other assorted organizations 
representing 80 million workers and their families, met in 
Jackson Hole, Wyoming. <a href="#N5">(5)</a> These are hardcore HMO advocates but 
they realize their cut-rate health care vision is in 
trouble. They have pledged to change their focus from 
reducing costs to increasing quality of managed health care. 
They are running scared because they know the results of 
emerging research and the people's experiences. They want to 
save managed care in order to secure their profits. Quality 
of care in HMOs and other managed care health plans is the 
Achilles heel of the scheme. </p>

<p> There is a tremendous amount of energy among community 
groups, public health professionals, the elderly and 
grassroots health reformers and advocates. This energy must 
be focused, first, to hone in on the quality of care issue 
under managed care. Questionnaires can be handed out to 
members of these plans, and hearings can be held. Inquiries 
can be made for information at state agencies, and if they 
don't have quality of care information or will not release 
it, then that in itself becomes part of the problem that 
must be publicized. Collect information from the library - 
there is more coming out every week.</p>

 <p><a name="R6">The energy of the people must be focused secondly on 
eliminating all profits from health care. It is simply too 
late for the popular single payer option that they have in 
Canada. As Physicians for a National Health Program 
(historically advocates for single payer) are now asking, 
"What would public financing of a system, dominated by large 
for-profit horizontally and vertically integrated firms and 
chains look like, and mean?" <a href="#N6">(6)</a> The only answer for the 
working people of the United States is a publicly financed 
and operated, democratically run National Health Service 
which eliminates all profit in health care. Legislation 
advocating a National Health Service was introduced once 
again by Representative Ron Dellums (D-CA) as HR 1798, on 
June 8, 1995 (104th Cong., 1st Sess.)</p>

 <p>The struggle must start with a crushing attack on the 
quality of care under for-profit managed care. This must be 
led by the labor movement and its allies in the community 
and professional ranks. The breadth of the struggle must 
include the saving and expanding of Medicare and Medicaid; 
immediate coverage of all uninsured people that single payer 
legislation will bring; major public housing programs; full-
scale environmental and occupational health prevention 
programs - all culminating around the fight for a national 
health service. These are the short and long-term goals that 
our movement needs and the politicians must respond to!</p>

 <h4>Reference Notes </h4>
<ol>
<li><a name="N1">Alvin L. Schorr, 1995, State Experimentation in Health Care: What Have
We Learned?, <em>Action for Universal Health Care,</em> July/August, pp. 1-2. <a href="#R1"><em>Return to text</em></a> 

<li><a name="N2"><em>Ibid.</em> <a href="#R2"><em>Return to text</em></a>

<li><a name="N3">Jane Bryant Quin, 1994, "Health Care Report Cards," 
<em>Newsweek,</em> October 17, p. 57. <a href="#R3"><em>Return to text</em></a>

<li><a name="N4">Ellyn E. Spragins, "Simon Says, Join Us!" <em>Medical Benefits,</em> July 15,
p. 3. <a href="#R4"><em>Return to text</em></a>

<li><a name="N5">See Phil Benjamin's article, "The Ongoing Struggle for National Health Care and OSHA Reform," in 
the November and December 1994 issues of <em>Political Affairs,</em> for more about Jackson Hole and related
issues. <a href="#R5"><em>Return to text</em></a>

<li><a name="N6">Gordon Schiff, 1995, "PNHP Broadens its Agenda," <em>Action,</em> July/August,
p. 5. <a href="#R6"><em>Return to text</em></a>
</ol>
<center><table border=2 cellpadding=6 cellseparation=2><tr>
<td><a href="health.html#toc">Table of contents</a></td>
<td><a href="../index.html">The CPUSA page</a></td>
<td><a href="health-2.html">To the next part</a></td>
</tr></table>
<img src="line-blue.gif"><br><em><font size=2><a href="mailto://brownh@hartford-hwp.com">
Hartford Web Publishing</a></font>
</em></center></body></html>







</DOC>
<DOC>
<DOCNO>WT03-B24-250</DOCNO>
<DOCOLDNO>IA027-000294-B004-210</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-12-21-2.html 206.119.5.80 19970120072152 text/html 4862
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:28:31 GMT
Last-modified: Saturday, 21-Dec-96 16:11:27 GMT
Content-length: 4678
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Gus Hall & Jarvis Tyner - CPUSA replies to slander in NY Times</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>CPUSA replies to slander in NY Times</h1>
<h2>by Gus Hall & Jarvis Tyner</h2>

<p><em>This article was reprinted from the <strong>CPUSA replies to slander
in NY Times</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><i>The following is the full text of a letter which appeared, 
abridged, in the Wednesday, Dec. 18 New York Times. It is a 
response to a vicious, FBI-like anti-Communist op-ed on Dec. 
10 which slandered the Communist Party's 77-year history of 
fighting for civil rights.</i></p>

<p>J. Edgar Hoover must be smiling from his grave. W.E.B. Du 
Bois must be turning in his.</p>

<p>Hoover, because the stench of the McCarthyism he helped 
create continues to foul the op-ed page of the New York 
Times. Du Bois, because opportunists continue to abuse the 
name and legacy of the organization he helped found.</p>

<p>Denton L. Watson's article on Thurgood Marshall is straight 
out of Hoover's McCarthyite Cold War propaganda machine - 
straight out of the gutter. The Communist Party 
"embarrassed" the NAACP during the Scottsboro case; 
organized African Americans as a "fifth column;" "used 
women" to seduce unsuspecting Blacks; Communists, not 
racists, were the "greatest threat" to the NAACP?</p>

<p>Echoes of McCarthy? This is demagogy that rivals, if not 
exceeds, the Big Lie of McCarthyism during the 1950s. That 
it appears in the New York Times in 1996 gives reason for 
pause.</p>

<p>One need not respond to the garbage, but to set the record 
straight: Socialism and Communism are not foreign imports 
but are home-grown American products. The lives and 
political legacies of figures like W.E.B. Du Bois and Mary 
Wright Ovington - both life-long advocates of socialism and 
founders of the NAACP - amply testify to this.</p>

<p>During the 77 years of the CPUSA, Communists worked side by 
side with many organizations in trade unions and civil 
rights organizations and, yes, with the NAACP for jobs, 
peace, against racism and for social equality.</p>

<p>That white people and African Americans - including Du Bois 
- joined the Communist Party was no crime. Nor was it the 
result of some hidden plot. Rather, people joined the Party 
because of their admiration of its work against racism and 
for the rights of workers, Black, Brown and white. Du Bois 
himself dismissed the conspiracy charge. "I reject the 
charge that Communism is a conspiracy," he said when joining 
the Communist Party.</p>

<p>It was the rabid anti-Communist hysteria of McCarthyism, 
falsely charging the Communist movement with conspiracies 
and plots, that led to the Smith Act trials for conspiring 
to "think" and "teach" - charges that many of us went to 
jail for.</p>

<p>We wonder at the publication of such patently false 
allegations today. We remember that Big Lie anti-Communism 
has always been the foundation of fascist-like thinking. Let 
all democratic-minded people be warned: this demagogy, if 
left unanswered, threatens democracy itself - it is the 
stuff of fascism.</p>

<p>We close with the words of Dr. Martin Luther King Jr., 
spoken when memorializing Dr. Du Bois in 1968 just weeks 
before King's assassination. Observing that Du Bois was a 
genius who chose to be a Communist, he said, "Irrational, 
obsessive anti-Communism has led us into too many quagmires 
to be retained as if it were a mode of scientific thinking."</p>

<p><i>Gus Hall, National Chairman, CPUSA
Jarvis Tyner, Vice-Chairman</i></p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="../pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-251</DOCNO>
<DOCOLDNO>IA027-000294-B003-246</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-30-3.html 206.119.5.80 19970120071819 text/html 9603
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:24:58 GMT
Last-modified: Sunday, 01-Dec-96 01:04:30 GMT
Content-length: 9421
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Fred Gaboury - 'The State of Black America 1996': bad and getting
worse</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>'The State of Black America 1996': bad and getting worse</h1>
<h2>by Fred Gaboury</h2>

<p><em>This article was reprinted from the <strong>November 30,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>NEW YORK</strong> - Advance copies of the 21st edition of the
Urban 
League's The State of Black America were made available to 
the press on Nov. 22. In nine essays discussing the 
questions of unemployment and underemployment; infant 
mortality and life expectancy; income, housing and health, 
the report documents its conclusion that the fundamental 
question facing Black America - and millions of other 
Americans - is poverty.</p>

<p>The League has always recognized the centrality of poverty 
as the determining factor in its report and has issued many 
calls for increased job opportunities. But this year there 
is something different: In words that leave no room for 
misunderstanding, Hugh Price, the League's president, calls 
for an urban policy centered on a modern-day Works Progress 
Administration (WPA) to end the "Great Depression in 
America's ghettos. There is nothing un-American about 
spending money to help fill gaping holes in the labor 
market," he writes.</p>

<p>And there are gaping holes:</p>

<p>* Even the understated "official" figures show an 
unemployment rate in the African American community double 
that among non-Hispanic white workers - and that has 
remained at or above 10 percent since the mid-1970s.</p>

<p>* More than 40 percent of African American households in 
metropolitan areas are trapped in what the Census Department 
calls "high poverty neighborhoods."</p>

<p>* One out of every three African Americans live in poverty, 
a rate three times that of whites. Although African 
Americans constitute only 15 percent of the total 
population, they constitute 40 percent of those living in 
poverty.</p>

<p>* In 1984 African American men working full-time year-round 
had incomes averaging less than 75 percent of non-Hispanic 
white men while the average annual earnings of African 
American women fell 15 percent below that of non-Hispanic 
white women.</p>

<p>* African American high school graduates earn about 82 
percent of what white graduates earn and the gap widens as 
the level of education increases: While Black male high 
school graduates earn $1,490 per year more than a white high 
school drop-outs, African American males with college 
degrees earn only $7,000 per year more than white high 
school graduates.</p>

<p>Dr. June Jackson Christmas, the Urban League's Urban Issues 
Group director, says that African Americans will not reach 
the goals set in Healthy People 2000, a government report 
that sets forth a national strategy to improve the nation's 
health, because of major disparities that continue to exist 
between their health status and that of white Americans.</p>

<p>"African Americans still endure significant health problems 
which are caused and exacerbated by poverty, lack of 
culturally competent health-care providers, ineffective 
health care and racial discrimination," Christmas writes. 
She adds that improvements in these areas are not enough to 
guarantee better health among African Americans. "The 
problems that afflict African Americans as a group begin, 
literally, before birth for far too many infants and 
continue to the end of life."</p>

<p>* In 1993, life expectancy for African Americans was 69.3 
years compared to 76.3 years for white Americans and more 
than 75 years for the population as a whole. The disparity 
is even more glaring for African American men whose life 
expectancy is more than eight years less than white men. 
While life expectancy for whites increased during the 1980s, 
it declined for African Americans.</p>

<p>* At 16.8 deaths per 100,000 births, African Americans have 
the highest infant mortality rates of all ethnic groups and 
nearly three times the mortality rate of white infants.</p>

<p>* If African Americans were considered a separate population 
group in the world, their infant mortality rate would rank number 40.</p>

<p>* A recent study by the Centers for Disease Control and 
Prevention found infant mortality rates to be 60 percent 
higher for women living below the poverty line than for 
those living above it.</p>

<p>* Among the leading causes of infant mortality are disorders 
due to short gestation and low birth weight, both associated 
with poverty sand malnutrition.</p>

<p>Christmas says the HMO drive to cut the cost of health care 
and a "mood of conservatism" among policy makers makes it 
harder for African Americans to achieve Year 2000 targets: 
The change from public responsibility to corporate 
privatization, mergers and "megasystem networks," block 
grant to states, a diminished role for the federal 
government and "a level of government historically 
inattentive to Black Americans" will deal heavy blows to the 
poor and especially to African Americans.</p>

<p>"Further," she says, "the policy of cutting back on the 
number of medical graduates and decreasing the ratio of 
specialists to primary care doctors does not address the 
gross under-representation of [African Americans] as both 
specialists and primary care physicians."</p>

<p>Timothy Bass, professor of labor and urban affairs at Wayne 
State University, criticizes the job-creation strategies of 
cities that, he says, are a two-edged sword: While 
development of central business districts creates more 
white-collar jobs, they will, if successful, create many 
low-wage service jobs, thus contributing to the 
proliferation of low-wage work.</p>

<p>Bass says such policies are "a cause of, not a cure for" low 
wages. He charges that maintaining the poverty inherent in 
low-wage industry is an important component of city 
development strategies. "It is the practices adopted by 
employers, not trends in worker productivity, which is 
increasingly responsible for rising poverty that is rooted 
in declining compensation and job security."</p>

<p>In closing, Bass says the "challenges to this emerging 
status quo, if they are forthcoming, will arise when younger 
generations put forth a class-based agenda to reverse the 
decline of the institutionalized power of labor."</p>

<p>While not written in the language of working people, the 
message of The State of Black America 1996 came through 
clearly: The fight for equality - and therefore, to close 
the "gaping holes" that are documented in the report - must 
go hand-in-hand with any struggle aimed at resolving the 
problems facing working people. And the fact that trade 
union and African American votes were two of the most 
important components of the coalition that denied Bob Dole 
the keys to the White House shows that it can be done.</p>

<h3>**'We need a modern-day WPA'**</h3>

<p>We believe the urban policy must have a laser-like focus on 
jobs for the inner-city poor. No fancy master plans. No 
complex policies with dozens of components. We need public 
policies which make work economically worthwhile ...</p>

<p>We've been content for too long with a low-wage economy that 
locks hard-working Americans into poverty. Boosting the 
minimum wage helps a bit, as does protecting the Earned 
Income Tax Credit from continuous assault by Congress.<p>

<p>Make no mistake. Inner city folk want to work. We've got to 
spread the job action around if inner city folk are to work 
- and if cities are to work.</p>

<p>There is no macro-economic policy, no economic growth 
scenario, no Model Cities approach, no black capitalism 
strategy and no enterprise zone experiment imaginable that 
can match the Depression-era Works Progress Administration 
in jumpstarting hope by driving unemployment down in a hurry 
...</p>

<p>There is nothing un-American about spending public money to 
help fill gaping holes in the labor market ... An urban jobs 
policy aimed at putting inner-city people back to work 
wouldn't differ in principle from such past efforts as the 
WPA.</p>

<p><i>-Hugh B. Price, president, National Urban League</i></p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-252</DOCNO>
<DOCOLDNO>IA027-000294-B004-77</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-12-14-1.html 206.119.5.80 19970120071954 text/html 8048
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:26:36 GMT
Last-modified: Wednesday, 18-Dec-96 22:43:55 GMT
Content-length: 7863
Content-type: text/html
</DOCHDR>

<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Fred Gaboury - Santa in seatshop protest; Sweeney goes to jail at
Yale</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Santa in seatshop protest; Sweeney goes to jail at Yale</h1>
<h2>by Fred Gaboury</h2>

<p><em>This article was reprinted from the <strong>December 14,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>NEW HAVEN, Conn.</strong> - The holiday season began in earnest 
recently with the Dec. 6 arrest of a Santa-suited union 
organizer in New York, followed with the Dec. 10 arrest of 
AFL-CIO President John J. Sweeney here.</p>

<p>Sweeney was arrested at a solidarity march and rally in 
support of the Federation of Union Employees at Yale 
University. He was also arrested earlier this year while 
supporting Detroit newspaper workers on strike against that 
city's daily papers.</p>

<p>'Santa,' in actuality UNITE organizer Kurt Edelman, was 
arrested while participating in a demonstration protesting 
the sale of garments produced by sweatshop labor at Lord & 
Taylor, an up-scale Manhattan clothing store.</p>

<p>"We are here to send a message from one of our nation's 
poorest communities to one of its richest institutions that 
we may be poor but we have a secret power," Sweeney told the 
more than 1,500 cheering demonstrators, "and we are going to 
use that power to keep Yale a civilized institution." Yale, 
with a $4.8 billion endowment is the largest employer in New 
Haven, a city where the per capita income is less than 
$13,000.</p>

<p>Sweeney said the battle of 3,700 technical, service and 
maintenance workers at Yale was part of a nationwide 
campaign to bring greedy employers "from New Haven to New 
Mexico" to justice.</p>

<p>Sweeney then led several hundred demonstrators into the 
street. When the group ignored a police order to disperse, 
Sweeney, together with more than 300 others, was escorted to 
waiting police vehicles as Rosa Dasher, a member of Local 
35, joined guitarist Tom Juravich in a spirited rendition of 
"You'll Never Walk Alone."</p>

<p>Even the police smiled as a voice from the crowd said, 
"Don't let them take you alive!" as the arrests began.</p>

<p>In an interview before the demonstration began, Sweeney 
told the World that civil disobedience is "part of the labor 
movement's arsenal. It is certainly a way of showing 
solidarity," he said. "It worked for the civil rights 
movement and there is no reason why it can't work for the 
labor movement."</p>

<p>Sweeney said he would give Labor '96, the AFL-CIO's 
electoral campaign, a "grade of 9.9 out of 10" and that he 
"had no regrets whatsoever" for his decision to run for the 
presidency of the 13-million-member labor federation last 
year.</p>

<p>The Dec. 10 demonstration was the latest in the year-long 
struggle by members of Locals 34 and 35 of the Hotel 
Employees and Restaurant Employees who have been working 
without a contract since February. The main issue is the 
demand of the university that it have the unilateral right 
to contract out much of the work done by dining hall and 
maintenance workers.</p>

<p>Al, a plumber who declined to give his last name, has worked 
at Yale for 17 years. "I went to Yale right after graduating 
from high school - but not as a student," he said jokingly. 
Al sees the fight at Yale as a fight for the future of all 
working families. "We just have to take a stand," he said.</p>

<p>Last month the National Labor Relations Board (NLRB) charged 
Yale with illegal retaliation against union members 
following two four-week strikes last spring. The illegal 
acts included the discharge of a part-time worker for 
supporting the strike, prohibiting certain employees from 
discussing the union, the involuntary transfer of a union 
steward to what amounts to solitary confinement, and 
refusing to honor contract language regarding payroll 
deduction of union dues.</p>

<p>In his speech Sweeney reminded university officials that the 
NLRB had found Yale guilty of violating federal labor laws. 
"Those are serious crimes," he said. "If members of the Yale 
Corporation board were members of the president's cabinet 
they would be forced to resign."</p>

<p>The Rev. Lillian Daniel told demonstrators that a Ph.D. from 
Yale is not needed to understand what constitutes a just 
contract. Then, in remarks directed at non-residents, she 
said she hoped that people would not take Yale's illegal 
union-busting activity to mean that New Haven is a "high 
crime city."</p>

<p>Rev. Boise Kimber, a leader of New Haven's African American 
clergy, called the struggle at Yale "a fight for the rights 
this country was founded on. It's a wrestling match against 
intolerance and wickedness in high places. It's a fight 
against a bottom line that keeps its workers at the bottom. 
I challenge Yale's board of directors and President Richard 
Levin to reexamine their values." Levin will be paid 
$350,000 in 1996, double his 1995 salary.</p>

<p>Among those arrested with Sweeney were Laura Smith, 
president of Local 34; Bob Proto, president of Local 35; 
Miles Rappaport, Connecticut secretary of state; John Olson, 
president of the Connecticut AFL-CIO; Joelle Fishman, chair 
of the Communist Party of Connecticut; and Blair Bertaccini, 
president of the Waterbury Central Labor Council. Those 
arrested face fines of $80.</p>


<h3>NLRB's Yale ruling sets precedent</h3>

<p>A recent NLRB charge against Yale has national importance. 
For many years, graduate teaching assistants at Yale have 
been trying to organize a union, the Graduate Employees and 
Students Organization (GESO). Yale has refused to recognize 
the union, claiming that grad students who work as teaching 
assistants are students rather than workers employed by the 
university.</p>

<p>A year ago it seemed possible that GESO could join with the 
other Yale employees in joint action to win contracts for 
all. As part of that effort, GESO called a grade strike last 
December and its members refused to turn in grades for the 
courses they teach.</p>

<p>Yale moved quickly to crush GESO, firing its members from 
their teaching positions, instituting academic disciplinary 
proceedings and blacklisting GESO activists. In the face of 
this, the strike was called off.</p>

<p>In its charge, the NLRB ruled that GESO members are 
employees covered by federal labor law, that they were 
engaged in a legal strike and that Yale acted illegally in 
taking retribution against its leaders and members. This 
ruling will give a boost to the growing unionization of 
graduate student teachers around the country, and to all the 
unions fighting for contracts at Yale.</p>

<strong>- Fred Gaboury</strong>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-253</DOCNO>
<DOCOLDNO>IA027-000294-B003-110</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-23-2.html 206.119.5.80 19970120071705 text/html 10480
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:23:45 GMT
Last-modified: Saturday, 23-Nov-96 15:46:33 GMT
Content-length: 10295
Content-type: text/html
</DOCHDR>

<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Rick Nagin - Kucinich win shows labor's political power</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Kucinich win shows labor's political power</h1>
<h2>by Rick Nagin</h2>

<p><em>This article was reprinted from the <strong>November 23,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>Cleveland</strong> - The election of Dennis Kucinich in Ohio's
10th 
Congressional District was a ground-breaking event 
demonstrating the powerful political potential of a mass, 
grassroots coalition led by labor.</p>

<p>Trade unionists and seniors provided the largest numbers of 
some 5,000 volunteers but many others came from Hispanic, 
environmental, peace and other organizations. Some were 
unemployed workers or shoppers at the outdoor mall where the 
headquarters was located who just walked in and offered to 
help. On any day after early September there were probably 
100 people working for some period of time in the 
headquarters, a beehive of activity and camaraderie, where 
anyone could find plenty of baked goods, bagels and cream 
cheese and other snacks brought in by the volunteers.</p>

<p>According to the campaign staff, the volunteers canvassed at 
least 600 of the district's 750 precincts, some as many as 
four times. They turned the western half of Cuyahoga County 
and especially the west side of Cleveland into a sea of 
15,000 bright yellow yard signs reading "Light Up Congress! 
Elect Dennis Kucinich" - a reminder of the historic fight 
Kucinich had waged as Cleveland mayor when he refused to 
sell the city-owned power plant to a private electric 
company.</p>

<p>The staff estimated that the volunteers made 100,000 phone 
calls and mailed out one million pieces of literature. Many 
organizations issued their own literature and did their own 
mailings including the AFL-CIO's Labor '96, the UAW CAP 
Council, the Sierra Club, Peace Voter '96, gay rights and 
senior groups. The United Auto Workers and the Steelworkers 
did plantgate distributions. The Ohio Council of Senior 
Citizens distributed 12,000 pieces with the positions of 
Kucinich and his opponent, incumbent Martin Hoke, on senior 
issues to senior buildings, nutrition sites and bingo games. 
This was after the National Council of Senior Citizens and 
the Cleveland AFL-CIO Retiree Council mailed voter 
registration and absentee ballot forms to 16,000 union 
retirees.</p>

<p>The coalition embraced many political viewpoints: Democrats, 
independents, Greens, socialists, Communists, members of the 
Labor Party, even some disgruntled Republicans. Democratic 
Party figures, including First Lady Hillary Clinton, 
Congressmen Louis Stokes, Joseph Kennedy and Barney Franks 
visited Cleveland to help in the effort. Especially 
significant were visits by Congresspersons Luis Gutierrez 
and Nydia Velazquez who spoke to large meetings and rallies 
and on the radio mobilizing an unprecedented vote in the 
Hispanic community.</p>

<p>But it was the grassroots, labor-community coalition that 
Kucinich had in mind on election night when he gave his 
impassioned victory speech with jubilant leaders of 
organized labor standing behind him, their right fists held 
high, chanting, "We are the party of the people! We are the 
party of the people!" The coalition was inspired by both 
Kucinich's personality and his program. </p>

<p>Respected as a champion of the underdog and working people, 
Kucinich was the son of a truck driver, who grew up in 
extreme poverty even living for a time out of the family 
car. As mayor, he had battled the power structure, the 
utilities, the banks, the mass media and, although his 
efforts saved the city light plant, he had waged the fight 
alone with no organized base and was ruthlessly crushed 
after the banks retaliated, forcing the city into default.</p>

<p>Despite years of ostracism and ridicule in the media, 
Kucinich staged a dramatic comeback in 1994, when he was 
elected to the state senate, one of the only Democrats in 
the country to unseat an incumbent Republican in the year of 
the Gingrich "revolution." At a time when other candidates 
of his party believed they should move to the right and fell 
like flies, Kucinich declared himself to be a Roosevelt 
Democrat and championed the views of an emerging left-
center, labor-community coalition.</p>

<p>In the state legislature he spoke out on behalf of this 
growing coalition, leading fights against privatization, the 
locating of a nuclear waste dump in Ohio, and the cutting of 
badly needed services to seniors and Hispanics. With the 
AFL-CIO mobilizing to defeat the Gingrich gang in Congress, 
it was only natural that Kucinich's campaign would become a 
national rallying point.</p>

<p>Unlike many other Democrats whom labor supported as "lesser 
evils," Kucinich raised the stakes. He issued a bill of 
rights for working people stating his belief that people 
have a right to a job, a right to a safe workplace, to 
decent wages and benefits, to strike, to participate freely 
in the political process. Issued on glossy paper with a 
bright yellow background, the program was distributed 
throughout the labor movement and posted on union bulletin 
boards everywhere.</p>

<p>The Republicans reacted with fury to this open challenge to 
their decades of labor-baiting bully tactics. Kucinich's 
program, Republican county chairman Jim Trakas announced, is 
"very similar to the Communist Manifesto" and is "what Lenin 
stood for." Kucinich blasted this reversion to 
"McCarthyism."</p>

<p>Martin Hoke, a loutish multi-millionaire, had been lucky to 
face seriously wounded opponents in his two previous races. 
He had unseated Mary Rose Oakar in 1992 when the longtime 
Congresswoman was embroiled in the House banking and post 
office "scandals." In 1994 he faced County Treasurer Francis 
Gaul, the focus of blame for the collapse of a key bond 
fund. Hoke, as Kucinich was fond of saying, was a man who 
woke up one day on third base and thought he had hit a 
triple.</p>

<p>After the 1994 elections, Hoke jumped on the Gingrich 
bandwagon with a vengeance, championing the Contract on 
America, denouncing labor, federal social programs and 
efforts to raise the minimum wage while skipping important 
votes for photo opportunities with the House Speaker.</p>

<p>At first Hoke adopted an upbeat, positive posture, with TV 
ads showing him fraternizing with workers and playing the 
piano for senior citizens. But as an AFL-CIO television 
campaign exposed his ultra-right voting record and 
positions, he found himself trailing by eight to ten points. 
The mask was then removed and the phony smile replaced with 
the snarl of labor-baiting and character assassination. 
Voicing his class hatred, Hoke assailed "Washington labor 
bosses" who, he said, were "stealing their members' dues" to 
"run a campaign of lies and smears" against him.</p>

<p>In fact, It was Hoke's campaign that degenerated into lies 
and smears as he saturated TV with ads slandering Kucinich's 
role as mayor and wildly charging that his health care 
proposals would bankrupt the country. When Rep. Barney Frank 
appeared for a Kucinich fundraiser, Hoke falsely charged 
that Kucinich advocated homosexual marriage and scurrilous, 
unsigned leaflets were distributed at churches, charging 
that Kucinich's supporters favored sex with children and 
animals.</p>

<p>The smears were endlessly propagated by a right-wing talk 
show host who made it his mission three hours every morning 
to stop Kucinich. The poisonous attacks, aimed at 
suppressing voter turnout, caused the race to tighten 
considerably. In the final week before the election the 
focus of the Hoke campaign shifted to virulent red-baiting 
directed at this writer.</p>

<p>In what was probably a first since the beginning of the Cold 
War, Kucinich refused to knuckle under, calmly stating that 
I was one of 5,000 volunteers and declaring, "It's Halloween 
and Hoke is dressing up as Joe McCarthy. Karl Marx is not 
running my campaign but apparently Harpo Marx is running 
his." </p>

<p>On Nov. 5 Hoke was defeated by a vote of 108,000 to 
102,000 with 10,000 going to a candidate of the Natural Law 
Party. It was a stunning rebuke to Hoke's shameful attempt 
to whip up hatred and hysteria. Although he spent a million 
dollars - over twice as much as Kucinich - he could not 
shake the solid majority of voters who showed outstanding 
maturity.</p>

<p>Unable to accept defeat gracefully, he never actually 
conceded and the next day denounced what he claimed was a 
"war that John Sweeney and the AFL-CIO declared on the 
people of America." The "war," he whined, will continue 
because the Republicans, although seriously weakened, retain 
control of Congress. While the war was hardly declared by 
labor, it is certain that labor and its allies will continue 
their efforts to reverse the nearly two decades of assault 
on unions and all that is decent in this country, and they 
will be able to count on the staunch, heart-felt support of 
Congressman Dennis Kucinich.</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-254</DOCNO>
<DOCOLDNO>IA027-000294-B002-454</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-16-1.html 206.119.5.80 19970120071457 text/html 13080
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:21:41 GMT
Last-modified: Sunday, 17-Nov-96 16:43:49 GMT
Content-length: 12897
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>CPUSA - 1996 Elections: the struggle continues</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>1996 Elections: the struggle continues</h1>
<h2>Statement of the National Board of the the Communist Party 
USA</h2>

<p><em>This article was reprinted from the <strong>November 16,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p>The 1996 election set the pace for the next steps in the 
struggle to meet the people's needs. Despite the record low 
turnout, the corporate-financed campaign of the ultra-right 
Republicans, the use of deceptive dirty tactics, the 
struggle to defeat the ultra right danger has had a big 
impact. The fascist threat which emerged in the course of 
the 104th Congress, and especially at the GOP convention, 
has been checked for now. as the ultra-right fell short of 
many of their goals.</p>

<p>Although Labor and the people's forces accepted the "lesser 
of two evils" tactic, it is now time to challenge the 
"lesser evil": the Clinton administration and the weaknesses 
of the Democratic Party's response to the concerns of 
working people.</p>

<p>The greater activity and and increased unity of labor, 
African American, Latino, women's, youth and senior votes 
was the key to defeating Bob Dole and winning other races. 
It also showed the potential for greater Independence and 
bigger victories in the future.</p>

<h3>Labor '96 made the difference</h3>

<p>The role of the AFL-CIO and its Labor 96 campaign was 
historic. Without it, the outcome of the '96 elections would 
have been far more negative, indeed could have been tragic. 
With the financial and street muscle of Labor and its 
allies, it was possible to put the right wing on the 
defensive, defeat Dole, 12 of the "Gang of 73" and another 
half dozen of the most rabid GOP incumbents, and to nearly 
defeat 22 others.</p>

<p>These are no small achievements considering that the 
Republican Right wanted to win all three branches of 
government by electing Dole, increasing their majorities in 
the U.S. House and in the Senate while winning additional 
state houses. If that had happened the Contract on America 
would have been on the fast track.</p>

<p>Instead, the ultra-right Republicans, although they 
increased in their Senate majority, were blunted in their 
overall efforts and were put on the defensive. The militant 
class conscious forces for political independence have a new 
basis to go on the offensive on the legislative front and to 
elect pro-labor, working class candidates in local elections 
next year and the midterm Congressional elections in 1998.</p>

<p>To list but a few of the outstanding victories won against 
the ultra-right on Nov. 5:</p>

<p>* Rep. Cynthia McKinney of Georgia won overwhelmingly 
despite being forced to run in a newly redistricted 70 
percent white district.</p>

<p>* Sen. Paul Wellstone of Minnesota, the only Democratic 
incumbent up for reelection who voted against the Welfare 
Bill and an unapologetic progressive was reelected despite a 
well-financed national effort to unseat him.</p>

<p>* Carolyn McCarthy, whose husband was killed and son 
seriously injured in the Long Island Railroad massacre, 
rejected the racist hysteria, and instead, changed from a 
life-long Republican to a Democrat to run for Congress and 
scored an impressive win over incumbent Dan Frisa, one of 
the Gang of 73.</p>

<p>* Dennis Kucinich winning the Congressional seat of 
millionaire Martin Hoke in Ohio after overcoming a vicious 
redbaiting attack.</p>

<p>* The defeat of Dick Zimmer for U.S. Senate in New Jersey, 
Rep. Dick Chrysler in Michigan, Gary Franks in Connecticut 
and in the State of Washington, the winning back of three of 
the six seats lost to the Gang in 1994.</p>

<p>When seen along with the near-defeat of other members of the 
Gang of 73, the outcome of the 1996 elections shows that it 
is possible to achieve total defeat of the ultra-right in 
the future.</p>

<p>The Communist Party in the 1996 elections was in harmony 
with the majority of working class voters. While we were 
sharply critical of Clinton and the Democratic Party, we 
understood that the most important challenge was to attack 
the main danger; the fascist threat coming from the far-
right Republicans.</p>

<p>Our efforts continued even after the Republicans, sensing 
the mood among the electorate, tried to hide Gingrich and 
other known extremists in their ranks. Our efforts, like the 
efforts of most, was to prevent them from expanding and 
solidifying their rule and implementing the Contract on 
America.</p>

<h3>Who voted against the right</h3>

<p>A powerful winning electoral coalition was born in the 
course of this 14-month struggle. The votes of union 
households, African Americans and Latinos, united with 
working class women, youth and seniors, made the difference.</p>

<p>The most significant feature in this year's election was the 
role of organized labor. Instead of endorsing and providing 
resources for candidates, the Labor 96 campaign concentrated 
on education, registration and getting out the vote. Union 
leaders called on rank-and-file unionists to ignore party 
labels and "vote like a worker."</p>

<p>The level of participation by African Americans, Latinos and 
women, including Catholic women, was at unprecedented 
levels. The emergence of the Latino vote is also important. 
Spurred on by the vicious attacks by the ultra right on 
immigrants, the Latino vote is reshaping the political 
landscape in important parts of the country. The Mexican 
American vote is now a powerful force in areas such as 
Orange County, Calif., long considered a bastion of the 
right wing.</p>

<p>While the racist Proposition 209, misnamed the California 
Civil Rights Initiative, won and Harvey Gantt lost his bid 
to unseat notorious racist Sen. Jesse Helms in North 
Carolina, this election was marked by a high level of grass 
roots anti-racist unity of Black, Brown and white workers, 
especially in the deep South and in the far West. Our party, 
labor and the people's forces must study why, after the 
Republicans shifted their tactics in order to hide their 
extremism, the Democrats didn't respond which may have made 
a difference in close congressional races?</p>

<p>Although economic issues were paramount in determining 
voting patterns, millions of voters, concerned about the 
Oklahoma City bombing of April 1995, the Gingrich-Dole 
conspiracy to cut Medicare and Medicaid, the government 
shutdown and church burnings, came to view extremism as a 
basic threat to democracy. This fear isolated Newt Gingrich, 
caused splits in Republican ranks and compelled millions of 
democratic-minded voters to reject the Republicans.</p>

<h3>Communist Party on the move</h3>

<p>Our party focused its energy in mobilizing and educating the 
voters on the key issues and bringing the danger of the 
ultra-right to the forefront of the political agenda. 
Hundreds of thousands of brochures and leaflets were 
distributed at union conventions and demonstrations, in mass 
mailings to labor and community leaders, given out door-to-
door and at workplaces. Our aim was to reach the majority 
with the message, "Vote as if your life depends on it."</p>

<p>From the primaries through the general election we carried 
on a crusade in the pages of the People's Weekly World to 
alert labor and the people's movements to what was at stake. 
We urged millions on syndicated talk shows to vote and who 
to vote against.</p>

<p>Our coalition relations were strengthened with labor and 
community forces because we worked shoulder to shoulder in 
the critical struggle to register and mobilize voters and 
get them to the polls on Nov. 5.</p>

<p>While we chose not to run candidates for national office, 
our local candidates were well received. Frank Soifer, who 
ran for mayor of Eugene, Ore., and David Mirtz, who ran for 
New York State Assembly, built grassroots bases that showed 
the necessity for the Communist Party to run campaigns to 
give a voice for all who seek a fundamental break with Big 
Business' domination of politics.</p>

<h3>Danger from the right remains</h3>

<p>Despite its many positives, the 1996 elections show that the 
danger from the far right remains. They have not given up on 
the Contract on America and will surely use their new 
strength in the Senate and Clinton's appeals to 
"bipartisanship" to advance their program. Passage of Prop. 
209 in California and of welfare and immigrant "reform" 
legislation are clear signs that the racist danger remains. 
The battle against the right must continue, become better 
organized, more united and more demonstrative.</p>

<p>While those who voted demonstrated a higher level of 
political understanding,we must understand that the vast 
majority who stayed home are an important part in the 
struggle to build an independent political movement.</p>

<p>Although the third party initiatives in 1996 remained 
outside the main electoral arena, a large majority of people 
have great doubts about voting and the possibility of 
changing the direction of the two major parties. The Stand 
for Children in June, the Oct. 12 demonstration for 
immigration rights and the AFL-CIO's America Needs a Raise 
rallies in 30 cities plainly show people's anger and 
willingness to fight back. But we must examine why these 
sentiments were not fully expressed in the election booth.</p>

<p>Although the elections held the ultra-right in check, the 
political and ideological struggles against their program 
must continue. This is the challenge for all forces of 
political independence and raises the question of how to 
organize the pressure for setting a new agenda in the 105th 
Congress.</p>

<p>Although we can learn from labor's coalition-building 
efforts which won passage of a minimum wage increase and 
defeated the Team Act in the 104th Congress, our party, 
labor and the people's movements must take a deeper look at 
how to reach the majority stay-at-home vote. We have to take 
new initiatives for election law reform to create a more 
democratic guarantee that pro-labor, working class, 
Communist, left and other third-party candidates can get 
elected.</p>

<p>Labor and the people's forces have established a lot of 
momentum out of this election. The challenge is to use that 
momentum to build a real bridge to the 21st century by 
rejecting the Contract, stopping the long-term decline in 
real wages, rejecting racism and organizing a movement for 
jobs, peace and equality.</p>

<p>That bridge will be built with people's struggle for passage 
of the Martinez Jobs Bill, in the fight against racism, in 
struggles to reverse the Welfare Bill, to stop the attacks 
on immigrants and spread of Prop.209-like measures in other 
states.</p>

<p>Real political independence and progress toward building a 
viable third party will take place in the context of 
building a movement for election law reform, to save public 
education and against poverty, unemployment and 
homelessness.</p>

<p>A bridge to the 21st century must be a bridge to peace built 
by cutting the military budget, withdrawing U.S. troops from 
around the world and ending the immoral and illegal U.S. 
blockade of Cuba.</p>

<p>Mass protest and action are the order of the day and are the 
surest guarantee that the right wing will not be able to 
regain the initiative. Let Clinton and the 105th Congress 
hear the angry voices and marching feet of millions 
demanding a progressive, pro-labor, anti-racist contract 
with the American people. That is our mandate.</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-255</DOCNO>
<DOCOLDNO>IA027-000294-B004-136</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-12-14-3.html 206.119.5.80 19970120072024 text/html 4042
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:26:58 GMT
Last-modified: Wednesday, 18-Dec-96 22:43:59 GMT
Content-length: 3857
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Joe Bernick - Prison labor: source of superprofits</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Prison labor: source of superprofits</h1>
<h2>by Joe Bernick</h2>

<p><em>This article was reprinted from the <strong>December 14,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>TUCSON, Ariz.</strong> - In a keynote speech to a Nov. 16 forum on 
prison labor, Patricia Clark compared prison labor in the 
U.S. to the maquiladora plants along the Mexican border. 
"Prison labor has taken a form much like maquiladoras" Clark 
said, adding that now, with privatization and "new" prison 
industries, prisoner labor has become a source of corporate 
superprofits.</p>

<p>Clark, who heads up the criminal justice program for the 
American Friends Service Committee, spoke at a one-day 
meeting titled "Factories with Fences." In her presentation, 
Clark gave a compelling overview of a US prison system 
which, she said, "is headed for disaster."</p>

<p>After pointing out that a majority of U.S. residents commit 
crimes for which they could be jailed, Clark reminded her 
audience that almost all prisoners are drawn from a narrow 
segment of society. "African American males, for example, 
make up only 6 percent of the total population, but account 
for the majority of prisoners," she said. "They are more 
likely to be arrested and more likely to be convicted." She 
said that white collar lawbreakers, on the other hand, are 
less likely to get caught and serve shorter sentences when 
they are.</p>

<p>The forum was initiated by the American Friends Service 
Committee and cosponsored by the Coalition of Black Trade 
Unionists, Salt of the Earth Labor College and groups 
concerned with peace and prisoner rights. Workshops were 
held on labor, chain gangs, privatization, and the rights of 
prison laborers.</p>

<p>The labor workshop included a panel made up of Clark, local 
Jobs with Justice leader Steve Valencia and Fred Markusen 
and James Beverly, both of whom are correction employees. 
Markusen described how in the 20 years since he began 
working, the prison population increased tenfold.</p>

<p>Beverly who is a leader of American Federation of State, 
County and Municipal Employees and the Coalition of Black 
Trade Unionists, blasted the idea of private prisons, citing 
studies showing that private prisons suffer from high staff 
turnover, lower pay, a high level of violence and high 
escape rates. "They have no rehab programs," he said, and 
are run by those who have a "lock 'em up" mentality.</p>

<p>Valencia said the issues of prison labor and privatization 
"are in character with the most vile features of corporate 
America." He said both were a "fast-track transfer of public 
wealth to private coffers."</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-256</DOCNO>
<DOCOLDNO>IA027-000294-B003-45</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-16-3.html 206.119.5.80 19970120071633 text/html 6367
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:23:06 GMT
Last-modified: Sunday, 17-Nov-96 16:43:55 GMT
Content-length: 6185
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Herb Kaye - Tire boycott flattens Bridgestone/Firestone</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Tire boycott flattens Bridgestone/Firestone</h1>
<h2>by Herb Kaye</h2>

<p><em>This article was reprinted from the <strong>November 16,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>CHICAGO </strong>- After a bitter 27-month strike and lockout, 
Bridgestone/Firestone (B/F), the world's largest tire 
manufacturer, has been forced to come to terms with the 
Steelworkers union (USWA).</p>

<p>Under terms of a tentative agreement reached earlier this 
month, B/F has agreed to rehire all strikers, grant an 
unconditional amnesty to more than 40 union members 
discharged for alleged strike-related misconduct and make 
lump sum payments totalling $15 million to strikers who were 
not recalled when the union agreed to return to work in May 
1995.</p>

<p>Union members will vote by mail within two weeks and ballots 
will be counted by mid-December. During the battle, the 
union had organized a national consumer boycott and 
mobilized solidarity with unions representing B/F workers in 
14 countries.</p>

<p>The strike began July 12, 1994 when B/F refused to accept 
the pattern established between the United Rubber Workers 
union (URW) and other tire companies insisting, instead, on 
wage and benefit cuts and around-the-clock production with 
seven-day weeks and 12-hour shifts. It ended in May 1995 
when the union agreed to return to work unconditionally and 
B/F, which had continued operations behind union picket 
lines, refused to rehire all strikers.</p>

<p>The USWA "inherited" the strike in July 1995 when the URW 
merged with the larger union. Within days, the merged union 
launched a wide-ranging corporate campaign. to mobilize 
support for a decent contract at B/F. "We may have agreed to 
return to work unconditionally, but we did not surrender 
unconditionally," USWA President George Becker said at the 
time.</p>

<p>The USWA conducted a militant, imaginative corporate 
campaign that saw picket lines at B/F outlets across the 
country. Steelworkers demonstrated at the Indianapolis 500 
and other car races demanding that B/F be "black flagged." 
More than 30 city councils passed resolutions refusing to 
use of B/F tires on city vehicles.</p>

<p>The union maintained a Camp Justice across the street from 
corporate headquarters in Nashville, Tenn. and sparked many 
steelworkers and other union supporters to run for public 
office on a platform of fighting for a settlement of the 
strike.</p>

<p>In March 1996, the USWA organized an international meeting 
of unions representing B/F workers in Nashville and 
delegations of U.S. rubber workers traveled to Japan, 
France, Brazil, Argentina, and other countries where B/F has 
plants.</p>

<p>The agreement provides for a $750 signing bonus, wage 
increases of 75 cents an hour over the life of the contract 
and B/F dropped its demand for increased co-pays for health 
insurance. If approved, the agreement expires on Sept. 1, 
1999, the date that other contracts in the industry 
terminate.</p>

<p>Sources in USWA headquarters told the World that the 
question of continuous production with seven-day weeks and 
12-hour shifts had become a "non-issue" in final 
negotiations. It was removed from the bargaining table and 
left for resolution in local negotiations The union also 
agreed not to press unfair labor charges previously filed 
with the National Labor Relations Board.</p>

<p>Local union officers expressed caution on how the membership 
might react to the agreement. Becky Bradish, recording 
secretary of USWA Local 310 in Des Moines said she was 
cautiously optimistic. "Working in a rubber factory, 
especially in the summer heat, is a hard enough job for 
eight hours a day - 12 hours is something else. I haven't 
seen the contract. We'll know more in a week or so. 
Meanwhile, I'm cautiously optimistic."</p>

<p>When reached at the office of USWA Local 138 in Noblesville, 
Ind., Charley Gibson pointed out that at his plant B/F never 
imposed 12-hour shifts, even when operating with strike 
breakers. "I doubt that the company would find it effective 
because the quality of the product would go down if workers 
were forced to work 12 hours a day, three or four days a 
week."</p>

<p>Though B/F claimed rising profits and production throughout 
the struggle, it could not ignore the negative effect of the 
union's relentless pressure on its public image and the 
clear evidence that the union would never quit the fight.</p>

<p>Many of the lessons learned in the fight at B/F need to be 
applied to the prolonged battles at places like Frontier 
Hotel in Las Vegas, Diamond Walnut at Watsonville, Calif., 
Uno-Ven Oil at Lemont, Illinois.</p>

<p>National and international labor solidarity, combined with 
independent political action and coalition-building, are 
crucial steps towards winning greater victories for labor in 
the coming period.</p>

<p>-Fred Gaboury contributed to this story.</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-257</DOCNO>
<DOCOLDNO>IA027-000294-B004-21</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-12-07-2.html 206.119.5.80 19970120071931 text/html 13485
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:26:10 GMT
Last-modified: Saturday, 07-Dec-96 17:03:17 GMT
Content-length: 13300
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Tim Wheeler - The cuban people defend and build their
revolution.</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>The cuban people defend and build their revolution</h1>
<h2>by Tim Wheeler</h2>

<p><em>This article was reprinted from the <strong>December 7,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>HAVANA</strong> - After five years of belt-tightening and self-
sacrifice to save their revolution, the Cuban people 
finally see signs of a dawn.</p>

<p>The economy is once again growing after the collapse of the 
Soviet Union destroyed 85 percent of Cuba's export market, a 
blow that struck the island with the force of ten 
hurricanes. Washington saw it as their chance, finally, to 
finish off Cuban socialism.</p>

<p>They enacted the Torricelli bill and the Helms-Burton bill 
to tighten the 34-year economic blockade, an act of war that 
still inflicts pain and suffering on the Cuban people. Jorge 
Mas Canosa and his Miami mafia were already packing their 
bags for a triumphant return to Havana.</p>

<p>Their plans haven't panned out.</p>

<p>Juan Triana Cordovi, director of the Center for the Study of 
the Cuban Economy, told me Cuba's 450,000 sugar cane workers 
are expected to harvest five million tons of sugar this year 
- double the tonnage during the depths of the "special 
period." The nickel miners have already produced 50,000 tons 
of refined nickel and cobalt in a joint venture with 
Sherritt International, the Canadian corporation that 
refuses to bow to Sen. Jesse Helms. Joint ventures in 
tourism and other industries are bringing in development 
capital.</p>

<p>It is all the result of the determined hard work by millions 
of Cuban workers and campesinos. They possess the 
indomitable spirit of the "Old Man and the Sea." Everywhere 
I visited during a one-week tour of Havana and nearby 
cities, this month, I saw signs of the material shortages 
inflicted by the blockade. And everywhere I witnessed the 
quiet determination not to "say uncle" to Washington's 
pressure tactics. Two slogans can be seen on walls and 
buildings everywhere: "Si se puede!" (Yes we can do it!) and 
"Patria o Muerte" (Fatherland or death).</p>

<p>Crowds wait with the patience of Job at bus stops. Every 
imaginable conveyance has been pressed into service, even ox 
carts. Hundreds of 1950s era Chevies trundle along, most of 
them running on hand-made spare parts. Soviet motorcycles 
with sidecars carry as many as five passengers.</p>

<p>The Cubans have invented the "camel" a semi trailer with two 
humps pulled by a truck. Passengers are packed in like 
sardines. Thousands ride Chinese-manufactured bicycles, 
hitchhike or walk. There are similar chronic problems with 
fitful elevators, water, electricity, and telephone service.</p>

<p>The "si se puede" spirit may be part of the Cuban character - 
but it is also organized by grassroots leaders like Maria 
Ducas Megret. In March 1993, Cuba held its first elections 
for municipal and national "Assemblies of People's Power." 
Maria Ducas Megret was elected to both the Municipal 
Assembly in Havana and the National Assembly representing 
the Marianao municipality, a neighborhood in west Havana 
where she lives.</p>

<p>"Our aim was to create a structure that would be closer to 
the population so that we could be more effective in helping 
solve the problems faced by the people," she said as she led 
my interpreter and me on a walking tour of her district.</p>

<p>Judging by the reception Ducas received from her 
constituents, Cuba's brand of grassroots democracy is 
working well. Everyone seemed to know her and rushed to 
embrace her.</p>

<p>Dominating Marianao is a sprawling former military base, the 
Columbia Fortress, built by the U.S. after the defeat of 
Spain in 1898. When Cuba's Revolutionary Army liberated 
Havana in January 1959, this was dictator Fulgencio 
Batista's last stronghold.</p>

<p>After it fell, the fort was renamed Ciudad Libertad (Freedom 
City). The barracks were converted into schools, a newly-
constructed pediatric hospital, day care centers and a 
senior citizen center. Also located here is a teacher's 
college and Cuba's School of Fine Arts.</p>

<p>The afternoon we visited, it was teeming with children 
enjoying after-school programs - sports, art, music and 
dance. Some children were demonstrating their skills with 
watercolors and pastels. Others were working with clay 
fashioning plates and bowls. A chorus of Young Pioneers sang 
patriotic songs and performed group dances.</p>

<p>Gretel Gil, 12, showed me the plate she had made with an 
excellent likeness of Jose Marti glazed into its surface. 
"Jose Marti made speeches in Tampa and New York City calling 
for Cuba's independence," she told me. "He died fighting for 
freedom because we were ruled first by Spain and then the 
U.S."</p>

<p>Maria Ducas took us to a residential neighborhood in 
Marianao where a group of volunteers, with the assistance of 
an architect and journeyman construction workers, built 
their own cinderblock apartment building, the Pilar House. 
Materials to construct the house were provided by the 
government.</p>

<p>The housing shortage is so acute that every one of the eight 
apartments is already furnished, decorated and occupied. The 
roof is a spacious patio that commands a panorama of the 
entire neighborhood. People from throughout Havana are now 
coming to learn the Marianao brigade's building methods.</p>

<p>We walked two blocks to the home of Rita Rios, another 
neighborhood activist. It was after dark by now but the 
house was packed with community residents who had gathered 
to welcome me. It included artists who use the Rios home as 
an art gallery and children who are studying dance at a 
neighborhood ballet school.</p>

<p>Several years ago, Rios learned that the celebrated Cuban 
artist Wifredo Lam had lived in her home from 1941 to 1945 
and had painted some of his greatest masterpieces there. 
Rios launched a campaign to restore the house. </p>

<p>Residents have joined in the campaign - typical of the type 
of grassroots initiative the "Assemblies of People's Power" 
seeks to stimulate. "The revolution gave me this house and I 
decided that I must give something back," Rios told me. "I 
am a revolutionary."</p>

<p>Havana's Spanish-style mansions date as early as the 16th 
century. They are decorated with fluted marble columns, 
ornate lintels and arches, wrought iron, stained glass and 
graceful porticos. The beauty is compounded by the lush 
semi-tropical vegetation-palm trees, blooming hibiscus and 
bougainvillea.</p>

<p>The climate is so balmy that few houses have glass windows. 
Most are fitted with louvered shutters. Open them and soft 
breezes warmed by the Gulf stream flow through the houses on 
a November afternoon. Yet many of Havana's lovely dwellings 
are crumbling because of shortages of building materials. </p>

<p>Here, too, I found a determined fightback. I went to the 
Maqueta de la Capital (Model of the Capital) in the Miramar 
municipality of Havana. This is a vast room-sized model of 
the city which enables the people to get a bird's-eye view 
of their city. Miguel Coyula, an architect who works with 
the Group for the Reconstruction of the Capital, a designer 
of the model, told me they are drawing up a plan for the 
restoration of the city, in part to make Havana a premier 
destination for tourism.</p>

<p>"Havana is a living museum," he told me. "The elite did not 
destroy their homes to build new ones. They simply abandoned 
them and moved further west. Now they live in Florida. So 
all the architectural monuments of the past are still 
standing, ready to be restored."</p>

Already, reconstruction has begun in Old Havana. "Part of my 
job is liaison with neighborhoods, to encourage the people 
who live there to join in the effort to restore their 
communities."</p>

<p>I told him we had just visited Wifredo Lam's house in 
Marianao. "Oh," he exclaimed, his eyes brightening. "Did you 
meet Maria Ducas? She is wonderful! The Wifredo Lam house is 
the kind of restoration project we are trying to encourage."</p>

<p>I traveled to the Antero Regalado cooperative farm near San 
Antonio de los Banos where Israeli-designed cultivation 
houses are used to produce big succulent tomatoes - part of 
the drive to dramatically increase the supply of vegetables 
for the Cuban people. Here, too, the "Si se puede" principal 
was in force.</p>

<p>There are no spare parts for the cooperative's fleet of 
aging Soviet tractors. Nivalbo Ortega, president of the co-
op, showed me the machine shop with an aging turret lathe, 
drill press, and other machine tools where they manufacture 
spare parts. "Before the revolution, we had millions of 
hectares of land that served only the needs of the wealthy," 
he told me. "Now our task is to guarantee a balanced diet 
for the Cuban people."</p>

<p>The 283-hectare co-op with 140 members produces vegetables 
that are sold to Acopio, the state agricultural marketing 
monopoly for distribution. Some of the tomatoes are 
earmarked for the restaurants in Cuba's spanking new hotels 
- part of the integrated economic complex to serve Cuba's 
new tourist industry.</p>

<p>The Saturday before my departure, I was driven 100 miles 
east to Varadero Beach, its white sandy peninsula curving 
for miles into the Florida Gulf. Warmed by the Gulf stream, 
the water's are a brilliant turquoise blue.</p>

<p>The DuPont family once owned much of Varadero and their 
mansion is still standing. But the commanding presence in 
Varadero today is the Cuban Communist Party. A big sign on 
the facade of the modern party headquarters proclaims 
"Patria o Muerte."</p>

<p>Armando Castaneda and Osmany Almeida, two regional Party 
leaders, are assigned to oversee this bold foray into joint 
ventures with foreign corporations. Spanish, Italian, 
German, French, Canadian and Mexican corporations have 
flocked to Varadero. Jointly with Cuba they have built a 
necklace of five-star luxury hotels along Varadero Beach 
that are now filling up with thousands of tourists from 
Canada, Latin America and Europe.</p>

<p>So far, 8,000 hotel room have been completed by 10,000 Cuban 
construction workers. Another 20,000 workers are employed in 
other parts of the tourist industry in Varadero. Profits are 
split 50-50 and Cuba retains ultimate ownership of the 
properties.</p>

<p>"DuPont owned much of this and now the DuPonts are claiming 
it under the Helms-Burton law," said Castaneda with a 
chuckle. "The U.S. is losing, of course. The longer the 
blockade exists, the more behind they get. When they awake 
from their dreams, there won't be any space left for joint 
ventures with U.S. companies."</p>

<p>It is not possible to take the measure of a nation and its 
people in one brief week. Yet there were so many poignant 
impressions I took home with me. I did not hear a single 
angry exchange between Cubans in the streets despite all the 
obvious hardships they face.</p>

<p>Cuba is a remarkably multiracial society with Black, white 
and brown peoples living and working side-by-side. There is 
none of the racist segregation that divides our 
neighborhoods and schools.</p>

<p>Pedro Ross Leal, a Cuban of African descent, is the 
president of the Cuban Labor Federation, a member of the 
ruling Council of State (equivalent to a cabinet minister). 
He granted me an interview and then took me to a celebration 
of the 35th anniversary of the founding of Cuba's Public 
Employees Union.</p>

<p>As we entered the meeting hall, he handed me a lapel button. 
It read, "Yo creo en la solidaridad" (I believe in 
solidarity). The buttons had been sent by a sister union in 
Puerto Rico. Solidarity seems to be a way of life in Cuba 
and a big rock in the way of those who would destroy the 
Cuban people's power.</p>

<p><strong>NEXT: A Visit to Cuba's Center for Genetic Engineering and 
Biotechnology</strong></p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-258</DOCNO>
<DOCOLDNO>IA027-000294-B002-393</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-09-2.html 206.119.5.80 19970120071425 text/html 9833
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:21:09 GMT
Last-modified: Sunday, 10-Nov-96 02:26:48 GMT
Content-length: 9651
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Tim Wheeler - The global pillage: Whose 'world economy' is it,
anyway?</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>The global pillage: Whose 'world economy' is it, anyway?</h1>
<h2>by Tim Wheeler</h2>

<p><em>This article was reprinted from the <strong>November 9,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p>NAFTA and the World Trade Organization (WTO) are tools with which
powerful corporations manipulate the "free market" to control the
flow of goods and money around the globe. The terms of these
treaties are subject neither to local nor to national law but to
the decisions of their boards of directors which answer to
corporate masters. The same may be said of the World Bank (WB)
and the International Monetary Fund (IMF). </p>

<p>These institutions determine who receives how much credit and
when - conditional on the implementation of neoliberal policies
specified by the suppliers of capital - again the powerful
transnational corporations. When loans are contingent on the sale
of natural resources and the privatization of state enterprises
with the corresponding dismissal of public workers, countries
become unable to develop their own economies and their burden of
debt increases until it is, for all intents and purposes,
unpayable. Burdened with debt and unable to make long-term
investments in their own futures they are obliged to import the
basics of life. Corporate concentration of capital thus proceeds
apace, dividing us into a shrinking world of privilege astride a
huge and growing world of abject poverty. Unless public
boundaries are placed on this flow of private capital,
concentration will continue and at its end is disaster, as surely
for the fortunate few, as for the oppressed billions. </p>

<p>That the world's governments and leaders are not unaware of this
disastrous course of events was evidenced at the World Summit for
Social Development held in Copenhagen, Denmark in March 1995.
Present for the largest gathering of world leaders held until
that time, 117 heads of state "pledged to make the conquest of
poverty, the goal of full employment, and the fostering of
stable, safe and just societies their overriding objectives." The
over 14,000 people who participated in the summit included
representatives of 186 countries and 811 non-governmental
organizations and some 2,800 journalists. </p>

<p>Because over one billion - 20 percent - of the people on earth
live on the equivalent of less than $1 a day, the summit
governments declared 1996 the International Year for the
Eradication of Poverty and committed themselves to that goal in
the summit's Declaration and Programme of Action. </p>

<p>Each government pledged to develop a national poverty eradication
plan that would promote sustained economic growth in a framework
of "sustainable development and equal opportunity." The plan
would expand productive employment, using policies for full,
decently paid and freely chosen work. </p>

<p>The governments pledged to protect human rights and promote
social integration, committing themselves to halting today's
extreme social polarization and burgeoning urban shantytowns and
to ending the illicit trading in arms, drugs and in human beings,
especially women and children. They committed themselves to work
toward attaining gender equality and equality before the law,
toward ensuring access to control over economic and social
resources and activities to disadvantaged and vulnerable groups
and to protecting the rights of the indigenous. Finally, they
agreed to strengthen cooperation for their social development
plans through the United Nations. </p>

<p>Each year the U.N. issues a Human Development Report in which it
quantifies national development according to an Index with three
key components: longevity, measured by life expectancy at birth;
knowledge, based on literacy rates and schooling; and standard of
living, measured by purchasing power based on Gross Domestic
Product (GDP) per capita adjusted for cost of living. </p>

<p>Seen in this framework the aims of the Copenhagen Summit include:
primary health care, particularly of women and children; family
planning services including prenatal care; safe drinking water
and an end to malnutrition; universal and equitable access to
education for all children with particular attention to schools
in rural areas, and to the children of migrant or nomadic peoples
and the indigenous; and increased adult literacy, particularly of
women. </p>

<p>At the end of the summit meeting the governments also committed
themselves to ratifying and implementing the 1990 Convention on
the Rights of Children. These pledges must now be ratified and
implemented in each country. Only action on the part of local
grassroots organizations will exert the pressure necessary to
obtain ratification in each country. </p>

<p>The riches to resolve these problems are clearly not lacking. To
raise the requisite funds some of the following might be
considered: </p>

<p>A transaction tax on speculative foreign exchange. This "betting"
on the futures of currencies and international notes moves $1
trillion in the world's financial markets every day - more than
the value of all the purchases and sales combined. Such a tax
would slow purely speculative capital investment; the trading
firms dealing in precisely such transactions generate more income
than any other "industry." First proposed by James Tobin, 1991
Nobel Prize Winner in Economics, an 0.5 percent tax would
generate over $1.5 trillion a year. </p>

<p>A globally agreed-upon limit to the interest specified for
international loans made to developing countries. This would make
credit more readily available to those who most need it. Loans
should not be contingent of the sale of state-owned enterprises
or land, rermoving subsidies on food or the dismissal of public
workers. </p>

<p>The complete cancellation of the foreign debt of developing
countries has been suggested and some debt has, in fact, been
forgiven. Complete cancellation is not likely, given the
intransigence of transnational corporations and the international
financial agencies such as the World Bank and International
Monetary Fund. However cancellation of the interest payments due
on those debts should be considered. The money thus released
could be earmarked for social development. </p>

<p>A globally agreed-upon rate for the taxation of profits taken out
of developing countries. Three quarters of this tax could revert
to the developing country; the remaining quarter could be
directed to a world body such as the UN's Food and Agriculture
Organization, or its Children's Fund or to a U.N. operating fund. </p>

<p>Each nation should commit itself to cutting its military and arms
budget until that budget reaches no more than ten percent of its
total national budget. In 1992, world military spending - $815
billion - equaled the combined income of 49 percent of the
world's people. A mere 3 percent annual reduction in this
spending would yield a "peace dividend" of nearly $460 billion by
the year 2000. In his Agenda for Peace, U.N. Secretary General
Boutros Boutros Ghali proposed a tax on the defense budgets of
industrial nations to finance the U.N.'s emergency peacekeeping
fund. </p>

<p>Parallel to those cuts, the nations which possess nuclear
stockpiles should commit themselves to cutting those stockpiles
by half each year for 10 years after which the remaining
stockpiles should be completely destroyed. Part or all of the
money recovered by these two measures could be channeled to an
international development fund so that the world's people could
truly "beat their swords into plowshares." </p>

<p>Since capital flows freely across national boundaries in search
of opportunity, labor must be able to do likewise. Developed
nations must reach agreements with developing nations for the
provision for workers who migrate from the latter to the former
in search of employment. At the same time, the world's nations
must agree to a minimum standard for wages. </p>

<p>The implementation of these last two measures ought to be seen as
goals: they will only be possible when the previous points have
been addressed and implemented. That they will be depends on just
how firmly we believe that where there is a will there is a way.
As has so often been said, it is not money which is lacking but
political will. </p>

<p><i>-Julia Lutsky contributed to this article</i>. </p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-259</DOCNO>
<DOCOLDNO>IA027-000294-B002-325</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-02-3.html 206.119.5.80 19970120071335 text/html 10094
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:20:00 GMT
Last-modified: Sunday, 03-Nov-96 21:03:21 GMT
Content-length: 9912
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Tim Wheeler - Campaiging against the corporate agenda</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Campaiging against the corporate agenda</h1>
<h2>by Tim Wheeler</h2>

<p><em>This article was reprinted from the <strong>November 2,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>NEW YORK</strong> - When David Mirtz finishes his daily shift as a 
Manhattan UPS driver, he hits the streets of the Bronx 
seeking votes in his campaign for the New York State 
Assembly. He hammers away with his slogans, "People before 
profits! Tax the rich! Rebuild the Bronx!"</p>

<p>In a city torn by poverty, unemployment, homelessness, crime 
and drugs, Mirtz, 31, who lives in a Bronx Co-op with his 
family, is the true messenger of hope. He is the candidate 
of the Communist Party USA to represent New York's 80th 
assembly district. More than 3,000 voters signed petitions 
to place him on the ballot and Mirtz' campaign workers have 
signed up 700 new voters.</p>

<p>Early in his campaign, Mirtz spoke at an AFL-CIO "America 
Needs a Raise" rally at Hostos Community College in the 
Bronx. "When I introduced myself as a candidate of the 
Communist Party USA, you could hear a pin drop," Mirtz said 
with a chuckle. "I told the crowd that a $5.15 an hour 
minimum wage is a step in the right direction but it is not 
nearly enough. I got a great response. People clapped and 
cheered."</p>

<p>New York's public schools opened this fall with reports of 
overcrowding so extreme that classes were crammed into 
closets and lavatories. Mirtz, newly-married and concerned 
about quality education, convened a sidewalk news conference 
in front of P.S. 20 in the Bronx. "We have a state of 
emergency in the schools," Mirtz told the crowd as reported 
in the Riverdale Press, Sept. 26. "The city and state should 
make funds available to do things now. Vouchers and sending 
1,000 kids to Catholic schools are just distractions," he 
added, referring to New York's Republican Mayor Rudolph 
Giuliani's panacea for dealing with the crisis.</p>

<p>Mirtz lashes Republicans for their drive to terminate 
welfare and other benefit programs. He scorns the GOP pleas 
that the public till is empty in a city with Wall Street 
banks crammed with tens of billions in profits. "All the 
talk about cutting back and downsizing - that's the 
corporate agenda," Mirtz told the news conference.</p>

<p>By coincidence, the incumbent Democratic assemblyman, 
Jeffrey Klein, showed up during Mirtz' news conference. 
BronxNet, a local cable news channel, broadcast a full 
report quoting both Mirtz and Klein. "Just knowing that we 
are in the race changes the political spectrum. We bring out 
much more clearly what is at stake in these elections." 
Mirtz told this reporter.</p>

<p>This is Mirtz' second run for office. In 1992 he ran as a 
Tax-the-Rich independent for the State Assembly to represent 
part of Harlem and Washington Heights, a section of 
Manhattan where he grew up. He attended Hunter College and 
was a leader of the citywide shutdown in 1989 of the City 
University of New York (CUNY) in protest against a $200 
increase in tuition. "We won that fight," Mirtz said. He 
joined the Young Communist League and the Communist Party. 
Later he was elected national coordinator of the YCL.</p>

<p>Mirtz said his ballot petitioners this past summer ran into 
more surprise than anti-communism. "One of our comrades 
distributed my campaign brochure in the Co-op where we 
live.The next morning a neighbor came up a bit breathless. 
'There's a guy running for the State Assembly as a 
Communist! Isn't that terrific?'"</p>

<p>Many older people, he said, remember the Party from years 
past. "But many younger people are hearing about the Party 
for the first time. It's such a step up when people know 
that there is a Communist Party organization in the 
neighborhood, that we are active on all the basic issues."</p>

<p>It includes even the Yankees' recent World Series victory 
which has turned the city, and especially the Bronx, 
delirious with joy. Mirtz is a Yankee fan who rejects 
proposals to move the team into a new stadium in Manhattan. 
"Yankee Stadium is the 'house that Ruth built,'" he said, 
referring to the legendary Yankee slugger, Babe Ruth. 
"[Yankee owner George] Stein-brenner's push to move the team 
out of the Bronx reflects his greed and disregard for the 
people of New York and history."</p>

<p>Mirtz was a panelist at a candidates forum at St. Brendan's 
Roman Catholic Church in the Norwood neighborhood recently. 
"This is a mainly Catholic white working class section," he 
said. "They were very 'pro-life.' But on other issues such 
as the budget cuts and helping the poor, this was not a 
right-wing crowd at all. Someone asked me about the Party's 
attitude toward religion. I told him our conflict is not 
with religion or God, but with capitalism."</p>

<p>Mirtz made his pitch for the defeat of the Republican ultra 
right. "When I got home there was an e-mail message from one 
of the participants telling me I had three votes - hers, her 
husband's and one of the other panelists. Her message said, 
'Your candidacy has made it worthwhile to go out and vote.'"</p>

<p>No wonder voters are sick and disheartened. In a cynical 
maneuver, the Republican and Demo-cratic machines in the 
Bronx made a deal: in exchange for support on certain 
legislation Democrats agreed not to challenge incumbent 
Republican State Senator Guy Velella, whose district 
encompasses much of the 80th. "This is a right-wing 
Republican the Democrats should have targeted for defeat. 
Instead they nominated Velella on the Democratic line. We 
are the real alternative to the right-wing extremists in the 
Bronx."</p>

<p>Rich Giovanoni, who serves as treasurer of Mirtz' campaign, 
said Mirtz is an effective candidate with a good speaking 
style, a quick wit and a mastery of the issues. But more 
than that, Mirtz is the most visible candidate. "What we 
notice most is that we are the only ones out campaigning on 
the streets here. There's no one else," Gio-vanoni said.</p>

<p>"They're having a get-out-the-vote rally at the Allerton 
Coops [housing project] this Saturday. The Tenants 
Association is a sponsor, Giovanoni added." Among the 
speakers at the rally will be Kathy Ciner, the president of 
Communications Workers of America Local 1105, Janice 
Walcott, who is the president of the Tenants Associa-tion, 
Mirtz and Jeffrey Klein, the incumbent. </p>

<p>Mirtz speaks with passion when he appeals to Communist Party 
organizations across the country to field more candidates in 
future elections. "There's no substitute for the CPUSA 
running its own candidates," he said. "We have spoken to 
tens of thousands of people. There are so many people who 
want to know about the Party and what we stand for. This is 
a chance to tell people what we're all about.</p>

<h2>A working people's program for the Bronx</h2>

<h3>Put the Bronx back to work</h3>

<p>Layoffs, unionbusting, poverty wages and part-time jobs is 
Big Business' agenda for working people. People need jobs at 
a living wage to live decent lives. We need a public works 
jobs program to rebuild New York at union wages with 
affirmative action guidelines. Double the minimum wage and 
guarantee the right to organize. Outlaw scabs. Protect 
workers' pensions and compensation.</p>

<h3>Tax the rich to fund people's needs</h3>

<p>End welfare for the rich and Big Business, not the people. 
Close tax loopholes and raise corporate taxes and taxes on 
the rich. Halve the tax rate of those who earn less than 
$50,000.</p>

<h3>Save our youth</h3>

<p>Curfews may keep kids off the streets but it won't give them 
a future. We must take emergency steps to save our youth. 
Defend public education. Full funding for public schools, 
recreational and cultural facilties, after school and youth 
job programs. Restore free tuition at the City University of 
New York.</p>

<h3>End Racism - Equality for all</h3>

<p>We need civilian control of the police to end harassment and 
attacks on Black and Latino people. Save affirmative action; 
only together can we beat the Big Business agenda that is 
impovering our communities.</p>

<h3>Healthcare for all</h3>

<p>We need free universal healthcare. Stop corporate 
profiteering at the expense of the elderly and sick. Stop 
the privatization of public city hospitals. Save Medicaid 
and Medicare.</p>

<h3>Housing is a right.</h3>

<p>Stop skyrocketing rents. Stop landlords warehousing 
apartments and violating building codes. Build affordable 
quality public housing. Reduce property taxes on small home 
owners.</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-260</DOCNO>
<DOCOLDNO>IA027-000294-B003-145</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-23-3.html 206.119.5.80 19970120071720 text/html 14390
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:23:59 GMT
Last-modified: Saturday, 23-Nov-96 15:46:38 GMT
Content-length: 14205
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Tim Wheeler - Wimpy</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Wimpy</h1>
<h2>by Tim Wheeler</h2>

<p><em>This article was reprinted from the <strong>November 23,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>BALTIMORE</strong> - William W. Winpisinger, who served as
president 
of the International Association of Machinists (IAM) from 
1977 to 1990, now enjoys a blissful retirement,touring the 
nation with his wife, Pearl, in their motor home. When at 
home near Baltimore, "Wimpy" (as he likes to be called) 
often picks up his grandchildren after school.</p>

<p>Last summer, the Winpisingers traveled to Alaska. They were 
so impressed by the natural splendor of the state that 
Winpisinger was wearing a T-shirt decorated with the Alaska 
State logo when Communist Party Labor Commission Chairman 
George Meyers and I met him over breakfast recently.</p>

<p>Winpisinger may be retired but his influence is still felt 
in the labor movement. Many say he plowed the ground and 
planted seeds for the AFL-CIO's remarkable rejuvenation 
since its 1995 convention in New York City when John Sweeney 
was elected president in the labor federation's first-ever 
contested election. Linda Chavez-Thompson and Richard Trumka 
joined him as executive vice president and secretary- 
treasurer. "They've made the fur fly ever since," 
Winpisinger said.</p>

<p>Winpisinger is impressed. "I think they get an A-plus for 
their efforts," he said. "There has been a substantial 
energizing of the labor movement since they took over. 
Organized labor's efforts in the 1996 elections really stand 
out. That victory holds the promise of better things to come 
across a broad front."</p>

<p>Labor, Wimpy said, played a crucial role in the defeat of 
GOP presidential nominee Bob Dole and many Republican 
extremists in the House and Senate. "I knew the AFL-CIO was 
doing something right when [Republican Party Chairman] Haley 
Barbour and the rest of the Republican leadership started 
squalling about the $35 million the labor movement raised 
for its election activities. That is peanuts compared to the 
$262 million the corporations contributed to the 
Republicans, but it's the first competition they've had in a 
long time."</p>

<p>Winpisinger said labor should work to avoid open clashes 
with a second Clinton administration but added, "We're going 
to have to cajole the man in order to hold our own. I have 
seen very few instances where you go out and fight the good 
fight that you don't get some kind of results."</p>

<p>But Winpisinger has no illusions about the Democratic Party. 
He told us a story about the struggle during the Carter 
administration to pass Labor Law Reform. The AFL-CIO's 
efforts fell one vote short of the 60 votes needed to end a 
Senate filibuster and Florida's Democratic Senator Lawton 
Chiles promised to vote to end the debate. But at the last 
minute he reneged.</p>

<p>A few months later, Chiles came to the IAM seeking 
reelection help. "I told him we would give him just as much 
support as he gave us on Labor Law Reform." As long as the 
status quo continues, Winpisinger said, "we'll always be 
faced with the lesser of two evils because we never develop 
a candidate recruitment and training program where we put 
our own people in the field and try to elect them."</p>

<p>In this election, labor started to change that, setting up 
its own independent grassroots apparatus to support 
candidates who would challenge the Gingrich gang. "No matter 
where I was during this election year," he said, "you could 
feel labor's new vitality at the grassroots. That's 
contagious."</p>

<p>Winpisinger praised the Communist Party USA for its role in 
exposing and helping to defeat Dole and other right-wing 
extremists. "The Party played an important role in the 
elections this year," he said.</p>

<p>The Republican platform included immediate development and 
deployment of "Star Wars," a space-based weapons system, now 
supported by President Clinton. The system will cost at 
least $300 billion, the costliest in history, with Boeing 
and Lockheed Martin the prime contractors.</p>

<p>I asked Winpisinger for his views. "I don't know of a single 
scientist who says it will work," he said. "I used to debate 
a Reagan administration guy who was obsessed with Star Wars. 
The guy was a nut case." In the mid-1980s, Winpisinger spoke 
out strongly against the arms race and for economic 
conversion, a stand that enraged some IAM members at 
McDonnell Douglas. Winpisinger told us he made many trips to 
St. Louis to meet with the workers - and won them over.</p>

<p>"I asked them: 'What do we do when the government changes 
its mind? If it ever does, you're going to be the first ones 
axed. I think we ought to be prepared with a program of 
conversion to insure that you have jobs and income.' Now 
they sidle up to me: 'Wimpy, how did you know this was going 
to happen?' I didn't - but part of a union's job is to look 
ahead."</p>

<p>Winpisinger pointed to the immense increase in worker 
productivity in the past 30 years and to Bethlehem Steel's 
nearby Sparrows Point mill which once employed 30,000 
workers but now produces more steel with 5,700 workers. For 
Wimpy there's only one answer: "Reduce the hours of work, as 
they have already done in Europe," with no cut in pay.</p>

<p>Winpisinger hailed the AFL-CIO's America Needs a Raise 
campaign. "We need to use our power more judiciously than 
ever before - focus it very tightly and not go out with a 
scatter gun," he said. "We focused on the minimum wage and 
we won a victory. And it's not a selfish interest. It's 
across the board. We're portrayed as a special interest but 
I can't remember an issue that we've fought for that didn't 
advance the living standards of all the people."</p>

<p>The change in the AFL-CIO was not a surprise to Winpisinger 
who said it "came naturally. There was no preconceived plan 
for John Sweeney to emerge. The change was brought about by 
necessity."</p>

<p>Winpisinger pooh-poohs suggestions that he got the ball 
rolling. "All I did was speak my piece," he said. "I felt 
that the labor movement had stagnated because the leadership 
became too complacent. They didn't want to take a chance on 
anything. Life is really a crap game and if you risk 
nothing, you gain nothing."</p>

<p>Winpisinger, an accomplished stump orator with a sharp 
tongue and keen wit, unleashed one broadside after another 
on the delusions peddled by class collaborationist labor 
leaders after he was elected IAM president in 1977. Rank and 
file workers loved his irreverent speaking style. Much of 
Winpisinger's thinking is reflected in his 1989 book, 
"Reclaiming the Future - An Agenda for American Labor" 
(Westview Press, 5500 Central Ave. Boulder, CO 80301). Based 
on Winpisinger's many speeches, the book burns with anger 
against the the Fortune 500 and their agents in government 
who unleashed a brutal drive to impose a "union free 
environment" and covered it with soothing cliches about 
"labor-management partnership."</p>

<p>In the chapter, "Labor Relations Today," Winpisinger writes, 
"You don't need to be a Marxist to observe that the conflict 
between capital and labor is as old as the history of the 
world ... In the last decade, class war has been declared 
not by trade unions or working people on their employers but 
by our employers and recently by our government on us."</p>

<p>For Wimpy, born in Cleveland, Ohio, on Dec. 10, 1924, 
militancy came early. His father was a union typographer at 
the Cleveland Plain Dealer. "I can remember as vividly as 
yesterday when I was 10 years old, my father coming home 
from night shift with the morning edition of the Plain 
Dealer. It had a picture on the front of a mountain of 
potatoes that was being bulldozed somewhere down in Georgia 
- and this in the depths of the Depression and people were 
starving." Winpisinger recalled, "I said to myself, 'What a 
crime! Why not distribute those potatoes to hungry people?' 
And the answer was: You couldn't do that! It would be 
socialism! I became a socialist - not a doctrinaire 
socialist but a seat-of-the-pants socialist."</p>

<p>Now, he said, "we've come full circle - back to the 
situation where the gap between rich and poor is becoming 
wider and wider. They are driving us into a corner and we 
will fight!"</p>

<p>When Winpisinger delivered speeches along those lines in the 
late 1970s, he was greeted by millions of working people 
across the country - yet at the leadership level, his was a 
lonely voice. Then came Ronald Reagan. "Reagan showed people 
what can happen when you've got a despotic s.o.b. in the 
White House," Winpisinger said. "Reagan gets a lot of credit 
for labor's resurgence - unwitting I'm sure, because 
Corporate America didn't believe we could do it. These birds 
are full of hops and are always ready to write our obituary.</p>

<p>"I constantly told people before I retired that there is a 
future for this movement. Without it, everybody is helpless 
before the absolute workplace power of the boss."</p>

<p>There were many harbingers of the things to come during the 
Reagan-Bush years, he said. Reagan's mass firing of the 
Professional Air Traffic Controllers (PATCO) in August 1981 
was one. The AFL-CIO Executive Council was meeting in 
Chicago the morning after the PATCO strike began.</p>

<p>PATCO had endorsed Reagan in the mistaken view that he would 
go easy on them should they strike. Nor had the union 
consulted with the AFL-CIO before walking out. Nevertheless, 
when the walkout and mass firing took place, Winpisinger 
announced that he would support the solidarity walkout 
provided it was an across-the-board walkout. But no one else 
on the executive council picked up on this proposal for what 
would have amounted to a general strike. Rather, the most 
conspicuous action by the AFL-CIO was Solidarity Day in 
which more than half a million trade unionists marched up 
Constitution Ave. on Sept. 19, 1981 with PATCO leading the 
way. Next in line was a huge IAM contingent carrying a curb-
to-curb banner reading, "Jobs Not Bombs."</p>

<p>"It was militancy rearing its head," Winpisinger said. 
"People wanted a more action-oriented labor movement."</p>

<p>Major strike battles followed - the Pittston Coal strike, 
Ravenswood and, more recently, strikes at Boeing, McDonnell 
Douglas and Bridgestone-Firestone. "Grassroots support 
developed for these strikers," he said. "It convinced 
everybody that the will was there. It was a question of 
getting it organized." A source of "disrepute" for labor in 
years past, according to Winpisinger, was "intramural 
warfare when we should have been fighting the boss." He was 
referring to unions competing for members, raiding each 
other and even in some cases crossing each others 
picketlines. Now, he said, the labor movement is entering a 
period of increased solidarity and joint action. That, in 
turn, is promoting the idea of mergers, the biggest of all 
the proposed amalgamation of the IAM with the United Auto 
Workers and the United Steel Workers of America.</p>

<p>Winpisinger told us that he and then-UAW President Douglas 
Fraser had opened talks on a merger back in the mid-1980s. 
When Owen Beiber succeeded Fraser, the talks were halted. " 
Then a few years later, Beiber came up to me and said, 'Hey, 
it's time to talk about a merger.' I told him, 'We never 
stopped talking about it. The ball is in your court.'"</p>

<p>Winpisinger said the unification into one union of 
machinists, autoworkers, steelworkers, rubber workers and 
glass workers is "a monumental task but it will be something 
to behold if they can bring it off. For the first time, we 
will be able to look at our biceps and say, we're not a 
mosquito bite anymore. It's about time that when we sit down 
at the bargaining table we have a howitzer as big as 
theirs!"</p>

<p>As he drained the last of his coffee, Winpisinger turned 
philosophical. "There's no question that the old leadership 
got in a rut and couldn't get out because they didn't have 
enough confidence in the American worker. People are not 
likely to join a powerless organization. If they pay union 
dues, they want a union." Then, his voice taking on the tone 
that that still inspires unionists, he added, "This economy 
is driven by the price-gouging of the entrepreneurs, not by 
wages. Wages have fallen behind and not enough is being done 
to make it up. Now we're beginning to talk about it.</p>

<p>"I see a determination at the grassroots level to get new 
members enrolled. And if that relentless pressure is kept 
on, the movement will grow. If we do our work right, it will 
attract people like honey attracts bees. We're demonstrating 
the ability to get in and mix it up to accomplish labor's 
fundamental goals."</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-261</DOCNO>
<DOCOLDNO>IA027-000294-B004-103</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-12-14-2.html 206.119.5.80 19970120072003 text/html 4259
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:26:46 GMT
Last-modified: Wednesday, 18-Dec-96 22:43:57 GMT
Content-length: 4074
Content-type: text/html
</DOCHDR>

<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Les Bayless - Clinton 'security team' signals more of the same</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Clinton 'security team' signals more of the same</h1>
<h2>by Les Bayless</h2>

<p><em>This article was reprinted from the <strong>December 14,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>WASHINGTON</strong> - President Clinton appointed a new "national 
security" team last week, tapping U.N. Ambassador Madeline 
Albright as secretary of state and Republican Senator 
William Cohen of Maine as defense secretary.</p>

<p>As part of the "shake up," Clinton also appointed national 
security advisor Anthony Lake CIA chief and Lake's deputy, 
Samuel Berger, to the national security council job.</p>

<p>The appointments, which are subject to Senate confirmation, 
received praise from Democrats and Republicans, including 
Jesse Helms of North Carolina, who called for a new spirit 
of bipartisanship. Peace forces, however, took a different 
view of the appointments.</p>

<p>Vice-Admiral John Shanahan, director of the Center for 
Defense information, said secretary Cohen would be "nibbling 
around the margins of the defense budget, rather than taking 
a serious look at reducing spending."</p>

<p>"I would like to think that the new secretary of defense 
would come up with a plan to reduce expenditures at least 
$50 billion. I sense that what will happen, however, is that 
expenditures will be kept at current levels," he said in a 
telephone interview.</p>

<p>Shanahan pointed to new military aircraft already in the 
authorization stage, including the F-22, the F-16 and the 
so-called "joint strike fighter" - which will cost $360 
billion to design and manufacture - as "unnecessary 
expenditures" that benefit only defense contractors.<p>

<p>"It's no secret that companies like Lockheed and Boeing 
[which will build the new aircraft] have too much influence 
on Congress," Shanahan told the World. He said the American 
people want more spending on health care and education and 
"according to a recent poll, 70 percent want to spend less 
on the Pentagon."</p>

<p>Cynde Nordone, a Catholic nun who directs a local chapter of 
Jobs with Peace, sees the appointments signaling business as 
usual in Washington. "Unfortunately, I've not heard or seen 
anything yet [from Clinton's new team] that would indicate a 
resolve to reduce military spending," she said.</p>

<p>Nordone is a member of the School Sisters of Notre Dame, an 
order which works with poor women in Baltimore. She agrees 
with Shanahan that money should be taken from military 
spending and put into domestic programs.</p>

<p>The appointment that has received the most attention is that 
of Albright. She is said to be fervently anti-Cuba, which 
explains the warm endorsement she received from Jesse Helms. 
Albright is not generally liked in the U.N., where she has 
spearheaded the effort to dump popular secretary-general 
Boutros Boutros-Ghali.</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-262</DOCNO>
<DOCOLDNO>IA027-000294-B003-175</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-30-1.html 206.119.5.80 19970120071742 text/html 8101
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:24:19 GMT
Last-modified: Sunday, 01-Dec-96 01:04:24 GMT
Content-length: 7919
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Daniel Vila - Fram Workers union to organize strawberry workers</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Farm Workers union to organize strawberry workers</h1>
<h2>by Daniel Vila</h2>

<p><em>This article was reprinted from the <strong>November 30,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>NEW YORK</strong> - The United Farm Workers and the AFL-CIO have 
launched the biggest organizing drive of an industry in 40 
years as they begin a united effort to unionize 20,000 
strawberry pickers. Those who work the strawberry fields 
work as many as 12 hours a day stooped over in the mud for 
an average of $20 a day.</p>

<p>The "National Strawberry Commission for Worker's Rights," a 
coalition of more that 40 national organizations, has held 
press conferences in Washington, New York, Boston, Baltimore 
and other cities to build support for the pickers across the 
country.</p>

Times are good for the strawberry industry with record sales 
of over $650 million and production topping a billion 
pounds. The growers are concentrated in California but the 
strawberry industry is dominated by eight giant corporations 
which buy, "cool," market and distribute the product around 
the globe.</p>

<p>"Coolers" tell the growers what type and amount of 
strawberries to grow, and even the type and amount of 
pesticides to use in the process. Strawberries picked in 
California end up as far away as France and Japan.</p>

<p>Per capita consumption of strawberries has grown from three 
pounds in 1974 to five pounds in 1994. Today strawberries 
are the fifth largest-selling crop in the country. If growth 
continues at its present pace - doubling between 1971 and 
1980 and again between 1981 and 1990 - the industry would 
gross $1.1 billion by the year 2000 and $2 billion by 2010.</p>

<p>The strawberry companies also receive help from their 
friends in government. Last year the federal government 
contributed close to $500,000 to subsidize the industry's 
overseas marketing. And the California Strawberry 
Commission, which consists of growers, shippers, processors 
and one public member, levies a tax on the industry which 
last year netted $4.5 million to be invested in the industry 
in the form of marketing and research. Recently, however, 
the companies have used part of this money to fight off 
accusations and improve their public image through 
advertising in the media.</p>

<p>For the workers, on the other hand, the fruit of their labor 
has not been so sweet. The average picker earns $8,500 per 
season. But this is only an estimate since some are paid by 
the hour, others by the crate and still others by a 
combination of both methods. Piece rates are often less than 
minimum wage and no premium pay for overtime.</p>

<p>When inflation is considered, the income of strawberry 
workers, who have not had a considerable raise in a decade, 
has plummeted between 25 and 53 percent. The cost of housing 
takes a considerable share of this income as dilapidated 
motels rent for $150-$200 a week.</p>

<p>The growers have various techniques for evading their 
responsibilities to the workers. Their favorite is having 
the pickers work as sharecroppers. This means they lease 
land to a person who turns over much of the crop to the 
field owner as payment for operating the field. Up to half 
of the state's strawberry workers are sharecroppers. But, 
sharecroppers must take whatever price is offered by the 
owner of the land and they often end up further in debt at 
the end of a season.</p>

<p>The sharecroppers, who are already under financial strain, 
often employ others who are legally the responsibility of 
the land owners. This situation increases the level of 
exploitation.</p>

<p>Another danger faced by the strawberry workers is 
pesticides. The rate of pesticides on strawberries can be up 
to 50 times that of grapes. The fields are covered with up 
to 300 pounds of pesticide per acre, more than any other 
crop in the state. More than four million pounds of methyl 
bromide is injected into the ground each year to fumigate 
the soil.</p>

<p>Methyl bromide has been linked to over 400 illnesses and was 
scheduled to be banned this year. But after heavy lobbying 
by the growers the California legislature delayed the ban. 
The Western Growers Association gave more than $30,000 to 
California Gov. Pete Wilson's campaign fund in 1994.</p>

<p>There are also widespread violations of state labor laws 
including child labor, sexual harassment, filthy - or no - 
bathrooms and no drinking water. Leobaldo Acosta, a 
strawberry worker from Salinas, Calif., said at the New York 
press conference on Nov. 21, "We have to work in the fields 
when it rains, in the mud and after accidents. We are not 
scared of working - we're just demanding a just wage. We 
have decided as farm workers that unity is the only way." 
Delfina Rodriguez, a mother of two, described how even after 
suffering a back accident she had to continue working to 
provide for her children.</p>

<p>The president of the New York City Central Labor Council, 
Brian McLaughlin, said at the conference, "We are not going 
to sit by as the companies buy off elected officials," and 
urged everyone to wage the type of grassroots campaign that 
brought victory to the grape workers.</p>

<p>Arturo Rodriguez, president of the United Farm Workers of 
America, called for a 5 cent increase in the price of a pint 
which consumers buy in stores which would result in a 
worker's salary being increased by 50 percent. The other 
demands of the union are clean drinking water and bathrooms, 
job security, health insurance, and an end to sexual 
harassment and other abuses.</p>

<p>Speaking at the conference in Washington, AFL-CIO President 
John Sweeney said, "Strawberry workers aren't on the bottom 
step of the economic ladder - they're not even on the 
ladder." Sweeney said African-American workers in Southern 
manufacturing plants, Asian Americans in sweatshops and 
restaurant workers are also on the same downward spiral. 
Calling for unity, he said, "Our fight is their fight and 
their fight is our fight." </p>

<p>A.L. Everett, president of the Texas Central Labor Council, 
told the World that they are also working with the national 
leadership supporting the campaign for justice for the 
strawberry pickers. The strategy of the UFW and AFL-CIO is 
to pressure the coolers to acknowledge that they control the 
industry and are accountable for the abuses they create and 
be encouraged to help improve conditions for strawberry 
workers. It is believed this pressure will convince the 
growers to negotiate a nationwide agreement which will 
improve the lives of the 20,000 workers.</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-263</DOCNO>
<DOCOLDNO>IA027-000294-B002-279</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-02-2.html 206.119.5.80 19970120071241 text/html 5584
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:19:13 GMT
Last-modified: Sunday, 03-Nov-96 21:03:17 GMT
Content-length: 5402
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Barbara Jean Hope - Study shows this election is life-or-death for
African Americans</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Study shows this election life-or-death for African Americans</h1>
<h2>by Barbara Jean Hope</h2>

<p><em>This article was reprinted from the <strong>November 2,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p>On Nov. 5, progressive people in the U.S. will be voting as 
if our lives depend upon it. For African American workers, 
the need to push back the racist, right-wing assault is 
indeed a life or death issue.</p>

<p>Racism in the U.S. is being pushed forward by the right wing 
to split our class unity. The racially oppressed, the 
targets of the right-wing racist assault, actually have our 
health imperiled by racism.</p>

<p>A recent study published by the American Journal of Public 
Health states that racial discrimination is seen as a major 
cause of high blood pressure in African Americans. Keeping 
anger and resentment bottled up, according to the study, is 
a key factor in why African Americans have higher rates of 
this life-threatening disease than white workers. High blood 
pressure is far more common in Blacks than in whites and is 
also more common to people, according to the report, of 
"lower social economic status."</p>

<p>More than 37 percent of Black men over the age of 20 have 
hypertension, compared with 25 percent of white men. More 
than 31 percent of Black women have the disease of 
hypertension, compared with 18 percent of white women.</p>

<p>The new study, conducted by epidemiologists at the Harvard 
School of Public Health and Kaiser Foundation Research 
Institute, is an eye-opener as to the insidious effects of 
racism and the human damage that the need to constantly 
battle that racism has on the African American population as 
a whole.</p>

<p>Nancy Krieger and Stephen Sidney questioned 4,086 men and 
women recruited in Birmingham, Ala, Chicago and Minneapolis 
as part of the Coronary Artery Risk Development in Young 
Adults (CARDIA) study. Participants were divided by race and 
sex. All were between 18 and 30 years of age when the study 
began in 1985.</p>

<p>According to Krieger, "Our study was intended to tell 
whether it makes a difference to ask questions about racial 
discrimination in order to help understand the variation of 
blood pressure among African Americans, and also to 
understand the Black-white differences in blood pressure. 
The answer is: It makes a difference."</p>

<p>Researchers asked if a person had ever experienced 
discrimination based on race and other variables such as 
"social class." The places in which African Americans were 
asked if they had experienced discrimination included 
school, on the job, while looking for work, while seeking 
housing, during medical care, on the street, or from the 
police or courts.</p>

<p>Overall, 77 percent of Black women and 84 percent of Black 
men reported experiencing racial discrimination in at least 
one of the seven specified situations. Nearly 50 percent of 
Black women and 60 percent of Black men reported 
discrimination in three or more categories.</p>

<p>Among Black working class men and women, those who reported 
"no racial discrimination" had systolic pressures 4 points 
higher on average than those who reported one or two 
episodes of discrimination. "No discrimination" was not 
taken on its face by the researchers, however. Instead, they 
saw that as evidence of "internalized oppression" in the 
response. That "internalized oppression" can clearly be seen 
as a factor that contributed to the higher blood pressure in 
those respondents.</p>

<p>While this study tells most of us nothing that we did not 
know beforehand - that racism kills - it is a point to 
ponder as we head toward Election Day. Among all the other 
solid working-class issues that demand that we vote to 
change the Congressional majority - to "boot Newt" and his 
gang of 73 - and to send Bob Dole into retirement, is simply 
to understand that the cost of having the right wing in 
place, dismantling affirmative action programs and affirming 
the right of racists to discriminate against African 
American workers in housing, health care and education is a 
cost too high to pay.</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-264</DOCNO>
<DOCOLDNO>IA027-000294-B003-216</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-30-2.html 206.119.5.80 19970120071804 text/html 5178
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:24:41 GMT
Last-modified: Sunday, 01-Dec-96 01:04:27 GMT
Content-length: 4996
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>ACLU files lawsuit to block Cal.'s Prop. 209</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>ACLU files lawsuit to block Cal.'s Prop. 209</h1>
<h2>Special to the World</h2>

<p><em>This article was reprinted from the <strong>November 30,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong></strong>SAN FRANCISCO - The ACLU affiliates in Northern and
Southern 
California - working with the Lawyers' Committee for Civil 
Rights, the Employment Law Center and a coalition of civil 
rights organizations - filed a lawsuit in federal district 
court in San Francisco last week to block implementation of 
Proposition 209.</p>

<p>Plaintiffs, which include a broad spectrum of business, 
education and civil rights groups and individuals, charge 
that the anti-affirmative action initiative, approved 
yesterday by California voters, violates the 14th Amendment 
and the Supremacy Clause of the United States Constitution.</p>

<p>"No statewide measure in American history has ever come 
close in scope or effect to Proposition 209's chokehold on 
state and local government," said Mark Rosenbaum, legal 
director of the ACLU of Southern California.</p>

<p>"The measure treats the unfinished business of rooting out 
discrimination as if it were none of the government's 
business," Rosenbaum said. "While the measure is 
breathtaking in its sweep, there is nothing new in its 
methodology which disenfranchises minorities and women from 
reliable and effective participation in our political 
process."</p>

<p>Plaintiffs argue that Prop. 209 violates the Equal 
Protection Clause of the Constitution because it would block 
legislation needed to protect minorities and women from 
discrimination. "While other groups may continue to pursue 
their interests in attaining preferential legislation and 
policies at every level of state and local government ... 
racial minorities, under Proposition 209, may now only do so 
by securing a popular majority and amending the state 
constitution."</p>

<p>"The anti-affirmative action law," said Ted Wang of the 
Lawyers' Committee for Civil Rights, "would prevent 
governments from eliminating ongoing, identified 
discrimination."</p>

<p>Alluding to Prop. 209's text of 37 words, attorney Judith 
Kurtz of Equal Rights Advocates said, "With just over 35 
words, Proposition 209 would negate 35 years of progress."</p>

<p>"This law turns back the clock on women's advancement," said 
Kathy Rodgers, executive director of the NOW Legal Defense 
and Education Fund. "Without affirmative action, women will 
once again lose critical opportunities for  economic 
equality."</p>

<p>Plaintiffs contend the initiative violates the Equal 
Protection clause by barring women and minorities from 
seeking protective race- or gender-conscious legislation 
when other groups are permitted to seek whatever 
preferential treatment they please. Further, plaintiff 
attorneys say that Prop. 209 prevents state and local 
governments from meeting their constitutionally-mandated 
duty to remedy discrimination against women and racial 
minorities.</p>

<p>"Proposition 209 would not only prevent states from adopting 
affirmative action programs designed to serve compelling 
interests, it would prevent them from fulfilling their 
constitutional duty under the Equal Protection Clause to 
redress past discrimination against minorities," court 
documents argue.</p>

<p>"Proposition 209 undermines enforcement of federal civil 
rights laws which depend upon voluntary compliance by 
government agencies, compliance which often requires 
affirmative action to undo the effects of prior 
discrimination," said Ed Chen, attorney with the ACLU of 
Northern California. "By outlawing all public affirmative 
action programs, the measure interferes with governmental 
efforts to comply voluntarily with federal civil rights 
laws."</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-265</DOCNO>
<DOCOLDNO>IA027-000294-B004-177</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-12-21-1.html 206.119.5.80 19970120072056 text/html 5969
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:27:22 GMT
Last-modified: Saturday, 21-Dec-96 16:11:24 GMT
Content-length: 5785
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Fred Gaboury & Wally Kaufman - Unions bring cheer to steel
strikers</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Unions bring cheer to steel strikers</h1>
<h2>by Fred Gaboury & Wally Kaufman</h2>

<p><em>This article was reprinted from the <strong>December 21,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>WARREN, Ohio</strong> - Unions across three states are raising
money 
and mobilizing their members to bring holiday joy to the 
families of some 4,500 members of five Steelworkers union 
locals who have been on strike against Wheeling-Pittsburgh 
Steel since Oct. 1.</p>

<p>Jerry Hartshorn, secretary of the grievance committee at 
Steelworkers Local 1375 here, said the local had filled 
three buses by midweek. "And we're taking $5,000 with us." 
Hartshorn told the World that $4,300 was collected at the 
plant gate of the Warren Consolidated Industries steel mill. 
"The local threw in enough to make it an even $5,000," he 
said.</p>

<p>Pointing to the victory that forced Bridgestone/Firestone to 
come to terms with the USWA after a bitter 27-month strike 
and lockout, Hartshorn said "W-P is the next battle the 
union has to win. We did it at Ravenswood Aluminum and here 
at WCI and we can do it there."</p>

<p>W-P forced the strike when management refused to fulfill its 
promise to reestablish a defined benefits pension plan and 
instead gave the union a "last, best and final" offer that 
would have allowed the company to gut insurance coverage and 
totally eliminate seniority, craft and contracting out 
protection.</p>

<p>On Dec. 4 the USWA sent a letter to the company reaffirming 
its willingness to resume negotiations "any time and 
anywhere" Wheeling Pitt "shows up willing to reach an 
agreement that does not destroy our union, does not gut our 
insurance program ... and does not line the already 
overflowing pockets of the vultures who control Wheeling-
Pittsburgh ..."</p>

<p>When informed of the plans of Local 1375, Jim King said USWA 
Local 1104 in Lorain, Ohio, had raised more than $2,000 in a 
plant gate collection and would be sending people to the 
Holiday Solidarity Rally in Steubenville, Ohio on Sunday 
afternoon, Dec. 22. He added that the "partnership" 
agreements that the union had signed with several 
steelmakers "may have weakened our ability to fight back."</p>

<p>King, who heads up the local's volunteer organizing 
committee, said the Wheeling-Pitt strike was a "very 
important strike" that the union "just had to win."</p>

<p>Steve Hega, vice-president of Local 1187, told the World 
that although pensions were important, "the other points are 
just as important. We just couldn't accept their offer."</p>

<p>Hega said Local 1187 pickets Wheeling-Pitt headquarters at 
least once a week. "We fill a bus and a couple of cars and 
go down there and hand out leaflets," Hega said.</p>

<p>Last week the union decided to change its tactics and sent 
union members into the office demanding to see the annual 
stockholder report.</p>

<p>"Every employee who owns even one share of stock has the 
right to see it. In fact, we each got a letter telling us of 
our right - only thing about it is that the print's so fine 
you can't hardly read it. But this year we got out a 
magnifying glass and read it."</p>

<p>When 50 union members entered the company office building 
with the demand to see the books, they were threatened with 
arrest. "But they backed down and we looked at the books," 
Hega said, laughing.</p>

<p>For Frank Ellis, president of the Ohio Valley Trades and 
Labor Assembly of Wheeling, W.Va., every union battle is 
everybody's fight. "We need solidarity - getting all unions 
together to fight back," he said. Then, pointing to the use 
of non-union labor by Wal-Mart, Sam's Club and Kroger to 
build a new shopping center on the Ohio side of the river, 
he said; "The battles at Wheeling-Pitt and to prevent use of 
scab are cut of the same cloth."</p>

<p>According to the USWA, production costs at Wheeling-Pitt are 
about half that of other domestic steelmakers. During a 
normal production day, union members at Wheeling-Pitt ship 
10,000 tons of steel to auto companies, heating and air 
conditioning manufacturers to producers of other steel 
products, including garbage cans.</p>

<p>Union officials point out that even if Wheeling Pitt signs a 
contract bringing its workers' pension into line with the 
rest of the industry, it will remain more profitable that 
other companies. When the strike began, the company had a 
nest egg of more than $400 million.</p>

<p><i>-Denise Winebrenner contributed to this story.</i></p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="../pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-266</DOCNO>
<DOCOLDNO>IA027-000294-B003-82</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-23-1.html 206.119.5.80 19970120071654 text/html 7512
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:23:33 GMT
Last-modified: Saturday, 23-Nov-96 15:46:29 GMT
Content-length: 7328
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Evelina Alarcon - Loretta Sanchez defeats ultra right-wing Dornan in
Cal.</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Loretta Sanchez defeats ultra right-wing Dornan in Cal.</h1>
<h2>by Evelina Alarcon</h2>

<p><em>This article was reprinted from the <strong>November 23,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>LOS ANGELES</strong> - The upset victory of Loretta Sanchez in 
California's 46th Congressional District has shaken the 
Republican Party establishment to its core. The defeat of 
nine-term Congressman Bob Dornan signals a historic turn 
away from right-wing politics in Orange County, a 
nationally-recognized citadel of conservatism.</p>

<p>Sanchez, a Mexican American, becomes the first Latino and 
first woman elected to Congress from Orange County. The fact 
that she is the daughter of Mexican immigrants and trade 
unionists makes the victory against Dornan, who is viciously 
anti-woman, anti-immigrant and anti-labor, even sweeter.</p>

<p>Sanchez was not intimidated by Dornan's tenure or his crass 
attacks against her. From the outset, she ran to win. A 
tactical decision to spend $100,000 for television and radio 
ads early in the campaign was successful in bringing in a 
flood of contributions and support.</p>

<p>Her campaign for jobs, a woman's right to choose, 
affirmative action and gun control stood in stark contrast 
to the bombastic Bob, whose approval rating in the polls 
sunk to 40 percent.</p>

<p>Ray Cordova, regional director of the Democratic Party in 
Orange County and a key figure in the Sanchez campaign, told 
the World that the Sanchez victory was due in the first 
place to a historic turnout by Mexican American and Latino 
voters. While over half the district is Latino, it has not 
been a decisive factor until now. Citizenship campaigns and 
voter registration drives were crucial to Sanchez' success.</p>

<p>Cordova, who is also a leader in the Communication Workers 
of America, emphasized the "tremendous role played by labor" 
in the 46th CD, one of the seven targeted Southern 
California races. He described the grassroots organizing 
that took place during the campaign.</p>

<p>Monday Night Football mobilizations took place at the 
International Brotherhood of Electrical Workers hall in 
Santa Ana, the largest city in the district. Unionists - 300 
strong - would meet to watch football, work on election 
mailings and posters and do whatever other work needed to be 
done for the candidates challenging the county's GOP. "The 
labor movement," Cordova said, "successfully adopted both 
the labor-to-labor and labor-to-neighbor strategies in the 
district."</p>

<p>Sanchez also mobilized the traditionally conservative 
Vietnamese community and, to the surprise of many, won their 
support and votes. Republican presidential candidate Bob 
Dole won the county only narrowly although in the past 
Orange County residents have voted overwhelmingly Republican 
in the presidential election.</p>

<p>The Sanchez campaign estimates that women voters turned out 
big for her. She also received the votes of many whites and 
Republicans. Dornan's brand of right-wing extremism turned 
off these Republican voters, especially pro-choice 
Republican women. Committees such as Republicans for Sanchez 
were organized for the election.</p>

<p>Ellen Padberg, a Republican political consultant from Orange 
County, wrote in the L. A. Times, "It will be poetic justice 
when a Latina sends Dornan to the unemployment office. 
Loretta Sanchez has everything that Bob Dornan can't stand 
in women - brains, courage, integrity and tenacity. 
Republicans and Democrats, men and women across the country 
will all raise a toast to Sanchez. She busted the bully."</p>

<p>Dornan has a history of slanderous attacks against his 
political opponents. While Democrats are his main target, 
when Dornan defeated Judy Ryan, a judge, in the 1992 
Republican primary he used racist and sexist terms to refer 
to her supporters.</p>

<p>In his early years, right-wing Hollywood figures such as 
Ronald Reagan, John Wayne and Bob Hope gave Dornan his 
springboard into politics. They considered him their "great 
right hope." He has been the leading voice in Congress for a 
military buildup, winning him the nickname of "B-1 Bob." He 
has received funds from right-wing groups throughout the 
country, at one time receiving more money than any other 
candidate for Congress.</p>

<p>A long-time friend of George Bush, Dornan developed the 
"Moscow strategy" for the 1992 presidential race. This was a 
last-ditch effort to paint Bill Clinton as a "traitor" for 
having visited the Soviet Union as a tourist during the days 
of the Vietnam War. Dornan said Clinton "went to the enemy 
heartland under the shadow of the Kremlin to be used by 
enemy forces" so he could "lick the boots of the Communist 
killers."</p>

<p>No other member of Congress has matched the venom spewed by 
Dornan. He has been a vile, publicity-seeking frontman for 
the ultra-right for all his 18 years in the House of 
Representatives. He was a harbinger of the ultra-right 
takeover of the Republican Party.</p>

<p>Dornan represents the worst and most dangerous fascist 
forces in our country. For this reason many are celebrating 
his defeat. A number of other races in the 46th CD reflected 
the new political realities. The most important was the 
strong campaign run by Lou Correa, a Mexican American, who 
lost his bid for the 69th Assembly District by only several 
hundred votes. His grassroots campaign was supported by 
labor and helped mobilize many Latinos who provided the 
margin of victory for Sanchez. Nativo Lopez, a leader of 
Hermandad Mexicana, an immigrants rights organization, won 
against Christian Coalition politics for a seat on the Santa 
Ana School Board.</p>

<p>At press time, Dornan was claiming that his loss was due to 
a massive case of "voter fraud" and the votes of non-
citizens. As usual, he is stooping to the lowest common 
denominator to try to win. While all the votes are still not 
counted, most are and Sanchez is still winning by 600 votes. 
Dornan's time is up.</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-267</DOCNO>
<DOCOLDNO>IA027-000294-B004-259</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-12-21-3.html 206.119.5.80 19970120072210 text/html 5540
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:28:51 GMT
Last-modified: Saturday, 21-Dec-96 16:11:29 GMT
Content-length: 5356
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Daniel Vila - The real Disney world - it's in Haiti</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>The real Disney world - it's in Haiti</h1>
<h2>by Daniel Vila</h2>

<p><em>This article was reprinted from the <strong>December 21,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>NEW YORK</strong> - How can Michael Eisner, CEO of the Walt Disney 
Company, afford to pay himself $97,600 an hour? Easy. He 
contracts manufacturers who pay workers in Haiti who sew 
Pocahantas, Mickey Mouse and other Disney clothing for 28 
cents an hour.</p>

<p>Responding to this and many other abusive conditions 
prevalent in the factories where The Disney Company gets its 
clothing manufactured, some 200 persons demonstrated in 
front of the Disney Store in midtown Manhattan Dec. 14. The 
National Labor Committee, a non-profit human rights advocacy 
group which has exposed the link between U.S. multinationals 
and sweatshops around the world, organized the protest.</p>

<p>Thousands of Christmas shoppers going into the store and 
passing by it were surprised to see protesters dressed up as 
Santa Claus, Mickey and Minnie Mouse and other Disney 
characters. Demonstrators passed out leaflets denouncing 
Disney's link to production shops with horrendous working 
conditions.</p>

<p>Charles Kernaghan, director of the National Labor Committee, 
detailed the abuses in "An Open Letter to Walt Disney." He 
wrote the letter earlier this year after returning from 
Haiti where he witnessed the conditions under which Disney 
manufactures the clothing which carries its label. Disney 
has contracted L.V. Myles and H.H. Cutler, which in turn 
contract production to L.V. Myles, N.S. Mart, Classic and 
Gilanex in Haiti.</p>

<p>In his letter Kernaghan states that N.S. Mart, located in 
the Sonapi Industrial Park, pays its workers 28 cents an 
hour. But to earn this a worker on the assembly line had to 
handle 375 Pocahantas shirts an hour. A week's salary was 
not enough to buy one of the shirts which sell at Wal-Mart 
for $10.97.</p>

<p>At a secret meeting with Kernaghan, workers told him 
management screamed and threatened them and young women are 
subjected to sexual assault by management. Toilets are 
filthy and there are rats everywhere, including dead ones in 
the water tank.</p>

<p>"Mickey's for Kids Stuff" is made at the Classic Apparel 
factory which is managed by John Paul Medina, a former 
member of the Fraph Death Squad which killed thousands of 
Haitians during the dictatorship. When President Jean-
Bertrande Aristide raised the minimum wage, Medina responded 
by increasing the daily piece rate quota from 720 to 1,200 
collars in eight hours.</p>

<p>Working conditions at other factories visited by Kernaghan 
were just as miserable. There are no applicable labor codes 
and even being suspected of trying to organize to improve 
working conditions is enough to get anyone fired.</p>

<p>Living conditions for the working class are deplorable. 
Since milk is too expensive, children are given sugar water. 
Parents are unable to afford medicines or meat for their 
children. Cough syrup costs a day's wage, $1.54, and a can 
of powdered milk $3.08. Since workers' neighborhoods do not 
have running water they must buy it by the bucket. A one-
room shack may be home for an entire family, and often 
several families must share a hole in the ground as a 
toilet.</p>

<p>Kernaghan's letter lists four proposals which the workers 
made to Disney: 1) that Disney send representatives to meet 
with them so that they may learn what their working and 
living conditions are.</p>

<p>2) help clean up the factories and guarantee respect for 
human rights including the right to organize.</p>

<p>3) an increase in wages to 58 cents an hour.</p>

<p>4) that local human rights organizations have access to the 
factories to monitor conditions as they do with factories 
contracted by the GAP.</p>

<p>The demonstration in front of the Disney Store ended with a 
march up Fifth Avenue. Nick Unger from the Union of Needle, 
Industrial and Textile Employees told the crowd Disney had 
to be made responsible for the sweatshop conditions in 
Honduras, El Salvador, Haiti and New York.</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="../pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-268</DOCNO>
<DOCOLDNO>IA027-000294-B002-427</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-09-3.html 206.119.5.80 19970120071439 text/html 6702
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:21:23 GMT
Last-modified: Sunday, 10-Nov-96 02:26:50 GMT
Content-length: 6520
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Julia Lutsky - The top 200 corporations: bigger than big</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>The top 200 corporations: Bigger than big</h1>
<h2>by Julia Lutsky</h2>

<p><em>This article was reprinted from the <strong>November 9,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p>The poorest 4.5 billion people on Earth - 80 percent of its
inhabitants - together earn only a little more than half the
amount earned from the sales made by the world's 200 largest
corporations. So says the Institute for Policy Studies (IPS) in
Washington, D.C., in its recent report, "The Top 200: The Rise of
Global Corporate Power." </p>

<p>"Two hundred giant corporations, most of them larger than many
national economies, now control well over a quarter of the
world's economic activity," states the report written by Sarah
Anderson and John Cavanagh. "Philip Morris is larger than New
Zealand and it operates in 170 countries ... The most alarming
finding is that as corporate concentration has risen, corporate
profits have soared, yet workers and communities are getting a
shrinking piece of the growing pie." </p>

<p>The income of these corporations is growing both absolutely and
as a proportion of the world's total Gross Domestic Product
(GDP). In 1982 world GDP was $12.6 trillion, of which sales of
the 200 equaled a bit less than a quarter. By 1995 world GDP had
doubled to $25.224 trillion; the sales of the top 200 had
increased to more than 28 percent of world GDP. </p>

<p>Japan and the United States accounted for 115 of the companies in
1982 and 117 in 1995. In 1982 only 15 of them were headquartered
in Japan. Today, however, 58 are headquartered there and account
for 39 percent of the 200's total sales while the 59 U.S. firms
generate only 28 percent of total sales. </p>

<p>Six of the top 10 companies in terms of sales - but not corporate
profits - are based in Japan, three in the United States and one
in South Korea. Ninety-three percent of the top 200 firms are
based in only seven countries - the United States, Japan,
Germany, France, the United Kingdom, the Netherlands and
Switzerland. </p>

<p>The total sales of these corporations exceeded one-quarter of the
world's 1995 GDP. Only two developing countries, South Korea and
Brazil, have firms in the top 200: Their six firms account for
under 2 percent of the 200's total sales. </p>

<p>Of the 191 countries in the world in 1995 only 21 had economies
which exceeded that of the largest corporation, Mitsubishi of
Japan. Mitsubishi had sales of $184.5 billion, more than the GDP
of Indonesia, the world's fourth most populous nation. In the
Americas, only the United States, Brazil, Canada, Mexico and
Argentina had GDPs greater than Mitsubishi's sales income. In
fact, the income of each of the 20 largest global corporations
exceeded the GDP of every country in Latin America except Brazil,
Mexico and Argentina. </p>

<p>The 200 corporations represent but one half of one percent of the
40,000 firms whose operations extend beyond the boundaries of the
nations in which they are headquartered. These 40,000 firms
conduct their business through some 250,000 affiliates. When
corporations establish branches in other countries to produce
parts then sold back to the original firms - or to affiliates in
still other countries - should this be considered trade?
One-third of world trade is made of just such "sales and
purchases." Forty percent of Japanese exports are to other
branches of the parent firms. </p>

<p>If the leading corporations account for a quarter of the world's
economic activity should they not also employ at least a quarter
of the world's work force? That would total about 650 million
people, according to U.N. figures cited by IPS. Actually, they
employ only about 18.8 million, less than one percent of those
workers. Only 118,000 people were employed in the 13 trading
firms represented in the top 200. </p>

<p>This "industry" had greater sales - $1.216 trillion in 1995 -
than any other industry represented. Automobiles, the second most
profitable industry, employed more than 2.876 million people.
Three of the 15 auto companies were U.S. corporations: General
Motors, Ford and Chrysler, who employed 1.168 million between
them. GM, with 709,000 employees, is the largest employer in the
entire group of corporations. </p>

<p>Non-productive industry, i.e., the 63 trading, banking, insurance
and finance firms, accounted for some $2.490 trillion in 1995
sales, 35 percent of the total sales of the 200, nearly 10
percent of world GDP. Five trading companies generated 12 percent
of the entire 200's sales - 3 percent of world GDP.
.Telecommunications alone now accounts for $289 billion in sales
annually - 1 percent of the world's economy. </p>

<p>But how much of that capital is available to the world's people?
The poorest 85 percent of the world's population live in
countries whose GDPs are less than $1,000 per person. By
comparison, the GDP per person in the United States is around
$25,000. </p>

<p>There is much ballyhoo that this is the era of the "information
super highway." As we visit AT&T's and GTE's world-wide computer
web sites, we should remember that more than 90 percent of the
world's people do not have access to telephones. In the words of
the IPS report, "the top 200 are creating a global apartheid, not
a global village." </p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-269</DOCNO>
<DOCOLDNO>IA027-000294-B003-1</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-16-2.html 206.119.5.80 19970120071530 text/html 7005
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:22:10 GMT
Last-modified: Sunday, 17-Nov-96 16:43:52 GMT
Content-length: 6823
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Tim Wheeler - Texaco boycott targets big oil racism</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Texaco boycott targets big oil racism</h1>
<h2>by Tim Wheeler</h2>

<p><em>This article was reprinted from the <strong>November 16,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><strong>NEW YORK</strong> - Responding to outrage against Texaco's
racist job 
discrimination, the Rev. Jesse Jackson called Tuesday for an 
immediate boycott of goods and services sold by the giant 
oil company.</p>

<p>Jackson announced the boycott after he and the Rev. Al 
Sharpton had lunch with Texaco Chief Executive Officer, 
Peter Bijur, at the company's headquarters in White Plains, 
New York.</p>

<p>Jackson said Bijur refused to budge on the issue of job 
discrimination despite the furor over the release of a tape 
recording of a 1994 Texaco board meeting in which top 
executives referred to African American workers as "black 
jelly beans" who "stick to the bottom of the bag." They made 
demeaning comments about Hanukkah, the Jewish festival of 
lights, and Kwaanza, an African American holiday patterned 
after an African harvest festival. </p>

<p>They went on to discuss shredding documents to conceal 
Texaco's record of discrimination in hiring and promotions 
from discovery in a $520 million discrimination lawsuit by 
the company's 1,400 minority workers. The tape recording was 
made by Richard A Lundwall, at the time senior coordinator 
for personnel services. He was later terminated when Texaco 
downsized. In revenge, he handed the tape over to attorneys 
representing the minority workers.</p>

<p> "It will be cheaper to settle this suit than to prolong 
it," Jackson added. "It should have been the first item on 
his agenda."</p>

<p>Asked by a reporter if the boycott is immediate, Jackson 
replied, "I hope when you leave here and you'll need gas, 
you'll see a Texaco station and go right by." Bijur decried 
the move. "Boycotts are divisive in my view, they cause 
economic disruption."</p>

<p>William Taylor, president of Oil, Chemical, and Atomic 
Workers Local 7-507 in Aurora, Illinois endorsed the Texaco 
boycott. "I've added Texaco to my list of companies not to 
patronize," he told the World in an interview. "A boycott 
can be very effective if it is properly organized. When 
enough people stop buying Texaco products the company will 
yield." Taylor's local represents hundreds of Amoco and 
Mobil oil workers while a Texas OCAW local represents many 
Texaco employees. "There's racism and discrimination in the 
boardrooms of all of these big corporations," he told the 
World. "Its the nature of the beast." </p>

<p>Lundwall's tape is now being compared to the videotaped 
beating of Rodney King by seven Los Angeles police officers 
in 1991 which forced the issue of police brutality into the 
public eye. It is a smoking gun that exposes the big lie 
(spouted by GOP Presidential nominee Bob Dole and other 
right-wing demagogues in this year's election) that racial 
discrimination is ended and that the U.S. is a "color-blind" 
society. New York Times columnist Bob Herbert wrote on Nov. 
11, "Even as the Texaco story was making its way around the 
country, voters in California were approving Proposition 
209, a measure aimed at dismantling affirmative action 
programs. Who needs affirmative action when discrimination 
is a thing of the past?" he asked sarcastically.</p>

<p>Herbert added, "Racial discrimination is as common as 
commercials on television. Employment discrimination is so 
widespread the agencies attempting to deal with it are 
overwhelmed. Most of it is ignored."</p>

<p>Richard T. Seymour, director of the Employment 
Discrimination Project of the Lawyer's Committee for Civil 
Rights Under Law in Washington, told the World, "The Texaco 
lawsuit makes the case very strongly that there is a need 
for continued affirmative action programs. It also shows 
that corporate executives need instruction in ethics." </p>

<p>If the Texaco executives destroyed documents, Seymour added, 
"it is obstruction of justice and they should face criminal 
charges. They should be prosecuted."</p>

<p>In cases in which evidence is destroyed, he added, "the 
judge has the option of declaring a very strong presumption 
that Texaco was guilty of discrimination."</p>

<p>Seymour cited the case of Mitsubishi, found guilty of sexual 
harassment and sex discrimination at its auto assembly plant 
in Illinois. "The Mitsubishi case was a powerful indicator 
of the pervasiveness of sex discrimination that went all the 
way to the top of the corporate structure." The Texaco case, 
he said, promises to be equally sweeping in exposing the 
racist practices of a corporate giant with $36 billion in 
annual revenues and net profits last year of $607 million, 
up 33 percent from a year earlier. </p>

<p>In a Nov. 5 letter to Bijur, H. Carl McCall, New York State 
Comptroller wrote: "I am profoundly dismayed by reports of 
Texaco executives planning to destroy documents relevant to 
a discrimination lawsuit and racial epithets to describe 
employees." He added, "I am the sole trustee of the New York 
State Common Retirement fund. The Fund owns over 1.2 million 
shares of Texaco with an estimated value of $114 million.</p>

<p>"On behalf of the 880,000 retirees and active members of the 
Fund, I am greatly concerned that a corporate culture of 
disrespect and discrimination could have a negative impact 
on performance and value," said McCall, the first African 
American elected to state-wide office in New York. He 
demanded an end to these practices. "I eagerly await your 
reply," he added.</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-270</DOCNO>
<DOCOLDNO>IA027-000294-B003-285</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-12-07-1.html 206.119.5.80 19970120071912 text/html 9064
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:25:54 GMT
Last-modified: Saturday, 07-Dec-96 17:03:12 GMT
Content-length: 8880
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Victor Perlo - New attacks on living standards</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>New attacks on living standards</h1>
<h2>by Victor Perlo</h2>

<p><em>This article was reprinted from the <strong>December 7,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p>Irwin L. Kellner, chief economist for Chase Manhattan Bank 
and I have something in common. We both have an interest in 
the cost of living, with mine going back many years when I 
did the research for the Congress of Industrial 
Organizations showing that during World War II workers' 
living costs went up much more than the amount recognized in 
the official Consumer Price Index (CPI).</p>

<p>A few years ago Kellner made a survey and found that the 
prices of products bought by the average family rose by 
about 12 percent a year. My survey - which I conducted at 
the local Shop-Rite - came to the same conclusion: Today I 
have to spend at least $20 for the same grocery items that I 
could get for between $14 and $17 less than a year ago.</p>

<p>And now the CPI is under renewed challenge. For some years 
the Wall Street Journal has been carping about the index, 
claiming it exaggerates increases in living costs. And now 
Alan Greenspan, chair of the Federal Reserve Board and 
establishment guru on economic matters, has joined the hue 
and cry. According to him, the CPI overstates the rise by 
between 0.5 percent and 1.5 percent per year and should be 
revised downward.</p>

<p>And the pressure is building. A panel, headed by Michael J. 
Boskin, chief economist for President Bush, has "found," 
using "scientific studies," that the CPI overestimates 
living costs by as much as 2.0 percent per year.</p>

<p>Most government officials who deal with the economy support 
the change - except for Katherine Graham, commissioner of 
the Bureau of Labor Statistics who defends the existing 
index. But Democrats cannot be expected to offer serious 
opposition to demands for a downward revision of the CPI, as 
witnessed by New York Sen. Daniel Patrick Moynihan's ardent 
support for such a revision.</p>

<p>Nor has the labor movement yet rallied its numbers to oppose 
these revisions. Instead, if the editors of Business Week 
are correct, union spokespersons say only that the panel 
"exaggerates the CPI's errors." If Boskin & Co. are to be 
defeated, organized labor should do more than oppose any 
reduction, it should call for an upward revision of the 
index.</p>

<p>But who cares whether the CPI goes up or down one or two 
percentage points? Does it make a real difference? And the 
answer is, "Yes, it makes a big difference - and workers 
will care plenty."</p>

<p>Alan Abelson, a columnist for Barron's Weekly, let the cat 
out of the in bag on Dec. 2 when he said, tongue-in-cheek, 
that the Boskin Commission was inspired by a Congress that 
"desperately needs a way to take the knife to Social 
Security without inciting the rage of the nation's 
politically potent old coots. Increases in Social Security 
payments are tied to inflation as measured by the CPI. Ergo, 
fiddling with the CPI is a perfect (read "blameless") way of 
diddling the geezers."</p>

<p>All federal social programs are linked to the CPI. Social 
Security payments will go up 2.9 percent in January because 
of the 2.9 percent increase in CPI. If the Boskin proposal 
to reduce the CPI were in effect, recipients would get only 
1.9 percent more. (When added up over 10 years, that one 
percent would amount to a 10 percent cut the tenth year.)</p>

<p>Similar downward adjustments in health and poverty programs 
would also be cumulative. Over a 10 year period, these 
adjustments would "save" the government $615 billion by 
taking the money out of the pockets of workers and their 
families. More billions would be taken by losses in benefits 
paid by state and city governments - and neither takes into 
account the disproportionate losses that would be borne by 
African Americans, Latinos and other racially- and 
nationally-oppressed minorities.</p>

<p>But the impact of Boskin would not be limited to those 
dependent on governmental benefit programs. Millions of 
workers are covered by union contracts that are linked to 
the CPI. Were wage increases cut by 1 percent each year for 
10 years it would cost workers $1,200 billion - bringing the 
total losses to nearly $2 trillion, with about a third 
coming from 18 million trade unionists.</p>

<p>I said earlier there was need for an upward revision in the 
CPI because it understates the rise in living costs. 
Consider, for instance, taxes - federal, state and local - 
that are taking more and more of workers' wages. But taxes 
aren't included in the CPI. If they were, it would increase 
the CPI and its rate of acceleration significantly.</p>

<p>And what about food, beginning with the fact that there has 
been a shift in consumption habits with millions of 
consumers recognizing that health and longevity require a 
reduction of the fat in their diet. As a result, there has 
been a shift away from eggs and red meat in favor of chicken 
and fish.</p>

<p>The CPI for food consists of several components, among them 
"fresh fish" (price up 96 percent since the index was last 
adjusted in 1987) and "meat and eggs" (price up 40 percent) 
But price alone does not take into account the share that 
fish and seafood now represents when compared with the total 
for meat, fish and eggs which the CPI puts at 7 percent. My 
calculations show that fish now represents at least 10 
percent of the total cost of meat, fish and eggs - a 
calculation more than substantiated by the line at the fish 
counter at Shop-Rite. Obviously, a correction here would be 
reflected in a higher CPI.</p>

<p>And what about automobiles? The Cost of Living Index for 
motor vehicles shows an increase to 143.8 percent since 
1982-84. But in the early 80s, the typical new car cost 
about $6-7,000. Today it is at least $14-15,000. What 
happened - and why?</p>

<p>Each year the BLS index allows liberal allowances for 
"quality improvement," in the finished product - 
improvements vouched for by none less than the auto makers 
themselves! Thus, the automobile component of the CPI goes 
up only 44 percent - and Cost of Living Adjustment to wages 
for auto workers are reduced and an understated CPI denies 
millions of people justifiable increases.</p>

<p>One could make similar calculations for medical care, and 
utilities, but these few examples typify the skullduggery.</p>

<p>Nor does the skullduggery end there. The Census Bureau has 
already finagled the index enough to wipe out part of the 
recent decline in family incomes and now proposes applying 
the new, indexes retroactively so as to statistically 
eliminate the decline in real wages - as if workers don't 
know they are getting shafted no matter how the data are 
manipulated!</p>

<p>The rationale I have seen for imposing the new criteria for 
CPI is that people are taking advantage of bargains. But 
there is no evidence that there are more bargains or that 
sales are more frequent than at other times - both factors 
that would have to exist for that argument to have merit.</p>

<p>Capitalist enthusiasm for the proposed "reforms" stems from 
the fact that workers' losses due to the changed indexes 
will mean corresponding escalation of capitalist profits. 
And there can be no doubt that the reduced expenditures for 
public benefits will strengthen, perhaps decisively, the 
capitalist campaign for reduction of their taxes - 
especially for slashing or eliminating the tax on capital 
gains, the means by which more and more of their profits are 
generated.</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-271</DOCNO>
<DOCOLDNO>IA027-000294-B002-366</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-11-09-1.html 206.119.5.80 19970120071407 text/html 6228
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:20:45 GMT
Last-modified: Sunday, 10-Nov-96 02:26:44 GMT
Content-length: 6046
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Fred Gaboury - Election '96: Labor holds the line</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>Election '96: Labor holds the line</h1>
<h2>by Fred Gaboury</h2>

<p><em>This article was reprinted from the <strong>November 9,1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p>The right-wing drive to seize control of the federal government
by capturing the White House and strengthening their grip on
Congress fell short on both counts Tuesday as voters gave
President Clinton a new lease on the presidential mansion and
significantly reduced the GOP majority in the House of
Representatives. </p>

<p>The right wing took it on the chin in campaign after campaign
across the county: Paul Wellstone's rout of Rudy Boschwitz in
Minnesota's senatorial contest, Cynthia McKinney's reelection to
Congress in Georgia; the defeat in Illinois of Al Salvi, the
darling of the militia groups; the victory of Julia Carson, the
first African American woman elected to Congress from Indiana.
Voters returned all sitting Democratic members of the House. </p>

<p>The string of GOP defeats continued with Carolyn McCarthy, the
Republican-turned-Democrat who boasted that she "defeated the
NRA" in her upset victory of a GOP first-termer in New York;
Dennis Kucinich, who overcame a vicious red-baiting attack to
defeat Martin Hoke, Ohio's millionaire GOP congressman; and the
election of the nation's first-ever Chinese-American governor. </p>

<p>And in all of them the AFL-CIO, with its nationally-coordinated
Labor '96 campaign, emerged as the driving force that set the
parameters of the debate, be it for the presidency of the United
States or seats on the Dade County School Board in Florida. </p>

<p>Gary Cox, a key staff member in McKinney's Georgia office, said
the contribution of the AFL-CIO to McKinney's "Street Heat Team"
- a team of 100 union volunteers that began a door-to-door "get
out the vote" drive early on election day - was "awesome. We had
an 80 percent turn-out in our targeted precincts." </p>

<p>McKinney, forced to run in a newly-formed district because of
court-ordered redistricting, won reelection by a 58-42 majority
in a district that is only 30 percent African American. Lynn
Wechsberg, who described herself as a "white, suburbanite soccer
grandmother" and former activist in the New Jersey Republican
Party, worked tirelessly in McKinney's campaign. </p>

<p>"I have become more thoughtful," she said, adding that she was
"particularly offended by the extreme, almost fanatical activity
of the Christian Coalition in Georgia." </p>

<p>Warren Gould called Labor '96 the first rung on the ladder for
change. The New Haven, Conn. Central Labor Council, of which
Gould is president, played a decisive role in two congressional
districts targeted by Labor '96. "We defeated Gary Franks and
increased Samuel Gejdenson's margin of victory from fewer than 50
votes in 1994 to more than 10 percent this year." </p>

<p>Gould said the next step was to "assure that regular, everyday
working and unemployed people get the representation they
deserve. And that means continuing what we've begun by organizing
the unorganized." </p>

<p>Charles Deppert, president of the Indiana AFL-CIO, agrees. "We
deserve an "A" for effort but the labor movement has to grow if
it is to provide a voice for working people." </p>

<p>Deppert said the Indianapolis labor council had a response team
of about 100 volunteers who canvassed Carson's district three
times on election day. "This made it possible for Carson to win
by 10,000 votes in a district that is only 27 percent Black. </p>

<p>Bill Moore, communications director for the Minnesota AFL-CIO,
called Sen. Wellstone's 52-to-41 win a "decisive victory" for
grassroots, door-to-door, one-on-one organizing. "We had more
than 2,000 people working the phones or ringing door bells." </p>

<p>Moore said the state federation had been instrumental in
increasing the bloc of labor-endorsed members of the state
legislature. Moore added that, although the right wing had been
"chastened," labor should have no illusions. "They are still
there and we have to keep the heat on [and] we aren't giving a
blank check to the Democratic Party." </p>

<p>For Cindy Hall, president of the South Florida AFL-CIO, the Labor
'96 campaign "helped us energize our members to deal with local
elections as well." </p>

<p>Hall, who is also legislative director for the teachers' union,
said, "We endorsed candidates for eight of the positions on the
nine-member board. We would have won all of them except for one
candidate who put $300,000 of her own money into her campaign ...
she bought the election." </p>

<p>The Center for Responsive Politics estimates that nearly $2
billion was spent on the presidential and congressional races in
1996, with corporations dishing out seven times as much money as
the $35 million spent by the AFL-CIO to finance Labor '96. </p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-272</DOCNO>
<DOCOLDNO>IA027-000294-B004-44</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/archives/96-12-07-3.html 206.119.5.80 19970120071943 text/html 13049
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:26:21 GMT
Last-modified: Saturday, 07-Dec-96 17:03:21 GMT
Content-length: 12864
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD
HTML//EN//2.0"  
"html.dtd">
<HTML>
<HEAD>

<title>Gus Hall - After the '96 elections - challenges facing the Communist
Party</title>

<!-- owner_name="CPUSA" E-mail: CPUSA@rednet.org -->
<!-- Web Support by Hartford Web Publishing    
http://www.hartford-hwp.com -->
</head>

<BODY><a name="top">

<h1>After the '96 elections - challenges facing the Communist Party</h1>
<h2>by Gus Hall</h2>

<p><em>This article was reprinted from the <strong>December 7,
1996</strong>   
issue of the
<strong>People's Weekly World</strong>. For subscription
information  
see
below. All rights reserved - may be used with PWW
credits.</em></p>
<center><img src="line-blue.gif"></center>

<p><i>(Gus Hall is national chairman of the Communist Party USA. 
The following article is taken from his report to the 
CPUSA's national board Nov.23-24.)</i></p>

<p>The activities, role, relations and achievements of the 
Party in the 96 elections call for a new estimate and a 
whole new concept of the Communist Party in our country.</p>

<p>We need a revised concept of the Party in order to 
realistically set our sights, our goals, our plans for the 
post-election period. We should base it on all that is new, 
emerging and developing in the Party, within the framework 
of a new situation in the country and in the class struggle.</p>

<p>Otherwise, we will not see, and therefore not realize, the 
vast new potential in just about every area of life and 
struggle, especially in our working and fraternal relations 
with the trade union movement, the AFL-CIO, but just as 
important the individual unions, their leadership and rank 
and file. Our mass relations are on a new level.</p>

<p>We are in the process of building a mass Communist Party. 
New developments, especially as a result of the elections, 
add new dimensions to our consideration of a new mass party, 
especially the much greater possibilities of recruiting 
workers, trade unionists and mass leaders.</p>

<p>Perhaps the most exciting and most potentially explosive 
developments are the responses to our People's Weekly World 
events by unions, leaders and activists and to our electoral 
role. These are very much interconnected.</p>

<p>Our electoral policy - especially our emphasis on the lesser 
evil approach and our singular contribution in educating, 
agitating and organizing against the fascist danger - 
greatly enhanced the respect of the trade union movement for 
our Party and opened up doors to winning workers and trade 
unionists to our politics and ideology. Our trade union 
relations are on a new level.</p>

<p>The electoral work of our our state organizations, 
especially in working with labor to defeat the ultra-right 
candidates, has gained the Party broader acceptance and 
influence. Some have won new respect in helping to build 
electoral coalitions. Some have achieved new mutually 
beneficial working relationships with local, city and state 
labor bodies, trade union activists and leaders. The base of 
support of many of our state and district organizations has 
significantly widened among all sectors of the people.</p>

<p>Our efforts in building support of the Martinez public works 
jobs bill, especially on the West Coast and in the trade 
union movement, has also raised our standing. In the post-
election period this movement has the makings of a 
successful national, mass campaign.</p>

<p>We will have a special meeting on the bill to discuss its 
status and lay plans for our role in helping to build a 
nationwide movement that unites labor and people's movement 
in support of massive jobs legislation. The impending cuts 
in welfare, that will throw millions of poor and oppressed 
peoples and especially disabled and poor children into 
deeper destitution and despair, are fast becoming an 
emergency crisis.</p>

<p>The special racist and anti-children impact, the anti-
immigration attacks and the workfare issue make the creation 
of millions of new, public works jobs an emergency, 
immediate priority. Parallel with this struggle, we must 
also help build a movement to compel Clinton to keep his 
promise to review and work to undo the damage of the 
Republican welfare bill he signed.</p>

<p>The ultra-right danger has been blunted. This is a 
tremendous achievement. The American people have rejected 
the Contract on America.</p>

<p>The Republican Party, calling for "cooperation" instead of 
"confrontation," is sounding more and more like phony 
liberals trying desperately to change its image because of 
the elections. They know they cannot return to the new 
Congress displaying the same reactionary bluster, arrogance 
and pushing openly anti-people policies. But everything has 
changed.</p>

<p>The trade union movement will never be the same. The 
communities of the racially and nationally oppressed will 
never be the same. The mass movements will never be the 
same. All labor and people's forces are in a new, more 
powerful position. The challenge now is to build on these 
changes and to continue moving in a positive direction to 
win new victories and further defeat the ultra-right in the 
New Year.</p>

<p>In light of our new achievements, to enable us to grow and 
to deepen our unique contributions to the class struggle and 
mass movements, I propose we adopt five main challenges for 
the immediate period ahead.</p>

<h3>1. We have to grow</h3>

<p>In many ways the biggest challenge is how to continue to 
recruit, how to make winning people to our Party a part of 
our everyday activities. And, how to consolidate all the new 
members.</p>

<p>The main approach to consolidation must be how to activate 
new members. The challenge is how to involve new members in 
mass struggles and actions, how to draw them out, onto 
picketlines, to distribute our newspaper on the streets, to 
hold forums that are relevant to their lives and, 
especially, conduct social affairs that will bring people 
out and together.</p>

<p>Club meetings should be a part of the activating process, 
but not the only approach. By now experience has proven that 
invitations to meetings alone are doomed to failure.</p>

<p>Consolidation and activization should be a single process. 
We cannot consolidate without activating new members.</p>

<h3>2. Winning workers</h3>

<p>The base of our Party is, and must be, industrial workers. 
Recruiting and consolidating workers cannot be achieved in 
the same way as mass, street recruiting. It is different and 
in some ways more difficult.</p>

<p>Thus, the second challenge we face is the re-establishment 
of our policy of industrial concentration. This must include 
regular distribution of the People's Weekly World at 
shopgates, the regular publication of special, industrial 
issues of the paper, the publication of regular shop papers. 
It includes drawing up district and club industrial 
concentration plans of work.</p>

<h3>3. The Party and labor</h3>

<p>The third challenge is how we can be more helpful in helping 
the trade union movement with its new challenges and 
problems.</p>

<p>For example, while there is some successful organizing of 
the unorganized, the majority of the working class remains 
unorganized. At the same time, the basic corporate policy 
remains the destruction of the trade unions. The 
corporations are especially committed to this goal because 
they are well aware that they will be forced to deal with a 
new, class struggle oriented trade union movement.</p>

<p>We have to play a role in helping to build labor's political 
independence. The potential is now tremendous. However, it 
is problematic whether the Labor Party can play a leading 
role in establishing labor's political independence in light 
of their non-involvement during the presidential elections. 
We should work to convince the Labor Party that their policy 
is wrong and help move them into electoral activities, if 
possible. Without some basic changes, the labor movement 
will not accept the Labor Party as a viable channel for 
labor's political independence.</p>

<p>We have to continue the correct tactic of building the 
united front that we pursued during the election campaign. 
The differences that mainly dissipated should not be the 
basis for post-election differences.</p>

<p>In fact, one of our immediate tasks should be to build unity 
with all progressive political forces. Everything is 
different now. We must reach out, seek for common ground and 
build unity in struggle with all forces, including those we 
may have had differences with during the election period. 
That is over now. There is a new situation.</p>

<p>Post-election tactics must be based on unity in struggle. 
This should include post-election unity of the trade union 
movement; post election unity in the area of independent 
political action; post-election unity in the struggle 
against racism, against chauvinism; post-election unity in 
the struggles of the unemployed and the homeless; post-
election unity in building a movement to win the Martinez 
Public Works legislation; post-election unity in the 
struggles against privatization to save public education and 
the environment.</p>

<p>We also face a challenge in building on the higher level of 
working relations we have developed especially with trade 
union forces, but also with many communities and people's 
organizations.</p>

<p>There is a new openness, a new willingness to work openly 
with, accept and respect Communists as part of coalitions, 
alliances and campaigns.</p>

<h3>4. Renewed struggle vs. racism</h3>

<p>A fourth challenge is to find ways to stimulate and activate 
the struggle against racism. We have to find ways to 
refresh, replace and restore the affirmative action programs 
that have been destroyed and play a role in the fight 
against the implementation of proposition 209 in California. 
In the struggle against racism, we have to intensify the 
struggle against police brutality, criminalization and the 
horrendous, racist cuts in welfare programs, at the same 
time fighting for jobs, not workfare.</p>

<p>We have to play a leading role in the struggle against the 
vicious, chauvinist, racist and anti-immigrant campaigns 
raging in many states. We have to take on the new level of 
anti-Semitism, especially in New York.</p>

<p>We have to convince and help the trade union movement become 
a more effective, powerful instrument in the struggle 
against racism, especially in the shops. We must raise the 
level of educational work within the Party as part of the 
struggle against racism, chauvinism and anti-Semitism.</p>

<h3>5. Financial questions</h3>

<p>In order to continue and increase our role and work, to 
build the Party and the movements, we have to accept a fifth 
main challenge - to change our attitude toward party 
finances.</p>

<p>Most wrong attitudes are fed by a main misconception that 
there are really no limits to our funds. Therefore, at times 
we make political decisions without any consideration about 
whether we can afford to carry them out. Making politically 
correct decisions does not mean our decisions are 
financially correct.</p>

<p>As a result of this discussion we must make concrete plans 
for a new advanced gift and wills campaign and a whole new 
set of attitudes toward our overall finances and building 
our "advanced gift" funds.</p>

<p>We are now in a position to set the stage for a successful 
campaign and to show potential contributors and investors 
that we have proven our ability to invest and secure their 
money in accord with their wishes and needs, and at the same 
time to benefit the Party and the paper.</p>

<p>Based on our great achievements, I am confident that we can 
meet all the challenges. I am confident that we can and will 
make all the adjustments and changes necessary to accomplish 
everything we set out to do in the coming post-election 
period.</p>

<hr><p><em>Read the Peoples Weekly World<br>
Sub info: <a
href="mailto:pww@igc.apc.org">pww@igc.apc.org</a><br>235  
W. 23rd St. NYC 10011<br>
$20/yr - $1-2 mos trial sub</em></p>
<p>Return to the <a href="#top">top</a> or to the <a  
href="pww.html">People's Weekly World</a> home page.</p>
<center><img src="line-blue.gif">
<br>&#160;<br><strong>Tired of the same old system? <br>Join the  
Communist Party, USA!<br>
Info: <a href="mailto:CPUSA@rednet.org">CPUSA@rednet.org</a>
(212)  
989-4994</strong><br>&#160;<br>
<img src="line-blue.gif"><h4>PEOPLE BEFORE PROFITS!</h4></center>
</BODY></HTML>

</DOC>
<DOC>
<DOCNO>WT03-B24-273</DOCNO>
<DOCOLDNO>IA027-000294-B005-10</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/prarchive/pr-96-08-07.html 206.119.5.80 19970120072326 text/html 3271
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:30:02 GMT
Last-modified: Sunday, 12-Jan-97 20:46:17 GMT
Content-length: 3089
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD HTML//EN//2.0" "html.dtd">
<HTML><HEAD><TITLE>CP-USA: press release archive</TITLE>
<!-- owner_name="Communist Party U.S.A." E-mail: CPUSA@rednet.org -->
<!-- Created 31 August, 1996 by Hartford Web Publishing  http://www.hartford-hwp.com  -->
</head><BODY><a name="top">
<center><img src="../line-rd.gif"><H1>CP-USA press release</H1>
<img src="../line-rd.gif"></center><br>&#160;<br>

August 7, 1996<br>
FOR IMMEDIATE RELEASE<br>  
Communist Party, USA<br>
235 West 23rd Street <br>
New York, N.Y. 10011<br>
Phone (212) 989-4994 <br>Fax: 212-229-1713 <br>E-mail: cpusa@rednet.org<br>
 Contact: Terrie Albano</p>
      
<p><strong>Welfare Bill is Economic Terrorism</strong>

<p>The Communist Party, USA denounced the so-called welfare "reform" bill as
economic and political terrorism against poor and working-class people. Gus
Hall, national chairman of the CPUSA, stated "By announcing that he will sign
this bill, President Clinton is making a serious election miscalculation. The
ultra-right, Republican bill will push millions more into poverty and death.
Which makes defeating the facist-like Republican Congressional majority even
more a life-and-death issue."  
</p><p>
The CPUSA agreed with the many labor, religious and people's organizations
who have said millions more children will suffer because of this bill. It
will have a racist and anti-immigrant impact, affecting African Americans and
Latinos disproportionately. This bill will affect negatively all working
class people, whether you are on welfare or not. Cutting food stamps, alone,
affects all in the food industry - from farmers to food processors to
grocers.
</p><p>
While cutting the lifeline for millions of families, why isn't Congress
taking action to cut corporate welfare? Corporations are the biggest welfare
cheats by getting tax cuts and government subsidies in the billions. The
CPUSA asserted that $104.3 billion is spent on corporate welfare, $619
billion on the military, while only 14.4 billion is spent on social welfare.
</p><p>
"To end welfare as we know it" means to pass a comprehensive jobs bill.
America needs legislation that will create jobs at union wages with benefits
and affirmative action guidelines. There is much work to be done building and
rebuilding roads, bridges, schools hospitals, parks, homes and cleaning the
environment. Pass the Martinez Public Works Jobs Bill, H.R. 1591, a bill
which is gaining broad support among labor and elected officials. The CPUSA
is working to defeat the Dole, Gingrich "gang of 73" in order to turn our
country around. 
</p>


<br>&#160;<br>
<center><table border="2" cellpadding="5" cellspacing="2">
<tr><td><a href="../index.html">Communist Party U.S.A. page</a></td>
<td><a href="../releases.html">CP-USA press releases page</a></td></tr></table><br> 
<img src="../line-rd.gif"><br><address><font size="2"><a href="mailto:brownh@hartford-hwp.com">
<strong>Hartford Web Publishing</strong></a></font></center></ADDRESS></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-274</DOCNO>
<DOCOLDNO>IA027-000294-B005-109</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/prarchive/pr-96-09-29.html 206.119.5.80 19970120072438 text/html 3800
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:31:20 GMT
Last-modified: Sunday, 12-Jan-97 20:46:24 GMT
Content-length: 3618
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD HTML//EN//2.0" "html.dtd">
<HTML><HEAD><TITLE>CP-USA: press release archive</TITLE>
<!-- owner_name="Communist Party U.S.A." E-mail: CPUSA@rednet.org -->
<!-- Created 31 August, 1996 by Hartford Web Publishing  http://www.hartford-hwp.com  -->
</head><BODY><a name="top">
<center><img src="../line-rd.gif">
<H1>CP-USA press release</H1>
<img src="../line-rd.gif"></center><br>&#160;<br>

<p>September 19, 1996     <br>
FOR IMMEDIATE RELEASE<br>   
Communist Party, USA<br>
235 West 23rd Street <br>
New York, N.Y. 10011<Br>
Phone: (212) 989-4994 <br>Fax: 212-229-1713 <br>E-mail: cpusa@rednet.org<br>
Contact: Terrie Albano</p>


<p><strong>Communist Party holds emergency summit on saving public education
Issues plan of action to halt right-wing attack on our schools.</strong>


</p><p><em>NEW YORK</em> - Calling public education a "cornerstone of our democratic
structure," the Communist Party USA held an emergency meeting here Saturday,
Sept. 21 to map out a plan of action to save our schools.
</p><p>
CPUSA Vice-Chair Sam Webb, in his opening remarks, said, "Up until now, we
have assumed that the public education system is untouchable. But the
American people can no longer afford to think that way. A section of the
ruling class is ready to scrap our system of public education with the same
ruthlessness that it closes factories, lays off masses of workers, and writes
off formerly thriving cities as bad investments."
</p><p>
Conference participants, including teachers, parents, students and trade
unionists from 10 east coast and Midwest states, denounced vouchers, "choice"
and charter schools, which coupled with cutbacks in government aid for
education, would cripple public education. Webb said, "We should reject
for-profit schools in any form. Children must not be turned into commodities.
Corporations will not solve the education crisis any more than they have
solved the crisis of joblessness."
</p><p>
The conference, which issued a six-point plan of action to defend public
education and preserve democracy, the most immediate task being the defeat of
Dole, Gingrich and the 73 ultra-right House Republicans on Nov. 5.
</p><p>
Webb said, "Getting rid of them would go a long way toward getting rid of the
"whiff of fascism" in the country.
</p><p>
The rest of the CPUSA program includes:
<ul>
<li>No to privatization schemes in any form.
<li>Organize unity coalitions of parents, schoolworkers, students and elected
officials to speak out and defend public education including ads in papers,
press conferences, letters to the editors, and visits to legislators'
offices.
<li>Cut class size to 15 as the first step in school reform. Hire teachers and
support personnel using affirmative action guidelines.
<li>End the use of local property taxes for school funding. Tax the rich and
corporations to pay for quality desegregated education. Reappropriate
military expenditures into the Department of Education.
<li>Pass the Martinez public works jobs bill (HR-1591) which would appropriate
$250 billion, much of it to build new schools and repair old ones.
</ul>

<br>&#160;<br>
<center><table border="2" cellpadding="5" cellspacing="2">
<tr><td><a href="../index.html">Communist Party U.S.A. page</a></td>
<td><a href="../releases.html">CP-USA press releases page</a></td></tr></table><br> 
<img src="../line-rd.gif"><br><address><font size="2"><a href="mailto:brownh@hartford-hwp.com">
<strong>Hartford Web Publishing</strong></a></font></center></ADDRESS></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-275</DOCNO>
<DOCOLDNO>IA027-000294-B004-315</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/prarchive/pr-96-06-19.html 206.119.5.80 19970120072245 text/html 3920
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:29:18 GMT
Last-modified: Sunday, 12-Jan-97 20:46:15 GMT
Content-length: 3738
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD HTML//EN//2.0" "html.dtd">
<HTML><HEAD><TITLE>CP-USA: press release archive</TITLE>
<!-- owner_name="Communist Party U.S.A." E-mail: CPUSA@rednet.org -->
<!-- Created 31 August, 1996 by Hartford Web Publishing  http://www.hartford-hwp.com  -->
</head><BODY><a name="top">
<center><img src="../line-rd.gif"><H1>CP-USA press release</H1>
<img src="../line-rd.gif"></center><br>&#160;<br>

<p>June 19, 1996     <br>
FOR IMMEDIATE RELEASE<br>   
Communist Party, USA<br>
235 West 23rd Street <br>
New York, N.Y. 10011<Br>
Phone: (212) 989-4994 <br>Fax: 212-229-1713 <br>E-mail: cpusa@rednet.org<br>
Contact: Terrie Albano</p>
      
<p><strong>Stop the Racist Church Burnings</strong></p>

<p>The Communist Party, USA joins with all Americans in expressing revulsion and
outrage at the firebombing of the African American churches across the United
States.  As the elections approach, the fire bombings have escalated. It
calls for the broadest urgent fightback response from the anti-racist
majority of the American people.
</p><p>
Newt Gingrich, Jesse Helms and other right-wing extremist politicians in
Washington have created the atmosphere for these hate crimes. There are daily
racist attacks on affirmative action and welfare. There is open instigation
to racist violence by talk-radio hatemongers like Bob Grant. There are the
Supreme Court rulings overturning majority Black and Latino congressional
districts.
</p><p>
The evidence is incontestable. Their aim is to roll back all the gains of the
Civil Rights movement and the New Deal and to terrorize and divide the
growing unity of Black, Brown and white people. It's an attempt to blunt the
resurgent AFL-CIO and the historic alliance between African American churches
and the labor movement.
</p><p>
Look at what life was lost from other hate crimes. Remember the bombing of
the Oklahoma City federal building in which 168 men, women and children of
all races and backgrounds died.
</p><p>
The federal government and law enforcement agencies have failed to vigorously
investigate and apprehend the perpetrators of these vile firebombings.
Instead, federal agents have often treated the victims of the crime as if
they were the perpetrators, interrogating the pastors and grilling church
members to the point of tears. Adding insult to injury, the FBI and Justice
Department has openly questioned whether the church firebombings are a
"conspiracy." We say: There are none so blind as those who will not see!
</p><p>
All who oppose racism should take initiative to demand government action to
halt the burnings. The time is now to build all people's unity to defeat the
forces of racist terrorism and violence. White supremacist groups like the Ku
Klux Klan must be outlawed.
</p><p>
All who cherish democracy must act now. Everyone, every religious
denomination, every labor union, every civil rights and community
organization should demand that the federal government act now to protect
these churches.
</p><p>
The answer to these hate crimes is greater unity and action to defend African
American churches everywhere. And registering millions to vote and defeat the
ultra-right in November gives a most resounding answer to crimes of hate.
</p>

<br>&#160;<br>
<center><table border="2" cellpadding="5" cellspacing="2">
<tr><td><a href="../index.html">Communist Party U.S.A. page</a></td>
<td><a href="../releases.html">CP-USA press releases page</a></td></tr></table><br> 
<img src="../line-rd.gif"><br><address><font size="2"><a href="mailto:brownh@hartford-hwp.com">
<strong>Hartford Web Publishing</strong></a></font></center></ADDRESS></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-276</DOCNO>
<DOCOLDNO>IA027-000294-B005-38</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/prarchive/pr-96-08-16.html 206.119.5.80 19970120072339 text/html 3664
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:30:19 GMT
Last-modified: Sunday, 12-Jan-97 20:46:19 GMT
Content-length: 3482
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD HTML//EN//2.0" "html.dtd">
<HTML><HEAD><TITLE>CP-USA: press release archive</TITLE>
<!-- owner_name="Communist Party U.S.A." E-mail: CPUSA@rednet.org -->
<!-- Created 31 August, 1996 by Hartford Web Publishing  http://www.hartford-hwp.com  -->
</head><BODY><a name="top">
<center><img src="../line-rd.gif"><H1>CP-USA press release</H1>
<img src="../line-rd.gif"></center><br>&#160;<br>

<p>16 August, 1996<br>
For Immediate Release<br>
Communist Party, USA<br>
235 W. 23rd St.<br>
New York, NY 10011<br>
E-mail: cpusarednet.org</strong></p>

<p><strong>Communists Say Republican Convention is a Wake-Up Call to Voters.</strong>
</p><p>Communist Party National Chairman, Gus Hall, branded the Republican national
convention "a scripted extravaganza of demagogy that raises the level of the
ultra right danger and the stakes in the 1996 elections."
</p><p>The Communist leader termed the convention "a corporate financed and
choreographed spectacle in which every tightly controlled speech was steeped
in hypocrisy with the aim of hoodwinking the millions of voters watching the
show on TV." Hall said attempts of the convention managers "to show inclusion
and diversity" came through "as total demagogy, considering the extremely
racist and anti-immigrant positions of the Republican platform." He predicted, "the
crude efforts to narrow the gender gap by highlighting a few women speakers
will fail to convince the mass of women who know the Republican anti-labor,
anti-people record." 
</p><p>Hall said that the smoke and mirrors convention recalled "the beginning of
fascism in Germany when Adolf Hitler's party called itself the 'German
National Socialist Party' with the sole aim of throwing people off guard. And
it worked -- for a while." He cautioned that "we must not allow the
exteme right forces in our country to portray themselves as the party that
will restore the American Dream when they are in fact promoting an American
nightmare."
</p><p>On the positive side Hall added, "This speaks volumes about the
democratic sentiments of the American people. The convention handlers felt
compelled to ban the words "Contract with America" and the candidates
distanced themselves from the platform, because the American people have rejected those
positions." "But the danger is great," he went on. President Clinton's
statement earlier that he would sign the Republican, anti-people welfare bill
was grist to the Republican mill. "That and the announcement of a Dole-Kemp ticket gave new
energy to the Republicans," he said. "It is already changing the electoral
picture and it will boost the sagging fortunes of the Gingrich Gang of 73,
the rich Republican right-wing businessmen and the religious right who
are out to destroy the economic and democratic rights of the people. The
deceptive tactics displayed at their convention should serve as a wake-up
call to step up voter registration and education campaigns. The stakes have
never been greater."

</p>
<br>&#160;<br>
<center><table border="2" cellpadding="5" cellspacing="2">
<tr><td><a href="../index.html">Communist Party U.S.A. page</a></td>
<td><a href="../releases.html">CP-USA press releases page</a></td></tr></table><br> 
<img src="../line-rd.gif"><br><address><font size="2"><a href="mailto:brownh@hartford-hwp.com">
<strong>Hartford Web Publishing</strong></a></font></center></ADDRESS></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-277</DOCNO>
<DOCOLDNO>IA027-000294-B005-72</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/prarchive/pr-96-08-28.html 206.119.5.80 19970120072416 text/html 2981
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:30:39 GMT
Last-modified: Sunday, 12-Jan-97 20:46:21 GMT
Content-length: 2799
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD HTML//EN//2.0" "html.dtd">
<HTML><HEAD><TITLE>CP-USA: press release archive</TITLE>
<!-- owner_name="Communist Party U.S.A." E-mail: CPUSA@rednet.org -->
<!-- Created 31 August, 1996 by Hartford Web Publishing  http://www.hartford-hwp.com  -->
</head><BODY><a name="top">
<center><img src="../line-rd.gif"><H1>CP-USA press release</H1>
<img src="../line-rd.gif"></center><br>&#160;<br>

<p>28 August, 1996<br>     
FOR IMMEDIATE RELEASE   
Communist Party, USA<br>
235 West 23rd Street<br> 
New York, N.Y. 10011<br>
Phone (212) 989-4994 <Br>Fax: 212-229-1713 <br>E-mail: cpusa@rednet.org<br>
Contact: Terrie Albano</p>
<p><strong>Public Education is a Pillar of Democracy and Equality</strong></p>

<p>In announcing today, The Emergency Conference to Save Public Education
sponsored by the Communist Party, USA, Gus Hall, National Chairman said:
"Public education is a pillar of democracy and equality. The fight for it has
deep, anti-racist and democratic roots in our country." Hall went on: "Bob
Dole's acceptance speech singled out the teachers' unions for special attack
and said that he is a firm supporter of school choice and vouchers."
</p><p>
Hall characterized the attack, along with Dole's tax cut for the rich and the
corporations as "a new and dangerous element to the campaign of the
ultra-right" to completely dismantle the public education system in our
country. He warned "Don't forget: Gingrich tried to do away with the
Department of Education."
</p><p>
"The corporations and the ultra-right have pushed for defunding,
privatization, vouchers and every other scheme to eliminate what the majority
of Americans see as a basic right, free, integrated, quality public
education." Hall continued: "Unity of all -  with teachers, parents, students
and school workers - unity - between Black, brown, red and white - unity with
the labor movement and community is key to defeating the Dole, Gingrich,
Kemp, corporate attack."
</p><p>
The conference will be held September 21 in New York City. It will bring
together teachers, other school workers, parents, students, professors and
all grassroots trade unionists and activists concerned about public schools
and universities. A comprehensive program of action will be drafted. For more
information call (212) 989-4994.
</p>

<br>&#160;<br>
<center><table border="2" cellpadding="5" cellspacing="2">
<tr><td><a href="../index.html">Communist Party U.S.A. page</a></td>
<td><a href="../releases.html">CP-USA press releases page</a></td></tr></table><br> 
<img src="../line-rd.gif"><br><address><font size="2"><a href="mailto:brownh@hartford-hwp.com">
<strong>Hartford Web Publishing</strong></a></font></center></ADDRESS></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-278</DOCNO>
<DOCOLDNO>IA027-000294-B005-139</DOCOLDNO>
<DOCHDR>
http://www.hartford-hwp.com:80/cp-usa/prarchive/pr-96-10-10.html 206.119.5.80 19970120072454 text/html 3758
HTTP/1.0 200 OK
Server: Netscape-Commerce/1.1
Date: Monday, 20-Jan-97 07:31:33 GMT
Last-modified: Sunday, 12-Jan-97 20:46:26 GMT
Content-length: 3576
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "+//ISBN 82-7640-037::WWW//DTD HTML//EN//2.0" "html.dtd">
<HTML><HEAD><TITLE>CP-USA: Communists say "The only way to win - vote"</TITLE>
<!-- owner_name="Communist Party U.S.A." E-mail: CPUSA@rednet.org -->
<!-- created by Hartford Web Publishing  http://www.hartford-hwp.com  -->
</head><BODY><a name="top">
<center><img src="../line-rd.gif"><H1>CP-USA press release</H1>
<img src="../line-rd.gif"></center><br>&#160;<br>

<p>October 10, 1996<br>
FOR IMMEDIATE RELEASE<br>   
Communist Party, USA<br>
235 West 23rd Street <br>
New York, N.Y. 10011<Br>
Phone: (212) 989-4994 <br>Fax: 212-229-1713 <br>E-mail: cpusa@rednet.org<br>
Contact: Terrie Albano</p>

<p><strong>Communists say "The only way to win - vote"</strong></p>

<p><strong>New York</strong> - Gus Hall, National Chairman of the Communist Party USA, outlined
the stakes in the 1996 presidential and congressional elections at a recent
public meeting here. "The outcome of the '96 presidential and congressional
elections will have a most profound impact on U.S. politics, on the people's
overall quality of life and the future direction of our country," Hall said.
Pointing out the dangers if the ultra-right Republicans recapture the
Congress and continue their Contract with America, Hall said, "The election
results can actually mean the difference between life and death for millions.
It will mean the difference between hunger and food stamps, between more
layoffs, joblessness and the Martinez jobs bill (HR1591), between public
education and no education, between union rights and union-busting. Who gets
elected can mean the difference between welfare and immigration laws that are
humane and just, or policies that are anti-people and racist."
In a biting criticism of the media Hall said, "The campaigns and mass media
are out to blur the issues, trivialize them and keep people from discussing,
debating and making the right choices."
</p><p>That is why Hall and the Communist Party USA are urging a massive voter turn
out on November 5. Emphasizing some of the most important arguments for
people to vote, Hall warned that if ultra-right candidates win, the
reactionary and fascist-like corporate sectors will become more aggressive
and emboldened in their attacks on the quality of life and democratic rights
of the people. Struggles will continue after the elections no matter who is
elected, Hall said, but "a Gingrich-led Congress will take no heed of
protests, demonstrations or people's pressure. The base of support for the
right-wingers are the most reactionary, extreme right sectors of monopoly
capital, the ruling class, the wealthy, the religious right and militia
fascist-fringe forces."
</p><p>Playing its part in voter mobilization, the Communist Party has registered
thousands of new voters and distributed hundreds of thousands of election
pamphlets as well as the CPUSA's newspaper the People's Weekly World. </p><p>For
copies of Hall's speech and interviews with a CPUSA representative, call
Terrie Albano at (212)989-4994 or email <a href="mailto:cpusa@rednet.org">cpusa@rednet.org.</a>

</p>
<br>&#160;<br>
<center><table border="2" cellpadding="5" cellspacing="2">
<tr><td><a href="../index.html">Communist Party U.S.A. page</a></td>
<td><a href="../releases.html">CP-USA press releases page</a></td></tr></table><br> 
<img src="../line-rd.gif"><br><address><font size="2"><a href="mailto:brownh@hartford-hwp.com">
<strong>Hartford Web Publishing</strong></a></font></center></ADDRESS></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-279</DOCNO>
<DOCOLDNO>IA009-000087-B035-227</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/ 207.44.128.99 19970222112010 text/html 12297
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:20:26 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 12125
Last-modified: Sun, 16 Feb 1997 22:03:48 GMT
</DOCHDR>
<HTML>
<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com -->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED: February, 1997   -->
<!--   FILE: Welcome.html   -->
<!--   PURPOSE: Homepage, Northern California Independent Booksellers Association   -->
<!--   DEDICATION: To Christy   --->
<!-    NOTICE: Original contents of this website copyright NCIBA   --->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>Northern California Independent Booksellers Association</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association. These pages are a resource for readers, book lovers and consumers alike. Regional bestsellers, recommended reading, event and happenings, news, a bookstore directory, links to other sites and more can be found at this site.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA bookstore bookstores books store regional bestseller shopping consumer author writer events reading literature literacy censorship free expression Good Reads Northern California Independent Booksellers Association NCIBA bookstore bookstores books store regional bestseller shopping consumer author writer events reading literature literacy censorship free expression Good Reads Northern California Independent Booksellers Association NCIBA bookstore bookstores books store regional bestseller shopping consumer author writer events reading literature literacy censorship free expression Good Reads Northern California Independent Booksellers Association NCIBA bookstore bookstores books store regional bestseller shopping consumer author writer events reading literature literacy censorship free expression Good Reads bookstore book books bookstores California bookstore book books bookstores California bookstore book books bookstores California bookstore book books bookstores California bookstore book books bookstores Californiabookstore book books bookstores California">

</HEAD>
<BODY BGCOLOR=#ffffff>

<FONT SIZE=+2><B>A resource for readers and . . . .</B></FONT>
<P>

<TABLE BORDER=0 WIDTH=100% HEIGHT=100% cellspacing=0 cellpadding=0>
<TR><TD valign=top><img width=186 height=192 src="image/nciba007.gif"  alt="nciba logo"><BR>
<CENTER><B><CENTER><P><FONT SIZE=-2>NORTHERN CALIFORNIA</FONT><BR>
<FONT SIZE=-1>INDEPENDENT BOOKSELLERS</FONT><BR>
<FONT SIZE=-2>ASSOCIATION</FONT></CENTER>
</B></CENTER></TD>

<TD align=right valign=top><FONT color=purple SIZE=+4><B> . . . . book lovers</B></FONT>

<P><FONT SIZE=+2><B>W</B></font><font size=+2>elcome to the<B> Northern California Independent Booksellers Association</B>. These pages are a resource for readers, book lovers and consumers alike. Bestsellers, a store directory, recommended reading, book news, links to related sites and much more can be found here. Scroll down to begin your adventure!</FONT>

</TD>
</TR>
</TABLE>

<table border=0 cellpadding=5 cellspacing=3>
<tr>

<td valign=top rowspan=14>

<img width=21 height=13 src="image/book.gif"> <FONT color=green><B> "Journalism allows its readers to witness history; fiction gives its readers an opportunity to live it."</B></FONT>

<P align=right><B>JOHN HERSEY, 1950</B>

<P><hr width=75%>

<P><CENTER><IMG hspace=10 width=120 height=181 SRC="image/foremost.gif" ALT="first & foremost"></CENTER>

<P><FONT SIZE=+1>"Getting a copy of <B>First & Foremost</B> would make many bibliophiles very, very happy."</FONT><BR>
---<B><I> Contra Costa Times</I></B> Book News

<P><img width=21 height=13 src="image/book.gif"> <B>The NCIBA - in association with Heydey Books - has published a guide to independent bookstores across Northern California. As every reader and browser knows, bookstores are not only a source for books - but, as the centers of their neighborhood or community, for information and entertainment. The book, which retails for $12.95, can be found in bookstores throughout the region.</B>

<P><FONT SIZE=+1>"This charming and exhaustive guide describes nearly 300 independent bookstores in Northern California . . . a nifty book."</FONT><BR>
--- Pat Holt, <B><I>San Francisco Chronicle</I></B>

</td>

<!---------------------------------------------------------------------------------------->

<td width=4% rowspan=14 valign=top align=center><IMG width=3 height=950 SRC="image/vrule.gif" alt="vertical line"></td>

<!---------------------------------------------------------------------------------------->

<td width=15% align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="purpose.html" onMouseOver="window.status='Some thoughts on what it means to be an independent bookseller . . . '; return true">INFORMATION</A></font></th>
</tr>
</table></td>

<td width=85%>
<P><FONT SIZE=+2><B>T</B></FONT>he NCIBA <B><A HREF="purpose.html">Declaration of Independents</a></B>: what every consumer should know; our <B><A HREF="purpose.html">F.A.Q.</a></B> and more.</td></tr>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="bestsell.html" onMouseOver="window.status='A bestseller list especially for Northern California . . .'; return true">BESTSELLERS</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>O</B></FONT>ur monthly list of Northern California <B><A HREF="bestsell.html">Bestsellers</a></B>. Find out what's really selling in your local bookstore.</TD></tr>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="goodread.html" onMouseOver="window.status='Looking for something good to read - here are suggestions from your local bookseller . . . '; return true">GOOD READS</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>R</B></FONT>ecommended reading from your local bookseller. <B><A HREF="goodread.html">Good Reads</a></B> are the books we want to tell you about . . . .</TD></TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="stores.html" onMouseOver="window.status='Find new & exciting places to shop all around the state . . . '; return true">BOOKSTORES</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>R</B></FONT>egional listings of NCIBA member stores. Locate a <B><A HREF="stores.html">Bookstore</a></B> near you!</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="profile.html" onMouseOver="window.status='Take a look at one of the independent bookstores serving Northern California . . . '; return true">PROFILE</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>O</B></FONT>ur monthly <B><A HREF="profile.html">Profile</a></B> of a Northern California bookstore. Find out more about some of your favorite places to shop.</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="aisles.html" onMouseOver="window.status='News, events and happenings from the local world of books . . .'; return true">IN THE AISLES</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>N</B></FONT>ews, announcements, <B><A HREF="aisles.html">Gossip and Goings-on</a></B> from your local bookseller. Newsletter clippings, fun facts and more.</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="online.html" onMouseOver="window.status='Many of your favorite independent bookstores are online . . . '; return true">ONLINE STORES</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>A</B></FONT> growing, hyperlinked list of <B><A HREF="online.html">Online Bookstores</a></B>. Cybershoppers should check this page often!</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="news.html" onMouseOver="window.status='Here is the latest from the larger world of books . . . '; return true">BOOK NEWS</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>N</B></FONT>ews, events and happenings in the larger<B> <A HREF="news.html"> World  of  Books</a></B>. From the Bay Area to Northern California and beyond.</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="censor.html" onMouseOver="window.status='Find out more about free speech issues . . .'; return true">FREE SPEECH</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>F</B></FONT>ind out about <B><A HREF="censor.html">Free Speech Issues</a></B> effecting not only bookstores, but the online community as well.</TD></TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="resource.html" onMouseOver="window.status='For students of literature to trivia buffs to those looking for something good to read . . .'; return true">RESOURCES</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>W</B></FONT>ant to know who won a Pulitzer or Nobel Prize? Curious about California's rich literary history? Visit our information packed page of <B><A HREF="resource.html">Reader Resources</a></B>.</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="links.html" onMouseOver="window.status='Travel through the world of online books and authors . . .'; return true">LINKS</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>L</B></FONT>iterary <B><A HREF="links.html">Links</a></B> on the net; our list of author pages, book-related web sites, newsgroups, online libraries and more.</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="feedback.html" onMouseOver="window.status='Our mailing list is a great way to keep informed . . .'; return true">MAILING LIST</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>J</B></FONT>oin the NCIBA <B><A HREF="feedback.html">Mailing List</a></B> and receive free updates from the world of books.</TD></tr>

</tr>
<td><BR></td>
<tr>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="home.html" onMouseOver="window.status='Further information for those who work in the bookstore trade . . . '; return true">NCIBA INFO</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>M</B></FONT>ore <B><A HREF="home.html">Information</a></B> about the Northern California Independent Booksellers Association. [<B>Of interest to bookstores and booksellers</B>.]</TD></tr>

</tr>
</table

<BR>

<CENTER><P><HR WIDTH=66% SIZE=5></CENTER>

<table border=0 cellpadding=10>
<tr>

<td align=left valign=top><IMG SRC="image/goldsite2.gif" ALT="NetGuide Gold Site" WIDTH="70" HEIGHT="70" BORDER="0" align=left vspace=5></td>

<td align=middle>

<P><font color=brown><center>Additional features are already in the works for this website.<BR>Be sure and check back as additional pages are posted.</font></CENTER>

<CENTER><P><B>We would appreciate hearing from you.<BR>
Please send your comments or suggestions to<BR><A
HREF="mailto:office@nciba.com"> office@nciba.com</A><BR>
</B><BR>

<P><B>YOU'RE BOOKLOVER</B><BR><IMG SRC="/cgi-bin/Count2?uname=nciba|num=1|dtype=C" alt="counter">

<P><FONT SIZE=-1>Designed and maintained by Thomas Gladysz.<BR>Comments or corrections regarding this website should be directed to the webmaster<BR><A
HREF="mailto:thomasg@pandorasbox.com">thomasg@pandorasbox.com</A><BR></FONT>

</CENTER>
</td>

<td align=right valign=top><CENTER> <FONT FACE="ARIAL,HELVETICA" SIZE="1"><CENTER><B>Best experienced with
<BR><A HREF="http://www.microsoft.com/ie/ie.htm"><IMG SRC="image/ie_static.gif" WIDTH="88" HEIGHT="31" BORDER="0" ALT="Microsoft Internet Explorer" VSPACE="7"> </A><BR>Click here to start</CENTER> </FONT></td>


</tr>
</table>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-280</DOCNO>
<DOCOLDNO>IA009-000087-B035-260</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/purpose.html 207.44.128.99 19970222112025 text/html 3969
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:20:42 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3798
Last-modified: Thu, 13 Feb 1997 19:36:44 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com-->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  December, 1996   -->
<!--   FILE: purpose.html   -->
<!--   PURPOSE: information page about the NCIBA -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>NCIBA Declaration of Independents</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association information page - here you will find our Declaration of Independents, links to our f.a.q. and more.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading book bookstore bookstores consumer information regional business literature faq">

</HEAD>
<BODY background="image/back.gif">

<CENTER><B><FONT color=brown SIZE=+1><FONT SIZE=+2>N</FONT>ORTHERN <FONT SIZE=+2>C</FONT>ALIFORNIA</font><BR><FONT color=brown SIZE=+2><FONT SIZE=+3>I</FONT>NDEPENDENT <FONT SIZE=+3>B</FONT>OOKSELLERS</font><BR><FONT color=brown SIZE=+1><FONT SIZE=+2>A</FONT>SSOCIATION</FONT></B>

<B><FONT SIZE=+2><P>DECLARATION OF
INDEPENDENTS</FONT></B>

<FONT SIZE=+2><P><B>A</B></font><FONT SIZE=+1>s cities, towns, and neighborhoods deal with the changing landscape of their local business community, we, the independent booksellers of California, reaffirm our commitment to our communities. Independent bookstores value our place in the community, as well as our ongoing connections within it. We'd like to offer some other defining thoughts about independent bookstores.</CENTER>

<P><img src="image/bkiconR.gif"> <B>INDEPENDENT BOOKSELLERS</B> talk with our customers directly and enjoy fulfilling - even exceeding - their expectations, whether its recommending a great book we've just read, or helping you discover new or little known authors or publishers.

<P><img src="image/bkiconR.gif"> <B>INDEPENDENT BOOKSTORES</B> have an onsite owner - we're right there answering questions and making decisions, rather than relying on a corporate office, thousands of miles away.

<P><img src="image/bkiconR.gif"> <B>INDEPENDENT BOOKSELLERS</B> are leaders in the fight against censorship and other threats to freedom of expression.

<P><img src="image/bkiconR.gif"> <B>INDEPENDENT BOOKSTORES</B> reflect the character of our communities. We support local causes. We participate in and fund community activities. We patronize other local businesses and keep our money in the community.</FONT>

<P><CENTER><img width=480 height=21 src="image/rule08.GIF"></CENTER>

<P><CENTER>Our mission is "To promote the vitality, diversity and prosperity of independent bookselling as essential to the life of our communities and crucial to the dissemination of ideas in society." To find out more about the NCIBA, please read our <A HREF="faq.html">F.A.Q. page </a> (frequently asked questions).</CENTER>

<CENTER><B><P>WE APPRECIATE YOUR INTEREST!</B></CENTER>

<P>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-281</DOCNO>
<DOCOLDNO>IA009-000087-B035-290</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/bestsell.html 207.44.128.99 19970222112047 text/html 5777
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:21:01 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 5606
Last-modified: Thu, 13 Feb 1997 21:55:51 GMT
</DOCHDR>
<HTML>
<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com-->
<!--   CREATED:  September, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  monthly, 1997   -->
<!--   FILE: bestsell.html   -->
<!--   PURPOSE: NCIBA bestseller list -->
<!---------------------------------------------------------------------------------------->
<HEAD>
<TITLE>NCIBA bestseller list</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association page of regional bestsellers.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading literature literary regional bestseller book bookstore author book bookstore bestseller bestsellers popular  book bookstore bestseller bestsellers popular  book bookstore bestseller bestsellers popular  book bookstore bestseller bestsellers popular  book bookstore bestseller bestsellers popular  book bookstore bestseller bestsellers popular  book bookstore bestseller bestsellers popular">

</HEAD>
<BODY bgcolor=#ffffff>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<CENTER><FONT SIZE=+2 COLOR=BROWN><B><FONT SIZE=+3>N</FONT>CIBA <FONT SIZE=+3>B</FONT>ESTSELLERS</B></FONT></CENTER>

<P>

<P><FONT SIZE=+1><B>T</B></FONT>he unique character of Northern California and the independent bookstores which serve the region help shape a bestseller list different from other such lists. Though there is some overlap with other regional and national bestseller lists, the NCIBA list reflects the unique hybrid that characterizes Northern California - "West Coast" and high-tech, socially aware and ethnically diverse. 

<P><hr size=12 width=33% align=center>
<P>

<table>
<tr>
<td width=49% valign=top>

<CENTER><H3><font color=brown>HARDCOVER</font></H3></CENTER>

<P> 1. <B>PATH TO LOVE</B>, by Deepak Chopra<BR> (Harmony)
<P> 2. <B>ANGELA'S ASHES</B>, by Frank McCourt<BR> (Scribner)
<P> 3. <B>KITCHEN TABLE WISDOM</B>, by Rachel Naomi Remen<BR> (Riverhead)
<P> 4. <B>ALIAS GRACE</B>, by Margaret Atwood<BR> (Nan A. Talese/Doubleday)
<P> 5.<B> FALLEN MAN</B>, by Tony Hillerman<BR>(HarperCollins)
<P> 6. <B>PARROT IN THE OVEN</B>, by Victor Martinez<BR>(HarperCollins)
<P> 7. <B>AIRFRAME</B>, by Michael Crichton<BR>(Knopf)
<P> 8. <B>A REPORTER'S LIFE</B>, by Walter Cronkite<BR>(Knopf)
<P> 9. <B>SOUL'S CODE</B>, by James Hillman<BR> (Random House)
<P>10. <B>UNDER THE TUSCAN SUN</B>, by Frances Mayes<BR>(Chronicle)

</td>
<td valign=top width=49%>

<CENTER><H3><font color=brown>SOFTCOVER</font></H3></CENTER>

<P> 1. <B>ENGLISH PATIENT</B>,  by Michael Ondaatje<BR>(Vintage)
<P> 2. <B>BOOK OF RUTH</B>, by Jane Hamilton<BR>(Anchor)
<P> 3. <B>SNOW FALLING ON CEDARS</B>, by David Guterson<BR>(Vintage)
<P> 4. <B>SPONTANEOUS HEALING</B>, by Andrew Weil<BR>(Fawcett)
<P> 5. <B>SONG OF SOLOMON</B>, by Toni Morrison<BR> (Penguin)
<P> 6. <B>BURY ME STANDING</B>, by Isabel Fonseca<BR>(Vintage)
<P> 7. <B>THINKING WITH PICTURES</B>, by Temple Grandin<BR>(Vintage)
<P> 8. <B>SHIP FEVER</B>, by Andrea Barrett<BR>(Norton)
<P> 9. <B>STORIES OF VLADIMIR NABOKOV</B>, by Vladimir Nabokov<BR>(Vintage)
<P>10.<B> LAST ORDERS</B>, by Graham Swift<BR>(Vintage)

</td>
</tr>
</table>

<P><hr size=12 width=33% align=center>
<P>

<CENTER><H3><font color=brown>MASS MARKET</font></H3>

<P> 1.<B> HUNDRED SECRET SENSES</B>, by Amy Tan <BR>(Ivy)
<P> 2. <B>HORSE WHISPERER</B>, by Nicholas Evans<BR>(Dell)
<P> 3. <B>LOST WORLD</B>, by Michael Crichton<BR>(Ballantine)
<P> 4. <B>THE POET</B>, by Michael Connelly<BR>(Warner)
<P> 5. <B>PASTWATCH</B>, by Orson Scott Card<BR>(Tor)
</CENTER>
<P>

<HR>

<P><img width=21 height=13 src="image/book.gif"> <B>*</B> The NCIBA bestseller list is compiled by the Northern California Independent Booksellers Association with the cooperation of the following bookstores: <B>The Booksmith</B> and <B>City Lights</B> in San Francisco; <B>A Clean Well-Lighted Place for Books</B> in Larkspur and San Francisco; <B>Kepler's</B> in Menlo Park;<B> Printer's Inc. </B>in Palo Alto; <B>The Avid Reader</B> and <B>The Next Chapter</B> in Davis; <B>Tower Books</B> on Broadway in Sacramento; <B>Walden Pond</B> and <B>Diesel - A Bookstore</B> in Oakland; <B>Moraga Book Company</B> in Moraga; <B>Orinda Books</B> in Orinda;<B> Books Inc.</B> in Walnut Creek; and <B>Avenue Books, Black Oak Books, Cody's Books, Gaia Bookstore,  Moe's Books</B>, and <B>Pegasus Books</B> in Berkeley.

<P><img width=21 height=13 src="image/book.gif"> The NCIBA bestseller list appears in print form in the<I> East Bay Express</I> and <I>Sacramento News and Review</I>.

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-282</DOCNO>
<DOCOLDNO>IA009-000087-B035-321</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/goodread.html 207.44.128.99 19970222112059 text/html 8371
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:21:19 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 8200
Last-modified: Mon, 17 Feb 1997 00:07:32 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com-->
<!--   CREATED:  July, 1996  Best viewed using Netscapeor Microsoft Explorer  -->
<!--   MODIFIED:  December, 1996   -->
<!--   FILE: goodread.html   -->
<!--   PURPOSE: Good Reads - suggested books from the NCIBA -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>"Good Reads" from the NCIBA</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association page of Good Reads - because there is more to reading than just bestsellers.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading literature Good Reads bestsellers author bookstore">

</HEAD>
<BODY bgcolor=#ffffff>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<CENTER><img width=49 height=33 src="image/bookicon.gif"><B><FONT SIZE=+3 color=brown> <FONT SIZE=+4>G</FONT>OOD <FONT SIZE=+4>R</FONT>EADS </B></FONT> <img width=49 height=33 src="image/bookiconL.gif">

<P><font color=green><B>From the members of the <FONT SIZE=+1>N</FONT>orthern <FONT SIZE=+1>C</FONT>alifornia <FONT SIZE=+1>I</FONT>ndependent <FONT SIZE=+1>B</FONT>ooksellers <FONT SIZE=+1>A</FONT>ssociation. These are recommended titles from your local booksellers . . . Good Reads are the books we want to tell you about. Good Reads are the books we are most passionate about.</B></font>

<P><B><I><FONT SIZE=+2>Because there's more to reading <BR>than bestsellers . . . .</FONT></I></B></CENTER>

<HR>

<table>
<tr>
<th><P><IMG align=left hspace=10 width=120 height=186 SRC="image/snow.gif" ALT="book cover"><BR>

<P><B><font color=brown>SNOW FALLING ON CEDARS</font></B><BR>

<B>David Guterson</B> (Vintage $12.00)

<P>The Buzz among independents for this Good Read began in 1994, when booksellers were first introduced to this compelling story of a Pacific Northwest fishing town's reaction to its Japanese-American citizens at the outbreal of WWII and a murder trial following the war that lays bare old wounds. Independent bookstores love discovering a gem like<B> Snow Falling on Cedars </B>and sharing their enthusiasm, with customers, and they've done it with these other featured titles.
</th>
</tr>
</table></TD>

<HR>

<table>
<tr>
<th><P><IMG align=right  hspace=10 width=100 height=160 SRC="image/emerald.gif" ALT="book cover"><BR>

<P><B><font color=brown>EMERALD CITY</font></B><BR>

<B>Jennifer Egan</B> (Doubleday $22.50)

<P>With <B>Invisible Circus </B>and now this collection of sensitive, sophisticated novellas, Jennifer Egan is a young writer to watch. She has a unique voice and her coming-of-age stories are peopled with a wonderful variety of characters.

<P><I>--Janet Boreta, Orinda Books, Orinda</I>
</th>
</tr>
</table></TD>

<HR>

<table>
<tr>
<th><P><IMG align=left width=100 hspace=10 height=160 SRC="image/vanished.gif" ALT="book cover"><BR>

<P><B><font color=brown>THE VANISHED CHILD</font></B><BR>

<B>Sarah Smith</B> (Ballantine $5.95)

<P>This little-known, compelling novel is not only a great read, its the best selling book in our store's history, It has outsold John Grisham, Anne Rice, Sue Grafton . . . just read the first page.

<P><I>--Christy Pascoe, A Clean Well Lighted Place for Books, San Francisco</I>

</th>
</tr>
</table></TD>

<HR>

<table>
<tr>
<th><P><IMG align=right border=1 hspace=10 width=100 height=145 SRC="image/veronica.gif" ALT="book cover"><BR>

<B><font color=brown>VERONICA</font></B><BR>

<B>Nicholas Christopher </B> (Dial Press $22.95)

<P>This is a novel that perhaps only a poet could write. Christopher orchestrates his characters through a mysterious, magical Manhattan with the studied knowledge that in the end, as in the beginning, he is working with symbols in a fictional world where anything is possible. The reader cannot but help but be seduced by his power as a storyteller.

<P><I>--Jeff Johnson, GAIA Bookstore & Community Center, Berkeley</I>
</th>
</tr>
</table></TD>

<HR>

<table>
<tr>
<th><P><IMG align=left hspace=10 width=100 height=160 SRC="image/anthro.gif" ALT="book cover"><BR>

<P><B><font color=brown>AN ANTHROPOLIGIST ON MARS</font></B><BR>

<B>Oliver Sacks</B> (Vintage $13.00)

<P>In seven true tales, Dr. Sacks continues his exploration of human beings with neurological disorders, offering case histories that read like novellas. The joy of this compassionate work is that we are made to see the person and not the disorder. While these are "deeply altered selves," they are also extraordinary doors to alternate ways of perceiving the self."

<P><I>--Amy Thomas, Pegasus Books, Berkeley</I>
</th>
</tr>
</table></TD>

<HR>

<table>
<tr>
<th><P><IMG align=right width=100  hspace=10 height=150 SRC="image/atticus.gif" ALT="book cover"><BR>

<P><B><font color=brown>ATTICUS</font></B><BR>

<B>Ron Hansen</B> (Harper Collins $22.00)

<P>Atticus goes to Mexico to recover the body of his dead son, and is compelled to investigate the circumstances of his son's suicide. Hansen (author of <B>Mariette in Ecstacy</B>) weaves a story that is both an intriguing mystery and a moving portrayal of a father's love.

<P><I>--Kara Jernstrom, Bookshop Santa Cruz, Santa Cruz</I>
</th>
</tr>
</table></TD>

<HR>

<table>
<tr>
<th><P><IMG align=left hspace=10 width=100 height=137 SRC="image/flying.gif" ALT="book cover"><BR>

<P><B><font color=brown>THE FLYING DRAGON ROOM</font></B><BR>

<B>Audrey Wood, illustrated by Mark Teague</B> (Blue Sky Press $14.95)

<P>With her magical prose, Wood explores a young boy's imagination. Using a magic toolbox, he creates a world where wild animals are friendly, a bubble machine works continuously, and extinct dinosaurs come to life. This book helps calm the night time fears of a young child afraid to go to sleep.

<P><I>--Kathleen Caldwell, Bonanza Street Books, Walnut Creek</I>
</th>
</tr>
</table></TD>

<HR>

<table>
<tr>
<th><P><IMG align=right width=100 height=150 hspace=10 SRC="image/man.gif" ALT="book cover"><BR>

<P><B><font color=brown>THE MAN OF THE HOUSE</font></B><BR>

<B>Stephen McCauley </B> (Simon & Schuster $22.00)

<P>A laugh-out-loud funny look at the ties that bind family and friends. The humor stems from McCauley's sharp social and psychological observations of the human foible and its many forms.

<P><I>--David Sjostedt, Copperfield's Books, Sebastopol</I>

</th>
</tr>
</table></TD>

<HR>

<CENTER><P><FONT SIZE=+2><B>AT NCIBA MEMBER STORES, YOU'LL FIND . . . . </B></FONT>

<P><font color=brown><B>Unique Selections & Diversity of Titles</B><BR>

<B>Knowledgeable Staff  Who Love to Read</B><BR>

<B>Stores Catering to Your Needs & Tastes</B><BR>

<B>Locally Owned & Community Involved Businesses</B></font><BR>

<BR>

<P><FONT SIZE=+1><B>T</B></FONT>he unique character of Northern California and the independent bookstores which serve the region help shape a bestseller list different from other such lists. To find out what's really selling in local independent bookstores, please visit our <B><a href="bestsell.html">NCIBA Bestseller</a></B> page.

</CENTER>

<P>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>



</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-283</DOCNO>
<DOCOLDNO>IA009-000087-B035-352</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/stores.html 207.44.128.99 19970222112108 text/html 5573
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:21:26 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 5402
Last-modified: Mon, 17 Feb 1997 00:08:31 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com -->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  December, 1996   -->
<!--   FILE: stores.html   -->
<!--   PURPOSE: NCIBA bookstore list  -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>Northern California bookstores</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association list of member bookstores - here you will find some of your favorite places to shop from all over the region.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading literature regional bookstore bookstores information San Francisco Bay Area East Bay Central Valley Gold Country Sierras North South West booksellers Palo Alto Berkeley San Jose Marin Oakland Silicon consumer shopping Mill Valley Sacramento Davis Fresno Lake Tahoe Santa Cruz Monterey Capitola Salinas Mountain View Santa Rosa Sonoma Napa Wine Country tourism alternative Peninsula Golden State Frisco Mill Valley Sausalito San Raphel">

</HEAD>
<BODY bgcolor=#ffffff>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<P><CENTER><FONT SIZE=+2 color=brown><B><FONT SIZE=+3>N</FONT>CIBA <FONT SIZE=+3>M</FONT>EMBER <FONT SIZE=+3>B</FONT>OOKSTORES</B></FONT></CENTER>

<P><FONT SIZE=+1><B>W</B></FONT>elcome booklovers to the NCIBA directory of member bookstores. Our organization represents more than 300 independent bookstores across Northern California. One of those stores is certainly located in your neighborhood or community. To find an independent bookstore near you, visit one of the regional pages outlined below.

<P>

<P><CENTER><img width=480 height=21 src="image/rule08.GIF"></CENTER>

<P><B><a href="north.html">N<FONT SIZE=-1>ORTH BAY, NORTH COAST </a></FONT> <BR>
(from Sausalito and Marin County north through Wine Country, Mendocino and Arcata)

<P><B><a href="sfstores.html">S<FONT SIZE=-1>AN FRANCISCO</FONT></a></B><BR>
(covers the city of San Francisco)

<P><B><a href="east.html">E<FONT SIZE=-1>AST BAY </FONT></a></B> <BR>
(includes Berkeley, Oakland, Walnut Creek, Hayward, Fremont and nearby communities)

<P><B><a href="south.html">S<FONT SIZE=-1>OUTH BAY, CENTRAL COAST</a> </FONT> </b><BR>
(the Peninsula and beyond; from Palo Alto, San Jose and Silicon Valley south to Santa Cruz, Carmel and Monterey)

<P><B><a href="valley.html">C<FONT SIZE=-1>ENTRAL VALLEY, GOLD COUNTRY, SIERRA NEVADAS</a> </FONT></B> <BR>
(from Mt. Shasta, Grass Valley and Tahoe to Modesto and Fresno; includes Sacramento and Davis)

<P><B><a href="castores.html">S<FONT SIZE=-1>OUTHERN CALIFORNIA AND ELSEWHERE </FONT></a></B> <BR>
(member stores in Southern California, Oregon, Arizona, Nevada and Utah)</B>

<P>

<P><FONT SIZE=+1><B>W</B></FONT>ith these regional directories, you have the opportunity to discover the vitality and diversity of independent booksellers. Usually, you'll find that these bookstores are a reflection of their neighborhood or community, with local owners and staff that love to read and recommend titles to customers. There are general bookstores, bookstores with two or three areas of special concentration, specialty bookstores, and used bookstores. Some are large, some are small, but all of them are unique. They have individual atmospheres, contain undiscovered treasures, and above all, offer staff who are passionate about books and bookselling.

<P><CENTER>Look for the NCIBA logo in the window of your neighborhood or community bookstore.

<P><IMG width=72 height=72 SRC="image/nciba_sml.gif" ALT="NCIBA logo"></CENTER>

<P>Our <B><A HREF="purpose.html">Declaration of Independents</a></B> outlines some of the things we as independent booksellers believe. To find out more about the NCIBA, please read our <B><A HREF="faq.html">F.A.Q. Page </a></B> (frequently asked questions).

<P><font color=brown size=+1><CENTER><B>THANK YOU FOR THINKING "INDEPENDENT."</B></CENTER></font>

<P><hr size=12 width=60% align=center>

<CENTER>
<P><B>To locate NCIBA bookstores with websites, check our page of <A HREF="online.html">Online Stores</a>.<BR>
For further information, please refer to the recently published<BR>
"First and Foremost: A Guide to Northern California's Independent Bookstores"<BR>
(available at independent bookstores everywhere).

<p>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-284</DOCNO>
<DOCOLDNO>IA009-000087-B035-389</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/profile.html 207.44.128.99 19970222112132 text/html 7561
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:21:48 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 7390
Last-modified: Mon, 17 Feb 1997 00:17:19 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com-->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  February, 1997   -->
<!--   FILE: profile.html   -->
<!--   PURPOSE: NCIBA store profile  -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>NCIBA Store Profile</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association profile page - here you will find our monthly profile of an NCIBA member store . . . and some of your favorite places to shop.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading literature regional bookstore consumer shopping book books bookstore bookstores California">

</HEAD>
<BODY bgcolor=#ffffff>

<IMG align=right SRC="/cgi-bin/Count2?uname=nciba|display=clock|dtype=C|negate=1">

<B>An NCIBA store profile . . . <BR>
drawn from FIRST & FOREMOST: A Guide to Northern California's Independent Bookstores</B>

<BR><BR><BR>

<CENTER><P><img src="image/bkiconR.gif"> <FONT color=brown SIZE=+1><B> CROOKS 'N' NOOKS MYSTERY BOOKS & COLLECTIBLES<img src="image/bkicon.gif"><BR></font>
<font color=green>16 Eureka Street,<BR>Sutter Creek, California  95685<BR>
<B>T<FONT SIZE=-1>ELEPHONE:</B></FONT> (209) 267-0956<BR>
<B>H<FONT SIZE=-1>OURS</FONT>:</B> Monday - Saturday 11 - 5:30,  Sun 12:30 - 5:30, Closed Wednesdays<BR>
<B>S<FONT SIZE=-1>TORE FOCUS</FONT>:</B> Mysteries, Gift Items, Children's Books</B>
</FONT></CENTER>

<P>

<P><IMG SRC="image/crooks.gif" hspace=10 width=108 height=151 border=1 align=left  ALT="logo">

<P>Crooks 'n' Nooks Mystery Books & Collectibles is a small bookstore in historic Sutter Creek, California specializing in mysteries, children's books, and unique gifts and cards. 
Two cozy book-lined rooms,<I> including a real nook</I> are furnished with wingback chairs, reading lamps, and tables. The store stocks new and used mysteries, true crime, spy thrillers and children's books. Other bookcases contain old collectible books and mystery puzzles and games. The antique furniture and lace curtains at the windows add to the charm of this unusual store which resides in a 90-year-old farm house. Though a business (and one of two bookstores in town) - the building still retains the cozy feel of home, especially when rain strikes the tin roof. 

<P>Crooks 'n' Nooks was begun when owners Diane Christensen and Sharon Martin met singing in the church choir. Christensen had always been interested in books (with a particular passion for mysteries), and Martin had always wanted to open a gift shop. They combined their talents and cemented their partnership by attending the American Booksellers Association school for booksellers. Christensen and Martin opened Crooks 'n' Nooks in June, 1993. As both women work full-time, Christensen as a librarian in Sacramento County and Martin for the California Youth Authority, their husbands - both Steves - help tend shop during the week. 

<P>Martin describes Crooks 'n' Nooks inventory as an "eclectic mix." The store carries the range of mystery and detective fiction, "everyone from Tony Hillerman to Dick Francis." However, Crooks 'n' Nooks specializes in female mystery writers such as Marcia Muller, Elizabeth George and P.D. James. "There just happen to be so many wonderful female mystery writers - and Elizabeth George is our favorite," raved the bookseller. 

<P>The store also stocks gifts and collectables, some of them mystery related. Among the more unusual items available at Crooks 'n' Nooks are mystery jigsaw puzzles. Individuals have to complete the puzzle in order to solve the mystery. Another unusual gift item is a party game called "Pasta, Passion and Pistols." Intended to be acted out over dinner,  "the game even includes recipes," notes Martin.

<P>The store also carries fantasy and children's books - especially series such as the wildly popular <B>Goosebumps</B>,as well as the Boxcar Children, Nancy Drew and Hardy Boys books. Combining store specialities is a series by the English writer Enid Blyton which are mysteries for children.

<P><IMG SRC="image/nooks.jpg" hspace=10 width=216 height=137 border=1 align=right ALT="storefront">

<P>One of Crooks 'n' Nooks distinguishing features is Bentley, a life-size wooden butler dressed according to season. Bently greets customers with his tray of "Mostly Murder" newsletters. Depending on the weather, Bently may be found on the front porch or inside the shop. And depending on the season, Bently has been known to sport a Halloween cape and mask, Christmas cap or even a springtime garland.

<P>Crooks 'n' Nooks prides itself on "the personal touch." The store provides customers with help in finding books, and it is not unusual for individuals to receive a phone call letting them know a book they might enjoy has arrived. The store hosts occassional author readings and signings. Other special events sponsored by the Crooks 'n' Nooks have included mystery weekends at a local bed & breakfast, and mystery dinners involving a local winery and theater group. Telephone for information on events or directions to the store, which is located just an hour from Sacramento. 

<P>Click on the <B><a href="http://www.mapblast.com/mapblast/locator.html">MapBlast</a></B> map below to zoom-in or zoom-out for additional detail, as well as obtain driving directions or yellow page listings of nearby businesses. [<B><font color=brown> Return to this page by using your back button.</font></B>]

<br clear=all>

<P><CENTER>
<!--Cut below this line----------------------------------------->
  <!--Free map from Vicinity-->
  <A
  HREF="http://www.vicinity.com/yt.hm?CMD=MAP&FAM=mapblast&SEC=blast&GC=X:-120.79495|Y:38.39319|LT:38.39319|LN:-120.79495|LS:20000|c:Sutter_Creek|s:CA|z:95685&IC=::Smallcross:Crooks+'n'+Nooks&LV=3">
  <IMG BORDER=3 WIDTH=425 HEIGHT=250 SRC="http://www.vicinity.com/gif?&CT=38.39319:-120.79495:20000&IC=38.39319:-120.79495:Smallcross:Crooks+'n'+Nooks&FAM=mapblast"></A>
  <center>Click on the map to browse</center>
  <!--End of Vicinity Map-->
  <!--Cut above this line----------------------------------------->


</CENTER>

<P>

<CENTER>
<P><B>To locate other NCIBA stores throughout Northern California,<BR> please check our <A HREF="members.html">Bookstore</a> page or refer to<BR>
"First and Foremost: A Guide to Northern California's Independent Bookstores"<BR>
(available at independent bookstores everywhere).

<p>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-285</DOCNO>
<DOCOLDNO>IA009-000087-B035-422</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/aisles.html 207.44.128.99 19970222112155 text/html 11817
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:22:07 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 11645
Last-modified: Thu, 13 Feb 1997 21:55:48 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com  -->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  February, 1997   -->
<!--   FILE: aisles.html   -->
<!--   PURPOSE:  bookstore news from the NCIBA -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>"In the Aisles," news from your local bookseller</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association "In the Aisles" page - here you'll find news, announcements, gossip and goings-on from your local bookseller.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading book bookstore bookstores consumer information regional business literature news">

</HEAD>
<BODY bgcolor=#ffffff>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<CENTER><FONT SIZE=+2 COLOR=BROWN><B><FONT SIZE=+3>I</FONT>N <FONT SIZE=+3>T</FONT>HE <FONT SIZE=+3>A</FONT>ISLES:</B> </FONT><FONT SIZE=+2 COLOR=BROWN><B><FONT SIZE=+3>N</FONT>EWS <FONT SIZE=+3>F</FONT>ROM <FONT SIZE=+3>Y</FONT>OUR <FONT SIZE=+3>L</FONT>OCAL <FONT SIZE=+3>B</FONT>OOKSELLER</B></FONT>

<P><font size=+1><B>Welcome to "In the Aisles" - news, announcements, gossip & goings-on from your local bookseller. Check back here for store milestones, special events, happenings, humor and more. Newest items are placed near the top of the page.</B></font>

<P><IMG SRC="/cgi-bin/Count2?uname=nciba|display=date|dtype=C|negate=1"></center><BR>

<P>

<P><CENTER><B><font color=green>AUTHOR SAYS "THANK YOU"</font></B></CENTER>

<P><IMG hspace=10 align=right width=107 height=147 SRC="image/smith.gif" ALT="sarah smith">

<P><img width=21 height=13 src="image/book.gif"> Boston author <B>Sarah Smith</B> (pictured holding book) paid a visit to <B>A Clean Well-Lighted Place for Books</B> in San Francisco to celebrate the publication of her novel "The Knowledge of Water" (Ballantine). A period mystery, the book takes place in the Paris of 1910, when a torrential flood ravages the city. The San Francisco store created a special window display around the book utilizing a 3-D puzzle of the Eiffel Tower. Pictured with the author is bookseller <B>Christy Pascoe</B>, whose enthuisiastic handselling of Smith's earlier paperback, "The Vanished Child" (Ballantine), made industry news last year. Pascoe and A Clean Well-Lighted Place have sold nearly 3000 copies of "The Vanished Child," making it the bestselling book in the store's history.

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>BOOKSELLERS RAISE FUNDS FOR LITERACY</font></B></CENTER>

<P><img width=21 height=13 src="image/book.gif"> A group of independent bookstores in Santa Cruz County recently presented a check for $350.00 to the Literacy Program of the Santa Cruz Volunteer Center. The check was presented by <B>Lee Duffus</B>, owner of <B>Bookworks</B> in Aptos, at a ceremony held at the<B> Santa Cruz City-County Public Library</B>. The money had been raised at "Word by Word," a literary event sponsored by area booksellers during National Independent Bookstore Week. The theme of this year's NIBW was "Building Community Foundations." Participating bookstores included Bookworks and <B>Mockingbird Books</B> in Aptos; <B>Village Book Cafe</B> in Scotts Valley; <B>Avalon Visions, Capitola Book Cafe</B> and <B>Seeds of Change</B> in Capitola; and <B>Bookshop Santa Cruz, Herland Book Cafe, The Literary Guillotine, Sleepy Dragon Book Bistro, Gateway Book and Gift, Logos Books and Records,  Westside Stories, Treasures of the Heart</B> and <B>Zamzam</B> in Santa Cruz.

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>MARIN BOOKSTORE HELPS CRACK THEFT RING</font></B></CENTER>

<P><IMG hspace=10 align=left SRC="image/bk_pass.gif" width=268 height=70 ALT="book passage">

<P><img width=21 height=13 src="image/book.gif"> <B>Book Passage</B> in Corte Madera was involved in a sting operation that led to the arrests of a bookstore owner and an alleged supplier of stolen books. According to published reports, police say the two suspects have been part of a stolen book ring operating in the Bay Area for 10 years. After suffering substantial shoplifting losses, Book Passage hired an undercover police officer to moniter the store. The off-duty officer caught a shoplifter who provided information pointing toward a book theft ring. The Corte Madera and San Francisco police departments then launched a criminal investigation using books supplied by the Corte Madera store. Police eventually arrested two men after one was allegedly observed selling stolen books to the other. Investigators recovered numerous boxes of books they suspected were stolen, including the books provided by Book Passage.

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>TWO STORES CELEBRATE BIG "TWO-O"</font></B></CENTER>

<P><img width=21 height=13 src="image/book.gif"> Two NCIBA member stores celebrating their 20th anniversaries are<B> Bookworks</B> in Aptos and <B>The Booksmith</B> in San Francisco. Bookworks celebrated two decades in business on September 20th by  serving customers slices of cake and discounting merchandise an approprate 20 percent. The Bookworks' celebration continues through the end of the year on the 20th of each month (sans cake) with special sales and drawings for free books and gift certificates.

<P><IMG hspace=10 align=right SRC="image/booksmit.gif" width=71 height=74 ALT="booksmith">

<P>And in San Francisco, The Booksmith celebrated its 20th anniversary on October 20th. A Haight Ashbury fixture, The Booksmith had a sale as well as hosting approximately 20 authors on the day of its anniversary celebration. Bay Area authors<B> Ron Hansen, Ginu Kumani, Joel Selvin</B> and others were on hand helping The Booksmith celebrate while "working" various sections of the store.

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>OVERHEARD IN THE AISLES</font></B></CENTER>

<P><img width=21 height=13 src="image/book.gif"> Overheard in the drama section of the <B>Alexander Book Company</B> in downtown San Francisco: "Oh, I just love Checkov - don't you?" "Ya, he was ok in <I>Star Trek</I> - but I haven't read his book."

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>BAY AREA BOOKSTORE EVENTS</font></B></CENTER>

<P><img width=21 height=13 src="image/book.gif"> With all the events going on in independent bookstores across the Bay Area, it can sometimes be difficult to keep up. One central source of information is a page devoted to <B><A HREF="http://www.culturewave.com/culturewave/ba-bookstore-events/">Bay Area Bookstore Events</A></B>. Check it out and keep your finger on the pulse.

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>LOCAL BOOKSTORES MAKE NEWS!</font></B></CENTER>

<P><img width=21 height=13 src="image/book.gif"> From community newspapers to the <I>New York Times</I> to local and network television, NCIBA member stores are making news. Whether its community involvement, new business practices, unusual or newsworthy happenings or the uniqueness of their stores, NCIBA member bookstores are at the forefront of the industry. Follow these outside links to news stories featuring Northern California bookstores. [ <font color=brown><B>Use your back button to return to this page. </B></font>]

<UL>

<li><P><A href="http://www.sfgate.com/cgi-bin/examiner/article.cgi?year=1997&month=01&day=05&article=METRO6384.dtl">"Ali brings his power to Oakland bookstore"</a>  [ <B>San Francisco Examiner</B> ] <I>January 5, 1997</I><P>

<li><P><A href="http://www.sfgate.com/programs/srch_archive/srch_archive_wrap?unregistered=true&WAISdocFile=/WAISlink/chronicle/archive/1996/12/29/RV66543.DTL&WAISdbName=/doc_root/wais/chronicle/1996&WAISaction=retrieve&WAISdocID=4038526973+1+0+0&WAISheadline=+BETWEEN+THE+LINES+--+The+Book+Capital+of+the+U.S.">"BETWEEN THE LINES -- The Book Capital of the U.S."</a> [ <B>San Francisco Chronicle</B> ] <I>December 29, 1996</I> <P>

<li><P><A href="http://www.sfgate.com/programs/srch_archive/srch_archive_wrap?unregistered=true&WAISdocFile=/WAISlink/examiner/archive/1996/11/03/BUSINESS2632.dtl&WAISdbName=/doc_root/wais/examiner/1996&WAISaction=retrieve&WAISdocID=3820117631+0+0+0&WAISheadline=Bound+and+determined">"Bound and determined: Bay Area booksellers find that reports of their imminent death were an exaggeration"</a> [ <B>San Francisco Examiner</B> ] <I>November 3, 1996</I> <P>

<LI><P><a href="http://www.bookweb.org/reading/specialty/travel/580.html">"Booksellers Toast to 20 Years!"</a> [ <B>Travel Bookselling</B> ] <I>Autumn, 1996</I><P>

<LI><P><a href="http://www.bookweb.org/news/btw/477.html#booksmith">"The Booksmith, San Francisco 20th Anniversary"</a> [ <B>Bookselling This Week</B> ] <I>October 28, 1996</I><P>

<LI><P><a href="http://www.bookweb.org/reading/features/491.html">"WEB WORLD: Looks Aren't Everything"</a> [ <B>American Bookseller</B> ] <I>October, 1996</I><P>

<li><P><a href="http://www.sfgate.com/programs/srch_archive/srch_archive_wrap?unregistered=true&WAISdocFile=/WAISlink/chronicle/archive/1996/09/18/DD65201.DTL&WAISdbName=/doc_root/wais/chronicle/1996&WAISaction=retrieve&WAISdocID=7081910815+0+0+0&WAISheadline=+Pages+on+the+Web+Fans+of+the+printed+word+are+finding+a+new+use+for+the+Internet+--+buying+books+online">"Pages on the Web: Fans of the printed word are finding a new use for the Internet - buying books online"</a> [ <B>San Francisco Chronicle</B> ]  <I>September 18, 1996</I><P>

<LI><P><a href="http://www.bookweb.org/reading/specialty/scitech/273.html">"More Than Medical Books at the Ever-Growing Stacey's"</a> [ <B>Scientific & Technical Bookselling</B> ] <I>Spring, 1996</I> <P>

<P>* free registration and password required to enter this site

</ul>
<P>

<P><hr size=12 width=33% align=center>

<CENTER><B><P>Individuals or bookstores wishing to submit material to be included on this page should email their submissions to the NCIBA <A
HREF="mailto:thomasg@slip.net">web administrator</A>. Electronic form and submission preferred. Material (including written comments, newsletters, clippings and photographs) may also be sent via postal mail to "NCIBA In the Aisles," 1518 Church Street, San Francisco, California  94131. Those desiring return of posted materials should enclose a stamped, self-addressed envelope.

<font color=purple><B><P>WE APPRECIATE YOUR INTEREST!</B></font></CENTER>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-286</DOCNO>
<DOCOLDNO>IA009-000087-B035-461</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/online.html 207.44.128.99 19970222112215 text/html 7045
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:22:33 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 6874
Last-modified: Sun, 16 Feb 1997 22:03:24 GMT
</DOCHDR>
<HTML>
<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com -->
<!--   CREATED:  August, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  January, 1997   -->
<!--   FILE: online.html   -->
<!--   PURPOSE: listing of online NCIBA stores   -->
<!-------------------------------------------------------------------------------------->

<HEAD>
<TITLE>Online NCIBA Bookstores</TITLE>

<META NAME="description" CONTENT="Listing of online bookstores who are members of the Northern California Independent Booksellers Association (NCIBA).">

<META NAME="keywords" CONTENT="Northern California Independent Booksellers Association NCIBA bookstore bookstores store stores book books regional online web page webpage internet virtual consumer information  bookstore bookstores store stores book books  bookstore bookstores store stores book books  bookstore bookstores store stores book books  bookstore bookstores store stores book books  bookstore bookstores store stores book books  bookstore bookstores store stores book books  bookstore bookstores store stores book books  bookstore bookstores store stores book books  bookstore bookstores store stores book books bookstore bookstores store stores book books ">

</HEAD>
<BODY BGCOLOR=#ffffff>

<CENTER><B><FONT SIZE=+2 color=brown> <FONT SIZE=+3>O</FONT>NLINE <FONT SIZE=+3>N</FONT>CIBA <FONT SIZE=+3>S</FONT>TORES</FONT></B></CENTER>

<CENTER><B>NCIBA member stores were among the first in the
nation to go online. They are also some of the most interesting and practical sites devoted to books that you will find on the net.<BR> Why not virtually visit one of these stores today!</B>
<P>

<img width=480 height=21 src="image/rule08.GIF"></CENTER>

<P><IMG align=right width=200 height=127 border=5 SRC="image/openbook.gif" ALT="openbook">

<P><A HREF="http://www.wheel.dcn.davis.ca.us/~bmickle/Avid_Reader/">Avid
Reader</A> [ Davis / Sacramento ] </P>

<P><A
HREF="http://www.bampfa.berkeley.edu">Berkeley Art Museum Store</a> [ Berkeley ]

<P><A HREF="http://www.culturewave.com/culturewave/ba-bookstore-events/boak.htm">Black
Oak Books</A> [ Berkeley ] </P>

<P><A HREF="http://abcbooks.com">A Book Collectors Bookstore</A>  [ Novato ]
</P>

<P><A HREF="http://www.bookpassage.com/">Book Passage, Inc.</A> [ Corte
Madera ] </P>

<P><A HREF="http://www.culturewave.com/culturewave/ba-bookstore-events/bksrev.htm">Books
Revisited</A> [ San Rafael ] </P>

<P><A
HREF="http://www.bookloft.com">Bookloft</a> [ Mendocino ]

<P><A HREF="http://www.insideout.com/pub/bkshlf/index.htm">Bookshelf at
Hooligan Rocks</A> [ Truckee ] </P>

<P><A HREF="http://www.booksmith.com">The Booksmith</A> [ San Francisco ] </P>

<P><a href="http://www.buildersbooksite.com">Builders Booksource</a> [ San Francisco / Berkeley ]

<P><A HREF="http://www.cruzio.com/~bookcafe">Capitola Book Cafe</A> [ Capitola ]
</P>

<P><A HREF="http://town.hall.org/places/city_lights/">City Lights Books</A>
[ San Francisco ] </P>

<P><A HREF="http://www.bookstore.com/">A Clean Well Lighted Place for Books</A>
[ Cupertino / San Francisco / Larkspur ] </P>

<P><a href="http://www.cobblestonebooks.com">Cobblestone Books</a> [ Sacramento ]

<P><A HREF="http://www.codysbooks.com/">Cody's Books</A> [ Berkeley ] </P>

<P><A HREF="http://www.clbooks.com/index.html">Computer Literacy Bookshops</A>
[ San Jose ] </P>

<P><A HREF="http://www.darkcarnival.com/">Dark Carnival Bookstore</A> [ Berkeley ]
</P>

<P><A HREF="http://www.adlbooks.com/">A Different Light</A> [ San Francisco ]
</P>

<P><A HREF="http://home.earthlink.net/~duttons">Dutton's Brentwood</a> [ Los Angeles ] </p>

<P><A HREF="http://futfan.com/home.html">Future Fantasy Bookstore</A> [ Palo
Alto ] </P>

<P><A HREF="http://www.culturewave.com/culturewave/ba-bookstore-events/gaia.htm">Gaia
Bookstore</A> [ Berkeley ] </P>

<P><a href="http://www.gallerybooks.com">Gallery Bookshop & Bookwinkle's Children's Books</a> [ Mendecino ]

<P><A
HREF="http://members.aol.com/gsteps/books.html">Giant Steps</a> [ Fremont ]

<P><A
HREF="http://www.goodvibes.com">Good Vibrations</a> [ San Francisco ] </p>

<P><A
HREF="http://members.aol.com/GBooksinc/goodenough.html">Goodenough Books</a> [ Livermore ]

<P><A
HREF="http://www.sfo.com/~kayo">Kayo Books</a>  [ San Francisco ] </p>

<P><A
HREF="http://www.keplers.com">Keplers</a> [ Menlo Park ]

<P><A HREF="http://msbooks.com/msbooks/">Midnight Special Bookstore</A>
[ Santa Monica ] </P>

<P><A HREF="http://www.mtbs.com">Modern Times Bookstore</A>
[ San Francisco ] </P>

<P><A HREF="http://moesbooks.com/moe.htm">Moe's Books</A> [ Berkeley ] </P>

<P><A HREF="http://www.kerouac.com/">Monterey Coffeehouse Bookstore</A>
[ Monterey ] </P>

<P><A HREF="http://www.pibooks.com/">Printer's Inc. Bookstore</A> [ Palo
Alto] </P>

<P><A
HREF="http://www.wco.com/~readrom">Reading, Rhythm and Rom</a> [ Petaluma ]

<P><A
HREF="http://www.bookstore.sfsu.edu">San Francisco State University Bookstore</a>  [ San Francisco ] </p>

<P><A HREF="http://www.secretstaircasebooks.com/">Secret Staircase Bookshop</A>
[ Redwood City ] </P>

<P><A HREF="http://www.bookweb.org/bookstore/shambhalabooks/">Shambhala
Booksellers</A> [ Berkeley ] </P>

<P><A HREF="http://www.staceys.com">Stacey's Professional Bookstore</A>
[ Palo Alto / Cupertino / San Francisco ] </P>

<P><A HREF="http://www-bookstore.ucdavis.edu">UCD Bookstore</A> [ Davis ]
</P>

<P><A HREF="http://www.aimnet.com/~upb/">University Press Books</A> [ Berkeley ]
</P>

<P><A HREF="http://www.bookweb.org//bookstore/villageb/">Village Books</A>
[ Mt. Shasta ] </P>

<P><A HREF="http://www.wessexbooks.com">Wessex Books &amp;
Records </A>[ Menlo Park ] </P>

<CENTER>

<P><B>To locate other NCIBA stores throughout Northern California,<BR> please check our <A HREF="stores.html">Bookstore</a> page or refer to the recently published<BR>
"First and Foremost: A Guide to Northern California's Independent Bookstores"<BR>
(available at independent bookstores everywhere).
<P>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-287</DOCNO>
<DOCOLDNO>IA009-000087-B036-16</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/news.html 207.44.128.99 19970222112226 text/html 20995
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:22:45 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 20823
Last-modified: Thu, 13 Feb 1997 21:55:58 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com -->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  February, 1997   -->
<!--   FILE: news.html   -->
<!--   PURPOSE:  book news from the NCIBA -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>News from the World of Books</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association Booknews page - here you'll find news, announcements and more from the world of books.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading book bookstore bookstores consumer information regional business literature news book books reading literature news California bookstore bookstores book books reading literature news California bookstore bookstores book books reading literature news California bookstore bookstores book books reading literature news California bookstore bookstores book books reading literature news California bookstore bookstoresbook books reading literature news California bookstore bookstores">

</HEAD>
<BODY bgcolor=#ffffff>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<CENTER><IMG width=40 height=32 SRC="image/newsL.gif" ALT="newspaper"><FONT SIZE=+2 COLOR=BROWN><B><FONT SIZE=+3>N</FONT>EWS <FONT SIZE=+3>F</FONT>ROM <FONT SIZE=+3>T</FONT>HE <FONT SIZE=+3>W</FONT>ORLD <FONT SIZE=+3>O</FONT>F <FONT SIZE=+3>B</FONT>OOKS</B></FONT> <IMG width=40 height=32 SRC="image/newsR.gif" ALT="newspaper">

<P><FONT SIZE=+1><B>News, events and happenings from the Bay Area to Northern California and beyond. Check back here for news from the world of books and publishing, including prize announcements (from the local "Great Read" awards to the Pulitzer and Nobel), book festivals, special events and more. Newest items are placed near the top of the page.</B></FONT>

<P><IMG SRC="/cgi-bin/Count2?uname=nciba|display=date|dtype=C|negate=1"><BR></CENTER>

<P>

<P><CENTER><B><font color=green>PIERPONT MORGAN LIBRARY EXHIBIT ON VIEW</font></B></CENTER>

<P><IMG SRC="image/pierpont.gif" align=right hspace=10 height=170 width=127 ALT="pierpont morgan">

<P><img width=21 height=13 src="image/book.gif"> A selection of masterpieces from the <B>The Pierpont Morgan Library</B> in New York City - including numerous literary manuscripts and books - is currently on display at the M.H. DeYoung Museum in San Francisco's Golden Gate Park (through April 27th).

<P>Masterpieces from Library includes ancient Near Eastern cylinder seals, medieval and renaissance illuminated manuscripts, early printed books and bindings, old master drawings, authors' and composers' original manuscripts, and Americana. Highlights include a mid-l0th-century Spanish manuscript, the earliest illustrated copy of Beatus's commentary on the Apocalypse; one of the 11 extant vellum copies of the Gutenberg Bible (ca. 1455); original manuscripts by Byron, Charlotte Bront, Charles Dickens, Henry David Thoreau and Mark Twain; and drawings by such artists/writers as William Blake, John Ruskin, William Morris and Beatrix Potter.

<P>The exhibit represents the most comprehensive selection from the Library's holdings to travel in 40 years, and presents a magnificent survey of the artistic, literary, and musical achievements of Western civilization from ancient to modern times. For more information on the DeYoung exhibit, visit their website at <B><a href="http://wwwfamsf.org/legion/exhibition/morgan/index.html">http://wwwfamsf.org/legion/exhibition/morgan/index.html</a></B>.

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>PLANS SET FOR NATIONAL POETRY MONTH</font></B></CENTER>

<P><IMG SRC="image/poster.gif" align=left hspace=10 width=191 height=261 ALT="national poetry month">

<P><img width=21 height=13 src="image/book.gif"> The <B>Academy of American Poets</B> has announced plans for the second annual National Poetry Month, to take place in April of this year. Among the scheduled events is a Tax Day celebration of T.S. Eliot's <B> <I>The Waste Land</I></B> ("April is the cruelest month . . . ."). The Acedemy will join with publisher <B>Harcourt Brace</B> to commemorate the poem's 75th anniversary by distributing thousands of free copies of a special edition of the poem at post offices all over the country. 

<P>The Academy will also work with the <B>American Booksellers Association</B>, the <B>American Library Association</B>, and other institutions to mount an ambitious program that will include a poetry website, readings at more than 30 major public libraries across the country, a special Poets Laureate reading at the <B>Library of Congress</B>, and the distribution of 180,000 posters to bookstores, libraries and schools. Among the featured items at the website (<B><a href="http://www.poets.org">http://www.poets.org</a></B>) will be a chat room, a listing of prominent poetry awards and winners and links to related sites.

<P>National Poetry Month made its debut in 1996, when organizers say more than 4,000 schools, libraries, bookstores and community centers participated with readings, contests, projects and displays. The month was officially recognized by President Clinton, New York City Mayor Rudolph Giuliani and other officials across the nation. 

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>ASTRONAUT LOVES BOOKSTORES</font></B></CENTER>

<P><img width=21 height=13 src="image/book.gif"> One of the things astronaut <B>Shannon Lucid</B> missed most while living on the Russian space station Mir was browsing through bookstores. Upon her return, the bookloving extra-terrestrial made up for lost time. ``We landed on a Thursday, didn't we? I was in the bookstore on Saturday,'' Lucid is reported to have said.

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>BAY AREA LOVES INDEPENDENTS</font></B></CENTER>

<P><img width=21 height=13 src="image/book.gif"> An informal survey of book consumers conducted at the <B>San Francisco Bay Area Book Festival</B> underscores the vitality of independent bookselling in Northern California. The survey asked, in part, where consumers bought books (independent bookstores or national chains) and what they liked best about buying from their preferred store.

<P>Independents were the primary source for 85% of the respondents, while 13% favored chains and 2% chose both options. Additionally, 60% of the consumers who preferred independents said that their bookstore has recommended a book to them, while the chain store recommended percentage was less than 10%. Most of those who completed the survey had special ordered a book and were pleased with the service provided. 

<P>When asked what they liked best about their preferred store, respondents who favored chain stores answered selection - 29%, price - 22% and convenient location - 12%. Respondents who favored independent bookstores answered selection - 45%, knowledge of books - 15%, support of local businesses - 13%, service - 12%, ambience/atmosphere - 12%, staff - 10%, and friendly people - 10%.

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>GRAHAM SWIFT WINS BOOKER PRIZE</font></B></CENTER>

<P><img width=21 height=13 src="image/book.gif"> <B>Graham Swift</B> won the 1996 Booker Prize for his comic novel, <B><I>Last Orders</I></B>. The prize was established in 1968 and honors the best novel written in English in Britian or one of its Commonwealth nations. The author, a 47-year old Londoner, collected a check for $32,000 at a ceremony to honor the winner.

<P><B><I>Last Orders</I></B> tells the story of four people who meet to carry out the dying wish of their friend, who asked that his ashes be scattered into the sea off the county of Kent.  The chairman of the Booker judges noted that "Choosing the winner was torture, but we finally settled on <B><I>Last Orders,</I></B> a wonderful book that will give great pleasure to thousands of people."

<P>For a list of previous winners, please refer to the NCIBA <B><a href="booker.html">Booker Award</a></B> page.

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>POLISH POET WINS NOBEL PRIZE</font></B></CENTER>

<P><IMG hspace=10 align=right width=100 height=179 SRC="image/nobel.gif" ALT="by Anna Baranczak">

<P><img width=21 height=13 src="image/book.gif"> Polish poet <B>Wislawa Szymborska</B>, described as ``the Mozart of poetry,'' won the 1996 Nobel Prize in literature.  Szymborska, 73, lives in the Polish city of Krakow. Her work has appeared frequently in the<I> New Yorker</I>, and she was the inspiration for the movie ``Red.''

<P>Critics have described her as being both deeply political and witty at the same time. Her verse is marked by high seriousness, delightful inventiveness, a prodigal imagination, and enormous technical skill. Szymborska is regarded as one of the best representitives of Polish poetry since the second World War. 

<P>The Nobel citation describes her as ``the Mozart of poetry, not without justice in view of her wealth of inspiration and the veritable ease with which her words seem to fall into place.'' Her most recent book is 1993's ``The End and the Beginning,'' not yet translated into English. Works available in English include ``View With a Grain of Sand'' (Harcourt, Brace) ``People on a Bridge'' (Dufour) and ``Sounds, Feelings, Thoughts: Seventy Poems'' (Princeton).  For further information, please refer to the <B><a href="http://www.nobel.se/announcement-96/presseng96.html">Press Release </a></B> from the Nobel Prize Foundation. (photo of the poet by Anna Baranczak)

<P><P>For a list of previous winners, please refer to the NCIBA <B><a href="nobel.html">Nobel Prize</a></B> page.

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>NCIBA CO-PUBLISHES REGIONAL BOOKSTORE GUIDE</font></B></CENTER>

<P><IMG hspace=10 width=120 height=181 align=left SRC="image/foremost.gif" ALT="first & foremost">

<P><img width=21 height=13 src="image/book.gif"> The Northern California Independent Booksellers Association - in association with <B>Heydey Books</B> - has published a guide to independent bookstores across Northern California. <B>First & Foremost: A Guide to Northern California's Independent Bookstores</B>, authored by local writer Charlene Akers, highlights more than 300 stores. As every reader and browser knows, bookstores are not only a source for books - but, as often the centers of their neighborhood or community, for information and entertainment.

<P>The book, which retails for $12.95, can be found in bookstores throughout the region. Ask your local bookseller how you can get a copy.

<br clear=all>

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>WEB SITE OFFERS INDEPENDENT RECOMMENDATIONS</font></B></CENTER>

<P><img width=21 height=13 src="image/book.gif"> Former bookseller <B>Joan Call</B> has launched <B><a href=" http://www.independentreader.com">The Independent Reader</a></B>, a World Wide Web site offering book recommendations from 13 independent bookstores around the country. Each of the participating stores submits a recomendation in five different categories: new fiction, new non-fiction, softcover fiction, softcover non-fiction, and mysteries. The site then gathers the listings from each bookstore while adding extra information from publishers and building links to related internet sites. A sixth listing for a wildcard selection can also be found at The Independent Reader. Web surfers can view the recommended titles by store or by category, as well as print out a combined list of all recommended books.

<P>The site also includes a miniature home page for each bookstore detailing the store's philosophy, community involvement and current and past recommendations. Participating NCIBA stores are <B>Cody's Books</B> in Berkeley and <B>A Clean Well-Lighted Place for Books</B> in San Francisco. Other independent stores from around the country who are also featured on the site are Powell's Books in Portland, Oregon; Elliott Bay Books in Seattle; Tattered Cover in Denver; Prairie Lights in Iowa City; Women & Children First in Chicago; Hungry Mind in St. Paul; That Bookstore in Blytheville, Arkansas; Talking Leaves Books in Buffalo, New York;  Partners & Crime in New York City; Bunch of Grapes Bookstore in Martha's Vineyard; and Harvard Book Store in Cambridge. 

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>NCIBA ISSUES REGIONAL BOOKSTORE DIRECTORIES</font></B></CENTER>

<P><IMG hspace=10 align=right width=150 height=190 SRC="image/art.gif" ALT="brochure art">

<P><img width=21 height=13 src="image/book.gif"> The<B> Northern California Independent Booksellers Association</B> announced the release of five new regional directories to bookstores across Northern California. The full-color brochures include maps and detailed listings of more than 300 NCIBA member stores throughout San Francisco, the East Bay, the North Bay and North Coast, the South Bay and South Coast, and the Central Valley, Gold Country and Sierras. The NCIBA hopes the brochures will give consumers the opportunity to discover the vitality and diversity of independent bookstores. 

<P>The brochures will be distributed to bookstores, libraries, chambers of commerce, hotel lobbies, bed and breakfasts and elsewhere.  Ask your local bookseller how you can get a copy.

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>FTC DROPS PROBE OF PUBLISHER DEALS WITH BOOKSTORES</font></B></CENTER>

<P><img width=21 height=13 src="image/book.gif"> The<B> Federal Trade Commission</B> has dropped its eight-year investigation into allegations that major publishing companies discriminated against independent booksellers by giving discounts to major bookstore chains. The FTC said the industry has changed so dramatically since 1988 - in part to private settlements between independents and publishing companies - that the investigation was no longer worth the time and expense. 

<P>

<P><hr size=12 width=33% align=center>

<P><CENTER><B><font color=green>OTHER NEWS FROM THE WORLD OF BOOKS</font></B></CENTER>

<P><img width=21 height=13 src="image/book.gif"> Booklovers and cybersurfers can follow these links to outside news stories from the world of books. [Use your back button to return to this page.]

<UL>

<li><P><a href="http://www.sfgate.com/cgi-bin/chronicle/article.cgi?file=DD65998.DTL&directory=/chronicle/archive/1997/02/11">"A Spicy Passage From India: Two worlds blend in author's prose"</a>  [ <B>San Francisco Chronicle</B> ]<I> February 11, 1997</I><P>

<li><P><a href="http://www.sfgate.com/cgi-bin/examiner/article.cgi?year=1997&month=01&day=03&article=PENINSUL5057.dtl">"New chapter for women: Redwood City bookstore focuses on women's issues, needs and comforts"</a>  [ <B>San Francisco Examiner</B> ] <I>January 3, 1997</I><P>

<li><P><A href="http://www.sfgate.com/programs/srch_archive/srch_archive_wrap?unregistered=true&WAISdocFile=/WAISlink/chronicle/archive/1996/12/29/RV66543.DTL&WAISdbName=/doc_root/wais/chronicle/1996&WAISaction=retrieve&WAISdocID=4038526973+1+0+0&WAISheadline=+BETWEEN+THE+LINES+--+The+Book+Capital+of+the+U.S.">"BETWEEN THE LINES -- The Book Capital of the U.S."</a> [ <B>San Francisco Chronicle</B> ] <I>December 29, 1996</I> <P>

<li><P><A href="http://www.bookweb.org/reading/features/538.html">"California Connections"</a> [ <B>American Bookseller</B> ] <I>December, 1996</I> <P>

<li><P><A href="http://www.sfgate.com/programs/srch_archive/srch_archive_wrap?unregistered=true&WAISdocFile=/WAISlink/examiner/archive/1996/11/27/NEWS11052.dtl&WAISdbName=/doc_root/wais/examiner/1996&WAISaction=retrieve&WAISdocID=3853819027+23+0+0&WAISheadline=Book+flow+stops+at+S.F.+Library">"Book flow stops at S.F. Library"</a> [ <B>San Francisco Examiner</B> ] <I>November 27, 1996</I> <P>

<li><P><A href="http://www.sfgate.com/programs/srch_archive/srch_archive_wrap?unregistered=true&WAISdocFile=/WAISlink/examiner/archive/1996/11/03/METRO2880.dtl&WAISdbName=/doc_root/wais/examiner/1996&WAISaction=retrieve&WAISdocID=3853819027+1+0+0&WAISheadline=Book+lovers+unite+in+S.F.">"Book lovers unite in S.F."</a>  [ <B>San Francisco Examiner</B> ] <I>November 3, 1996</I> <P>

<li><P><A href="http://www.sfgate.com/programs/srch_archive/srch_archive_wrap?unregistered=true&WAISdocFile=/WAISlink/chronicle/archive/1996/11/01/DD44002.DTL&WAISdbName=/doc_root/wais/chronicle/1996&WAISaction=retrieve&WAISdocID=3985924639+75+0+0&WAISheadline=BOOKS+--+Beat+Generation+Women+Get+Their+Due">"BOOKS -- Beat Generation Women Get Their Due"</a>  [ <B>San Francisco Chronicle</B> ] <I>November 1, 1996</I> <P>

<li><P><A href="http://www2.gallerybooks.com/b/gallerybooks/bkm61010.htm">"Bookmark Column"</a> [ <B>Mendocino Beacon</B>  ]  <I>October 10, 1996</I> <P>

<li><P><A href="http://bookweb.org/news/btw/444.html">"Jewish Congress Asks for B&N Book Recall"</a> [ <B>Bookselling This Week</B> ]  <I>September 30, 1996</I><P>

<li><P><A href="http://www.thesite.com/0996w4/play/play165_092696.html">"Online Bookshopping: A Novel Idea"</a> [ <B>The Site</B> ] <I>September 26, 1996</I><P>

<li><P><a href="http://www.sfgate.com/programs/srch_archive/srch_archive_wrap?unregistered=true&WAISdocFile=/WAISlink/chronicle/archive/1996/09/18/DD65201.DTL&WAISdbName=/doc_root/wais/chronicle/1996&WAISaction=retrieve&WAISdocID=7081910815+0+0+0&WAISheadline=+Pages+on+the+Web+Fans+of+the+printed+word+are+finding+a+new+use+for+the+Internet+--+buying+books+online">"Pages on the Web: Fans of the printed word are finding a new use for the Internet - buying books online"</a> [ <B>San Francisco Chronicle</B> ]  <I>September 18, 1996</I><P>

<li><P><a href="http://www.sfgate.com/programs/srch_archive/srch_archive_wrap?unregistered=true&WAISdocFile=/WAISlink/chronicle/archive/1996/09/01/PK57677.DTL&WAISdbName=/doc_root/wais/chronicle/1996&WAISaction=retrieve&WAISdocID=2286719790+0+0+0&WAISheadline=Gary+Snyder's+Work+Comes+Full+Circle+After+40+years,+Zen+poet+finishes+`Mountains+and+Rivers+Without+End'">"Gary Snyder's Work Comes Full Circle
After 40 years, Zen poet finishes `Mountains and Rivers Without End' "</a>  [ <B>San Francisco Chronicle</B> ] <I>September 1, 1996</I><P>

<li><P><a href="http://www.sfgate.com/programs/srch_archive/srch_archive_wrap?unregistered=true&WAISdocFile=/WAISlink/examiner/archive/1996/03/31/MAGAZINE9336.dtl&WAISdbName=/doc_root/wais/examiner/1996&WAISaction=retrieve&WAISdocID=2396319492+63+0+0&WAISheadline=Poetry+Man">"Poetry Man: Berkley's Robert Hass, the first Western poet laureate is committed to spreading the word about words"</a>  [ <B>San Francisco Examiner</B> ] <I>March 31, 1996</I><P>

<li><P><a href="http://www.well.com/user/bookstore.jpg">"This Modern World"</a> [ a still timely cartoon by <B>Tom Tomorrow</B> ]

<P>* free registration and password required to enter site

</ul>
<P>

<P><hr size=12 width=33% align=center>

<CENTER><B><P>Individuals wishing to submit material should email their submissions to the NCIBA <A
HREF="mailto:thomasg@slip.net">web administrator</A>. Electronic form and submission preferred. Material (including printed material, clippings and photographs) may also be sent via postal mail to "NCIBA Book News," 1518 Church Street, San Francisco, California  94131. Those desiring return of posted materials should enclose a stamped, self-addressed envelope.

<font color=BROWN><B><P>WE APPRECIATE YOUR INTEREST IN INDEPENDENT BOOKSTORES!</B></font></CENTER>

<P>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-288</DOCNO>
<DOCOLDNO>IA009-000087-B036-48</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/censor.html 207.44.128.99 19970222112236 text/html 8908
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:22:54 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 8737
Last-modified: Wed, 11 Dec 1996 21:29:49 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com -->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  December, 1996   -->
<!--   FILE: censor.html   -->
<!--   PURPOSE:  NCIBA free speech information page  -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>NCIBA free speech information page</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association information page on free speech issues.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA banned books reading literature censorship free expression freedom information">

</HEAD>
<BODY bgcolor=#ffffff>

<P><FONT SIZE=+3>If you think we're free from censorship . . . </FONT>

<P  align=right><FONT color=red SIZE=+5> . . . . think again</FONT>

<B><P>If you think books aren't banned . . . you're wrong.

<P>Censors have been trying to ban books with unorthodox or unpopular points-of-view  since at least 387 B.C. Even books like dictionaries, textbooks, travel guides and the Bible have been banned. Censors have attacked everything from the plays of William Shakespeare to the novels of Mark Twain. If every book that anyone found objectionable were banned, there would be no books left. 

<P>Books are sometimes censored because of a single word or because the cover suggests a subject matter offensive to someone, even if that person has not read the book. (Some do <I>judge</I> a book by its cover.) Censors have also targetted all works by an author after reading only one. Every year, hundreds of books are challenged and banned in libraries and schools all over the world. In the United States, censorship incidents have been documented in every state, including California. At the Northern California Independent Booksellers Association, we think books are a great way to learn about many issues - things we sometimes have a hard time talking about. Not everyone will agree on everything, but if we read, reason and think, books will help us to a better future. Reading is not just a privilege in this country, it's a right. Let's keep it that way.

<P>If you think there is room for more than one opinion . . . you're right ! </B>

<IMG align=right hspace=10 width=162 height=198 SRC="image/flag.gif" ALT="flag">

<P>At the NCIBA, we maintain an active vigil in defense of free speech. We believe the free exchange of ideas cannot be taken for granted. Free speech is as intrinsic to a democratic society as it is to our own livelihoods.

<P>Members of the NCIBA have testified before the State Assembly in Sacramento regarding free speech issues, and we have joined with concerned parties in other industries in voicing our concern over threatening legislation. When the Board of Education removed short stories by Alice Walker and Annie Dillard from statewide tests for 10th graders, the NCIBA coordinated a joint effort with publishers to place copies of those author's books in every high school library in the State of California. Our member stores have also led local campaigns in their own cities and neighborhoods to raise awareness around censorship concerns. We believe free speech cannot be taken for granted.

<BR> 

<P><hr size=12 width=33% align=center>

<P><h3>A shortlist of books challenged in California during the last five years *</h3>
<ul>

<li><B>House of the Spirits</B>, by Isabel Allende<BR>
---retained in the Paso Robles High School despite objections to accounts of sexual encounters and violence<BR>

<LI><B>Clan of the Cave Bear</B>, by Jean Auel<BR>
---challenged, but retained from the Moorpark High School recommended reading list in Simi Valley despite objections that it contains "hardcore graphic sexual content"<BR>

<LI><B>We All Fall Down</B>, by Robert Cormier<BR>
---pulled out of elementary and junior high school libraries in Stockton after parents complained that it glorifies alcoholism and violence, contains a rape scene and its characters use too much profanity<BR>

<LI><B>Brave New World</B>, by Aldous Huxley<BR>
---challenged as required reading in the Corona-Norco Unified School District because it is "centered around negative activity." The book was retained and teachers selected alternatives if students object to Huxley's novel<BR>

<LI><B>The Giver</B>, by Lois Lowry<BR>
---temporarily banned from classes by the Bonita Unified School District in La Verne and San Dimas after four parents complained that violent and sexual passages were inappropriate for children<BR>

<LI><B>Thousand Pieces of Gold</B>, by Ruthanne Lum McCunn<BR>
---rejected as an addition to a core literature list by the Amador County Unified School District because "it makes America look bad"<BR>

</ul>

<B>*</B> source: American Booksellers Foundation for Free Expression

<P><CENTER><img src="image/message.gif" alt="banner"></CENTER>
 
<P>Freedom of speech is the foundation of bookselling in the United States. Without the First Admendment, publishers are not free to choose which books to publish, booksellers are not free to choose which books to order, display and sell, and readers are not free to decide which books they wish to read. Without freedom of speech, not only books but the very commerce of ideas would be stifled.

<P>In this American election year, its <I>especially</I> important to cast your vote for free speech on-line and in print !

<P><hr size=12 width=33% align=center>

<P><h3>Free speech links:</h3>

<P>The NCIBA suggests concerned individuals stay on top of the issues. One excellent source of information is the American Booksellers Foundation for Free Expression page on the internet devoted to <B><A HREF="http://www.bookweb.org/abffe/news/">free speech news</a></B>. There you can find numerous ABFEE newsletter articles and information on the annual Banned Books Week. The Northern California Independent Booksellers Association also suggest you visit these related web sites and newsgroups.

<ul>
<B>

<LI><A HREF="news:alt.censorship">alt.censorship</A><BR>

<LI><A HREF="http://www.ala.org/bbooks/">American Library Association</a> [ banned books page ]

<LI><a href="http://www.ambook/abffe/">American Booksellers Foundation for Free Expression</a> ( ABFFE )<BR>

<LI><a href="http://www.aclu.org/">American Civil Liberties Union</a> ( ACLU )<BR>

<li><a href="http://www.eff.org/blueribbon.html">Blue Ribbon Campaign</A><BR>

<LI><a href="http://www.humanities-interactive.org/">The Bonfire of the
Liberties</a> <BR>

<LI><A href="http://www.cdt.org/">Center for Democracy & Technology</a><BR>

<LI><a href="http://www.io.org/~sherlock/doom/doom.html">Countdown clock on civil liberties</a><BR>

<LI><A HREF="http://www.cybersquirrel.com/clc/expression.html">CyberSpace
Law Center Freedom of Expression Resources</A><BR>

<LI><a href="http://www.dfc.org/dfc/">Digital Future Coalition</a><BR>

<LI><a href="http://www.eff.org/">Electronic Frontier Foundation</A> <BR>

<LI><a HREF="http://www.epic.org/">Electronic Privacy Information Center</a><BR>

<LI><a href="http://www.fileroom.aaup.uic.edu/FileRoom/documents/homepage.html">The File Room Censorship Archive</a><BR>

<LI><A HREF="http://www.FreeExpression.org/">The Free Expression
Clearinghouse</A> <BR>

<li><a href="http://www.privacy.org/ipc/">Internet Privacy Coalition</a><BR>

<li><a href="http://www.nyu.edu/pages/wsn/subir/rushdie.html">Salman Rushdie Page</a> [ contains links to related pages ]<BR>

<LI><A href="http://www.vtc.org/">Voter's Telecommunication Watch</A><BR>

</B>
</ul>

<center><P><a href="http://www.eff.org/blueribbon.html"><img src="image/rib_bar_.gif" alt="Free Speech Online Blue Ribbon Campaign "></a>
<P>

<A HREF="http://www.privacy.org/ipc/"><IMG SRC="image/gk9.gif" ALT="Golden Key"></A><P>

<P>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-289</DOCNO>
<DOCOLDNO>IA009-000087-B036-86</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/resource.html 207.44.128.99 19970222112300 text/html 9411
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:23:13 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 9240
Last-modified: Mon, 17 Feb 1997 00:08:25 GMT
</DOCHDR>
<HTML>
<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com -->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  January, 1997   -->
<!--   FILE: resource.html   -->
<!--   PURPOSE: reader resources from the NCIBA -->
<!---------------------------------------------------------------------------------------->
<HEAD>
<TITLE>Reader resources from the NCIBA</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association page of reader resources.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading literature literary links resources web sites authors libraries library book bookstores free speech">

</HEAD>
<BODY bgcolor=#ffffff>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<CENTER><FONT color=BROWN SIZE=+2><B><FONT SIZE=+3>R</FONT>EADER <FONT SIZE=+3>R</FONT>ESOURCES</FONT></B></center>

<CENTER><P><B><FONT SIZE=+1>W</FONT>elcome to the NCIBA page of reader resources. Here you will find information on books, authors, reading and more. Additional features are already in the works, so please be sure and check back as additional topics are posted. Click on the categories below to jump around this page.</B></CENTER>

<CENTER><B><P><A HREF="#CALIFORNIA">ABOUT CALIFORNIA LITERATURE</A> // <A HREF="#AWARDS">LITERARY AWARDS & PRIZES</A> // <A HREF="#TRIVIA">LITERARY TRIVIA !</A></B>
</CENTER>
<P>

<hr size=12 width=33% align=center>

<A NAME="CALIFORNIA">
<CENTER><FONT color=red SIZE=+1><B><P>CALIFORNIA LITERATURE</B></FONT></CENTER>

<P><img width=21 height=13 src="image/book.gif"> <FONT SIZE=+1>C</FONT>alifornia's rich literary history makes for great reading - as do the works of the many authors who currently live and write in the Golden State. Residents of California are blessed not just with a rich<I> literature of their own</I> - but with the opportunity to often see and hear writers who may well be their neighbors. California's many independent bookstores act as a link in the chain of literature: independent bookstores host readings with local authors;  stock titles from regional presses; and maintain sections devoted to local interests and writers. <B><a href="stores.html">NCIBA bookstores</a></B> - which are locally owned and operated - bring writers and readers together. 

<P>The literature of California begins with the Native American oral traditions and the earliest printed material of the Spanish and Mexican periods. Since then, a great body of work - novels, stories, poems, plays, essays, memoirs, histories and much else - has grown out the state's often tumultous history. Through the early adventure stories of Jack London through the Depression-era novels of John Steinbeck till the jazz-inspired poetry of the Beats until today's multicultural writers - California has contributed not only to the literature of the United States but to the world. Be sure and visit your local library or bookstore - where books by California authors or books on California subjects may be found. Also, please visit the NCIBA page on <B><a href="californ.html">California Literature</a></B>, where you can find out more about the state's abundant literary history, including:

<P>A BRIEF <B><a href="californ.html#HISTORY">HISTORY OF CALIFORNIA LITERATURE</A></B>

<P><B><a href="californ.html#NOTABLE">NOTABLE BOOKS</A></B> WITH CALIFORNIA SETTINGS

<P>SIGNIFICANT <B><a href="californ.html#WRITERS">CALIFORNIA WRITERS</A></B>

<UL>

<P>
<B><li><A href="californ.html#before">before 1900</a><BR>
<li><A href="californ.html#through">1900 through 1950</a><BR>
<li><A href="californ.html#present">1950 through the present</a></B>

</UL>

<P>
<hr size=12 width=33% align=center>

<A NAME="AWARDS">
<CENTER><FONT color=red SIZE=+1><B><P>LITERARY AWARDS and PRIZES</B></FONT></CENTER>

<P>Looking for something good to read? Click on the hyperlinks for a list of award winning books. And please check back as we plan on adding more awards over time in various categories.

<P>CALIFORNIA BOOK AWARDS 

<UL>
<P><B><a href="reads.html">NCIBA Great Reads Award</a></B>
</UL>

<P>NATIONAL PRIZES <IMG width=27 height=16 SRC="image/soon.gif" ALT="soon">

<UL>
<P>Pulitzer Prize<BR>
National Book Award
</UL>

<P>INTERNATIONAL AWARDS 

<UL>
<P><B><A HREF="nobel.html">Nobel Prize in Literature</a></B><BR>
<B><a href="booker.html">Booker Prize</a></B>
</UL>

<P>MYSTERY AWARDS

<UL>
<P><B><a href="edgar.html">Edgar Award</a></B>
</UL>

<P>POETRY AWARDS

<UL>
<P><B><a href="poetry.html">Recent American Poetry Awards</a></B>
</UL>

<P>SCIENCE FICTION & FANTASY AWARDS

<UL>
<P><B><a href="hugo.html">Hugo Award</a></B><BR>
<B><a href="nebula.html">Nebula Award</a></B>
</UL>

<P>CHILDREN'S BOOK AWARDS 

<UL>
<P><B><a href="caldecot.html">Caldecott Medal</a></B><BR>
<B><a href="newberry.html">Newberry Medal</a></B>
</UL>

<P>
<hr size=12 width=33% align=center>

<A NAME="TRIVIA">
<CENTER><FONT color=red SIZE=+1><B><P>CALIFORNIA LITERARY TRIVIA</B></FONT></CENTER>

<P><img width=21 height=13 src="image/book.gif"> The name "California" is derived from an old Spanish novel, "Las Sergas de Esplandian" ("The Exploits of Esplandian"). Written about 1500 by <B>Garci Ordonez de Montalvo</B>, the book contains several fanciful references to an island called <I>California </I> populated by Amazons. The early European explorers who ventured into the region undoubtably had this place-name in mind when they first described the State.

<P><img width=21 height=13 src="image/book.gif"> The first book in English to be printed in California was written by a Pole naturalized as an American citizen, <B>Felix Paul Wierzbicki</B>. The book was "California As It Is, And As It May Be" (1849).

<P><img width=21 height=13 src="image/book.gif"> <B>Robert Frost</B> - best known as a poet of New England life, was born in San Francisco in 1874.

<P><img width=21 height=13 src="image/book.gif"> During Hollywood's early days, the Belgian playwright and Nobel Prizewinner<B> Maurice Maeterlinck</B>, who spoke no English, was hired to adapt his novel<I> La vie des abeilles</I> for film. However, when the screenplay was translated, movie moguls were shocked to find the hero was a bee, the producers not knowing what the word <I>abeille</I> meant.

<P><img width=21 height=13 src="image/book.gif"> "They Knew What They Wanted" (1924), a play by <B>Sidney Howard</B>, was the first work by a Californian to win the Pulitzer Prize.

<P><img width=21 height=13 src="image/book.gif"> <B>John Steinbeck</B> is the only Californian to have won both the Pulitzer Prize (fiction, 1940) and Nobel Prize (literature, 1962).

<P><img width=21 height=13 src="image/book.gif"> Other California winners of the Pulitzer Prize include <B>William Saroyan</B> (drama, 1940), <B>Upton Sinclair</B> (fiction, 1943), <B>George Oppen</B> (poetry, 1969), <B>Wallace Stegner</B> (fiction, 1973),<B> Gary Snyder</B> (poetry, 1974) and<B> Alice Walker</B> (fiction, 1984).

<P><img width=21 height=13 src="image/book.gif"> San Francisco's City Lights Bookstore, co-founded by poet <B>Lawrence Ferlinghetti</B> in June 1953, was the nation's first all paperback bookstore.

<P><img width=21 height=13 src="image/book.gif"> Polish poet<B> Czeslaw Milosz</B>, who won the Nobel Prize in Literature in 1980, has lived and taught in Berkeley since the early 1960's.

<P><img width=21 height=13 src="image/book.gif"> Some of the many non-California writers who have lived and worked in the state for considerable periods of time include <B>Mark Twain, Henryk Sienkiewicz, F. Scott Fitzgerald, William Faulkner, Thomas Mann, Aldous Huxley, Bertolt Brecht, Christopher Isherwood, Jack Kerouac</B> and <B>Allen Ginsberg</B>.

<P><img width=21 height=13 src="image/book.gif"> Berkeley poet <B>Robert Hass</B> was the first California writer to be named Poet Laureate of the United States (1995).

<P>
<hr size=12 width=33% align=center>

<CENTER>

<P>To find online information about literature, please visit our page of <B><a href="links.html">Literary Links</a></B>. Websites with a California connection are indicated with an asterik.

<p>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-290</DOCNO>
<DOCOLDNO>IA009-000087-B036-127</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/links.html 207.44.128.99 19970222112315 text/html 19867
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:23:30 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 19695
Last-modified: Sun, 16 Feb 1997 22:03:13 GMT
</DOCHDR>
<HTML>
<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com-->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  February, 1997   -->
<!--   FILE: links.html   -->
<!--   PURPOSE: literary links on the net  -->
<!---------------------------------------------------------------------------------------->
<HEAD>
<TITLE>Literary Links from the NCIBA</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association page of literary links.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading literature literary links resources web sites authors libraries library book bookstores free speech authors homepage book bookstore Northern California Independent Booksellers Association NCIBA books reading literature literary links resources web sites authors libraries library book bookstores free speech authors homepage book bookstore Northern California Independent Booksellers Association NCIBA books reading literature literary links resources web sites authors libraries library book bookstores free speech authors homepage book bookstore links web website www internet authors literature book books bookstore bookstores book bookstore links web website www internet authors literature book books bookstore bookstores book bookstore links web website www internet authors literature book books bookstore bookstores book bookstore links web website www internet authors literature book books bookstore bookstores">

</HEAD>
<BODY bgcolor=#ffffff>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<CENTER><FONT color=brown SIZE=+3><B><FONT SIZE=+4>L</FONT>ITERARY <FONT SIZE=+4>L</FONT>INKS</FONT></font></center>

<P><IMG align=left hspace=10 SRC="image/book2.gif" ALT="books">

<B><P><FONT SIZE=+1>W</FONT>elcome to the NCIBA page of literary links. Here you will find some of the best sites on the net devoted to authors, books and book-related interests. Those marked with an <B>*</B> indicate a California author or subject matter. Since this page is made up of a set of extensive lists, we've provided a hyperlinked table of contents. Just click on the categories below to jump around the page. Use your back button to return to your previous position.

<CENTER><P>
<A HREF="#featured">FEATURED LINK</A> // 
<A HREF="#authors">AUTHORS</A> // 
<A HREF="#related">LITERARY LINKS</A> //
<A HREF="#book">BOOK RELATED SITES</A> // 
<A HREF="#libraries">LIBRARIES</A>
</CENTER>

<center><P>If you know of other book related web sites, we would certainly like to know about them. Please email your suggestions to <B><A
HREF="mailto:websuggestions@pandorasbox.com">web suggestions</A></B>. Thank you and happy mouse trails!</B></CENTER>

<P><hr size=12 width=33% align=center>
<a name="featured">

<CENTER><P><IMG width=14 height=14 SRC="image/hotball.gif" alt="flashing"> <IMG width=14 height=14 SRC="image/hotball.gif" alt="flashing"> <font color=green size=+2> <FONT SIZE=+3>F</FONT>EATURED <FONT SIZE=+3>L</FONT>INK </font> <IMG width=14 height=14 SRC="image/hotball.gif" alt="flashing"> <IMG width=14 height=14 SRC="image/hotball.gif" alt="flashing"></CENTER>

<P><TABLE align=left>
<TR><TD><IMG SRC="image/atwood.jpg" border=1 width=164 height=148 hspace=10 align=left ALT="margaret atwood"> </TD></TR>
<TD align=center><B><font color=brown>M<FONT SIZE=-1>ARGARET ATWOOD</FONT></B></TD></td></TR></table>

<P><FONT SIZE=+2><B>O</B></FONT><FONT SIZE=+1>ur featured link is the outstanding <B><a href="http://www.io.org/~toadaly/toc.htm">Margaret Atwood</a></B> Homepage. This extensive, author sanctioned site is a model for what every author website might be. Chock full of content, these pages contain a list of books by Atwood (including hard-to-find small press editions), biographical information, a speaking schedule, a few pictures, questions & answers, and the texts of the author's recent book reviews and lectures. There is also a list of recent publications, including a few pages on <B>Alias Grace</B>, the Canadian novelist's newest book. For students and scholars, there is a listing of books and other material about the author, including information on the Margaret Atwood Society. Atwood's many readers won't want to miss this featured link. (photo by <B><a href="http://www.io.org/~toadaly/toc.htm">Lenore Atwood</a></B>)

</FONT>

<P><hr size=12 width=33% align=center>
<P>

<CENTER><H3><font color=green>AUTHOR WEB SITES</font></H3></CENTER>

<table width=100%>
<tr>
<td width=50% valign=top>

<UL>
<a name="authors">

<li><a href="http://www.uidaho.edu/~dody9102/acker3.html">Kathy Acker</a> *

<li><a href="http://www.io.org/~toadaly/toc.htm">Margaret Atwood</a>

<li><a href="http://uts.cc.utexas.edu/~churchh/janeinfo.html">Jane Austen</a>

<li><A HREF="http://alexia.lis.uiuc.edu/~hjerpe/austen.html">Jane Austen</A> [Jane Austen Society]

<li><a href="http://rwd.goucher.edu/~mbell">Madison Smartt Bell</a>

<li><A HREF="http://www.uio.no/~mwatz/bey/">Hakim Bey</A>

<li><A HREF="http://www.vdgi.com/bizarro.htm">Bizarro</A> [Dan Pirarro]

<li><A HREF="http://www.aa.net/~urizen/blake.html">William Blake</A>

<li><A HREF="http://www.microserve.net/~thequail/libyrinth/borges.html">Jorge Borges</A>

<li><a href="http://zaraza.netmedia.net.il/Nossik/brodsky/">Joseph Brodsky</a>

<li><A HREF="http://www.hyperreal.com/wsb/">William S. Burroughs</A>

<LI><a href="http://www.bgsu.edu/~ccarter/carrol.htm">Jim Carroll</a>

<li><a href="http://www.students.uiuc.edu/~jbirenba.carroll.html">Lewis Carroll</a>

<li><A HREF="http://world.std.com/~ptc/">Raymond Carver</A>

<LI><A HREF="http://www.interlog.com/~spiff/coupland/">Douglas Coupland</A>

<li><A HREF="http://www.li.net/~scharf/defoe.html">Daniel Defoe</A>

<LI><A HREF="http://hum.ucsc.edu/dickens/index.html">Charles Dickens</A>

<li><A HREF="http://www.cc.columbia.edu/~svl2/dickinson/">Emily Dickinson</A>

<LI><A HREF="http://lal.cs.byu.edu/people/black/dickinson.html">Emily Dickinson</A>

<li><A HREF="http://www.next.com/~bong/eliot/index.html">T. S. Eliot</A>

<LI><A HREF="http://mason.gmu.edu/~cforchem/">Carolyn Forche</a>

<li><a href="http://www.tiac.net/users/eldred/nh/hawthorne.html">Nathaniel Hawthorne</a>

<li><A HREF="http://www.az.com/~paulb/hemingway">Ernest Hemingway</A>

<li><A HREF="http://ie.uwindsor.ca/jazz/hughes.html">Langston Hughes</A>

<li><A HREF="http://www.cowland.com/josephk/josephk.htm">Franz Kafka</A>

<li><A HREF="http://www.cc.columbia.edu:/~svl2/keats/">John Keats</A>

<LI><A HREF="http://www.du.edu/~staylor/kundera.html" >Milan Kundera</A>

<LI><a href="http://www.typo.com/lamott/lamott.htm">Anne Lamott</a> *

<li><A HREF="http://www.lsi.usp.br/usp/rod/text/lautreamont/lautreamont.html">Comte de Lautr&eacute;amont</A>

<li><A HREF="http://www2.pair.com/mgraz/Lear/index.html">Edward Lear</A>

<LI><A HREF="http://sleepy.usu.edu/~slq9v/cslewis/index.html">C.S. Lewis</A>

<li><A HREF="http://www.primenet.com/~dloucks/hplpage.html">H. P. Lovecraft</A>

</td>

<td valign=top>

<li><A HREF="http://www.xs4all.nl/~hanswint/garconne.htm">Victor Margueritte</A>

<LI><A HREF="http://pages.prodigy.com/TN/dctw04a/cormac1.html">Cormac McCarthy</A>

<li><a href="http://www.pandorasbox.com/littlenemo.html">Winsor McCay</a> 

<LI><A HREF="http://cathouse.org/Literature/CarsonMcCullers/" >Carson McCullers</A>

<LI><A HREF="http://www.melville.org/">Herman Melville</A>

<LI><A HREF="http://www2.gvsu.edu/~vanoflej/HenryMiller/Welcome.html">Henry Miller</A> *

<LI><a href="http://www.injapan.net/members/tokyojon/cjourn.htm">Yukio Mishima</a> 

<LI><a href="http://storm.usfca.edu/~southerr/jco.html">Joyce Carol Oates</A>

<LI><a href="http://www.wilmington.net/arts/poets/olds.html">Sharon Olds</A>

<li><a href="http://ourworld.compuserve.com/homepage/Patchen/">Kenneth Patchen</a> *

<LI><A HREF="http://www.cs.umu.se/~dpcnn/eapoe/ea_poe.html">Edgar Allan Poe</A>

<LI><A HREF="http://polyglot.lss.wisc.edu/lss/staff/stephy/Pushkin.html">Alexandr Pushkin</A>

<li><A HREF="http://www.pomona.edu/pynchon/index.html">Thomas Pynchon</A>

<li><a href="http://jefferson.village.virginia.edu/rossetti/rossetti.html">Dante Gabriel Rossetti</a>

<li><A HREF="http://orpheus.ucsd.edu/speccoll/testing/html/mss0010d.html">Jerome Rothenberg</A> [author archive]

<li><a href="http://www.nyu.edu/pages/wsn/subir/rushdie.html">Salman Rushdie</a>

<LI><A HREF="http://www.sas.upenn.edu/~smfriedm/exupery/">Antoine de Saint-Exupery</A>

<LI><A HREF="http://www.iii.net/users/sfoskett/jds/">J.D. Salinger</A>

<li><a href="http://the-tech.mit.edu/Shakespeare/works.html">William Shakespeare</a> [ searchable ]

<li><A HREF="http://www.cc.columbia.edu:/~svl2/shelley/">Percy Bysshe Shelley</A>

<li><a href="http://www.levity.com/digaland/index.html>Steve Silberman</a> *

<li><a href="www.comet.net/writersc/RSMITH">Roland Smith</a>

<li><a href="http://world.std.com/~swrs/">Sarah Smith</a>

<LI><a href="http://www.csclub.uwaterloo.ca/~relipper/tolkien/rootpage.html">J. R. R. Tolkien</a>

<li><a href="http://www.well.com/user/tomorrow">Tom Tomorrow</a>

<LI><A HREF="http://hydor.colorado.edu/twain/">Mark Twain</A>

<LI><A HREF="http://www.cas.usf.edu/english/boon/vonnegut/kv.html" >Kurt Vonnegut</A>

<li><A HREF="http://www.cc.columbia.edu:/~svl2/whitman/">Walt Whitman</A>

<LI><A HREF="http://www.charm.net/~brooklyn/People/WilliamCarlosWilliams.html" >William Carlos Williams</A>

<LI><A HREF="http://www.cms.uncwil.edu/~connelly/wolfe.html">Thomas Wolfe</A>

<LI><A HREF="http://www.cc.columbia.edu:/~svl2/wordsworth/">William Wordsworth</A>

</UL>

</tr></table>

<P><hr size=12 width=33% align=center>

<table>
<tr>
<td width=50% valign=top>

<a name="related">

<UL>

<H3><font color=green>LITERARY LINKS</font></H3>

<LI><A HREF="http://dc.smu.edu/Arthuriana/">Arthuriana Homepage</A>

<LI><a href="http://www.vicnet.net.au/~ozlit/">Australian Literature</a>

<li><a href="http://www.li.net/~scharf/author.html">Author! Author!</a> 

<LI><A HREF="http://www.lib.virginia.edu/etext/britpo/britpo.html">British Poetry 1780-1910</A> [ hypertext archive of scholarly editions ]

<LI><A HREF="http://www.cs.cmu.edu/Web/People/mmbt/women/celebration.html">A Celebration of Women Writers</A>

<LI><A HREF="http://www.ucalgary.ca/~dkbrown/index.html">Children's Literature Web Guide</A>

<LI><a href="http://wings.buffalo.edu/epc/">Electronic Poetry Center</a>

<li><a href="http://www.history.rochester.edu/godeys/">Godey's Journal</a> [19th c. lady's journal]

<li><a href="http://kufacts.cc.ukans.edu/~marc/natlit/native_lit_main.html">Indigenous People's Literature</a>

<LI><A HREF="http://sunsite.unc.edu/dykki/poetry/home.html">Internet Poetry Archive</A>

<LI><A HREF="http://www-bprc.mps.ohio-state.edu/cgi-bin/hpp?poetry.html">The Internet Poetry Resource</A>

<li><A HREF="http://www.charm.net/~brooklyn/litkicks.html" >Literary Kicks</A> *  [Beat writers]

<li><A HREF="http://dns.worldweb.net/~jharris/">The Musil Institut</A> [fin de siecle literature]

<LI><A HREF="http://www.murderonthemenu.com/mystery">Mystery Reader's Journal</a>

<li><A HREF="http://www.clever.net/19cwww/">19th Century Women Writers</A>

<li><a href="http://wwwrci.rutgers.edu/~mjoseph/newberry.html">Newberry Classroom</a> [children's literature]

<LI><A HREF = "http://www.nobel.se/">Nobel Prize Winners</a>

<li><a href="http://www.cs.cmu.edu/Web/books.html">Online Book Page</a> [online texts]

<li><a href="http://www.aether.com/Aether/gutenberg.html">Project Gutenberg</a> [online texts]

<LI><a href="http://sunsite.unc.edu/dykki/poetry/">Poetry Website</a> [Milosz, Heaney, etc...]

<LI><A HREF="http://www.lysator.liu.se/runeberg/">Project Runeberg</A>

<LI><A HREF="http://alpha.acast.nova.edu/cgi-bin/bard.pl">Shakespearean Insults</A> [ drats! ]

<LI><A HREF = "http://pharmdec.wustl.edu/juju/surr/surrealism.html">The Surrealism Server</A>

<LI><A HREF = "http://www.lm.com/~kalin/author.html">Surrealism</a>

<li><A HREF="http://www.lit.kobe-u.ac.jp/~hishika/20c_poet.htm" >Twentieth Century Poetry in English</A>

<LI><A HREF="http://sunsite.unc.edu/ibic/IBIC-homepage.html">World Wide Web Virtual Library: Literature</A>

</td>

<td valign=top>

<a name="book">
<H3><font color=green>BOOK RELATED SITES</font></H3>

<li><A HREF="http://www.bookweb.org/">American Bookseller's Association</A>

<LI><A HREF="http://www.ala.org">American Library Association</a>

<li><A HREF="http://www.clark.net/pub/rmharris/booknet1.html">Antiquarian Booksellers'  Association of America</A>

<LI><A HREF="http://www.gold.net:80/users/av20/arbv.html">Annual Register of Book Values</A>

<LI><A HREF="http://altair.stmarys-ca.edu:70/0/studwork/integral/integral.html">Arachne, a Great Books Server</A>

<li><A HREF="http://www.lib.berkeley.edu/BANC/">The Bancroft Library</A> *

<li><A HREF="http://www.culturewave.com/culturewave/ba-bookstore-events/">Bay Area Bookstore Events</A> *

<LI><A HREF="http://www.smartdocs.com:80/~bree/">The Bibliophile Home Page</A>

<LI><A HREF="http://www.bookport.com/source/9502.html">BOOKPORT(tm): Access to Books</A>

<li><A HREF="http://www.reedref.com/boop.html">Books Out-of-Print</A>

<li><a href="http://www.bookwire.com/">Bookwire</a> [industry news]

<li><A HREF="http://www.bookwire.com/bbr/bbr-home.html">The Boston Book Review</A>

<li><A HREF="http://www.bookwire.com/cbr/">Computer Book Review</A>

<li><A HREF="http://www.bookwire.com/hmr/">Hungry Mind Review</A>

<li><a HREF="aisles.html">In the Aisles</A> [regional book-related news]

<li><A HREF="http://www.independentreader.com/">The Independent Reader</A>

<LI><A HREF="http://www.bocklabs.wisc.edu/ims/writers.html">Internet Directory of Published Writers</A>

<li><a HREF="http://loc.gov">Library of Congress</A>

<li><A HREF="http://uacsc1.albany.edu/~ms0669/mike/libs.html">Libraries on the Web</A>

<li><a HREF="http://www.bookwire.com/nbcc/">National Book Critics Circle</a>

<LI><A HREF="http://www.loria.fr/~charoy/zines.html">Newsletters, Journal and Zines on the Internet</A>

<li><a HREF="news.html">NCIBA Book News</A> *

<li><a href="http://www.voyagerco.com/Pr/p.toc.html">Paris Review</a>

<LI><A HREF="http://www.bookwire.com/PW/">Publishers Weekly</A>

<li><A HREF="http://www.bookwire.com/qbr/qbr.html">Quarterly Black Review of Books</a>

<li><a HREF="http://www.sfbook.org">San Francisco Bay Area Book Council</A> *

</UL>

</tr></table>

<P><hr size=12 width=33% align=center>
<P>

<CENTER><a name="libraries">
<H3><font color=green>CALIFORNIA LIBRARIES</font></H3>

<table width=100%>
<tr>
<td width=50% valign=top>

<UL>

<LI><A HREF=http://library.berkeley.edu:8000/alco/>Alameda County Libraries</A>

<LI><A HREF=http://www-scf.usc.edu/~slo/www_ald/library.html>Altadena Public Library </A> 

<li><A HREF="http://www.lib.berkeley.edu/BANC/">The Bancroft Library</A>

<LI><A HREF=http://www.ci.berkeley.ca.us/bpl/>Berkeley Public Library</A>

<LI><a href="http://www.csuchico.edu/library/">California State University, Chico</a>

<li><a href="http://athena.lib.csufresno.edu/">California State University, Fresno</a>

<LI><A HREF=http://gfecnet.gmi.edu/Libraries/public.html>City of Palo Alto Libraries</A>

<LI><A HREF=http://www.dcn.davis.ca.us/~dixonlib/>Dixon Public Library </A>

<LI><A HREF=http://spider.lloyd.com/~lib-pl/homepage.html>El Dorado County Library</A> 

<LI><A HREF=http://www.cybergate.com/~libfres1/>Fresno County Free Library </A>

<LI><A HREF=http://www.scruznet.com/~jamesa/>Garfield Park Branch Library</A>
 
<LI><A HREF=http://saturn.netrep.com:80/home/library/>Livermore Public Library</A> 

<LI><A HREF=http://www.ci.long-beach.ca.us/citygov/lib/longbch.htm>Long Beach Public Library</A>

<LI><A HREF=http://www.lapl.org/>Los Angeles Public Library</A>

<LI><A HREF=http://www.nps.navy.mil/VisLab/sealib/>Monterey County Free Libraries </A>

<LI><A HREF=http://www.abag.ca.gov/abag/local_gov/city/client/mt_view/mvlibrary/mvlibrary.html>Mountain View Library</A> 

<LI><A HREF=http://www.hugin.imat.com/~alicem/libhpg.html>Oakland Public Library</A>

<LI><a href="http://oasys.lib.oxy.edu">Occidental College</a>

<LI><A HREF=http://www.ci.pasadena.ca.us/library.html>Pasadena Public Library</A> 

<LI><A HREF=http://www.rcpl.lib.ca.us/>Rancho Cucamonga Public Library</A>

<LI><A HREF=http://paladin.cirrus.co.riverside.ca.us/community/rccpl/>Riverside City and County Public Library</A>

</td>

<td valign=top>

<LI><A HREF=http://www.sna.com/saclib/>Sacramento Public Library</A>

<LI><A HREF=http://www.sannet.gov/public-library/>San Diego Public Library</A>

<LI><A HREF=http://sfpl.lib.ca.us/>San Francisco Public Library</A>

<LI><A HREF=http://www.lib.ci.sj.ca.us/>San Jose Public Library</A>

<LI><A HREF=http://biggulp.callamer.com/vv/slo_library/>San Luis Obispo City-County Library</A>

<LI><A HREF=http://www.reg.uci.edu/SANTA_ANA/LIBRARY/>Santa Ana Public Library</A> 

<LI><A HREF=http://www.cruzio.com/~sclibs/>Santa Cruz Public Libraries</A>

<LI><A HREF=http://pen.ci.santa-monica.ca.us/cityhall/library/>Santa Monica Public Library</A>

<LI><A HREF=http://bbs.ci.seaside.ca.us/sealib/index.html>Seaside Community Library </A> 

<LI><A HREF=http://www.sonoma.lib.ca.us/>Sonoma County Library</A>

<LI><a href="http://www.sonoma.edu/">Sonoma State University</a>

<LI><A HREF=http://ainet.com/scfl/welcome.html>Stanislaus County Free Library</A>

<LI><A HREF=http://www.best.com:80/~sunlib2/>Sunnyvale Public Library</A>

<LI><A HREF=http://www.tol.lib.ca.us/>Thousand Oaks Library</A>

<LI><A HREF=http://www.ci.torrance.ca.us/city/dept/library/torrlib.htm>Torrance Public Library</A>

<li> <a href="http://dla.ucop.edu/">University of California MELVYL Catalog</a>

<li><a href="http://www.lib.uci.edu/">University of California, Irvine</a>

<li><a href="http://lib-www.ucr.edu/">University of California, Riverside</a>

<li><a href="http://www.ucsd.edu/library/index.html">University of California, San Diego</a>

<li><a href="http://www.library.ucsf.edu/">University of California, San Francisco</a>

<li><a href="http://www.ucsc.edu/library/index.html">University of California, Santa Cruz</a>

<li><a href="http://www.usfca.edu/usf/neufeld/gleeson.html">University of San Francisco</a>

<LI><A HREF=http://www.mother.com/yo/woodland/wlibmain.htm>Woodland Public Library </A>

</UL>
</tr></table>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-291</DOCNO>
<DOCOLDNO>IA009-000087-B036-151</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/feedback.html 207.44.128.99 19970222112325 text/html 4334
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:23:44 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 4163
Last-modified: Mon, 17 Feb 1997 00:07:26 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com -->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  December, 1996   -->
<!--   FILE: feedback.html   -->
<!--   PURPOSE: NCIBA mailing list page  -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>NCIBA mailing list</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association mailing list page - here you will find an opportunity to join our mailing list and receive free updates from the world of books.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading author bookstore consumer information literature mailing list books news bookstores consumer information fun mailing list books news bookstores consumer information fun mailing list books news bookstores consumer information fun mailing list books news bookstores consumer information fun">

</HEAD>
<BODY bgcolor=#ffffff>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<CENTER><FONT SIZE=+2 color=brown><B><FONT SIZE=+3>J</FONT>OIN <FONT SIZE=+3>O</FONT>UR <FONT SIZE=+3>M</FONT>AILING <FONT SIZE=+3>L</FONT>IST <FONT SIZE=+3> !</FONT> </B></FONT> </CENTER>

<IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"><B><FONT SIZE=+1>If</FONT></B> you would like to join our mailing list and receive free updates from the world of books (we promise no more than a dozen emails per year), just fill out the form below. Its that simple! Your name and address will remain confidential. (<I>And no, we don't collect cookies</I>.)

<P>By joining our list, we'll let you know when book prizes are announced, when events, festivals and other happenings take place (such as Tahoe's <B>Books-by-the-Lake</B> or San Francisco's<B> Books-by-the-Bay</B>) or when new features are added to our web site. We will also send consumer information, internet tips, suggested book-related web sites and more. If you love reading and the world of books, this list is for you!

<BR>

<ul>

<FORM METHOD=POST ACTION="/cgi-bin/cgiemail/~nciba/feedback.txt">

<B>EMAIL ADDRESS: </B> <INPUT TYPE=TEXT NAME="required-email"> <BR>

<font color=green><B>Please enter your email address.</B></font><P>

<B>YOUR NAME: </B> <INPUT TYPE=TEXT NAME="required-realname"> <BR>

<font color=green><B>Please enter your name or "handle."</B></font><P>

<B>INTEREST :</B> <INPUT TYPE=TEXT NAME="required-category"> <BR>

<font color=green><B>Please state your interest:</font></B> [consumer, librarian, media, publishing, bookseller, "just plain interested," etc...]. <P>

<B>COMMENTS: </B> <BR>

<font color=green><B>We're interested in hearing from you ! </B></font>

<P><TEXTAREA NAME="required-comments" ROWS=15 COLS=60></TEXTAREA><P>

</ul>

<BR>
<CENTER><font color=brown><B>To submit your request, please press this button:</B></font>

<P> </CENTER><CENTER><INPUT TYPE=SUBMIT NAME="button" VALUE="Send Request"></CENTER>

<INPUT TYPE=HIDDEN NAME="success" VALUE="/~nciba/thankyou.html">

</FORM>

<BR>

<CENTER><B><P>WE APPRECIATE YOUR INTEREST !</B></CENTER>

<P>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-292</DOCNO>
<DOCOLDNO>IA009-000087-B036-187</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/home.html 207.44.128.99 19970222112348 text/html 10386
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:24:02 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 10214
Last-modified: Mon, 17 Feb 1997 00:07:39 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com -->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED: January, 1997   -->
<!--   FILE: home.html   -->
<!--   PURPOSE: information about the NCIBA -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>Homepage of the NCIBA</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association This page is primarily of interest to bookstores and booksellers.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading book bookstore bookstores consumer information regional business literature faq Northern California Independent Booksellers Association NCIBA books reading book bookstore bookstores consumer information regional business literature faq Northern California Independent Booksellers Association NCIBA books reading book bookstore bookstores consumer information regional business literature faq Northern California Independent Booksellers Association NCIBA books reading book bookstore bookstores consumer information regional business literature faq Northern California Independent Booksellers Association NCIBA books reading book bookstore bookstores consumer information regional business literature faq">

</HEAD>
<BODY background="image/back.gif">

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<P><CENTER><B><FONT SIZE=+2 color=brown><FONT SIZE=+3>W</FONT>ELCOME <FONT SIZE=+3>B</FONT>OOKSTORES <FONT SIZE=+3>A</FONT>ND <FONT SIZE=+3>B</FONT>OOKSELLERS</FONT></B></FONT></CENTER>

<P>The Northern California Independent Booksellers Association (NCIBA) is a trade organization dedicated to supporting, nurturing and promoting independent retail bookselling in California. With over 600 members, including more than 300 booksellers, the NCIBA has been an experienced provider of services for over two decades.

<P>Organized as a mutual benefit non-profit corporation, the Northern California Independent Booksellers Association is led by a 15-person Board of Directors that includes four Officers and two associate representitives from the publishing community. Officers serve two-year terms, while Board members are elected for one to three years, with elections held each spring.

<P>The NCIBA also employs an Executive Director and an Associate Director while maintaining offices in Corte Madera, California. To find out more about the NCIBA, please refer to our <B><A HREF="faq.html">F.A.Q. page </a></B> (frequently asked questions) and the NCIBA <B><A HREF="purpose.html">Declaration of Independents</a></B>.

<ul>

<B>
<P><LI> <a href="info.html">The NCIBA Board of Directors</a>

<P><LI> <a href="info.html#comm">NCIBA committees</a>

<P><LI> <a href="info.html#contact">Contact and office information</a>

<P><LI> <a href="stats.html">Northern California bookstore sales</a>

</B>

</UL>

<P><CENTER>The NCIBA conducts many projects and activities for its members. We are a proactive organization. Here is a brief description of some of what we offer.</CENTER>

<P>
<HR>
<CENTER><B>W<FONT SIZE=-1>HAT WE DO</FONT></B></CENTER>
<HR>

<P>

<P><CENTER><B><font color=brown>C<FONT SIZE=-1>ALIFORNIA TRADE SHOW</FONT></font></B></CENTER>

<P>This three-day annual event, currently held the first weekend of October (Friday- Sunday) brings together over 1000 booksellers from Northern and Southern California, Nevada, and Arizona with publishers, authors and other members of the book community. Show activities include exhibits representing over 500 publishers and other book-related vendors, numerous education workshops, our annual membership meeting, author breakfasts, plus author readings and autographings.This event is not open to the public.  Pre-registration is encouraged. Show admission is free to all NCIBA members and their employees.

<P>Day-long educational programming for booksellers is offered by the NCIBA on Friday, which is also the set-up day for exhibitors. We also host a social gathering in the evening.

<P>Exhibit days are Saturday and Sunday, with publishers displaying new and backlist titles, taking orders, offering show specials, and meeting with customers new and old. For booksellers, there are also a full slate of educational workshops to choose from as well as a schedule of over 80 authors signing books over the course of both days. The Saturday breakfast features authors of adult books, while Sunday's is devoted to children's authors. 

<P><CENTER><B><font color=brown>H<FONT SIZE=-1>OLIDAY BOOK CATALOG</FONT></FONT></B></CENTER>

<P>Our California Catalog features adult and children's titles in a beautifully designed full color format. This holiday book catalog, with a print run of nearly 1.5 million, is inserted in key media throughout the state and available to member bookstores in bulk quantities, with every store receiving 100 copies free.

<P>The books appearing in the catalog are the result of the NCIBA's best efforts to solicit titles of interest to customers of independent bookstores. As such, the California Catalog has proved to be very popular with customers and an effective holiday sales tool for our members.

<P><CENTER><B><font color=brown>E<FONT SIZE=-1>DUCATION PROGRAMS</FONT></FONT></B></CENTER>

<P>The NCIBA produces annual spring workshops, a daylong program that includes a variety of concurrent sessions dealing with topics of concern to our members.

<P>Our regional gatherings send a contingent of Board members out of the immediate Bay Area to meet with booksellers in a specific region in order to get feedback and discuss issues with members whose geography makes direct access more difficult.

<P><CENTER><B><font color=brown>P<FONT SIZE=-1>ROMOTIONS</FONT></FONT></B></CENTER>

<P>The NCIBA's <B><A HREF="goodread.html">Good Reads</a></B> advertising campaign features periodic full-page ads in the <I>San Francisco Chronicle </I> Book Review section. The ads feature bookseller reviews of distinctive titles, and serve to generate sales and to distinguish independent bookstores in the marketplace.

<P>Full color regional membership brochures are distributed in stores and high-traffic locations throughout the state. In the Fall of 1996, Heyday Books and the NCIBA co-published a guidebook, "First and Foremost: A Guide to Northern California Independent Bookstores." This book is available at independent bookstores across the state.

<P>The California Independent Booksellers <B>Great Reads Book Awards</B> honor exceptional titles, voted upon annually by member booksellers. The awards are publicized through store posters and media attention, reinforcing independents' link with quality writing.

<P><CENTER><B><font color=brown>M<FONT SIZE=-1>EMBER PUBLICATIONS</FONT></FONT></B></CENTER>

<P>Our monthly newsletter disseminates association news, reports on bookstore activities and industry issues, and prints a monthly independent Bestseller List. It's also used to distribute media reprints and material produced for in-store displays.

<P>The California Rep directory, a guide to area sales reps, is updated and distributed every January.

<P>

<HR>
<CENTER><B>W<FONT SIZE=-1>HO MAY JOIN</FONT></B></CENTER>
<HR>

<P>Membership is limited to those "in the trade." Regular voting membership is open to any individual member of the retail bookselling community whose primary place of business is California. Each company is entitled to one voting member. Membership dues for each voting member are $50.00 per year, and runs April 1 through March 31 (we do not prorate).

<P>We also welcome associate members, who while not entitled to vote, are vital to our community and its dialogue and receive all other benefits of membership. Associate members may include prospective booksellers, publishers, sales reps, wholesalers, members of the media, librarians, authors or illustrators and sideline/service/supply vendors. Dues for associate members are also $50.00.

<P>Both regular and associate members may choose to designate other persons within the organization to receive mailings from the NCIBA (newsletter, events announcements, etc...). These additional members may be added at any time, at $25.00 per person.

<P>Membership entitles you to free admission to our Trade Show, reduced rates at educational programs, participation in member services programs, subscription to our newsletter "NCIBA News," one free copy of the annual Rep Guide, one free copy of the Membership Directory, appropriate inclusion on our web site and many other benefits. 

<ul>

<P><LI> <B><a href="apply.html">Application for Membership</a></B>

</ul>

<P>For more information about joining the NCIBA, please contact our office at 5643 Paradise Dr. Suite 12, Corte Madera, California 94925 or call 415-927-3971. We may be reached by email at  <B><A
HREF="mailto:office@nciba.com">office@nciba.com</A>.</B>

<P><CENTER><img width=480 height=21 src="image/rule08.GIF"></CENTER>

<CENTER><B><P>WE APPRECIATE YOUR INTEREST!</B></CENTER>

<P><CENTER><font color=brown>Additional features are already in the works for this section of the website.<BR>Be sure and check back as additional pages are posted.</font></CENTER>

<P><CENTER>YOU'RE VISITOR<BR><IMG SRC="/cgi-bin/Count2?uname=nciba|num=2|dtype=C|st=100" alt="counter"> </CENTER>

<P><hr size=12 width=60% align=center>

<CENTER>
<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <B><A
HREF="mailto:office@nciba.com">office@nciba.com</A> </B>

<P><B> <IMG SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B>
</A></P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-293</DOCNO>
<DOCOLDNO>IA009-000087-B036-210</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/faq.html 207.44.128.99 19970222112401 text/html 8241
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:24:20 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 8070
Last-modified: Mon, 17 Feb 1997 00:07:23 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com-->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  December, 1996   -->
<!--   FILE: faq.html   -->
<!--   PURPOSE: faq page about the NCIBA -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>NCIBA F.A.Q. page</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association F.A.Q. page. We have answers to some of your most asked questions.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books bookstores consumer information reading literature faq book bookstore book bookstore book bookstore book bookstore book bookstore book bookstore independent California Northern California Independent Booksellers Association NCIBA books bookstores consumer information reading literature faq book bookstore book bookstore book bookstore book bookstore book bookstore book bookstore independent California Northern California Independent Booksellers Association NCIBA books bookstores consumer information reading literature faq book bookstore book bookstore book bookstore book bookstore book bookstore book bookstore independent California independent California independent California">

</HEAD>
<BODY bgcolor=#ffffff>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<CENTER><B><FONT SIZE=+2 color=brown><FONT SIZE=+3>W</FONT>ELCOME <FONT SIZE=+3>T</FONT>O <FONT SIZE=+3>T</FONT>HE <FONT SIZE=+3>N</FONT>CIBA <FONT SIZE=+3>P</FONT>AGE <FONT SIZE=+3>O</FONT>F<BR> <font color=red>F</font>REQUENTLY <font color=red>A</font>SKED <font color=red>Q</font>UESTIONS</FONT></B>

<P><img src="image/book-question.gif" alt="question"><BR></CENTER>

<P><FONT SIZE=+1><B>What is the Northern California Independent Booksellers Association ?</B></FONT>

<P><img width=21 height=13 src="image/book.gif"> The Northern California Independent Booksellers Association, or NCIBA, is a trade organization dedicated to supporting, nurturing and promoting independent retail bookselling. With hundreds of member stores in just about every community in Northern California (from Arcata in the north to Monterey in the South), the NCIBA has been an experienced provider of services for over two decades.

<P><FONT SIZE=+1><B>What kind of bookstores are independent bookstores ?</B></FONT>

<P><img width=21 height=13 src="image/book.gif"> All kinds ! Our diversity is our strength. Our membership includes general interest bookstores as well as specialty shops. Children's, travel, mystery, science fiction, antiquarian, used and even museum bookstores belong to the NCIBA. Some stores are as small as 100 square feet, some as large as 33,000 square feet. What matters is not the size of the store or the volume of business, but our dedication to quality service, community involvement and most importantly - books.

<P><FONT SIZE=+1><B>"Independent" seems to be a defining characteristic of your organization. What's the difference between an independent bookstore and a chain bookstore ?</B></FONT>

<P><img width=21 height=13 src="image/book.gif"> Have you ever walked into a chain bookstore and asked for the Pulitzer Prize winning novel <B>Shipping News</B>, and been told they don't carry that <I>magazine</I>. Or have you asked for <B>Lolita</B>, and been refered to the Amy Fischer story ? 

<P>As more and more people are discovering, the so-called "super" stores are not really all that "super." In fact, many of the leading chain bookstores have begun to model their business operations after independent stores. However, without the dedication of knowledgeable and experienced employees, of community involvement and responsiveness, and of our own love of books and enthuisiasm for sharing our passion - chain bookstores are not all they appear to be. Independent bookstores stand for something different - and we believe, something better.

<P><FONT SIZE=+1><B>What exactly does the NCIBA do ? </B></FONT>

<P><img width=21 height=13 src="image/book.gif"> Among our many projects is the <B>California Catalog</B>, a holiday catalog distributed throughout California. The books appearing in this catalog are the result of the NCIBA's best efforts in soliciting titles of interest to customers of independent bookstores. With its 1.5 million print run, full color format and popularity with consumers, the <B>California Catalog</B> has proven to be the leading holiday book catalog in the state.

<P>One recent project is<B> First and Foremost: A Guide to Northern California Independent Bookstores</B>. This comprehensive guide - co-published with Heydey Books - is essential reading for any book or bookstore lover. Another recent project includes five regional directories to independent bookstores throughout Northern California. These full color brochures feature maps and a listing of the best bookstores throughout the East Bay, San Francisco, North Bay & North Coast, South Bay & South Coast, and the Central Valley, Gold Country and Sierras. These brochures can be found in bookstores, hotel lobbies, chambers of commerce, bed & breakfasts and other high traffic locations throughout the region.

<P>Each month, the NCIBA issues a regional best-seller list published in alternative newspapers such as the <I>East Bay Express</I> and the <I>Sacramento News & Review</I>. This list differs from other bestseller lists and reflects what is really selling in independent bookstores in Northern California. The NCIBA is also the source of the popular " <B><A HREF="goodread.html">Good Reads</a></B>" ads found in the<B> San Francisco Chronicle</B> and elsewhere. These ads feature bookseller reviews of distinctive titles - the kind we love to tell our customers about. Adjunct to the "Good Reads" campaign is the "Great Reads Book Award," which honors exceptional books and is voted upon annually by member bookstores.

<P>Besides these activities, the NCIBA also sponsors an annual trade show and educational workshops as well as producing a monthly newsletter and a California rep directory geared toward those in the retail bookselling community.

<P><FONT SIZE=+1><B>Can I join the NCIBA ?</B></FONT>

<P><img width=21 height=13 src="image/book.gif"> Membership is limited to those "in the trade." Regular membership is open to any individual member of the retail bookselling community whose primary place of business is California. We also welcome associate members, who while not entitled to vote, are vital to our community and its dialogue and receive all other benefits of membership. Associate members may include prospective booksellers, publishers, sales reps, wholesalers, members of the media, librarians, authors or illustrators and sideline/service/supply vendors. For more information about joining the NCIBA, please contact our office at 5643 Paradise Dr. Suite 12, Corte Madera, California 94925 or call 415-927-3971. We may be reached by email at <B> <A
HREF="mailto:office@nciba.com">office@nciba.com</A></B>.

<P>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-294</DOCNO>
<DOCOLDNO>IA009-000087-B036-237</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/Welcome.html 207.44.128.99 19970222112411 text/html 12297
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:24:29 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 12125
Last-modified: Sun, 16 Feb 1997 22:03:48 GMT
</DOCHDR>
<HTML>
<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com -->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED: February, 1997   -->
<!--   FILE: Welcome.html   -->
<!--   PURPOSE: Homepage, Northern California Independent Booksellers Association   -->
<!--   DEDICATION: To Christy   --->
<!-    NOTICE: Original contents of this website copyright NCIBA   --->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>Northern California Independent Booksellers Association</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association. These pages are a resource for readers, book lovers and consumers alike. Regional bestsellers, recommended reading, event and happenings, news, a bookstore directory, links to other sites and more can be found at this site.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA bookstore bookstores books store regional bestseller shopping consumer author writer events reading literature literacy censorship free expression Good Reads Northern California Independent Booksellers Association NCIBA bookstore bookstores books store regional bestseller shopping consumer author writer events reading literature literacy censorship free expression Good Reads Northern California Independent Booksellers Association NCIBA bookstore bookstores books store regional bestseller shopping consumer author writer events reading literature literacy censorship free expression Good Reads Northern California Independent Booksellers Association NCIBA bookstore bookstores books store regional bestseller shopping consumer author writer events reading literature literacy censorship free expression Good Reads bookstore book books bookstores California bookstore book books bookstores California bookstore book books bookstores California bookstore book books bookstores California bookstore book books bookstores Californiabookstore book books bookstores California">

</HEAD>
<BODY BGCOLOR=#ffffff>

<FONT SIZE=+2><B>A resource for readers and . . . .</B></FONT>
<P>

<TABLE BORDER=0 WIDTH=100% HEIGHT=100% cellspacing=0 cellpadding=0>
<TR><TD valign=top><img width=186 height=192 src="image/nciba007.gif"  alt="nciba logo"><BR>
<CENTER><B><CENTER><P><FONT SIZE=-2>NORTHERN CALIFORNIA</FONT><BR>
<FONT SIZE=-1>INDEPENDENT BOOKSELLERS</FONT><BR>
<FONT SIZE=-2>ASSOCIATION</FONT></CENTER>
</B></CENTER></TD>

<TD align=right valign=top><FONT color=purple SIZE=+4><B> . . . . book lovers</B></FONT>

<P><FONT SIZE=+2><B>W</B></font><font size=+2>elcome to the<B> Northern California Independent Booksellers Association</B>. These pages are a resource for readers, book lovers and consumers alike. Bestsellers, a store directory, recommended reading, book news, links to related sites and much more can be found here. Scroll down to begin your adventure!</FONT>

</TD>
</TR>
</TABLE>

<table border=0 cellpadding=5 cellspacing=3>
<tr>

<td valign=top rowspan=14>

<img width=21 height=13 src="image/book.gif"> <FONT color=green><B> "Journalism allows its readers to witness history; fiction gives its readers an opportunity to live it."</B></FONT>

<P align=right><B>JOHN HERSEY, 1950</B>

<P><hr width=75%>

<P><CENTER><IMG hspace=10 width=120 height=181 SRC="image/foremost.gif" ALT="first & foremost"></CENTER>

<P><FONT SIZE=+1>"Getting a copy of <B>First & Foremost</B> would make many bibliophiles very, very happy."</FONT><BR>
---<B><I> Contra Costa Times</I></B> Book News

<P><img width=21 height=13 src="image/book.gif"> <B>The NCIBA - in association with Heydey Books - has published a guide to independent bookstores across Northern California. As every reader and browser knows, bookstores are not only a source for books - but, as the centers of their neighborhood or community, for information and entertainment. The book, which retails for $12.95, can be found in bookstores throughout the region.</B>

<P><FONT SIZE=+1>"This charming and exhaustive guide describes nearly 300 independent bookstores in Northern California . . . a nifty book."</FONT><BR>
--- Pat Holt, <B><I>San Francisco Chronicle</I></B>

</td>

<!---------------------------------------------------------------------------------------->

<td width=4% rowspan=14 valign=top align=center><IMG width=3 height=950 SRC="image/vrule.gif" alt="vertical line"></td>

<!---------------------------------------------------------------------------------------->

<td width=15% align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="purpose.html" onMouseOver="window.status='Some thoughts on what it means to be an independent bookseller . . . '; return true">INFORMATION</A></font></th>
</tr>
</table></td>

<td width=85%>
<P><FONT SIZE=+2><B>T</B></FONT>he NCIBA <B><A HREF="purpose.html">Declaration of Independents</a></B>: what every consumer should know; our <B><A HREF="purpose.html">F.A.Q.</a></B> and more.</td></tr>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="bestsell.html" onMouseOver="window.status='A bestseller list especially for Northern California . . .'; return true">BESTSELLERS</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>O</B></FONT>ur monthly list of Northern California <B><A HREF="bestsell.html">Bestsellers</a></B>. Find out what's really selling in your local bookstore.</TD></tr>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="goodread.html" onMouseOver="window.status='Looking for something good to read - here are suggestions from your local bookseller . . . '; return true">GOOD READS</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>R</B></FONT>ecommended reading from your local bookseller. <B><A HREF="goodread.html">Good Reads</a></B> are the books we want to tell you about . . . .</TD></TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="stores.html" onMouseOver="window.status='Find new & exciting places to shop all around the state . . . '; return true">BOOKSTORES</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>R</B></FONT>egional listings of NCIBA member stores. Locate a <B><A HREF="stores.html">Bookstore</a></B> near you!</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="profile.html" onMouseOver="window.status='Take a look at one of the independent bookstores serving Northern California . . . '; return true">PROFILE</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>O</B></FONT>ur monthly <B><A HREF="profile.html">Profile</a></B> of a Northern California bookstore. Find out more about some of your favorite places to shop.</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="aisles.html" onMouseOver="window.status='News, events and happenings from the local world of books . . .'; return true">IN THE AISLES</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>N</B></FONT>ews, announcements, <B><A HREF="aisles.html">Gossip and Goings-on</a></B> from your local bookseller. Newsletter clippings, fun facts and more.</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="online.html" onMouseOver="window.status='Many of your favorite independent bookstores are online . . . '; return true">ONLINE STORES</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>A</B></FONT> growing, hyperlinked list of <B><A HREF="online.html">Online Bookstores</a></B>. Cybershoppers should check this page often!</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="news.html" onMouseOver="window.status='Here is the latest from the larger world of books . . . '; return true">BOOK NEWS</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>N</B></FONT>ews, events and happenings in the larger<B> <A HREF="news.html"> World  of  Books</a></B>. From the Bay Area to Northern California and beyond.</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="censor.html" onMouseOver="window.status='Find out more about free speech issues . . .'; return true">FREE SPEECH</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>F</B></FONT>ind out about <B><A HREF="censor.html">Free Speech Issues</a></B> effecting not only bookstores, but the online community as well.</TD></TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="resource.html" onMouseOver="window.status='For students of literature to trivia buffs to those looking for something good to read . . .'; return true">RESOURCES</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>W</B></FONT>ant to know who won a Pulitzer or Nobel Prize? Curious about California's rich literary history? Visit our information packed page of <B><A HREF="resource.html">Reader Resources</a></B>.</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="links.html" onMouseOver="window.status='Travel through the world of online books and authors . . .'; return true">LINKS</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>L</B></FONT>iterary <B><A HREF="links.html">Links</a></B> on the net; our list of author pages, book-related web sites, newsgroups, online libraries and more.</TD>
</TR>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="feedback.html" onMouseOver="window.status='Our mailing list is a great way to keep informed . . .'; return true">MAILING LIST</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>J</B></FONT>oin the NCIBA <B><A HREF="feedback.html">Mailing List</a></B> and receive free updates from the world of books.</TD></tr>

</tr>
<td><BR></td>
<tr>

<TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2> <A HREF="home.html" onMouseOver="window.status='Further information for those who work in the bookstore trade . . . '; return true">NCIBA INFO</A></font></th>
</tr>
</table></TD>

<TD align=left><FONT SIZE=+2><B>M</B></FONT>ore <B><A HREF="home.html">Information</a></B> about the Northern California Independent Booksellers Association. [<B>Of interest to bookstores and booksellers</B>.]</TD></tr>

</tr>
</table

<BR>

<CENTER><P><HR WIDTH=66% SIZE=5></CENTER>

<table border=0 cellpadding=10>
<tr>

<td align=left valign=top><IMG SRC="image/goldsite2.gif" ALT="NetGuide Gold Site" WIDTH="70" HEIGHT="70" BORDER="0" align=left vspace=5></td>

<td align=middle>

<P><font color=brown><center>Additional features are already in the works for this website.<BR>Be sure and check back as additional pages are posted.</font></CENTER>

<CENTER><P><B>We would appreciate hearing from you.<BR>
Please send your comments or suggestions to<BR><A
HREF="mailto:office@nciba.com"> office@nciba.com</A><BR>
</B><BR>

<P><B>YOU'RE BOOKLOVER</B><BR><IMG SRC="/cgi-bin/Count2?uname=nciba|num=1|dtype=C" alt="counter">

<P><FONT SIZE=-1>Designed and maintained by Thomas Gladysz.<BR>Comments or corrections regarding this website should be directed to the webmaster<BR><A
HREF="mailto:thomasg@pandorasbox.com">thomasg@pandorasbox.com</A><BR></FONT>

</CENTER>
</td>

<td align=right valign=top><CENTER> <FONT FACE="ARIAL,HELVETICA" SIZE="1"><CENTER><B>Best experienced with
<BR><A HREF="http://www.microsoft.com/ie/ie.htm"><IMG SRC="image/ie_static.gif" WIDTH="88" HEIGHT="31" BORDER="0" ALT="Microsoft Internet Explorer" VSPACE="7"> </A><BR>Click here to start</CENTER> </FONT></td>


</tr>
</table>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-295</DOCNO>
<DOCOLDNO>IA009-000087-B036-265</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/north.html 207.44.128.99 19970222112421 text/html 15753
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:24:40 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 15581
Last-modified: Sun, 16 Feb 1997 22:03:20 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox.com -->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  January, 1997   -->
<!--   FILE: north.html   -->
<!--   PURPOSE: list of North Bay / North Coast NCIBA bookstores  -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>North Bay / North Coast Bookstores</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association page of North Bay / North Coast bookstores - - here you will find some of your favorite places to shop in the Northern California.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading book bookstore bookstores consumer information regional business literature new used antiquarian children's speciality west north south east San Francisco Bay Area Petaluma San Anselmo Tiburon Rohnert park Healdburg Stinson Beach Santa Rosa San Rafael Larkspur Mill valley Mendocino napa Sonoma Kentfield Arcata Sebastapol Humboldt Russian River wine country coast bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore books books books books bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore">

</HEAD>
<BODY bgcolor=#ffffff>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<CENTER><FONT SIZE=+2 COLOR=BROWN> <img src="image/bkiconR.gif"> <B><FONT SIZE=+3>N</FONT>ORTH <FONT SIZE=+3>B</FONT>AY / <FONT SIZE=+3>N</FONT>ORTH <FONT SIZE=+3>C</FONT>OAST <img src="image/bkicon.gif"><BR>BOOKSTORES</FONT></B></CENTER>

<P><FONT SIZE=+1><B>W</B></FONT>elcome to the North Bay / North Coast  membership directory of the Northern California Independent Booksellers Association. Here you will find an alphabetical listing of dozens of member bookstores. Stores are designated as being NEW, USED or NEW & USED as well as GENERAL interest or SPECIALTY shops. Additional store specialties are also noted. If you know the name of the bookstore you are looking for, simply click on the appropriate letter of the alphabet to move around this page. These alphabetical links will take you to the beginning of that letter's listing.

<CENTER><B><P><A HREF="#A">A</A> / <A HREF="#B">B</A> / <A HREF="#C">C</A> / <A HREF="#D">D</A> / <A HREF="#E">E</A> / <A HREF="#F">F</A> / <A HREF="#G">G</A> / <A HREF="#H">H</A> / <A HREF="#I">I</A> / <A HREF="#J">J</A> / <A HREF="#K">K</A> / <A HREF="#L">L</A> / <A HREF="#M">M</A> / <A HREF="#N">N</A> / <A HREF="#O">O</A> / <A HREF="#P">P</A> / <A HREF="#Q">Q</A> / <A HREF="#R">R</A> / <A HREF="#S">S</A> / <A HREF="#T">T</A> / <A HREF="#U">U</A> / <A HREF="#V">V</A> / <A HREF="#W">W</A> / <A HREF="#X">X</A> / <A HREF="#Y">Y</A> / <A HREF="#Z">Z</A><BR></B></CENTER>

<P>You may also create a local map to the bookstore of your choice. Follow the simple directions on the <B><a href="http://www.mapblast.com/mapblast/locator.html">MapBlast</a> </B>page. You will need the address, city and state of the bookstore. Once you have generated a map, you may zoom-in or zoom-out for additional detail as well as print out the results. [<font color=green> Return to this page by using your back button.</font> ]

<P>

<CENTER><TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2><a href="http://www.mapblast.com/mapblast/locator.html">CREATE A MAP TO YOUR FAVORITE BOOKSTORE</a>  </font></th>
</tr>
</table></TD></CENTER>

<P>

<P><B>1ST STREET BOOKS<BR></B>
850 College Avenue<BR>
Kentfield<BR>
415-456-8770<BR>
<font color=brown>New Books<BR>
General:</font> Children's	

<A NAME="A">

<A NAME="B">

<P><B>BOOK LOFT<BR></B>
45050  Main Street<BR>
Mendocino<BR>
707-937-0890<BR>
<B><A
HREF="http://www.bookloft.com">http://www.bookloft.com</a></B><BR>
<font color=brown>email:</font> <B><A
HREF="mailto:hope@bookloft.com">hope@bookloft.com</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Non-Fiction

<P><B>BOOK PASSAGE<BR></B>
51 Tamal Vista Blvd.<BR>
Corte Madera<BR>
415-927-0960<BR>
<B><A
HREF="http://www.bookpassage.com">http://www.bookpassage.com</a></B><BR>
 <font color=brown>email:</font> <B><A
HREF="mailto:messages@bookpassage.com">messages@bookpassage.com</a></B><BR>
<font color=brown>New & Used Books<BR>
General:</font> Travel, Mystery, Writer's Craft

<P><B>BOOK STOP<BR></B>
305 North Main Street<BR>
Lakeport<BR>
707-263-5787<BR>
<font color=brown>New & Used Books<BR>
General:</font> Mystery, Children's, Antiquarian

<P><B>BOOKENDS BOOKSTORE<BR></B>
1014 Coombs Street<BR>
Napa<BR>
707-224-7455<BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Non-Fiction

<P><B>BOOKS REVISITED<BR></B>
1122 Fourth Street<BR>
San Rafael<BR>
415-459-5788<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:bksrev@ix.netcom.com">bksrev@ix.netcom.com</a></B><BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Used

<P><B>BOOKSHOP BENICIA<BR></B>
856 Southampton Road<BR>
Benicia<BR>
707-747-5155<BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Children's, Mystery

<A NAME="C">

<P><B>CATFISH BOOKS<BR></B>
1013 11th Street<BR>
Lakeport<BR>
707-263-4454<BR>
<font color=brown>New & Used Books<BR>
General:</font> Software, Easy Listening Music

<P><B>CHESHIRE CAT BOOKS<BR></B>
1207 Bridgeway  #E<BR>
Sausalito<BR>
415-332-7885<BR>
<font color=brown>New & Used Books<BR>
General:</font> Fiction, Mystery, Biography

<P><B>A CLEAN WELL-LIGHTED PLACE FOR BOOKS<BR></B>
2417 Larkspur Landing Circle<BR>
Larkspur<BR>
415-461-0171<BR>
<B><A
HREF="http://www.bookstore.com">http://www.bookstore.com</a></B><BR>
<font color=brown>email:</font> <B><A
HREF="mailto:linfo@bookstore.com">linfo@bookstore.com</a></B><BR>
<font color=brown>New & Used Books<BR>
General:</font> Children's, Business, Science Fiction

<P><B>COPPERFIELD'S ANNEX<BR></B>
176 N. Main Street<BR>
Sebastopol<BR>
707-829-0429<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:copfldbks@monitor.net">copfldbks@monitor.net</a></B><BR>
<font color=brown>Used Books<BR>
Specialty:</font> Fiction, Non-Fiction

<P><B>COPPERFIELD'S BOOKS<BR></B>
138 N. Main Street<BR>
Sebastopol<BR>
707-823-8991<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:copfldbks@monitor.net">copfldbks@monitor.net</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Metaphysics, Reference, Fiction

<P><B>COPPERFIELD'S BOOKS<BR></B>
1303 First  Street<BR>
Napa<BR>
707-252-8002<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:copfldbks@monitor.net">copfldbks@monitor.net</a></B><BR>
<font color=brown>New & Used Books<BR>
General:</font> Fiction, Non-Fiction

<P><B>COPPERFIELD'S BOOKS<BR></B>
540 Raley Town Center<BR>
Rohnert Park<BR>
707-584-4240<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:copfldbks@monitor.net">copfldbks@monitor.net</a></B><BR>
<font color=brown>email:</font> <B><A
HREF="mailto:"></a></B><BR>
<font color=brown>New Books<BR>
General:</font> Mystery, Cards & Magazines

<P><B>COPPERFIELD'S BOOKS<BR></B>
140 Kentucky Street<BR>
Petaluma<BR>
707-762-0563<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:copfldbks@monitor.net">copfldbks@monitor.net</a></B><BR>
<font color=brown>New & Used Books<BR>
General:</font> Fiction, Children's

<P><B>COPPERFIELD'S BOOKS<BR></B>
650 Fourth Street<BR>
Santa Rosa<BR>
707-545-5326<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:copfldbks@monitor.net">copfldbks@monitor.net</a></B><BR>
<font color=brown>New & Used Books<BR>
General:</font> Spiritual, Metaphysics, Recorded Music

<P><B>COPPERFIELD'S BOOKS<BR></B>
2316 Montgomery Drive<BR>
Santa Rosa<BR>
707-578-8938<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:copfldbks@monitor.net">copfldbks@monitor.net</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Children's, Recorded Music

<P><B>CORRICK'S, INC<BR></B>
637 4th Street<BR>
Santa Rosa<BR>
707-546-2423<BR>
<font color=brown>New Books<BR>
General:</font> Cooking, Globes & Maps

<A NAME="D">

<P><B>DEPOT BOOKSTORE & CAFE<BR></B>
87 Throckmorton  Avenue<BR>
Mill Valley<BR>
415-383-2665<BR>
<font color=brown>New Books<BR>
General:</font> Nonfiction, Psychology, Fiction

<A NAME="E">

<A NAME="F">

<A NAME="G">

<P><B>GALLERY BOOKSHOP & BOOKSWINKLE'S CHILDREN'S BOOKS<BR></B>
Corner of Main & Kasten Sts.<BR>
P.O. Box 270<BR>
Mendocino<BR>
707-937-2665<BR>
<B><A HREF="http://www.gallerybooks.com">http://www.gallerybooks.com</A></B><BR>
<font color=brown>email:</font> <B><A
HREF="mailto:amiksak@mcn.org">amiksak@mcn.org</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Children's, Cards, Magazines

<P><B>GUALALA BOOKS<BR></B>
39145 Highway One<BR>
Gualala<BR>
707-884-4255<BR>
<font color=brown>New Books<BR>
General:</font> Nature, Children's, Local Authors / Interest, Literature

<A NAME="H">

<P><B>HSU BOOKSTORE<BR></B>
Humbolt State University<BR>
Arcata<BR>
707-826-3958<BR>
<font color=brown>New & Used Text Books<BR>
Specialty:</font> Natural Resources, Fiction, Study Aids, Nursing

<A NAME="I">

<A NAME="J">

<A NAME="K">

<A NAME="L">

<P><B>LANDON BOOKS<BR></B>
404 Strawberry Village<BR>
Mill Valley<BR>
415-388-7929<BR>
<font color=brown>New & Used Books<BR>
General:</font> Mystery, Audio Rental

<P><B>LARKFIELD BOOK COMPANY<BR></B>
420 Larkfield Center<BR>
Santa Rosa<BR>
707-542-2665<BR>
<font color=brown>New & Used Books<BR>
General:</font> Mysteries, Children's, Rubber Art Stamps

<P><B>LEAVES OF GRASS<BR></B>
630 S. Main St.<BR>
Willits<BR>
707-459-3744<BR>
<font color=brown>New Books<BR>
General:</font> Children's, Fiction, How-to, Metaphysics

<P><B>LEVIN & COMPANY<BR></B>
306 Center Street<BR>
Healdsburg<BR>
707-433-1118<BR>
<font color=brown>New & Used Books<BR>
General:</font> Children's, Literature 

<A NAME="M">

<P><B>MARIN TEACHERS'  STORE<BR></B>
901 C Stree<BR>
San Rafael<BR>
415-453-9197<BR>
<font color=brown>New Books<BR>
Specialty:</font> Children's, Educational Supplies

<P><B>MENDOCINO BOOK CO.<BR></B>
102 S. School Street	Ukiah<BR>
707-468-5940<BR>
<font color=brown>New Books<BR>
General:</font> Children's, Fiction, Mystery, Magazines

<A NAME="N">

<P><B>NEW LEAF BOOKSTORE<BR></B>
545 Magnolia Avenue<BR>
Larkspur<BR>
415-924-8970 or 1-800-850-5323<BR>
<font color=brown>New Books<BR>
Specialty:</font> Personal Growth, Conscious Living

<P><B>NORTHTOWN BOOKS<BR></B>
957 H Street<BR>
Arcata<BR>
707-822-2834<BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Children's, Periodicals

<P><B>NORTH LIGHT BOOKS<BR></B>
95 Fifth Street<BR>
Santa Rosa<BR>
707-579-9000<BR>
<font color=brown>New & Used Books<BR>
General:</font> Fiction, Non-Fiction, Spirituality

<A NAME="O">

<P><B>OLIVER'S BOOKS<BR></B>
645 San Anselmo Avenue<BR>
San Anselmo<BR>
415-454-4421<BR>
<font color=brown>New & Used Books<BR>
General:</font> Modern Fiction, Natural History, Native Americana

<A NAME="P">

<P><B>PACIFIC UNION COLLEGE BOOKSTORE<BR></B>
 # 9 Angwin Plaza <BR>
Angwin<BR>
707-965-6271<BR>
<font color=brown>New & Used Text Books<BR>
General:</font> Textbooks

<A NAME="Q">

<A NAME="R">

<P><B>READERS' BOOKS<BR></B>
127 E. Napa Street<BR>
Sonoma<BR>
707-939-1779<BR>
<font color=brown>New Books<BR>
General:</font> Literature, Children's, Food, Wine

<P><B>READING, RHYTHM AND ROM<BR></B>
6 Petaluma Blvd. North<BR>
Petaluma<BR>
707-762-2912<BR>
<B><A
HREF="http://www.wco.com/~readrom">http://www.wco.com/~readrom</a></B><BR>
<font color=brown>email:</font> <B><A
HREF="mailto:readrom@wco.com">readrom@wco.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Computer, Software, Music, Children's

<P><B>RIVER READER, INC<BR></B>
16355 Main St.<BR>
Guerneville<BR>
707-869-2240<BR>
<font color=brown>New & Used Books<BR>
General:</font> Fiction, Gay / Lesbian, Spirituality

<A NAME="S">

<P><B>SONOMA BOOK ENDS BOOKSTORE<BR></B>
201 W. Napa Street  #15<BR>
Sonoma<BR>
707-938-5926<BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Cooking, Maps

<P><B>STINSON BEACH BOOKS<BR></B>
3455 Shoreline Hwy.<BR>
Stinson Beach<BR>
415-868-0700<BR>
<font color=brown>New & Used Books<BR>
General:</font> Nature, Children's, Fiction	

<A NAME="T">

<P><B>TOYON BOOKS<BR></B>
104 Matheson Street<BR>
Healdsburg<BR>
707-433-9270<BR>
<font color=brown>New Books<BR>
General:</font> Wine, Children's, Spanish Language, Audio Book Rentals		

<P><B>TREASURE BOOKS<BR></B>
101 Golf Course Dr. , #A4<BR>
Rohnert Park<BR>
707-584-3992<BR>
<font color=brown>New Books<BR>
Specialty:</font> Children's

<P><B>TREEHORN BOOKS<BR></B>
625 4th Street<BR>
Santa Rosa<BR>
707-525-1782<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:thornbks@aol.com">thornbks@aol.com</a></B><BR>
<font color=brown>Used Books<BR>
General:</font> California History, Food, Wine, Children's 	

<A NAME="U">

<A NAME="V">

<A NAME="W">

<P><B>WATERMARK AT TIBURON BOOKS<BR></B>
82 Main Street<BR>
Tiburon<BR>
415-435-4960<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:ellupton@aol.com">ellupton@aol.com</a></B><BR>
<font color=brown>New & Used Books<BR>
General:</font> Fiction, Non-Fiction, Children's

<P><B>WHYTE'S BOOKSMITH<BR></B>
615 San Anselmo Avenue<BR>
San Anselmo<BR>
415-459-7323<BR>
<font color=brown>New & Used Books<BR>
General:</font> School Texts, Academic

<P><B>WORDSWORTH BOOKS<BR></B>
283 B North McDowell Blvd.<BR>
Petaluma<BR>
707-762-5665<BR>
<font color=brown>New & Used Books<BR>
General:</font> Fiction, Non-Fiction

<A NAME="X">

<A NAME="Y">

<A NAME="Z">

<P>

<CENTER><P>For further information on these and other stores, please refer to the recently published<BR>"First and Foremost: A Guide to Northern California's Independent Bookstores"<BR>
(<font color=red>available at independent bookstores everywhere</font>).

<B><P>WE APPRECIATE YOUR INTEREST!</B></CENTER>

<P>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-296</DOCNO>
<DOCOLDNO>IA009-000087-B036-293</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/sfstores.html 207.44.128.99 19970222112431 text/html 15401
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:24:50 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 15229
Last-modified: Sun, 16 Feb 1997 22:03:32 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasG@pandorasbox.com -->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  December, 1996   -->
<!--   FILE: sfstores.html   -->
<!--   PURPOSE: list of San Francisco NCIBA bookstores  -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>San Francisco Bookstores</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association page of San Francisco bookstores - - here you will find some of your favorite places to shop in the City by the Bay.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading book bookstore bookstores consumer information regional business literature new used antiquarian children's speciality west north south east San Francisco Bay Area bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore Haight Ashbury Noe Valley Glen Park Richmond Sunset Russian Hill Hayes Valley Potrero Mission Presido downtown Civic Center Outer Inner Western Addition Hill District Bernal Heights Hunters Point Ingelside Excelsior Portal Frisco books books books books bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore">

</HEAD>
<BODY bgcolor=#ffffff>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<CENTER><FONT SIZE=+2 color=brown> <img src="image/bkiconR.gif"><B> <FONT SIZE=+3>S</FONT>AN <FONT SIZE=+3>F</FONT>RANCISCO <FONT SIZE=+3>B</FONT>OOKSTORES </B> <img src="image/bkicon.gif"></FONT></CENTER>

<P><FONT SIZE=+1><B>W</B></FONT>elcome to the San Francisco membership directory of the Northern California Independent Booksellers Association. Here you will find an alphabetical listing of more than 40 member bookstores. Stores are designated as being NEW, USED or NEW & USED as well as GENERAL interest or SPECIALTY shops. Additional store specialties are also noted. If you know the name of the bookstore you are looking for, simply click on the appropriate letter of the alphabet to move around this page. These alphabetical links will take you to the beginning of that letter's listing.

<CENTER><B><P><A HREF="#A">A</A> / <A HREF="#B">B</A> / <A HREF="#C">C</A> / <A HREF="#D">D</A> / <A HREF="#E">E</A> / <A HREF="#F">F</A> / <A HREF="#G">G</A> / <A HREF="#H">H</A> / <A HREF="#I">I</A> / <A HREF="#J">J</A> / <A HREF="#K">K</A> / <A HREF="#L">L</A> / <A HREF="#M">M</A> / <A HREF="#N">N</A> / <A HREF="#O">O</A> / <A HREF="#P">P</A> / <A HREF="#Q">Q</A> / <A HREF="#R">R</A> / <A HREF="#S">S</A> / <A HREF="#T">T</A> / <A HREF="#U">U</A> / <A HREF="#V">V</A> / <A HREF="#W">W</A> / <A HREF="#X">X</A> / <A HREF="#Y">Y</A> / <A HREF="#Z">Z</A><BR></B></CENTER>

<P>You may also create a local map to the bookstore of your choice. Follow the simple directions on the <B><a href="http://www.mapblast.com/mapblast/locator.html">MapBlast</a> </B>page. You will need the address, city and state of the bookstore. Once you have generated a map, you may zoom-in or zoom-out for additional detail as well as print out the results. [<font color=green> Return to this page by using your back button.</font> ]

<P>

<CENTER><TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2><a href="http://www.mapblast.com/mapblast/locator.html">CREATE A MAP TO YOUR FAVORITE BOOKSTORE</a>  </font></th>
</tr>
</table></TD></CENTER>

<P>

<A NAME="A">

<P><B>ALEXANDER BOOK COMPANY<BR></B>
50 Second Street, San Francisco<BR>
415-495-2992<BR>
<font color=brown>New Books<BR>
General:</font> Literature, World Studies, Children's
 
<A NAME="B">

<P><B>BERNAL BOOKS<BR></B>
401 Cortland Avenue, San Francisco<BR>
415-550-0293<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:BERNALBKS@AOL.COM">BERNALBKS@aol.com</a></B><BR>
<font color=brown>New Books<BR>
General:</font> New Releases, Mystery, Fiction, Children's

<P><B>BOOKS INC.<BR></B>
3515 California Street, San Francisco<BR>
415-221-3666<BR>
<font color=brown>New Books<BR>
General:</font> Children's, Literature, Gift Books

<P><B>BOOKS INC.<BR></B>
2275 Market Street, Market Village Mall, San Francisco<BR>
415-864-6777<BR>
<font color=brown>New Books<BR>
General: </font>Travel, Gay / Lesbian, Wired Culture

<P><B>THE BOOKSMITH<BR></B>
1644 Haight Street, San Francisco<BR>
415-863-8688 or 1-800-493-7323<BR>
<B><A
HREF="http://www.booksmith.com">http://www.booksmith.com</a></B><BR>
<font color=brown>email:</font> <B><A
HREF="mailto:read@booksmith.com">read@booksmith.com</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Children's, Music, Cookbooks, Remainders

<P><B>BUILDERS BOOKSOURCE SF</B><BR>
900 Northpoint, Ghirardelli Square, San Francisco<BR>
415-440-5773<BR>
<B><A
HREF="http://www.buildersbooksite.com">http://www.buildersbooksite.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Design, Construction

<A NAME="C">

<P><B>CHRISTOPHER'S BOOKS</B><BR>
1400 18th Street, San Francisco<BR>
415-255-8802<BR>
<font color=brown>New Books<BR>
General: </font>Literature,Children's, History	

<P><B>CITY LIGHTS BOOKS</B><BR>
261 Columbus Avenue, San Francisco<BR>
415-362-8193<BR>
<B><A HREF="http://town.hall.org/places/city_lights/">http://town.hall.org/places/city_lights/</a><BR></B>
<font color=brown>New Books<BR>
General: </font>Contemporary Literature, Poetry, Beat Literature

<P><B>A CLEAN WELL LIGHTED PLACE FOR BOOKS</B><BR>
601 Van Ness, San Francisco<BR>
415-441-6670<BR>
<B><A
HREF="http://bookstore.com">http://bookstore.com</a></B><BR>
<font color=brown>email:</font> <B><A
HREF="mailto:info@bookstore.com">info@bookstore.com</a></B><BR>
<font color=brown>New Books<BR>
General: </font> Music, Mystery, Fiction, Travel, Cooking

<P><B>COMPASS BOOKS INC.</B><BR>
SF International Airport, North Terminal, San Francisco<BR>
415-244-0610<BR>
<font color=brown>New Books<BR>
General: </font>New Releases, Business, Fiction

<P><B>COVER TO COVER BOOKSELLERS</B><BR>
3910 24th Streeet, San Francisco<BR>
415-282-8080<BR>
<font color=brown>New Books<BR>
General: </font>Children's, Fiction, Travel, Poetry

<A NAME="D">

<P><B>A DIFFERENT LIGHT</B><BR>
489 Castro StreetSan Francisco<BR>
415-431-0891<BR>
<B><A HREF="http://www.adlbooks.com/">http://www.adlbooks.com/</a></B><BR>
<font color=brown>email:</font> <B><A
HREF="mailto:adl@adlbooks.com">adl@adlbooks.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty: </font>Gay / Lesbian
 
<P><B>DRAMA BOOKS</B><BR>
134 Ninth Street, San Francisco<BR>
415-255-0604<BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Performing Arts

<A NAME="E">

<P><B>EUROPEAN BOOK COMPANY Inc.</B><BR>
925 Larkin Street, San Francisco<BR>
415-474-0626<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:europeanbk@aol.com">europeanbk@aol.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty: </font>Foreign Language

<P><B>EXPLORATORIUM BOOKSTORE</B><BR>
3601 Lyon Street, San Francisco<BR>
415-561-0390<BR>
<font color=brown>New Books<BR>
Specialty: </font>Science

<A NAME="F">

<P><B>FANTASY ETC.</B><BR>
808 Larkin Street, San Francisco<BR>
415-441-7617<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:chasfant@ix.netcom.com">chasfant@ix.netcom.com</a></B><BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Mystery, Gay, Lesbian<BR>

<P><B>FOREVER AFTER</B><BR>
1475 Haight Street, San Francisco<BR>
415-431-8299<BR>
<font color=brown>New & Used Books<BR>
General:</font>Spirituality, Psychology, History, Holistic Health, True Crime

<P><B>FRIENDS OF PHOTOGRAPHY</B><BR>
250 Fourth Street, San Francisco<BR>
415-495-7242<BR>
<font color=brown>New Books<BR>
Specialty:</font> Photography

<A NAME="G">

<P><B>GLEN PARK BOOKS</B><BR>
2788 Diamond Street, San Francisco<BR>
415-586-3733<BR>
<font color=brown>New & Used Books<BR>
General: </font>Mystery, Gay / Lesbian, Women's Studies, Children's

<P><B>GOLDEN GATE NATIONAL PARKS BOOKSTORE</B><BR>
Pier 39 and stores throughout  the Golden Gate National Parks,	San Francisco<BR>
415-433-7221<BR>
<font color=brown>New Books<BR>
Specialty:</font> Natural and Cultural History	

<P><B>GOOD VIBRATIONS</B><BR>
1210 Valencia Street, San Francisco<BR>
415-974-8980 or 1-800-289-8423	<BR>
<B><A
HREF="http://www.goodvibes.com">http://www.goodvibes.com</a></B><BR>
<font color=brown>email:</font> <B><A
HREF="mailto:goodvibe@well.com">goodvibe@well.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty: </font>Sexuality

<P><B>GREEN APPLE BOOKS</B><BR>
506 Clement Street, San Francisco<BR>
415-387-2272<BR>
<font color=brown>New & Used Books<BR>
General: </font>Psychology, History, Cooking

<A NAME="H">

<P><B>HARRIS BOOKS</B><BR>
211 Steiner Street, San Francisco<BR>
415-626-6733<BR>
<font color=brown>New Books<BR>
General:</font> Buddhism, Black Sparrow Books, City Lights Books, Penguin Classics

<A NAME="I">

<A NAME="J">

<A NAME="K">

<P><B>KAYO BOOKS</B><BR>
814 Post St., San Francisco<BR>
415-749-0554<BR>
<B><A
HREF="http://www.sfo.com/~kayo">http://www.sfo.com/~kayo</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:kayo@sfo.com">kayo@sfo.com</a></B><BR>
<font color=brown>New & Used Books<BR>
Specialty:	</font>Vintage Paperbacks and Pulps

<P><B>KINOKUNIYA BOOK STORES OF AMERICA</B><BR>
1581 Webster St., San Francisco<BR>
415-567-7625<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:tokazaki@ix.net.com">tokazaki@ix.net.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Japan / Asia

<A NAME="L">

<P><B>LA CASA DEL LIBROS</B><BR>
973 Valencia Street, San Francisco<BR>
415-285-1145<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:casalibros@aol.com">casalibros@aol.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Spanish Language Books<BR>

<P><B>LEVI'S PLAZA BOOKS</B><BR>
1255 Battery St., #300, San Francisco<BR>
415-433-2665<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:lpb@dnai.com">lpb@dnai.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty: </font>Business

<A NAME="M"></a>

<P><B>MARIUCCIA IACONI BOOK IMPORTS, INC.</B><BR>
970 Tennessee, San Francisco<BR>
415-821-1216<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:mibook@ix.netcom.com">mibook@ix.netcom.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty: </font>Spanish Language For All Ages

<P><B>MODERN TIMES BOOKSTORE</B><BR>
888 Valencia Street, San Francisco<BR>
415-282-9246<BR>
<B><A HREF="http://www.mtbs.com">http://www.mtbs.com</a></B><BR>
<font color=brown>New Books<BR>
General: </font>Social Issues, Cultural Studies, Literature

<P><B>MUSEUM BOOKS - SFMOMA</B><BR>
151 Third Street, San Francisco<BR>
415-357-4035<BR>
<font color=brown>New Books<BR>
Specialty:</font> Art, Photography, Design

<P><B>MUSEUM STORES</B><BR>
 M.H. De Young Memorial Museum, Golden Gate Park, San Francisco<BR>
415-750-3642<BR>
<font color=brown>New Books<BR>
Specialty:</font> Art, Art History

<A NAME="N"></a><A NAME="O"></a><A NAME="P"></a>

<P><B>PAULIST CENTER BOOKSTORE</B><BR>
614 Grant Street, San Francisco<BR>
415-288-3844<BR>
<font color=brown>New Books<BR>
Specialty:</font> Religious

<A NAME="Q">

<A NAME="R">

<P><B>RICHARD HILKERT BOOKSELLER</B><BR>
333 Hayes Street, San Francisco<BR>
415-863-3339<BR>
<font color=brown>New & Used Books<BR>
General:</font> Interior Design, Architecture, Literature, Music

<P><B>ROMANTASY</B><BR>
199 Moulton Street, San Francisco<BR>
415-673 3137<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:anng@romantasy.com">anng@romantasy.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Romance, Love, Sex

<A NAME="S"></a>

<P><B>SAN FRANCISCO STATE UNIVERSITY BOOKSTORE</B><BR>
San Francisco State University, 1650 Holloway Avenue, San Francisco<BR>
415-338-1475<BR>
<B><A
HREF="http://www.bookstore.sfsu.edu">http://www.bookstore.sfsu.edu</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:bookstore@bookstore.sfsu.edu">bookstore@bookstore.sfsu.edu</a></B><BR>
<font color=brown>New & Used Books<BR>
General:</font> Modern Literature, Cultural Criticism, Reference, Ethnic Studies, Psycholgy

<P><B>SOLAR LIGHT BOOKS</B><BR>
2068 Union Street, San Francisco<BR>
415-567-6082<BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Psychology, Travel

<P><B>STACEY'S BOOKSTORE</B><BR>
581 Market Street, San Francisco<BR>
415-421-4687<BR>
<font color=brown>email:</font> <B><A
HREF="mailto:staceysbk@aol.com">staceysbk@aol.com</a></B><BR>
<A HREF="http://www.staceys.com">http://www.staceys.com</a><BR>
<font color=brown>New Books<BR>
General:</font> Computers, Business, Health

<P><B>STRING BOX BOOKS</B><BR>
1210 Union Street, San Francisco<BR>
415-776-2665<BR>
<font color=brown>New & Used Books<BR>
General:</font> Literature

<P><B>STRYBING ARBORETUM BOOKSTORE</B><BR>
9th Avenue at Lincoln Way, San Francisco<BR>
415-661-5191<BR>
<font color=brown>New Books<BR>
Specialty:</font> Botany, Gardening, Field Guides

<A NAME="T">

<A NAME="U">

<A NAME="V">

<A NAME="W">

<A NAME="X">

<A NAME="Y">

<A NAME="Z">

<P><B>ZEN CENTER BOOKSTORE</B><BR>
300 Page Street, San Francisco<BR>
415-863-3136<BR>
<font color=brown>New Books<BR>
Specialty:</font> Zen Buddhist

<P>

<CENTER><P>For further information on these and other stores, please refer to the recently published<BR>"First and Foremost: A Guide to Northern California's Independent Bookstores"<BR>
(<font color=red>available at independent bookstores everywhere</font>).

<B><P>WE APPRECIATE YOUR INTEREST!</B></CENTER>

<P>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-297</DOCNO>
<DOCOLDNO>IA009-000087-B036-322</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/east.html 207.44.128.99 19970222112441 text/html 19621
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:25:00 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 19449
Last-modified: Sun, 16 Feb 1997 22:03:08 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox-->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  December, 1996   -->
<!--   FILE: east.html   -->
<!--   DEDICATION: to Ebony, my wonderfull cat  -->
<!--   PURPOSE: list of other NCIBA bookstores  -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>East Bay Bookstores</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association page of member bookstores - - here you will find some of your favorite places to shop in the East Bay and neighboring communities.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading book bookstore bookstores consumer information regional business literature new used antiquarian children's speciality west north south east southern Berkeley Oakland Fremont Hayward Contra Costa Alameda Vallejo Concord Walnut Creek Orinda Danville Castro Valley Lafayette Martinez bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore books books books books bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore">

</HEAD>
<BODY bgcolor=#ffffff>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<CENTER><FONT SIZE=+2 color=brown> <img src="image/bkiconR.gif"><B> <FONT SIZE=+3>E</FONT>AST <FONT SIZE=+3>B</FONT>AY <FONT SIZE=+3>B</FONT>OOKSTORES</B> <img src="image/bkicon.gif"></FONT></CENTER>

<P><FONT SIZE=+1><B>W</B></FONT>elcome to the membership directory of the Northern California Independent Booksellers Association. Here you will find an alphabetical listing of dozens of member bookstores scattered throughout the East Bay and neighboring communities. Stores are designated as being NEW, USED or NEW & USED as well as GENERAL interest or SPECIALTY shops. Additional store specialties are also noted. If you know the name of the bookstore you are looking for, simply click on the appropriate letter of the alphabet to move around this page. These alphabetical links will take you to the beginning of that letter's listing.

<CENTER><B><P><A HREF="#A">A</A> / <A HREF="#B">B</A> / <A HREF="#C">C</A> / <A HREF="#D">D</A> / <A HREF="#E">E</A> / <A HREF="#F">F</A> / <A HREF="#G">G</A> / <A HREF="#H">H</A> / <A HREF="#I">I</A> / <A HREF="#J">J</A> / <A HREF="#K">K</A> / <A HREF="#L">L</A> / <A HREF="#M">M</A> / <A HREF="#N">N</A> / <A HREF="#O">O</A> / <A HREF="#P">P</A> / <A HREF="#Q">Q</A> / <A HREF="#R">R</A> / <A HREF="#S">S</A> / <A HREF="#T">T</A> / <A HREF="#U">U</A> / <A HREF="#V">V</A> / <A HREF="#W">W</A> / <A HREF="#X">X</A> / <A HREF="#Y">Y</A> / <A HREF="#Z">Z</A><BR></B></CENTER>

<P>You may also create a local map to the bookstore of your choice. Follow the simple directions on the <B><a href="http://www.mapblast.com/mapblast/locator.html">MapBlast</a> </B>page. You will need the address, city and state of the bookstore. Once you have generated a map, you may zoom-in or zoom-out for additional detail as well as print out the results. [<font color=green> Return to this page by using your back button.</font> ]

<P>

<CENTER><TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2><a href="http://www.mapblast.com/mapblast/locator.html">CREATE A MAP TO YOUR FAVORITE BOOKSTORE</a>  </font></th>
</tr>
</table></TD></CENTER>

<P>

<A NAME="A">

<P><B>4-M ENTERPRISES, INC</B><BR>
1280 Pacific Street<BR>
Union City<BR>
510-489-8722<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:Books4M@aol.com">Books4M@aol.com</a></B><BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Dogs, Horses

<P><B>AFIKOMEN JEWISH BOOKS</B><BR>
3042 Claremont Avenue<BR>
Berkeley<BR>
510-655-1977<BR>
<font color=brown>New Books<BR>
Specialty:</font> Judaica

<P><B>ASUC BOOKSTORE</B><BR>
University of California<BR>
Berkeley<BR>
510-642-7294<BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Non-Fiction

<P><B>AVENUE BOOKS </B><BR>
2904 College Avenue<BR>
Berkeley<BR>
510-549-3532<BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Mystery, Children's

<A NAME="B">

<P><B>BAY BOOKS</B><BR>
1669 Willow Pass Road<BR>
Concord<BR>
510--671-2245<BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Antiquarian, Remainders

<P><B>BERKELEY ART MUSEUM STORE</B><BR>
2626 Bancroft Ave<BR>
Berkeley<BR>
510-642-1475<BR>
<B><A
HREF="http://www.bampfa.berkeley.edu">http://www.bampfa.berkeley.edu</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:dug@uclink2.berkeley.edu">dug@uclink2.berkeley.edu</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Art, Architecture, Photography, Film, Aesthetics	

<P><B>BLACK OAK BOOKS</B><BR>
1491 Shattuck Avenue<BR>
Berkeley<BR>
510-486-0698<BR>
<B><A
HREF="http://www.culturewave.com/culturewave/ba-bookstore-events/boak.htm">http://www.culturewave.com/culturewave/ba-bookstore-events/boak.htm</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:blackoak@emf.net">blackoak@emf.net</a></B><BR>
<font color=brown>New & Used Books<BR>
General:</font> Fiction, Poetry, Antiquarian

<P><B>BONANZA STREET BOOKS</B><BR>
1605 Bonanza Street	<BR>
Walnut Creek<BR>
510-932-2466<BR>
<font color=brown>New & Used Books<BR>
General:</font> Californiana, Children's, Collectables

<P><B>BOOK CENTER</B><BR>
879-A  Island Drive<BR>
Alameda<BR>
510-523-0474<BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Non-Fiction

<P><B>BOOK END</B><BR>
5678 Thornton Ave.<BR>
Newark<BR>
510-797-4100<BR>
<font color=brown>New & Used Books<BR>
General:</font> Romance, Mystery, Science Fiction

<P><B>BOOK MARK</B><BR>
39209 Fremont Hub<BR>
Fremont<BR>
510-793-7016<BR>
<font color=brown>New & Used Books<BR>
General:</font> Romance, Science Fiction, Mystery

<P><B>BOOK SHOP</B><BR>
1007 B Street<BR>
Hayward<BR>
510-538-3943<BR>
<font color=brown>New & Used Books<BR>
General:</font> Fiction, Non-Fiction

<P><B>BUILDERS BOOKSOURCE</B><BR>
1817 Fourth Street<BR>
Berkeley<BR>
510-845-6874<BR>
<B><a href="http://www.buildersbooksite.com">http://www.buildersbooksite.com</B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Design, Construction	

<A NAME="C">

<P><B>CLAY'S COMICS</B><BR>
1018 B Street<BR>
Hayward<BR>
510-733-9633<BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Comics

<P><B>CODY'S BOOKS</B><BR>
2454 Telegraph Ave<BR>
Berkeley<BR>
510-845-7852 <BR>
<B><A
HREF="http://www.codysbooks.com/">http://www.codysbooks.com/</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:codysbks@well.com">codysbks@well.com</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Computer, Psychology, Fiction

<P><B>COLLECTED THOUGHTS BOOKSHOP</B><BR>
1816 Euclid Avenue<BR>
Berkeley<BR>
510-843-1816<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:lorrainezi.aol.com">lorrainezi.aol.com</a></B><BR>
<font color=brown>New & Used Books<BR>
General:</font> Poetry, Science, Literature

<A NAME="D">

<P><B>DARK CARNIVAL BOOKSTORE</B><BR>
3086 Claremont Ave<BR>
Berkeley<BR>
510-654-7323<BR>
<B><A
HREF="http://www.darkcarnival.com/">http://www.darkcarnival.com/</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Mystery, Science Fiction	

<P><B>DIESEL, A BOOKSTORE</B><BR>
5433 College Avenue<BR>
Oakland<BR>
510-653-9965<BR>
<font color=brown>New & Used Books<BR>
General:</font> Children's, Contemporary Fiction, Culture Studies

<P><B>DISCOVEREAD</B><BR>
3052 Castro Valley Blvd.<BR>
Castro Valley<BR>
510-581-2160<BR>
<font color=brown>New Books<BR>
Specialty:</font> Children's

<P><B>DOLPHIN DREAM</B><BR>
1437 N. Broadway<BR>
Walnut Creek<BR>
510-933-2342<BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Metaphysics

<A NAME="E">

<P><B>E.A.R. BOOKS</B><BR>
1513 Cypress Street	<BR>
Walnut Creek<BR>
510-932-6023<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:MicheleEAR@aol.com">MicheleEAR@aol.com</a></B><BR>
<font color=brown>New & Used Audio Books<BR>
Specialty:</font> Audio

<P><B>EAST BAY BOOKS INC.</B><BR>
1555 Washington Avenue<BR>
San Leandro<BR>
510-483-3990<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:EBAYBOOKIT@aol.com">EBAYBOOKIT@aol.com</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Religion, Metaphysics

<P><B>EAST GOING TRAVEL SHOP & BOOKSHOP</B><BR>
1617 Locust Street<BR>
Walnut Creek<BR>
510-947-6660<BR>
<font color=brown>New Books<BR>
Specialty:</font> Travel, Guides, Maps

<P><B>EASY GOING TRAVEL SHOP & BOOKSTORE</B><BR>
1385 Shattuck Ave. <BR>
Berkeley<BR>
510-843-3533<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:easygo1@aol.com">easygo1@aol.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Travel Books, Guides, Maps

<P><B>ECOLOGY CENTER BOOKSTORE</B><BR>
2530 San Pablo Avenue<BR>
Berkeley<BR>
510-548-3402<BR>
<font color=brown>New Books<BR>
Specialty:</font> Environmental, Multicultural, Gardening

<A NAME="F">

<P><B>FRANK MIKESH NATURAL HISTORY BOOKS</B><BR>
1356 Walden Road<BR>
Walnut Creek<BR>
510-934-9243<BR>
<font color=brown>Used Books<BR>
Specialty:</font> Antiquarian

<A NAME="G">

<P><B>GAIA BOOKSTORE</B><BR>
1400 Shattuck Avenue<BR>
Berkeley<BR>
510-548-4172<BR>
<font color=brown>New Books<BR>
Specialty:</font> Spiritual, Feminism

<P><B>GIANT STEPS</B><BR>
39199A Farwell Drive<BR>
Fremont<BR>
510-793-1979<BR>
<B><A
HREF="http://members.aol.com/gsteps/books.html">http://members.aol.com/gsteps/books.html</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Children's

<P><B>GOODENOUGH BOOKS</B><BR>
1362 Railroad Avenue<BR>
Livermore<BR>
510-443-4354<BR>
<B><A
HREF="http://members.aol.com/GBooksinc/goodenough.html">http://members.aol.com/GBooksinc/goodenough.html</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:GBooksinc@aol.com">GBooksinc@aol.com</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Children's, Science Fiction, Mystery

<P><B>GRADUATE THEOLOGICAL UNION BOOKSTORE</B><BR>
2465 Le Conte<BR>
Berkeley<BR>
510-649-2470<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:gtu_bookstore@ecunet.org">gtu_bookstore@ecunet.org</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Religious	

<P><B>HALF PRICE BOOKS</B><BR>
1849 Solano Avenue<BR>
Berkeley<BR>
510-526-6080<BR>
<font color=brown>New & Used Books<BR>
General:</font> Discount Audio, Back Issue Magazines

<A NAME="H">

<P><B>HISTORIC SIGHTS</B><BR>
1605 Solano Ave.<BR>
Berkeley<BR>
510-525-9665<BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> History, Archaeology

<P><B>HOOKED ON BOOKS</B><BR>
1956 Tice Valley Blvd.<BR>
Walnut Creek<BR>
510-933-1025<BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Fiction, Non-Fiction, Used

<A NAME="I">

<A NAME="J">

<A NAME="K">

<P><B>KEY BOOK SHOP</B><BR>
1800 Telegraph Ave.<BR>
Oakland<BR>
510-444-2915<BR>
<font color=brown>New & Used Books<BR>
General:</font> Black Studies, Occult, Vintage Pocket Books

<A NAME="L">

<P><B>L'IL READER</B><BR>
1400 Shattuck Avenue #3<BR>
Berkeley<BR>
510-883-0803<BR>
<font color=brown>New Books<BR>
Specialty:</font> Children's Books & Educational Toys

<P><B>LAFAYETTE BOOK STORE</B><BR>
3579 Mt. Diablo Blvd.<BR>
Lafayette<BR>
510-284-1233<BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Non-Fiction, Children's

<P><B>LARRY'S BOOK NOOK</B><BR>
730-A Bancroft  Road<BR>
Walnut Creek<BR>
510-933-2665<BR>
<font color=brown>New Books<BR>
General:</font> Children's, Psychology, Mystery

<P><B>LAWRENCE HALL OF SCIENCE DISCOVERY CORNER</B><BR>
Centennial Dr. at Grizzly Peak Blvd., U C Berkeley<BR>
Berkeley<BR>
510-642-8856<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:Lhseur@uclink.berkeley.edu">Lhseur@uclink.berkeley.edu</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Museum, Science, Math, Children's Books, Teachers Guides	

<A NAME="M">

<P><B>MAMA BEARS</B><BR>
6536 Telegraph Avenue<BR>
Oakland<BR>
510-428-9684<BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Feminist, Gay & Lesbian, Children's, Parenting, Health

<P><B>MOE'S BOOKS</B><BR>
2476 Telegraph Avenue<BR>
Berkeley<BR>
510-849-2087<BR>
<B><A
HREF="http://moesbooks.com/moe.htm">http://moesbooks.com/moe.htm</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:MOE@MOESBOOKS.COM">MOE@MOESBOOKS.COM</a></B><BR>
<font color=brown>New & Used Books<BR>
General:</font> Art, Fiction, Non-Fiction

<P><B>MORAGA BOOK COMPANY</B><BR>
1460 Moraga Road<BR>
Moraga<BR>
510-376-1030<BR>
<font color=brown>New & Used Books<BR>
General:</font> Fiction, Non-Fiction, Children's	

<P><B>MR. MOPPS' CHILDREN'S BOOKSHOP</B><BR>
1405 Martin Luther King Way<BR>
Berkeley<BR>
510-525-9633<BR>
<font color=brown>New Books<BR>
Specialty:</font> Children's Books, Tapes, Toys, Educational Materials

<P><B>MUSEUM OF CHILDREN'S ART</B><BR>
560 Second St.<BR>
Oakland<BR>
510-465-3062<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:mocha@netcom.com">mocha@netcom.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Children's, Museum

<A NAME="N">

<P><B>NOLO PRESS BOOKSTORE</B><BR>
950 Parker Street<BR>
Berkeley<BR>
510-704-2248<BR>
<font color=brown>New Books<BR>
Specialty:</font> Self Help Legal, Business

<A NAME="O">

<P><B>OAKLAND MUSEUM STORE</B><BR>
1000 Oak Street<BR>
Oakland<BR>
510-834-2129<BR>
<font color=brown>New Books<BR>
Specialty:</font> Art, Photography, California

<P><B>ORINDA BOOKS</B><BR>
276 Village Square<BR>
Orinda<BR>
510-254-7606<BR>
<font color=brown>New & Used Books<BR>
General:</font> Textbooks for JFK University, Psychology, Fiction

<A NAME="P">

<P><B>PEGASUS BOOKS</B><BR>
1855 Solano Avenue<BR>
Berkeley<BR>
510-525-6888<BR>
<font color=brown>New & Used Books<BR>
General:</font> Literature, Art, Children's

<P><B>PEGASUS BOOKS DOWNTOWN</B><BR>
2349 Shattuck Avenue<BR>
Berkeley<BR>
510-649-1320<BR>
<font color=brown>Used Books<BR>
General:</font> Fiction, Cookbooks, Metaphysics

<P><B>PEGASUS WALNUT CREEK</B><BR>
1333 N. Main Street<BR>
Walnut Creek<BR>
510-934-4449<BR>
<font color=brown>New & Used Books<BR>
General:</font> Literature, Metaphysics, Magazines

<P><B>PENDRAGON BOOKS</B><BR>
5560 College Avenue<BR>
Oakland<BR>
510-652-6259<BR>
<font color=brown>New & Used Books<BR>
General:</font> Fiction, Art, Magazines

<P><B>PIONEER BOOKSTORE</B><BR>
California State University<BR>
25976 Carlos Bee Blvd.<BR>
HAYWARD<BR>
510-885-3507<BR>
<font color=brown>New & Used Text Books<BR>
General:</font> Test Books, Reference, Study Guides, Children's		

<A NAME="Q">

<A NAME="R">

<P><B>RAKESTRAW BOOKS</B><BR>
308 Sycamore Valley Road West<BR>
Danville<BR>
510-837-7337<BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Children's, Cookbooks

<A NAME="S">

<P><B>SHAMBHALA BOOKSELLERS</B><BR>
2482 Telegraph Avenue<BR>
Berkeley<BR>
510-848-8443<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:shambhalabooksellers@internetMCI.com">shambhalabooksellers@internetMCI.com</a></B><BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Metaphysics, Religion

<P><B>SHEILA A. GRILLI, BOOKSELLER</B><BR>
610 Ferry Street<BR>
Maretinez<BR>
510-228-6422<BR>
<font color=brown>New & Used Books<BR>
General:</font> Literature, California, Biography

<P><B>SIERRA CLUB BOOKSTORE</B><BR>
6014 College Avenue<BR>
Oakland<BR>
510-658-7470<BR>
<font color=brown>New Books<BR>
Specialty:</font> Environmental / Travel

<P><B>STORYTELLER</B><BR>
49 Lafayette Circle<BR>
LAFAYETTE<BR>
510-284-3480<BR>
<font color=brown>New Books<BR>
Specialty:</font> Children's

<P><B>SUNRISE BOOKSHOP</B><BR>
3054 Telegraph Avenue<BR>
Berkeley<BR>
510-841-6372<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:CHARCOOK@AOL.COM">CHARCOOK@AOL.COM</a></B><BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Metaphysics

<A NAME="T">

<P><B>TOWER BOOKS</B><BR>
1280 Willow Pass Road, Suite E<BR>
Concord<BR>
510-827-2920<BR>
<font color=brown>New Books<BR>
General:</font> Science Fiction, Computers, Children's

<P><B>TOWNE CENTER BOOKS</B><BR>
555 Main Street<BR>
Pleasonton<BR>
510-846-8826<BR>
<font color=brown>New Books<BR>
General:</font> Travel, Children's, Reference

<A NAME="U">

<P><B>UC BOTANICAL GARDEN</B><BR>
Centennial Drive<BR>
Berkeley<BR>
510-642-3343<BR>
<font color=brown>New Books<BR>
Specialty:</font> Botany / Gardening

<P><B>UNIVERSITY PRESS BOOKS / BERKELEY</B><BR>
2430 Bancroft Way<BR>
Berkeley<BR>
510-548-0585<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:upb@aimnet.com">upb@aimnet.com</a></B><BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> University Presses

<A NAME="V">

<A NAME="W">

<P><B>WALDEN POND BOOKS</B><BR>
3316 Grand Avenue<BR>
Oakland<BR>
510-832-4438<BR>
<font color=brown>New & Used Books<BR>
General:</font> Fiction, History, Art, Radical Literature

<P><B>WARM SPRINGS BOOK COMPANY</B><BR>
46695 Mission Blvd.<BR>
Fremont<BR>
510-683-9038<BR>
<font color=brown>New & Used Books<BR>
Specialt:</font> Used

<P><B>WEST BERKELEY WOMEN'S BOOKS</B><BR>
2514 San Pablo Avenue<BR>
Berkeley<BR>
510-204-9399<BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Feminist, Gay & Lesbian, Children's
<A NAME="X">

<A NAME="Y">

<A NAME="Z">

<P>


<CENTER><P>For further information on these and other stores, please refer to the recently published<BR>"First and Foremost: A Guide to Northern California's Independent Bookstores"<BR>
(<font color=red>available at independent bookstores everywhere</font>).

<B><P>WE APPRECIATE YOUR INTEREST!</B></CENTER>

<P>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT03-B24-298</DOCNO>
<DOCOLDNO>IA009-000087-B036-355</DOCOLDNO>
<DOCHDR>
http://www.nciba.com:80/south.html 207.44.128.99 19970222112503 text/html 18799
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 11:25:18 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 18627
Last-modified: Sun, 16 Feb 1997 22:03:38 GMT
</DOCHDR>
<HTML>

<!-------------------------------------------------------------------------------------->
<!--   AUTHOR:  thomas gladysz  email: thomasg@pandorasbox-->
<!--   CREATED:  July, 1996  Best viewed using Netscape or Microsoft Explorer  -->
<!--   MODIFIED:  February, 1997   -->
<!--   FILE: south.html   -->
<!--   PURPOSE: list of other NCIBA bookstores  -->
<!---------------------------------------------------------------------------------------->

<HEAD>
<TITLE>South Bay & Central Coast Bookstores</TITLE>

<META Name="description" Content="Welcome to the Northern California Independent Booksellers Association page of member bookstores - - here you will find some of your favorite places to shop in the South Bay and Central Coast regions.">

<META Name="keywords" Content="Northern California Independent Booksellers Association NCIBA books reading book bookstore bookstores consumer information regional business literature new used antiquarian children's speciality west north south east southern beach Hollister Carmel San Jose Mountain View Palo Alto Stanford Monterey Salinas Pacifica Half Moon Bay Milpitas Belmont Santa Cruz Los Aptos Cupertino Capitola Redwood City San Mateo Watsonville bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore books books books books bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore bookstores bookstore">

</HEAD>
<BODY bgcolor=#ffffff>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<HR SIZE=1>
<CENTER><B>N<FONT SIZE=-1>ORTHERN</FONT> C<FONT SIZE=-1>ALIFORNIA</FONT> I<FONT SIZE=-1>NDEPENDENT</FONT> B<FONT SIZE=-1>OOKSELLERS</FONT> A<FONT SIZE=-1>SSOCIATION</FONT></B></CENTER>
<HR SIZE=1>

<CENTER><FONT SIZE=+2 color=brown> <img src="image/bkiconR.gif"><B> <FONT SIZE=+3>S</FONT>OUTH <FONT SIZE=+3>B</FONT>AY & <FONT SIZE=+3>C</FONT>ENTRAL <FONT SIZE=+3>C</FONT>OAST  <img src="image/bkicon.gif"><BR> BOOKSTORES</B></FONT></CENTER>

<P><FONT SIZE=+1><B>W</B></FONT>elcome to the membership directory of the Northern California Independent Booksellers Association. Here you will find an alphabetical listing of dozens of member bookstores scattered throughout the South Bay and Central Coast region . Stores are designated as being NEW, USED or NEW & USED as well as GENERAL interest or SPECIALTY shops. Additional store specialties are also noted. If you know the name of the bookstore you are looking for, simply click on the appropriate letter of the alphabet to move around this page. These alphabetical links will take you to the beginning of that letter's listing.

<CENTER><B><P><A HREF="#A">A</A> / <A HREF="#B">B</A> / <A HREF="#C">C</A> / <A HREF="#D">D</A> / <A HREF="#E">E</A> / <A HREF="#F">F</A> / <A HREF="#G">G</A> / <A HREF="#H">H</A> / <A HREF="#I">I</A> / <A HREF="#J">J</A> / <A HREF="#K">K</A> / <A HREF="#L">L</A> / <A HREF="#M">M</A> / <A HREF="#N">N</A> / <A HREF="#O">O</A> / <A HREF="#P">P</A> / <A HREF="#Q">Q</A> / <A HREF="#R">R</A> / <A HREF="#S">S</A> / <A HREF="#T">T</A> / <A HREF="#U">U</A> / <A HREF="#V">V</A> / <A HREF="#W">W</A> / <A HREF="#X">X</A> / <A HREF="#Y">Y</A> / <A HREF="#Z">Z</A><BR></B></CENTER>

<P>You may also create a local map to the bookstore of your choice. Follow the simple directions on the <B><a href="http://www.mapblast.com/mapblast/locator.html">MapBlast</a> </B>page. You will need the address, city and state of the bookstore. Once you have generated a map, you may zoom-in or zoom-out for additional detail as well as print out the results. [<font color=green> Return to this page by using your back button.</font> ]

<P>

<CENTER><TD align=center><table border=5>
<tr>
<th bgcolor="#ffcc66"> <font size=2><a href="http://www.mapblast.com/mapblast/locator.html">CREATE A MAP TO YOUR FAVORITE BOOKSTORE</a>  </font></th>
</tr>
</table></TD></CENTER>

<P>

<A NAME="A">

<P><B>ALEF BET</B><BR>
14103 D Winchester Blvd.<BR>
Los Gatos	<BR>
408-370-1818<BR>
<font color=brown>New Books<BR>
Specialty:</font> Judaica

<A NAME="B">

<P><B>BAY BOOK & TOBACCO CO. / BAY BOOK & VIDEO</B><BR>
80 N. Cabrillo Hwy,  Suite F<BR>
Half Moon Bay<BR>
415-726-3488<BR>
<font color=brown>New Books<BR>
General:</font> Mystery, Science-Fiction, Children's 

<P><B>BAY BOOKS</B><BR>
316 Alvarado Street<BR>
Monterey<BR>
408-375-1855<BR>
<font color=brown>New Books<BR>
General:</font> Children's, Foreign Language, Business 	

<P><B>BELL'S BOOKSTORE</B><BR>
536 Emerson Street<BR>
Palo Alto<BR>
415-323-7822<BR>
<font color=brown>New & Used Books<BR>
General:</font> Out-of-Print Hardcover, Horticulture, History

<P><B>BOB AND BOB</B><BR>
151 Forest  Avenue<BR>
Palo Alto<BR>
415-329-9050<BR>
<font color=brown>New Books<BR>
Specialty:</font> Judaica

<P><B>BOOK BARTERERS EXCHANGE</B><BR>
2025  W. El Camino Real<BR>
Mountain View<BR>
415-961-3747<BR>
<font color=brown>Used Books<BR>
Specialty:</font> Used

<P><B>BOOK CARAVAN</B><BR>
2103 Shirley Road<BR>
Belmont<BR>
415-595-5492<BR>
<font color=brown>New Books<BR>
Specialty:</font> Children's	

<P><B>BOOK GARDEN</B><BR>
1215 E. Calaveras Blvd.<BR>
Milpitas<BR>
408-262-9003<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:abgbooks@netcom.com">abgbooks@netcom.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Self-Help, Nutrition, Spirituality	

<P><B>BOOKS INC.</B><BR>
157 Stanford Shopping Center<BR>
Palo Alto<BR>
415-321-0600<BR>
<font color=brown>New Books<BR>
General</font>: Fiction, Travel, Kids	

<P><B>BOOKS INC.</B><BR>
Carmel Plaza<BR>
Carmel by the Sea<BR>
408-625-0440<BR>
<font color=brown>New Books<BR>
General:</font> Travel, Regional, Mystery

<P><B>BOOKSHOP SANTA CRUZ</B><BR>
1520 Pacific Avenue<BR>
Santa Cruz<BR>
408-423-0900<BR>
<font color=brown>New Books<BR>
General:</font> Children's, Women's, Magazines / Newspapers

<P><B>BOOKWORKS</B><BR>
667 Lighthouse<BR>
Pacific Grove<BR>
408-372-2242<BR>
<font color=brown>New Books<BR>
General:</font> Mystery, Childrens, Magazines, Regional

<P><B>BOOKWORKS</B><BR>
36 Rancho Del Mar Center<BR>
Aptos<BR>
408-688-4554<BR>
<font color=brown>New & Used Books<BR>
General:</font> Children's, Travel, Fiction

<A NAME="C">

<P><B>CAPITOLA BOOK CAFE</B><BR>
1475 41st  Avenue<BR>
Capitola<BR>
408-462-4415<BR>
<B><A
HREF="http://www.clbooks.com/index.html">http://www.clbooks.com/index.html</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:bookcafe@cruzio.com">bookcafe@cruzio.com</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Mystery, Science Fiction

<P><B>CLEAN WELL LIGHTED PLACE FOR BOOKS</B><BR>
21269 Stevens Creek Blvd<BR>
Cupertino<BR>
408-255-7600<BR>
<B><A
HREF="http://bookstore.com">http://bookstore.com</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:info@bookstore.com">info@bookstore.com</a></B><BR>
<font color=brown>New & Used Books<BR>
General:</font> Children's, Business

<P><B>COASTSIDE BOOKS</B><BR>
521 Main Street<BR>
Half Moon Bay<BR>
415-726-5889
<font color=brown>New Books<BR>
General:</font> Children's, Art, Metaphysics 

<P><B>COMPUTER LITERACY BOOKSHOPS, INC.</B><BR>
2590 North First Street<BR>
San Jose<BR>
408-435-1118<BR>
<B><A
HREF="http://www.clbooks.com/">http://www.clbooks.com/</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:info@clbooks.com">info@clbooks.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Computer Books

<P><B>CROSSROADS BOOKS</B><BR>
1935 Main Street<BR>
Watsonville<BR>
408-728-4139<BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Childen's, Paperback Exchange

<A NAME="D">

<P><B>DE ANZA COLLEGE BOOKSTORE</B><BR>
21250 Stevens Creek Blvd.<BR>
Cupertino<BR>
408-864-8460<BR>
<font color=brown>New & Used Text Books<BR>
Specialty:</font> Study Guides, Nursing, Technical	

<A NAME="E">

<P><B>EAST  WEST BOOKSHOP</B><BR>
324 Castro Street<BR>
Mountain View<BR>
415-988-9800 or 800-909-6161<BR>
<B><A
HREF="http://www.eastwest.com">http://www.eastwest.com</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:eastwestmv@aol.com">eastwestmv@aol.com</a></B><BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> New Age

<P><B>EDUCATIONAL STUFF</B><BR>
908 1/2 S. Main Street<BR>
Salinas<BR>
408-422-5044<BR>
<font color=brown>New Books<BR>
Specialty:</font> Children's, Teacher's Supplies

<A NAME="F">

<P><B>FAMILY BOOK CENTER</B><BR>
144 E. Laurel Drive<BR>
Salinas<BR>
408-759-2665<BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Used Paperbacks

<P><B>FUTURE FANTASY BOOKS</B><BR>
3705 El Camino Real<BR>
Palo Alto<BR>
415-855-9771<BR>
<B><A
HREF="http://futfan.com/home.html">http://futfan.com/home.html</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:Futfan@netcom.com">Futfan@netcom.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Science Fiction, Fantasy, Mystery

<A NAME="G">

<P><B>GAME* ALOT TOYS & GAMES</B><BR>
1526 Pacific Avenue<BR>
Santa Cruz<BR>
408-429-9009<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:GAMEALOT@HOLONET.NET">GAMEALOT@HOLONET.NET</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Hobbies, Games

<P><B>GATEWAYS BOOK & GIFT</B><BR>
1018 Pacific Avenue<BR>
Santa Cruz<BR>
408-429-9600<BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Spiritual, Religious

<A NAME="H">

<P><B>HEINTZELMAN'S BOOKSTORE</B><BR>
205 State Street<BR>
Los Altos<BR>
415-941-1842<BR>
<font color=brown>New Books<BR>
General:</font> Cooking, Gardening, Travel

<P><B>HICKLEBEE'S</B><BR>
1378 Lincoln Avenue<BR>
San Jose<BR>
408-292-8880<BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Children's	

<A NAME="I">

<A NAME="J">

<A NAME="K">

<P><B>KEPLER'S BOOKS & MAGAZINES</B><BR>
1010 El Camino Real<BR>
Menlo Park<BR>
415-324-4321<BR>
<B><A
HREF="http://www.keplers.com">http://www.keplers.com</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Children's, Computer, Business

<A NAME="L">

<P><B>LEGAL RECOURSE</B><BR>
2431 Park Boulevard<BR>
Palo Alto<BR>
415-324-2575<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:dalden@legal.com">dalden@legal.com</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Legal Books, Law

<P><B>LINDEN TREE CHILDREN'S RECORDS AND BOOKS</B><BR>
170 State Street<BR>
LOS ALTOS<BR>
415-949-3390<BR>
<font color=brown>New Books<BR>
Specialty:</font> Children's

<P><B>LOGOS BOOKS & RECORDS</B><BR>
1117 Pacific Avenue<BR>
Santa Cruz<BR>
408-427-5100<BR>
<font color=brown>New & Used Books<BR>
General:</font> Rare & Out of Print

<A NAME="M">

<P><B>MARITIME MUSEUM OF MONTEREY</B><BR>
5 Custom House Plaza<BR>
Monterey<BR>
408-375-1643<BR>
<font color=brown>New Books<BR>
General:</font> Maritime, California History

<P><B>MONTEREY BAY AQUARIUM BOOKSTORE</B><BR>
886 Cannery Row<BR>
Monterey<BR>
408-648-4848<BR>
<B><A
HREF="http://www.mbayaq.org">http://www.mbayaq.org</a></B><BR>
<font color=brown>New Books<BR>
Specialty:</font> Science/Nature

<P><B>MULBERRY, A BOOKSHOP FOR CHILDREN</B><BR>
716 Lighthouse Avenue<BR>
Pacific Grove<BR>
408-375-3016<BR>
<font color=brown>New Books<BR>
Specialty:</font> Children's	

<A NAME="N">

<A NAME="O">

<P><B>OCEAN BOOKS</B><BR>
416 Main Street<BR>
Half Moon Bay<BR>
415-726-2665<BR>
<font color=brown>New & Used Books<BR>
General:</font> Cookbooks, History, Art, Fiction

<A NAME="P">

<P><B>PHILEAS FOGG'S BOOKS, MAPS & MORE</B><BR>
#87 Stanford Shopping Center <BR>
Palo Alto<BR>
415-327-1754<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:foggs@aol.com">foggs@aol.com</a></B><BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Travel, Antiquarian

<P><B>PRINTER'S INC. BOOKSTORE</B><BR>
310 California Avenue<BR>
Palo Alto<BR>
415-327-6500<BR>
<B><A
HREF="http://www.pibooks.com">http://www.pibooks.com</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:pibooks@pibooks.com">pibooks@pibooks.com</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Non-Fiction

<P><B>PRINTER'S INC. BOOKSTORE</B><BR>
301 Castro Street<BR>
Mountain View<BR>
415-961-8500<BR>
<B><A
HREF="http://www.pibooks.com">http://www.pibooks.com</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Computer, Business, Children's, Magazines

<A NAME="Q">

<A NAME="R">

<A NAME="S">

<P><B>SARATOGA BOOK MARKET</B><BR>
14523 Big Basin Way<BR>
Saratoga<BR>
408-741-5180<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:rachel@saratogabks.us.com">rachel@saratogabks.us.com</a></B><BR>
<font color=brown>New & Used Books<BR>
General:</font> California, Fiction, Children's

<P><B>SECRET STAIRCASE BOOKSTORE</B><BR>
2223 Broadway<BR>
Redwood City<BR>
415-366-1222<BR>
<B><A
HREF="http://www.secretstaircasebooks.com">http://www.secretstaircasebooks.com</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:secstbks@secretstaircasebooks.com">secstbks@secretstaircasebooks.com</a></B><BR>
<font color=brown>New & Used Books<BR>
Specialty:</font> Mysteries, Children's Books

<P><B>SEEDS OF CHANGE </B><BR>
417 Capitola Avenue<BR>
Capitola<BR>
408-464-1601<BR>
<font color=brown>New Books<BR>
Specialty:</font> Children's

<P><B>SLEEPY DRAGON BOOK BISTRO</B><BR>
2222 E. Cliff Drive  Suite #2-A<BR>
Santa Cruz<BR>
408-476-9136<BR>
<font color=brown>New & Used Books<BR>
General:</font> Nature, New Age, Children's

<P><B>SPARTAN BOOKSTORE</B><BR>
San Jose State University<BR>
1125 North 7th Street<BR>
SAN JOSE<BR>
408-924-1814<BR>
<font color=brown>New & Used Text Books<BR>
General:</font> Test Prep / Study Aids, Computer, Magazines

<P><B>STACEY'S BOOKSTORE</B><BR>
219 University Avenue<BR>
Palo Alto<BR>
415-326-0681<BR>
<B><A
HREF="http://www.staceys.com">http://www.staceys.com</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:staceyspa@aol.com">staceyspa@aol.com</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Computers, Business

<P><B>STACEY'S BOOKSTORE</B><BR>
19625 Stevens Creek Blvd<BR>
Cupertino	<BR>
408-253-752<BR>
<B><A
HREF="http://www.staceys.com">http://www.staceys.com</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:staceyspa@aol.com">staceyspa@aol.com</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Computer, Business, Medical

<P><B>STANFORD BOOKSTORE</B><BR>
White Plaza<BR>
Stanford<BR>
415-329-1217<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:mailorder@bookstore.stanford.edu">mailorder@bookstore.stanford.edu</a></B><BR>
<font color=brown>New & Used Text Books<BR>
General:</font> Technical, Humanities, Business

<P><B>STANFORD BOOKSTORE - PALO ALTO</B><BR>
135 University Avenue<BR>
Palo Alto<BR>
415-614-0280<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:Stanbook@cerf.net">Stanbook@cerf.net</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Medical, Psycholgy, Technical

<P><B>STANFORD PUBLICATIONS INTL.</B><BR>
941 Hamilton Avenue<BR>
Menlo Park<BR>
415-494-6692<BR>
<font color=brown>New Books<BR>
General:</font> Computer, Engineering, Medical, Academic

<A NAME="T">

<P><B>THE BOOKSTORE</B><BR>
217 Fifth Street<BR>
Hollister<BR>
408-637-3400<BR>
<font color=brown>email:</font><B> <A
HREF="mailto:egage@aol.com">egage@aol.com</a></B><BR>
<font color=brown>New Books<BR>
General:</font> Local & California History, Children's

<P><B>THUNDERBIRD BOOKSHOPS INC.</B><BR>
P.O. Box 22830<BR>
3600 The Barnyard
Carmel<BR>
408-624-1803<BR>
<font color=brown>New Books<BR>
General:</font> Psychology, Metaphysics, Childrens, Cooking, Eastern Religion

<P><B>TOWER BOOKS</B><BR>
630 San Antonio Road
Mountain View<BR>
415-941-7300<BR>
<font color=brown>New Books<BR>
General:</font> Popular Culture, Computers, Science Fiction

<P><B>TOWER BOOKS</B><BR>
2727 El Camino Real<BR>
San Mateo<BR>
415-570-7444<BR>
<font color=brown>New Books<BR>
General:</font> Fiction, Children's, Science-Fiction, Local History

<P><B>TRAVEL STORE</B><BR>
56 1/2 N. Santa Cruz  Avenue<BR>
Los Gatos<BR>
408-354-9909<BR>
<font color=brown>New Books<BR>
Specialty:</font> Travel Guides, Maps

<A NAME="U">

<A NAME="V">

<A NAME="W">

<P><B>WESSEX BOOKS</B><BR>
558 Santa Cruz Avenue<BR>
Menlo Park<BR>
415-321-1333<BR>
<B><A
HREF="http://www.wessexbooks.com">http://www.wessexbooks.com</a></B><BR>
<font color=brown>email:</font><B> <A
HREF="mailto:wwwessex@best.com">wwwessex@best.com</a></B><BR>
<font color=brown>Used Books<BR>
Specialty:</font>Fiction, History, University Press Titles

<P><B>WILLOW GLEN BOOKS</B><BR>
1330 Lincoln Avenue<BR>
San Jose<BR>
408-298-8141<BR>
<font color=brown>New Books<BR>
General:</font> Women's, Mystery, Local Authors / Interest	

<A NAME="X">

<A NAME="Y">

<A NAME="Z">

<P>

<P>

<CENTER><P>For further information on these and other stores, please refer to the recently published<BR>"First and Foremost: A Guide to Northern California's Independent Bookstores"<BR>
(<font color=red>available at independent bookstores everywhere</font>).

<B><P>WE APPRECIATE YOUR INTEREST!</B></CENTER>

<P>

<CENTER>
<P>
<P><B><FONT SIZE=-1>[ <a href="stores.html">BOOKSTORES</a> | <a href="bestsell.html">BESTSELLERS</a> | <a href="goodread.html">GOOD READS</a> | <a href="censor.html">FREE SPEECH</a> | <a href="resource.html">READER RESOURCES</a> ]</FONT></B>

<p><B>We would enjoy hearing from you.<BR>
Please email your comments or suggestions to <A
HREF="mailto:office@nciba.com">office@nciba.com</a>

<P><B> <IMG valign=middle SRC="image/l_hand.gif" ALT="thata way" HEIGHT=14 WIDTH=33>Return
to the <A HREF="Welcome.html">NCIBA Homepage<BR><IMG border=0 height=48 width=46 SRC="image/nciba_sm.gif"></B></a>
</P></CENTER>

</BODY>
</HTML>
</DOC>
